cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
LGG	cis	1	rs10000348	chr4:111379036	ENPEP	chr4:111397229-111484491:+	0.22	4.94	1.09E-6	Blood pressure	
LGG	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.45	5.02	7.17E-7	Crohn's disease	
LGG	cis	1	rs10002332	chr4:129875301	C4orf33	chr4:130014829-130033842:+	0.59	9.6	4.2E-20	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs10002541	chr4:56395011	TMEM165	chr4:56262090-56292342:+	0.17	5.03	6.8E-7	Personality dimensions	
LGG	cis	1	rs10005733	chr4:292001	ZNF718	chr4:53272-156488:+	0.25	5.26	2.19E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs1000597	chr7:30937178	C7orf16	chr7:31726799-31748068:+	0.36	4.8	2.16E-6	Nephrolithiasis	
LGG	cis	1	rs10005989	chr4:56405206	TMEM165	chr4:56262090-56292342:+	0.18	5.24	2.41E-7	Personality dimensions	
LGG	cis	1	rs10006789	chr4:1330333	CRIPAK	chr4:1385340-1389782:+	0.25	5.5	5.99E-8	Systolic blood pressure	
LGG	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.46	-11.13	8.51E-26	Longevity	
LGG	cis	1	rs10010758	chr4:37938518	PTTG2	chr4:37962056-37962630:+	0.28	4.74	2.83E-6	Periodontal microbiota	
LGG	cis	1	rs10010758	chr4:37938518	TBC1D1	chr4:37892720-38140793:+	0.15	3.59	0.00037	Periodontal microbiota	
LGG	cis	1	rs10011865	chr4:17645710	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10012335	chr4:17628630	MED28	chr4:17616273-17629791:+	0.21	4.44	1.1E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1001530	chr5:176985515	DOK3	chr5:176928915-176937427:-	0.21	3.78	0.000179	Alzheimer disease and age of onset	
LGG	cis	1	rs10016506	chr4:56396674	TMEM165	chr4:56262090-56292342:+	0.17	4.99	8.2E-7	Personality dimensions	
LGG	cis	1	rs10016562	chr4:122949327	SPATA5	chr4:123844225-124240602:+	-0.16	-3.8	0.000164	Emphysema imaging phenotypes	
LGG	cis	1	rs10019856	chr4:17615742	MED28	chr4:17616273-17629791:+	0.21	4.52	7.79E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10021364	chr4:310691	ZNF718	chr4:53272-156488:+	-0.27	-5.25	2.32E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs10023335	chr4:77358987	FAM47E	chr4:77135193-77204923:+	0.22	4.99	8.59E-7	Creatinine levels	
LGG	cis	1	rs10023335	chr4:77358987	STBD1	chr4:77172853-77232282:+	-0.2	-5.02	7.26E-7	Creatinine levels	
LGG	cis	1	rs10026676	chr4:56478752	SRD5A3	chr4:56212409-56237866:+	-0.17	-3.66	0.000276	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs10027325	chr4:282608	ZNF718	chr4:53272-156488:+	0.23	4.61	5.07E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs10027755	chr4:17615954	MED28	chr4:17616273-17629791:+	0.21	4.39	1.41E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10029750	chr4:120172543	MYOZ2	chr4:120056939-120108935:+	0.23	4.48	9.39E-6	Corneal astigmatism	
LGG	cis	1	rs10030019	chr4:106998448	NPNT	chr4:106816605-106892827:+	-0.23	-4.86	1.61E-6	Airflow obstruction	
LGG	cis	1	rs10032326	chr4:17630717	MED28	chr4:17616273-17629791:+	0.21	4.47	9.64E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10033071	chr4:111375852	ENPEP	chr4:111397229-111484491:+	0.22	4.93	1.12E-6	Blood pressure	
LGG	cis	1	rs10034433	chr4:56421176	TMEM165	chr4:56262090-56292342:+	0.17	5.18	3.17E-7	Personality dimensions	
LGG	cis	1	rs10035646	chr5:115534974	COMMD10	chr5:115420727-115628978:+	0.47	5.96	4.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1003623	chr11:108152582	ATM	chr11:108093559-108239826:+	-0.11	-3.53	0.000456	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs10036292	chr5:115595871	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10037055	chr5:176691279	MXD3	chr5:176732501-176739292:-	0.13	3.55	0.000418	Migraine without aura	
LGG	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.46	-12.3	1.63E-30	Eye color traits	
LGG	cis	1	rs1003719	chr21:38491095	TTC3	chr21:38445571-38575406:+	0.12	3.85	0.000132	Eye color traits	
LGG	cis	1	rs10037375	chr5:115533407	COMMD10	chr5:115420727-115628978:+	-0.2	-3.72	0.000221	Metabolite levels  (X-11787)	
LGG	cis	1	rs10041072	chr5:150259642	LOC134466	chr5:150310000-150326146:-	0.38	4.37	1.53E-5	Crohn's disease	
LGG	cis	1	rs10042278	chr5:115532928	COMMD10	chr5:115420727-115628978:+	0.47	5.96	4.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10043228	chr5:115597048	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1004401	chr7:50755273	FIGNL1	chr7:50511834-50518088:-	0.18	3.81	0.000159	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs1004467	chr10:104594507	SFXN2	chr10:104474298-104498946:+	-0.32	-4.21	3.1E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs10048648	chr2:26320315	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.000149	Gut microbiome composition (summer)	
LGG	cis	1	rs10048683	chr2:26320519	GPR113	chr2:26531041-26569685:-	-0.23	-3.69	0.000253	Gut microbiome composition (summer)	
LGG	cis	1	rs10050311	chr4:87754419	C4orf36	chr4:87797359-87813575:-	-0.29	-3.79	0.000169	Insulin-related traits	
LGG	cis	1	rs10051240	chr5:115569931	COMMD10	chr5:115420727-115628978:+	0.47	5.91	6.57E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.81	14.94	7.36E-42	Type 2 diabetes	
LGG	cis	1	rs10051804	chr5:150226424	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs10051924	chr5:150226639	LOC134466	chr5:150310000-150326146:-	0.4	4.63	4.71E-6	Crohn's disease	
LGG	cis	1	rs1005224	chr14:76173860	TTLL5	chr14:76127621-76421421:+	0.25	5.52	5.45E-8	Large artery stroke	
LGG	cis	1	rs10052606	chr5:150272217	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs10053750	chr5:150270051	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs10055868	chr5:115471612	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10056179	chr5:110442137	TSLP	chr5:110405778-110413722:+	-0.31	-4.56	6.47E-6	Eosinophil counts	
LGG	cis	1	rs10057988	chr5:150272062	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs10058821	chr5:150226385	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs10058943	chr5:150226586	LOC134466	chr5:150310000-150326146:-	0.4	4.63	4.71E-6	Crohn's disease	
LGG	cis	1	rs10061105	chr5:150255185	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs10061842	chr5:110402855	TSLP	chr5:110405778-110413722:+	-0.31	-4.27	2.31E-5	Eosinophil counts	
LGG	cis	1	rs10062350	chr5:115453497	COMMD10	chr5:115420727-115628978:+	0.46	5.75	1.56E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10062929	chr5:110408179	TSLP	chr5:110405778-110413722:+	-0.31	-4.15	3.97E-5	Eosinophil counts	
LGG	cis	1	rs10063647	chr5:127371588	FLJ33630	chr5:127276135-127419299:-	-0.26	-6.18	1.35E-9	Height	
LGG	cis	1	rs10064106	chr5:115572158	COMMD10	chr5:115420727-115628978:+	0.2	3.76	0.000188	Metabolite levels  (X-11787)	
LGG	cis	1	rs10064130	chr5:138309307	FAM53C	chr5:137673224-137685416:+	0.19	3.64	0.000298	Age-related hearing impairment (interaction)	
LGG	cis	1	rs10064130	chr5:138309307	SIL1	chr5:138282412-138534065:-	0.14	4.03	6.59E-5	Age-related hearing impairment (interaction)	
LGG	cis	1	rs10064201	chr5:138309405	FAM53C	chr5:137673224-137685416:+	0.18	3.52	0.000464	Age-related hearing impairment (interaction)	
LGG	cis	1	rs10064201	chr5:138309405	SIL1	chr5:138282412-138534065:-	0.13	3.81	0.000155	Age-related hearing impairment (interaction)	
LGG	cis	1	rs10065172	chr5:150227998	LOC134466	chr5:150310000-150326146:-	0.41	4.72	3.11E-6	Crohn's disease	
LGG	cis	1	rs10066259	chr5:115451892	COMMD10	chr5:115420727-115628978:+	0.41	5.09	5.21E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1006722	chr4:17618713	MED28	chr4:17616273-17629791:+	-0.22	-4.7	3.36E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10073364	chr5:115592582	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10074715	chr5:115515719	COMMD10	chr5:115420727-115628978:+	0.19	3.66	0.000282	Metabolite levels  (X-11787)	
LGG	cis	1	rs10076701	chr5:131596419	SLC22A5	chr5:131705401-131731302:+	0.18	3.61	0.00034	Blood metabolite levels	
LGG	cis	1	rs10077411	chr5:156015151	SGCD	chr5:155135063-156194796:+	0.3	4.67	3.81E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs10077734	chr5:156009720	SGCD	chr5:155135063-156194796:+	0.3	4.59	5.67E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs10077875	chr5:128722696	CHSY3	chr5:129240523-129522326:+	0.17	3.81	0.000159	Obesity-related traits	
LGG	cis	1	rs10078968	chr5:150244273	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs10078	chr5:438102	C5orf55	chr5:441645-443258:-	0.37	6.46	2.57E-10	Fat distribution (HIV)	
LGG	cis	1	rs10078	chr5:438102	SLC9A3	chr5:473334-524549:-	0.22	4.82	1.94E-6	Fat distribution (HIV)	
LGG	cis	1	rs10079394	chr5:115600919	COMMD10	chr5:115420727-115628978:+	0.45	5.71	1.91E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10080429	chr6:109738106	AKD1	chr6:109814059-110012415:-	-0.29	-5.89	6.99E-9	Height	
LGG	cis	1	rs10080429	chr6:109738106	MICAL1	chr6:109765268-109787171:-	-0.32	-7.58	1.77E-13	Height	
LGG	cis	1	rs10080429	chr6:109738106	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.65	0.000288	Height	
LGG	cis	1	rs10082278	chr1:202495120	UBE2T	chr1:202300786-202311094:-	-0.12	-3.7	0.000244	Sex ratio	
LGG	cis	1	rs10083343	chr14:65853133	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10083346	chr14:65853273	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10083348	chr14:65853401	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10083421	chr14:65851158	LOC645431	chr14:65877313-65879335:-	-0.43	-6.01	3.52E-9	Ischemic stroke	
LGG	cis	1	rs10083485	chr14:65853114	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10083488	chr14:65853346	LOC645431	chr14:65877313-65879335:-	-0.43	-5.92	6.14E-9	Ischemic stroke	
LGG	cis	1	rs10083525	chr14:65851556	LOC645431	chr14:65877313-65879335:-	0.42	6.12	1.94E-9	Ischemic stroke	
LGG	cis	1	rs1008374	chr4:17683219	LAP3	chr4:17578927-17609590:+	-0.13	-3.71	0.000231	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1008375	chr4:17682834	LAP3	chr4:17578927-17609590:+	-0.14	-3.8	0.000165	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1008375	chr4:17682834	MED28	chr4:17616273-17629791:+	0.17	3.75	0.000195	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10084714	chr3:20183332	EFHB	chr3:19920968-19988501:-	0.34	4.52	7.71E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs10086778	chr8:10814140	RP1L1	chr8:10463862-10512617:-	-0.3	-3.88	0.000118	Asthma and hay fever	
LGG	cis	1	rs10086872	chr8:10814210	RP1L1	chr8:10463862-10512617:-	-0.26	-3.46	0.000587	Asthma and hay fever	
LGG	cis	1	rs10088139	chr8:27740661	CCDC25	chr8:27590835-27630170:-	-0.18	-3.51	0.000487	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
LGG	cis	1	rs10088439	chr8:8576699	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.79	2.23E-6	Obesity-related traits	
LGG	cis	1	rs10088835	chr8:27740523	CCDC25	chr8:27590835-27630170:-	-0.18	-3.51	0.000487	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
LGG	cis	1	rs1009051	chr3:49521549	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.14	4.02E-5	Menarche (age at onset)	
LGG	cis	1	rs1009051	chr3:49521549	GMPPB	chr3:49758932-49761384:-	-0.22	-4.34	1.71E-5	Menarche (age at onset)	
LGG	cis	1	rs1009051	chr3:49521549	NCKIPSD	chr3:48711280-48723334:-	0.15	3.49	0.00052	Menarche (age at onset)	
LGG	cis	1	rs10095261	chr8:10815377	RP1L1	chr8:10463862-10512617:-	-0.26	-3.47	0.000575	Asthma and hay fever	
LGG	cis	1	rs10095390	chr8:10815515	RP1L1	chr8:10463862-10512617:-	-0.27	-3.56	0.000401	Asthma and hay fever	
LGG	cis	1	rs10095733	chr8:8574646	FLJ10661	chr8:8086092-8102386:+	-0.27	-5	8.11E-7	Obesity-related traits	
LGG	cis	1	rs10098234	chr8:8576692	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.82	1.93E-6	Obesity-related traits	
LGG	cis	1	rs1009977	chr14:55603002	FBXO34	chr14:55738021-55893431:+	0.13	4.06	5.66E-5	Protein biomarker	
LGG	cis	1	rs1010181	chr7:118160303	ANKRD7	chr7:117864712-117882782:+	0.21	3.68	0.000261	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs1010254	chr5:151734109	NMUR2	chr5:151771102-151784840:-	-0.25	-4.23	2.79E-5	Optic nerve measurement (cup area)	
LGG	cis	1	rs10103507	chr8:27740693	CCDC25	chr8:27590835-27630170:-	-0.18	-3.51	0.000487	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
LGG	cis	1	rs10103769	chr8:8573036	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.01	7.51E-7	Obesity-related traits	
LGG	cis	1	rs10107591	chr8:10812785	RP1L1	chr8:10463862-10512617:-	-0.29	-3.7	0.000243	Asthma and hay fever	
LGG	cis	1	rs1011054	chr4:120202387	MYOZ2	chr4:120056939-120108935:+	-0.19	-3.58	0.000378	Corneal astigmatism	
LGG	cis	1	rs10110591	chr8:8576608	FLJ10661	chr8:8086092-8102386:+	0.25	4.56	6.38E-6	Obesity-related traits	
LGG	cis	1	rs10117059	chr9:123653477	LOC253039	chr9:123605320-123616644:+	-0.66	-11.85	1.11E-28	Rheumatoid arthritis	
LGG	cis	1	rs10117059	chr9:123653477	PSMD5	chr9:123578334-123605206:-	-0.35	-6.51	1.86E-10	Rheumatoid arthritis	
LGG	cis	1	rs10117059	chr9:123653477	TRAF1	chr9:123664672-123691479:-	0.18	4	7.27E-5	Rheumatoid arthritis	
LGG	cis	1	rs10118617	chr9:99550469	FAM22G	chr9:99690592-99704572:+	0.57	4.59	5.51E-6	Height	
LGG	cis	1	rs10119803	chr9:21666066	KLHL9	chr9:21324054-21335429:-	-0.21	-4.19	3.35E-5	Gut microbiome composition (winter)	
LGG	cis	1	rs10121901	chr9:107553524	NIPSNAP3B	chr9:107526451-107553175:+	0.46	8.59	1.17E-16	Gout	
LGG	cis	1	rs10124033	chr9:99614104	FAM22G	chr9:99690592-99704572:+	-0.82	-6.19	1.25E-9	Height	
LGG	cis	1	rs10124033	chr9:99614104	HIATL2	chr9:99695549-99775862:-	-0.43	-3.47	0.000575	Height	
LGG	cis	1	rs10127539	chr1:110620117	ALX3	chr1:110602998-110613322:-	-0.26	-5.97	4.66E-9	Blood metabolite levels	
LGG	cis	1	rs10127539	chr1:110620117	FAM40A	chr1:110574199-110597424:+	0.11	4.02	6.78E-5	Blood metabolite levels	
LGG	cis	1	rs10128658	chr11:71733519	FAM86C	chr11:71498557-71512276:+	0.5	4.88	1.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1013338	chr22:38974154	LOC646851	chr22:38974125-39052634:-	0.25	7.67	9.06E-14	Resting heart rate	
LGG	cis	1	rs10134944	chr14:58119196	ARID4A	chr14:58765222-58840448:+	-0.19	-3.52	0.000463	Bipolar disorder	
LGG	cis	1	rs10134944	chr14:58119196	EXOC5	chr14:57669196-57735617:-	-0.22	-3.64	0.000302	Bipolar disorder	
LGG	cis	1	rs10134944	chr14:58119196	KIAA0586	chr14:58894120-59015548:+	-0.23	-4.17	3.59E-5	Bipolar disorder	
LGG	cis	1	rs10134944	chr14:58119196	MUDENG	chr14:57735606-57756796:+	-0.27	-4.31	2.01E-5	Bipolar disorder	
LGG	cis	1	rs10134944	chr14:58119196	PSMA3	chr14:58711593-58738726:+	-0.23	-3.69	0.000245	Bipolar disorder	
LGG	cis	1	rs10134944	chr14:58119196	TIMM9	chr14:58875371-58894232:-	-0.27	-4.24	2.72E-5	Bipolar disorder	
LGG	cis	1	rs10135	chr22:39082174	LOC646851	chr22:38974125-39052634:-	-0.22	-6.95	1.19E-11	Resting heart rate	
LGG	cis	1	rs10136440	chr14:104397367	TDRD9	chr14:104394817-104519002:+	-0.24	-4.72	3.03E-6	Bipolar disorder	
LGG	cis	1	rs10136947	chr14:65854611	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10136948	chr14:75511075	ACYP1	chr14:75519930-75530736:-	-0.13	-3.52	0.000472	Height	
LGG	cis	1	rs10136948	chr14:75511075	EIF2B2	chr14:75469612-75476292:+	0.19	3.64	0.000301	Height	
LGG	cis	1	rs10136948	chr14:75511075	MLH3	chr14:75480467-75518235:-	0.21	3.6	0.000355	Height	
LGG	cis	1	rs10136953	chr14:65854676	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs10137323	chr14:76685733	ESRRB	chr14:76837690-76968178:+	-0.43	-6.52	1.76E-10	Blood pressure	
LGG	cis	1	rs10138183	chr14:75615227	ACYP1	chr14:75519930-75530736:-	-0.14	-3.82	0.000151	Height	
LGG	cis	1	rs10138183	chr14:75615227	EIF2B2	chr14:75469612-75476292:+	0.2	3.94	9.44E-5	Height	
LGG	cis	1	rs10138183	chr14:75615227	MLH3	chr14:75480467-75518235:-	0.2	3.54	0.000433	Height	
LGG	cis	1	rs10138765	chr14:65860239	LOC645431	chr14:65877313-65879335:-	-0.49	-6.76	3.96E-11	Ischemic stroke	
LGG	cis	1	rs1013885	chr7:105533385	CDHR3	chr7:105517264-105676876:+	0.22	5.22	2.67E-7	Obesity-related traits	
LGG	cis	1	rs10138868	chr14:81776770	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs10140433	chr14:74659989	C14orf45	chr14:74486059-74549566:+	-0.14	-3.72	0.000218	Common traits (Other)	
LGG	cis	1	rs10140433	chr14:74659989	LIN52	chr14:74551656-74667117:+	-0.49	-11.21	3.93E-26	Common traits (Other)	
LGG	cis	1	rs10140851	chr14:75512612	EIF2B2	chr14:75469612-75476292:+	0.19	3.71	0.000227	Height	
LGG	cis	1	rs10140851	chr14:75512612	MLH3	chr14:75480467-75518235:-	0.21	3.54	0.000438	Height	
LGG	cis	1	rs10140857	chr14:55619611	FBXO34	chr14:55738021-55893431:+	0.13	4.02	6.69E-5	Protein biomarker	
LGG	cis	1	rs1014098	chr1:119458215	WARS2	chr1:119573841-119683295:-	-0.22	-4.31	1.96E-5	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs10142626	chr14:75555636	ACYP1	chr14:75519930-75530736:-	-0.14	-3.82	0.000151	Height	
LGG	cis	1	rs10142626	chr14:75555636	EIF2B2	chr14:75469612-75476292:+	0.18	3.51	0.000482	Height	
LGG	cis	1	rs10142626	chr14:75555636	MLH3	chr14:75480467-75518235:-	0.2	3.5	0.000507	Height	
LGG	cis	1	rs1014268	chr7:118035388	ANKRD7	chr7:117864712-117882782:+	-0.23	-3.94	9.5E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10142865	chr14:75555624	ACYP1	chr14:75519930-75530736:-	-0.14	-3.82	0.000151	Height	
LGG	cis	1	rs10142865	chr14:75555624	EIF2B2	chr14:75469612-75476292:+	0.18	3.51	0.000482	Height	
LGG	cis	1	rs10142865	chr14:75555624	MLH3	chr14:75480467-75518235:-	0.2	3.5	0.000507	Height	
LGG	cis	1	rs10143132	chr14:75525850	EIF2B2	chr14:75469612-75476292:+	0.19	3.67	0.000269	Height	
LGG	cis	1	rs10143132	chr14:75525850	MLH3	chr14:75480467-75518235:-	0.21	3.59	0.00037	Height	
LGG	cis	1	rs10144220	chr14:74647904	C14orf45	chr14:74486059-74549566:+	-0.13	-3.57	0.000399	Common traits (Other)	
LGG	cis	1	rs10144220	chr14:74647904	LIN52	chr14:74551656-74667117:+	-0.48	-11.09	1.15E-25	Common traits (Other)	
LGG	cis	1	rs10146374	chr14:65857412	LOC645431	chr14:65877313-65879335:-	-0.43	-6.08	2.35E-9	Ischemic stroke	
LGG	cis	1	rs10146482	chr14:75574087	ACYP1	chr14:75519930-75530736:-	-0.15	-3.91	0.000103	Height	
LGG	cis	1	rs10149435	chr14:55627489	FBXO34	chr14:55738021-55893431:+	0.15	4.55	6.85E-6	Protein biomarker	
LGG	cis	1	rs10149489	chr14:81776403	STON2	chr14:81727000-81893748:-	-0.14	-3.56	0.000404	Obesity-related traits	
LGG	cis	1	rs10149651	chr14:104394440	TDRD9	chr14:104394817-104519002:+	-0.23	-4.55	6.75E-6	Bipolar disorder	
LGG	cis	1	rs10149880	chr14:75633008	ACYP1	chr14:75519930-75530736:-	0.14	3.73	0.000212	Height	
LGG	cis	1	rs10149880	chr14:75633008	EIF2B2	chr14:75469612-75476292:+	-0.22	-4.34	1.71E-5	Height	
LGG	cis	1	rs10149880	chr14:75633008	MLH3	chr14:75480467-75518235:-	-0.22	-3.71	0.000233	Height	
LGG	cis	1	rs10150201	chr14:74649157	C14orf45	chr14:74486059-74549566:+	-0.14	-3.87	0.000121	Common traits (Other)	
LGG	cis	1	rs10150201	chr14:74649157	LIN52	chr14:74551656-74667117:+	-0.48	-11.14	7.54E-26	Common traits (Other)	
LGG	cis	1	rs10153800	chr2:242179134	SEPT2	chr2:242254723-242293439:+	-0.21	-4.18	3.48E-5	Chronic lymphocytic leukemia	
LGG	cis	1	rs1015424	chr7:118172840	ANKRD7	chr7:117864712-117882782:+	0.21	3.74	0.000202	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10155014	chr3:49432321	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.2	3.13E-5	Menarche (age at onset)	
LGG	cis	1	rs10155014	chr3:49432321	GMPPB	chr3:49758932-49761384:-	-0.22	-4.34	1.72E-5	Menarche (age at onset)	
LGG	cis	1	rs10155014	chr3:49432321	NCKIPSD	chr3:48711280-48723334:-	0.15	3.47	0.000557	Menarche (age at onset)	
LGG	cis	1	rs10155014	chr3:49432321	TREX1	chr3:48501186-48509043:+	-0.25	-5.27	2.08E-7	Menarche (age at onset)	
LGG	cis	1	rs10155600	chr5:115620107	COMMD10	chr5:115420727-115628978:+	0.38	4.96	9.64E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.27	-7.47	3.6E-13	Homocysteine levels	
LGG	cis	1	rs10157597	chr1:45990278	MMACHC	chr1:45965856-45976737:+	0.26	5.57	4.24E-8	Homocysteine levels	
LGG	cis	1	rs10157597	chr1:45990278	MUTYH	chr1:45794915-45806142:-	0.13	4.4	1.32E-5	Homocysteine levels	
LGG	cis	1	rs10158100	chr1:202394199	UBE2T	chr1:202300786-202311094:-	-0.14	-4.16	3.73E-5	Sex ratio	
LGG	cis	1	rs10158107	chr1:202394315	UBE2T	chr1:202300786-202311094:-	-0.13	-3.99	7.74E-5	Sex ratio	
LGG	cis	1	rs10159280	chr1:202394287	UBE2T	chr1:202300786-202311094:-	-0.13	-4.11	4.55E-5	Sex ratio	
LGG	cis	1	rs10160639	chr11:69999122	FADD	chr11:70049269-70053508:+	0.14	3.72	0.000221	Survival in rectal cancer	
LGG	cis	1	rs10160719	chr11:70000259	FADD	chr11:70049269-70053508:+	0.14	3.74	0.000203	Survival in rectal cancer	
LGG	cis	1	rs10162376	chr14:81030493	SEL1L	chr14:81939240-82000205:-	0.29	4.65	4.19E-6	Mild influenza (H1N1) infection	
LGG	cis	1	rs10164319	chr19:18569833	LRRC25	chr19:18501955-18508421:-	-0.17	-5.89	7.18E-9	Breast cancer	
LGG	cis	1	rs10164323	chr19:18569492	LRRC25	chr19:18501955-18508421:-	-0.16	-5.74	1.7E-8	Breast cancer	
LGG	cis	1	rs10165098	chr2:27796526	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs10165098	chr2:27796526	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs10165485	chr2:54481636	C2orf73	chr2:54558071-54588714:+	0.33	4.76	2.6E-6	Telomere length	
LGG	cis	1	rs10165485	chr2:54481636	TSPYL6	chr2:54480315-54483409:-	-0.44	-5.3	1.73E-7	Telomere length	
LGG	cis	1	rs10165561	chr2:234172915	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.14	4.09E-5	Crohn's disease	
LGG	cis	1	rs1016669	chr3:41894440	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs1016799	chr2:179749332	CCDC141	chr2:179697347-179914786:-	-0.34	-5.13	4.09E-7	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.41	7.22	2.04E-12	Metabolite levels	
LGG	cis	1	rs10169714	chr2:73808773	NAT8	chr2:73867850-73869537:-	0.27	4.41	1.24E-5	Metabolite levels	
LGG	cis	1	rs10170359	chr2:26272219	GPR113	chr2:26531041-26569685:-	-0.23	-3.64	0.000307	Gut microbiome composition (summer)	
LGG	cis	1	rs10171447	chr2:179747390	CCDC141	chr2:179697347-179914786:-	-0.29	-4.7	3.33E-6	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs1017302	chr12:9367402	LOC642846	chr12:9436253-9466684:+	0.31	6.12	1.88E-9	Non-alcoholic fatty liver disease histology (AST)	
LGG	cis	1	rs10173081	chr2:102957348	IL18R1	chr2:102927962-103015215:+	-0.49	-6.63	8.73E-11	Asthma	
LGG	cis	1	rs10173081	chr2:102957348	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.92	9.91E-5	Asthma	
LGG	cis	1	rs10173181	chr2:17780733	GEN1	chr2:17935162-17966632:+	0.31	4.65	4.33E-6	Psychosis and Alzheimer's disease	
LGG	cis	1	rs10173181	chr2:17780733	SMC6	chr2:17845080-17981462:-	0.27	3.7	0.000239	Psychosis and Alzheimer's disease	
LGG	cis	1	rs10174456	chr2:188198652	CALCRL	chr2:188207851-188313021:-	-0.21	-5.17	3.35E-7	Coronary heart disease	
LGG	cis	1	rs10174942	chr2:188143075	CALCRL	chr2:188207851-188313021:-	-0.21	-5.15	3.87E-7	Coronary heart disease	
LGG	cis	1	rs10175064	chr2:25117537	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs10175180	chr2:73673123	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.61E-12	Metabolite levels	
LGG	cis	1	rs10175180	chr2:73673123	NAT8	chr2:73867850-73869537:-	0.27	4.47	9.87E-6	Metabolite levels	
LGG	cis	1	rs10177970	chr2:37512968	CEBPZ	chr2:37428778-37458740:-	0.18	4.84	1.75E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.45	8.01	8.13E-15	Urinary metabolites	
LGG	cis	1	rs10178409	chr2:73855507	MRPL53	chr2:74699110-74699923:-	0.14	3.46	0.00058	Urinary metabolites	
LGG	cis	1	rs10178409	chr2:73855507	NAT8	chr2:73867850-73869537:-	0.31	5.01	7.69E-7	Urinary metabolites	
LGG	cis	1	rs10178975	chr2:37514564	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.88	1.45E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs10178982	chr2:202227640	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.94	9.34E-5	Basal cell carcinoma	
LGG	cis	1	rs10178982	chr2:202227640	ALS2CR4	chr2:202484907-202508224:-	0.19	5.04	6.49E-7	Basal cell carcinoma	
LGG	cis	1	rs10178982	chr2:202227640	PPIL3	chr2:201735680-201753999:-	-0.2	-4.13	4.18E-5	Basal cell carcinoma	
LGG	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.4	7.07	5.4E-12	Metabolite levels	
LGG	cis	1	rs10179134	chr2:73637519	NAT8	chr2:73867850-73869537:-	0.26	4.2	3.17E-5	Metabolite levels	
LGG	cis	1	rs10179458	chr2:102934974	IL18R1	chr2:102927962-103015215:+	-0.5	-6.8	2.98E-11	Asthma	
LGG	cis	1	rs10179458	chr2:102934974	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.96	8.6E-5	Asthma	
LGG	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.51	10.62	7.74E-24	Response to antipsychotic treatment	
LGG	cis	1	rs10182857	chr2:26344411	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs10183486	chr2:171990971	GAD1	chr2:171673200-171717657:+	0.16	3.73	0.00021	Menopause (age at onset)	
LGG	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.4	7.13	3.7E-12	Metabolite levels	
LGG	cis	1	rs10184268	chr2:73627044	NAT8	chr2:73867850-73869537:-	0.28	4.59	5.7E-6	Metabolite levels	
LGG	cis	1	rs10185007	chr2:166893634	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs10185007	chr2:166893634	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs10186501	chr2:73697844	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.61E-12	Metabolite levels	
LGG	cis	1	rs10186501	chr2:73697844	NAT8	chr2:73867850-73869537:-	0.27	4.47	9.87E-6	Metabolite levels	
LGG	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.39	6.97	1.06E-11	Metabolite levels	
LGG	cis	1	rs10187192	chr2:73713500	NAT8	chr2:73867850-73869537:-	0.26	4.29	2.18E-5	Metabolite levels	
LGG	cis	1	rs10187264	chr2:53727267	ASB3	chr2:53897118-54087170:-	-0.25	-3.46	0.000589	Bulimia nervosa	
LGG	cis	1	rs10187416	chr2:73713741	ALMS1P	chr2:73872046-73912692:+	0.39	7.15	3.18E-12	Metabolite levels	
LGG	cis	1	rs10187416	chr2:73713741	NAT8	chr2:73867850-73869537:-	0.28	4.64	4.44E-6	Metabolite levels	
LGG	cis	1	rs10188003	chr2:66773469	MEIS1	chr2:66662532-66799890:+	0.19	4.26	2.46E-5	PR interval	
LGG	cis	1	rs10189154	chr2:102937544	IL18R1	chr2:102927962-103015215:+	-0.5	-6.85	2.16E-11	Asthma	
LGG	cis	1	rs10189154	chr2:102937544	IL1R1	chr2:102686836-102796333:+	-0.2	-3.5	0.000506	Asthma	
LGG	cis	1	rs10189154	chr2:102937544	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.99	7.77E-5	Asthma	
LGG	cis	1	rs10189526	chr2:102937883	IL18R1	chr2:102927962-103015215:+	-0.5	-6.85	2.16E-11	Asthma	
LGG	cis	1	rs10189526	chr2:102937883	IL1R1	chr2:102686836-102796333:+	-0.2	-3.5	0.000506	Asthma	
LGG	cis	1	rs10189526	chr2:102937883	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.99	7.77E-5	Asthma	
LGG	cis	1	rs10189574	chr2:73698518	ALMS1P	chr2:73872046-73912692:+	0.39	7.08	4.9E-12	Metabolite levels	
LGG	cis	1	rs10189574	chr2:73698518	NAT8	chr2:73867850-73869537:-	0.27	4.51	7.98E-6	Metabolite levels	
LGG	cis	1	rs10189996	chr2:240908800	NDUFA10	chr2:240900158-240964798:-	0.43	8.25	1.49E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.4	7.09	4.75E-12	Metabolite levels	
LGG	cis	1	rs10190219	chr2:73658331	NAT8	chr2:73867850-73869537:-	0.25	4	7.46E-5	Metabolite levels	
LGG	cis	1	rs10191833	chr2:188171337	CALCRL	chr2:188207851-188313021:-	-0.21	-5.17	3.35E-7	Coronary heart disease	
LGG	cis	1	rs1019301	chr7:33272922	BBS9	chr7:33169152-33645680:+	0.43	5.8	1.17E-8	Smooth-surface caries	
LGG	cis	1	rs10193261	chr2:47239142	MCFD2	chr2:47129017-47168878:-	-0.25	-3.95	8.85E-5	Response to statin therapy	
LGG	cis	1	rs10193373	chr2:281886	FAM150B	chr2:279563-288308:-	-0.34	-6.4	3.56E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs10193373	chr2:281886	SNTG2	chr2:946555-1371382:+	0.21	3.78	0.000175	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs10193610	chr2:240940618	NDUFA10	chr2:240900158-240964798:-	0.43	8.18	2.47E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs10193972	chr2:73717656	ALMS1P	chr2:73872046-73912692:+	0.4	7.16	3.01E-12	Metabolite levels	
LGG	cis	1	rs10193972	chr2:73717656	NAT8	chr2:73867850-73869537:-	0.28	4.58	6.03E-6	Metabolite levels	
LGG	cis	1	rs10194115	chr2:47240012	MCFD2	chr2:47129017-47168878:-	-0.25	-3.94	9.32E-5	Response to statin therapy	
LGG	cis	1	rs10196993	chr2:47240485	MCFD2	chr2:47129017-47168878:-	-0.25	-3.9	0.000108	Response to statin therapy	
LGG	cis	1	rs1019722	chr2:166896362	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1019722	chr2:166896362	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1019724	chr2:166895725	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1019724	chr2:166895725	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs10197284	chr2:102982703	IL18R1	chr2:102927962-103015215:+	-0.36	-5.6	3.54E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs10197284	chr2:102982703	IL1RL1	chr2:102927962-102968497:+	-0.34	-4.86	1.59E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs10197480	chr2:230521253	DNER	chr2:230222346-230579286:-	0.28	6.22	1.06E-9	Type 2 diabetes	
LGG	cis	1	rs10202478	chr2:26276049	GPR113	chr2:26531041-26569685:-	-0.23	-3.64	0.000299	Gut microbiome composition (summer)	
LGG	cis	1	rs10205364	chr2:27794233	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs10205364	chr2:27794233	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs10205487	chr2:70151471	SNRNP27	chr2:70121090-70132348:+	0.21	4.64	4.45E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs10206231	chr2:202229225	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.82	0.000148	Basal cell carcinoma	
LGG	cis	1	rs10206231	chr2:202229225	ALS2CR4	chr2:202484907-202508224:-	0.19	4.89	1.35E-6	Basal cell carcinoma	
LGG	cis	1	rs10206231	chr2:202229225	PPIL3	chr2:201735680-201753999:-	-0.21	-4.31	1.96E-5	Basal cell carcinoma	
LGG	cis	1	rs10206993	chr2:240900919	NDUFA10	chr2:240900158-240964798:-	0.42	8.19	2.32E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.4	7.17	2.74E-12	Metabolite levels	
LGG	cis	1	rs10207220	chr2:73785046	NAT8	chr2:73867850-73869537:-	0.27	4.31	1.94E-5	Metabolite levels	
LGG	cis	1	rs10207698	chr2:25117672	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs10208155	chr2:61115039	AHSA2	chr2:61404553-61414058:+	-0.25	-6.5	1.98E-10	Inflammatory skin disease	
LGG	cis	1	rs10208155	chr2:61115039	C2orf74	chr2:61372243-61391964:+	0.31	5.28	1.95E-7	Inflammatory skin disease	
LGG	cis	1	rs10209620	chr2:61173941	AHSA2	chr2:61404553-61414058:+	-0.23	-5.93	5.74E-9	Inflammatory skin disease	
LGG	cis	1	rs10209620	chr2:61173941	C2orf74	chr2:61372243-61391964:+	0.33	5.59	3.78E-8	Inflammatory skin disease	
LGG	cis	1	rs10209928	chr2:108863898	SULT1C2	chr2:108905095-108926370:+	0.6	9.55	5.97E-20	Blood pressure	
LGG	cis	1	rs10209928	chr2:108863898	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.21	3.08E-5	Blood pressure	
LGG	cis	1	rs10212536	chr3:41827026	ULK4	chr3:41288091-42003660:-	0.75	14.49	7.11E-40	Diastolic blood pressure	
LGG	cis	1	rs10214634	chr6:26564582	BTN2A3	chr6:26422317-26431927:+	0.13	3.71	0.00023	Educational attainment	
LGG	cis	1	rs10214634	chr6:26564582	HMGN4	chr6:26538572-26547162:+	-0.18	-4.61	5.11E-6	Educational attainment	
LGG	cis	1	rs10215453	chr7:77488678	PTPN12	chr7:77166773-77269388:+	-0.18	-3.96	8.56E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs10215948	chr7:65747786	ASL	chr7:65540776-65558321:+	0.22	5.49	6.53E-8	Aortic root size	
LGG	cis	1	rs10216533	chr8:143763690	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10216533	chr8:143763690	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10216533	chr8:143763690	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10218795	chr1:145416056	GNRHR2	chr1:145509753-145516076:-	-0.46	-5.29	1.85E-7	Coronary heart disease	
LGG	cis	1	rs10218795	chr1:145416056	NBPF10	chr1:144201705-146424095:+	0.35	4.06	5.72E-5	Coronary heart disease	
LGG	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	0.68	6.39	3.86E-10	Coronary heart disease	
LGG	cis	1	rs10220371	chr14:88501852	EML5	chr14:89081205-89259157:-	0.3	4.74	2.78E-6	Multiple sclerosis	
LGG	cis	1	rs10220371	chr14:88501852	SPATA7	chr14:88852012-88904802:+	0.35	4.54	7.01E-6	Multiple sclerosis	
LGG	cis	1	rs10220371	chr14:88501852	TTC8	chr14:89290497-89344334:+	0.42	5.67	2.4E-8	Multiple sclerosis	
LGG	cis	1	rs10220371	chr14:88501852	ZC3H14	chr14:89029253-89079852:+	0.29	4.23	2.76E-5	Multiple sclerosis	
LGG	cis	1	rs1022687	chr20:47648854	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.09	5.12E-5	Anger	
LGG	cis	1	rs1022687	chr20:47648854	CSE1L	chr20:47662838-47713484:+	-0.18	-5	7.98E-7	Anger	
LGG	cis	1	rs10229552	chr7:99234899	CYP3A5	chr7:99245818-99332821:-	0.36	3.66	0.00028	Blood metabolite levels	
LGG	cis	1	rs10233560	chr7:1885415	FTSJ2	chr7:2273928-2281833:-	0.19	4.18	3.51E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs10234018	chr7:66146284	ASL	chr7:65540776-65558321:+	0.18	4.45	1.08E-5	Aortic root size	
LGG	cis	1	rs10234018	chr7:66146284	TYW1	chr7:66461817-66704496:+	-0.17	-3.59	0.000369	Aortic root size	
LGG	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.45	8.75	3.33E-17	Paget's disease	
LGG	cis	1	rs10234309	chr7:135311167	SLC13A4	chr7:135365993-135412933:-	-0.37	-5.29	1.84E-7	Paget's disease	
LGG	cis	1	rs10238070	chr7:23909791	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.84E-5	Schizophrenia	
LGG	cis	1	rs1024037	chr3:47318449	NRADDP	chr3:47053032-47054957:+	0.22	3.8	0.000161	Colorectal cancer	
LGG	cis	1	rs10240648	chr7:118083471	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.88	0.000117	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10242455	chr7:99240179	CYP3A5	chr7:99245818-99332821:-	-0.43	-4.29	2.19E-5	Blood metabolite levels	
LGG	cis	1	rs10244498	chr7:66116056	ASL	chr7:65540776-65558321:+	-0.2	-5.11	4.6E-7	Aortic root size	
LGG	cis	1	rs1024460	chr7:118000843	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10245161	chr7:23907692	C7orf46	chr7:23719749-23742268:+	0.2	4.21	2.98E-5	Schizophrenia	
LGG	cis	1	rs10247443	chr7:50620586	FIGNL1	chr7:50511834-50518088:-	-0.21	-5	8.1E-7	Malaria	
LGG	cis	1	rs10247526	chr7:65780696	CCT6P1	chr7:65216092-65228661:+	-0.23	-4.17	3.55E-5	Diabetic kidney disease	
LGG	cis	1	rs10248619	chr7:50751090	FIGNL1	chr7:50511834-50518088:-	0.19	4.05	5.98E-5	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs10250513	chr7:50621488	FIGNL1	chr7:50511834-50518088:-	-0.21	-5.14	4.03E-7	Malaria	
LGG	cis	1	rs10252662	chr7:44811223	PPIA	chr7:44836241-44842715:+	0.19	4.82	1.91E-6	Educational attainment (years of education)	
LGG	cis	1	rs1025317	chr16:77335213	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.26	2.49E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs1025646	chr3:41754422	ULK4	chr3:41288091-42003660:-	0.71	12.92	4.55E-33	Diastolic blood pressure	
LGG	cis	1	rs10256972	chr7:1039003	GPR146	chr7:1084243-1098897:+	-0.17	-3.56	0.000401	Longevity;Endometriosis	
LGG	cis	1	rs10257427	chr7:65743208	ASL	chr7:65540776-65558321:+	0.22	5.49	6.53E-8	Aortic root size	
LGG	cis	1	rs10257777	chr7:23910981	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.78E-5	Schizophrenia	
LGG	cis	1	rs10260585	chr7:1889521	FTSJ2	chr7:2273928-2281833:-	0.22	4.86	1.6E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs10262624	chr7:23915676	C7orf46	chr7:23719749-23742268:+	0.2	4.24	2.62E-5	Schizophrenia	
LGG	cis	1	rs10269945	chr7:33216690	BBS9	chr7:33169152-33645680:+	0.43	5.75	1.6E-8	Smooth-surface caries	
LGG	cis	1	rs1027087	chr12:26470850	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.37	1.5E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs10274773	chr7:66133578	ASL	chr7:65540776-65558321:+	0.19	4.95	1.01E-6	Aortic root size	
LGG	cis	1	rs10274773	chr7:66133578	TYW1	chr7:66461817-66704496:+	-0.17	-3.57	0.000393	Aortic root size	
LGG	cis	1	rs10274959	chr7:33218314	BBS9	chr7:33169152-33645680:+	0.43	5.75	1.6E-8	Smooth-surface caries	
LGG	cis	1	rs10279537	chr7:77474961	PTPN12	chr7:77166773-77269388:+	-0.2	-4.34	1.73E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs1029406	chr11:2309580	C11orf21	chr11:2317507-2323143:-	-0.31	-4.09	4.94E-5	Obesity-related traits	
LGG	cis	1	rs1029407	chr11:2309582	C11orf21	chr11:2317507-2323143:-	-0.31	-4.09	4.94E-5	Obesity-related traits	
LGG	cis	1	rs1029408	chr11:2309855	C11orf21	chr11:2317507-2323143:-	-0.34	-4.36	1.62E-5	Obesity-related traits	
LGG	cis	1	rs1029740	chr7:22873586	NUPL2	chr7:23221446-23240629:+	0.15	3.5	0.000513	Fibrinogen	
LGG	cis	1	rs1030136	chr2:190735660	ORMDL1	chr2:190634994-190649097:-	0.35	5.25	2.32E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs1030420	chr8:67360725	ADHFE1	chr8:67344718-67381042:+	-0.32	-7.85	2.67E-14	Blood metabolite levels	
LGG	cis	1	rs1030730	chr2:26284143	GPR113	chr2:26531041-26569685:-	-0.22	-3.49	0.000522	Gut microbiome composition (summer)	
LGG	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.55	-9.26	6.5E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1032094	chr8:21820479	XPO7	chr8:21777180-21864095:+	0.16	3.52	0.00047	Mean corpuscular volume	
LGG	cis	1	rs1032524	chr1:201790826	LMOD1	chr1:201865585-201915716:-	0.2	4.32	1.92E-5	Body mass index	
LGG	cis	1	rs1032524	chr1:201790826	SHISA4	chr1:201858032-201861426:+	0.3	7.58	1.77E-13	Body mass index	
LGG	cis	1	rs1033299	chr2:17774153	GEN1	chr2:17935162-17966632:+	0.26	4.2	3.23E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs1033301	chr2:17773998	GEN1	chr2:17935162-17966632:+	0.26	4.2	3.23E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs1033665	chr22:50252127	ALG12	chr22:50296856-50312106:-	0.26	5.32	1.59E-7	Schizophrenia	
LGG	cis	1	rs1034219	chr1:93022678	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs1035127	chr2:103019919	IL18R1	chr2:102927962-103015215:+	0.38	6.01	3.7E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1035127	chr2:103019919	IL1RL1	chr2:102927962-102968497:+	0.37	5.32	1.62E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1035142	chr2:202153078	ALS2CR12	chr2:202153148-202222101:-	-0.35	-7.23	1.88E-12	Melanoma;Esophageal squamous cell carcinoma	
LGG	cis	1	rs1036554	chr2:86236099	LOC90784	chr2:86247339-86250991:-	-0.43	-4.66	4.17E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs1037036	chr17:18764077	FAM18B	chr17:18684582-18710026:+	-0.17	-4.37	1.53E-5	Educational attainment (years of education)	
LGG	cis	1	rs1037036	chr17:18764077	FBXW10	chr17:18647326-18682661:+	-0.21	-4.66	3.99E-6	Educational attainment (years of education)	
LGG	cis	1	rs1037036	chr17:18764077	TRIM16L	chr17:18601311-18639431:+	0.15	3.51	0.000486	Educational attainment (years of education)	
LGG	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1037590	chr17:33902635	PEX12	chr17:33901815-33905656:-	-0.23	-4.08	5.2E-5	Platelet count	
LGG	cis	1	rs1038108	chr17:20921548	USP22	chr17:20902908-20947073:-	-0.2	-4.54	7.0E-6	Blood trace element (Se levels)	
LGG	cis	1	rs1039302	chr12:121236258	SPPL3	chr12:121201036-121342151:-	0.26	3.72	0.000223	Quantitative traits	
LGG	cis	1	rs1039438	chr5:156476770	TIMD4	chr5:156346293-156390266:-	-0.25	-4.47	9.91E-6	Hypertriglyceridemia	
LGG	cis	1	rs1039664	chr7:65449716	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.53E-7	Diabetic kidney disease	
LGG	cis	1	rs10400248	chr11:247029	PSMD13	chr11:236808-252984:+	-0.21	-4.78	2.37E-6	Menarche (age at onset)	
LGG	cis	1	rs10403249	chr19:18604942	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.05E-8	Breast cancer	
LGG	cis	1	rs1040393	chr1:166861596	MAEL	chr1:166958519-166991447:+	0.49	8.45	3.29E-16	Schizophrenia	
LGG	cis	1	rs1040393	chr1:166861596	POGK	chr1:166808724-166823709:+	-0.2	-3.74	0.000208	Schizophrenia	
LGG	cis	1	rs10404211	chr19:33093565	C19orf40	chr19:33463148-33467955:+	0.23	3.9	0.000108	Eosinophilic esophagitis	
LGG	cis	1	rs10404211	chr19:33093565	PDCD5	chr19:33072104-33078322:+	-0.19	-4.3	2.08E-5	Eosinophilic esophagitis	
LGG	cis	1	rs10405382	chr19:32896716	ZNF507	chr19:32836514-32878571:+	0.13	3.8	0.000164	Bipolar disorder	
LGG	cis	1	rs10405636	chr19:18538742	LRRC25	chr19:18501955-18508421:-	-0.16	-5.72	1.82E-8	Breast cancer	
LGG	cis	1	rs10406750	chr19:33097144	C19orf40	chr19:33463148-33467955:+	0.22	3.95	8.91E-5	Eosinophilic esophagitis	
LGG	cis	1	rs10406750	chr19:33097144	PDCD5	chr19:33072104-33078322:+	-0.16	-3.75	0.000199	Eosinophilic esophagitis	
LGG	cis	1	rs10407204	chr19:33097353	C19orf40	chr19:33463148-33467955:+	0.21	3.87	0.000126	Eosinophilic esophagitis	
LGG	cis	1	rs10407204	chr19:33097353	PDCD5	chr19:33072104-33078322:+	-0.16	-3.86	0.000127	Eosinophilic esophagitis	
LGG	cis	1	rs1040726	chr20:3264267	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs1040727	chr20:3264292	ITPA	chr20:3190056-3204504:+	-0.36	-8.42	4.12E-16	IFN-related cytopenia	
LGG	cis	1	rs10408916	chr19:10447770	ICAM3	chr19:10444452-10450345:-	-0.3	-5.73	1.73E-8	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs10409483	chr19:18590223	LRRC25	chr19:18501955-18508421:-	-0.16	-5.71	1.91E-8	Breast cancer	
LGG	cis	1	rs10409485	chr19:41920765	ATP5SL	chr19:41937224-41945810:-	-0.16	-4.24	2.7E-5	Height	
LGG	cis	1	rs10409485	chr19:41920765	B9D2	chr19:41860322-41870078:-	0.11	3.54	0.000431	Height	
LGG	cis	1	rs10409485	chr19:41920765	EXOSC5	chr19:41892278-41903256:-	0.13	3.88	0.000119	Height	
LGG	cis	1	rs10409505	chr19:18590251	LRRC25	chr19:18501955-18508421:-	-0.16	-5.71	1.91E-8	Breast cancer	
LGG	cis	1	rs10409835	chr19:32888660	ZNF507	chr19:32836514-32878571:+	0.12	3.46	0.000582	Bipolar disorder	
LGG	cis	1	rs10410770	chr19:32902404	DPY19L3	chr19:32896677-32975236:+	0.13	3.51	0.000481	Bipolar disorder	
LGG	cis	1	rs10410770	chr19:32902404	ZNF507	chr19:32836514-32878571:+	0.14	3.71	0.000231	Bipolar disorder	
LGG	cis	1	rs10411009	chr19:18606266	LRRC25	chr19:18501955-18508421:-	-0.16	-5.75	1.61E-8	Breast cancer	
LGG	cis	1	rs10413237	chr19:18548249	LRRC25	chr19:18501955-18508421:-	-0.16	-5.56	4.38E-8	Breast cancer	
LGG	cis	1	rs10415219	chr19:39150235	LGALS4	chr19:39292312-39303740:-	-0.16	-3.85	0.000131	Heart rate	
LGG	cis	1	rs10415744	chr19:32880580	ZNF507	chr19:32836514-32878571:+	0.13	3.56	0.000414	Bipolar disorder	
LGG	cis	1	rs10416600	chr19:18386063	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.37	1.5E-5	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs10417152	chr19:32888900	ZNF507	chr19:32836514-32878571:+	0.13	3.66	0.000282	Bipolar disorder	
LGG	cis	1	rs1041748	chr22:24700854	POM121L9P	chr22:24647589-24661490:+	-0.26	-5.56	4.39E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs10417997	chr19:41902361	ATP5SL	chr19:41937224-41945810:-	0.16	4.69	3.62E-6	Height	
LGG	cis	1	rs10417997	chr19:41902361	EXOSC5	chr19:41892278-41903256:-	-0.11	-3.53	0.000458	Height	
LGG	cis	1	rs10421129	chr19:45695836	GEMIN7	chr19:45582518-45594782:+	-0.12	-3.66	0.000277	Quantitative traits	
LGG	cis	1	rs10421887	chr19:44294849	KCNN4	chr19:44270687-44285409:-	0.2	4.36	1.57E-5	Breast cancer	
LGG	cis	1	rs10421887	chr19:44294849	ZNF404	chr19:44376516-44384288:-	0.16	3.91	0.000107	Breast cancer	
LGG	cis	1	rs10425982	chr19:18586519	LRRC25	chr19:18501955-18508421:-	-0.16	-5.71	1.91E-8	Breast cancer	
LGG	cis	1	rs1042658	chr17:38173902	GSDMA	chr17:38119226-38134019:+	-0.71	-15.37	7.97E-44	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs10427083	chr19:18550276	LRRC25	chr19:18501955-18508421:-	-0.16	-5.69	2.13E-8	Breast cancer	
LGG	cis	1	rs10431058	chr11:107481518	LOC643923	chr11:107462471-107463949:+	0.45	8.75	3.55E-17	Common traits (Other)	
LGG	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.47	11.51	2.66E-27	Multiple sclerosis	
LGG	cis	1	rs10431505	chr12:58178589	TSFM	chr12:58176536-58191367:+	-0.45	-8.62	9.17E-17	Multiple sclerosis	
LGG	cis	1	rs10431505	chr12:58178589	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.48	0.000543	Multiple sclerosis	
LGG	cis	1	rs1043441	chr22:39130964	LOC646851	chr22:38974125-39052634:-	0.24	7.12	3.8E-12	Resting heart rate	
LGG	cis	1	rs1043674	chr14:75549370	ACYP1	chr14:75519930-75530736:-	-0.15	-3.89	0.000116	Height	
LGG	cis	1	rs10438781	chr17:45323819	ITGB3	chr17:45331208-45421658:+	-0.21	-4.29	2.17E-5	Body mass index	
LGG	cis	1	rs10439607	chr20:30258541	BCL2L1	chr20:30252263-30311729:-	0.16	3.47	0.000565	Subcortical brain region volumes	
LGG	cis	1	rs10439607	chr20:30258541	COX4I2	chr20:30225691-30232800:+	0.18	4.23	2.77E-5	Subcortical brain region volumes	
LGG	cis	1	rs10439607	chr20:30258541	DUSP15	chr20:30435441-30458479:-	0.17	4.27	2.39E-5	Subcortical brain region volumes	
LGG	cis	1	rs10439607	chr20:30258541	FRG1B	chr20:29611879-29653908:+	0.24	4.37	1.51E-5	Subcortical brain region volumes	
LGG	cis	1	rs10439608	chr20:30258814	COX4I2	chr20:30225691-30232800:+	0.19	4.31	1.94E-5	Subcortical brain region volumes	
LGG	cis	1	rs10439608	chr20:30258814	DUSP15	chr20:30435441-30458479:-	0.17	4.21	3.03E-5	Subcortical brain region volumes	
LGG	cis	1	rs10439608	chr20:30258814	FRG1B	chr20:29611879-29653908:+	0.21	3.9	0.000109	Subcortical brain region volumes	
LGG	cis	1	rs10442	chr19:18545341	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.04E-8	Breast cancer	
LGG	cis	1	rs1044414	chr17:20904451	USP22	chr17:20902908-20947073:-	-0.2	-4.72	3.08E-6	Blood trace element (Se levels)	
LGG	cis	1	rs1044420	chr17:20903776	USP22	chr17:20902908-20947073:-	-0.21	-4.87	1.5E-6	Blood trace element (Se levels)	
LGG	cis	1	rs10445014	chr16:58160974	C16orf80	chr16:58147497-58163296:-	0.32	3.72	0.000218	Telomere length	
LGG	cis	1	rs10454142	chr2:48646399	GTF2A1L	chr2:48844948-48960284:+	-0.24	-4.28	2.23E-5	Sex hormone-binding globulin levels	
LGG	cis	1	rs10454142	chr2:48646399	KLRAQ1	chr2:48667908-48742524:+	0.2	4.54	7.22E-6	Sex hormone-binding globulin levels	
LGG	cis	1	rs10454142	chr2:48646399	STON1-GTF2A1L	chr2:48796159-48906746:+	-0.23	-4.04	6.33E-5	Sex hormone-binding globulin levels	
LGG	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.5	-10.27	1.46E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1045531	chr8:143763547	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045531	chr8:143763547	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045531	chr8:143763547	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.52	-10.59	9.3E-24	Response to antipsychotic treatment	
LGG	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.51	-10.39	5.52E-23	Response to antipsychotic treatment	
LGG	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.5	-10.27	1.46E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1045547	chr8:143763757	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045547	chr8:143763757	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045547	chr8:143763757	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045574	chr8:143763958	LY6K	chr8:143781529-143785582:+	0.32	6.09	2.25E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045574	chr8:143763958	PSCA	chr8:143761875-143764142:+	0.34	6.02	3.33E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10455861	chr6:160401662	WTAP	chr6:160148129-160177349:+	0.27	3.87	0.000122	Brain lesion load	
LGG	cis	1	rs1045605	chr8:143764101	C8orf55	chr8:143808621-143818350:+	0.17	3.65	0.00029	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045605	chr8:143764101	LY6K	chr8:143781529-143785582:+	0.33	6.35	5.06E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs1045605	chr8:143764101	PSCA	chr8:143761875-143764142:+	0.35	6.12	1.9E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs10456078	chr6:35118075	TCP11	chr6:35085849-35109187:-	-0.35	-5.77	1.43E-8	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs10456362	chr6:28221816	ZNF165	chr6:28046572-28057338:+	0.3	4.44	1.14E-5	Depression	
LGG	cis	1	rs10456362	chr6:28221816	ZNF187	chr6:28234788-28245978:+	0.26	4.52	7.61E-6	Depression	
LGG	cis	1	rs10456362	chr6:28221816	ZNF389	chr6:28129551-28137375:+	-0.4	-6.51	1.82E-10	Depression	
LGG	cis	1	rs10456362	chr6:28221816	ZSCAN12	chr6:28346770-28367544:-	0.3	4.23	2.75E-5	Depression	
LGG	cis	1	rs10456362	chr6:28221816	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.37	1.51E-5	Depression	
LGG	cis	1	rs10456622	chr6:49396453	CENPQ	chr6:49431096-49460820:+	-0.22	-4.91	1.25E-6	Folate pathway vitamin levels	
LGG	cis	1	rs10459230	chr12:48850996	VDR	chr12:48235322-48298814:-	0.22	3.5	0.00051	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs10459866	chr16:77329578	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs10460009	chr18:2948029	MYL12A	chr18:3247528-3256228:+	-0.14	-3.96	8.58E-5	Type 2 diabetes	
LGG	cis	1	rs1046073	chr20:25281333	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1046073	chr20:25281333	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1046073	chr20:25281333	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.82	15.53	1.48E-44	Type 2 diabetes	
LGG	cis	1	rs10463240	chr5:150256853	LOC134466	chr5:150310000-150326146:-	0.42	4.84	1.75E-6	Crohn's disease	
LGG	cis	1	rs10463307	chr5:150254620	LOC134466	chr5:150310000-150326146:-	0.43	4.8	2.12E-6	Crohn's disease	
LGG	cis	1	rs10463310	chr5:150260905	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs10463316	chr5:150746034	FAT2	chr5:150883654-150948505:-	0.25	5.32	1.61E-7	Metabolite levels (Pyroglutamine)	
LGG	cis	1	rs10463316	chr5:150746034	SLC36A1	chr5:150816553-150871939:+	0.16	3.68	0.000259	Metabolite levels (Pyroglutamine)	
LGG	cis	1	rs10465591	chr1:202308344	UBE2T	chr1:202300786-202311094:-	-0.13	-3.81	0.000155	Sex ratio	
LGG	cis	1	rs10465756	chr1:93029698	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs10466624	chr11:130476537	SNX19	chr11:130745767-130786382:-	-0.27	-3.7	0.000237	Urate levels in lean individuals	
LGG	cis	1	rs1046701	chr14:59939804	C14orf149	chr14:59939406-59951126:-	0.54	6.32	5.83E-10	Schizophrenia	
LGG	cis	1	rs10468513	chr17:53062903	STXBP4	chr17:53046126-53241449:+	-0.16	-3.69	0.000251	Breast cancer	
LGG	cis	1	rs10468513	chr17:53062903	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.32	1.56E-7	Breast cancer	
LGG	cis	1	rs1046875	chr17:80685426	FN3KRP	chr17:80674582-80685889:+	0.33	6.87	1.95E-11	Glycated hemoglobin levels	
LGG	cis	1	rs1046896	chr17:80685533	FN3KRP	chr17:80674582-80685889:+	0.35	7.19	2.43E-12	Glycated hemoglobin levels	
LGG	cis	1	rs1046917	chr17:80685655	FN3KRP	chr17:80674582-80685889:+	0.34	6.91	1.48E-11	Glycated hemoglobin levels	
LGG	cis	1	rs10469840	chr2:103093243	IL18R1	chr2:102927962-103015215:+	-0.39	-6.18	1.34E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs10469840	chr2:103093243	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.32	1.62E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs10470686	chr3:48449956	ATRIP	chr3:48488141-48507708:+	0.18	4.42	1.2E-5	Longevity	
LGG	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.42	-10.92	5.51E-25	Longevity	
LGG	cis	1	rs1047171	chr20:25428786	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1047171	chr20:25428786	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1047171	chr20:25428786	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1047206	chr11:64089216	C11orf20	chr11:64067863-64072238:+	-0.31	-4.63	4.72E-6	Mean platelet volume	
LGG	cis	1	rs1047418	chr14:75605792	ACYP1	chr14:75519930-75530736:-	-0.14	-3.72	0.000218	Height	
LGG	cis	1	rs1047418	chr14:75605792	EIF2B2	chr14:75469612-75476292:+	0.19	3.7	0.00024	Height	
LGG	cis	1	rs1047418	chr14:75605792	MLH3	chr14:75480467-75518235:-	0.21	3.55	0.000417	Height	
LGG	cis	1	rs1047556	chr14:55600282	FBXO34	chr14:55738021-55893431:+	0.14	4.34	1.74E-5	Protein biomarker	
LGG	cis	1	rs10478278	chr5:115452758	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10478288	chr5:115505621	COMMD10	chr5:115420727-115628978:+	0.47	5.95	5.04E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs10484442	chr6:26555879	BTN2A3	chr6:26422317-26431927:+	0.13	3.68	0.000263	Educational attainment	
LGG	cis	1	rs10484442	chr6:26555879	HMGN4	chr6:26538572-26547162:+	-0.19	-4.97	9.49E-7	Educational attainment	
LGG	cis	1	rs10485508	chr20:33605098	PROCR	chr20:33758727-33765164:+	-0.33	-5.86	8.28E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs10486406	chr7:25615391	SNX10	chr7:26331515-26413937:+	-0.23	-3.67	0.000264	Preeclampsia	
LGG	cis	1	rs10486523	chr7:33241996	BBS9	chr7:33169152-33645680:+	0.42	5.63	3.09E-8	Smooth-surface caries	
LGG	cis	1	rs10486525	chr7:33320441	BBS9	chr7:33169152-33645680:+	0.47	6.47	2.43E-10	Smooth-surface caries	
LGG	cis	1	rs10486607	chr7:29184489	CPVL	chr7:29035249-29234892:-	-0.23	-4.01	7.05E-5	Diabetes related insulin traits	
LGG	cis	1	rs10487397	chr7:118007961	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10489073	chr4:10272788	SLC2A9	chr4:9827850-10041872:-	0.22	5.19	3.03E-7	Schizophrenia (age at onset)	
LGG	cis	1	rs10490541	chr2:207587173	MDH1B	chr2:207598943-207630050:-	0.34	5.05	6.16E-7	Episodic memory	
LGG	cis	1	rs10490958	chr10:17233450	TRDMT1	chr10:17184983-17243681:-	0.21	4.49	9.08E-6	Homocysteine levels	
LGG	cis	1	rs10494304	chr1:156285764	BGLAP	chr1:156182784-156213112:+	-0.25	-5.26	2.17E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10494304	chr1:156285764	CCT3	chr1:156278752-156308195:-	0.17	4.17	3.62E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10494833	chr1:202467427	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs10494833	chr1:202467427	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.68E-5	Sex ratio	
LGG	cis	1	rs10494874	chr1:205754688	PM20D1	chr1:205797154-205819245:-	-0.46	-7.99	9.91E-15	Prostate-specific antigen levels	
LGG	cis	1	rs10495948	chr2:48144409	FBXO11	chr2:48034061-48132814:-	-0.24	-4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs10496174	chr2:70153436	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.33	1.82E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs10496191	chr2:73673798	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.61E-12	Metabolite levels	
LGG	cis	1	rs10496191	chr2:73673798	NAT8	chr2:73867850-73869537:-	0.27	4.47	9.87E-6	Metabolite levels	
LGG	cis	1	rs10496193	chr2:73773503	ALMS1P	chr2:73872046-73912692:+	0.38	6.65	7.63E-11	Metabolite levels	
LGG	cis	1	rs10496193	chr2:73773503	NAT8	chr2:73867850-73869537:-	0.26	4.29	2.18E-5	Metabolite levels	
LGG	cis	1	rs10498471	chr14:55353717	GCH1	chr14:55308724-55369542:-	-0.29	-4.72	3.08E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.51	10.39	5.52E-23	Response to antipsychotic treatment	
LGG	cis	1	rs10500635	chr11:5386668	FAM160A2	chr11:6232565-6255941:-	0.2	4.06	5.78E-5	Fetal hemoglobin levels	
LGG	cis	1	rs10500636	chr11:5386755	FAM160A2	chr11:6232565-6255941:-	-0.17	-3.51	0.000481	Fetal hemoglobin levels	
LGG	cis	1	rs10501703	chr11:89180884	NOX4	chr11:89057524-89322779:-	0.37	3.94	9.17E-5	Homocysteine levels	
LGG	cis	1	rs10501705	chr11:89188275	NOX4	chr11:89057524-89322779:-	0.37	3.94	9.17E-5	Homocysteine levels	
LGG	cis	1	rs1050274	chr3:186435370	KNG1	chr3:186435120-186461741:+	-0.15	-3.51	0.000489	Adiponectin levels	
LGG	cis	1	rs10503715	chr8:21850687	XPO7	chr8:21777180-21864095:+	0.17	3.9	0.000107	Mean corpuscular volume	
LGG	cis	1	rs10504229	chr8:58196495	C8orf71	chr8:58192102-58197288:+	0.38	6.32	6.05E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs10504554	chr8:74919713	TMEM70	chr8:74888430-74895011:+	0.25	5.21	2.84E-7	Postoperative atrial fibrillation in coronary artery bypass grafting surgery	
LGG	cis	1	rs10507233	chr12:109103684	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs10507380	chr13:27879526	RASL11A	chr13:27844464-27847827:+	0.39	6.35	4.77E-10	Electrocardiographic traits	
LGG	cis	1	rs10508206	chr10:1075777	C10orf110	chr10:1068577-1090141:+	0.3	5.79	1.26E-8	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs10508921	chr10:52010708	FAM21A	chr10:51827684-51893268:+	-0.62	-6.82	2.68E-11	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs10509744	chr10:102271579	HIF1AN	chr10:102295641-102313680:+	0.18	3.5	0.000504	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10509744	chr10:102271579	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.45E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10509744	chr10:102271579	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.21E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10509767	chr10:74045917	DNAJB12	chr10:74092588-74114907:-	-0.14	-3.8	0.000161	Heschl's gyrus morphology	
LGG	cis	1	rs10510110	chr10:124192430	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.25	2.56E-5	Height	
LGG	cis	1	rs10511191	chr3:101645852	CEP97	chr3:101443494-101486181:+	0.12	3.6	0.000352	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs10511191	chr3:101645852	LOC285359	chr3:101431278-101432259:+	-0.22	-4.9	1.33E-6	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs10511775	chr9:26788498	LRRC19	chr9:26993143-27005691:-	-0.23	-3.91	0.000105	Smoking behavior	
LGG	cis	1	rs10512472	chr17:33884804	PEX12	chr17:33901815-33905656:-	-0.24	-4.4	1.3E-5	Platelet count	
LGG	cis	1	rs10514382	chr5:93566534	FAM172A	chr5:92953432-93447404:-	-0.28	-3.59	0.000358	Diabetic retinopathy	
LGG	cis	1	rs10515505	chr5:138313146	SIL1	chr5:138282412-138534065:-	0.14	3.89	0.000114	Age-related hearing impairment (interaction)	
LGG	cis	1	rs10516527	chr4:106734346	GSTCD	chr4:106629941-106768881:+	0.31	3.48	0.000538	Post bronchodilator FEV1	
LGG	cis	1	rs10517025	chr4:42453253	SHISA3	chr4:42399856-42404503:+	0.28	4.4	1.35E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs10518693	chr15:40700022	C15orf23	chr15:40674922-40686488:+	-0.17	-3.51	0.000488	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs10518693	chr15:40700022	DISP2	chr15:40650434-40663256:+	0.18	4.32	1.86E-5	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs10518693	chr15:40700022	IVD	chr15:40697686-40713512:+	0.33	5.91	6.55E-9	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs10519203	chr15:78814046	CHRNA5	chr15:78857906-78886458:+	0.67	13.15	4.63E-34	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1052501	chr3:41925398	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs1054399	chr10:102312565	HIF1AN	chr10:102295641-102313680:+	0.19	3.57	0.000386	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1054399	chr10:102312565	NDUFB8	chr10:102283497-102289636:-	0.17	4.56	6.33E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1054399	chr10:102312565	WNT8B	chr10:102222812-102243397:+	0.48	7.61	1.37E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1055429	chr3:51570508	HEMK1	chr3:50606583-50622419:+	0.2	3.47	0.000559	Melanoma	
LGG	cis	1	rs1056610	chr22:39080078	LOC646851	chr22:38974125-39052634:-	-0.25	-7.72	6.39E-14	Resting heart rate	
LGG	cis	1	rs1056667	chr6:26510564	HMGN4	chr6:26538572-26547162:+	-0.2	-5.15	3.72E-7	Educational attainment	
LGG	cis	1	rs1056801	chr2:242292307	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.39E-10	Prostate cancer	
LGG	cis	1	rs1056964	chr22:51017476	CPT1B	chr22:51007291-51017096:-	-0.34	-6.73	4.77E-11	Narcolepsy	
LGG	cis	1	rs1057027	chr1:159002377	IFI16	chr1:158969758-159024943:+	-0.19	-4.17	3.56E-5	Obesity-related traits	
LGG	cis	1	rs1057028	chr1:159002389	IFI16	chr1:158969758-159024943:+	0.19	4.15	3.94E-5	Obesity-related traits	
LGG	cis	1	rs1058600	chr5:115166713	ATG12	chr5:115165818-115177520:-	0.2	4.36	1.57E-5	IgG glycosylation	
LGG	cis	1	rs1060330	chr3:52288945	GNL3	chr3:52719936-52728508:+	-0.17	-3.67	0.000269	Electroencephalogram traits	
LGG	cis	1	rs1060547	chr16:77316150	ADAMTS18	chr16:77316026-77469011:-	-0.3	-4.27	2.31E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs1062687	chr22:39134715	LOC646851	chr22:38974125-39052634:-	0.25	7.52	2.6E-13	Resting heart rate	
LGG	cis	1	rs1062794	chr20:30381758	BCL2L1	chr20:30252263-30311729:-	0.16	3.62	0.000329	Subcortical brain region volumes	
LGG	cis	1	rs1062794	chr20:30381758	COX4I2	chr20:30225691-30232800:+	0.19	4.35	1.69E-5	Subcortical brain region volumes	
LGG	cis	1	rs1062794	chr20:30381758	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.49E-5	Subcortical brain region volumes	
LGG	cis	1	rs1062794	chr20:30381758	FRG1B	chr20:29611879-29653908:+	0.2	3.78	0.000179	Subcortical brain region volumes	
LGG	cis	1	rs1065201	chr22:39069510	LOC646851	chr22:38974125-39052634:-	0.23	6.87	1.98E-11	Resting heart rate	
LGG	cis	1	rs1067327	chr2:44628529	SLC3A1	chr2:44502597-44547959:+	0.18	4.4	1.36E-5	Anxiety disorder (factor score)	
LGG	cis	1	rs1067352	chr2:44669724	SLC3A1	chr2:44502597-44547959:+	0.19	4.49	9.05E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LGG	cis	1	rs10734259	chr11:18314865	GTF2H1	chr11:18343816-18388590:+	0.41	7.67	9.42E-14	Pancreatic cancer	
LGG	cis	1	rs10734259	chr11:18314865	LDHC	chr11:18433853-18472792:+	0.22	4.12	4.36E-5	Pancreatic cancer	
LGG	cis	1	rs10734765	chr12:9369385	LOC642846	chr12:9436253-9466684:+	0.31	6.12	1.88E-9	Non-alcoholic fatty liver disease histology (AST)	
LGG	cis	1	rs10736378	chr1:248455769	OR2L13	chr1:248100493-248264223:+	0.2	3.63	0.000307	Common traits (Other)	
LGG	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.26	7.4	6.13E-13	Homocysteine levels	
LGG	cis	1	rs10736426	chr1:45984353	MMACHC	chr1:45965856-45976737:+	-0.24	-5.22	2.69E-7	Homocysteine levels	
LGG	cis	1	rs10736426	chr1:45984353	MUTYH	chr1:45794915-45806142:-	-0.13	-4.55	6.79E-6	Homocysteine levels	
LGG	cis	1	rs10736781	chr11:71650368	FAM86C	chr11:71498557-71512276:+	0.39	4.23	2.82E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10736786	chr11:71763274	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10739388	chr9:115977175	CDC26	chr9:116029290-116037869:-	-0.58	-13.6	5.52E-36	Hematology traits	
LGG	cis	1	rs10739496	chr9:100552559	C9orf156	chr9:100666772-100684852:-	0.2	4.23	2.77E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs10741741	chr11:18342081	GTF2H1	chr11:18343816-18388590:+	-0.4	-7.77	4.49E-14	Pancreatic cancer	
LGG	cis	1	rs10741742	chr11:18342160	GTF2H1	chr11:18343816-18388590:+	0.42	7.95	1.26E-14	Pancreatic cancer	
LGG	cis	1	rs10741742	chr11:18342160	LDHC	chr11:18433853-18472792:+	0.19	3.52	0.000471	Pancreatic cancer	
LGG	cis	1	rs10743579	chr12:26461145	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.25	2.6E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs1074407	chr22:38156183	GALR3	chr22:38219389-38221502:+	-0.26	-5.84	9.39E-9	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs1074407	chr22:38156183	GCAT	chr22:38203955-38213183:+	0.17	3.49	0.000525	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs1074407	chr22:38156183	TRIOBP	chr22:38082344-38172562:+	0.24	5.68	2.36E-8	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs10745505	chr12:89910684	GALNT4	chr12:89913192-89919777:-	0.18	4.74	2.75E-6	Schizophrenia	
LGG	cis	1	rs10747586	chr12:50983565	ATF1	chr12:51157819-51214906:+	0.25	5.37	1.24E-7	Fibrinogen	
LGG	cis	1	rs10747586	chr12:50983565	SLC11A2	chr12:51373319-51422058:-	-0.17	-3.71	0.00023	Fibrinogen	
LGG	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.46	11.3	1.81E-26	Multiple sclerosis	
LGG	cis	1	rs10747783	chr12:58176614	TSFM	chr12:58176536-58191367:+	-0.44	-8.44	3.7E-16	Multiple sclerosis	
LGG	cis	1	rs10747783	chr12:58176614	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.48	0.000547	Multiple sclerosis	
LGG	cis	1	rs10749674	chr1:150077069	RPRD2	chr1:150336990-150449039:+	-0.15	-3.78	0.000173	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.17	-5	8.18E-7	Body mass index	
LGG	cis	1	rs10749860	chr1:46328210	MUTYH	chr1:45794915-45806142:-	0.14	5.17	3.37E-7	Body mass index	
LGG	cis	1	rs10750100	chr11:116917244	SIDT2	chr11:117049939-117068161:+	0.31	3.77	0.000182	Protein quantitative trait loci	
LGG	cis	1	rs10750101	chr11:116979689	SIDT2	chr11:117049939-117068161:+	0.32	3.59	0.000363	Protein quantitative trait loci	
LGG	cis	1	rs10750173	chr11:120288368	TMEM136	chr11:120196016-120204388:+	0.2	4.48	9.2E-6	Intraocular pressure	
LGG	cis	1	rs10750174	chr11:120292097	TMEM136	chr11:120196016-120204388:+	0.2	4.5	8.52E-6	Intraocular pressure	
LGG	cis	1	rs10751189	chr11:71670578	FAM86C	chr11:71498557-71512276:+	-0.39	-4.31	1.98E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10751190	chr11:71680757	FAM86C	chr11:71498557-71512276:+	0.49	4.86	1.61E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10751193	chr11:71785356	FAM86C	chr11:71498557-71512276:+	0.5	4.92	1.19E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10751194	chr11:70001637	FADD	chr11:70049269-70053508:+	0.14	3.73	0.000212	Survival in rectal cancer	
LGG	cis	1	rs10751195	chr11:70001976	FADD	chr11:70049269-70053508:+	0.13	3.46	0.000595	Survival in rectal cancer	
LGG	cis	1	rs10751667	chr11:941941	MUC6	chr11:1012824-1036706:-	-0.19	-4.02	6.71E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs10752615	chr1:156248609	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10752615	chr1:156248609	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs1075265	chr2:54354927	ACYP2	chr2:54342410-54532433:+	-0.14	-3.72	0.000221	Chronotype;Morning vs. evening chronotype	
LGG	cis	1	rs10753918	chr1:202503061	UBE2T	chr1:202300786-202311094:-	-0.12	-3.67	0.000266	Sex ratio	
LGG	cis	1	rs10754283	chr1:90112431	LRRC8C	chr1:90098644-90185093:+	0.14	4.4	1.33E-5	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs10754323	chr1:89119492	CCBL2	chr1:89401456-89458643:-	0.53	12.39	7.44E-31	Height	
LGG	cis	1	rs10758308	chr9:35509782	TPM2	chr9:35681990-35690054:-	0.15	3.55	0.000426	Psoriasis	
LGG	cis	1	rs10759636	chr9:116018777	CDC26	chr9:116029290-116037869:-	-0.58	-13.68	2.64E-36	Hematology traits	
LGG	cis	1	rs10759927	chr9:100542176	C9orf156	chr9:100666772-100684852:-	0.18	3.81	0.00016	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.66	-11.74	3.24E-28	Rheumatoid arthritis	
LGG	cis	1	rs10760118	chr9:123641616	PSMD5	chr9:123578334-123605206:-	-0.37	-6.77	3.69E-11	Rheumatoid arthritis	
LGG	cis	1	rs10760118	chr9:123641616	TRAF1	chr9:123664672-123691479:-	0.18	3.78	0.000175	Rheumatoid arthritis	
LGG	cis	1	rs10760121	chr9:123647915	LOC253039	chr9:123605320-123616644:+	-0.65	-11.67	6.21E-28	Rheumatoid arthritis	
LGG	cis	1	rs10760121	chr9:123647915	PSMD5	chr9:123578334-123605206:-	-0.34	-6.32	5.92E-10	Rheumatoid arthritis	
LGG	cis	1	rs10760121	chr9:123647915	TRAF1	chr9:123664672-123691479:-	0.18	3.95	9.06E-5	Rheumatoid arthritis	
LGG	cis	1	rs1076160	chr9:135776034	C9orf98	chr9:135600965-135754198:-	-0.34	-9.11	2.17E-18	Psoriasis	
LGG	cis	1	rs1076160	chr9:135776034	GFI1B	chr9:135854098-135867083:+	0.21	3.62	0.000327	Psoriasis	
LGG	cis	1	rs10761723	chr10:64955581	NRBF2	chr10:64893007-64914785:+	-0.22	-5.28	1.91E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10761723	chr10:64955581	REEP3	chr10:65281123-65381971:+	0.14	4.16	3.78E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10761727	chr10:64995493	NRBF2	chr10:64893007-64914785:+	-0.22	-5.28	1.94E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10761727	chr10:64995493	REEP3	chr10:65281123-65381971:+	0.14	4.2	3.22E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10761742	chr10:65085048	NRBF2	chr10:64893007-64914785:+	-0.23	-5.49	6.33E-8	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10761742	chr10:65085048	REEP3	chr10:65281123-65381971:+	0.13	3.78	0.000173	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1076394	chr3:47322781	NRADDP	chr3:47053032-47054957:+	0.24	4.12	4.54E-5	Colorectal cancer	
LGG	cis	1	rs10765202	chr11:89141996	NOX4	chr11:89057524-89322779:-	0.34	3.79	0.000169	Homocysteine levels	
LGG	cis	1	rs10765205	chr11:89206677	NOX4	chr11:89057524-89322779:-	0.37	4.01	6.92E-5	Homocysteine levels	
LGG	cis	1	rs10765206	chr11:89207200	NOX4	chr11:89057524-89322779:-	0.37	4.09	4.98E-5	Homocysteine levels	
LGG	cis	1	rs10765207	chr11:89207210	NOX4	chr11:89057524-89322779:-	0.39	4.28	2.24E-5	Homocysteine levels	
LGG	cis	1	rs10765208	chr11:89207232	NOX4	chr11:89057524-89322779:-	-0.38	-4.38	1.44E-5	Homocysteine levels	
LGG	cis	1	rs10765209	chr11:89207367	NOX4	chr11:89057524-89322779:-	-0.37	-4.16	3.8E-5	Homocysteine levels	
LGG	cis	1	rs10765210	chr11:89207402	NOX4	chr11:89057524-89322779:-	0.39	4.3	2.08E-5	Homocysteine levels	
LGG	cis	1	rs1076542	chr22:18446452	PEX26	chr22:18560686-18572206:+	0.14	3.64	0.000307	Presence of antiphospholipid antibodies	
LGG	cis	1	rs10765688	chr11:94309859	MRE11A	chr11:94150469-94227040:-	-0.14	-3.65	0.000293	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs10766494	chr11:18738281	LDHC	chr11:18433853-18472792:+	0.23	3.94	9.26E-5	Diabetic kidney disease	
LGG	cis	1	rs10766496	chr11:18738718	LDHC	chr11:18433853-18472792:+	-0.23	-3.99	7.47E-5	Diabetic kidney disease	
LGG	cis	1	rs10767971	chr11:32895664	CCDC73	chr11:32623627-32816187:-	0.23	4.74	2.79E-6	Parkinson's disease (age of onset)	
LGG	cis	1	rs10767972	chr11:32896419	CCDC73	chr11:32623627-32816187:-	0.23	4.72	3.02E-6	Parkinson's disease (age of onset)	
LGG	cis	1	rs10771431	chr12:9380859	DDX12	chr12:9570288-9600768:-	0.16	5.14	3.99E-7	Breast size	
LGG	cis	1	rs10771431	chr12:9380859	LOC642846	chr12:9436253-9466684:+	0.4	10.9	6.64E-25	Breast size	
LGG	cis	1	rs10777165	chr12:89840865	GALNT4	chr12:89913192-89919777:-	-0.15	-4.07	5.41E-5	Schizophrenia	
LGG	cis	1	rs10777165	chr12:89840865	POC1B	chr12:89813501-89919777:-	-0.17	-3.56	0.000405	Schizophrenia	
LGG	cis	1	rs1077889	chr20:25267893	ABHD12	chr20:25275380-25371477:-	0.26	6.96	1.13E-11	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1077889	chr20:25267893	FAM182A	chr20:26035250-26067552:+	-0.54	-10.64	6.1E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1077889	chr20:25267893	FAM182B	chr20:25744102-25848786:-	0.21	4.64	4.55E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10781499	chr9:139266405	C8G	chr9:139839698-139841426:+	0.17	3.53	0.000456	IgA nephropathy;Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs10782922	chr1:92974595	EVI5	chr1:92974255-93257961:-	-0.29	-7.01	7.83E-12	Cholesterol, total	
LGG	cis	1	rs10783342	chr12:50628466	ATF1	chr12:51157819-51214906:+	-0.21	-4.68	3.77E-6	Schizophrenia	
LGG	cis	1	rs10783594	chr12:54067135	PRR13	chr12:53835433-53840426:+	-0.12	-3.53	0.000461	Height	
LGG	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.47	11.59	1.25E-27	Multiple sclerosis	
LGG	cis	1	rs10783847	chr12:58196447	TSFM	chr12:58176536-58191367:+	-0.45	-8.63	8.9E-17	Multiple sclerosis	
LGG	cis	1	rs10783847	chr12:58196447	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.49	0.000523	Multiple sclerosis	
LGG	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.47	11.59	1.25E-27	Multiple sclerosis	
LGG	cis	1	rs10783848	chr12:58196528	TSFM	chr12:58176536-58191367:+	-0.45	-8.63	8.9E-17	Multiple sclerosis	
LGG	cis	1	rs10783848	chr12:58196528	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.49	0.000523	Multiple sclerosis	
LGG	cis	1	rs10786596	chr10:102282126	HIF1AN	chr10:102295641-102313680:+	0.18	3.51	0.000485	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786596	chr10:102282126	NDUFB8	chr10:102283497-102289636:-	0.17	4.74	2.79E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786596	chr10:102282126	WNT8B	chr10:102222812-102243397:+	0.46	7.55	2.14E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786597	chr10:102291287	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786597	chr10:102291287	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786597	chr10:102291287	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786598	chr10:102291579	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786598	chr10:102291579	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10786598	chr10:102291579	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1078679	chr6:26568741	BTN2A3	chr6:26422317-26431927:+	0.13	3.63	0.000315	Educational attainment	
LGG	cis	1	rs1078679	chr6:26568741	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.55E-6	Educational attainment	
LGG	cis	1	rs10787429	chr10:113949664	ZDHHC6	chr10:114190060-114207306:-	0.25	4.66	4.03E-6	HDL cholesterol	
LGG	cis	1	rs10788775	chr1:248471945	OR2L13	chr1:248100493-248264223:+	0.2	3.52	0.00047	Common traits (Other)	
LGG	cis	1	rs10788795	chr1:150758047	ARNT	chr1:150782186-150849186:-	-0.25	-4.56	6.57E-6	Congenital left-sided heart lesions	
LGG	cis	1	rs10788795	chr1:150758047	OAZ3	chr1:151735445-151743805:+	-0.27	-3.52	0.000466	Congenital left-sided heart lesions	
LGG	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.94	1.07E-6	Body mass index	
LGG	cis	1	rs10789475	chr1:46304177	MUTYH	chr1:45794915-45806142:-	0.14	4.94	1.08E-6	Body mass index	
LGG	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.27	2.03E-7	Body mass index	
LGG	cis	1	rs10789481	chr1:46383583	MUTYH	chr1:45794915-45806142:-	0.13	4.74	2.75E-6	Body mass index	
LGG	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.86	1.58E-6	Body mass index	
LGG	cis	1	rs10789487	chr1:46420221	MUTYH	chr1:45794915-45806142:-	0.13	4.97	9.48E-7	Body mass index	
LGG	cis	1	rs1078968	chr3:53123486	RFT1	chr3:53122503-53164470:-	-0.47	-10.06	8.66E-22	Height	
LGG	cis	1	rs10790034	chr11:114629890	C11orf71	chr11:114262170-114271255:-	0.21	4.48	9.35E-6	Urinary albumin excretion	
LGG	cis	1	rs10790172	chr11:116927740	SIDT2	chr11:117049939-117068161:+	0.3	3.51	0.000488	Protein quantitative trait loci	
LGG	cis	1	rs10790268	chr11:118729391	PHLDB1	chr11:118477213-118528741:+	0.21	3.95	9.07E-5	Rheumatoid arthritis	
LGG	cis	1	rs10790380	chr11:120233158	TMEM136	chr11:120196016-120204388:+	0.2	4.63	4.76E-6	Intraocular pressure	
LGG	cis	1	rs10790382	chr11:120288372	TMEM136	chr11:120196016-120204388:+	0.2	4.6	5.38E-6	Intraocular pressure	
LGG	cis	1	rs10790383	chr11:120344526	TMEM136	chr11:120196016-120204388:+	0.21	4.86	1.59E-6	Intraocular pressure	
LGG	cis	1	rs10791504	chr11:101436689	TRPC6	chr11:101322296-101454659:-	0.25	4.61	5.04E-6	Menarche (age at onset)	
LGG	cis	1	rs10793016	chr11:71755063	FAM86C	chr11:71498557-71512276:+	-0.44	-4.53	7.38E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10793273	chr11:77742595	KCTD21	chr11:77882301-77899664:-	0.36	9.23	8.07E-19	Pelvic organ prolapse	
LGG	cis	1	rs10793273	chr11:77742595	USP35	chr11:77899858-77925753:+	0.26	5.82	1.07E-8	Pelvic organ prolapse	
LGG	cis	1	rs10793302	chr11:78040961	NARS2	chr11:78147017-78285909:-	-0.18	-3.48	0.000552	Testicular germ cell tumor	
LGG	cis	1	rs1079389	chr10:1161980	IDI2	chr10:1064847-1071799:-	0.33	4.02	6.73E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs1079390	chr10:1161653	IDI2	chr10:1064847-1071799:-	0.35	4.2	3.2E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs10794302	chr11:234102	PSMD13	chr11:236808-252984:+	-0.24	-5.22	2.68E-7	Menarche (age at onset)	
LGG	cis	1	rs10794349	chr11:945678	MUC6	chr11:1012824-1036706:-	-0.19	-4.1	4.8E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs10794357	chr11:973374	MUC6	chr11:1012824-1036706:-	-0.17	-3.63	0.000313	Alzheimer's disease (late onset)	
LGG	cis	1	rs10794720	chr10:1156165	IDI2	chr10:1064847-1071799:-	-0.29	-3.69	0.000251	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs10795452	chr10:17192712	TRDMT1	chr10:17184983-17243681:-	0.18	4	7.39E-5	Homocysteine levels	
LGG	cis	1	rs10795465	chr10:17260525	TRDMT1	chr10:17184983-17243681:-	0.2	4.31	1.99E-5	Cholesterol, total	
LGG	cis	1	rs1079576	chr22:18446318	PEX26	chr22:18560686-18572206:+	-0.14	-3.46	0.000579	Presence of antiphospholipid antibodies	
LGG	cis	1	rs1079596	chr11:113296619	TTC12	chr11:113185251-113244016:+	0.25	5.52	5.43E-8	Select biomarker traits	
LGG	cis	1	rs1079597	chr11:113296286	TTC12	chr11:113185251-113244016:+	0.26	5.59	3.82E-8	Select biomarker traits	
LGG	cis	1	rs10798304	chr1:171258642	FMO4	chr1:171283486-171311222:+	-0.2	-4.98	8.9E-7	Sudden cardiac arrest	
LGG	cis	1	rs10798686	chr1:179470357	C1orf125	chr1:179335107-179523868:+	0.45	6.03	3.3E-9	Multiple sclerosis (age of onset)	
LGG	cis	1	rs10798847	chr1:31858984	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.77	0.000186	Schizophrenia	
LGG	cis	1	rs10799428	chr1:227798565	JMJD4	chr1:227918891-227923112:-	0.26	4.26	2.5E-5	Height	
LGG	cis	1	rs1080060	chr2:27768808	PPM1G	chr2:27604062-27632496:-	0.14	4.36	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs1080060	chr2:27768808	SNX17	chr2:27593363-27599994:+	-0.12	-3.63	0.000314	Oral cavity cancer	
LGG	cis	1	rs10800830	chr1:202323296	PTPN7	chr1:202116143-202130709:-	-0.11	-3.51	0.000495	Sex ratio	
LGG	cis	1	rs10800830	chr1:202323296	UBE2T	chr1:202300786-202311094:-	-0.12	-3.78	0.000176	Sex ratio	
LGG	cis	1	rs10800831	chr1:202323506	UBE2T	chr1:202300786-202311094:-	-0.13	-4.03	6.44E-5	Sex ratio	
LGG	cis	1	rs10800833	chr1:202330653	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs10800833	chr1:202330653	UBE2T	chr1:202300786-202311094:-	-0.13	-3.98	7.82E-5	Sex ratio	
LGG	cis	1	rs10800836	chr1:202410429	UBE2T	chr1:202300786-202311094:-	-0.13	-4.13	4.35E-5	Sex ratio	
LGG	cis	1	rs10800839	chr1:202518950	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs10804111	chr2:202145612	ALS2CR12	chr2:202153148-202222101:-	-0.36	-7.16	2.92E-12	Melanoma;Esophageal squamous cell carcinoma	
LGG	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.29	7.8	3.87E-14	Height	
LGG	cis	1	rs10804632	chr3:134294501	CEP63	chr3:134204575-134293852:+	0.19	3.58	0.000375	Height	
LGG	cis	1	rs10805357	chr4:17652352	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10805358	chr4:17652450	MED28	chr4:17616273-17629791:+	0.18	3.94	9.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10805359	chr4:17684886	LAP3	chr4:17578927-17609590:+	-0.13	-3.62	0.00033	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10805359	chr4:17684886	MED28	chr4:17616273-17629791:+	0.16	3.48	0.000555	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1080698	chr10:102295114	NDUFB8	chr10:102283497-102289636:-	0.18	4.87	1.51E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1080698	chr10:102295114	WNT8B	chr10:102222812-102243397:+	0.5	8.11	3.94E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10807701	chr7:65724686	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs10807702	chr7:65767843	CCT6P1	chr7:65216092-65228661:+	0.21	3.68	0.000259	Diabetic kidney disease	
LGG	cis	1	rs10814247	chr9:35507290	TPM2	chr9:35681990-35690054:-	-0.15	-3.58	0.000382	Psoriasis	
LGG	cis	1	rs10815380	chr9:6226086	ERMP1	chr9:5765076-5833081:-	0.14	3.59	0.000365	Acute kidney injury in critical illness	
LGG	cis	1	rs10815381	chr9:6226289	ERMP1	chr9:5765076-5833081:-	0.15	3.61	0.000332	Acute kidney injury in critical illness	
LGG	cis	1	rs10816600	chr9:99576424	FAM22G	chr9:99690592-99704572:+	0.66	5.11	4.67E-7	Height	
LGG	cis	1	rs10817184	chr9:114293535	PTGR1	chr9:114312003-114362135:-	-0.36	-5.05	6.17E-7	Menarche (age at onset)	
LGG	cis	1	rs10817184	chr9:114293535	ZNF483	chr9:114287447-114340124:+	0.24	3.64	0.000301	Menarche (age at onset)	
LGG	cis	1	rs10818480	chr9:123643170	LOC253039	chr9:123605320-123616644:+	-0.65	-11.61	1.05E-27	Rheumatoid arthritis	
LGG	cis	1	rs10818480	chr9:123643170	PSMD5	chr9:123578334-123605206:-	-0.35	-6.32	5.75E-10	Rheumatoid arthritis	
LGG	cis	1	rs10818480	chr9:123643170	TRAF1	chr9:123664672-123691479:-	0.18	3.97	8.26E-5	Rheumatoid arthritis	
LGG	cis	1	rs10819469	chr9:131882067	CRAT	chr9:131857075-131873070:-	0.2	3.6	0.000353	Blood metabolite ratios	
LGG	cis	1	rs10820614	chr9:99196094	CDC14B	chr9:99262397-99382112:-	-0.24	-4.29	2.11E-5	Resting heart rate	
LGG	cis	1	rs10820614	chr9:99196094	HABP4	chr9:99212414-99253617:+	-0.23	-5.09	5.09E-7	Resting heart rate	
LGG	cis	1	rs10820614	chr9:99196094	SLC35D2	chr9:99075727-99145992:-	-0.16	-3.75	0.000195	Resting heart rate	
LGG	cis	1	rs10820633	chr9:99214796	CDC14B	chr9:99262397-99382112:-	-0.29	-5.19	3.03E-7	Height	
LGG	cis	1	rs10820633	chr9:99214796	HABP4	chr9:99212414-99253617:+	-0.23	-5.18	3.31E-7	Height	
LGG	cis	1	rs10820633	chr9:99214796	SLC35D2	chr9:99075727-99145992:-	-0.17	-3.85	0.000135	Height	
LGG	cis	1	rs10822145	chr10:64934548	NRBF2	chr10:64893007-64914785:+	-0.21	-5.03	7.04E-7	Triglycerides	
LGG	cis	1	rs10822145	chr10:64934548	REEP3	chr10:65281123-65381971:+	0.14	3.98	7.99E-5	Triglycerides	
LGG	cis	1	rs10822149	chr10:64987412	NRBF2	chr10:64893007-64914785:+	-0.22	-5.28	1.96E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10822149	chr10:64987412	REEP3	chr10:65281123-65381971:+	0.14	4.14	4.16E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10822161	chr10:65118203	NRBF2	chr10:64893007-64914785:+	-0.22	-5.27	2.01E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10822161	chr10:65118203	REEP3	chr10:65281123-65381971:+	0.13	3.83	0.000144	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10822163	chr10:65124098	NRBF2	chr10:64893007-64914785:+	-0.22	-5.22	2.62E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10822163	chr10:65124098	REEP3	chr10:65281123-65381971:+	0.13	3.72	0.000218	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10824026	chr10:75421208	NUDT13	chr10:74870210-74891580:+	-0.21	-3.78	0.000179	Atrial fibrillation	
LGG	cis	1	rs10825492	chr10:52008730	FAM21A	chr10:51827684-51893268:+	-0.61	-6.73	4.71E-11	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs10830275	chr11:89205418	NOX4	chr11:89057524-89322779:-	0.37	4.01	6.92E-5	Homocysteine levels	
LGG	cis	1	rs10830276	chr11:89205925	NOX4	chr11:89057524-89322779:-	0.36	3.89	0.000113	Homocysteine levels	
LGG	cis	1	rs10832921	chr11:18380835	GTF2H1	chr11:18343816-18388590:+	0.39	7.41	5.39E-13	Pancreatic cancer	
LGG	cis	1	rs10837697	chr11:5281018	HBG2	chr11:5269502-5667011:-	0.31	5.13	4.25E-7	Hemoglobin levels	
LGG	cis	1	rs10838738	chr11:47663049	MTCH2	chr11:47638859-47664206:-	0.25	4.86	1.56E-6	Subjective well-being	
LGG	cis	1	rs10838738	chr11:47663049	PSMC3	chr11:47440320-47448024:-	0.15	3.6	0.000349	Subjective well-being	
LGG	cis	1	rs10838747	chr11:47716324	MTCH2	chr11:47638859-47664206:-	0.24	4.54	6.94E-6	Subjective well-being	
LGG	cis	1	rs10838748	chr11:47716381	MTCH2	chr11:47638859-47664206:-	0.24	4.54	7.1E-6	Subjective well-being	
LGG	cis	1	rs10838757	chr11:47763016	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs10838757	chr11:47763016	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs10838757	chr11:47763016	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs10840085	chr11:8613949	STK33	chr11:8413418-8615775:-	-0.22	-6.19	1.28E-9	Body mass index	
LGG	cis	1	rs10842703	chr12:26456188	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.31	1.94E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs10842708	chr12:26474867	BHLHE41	chr12:26272961-26278003:-	-0.14	-4.02	6.61E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs10848943	chr12:3944022	PARP11	chr12:3918027-3982608:-	-0.24	-5.06	5.86E-7	Cognitive performance	
LGG	cis	1	rs10849605	chr12:1064438	RAD52	chr12:1021255-1099219:-	-0.15	-4.45	1.08E-5	Lung cancer	
LGG	cis	1	rs10849786	chr12:121209302	SPPL3	chr12:121201036-121342151:-	0.27	3.79	0.000168	Quantitative traits	
LGG	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.86	1.55E-6	Body mass index	
LGG	cis	1	rs1085243	chr1:46544768	MUTYH	chr1:45794915-45806142:-	0.14	5.21	2.72E-7	Body mass index	
LGG	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.73	2.89E-6	Body mass index	
LGG	cis	1	rs1085244	chr1:46563680	MUTYH	chr1:45794915-45806142:-	0.14	5.09	5.17E-7	Body mass index	
LGG	cis	1	rs10852562	chr16:58329828	PRSS54	chr16:58313902-58328951:-	0.37	6.82	2.74E-11	Systemic lupus erythematosus	
LGG	cis	1	rs10853287	chr18:2941377	MYL12A	chr18:3247528-3256228:+	-0.16	-4.33	1.82E-5	Type 2 diabetes	
LGG	cis	1	rs10857712	chr10:135225666	LOC619207	chr10:135267432-135337062:+	-0.19	-5.21	2.83E-7	Systemic lupus erythematosus	
LGG	cis	1	rs10857712	chr10:135225666	MTG1	chr10:135207621-135234173:+	0.54	12.3	1.67E-30	Systemic lupus erythematosus	
LGG	cis	1	rs10857811	chr1:110617688	ALX3	chr1:110602998-110613322:-	0.28	6.27	7.82E-10	Blood metabolite levels	
LGG	cis	1	rs10857811	chr1:110617688	FAM40A	chr1:110574199-110597424:+	-0.12	-4.15	3.89E-5	Blood metabolite levels	
LGG	cis	1	rs10858884	chr12:89893712	GALNT4	chr12:89913192-89919777:-	-0.18	-5.12	4.46E-7	Schizophrenia	
LGG	cis	1	rs10858884	chr12:89893712	POC1B	chr12:89813501-89919777:-	-0.19	-4.18	3.41E-5	Schizophrenia	
LGG	cis	1	rs10858907	chr12:89934560	GALNT4	chr12:89913192-89919777:-	-0.16	-4.51	8.12E-6	Schizophrenia	
LGG	cis	1	rs10861360	chr12:105570041	EID3	chr12:104697549-104698980:+	-0.18	-3.53	0.000458	IgG glycosylation	
LGG	cis	1	rs10864655	chr1:231172810	FAM89A	chr1:231154704-231175995:-	0.26	4.67	3.95E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs10865914	chr3:41919499	ULK4	chr3:41288091-42003660:-	-0.76	-14.94	7.26E-42	Diastolic blood pressure	
LGG	cis	1	rs10865956	chr3:49581559	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.59	5.56E-6	Menarche (age at onset)	
LGG	cis	1	rs10865956	chr3:49581559	GMPPB	chr3:49758932-49761384:-	-0.23	-4.56	6.39E-6	Menarche (age at onset)	
LGG	cis	1	rs10865956	chr3:49581559	NCKIPSD	chr3:48711280-48723334:-	0.15	3.46	0.000578	Menarche (age at onset)	
LGG	cis	1	rs10865970	chr3:51357501	HEMK1	chr3:50606583-50622419:+	0.22	3.75	0.000198	Melanoma	
LGG	cis	1	rs10871290	chr16:74472696	RFWD3	chr16:74655298-74700779:-	0.13	4.27	2.3E-5	Breast cancer	
LGG	cis	1	rs10872032	chr6:109676776	AKD1	chr6:109814059-110012415:-	-0.28	-5.75	1.6E-8	Height	
LGG	cis	1	rs10872032	chr6:109676776	MICAL1	chr6:109765268-109787171:-	-0.32	-7.57	1.82E-13	Height	
LGG	cis	1	rs10872032	chr6:109676776	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.62	0.00033	Height	
LGG	cis	1	rs10873086	chr14:55349258	GCH1	chr14:55308724-55369542:-	-0.29	-4.8	2.13E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs10873275	chr14:75531460	ACYP1	chr14:75519930-75530736:-	-0.13	-3.54	0.000439	Height	
LGG	cis	1	rs10873275	chr14:75531460	EIF2B2	chr14:75469612-75476292:+	0.18	3.52	0.000464	Height	
LGG	cis	1	rs10873275	chr14:75531460	MLH3	chr14:75480467-75518235:-	0.21	3.64	0.000307	Height	
LGG	cis	1	rs10873336	chr14:81779134	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs10874122	chr1:75235866	CRYZ	chr1:75171175-75199092:-	-0.2	-5.06	5.95E-7	Resistin levels	
LGG	cis	1	rs10874656	chr1:92947024	EVI5	chr1:92974255-93257961:-	-0.28	-6.62	9.38E-11	Cholesterol, total	
LGG	cis	1	rs10875746	chr12:48518264	ASB8	chr12:48541575-48551377:-	0.32	5.71	1.98E-8	Longevity (90 years and older)	
LGG	cis	1	rs10875804	chr12:48784974	VDR	chr12:48235322-48298814:-	0.22	3.51	0.000481	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs10876480	chr12:54066271	PRR13	chr12:53835433-53840426:+	-0.13	-3.56	0.000405	Height	
LGG	cis	1	rs10876481	chr12:54066743	PRR13	chr12:53835433-53840426:+	-0.13	-3.56	0.000405	Height	
LGG	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.45	10.89	7.24E-25	Multiple sclerosis	
LGG	cis	1	rs10877012	chr12:58162085	TSFM	chr12:58176536-58191367:+	-0.45	-8.65	7.21E-17	Multiple sclerosis	
LGG	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.45	11.11	9.59E-26	Multiple sclerosis	
LGG	cis	1	rs10877013	chr12:58165085	TSFM	chr12:58176536-58191367:+	-0.44	-8.5	2.25E-16	Multiple sclerosis	
LGG	cis	1	rs10877013	chr12:58165085	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.5	0.000506	Multiple sclerosis	
LGG	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.45	11.14	7.22E-26	Multiple sclerosis	
LGG	cis	1	rs10877014	chr12:58167661	TSFM	chr12:58176536-58191367:+	-0.44	-8.51	2.19E-16	Multiple sclerosis	
LGG	cis	1	rs10877014	chr12:58167661	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.46	0.000592	Multiple sclerosis	
LGG	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.46	11.08	1.23E-25	Multiple sclerosis	
LGG	cis	1	rs10877015	chr12:58167788	TSFM	chr12:58176536-58191367:+	-0.45	-8.6	1.1E-16	Multiple sclerosis	
LGG	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.45	-10.69	4.16E-24	Multiple sclerosis	
LGG	cis	1	rs10877019	chr12:58172929	TSFM	chr12:58176536-58191367:+	0.44	8.17	2.69E-15	Multiple sclerosis	
LGG	cis	1	rs10877019	chr12:58172929	XRCC6BP1	chr12:58335445-58351051:+	0.21	3.62	0.000324	Multiple sclerosis	
LGG	cis	1	rs10878386	chr12:40725928	KIF21A	chr12:39687031-39836918:-	0.3	3.84	0.000139	Subjective well-being	
LGG	cis	1	rs10881843	chr10:92646522	RPP30	chr10:92631474-92668312:+	0.18	3.76	0.000192	Economic and political preferences (time)	
LGG	cis	1	rs10881846	chr10:92648931	RPP30	chr10:92631474-92668312:+	0.18	3.75	0.0002	Economic and political preferences (time)	
LGG	cis	1	rs10881848	chr10:92655559	RPP30	chr10:92631474-92668312:+	0.17	3.51	0.000487	Economic and political preferences (time)	
LGG	cis	1	rs10881850	chr10:92670328	RPP30	chr10:92631474-92668312:+	0.18	3.53	0.000452	Economic and political preferences (time)	
LGG	cis	1	rs10883492	chr10:102206089	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883492	chr10:102206089	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883492	chr10:102206089	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883493	chr10:102208188	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883493	chr10:102208188	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883493	chr10:102208188	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883496	chr10:102221931	HIF1AN	chr10:102295641-102313680:+	0.2	3.86	0.000131	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883496	chr10:102221931	NDUFB8	chr10:102283497-102289636:-	0.17	4.85	1.63E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883496	chr10:102221931	WNT8B	chr10:102222812-102243397:+	0.51	8.53	1.85E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883497	chr10:102228519	HIF1AN	chr10:102295641-102313680:+	0.18	3.61	0.000341	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883497	chr10:102228519	NDUFB8	chr10:102283497-102289636:-	0.16	4.4	1.33E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883497	chr10:102228519	WNT8B	chr10:102222812-102243397:+	0.51	8.63	8.36E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883499	chr10:102232188	HIF1AN	chr10:102295641-102313680:+	0.19	3.77	0.000182	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883499	chr10:102232188	NDUFB8	chr10:102283497-102289636:-	0.16	4.59	5.64E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883499	chr10:102232188	WNT8B	chr10:102222812-102243397:+	0.51	8.74	3.73E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883500	chr10:102238324	HIF1AN	chr10:102295641-102313680:+	0.18	3.56	0.000402	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883500	chr10:102238324	NDUFB8	chr10:102283497-102289636:-	0.15	4.28	2.2E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883500	chr10:102238324	WNT8B	chr10:102222812-102243397:+	0.51	8.75	3.44E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883501	chr10:102238326	HIF1AN	chr10:102295641-102313680:+	0.18	3.56	0.000402	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883501	chr10:102238326	NDUFB8	chr10:102283497-102289636:-	0.15	4.28	2.2E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883501	chr10:102238326	WNT8B	chr10:102222812-102243397:+	0.51	8.75	3.44E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883502	chr10:102238343	HIF1AN	chr10:102295641-102313680:+	0.18	3.56	0.000402	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883502	chr10:102238343	NDUFB8	chr10:102283497-102289636:-	0.15	4.28	2.2E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883502	chr10:102238343	WNT8B	chr10:102222812-102243397:+	0.51	8.75	3.44E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883503	chr10:102275504	HIF1AN	chr10:102295641-102313680:+	0.18	3.45	0.000599	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883503	chr10:102275504	NDUFB8	chr10:102283497-102289636:-	0.18	4.93	1.1E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883503	chr10:102275504	WNT8B	chr10:102222812-102243397:+	0.49	7.89	1.93E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883504	chr10:102280687	HIF1AN	chr10:102295641-102313680:+	0.18	3.46	0.000585	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883504	chr10:102280687	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883504	chr10:102280687	WNT8B	chr10:102222812-102243397:+	0.49	8	9.26E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883505	chr10:102280772	HIF1AN	chr10:102295641-102313680:+	0.19	3.72	0.000223	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883505	chr10:102280772	NDUFB8	chr10:102283497-102289636:-	0.17	4.82	1.96E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883505	chr10:102280772	WNT8B	chr10:102222812-102243397:+	0.48	7.89	2.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883506	chr10:102289743	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883506	chr10:102289743	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883506	chr10:102289743	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883507	chr10:102291275	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883507	chr10:102291275	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883507	chr10:102291275	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883508	chr10:102294413	HIF1AN	chr10:102295641-102313680:+	0.19	3.62	0.000325	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883508	chr10:102294413	NDUFB8	chr10:102283497-102289636:-	0.17	4.69	3.57E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883508	chr10:102294413	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.25E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883509	chr10:102296461	HIF1AN	chr10:102295641-102313680:+	0.2	3.73	0.00021	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883509	chr10:102296461	NDUFB8	chr10:102283497-102289636:-	0.18	4.85	1.64E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883509	chr10:102296461	WNT8B	chr10:102222812-102243397:+	0.48	7.86	2.37E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883510	chr10:102297018	HIF1AN	chr10:102295641-102313680:+	0.18	3.46	0.000589	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883510	chr10:102297018	NDUFB8	chr10:102283497-102289636:-	0.18	4.9	1.3E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883510	chr10:102297018	WNT8B	chr10:102222812-102243397:+	0.54	8.7	4.94E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883511	chr10:102299407	HIF1AN	chr10:102295641-102313680:+	0.19	3.67	0.000273	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883511	chr10:102299407	NDUFB8	chr10:102283497-102289636:-	0.17	4.71	3.26E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883511	chr10:102299407	WNT8B	chr10:102222812-102243397:+	0.48	7.73	6.1E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883512	chr10:102308516	HIF1AN	chr10:102295641-102313680:+	0.19	3.65	0.000285	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883512	chr10:102308516	NDUFB8	chr10:102283497-102289636:-	0.17	4.73	2.99E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883512	chr10:102308516	WNT8B	chr10:102222812-102243397:+	0.47	7.63	1.2E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883513	chr10:102316964	HIF1AN	chr10:102295641-102313680:+	0.2	3.48	0.000542	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883513	chr10:102316964	NDUFB8	chr10:102283497-102289636:-	0.14	3.58	0.000383	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10883513	chr10:102316964	WNT8B	chr10:102222812-102243397:+	0.47	7.01	7.91E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs10887150	chr10:124180578	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.37	1.49E-5	Height	
LGG	cis	1	rs10888351	chr1:248451608	OR2L13	chr1:248100493-248264223:+	0.2	3.61	0.00034	Common traits (Other)	
LGG	cis	1	rs10888352	chr1:248451965	OR2L13	chr1:248100493-248264223:+	0.21	3.75	0.000195	Common traits (Other)	
LGG	cis	1	rs10888352	chr1:248451965	OR2L2	chr1:248201474-248202606:+	0.2	3.46	0.000582	Common traits (Other)	
LGG	cis	1	rs10888356	chr1:248465044	OR2L13	chr1:248100493-248264223:+	-0.2	-3.61	0.000337	Common traits (Other)	
LGG	cis	1	rs10888358	chr1:248471467	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000448	Common traits (Other)	
LGG	cis	1	rs10888362	chr1:248483975	OR2L13	chr1:248100493-248264223:+	-0.19	-3.46	0.000579	Common traits (Other)	
LGG	cis	1	rs10888362	chr1:248483975	OR2L2	chr1:248201474-248202606:+	-0.2	-3.47	0.000558	Common traits (Other)	
LGG	cis	1	rs10888396	chr1:150777514	ARNT	chr1:150782186-150849186:-	-0.23	-4.14	4.16E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs10888396	chr1:150777514	OAZ3	chr1:151735445-151743805:+	-0.29	-3.7	0.000243	Congenital left-sided heart lesions	
LGG	cis	1	rs10888527	chr1:153001363	LOR	chr1:153232179-153234598:+	0.15	3.54	0.00044	Inflammatory skin disease	
LGG	cis	1	rs10888569	chr1:150025672	RPRD2	chr1:150336990-150449039:+	-0.15	-3.87	0.000125	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs10888576	chr1:150200792	LOC388692	chr1:149279476-149291742:+	0.23	4.15	3.88E-5	Morning vs. evening chronotype	
LGG	cis	1	rs10888576	chr1:150200792	MRPS21	chr1:150266269-150280818:+	-0.14	-3.7	0.000244	Morning vs. evening chronotype	
LGG	cis	1	rs10889406	chr1:63599390	ITGB3BP	chr1:63906462-63988835:-	-0.2	-3.51	0.000494	Brain imaging	
LGG	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	3.9E-7	Body mass index	
LGG	cis	1	rs10890352	chr1:46283628	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.06E-7	Body mass index	
LGG	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.02	7.37E-7	Body mass index	
LGG	cis	1	rs10890354	chr1:46305347	MUTYH	chr1:45794915-45806142:-	0.14	5.02	7.23E-7	Body mass index	
LGG	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.05	6.03E-5	Body mass index	
LGG	cis	1	rs10890361	chr1:46346234	MUTYH	chr1:45794915-45806142:-	0.17	5.5	6.16E-8	Body mass index	
LGG	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.18	5.3	1.73E-7	Body mass index	
LGG	cis	1	rs10890363	chr1:46356148	MUTYH	chr1:45794915-45806142:-	-0.13	-4.86	1.6E-6	Body mass index	
LGG	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.19	-5.41	1.01E-7	Body mass index	
LGG	cis	1	rs10890383	chr1:46588503	MUTYH	chr1:45794915-45806142:-	0.13	4.78	2.33E-6	Body mass index	
LGG	cis	1	rs10892566	chr11:120241923	TMEM136	chr11:120196016-120204388:+	0.19	4.43	1.16E-5	Intraocular pressure	
LGG	cis	1	rs10892567	chr11:120244192	TMEM136	chr11:120196016-120204388:+	0.2	4.48	9.5E-6	Intraocular pressure	
LGG	cis	1	rs10892574	chr11:120288944	TMEM136	chr11:120196016-120204388:+	0.2	4.59	5.68E-6	Intraocular pressure	
LGG	cis	1	rs10892576	chr11:120294423	TMEM136	chr11:120196016-120204388:+	0.2	4.5	8.57E-6	Intraocular pressure	
LGG	cis	1	rs10892578	chr11:120308290	TMEM136	chr11:120196016-120204388:+	0.21	4.9	1.31E-6	Intraocular pressure	
LGG	cis	1	rs10892582	chr11:120347715	TMEM136	chr11:120196016-120204388:+	0.19	4.44	1.1E-5	Intraocular pressure	
LGG	cis	1	rs10895140	chr11:101436721	TRPC6	chr11:101322296-101454659:-	0.25	4.61	5.04E-6	Menarche (age at onset)	
LGG	cis	1	rs10896043	chr11:65543827	RNASEH2C	chr11:65485146-65488409:-	0.2	4.8	2.14E-6	Systemic lupus erythematosus	
LGG	cis	1	rs10896043	chr11:65543827	SNX32	chr11:65601410-65621170:+	-0.23	-4.96	9.61E-7	Systemic lupus erythematosus	
LGG	cis	1	rs10898191	chr11:71194601	KRTAP5-9	chr11:71259466-71260653:+	0.28	4.45	1.06E-5	Vitamin D levels	
LGG	cis	1	rs10898193	chr11:71197083	KRTAP5-9	chr11:71259466-71260653:+	-0.28	-4.54	6.98E-6	Vitamin D levels	
LGG	cis	1	rs10898211	chr11:71210677	KRTAP5-9	chr11:71259466-71260653:+	0.26	4.17	3.68E-5	Vitamin D levels	
LGG	cis	1	rs10898223	chr11:71219264	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.37	1.52E-5	Vitamin D levels	
LGG	cis	1	rs10898234	chr11:71236684	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.39	1.41E-5	Vitamin D levels	
LGG	cis	1	rs10898814	chr11:71736505	FAM86C	chr11:71498557-71512276:+	0.5	4.88	1.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs10899478	chr11:78052238	NARS2	chr11:78147017-78285909:-	-0.18	-3.45	0.0006	Testicular germ cell tumor	
LGG	cis	1	rs10900224	chr10:46024534	ALOX5	chr10:45869629-45941561:+	-0.11	-3.92	0.000101	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs10900589	chr1:203656974	SNRPE	chr1:203830727-203840278:+	0.29	4.55	6.85E-6	Mean corpuscular hemoglobin concentration	
LGG	cis	1	rs10901513	chr10:127699936	UROS	chr10:127477148-127511837:-	-0.16	-5.18	3.19E-7	Visceral fat	
LGG	cis	1	rs10901514	chr10:127700066	UROS	chr10:127477148-127511837:-	-0.16	-5.18	3.19E-7	Visceral fat	
LGG	cis	1	rs10901520	chr10:127718837	UROS	chr10:127477148-127511837:-	-0.16	-5.23	2.52E-7	Visceral fat	
LGG	cis	1	rs10902110	chr11:237648	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs10902112	chr11:244106	PSMD13	chr11:236808-252984:+	-0.22	-4.97	9.24E-7	Menarche (age at onset)	
LGG	cis	1	rs10902113	chr11:245523	PSMD13	chr11:236808-252984:+	-0.21	-4.75	2.65E-6	Menarche (age at onset)	
LGG	cis	1	rs10902114	chr11:246234	PSMD13	chr11:236808-252984:+	-0.21	-4.74	2.85E-6	Menarche (age at onset)	
LGG	cis	1	rs10902233	chr11:925510	MUC6	chr11:1012824-1036706:-	-0.18	-3.9	0.000111	Alzheimer's disease (late onset)	
LGG	cis	1	rs10902246	chr11:953674	MUC6	chr11:1012824-1036706:-	-0.18	-3.95	9.04E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs10902728	chr1:26598281	UBXN11	chr1:26608773-26644756:-	0.12	4.39	1.38E-5	Obesity-related traits	
LGG	cis	1	rs10902728	chr1:26598281	ZNF593	chr1:26496388-26497362:+	0.14	4.26	2.47E-5	Obesity-related traits	
LGG	cis	1	rs10904908	chr10:17260290	TRDMT1	chr10:17184983-17243681:-	0.2	4.31	2.0E-5	Cholesterol, total	
LGG	cis	1	rs10906228	chr10:12849790	PRPF18	chr10:13628939-13697927:+	0.41	3.68	0.000261	Coronary artery aneurysm in Kawasaki disease	
LGG	cis	1	rs10908494	chr1:156263097	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.41E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908494	chr1:156263097	CCT3	chr1:156278752-156308195:-	-0.16	-4.09	5.07E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908495	chr1:156263940	BGLAP	chr1:156182784-156213112:+	0.25	5.29	1.83E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908495	chr1:156263940	CCT3	chr1:156278752-156308195:-	-0.17	-4.21	3.1E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908496	chr1:156264000	BGLAP	chr1:156182784-156213112:+	0.25	5.33	1.52E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908496	chr1:156264000	CCT3	chr1:156278752-156308195:-	-0.16	-4.02	6.66E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908498	chr1:156278175	BGLAP	chr1:156182784-156213112:+	0.25	5.26	2.16E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908498	chr1:156278175	CCT3	chr1:156278752-156308195:-	-0.17	-4.18	3.52E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908499	chr1:156279176	BGLAP	chr1:156182784-156213112:+	0.25	5.26	2.16E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908499	chr1:156279176	CCT3	chr1:156278752-156308195:-	-0.17	-4.18	3.52E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908500	chr1:156280671	BGLAP	chr1:156182784-156213112:+	0.24	5.06	5.99E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908500	chr1:156280671	CCT3	chr1:156278752-156308195:-	-0.17	-4.37	1.53E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908502	chr1:156300082	BGLAP	chr1:156182784-156213112:+	0.24	4.89	1.39E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10908502	chr1:156300082	CCT3	chr1:156278752-156308195:-	-0.17	-4.3	2.05E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs10910845	chr1:145723120	NUDT17	chr1:145586494-145590461:-	-0.19	-3.5	0.000509	Urate levels;Urate levels in overweight individuals	
LGG	cis	1	rs10911637	chr1:184671909	C1orf21	chr1:184356150-184598155:+	-0.35	-3.62	0.000327	Systemic lupus erythematosus	
LGG	cis	1	rs10912749	chr1:171277506	FMO4	chr1:171283486-171311222:+	0.18	4.44	1.13E-5	Sudden cardiac arrest	
LGG	cis	1	rs10914371	chr1:31857590	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.66	0.000276	Schizophrenia	
LGG	cis	1	rs10914374	chr1:31872581	ZCCHC17	chr1:31769842-31837780:+	-0.2	-4.47	9.75E-6	Schizophrenia	
LGG	cis	1	rs10916154	chr1:227707361	JMJD4	chr1:227918891-227923112:-	0.22	3.78	0.000177	Height	
LGG	cis	1	rs10916157	chr1:227714477	JMJD4	chr1:227918891-227923112:-	0.22	3.73	0.000211	Height	
LGG	cis	1	rs10916160	chr1:227728219	JMJD4	chr1:227918891-227923112:-	-0.22	-3.61	0.00034	Height	
LGG	cis	1	rs10916162	chr1:227737793	JMJD4	chr1:227918891-227923112:-	0.23	3.84	0.000139	Height	
LGG	cis	1	rs10916162	chr1:227737793	SNAP47	chr1:227916240-227968932:+	-0.19	-3.61	0.000336	Height	
LGG	cis	1	rs10916199	chr1:227902472	JMJD4	chr1:227918891-227923112:-	0.26	4.37	1.52E-5	Height	
LGG	cis	1	rs10919070	chr1:169099037	NME7	chr1:169101771-169337186:-	0.28	4.04	6.15E-5	QT interval	
LGG	cis	1	rs10919071	chr1:169099483	NME7	chr1:169101771-169337186:-	0.28	4.04	6.15E-5	QT interval	
LGG	cis	1	rs10920392	chr1:202321123	UBE2T	chr1:202300786-202311094:-	-0.13	-4.03	6.5E-5	Sex ratio	
LGG	cis	1	rs10920409	chr1:202443663	PTPN7	chr1:202116143-202130709:-	-0.12	-3.51	0.000484	Sex ratio	
LGG	cis	1	rs10920409	chr1:202443663	UBE2T	chr1:202300786-202311094:-	-0.13	-3.93	9.89E-5	Sex ratio	
LGG	cis	1	rs10920410	chr1:202445856	UBE2T	chr1:202300786-202311094:-	0.13	4	7.43E-5	Sex ratio	
LGG	cis	1	rs10920412	chr1:202454413	UBE2T	chr1:202300786-202311094:-	-0.13	-3.88	0.000118	Sex ratio	
LGG	cis	1	rs10920414	chr1:202476924	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs10920414	chr1:202476924	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.68E-5	Sex ratio	
LGG	cis	1	rs10920421	chr1:202517196	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs10926984	chr1:243462153	SDCCAG8	chr1:243419320-243663392:+	-0.27	-4.49	8.92E-6	Obesity (early onset extreme)	
LGG	cis	1	rs10926986	chr1:243467611	SDCCAG8	chr1:243419320-243663392:+	0.3	5.02	7.34E-7	Obesity (early onset extreme)	
LGG	cis	1	rs10929965	chr2:160906931	LY75	chr2:160625141-160761262:-	-0.13	-3.62	0.000325	Idiopathic membranous nephropathy	
LGG	cis	1	rs10929966	chr2:160908341	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs10930201	chr2:166915335	TTC21B	chr2:166713988-166810348:-	-0.12	-3.54	0.000431	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs10933307	chr2:230521300	DNER	chr2:230222346-230579286:-	0.29	6.48	2.2E-10	Type 2 diabetes	
LGG	cis	1	rs10934254	chr3:113841634	KIAA1407	chr3:113682986-113775460:-	0.15	4.13	4.27E-5	Personality dimensions	
LGG	cis	1	rs10934255	chr3:113842444	KIAA1407	chr3:113682986-113775460:-	0.14	3.86	0.000127	Personality dimensions	
LGG	cis	1	rs10934850	chr3:127886957	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.22	2.9E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.3	-8.07	5.27E-15	Height	
LGG	cis	1	rs10935120	chr3:134233092	CEP63	chr3:134204575-134293852:+	-0.2	-3.74	0.000202	Height	
LGG	cis	1	rs10935186	chr3:136346206	PCCB	chr3:135969167-136056737:+	0.21	4.42	1.22E-5	Schizophrenia	
LGG	cis	1	rs10936601	chr3:169528449	LRRC34	chr3:169511266-169530720:-	0.29	5.14	4.02E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs10937158	chr3:183708439	ABCC5	chr3:183637726-183735727:-	0.11	3.51	0.000487	Anterior chamber depth	
LGG	cis	1	rs10937266	chr3:186433075	KNG1	chr3:186435120-186461741:+	-0.16	-3.56	0.000407	Adiponectin levels	
LGG	cis	1	rs10937275	chr3:186650790	ST6GAL1	chr3:186648516-186796339:+	0.26	4.33	1.83E-5	Drug-induced liver injury (flucloxacillin)	
LGG	cis	1	rs10938353	chr4:44582487	GNPDA2	chr4:44704169-44728612:-	0.26	5.02	7.34E-7	Body mass index	
LGG	cis	1	rs10938353	chr4:44582487	GUF1	chr4:44680433-44702696:+	-0.42	-6.9	1.6E-11	Body mass index	
LGG	cis	1	rs10939738	chr4:17604295	MED28	chr4:17616273-17629791:+	0.2	4.12	4.44E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939740	chr4:17617490	MED28	chr4:17616273-17629791:+	0.21	4.41	1.24E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939742	chr4:17659936	MED28	chr4:17616273-17629791:+	0.18	3.94	9.51E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939743	chr4:17662731	LAP3	chr4:17578927-17609590:+	-0.13	-3.53	0.000453	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939743	chr4:17662731	MED28	chr4:17616273-17629791:+	0.16	3.5	0.00051	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939744	chr4:17664473	LAP3	chr4:17578927-17609590:+	-0.13	-3.58	0.000379	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939744	chr4:17664473	MED28	chr4:17616273-17629791:+	0.17	3.56	0.000411	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10939746	chr4:17684951	LAP3	chr4:17578927-17609590:+	0.13	3.66	0.000277	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.52	-10.47	2.76E-23	Response to antipsychotic treatment	
LGG	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.49	-10.24	1.91E-22	Response to antipsychotic treatment	
LGG	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.5	-10.27	1.46E-22	Response to antipsychotic treatment	
LGG	cis	1	rs10946700	chr6:24442158	MRS2	chr6:24403153-24425809:+	-0.21	-3.54	0.000436	Liver enzyme levels	
LGG	cis	1	rs1094677	chr3:195129744	ACAP2	chr3:194995475-195163817:-	0.35	8.31	9.25E-16	Body mass index	
LGG	cis	1	rs10946834	chr6:26533664	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs10946834	chr6:26533664	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs10946835	chr6:26533757	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs10946835	chr6:26533757	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs10950032	chr7:65738591	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs10950973	chr7:23917277	C7orf46	chr7:23719749-23742268:+	0.2	4.22	2.86E-5	Schizophrenia	
LGG	cis	1	rs10950974	chr7:23917280	C7orf46	chr7:23719749-23742268:+	0.2	4.22	2.86E-5	Schizophrenia	
LGG	cis	1	rs10950975	chr7:23917480	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.84E-5	Schizophrenia	
LGG	cis	1	rs10951078	chr7:25622339	SNX10	chr7:26331515-26413937:+	-0.23	-3.59	0.000362	Preeclampsia	
LGG	cis	1	rs10953870	chr7:118205866	ANKRD7	chr7:117864712-117882782:+	0.21	3.8	0.00016	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs10954872	chr8:29978612	MBOAT4	chr8:29989188-30002200:-	-0.31	-3.63	0.000317	Migraine	
LGG	cis	1	rs10955943	chr8:120944143	DSCC1	chr8:120846182-120868170:-	-0.25	-5.76	1.46E-8	Interstitial lung disease	
LGG	cis	1	rs10957375	chr8:67355484	ADHFE1	chr8:67344718-67381042:+	0.31	7.33	9.74E-13	Blood metabolite levels	
LGG	cis	1	rs10966	chr20:25282944	ABHD12	chr20:25275380-25371477:-	0.28	7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10966	chr20:25282944	FAM182A	chr20:26035250-26067552:+	-0.54	-10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10966	chr20:25282944	FAM182B	chr20:25744102-25848786:-	0.22	4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs10973956	chr9:38645055	C9orf122	chr9:38621085-38623275:+	-0.21	-3.79	0.000169	Tourette's syndrome or obsessive-compulsive disorder	
LGG	cis	1	rs10979212	chr9:99591728	FAM22G	chr9:99690592-99704572:+	0.76	5.92	6.09E-9	Height	
LGG	cis	1	rs10979329	chr9:99616824	FAM22G	chr9:99690592-99704572:+	0.74	5.76	1.48E-8	Height	
LGG	cis	1	rs10980854	chr9:114050357	PTGR1	chr9:114312003-114362135:-	0.28	3.5	0.000512	Menarche (age at onset)	
LGG	cis	1	rs10980856	chr9:114053425	PTGR1	chr9:114312003-114362135:-	-0.28	-3.58	0.000372	Menarche (age at onset)	
LGG	cis	1	rs10980921	chr9:114279912	PTGR1	chr9:114312003-114362135:-	0.32	4.6	5.31E-6	Menarche (age at onset)	
LGG	cis	1	rs10980921	chr9:114279912	ZNF483	chr9:114287447-114340124:+	-0.24	-3.75	0.0002	Menarche (age at onset)	
LGG	cis	1	rs10981012	chr9:114453006	PTGR1	chr9:114312003-114362135:-	-0.27	-4.21	2.98E-5	Coronary artery disease	
LGG	cis	1	rs10983700	chr9:100537455	C9orf156	chr9:100666772-100684852:-	0.18	3.8	0.000166	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs10983701	chr9:100537577	C9orf156	chr9:100666772-100684852:-	0.18	3.8	0.000166	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs10983761	chr9:100553957	C9orf156	chr9:100666772-100684852:-	0.19	3.93	9.88E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs10985090	chr9:123677980	TRAF1	chr9:123664672-123691479:-	0.39	4.75	2.62E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs10985091	chr9:123680449	TRAF1	chr9:123664672-123691479:-	0.39	4.54	7.2E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs10985112	chr9:123731408	TRAF1	chr9:123664672-123691479:-	-0.33	-4.58	5.9E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs10985817	chr9:101071090	TDRD7	chr9:100174302-100258403:+	0.18	3.49	0.000526	Schizophrenia	
LGG	cis	1	rs10985819	chr9:101071192	TDRD7	chr9:100174302-100258403:+	0.18	3.49	0.000526	Schizophrenia	
LGG	cis	1	rs10988125	chr9:131572903	ENDOG	chr9:131580779-131584954:+	0.34	8.08	5.09E-15	Blood metabolite levels	
LGG	cis	1	rs10988125	chr9:131572903	LRRC8A	chr9:131644391-131680315:+	0.19	4.21	2.98E-5	Blood metabolite levels	
LGG	cis	1	rs10988223	chr9:131903021	CRAT	chr9:131857075-131873070:-	0.19	3.57	0.000398	Blood metabolite ratios	
LGG	cis	1	rs10995335	chr10:64623533	ARID5B	chr10:63661443-63856703:+	0.37	3.45	0.000599	Cutaneous psoriasis	
LGG	cis	1	rs11004802	chr10:52011440	FAM21A	chr10:51827684-51893268:+	-0.56	-6.34	5.13E-10	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs11018603	chr11:89138122	NOX4	chr11:89057524-89322779:-	0.32	3.51	0.000497	Homocysteine levels	
LGG	cis	1	rs11018608	chr11:89149278	NOX4	chr11:89057524-89322779:-	0.32	3.79	0.000173	Homocysteine levels	
LGG	cis	1	rs11018611	chr11:89159814	NOX4	chr11:89057524-89322779:-	0.37	3.97	8.28E-5	Homocysteine levels	
LGG	cis	1	rs11018613	chr11:89166307	NOX4	chr11:89057524-89322779:-	0.36	3.86	0.000127	Homocysteine levels	
LGG	cis	1	rs11018625	chr11:89202569	NOX4	chr11:89057524-89322779:-	0.32	3.5	0.000508	Homocysteine levels	
LGG	cis	1	rs11018626	chr11:89203987	NOX4	chr11:89057524-89322779:-	0.36	3.89	0.000113	Homocysteine levels	
LGG	cis	1	rs11018628	chr11:89206511	NOX4	chr11:89057524-89322779:-	0.37	4.01	6.92E-5	Homocysteine levels	
LGG	cis	1	rs11018629	chr11:89206964	NOX4	chr11:89057524-89322779:-	-0.36	-3.93	9.7E-5	Homocysteine levels	
LGG	cis	1	rs11020836	chr11:94308892	MRE11A	chr11:94150469-94227040:-	-0.14	-3.75	0.000196	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs11020840	chr11:94313514	MRE11A	chr11:94150469-94227040:-	-0.14	-3.62	0.000319	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs11020847	chr11:94323912	MRE11A	chr11:94150469-94227040:-	0.13	3.47	0.000568	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs11025523	chr11:20378124	HTATIP2	chr11:20385231-20405329:+	0.21	5.33	1.5E-7	Obesity-related traits	
LGG	cis	1	rs11036474	chr11:5275178	HBG2	chr11:5269502-5667011:-	0.3	4.97	9.25E-7	Hemoglobin levels	
LGG	cis	1	rs11039255	chr11:47495746	ACP2	chr11:47260854-47270457:-	0.17	3.54	0.000436	Subjective well-being	
LGG	cis	1	rs11039255	chr11:47495746	MTCH2	chr11:47638859-47664206:-	0.25	4.9	1.3E-6	Subjective well-being	
LGG	cis	1	rs11039255	chr11:47495746	PSMC3	chr11:47440320-47448024:-	0.18	4.45	1.04E-5	Subjective well-being	
LGG	cis	1	rs11039390	chr11:47796295	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs11039390	chr11:47796295	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs11039390	chr11:47796295	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs11039412	chr11:47841581	ACP2	chr11:47260854-47270457:-	0.16	3.52	0.000464	Subjective well-being	
LGG	cis	1	rs11039412	chr11:47841581	MTCH2	chr11:47638859-47664206:-	0.25	4.78	2.27E-6	Subjective well-being	
LGG	cis	1	rs11039412	chr11:47841581	PSMC3	chr11:47440320-47448024:-	0.15	3.76	0.000193	Subjective well-being	
LGG	cis	1	rs11039426	chr11:47863119	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000365	Subjective well-being	
LGG	cis	1	rs11039426	chr11:47863119	MTCH2	chr11:47638859-47664206:-	0.25	4.81	2.03E-6	Subjective well-being	
LGG	cis	1	rs11039426	chr11:47863119	PSMC3	chr11:47440320-47448024:-	0.15	3.71	0.000235	Subjective well-being	
LGG	cis	1	rs11041476	chr11:1875067	LSP1	chr11:1874200-1913492:+	0.19	4.67	3.93E-6	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LGG	cis	1	rs11042114	chr11:8919889	C11orf17	chr11:8932701-8941624:+	-0.19	-3.61	0.00034	Schizophrenia	
LGG	cis	1	rs11043133	chr11:2232665	C11orf21	chr11:2317507-2323143:-	0.26	4.48	9.43E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs11043134	chr11:2232682	C11orf21	chr11:2317507-2323143:-	0.26	4.48	9.43E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs11043143	chr11:2234093	C11orf21	chr11:2317507-2323143:-	0.27	4.69	3.59E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs11048457	chr12:26463174	BHLHE41	chr12:26272961-26278003:-	0.13	3.86	0.000128	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs1105856	chr13:44227067	C13orf31	chr13:44453420-44468067:+	0.1	3.5	0.000502	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs1105978	chr3:195929380	SENP5	chr3:196594727-196661582:+	0.2	3.7	0.000236	HIV-1 susceptibility	
LGG	cis	1	rs1106287	chr1:113242122	ST7L	chr1:113066142-113162405:-	0.25	5.75	1.53E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs1106287	chr1:113242122	WNT2B	chr1:113010040-113063908:+	0.19	3.81	0.000157	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs1106565	chr10:102211613	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1106565	chr10:102211613	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1106565	chr10:102211613	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11070148	chr13:96304666	UGGT2	chr13:96453838-96705736:-	-0.27	-4.26	2.5E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs11070798	chr15:50883263	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs11070800	chr15:50907347	SPPL2A	chr15:50999739-51057910:-	0.12	3.95	8.79E-5	QT interval	
LGG	cis	1	rs11070805	chr15:50964192	SPPL2A	chr15:50999739-51057910:-	0.13	4.2	3.23E-5	QT interval	
LGG	cis	1	rs11070807	chr15:50974505	SPPL2A	chr15:50999739-51057910:-	0.14	4.36	1.58E-5	QT interval	
LGG	cis	1	rs11072567	chr15:76298744	NRG4	chr15:76235385-76352069:-	0.17	3.74	0.000208	Urate levels in obese individuals	
LGG	cis	1	rs11072804	chr15:79078486	ADAMTS7	chr15:79051546-79103773:-	0.18	3.73	0.000217	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11072804	chr15:79078486	CHRNA5	chr15:78857906-78886458:+	-0.24	-4.05	5.99E-5	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11072805	chr15:79078518	ADAMTS7	chr15:79051546-79103773:-	0.18	3.74	0.000205	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11072805	chr15:79078518	CHRNA5	chr15:78857906-78886458:+	-0.24	-4.04	6.23E-5	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1107328	chr9:131917534	CRAT	chr9:131857075-131873070:-	-0.22	-3.96	8.52E-5	Blood metabolite ratios	
LGG	cis	1	rs11077773	chr17:73060073	ATP5H	chr17:73034955-73043074:-	-0.19	-3.81	0.000157	Information processing speed	
LGG	cis	1	rs11077773	chr17:73060073	C17orf28	chr17:72946840-72968900:-	-0.25	-4.3	2.02E-5	Information processing speed	
LGG	cis	1	rs11077773	chr17:73060073	CASKIN2	chr17:73496343-73511627:-	-0.21	-3.63	0.000318	Information processing speed	
LGG	cis	1	rs11079034	chr17:40288890	DHX58	chr17:40253422-40264751:-	-0.2	-4.04	6.08E-5	Fibrinogen levels	
LGG	cis	1	rs11079034	chr17:40288890	HSPB9	chr17:40274756-40275371:+	-0.16	-3.49	0.000528	Fibrinogen levels	
LGG	cis	1	rs11079508	chr17:61750066	DDX42	chr17:61851567-61896676:+	-0.16	-3.74	0.000209	Body mass index	
LGG	cis	1	rs11079508	chr17:61750066	FTSJ3	chr17:61896795-61905031:-	0.41	8.36	6.51E-16	Body mass index	
LGG	cis	1	rs11079508	chr17:61750066	SMARCD2	chr17:61909441-61920351:-	0.18	3.96	8.52E-5	Body mass index	
LGG	cis	1	rs11079509	chr17:61762148	FTSJ3	chr17:61896795-61905031:-	0.42	8.17	2.73E-15	Body mass index	
LGG	cis	1	rs11079509	chr17:61762148	SMARCD2	chr17:61909441-61920351:-	0.18	3.96	8.47E-5	Body mass index	
LGG	cis	1	rs11079511	chr17:61858537	DDX42	chr17:61851567-61896676:+	-0.16	-3.63	0.000308	Body mass index	
LGG	cis	1	rs11079511	chr17:61858537	FTSJ3	chr17:61896795-61905031:-	0.42	8.47	2.91E-16	Body mass index	
LGG	cis	1	rs11079511	chr17:61858537	SMARCD2	chr17:61909441-61920351:-	0.18	3.9	0.000111	Body mass index	
LGG	cis	1	rs11079706	chr17:65835470	LOC440461	chr17:66194801-66196436:+	0.27	4.5	8.63E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs11079707	chr17:65835617	LOC440461	chr17:66194801-66196436:+	-0.26	-4.28	2.25E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs11079757	chr17:45195850	ARL17B	chr17:44363863-44417140:-	-0.38	-5.43	8.89E-8	Erythema nodosum in inflammatory bowel disease	
LGG	cis	1	rs11079818	chr17:46454177	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000504	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs11080114	chr17:28407287	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.98	4.34E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs11083274	chr18:19257123	ESCO1	chr18:19109262-19180693:-	0.22	4.29	2.13E-5	Phospholipid levels (plasma)	
LGG	cis	1	rs11084085	chr19:52030384	ZNF175	chr19:52074531-52092990:+	-0.31	-3.93	9.59E-5	Carotid intima media thickness	
LGG	cis	1	rs1108431	chr16:31054607	MYST1	chr16:31128985-31142713:+	0.15	4.1	4.79E-5	Response to metformin (IC50)	
LGG	cis	1	rs1108431	chr16:31054607	PRSS53	chr16:31094747-31106276:-	-0.17	-4.44	1.11E-5	Response to metformin (IC50)	
LGG	cis	1	rs11084785	chr19:35282054	ZNF181	chr19:35225151-35233774:+	-0.15	-4.43	1.14E-5	Urate levels (BMI interaction)	
LGG	cis	1	rs11084786	chr19:35282181	ZNF181	chr19:35225151-35233774:+	-0.15	-4.43	1.16E-5	Urate levels (BMI interaction)	
LGG	cis	1	rs11086102	chr19:18398628	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.4	1.35E-5	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs11086102	chr19:18398628	TMEM161A	chr19:19230431-19249267:-	-0.13	-3.54	0.000439	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs11087520	chr20:25436827	ABHD12	chr20:25275380-25371477:-	0.26	7.12	3.97E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11087520	chr20:25436827	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	2.98E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11087520	chr20:25436827	FAM182B	chr20:25744102-25848786:-	0.21	4.81	1.99E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11087521	chr20:25440648	ABHD12	chr20:25275380-25371477:-	0.27	7.24	1.69E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11087521	chr20:25440648	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	3.15E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11087521	chr20:25440648	FAM182B	chr20:25744102-25848786:-	0.22	4.98	8.86E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11088226	chr21:33925531	TCP10L	chr21:33947152-33957845:-	-0.34	-6.11	2.0E-9	Gastritis	
LGG	cis	1	rs1109227	chr3:48479207	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.18E-5	Longevity	
LGG	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.43	-11.2	4.57E-26	Longevity	
LGG	cis	1	rs1109619	chr8:8571616	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.87	1.5E-6	Obesity-related traits	
LGG	cis	1	rs11097912	chr4:107000462	NPNT	chr4:106816605-106892827:+	-0.23	-4.85	1.65E-6	Airflow obstruction	
LGG	cis	1	rs11098499	chr4:120187611	MYOZ2	chr4:120056939-120108935:+	0.22	4.1	4.9E-5	Corneal astigmatism	
LGG	cis	1	rs11098500	chr4:120219239	MYOZ2	chr4:120056939-120108935:+	0.23	4.4	1.36E-5	Corneal astigmatism	
LGG	cis	1	rs1110042	chr1:113236534	ST7L	chr1:113066142-113162405:-	0.24	5.72	1.84E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs1110042	chr1:113236534	WNT2B	chr1:113010040-113063908:+	0.19	3.9	0.00011	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs11100	chr20:25281184	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11100	chr20:25281184	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11100	chr20:25281184	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs11110758	chr12:101734947	UTP20	chr12:101673905-101780397:+	-0.15	-3.52	0.000464	Alcohol dependence (age at onset)	
LGG	cis	1	rs11111789	chr12:104191540	NT5DC3	chr12:104164231-104234975:-	-0.22	-4.6	5.4E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs11111791	chr12:104193271	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.53	7.4E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs11111792	chr12:104194857	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.73	2.9E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs11113818	chr12:108717929	ISCU	chr12:108956294-108963158:+	0.18	4.55	6.89E-6	Response to methotrexate in juvenile idiopathic arthritis	
LGG	cis	1	rs11114040	chr12:109121759	SELPLG	chr12:109015682-109027670:-	0.21	3.67	0.000266	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs11119742	chr1:211624504	C1orf97	chr1:211556097-211605876:+	0.2	3.51	0.000492	Educational attainment (years of education)	
LGG	cis	1	rs1112137	chr1:247215375	ZNF670	chr1:247200087-247242069:-	-0.23	-5.25	2.26E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs11122198	chr1:231171139	FAM89A	chr1:231154704-231175995:-	0.27	4.58	5.87E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs11122199	chr1:231172686	FAM89A	chr1:231154704-231175995:-	0.26	4.67	3.95E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.8	-16.17	1.91E-47	Renal function-related traits (BUN)	
LGG	cis	1	rs11123170	chr2:113978940	PAX8	chr2:113973575-114036498:-	-0.73	-14.24	9.13E-39	Renal function-related traits (BUN)	
LGG	cis	1	rs111237243	chr14:59991030	C14orf149	chr14:59939406-59951126:-	-0.44	-4.65	4.22E-6	Schizophrenia	
LGG	cis	1	rs111237243	chr14:59991030	JKAMP	chr14:59951161-59972080:+	0.4	3.81	0.000159	Schizophrenia	
LGG	cis	1	rs11123931	chr2:103085660	IL18R1	chr2:102927962-103015215:+	-0.39	-6.19	1.3E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11123931	chr2:103085660	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.45	7.89E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11124575	chr2:37500435	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.72	3.07E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs11125529	chr2:54475866	C2orf73	chr2:54558071-54588714:+	-0.35	-4.87	1.5E-6	Telomere length	
LGG	cis	1	rs11125529	chr2:54475866	TSPYL6	chr2:54480315-54483409:-	0.46	5.38	1.14E-7	Telomere length	
LGG	cis	1	rs11125949	chr2:63357876	TMEM17	chr2:62727356-62762780:-	-0.18	-3.5	0.000508	Subjective well-being	
LGG	cis	1	rs11126251	chr2:70163434	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.41	1.26E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs11126364	chr2:26314515	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs11126375	chr2:26344787	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs11127071	chr2:27838058	PPM1G	chr2:27604062-27632496:-	0.13	4.12	4.37E-5	Oral cavity cancer	
LGG	cis	1	rs11127071	chr2:27838058	SNX17	chr2:27593363-27599994:+	-0.11	-3.49	0.000526	Oral cavity cancer	
LGG	cis	1	rs11127188	chr2:28972852	FAM179A	chr2:29204164-29275094:+	-0.19	-3.73	0.000215	Body mass index	
LGG	cis	1	rs11127188	chr2:28972852	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.58	1.07E-23	Body mass index	
LGG	cis	1	rs111295372	chr2:86283357	LOC90784	chr2:86247339-86250991:-	-0.48	-5	8.1E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs11130127	chr3:47398793	NRADDP	chr3:47053032-47054957:+	0.23	3.99	7.7E-5	Colorectal cancer	
LGG	cis	1	rs11130170	chr3:48449897	ATRIP	chr3:48488141-48507708:+	0.18	4.42	1.2E-5	Longevity	
LGG	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.42	-10.92	5.51E-25	Longevity	
LGG	cis	1	rs11130171	chr3:48462461	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.94E-6	Longevity	
LGG	cis	1	rs11130171	chr3:48462461	TREX1	chr3:48501186-48509043:+	-0.43	-11.11	9.53E-26	Longevity	
LGG	cis	1	rs11130189	chr3:49347357	AMIGO3	chr3:49754268-49757238:-	-0.17	-3.87	0.000123	Menarche (age at onset)	
LGG	cis	1	rs11130189	chr3:49347357	GMPPB	chr3:49758932-49761384:-	-0.2	-3.77	0.000185	Menarche (age at onset)	
LGG	cis	1	rs11130189	chr3:49347357	NCKIPSD	chr3:48711280-48723334:-	0.16	3.59	0.000363	Menarche (age at onset)	
LGG	cis	1	rs11130189	chr3:49347357	TREX1	chr3:48501186-48509043:+	-0.25	-5.25	2.25E-7	Menarche (age at onset)	
LGG	cis	1	rs11130190	chr3:49402137	AMIGO3	chr3:49754268-49757238:-	-0.19	-4.5	8.5E-6	Menarche (age at onset)	
LGG	cis	1	rs11130190	chr3:49402137	GMPPB	chr3:49758932-49761384:-	-0.23	-4.51	7.99E-6	Menarche (age at onset)	
LGG	cis	1	rs11130190	chr3:49402137	TREX1	chr3:48501186-48509043:+	-0.25	-5.15	3.69E-7	Menarche (age at onset)	
LGG	cis	1	rs11130213	chr3:49712297	MST1R	chr3:49924438-49941306:-	-0.2	-3.88	0.000118	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11130213	chr3:49712297	RBM6	chr3:49977592-50137484:+	0.16	4.49	8.7E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11130213	chr3:49712297	SEMA3F	chr3:50192848-50226507:+	0.19	4.37	1.5E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11130214	chr3:49735746	MST1R	chr3:49924438-49941306:-	-0.27	-5.11	4.73E-7	Resting heart rate	
LGG	cis	1	rs11130216	chr3:49736172	MST1R	chr3:49924438-49941306:-	0.26	4.9	1.34E-6	Resting heart rate	
LGG	cis	1	rs11130338	chr3:53120924	RFT1	chr3:53122503-53164470:-	-0.47	-10.05	1.02E-21	Height	
LGG	cis	1	rs111315781	chr2:201738724	NDUFB3	chr2:201936462-201950471:+	-0.21	-3.86	0.000131	Triptolide cytotoxicity	
LGG	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-0.98	-18.01	4.83E-56	Triptolide cytotoxicity	
LGG	cis	1	rs11132254	chr4:185611592	CCDC111	chr4:185570767-185616112:+	0.2	4.2	3.19E-5	Kawasaki disease	
LGG	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.23	-6.65	7.93E-11	Kawasaki disease	
LGG	cis	1	rs111323769	chr4:171049059	AADAT	chr4:170981374-171011372:-	-0.28	-3.47	0.000559	Thyroid hormone levels	
LGG	cis	1	rs11133399	chr4:56413831	TMEM165	chr4:56262090-56292342:+	0.18	5.12	4.34E-7	Personality dimensions	
LGG	cis	1	rs111355947	chr14:59911985	C14orf149	chr14:59939406-59951126:-	-0.44	-4.62	4.91E-6	Schizophrenia	
LGG	cis	1	rs111355947	chr14:59911985	JKAMP	chr14:59951161-59972080:+	0.49	4.58	5.83E-6	Schizophrenia	
LGG	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.41	7.22	2.04E-12	Metabolite levels	
LGG	cis	1	rs1114380	chr2:73804708	NAT8	chr2:73867850-73869537:-	0.27	4.41	1.24E-5	Metabolite levels	
LGG	cis	1	rs111476301	chr14:59920191	C14orf149	chr14:59939406-59951126:-	-0.44	-4.62	4.91E-6	Schizophrenia	
LGG	cis	1	rs111476301	chr14:59920191	JKAMP	chr14:59951161-59972080:+	0.49	4.58	5.83E-6	Schizophrenia	
LGG	cis	1	rs11148252	chr13:53009048	CKAP2	chr13:53029495-53050763:+	-0.28	-8.51	2.08E-16	Lewy body disease	
LGG	cis	1	rs11148252	chr13:53009048	NEK3	chr13:52706780-52733996:-	0.26	8	9.26E-15	Lewy body disease	
LGG	cis	1	rs11148252	chr13:53009048	TPTE2P3	chr13:53063128-53161224:+	-0.17	-4.1	4.87E-5	Lewy body disease	
LGG	cis	1	rs11148252	chr13:53009048	VPS36	chr13:52986739-53024763:-	0.16	4.37	1.51E-5	Lewy body disease	
LGG	cis	1	rs111489600	chr14:59993021	C14orf149	chr14:59939406-59951126:-	-0.44	-4.65	4.22E-6	Schizophrenia	
LGG	cis	1	rs111489600	chr14:59993021	JKAMP	chr14:59951161-59972080:+	0.4	3.81	0.000159	Schizophrenia	
LGG	cis	1	rs11149710	chr16:74472546	RFWD3	chr16:74655298-74700779:-	0.14	4.55	6.65E-6	Breast cancer	
LGG	cis	1	rs11157696	chr14:50105746	RPL36AL	chr14:50085407-50087349:-	-0.31	-8.27	1.29E-15	Carotid intima media thickness	
LGG	cis	1	rs11158027	chr14:55349103	GCH1	chr14:55308724-55369542:-	-0.29	-4.8	2.13E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs11159067	chr14:74637444	LIN52	chr14:74551656-74667117:+	0.46	9.7	1.84E-20	Common traits (Other)	
LGG	cis	1	rs11159117	chr14:75584867	ACYP1	chr14:75519930-75530736:-	-0.14	-3.85	0.000136	Height	
LGG	cis	1	rs11159117	chr14:75584867	EIF2B2	chr14:75469612-75476292:+	0.18	3.51	0.000491	Height	
LGG	cis	1	rs11159183	chr14:76662902	ESRRB	chr14:76837690-76968178:+	0.43	7.04	6.42E-12	Blood pressure	
LGG	cis	1	rs111596617	chr6:26191678	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs111596617	chr6:26191678	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs11159856	chr14:88883929	KCNK10	chr14:88646454-88793256:-	-0.18	-3.49	0.000533	Coronary artery calcification	
LGG	cis	1	rs11159856	chr14:88883929	SPATA7	chr14:88852012-88904802:+	-0.5	-8.96	6.72E-18	Coronary artery calcification	
LGG	cis	1	rs11161510	chr1:76210289	ACADM	chr1:76190043-76229353:+	-0.12	-3.46	0.000591	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11161510	chr1:76210289	MSH4	chr1:76262630-76378923:+	-0.24	-4.28	2.26E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11161511	chr1:76210477	MSH4	chr1:76262630-76378923:+	-0.19	-3.57	0.000393	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11161515	chr1:76212559	ACADM	chr1:76190043-76229353:+	0.12	3.47	0.000562	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11161515	chr1:76212559	MSH4	chr1:76262630-76378923:+	0.25	4.41	1.3E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11161521	chr1:76216330	MSH4	chr1:76262630-76378923:+	0.25	4.34	1.73E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs11163924	chr1:76132070	MSH4	chr1:76262630-76378923:+	-0.26	-4.48	9.17E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs111640872	chr19:30290357	CCNE1	chr19:30302901-30315218:+	-0.21	-4.31	2.0E-5	Bladder cancer	
LGG	cis	1	rs111641740	chr20:33707177	PROCR	chr20:33758727-33765164:+	-0.35	-6.38	4.04E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11164654	chr1:92968312	EVI5	chr1:92974255-93257961:-	-0.29	-6.96	1.1E-11	Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs111649495	chr5:118356415	DTWD2	chr5:118172571-118324240:-	-0.35	-4.81	2.06E-6	Response to amphetamines	
LGG	cis	1	rs11167254	chr20:33654584	PROCR	chr20:33758727-33765164:+	-0.3	-5.78	1.32E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11167260	chr20:33775200	PROCR	chr20:33758727-33765164:+	-0.35	-6.03	3.25E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11167515	chr5:150239471	LOC134466	chr5:150310000-150326146:-	0.49	5.38	1.18E-7	Crohn's disease	
LGG	cis	1	rs11167518	chr5:150258920	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11167519	chr5:150265407	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11167520	chr5:150265639	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11167521	chr5:150271785	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11167526	chr5:150332481	LOC134466	chr5:150310000-150326146:-	0.48	5.14	3.93E-7	Crohn's disease	
LGG	cis	1	rs11168351	chr12:48403765	H1FNT	chr12:48722763-48724061:+	-0.22	-4.9	1.29E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs11168576	chr12:48840418	VDR	chr12:48235322-48298814:-	0.22	3.52	0.000463	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168628	chr12:48949564	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168629	chr12:48949622	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168630	chr12:48950070	ZNF641	chr12:48735912-48745021:-	0.26	3.86	0.000127	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168631	chr12:48950129	ZNF641	chr12:48735912-48745021:-	0.26	3.86	0.000127	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168632	chr12:48950578	ZNF641	chr12:48735912-48745021:-	0.26	3.86	0.000127	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168633	chr12:48951224	ZNF641	chr12:48735912-48745021:-	0.25	3.84	0.000139	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168634	chr12:48951593	ZNF641	chr12:48735912-48745021:-	0.24	3.65	0.000288	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168635	chr12:48951718	ZNF641	chr12:48735912-48745021:-	0.23	3.55	0.000422	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168636	chr12:48951840	ZNF641	chr12:48735912-48745021:-	0.24	3.65	0.000288	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11168639	chr12:48953682	ZNF641	chr12:48735912-48745021:-	0.24	3.65	0.000288	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs11171803	chr12:56718422	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs11171806	chr12:56733531	IL23A	chr12:56732663-56734193:+	-0.57	-5.1	4.89E-7	Psoriasis vulgaris	
LGG	cis	1	rs11172254	chr12:57968738	FAM119B	chr12:58166383-58176323:+	-0.27	-6.68	6.47E-11	Rheumatoid arthritis	
LGG	cis	1	rs11172254	chr12:57968738	TSFM	chr12:58176536-58191367:+	0.2	3.82	0.000149	Rheumatoid arthritis	
LGG	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.46	11.21	3.89E-26	Multiple sclerosis	
LGG	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.45	-8.47	2.88E-16	Multiple sclerosis	
LGG	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.46	11.16	6.48E-26	Multiple sclerosis	
LGG	cis	1	rs11172335	chr12:58175201	TSFM	chr12:58176536-58191367:+	-0.47	-8.92	8.92E-18	Multiple sclerosis	
LGG	cis	1	rs11172335	chr12:58175201	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-3.62	0.000328	Multiple sclerosis	
LGG	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.47	11.36	1.03E-26	Multiple sclerosis	
LGG	cis	1	rs11172342	chr12:58187758	TSFM	chr12:58176536-58191367:+	-0.46	-8.8	2.39E-17	Multiple sclerosis	
LGG	cis	1	rs11172342	chr12:58187758	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-3.7	0.000237	Multiple sclerosis	
LGG	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.47	11.36	1.03E-26	Multiple sclerosis	
LGG	cis	1	rs11172343	chr12:58188157	TSFM	chr12:58176536-58191367:+	-0.46	-8.8	2.39E-17	Multiple sclerosis	
LGG	cis	1	rs11172343	chr12:58188157	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-3.7	0.000237	Multiple sclerosis	
LGG	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.47	11.59	1.25E-27	Multiple sclerosis	
LGG	cis	1	rs11172344	chr12:58193448	TSFM	chr12:58176536-58191367:+	-0.45	-8.63	8.9E-17	Multiple sclerosis	
LGG	cis	1	rs11172344	chr12:58193448	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.49	0.000523	Multiple sclerosis	
LGG	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.48	11.49	3.15E-27	Multiple sclerosis	
LGG	cis	1	rs11172349	chr12:58212528	TSFM	chr12:58176536-58191367:+	-0.45	-8.42	4.3E-16	Multiple sclerosis	
LGG	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.48	11.24	3.18E-26	Multiple sclerosis	
LGG	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.46	-8.53	1.87E-16	Multiple sclerosis	
LGG	cis	1	rs111745772	chr14:60011260	C14orf149	chr14:59939406-59951126:-	-0.43	-4.47	9.83E-6	Schizophrenia	
LGG	cis	1	rs111745772	chr14:60011260	JKAMP	chr14:59951161-59972080:+	0.45	4.21	3.0E-5	Schizophrenia	
LGG	cis	1	rs111803315	chr14:59965293	C14orf149	chr14:59939406-59951126:-	-0.4	-4.26	2.41E-5	Schizophrenia	
LGG	cis	1	rs111803315	chr14:59965293	JKAMP	chr14:59951161-59972080:+	0.51	4.91	1.25E-6	Schizophrenia	
LGG	cis	1	rs11180559	chr12:75920285	GLIPR1L2	chr12:75784889-75825591:+	0.39	5.45	7.92E-8	Daytime sleep phenotypes	
LGG	cis	1	rs11186358	chr10:92667175	RPP30	chr10:92631474-92668312:+	0.19	3.68	0.000256	Economic and political preferences (time)	
LGG	cis	1	rs11186359	chr10:92667387	RPP30	chr10:92631474-92668312:+	0.19	3.72	0.000224	Economic and political preferences (time)	
LGG	cis	1	rs11186361	chr10:92668274	RPP30	chr10:92631474-92668312:+	0.19	3.68	0.000256	Economic and political preferences (time)	
LGG	cis	1	rs11186367	chr10:92673607	RPP30	chr10:92631474-92668312:+	0.19	3.73	0.00021	Economic and political preferences (time)	
LGG	cis	1	rs111882043	chr14:59899356	C14orf149	chr14:59939406-59951126:-	-0.42	-4.52	7.93E-6	Schizophrenia	
LGG	cis	1	rs111882043	chr14:59899356	JKAMP	chr14:59951161-59972080:+	0.43	4.14	4.12E-5	Schizophrenia	
LGG	cis	1	rs11188394	chr10:97365458	TCTN3	chr10:97423154-97453900:-	0.2	3.89	0.000113	Blood metabolite levels	
LGG	cis	1	rs11188396	chr10:97367510	TCTN3	chr10:97423154-97453900:-	0.19	3.78	0.000173	Blood metabolite levels	
LGG	cis	1	rs11188398	chr10:97369093	TCTN3	chr10:97423154-97453900:-	0.2	3.92	0.000102	Blood metabolite levels	
LGG	cis	1	rs11188400	chr10:97371327	TCTN3	chr10:97423154-97453900:-	0.2	3.98	7.96E-5	Blood metabolite levels	
LGG	cis	1	rs11188407	chr10:97390533	TCTN3	chr10:97423154-97453900:-	0.17	3.46	0.000577	Blood metabolite levels	
LGG	cis	1	rs11188411	chr10:97397344	TCTN3	chr10:97423154-97453900:-	0.18	3.62	0.00032	Blood metabolite levels	
LGG	cis	1	rs11188417	chr10:97411680	TCTN3	chr10:97423154-97453900:-	-0.19	-3.81	0.000157	Blood metabolite levels	
LGG	cis	1	rs111885088	chr12:56657216	IL23A	chr12:56732663-56734193:+	0.53	4.79	2.26E-6	Psoriasis vulgaris	
LGG	cis	1	rs111901203	chr11:58297542	ZFP91-CNTF	chr11:58346587-58393203:+	0.35	5.79	1.27E-8	Lymphoma	
LGG	cis	1	rs11190466	chr10:102061908	BLOC1S2	chr10:102033713-102046439:-	-0.32	-4.76	2.5E-6	Obesity-related traits	
LGG	cis	1	rs11190470	chr10:102069074	BLOC1S2	chr10:102033713-102046439:-	-0.31	-4.56	6.32E-6	Obesity-related traits	
LGG	cis	1	rs11190540	chr10:102202629	HIF1AN	chr10:102295641-102313680:+	0.18	3.56	0.000408	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190540	chr10:102202629	NDUFB8	chr10:102283497-102289636:-	0.15	4.24	2.66E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190540	chr10:102202629	WNT8B	chr10:102222812-102243397:+	0.5	8.62	8.96E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190541	chr10:102203071	HIF1AN	chr10:102295641-102313680:+	0.19	3.77	0.000185	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190541	chr10:102203071	NDUFB8	chr10:102283497-102289636:-	0.16	4.64	4.53E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190541	chr10:102203071	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.13E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190551	chr10:102204734	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190551	chr10:102204734	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190551	chr10:102204734	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190552	chr10:102206607	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190552	chr10:102206607	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190552	chr10:102206607	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190555	chr10:102209160	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190555	chr10:102209160	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190555	chr10:102209160	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190556	chr10:102209223	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190556	chr10:102209223	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190556	chr10:102209223	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190557	chr10:102209369	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190557	chr10:102209369	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190557	chr10:102209369	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190558	chr10:102209397	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190558	chr10:102209397	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190558	chr10:102209397	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190569	chr10:102227409	NDUFB8	chr10:102283497-102289636:-	0.13	3.87	0.000126	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190569	chr10:102227409	WNT8B	chr10:102222812-102243397:+	0.51	8.9	1.07E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190570	chr10:102227702	HIF1AN	chr10:102295641-102313680:+	0.18	3.53	0.000447	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190570	chr10:102227702	NDUFB8	chr10:102283497-102289636:-	0.15	4.32	1.93E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190570	chr10:102227702	WNT8B	chr10:102222812-102243397:+	0.51	8.73	3.9E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190572	chr10:102232879	HIF1AN	chr10:102295641-102313680:+	0.18	3.56	0.000402	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190572	chr10:102232879	NDUFB8	chr10:102283497-102289636:-	0.15	4.31	1.97E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190572	chr10:102232879	WNT8B	chr10:102222812-102243397:+	0.51	8.66	7.06E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190578	chr10:102238953	HIF1AN	chr10:102295641-102313680:+	0.19	3.78	0.000173	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190578	chr10:102238953	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190578	chr10:102238953	WNT8B	chr10:102222812-102243397:+	0.52	8.83	1.87E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190587	chr10:102266638	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.15E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190587	chr10:102266638	SEC31B	chr10:102246403-102289636:-	-0.11	-3.47	0.000559	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190587	chr10:102266638	WNT8B	chr10:102222812-102243397:+	0.5	8.12	3.69E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190589	chr10:102275471	HIF1AN	chr10:102295641-102313680:+	0.19	3.65	0.00029	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190589	chr10:102275471	NDUFB8	chr10:102283497-102289636:-	0.17	4.73	2.99E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190589	chr10:102275471	WNT8B	chr10:102222812-102243397:+	0.48	7.81	3.54E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190592	chr10:102291059	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190592	chr10:102291059	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190592	chr10:102291059	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190595	chr10:102291761	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190595	chr10:102291761	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190595	chr10:102291761	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190596	chr10:102293238	HIF1AN	chr10:102295641-102313680:+	0.19	3.54	0.000433	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190596	chr10:102293238	NDUFB8	chr10:102283497-102289636:-	0.18	4.96	9.59E-7	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190596	chr10:102293238	WNT8B	chr10:102222812-102243397:+	0.49	7.94	1.4E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190597	chr10:102293676	HIF1AN	chr10:102295641-102313680:+	0.19	3.69	0.000251	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190597	chr10:102293676	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.08E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190597	chr10:102293676	WNT8B	chr10:102222812-102243397:+	0.49	8	8.83E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190599	chr10:102295420	HIF1AN	chr10:102295641-102313680:+	0.19	3.69	0.000251	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190599	chr10:102295420	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.08E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190599	chr10:102295420	WNT8B	chr10:102222812-102243397:+	0.49	8	8.83E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190601	chr10:102296730	HIF1AN	chr10:102295641-102313680:+	0.2	3.8	0.00016	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190601	chr10:102296730	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190601	chr10:102296730	WNT8B	chr10:102222812-102243397:+	0.51	8.37	5.87E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190602	chr10:102297256	HIF1AN	chr10:102295641-102313680:+	0.2	3.75	0.000196	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190602	chr10:102297256	NDUFB8	chr10:102283497-102289636:-	0.18	4.87	1.51E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190602	chr10:102297256	WNT8B	chr10:102222812-102243397:+	0.49	8.02	8.07E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190604	chr10:102302457	NDUFB8	chr10:102283497-102289636:-	0.17	4.62	4.95E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190604	chr10:102302457	WNT8B	chr10:102222812-102243397:+	0.49	7.86	2.49E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190607	chr10:102303614	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190607	chr10:102303614	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190607	chr10:102303614	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190613	chr10:102313997	NDUFB8	chr10:102283497-102289636:-	-0.13	-3.49	0.000535	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11190613	chr10:102313997	WNT8B	chr10:102222812-102243397:+	-0.46	-7.52	2.7E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11191416	chr10:104604916	SFXN2	chr10:104474298-104498946:+	0.28	3.58	0.000384	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs11191419	chr10:104612335	AS3MT	chr10:104613967-104661653:+	-0.73	-18.56	1.12E-58	Schizophrenia	
LGG	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.32	-7.12	3.92E-12	Schizophrenia	
LGG	cis	1	rs11191425	chr10:104625970	SFXN2	chr10:104474298-104498946:+	-0.28	-3.46	0.000583	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs111915672	chr8:58191665	C8orf71	chr8:58192102-58197288:+	0.36	6.08	2.36E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11200595	chr10:124142629	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.11	4.7E-5	Height	
LGG	cis	1	rs11200606	chr10:124148765	PLEKHA1	chr10:124134220-124191866:+	-0.11	-3.95	8.85E-5	Height	
LGG	cis	1	rs11200608	chr10:124157821	PLEKHA1	chr10:124134220-124191866:+	-0.11	-3.89	0.000112	Height	
LGG	cis	1	rs11200609	chr10:124157858	PLEKHA1	chr10:124134220-124191866:+	-0.11	-3.9	0.000109	Height	
LGG	cis	1	rs11200629	chr10:124198585	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.05	5.86E-5	Height	
LGG	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.48	-8.99	5.45E-18	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs11201799	chr10:81881954	LOC219347	chr10:81805991-81838949:-	-0.47	-8.37	6.21E-16	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs11204330	chr17:20925846	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs11204626	chr1:248458974	OR2L13	chr1:248100493-248264223:+	0.2	3.64	0.000307	Common traits (Other)	
LGG	cis	1	rs11204636	chr1:248492409	OR2L13	chr1:248100493-248264223:+	-0.2	-3.53	0.000455	Common traits (Other)	
LGG	cis	1	rs11204700	chr1:150660702	ARNT	chr1:150782186-150849186:-	-0.24	-4.36	1.6E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs11204971	chr1:152259078	HRNR	chr1:152184558-152196669:-	-0.57	-7.99	1.0E-14	Atopic dermatitis	
LGG	cis	1	rs11205132	chr1:152882135	SMCP	chr1:152850798-152857515:+	-0.33	-5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11205316	chr1:150007105	RPRD2	chr1:150336990-150449039:+	-0.15	-3.85	0.000134	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11205319	chr1:150017823	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11205321	chr1:150026207	RPRD2	chr1:150336990-150449039:+	0.16	3.92	0.000101	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11205326	chr1:150076542	RPRD2	chr1:150336990-150449039:+	-0.15	-3.78	0.000173	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11205333	chr1:150107136	RPRD2	chr1:150336990-150449039:+	-0.15	-3.74	0.000206	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs112062277	chr11:94314273	MRE11A	chr11:94150469-94227040:-	-0.14	-3.6	0.000348	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs112071449	chr4:171013233	AADAT	chr4:170981374-171011372:-	-0.31	-4.01	7.09E-5	Thyroid hormone levels	
LGG	cis	1	rs1121089	chr4:17676476	LAP3	chr4:17578927-17609590:+	-0.14	-3.82	0.00015	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1121090	chr4:17676437	LAP3	chr4:17578927-17609590:+	-0.14	-3.83	0.000147	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1121091	chr4:17676386	LAP3	chr4:17578927-17609590:+	-0.14	-3.83	0.000147	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.27	-7.47	3.6E-13	Homocysteine levels	
LGG	cis	1	rs11211132	chr1:45990516	MMACHC	chr1:45965856-45976737:+	0.26	5.57	4.24E-8	Homocysteine levels	
LGG	cis	1	rs11211132	chr1:45990516	MUTYH	chr1:45794915-45806142:-	0.13	4.4	1.32E-5	Homocysteine levels	
LGG	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.08	5.49E-7	Body mass index	
LGG	cis	1	rs11211199	chr1:46287869	MUTYH	chr1:45794915-45806142:-	0.14	5.15	3.86E-7	Body mass index	
LGG	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.96	9.88E-7	Body mass index	
LGG	cis	1	rs11211208	chr1:46334256	MUTYH	chr1:45794915-45806142:-	0.14	5.12	4.5E-7	Body mass index	
LGG	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.11	4.53E-7	Body mass index	
LGG	cis	1	rs11211230	chr1:46406767	MUTYH	chr1:45794915-45806142:-	0.14	5.03	7.01E-7	Body mass index	
LGG	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.72	3.13E-6	Body mass index	
LGG	cis	1	rs11211234	chr1:46438787	MUTYH	chr1:45794915-45806142:-	0.13	4.96	9.68E-7	Body mass index	
LGG	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.72	3.15E-6	Body mass index	
LGG	cis	1	rs11211241	chr1:46452683	MUTYH	chr1:45794915-45806142:-	0.13	4.95	1.01E-6	Body mass index	
LGG	cis	1	rs11212579	chr11:108150664	ATM	chr11:108093559-108239826:+	-0.11	-3.49	0.000529	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs112143304	chr17:61822401	FTSJ3	chr17:61896795-61905031:-	0.42	8.21	2.03E-15	Body mass index	
LGG	cis	1	rs112143304	chr17:61822401	SMARCD2	chr17:61909441-61920351:-	0.19	4.15	3.97E-5	Body mass index	
LGG	cis	1	rs11216316	chr11:117081500	SIDT2	chr11:117049939-117068161:+	-0.34	-4.01	6.99E-5	Protein quantitative trait loci	
LGG	cis	1	rs11217841	chr11:120238721	TMEM136	chr11:120196016-120204388:+	0.2	4.58	5.94E-6	Intraocular pressure	
LGG	cis	1	rs11217852	chr11:120261187	TMEM136	chr11:120196016-120204388:+	0.21	4.73	2.94E-6	Intraocular pressure	
LGG	cis	1	rs1122326	chr17:40274873	DHX58	chr17:40253422-40264751:-	-0.21	-4.2	3.21E-5	Fibrinogen levels	
LGG	cis	1	rs112261101	chr14:59917544	C14orf149	chr14:59939406-59951126:-	-0.44	-4.62	4.91E-6	Schizophrenia	
LGG	cis	1	rs112261101	chr14:59917544	JKAMP	chr14:59951161-59972080:+	0.49	4.58	5.83E-6	Schizophrenia	
LGG	cis	1	rs112272435	chr8:58170371	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11227284	chr11:65503224	RNASEH2C	chr11:65485146-65488409:-	-0.2	-4.61	5.07E-6	Systemic lupus erythematosus	
LGG	cis	1	rs11227284	chr11:65503224	SNX32	chr11:65601410-65621170:+	0.23	4.71	3.25E-6	Systemic lupus erythematosus	
LGG	cis	1	rs11227288	chr11:65516588	RNASEH2C	chr11:65485146-65488409:-	-0.21	-4.82	1.93E-6	Systemic lupus erythematosus	
LGG	cis	1	rs11227288	chr11:65516588	SNX32	chr11:65601410-65621170:+	0.22	4.71	3.18E-6	Systemic lupus erythematosus	
LGG	cis	1	rs112284078	chr8:58191640	C8orf71	chr8:58192102-58197288:+	0.36	5.99	3.99E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11229535	chr11:58348386	ZFP91-CNTF	chr11:58346587-58393203:+	0.35	5.87	8.15E-9	Lymphoma	
LGG	cis	1	rs11230394	chr11:60346932	MS4A14	chr11:60145958-60185226:+	0.16	4.05	5.93E-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	
LGG	cis	1	rs11230850	chr11:61751143	RAB3IL1	chr11:61664774-61687741:-	0.32	3.52	0.000468	Phospholipid levels (plasma)	
LGG	cis	1	rs11231757	chr11:64106317	C11orf20	chr11:64067863-64072238:+	0.18	3.91	0.000104	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs11231757	chr11:64106317	CCDC88B	chr11:64107695-64125005:+	-0.12	-4.54	6.93E-6	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs11231757	chr11:64106317	PPP1R14B	chr11:64011953-64014413:-	-0.13	-3.86	0.000131	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs11233933	chr11:71210070	KRTAP5-9	chr11:71259466-71260653:+	0.24	3.78	0.000177	Vitamin D levels	
LGG	cis	1	rs11233977	chr11:71221605	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.43	1.18E-5	Vitamin D levels	
LGG	cis	1	rs11234027	chr11:71234107	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.44	1.13E-5	Vitamin D levels	
LGG	cis	1	rs11235440	chr11:71826644	FAM86C	chr11:71498557-71512276:+	-0.46	-4.48	9.16E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs11237456	chr11:78040780	NARS2	chr11:78147017-78285909:-	-0.18	-3.46	0.000592	Testicular germ cell tumor	
LGG	cis	1	rs11239544	chr10:46007533	ALOX5	chr10:45869629-45941561:+	-0.1	-3.66	0.000284	Cholesterol, total	
LGG	cis	1	rs11239544	chr10:46007533	FAM21C	chr10:46222667-46288411:+	-0.19	-3.54	0.000444	Cholesterol, total	
LGG	cis	1	rs11239545	chr10:46012245	ALOX5	chr10:45869629-45941561:+	0.1	3.77	0.000183	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs1124200	chr2:1778558	PXDN	chr2:1635660-1748291:-	-0.16	-3.53	0.000456	Response to antipsychotic treatment	
LGG	cis	1	rs11242077	chr5:130771037	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.59	5.65E-6	Life satisfaction	
LGG	cis	1	rs112428033	chr5:115618260	COMMD10	chr5:115420727-115628978:+	0.43	5.17	3.37E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs11242	chr3:53125922	RFT1	chr3:53122503-53164470:-	0.44	9.29	4.88E-19	Height	
LGG	cis	1	rs112434347	chr3:127840447	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1	
LGG	cis	1	rs1124376	chr3:20108546	EFHB	chr3:19920968-19988501:-	-0.39	-5.13	4.24E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs11246359	chr11:967943	MUC6	chr11:1012824-1036706:-	-0.18	-3.83	0.000147	Alzheimer's disease (late onset)	
LGG	cis	1	rs11247124	chr15:100265725	LYSMD4	chr15:100255906-100273626:-	0.21	4.16	3.73E-5	Post bronchodilator FEV1/FVC ratio in COPD	
LGG	cis	1	rs112476368	chr14:59991452	C14orf149	chr14:59939406-59951126:-	-0.44	-4.65	4.22E-6	Schizophrenia	
LGG	cis	1	rs112476368	chr14:59991452	JKAMP	chr14:59951161-59972080:+	0.4	3.81	0.000159	Schizophrenia	
LGG	cis	1	rs1124769	chr15:51352249	SPPL2A	chr15:50999739-51057910:-	0.2	5.15	3.77E-7	Cognitive performance	
LGG	cis	1	rs11248009	chr4:220149	ZNF718	chr4:53272-156488:+	0.28	5.32	1.61E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11248013	chr4:311425	ZNF718	chr4:53272-156488:+	0.28	5.38	1.13E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11250096	chr8:10811574	RP1L1	chr8:10463862-10512617:-	-0.29	-3.7	0.000243	Asthma and hay fever	
LGG	cis	1	rs11250228	chr10:1074887	C10orf110	chr10:1068577-1090141:+	0.28	5.49	6.49E-8	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs11250249	chr10:1116999	IDI2	chr10:1064847-1071799:-	0.33	3.72	0.000219	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11250252	chr10:1124939	IDI2	chr10:1064847-1071799:-	0.3	3.63	0.000311	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11250264	chr10:1151723	IDI2	chr10:1064847-1071799:-	0.33	4.01	6.96E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs1125203	chr3:41760895	ULK4	chr3:41288091-42003660:-	0.74	14.31	4.61E-39	Diastolic blood pressure	
LGG	cis	1	rs112537273	chr8:38248306	LSM1	chr8:38020861-38034169:-	-0.2	-4.24	2.64E-5	Schizophrenia	
LGG	cis	1	rs1125394	chr11:113297185	TTC12	chr11:113185251-113244016:+	0.25	5.52	5.43E-8	Select biomarker traits	
LGG	cis	1	rs112555934	chr14:59977232	C14orf149	chr14:59939406-59951126:-	-0.42	-4.58	5.79E-6	Schizophrenia	
LGG	cis	1	rs112555934	chr14:59977232	JKAMP	chr14:59951161-59972080:+	0.4	3.95	8.91E-5	Schizophrenia	
LGG	cis	1	rs112564090	chr4:171024368	AADAT	chr4:170981374-171011372:-	-0.31	-3.94	9.45E-5	Thyroid hormone levels	
LGG	cis	1	rs11264462	chr1:156241728	BGLAP	chr1:156182784-156213112:+	0.24	5.01	7.46E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264462	chr1:156241728	CCT3	chr1:156278752-156308195:-	-0.14	-3.55	0.000415	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264464	chr1:156250887	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264464	chr1:156250887	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264467	chr1:156273061	BGLAP	chr1:156182784-156213112:+	-0.2	-4.37	1.53E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264467	chr1:156273061	CCT3	chr1:156278752-156308195:-	0.17	4.3	2.03E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264468	chr1:156274585	BGLAP	chr1:156182784-156213112:+	0.25	5.31	1.62E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs11264468	chr1:156274585	CCT3	chr1:156278752-156308195:-	-0.16	-4.01	7.03E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs112661971	chr14:59901054	C14orf149	chr14:59939406-59951126:-	-0.44	-4.67	3.88E-6	Schizophrenia	
LGG	cis	1	rs112661971	chr14:59901054	JKAMP	chr14:59951161-59972080:+	0.45	4.26	2.41E-5	Schizophrenia	
LGG	cis	1	rs1127489	chr6:170107702	WDR27	chr6:169857307-170102159:-	-0.38	-8.65	7.24E-17	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs112751982	chr6:26191958	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs112751982	chr6:26191958	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs112777695	chr20:33693177	GDF5	chr20:33897002-34042568:-	0.28	3.57	0.000385	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs112777695	chr20:33693177	PROCR	chr20:33758727-33765164:+	-0.33	-6.11	2.06E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs1127857	chr9:95883865	NINJ1	chr9:95883772-95896570:-	-0.26	-4.71	3.22E-6	Obesity (early onset extreme)	
LGG	cis	1	rs112819780	chr14:60001564	C14orf149	chr14:59939406-59951126:-	-0.46	-4.76	2.5E-6	Schizophrenia	
LGG	cis	1	rs112819780	chr14:60001564	JKAMP	chr14:59951161-59972080:+	0.47	4.28	2.21E-5	Schizophrenia	
LGG	cis	1	rs1128320	chr11:244167	PSMD13	chr11:236808-252984:+	-0.22	-4.97	9.24E-7	Menarche (age at onset)	
LGG	cis	1	rs1128322	chr11:244197	PSMD13	chr11:236808-252984:+	0.19	4.15	3.99E-5	Menarche (age at onset)	
LGG	cis	1	rs112879614	chr14:60001681	C14orf149	chr14:59939406-59951126:-	-0.46	-4.76	2.5E-6	Schizophrenia	
LGG	cis	1	rs112879614	chr14:60001681	JKAMP	chr14:59951161-59972080:+	0.47	4.28	2.21E-5	Schizophrenia	
LGG	cis	1	rs11292	chr10:102313607	HIF1AN	chr10:102295641-102313680:+	0.2	3.76	0.000194	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11292	chr10:102313607	NDUFB8	chr10:102283497-102289636:-	0.17	4.58	5.99E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11292	chr10:102313607	WNT8B	chr10:102222812-102243397:+	0.47	7.62	1.34E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1129448	chr22:38170026	GALR3	chr22:38219389-38221502:+	-0.25	-5.56	4.34E-8	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs1129448	chr22:38170026	TRIOBP	chr22:38082344-38172562:+	0.23	5.43	8.87E-8	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs112952088	chr14:60027907	C14orf149	chr14:59939406-59951126:-	-0.44	-4.58	5.79E-6	Schizophrenia	
LGG	cis	1	rs112952088	chr14:60027907	JKAMP	chr14:59951161-59972080:+	0.43	3.99	7.5E-5	Schizophrenia	
LGG	cis	1	rs1129555	chr10:113910721	ZDHHC6	chr10:114190060-114207306:-	-0.26	-5.19	3.08E-7	HDL cholesterol	
LGG	cis	1	rs113031122	chr4:171049923	AADAT	chr4:170981374-171011372:-	-0.29	-3.49	0.000531	Thyroid hormone levels	
LGG	cis	1	rs113075795	chr14:65968955	LOC645431	chr14:65877313-65879335:-	-0.48	-6.53	1.65E-10	Ischemic stroke	
LGG	cis	1	rs113097743	chr14:60018216	C14orf149	chr14:59939406-59951126:-	-0.47	-4.78	2.31E-6	Schizophrenia	
LGG	cis	1	rs113097743	chr14:60018216	JKAMP	chr14:59951161-59972080:+	0.39	3.57	0.000388	Schizophrenia	
LGG	cis	1	rs1131095	chr3:49714225	MST1R	chr3:49924438-49941306:-	-0.2	-3.88	0.000118	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs1131095	chr3:49714225	RBM6	chr3:49977592-50137484:+	0.16	4.49	8.7E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs1131095	chr3:49714225	SEMA3F	chr3:50192848-50226507:+	0.19	4.37	1.5E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs113112586	chr14:59969142	C14orf149	chr14:59939406-59951126:-	-0.42	-4.6	5.38E-6	Schizophrenia	
LGG	cis	1	rs113112586	chr14:59969142	JKAMP	chr14:59951161-59972080:+	0.41	3.99	7.64E-5	Schizophrenia	
LGG	cis	1	rs113134232	chr17:61715461	DDX42	chr17:61851567-61896676:+	-0.16	-3.53	0.000455	Body mass index	
LGG	cis	1	rs113134232	chr17:61715461	FTSJ3	chr17:61896795-61905031:-	0.41	8.02	7.72E-15	Body mass index	
LGG	cis	1	rs113134232	chr17:61715461	SMARCD2	chr17:61909441-61920351:-	0.19	4.18	3.46E-5	Body mass index	
LGG	cis	1	rs113143821	chr5:127893353	FBN2	chr5:127593602-127873916:-	0.42	4.88	1.43E-6	Multiple system atrophy	
LGG	cis	1	rs113172694	chr14:59998219	C14orf149	chr14:59939406-59951126:-	-0.46	-4.78	2.32E-6	Schizophrenia	
LGG	cis	1	rs113172694	chr14:59998219	JKAMP	chr14:59951161-59972080:+	0.44	4.02	6.86E-5	Schizophrenia	
LGG	cis	1	rs113284747	chr14:59955937	C14orf149	chr14:59939406-59951126:-	-0.4	-4.07	5.45E-5	Schizophrenia	
LGG	cis	1	rs113284747	chr14:59955937	JKAMP	chr14:59951161-59972080:+	0.59	5.42	9.42E-8	Schizophrenia	
LGG	cis	1	rs113337957	chr14:59967329	C14orf149	chr14:59939406-59951126:-	-0.42	-4.6	5.38E-6	Schizophrenia	
LGG	cis	1	rs113337957	chr14:59967329	JKAMP	chr14:59951161-59972080:+	0.41	3.99	7.64E-5	Schizophrenia	
LGG	cis	1	rs113352275	chr15:78840567	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.37	4.39E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs113379066	chr5:156015359	SGCD	chr5:155135063-156194796:+	0.32	4.76	2.53E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs113379801	chr8:58173686	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11344	chr16:29910518	BOLA2	chr16:29454226-29466285:-;chr16	-0.2	-4.44	1.1E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs11344	chr16:29910518	LOC440356	chr16:29875004-29879374:+	-0.26	-5.55	4.75E-8	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs113482756	chr14:59948622	C14orf149	chr14:59939406-59951126:-	-0.41	-4.24	2.66E-5	Schizophrenia	
LGG	cis	1	rs113482756	chr14:59948622	JKAMP	chr14:59951161-59972080:+	0.53	4.99	8.25E-7	Schizophrenia	
LGG	cis	1	rs113558975	chr14:59998385	C14orf149	chr14:59939406-59951126:-	-0.46	-4.78	2.32E-6	Schizophrenia	
LGG	cis	1	rs113558975	chr14:59998385	JKAMP	chr14:59951161-59972080:+	0.44	4.02	6.86E-5	Schizophrenia	
LGG	cis	1	rs113572538	chr4:171036112	AADAT	chr4:170981374-171011372:-	-0.28	-3.51	0.000481	Thyroid hormone levels	
LGG	cis	1	rs113613442	chr14:59972563	C14orf149	chr14:59939406-59951126:-	-0.42	-4.6	5.38E-6	Schizophrenia	
LGG	cis	1	rs113613442	chr14:59972563	JKAMP	chr14:59951161-59972080:+	0.41	3.99	7.64E-5	Schizophrenia	
LGG	cis	1	rs113638727	chr15:40706101	C15orf23	chr15:40674922-40686488:+	1.06	16.58	2.48E-49	Heschl's gyrus morphology	
LGG	cis	1	rs113638727	chr15:40706101	IVD	chr15:40697686-40713512:+	-0.33	-3.5	0.00051	Heschl's gyrus morphology	
LGG	cis	1	rs113641235	chr11:118700264	MPZL3	chr11:118100337-118123011:-	0.26	3.95	8.82E-5	Vitiligo	
LGG	cis	1	rs113647687	chr7:33181578	BBS9	chr7:33169152-33645680:+	0.4	5.11	4.63E-7	Smooth-surface caries	
LGG	cis	1	rs113751790	chr4:171024528	AADAT	chr4:170981374-171011372:-	-0.3	-3.85	0.000132	Thyroid hormone levels	
LGG	cis	1	rs113752978	chr4:171047434	AADAT	chr4:170981374-171011372:-	-0.29	-3.49	0.000531	Thyroid hormone levels	
LGG	cis	1	rs113797613	chr2:48069445	FBXO11	chr2:48034061-48132814:-	0.22	4.05	5.99E-5	Schizophrenia	
LGG	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.29	7.58	1.73E-13	Height	
LGG	cis	1	rs1138273	chr3:134261437	CEP63	chr3:134204575-134293852:+	0.21	3.81	0.000156	Height	
LGG	cis	1	rs113835537	chr11:66339639	BBS1	chr11:66276550-66301084:+	-0.18	-4.02	6.76E-5	Airway imaging phenotypes	
LGG	cis	1	rs113835537	chr11:66339639	CTSF	chr11:66330936-66336047:-	0.23	4.1	4.81E-5	Airway imaging phenotypes	
LGG	cis	1	rs113869004	chr14:59918731	C14orf149	chr14:59939406-59951126:-	-0.42	-4.32	1.86E-5	Schizophrenia	
LGG	cis	1	rs113869004	chr14:59918731	JKAMP	chr14:59951161-59972080:+	0.56	5.22	2.58E-7	Schizophrenia	
LGG	cis	1	rs113872281	chr3:108653832	MORC1	chr3:108677089-108836993:-	-0.21	-4.48	9.38E-6	Pelvic organ prolapse (moderate/severe)	
LGG	cis	1	rs113878281	chr14:59917494	C14orf149	chr14:59939406-59951126:-	-0.44	-4.62	4.91E-6	Schizophrenia	
LGG	cis	1	rs113878281	chr14:59917494	JKAMP	chr14:59951161-59972080:+	0.49	4.58	5.83E-6	Schizophrenia	
LGG	cis	1	rs113919636	chr17:41877740	VAT1	chr17:41166622-41174459:-	-0.18	-3.88	0.000119	Triglycerides	
LGG	cis	1	rs1140047	chr11:18327684	GTF2H1	chr11:18343816-18388590:+	0.42	7.89	2.0E-14	Pancreatic cancer	
LGG	cis	1	rs1140047	chr11:18327684	LDHC	chr11:18433853-18472792:+	0.22	4.07	5.56E-5	Pancreatic cancer	
LGG	cis	1	rs114007205	chr20:33647503	PROCR	chr20:33758727-33765164:+	-0.32	-5.73	1.74E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs114031213	chr2:207619463	MDH1B	chr2:207598943-207630050:-	0.33	4.85	1.64E-6	Episodic memory	
LGG	cis	1	rs1141313	chr2:27460968	SLC5A6	chr2:27422459-27435071:-	-0.31	-6.35	4.86E-10	Blood metabolite levels	
LGG	cis	1	rs1141321	chr6:49412433	CENPQ	chr6:49431096-49460820:+	-0.23	-5.1	4.95E-7	Folate pathway vitamin levels	
LGG	cis	1	rs114244137	chr5:150264753	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs1142469	chr1:207965427	CD46	chr1:207925402-207968857:+	-0.24	-7.04	6.38E-12	Schizophrenia	
LGG	cis	1	rs114304428	chr1:152254010	HRNR	chr1:152184558-152196669:-	-0.57	-7.99	1.0E-14	Atopic dermatitis	
LGG	cis	1	rs114312649	chr8:58182539	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs1144815	chr1:247781569	OR2W3	chr1:248031265-248060142:+	-0.14	-3.55	0.00043	Response to platinum-based chemotherapy (carboplatin)	
LGG	cis	1	rs114486414	chr8:58185103	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs114490726	chr4:17680898	LAP3	chr4:17578927-17609590:+	-0.13	-3.71	0.000232	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11466750	chr5:110412894	TSLP	chr5:110405778-110413722:+	-0.32	-4.59	5.56E-6	Eosinophil counts	
LGG	cis	1	rs11466754	chr5:110413731	TSLP	chr5:110405778-110413722:+	-0.31	-4.36	1.61E-5	Eosinophil counts	
LGG	cis	1	rs1147610	chr10:105941167	C10orf79	chr10:105889647-105992120:-	0.17	4.72	3.03E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs114799538	chr8:10815827	RP1L1	chr8:10463862-10512617:-	-0.27	-3.56	0.000401	Asthma and hay fever	
LGG	cis	1	rs1148000	chr12:75936301	GLIPR1L2	chr12:75784889-75825591:+	-0.3	-5.09	5.02E-7	Polycystic ovary syndrome	
LGG	cis	1	rs1148003	chr12:75978996	GLIPR1L2	chr12:75784889-75825591:+	-0.28	-4.79	2.19E-6	Polycystic ovary syndrome	
LGG	cis	1	rs1148004	chr12:75978677	GLIPR1L2	chr12:75784889-75825591:+	-0.32	-5.41	9.86E-8	Polycystic ovary syndrome	
LGG	cis	1	rs1148005	chr12:75978513	GLIPR1L2	chr12:75784889-75825591:+	-0.32	-5.48	6.74E-8	Polycystic ovary syndrome	
LGG	cis	1	rs1148006	chr12:75978358	GLIPR1L2	chr12:75784889-75825591:+	-0.28	-4.83	1.82E-6	Polycystic ovary syndrome	
LGG	cis	1	rs114873854	chr4:42464223	SHISA3	chr4:42399856-42404503:+	0.26	3.98	7.94E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs11487418	chr1:170996229	FMO4	chr1:171283486-171311222:+	0.19	3.55	0.000416	Number of children (6+ vs. 0 or 1)	
LGG	cis	1	rs114948279	chr20:33733641	PROCR	chr20:33758727-33765164:+	-0.36	-6.45	2.62E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs114960066	chr3:41882323	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs114976176	chr2:264621	FAM150B	chr2:279563-288308:-	-0.32	-6.03	3.14E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs114976176	chr2:264621	SNTG2	chr2:946555-1371382:+	0.21	3.76	0.000192	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs115047304	chr2:48078211	FBXO11	chr2:48034061-48132814:-	0.23	4.14	4.01E-5	Schizophrenia	
LGG	cis	1	rs11535	chr2:233743532	C2orf82	chr2:233734994-233741107:+	0.36	6.9	1.59E-11	Schizophrenia	
LGG	cis	1	rs11538349	chr7:65421871	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs11542436	chr17:61778689	DDX42	chr17:61851567-61896676:+	-0.15	-3.5	0.000505	Body mass index	
LGG	cis	1	rs11542436	chr17:61778689	FTSJ3	chr17:61896795-61905031:-	0.4	8.32	8.6E-16	Body mass index	
LGG	cis	1	rs11542436	chr17:61778689	SMARCD2	chr17:61909441-61920351:-	0.19	4.41	1.29E-5	Body mass index	
LGG	cis	1	rs11553387	chr20:47841660	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.28	2.25E-5	Height	
LGG	cis	1	rs11553746	chr2:272203	FAM150B	chr2:279563-288308:-	-0.35	-6.61	9.83E-11	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs11553746	chr2:272203	SNTG2	chr2:946555-1371382:+	0.19	3.53	0.000456	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs115548028	chr8:58170672	C8orf71	chr8:58192102-58197288:+	0.38	6.43	2.94E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11557072	chr15:40713374	C15orf23	chr15:40674922-40686488:+	1.05	16.51	4.77E-49	Heschl's gyrus morphology	
LGG	cis	1	rs11557072	chr15:40713374	IVD	chr15:40697686-40713512:+	-0.32	-3.46	0.000596	Heschl's gyrus morphology	
LGG	cis	1	rs115579188	chr4:25197308	ANAPC4	chr4:25378848-25420119:+	0.31	4.79	2.25E-6	Cannabis dependence	
LGG	cis	1	rs115579188	chr4:25197308	PI4K2B	chr4:25162285-25280831:+	0.28	4.78	2.37E-6	Cannabis dependence	
LGG	cis	1	rs115579188	chr4:25197308	SEL1L3	chr4:25749050-25864610:-	0.26	3.57	0.000397	Cannabis dependence	
LGG	cis	1	rs11562317	chr9:99568735	FAM22G	chr9:99690592-99704572:+	-0.67	-5.24	2.37E-7	Height	
LGG	cis	1	rs115630919	chr5:115505416	COMMD10	chr5:115420727-115628978:+	0.46	5.7	2.04E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs115634863	chr2:63328774	TMEM17	chr2:62727356-62762780:-	-0.2	-3.48	0.00054	Subjective well-being	
LGG	cis	1	rs115669892	chr2:190755706	ORMDL1	chr2:190634994-190649097:-	0.34	5.23	2.57E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs11569494	chr19:6692512	GPR108	chr19:6729927-6737633:-	-0.27	-3.85	0.000136	Complement C3 and C4 levels	
LGG	cis	1	rs11569495	chr19:6692443	GPR108	chr19:6729927-6737633:-	-0.27	-3.85	0.000136	Complement C3 and C4 levels	
LGG	cis	1	rs11569496	chr19:6692321	GPR108	chr19:6729927-6737633:-	-0.27	-3.85	0.000136	Complement C3 and C4 levels	
LGG	cis	1	rs11569501	chr19:6691631	GPR108	chr19:6729927-6737633:-	0.28	4.07	5.59E-5	Complement C3 and C4 levels	
LGG	cis	1	rs11569502	chr19:6691534	GPR108	chr19:6729927-6737633:-	-0.27	-3.85	0.000136	Complement C3 and C4 levels	
LGG	cis	1	rs11569507	chr19:6690805	GPR108	chr19:6729927-6737633:-	-0.26	-3.77	0.00018	Complement C3 and C4 levels	
LGG	cis	1	rs11569511	chr19:6690571	GPR108	chr19:6729927-6737633:-	-0.27	-3.84	0.000137	Complement C3 and C4 levels	
LGG	cis	1	rs11569513	chr19:6690460	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs11569514	chr19:6690276	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs11569515	chr19:6690244	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs11569519	chr19:6689854	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs11569520	chr19:6689507	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs11569521	chr19:6689487	GPR108	chr19:6729927-6737633:-	-0.27	-3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs115743514	chr22:51011933	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs11575229	chr12:56750737	IL23A	chr12:56732663-56734193:+	0.58	5.02	7.32E-7	Psoriasis vulgaris	
LGG	cis	1	rs11575231	chr12:56744445	IL23A	chr12:56732663-56734193:+	0.57	4.99	8.24E-7	Psoriasis vulgaris	
LGG	cis	1	rs11575232	chr12:56744422	IL23A	chr12:56732663-56734193:+	0.57	4.99	8.24E-7	Psoriasis vulgaris	
LGG	cis	1	rs11575234	chr12:56744276	IL23A	chr12:56732663-56734193:+	0.56	5.56	4.47E-8	Psoriasis vulgaris	
LGG	cis	1	rs11577134	chr1:211602624	C1orf97	chr1:211556097-211605876:+	-0.2	-3.51	0.000497	Educational attainment (years of education)	
LGG	cis	1	rs115779493	chr13:96300448	UGGT2	chr13:96453838-96705736:-	-0.26	-4.38	1.46E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs11579557	chr1:211619703	C1orf97	chr1:211556097-211605876:+	-0.21	-3.79	0.00017	Educational attainment (years of education)	
LGG	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.13	3.65	0.000285	Body mass index	
LGG	cis	1	rs11579634	chr1:46466391	MUTYH	chr1:45794915-45806142:-	-0.12	-4.17	3.57E-5	Body mass index	
LGG	cis	1	rs11580331	chr1:175123288	TNN	chr1:175036994-175117202:+	-0.17	-3.58	0.000376	Alcohol dependence	
LGG	cis	1	rs11582702	chr1:160727986	PCP4L1	chr1:161228517-161255239:+	0.12	3.52	0.00048	Cervical cancer	
LGG	cis	1	rs1158282	chr14:76172916	TTLL5	chr14:76127621-76421421:+	0.22	4.89	1.36E-6	Large artery stroke	
LGG	cis	1	rs11583720	chr1:150043471	RPRD2	chr1:150336990-150449039:+	0.16	3.9	0.000112	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11585617	chr1:175123186	TNN	chr1:175036994-175117202:+	-0.17	-3.58	0.000376	Alcohol dependence	
LGG	cis	1	rs11585955	chr1:150043544	RPRD2	chr1:150336990-150449039:+	-0.16	-3.9	0.000108	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11588170	chr1:152286032	HRNR	chr1:152184558-152196669:-	-0.56	-7.89	2.0E-14	Atopic dermatitis	
LGG	cis	1	rs115889150	chr2:207597807	MDH1B	chr2:207598943-207630050:-	0.34	5.28	1.95E-7	Episodic memory	
LGG	cis	1	rs11589922	chr1:150133323	RPRD2	chr1:150336990-150449039:+	0.16	3.99	7.59E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs11590365	chr1:152165489	HRNR	chr1:152184558-152196669:-	-0.59	-8.26	1.4E-15	Atopic dermatitis	
LGG	cis	1	rs11591200	chr1:150133563	RPRD2	chr1:150336990-150449039:+	-0.15	-3.55	0.000423	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs115933968	chr2:48156909	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs115965884	chr22:24594662	SUSD2	chr22:24577444-24585074:+	0.52	6.37	4.41E-10	Amyotrophic lateral sclerosis	
LGG	cis	1	rs11600703	chr11:120249287	TMEM136	chr11:120196016-120204388:+	0.21	4.79	2.23E-6	Intraocular pressure	
LGG	cis	1	rs1160072	chr3:161546498	NMD3	chr3:160939099-160971319:+	-0.15	-3.51	0.000489	IgG1 response to Plasmodium falciparum antigen (GLURP)	
LGG	cis	1	rs11600990	chr11:64082807	C11orf20	chr11:64067863-64072238:+	-0.31	-4.65	4.32E-6	Mean platelet volume	
LGG	cis	1	rs11601205	chr11:34768479	APIP	chr11:34896714-34937939:-	0.19	4.17	3.66E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs11601535	chr11:120333801	TMEM136	chr11:120196016-120204388:+	0.21	4.83	1.85E-6	Intraocular pressure	
LGG	cis	1	rs11601872	chr11:64147627	C11orf20	chr11:64067863-64072238:+	0.25	4.07	5.52E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs11601923	chr11:34764354	APIP	chr11:34896714-34937939:-	0.18	3.96	8.68E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1160267	chr8:23529521	NKX3-1	chr8:23536207-23540450:-	0.19	3.7	0.00024	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs11602909	chr11:34768003	APIP	chr11:34896714-34937939:-	0.18	4.06	5.65E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs116034011	chr4:106735622	GSTCD	chr4:106629941-106768881:+	0.31	3.48	0.000538	Post bronchodilator FEV1	
LGG	cis	1	rs11604069	chr11:34764251	APIP	chr11:34896714-34937939:-	0.17	3.72	0.000226	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs116041997	chr2:48109919	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs11605774	chr11:47832793	MTCH2	chr11:47638859-47664206:-	0.24	4.69	3.59E-6	Subjective well-being	
LGG	cis	1	rs11605774	chr11:47832793	PSMC3	chr11:47440320-47448024:-	0.15	3.66	0.000282	Subjective well-being	
LGG	cis	1	rs11605924	chr11:45873091	DKFZp779M0652	chr11:45792983-45793908:+	-0.13	-3.88	0.000119	Fasting glucose-related traits (interaction with BMI);Fasting glucose-related traits	
LGG	cis	1	rs11607300	chr11:34759319	APIP	chr11:34896714-34937939:-	0.17	3.84	0.000142	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs11609231	chr12:50932430	ATF1	chr12:51157819-51214906:+	-0.21	-4.4	1.33E-5	Fibrinogen	
LGG	cis	1	rs11609231	chr12:50932430	LETMD1	chr12:51442084-51454206:+	0.15	3.57	0.000396	Fibrinogen	
LGG	cis	1	rs11609231	chr12:50932430	SLC11A2	chr12:51373319-51422058:-	0.17	3.64	0.000302	Fibrinogen	
LGG	cis	1	rs11611670	chr12:9385535	DDX12	chr12:9570288-9600768:-	0.17	5.38	1.13E-7	Breast size	
LGG	cis	1	rs11611670	chr12:9385535	LOC642846	chr12:9436253-9466684:+	0.4	11.15	6.65E-26	Breast size	
LGG	cis	1	rs11613331	chr12:351467	CCDC77	chr12:498516-551804:+	-0.18	-4.62	4.87E-6	Blood metabolite ratios	
LGG	cis	1	rs116134049	chr5:115529655	COMMD10	chr5:115420727-115628978:+	0.46	5.59	3.79E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs116139393	chr7:6771660	C7orf26	chr7:6629915-6648355:+	-0.19	-3.58	0.000382	Alzheimer's disease (APOE e4 interaction)	
LGG	cis	1	rs116139393	chr7:6771660	PMS2CL	chr7:6749757-6793492:+	-0.4	-7.22	2.06E-12	Alzheimer's disease (APOE e4 interaction)	
LGG	cis	1	rs116139393	chr7:6771660	RSPH10B2	chr7:6793740-6838396:+;chr7	-0.37	-5.56	4.45E-8	Alzheimer's disease (APOE e4 interaction)	
LGG	cis	1	rs116139393	chr7:6771660	ZNF12	chr7:6728064-6746566:-	-0.21	-4.01	7.01E-5	Alzheimer's disease (APOE e4 interaction)	
LGG	cis	1	rs11621351	chr14:55616740	FBXO34	chr14:55738021-55893431:+	0.14	4.45	1.08E-5	Protein biomarker	
LGG	cis	1	rs11622475	chr14:104509076	TDRD9	chr14:104394817-104519002:+	0.19	3.82	0.000151	Bipolar disorder	
LGG	cis	1	rs11623413	chr14:75588824	ACYP1	chr14:75519930-75530736:-	0.15	3.86	0.000127	Height	
LGG	cis	1	rs11625697	chr14:104464800	TDRD9	chr14:104394817-104519002:+	0.22	4.38	1.43E-5	Bipolar disorder	
LGG	cis	1	rs11627546	chr14:70365924	COX16	chr14:70791799-70826444:-	-0.21	-3.92	0.000103	Red blood cell traits	
LGG	cis	1	rs11627546	chr14:70365924	SLC39A9	chr14:69865407-69929105:+	-0.22	-3.97	8.16E-5	Red blood cell traits	
LGG	cis	1	rs11628710	chr14:74649280	C14orf45	chr14:74486059-74549566:+	0.13	3.59	0.000364	Common traits (Other)	
LGG	cis	1	rs11628710	chr14:74649280	LIN52	chr14:74551656-74667117:+	0.48	11.25	2.71E-26	Common traits (Other)	
LGG	cis	1	rs116300850	chr5:76852234	WDR41	chr5:76728069-76788332:-	0.22	3.59	0.000357	Alzheimer disease and age of onset	
LGG	cis	1	rs11630417	chr15:68012609	IQCH	chr15:67547188-67794139:+	0.13	3.69	0.000247	Motion sickness	
LGG	cis	1	rs11631955	chr15:79085915	ADAMTS7	chr15:79051546-79103773:-	0.17	3.52	0.000479	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11631955	chr15:79085915	CHRNA5	chr15:78857906-78886458:+	-0.25	-4.2	3.19E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11631963	chr15:83318202	FAM154B	chr15:82555152-82577265:+	0.2	4.31	2.0E-5	Schizophrenia	
LGG	cis	1	rs11631963	chr15:83318202	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.18	4.42	1.19E-5	Schizophrenia	
LGG	cis	1	rs11632465	chr15:85282045	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.41	1.26E-5	Schizophrenia	
LGG	cis	1	rs11632465	chr15:85282045	LOC388152	chr15:84867600-84898920:-	-0.3	-5.63	3.07E-8	Schizophrenia	
LGG	cis	1	rs11632465	chr15:85282045	WDR73	chr15:85186012-85197524:-	-0.19	-3.58	0.000374	Schizophrenia	
LGG	cis	1	rs11633958	chr15:78862064	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.41	3.85E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11634746	chr15:50941496	SPPL2A	chr15:50999739-51057910:-	0.13	4.11	4.63E-5	QT interval	
LGG	cis	1	rs116364352	chr4:42470279	SHISA3	chr4:42399856-42404503:+	0.29	4.53	7.29E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs11636964	chr15:50899616	SPPL2A	chr15:50999739-51057910:-	0.12	3.93	9.67E-5	QT interval	
LGG	cis	1	rs11637027	chr15:67937755	IQCH	chr15:67547188-67794139:+	0.13	3.78	0.000175	Motion sickness	
LGG	cis	1	rs11637142	chr15:85295927	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.42	1.22E-5	Schizophrenia	
LGG	cis	1	rs11637142	chr15:85295927	LOC388152	chr15:84867600-84898920:-	-0.3	-5.64	2.95E-8	Schizophrenia	
LGG	cis	1	rs11637142	chr15:85295927	WDR73	chr15:85186012-85197524:-	-0.19	-3.57	0.000385	Schizophrenia	
LGG	cis	1	rs11637228	chr15:50899972	SPPL2A	chr15:50999739-51057910:-	0.12	3.93	9.67E-5	QT interval	
LGG	cis	1	rs11637433	chr15:83321336	FAM154B	chr15:82555152-82577265:+	0.2	4.25	2.51E-5	Schizophrenia	
LGG	cis	1	rs11637433	chr15:83321336	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.19	4.75	2.67E-6	Schizophrenia	
LGG	cis	1	rs11637852	chr15:63397151	LACTB	chr15:63414032-63434254:+	0.22	4.62	4.84E-6	HDL cholesterol	
LGG	cis	1	rs11638290	chr15:85227636	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.44	1.13E-5	Schizophrenia	
LGG	cis	1	rs11638290	chr15:85227636	LOC388152	chr15:84867600-84898920:-	-0.31	-5.73	1.78E-8	Schizophrenia	
LGG	cis	1	rs11638297	chr15:84782417	GOLGA6L5	chr15:85047738-85060078:-	-0.25	-5.9	6.87E-9	Schizophrenia	
LGG	cis	1	rs11638297	chr15:84782417	LOC388152	chr15:84867600-84898920:-	-0.33	-6.64	8.51E-11	Schizophrenia	
LGG	cis	1	rs11638394	chr15:84778928	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.61	3.46E-8	Schizophrenia	
LGG	cis	1	rs11638394	chr15:84778928	LOC388152	chr15:84867600-84898920:-	-0.33	-6.59	1.12E-10	Schizophrenia	
LGG	cis	1	rs11638394	chr15:84778928	UBE2Q2P1	chr15:85070427-85114026:-	0.15	3.51	0.000486	Schizophrenia	
LGG	cis	1	rs11638815	chr15:83352282	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.19	4.32	1.88E-5	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	
LGG	cis	1	rs116397649	chr5:115506021	COMMD10	chr5:115420727-115628978:+	0.46	5.7	2.04E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs11643434	chr16:1838375	C16orf73	chr16:1883984-1934295:-	0.27	4.21	3.05E-5	Blood metabolite levels	
LGG	cis	1	rs116434420	chr5:115582971	COMMD10	chr5:115420727-115628978:+	0.43	5.3	1.72E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs116444534	chr8:58181915	C8orf71	chr8:58192102-58197288:+	0.35	6.12	1.9E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11645002	chr16:20617841	ACSM1	chr16:20634559-20709066:-	0.3	3.77	0.000185	Urinary metabolites	
LGG	cis	1	rs116477327	chr2:48057557	FBXO11	chr2:48034061-48132814:-	0.23	4.16	3.68E-5	Schizophrenia	
LGG	cis	1	rs11647946	chr16:4462836	CORO7	chr16:4390253-4466962:-	0.56	13.83	5.92E-37	Schizophrenia	
LGG	cis	1	rs11647946	chr16:4462836	NMRAL1	chr16:4511696-4526307:-	-0.42	-8.57	1.3E-16	Schizophrenia	
LGG	cis	1	rs11648292	chr16:4462897	CORO7	chr16:4390253-4466962:-	0.55	13.41	3.54E-35	Schizophrenia	
LGG	cis	1	rs11648292	chr16:4462897	NMRAL1	chr16:4511696-4526307:-	-0.41	-8.52	1.98E-16	Schizophrenia	
LGG	cis	1	rs11650372	chr17:45721795	C17orf57	chr17:45401142-45518675:+	0.16	3.96	8.77E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs11651264	chr17:79576394	PDE6G	chr17:79617489-79623607:-	0.23	5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs11651264	chr17:79576394	TSPAN10	chr17:79609349-79615778:+	-0.68	-17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs11652797	chr17:79574124	PDE6G	chr17:79617489-79623607:-	-0.23	-6.14	1.72E-9	Eye color traits	
LGG	cis	1	rs11652797	chr17:79574124	TSPAN10	chr17:79609349-79615778:+	0.68	17.52	9.49E-54	Eye color traits	
LGG	cis	1	rs116535779	chr12:56739261	IL23A	chr12:56732663-56734193:+	0.59	5.94	5.53E-9	Psoriasis vulgaris	
LGG	cis	1	rs11654335	chr17:61797579	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs11654335	chr17:61797579	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs11654335	chr17:61797579	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs11655672	chr17:46456850	HOXB2	chr17:46620021-46622393:-	-0.19	-3.54	0.000433	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs11657081	chr17:61792339	FTSJ3	chr17:61896795-61905031:-	0.43	9.04	3.74E-18	Body mass index	
LGG	cis	1	rs11657081	chr17:61792339	SMARCD2	chr17:61909441-61920351:-	0.2	4.6	5.48E-6	Body mass index	
LGG	cis	1	rs11657120	chr17:61857218	DDX42	chr17:61851567-61896676:+	-0.16	-3.63	0.000312	Body mass index	
LGG	cis	1	rs11657120	chr17:61857218	FTSJ3	chr17:61896795-61905031:-	0.41	8.46	3.05E-16	Body mass index	
LGG	cis	1	rs11657120	chr17:61857218	SMARCD2	chr17:61909441-61920351:-	0.19	4.28	2.2E-5	Body mass index	
LGG	cis	1	rs11657306	chr17:61704822	FTSJ3	chr17:61896795-61905031:-	0.42	8.59	1.12E-16	Body mass index	
LGG	cis	1	rs11657306	chr17:61704822	SMARCD2	chr17:61909441-61920351:-	0.19	4.34	1.73E-5	Body mass index	
LGG	cis	1	rs11657371	chr17:46843873	SNF8	chr17:47007461-47022154:-	-0.16	-4.05	6.01E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs11658175	chr17:61923838	DDX42	chr17:61851567-61896676:+	-0.16	-3.7	0.000244	Body mass index	
LGG	cis	1	rs11658175	chr17:61923838	FTSJ3	chr17:61896795-61905031:-	0.4	8.26	1.37E-15	Body mass index	
LGG	cis	1	rs11658175	chr17:61923838	SMARCD2	chr17:61909441-61920351:-	0.2	4.47	9.8E-6	Body mass index	
LGG	cis	1	rs11658329	chr17:61763031	FTSJ3	chr17:61896795-61905031:-	-0.42	-8.71	4.76E-17	Body mass index	
LGG	cis	1	rs11658329	chr17:61763031	SMARCD2	chr17:61909441-61920351:-	-0.19	-4.42	1.22E-5	Body mass index	
LGG	cis	1	rs11658555	chr17:18817486	FAM18B	chr17:18684582-18710026:+	0.15	3.57	0.000395	Pancreatic cancer	
LGG	cis	1	rs11658555	chr17:18817486	PRPSAP2	chr17:18759663-18834580:+	-0.2	-5.42	9.53E-8	Pancreatic cancer	
LGG	cis	1	rs11658555	chr17:18817486	TRIM16L	chr17:18601311-18639431:+	-0.16	-3.52	0.000472	Pancreatic cancer	
LGG	cis	1	rs11658740	chr17:61751069	DDX42	chr17:61851567-61896676:+	-0.15	-3.55	0.000419	Body mass index	
LGG	cis	1	rs11658740	chr17:61751069	FTSJ3	chr17:61896795-61905031:-	0.42	8.71	4.7E-17	Body mass index	
LGG	cis	1	rs11658740	chr17:61751069	SMARCD2	chr17:61909441-61920351:-	0.18	4.05	5.93E-5	Body mass index	
LGG	cis	1	rs11662721	chr18:19261413	ESCO1	chr18:19109262-19180693:-	0.21	4.1	4.89E-5	Phospholipid levels (plasma)	
LGG	cis	1	rs11662840	chr18:19261864	ESCO1	chr18:19109262-19180693:-	0.21	4.08	5.31E-5	Phospholipid levels (plasma)	
LGG	cis	1	rs11663558	chr18:21133937	C18orf8	chr18:21083462-21111742:+	0.19	3.68	0.000262	Body mass index	
LGG	cis	1	rs11666415	chr19:24228512	LOC100101266	chr19:24344995-24346249:-	0.27	4.31	2.01E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs11667192	chr19:9975970	ZNF266	chr19:9523272-9546234:-	-0.16	-4.2	3.2E-5	Sleep duration	
LGG	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.4	7.2	2.32E-12	Metabolite levels	
LGG	cis	1	rs11674602	chr2:73723185	NAT8	chr2:73867850-73869537:-	0.26	4.22	2.93E-5	Metabolite levels	
LGG	cis	1	rs1167613	chr7:65487439	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.56E-6	Diabetic kidney disease	
LGG	cis	1	rs11677107	chr2:103057087	IL18R1	chr2:102927962-103015215:+	-0.36	-5.71	1.91E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11677107	chr2:103057087	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.21	2.73E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11677371	chr2:66756413	MEIS1	chr2:66662532-66799890:+	0.18	4.23	2.8E-5	PR interval	
LGG	cis	1	rs11678157	chr2:26321526	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.000149	Gut microbiome composition (summer)	
LGG	cis	1	rs116781589	chr11:71825006	FAM86C	chr11:71498557-71512276:+	-0.47	-4.57	6.25E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1167827	chr7:75163169	GATSL1	chr7:74379083-74438803:+	-0.16	-3.51	0.000484	Body mass index	
LGG	cis	1	rs1167827	chr7:75163169	PMS2L3	chr7:75137070-75157418:-	-0.43	-12.46	3.61E-31	Body mass index	
LGG	cis	1	rs1167827	chr7:75163169	STAG3L1	chr7:74988447-75026250:+	-0.23	-4.74	2.81E-6	Body mass index	
LGG	cis	1	rs116795182	chr5:76852236	WDR41	chr5:76728069-76788332:-	0.22	3.59	0.000357	Alzheimer disease and age of onset	
LGG	cis	1	rs116797362	chr2:48117875	FBXO11	chr2:48034061-48132814:-	0.22	4.05	6.02E-5	Schizophrenia	
LGG	cis	1	rs11681299	chr2:88901732	EIF2AK3	chr2:88856261-88926994:-	0.16	3.76	0.00019	Height	
LGG	cis	1	rs11681497	chr2:242344333	SEPT2	chr2:242254723-242293439:+	0.54	7.86	2.53E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs11683212	chr2:25120196	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs116849218	chr12:56683975	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs116867513	chr19:22166026	ZNF257	chr19:22235266-22273901:+	0.56	8.7	5.14E-17	Body mass index (change over time)	
LGG	cis	1	rs11688116	chr2:188149415	CALCRL	chr2:188207851-188313021:-	-0.21	-5.14	3.98E-7	Coronary heart disease	
LGG	cis	1	rs11688129	chr2:28952581	FAM179A	chr2:29204164-29275094:+	0.2	3.87	0.000121	Body mass index	
LGG	cis	1	rs11688129	chr2:28952581	TRMT61B	chr2:29072690-29093175:-	0.51	10.7	3.62E-24	Body mass index	
LGG	cis	1	rs11689392	chr2:73622026	ALMS1P	chr2:73872046-73912692:+	0.4	7.13	3.7E-12	Metabolite levels	
LGG	cis	1	rs11689392	chr2:73622026	NAT8	chr2:73867850-73869537:-	0.28	4.59	5.7E-6	Metabolite levels	
LGG	cis	1	rs11689927	chr2:29248604	TRMT61B	chr2:29072690-29093175:-	-0.22	-4.14	4.09E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs11690423	chr2:28951537	FAM179A	chr2:29204164-29275094:+	0.19	3.71	0.000229	Body mass index	
LGG	cis	1	rs11690423	chr2:28951537	TRMT61B	chr2:29072690-29093175:-	0.51	10.66	5.06E-24	Body mass index	
LGG	cis	1	rs11691201	chr2:29248816	TRMT61B	chr2:29072690-29093175:-	0.23	4.37	1.53E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs11693319	chr2:179738269	CCDC141	chr2:179697347-179914786:-	-0.33	-5.12	4.38E-7	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs11693697	chr2:102915662	IL18R1	chr2:102927962-103015215:+	-0.39	-6.09	2.27E-9	Serum protein levels (sST2)	
LGG	cis	1	rs11693697	chr2:102915662	IL1RL1	chr2:102927962-102968497:+	-0.31	-4.44	1.14E-5	Serum protein levels (sST2)	
LGG	cis	1	rs11694658	chr2:103045020	IL18R1	chr2:102927962-103015215:+	-0.37	-5.92	6.06E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11694658	chr2:103045020	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.18	3.29E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs11695244	chr2:242176706	SEPT2	chr2:242254723-242293439:+	-0.19	-3.77	0.000183	Chronic lymphocytic leukemia	
LGG	cis	1	rs11696396	chr20:47753019	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs11696396	chr20:47753019	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs11696501	chr20:44124523	WFDC3	chr20:44402847-44420547:-	0.29	4.51	8.24E-6	Brain structure	
LGG	cis	1	rs11696870	chr20:47725607	ARFGEF2	chr20:47538275-47653229:+	0.11	4.02	6.74E-5	Anger	
LGG	cis	1	rs11696870	chr20:47725607	CSE1L	chr20:47662838-47713484:+	0.18	5	7.87E-7	Anger	
LGG	cis	1	rs116995796	chr8:58181960	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11701091	chr21:33920244	TCP10L	chr21:33947152-33957845:-	-0.35	-6.36	4.58E-10	Gastritis	
LGG	cis	1	rs11701627	chr21:33927794	TCP10L	chr21:33947152-33957845:-	-0.34	-6.21	1.15E-9	Gastritis	
LGG	cis	1	rs11703914	chr22:24767602	GGT5	chr22:24615623-24641110:-	-0.16	-3.53	0.000454	Gut microbiome composition (summer)	
LGG	cis	1	rs11703914	chr22:24767602	POM121L9P	chr22:24647589-24661490:+	-0.26	-5.47	7.03E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs11704021	chr22:39074716	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs11705483	chr22:46630544	PKDREJ	chr22:46651561-46659219:-	-0.58	-6.98	9.9E-12	Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.28	7.17	2.82E-12	Height	
LGG	cis	1	rs11706117	chr3:134212526	CEP63	chr3:134204575-134293852:+	0.19	3.52	0.000468	Height	
LGG	cis	1	rs11706304	chr3:128050614	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.93	9.81E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706304	chr3:128050614	LOC90246	chr3:128226678-128229427:+	-0.28	-3.54	0.000435	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706455	chr3:127891991	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706826	chr3:128032991	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.92	0.000102	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706826	chr3:128032991	LOC90246	chr3:128226678-128229427:+	-0.29	-3.76	0.000192	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706852	chr3:128032887	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.93	9.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706852	chr3:128032887	LOC90246	chr3:128226678-128229427:+	-0.29	-3.74	0.000206	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706908	chr3:128033048	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.95	9.03E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11706908	chr3:128033048	LOC90246	chr3:128226678-128229427:+	-0.29	-3.75	0.000199	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11707462	chr3:127838630	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.15	3.92E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11707527	chr3:65450416	MAGI1	chr3:65339907-66024509:-	0.22	4.58	5.83E-6	PR interval	
LGG	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.28	7.42	5.35E-13	Height	
LGG	cis	1	rs11708531	chr3:134224902	CEP63	chr3:134204575-134293852:+	0.2	3.62	0.000327	Height	
LGG	cis	1	rs11709066	chr3:127874912	EEFSEC	chr3:127872313-128127488:+	0.2	3.76	0.000188	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11709377	chr3:127815670	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1	
LGG	cis	1	rs11709525	chr3:49690496	MST1R	chr3:49924438-49941306:-	-0.2	-3.79	0.000172	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11709525	chr3:49690496	RBM6	chr3:49977592-50137484:+	0.16	4.48	9.1E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11709525	chr3:49690496	SEMA3F	chr3:50192848-50226507:+	0.2	4.43	1.18E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11709611	chr3:128067275	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.05	5.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11709611	chr3:128067275	LOC90246	chr3:128226678-128229427:+	-0.29	-3.62	0.000331	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11709840	chr3:169570241	LRRC34	chr3:169511266-169530720:-	-0.28	-4.61	5.24E-6	Glioma (high-grade)	
LGG	cis	1	rs11710434	chr3:49346130	AMIGO3	chr3:49754268-49757238:-	-0.17	-3.87	0.000123	Menarche (age at onset)	
LGG	cis	1	rs11710434	chr3:49346130	GMPPB	chr3:49758932-49761384:-	-0.21	-4.1	4.75E-5	Menarche (age at onset)	
LGG	cis	1	rs11710434	chr3:49346130	NCKIPSD	chr3:48711280-48723334:-	0.17	3.96	8.64E-5	Menarche (age at onset)	
LGG	cis	1	rs11710434	chr3:49346130	TREX1	chr3:48501186-48509043:+	-0.25	-5.21	2.72E-7	Menarche (age at onset)	
LGG	cis	1	rs11710627	chr3:128047009	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.8	0.00016	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11710627	chr3:128047009	LOC90246	chr3:128226678-128229427:+	-0.29	-3.61	0.000342	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11710675	chr3:49751900	MST1R	chr3:49924438-49941306:-	0.25	4.81	2.04E-6	Resting heart rate	
LGG	cis	1	rs11710704	chr3:128047236	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.8	0.00016	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11710704	chr3:128047236	LOC90246	chr3:128226678-128229427:+	-0.29	-3.61	0.000342	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1171112	chr6:84226568	SNAP91	chr6:84262607-84419127:-	-0.09	-4.69	3.59E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs1171113	chr6:84226595	SNAP91	chr6:84262607-84419127:-	-0.09	-4.69	3.59E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs1171115	chr6:84229623	SNAP91	chr6:84262607-84419127:-	-0.1	-4.77	2.38E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs11711710	chr3:127872506	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.16	3.69E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11712561	chr3:48435272	ATRIP	chr3:48488141-48507708:+	0.18	4.41	1.3E-5	Longevity	
LGG	cis	1	rs11712561	chr3:48435272	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	1.01E-24	Longevity	
LGG	cis	1	rs11712709	chr3:20139777	EFHB	chr3:19920968-19988501:-	0.38	4.96	9.5E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs11712798	chr3:127894294	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.3	2.1E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11714052	chr3:127814457	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.07	5.4E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11714294	chr3:47339723	NRADDP	chr3:47053032-47054957:+	0.22	3.77	0.00018	Colorectal cancer	
LGG	cis	1	rs11714406	chr3:121372513	IQCB1	chr3:121488610-121553926:-	0.37	6.9	1.63E-11	Cognitive performance	
LGG	cis	1	rs11714574	chr3:58380465	PDHB	chr3:58413355-58419565:-	0.24	5.02	7.19E-7	Response to abacavir-containing treatment in HIV-1 infection (virologic failure)	
LGG	cis	1	rs11714619	chr3:127850076	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11715394	chr3:127893564	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.05	5.98E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11715906	chr3:113839235	KIAA1407	chr3:113682986-113775460:-	0.15	4.01	7.03E-5	Personality dimensions	
LGG	cis	1	rs11716941	chr3:127875374	EEFSEC	chr3:127872313-128127488:+	0.21	3.95	8.88E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11717256	chr3:49868520	MST1R	chr3:49924438-49941306:-	0.25	4.85	1.67E-6	Resting heart rate	
LGG	cis	1	rs11717256	chr3:49868520	RBM6	chr3:49977592-50137484:+	-0.14	-3.74	0.000202	Resting heart rate	
LGG	cis	1	rs11718165	chr3:49696797	MST1R	chr3:49924438-49941306:-	-0.21	-4.07	5.38E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11718165	chr3:49696797	RBM6	chr3:49977592-50137484:+	0.16	4.29	2.12E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11718165	chr3:49696797	SEMA3F	chr3:50192848-50226507:+	0.19	4.19	3.26E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs11719079	chr3:127824049	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.32	1.9E-5	Post bronchodilator FEV1	
LGG	cis	1	rs11719448	chr3:119234594	KTELC1	chr3:119187785-119213552:+	-0.19	-3.59	0.000361	Arthritis (juvenile idiopathic)	
LGG	cis	1	rs11719458	chr3:121382005	IQCB1	chr3:121488610-121553926:-	0.38	7.06	5.65E-12	Cognitive performance	
LGG	cis	1	rs11719546	chr3:127872602	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.16	3.69E-5	Post bronchodilator FEV1	
LGG	cis	1	rs11719762	chr3:49409002	AMIGO3	chr3:49754268-49757238:-	-0.19	-4.43	1.17E-5	Menarche (age at onset)	
LGG	cis	1	rs11719762	chr3:49409002	GMPPB	chr3:49758932-49761384:-	-0.23	-4.53	7.49E-6	Menarche (age at onset)	
LGG	cis	1	rs11719762	chr3:49409002	TREX1	chr3:48501186-48509043:+	-0.25	-5.34	1.42E-7	Menarche (age at onset)	
LGG	cis	1	rs11719771	chr3:65481987	MAGI1	chr3:65339907-66024509:-	0.22	4.36	1.57E-5	PR interval	
LGG	cis	1	rs11720239	chr3:127817955	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11720542	chr3:49357427	AMIGO3	chr3:49754268-49757238:-	-0.17	-3.9	0.000109	Menarche (age at onset)	
LGG	cis	1	rs11720542	chr3:49357427	GMPPB	chr3:49758932-49761384:-	-0.21	-4.13	4.33E-5	Menarche (age at onset)	
LGG	cis	1	rs11720542	chr3:49357427	NCKIPSD	chr3:48711280-48723334:-	0.17	3.96	8.44E-5	Menarche (age at onset)	
LGG	cis	1	rs11720542	chr3:49357427	TREX1	chr3:48501186-48509043:+	-0.25	-5.24	2.44E-7	Menarche (age at onset)	
LGG	cis	1	rs11721213	chr3:128067441	EEFSEC	chr3:127872313-128127488:+	0.23	4.33	1.82E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11721318	chr3:121429485	IQCB1	chr3:121488610-121553926:-	0.37	6.82	2.7E-11	Cognitive performance	
LGG	cis	1	rs11722037	chr4:17683811	LAP3	chr4:17578927-17609590:+	-0.13	-3.67	0.000267	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11722037	chr4:17683811	MED28	chr4:17616273-17629791:+	0.16	3.47	0.000561	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11722197	chr4:281707	ZNF718	chr4:53272-156488:+	0.27	5.3	1.75E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11722521	chr4:276765	ZNF718	chr4:53272-156488:+	0.26	5.15	3.72E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs117231141	chr8:58185465	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs11723225	chr4:106746065	GSTCD	chr4:106629941-106768881:+	0.31	3.48	0.000538	Post bronchodilator FEV1	
LGG	cis	1	rs11723240	chr4:106736936	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000562	Post bronchodilator FEV1	
LGG	cis	1	rs11723261	chr4:282499	ZNF718	chr4:53272-156488:+	0.27	5.3	1.75E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11723615	chr4:276983	ZNF718	chr4:53272-156488:+	0.25	4.93	1.13E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11723639	chr4:106741163	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000564	Post bronchodilator FEV1	
LGG	cis	1	rs117236853	chr20:33667783	PROCR	chr20:33758727-33765164:+	-0.32	-5.64	2.93E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11723803	chr4:292369	ZNF718	chr4:53272-156488:+	0.27	6.09	2.31E-9	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11724176	chr4:224901	ZNF718	chr4:53272-156488:+	0.28	5.41	9.74E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11724417	chr4:223352	ZNF718	chr4:53272-156488:+	0.28	5.41	9.74E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11724495	chr4:17621310	MED28	chr4:17616273-17629791:+	0.2	4.32	1.93E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs117249133	chr20:33773630	PROCR	chr20:33758727-33765164:+	-0.36	-6.37	4.35E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11726229	chr4:120211580	MYOZ2	chr4:120056939-120108935:+	0.22	4.13	4.35E-5	Corneal astigmatism	
LGG	cis	1	rs11726248	chr4:171053519	AADAT	chr4:170981374-171011372:-	-0.28	-3.48	0.000538	Thyroid hormone levels	
LGG	cis	1	rs11726249	chr4:171053563	AADAT	chr4:170981374-171011372:-	-0.28	-3.48	0.000538	Thyroid hormone levels	
LGG	cis	1	rs11726609	chr4:56400869	TMEM165	chr4:56262090-56292342:+	-0.15	-4.4	1.3E-5	Personality dimensions	
LGG	cis	1	rs11726829	chr4:224948	ZNF718	chr4:53272-156488:+	0.28	5.79	1.25E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11727312	chr4:17669185	LAP3	chr4:17578927-17609590:+	-0.14	-3.77	0.000186	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11727500	chr4:106745948	GSTCD	chr4:106629941-106768881:+	0.31	3.48	0.000538	Post bronchodilator FEV1	
LGG	cis	1	rs11729169	chr4:171019391	AADAT	chr4:170981374-171011372:-	-0.31	-4.01	7.11E-5	Thyroid hormone levels	
LGG	cis	1	rs11729365	chr4:272524	ZNF718	chr4:53272-156488:+	0.26	5.15	3.72E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11729657	chr4:1737585	TMEM129	chr4:1717680-1723084:-	-0.17	-3.74	0.00021	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs11730202	chr4:210096	ZNF718	chr4:53272-156488:+	0.18	3.55	0.000421	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11730202	chr4:210096	ZNF721	chr4:433781-493442:-	-0.22	-3.63	0.000308	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs11731417	chr4:106746012	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000562	Post bronchodilator FEV1	
LGG	cis	1	rs11731442	chr4:171006215	AADAT	chr4:170981374-171011372:-	-0.3	-3.63	0.000313	Thyroid hormone levels	
LGG	cis	1	rs117316403	chr20:33693175	GDF5	chr20:33897002-34042568:-	0.29	3.68	0.000257	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs117316403	chr20:33693175	PROCR	chr20:33758727-33765164:+	-0.33	-6.02	3.4E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11732383	chr4:171051627	AADAT	chr4:170981374-171011372:-	-0.28	-3.48	0.000538	Thyroid hormone levels	
LGG	cis	1	rs11733284	chr4:48028097	CNGA1	chr4:47937996-48018610:-	0.6	12.5	2.54E-31	Renal underexcretion gout;Gout	
LGG	cis	1	rs11733850	chr4:171023301	AADAT	chr4:170981374-171011372:-	-0.3	-3.98	8.06E-5	Thyroid hormone levels	
LGG	cis	1	rs11733864	chr4:56321530	TMEM165	chr4:56262090-56292342:+	-0.17	-4.91	1.22E-6	Personality dimensions	
LGG	cis	1	rs11735213	chr4:106527508	GSTCD	chr4:106629941-106768881:+	0.31	3.69	0.000254	Post bronchodilator FEV1	
LGG	cis	1	rs11736939	chr4:171031170	AADAT	chr4:170981374-171011372:-	-0.29	-3.74	0.000206	Thyroid hormone levels	
LGG	cis	1	rs11737138	chr4:17657986	MED28	chr4:17616273-17629791:+	0.18	3.94	9.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs11737268	chr4:224452	ZNF718	chr4:53272-156488:+	0.28	5.79	1.25E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs117372845	chr11:71568849	FAM86C	chr11:71498557-71512276:+	-0.43	-4.32	1.86E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs11737481	chr4:159621250	ETFDH	chr4:159593277-159629839:+	0.32	6.39	3.81E-10	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs11737950	chr5:156436211	TIMD4	chr5:156346293-156390266:-	-0.26	-4.71	3.3E-6	Hypertriglyceridemia	
LGG	cis	1	rs11738587	chr5:112693781	SRP19	chr5:112196993-112228774:+	0.27	3.51	0.000483	F-cell distribution	
LGG	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs11739619	chr5:150264662	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11739677	chr5:150294883	LOC134466	chr5:150310000-150326146:-	0.53	5.88	7.72E-9	Crohn's disease	
LGG	cis	1	rs11740172	chr5:150300278	LOC134466	chr5:150310000-150326146:-	0.51	5.77	1.41E-8	Crohn's disease	
LGG	cis	1	rs11740496	chr5:156435402	TIMD4	chr5:156346293-156390266:-	0.27	4.89	1.39E-6	Hypertriglyceridemia	
LGG	cis	1	rs11740499	chr5:156431741	TIMD4	chr5:156346293-156390266:-	-0.25	-4.62	4.84E-6	Hypertriglyceridemia	
LGG	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-0.48	-5.06	5.93E-7	Crohn's disease	
LGG	cis	1	rs117431270	chr9:123677597	TRAF1	chr9:123664672-123691479:-	0.4	4.57	6.15E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs11743488	chr5:150279218	LOC134466	chr5:150310000-150326146:-	0.5	5.32	1.55E-7	Crohn's disease	
LGG	cis	1	rs11744988	chr5:42474696	C5orf51	chr5:41904470-41921737:+	-0.29	-3.49	0.000519	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs11746108	chr5:150264622	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11746128	chr5:156421250	TIMD4	chr5:156346293-156390266:-	-0.23	-4.35	1.65E-5	Hypertriglyceridemia	
LGG	cis	1	rs11746560	chr5:150185925	LOC134466	chr5:150310000-150326146:-	0.38	3.98	7.97E-5	Crohn's disease	
LGG	cis	1	rs11746807	chr5:150300419	LOC134466	chr5:150310000-150326146:-	0.51	5.76	1.48E-8	Crohn's disease	
LGG	cis	1	rs11746828	chr5:112718008	SRP19	chr5:112196993-112228774:+	0.28	3.48	0.000539	F-cell distribution	
LGG	cis	1	rs11746907	chr5:598224	SDHA	chr5:218356-256812:+	-0.2	-4.46	1.04E-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs11747065	chr5:150295486	LOC134466	chr5:150310000-150326146:-	0.51	5.77	1.41E-8	Crohn's disease	
LGG	cis	1	rs11747270	chr5:150258867	LOC134466	chr5:150310000-150326146:-	-0.4	-4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs11748151	chr5:150226292	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs11748158	chr5:150226345	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs11748553	chr5:150184553	LOC134466	chr5:150310000-150326146:-	0.38	3.98	7.97E-5	Crohn's disease	
LGG	cis	1	rs11749391	chr5:150229066	LOC134466	chr5:150310000-150326146:-	0.42	4.76	2.5E-6	Crohn's disease	
LGG	cis	1	rs11750254	chr5:112718137	SRP19	chr5:112196993-112228774:+	0.28	3.53	0.000455	F-cell distribution	
LGG	cis	1	rs117517262	chr7:86939127	CROT	chr7:86974951-87029112:+	0.33	4.28	2.3E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11752297	chr6:33735154	BAK1	chr6:33540324-33548070:-	-0.15	-3.5	0.000501	Crohn's disease	
LGG	cis	1	rs11752297	chr6:33735154	LEMD2	chr6:33738991-33756906:-	-0.14	-4.42	1.24E-5	Crohn's disease	
LGG	cis	1	rs11753083	chr6:33761111	LEMD2	chr6:33738991-33756906:-	0.19	5.49	6.33E-8	Body mass index	
LGG	cis	1	rs11754690	chr6:33744157	LEMD2	chr6:33738991-33756906:-	0.19	5.67	2.46E-8	Body mass index	
LGG	cis	1	rs11754744	chr6:26202605	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.28	2.22E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs11754744	chr6:26202605	HIST1H3E	chr6:26224427-26226589:+	0.65	10.86	9.44E-25	Renal underexcretion gout;Gout	
LGG	cis	1	rs11755164	chr6:44639184	SUPT3H	chr6:44777054-45345670:-	-0.21	-4.75	2.65E-6	Bone mineral density	
LGG	cis	1	rs11755210	chr6:26202768	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.28	2.22E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs11755210	chr6:26202768	HIST1H3E	chr6:26224427-26226589:+	0.65	10.86	9.44E-25	Renal underexcretion gout;Gout	
LGG	cis	1	rs11755593	chr6:33740325	LEMD2	chr6:33738991-33756906:-	0.19	5.59	3.87E-8	Body mass index	
LGG	cis	1	rs11756120	chr6:26529808	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs11756120	chr6:26529808	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs117573845	chr20:33651621	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.0E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs1175739	chr18:24567239	C18orf16	chr18:24445272-24770650:+	-0.2	-4.7	3.32E-6	Breast cancer	
LGG	cis	1	rs11757617	chr6:166018432	PRR18	chr6:166719168-166721871:-	-0.13	-3.5	0.00051	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs11758351	chr6:26203910	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.3	2.1E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs11758351	chr6:26203910	HIST1H3E	chr6:26224427-26226589:+	0.63	10.52	1.85E-23	Renal underexcretion gout;Gout	
LGG	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.48	-9.63	3.27E-20	Response to antipsychotic treatment	
LGG	cis	1	rs11759804	chr6:151875122	C6orf97	chr6:151815175-151942327:+	0.26	4.26	2.46E-5	Bone mineral density (spine)	
LGG	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.49	-10.11	5.77E-22	Response to antipsychotic treatment	
LGG	cis	1	rs11760687	chr7:86962741	CROT	chr7:86974951-87029112:+	0.36	4.61	5.25E-6	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11760719	chr7:86958829	CROT	chr7:86974951-87029112:+	0.38	4.9	1.32E-6	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11761383	chr7:99519995	TRIM4	chr7:99488037-99517154:-	-0.39	-3.66	0.000275	Dehydroepiandrosterone sulphate levels;Metabolic traits	
LGG	cis	1	rs117616040	chr20:33565528	PROCR	chr20:33758727-33765164:+	-0.32	-5.52	5.63E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11762311	chr7:86942825	CROT	chr7:86974951-87029112:+	0.33	4.23	2.78E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11763147	chr7:65326821	ASL	chr7:65540776-65558321:+	0.17	4.47	9.78E-6	Corneal structure	
LGG	cis	1	rs117638181	chr19:22163014	ZNF257	chr19:22235266-22273901:+	0.56	9	4.88E-18	Body mass index (change over time)	
LGG	cis	1	rs1176555	chr1:157136541	ETV3L	chr1:157061836-157069600:-	-0.22	-4.38	1.43E-5	Attention deficit hyperactivity disorder and conduct disorder	
LGG	cis	1	rs11765693	chr7:75985373	POR	chr7:75544420-75616172:+	0.19	3.97	8.39E-5	Multiple sclerosis	
LGG	cis	1	rs11765693	chr7:75985373	SRCRB4D	chr7:76018647-76039012:-	0.27	5.99	4.09E-9	Multiple sclerosis	
LGG	cis	1	rs11765693	chr7:75985373	UPK3B	chr7:76139745-76157197:+	-0.24	-4.47	9.52E-6	Multiple sclerosis	
LGG	cis	1	rs11765986	chr7:77357274	PTPN12	chr7:77166773-77269388:+	-0.16	-3.64	0.000298	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11767124	chr7:23919080	C7orf46	chr7:23719749-23742268:+	0.2	4.32	1.89E-5	Schizophrenia	
LGG	cis	1	rs11767651	chr7:77390380	PTPN12	chr7:77166773-77269388:+	-0.19	-4.11	4.67E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11768281	chr7:86956106	CROT	chr7:86974951-87029112:+	0.36	4.61	5.16E-6	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs117683816	chr12:56638267	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs11768889	chr7:117993350	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000179	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs11769063	chr7:86918603	CROT	chr7:86974951-87029112:+	-0.3	-4.04	6.18E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11770446	chr7:77358072	PTPN12	chr7:77166773-77269388:+	-0.17	-3.67	0.000269	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11770633	chr7:155008951	INSIG1	chr7:155089486-155101942:+	-0.22	-3.46	0.000593	Personality dimensions	
LGG	cis	1	rs11771466	chr7:86962803	CROT	chr7:86974951-87029112:+	0.36	4.63	4.72E-6	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11773164	chr7:86909939	CROT	chr7:86974951-87029112:+	0.33	4.27	2.34E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11773829	chr7:66141074	ASL	chr7:65540776-65558321:+	0.19	4.95	1.03E-6	Aortic root size	
LGG	cis	1	rs11773829	chr7:66141074	TYW1	chr7:66461817-66704496:+	-0.17	-3.57	0.000393	Aortic root size	
LGG	cis	1	rs11775444	chr8:21813018	XPO7	chr8:21777180-21864095:+	0.16	3.58	0.000374	Mean corpuscular volume	
LGG	cis	1	rs11776767	chr8:10683929	RP1L1	chr8:10463862-10512617:-	-0.21	-3.76	0.000188	Triglycerides	
LGG	cis	1	rs117779516	chr12:56750872	IL23A	chr12:56732663-56734193:+	0.61	5.14	3.99E-7	Psoriasis vulgaris	
LGG	cis	1	rs117785694	chr13:97148813	UGGT2	chr13:96453838-96705736:-	-0.28	-3.51	0.000497	Schizophrenia	
LGG	cis	1	rs117802529	chr20:33786677	PROCR	chr20:33758727-33765164:+	-0.37	-6.52	1.79E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11782388	chr8:23525358	NKX3-1	chr8:23536207-23540450:-	0.21	4.36	1.58E-5	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.46	-4.8	2.09E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs11789898	chr9:136925663	SURF4	chr9:136228341-136242970:-	-0.18	-3.46	0.000581	Platelet count	
LGG	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.53	-11.25	2.77E-26	Response to antipsychotic treatment	
LGG	cis	1	rs11791066	chr9:88869630	C9orf153	chr9:88835181-88874519:-	-0.25	-3.53	0.000458	Diisocyanate-induced asthma	
LGG	cis	1	rs11792346	chr9:138275685	CAMSAP1	chr9:138700334-138799005:-	0.14	3.64	0.000306	Attention deficit hyperactivity disorder	
LGG	cis	1	rs11792804	chr9:88925774	C9orf153	chr9:88835181-88874519:-	0.25	3.54	0.000436	Diisocyanate-induced asthma	
LGG	cis	1	rs11801695	chr1:205916175	PM20D1	chr1:205797154-205819245:-	-0.29	-5.13	4.2E-7	Cystic fibrosis-related diabetes	
LGG	cis	1	rs118030231	chr11:65501905	DKFZp761E198	chr11:65543380-65547822:-	-0.29	-3.65	0.000289	Atopic dermatitis	
LGG	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.15	-4.38	1.46E-5	Body mass index	
LGG	cis	1	rs11810993	chr1:46478793	MUTYH	chr1:45794915-45806142:-	0.13	4.91	1.23E-6	Body mass index	
LGG	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	0.53	8.93	8.82E-18	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs118130855	chr12:56677979	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs11813099	chr10:17183451	TRDMT1	chr10:17184983-17243681:-	-0.2	-4.03	6.58E-5	Homocysteine levels	
LGG	cis	1	rs11816485	chr10:1147974	IDI2	chr10:1064847-1071799:-	0.33	4	7.39E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11816840	chr10:102309220	HIF1AN	chr10:102295641-102313680:+	0.19	3.65	0.000285	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11816840	chr10:102309220	NDUFB8	chr10:102283497-102289636:-	0.17	4.73	2.99E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11816840	chr10:102309220	WNT8B	chr10:102222812-102243397:+	0.47	7.63	1.2E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs11818314	chr10:1148157	IDI2	chr10:1064847-1071799:-	0.33	4.01	6.96E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11819230	chr10:1128812	IDI2	chr10:1064847-1071799:-	0.31	3.76	0.000192	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs11826587	chr11:5388696	FAM160A2	chr11:6232565-6255941:-	0.19	3.87	0.000121	Fetal hemoglobin levels	
LGG	cis	1	rs1182882	chr7:65562063	ASL	chr7:65540776-65558321:+	0.17	4.12	4.45E-5	Aortic root size	
LGG	cis	1	rs11832315	chr12:50943932	ATF1	chr12:51157819-51214906:+	-0.2	-4.29	2.15E-5	Fibrinogen	
LGG	cis	1	rs11832315	chr12:50943932	LETMD1	chr12:51442084-51454206:+	0.15	3.73	0.000214	Fibrinogen	
LGG	cis	1	rs11832315	chr12:50943932	SLC11A2	chr12:51373319-51422058:-	0.17	3.71	0.000227	Fibrinogen	
LGG	cis	1	rs11838553	chr13:98013862	OXGR1	chr13:97637973-97646604:-	0.32	3.73	0.000211	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score)	
LGG	cis	1	rs11844348	chr14:65859480	LOC645431	chr14:65877313-65879335:-	-0.43	-6.08	2.35E-9	Ischemic stroke	
LGG	cis	1	rs11844747	chr14:65870128	LOC645431	chr14:65877313-65879335:-	0.51	7.05	5.97E-12	Ischemic stroke	
LGG	cis	1	rs11845639	chr14:75570293	ACYP1	chr14:75519930-75530736:-	-0.13	-3.52	0.000465	Height	
LGG	cis	1	rs11845639	chr14:75570293	EIF2B2	chr14:75469612-75476292:+	0.19	3.74	0.000203	Height	
LGG	cis	1	rs11845794	chr14:65848118	LOC645431	chr14:65877313-65879335:-	-0.45	-6.11	2.05E-9	Ischemic stroke	
LGG	cis	1	rs11849252	chr14:66069769	LOC645431	chr14:65877313-65879335:-	-0.45	-6.15	1.59E-9	Ischemic stroke	
LGG	cis	1	rs11850160	chr14:65848123	LOC645431	chr14:65877313-65879335:-	-0.45	-6.11	2.05E-9	Ischemic stroke	
LGG	cis	1	rs11850163	chr14:65848145	LOC645431	chr14:65877313-65879335:-	-0.42	-5.94	5.36E-9	Ischemic stroke	
LGG	cis	1	rs11850847	chr14:65933798	LOC645431	chr14:65877313-65879335:-	-0.51	-6.86	2.02E-11	Ischemic stroke	
LGG	cis	1	rs11851013	chr14:66016212	LOC645431	chr14:65877313-65879335:-	-0.46	-6.09	2.29E-9	Ischemic stroke	
LGG	cis	1	rs11851772	chr14:66022047	LOC645431	chr14:65877313-65879335:-	-0.49	-6.51	1.81E-10	Ischemic stroke	
LGG	cis	1	rs11853024	chr15:91514797	RCCD1	chr15:91498106-91506353:+	0.18	3.77	0.000183	Type 2 diabetes	
LGG	cis	1	rs11856184	chr15:43919162	ADAL	chr15:43622872-43646094:+	-0.61	-7.8	3.84E-14	Tumor biomarkers	
LGG	cis	1	rs11856184	chr15:43919162	LCMT2	chr15:43619976-43622891:-	-0.29	-3.74	0.000208	Tumor biomarkers	
LGG	cis	1	rs11856184	chr15:43919162	STRC	chr15:43891762-43924561:-	0.39	6.99	8.93E-12	Tumor biomarkers	
LGG	cis	1	rs11858210	chr15:79078358	ADAMTS7	chr15:79051546-79103773:-	0.19	3.89	0.000116	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11858210	chr15:79078358	CHRNA5	chr15:78857906-78886458:+	-0.25	-4.08	5.19E-5	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs11858714	chr15:40717447	C15orf23	chr15:40674922-40686488:+	1.04	16.2	1.34E-47	Heschl's gyrus morphology	
LGG	cis	1	rs11861657	chr16:67824395	LRRC36	chr16:67360747-67419108:+	0.49	4.52	7.69E-6	Crohn's disease	
LGG	cis	1	rs11861657	chr16:67824395	RANBP10	chr16:67757006-67840555:-	-0.31	-3.59	0.000367	Crohn's disease	
LGG	cis	1	rs11862744	chr16:31057800	MYST1	chr16:31128985-31142713:+	0.15	4.27	2.38E-5	Response to metformin (IC50)	
LGG	cis	1	rs11862744	chr16:31057800	PRSS53	chr16:31094747-31106276:-	-0.17	-4.72	3.06E-6	Response to metformin (IC50)	
LGG	cis	1	rs11868085	chr17:46847575	SNF8	chr17:47007461-47022154:-	-0.16	-4.17	3.63E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs11869069	chr17:40287101	DHX58	chr17:40253422-40264751:-	-0.19	-3.99	7.66E-5	Fibrinogen levels	
LGG	cis	1	rs11869819	chr17:65868669	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs11870068	chr17:65944515	LOC440461	chr17:66194801-66196436:+	0.3	4.98	8.67E-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs11870797	chr17:61804622	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs11870797	chr17:61804622	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs11870797	chr17:61804622	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs11870935	chr17:45732605	C17orf57	chr17:45401142-45518675:+	-0.15	-3.64	0.000302	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs11870935	chr17:45732605	LOC100272146	chr17:45500843-45504056:+	-0.15	-3.75	0.000199	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs11871767	chr17:61698723	DDX42	chr17:61851567-61896676:+	-0.15	-3.52	0.000479	Body mass index	
LGG	cis	1	rs11871767	chr17:61698723	FTSJ3	chr17:61896795-61905031:-	0.41	8.51	2.19E-16	Body mass index	
LGG	cis	1	rs11871767	chr17:61698723	SMARCD2	chr17:61909441-61920351:-	0.19	4.27	2.34E-5	Body mass index	
LGG	cis	1	rs1187446	chr14:104409896	TDRD9	chr14:104394817-104519002:+	0.23	4.6	5.39E-6	Bipolar disorder	
LGG	cis	1	rs1187448	chr14:104406627	TDRD9	chr14:104394817-104519002:+	0.23	4.67	3.88E-6	Bipolar disorder	
LGG	cis	1	rs11879853	chr19:23029434	ZNF492	chr19:22817126-22850472:+	0.21	4.23	2.75E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs11880333	chr19:49144790	SEC1	chr19:49141296-49185501:+	-0.61	-7.57	1.81E-13	Elevated serum carcinoembryonic antigen levels	
LGG	cis	1	rs11880539	chr19:41918949	ATP5SL	chr19:41937224-41945810:-	-0.22	-5.78	1.3E-8	Height	
LGG	cis	1	rs11881224	chr19:22220340	ZNF257	chr19:22235266-22273901:+	0.56	8.91	9.69E-18	Body mass index (change over time)	
LGG	cis	1	rs11882234	chr19:22145727	ZNF257	chr19:22235266-22273901:+	0.56	8.98	5.72E-18	Body mass index (change over time)	
LGG	cis	1	rs11882498	chr19:23060012	ZNF492	chr19:22817126-22850472:+	-0.22	-4.38	1.45E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs11883104	chr19:41923799	ATP5SL	chr19:41937224-41945810:-	0.19	5.52	5.47E-8	Height	
LGG	cis	1	rs11893500	chr2:70154187	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.5	8.49E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs11893832	chr2:88507537	FABP1	chr2:88422510-88427578:-	-0.31	-4.2	3.24E-5	Plasma clusterin levels	
LGG	cis	1	rs11893832	chr2:88507537	THNSL2	chr2:88469835-88486145:+	-0.58	-8.4	4.9E-16	Plasma clusterin levels	
LGG	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.4	7.28	1.34E-12	Metabolite levels	
LGG	cis	1	rs11893881	chr2:73824373	NAT8	chr2:73867850-73869537:-	0.27	4.5	8.45E-6	Metabolite levels	
LGG	cis	1	rs11896604	chr2:54479199	C2orf73	chr2:54558071-54588714:+	-0.32	-4.68	3.64E-6	Telomere length	
LGG	cis	1	rs11896604	chr2:54479199	TSPYL6	chr2:54480315-54483409:-	0.47	5.68	2.31E-8	Telomere length	
LGG	cis	1	rs11899576	chr2:86256193	LOC90784	chr2:86247339-86250991:-	-0.47	-5.04	6.43E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.38	6.87	1.98E-11	Metabolite levels	
LGG	cis	1	rs11899740	chr2:73631212	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.58E-5	Metabolite levels	
LGG	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.39	7.04	6.54E-12	Metabolite levels	
LGG	cis	1	rs11899902	chr2:73631564	NAT8	chr2:73867850-73869537:-	0.25	4.15	3.97E-5	Metabolite levels	
LGG	cis	1	rs11901272	chr2:73720444	ALMS1P	chr2:73872046-73912692:+	0.4	7.19	2.41E-12	Metabolite levels	
LGG	cis	1	rs11901272	chr2:73720444	NAT8	chr2:73867850-73869537:-	0.28	4.65	4.26E-6	Metabolite levels	
LGG	cis	1	rs11902198	chr2:70144596	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.12	4.4E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs11903916	chr2:73815328	ALMS1P	chr2:73872046-73912692:+	0.37	6.71	5.32E-11	Metabolite levels	
LGG	cis	1	rs11903916	chr2:73815328	NAT8	chr2:73867850-73869537:-	0.26	4.31	1.97E-5	Metabolite levels	
LGG	cis	1	rs1190447	chr2:233420052	EIF4E2	chr2:233415357-233448349:+	0.22	3.62	0.000325	Height	
LGG	cis	1	rs11905214	chr20:47888610	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.09	5.14E-5	Height	
LGG	cis	1	rs11905354	chr20:33677164	PROCR	chr20:33758727-33765164:+	-0.32	-5.99	4.11E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs1190553	chr14:102915331	ANKRD9	chr14:102973198-102976128:-	-0.2	-4.73	2.92E-6	QT interval	
LGG	cis	1	rs1190554	chr14:102918686	ANKRD9	chr14:102973198-102976128:-	0.2	4.61	5.04E-6	QT interval	
LGG	cis	1	rs11906148	chr20:33784021	PROCR	chr20:33758727-33765164:+	-0.37	-6.52	1.79E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11906318	chr20:33729442	PROCR	chr20:33758727-33765164:+	-0.32	-5.84	9.33E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11907010	chr20:33737661	PROCR	chr20:33758727-33765164:+	-0.36	-6.42	3.26E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11907011	chr20:33767770	PROCR	chr20:33758727-33765164:+	-0.36	-6.52	1.78E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11907438	chr20:33641220	PROCR	chr20:33758727-33765164:+	-0.31	-5.8	1.2E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11907594	chr20:33673843	PROCR	chr20:33758727-33765164:+	-0.3	-5.78	1.32E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11908100	chr20:33729479	PROCR	chr20:33758727-33765164:+	-0.32	-5.96	4.69E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11908232	chr20:33729477	PROCR	chr20:33758727-33765164:+	-0.32	-5.96	4.69E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11908424	chr20:61863955	BIRC7	chr20:61867276-61871853:+	0.34	4.45	1.06E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs11908424	chr20:61863955	NKAIN4	chr20:61872137-61885892:-	0.27	4.78	2.34E-6	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs11908683	chr20:33720920	PROCR	chr20:33758727-33765164:+	-0.38	-6.72	4.99E-11	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.49	3.17E-13	Height	
LGG	cis	1	rs11919350	chr3:134235970	CEP63	chr3:134204575-134293852:+	-0.21	-3.76	0.00019	Height	
LGG	cis	1	rs11919484	chr3:186432839	KNG1	chr3:186435120-186461741:+	-0.16	-3.55	0.000418	Adiponectin levels	
LGG	cis	1	rs11920900	chr3:49823024	MST1R	chr3:49924438-49941306:-	0.25	4.69	3.47E-6	Resting heart rate	
LGG	cis	1	rs11920900	chr3:49823024	RBM6	chr3:49977592-50137484:+	-0.14	-3.64	0.000299	Resting heart rate	
LGG	cis	1	rs11923562	chr3:41760331	ULK4	chr3:41288091-42003660:-	0.71	13.12	6.56E-34	Diastolic blood pressure	
LGG	cis	1	rs11924390	chr3:186433099	KNG1	chr3:186435120-186461741:+	-0.16	-3.56	0.000407	Adiponectin levels	
LGG	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs11927068	chr3:134266321	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs11927941	chr3:186433046	KNG1	chr3:186435120-186461741:+	-0.16	-3.56	0.000407	Adiponectin levels	
LGG	cis	1	rs11928090	chr3:49604904	AMIGO3	chr3:49754268-49757238:-	-0.17	-4.04	6.16E-5	Menarche (age at onset)	
LGG	cis	1	rs11928090	chr3:49604904	GMPPB	chr3:49758932-49761384:-	-0.22	-4.28	2.28E-5	Menarche (age at onset)	
LGG	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.66	1.0E-13	Height	
LGG	cis	1	rs11928499	chr3:134232350	CEP63	chr3:134204575-134293852:+	-0.21	-3.79	0.00017	Height	
LGG	cis	1	rs11928580	chr3:41885722	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs11931061	chr4:56338793	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs11942153	chr4:106960172	NPNT	chr4:106816605-106892827:+	-0.24	-5.18	3.28E-7	Airflow obstruction	
LGG	cis	1	rs11948089	chr5:110464393	TSLP	chr5:110405778-110413722:+	-0.27	-3.94	9.18E-5	Eosinophil counts	
LGG	cis	1	rs11949373	chr5:126729984	FLJ44606	chr5:126381051-126409172:-	0.26	3.48	0.000553	IgG glycosylation	
LGG	cis	1	rs11949845	chr5:171163473	NEURL1B	chr5:172068276-172118531:+	-0.16	-3.45	0.000603	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs11950058	chr5:126730147	FLJ44606	chr5:126381051-126409172:-	0.26	3.48	0.000553	IgG glycosylation	
LGG	cis	1	rs11950199	chr5:171158742	NEURL1B	chr5:172068276-172118531:+	-0.16	-3.48	0.000555	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs11950957	chr5:150253914	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs11951694	chr5:150254338	LOC134466	chr5:150310000-150326146:-	0.42	4.77	2.42E-6	Crohn's disease	
LGG	cis	1	rs11953024	chr5:126726135	FLJ44606	chr5:126381051-126409172:-	0.29	3.94	9.33E-5	IgG glycosylation	
LGG	cis	1	rs11955172	chr5:150254378	LOC134466	chr5:150310000-150326146:-	0.42	4.77	2.42E-6	Crohn's disease	
LGG	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.48	-5.19	3.02E-7	Crohn's disease	
LGG	cis	1	rs11958435	chr5:126728811	FLJ44606	chr5:126381051-126409172:-	0.28	3.78	0.000176	IgG glycosylation	
LGG	cis	1	rs11959505	chr5:126726288	FLJ44606	chr5:126381051-126409172:-	0.25	3.51	0.000491	IgG glycosylation	
LGG	cis	1	rs11961560	chr6:170130121	WDR27	chr6:169857307-170102159:-	-0.36	-8.13	3.49E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs11963889	chr6:46318568	ENPP5	chr6:46127762-46138717:-	0.15	3.58	0.000377	Body mass index	
LGG	cis	1	rs11965538	chr6:28239915	ZNF165	chr6:28046572-28057338:+	-0.32	-4.71	3.24E-6	Depression	
LGG	cis	1	rs11965538	chr6:28239915	ZNF187	chr6:28234788-28245978:+	-0.26	-4.52	7.75E-6	Depression	
LGG	cis	1	rs11965538	chr6:28239915	ZNF389	chr6:28129551-28137375:+	0.43	6.84	2.41E-11	Depression	
LGG	cis	1	rs11965538	chr6:28239915	ZSCAN12	chr6:28346770-28367544:-	-0.33	-4.67	3.91E-6	Depression	
LGG	cis	1	rs11965538	chr6:28239915	ZSCAN23	chr6:28393287-28411279:-	0.18	4.31	2.01E-5	Depression	
LGG	cis	1	rs11970772	chr6:41925290	PTCRA	chr6:42883727-42893573:+	-0.16	-3.54	0.000441	Hematological parameters	
LGG	cis	1	rs11971779	chr7:139040258	C7orf55	chr7:139025897-139030539:+	0.2	4.37	1.54E-5	Diisocyanate-induced asthma	
LGG	cis	1	rs11971949	chr7:65626014	ASL	chr7:65540776-65558321:+	0.22	5.55	4.79E-8	Aortic root size	
LGG	cis	1	rs11974219	chr7:65647410	ASL	chr7:65540776-65558321:+	0.22	5.61	3.39E-8	Aortic root size	
LGG	cis	1	rs11974264	chr7:65647582	ASL	chr7:65540776-65558321:+	0.22	5.61	3.39E-8	Aortic root size	
LGG	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	1.05	20.95	4.42E-70	Educational attainment (years of education)	
LGG	cis	1	rs11983450	chr7:86875842	CROT	chr7:86974951-87029112:+	0.31	4.09	5.05E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs11986181	chr8:98326549	HRSP12	chr8:99114567-99129418:-	0.16	3.83	0.000146	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs11986414	chr8:1746950	CLN8	chr8:1711870-1734735:+	0.18	3.52	0.000465	Gaucher disease severity	
LGG	cis	1	rs11995536	chr8:120945268	DSCC1	chr8:120846182-120868170:-	-0.25	-5.78	1.3E-8	Interstitial lung disease	
LGG	cis	1	rs11996689	chr8:98326414	HRSP12	chr8:99114567-99129418:-	0.16	3.83	0.000146	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs11996961	chr8:10812204	RP1L1	chr8:10463862-10512617:-	-0.29	-3.7	0.000243	Asthma and hay fever	
LGG	cis	1	rs12003641	chr9:114279497	PTGR1	chr9:114312003-114362135:-	0.31	4.59	5.56E-6	Menarche (age at onset)	
LGG	cis	1	rs12003641	chr9:114279497	ZNF483	chr9:114287447-114340124:+	-0.24	-3.9	0.000109	Menarche (age at onset)	
LGG	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.15	-4.3	2.09E-5	Body mass index	
LGG	cis	1	rs12021587	chr1:46472759	MUTYH	chr1:45794915-45806142:-	0.14	4.93	1.13E-6	Body mass index	
LGG	cis	1	rs12022194	chr1:156312331	BGLAP	chr1:156182784-156213112:+	0.24	4.92	1.19E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12022194	chr1:156312331	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.91E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12022784	chr1:179469016	C1orf125	chr1:179335107-179523868:+	0.47	6.24	9.23E-10	Multiple sclerosis (age of onset)	
LGG	cis	1	rs12023106	chr1:202365332	UBE2T	chr1:202300786-202311094:-	-0.13	-4.12	4.51E-5	Sex ratio	
LGG	cis	1	rs12023357	chr1:179474732	C1orf125	chr1:179335107-179523868:+	0.47	6.24	9.23E-10	Multiple sclerosis (age of onset)	
LGG	cis	1	rs12023438	chr1:156254358	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12023438	chr1:156254358	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12023704	chr1:156294149	BGLAP	chr1:156182784-156213112:+	0.25	5.25	2.32E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12023704	chr1:156294149	CCT3	chr1:156278752-156308195:-	-0.16	-4.01	7.02E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12024813	chr1:156224529	BGLAP	chr1:156182784-156213112:+	0.23	4.82	1.96E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12024813	chr1:156224529	CCT3	chr1:156278752-156308195:-	-0.14	-3.47	0.000562	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12027103	chr1:156244856	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12027103	chr1:156244856	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12027542	chr1:233340154	C1orf57	chr1:233086370-233114219:+	0.39	3.81	0.000156	Type 2 diabetes	
LGG	cis	1	rs12027741	chr1:156248148	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12027741	chr1:156248148	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12029787	chr1:179473917	C1orf125	chr1:179335107-179523868:+	0.47	6.24	9.23E-10	Multiple sclerosis (age of onset)	
LGG	cis	1	rs1203156	chr6:88079694	C6orf163	chr6:88057220-88075180:+	0.2	3.57	0.000393	Depressive episodes in bipolar disorder	
LGG	cis	1	rs12031720	chr1:202449706	UBE2T	chr1:202300786-202311094:-	-0.13	-4.08	5.18E-5	Sex ratio	
LGG	cis	1	rs12034881	chr1:233308562	C1orf57	chr1:233086370-233114219:+	-0.39	-3.89	0.000115	Type 2 diabetes	
LGG	cis	1	rs12036501	chr1:202336996	UBE2T	chr1:202300786-202311094:-	-0.13	-4.01	7.09E-5	Sex ratio	
LGG	cis	1	rs12037876	chr1:202469970	UBE2T	chr1:202300786-202311094:-	-0.14	-4.16	3.82E-5	Sex ratio	
LGG	cis	1	rs12038203	chr1:156248265	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12038203	chr1:156248265	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12038217	chr1:156248297	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.73E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12038217	chr1:156248297	CCT3	chr1:156278752-156308195:-	-0.16	-3.94	9.24E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12038481	chr1:156284815	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.79E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12038481	chr1:156284815	CCT3	chr1:156278752-156308195:-	-0.16	-3.99	7.54E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12040868	chr1:156284803	BGLAP	chr1:156182784-156213112:+	0.25	5.25	2.32E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12040868	chr1:156284803	CCT3	chr1:156278752-156308195:-	-0.16	-4.01	7.02E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12041164	chr1:156279811	BGLAP	chr1:156182784-156213112:+	0.25	5.26	2.16E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12041164	chr1:156279811	CCT3	chr1:156278752-156308195:-	-0.17	-4.18	3.52E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12041202	chr1:202457177	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000533	Sex ratio	
LGG	cis	1	rs12041202	chr1:202457177	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.72E-5	Sex ratio	
LGG	cis	1	rs12042669	chr1:202453928	UBE2T	chr1:202300786-202311094:-	-0.13	-3.9	0.00011	Sex ratio	
LGG	cis	1	rs12045339	chr1:156294211	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.4E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12045339	chr1:156294211	CCT3	chr1:156278752-156308195:-	-0.17	-4.23	2.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12045807	chr1:150584834	ARNT	chr1:150782186-150849186:-	-0.23	-4.24	2.68E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs12047808	chr1:179469314	C1orf125	chr1:179335107-179523868:+	0.46	6.11	2.05E-9	Multiple sclerosis (age of onset)	
LGG	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.15	-4.3	2.09E-5	Body mass index	
LGG	cis	1	rs12049588	chr1:46472422	MUTYH	chr1:45794915-45806142:-	0.14	4.93	1.13E-6	Body mass index	
LGG	cis	1	rs12050794	chr15:72169466	NR2E3	chr15:72102894-72110595:+	0.25	4.26	2.4E-5	Metabolite levels (HVA/MHPG ratio)	
LGG	cis	1	rs12051247	chr16:67241282	ACD	chr16:67691416-67694718:-	-0.24	-3.73	0.000211	HDL cholesterol	
LGG	cis	1	rs12051247	chr16:67241282	CENPT	chr16:67862064-67881361:-	-0.18	-3.48	0.000541	HDL cholesterol	
LGG	cis	1	rs12051247	chr16:67241282	CES2	chr16:66968347-66978992:+	-0.34	-3.58	0.000371	HDL cholesterol	
LGG	cis	1	rs12051249	chr16:67241427	ACD	chr16:67691416-67694718:-	-0.21	-3.45	0.000602	HDL cholesterol	
LGG	cis	1	rs12051249	chr16:67241427	CENPT	chr16:67862064-67881361:-	-0.18	-3.66	0.000281	HDL cholesterol	
LGG	cis	1	rs12051249	chr16:67241427	CES2	chr16:66968347-66978992:+	-0.33	-3.62	0.000323	HDL cholesterol	
LGG	cis	1	rs12051443	chr16:71691329	ZNF19	chr16:71507976-71523254:-	-0.18	-3.82	0.000153	Prostate cancer	
LGG	cis	1	rs12052257	chr2:202241594	ALS2CR12	chr2:202153148-202222101:-	0.23	4.62	4.87E-6	Basal cell carcinoma	
LGG	cis	1	rs12052257	chr2:202241594	ALS2CR4	chr2:202484907-202508224:-	-0.16	-4.47	9.66E-6	Basal cell carcinoma	
LGG	cis	1	rs12052257	chr2:202241594	PPIL3	chr2:201735680-201753999:-	0.18	3.74	0.000203	Basal cell carcinoma	
LGG	cis	1	rs12053254	chr2:190607153	ASNSD1	chr2:190526125-190535556:+	-0.34	-3.63	0.000311	Subcutaneous adipose tissue	
LGG	cis	1	rs12053254	chr2:190607153	ORMDL1	chr2:190634994-190649097:-	0.38	5.4	1.02E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs12054923	chr5:150249059	LOC134466	chr5:150310000-150326146:-	0.43	4.8	2.12E-6	Crohn's disease	
LGG	cis	1	rs12058090	chr1:150011145	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12058502	chr1:150009841	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12060027	chr1:150015482	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12060211	chr1:150011323	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12060621	chr1:184669106	C1orf21	chr1:184356150-184598155:+	-0.35	-3.62	0.000327	Systemic lupus erythematosus	
LGG	cis	1	rs12063281	chr1:150002293	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12063329	chr1:150002436	RPRD2	chr1:150336990-150449039:+	0.15	3.7	0.000238	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12064532	chr1:150014078	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12065681	chr1:150013656	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12066293	chr1:150015625	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12067111	chr1:184704883	C1orf21	chr1:184356150-184598155:+	-0.39	-3.95	9.02E-5	Systemic lupus erythematosus	
LGG	cis	1	rs12067422	chr1:150015805	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12073219	chr1:169613369	SCYL3	chr1:169821804-169863076:-	-0.28	-3.8	0.00016	Late-onset Alzheimer's disease	
LGG	cis	1	rs12074281	chr1:150025377	RPRD2	chr1:150336990-150449039:+	0.15	3.7	0.000238	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs12087964	chr1:248011232	TRIM58	chr1:248020501-248043436:+	-0.46	-4.19	3.29E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs12091564	chr1:145395604	GNRHR2	chr1:145509753-145516076:-	0.43	5.07	5.62E-7	Coronary heart disease	
LGG	cis	1	rs12091564	chr1:145395604	NBPF10	chr1:144201705-146424095:+	-0.32	-3.81	0.000154	Coronary heart disease	
LGG	cis	1	rs12091564	chr1:145395604	NOTCH2NL	chr1:145209111-145295525:+	-0.66	-6.25	9.13E-10	Coronary heart disease	
LGG	cis	1	rs12091720	chr1:76186949	MSH4	chr1:76262630-76378923:+	0.23	4.11	4.66E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs12092054	chr1:227744249	JMJD4	chr1:227918891-227923112:-	0.23	3.83	0.000148	Height	
LGG	cis	1	rs12092054	chr1:227744249	SNAP47	chr1:227916240-227968932:+	-0.19	-3.73	0.000217	Height	
LGG	cis	1	rs12093031	chr1:227743875	JMJD4	chr1:227918891-227923112:-	-0.22	-3.72	0.000222	Height	
LGG	cis	1	rs12093031	chr1:227743875	SNAP47	chr1:227916240-227968932:+	0.19	3.68	0.000262	Height	
LGG	cis	1	rs12096214	chr1:184689823	C1orf21	chr1:184356150-184598155:+	0.35	3.74	0.000206	Systemic lupus erythematosus	
LGG	cis	1	rs12096473	chr1:248016894	TRIM58	chr1:248020501-248043436:+	-0.4	-3.61	0.000333	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs12097884	chr1:31864518	ZCCHC17	chr1:31769842-31837780:+	-0.16	-4.06	5.68E-5	Schizophrenia	
LGG	cis	1	rs12103803	chr17:20944604	USP22	chr17:20902908-20947073:-	-0.2	-4.6	5.34E-6	Blood trace element (Se levels)	
LGG	cis	1	rs12105996	chr20:33731010	PROCR	chr20:33758727-33765164:+	-0.32	-6	3.84E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs12113244	chr7:105542405	CDHR3	chr7:105517264-105676876:+	0.22	5.05	6.35E-7	Obesity-related traits	
LGG	cis	1	rs12117903	chr1:156311165	BGLAP	chr1:156182784-156213112:+	0.24	4.88	1.41E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12117903	chr1:156311165	CCT3	chr1:156278752-156308195:-	-0.17	-4.28	2.25E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12117947	chr1:156244058	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12117947	chr1:156244058	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12117951	chr1:156305286	BGLAP	chr1:156182784-156213112:+	0.24	4.92	1.17E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12117951	chr1:156305286	CCT3	chr1:156278752-156308195:-	-0.17	-4.12	4.47E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12118238	chr1:156235221	BGLAP	chr1:156182784-156213112:+	0.24	5.01	7.56E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12118238	chr1:156235221	CCT3	chr1:156278752-156308195:-	-0.14	-3.53	0.000449	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12120182	chr1:227814332	JMJD4	chr1:227918891-227923112:-	0.27	4.63	4.6E-6	Height	
LGG	cis	1	rs12120182	chr1:227814332	SNAP47	chr1:227916240-227968932:+	-0.2	-3.82	0.000153	Height	
LGG	cis	1	rs12121805	chr1:156257876	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12121805	chr1:156257876	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12122180	chr1:156244559	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12122180	chr1:156244559	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12122184	chr1:31858784	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.77	0.000186	Schizophrenia	
LGG	cis	1	rs12122236	chr1:31858901	ZCCHC17	chr1:31769842-31837780:+	-0.16	-3.87	0.000125	Schizophrenia	
LGG	cis	1	rs12122290	chr1:247215810	ZNF670	chr1:247200087-247242069:-	-0.23	-5.25	2.26E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs12123006	chr1:202435228	UBE2T	chr1:202300786-202311094:-	-0.13	-3.88	0.00012	Sex ratio	
LGG	cis	1	rs12123251	chr1:207992546	CD46	chr1:207925402-207968857:+	-0.24	-7.16	2.91E-12	Schizophrenia	
LGG	cis	1	rs12123977	chr1:76209754	MSH4	chr1:76262630-76378923:+	-0.23	-3.88	0.000119	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs12123996	chr1:227745090	JMJD4	chr1:227918891-227923112:-	0.23	3.83	0.000148	Height	
LGG	cis	1	rs12123996	chr1:227745090	SNAP47	chr1:227916240-227968932:+	-0.19	-3.73	0.000217	Height	
LGG	cis	1	rs12126607	chr1:76217097	MSH4	chr1:76262630-76378923:+	0.23	4.28	2.24E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs12126971	chr1:113231286	RHOC	chr1:113243749-113250025:-	-0.12	-3.47	0.000557	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs12126971	chr1:113231286	ST7L	chr1:113066142-113162405:-	0.25	5.71	1.95E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs12126971	chr1:113231286	WNT2B	chr1:113010040-113063908:+	0.18	3.68	0.000261	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs12127402	chr1:76205643	MSH4	chr1:76262630-76378923:+	0.24	4.41	1.28E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs12128789	chr1:212852832	BATF3	chr1:212859760-212873327:-	0.17	3.81	0.000159	Leprosy	
LGG	cis	1	rs12130075	chr1:247218491	ZNF670	chr1:247200087-247242069:-	-0.23	-5.2	2.92E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs12130219	chr1:152162106	FLG	chr1:152274651-152297679:-	0.4	6.34	5.08E-10	Inflammatory skin disease	
LGG	cis	1	rs12130361	chr1:156260301	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12130361	chr1:156260301	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12130379	chr1:63598363	ITGB3BP	chr1:63906462-63988835:-	-0.19	-3.5	0.000504	Brain imaging	
LGG	cis	1	rs12132794	chr1:156281020	BGLAP	chr1:156182784-156213112:+	-0.25	-5.09	5.04E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12132794	chr1:156281020	CCT3	chr1:156278752-156308195:-	0.16	3.93	9.7E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12132919	chr1:156318141	BGLAP	chr1:156182784-156213112:+	0.25	5.08	5.3E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12132919	chr1:156318141	CCT3	chr1:156278752-156308195:-	-0.16	-3.86	0.000131	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12133583	chr1:113240790	ST7L	chr1:113066142-113162405:-	0.25	5.9	6.94E-9	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs12133583	chr1:113240790	WNT2B	chr1:113010040-113063908:+	0.19	3.81	0.000158	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs12133919	chr1:212870612	BATF3	chr1:212859760-212873327:-	0.19	4.03	6.5E-5	Leprosy	
LGG	cis	1	rs12134983	chr1:156290409	BGLAP	chr1:156182784-156213112:+	0.25	5.23	2.51E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12134983	chr1:156290409	CCT3	chr1:156278752-156308195:-	-0.16	-4	7.43E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12139321	chr1:156230429	BGLAP	chr1:156182784-156213112:+	0.23	4.85	1.66E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12139321	chr1:156230429	CCT3	chr1:156278752-156308195:-	-0.14	-3.58	0.000375	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.32	1.57E-7	Body mass index	
LGG	cis	1	rs12139630	chr1:46350935	MUTYH	chr1:45794915-45806142:-	0.13	4.85	1.68E-6	Body mass index	
LGG	cis	1	rs12140848	chr1:227776942	JMJD4	chr1:227918891-227923112:-	0.26	4.34	1.77E-5	Height	
LGG	cis	1	rs12140848	chr1:227776942	SNAP47	chr1:227916240-227968932:+	-0.18	-3.49	0.000521	Height	
LGG	cis	1	rs12141236	chr1:156302575	BGLAP	chr1:156182784-156213112:+	0.24	4.89	1.39E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12141236	chr1:156302575	CCT3	chr1:156278752-156308195:-	-0.17	-4.3	2.05E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12142808	chr1:156230546	BGLAP	chr1:156182784-156213112:+	0.23	4.72	3.09E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12142808	chr1:156230546	CCT3	chr1:156278752-156308195:-	-0.14	-3.53	0.000457	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12143789	chr1:119497154	WARS2	chr1:119573841-119683295:-	-0.21	-3.69	0.000251	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.32	1.57E-7	Body mass index	
LGG	cis	1	rs12144263	chr1:46352446	MUTYH	chr1:45794915-45806142:-	0.13	4.85	1.68E-6	Body mass index	
LGG	cis	1	rs12145004	chr1:243483365	SDCCAG8	chr1:243419320-243663392:+	-0.28	-4.4	1.31E-5	Obesity (early onset extreme)	
LGG	cis	1	rs12145310	chr1:20901064	CDA	chr1:20915444-20945398:+	-0.2	-3.78	0.000178	Age-related hearing impairment (interaction)	
LGG	cis	1	rs12145351	chr1:20901181	CDA	chr1:20915444-20945398:+	-0.19	-3.6	0.000349	Age-related hearing impairment (interaction)	
LGG	cis	1	rs12145450	chr1:31862949	ZCCHC17	chr1:31769842-31837780:+	-0.16	-3.91	0.000104	Schizophrenia	
LGG	cis	1	rs12145833	chr1:243483754	SDCCAG8	chr1:243419320-243663392:+	0.31	5.08	5.48E-7	Obesity (early onset extreme)	
LGG	cis	1	rs12145953	chr1:31793766	ZCCHC17	chr1:31769842-31837780:+	-0.17	-4.28	2.28E-5	Schizophrenia	
LGG	cis	1	rs12147118	chr14:81652975	STON2	chr14:81727000-81893748:-	0.2	6.02	3.34E-9	Schizophrenia	
LGG	cis	1	rs12147422	chr14:55344015	GCH1	chr14:55308724-55369542:-	-0.3	-5.05	6.3E-7	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs12147450	chr14:20957433	TMEM55B	chr14:20926012-20929637:-	-0.22	-3.85	0.000134	Response to antipsychotic therapy (extrapyramidal side effects)	
LGG	cis	1	rs12147952	chr14:76624884	ESRRB	chr14:76837690-76968178:+	-0.44	-6.97	1.0E-11	Blood pressure	
LGG	cis	1	rs12152964	chr5:115609965	COMMD10	chr5:115420727-115628978:+	0.46	5.75	1.58E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12153717	chr5:115571914	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.29E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12161990	chr15:72202440	NR2E3	chr15:72102894-72110595:+	0.26	4.23	2.77E-5	Metabolite levels (HVA/MHPG ratio)	
LGG	cis	1	rs12171333	chr4:129879711	C4orf33	chr4:130014829-130033842:+	0.55	8.58	1.25E-16	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs12172	chr2:97500852	FAM178B	chr2:97541620-97652301:-	-0.15	-3.6	0.000346	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs12184327	chr1:207978780	CD46	chr1:207925402-207968857:+	-0.23	-7.03	7.09E-12	Schizophrenia	
LGG	cis	1	rs12185102	chr15:75352201	PPCDC	chr15:75315927-75343066:+	0.25	5.33	1.47E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs12187701	chr5:93522290	FAM172A	chr5:92953432-93447404:-	-0.3	-4.03	6.33E-5	Diabetic retinopathy	
LGG	cis	1	rs12188164	chr5:428236	EXOC3	chr5:443334-467407:+	-0.24	-5.51	5.83E-8	Cystic fibrosis severity	
LGG	cis	1	rs12188453	chr5:93560807	FAM172A	chr5:92953432-93447404:-	0.3	4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs12188678	chr5:428231	EXOC3	chr5:443334-467407:+	-0.24	-5.51	5.83E-8	Cystic fibrosis severity	
LGG	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.42	-8.35	7.16E-16	Response to antipsychotic treatment	
LGG	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.49	-10.03	1.16E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12192279	chr6:110055313	AKD1	chr6:109814059-110012415:-	0.29	3.56	0.000405	Hematological parameters	
LGG	cis	1	rs12192968	chr6:166017105	PRR18	chr6:166719168-166721871:-	-0.13	-3.59	0.000358	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.49	-9.99	1.57E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.51	-10.37	6.72E-23	Response to antipsychotic treatment	
LGG	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.51	-10.29	1.31E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12196937	chr6:49382808	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs12197114	chr6:109735498	AKD1	chr6:109814059-110012415:-	-0.33	-6.88	1.87E-11	Height	
LGG	cis	1	rs12197114	chr6:109735498	MICAL1	chr6:109765268-109787171:-	-0.34	-7.98	1.03E-14	Height	
LGG	cis	1	rs12197114	chr6:109735498	SMPD2	chr6:109761931-109765121:+	0.24	5.08	5.26E-7	Height	
LGG	cis	1	rs12199015	chr6:132058947	ENPP3	chr6:131949582-132068549:+	-0.37	-3.55	0.000417	Response to fenofibrate (adiponectin levels)	
LGG	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.51	-10.32	1.03E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.51	-10.33	8.84E-23	Response to antipsychotic treatment	
LGG	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.5	-10.22	2.27E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.49	-10.11	5.77E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.5	-10.29	1.32E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.49	-10.24	1.95E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12202075	chr6:49427655	CENPQ	chr6:49431096-49460820:+	-0.23	-5	7.88E-7	Folate pathway vitamin levels	
LGG	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.49	-9.96	2.16E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.49	-9.96	2.16E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.52	-11.19	4.84E-26	Response to antipsychotic treatment	
LGG	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.5	-10.24	1.98E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.5	-10.01	1.39E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.5	-10.13	5.14E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12206574	chr6:110067773	AKD1	chr6:109814059-110012415:-	-0.29	-3.55	0.000421	Hematological parameters	
LGG	cis	1	rs12206779	chr6:132055593	ENPP3	chr6:131949582-132068549:+	0.39	3.57	0.000386	Response to fenofibrate (adiponectin levels)	
LGG	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.51	-10.33	8.84E-23	Response to antipsychotic treatment	
LGG	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.5	-10.28	1.34E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.5	-10.22	2.27E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.5	-10.01	1.39E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.5	-10.13	4.87E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.5	-10.22	2.27E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.5	-10.28	1.34E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.5	-10.17	3.56E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.49	-10.04	1.09E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.5	-10.36	7.25E-23	Response to antipsychotic treatment	
LGG	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.5	-10.32	1.01E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12216994	chr1:179477137	C1orf125	chr1:179335107-179523868:+	0.47	6.24	9.23E-10	Multiple sclerosis (age of onset)	
LGG	cis	1	rs12216996	chr1:179477591	C1orf125	chr1:179335107-179523868:+	-0.46	-6.14	1.75E-9	Multiple sclerosis (age of onset)	
LGG	cis	1	rs12219158	chr10:102302923	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12219158	chr10:102302923	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12219158	chr10:102302923	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12219789	chr10:102213778	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12219789	chr10:102213778	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12219789	chr10:102213778	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12220777	chr10:81788104	LOC219347	chr10:81805991-81838949:-	-0.54	-9.2	1.01E-18	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs12228207	chr12:104196734	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.54	6.93E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs12230448	chr12:48950938	ZNF641	chr12:48735912-48745021:-	0.25	3.84	0.000139	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs12230471	chr12:48951189	ZNF641	chr12:48735912-48745021:-	0.25	3.84	0.000139	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs12231229	chr12:48809908	VDR	chr12:48235322-48298814:-	0.21	3.56	0.000414	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs12232914	chr2:70117176	SNRNP27	chr2:70121090-70132348:+	-0.18	-3.96	8.77E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs12240158	chr1:152879103	LCE1C	chr1:152777311-152779107:-	-0.34	-4.16	3.8E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12240158	chr1:152879103	LCE1E	chr1:152758753-152760898:+	-0.32	-3.91	0.000105	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12240158	chr1:152879103	SMCP	chr1:152850798-152857515:+	-0.39	-5.33	1.53E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12243096	chr10:101812302	CWF19L1	chr10:101992055-102027437:-	0.16	4.22	2.94E-5	Bone mineral density	
LGG	cis	1	rs12250141	chr10:1160106	IDI2	chr10:1064847-1071799:-	0.36	4.02	6.6E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs12257549	chr10:46029631	ALOX5	chr10:45869629-45941561:+	-0.1	-3.78	0.000179	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs12265204	chr10:111752163	ADD3	chr10:111756108-111895320:+	0.17	3.74	0.000204	Biliary atresia	
LGG	cis	1	rs12272213	chr11:71816219	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.33E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs12283462	chr11:71835406	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.48E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1228632	chr11:83325114	CCDC90B	chr11:82972506-82997414:-	-0.24	-5.63	3.01E-8	Subcortical brain region volumes	
LGG	cis	1	rs12286683	chr11:18348662	GTF2H1	chr11:18343816-18388590:+	0.42	7.91	1.76E-14	Pancreatic cancer	
LGG	cis	1	rs12286683	chr11:18348662	LDHC	chr11:18433853-18472792:+	0.21	3.98	8.06E-5	Pancreatic cancer	
LGG	cis	1	rs12287832	chr11:65553492	RNASEH2C	chr11:65485146-65488409:-	-0.23	-5.26	2.21E-7	Systemic lupus erythematosus	
LGG	cis	1	rs12287832	chr11:65553492	SNX32	chr11:65601410-65621170:+	0.24	5.04	6.56E-7	Systemic lupus erythematosus	
LGG	cis	1	rs12288023	chr11:67421341	ACY3	chr11:67410027-67418130:-	-0.33	-4.5	8.31E-6	Serum metabolite levels	
LGG	cis	1	rs12290322	chr11:89174214	NOX4	chr11:89057524-89322779:-	0.35	3.8	0.000166	Homocysteine levels	
LGG	cis	1	rs12291678	chr11:71570977	FAM86C	chr11:71498557-71512276:+	-0.46	-4.6	5.49E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs12293885	chr11:71816092	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.33E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs12294369	chr11:5567068	HBE1	chr11:5289580-5526882:-	-0.18	-3.53	0.000454	QRS duration in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12298679	chr12:11555011	MAGOHB	chr12:10756794-10766183:-	-0.3	-3.83	0.000147	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs12298871	chr12:48788977	VDR	chr12:48235322-48298814:-	-0.24	-3.78	0.000179	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs12300672	chr12:48932867	VDR	chr12:48235322-48298814:-	0.27	3.84	0.000139	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs12301299	chr12:991710	RAD52	chr12:1021255-1099219:-	-0.18	-3.8	0.000166	Colorectal cancer	
LGG	cis	1	rs12306335	chr12:11555467	MAGOHB	chr12:10756794-10766183:-	0.32	3.81	0.000158	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs12312603	chr12:988269	RAD52	chr12:1021255-1099219:-	-0.18	-3.64	0.000299	Colorectal cancer	
LGG	cis	1	rs12324912	chr15:75361006	PPCDC	chr15:75315927-75343066:+	0.23	4.93	1.11E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs12325866	chr17:61755974	DDX42	chr17:61851567-61896676:+	-0.16	-3.74	0.000205	Body mass index	
LGG	cis	1	rs12325866	chr17:61755974	FTSJ3	chr17:61896795-61905031:-	0.41	8.34	7.3E-16	Body mass index	
LGG	cis	1	rs12325866	chr17:61755974	SMARCD2	chr17:61909441-61920351:-	0.18	3.97	8.41E-5	Body mass index	
LGG	cis	1	rs12326600	chr18:44596497	HDHD2	chr18:44633782-44676871:-	0.47	4.74	2.79E-6	Sitting height ratio	
LGG	cis	1	rs12328085	chr2:86262009	LOC90784	chr2:86247339-86250991:-	-0.47	-5.04	6.43E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs12332489	chr5:115579386	COMMD10	chr5:115420727-115628978:+	0.44	5.51	5.73E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12332585	chr5:115581395	COMMD10	chr5:115420727-115628978:+	0.44	5.51	5.73E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12332658	chr5:115545606	COMMD10	chr5:115420727-115628978:+	0.45	5.67	2.41E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12338076	chr9:139121740	QSOX2	chr9:139098182-139137687:-	0.26	5.11	4.59E-7	Height	
LGG	cis	1	rs12354411	chr10:102294537	HIF1AN	chr10:102295641-102313680:+	0.19	3.69	0.000251	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12354411	chr10:102294537	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.08E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12354411	chr10:102294537	WNT8B	chr10:102222812-102243397:+	0.49	8	8.83E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12355721	chr10:102244911	HIF1AN	chr10:102295641-102313680:+	0.19	3.79	0.00017	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12355721	chr10:102244911	NDUFB8	chr10:102283497-102289636:-	0.16	4.63	4.63E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12355721	chr10:102244911	WNT8B	chr10:102222812-102243397:+	0.52	8.8	2.36E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12355784	chr10:65121565	NRBF2	chr10:64893007-64914785:+	-0.23	-5.39	1.07E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs12355784	chr10:65121565	REEP3	chr10:65281123-65381971:+	0.14	4.12	4.39E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs12358187	chr10:102284449	HIF1AN	chr10:102295641-102313680:+	0.19	3.72	0.000223	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12358187	chr10:102284449	NDUFB8	chr10:102283497-102289636:-	0.17	4.82	1.96E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12358187	chr10:102284449	WNT8B	chr10:102222812-102243397:+	0.48	7.89	2.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs12359272	chr10:97365163	TCTN3	chr10:97423154-97453900:-	0.18	3.56	0.000405	Blood metabolite levels	
LGG	cis	1	rs12361031	chr11:47783076	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs12361031	chr11:47783076	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs12361031	chr11:47783076	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs12361333	chr11:5387904	FAM160A2	chr11:6232565-6255941:-	0.19	3.87	0.000121	Fetal hemoglobin levels	
LGG	cis	1	rs12363232	chr11:47623890	ACP2	chr11:47260854-47270457:-	0.16	3.49	0.000528	Subjective well-being	
LGG	cis	1	rs12363232	chr11:47623890	MTCH2	chr11:47638859-47664206:-	0.25	4.78	2.32E-6	Subjective well-being	
LGG	cis	1	rs12363232	chr11:47623890	PSMC3	chr11:47440320-47448024:-	0.17	4.06	5.63E-5	Subjective well-being	
LGG	cis	1	rs12365551	chr11:58358368	ZFP91-CNTF	chr11:58346587-58393203:+	0.36	5.95	5.02E-9	Lymphoma	
LGG	cis	1	rs12372990	chr15:24840137	PWRN1	chr15:24778839-24832924:+	0.25	4.34	1.7E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs12401978	chr1:169604785	SCYL3	chr1:169821804-169863076:-	-0.3	-3.99	7.6E-5	Late-onset Alzheimer's disease	
LGG	cis	1	rs12405278	chr1:152282267	HRNR	chr1:152184558-152196669:-	-0.56	-7.8	3.74E-14	Atopic dermatitis	
LGG	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.19	3.06E-7	Body mass index	
LGG	cis	1	rs12405451	chr1:46384326	MUTYH	chr1:45794915-45806142:-	0.14	5.04	6.47E-7	Body mass index	
LGG	cis	1	rs12405771	chr1:202464280	PTPN7	chr1:202116143-202130709:-	-0.11	-3.47	0.00056	Sex ratio	
LGG	cis	1	rs12405771	chr1:202464280	UBE2T	chr1:202300786-202311094:-	-0.13	-3.92	0.000101	Sex ratio	
LGG	cis	1	rs12406341	chr1:169099795	NME7	chr1:169101771-169337186:-	0.28	4.04	6.15E-5	QT interval	
LGG	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.47	7.1E-8	Body mass index	
LGG	cis	1	rs12409773	chr1:46358831	MUTYH	chr1:45794915-45806142:-	0.14	5.03	6.95E-7	Body mass index	
LGG	cis	1	rs12410060	chr1:75245848	CRYZ	chr1:75171175-75199092:-	-0.2	-4.87	1.52E-6	Resistin levels	
LGG	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.47	7.1E-8	Body mass index	
LGG	cis	1	rs12410071	chr1:46358886	MUTYH	chr1:45794915-45806142:-	0.14	5.03	6.95E-7	Body mass index	
LGG	cis	1	rs12410786	chr1:207976205	CD46	chr1:207925402-207968857:+	-0.24	-7.07	5.47E-12	Schizophrenia	
LGG	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	3.9E-7	Body mass index	
LGG	cis	1	rs12411269	chr1:46271052	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.06E-7	Body mass index	
LGG	cis	1	rs12414891	chr10:81690385	PLAC9	chr10:81892258-81904784:+	-0.5	-6.86	2.14E-11	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs12414891	chr10:81690385	SFTPA2	chr10:81315609-81320163:-	-0.39	-4.03	6.39E-5	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs12416687	chr10:104629011	AS3MT	chr10:104613967-104661653:+	-0.75	-17.58	5.15E-54	Arsenic metabolism	
LGG	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.43	-9.35	3.21E-19	Arsenic metabolism	
LGG	cis	1	rs12417256	chr11:120337519	TMEM136	chr11:120196016-120204388:+	0.2	4.52	7.61E-6	Intraocular pressure	
LGG	cis	1	rs12418015	chr11:60343295	MS4A14	chr11:60145958-60185226:+	0.16	3.8	0.00016	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	
LGG	cis	1	rs12418852	chr11:47868853	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000365	Subjective well-being	
LGG	cis	1	rs12418852	chr11:47868853	MTCH2	chr11:47638859-47664206:-	0.25	4.81	2.03E-6	Subjective well-being	
LGG	cis	1	rs12418852	chr11:47868853	PSMC3	chr11:47440320-47448024:-	0.15	3.71	0.000235	Subjective well-being	
LGG	cis	1	rs12419692	chr11:47624714	MTCH2	chr11:47638859-47664206:-	-0.19	-3.7	0.00024	Subjective well-being	
LGG	cis	1	rs12421210	chr11:47779586	MTCH2	chr11:47638859-47664206:-	0.24	4.63	4.78E-6	Subjective well-being	
LGG	cis	1	rs12421210	chr11:47779586	PSMC3	chr11:47440320-47448024:-	0.15	3.54	0.000434	Subjective well-being	
LGG	cis	1	rs12421382	chr11:109378071	FDX1	chr11:110300594-110335604:+	0.15	3.56	0.000412	Schizophrenia	
LGG	cis	1	rs1242229	chr11:117062370	SIDT2	chr11:117049939-117068161:+	0.33	3.84	0.000139	Protein quantitative trait loci	
LGG	cis	1	rs12425790	chr12:121452504	SPPL3	chr12:121201036-121342151:-	0.29	4.06	5.6E-5	Type 2 diabetes	
LGG	cis	1	rs12427083	chr12:109113241	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs12428035	chr13:96300872	UGGT2	chr13:96453838-96705736:-	0.28	4.66	4.17E-6	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs12428	chr20:25433821	ABHD12	chr20:25275380-25371477:-	-0.27	-7.33	9.23E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs12428	chr20:25433821	FAM182A	chr20:26035250-26067552:+	0.54	10.45	3.26E-23	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs12428	chr20:25433821	FAM182B	chr20:25744102-25848786:-	-0.22	-4.97	9.18E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs12429254	chr13:96299663	UGGT2	chr13:96453838-96705736:-	-0.25	-4.13	4.32E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs12429385	chr13:96301936	UGGT2	chr13:96453838-96705736:-	-0.26	-4.31	1.96E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs12431420	chr14:66001076	LOC645431	chr14:65877313-65879335:-	-0.46	-6.31	6.23E-10	Ischemic stroke	
LGG	cis	1	rs12433416	chr14:65854175	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs12433423	chr14:65854237	LOC645431	chr14:65877313-65879335:-	-0.43	-6.14	1.72E-9	Ischemic stroke	
LGG	cis	1	rs12433464	chr14:88824015	SPATA7	chr14:88852012-88904802:+	-0.43	-7.61	1.41E-13	Coronary artery calcification	
LGG	cis	1	rs12433827	chr14:66055610	LOC645431	chr14:65877313-65879335:-	-0.47	-6.04	3.05E-9	Ischemic stroke	
LGG	cis	1	rs12434047	chr14:53837485	DDHD1	chr14:53503459-53620046:-	-0.2	-3.66	0.000284	Economic and political preferences (fairness)	
LGG	cis	1	rs12434585	chr14:65938368	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.24E-12	Ischemic stroke	
LGG	cis	1	rs12435391	chr14:75601737	ACYP1	chr14:75519930-75530736:-	-0.13	-3.54	0.000434	Height	
LGG	cis	1	rs12435391	chr14:75601737	EIF2B2	chr14:75469612-75476292:+	0.2	3.87	0.000126	Height	
LGG	cis	1	rs12435391	chr14:75601737	MLH3	chr14:75480467-75518235:-	0.2	3.49	0.000523	Height	
LGG	cis	1	rs12435835	chr14:65499909	RAB15	chr14:65412532-65438875:-	0.12	3.82	0.00015	Red blood cell traits	
LGG	cis	1	rs12435908	chr14:66121468	LOC645431	chr14:65877313-65879335:-	0.37	5.32	1.6E-7	Ischemic stroke	
LGG	cis	1	rs12437310	chr14:76642757	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs12438181	chr15:78812098	CHRNA5	chr15:78857906-78886458:+	-0.43	-6.34	5.15E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12438305	chr15:50912454	SPPL2A	chr15:50999739-51057910:-	0.12	3.76	0.00019	QT interval	
LGG	cis	1	rs12438659	chr15:78824924	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.72	4.94E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12439744	chr15:50899211	SPPL2A	chr15:50999739-51057910:-	0.12	3.93	9.67E-5	QT interval	
LGG	cis	1	rs12441354	chr15:78821016	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.82	2.76E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12441426	chr15:78812329	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.51	1.9E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12442787	chr15:50918107	SPPL2A	chr15:50999739-51057910:-	0.12	4.02	6.87E-5	QT interval	
LGG	cis	1	rs12443102	chr15:43932103	ADAL	chr15:43622872-43646094:+	-0.6	-7.62	1.33E-13	Tumor biomarkers	
LGG	cis	1	rs12443102	chr15:43932103	LCMT2	chr15:43619976-43622891:-	-0.29	-3.71	0.000227	Tumor biomarkers	
LGG	cis	1	rs12443102	chr15:43932103	STRC	chr15:43891762-43924561:-	0.4	7.15	3.2E-12	Tumor biomarkers	
LGG	cis	1	rs12444810	chr16:50080597	HEATR3	chr16:50099881-50139373:+	-0.3	-4.04	6.17E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs12445650	chr16:31044897	MYST1	chr16:31128985-31142713:+	0.15	4.24	2.71E-5	Response to metformin (IC50)	
LGG	cis	1	rs12445650	chr16:31044897	PRSS53	chr16:31094747-31106276:-	-0.17	-4.57	6.19E-6	Response to metformin (IC50)	
LGG	cis	1	rs12446632	chr16:19935389	C16orf88	chr16:19717676-19729492:-	0.63	8.33	8.22E-16	Body mass index;Menarche (age at onset);Childhood body mass index;Obesity	
LGG	cis	1	rs12446947	chr16:50095385	HEATR3	chr16:50099881-50139373:+	-0.31	-4.14	4.12E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs12447826	chr16:4464617	CORO7	chr16:4390253-4466962:-	0.56	13.81	7.24E-37	Schizophrenia	
LGG	cis	1	rs12447826	chr16:4464617	NMRAL1	chr16:4511696-4526307:-	-0.42	-8.57	1.4E-16	Schizophrenia	
LGG	cis	1	rs12448508	chr16:50093538	HEATR3	chr16:50099881-50139373:+	-0.31	-4.14	4.12E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs12450014	chr17:46415342	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs12451511	chr17:65874861	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12451707	chr17:65871598	LOC440461	chr17:66194801-66196436:+	0.28	4.53	7.42E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12451721	chr17:65939075	LOC440461	chr17:66194801-66196436:+	0.28	4.57	6.27E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12452212	chr17:46391078	HOXB2	chr17:46620021-46622393:-	0.18	3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs12452225	chr17:33266431	RAD51L3	chr17:33426811-33448541:-	-0.31	-3.84	0.000138	Night sleep phenotypes	
LGG	cis	1	rs12452511	chr17:65832576	LOC440461	chr17:66194801-66196436:+	0.27	4.39	1.39E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12453104	chr17:33264248	RAD51L3	chr17:33426811-33448541:-	-0.31	-3.81	0.000155	Night sleep phenotypes	
LGG	cis	1	rs1245507	chr10:73799349	ASCC1	chr10:73856278-73976892:-	-0.13	-3.96	8.64E-5	Smoking behavior	
LGG	cis	1	rs1245513	chr10:73802257	ASCC1	chr10:73856278-73976892:-	-0.13	-3.94	9.45E-5	Smoking behavior	
LGG	cis	1	rs1245574	chr10:73808467	ASCC1	chr10:73856278-73976892:-	0.14	4.19	3.26E-5	Smoking behavior	
LGG	cis	1	rs1245577	chr10:73810914	ASCC1	chr10:73856278-73976892:-	-0.13	-3.94	9.24E-5	Smoking behavior	
LGG	cis	1	rs12459123	chr19:12689741	MAN2B1	chr19:12757322-12777591:-	0.15	4.9	1.31E-6	Bipolar disorder	
LGG	cis	1	rs12462270	chr19:39201488	LGALS4	chr19:39292312-39303740:-	-0.15	-3.49	0.000523	Heart rate	
LGG	cis	1	rs12464151	chr2:179690909	CCDC141	chr2:179697347-179914786:-	0.17	3.49	0.000536	QT interval	
LGG	cis	1	rs12465922	chr2:48389336	FOXN2	chr2:48541795-48606434:+	0.29	5.67	2.38E-8	Schizophrenia	
LGG	cis	1	rs12469163	chr2:26283587	GPR113	chr2:26531041-26569685:-	-0.23	-3.73	0.000212	Gut microbiome composition (summer)	
LGG	cis	1	rs12469367	chr2:179691670	CCDC141	chr2:179697347-179914786:-	0.17	3.49	0.000525	QT interval	
LGG	cis	1	rs12470450	chr2:232113888	HTR2B	chr2:231972952-231989824:-	0.43	6.96	1.11E-11	Food antigen IgG levels	
LGG	cis	1	rs12470864	chr2:102926362	IL18R1	chr2:102927962-103015215:+	-0.34	-6.57	1.3E-10	Serum protein levels (sST2)	
LGG	cis	1	rs12470864	chr2:102926362	IL1RL1	chr2:102927962-102968497:+	-0.37	-6.51	1.92E-10	Serum protein levels (sST2)	
LGG	cis	1	rs12471809	chr2:26307140	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000209	Gut microbiome composition (summer)	
LGG	cis	1	rs12472278	chr2:108873433	SULT1C2	chr2:108905095-108926370:+	-0.62	-9.88	3.97E-21	Blood pressure	
LGG	cis	1	rs12472278	chr2:108873433	SULT1C4	chr2:108994421-109004270:+	0.22	4.39	1.37E-5	Blood pressure	
LGG	cis	1	rs12473740	chr2:88527647	FABP1	chr2:88422510-88427578:-	-0.3	-4.16	3.83E-5	Plasma clusterin levels	
LGG	cis	1	rs12473740	chr2:88527647	THNSL2	chr2:88469835-88486145:+	-0.57	-8.41	4.33E-16	Plasma clusterin levels	
LGG	cis	1	rs12474201	chr2:46921285	CRIPT	chr2:46844325-46852880:+	0.21	4.4	1.35E-5	Height	
LGG	cis	1	rs12475492	chr2:48380718	FOXN2	chr2:48541795-48606434:+	0.29	5.68	2.32E-8	Schizophrenia	
LGG	cis	1	rs12475854	chr2:26267375	GPR113	chr2:26531041-26569685:-	-0.24	-3.87	0.000123	Gut microbiome composition (summer)	
LGG	cis	1	rs12477202	chr2:108867112	SULT1C2	chr2:108905095-108926370:+	0.62	9.81	7.0E-21	Blood pressure	
LGG	cis	1	rs12477202	chr2:108867112	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.09	5.13E-5	Blood pressure	
LGG	cis	1	rs12478744	chr2:23947589	C2orf84	chr2:24397531-24414566:+	-0.18	-3.59	0.000359	Obesity-related traits	
LGG	cis	1	rs12478744	chr2:23947589	LOC375190	chr2:24299728-24397519:+	0.22	5.17	3.37E-7	Obesity-related traits	
LGG	cis	1	rs12478744	chr2:23947589	TP53I3	chr2:24300305-24307728:-	0.18	3.59	0.000368	Obesity-related traits	
LGG	cis	1	rs12478819	chr2:207645078	MDH1B	chr2:207598943-207630050:-	0.33	4.84	1.74E-6	Episodic memory	
LGG	cis	1	rs12479210	chr2:102949161	IL18R1	chr2:102927962-103015215:+	-0.34	-6.52	1.79E-10	Serum protein levels (sST2)	
LGG	cis	1	rs12479210	chr2:102949161	IL1RL1	chr2:102927962-102968497:+	-0.37	-6.4	3.58E-10	Serum protein levels (sST2)	
LGG	cis	1	rs12479491	chr20:30265450	COX4I2	chr20:30225691-30232800:+	0.19	4.43	1.16E-5	Subcortical brain region volumes	
LGG	cis	1	rs12479491	chr20:30265450	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs12479491	chr20:30265450	FRG1B	chr20:29611879-29653908:+	0.21	3.83	0.000147	Subcortical brain region volumes	
LGG	cis	1	rs12482477	chr21:43517233	C21orf128	chr21:43522244-43528644:-	0.6	11.71	4.26E-28	IgG glycosylation	
LGG	cis	1	rs12483517	chr21:42691920	FAM3B	chr21:42676177-42729654:+	0.41	7.54	2.23E-13	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LGG	cis	1	rs12487542	chr3:48426076	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs12487542	chr3:48426076	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs12488369	chr3:20154059	EFHB	chr3:19920968-19988501:-	-0.34	-4.59	5.53E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs12488768	chr3:53086234	ITIH4	chr3:52847007-52866554:-	0.18	5.02	7.34E-7	Ulcerative colitis	
LGG	cis	1	rs12488768	chr3:53086234	RFT1	chr3:53122503-53164470:-	0.2	3.95	9.06E-5	Ulcerative colitis	
LGG	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.28	7.26	1.55E-12	Height	
LGG	cis	1	rs12490835	chr3:134223730	CEP63	chr3:134204575-134293852:+	0.19	3.5	0.000516	Height	
LGG	cis	1	rs12501454	chr4:42480864	SHISA3	chr4:42399856-42404503:+	0.29	4.45	1.08E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12503995	chr4:42480504	SHISA3	chr4:42399856-42404503:+	0.29	4.47	9.57E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12504643	chr4:159634916	ETFDH	chr4:159593277-159629839:+	0.31	6.24	9.42E-10	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs12504802	chr4:42454317	SHISA3	chr4:42399856-42404503:+	0.27	4.12	4.5E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12505475	chr4:159635244	ETFDH	chr4:159593277-159629839:+	0.31	6.32	5.8E-10	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs12505749	chr4:57334112	SRP72	chr4:57333762-57369846:+	-0.35	-4.55	6.91E-6	Airflow obstruction	
LGG	cis	1	rs12505835	chr4:297525	ZNF718	chr4:53272-156488:+	0.27	5.3	1.74E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs12506030	chr4:42464624	SHISA3	chr4:42399856-42404503:+	0.28	4.33	1.82E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12506395	chr4:120185094	MYOZ2	chr4:120056939-120108935:+	0.22	4.25	2.58E-5	Corneal astigmatism	
LGG	cis	1	rs12506526	chr4:42460758	SHISA3	chr4:42399856-42404503:+	0.26	3.88	0.000121	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12507142	chr4:17656103	MED28	chr4:17616273-17629791:+	0.2	4.3	2.05E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12509366	chr4:107003343	NPNT	chr4:106816605-106892827:+	-0.23	-4.87	1.5E-6	Airflow obstruction	
LGG	cis	1	rs12509640	chr4:106996677	NPNT	chr4:106816605-106892827:+	0.24	5.12	4.31E-7	Airflow obstruction	
LGG	cis	1	rs12510143	chr4:42434745	SHISA3	chr4:42399856-42404503:+	0.3	4.36	1.6E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12510207	chr4:42434941	SHISA3	chr4:42399856-42404503:+	0.29	4.32	1.89E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs12510966	chr4:106983604	NPNT	chr4:106816605-106892827:+	-0.23	-4.96	9.76E-7	Airflow obstruction	
LGG	cis	1	rs12512683	chr4:106999471	NPNT	chr4:106816605-106892827:+	-0.23	-4.86	1.61E-6	Airflow obstruction	
LGG	cis	1	rs12514600	chr5:115470655	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.35E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12515251	chr5:115626966	COMMD10	chr5:115420727-115628978:+	0.45	5.55	4.62E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12515308	chr5:115450441	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12515466	chr5:115591877	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12515585	chr5:156430150	TIMD4	chr5:156346293-156390266:-	-0.26	-4.79	2.19E-6	Hypertriglyceridemia	
LGG	cis	1	rs12516100	chr5:115451750	COMMD10	chr5:115420727-115628978:+	0.46	5.64	2.94E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12517431	chr5:156392248	TIMD4	chr5:156346293-156390266:-	-0.2	-4.12	4.48E-5	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs12517508	chr5:115423574	COMMD10	chr5:115420727-115628978:+	0.46	5.83	1.0E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12517604	chr5:130748500	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.63	4.63E-6	Life satisfaction	
LGG	cis	1	rs12517986	chr5:172995160	LOC285593	chr5:173006646-173012074:+	-0.26	-4.81	1.99E-6	Height	
LGG	cis	1	rs12519989	chr5:115562642	COMMD10	chr5:115420727-115628978:+	0.48	6.01	3.61E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12520076	chr5:115458830	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.31E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12520121	chr5:156008760	SGCD	chr5:155135063-156194796:+	0.31	4.7	3.35E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs12520568	chr5:115621505	COMMD10	chr5:115420727-115628978:+	0.45	5.64	2.94E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12520632	chr5:115591766	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.29E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12521320	chr5:130755920	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.61	5.11E-6	Life satisfaction	
LGG	cis	1	rs12521440	chr5:115670364	COMMD10	chr5:115420727-115628978:+	0.48	5.79	1.28E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12521612	chr5:115582605	COMMD10	chr5:115420727-115628978:+	0.43	5.3	1.72E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12522027	chr5:115616531	COMMD10	chr5:115420727-115628978:+	0.45	5.49	6.61E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12522248	chr5:156479426	TIMD4	chr5:156346293-156390266:-	-0.24	-4.36	1.56E-5	Hypertriglyceridemia	
LGG	cis	1	rs12522441	chr5:115523805	COMMD10	chr5:115420727-115628978:+	0.47	5.93	5.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12523022	chr5:598643	SDHA	chr5:218356-256812:+	-0.2	-4.51	7.96E-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs12523347	chr5:115572395	COMMD10	chr5:115420727-115628978:+	0.47	5.91	6.57E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs12524768	chr6:33760478	LEMD2	chr6:33738991-33756906:-	0.18	5.5	6.06E-8	Body mass index	
LGG	cis	1	rs12524835	chr6:33730843	LEMD2	chr6:33738991-33756906:-	0.18	5.34	1.44E-7	Body mass index	
LGG	cis	1	rs12526680	chr6:26550954	BTN2A3	chr6:26422317-26431927:+	0.13	3.75	0.000198	Educational attainment	
LGG	cis	1	rs12526680	chr6:26550954	HMGN4	chr6:26538572-26547162:+	-0.19	-4.84	1.73E-6	Educational attainment	
LGG	cis	1	rs12530845	chr7:135329978	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs1253099	chr14:59946830	C14orf149	chr14:59939406-59951126:-	-0.42	-4.56	6.59E-6	Schizophrenia	
LGG	cis	1	rs1253099	chr14:59946830	JKAMP	chr14:59951161-59972080:+	0.49	4.84	1.78E-6	Schizophrenia	
LGG	cis	1	rs12530	chr22:32783904	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.42	9.44E-8	IgG glycosylation	
LGG	cis	1	rs1253102	chr14:59947861	C14orf149	chr14:59939406-59951126:-	-0.42	-4.56	6.59E-6	Schizophrenia	
LGG	cis	1	rs1253102	chr14:59947861	JKAMP	chr14:59951161-59972080:+	0.49	4.84	1.78E-6	Schizophrenia	
LGG	cis	1	rs1253107	chr14:59952947	C14orf149	chr14:59939406-59951126:-	-0.4	-4.47	9.65E-6	Schizophrenia	
LGG	cis	1	rs1253107	chr14:59952947	JKAMP	chr14:59951161-59972080:+	0.44	4.41	1.28E-5	Schizophrenia	
LGG	cis	1	rs12531468	chr7:135336264	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.03	6.49E-5	Red blood cell traits	
LGG	cis	1	rs12532998	chr7:65967459	ASL	chr7:65540776-65558321:+	-0.22	-5.54	4.84E-8	Aortic root size	
LGG	cis	1	rs12533997	chr7:65965377	ASL	chr7:65540776-65558321:+	-0.22	-5.64	2.85E-8	Aortic root size	
LGG	cis	1	rs12535799	chr7:118161181	ANKRD7	chr7:117864712-117882782:+	0.2	3.54	0.000445	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs12537555	chr7:135334061	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.06	5.6E-5	Red blood cell traits	
LGG	cis	1	rs12538804	chr7:7693919	RPA3	chr7:7676577-7758238:-	-0.15	-3.49	0.000528	Urate levels in obese individuals	
LGG	cis	1	rs12539061	chr7:118206237	ANKRD7	chr7:117864712-117882782:+	0.2	3.48	0.000549	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs12540325	chr7:135334111	SLC13A4	chr7:135365993-135412933:-	-0.27	-3.96	8.64E-5	Red blood cell traits	
LGG	cis	1	rs12540579	chr7:1882227	FTSJ2	chr7:2273928-2281833:-	0.21	4.61	5.13E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs12540688	chr7:135329690	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs12545771	chr8:8567977	FLJ10661	chr8:8086092-8102386:+	-0.27	-5	7.83E-7	Obesity-related traits	
LGG	cis	1	rs12546225	chr8:59307338	UBXN2B	chr8:59323823-59364059:+	-0.22	-3.87	0.000123	Gut microbiome composition (summer)	
LGG	cis	1	rs12547721	chr8:8570671	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.01	7.57E-7	Obesity-related traits	
LGG	cis	1	rs12547941	chr8:29980332	MBOAT4	chr8:29989188-30002200:-	0.32	3.73	0.000214	Migraine	
LGG	cis	1	rs12550458	chr8:8567832	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.9	1.32E-6	Obesity-related traits	
LGG	cis	1	rs12550762	chr8:8576535	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.96	9.76E-7	Obesity-related traits	
LGG	cis	1	rs12554057	chr9:114345228	PTGR1	chr9:114312003-114362135:-	0.18	3.55	0.000415	Monocyte count	
LGG	cis	1	rs12555931	chr9:114343376	PTGR1	chr9:114312003-114362135:-	0.19	3.72	0.000225	Monocyte count	
LGG	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	4.07E-7	Body mass index	
LGG	cis	1	rs12561806	chr1:46396776	MUTYH	chr1:45794915-45806142:-	0.13	4.84	1.78E-6	Body mass index	
LGG	cis	1	rs12563631	chr1:156258953	BGLAP	chr1:156182784-156213112:+	0.25	5.14	3.95E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12563631	chr1:156258953	CCT3	chr1:156278752-156308195:-	-0.16	-4.11	4.57E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.15	3.73E-7	Body mass index	
LGG	cis	1	rs12564541	chr1:46380237	MUTYH	chr1:45794915-45806142:-	0.14	5.09	5.01E-7	Body mass index	
LGG	cis	1	rs12567463	chr1:152180128	HRNR	chr1:152184558-152196669:-	-0.53	-7.98	1.07E-14	Atopic dermatitis	
LGG	cis	1	rs12569232	chr1:211553064	C1orf97	chr1:211556097-211605876:+	0.2	3.55	0.000417	Educational attainment (years of education)	
LGG	cis	1	rs12570188	chr10:100855702	C10orf28	chr10:99894381-100004653:+	-0.31	-3.52	0.000465	Asthma (childhood onset)	
LGG	cis	1	rs12570188	chr10:100855702	SLC25A28	chr10:101370275-101418994:-	-0.22	-3.52	0.000473	Asthma (childhood onset)	
LGG	cis	1	rs12570230	chr10:111691614	ADD3	chr10:111756108-111895320:+	0.15	3.47	0.000567	Biliary atresia	
LGG	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.51	-11.04	1.86E-25	Forced vital capacity	
LGG	cis	1	rs12581386	chr12:109082999	SELPLG	chr12:109015682-109027670:-	-0.2	-3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs12582815	chr12:109117378	SELPLG	chr12:109015682-109027670:-	0.2	3.73	0.000211	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs12583	chr3:49571462	AMIGO3	chr3:49754268-49757238:-	0.2	4.46	1.01E-5	Menarche (age at onset)	
LGG	cis	1	rs12583	chr3:49571462	GMPPB	chr3:49758932-49761384:-	0.22	4.17	3.54E-5	Menarche (age at onset)	
LGG	cis	1	rs12587386	chr14:88827764	SPATA7	chr14:88852012-88904802:+	-0.44	-7.88	2.12E-14	Coronary artery calcification	
LGG	cis	1	rs12588160	chr14:81776666	STON2	chr14:81727000-81893748:-	-0.14	-3.56	0.000404	Obesity-related traits	
LGG	cis	1	rs12588234	chr14:81773032	STON2	chr14:81727000-81893748:-	-0.14	-3.61	0.000332	Obesity-related traits	
LGG	cis	1	rs12588240	chr14:75612083	ACYP1	chr14:75519930-75530736:-	-0.15	-3.97	8.38E-5	Height	
LGG	cis	1	rs12588240	chr14:75612083	EIF2B2	chr14:75469612-75476292:+	0.2	3.93	9.8E-5	Height	
LGG	cis	1	rs12588240	chr14:75612083	MLH3	chr14:75480467-75518235:-	0.21	3.64	0.000305	Height	
LGG	cis	1	rs12589376	chr14:75561152	ACYP1	chr14:75519930-75530736:-	-0.14	-3.57	0.000397	Height	
LGG	cis	1	rs12589376	chr14:75561152	EIF2B2	chr14:75469612-75476292:+	0.18	3.52	0.00048	Height	
LGG	cis	1	rs12589467	chr14:88823583	SPATA7	chr14:88852012-88904802:+	-0.44	-7.71	6.88E-14	Coronary artery calcification	
LGG	cis	1	rs12589480	chr14:88881270	KCNK10	chr14:88646454-88793256:-	-0.19	-3.77	0.000186	Coronary artery calcification	
LGG	cis	1	rs12589480	chr14:88881270	SPATA7	chr14:88852012-88904802:+	-0.49	-8.8	2.35E-17	Coronary artery calcification	
LGG	cis	1	rs12589815	chr14:75544101	ACYP1	chr14:75519930-75530736:-	-0.13	-3.55	0.00042	Height	
LGG	cis	1	rs12589815	chr14:75544101	MLH3	chr14:75480467-75518235:-	0.2	3.46	0.000583	Height	
LGG	cis	1	rs12589876	chr14:75544189	ACYP1	chr14:75519930-75530736:-	-0.13	-3.55	0.00042	Height	
LGG	cis	1	rs12589876	chr14:75544189	MLH3	chr14:75480467-75518235:-	0.2	3.46	0.000583	Height	
LGG	cis	1	rs12590407	chr14:24835115	ADCY4	chr14:24787571-24804277:-	0.13	3.49	0.000529	Height	
LGG	cis	1	rs12590407	chr14:24835115	IL25	chr14:23842018-23845605:+	-0.19	-3.49	0.000536	Height	
LGG	cis	1	rs12590407	chr14:24835115	TGM1	chr14:24718322-24732416:-	0.13	3.47	0.000565	Height	
LGG	cis	1	rs12590452	chr14:75548756	ACYP1	chr14:75519930-75530736:-	-0.15	-3.89	0.000116	Height	
LGG	cis	1	rs12591751	chr15:50972497	SPPL2A	chr15:50999739-51057910:-	0.13	4.1	4.88E-5	QT interval	
LGG	cis	1	rs1259180	chr15:83244680	FAM154B	chr15:82555152-82577265:+	-0.19	-4.08	5.18E-5	Schizophrenia	
LGG	cis	1	rs1259180	chr15:83244680	GOLGA6L9	chr15:82711895-82731584:+;chr15	-0.17	-4.16	3.8E-5	Schizophrenia	
LGG	cis	1	rs12593261	chr15:91520319	RCCD1	chr15:91498106-91506353:+	0.18	3.65	0.000293	Type 2 diabetes	
LGG	cis	1	rs12598978	chr16:30482540	ITGAL	chr16:30483983-30534505:+	-0.09	-3.46	0.000591	Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs12600855	chr17:28279591	EFCAB5	chr17:28256874-28435469:+	0.22	5.95	5.01E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs12600941	chr17:65918807	LOC440461	chr17:66194801-66196436:+	0.27	4.51	8.27E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12600993	chr17:28291222	EFCAB5	chr17:28256874-28435469:+	0.22	5.95	5.01E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs12602655	chr17:65909442	LOC440461	chr17:66194801-66196436:+	0.27	4.56	6.56E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12602901	chr17:4824625	INCA1	chr17:4891426-4900905:-	-0.29	-5.28	1.95E-7	Blood metabolite levels	
LGG	cis	1	rs12602901	chr17:4824625	SLC25A11	chr17:4840605-4843325:-	-0.16	-3.51	0.000497	Blood metabolite levels	
LGG	cis	1	rs12602912	chr17:65870073	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs12603327	chr17:40290552	DHX58	chr17:40253422-40264751:-	-0.19	-3.89	0.000113	Fibrinogen levels	
LGG	cis	1	rs12603330	chr17:40290589	DHX58	chr17:40253422-40264751:-	-0.19	-3.94	9.31E-5	Fibrinogen levels	
LGG	cis	1	rs12604067	chr17:33952103	PEX12	chr17:33901815-33905656:-	-0.22	-3.93	9.58E-5	Platelet count	
LGG	cis	1	rs12608504	chr19:18389135	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.49	9.01E-6	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12608504	chr19:18389135	TMEM161A	chr19:19230431-19249267:-	-0.13	-3.64	0.000305	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12608544	chr19:49136651	MAMSTR	chr19:49216255-49222976:-	-0.28	-3.59	0.000361	Elevated serum carcinoembryonic antigen levels	
LGG	cis	1	rs12608544	chr19:49136651	SEC1	chr19:49141296-49185501:+	-0.69	-7.87	2.36E-14	Elevated serum carcinoembryonic antigen levels	
LGG	cis	1	rs12609594	chr19:9972417	ZNF266	chr19:9523272-9546234:-	0.18	4.53	7.56E-6	Sleep duration	
LGG	cis	1	rs12610373	chr19:18398284	JUND	chr19:18390563-18392432:-	-0.16	-3.48	0.000543	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12610373	chr19:18398284	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.5	8.51E-6	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12610373	chr19:18398284	TMEM161A	chr19:19230431-19249267:-	-0.13	-3.54	0.000443	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12613947	chr2:70161342	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.35	1.68E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs12614581	chr2:70079400	SNRNP27	chr2:70121090-70132348:+	-0.18	-3.64	0.000304	Colorectal or endometrial cancer	
LGG	cis	1	rs12615749	chr2:54475885	C2orf73	chr2:54558071-54588714:+	0.33	4.69	3.48E-6	Telomere length	
LGG	cis	1	rs12615749	chr2:54475885	TSPYL6	chr2:54480315-54483409:-	-0.45	-5.45	8.08E-8	Telomere length	
LGG	cis	1	rs12615793	chr2:54475914	C2orf73	chr2:54558071-54588714:+	-0.32	-4.64	4.5E-6	Telomere length	
LGG	cis	1	rs12615793	chr2:54475914	TSPYL6	chr2:54480315-54483409:-	0.37	4.52	7.82E-6	Telomere length	
LGG	cis	1	rs12615966	chr2:105378957	MRPS9	chr2:105654483-105716417:+	0.25	4.22	2.88E-5	Pancreatic cancer	
LGG	cis	1	rs12616140	chr2:108867728	SULT1C2	chr2:108905095-108926370:+	0.61	9.56	5.78E-20	Blood pressure	
LGG	cis	1	rs12616140	chr2:108867728	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.23	2.73E-5	Blood pressure	
LGG	cis	1	rs12617717	chr2:86342303	LOC90784	chr2:86247339-86250991:-	-0.42	-4.2	3.16E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs12618262	chr2:190708073	ORMDL1	chr2:190634994-190649097:-	-0.36	-5.47	7.05E-8	Subcutaneous adipose tissue	
LGG	cis	1	rs12618379	chr2:105386854	MRPS9	chr2:105654483-105716417:+	-0.24	-4.12	4.42E-5	Pancreatic cancer	
LGG	cis	1	rs12619369	chr2:242282957	ANO7	chr2:242127924-242164791:+	0.34	6.13	1.83E-9	Prostate cancer	
LGG	cis	1	rs12620050	chr2:108919798	SULT1C2	chr2:108905095-108926370:+	0.96	17.64	2.56E-54	Lobe size	
LGG	cis	1	rs12620555	chr2:105379115	MRPS9	chr2:105654483-105716417:+	-0.25	-4.18	3.44E-5	Pancreatic cancer	
LGG	cis	1	rs12620810	chr2:86391481	LOC90784	chr2:86247339-86250991:-	-0.42	-4.39	1.37E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs12621280	chr2:232132984	HTR2B	chr2:231972952-231989824:-	0.52	7.88	2.06E-14	Food antigen IgG levels	
LGG	cis	1	rs12621567	chr2:232118813	HTR2B	chr2:231972952-231989824:-	0.45	7.17	2.84E-12	Food antigen IgG levels	
LGG	cis	1	rs1262174	chr14:60887194	DHRS7	chr14:60611502-60636561:-	0.29	3.94	9.22E-5	Gut microbiota (bacterial taxa)	
LGG	cis	1	rs1262174	chr14:60887194	PPM1A	chr14:60712470-60765803:+	0.22	4.05	5.95E-5	Gut microbiota (bacterial taxa)	
LGG	cis	1	rs12622009	chr2:86248325	LOC90784	chr2:86247339-86250991:-	-0.47	-5.01	7.7E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs12624898	chr20:16046621	SNRPB2	chr20:16710629-16722037:+	-0.24	-3.52	0.000465	Brain connectivity	
LGG	cis	1	rs12627787	chr22:51012381	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs12630450	chr3:169480204	LOC100128164	chr3:169661774-169684522:-	-0.21	-3.81	0.000159	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs12630450	chr3:169480204	LRRC34	chr3:169511266-169530720:-	-0.3	-5.34	1.4E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs12636133	chr3:113839724	KIAA1407	chr3:113682986-113775460:-	0.14	3.92	0.000101	Personality dimensions	
LGG	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs12637751	chr3:134266124	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs12642900	chr4:107010329	NPNT	chr4:106816605-106892827:+	-0.22	-4.79	2.26E-6	Airflow obstruction	
LGG	cis	1	rs12643926	chr4:56310621	TMEM165	chr4:56262090-56292342:+	-0.17	-4.91	1.22E-6	Personality dimensions	
LGG	cis	1	rs12646078	chr4:56368204	TMEM165	chr4:56262090-56292342:+	-0.17	-4.95	1.01E-6	Personality dimensions	
LGG	cis	1	rs12648232	chr4:17612537	MED28	chr4:17616273-17629791:+	-0.2	-4.3	2.02E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.49	5.38	1.18E-7	Crohn's disease	
LGG	cis	1	rs12654593	chr5:130756867	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.68	3.7E-6	Life satisfaction	
LGG	cis	1	rs12656538	chr5:150251380	LOC134466	chr5:150310000-150326146:-	0.5	5.35	1.37E-7	Crohn's disease	
LGG	cis	1	rs12656600	chr5:150311872	LOC134466	chr5:150310000-150326146:-	0.52	5.84	9.36E-9	Crohn's disease	
LGG	cis	1	rs12657266	chr5:156396003	TIMD4	chr5:156346293-156390266:-	-0.23	-4.64	4.38E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs12658131	chr5:171168572	NEURL1B	chr5:172068276-172118531:+	-0.17	-3.54	0.00044	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs12658240	chr5:81173265	ATG10	chr5:81267844-81551211:+	-0.27	-4.15	3.88E-5	Cognitive function	
LGG	cis	1	rs12658240	chr5:81173265	RPS23	chr5:81569141-81574235:-	0.17	3.86	0.00013	Cognitive function	
LGG	cis	1	rs12658259	chr5:81173250	ATG10	chr5:81267844-81551211:+	-0.26	-4.02	6.69E-5	Cognitive function	
LGG	cis	1	rs12658259	chr5:81173250	RPS23	chr5:81569141-81574235:-	0.18	3.99	7.77E-5	Cognitive function	
LGG	cis	1	rs12659118	chr5:150324622	LOC134466	chr5:150310000-150326146:-	0.53	5.88	7.4E-9	Crohn's disease	
LGG	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.52	-10.47	2.76E-23	Response to antipsychotic treatment	
LGG	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.5	-10.24	1.98E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.48	9.81	7.54E-21	Response to antipsychotic treatment	
LGG	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.49	10.11	5.81E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.5	-10.16	3.9E-22	Response to antipsychotic treatment	
LGG	cis	1	rs12671584	chr7:23915422	C7orf46	chr7:23719749-23742268:+	0.2	4.24	2.62E-5	Schizophrenia	
LGG	cis	1	rs12671624	chr7:23915413	C7orf46	chr7:23719749-23742268:+	0.2	4.24	2.62E-5	Schizophrenia	
LGG	cis	1	rs12673970	chr7:19813018	TMEM196	chr7:19758939-19813216:-	0.19	3.47	0.000575	Thyroid stimulating hormone	
LGG	cis	1	rs12675542	chr8:29986454	MBOAT4	chr8:29989188-30002200:-	-0.35	-3.84	0.000138	Migraine	
LGG	cis	1	rs1267657	chr15:83215251	FAM154B	chr15:82555152-82577265:+	-0.21	-4.37	1.52E-5	Schizophrenia	
LGG	cis	1	rs1267657	chr15:83215251	GOLGA6L9	chr15:82711895-82731584:+;chr15	-0.19	-4.68	3.66E-6	Schizophrenia	
LGG	cis	1	rs12677663	chr8:74007347	C8orf84	chr8:73976779-74005507:-	0.25	5.44	8.49E-8	Crohn's disease	
LGG	cis	1	rs12677676	chr8:126502526	TRIB1	chr8:126442563-126450642:+	-0.23	-4.26	2.5E-5	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs1267813	chr11:133981075	JAM3	chr11:133938820-134021649:+	-0.15	-3.48	0.00055	Schizophrenia	
LGG	cis	1	rs1267817	chr7:66110040	CCT6P1	chr7:65216092-65228661:+	0.21	3.64	0.000302	Gout	
LGG	cis	1	rs1267818	chr7:66107024	CCT6P1	chr7:65216092-65228661:+	0.2	3.6	0.000344	Gout	
LGG	cis	1	rs1267820	chr7:66050295	CCT6P1	chr7:65216092-65228661:+	0.22	4.05	6.01E-5	Diabetic kidney disease	
LGG	cis	1	rs12680842	chr8:95582606	KIAA1429	chr8:95500600-95565688:-	-0.15	-3.5	0.000509	Body mass index	
LGG	cis	1	rs12691307	chr16:29939877	GDPD3	chr16:30116132-30124878:-	-0.13	-4.04	6.3E-5	Schizophrenia	
LGG	cis	1	rs12691307	chr16:29939877	TBX6	chr16:30097117-30103208:-	0.21	4.81	1.97E-6	Schizophrenia	
LGG	cis	1	rs12692544	chr2:160082354	CCDC148	chr2:159028479-159313214:-	-0.26	-3.58	0.000373	Sudden cardiac arrest	
LGG	cis	1	rs12693043	chr2:175377565	GPR155	chr2:175296376-175351811:-	0.15	3.9	0.000109	Urate levels (BMI interaction)	
LGG	cis	1	rs12693043	chr2:175377565	WIPF1	chr2:175424303-175547627:-	0.2	5.76	1.49E-8	Urate levels (BMI interaction)	
LGG	cis	1	rs12696304	chr3:169481271	LOC100128164	chr3:169661774-169684522:-	-0.21	-3.81	0.000159	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs12696304	chr3:169481271	LRRC34	chr3:169511266-169530720:-	-0.3	-5.45	7.85E-8	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs12696304	chr3:169481271	MYNN	chr3:169490853-169505335:+	-0.14	-3.85	0.000131	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs12698509	chr7:65418876	CCT6P1	chr7:65216092-65228661:+	0.25	4.68	3.71E-6	Diabetic kidney disease	
LGG	cis	1	rs12698523	chr7:65968113	ASL	chr7:65540776-65558321:+	-0.22	-5.55	4.64E-8	Aortic root size	
LGG	cis	1	rs12700743	chr7:26567398	KIAA0087	chr7:26572740-26578444:-	0.19	3.79	0.000169	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12700744	chr7:26567494	KIAA0087	chr7:26572740-26578444:-	0.19	3.79	0.000169	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12700745	chr7:26570535	KIAA0087	chr7:26572740-26578444:-	0.19	3.77	0.000186	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs12701220	chr7:1022728	GPR146	chr7:1084243-1098897:+	0.21	3.51	0.000487	Bronchopulmonary dysplasia	
LGG	cis	1	rs12702087	chr7:44812607	PPIA	chr7:44836241-44842715:+	0.17	4.39	1.38E-5	Educational attainment (years of education)	
LGG	cis	1	rs12706181	chr7:118002480	ANKRD7	chr7:117864712-117882782:+	0.21	3.71	0.00023	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs12710437	chr21:37808771	DOPEY2	chr21:37536839-37666571:+	0.16	3.48	0.000556	Myopia (pathological)	
LGG	cis	1	rs12712133	chr2:102866273	IL18R1	chr2:102927962-103015215:+	-0.26	-5.12	4.4E-7	Primary biliary cirrhosis	
LGG	cis	1	rs12712133	chr2:102866273	IL1RL1	chr2:102927962-102968497:+	-0.22	-3.86	0.00013	Primary biliary cirrhosis	
LGG	cis	1	rs12712145	chr2:103008710	IL18R1	chr2:102927962-103015215:+	-0.38	-6.14	1.71E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs12712145	chr2:103008710	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.35	1.34E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs12712530	chr2:37505561	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.79	2.23E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs12713419	chr2:25121853	ADCY3	chr2:25042041-25142055:-	-0.19	-4.28	2.24E-5	Body mass index	
LGG	cis	1	rs12724265	chr1:31806081	ZCCHC17	chr1:31769842-31837780:+	-0.17	-4.09	5.14E-5	Schizophrenia	
LGG	cis	1	rs12725198	chr1:16080171	SLC25A34	chr1:16062809-16067885:+	0.32	6.75	4.17E-11	Cardiac Troponin-T levels	
LGG	cis	1	rs12725694	chr1:16080501	SLC25A34	chr1:16062809-16067885:+	-0.33	-6.74	4.4E-11	Cardiac Troponin-T levels	
LGG	cis	1	rs12725833	chr1:16080618	SLC25A34	chr1:16062809-16067885:+	-0.32	-6.66	7.41E-11	Cardiac Troponin-T levels	
LGG	cis	1	rs1273153	chr14:59946459	C14orf149	chr14:59939406-59951126:-	0.39	4.33	1.84E-5	Schizophrenia	
LGG	cis	1	rs1273153	chr14:59946459	JKAMP	chr14:59951161-59972080:+	-0.46	-4.51	8.08E-6	Schizophrenia	
LGG	cis	1	rs12733173	chr1:152173972	FLG	chr1:152274651-152297679:-	0.4	6.41	3.4E-10	Inflammatory skin disease	
LGG	cis	1	rs12733930	chr1:211603026	C1orf97	chr1:211556097-211605876:+	0.21	3.63	0.00031	Educational attainment (years of education)	
LGG	cis	1	rs12739630	chr1:211591687	C1orf97	chr1:211556097-211605876:+	0.2	3.49	0.000518	Educational attainment (years of education)	
LGG	cis	1	rs12740755	chr1:211591669	C1orf97	chr1:211556097-211605876:+	0.21	3.63	0.00031	Educational attainment (years of education)	
LGG	cis	1	rs12744221	chr1:145645606	NUDT17	chr1:145586494-145590461:-	0.44	8.51	2.15E-16	Epilepsy (remission after treatment)	
LGG	cis	1	rs12744221	chr1:145645606	POLR3C	chr1:145592606-145610884:-	0.17	3.85	0.000134	Epilepsy (remission after treatment)	
LGG	cis	1	rs1274493	chr12:56682371	IL23A	chr12:56732663-56734193:+	-0.57	-5.77	1.37E-8	Psoriasis vulgaris	
LGG	cis	1	rs12747817	chr1:175118895	TNN	chr1:175036994-175117202:+	-0.18	-3.72	0.000225	Alcohol dependence	
LGG	cis	1	rs1275468	chr12:75935157	GLIPR1L2	chr12:75784889-75825591:+	-0.31	-5.32	1.6E-7	Polycystic ovary syndrome	
LGG	cis	1	rs1275469	chr12:75935230	GLIPR1L2	chr12:75784889-75825591:+	-0.3	-5.22	2.59E-7	Polycystic ovary syndrome	
LGG	cis	1	rs1275501	chr2:27419282	SLC5A6	chr2:27422459-27435071:-	0.3	6.24	9.71E-10	Blood metabolite levels	
LGG	cis	1	rs1275522	chr2:27426878	SLC5A6	chr2:27422459-27435071:-	0.3	6.24	9.71E-10	Blood metabolite levels	
LGG	cis	1	rs1275528	chr2:27430781	SLC5A6	chr2:27422459-27435071:-	0.31	6.27	7.73E-10	Blood metabolite levels	
LGG	cis	1	rs1275530	chr2:27432547	SLC5A6	chr2:27422459-27435071:-	0.3	6.06	2.67E-9	Blood metabolite levels	
LGG	cis	1	rs1275537	chr2:27441302	SLC5A6	chr2:27422459-27435071:-	-0.31	-6.41	3.42E-10	Blood metabolite levels	
LGG	cis	1	rs1275538	chr2:27441397	SLC5A6	chr2:27422459-27435071:-	-0.33	-6.76	3.88E-11	Blood metabolite levels	
LGG	cis	1	rs1275847	chr14:70371703	SLC39A9	chr14:69865407-69929105:+	-0.19	-3.6	0.000347	Red blood cell traits	
LGG	cis	1	rs1275849	chr14:70371202	SLC39A9	chr14:69865407-69929105:+	-0.19	-3.6	0.000347	Red blood cell traits	
LGG	cis	1	rs12758548	chr1:172518896	C1orf9	chr1:172502260-172580971:+	-0.16	-3.54	0.000441	Erythrocyte cadmium concentration in never smokers	
LGG	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.19	-5.42	9.48E-8	Body mass index	
LGG	cis	1	rs12760175	chr1:46447840	MUTYH	chr1:45794915-45806142:-	0.13	4.72	3.02E-6	Body mass index	
LGG	cis	1	rs12762955	chr10:1078782	C10orf110	chr10:1068577-1090141:+	0.26	5.01	7.5E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs12767171	chr10:1084491	C10orf110	chr10:1068577-1090141:+	0.25	4.85	1.62E-6	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs12767633	chr10:102056440	BLOC1S2	chr10:102033713-102046439:-	0.31	4.37	1.52E-5	Obesity-related traits	
LGG	cis	1	rs12768613	chr10:81916566	PLAC9	chr10:81892258-81904784:+	-0.36	-6.2	1.19E-9	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs12771477	chr10:17209464	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.53	7.25E-6	Homocysteine levels	
LGG	cis	1	rs12772275	chr10:17204542	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.57	6.26E-6	Homocysteine levels	
LGG	cis	1	rs12773642	chr10:17196055	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.72	3.02E-6	Homocysteine levels	
LGG	cis	1	rs12774134	chr10:4963327	AKR1C2	chr10:4964715-5060207:-	0.42	5.6	3.61E-8	Height	
LGG	cis	1	rs12776158	chr10:71218094	TSPAN15	chr10:71211226-71267423:+	0.25	3.92	0.000101	Age-related hearing impairment (interaction)	
LGG	cis	1	rs12777800	chr10:1070361	C10orf110	chr10:1068577-1090141:+	0.29	5.35	1.34E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs12780845	chr10:17223244	TRDMT1	chr10:17184983-17243681:-	-0.18	-3.74	0.000204	Homocysteine levels	
LGG	cis	1	rs12781019	chr10:102057568	BLOC1S2	chr10:102033713-102046439:-	-0.32	-4.59	5.59E-6	Obesity-related traits	
LGG	cis	1	rs12782687	chr10:17223368	TRDMT1	chr10:17184983-17243681:-	-0.2	-4.17	3.54E-5	Homocysteine levels	
LGG	cis	1	rs12783490	chr10:17223716	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.47	9.75E-6	Homocysteine levels	
LGG	cis	1	rs12783621	chr10:1083304	C10orf110	chr10:1068577-1090141:+	0.26	5.05	6.15E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs1278493	chr3:135814009	PCCB	chr3:135969167-136056737:+	-0.19	-3.92	9.93E-5	Gestational age at birth (child effect)	
LGG	cis	1	rs12785488	chr11:64107521	C11orf20	chr11:64067863-64072238:+	-0.31	-4.53	7.53E-6	Mean platelet volume	
LGG	cis	1	rs12787330	chr11:47812311	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000367	Subjective well-being	
LGG	cis	1	rs12787330	chr11:47812311	MTCH2	chr11:47638859-47664206:-	0.25	4.8	2.12E-6	Subjective well-being	
LGG	cis	1	rs12787330	chr11:47812311	PSMC3	chr11:47440320-47448024:-	0.15	3.7	0.000241	Subjective well-being	
LGG	cis	1	rs12787536	chr11:5224585	TRIM78P	chr11:5664412-5687608:+	0.26	3.52	0.000474	HbA2 levels	
LGG	cis	1	rs12789252	chr11:18690389	GTF2H1	chr11:18343816-18388590:+	-0.19	-3.64	0.000297	Ovarian reserve	
LGG	cis	1	rs12792532	chr11:34765782	APIP	chr11:34896714-34937939:-	0.18	4.08	5.36E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs12794698	chr11:45871861	DKFZp779M0652	chr11:45792983-45793908:+	-0.14	-3.97	8.33E-5	Fasting glucose-related traits (interaction with BMI);Fasting glucose-related traits	
LGG	cis	1	rs12798036	chr11:947585	MUC6	chr11:1012824-1036706:-	-0.18	-3.97	8.4E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs1279831	chr3:135933264	PCCB	chr3:135969167-136056737:+	0.18	3.69	0.000245	Gestational age at birth (child effect)	
LGG	cis	1	rs12800378	chr11:87865942	RAB38	chr11:87846431-87908599:-	0.33	7.81	3.42E-14	Frontotemporal dementia	
LGG	cis	1	rs12802242	chr11:5390446	FAM160A2	chr11:6232565-6255941:-	0.2	3.92	0.000101	Fetal hemoglobin levels	
LGG	cis	1	rs12806120	chr11:5224484	TRIM78P	chr11:5664412-5687608:+	0.26	3.52	0.000474	HbA2 levels	
LGG	cis	1	rs12808928	chr11:5391517	FAM160A2	chr11:6232565-6255941:-	0.19	3.79	0.000167	Fetal hemoglobin levels	
LGG	cis	1	rs12821008	chr12:49474605	TUBA1C	chr12:49621709-49667113:+	0.17	4.3	2.05E-5	Bone mineral density	
LGG	cis	1	rs12828040	chr12:7326541	PEX5	chr12:7341759-7371167:+	0.33	7.18	2.53E-12	IgG glycosylation	
LGG	cis	1	rs12828421	chr12:7335217	PEX5	chr12:7341759-7371167:+	-0.34	-7.51	2.86E-13	IgG glycosylation	
LGG	cis	1	rs1284464	chr12:57964617	FAM119B	chr12:58166383-58176323:+	0.28	6.91	1.55E-11	Rheumatoid arthritis	
LGG	cis	1	rs1284464	chr12:57964617	TSFM	chr12:58176536-58191367:+	-0.2	-3.78	0.000175	Rheumatoid arthritis	
LGG	cis	1	rs12870594	chr13:31462909	C13orf33	chr13:31480312-31499708:+	0.42	5.83	9.88E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs12872801	chr13:40354200	COG6	chr13:40229764-40365802:+	-0.27	-5.8	1.19E-8	Rheumatoid arthritis	
LGG	cis	1	rs12874929	chr13:26781607	RNF6	chr13:26706253-26796508:-	0.15	3.53	0.000454	Type 2 diabetes	
LGG	cis	1	rs12875311	chr13:40342557	COG6	chr13:40229764-40365802:+	-0.27	-5.83	9.79E-9	Rheumatoid arthritis	
LGG	cis	1	rs12876002	chr13:31467467	C13orf33	chr13:31480312-31499708:+	0.44	6	3.87E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs12878477	chr14:81673091	STON2	chr14:81727000-81893748:-	0.2	3.73	0.000213	IgG glycosylation	
LGG	cis	1	rs12878503	chr14:81643053	STON2	chr14:81727000-81893748:-	0.22	3.66	0.000283	IgG glycosylation	
LGG	cis	1	rs12879542	chr14:75507525	EIF2B2	chr14:75469612-75476292:+	0.19	3.68	0.000263	Height	
LGG	cis	1	rs12879542	chr14:75507525	MLH3	chr14:75480467-75518235:-	0.2	3.47	0.00057	Height	
LGG	cis	1	rs12879642	chr14:76682967	ESRRB	chr14:76837690-76968178:+	0.42	6.41	3.47E-10	Blood pressure	
LGG	cis	1	rs12880414	chr14:81705090	STON2	chr14:81727000-81893748:-	0.2	3.7	0.000244	IgG glycosylation	
LGG	cis	1	rs12883359	chr14:81665187	STON2	chr14:81727000-81893748:-	0.21	3.76	0.000189	IgG glycosylation	
LGG	cis	1	rs12889168	chr14:104481957	TDRD9	chr14:104394817-104519002:+	0.22	4.41	1.29E-5	Bipolar disorder	
LGG	cis	1	rs12889309	chr14:75593902	ACYP1	chr14:75519930-75530736:-	-0.15	-3.99	7.52E-5	Height	
LGG	cis	1	rs12889309	chr14:75593902	EIF2B2	chr14:75469612-75476292:+	0.2	3.83	0.000145	Height	
LGG	cis	1	rs12889309	chr14:75593902	MLH3	chr14:75480467-75518235:-	0.2	3.48	0.000547	Height	
LGG	cis	1	rs12889472	chr14:75543979	ACYP1	chr14:75519930-75530736:-	-0.14	-3.7	0.000243	Height	
LGG	cis	1	rs12889813	chr14:24306537	CMTM5	chr14:23846017-23848980:+	0.14	4.08	5.2E-5	Antibody level in response to infection	
LGG	cis	1	rs12895990	chr14:81676282	STON2	chr14:81727000-81893748:-	0.2	3.48	0.000536	IgG glycosylation	
LGG	cis	1	rs12897094	chr14:75579416	ACYP1	chr14:75519930-75530736:-	-0.14	-3.73	0.000214	Height	
LGG	cis	1	rs12898259	chr15:75369780	PPCDC	chr15:75315927-75343066:+	0.24	5.24	2.36E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs12898311	chr15:91517780	RCCD1	chr15:91498106-91506353:+	0.18	3.69	0.000254	Type 2 diabetes	
LGG	cis	1	rs12899618	chr15:71645120	LARP6	chr15:71123891-71146498:-	0.15	3.48	0.000539	Pulmonary function;Pulmonary function (interaction)	
LGG	cis	1	rs12899981	chr15:85302373	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.41	1.26E-5	Schizophrenia	
LGG	cis	1	rs12899981	chr15:85302373	LOC388152	chr15:84867600-84898920:-	-0.3	-5.63	3.07E-8	Schizophrenia	
LGG	cis	1	rs12899981	chr15:85302373	WDR73	chr15:85186012-85197524:-	-0.19	-3.58	0.000374	Schizophrenia	
LGG	cis	1	rs12900413	chr15:90321039	WDR93	chr15:90234028-90286868:+	-0.19	-4.37	1.51E-5	Coronary artery aneurysm in Kawasaki disease	
LGG	cis	1	rs12901243	chr15:75374233	PPCDC	chr15:75315927-75343066:+	0.24	5.28	1.95E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs12902672	chr15:84716986	GOLGA6L5	chr15:85047738-85060078:-	-0.23	-5.38	1.17E-7	Schizophrenia	
LGG	cis	1	rs12902672	chr15:84716986	LOC388152	chr15:84867600-84898920:-	-0.32	-6.35	4.78E-10	Schizophrenia	
LGG	cis	1	rs12903134	chr15:85337699	GOLGA6L5	chr15:85047738-85060078:-	-0.19	-4.17	3.53E-5	Schizophrenia	
LGG	cis	1	rs12903134	chr15:85337699	LOC388152	chr15:84867600-84898920:-	-0.29	-5.45	8.12E-8	Schizophrenia	
LGG	cis	1	rs12903201	chr15:75370776	PPCDC	chr15:75315927-75343066:+	0.24	5.24	2.36E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs12903402	chr15:100300806	C15orf51	chr15:100330361-100347132:-	-0.31	-4.12	4.4E-5	Major depressive disorder	
LGG	cis	1	rs12903750	chr15:100300341	C15orf51	chr15:100330361-100347132:-	-0.31	-4.07	5.59E-5	Major depressive disorder	
LGG	cis	1	rs12903765	chr15:100300362	C15orf51	chr15:100330361-100347132:-	-0.31	-4.07	5.47E-5	Major depressive disorder	
LGG	cis	1	rs12903820	chr15:84723820	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.54	4.91E-8	Schizophrenia	
LGG	cis	1	rs12903820	chr15:84723820	LOC388152	chr15:84867600-84898920:-	-0.32	-6.33	5.62E-10	Schizophrenia	
LGG	cis	1	rs12904259	chr15:100300606	C15orf51	chr15:100330361-100347132:-	-0.31	-4.12	4.4E-5	Major depressive disorder	
LGG	cis	1	rs12904329	chr15:24839870	PWRN1	chr15:24778839-24832924:+	0.24	4.21	2.98E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs12905057	chr15:85210765	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.36	1.57E-5	Schizophrenia	
LGG	cis	1	rs12905057	chr15:85210765	LOC388152	chr15:84867600-84898920:-	-0.31	-5.79	1.25E-8	Schizophrenia	
LGG	cis	1	rs12906032	chr15:24822388	PWRN1	chr15:24778839-24832924:+	0.21	4.42	1.23E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs12907687	chr15:100305120	C15orf51	chr15:100330361-100347132:-	-0.34	-4.37	1.51E-5	Major depressive disorder	
LGG	cis	1	rs12908161	chr15:85207825	GOLGA6L5	chr15:85047738-85060078:-	-0.21	-4.55	6.77E-6	Schizophrenia	
LGG	cis	1	rs12908161	chr15:85207825	LOC388152	chr15:84867600-84898920:-	-0.3	-5.67	2.47E-8	Schizophrenia	
LGG	cis	1	rs12908161	chr15:85207825	WDR73	chr15:85186012-85197524:-	-0.19	-3.54	0.000442	Schizophrenia	
LGG	cis	1	rs12908539	chr15:100300268	C15orf51	chr15:100330361-100347132:-	-0.31	-4.13	4.34E-5	Major depressive disorder	
LGG	cis	1	rs12908549	chr15:85322351	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.35	1.66E-5	Schizophrenia	
LGG	cis	1	rs12908549	chr15:85322351	LOC388152	chr15:84867600-84898920:-	-0.29	-5.47	7.21E-8	Schizophrenia	
LGG	cis	1	rs12908549	chr15:85322351	WDR73	chr15:85186012-85197524:-	-0.19	-3.47	0.000573	Schizophrenia	
LGG	cis	1	rs12908758	chr15:100300447	C15orf51	chr15:100330361-100347132:-	-0.31	-4.07	5.47E-5	Major depressive disorder	
LGG	cis	1	rs12909095	chr15:43558142	STRC	chr15:43891762-43924561:-	0.25	5.42	9.21E-8	Lung cancer	
LGG	cis	1	rs12909095	chr15:43558142	TGM5	chr15:43525375-43559055:-	-0.21	-3.81	0.000156	Lung cancer	
LGG	cis	1	rs12910012	chr15:85298662	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.41	1.26E-5	Schizophrenia	
LGG	cis	1	rs12910012	chr15:85298662	LOC388152	chr15:84867600-84898920:-	-0.3	-5.63	3.07E-8	Schizophrenia	
LGG	cis	1	rs12910012	chr15:85298662	WDR73	chr15:85186012-85197524:-	-0.19	-3.58	0.000374	Schizophrenia	
LGG	cis	1	rs12910404	chr15:74026781	CLK3	chr15:74890843-74922541:+	0.24	3.88	0.000119	Bipolar disorder	
LGG	cis	1	rs12910644	chr15:75358388	PPCDC	chr15:75315927-75343066:+	0.23	4.97	9.32E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs12910759	chr15:100305314	C15orf51	chr15:100330361-100347132:-	-0.34	-4.37	1.51E-5	Major depressive disorder	
LGG	cis	1	rs12910930	chr15:55545706	RAB27A	chr15:55495802-55582001:-	-0.13	-3.56	0.0004	Fractional exhaled nitric oxide levels	
LGG	cis	1	rs12910992	chr15:90372465	AP3S2	chr15:90373832-90456222:-	-0.47	-8.97	6.28E-18	Type 2 diabetes	
LGG	cis	1	rs12911132	chr15:43560436	STRC	chr15:43891762-43924561:-	0.26	5.49	6.62E-8	Lung cancer	
LGG	cis	1	rs12911132	chr15:43560436	TGM5	chr15:43525375-43559055:-	-0.2	-3.68	0.00026	Lung cancer	
LGG	cis	1	rs12911736	chr15:85240008	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.44	1.13E-5	Schizophrenia	
LGG	cis	1	rs12911736	chr15:85240008	LOC388152	chr15:84867600-84898920:-	-0.31	-5.73	1.78E-8	Schizophrenia	
LGG	cis	1	rs12912388	chr15:85344550	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.24	2.67E-5	Schizophrenia	
LGG	cis	1	rs12912388	chr15:85344550	LOC388152	chr15:84867600-84898920:-	-0.29	-5.44	8.2E-8	Schizophrenia	
LGG	cis	1	rs12914773	chr15:68019958	IQCH	chr15:67547188-67794139:+	0.13	3.7	0.000239	Motion sickness	
LGG	cis	1	rs12915234	chr15:84758301	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.54	4.97E-8	Schizophrenia	
LGG	cis	1	rs12915234	chr15:84758301	LOC388152	chr15:84867600-84898920:-	-0.33	-6.43	3.02E-10	Schizophrenia	
LGG	cis	1	rs12916348	chr15:84765527	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.55	4.69E-8	Schizophrenia	
LGG	cis	1	rs12916348	chr15:84765527	LOC388152	chr15:84867600-84898920:-	-0.32	-6.41	3.49E-10	Schizophrenia	
LGG	cis	1	rs12917099	chr15:74028569	CLK3	chr15:74890843-74922541:+	0.23	3.79	0.000169	Bipolar disorder	
LGG	cis	1	rs12917342	chr15:100297845	C15orf51	chr15:100330361-100347132:-	-0.3	-4.04	6.27E-5	Major depressive disorder	
LGG	cis	1	rs12919718	chr16:58350225	PRSS54	chr16:58313902-58328951:-	0.38	6.84	2.4E-11	Systemic lupus erythematosus	
LGG	cis	1	rs12923460	chr16:77324328	ADAMTS18	chr16:77316026-77469011:-	-0.31	-4.53	7.46E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12925274	chr16:77320515	ADAMTS18	chr16:77316026-77469011:-	0.31	4.54	7.0E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12927388	chr16:77324406	ADAMTS18	chr16:77316026-77469011:-	-0.31	-4.53	7.46E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12930239	chr16:29908777	BOLA2	chr16:29454226-29466285:-;chr16	-0.2	-4.38	1.47E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs12930239	chr16:29908777	LOC440356	chr16:29875004-29879374:+	-0.28	-5.81	1.1E-8	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs12933721	chr16:77328639	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12935229	chr16:77328895	ADAMTS18	chr16:77316026-77469011:-	-0.32	-4.54	7.03E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12935394	chr16:77328990	ADAMTS18	chr16:77316026-77469011:-	-0.32	-4.51	8.12E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs12940106	chr17:53067683	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.29	1.83E-7	Breast cancer	
LGG	cis	1	rs12942660	chr17:37982038	GSDMB	chr17:38060850-38074903:-	-0.23	-3.55	0.000419	Systemic lupus erythematosus	
LGG	cis	1	rs12944592	chr17:46430405	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs12946636	chr17:46472432	HOXB2	chr17:46620021-46622393:-	-0.2	-3.47	0.000556	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs12948017	chr17:46439246	HOXB2	chr17:46620021-46622393:-	0.19	3.56	0.000412	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs12948099	chr17:79600799	PDE6G	chr17:79617489-79623607:-	-0.23	-5.95	5.05E-9	Eye color traits	
LGG	cis	1	rs12948099	chr17:79600799	TSPAN10	chr17:79609349-79615778:+	0.68	17.35	6.09E-53	Eye color traits	
LGG	cis	1	rs1296028	chr8:11698747	CTSB	chr8:11700036-11725646:-	0.19	5.56	4.33E-8	Parkinson's disease	
LGG	cis	1	rs1296028	chr8:11698747	FAM66A	chr8:12219528-12279968:+	-0.22	-3.66	0.000284	Parkinson's disease	
LGG	cis	1	rs12971120	chr18:72174023	CNDP2	chr18:72163597-72188356:+	0.25	5.74	1.69E-8	Refractive error	
LGG	cis	1	rs12973620	chr19:58249643	ZNF586	chr19:58281025-58311962:+	-0.33	-5.93	5.85E-9	Allergic rhinitis	
LGG	cis	1	rs12980225	chr19:23026745	ZNF492	chr19:22817126-22850472:+	-0.21	-4.27	2.37E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs12980403	chr19:18398139	JUND	chr19:18390563-18392432:-	-0.16	-3.48	0.000543	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12980403	chr19:18398139	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.5	8.51E-6	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12980403	chr19:18398139	TMEM161A	chr19:19230431-19249267:-	-0.13	-3.54	0.000443	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs12983770	chr19:23023614	ZNF492	chr19:22817126-22850472:+	-0.21	-4.27	2.37E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs12992014	chr2:179691285	CCDC141	chr2:179697347-179914786:-	0.17	3.51	0.000497	QT interval	
LGG	cis	1	rs12994971	chr2:234178453	ATG16L1	chr2:234160217-234204319:+	-0.17	-4.04	6.22E-5	Crohn's disease	
LGG	cis	1	rs12994997	chr2:234173503	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.14	4.09E-5	Crohn's disease	
LGG	cis	1	rs1299548	chr7:7302293	C1GALT1	chr7:7222246-7283979:+	-0.14	-3.7	0.000243	Visceral adipose tissue adjusted for BMI	
LGG	cis	1	rs12995491	chr2:88527414	THNSL2	chr2:88469835-88486145:+	-0.21	-4.59	5.62E-6	Response to metformin (IC50)	
LGG	cis	1	rs13001325	chr2:102939036	IL18R1	chr2:102927962-103015215:+	-0.34	-6.52	1.77E-10	Serum protein levels (sST2)	
LGG	cis	1	rs13001325	chr2:102939036	IL1RL1	chr2:102927962-102968497:+	-0.37	-6.41	3.48E-10	Serum protein levels (sST2)	
LGG	cis	1	rs13003040	chr2:66756270	MEIS1	chr2:66662532-66799890:+	-0.18	-4.21	3.09E-5	PR interval	
LGG	cis	1	rs13003464	chr2:61186829	AHSA2	chr2:61404553-61414058:+	-0.25	-7.52	2.55E-13	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs13003464	chr2:61186829	C2orf74	chr2:61372243-61391964:+	0.31	6.3	6.69E-10	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs13004237	chr2:172833139	SLC25A12	chr2:172639915-172750813:-	0.15	4.19	3.37E-5	Schizophrenia	
LGG	cis	1	rs13006833	chr2:191205499	HIBCH	chr2:191069361-191184559:-	0.52	12.28	2.06E-30	Urinary metabolites	
LGG	cis	1	rs13008299	chr2:29247997	TRMT61B	chr2:29072690-29093175:-	-0.24	-4.51	8.02E-6	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs13008525	chr2:29248340	TRMT61B	chr2:29072690-29093175:-	0.23	4.4	1.31E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs13008738	chr2:61078921	AHSA2	chr2:61404553-61414058:+	-0.23	-5.68	2.28E-8	Inflammatory skin disease	
LGG	cis	1	rs13008738	chr2:61078921	C2orf74	chr2:61372243-61391964:+	0.3	5.07	5.63E-7	Inflammatory skin disease	
LGG	cis	1	rs13009506	chr2:234175706	ATG16L1	chr2:234160217-234204319:+	0.18	4.29	2.14E-5	Crohn's disease	
LGG	cis	1	rs13012870	chr2:230522035	DNER	chr2:230222346-230579286:-	0.28	6.33	5.38E-10	Type 2 diabetes	
LGG	cis	1	rs13013355	chr2:188177314	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs13014235	chr2:202215492	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.91	0.000103	Basal cell carcinoma	
LGG	cis	1	rs13014235	chr2:202215492	ALS2CR4	chr2:202484907-202508224:-	0.18	4.69	3.6E-6	Basal cell carcinoma	
LGG	cis	1	rs13014235	chr2:202215492	PPIL3	chr2:201735680-201753999:-	-0.21	-4.26	2.43E-5	Basal cell carcinoma	
LGG	cis	1	rs13014261	chr2:29248414	TRMT61B	chr2:29072690-29093175:-	0.23	4.4	1.31E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs13015457	chr2:70125763	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.37	1.5E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs13015714	chr2:102971865	IL18R1	chr2:102927962-103015215:+	-0.39	-6.14	1.75E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs13015714	chr2:102971865	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.14	4.04E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs13016963	chr2:202162811	ALS2CR12	chr2:202153148-202222101:-	-0.36	-7.31	1.07E-12	Melanoma;Esophageal squamous cell carcinoma	
LGG	cis	1	rs13019081	chr2:102950822	IL18R1	chr2:102927962-103015215:+	0.34	6.51	1.82E-10	Serum protein levels (sST2)	
LGG	cis	1	rs13019081	chr2:102950822	IL1RL1	chr2:102927962-102968497:+	0.36	6.38	4.19E-10	Serum protein levels (sST2)	
LGG	cis	1	rs13020991	chr2:70068642	SNRNP27	chr2:70121090-70132348:+	-0.19	-3.68	0.000258	Colorectal or endometrial cancer	
LGG	cis	1	rs13022357	chr2:160069756	CCDC148	chr2:159028479-159313214:-	-0.29	-3.93	9.55E-5	Sudden cardiac arrest	
LGG	cis	1	rs13026621	chr2:27807624	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs13026621	chr2:27807624	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs13026779	chr2:29247963	TRMT61B	chr2:29072690-29093175:-	0.23	4.4	1.31E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs13028508	chr2:70118427	SNRNP27	chr2:70121090-70132348:+	0.19	4.21	3.01E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs13029520	chr2:66772962	MEIS1	chr2:66662532-66799890:+	0.19	4.28	2.29E-5	PR interval	
LGG	cis	1	rs13030858	chr2:26315451	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs13031901	chr2:188192019	CALCRL	chr2:188207851-188313021:-	0.22	5.35	1.37E-7	Coronary heart disease	
LGG	cis	1	rs13033143	chr2:61161095	AHSA2	chr2:61404553-61414058:+	-0.24	-6.07	2.61E-9	Inflammatory skin disease	
LGG	cis	1	rs13033143	chr2:61161095	C2orf74	chr2:61372243-61391964:+	0.32	5.4	1.07E-7	Inflammatory skin disease	
LGG	cis	1	rs13038202	chr20:47835618	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.28	2.25E-5	Height	
LGG	cis	1	rs13038621	chr20:47908060	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.96	8.69E-5	Height	
LGG	cis	1	rs13038834	chr20:25441433	ABHD12	chr20:25275380-25371477:-	0.27	7.24	1.69E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs13038834	chr20:25441433	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	3.15E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs13038834	chr20:25441433	FAM182B	chr20:25744102-25848786:-	0.22	4.98	8.86E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1303	chr14:94844843	PPP4R4	chr14:94640649-94746072:+	-0.12	-3.83	0.000147	Metabolite levels	
LGG	cis	1	rs13054220	chr22:31704492	LIMK2	chr22:31608250-31676064:+	-0.26	-5.51	5.67E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs13054985	chr22:23458577	RTDR1	chr22:23401594-23484241:-	-0.18	-4.11	4.71E-5	Bone mineral density	
LGG	cis	1	rs13056719	chr22:24724099	POM121L9P	chr22:24647589-24661490:+	-0.26	-5.56	4.4E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs13058084	chr22:30679682	CCDC157	chr22:30752627-30772816:+	0.36	4.8	2.09E-6	Coronary artery calcification	
LGG	cis	1	rs13058399	chr22:30694428	CCDC157	chr22:30752627-30772816:+	0.33	4.47	9.81E-6	Coronary artery calcification	
LGG	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.62	1.32E-13	Height	
LGG	cis	1	rs13059720	chr3:134242021	CEP63	chr3:134204575-134293852:+	-0.21	-3.84	0.00014	Height	
LGG	cis	1	rs13059843	chr3:195028183	ACAP2	chr3:194995475-195163817:-	-0.38	-9.03	3.87E-18	Body mass index	
LGG	cis	1	rs13059975	chr3:127849684	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13060453	chr3:127810738	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13062252	chr3:127828631	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.21	2.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13062518	chr3:195038287	ACAP2	chr3:194995475-195163817:-	-0.37	-8.88	1.24E-17	Body mass index	
LGG	cis	1	rs13067306	chr3:94243713	STX19	chr3:93733215-93747454:-	0.68	9.69	1.93E-20	Blood pressure measurement (high sodium intervention)	
LGG	cis	1	rs13067650	chr3:127889542	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.22	2.9E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13069054	chr3:127855982	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.59E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13069724	chr3:48478039	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.15E-5	Longevity	
LGG	cis	1	rs13069724	chr3:48478039	TREX1	chr3:48501186-48509043:+	-0.42	-10.93	4.8E-25	Longevity	
LGG	cis	1	rs13071337	chr3:48438189	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs13071337	chr3:48438189	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs13071551	chr3:134310867	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs13071740	chr3:127881568	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13072818	chr3:53074263	RFT1	chr3:53122503-53164470:-	0.31	3.56	0.000407	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs13072826	chr3:195064755	ACAP2	chr3:194995475-195163817:-	-0.38	-9.14	1.71E-18	Body mass index	
LGG	cis	1	rs13076033	chr3:52898427	ABHD14B	chr3:52002527-52017425:-	0.22	3.49	0.000523	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs13076076	chr3:48479039	ATRIP	chr3:48488141-48507708:+	0.18	4.51	8.04E-6	Longevity	
LGG	cis	1	rs13076076	chr3:48479039	TREX1	chr3:48501186-48509043:+	-0.43	-11.11	9.43E-26	Longevity	
LGG	cis	1	rs13077790	chr3:127882658	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13077913	chr3:127882604	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.3	-7.65	1.08E-13	Height	
LGG	cis	1	rs13081177	chr3:134289860	CEP63	chr3:134204575-134293852:+	-0.21	-3.77	0.000187	Height	
LGG	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.62	1.32E-13	Height	
LGG	cis	1	rs13081688	chr3:134259954	CEP63	chr3:134204575-134293852:+	-0.21	-3.84	0.00014	Height	
LGG	cis	1	rs13082038	chr3:127828456	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13083794	chr3:121464928	IQCB1	chr3:121488610-121553926:-	0.37	6.82	2.7E-11	Cognitive performance	
LGG	cis	1	rs13085791	chr3:49721798	MST1R	chr3:49924438-49941306:-	-0.21	-4.06	5.82E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13085791	chr3:49721798	RBM6	chr3:49977592-50137484:+	0.15	4.21	3.0E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13085791	chr3:49721798	SEMA3F	chr3:50192848-50226507:+	0.2	4.45	1.05E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13086611	chr3:49385417	MST1R	chr3:49924438-49941306:-	-0.23	-4.4	1.35E-5	Educational attainment	
LGG	cis	1	rs13086611	chr3:49385417	RBM6	chr3:49977592-50137484:+	0.14	3.93	9.61E-5	Educational attainment	
LGG	cis	1	rs13086611	chr3:49385417	SEMA3F	chr3:50192848-50226507:+	0.21	4.71	3.27E-6	Educational attainment	
LGG	cis	1	rs13087299	chr3:94229344	STX19	chr3:93733215-93747454:-	0.71	10.44	3.62E-23	Blood pressure measurement (high sodium intervention)	
LGG	cis	1	rs13087578	chr3:121369207	IQCB1	chr3:121488610-121553926:-	0.37	6.79	3.3E-11	Cognitive performance	
LGG	cis	1	rs13087719	chr3:41951576	ULK4	chr3:41288091-42003660:-	-0.78	-15.42	4.72E-44	Diastolic blood pressure	
LGG	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs13087875	chr3:134261123	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs13088309	chr3:49368317	AMIGO3	chr3:49754268-49757238:-	-0.17	-4.01	7.03E-5	Menarche (age at onset)	
LGG	cis	1	rs13088309	chr3:49368317	GMPPB	chr3:49758932-49761384:-	-0.21	-4.13	4.24E-5	Menarche (age at onset)	
LGG	cis	1	rs13088309	chr3:49368317	NCKIPSD	chr3:48711280-48723334:-	0.15	3.48	0.000539	Menarche (age at onset)	
LGG	cis	1	rs13088309	chr3:49368317	TREX1	chr3:48501186-48509043:+	-0.26	-5.37	1.21E-7	Menarche (age at onset)	
LGG	cis	1	rs13088455	chr3:53087482	ITIH4	chr3:52847007-52866554:-	0.18	4.95	1.03E-6	Ulcerative colitis	
LGG	cis	1	rs13088455	chr3:53087482	RFT1	chr3:53122503-53164470:-	0.2	3.92	0.000103	Ulcerative colitis	
LGG	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs13089966	chr3:134279197	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs13090388	chr3:49391082	MST1R	chr3:49924438-49941306:-	-0.22	-4.37	1.49E-5	Educational attainment (years of education)	
LGG	cis	1	rs13090388	chr3:49391082	RBM6	chr3:49977592-50137484:+	0.14	3.93	9.64E-5	Educational attainment (years of education)	
LGG	cis	1	rs13090388	chr3:49391082	SEMA3F	chr3:50192848-50226507:+	0.21	4.77	2.44E-6	Educational attainment (years of education)	
LGG	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs13090969	chr3:134307257	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs13091785	chr3:48494098	ATRIP	chr3:48488141-48507708:+	0.19	4.79	2.25E-6	Longevity	
LGG	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.43	-11.07	1.36E-25	Longevity	
LGG	cis	1	rs13091924	chr3:195051136	ACAP2	chr3:194995475-195163817:-	-0.37	-8.93	8.69E-18	Body mass index	
LGG	cis	1	rs13095338	chr3:186435583	KNG1	chr3:186435120-186461741:+	-0.15	-3.51	0.000489	Adiponectin levels	
LGG	cis	1	rs13095660	chr3:127848156	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs13096474	chr3:49443081	AMIGO3	chr3:49754268-49757238:-	0.16	3.82	0.000149	Menarche (age at onset)	
LGG	cis	1	rs13096474	chr3:49443081	GMPPB	chr3:49758932-49761384:-	0.2	3.98	7.94E-5	Menarche (age at onset)	
LGG	cis	1	rs13096474	chr3:49443081	NCKIPSD	chr3:48711280-48723334:-	-0.17	-3.94	9.18E-5	Menarche (age at onset)	
LGG	cis	1	rs13096474	chr3:49443081	TREX1	chr3:48501186-48509043:+	0.23	4.93	1.15E-6	Menarche (age at onset)	
LGG	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.62	1.32E-13	Height	
LGG	cis	1	rs13096604	chr3:134250099	CEP63	chr3:134204575-134293852:+	-0.21	-3.84	0.00014	Height	
LGG	cis	1	rs13096715	chr3:195074488	ACAP2	chr3:194995475-195163817:-	-0.38	-9.13	1.84E-18	Body mass index	
LGG	cis	1	rs13099	chr14:75599155	ACYP1	chr14:75519930-75530736:-	0.15	3.92	0.000102	Height	
LGG	cis	1	rs13102385	chr4:56345255	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs13108904	chr4:1291113	MAEA	chr4:1283672-1333924:+	0.17	3.87	0.000122	Obesity-related traits	
LGG	cis	1	rs13108904	chr4:1291113	SPON2	chr4:1160722-1166980:-	-0.17	-4.19	3.24E-5	Obesity-related traits	
LGG	cis	1	rs13109003	chr4:129975969	C4orf33	chr4:130014829-130033842:+	-0.6	-9.99	1.56E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs13116504	chr4:120209412	MYOZ2	chr4:120056939-120108935:+	0.22	4.21	3.02E-5	Corneal astigmatism	
LGG	cis	1	rs13120847	chr4:48030036	CNGA1	chr4:47937996-48018610:-	0.6	12.53	1.94E-31	Renal underexcretion gout;Gout	
LGG	cis	1	rs13121235	chr4:56311947	TMEM165	chr4:56262090-56292342:+	-0.17	-4.91	1.22E-6	Personality dimensions	
LGG	cis	1	rs13122400	chr4:39713743	RPL9	chr4:39455747-39460568:-	-0.4	-7.55	2.1E-13	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs13125949	chr4:48026560	CNGA1	chr4:47937996-48018610:-	0.6	12.55	1.65E-31	Renal underexcretion gout;Gout	
LGG	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs13140744	chr4:122950069	SPATA5	chr4:123844225-124240602:+	0.16	3.71	0.000229	Emphysema imaging phenotypes	
LGG	cis	1	rs13140968	chr4:48025095	CNGA1	chr4:47937996-48018610:-	0.59	12.16	6.53E-30	Renal underexcretion gout;Gout	
LGG	cis	1	rs13142905	chr4:48025298	CNGA1	chr4:47937996-48018610:-	0.6	12.55	1.65E-31	Renal underexcretion gout;Gout	
LGG	cis	1	rs13146880	chr4:48031499	CNGA1	chr4:47937996-48018610:-	0.59	12.26	2.48E-30	Renal underexcretion gout;Gout	
LGG	cis	1	rs13153099	chr5:156436195	TIMD4	chr5:156346293-156390266:-	-0.26	-4.71	3.3E-6	Hypertriglyceridemia	
LGG	cis	1	rs13154249	chr5:93550508	FAM172A	chr5:92953432-93447404:-	-0.29	-3.97	8.24E-5	Diabetic retinopathy	
LGG	cis	1	rs13162970	chr5:112733357	SRP19	chr5:112196993-112228774:+	0.3	3.66	0.000281	F-cell distribution	
LGG	cis	1	rs13163610	chr5:93548877	FAM172A	chr5:92953432-93447404:-	-0.29	-3.97	8.24E-5	Diabetic retinopathy	
LGG	cis	1	rs13168670	chr5:140146899	PCDHA13	chr5:140261854-140391929:+	0.25	4.57	6.21E-6	Schizophrenia	
LGG	cis	1	rs13168670	chr5:140146899	PCDHA6	chr5:140207650-140391929:+	0.2	3.67	0.000266	Schizophrenia	
LGG	cis	1	rs13168670	chr5:140146899	WDR55	chr5:140044384-140050551:+	-0.2	-4.61	5.07E-6	Schizophrenia	
LGG	cis	1	rs13169155	chr5:156426663	TIMD4	chr5:156346293-156390266:-	-0.24	-4.44	1.11E-5	Hypertriglyceridemia	
LGG	cis	1	rs13169465	chr5:156426916	TIMD4	chr5:156346293-156390266:-	-0.24	-4.45	1.06E-5	Hypertriglyceridemia	
LGG	cis	1	rs13169621	chr5:156426974	TIMD4	chr5:156346293-156390266:-	-0.26	-4.79	2.19E-6	Hypertriglyceridemia	
LGG	cis	1	rs1317140	chr3:49878652	MST1R	chr3:49924438-49941306:-	0.27	5.06	5.94E-7	Resting heart rate	
LGG	cis	1	rs1317140	chr3:49878652	RBM6	chr3:49977592-50137484:+	-0.14	-3.75	0.000195	Resting heart rate	
LGG	cis	1	rs1317149	chr11:47486885	ACP2	chr11:47260854-47270457:-	0.17	3.6	0.000355	Subjective well-being	
LGG	cis	1	rs1317149	chr11:47486885	MTCH2	chr11:47638859-47664206:-	0.26	4.94	1.06E-6	Subjective well-being	
LGG	cis	1	rs1317149	chr11:47486885	PSMC3	chr11:47440320-47448024:-	0.17	4.16	3.81E-5	Subjective well-being	
LGG	cis	1	rs13174348	chr5:115138748	ATG12	chr5:115165818-115177520:-	0.2	4.45	1.06E-5	IgG glycosylation	
LGG	cis	1	rs13174700	chr5:93554644	FAM172A	chr5:92953432-93447404:-	-0.29	-3.97	8.24E-5	Diabetic retinopathy	
LGG	cis	1	rs13177576	chr5:125917249	ALDH7A1	chr5:125878918-125931082:-	0.46	5.43	8.85E-8	Osteoporosis	
LGG	cis	1	rs131801	chr22:50966634	CPT1B	chr22:51007291-51017096:-	0.11	3.8	0.000164	Mean corpuscular hemoglobin	
LGG	cis	1	rs131801	chr22:50966634	TYMP	chr22:50964184-50968514:-	0.16	5.12	4.47E-7	Mean corpuscular hemoglobin	
LGG	cis	1	rs13181660	chr5:93533658	FAM172A	chr5:92953432-93447404:-	-0.27	-3.68	0.000261	Diabetic retinopathy	
LGG	cis	1	rs13181803	chr5:156429177	TIMD4	chr5:156346293-156390266:-	-0.26	-4.79	2.19E-6	Hypertriglyceridemia	
LGG	cis	1	rs13182359	chr5:112721135	SRP19	chr5:112196993-112228774:+	0.29	3.53	0.000454	F-cell distribution	
LGG	cis	1	rs13182402	chr5:125918148	ALDH7A1	chr5:125878918-125931082:-	-0.47	-5.75	1.55E-8	Osteoporosis	
LGG	cis	1	rs13183901	chr5:172990492	LOC285593	chr5:173006646-173012074:+	0.26	4.77	2.41E-6	Height	
LGG	cis	1	rs13185608	chr5:93509688	FAM172A	chr5:92953432-93447404:-	-0.31	-4.21	3.01E-5	Diabetic retinopathy	
LGG	cis	1	rs13190742	chr6:163008758	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs13191362	chr6:163033350	PACRG	chr6:163148164-163736523:+	0.3	4.37	1.49E-5	Body mass index	
LGG	cis	1	rs13192894	chr6:163052444	PACRG	chr6:163148164-163736523:+	0.36	4.88	1.43E-6	Body mass index	
LGG	cis	1	rs13193282	chr6:163015442	PACRG	chr6:163148164-163736523:+	0.29	4.29	2.14E-5	Body mass index	
LGG	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.5	-10.27	1.49E-22	Response to antipsychotic treatment	
LGG	cis	1	rs13195182	chr6:52886703	ICK	chr6:52866098-52926600:-	-0.22	-3.89	0.000113	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs13195226	chr6:163006421	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-0.95	-10.88	7.52E-25	Schizophrenia	
LGG	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-0.95	-10.88	7.52E-25	Schizophrenia	
LGG	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.51	-10.39	5.52E-23	Response to antipsychotic treatment	
LGG	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.52	-11.09	1.19E-25	Response to antipsychotic treatment	
LGG	cis	1	rs13199223	chr6:163001083	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs13200329	chr6:163004418	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs13200462	chr6:28218199	ZNF165	chr6:28046572-28057338:+	-0.33	-4.8	2.15E-6	Depression	
LGG	cis	1	rs13200462	chr6:28218199	ZNF187	chr6:28234788-28245978:+	-0.28	-4.71	3.28E-6	Depression	
LGG	cis	1	rs13200462	chr6:28218199	ZNF389	chr6:28129551-28137375:+	0.43	6.85	2.23E-11	Depression	
LGG	cis	1	rs13200462	chr6:28218199	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.67	3.91E-6	Depression	
LGG	cis	1	rs13200462	chr6:28218199	ZSCAN23	chr6:28393287-28411279:-	0.18	4.16	3.77E-5	Depression	
LGG	cis	1	rs13201023	chr6:162981381	PACRG	chr6:163148164-163736523:+	0.33	4.75	2.64E-6	Body mass index	
LGG	cis	1	rs13202339	chr6:163081812	PACRG	chr6:163148164-163736523:+	0.41	5.42	9.44E-8	Body mass index	
LGG	cis	1	rs13204013	chr6:163002480	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs13204439	chr6:163015358	PACRG	chr6:163148164-163736523:+	-0.28	-4.33	1.84E-5	Body mass index	
LGG	cis	1	rs13206253	chr6:163166902	PACRG	chr6:163148164-163736523:+	0.4	5.86	8.42E-9	Body mass index	
LGG	cis	1	rs13207239	chr6:163008772	PACRG	chr6:163148164-163736523:+	0.29	4.34	1.72E-5	Body mass index	
LGG	cis	1	rs13207671	chr6:162979056	PACRG	chr6:163148164-163736523:+	0.33	4.83	1.85E-6	Body mass index	
LGG	cis	1	rs1320893	chr7:143752112	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.62	0.000325	Obesity-related traits	
LGG	cis	1	rs1320894	chr7:143751802	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.65	0.000287	Obesity-related traits	
LGG	cis	1	rs13209100	chr6:163159350	PACRG	chr6:163148164-163736523:+	0.41	6.04	3.07E-9	Body mass index	
LGG	cis	1	rs13209728	chr6:162997533	PACRG	chr6:163148164-163736523:+	0.3	4.55	6.69E-6	Body mass index	
LGG	cis	1	rs13210412	chr6:163019478	PACRG	chr6:163148164-163736523:+	0.29	4.41	1.26E-5	Body mass index	
LGG	cis	1	rs13210756	chr6:163009030	PACRG	chr6:163148164-163736523:+	0.29	4.43	1.19E-5	Body mass index	
LGG	cis	1	rs13212608	chr6:163032128	PACRG	chr6:163148164-163736523:+	0.31	4.6	5.35E-6	Body mass index	
LGG	cis	1	rs13213408	chr6:162998049	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs13213582	chr6:151873896	C6orf97	chr6:151815175-151942327:+	0.26	4.18	3.4E-5	Bone mineral density (spine)	
LGG	cis	1	rs13214516	chr6:163121583	PACRG	chr6:163148164-163736523:+	0.43	5.78	1.31E-8	Body mass index	
LGG	cis	1	rs1321479	chr6:26501897	HMGN4	chr6:26538572-26547162:+	0.17	4.52	7.68E-6	Educational attainment	
LGG	cis	1	rs1321480	chr6:26532742	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000448	Educational attainment	
LGG	cis	1	rs1321480	chr6:26532742	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.39E-7	Educational attainment	
LGG	cis	1	rs1321481	chr6:26538210	BTN2A3	chr6:26422317-26431927:+	0.12	3.55	0.000418	Educational attainment	
LGG	cis	1	rs1321481	chr6:26538210	HMGN4	chr6:26538572-26547162:+	-0.2	-5.12	4.37E-7	Educational attainment	
LGG	cis	1	rs13215491	chr6:163010325	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.5	-10.12	5.25E-22	Response to antipsychotic treatment	
LGG	cis	1	rs13218900	chr6:163081638	PACRG	chr6:163148164-163736523:+	0.41	5.46	7.73E-8	Body mass index	
LGG	cis	1	rs13220048	chr6:163004325	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs13220181	chr6:163004401	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs13220495	chr6:26441640	BTN3A2	chr6:26365398-26378546:+	-0.95	-10.73	2.83E-24	Schizophrenia	
LGG	cis	1	rs13220510	chr6:56779141	BEND6	chr6:56819773-56892138:+	-0.31	-5.44	8.61E-8	Menarche (age at onset)	
LGG	cis	1	rs13220510	chr6:56779141	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.81	0.000159	Menarche (age at onset)	
LGG	cis	1	rs13220979	chr7:65363204	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs13222291	chr7:6517440	KDELR2	chr7:6500713-6523849:-	0.13	3.59	0.000368	Irritable bowel syndrome	
LGG	cis	1	rs13224397	chr7:118008745	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs13226728	chr7:143746578	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.61	0.000334	Obesity-related traits	
LGG	cis	1	rs13227433	chr7:74094721	STAG3L2	chr7:74298846-74306731:-	-0.25	-3.69	0.000246	Menarche (age at onset)	
LGG	cis	1	rs1323300	chr20:16053444	SNRPB2	chr20:16710629-16722037:+	-0.24	-3.54	0.000442	Brain connectivity	
LGG	cis	1	rs13235972	chr7:65883605	CCT6P1	chr7:65216092-65228661:+	0.23	4.2	3.12E-5	Diabetic kidney disease	
LGG	cis	1	rs13237037	chr7:65997882	CCT6P1	chr7:65216092-65228661:+	0.23	4.15	3.85E-5	Diabetic kidney disease	
LGG	cis	1	rs13237206	chr7:117999451	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs13238274	chr7:29180335	CPVL	chr7:29035249-29234892:-	-0.22	-3.98	7.81E-5	Diabetes related insulin traits	
LGG	cis	1	rs13239306	chr7:66136017	ASL	chr7:65540776-65558321:+	0.18	4.49	8.94E-6	Aortic root size	
LGG	cis	1	rs13239306	chr7:66136017	TYW1	chr7:66461817-66704496:+	-0.17	-3.63	0.000316	Aortic root size	
LGG	cis	1	rs13243677	chr7:143746572	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.61	0.000334	Obesity-related traits	
LGG	cis	1	rs13244265	chr7:23917903	C7orf46	chr7:23719749-23742268:+	0.2	4.33	1.82E-5	Schizophrenia	
LGG	cis	1	rs13245225	chr7:29181626	CPVL	chr7:29035249-29234892:-	-0.22	-3.93	9.91E-5	Diabetes related insulin traits	
LGG	cis	1	rs13247184	chr7:65358928	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs13248727	chr8:21842063	XPO7	chr8:21777180-21864095:+	0.16	3.72	0.000226	Mean corpuscular volume	
LGG	cis	1	rs1325195	chr1:179071756	ABL2	chr1:179068463-179198819:-	-0.16	-4.32	1.86E-5	IgE grass sensitization	
LGG	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.64	15.57	1.01E-44	Bone mineral density	
LGG	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.64	15.69	2.95E-45	Bone mineral density	
LGG	cis	1	rs13256369	chr8:8577379	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.84	1.73E-6	Obesity-related traits	
LGG	cis	1	rs1326120	chr13:50729244	EBPL	chr13:50234811-50265623:-	-0.17	-3.65	0.000288	Height	
LGG	cis	1	rs13264970	chr8:83073829	FABP4	chr8:82390732-82395473:-	-0.18	-3.51	0.000481	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs13265330	chr8:23525543	NKX3-1	chr8:23536207-23540450:-	0.21	4.37	1.52E-5	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs13266699	chr8:8570313	FLJ10661	chr8:8086092-8102386:+	0.27	4.96	9.53E-7	Obesity-related traits	
LGG	cis	1	rs13267501	chr8:8574058	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.98	8.84E-7	Obesity-related traits	
LGG	cis	1	rs13267884	chr8:23531987	NKX3-1	chr8:23536207-23540450:-	0.2	3.92	0.0001	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs13271368	chr8:126506140	TRIB1	chr8:126442563-126450642:+	-0.22	-4.14	4.09E-5	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs13271966	chr8:8575472	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.02	7.1E-7	Obesity-related traits	
LGG	cis	1	rs13272392	chr8:23528511	NKX3-1	chr8:23536207-23540450:-	0.21	4.2	3.12E-5	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs13276082	chr8:21823184	XPO7	chr8:21777180-21864095:+	0.16	3.52	0.00047	Mean corpuscular volume	
LGG	cis	1	rs13282915	chr8:8570891	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.09	5.06E-7	Obesity-related traits	
LGG	cis	1	rs13284407	chr9:95888521	NINJ1	chr9:95883772-95896570:-	-0.26	-4.62	4.82E-6	Obesity (early onset extreme)	
LGG	cis	1	rs13298119	chr9:95887154	NINJ1	chr9:95883772-95896570:-	-0.26	-4.59	5.57E-6	Obesity (early onset extreme)	
LGG	cis	1	rs13299270	chr9:95887108	NINJ1	chr9:95883772-95896570:-	-0.26	-4.59	5.57E-6	Obesity (early onset extreme)	
LGG	cis	1	rs13310597	chr7:65598540	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs1331215	chr20:3376565	ITPA	chr20:3190056-3204504:+	-0.36	-8.47	2.81E-16	IFN-related cytopenia	
LGG	cis	1	rs13314659	chr3:48449149	ATRIP	chr3:48488141-48507708:+	-0.17	-4.29	2.17E-5	Longevity	
LGG	cis	1	rs13314659	chr3:48449149	TREX1	chr3:48501186-48509043:+	0.42	10.94	4.29E-25	Longevity	
LGG	cis	1	rs13314673	chr3:101661383	LOC285359	chr3:101431278-101432259:+	-0.2	-4.41	1.26E-5	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs13314993	chr3:33015469	CCR4	chr3:32993066-32996403:+	-0.15	-3.63	0.000318	Celiac disease	
LGG	cis	1	rs13316695	chr3:49684917	MST1R	chr3:49924438-49941306:-	-0.2	-3.84	0.000139	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13316695	chr3:49684917	RBM6	chr3:49977592-50137484:+	0.16	4.52	7.65E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13316695	chr3:49684917	SEMA3F	chr3:50192848-50226507:+	0.2	4.48	9.11E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs13317089	chr3:186436217	KNG1	chr3:186435120-186461741:+	-0.15	-3.51	0.000489	Adiponectin levels	
LGG	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs13322305	chr3:134310791	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs13322887	chr3:49555583	AMIGO3	chr3:49754268-49757238:-	0.2	4.53	7.36E-6	Menarche (age at onset)	
LGG	cis	1	rs13322887	chr3:49555583	GMPPB	chr3:49758932-49761384:-	0.23	4.51	8.15E-6	Menarche (age at onset)	
LGG	cis	1	rs13323323	chr3:44333324	KIAA1143	chr3:44790239-44803173:-	-0.2	-3.86	0.000128	IgG glycosylation	
LGG	cis	1	rs13323787	chr3:128602135	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs13324903	chr3:195086647	ACAP2	chr3:194995475-195163817:-	0.37	8.73	4.05E-17	Body mass index	
LGG	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.76	13.97	1.4E-37	Diastolic blood pressure	
LGG	cis	1	rs13331733	chr16:29848417	LOC440356	chr16:29875004-29879374:+	-0.23	-3.87	0.000122	Multiple sclerosis	
LGG	cis	1	rs13332078	chr16:29850705	LOC440356	chr16:29875004-29879374:+	-0.24	-3.98	7.92E-5	Multiple sclerosis	
LGG	cis	1	rs13338688	chr16:67248831	CES2	chr16:66968347-66978992:+	-0.35	-3.61	0.000342	HDL cholesterol	
LGG	cis	1	rs13339262	chr16:50091383	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs1333963	chr6:163192571	PACRG	chr6:163148164-163736523:+	0.39	5.37	1.25E-7	Body mass index	
LGG	cis	1	rs13342397	chr17:17460926	ATPAF2	chr17:17918373-17942480:-	-0.25	-3.47	0.000561	Obsessive-compulsive symptoms	
LGG	cis	1	rs13357258	chr5:115444166	COMMD10	chr5:115420727-115628978:+	0.46	5.88	7.68E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs13359107	chr5:110458812	TSLP	chr5:110405778-110413722:+	-0.29	-4.2	3.17E-5	Eosinophil counts	
LGG	cis	1	rs13361189	chr5:150223387	LOC134466	chr5:150310000-150326146:-	0.37	4.29	2.11E-5	Crohn's disease	
LGG	cis	1	rs13362043	chr5:115596262	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.5	-10.28	1.45E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.5	-10.2	2.69E-22	Response to antipsychotic treatment	
LGG	cis	1	rs13380863	chr17:61780793	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.00027	Body mass index	
LGG	cis	1	rs13380863	chr17:61780793	FTSJ3	chr17:61896795-61905031:-	0.42	8.47	2.96E-16	Body mass index	
LGG	cis	1	rs13380863	chr17:61780793	SMARCD2	chr17:61909441-61920351:-	0.17	3.8	0.000161	Body mass index	
LGG	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.39	6.97	1.05E-11	Metabolite levels	
LGG	cis	1	rs13383871	chr2:73631779	NAT8	chr2:73867850-73869537:-	0.25	4.11	4.57E-5	Metabolite levels	
LGG	cis	1	rs13385191	chr2:20888265	C2orf43	chr2:20883803-21022827:-	-0.76	-15.44	4.19E-44	Prostate cancer	
LGG	cis	1	rs13387221	chr2:44135314	LRPPRC	chr2:44113363-44223144:-	-0.19	-4.31	1.95E-5	Intelligence (childhood)	
LGG	cis	1	rs13390389	chr2:188112487	CALCRL	chr2:188207851-188313021:-	-0.21	-5.03	6.78E-7	Coronary heart disease	
LGG	cis	1	rs13390577	chr2:113860310	RABL2A	chr2:114384817-114400974:+	0.2	3.46	0.000597	Stroke	
LGG	cis	1	rs13391356	chr2:234170369	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.14	4.09E-5	Crohn's disease	
LGG	cis	1	rs1339494	chr1:150001470	RPRD2	chr1:150336990-150449039:+	-0.15	-3.71	0.00023	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs1339495	chr1:150001233	RPRD2	chr1:150336990-150449039:+	-0.15	-3.7	0.00024	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.79	10.91	5.7E-25	Rheumatoid arthritis	
LGG	cis	1	rs13398122	chr2:206835414	MDH1B	chr2:207598943-207630050:-	0.16	3.72	0.000225	Obesity (extreme)	
LGG	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.4	7.19	2.37E-12	Metabolite levels	
LGG	cis	1	rs13398956	chr2:73720258	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.59E-5	Metabolite levels	
LGG	cis	1	rs13404250	chr2:188116196	CALCRL	chr2:188207851-188313021:-	-0.21	-5.03	6.78E-7	Coronary heart disease	
LGG	cis	1	rs13406085	chr2:113861561	RABL2A	chr2:114384817-114400974:+	0.2	3.46	0.000597	Stroke	
LGG	cis	1	rs13408294	chr2:202171573	ALS2CR12	chr2:202153148-202222101:-	0.28	3.5	0.000512	Rheumatoid arthritis	
LGG	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.8	-11.89	7.73E-29	Rheumatoid arthritis	
LGG	cis	1	rs13408569	chr2:102955056	IL18R1	chr2:102927962-103015215:+	-0.5	-6.82	2.69E-11	Asthma	
LGG	cis	1	rs13408569	chr2:102955056	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.92	0.000101	Asthma	
LGG	cis	1	rs13408661	chr2:102955082	IL18R1	chr2:102927962-103015215:+	-0.49	-6.7	5.59E-11	Asthma	
LGG	cis	1	rs13408661	chr2:102955082	IL1RL1	chr2:102927962-102968497:+	-0.31	-3.81	0.000159	Asthma	
LGG	cis	1	rs13409250	chr2:37463642	CEBPZ	chr2:37428778-37458740:-	-0.19	-5.02	7.22E-7	Chronic lymphocytic leukemia	
LGG	cis	1	rs13409829	chr2:188182661	CALCRL	chr2:188207851-188313021:-	-0.21	-5.17	3.35E-7	Coronary heart disease	
LGG	cis	1	rs13410552	chr2:113855406	RABL2A	chr2:114384817-114400974:+	0.2	3.46	0.000597	Stroke	
LGG	cis	1	rs13411741	chr2:127666335	PROC	chr2:128176017-128186816:+	0.37	3.47	0.000561	Heart failure	
LGG	cis	1	rs13413635	chr2:178680431	PDE11A	chr2:178487979-178973066:-	0.18	4.38	1.45E-5	Heart rate	
LGG	cis	1	rs13415839	chr2:232126534	HTR2B	chr2:231972952-231989824:-	0.42	6.75	4.1E-11	Food antigen IgG levels	
LGG	cis	1	rs1341759	chr6:26195502	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs1341759	chr6:26195502	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs13418561	chr2:188150214	CALCRL	chr2:188207851-188313021:-	-0.21	-5.14	3.98E-7	Coronary heart disease	
LGG	cis	1	rs13419073	chr2:97507554	FAM178B	chr2:97541620-97652301:-	-0.15	-3.68	0.000261	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs13421166	chr2:166903756	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs13421166	chr2:166903756	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.39	7.07	5.32E-12	Metabolite levels	
LGG	cis	1	rs13421462	chr2:73719875	NAT8	chr2:73867850-73869537:-	0.25	4.13	4.27E-5	Metabolite levels	
LGG	cis	1	rs13424612	chr2:240900121	NDUFA10	chr2:240900158-240964798:-	0.42	8.06	6.05E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs13427277	chr2:188075497	CALCRL	chr2:188207851-188313021:-	-0.21	-4.94	1.08E-6	Coronary heart disease	
LGG	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.39	7.04	6.54E-12	Metabolite levels	
LGG	cis	1	rs13428235	chr2:73633430	NAT8	chr2:73867850-73869537:-	0.25	4.15	3.97E-5	Metabolite levels	
LGG	cis	1	rs13430665	chr2:188229007	CALCRL	chr2:188207851-188313021:-	-0.22	-5.26	2.13E-7	Coronary heart disease	
LGG	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.41	7.22	1.97E-12	Metabolite levels	
LGG	cis	1	rs13431267	chr2:73782200	NAT8	chr2:73867850-73869537:-	0.26	4.29	2.15E-5	Metabolite levels	
LGG	cis	1	rs13431828	chr2:102954653	IL18R1	chr2:102927962-103015215:+	-0.5	-6.82	2.69E-11	Asthma	
LGG	cis	1	rs13431828	chr2:102954653	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.92	0.000101	Asthma	
LGG	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.39	6.79	3.21E-11	Metabolite levels	
LGG	cis	1	rs13432605	chr2:73810981	NAT8	chr2:73867850-73869537:-	0.26	4.15	3.95E-5	Metabolite levels	
LGG	cis	1	rs13434201	chr3:128609255	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs13435802	chr4:120177960	MYOZ2	chr4:120056939-120108935:+	-0.23	-4.37	1.54E-5	Corneal astigmatism	
LGG	cis	1	rs13438712	chr7:105542580	CDHR3	chr7:105517264-105676876:+	0.22	5.05	6.35E-7	Obesity-related traits	
LGG	cis	1	rs1344513	chr12:109090581	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs1344682	chr12:89852377	GALNT4	chr12:89913192-89919777:-	-0.16	-4.33	1.79E-5	Schizophrenia	
LGG	cis	1	rs1344682	chr12:89852377	POC1B	chr12:89813501-89919777:-	-0.17	-3.65	0.000287	Schizophrenia	
LGG	cis	1	rs134869	chr22:42652074	C22orf32	chr22:42475699-42480287:+	0.17	4.72	3.07E-6	Cognitive function	
LGG	cis	1	rs134869	chr22:42652074	CYP2D6	chr22:42522502-42526883:-	-0.26	-7.67	9.09E-14	Cognitive function	
LGG	cis	1	rs134869	chr22:42652074	LOC339674	chr22:42120359-42354945:+	0.13	3.9	0.00011	Cognitive function	
LGG	cis	1	rs134869	chr22:42652074	NAGA	chr22:42454339-42466846:-	0.09	3.6	0.000351	Cognitive function	
LGG	cis	1	rs134873	chr22:42657566	C22orf32	chr22:42475699-42480287:+	0.16	4.4	1.35E-5	Cognitive function	
LGG	cis	1	rs134873	chr22:42657566	CYP2D6	chr22:42522502-42526883:-	-0.26	-7.96	1.17E-14	Cognitive function	
LGG	cis	1	rs134873	chr22:42657566	LOC339674	chr22:42120359-42354945:+	0.12	3.85	0.000135	Cognitive function	
LGG	cis	1	rs134873	chr22:42657566	WBP2NL	chr22:42120334-42454460:+	0.19	3.59	0.000368	Cognitive function	
LGG	cis	1	rs134882	chr22:42670965	C22orf32	chr22:42475699-42480287:+	0.14	3.95	8.95E-5	Cognitive function	
LGG	cis	1	rs134882	chr22:42670965	CYP2D6	chr22:42522502-42526883:-	-0.26	-8.06	5.98E-15	Cognitive function	
LGG	cis	1	rs134882	chr22:42670965	LOC339674	chr22:42120359-42354945:+	0.12	3.73	0.000216	Cognitive function	
LGG	cis	1	rs134882	chr22:42670965	WBP2NL	chr22:42120334-42454460:+	0.18	3.49	0.000528	Cognitive function	
LGG	cis	1	rs134900	chr22:42683343	C22orf32	chr22:42475699-42480287:+	0.15	4.21	3.07E-5	Cognitive function	
LGG	cis	1	rs134900	chr22:42683343	CYP2D6	chr22:42522502-42526883:-	-0.28	-8.84	1.73E-17	Cognitive function	
LGG	cis	1	rs134900	chr22:42683343	LOC339674	chr22:42120359-42354945:+	0.12	3.86	0.000127	Cognitive function	
LGG	cis	1	rs134900	chr22:42683343	NAGA	chr22:42454339-42466846:-	0.1	3.91	0.000106	Cognitive function	
LGG	cis	1	rs134900	chr22:42683343	WBP2NL	chr22:42120334-42454460:+	0.2	3.96	8.56E-5	Cognitive function	
LGG	cis	1	rs134902	chr22:42683997	C22orf32	chr22:42475699-42480287:+	0.14	4.04	6.15E-5	Cognitive function	
LGG	cis	1	rs134902	chr22:42683997	CYP2D6	chr22:42522502-42526883:-	-0.28	-8.68	6.06E-17	Cognitive function	
LGG	cis	1	rs134902	chr22:42683997	LOC339674	chr22:42120359-42354945:+	0.13	3.95	8.89E-5	Cognitive function	
LGG	cis	1	rs134902	chr22:42683997	NAGA	chr22:42454339-42466846:-	0.1	3.89	0.000116	Cognitive function	
LGG	cis	1	rs134902	chr22:42683997	WBP2NL	chr22:42120334-42454460:+	0.2	3.86	0.000129	Cognitive function	
LGG	cis	1	rs1351452	chr11:116943354	SIDT2	chr11:117049939-117068161:+	-0.3	-3.51	0.000495	Protein quantitative trait loci	
LGG	cis	1	rs1353027	chr12:89871180	GALNT4	chr12:89913192-89919777:-	-0.16	-4.34	1.69E-5	Schizophrenia	
LGG	cis	1	rs1353027	chr12:89871180	POC1B	chr12:89813501-89919777:-	-0.17	-3.54	0.000431	Schizophrenia	
LGG	cis	1	rs1354264	chr7:25615221	SNX10	chr7:26331515-26413937:+	-0.23	-3.67	0.000264	Preeclampsia	
LGG	cis	1	rs1355221	chr11:34758609	APIP	chr11:34896714-34937939:-	0.19	4.25	2.6E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1355222	chr11:34758716	APIP	chr11:34896714-34937939:-	0.17	3.79	0.000167	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1355223	chr11:34764479	APIP	chr11:34896714-34937939:-	0.18	4.02	6.65E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.29	7.76	4.83E-14	Height	
LGG	cis	1	rs1357762	chr3:134264859	CEP63	chr3:134204575-134293852:+	0.2	3.65	0.000295	Height	
LGG	cis	1	rs1359781	chr6:33762104	LEMD2	chr6:33738991-33756906:-	-0.14	-4.63	4.67E-6	Crohn's disease	
LGG	cis	1	rs1362370	chr7:33276017	BBS9	chr7:33169152-33645680:+	0.43	5.81	1.12E-8	Smooth-surface caries	
LGG	cis	1	rs1363055	chr7:65943275	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs1363481	chr5:115541820	COMMD10	chr5:115420727-115628978:+	0.19	3.63	0.000312	Metabolite levels  (X-11787)	
LGG	cis	1	rs1370964	chr5:110429955	TSLP	chr5:110405778-110413722:+	-0.32	-4.67	3.89E-6	Eosinophil counts	
LGG	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.51	-9.95	2.2E-21	Type 2 diabetes	
LGG	cis	1	rs137115	chr22:43011403	SERHL2	chr22:42949925-42970387:+	0.25	3.88	0.000117	Parental extreme longevity (95 years and older)	
LGG	cis	1	rs137115	chr22:43011403	SERHL	chr22:42896585-42968535:+	0.28	3.69	0.00025	Parental extreme longevity (95 years and older)	
LGG	cis	1	rs1371553	chr2:26262948	GPR113	chr2:26531041-26569685:-	-0.24	-3.85	0.000135	Gut microbiome composition (summer)	
LGG	cis	1	rs1373270	chr11:120324080	TMEM136	chr11:120196016-120204388:+	0.21	4.79	2.21E-6	Intraocular pressure	
LGG	cis	1	rs1374469	chr4:1724799	TMEM129	chr4:1717680-1723084:-	-0.18	-3.81	0.000159	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs1379299	chr5:110435661	TSLP	chr5:110405778-110413722:+	-0.32	-4.56	6.38E-6	Eosinophil counts	
LGG	cis	1	rs138022915	chr8:19885934	LPL	chr8:19796582-19824769:+	-0.33	-3.5	0.000515	Gut microbiota (beta diversity)	
LGG	cis	1	rs138118	chr22:44264502	TTLL1	chr22:43435524-43485434:-	0.21	3.88	0.000118	Type 2 diabetes (dietary heme iron intake interaction)	
LGG	cis	1	rs1382339	chr5:115558163	COMMD10	chr5:115420727-115628978:+	0.48	5.98	4.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1382340	chr5:115558161	COMMD10	chr5:115420727-115628978:+	0.48	5.98	4.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1383251	chr3:51366840	HEMK1	chr3:50606583-50622419:+	0.22	3.77	0.000181	Melanoma	
LGG	cis	1	rs138544659	chr15:78900701	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.43	3.02E-35	Post bronchodilator FEV1;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs138573550	chr3:127840025	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1	
LGG	cis	1	rs1385884	chr3:113841625	KIAA1407	chr3:113682986-113775460:-	-0.14	-3.93	9.83E-5	Personality dimensions	
LGG	cis	1	rs1386478	chr3:113680951	KIAA1407	chr3:113682986-113775460:-	0.16	4.22	2.95E-5	Crohn's disease and psoriasis	
LGG	cis	1	rs138702	chr22:39132601	LOC646851	chr22:38974125-39052634:-	-0.24	-7.56	2.02E-13	Resting heart rate	
LGG	cis	1	rs138704	chr22:39133410	LOC646851	chr22:38974125-39052634:-	0.25	7.72	6.56E-14	Resting heart rate	
LGG	cis	1	rs138705	chr22:39133803	LOC646851	chr22:38974125-39052634:-	0.24	7.29	1.27E-12	Resting heart rate	
LGG	cis	1	rs138706	chr22:39137834	LOC646851	chr22:38974125-39052634:-	0.26	7.85	2.56E-14	Resting heart rate	
LGG	cis	1	rs138709	chr22:39139216	LOC646851	chr22:38974125-39052634:-	0.27	8	8.76E-15	Resting heart rate	
LGG	cis	1	rs138712	chr22:39141600	LOC646851	chr22:38974125-39052634:-	0.25	7.63	1.27E-13	Resting heart rate	
LGG	cis	1	rs138713	chr22:39142615	LOC646851	chr22:38974125-39052634:-	0.27	8.02	7.73E-15	Resting heart rate	
LGG	cis	1	rs138716	chr22:39146527	LOC646851	chr22:38974125-39052634:-	0.24	7.17	2.82E-12	Resting heart rate	
LGG	cis	1	rs1388527	chr11:6948441	ZNF215	chr11:6947654-7005861:+	-0.22	-4.18	3.51E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs1390411	chr8:58194146	C8orf71	chr8:58192102-58197288:+	0.35	6.07	2.55E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs139148	chr22:44594033	PRR5	chr22:45064593-45133561:+	0.24	3.91	0.000105	Survival in colon cancer	
LGG	cis	1	rs139149	chr22:44594135	PRR5	chr22:45064593-45133561:+	-0.25	-3.99	7.5E-5	Survival in colon cancer	
LGG	cis	1	rs139156	chr22:44596085	PRR5	chr22:45064593-45133561:+	-0.25	-3.81	0.000154	Survival in colon cancer	
LGG	cis	1	rs139157	chr22:44596207	PRR5	chr22:45064593-45133561:+	0.25	4	7.45E-5	Survival in colon cancer	
LGG	cis	1	rs1392104	chr7:65759107	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.29	2.12E-5	Diabetic kidney disease	
LGG	cis	1	rs13943	chr22:22116202	CCDC116	chr22:21987086-21991615:+	0.17	3.58	0.00038	Multiple sclerosis	
LGG	cis	1	rs1395297	chr15:50878509	SPPL2A	chr15:50999739-51057910:-	-0.12	-4.08	5.35E-5	QT interval	
LGG	cis	1	rs1395	chr2:27424636	SLC5A6	chr2:27422459-27435071:-	0.3	6.22	1.05E-9	Blood metabolite levels	
LGG	cis	1	rs1396879	chr11:34766653	APIP	chr11:34896714-34937939:-	0.17	3.78	0.000179	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1396883	chr11:34757447	APIP	chr11:34896714-34937939:-	0.2	4.45	1.04E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs1398057	chr2:188217500	CALCRL	chr2:188207851-188313021:-	-0.21	-5.1	4.79E-7	Coronary heart disease	
LGG	cis	1	rs1398676	chr12:26459420	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.31	2.02E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs1399715	chr3:108858490	MORC1	chr3:108677089-108836993:-	-0.39	-7	8.67E-12	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs1401419	chr11:45879739	DKFZp779M0652	chr11:45792983-45793908:+	-0.14	-3.99	7.65E-5	Fasting glucose-related traits (interaction with BMI);Fasting glucose-related traits	
LGG	cis	1	rs1401999	chr3:183678342	ABCC5	chr3:183637726-183735727:-	0.11	3.53	0.000456	Anterior chamber depth	
LGG	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.39	-7.06	5.9E-12	Metabolite levels	
LGG	cis	1	rs1403284	chr2:73726662	NAT8	chr2:73867850-73869537:-	-0.26	-4.33	1.84E-5	Metabolite levels	
LGG	cis	1	rs140330585	chr15:78866445	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.56	7.97E-36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1403491	chr8:133922970	TG	chr8:133879205-134147141:+	-0.22	-3.96	8.47E-5	Vitiligo	
LGG	cis	1	rs1404147	chr7:65264524	CCT6P1	chr7:65216092-65228661:+	0.26	5.14	4.03E-7	Diabetic kidney disease	
LGG	cis	1	rs1406947	chr20:33969530	CPNE1	chr20:34213968-34262539:-	0.25	5.44	8.44E-8	Height	
LGG	cis	1	rs1406947	chr20:33969530	GDF5	chr20:33897002-34042568:-	-0.36	-7.1	4.31E-12	Height	
LGG	cis	1	rs1406947	chr20:33969530	UQCC	chr20:33890383-33999833:-	0.23	5.06	5.79E-7	Height	
LGG	cis	1	rs1408916	chr1:92992627	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs1412444	chr10:91002927	LIPA	chr10:90973328-91174382:-	0.18	5.15	3.76E-7	Fibrinogen levels	
LGG	cis	1	rs1412445	chr10:91002804	LIPA	chr10:90973328-91174382:-	0.2	5.5	6.08E-8	Fibrinogen levels	
LGG	cis	1	rs141518190	chr15:78900647	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.43	3.02E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.5	-10.05	1.0E-21	Response to antipsychotic treatment	
LGG	cis	1	rs1417804	chr1:159003983	IFI16	chr1:158969758-159024943:+	-0.17	-3.8	0.000165	Obesity-related traits	
LGG	cis	1	rs1417823	chr10:102227886	NDUFB8	chr10:102283497-102289636:-	-0.13	-3.9	0.000108	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1417823	chr10:102227886	WNT8B	chr10:102222812-102243397:+	-0.5	-8.64	8.16E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs14178	chr16:67969531	LRRC36	chr16:67360747-67419108:+	0.48	4.46	1.0E-5	Crohn's disease	
LGG	cis	1	rs14178	chr16:67969531	RANBP10	chr16:67757006-67840555:-	-0.31	-3.68	0.000263	Crohn's disease	
LGG	cis	1	rs14178	chr16:67969531	TSNAXIP1	chr16:67840977-67861970:+	0.25	3.51	0.000489	Crohn's disease	
LGG	cis	1	rs1419183	chr6:28242794	ZNF165	chr6:28046572-28057338:+	-0.32	-4.71	3.24E-6	Depression	
LGG	cis	1	rs1419183	chr6:28242794	ZNF187	chr6:28234788-28245978:+	-0.26	-4.52	7.75E-6	Depression	
LGG	cis	1	rs1419183	chr6:28242794	ZNF389	chr6:28129551-28137375:+	0.43	6.84	2.41E-11	Depression	
LGG	cis	1	rs1419183	chr6:28242794	ZSCAN12	chr6:28346770-28367544:-	-0.33	-4.67	3.91E-6	Depression	
LGG	cis	1	rs1419183	chr6:28242794	ZSCAN23	chr6:28393287-28411279:-	0.18	4.31	2.01E-5	Depression	
LGG	cis	1	rs1420101	chr2:102957716	IL18R1	chr2:102927962-103015215:+	-0.35	-6.79	3.2E-11	Serum protein levels (sST2)	
LGG	cis	1	rs1420101	chr2:102957716	IL1RL1	chr2:102927962-102968497:+	-0.38	-6.6	1.09E-10	Serum protein levels (sST2)	
LGG	cis	1	rs1420106	chr2:103035044	IL18R1	chr2:102927962-103015215:+	0.36	5.7	2.12E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1420106	chr2:103035044	IL1RL1	chr2:102927962-102968497:+	0.34	4.76	2.53E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1422500	chr5:115569312	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.29E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.82	15.76	1.33E-45	Type 2 diabetes	
LGG	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.8	15.35	1.04E-43	Type 2 diabetes	
LGG	cis	1	rs1423621	chr5:56101035	MIER3	chr5:56215429-56267501:-	0.16	3.53	0.000448	Type 2 diabetes	
LGG	cis	1	rs142463603	chr8:23507262	NKX3-1	chr8:23536207-23540450:-	0.21	4.13	4.19E-5	Prostate cancer	
LGG	cis	1	rs1427652	chr2:166907344	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1427652	chr2:166907344	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1428551	chr5:150259832	LOC134466	chr5:150310000-150326146:-	0.4	4.57	6.25E-6	Crohn's disease	
LGG	cis	1	rs1428552	chr5:150259831	LOC134466	chr5:150310000-150326146:-	0.39	4.55	6.89E-6	Crohn's disease	
LGG	cis	1	rs1428554	chr5:150257616	LOC134466	chr5:150310000-150326146:-	0.42	4.84	1.75E-6	Crohn's disease	
LGG	cis	1	rs1428555	chr5:150257391	LOC134466	chr5:150310000-150326146:-	-0.37	-4.26	2.46E-5	Crohn's disease	
LGG	cis	1	rs142958719	chr5:131232959	P4HA2	chr5:131528306-131563556:-	-0.16	-3.55	0.000426	Alzheimer's disease in APOE e4- carriers	
LGG	cis	1	rs142958719	chr5:131232959	SLC22A5	chr5:131705401-131731302:+	-0.29	-4.98	8.63E-7	Alzheimer's disease in APOE e4- carriers	
LGG	cis	1	rs1432056	chr11:83285438	CCDC90B	chr11:82972506-82997414:-	0.24	5.63	3.03E-8	Subcortical brain region volumes	
LGG	cis	1	rs1436904	chr18:24570667	C18orf16	chr18:24445272-24770650:+	0.21	4.84	1.71E-6	Breast cancer	
LGG	cis	1	rs1440372	chr15:67033151	SMAD6	chr15:66994674-67074335:+	-0.2	-3.69	0.00025	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs144098432	chr18:51816394	POLI	chr18:51795849-51824602:+	0.24	5.48	6.93E-8	Inflammatory skin disease	
LGG	cis	1	rs1443438	chr9:100550028	C9orf156	chr9:100666772-100684852:-	0.18	3.73	0.00021	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs144495862	chr7:48233391	ABCA13	chr7:48211057-48687091:+	0.25	4.41	1.25E-5	Cerebrospinal fluid clusterin levels	
LGG	cis	1	rs14451	chr1:202304868	UBE2T	chr1:202300786-202311094:-	0.12	3.74	0.000209	Sex ratio	
LGG	cis	1	rs1446682	chr8:27076598	STMN4	chr8:27093816-27115903:-	-0.16	-3.94	9.29E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs1451374	chr7:50622653	FIGNL1	chr7:50511834-50518088:-	-0.22	-5.28	1.91E-7	Malaria	
LGG	cis	1	rs1451375	chr7:50622712	FIGNL1	chr7:50511834-50518088:-	0.2	4.76	2.58E-6	Malaria	
LGG	cis	1	rs1451707	chr6:56801877	BEND6	chr6:56819773-56892138:+	-0.34	-5.96	4.95E-9	Menarche (age at onset)	
LGG	cis	1	rs1451707	chr6:56801877	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.02	6.85E-5	Menarche (age at onset)	
LGG	cis	1	rs1451708	chr6:56802201	BEND6	chr6:56819773-56892138:+	-0.34	-5.96	4.95E-9	Menarche (age at onset)	
LGG	cis	1	rs1451708	chr6:56802201	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.02	6.85E-5	Menarche (age at onset)	
LGG	cis	1	rs1452408	chr15:90891117	IQGAP1	chr15:90931473-91045475:+	0.12	3.83	0.000142	Rheumatoid arthritis	
LGG	cis	1	rs145241704	chr7:141505087	TAS2R4	chr7:141478289-141479188:+	0.44	3.97	8.13E-5	Anorexia nervosa	
LGG	cis	1	rs1453160	chr2:207877465	ADAM23	chr2:207308368-207482677:+	-0.22	-4.57	6.22E-6	Subcutaneous adipose tissue	
LGG	cis	1	rs1453560	chr17:38023441	GSDMB	chr17:38060850-38074903:-	-0.22	-3.53	0.00046	Systemic lupus erythematosus	
LGG	cis	1	rs1454499	chr2:70062939	SNRNP27	chr2:70121090-70132348:+	-0.19	-3.77	0.000184	Colorectal or endometrial cancer	
LGG	cis	1	rs1459242	chr3:48413537	ATRIP	chr3:48488141-48507708:+	-0.19	-4.82	1.89E-6	Longevity	
LGG	cis	1	rs1459242	chr3:48413537	TREX1	chr3:48501186-48509043:+	0.38	9.48	1.12E-19	Longevity	
LGG	cis	1	rs146009840	chr15:78906177	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.25	1.79E-34	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1460561	chr6:56797574	BEND6	chr6:56819773-56892138:+	-0.29	-4.92	1.18E-6	Menarche (age at onset)	
LGG	cis	1	rs1460561	chr6:56797574	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.46	0.000595	Menarche (age at onset)	
LGG	cis	1	rs1461193	chr2:166904346	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1461193	chr2:166904346	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1463679	chr12:26470169	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.21	3.01E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs1464569	chr3:49460350	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.18	3.44E-5	Menarche (age at onset)	
LGG	cis	1	rs1464569	chr3:49460350	GMPPB	chr3:49758932-49761384:-	-0.22	-4.4	1.33E-5	Menarche (age at onset)	
LGG	cis	1	rs1464569	chr3:49460350	NCKIPSD	chr3:48711280-48723334:-	0.15	3.58	0.000384	Menarche (age at onset)	
LGG	cis	1	rs1464569	chr3:49460350	TREX1	chr3:48501186-48509043:+	-0.26	-5.45	7.93E-8	Menarche (age at onset)	
LGG	cis	1	rs1465321	chr2:102986618	IL18R1	chr2:102927962-103015215:+	-0.36	-5.68	2.26E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1465321	chr2:102986618	IL1RL1	chr2:102927962-102968497:+	-0.35	-4.93	1.12E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1465880	chr2:240932326	NDUFA10	chr2:240900158-240964798:-	0.43	8.17	2.59E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs1466211	chr2:108856412	SULT1C2	chr2:108905095-108926370:+	0.62	9.83	6.16E-21	Blood pressure	
LGG	cis	1	rs1466211	chr2:108856412	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.07	5.46E-5	Blood pressure	
LGG	cis	1	rs1466212	chr2:108856532	SULT1C2	chr2:108905095-108926370:+	0.62	9.81	7.31E-21	Blood pressure	
LGG	cis	1	rs1466212	chr2:108856532	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.1	4.75E-5	Blood pressure	
LGG	cis	1	rs1466213	chr2:108856607	SULT1C2	chr2:108905095-108926370:+	0.6	9.51	8.85E-20	Blood pressure	
LGG	cis	1	rs1466213	chr2:108856607	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.13	4.33E-5	Blood pressure	
LGG	cis	1	rs1466788	chr1:110618730	ALX3	chr1:110602998-110613322:-	-0.28	-6.29	7.05E-10	Blood metabolite levels	
LGG	cis	1	rs1466788	chr1:110618730	FAM40A	chr1:110574199-110597424:+	0.12	4.32	1.92E-5	Blood metabolite levels	
LGG	cis	1	rs1468791	chr2:103092021	IL18R1	chr2:102927962-103015215:+	-0.39	-6.16	1.55E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1468791	chr2:103092021	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.38	1.17E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1469712	chr19:19528821	GMIP	chr19:19740286-19754455:-	0.13	3.83	0.000143	Schizophrenia	
LGG	cis	1	rs1469712	chr19:19528821	TSSK6	chr19:19623230-19626469:-	0.2	4.34	1.74E-5	Schizophrenia	
LGG	cis	1	rs1470097	chr2:26312840	GPR113	chr2:26531041-26569685:-	-0.24	-3.87	0.000123	Gut microbiome composition (summer)	
LGG	cis	1	rs147144681	chr15:78900908	CHRNA5	chr15:78857906-78886458:+	-0.67	-13.21	2.6E-34	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1472750	chr10:115235114	C10orf118	chr10:115881974-115934364:-	-0.2	-4.38	1.42E-5	Migraine without aura	
LGG	cis	1	rs1472750	chr10:115235114	DCLRE1A	chr10:115594484-115613859:-	-0.26	-4.49	8.88E-6	Migraine without aura	
LGG	cis	1	rs1472750	chr10:115235114	NHLRC2	chr10:115614420-115668452:+	-0.18	-3.82	0.000148	Migraine without aura	
LGG	cis	1	rs1473248	chr19:41923314	ATP5SL	chr19:41937224-41945810:-	-0.19	-5.29	1.89E-7	Height	
LGG	cis	1	rs1473857	chr3:101635645	CEP97	chr3:101443494-101486181:+	0.11	3.48	0.000542	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs1473857	chr3:101635645	LOC285359	chr3:101431278-101432259:+	-0.22	-4.82	1.9E-6	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs1474723	chr6:99780492	COQ3	chr6:99817349-99842082:-	-0.28	-3.74	0.000207	Illicit drug use	
LGG	cis	1	rs147499554	chr15:78900650	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.43	3.02E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1475911	chr21:43513480	C21orf128	chr21:43522244-43528644:-	0.57	11.27	2.36E-26	IgG glycosylation	
LGG	cis	1	rs1480354	chr3:51364458	HEMK1	chr3:50606583-50622419:+	0.22	3.75	0.000198	Melanoma	
LGG	cis	1	rs1481824	chr4:54241402	RPL21P44	chr4:54851668-54853449:-	0.21	3.58	0.000372	DNA methylation (variation)	
LGG	cis	1	rs1484994	chr20:30305975	COX4I2	chr20:30225691-30232800:+	0.19	4.39	1.37E-5	Subcortical brain region volumes	
LGG	cis	1	rs1484994	chr20:30305975	DUSP15	chr20:30435441-30458479:-	0.17	4.23	2.79E-5	Subcortical brain region volumes	
LGG	cis	1	rs1484994	chr20:30305975	FRG1B	chr20:29611879-29653908:+	0.21	3.87	0.000125	Subcortical brain region volumes	
LGG	cis	1	rs1486012	chr3:113839422	KIAA1407	chr3:113682986-113775460:-	0.14	3.92	0.000101	Personality dimensions	
LGG	cis	1	rs148734725	chr3:49406708	MST1R	chr3:49924438-49941306:-	-0.22	-4.36	1.56E-5	Educational attainment (college completion)	
LGG	cis	1	rs148734725	chr3:49406708	RBM6	chr3:49977592-50137484:+	0.14	3.96	8.74E-5	Educational attainment (college completion)	
LGG	cis	1	rs148734725	chr3:49406708	SEMA3F	chr3:50192848-50226507:+	0.2	4.66	4.04E-6	Educational attainment (college completion)	
LGG	cis	1	rs1488049	chr12:55427311	ITGA7	chr12:56078356-56106089:-	-0.16	-3.46	0.000578	IgG glycosylation	
LGG	cis	1	rs1492140	chr3:161549965	NMD3	chr3:160939099-160971319:+	-0.15	-3.5	0.000509	IgG1 response to Plasmodium falciparum antigen (GLURP)	
LGG	cis	1	rs1498312	chr1:76177849	MSH4	chr1:76262630-76378923:+	0.23	4.14	4.07E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs1498315	chr1:76159225	MSH4	chr1:76262630-76378923:+	0.23	4.27	2.39E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs1498316	chr1:76159198	MSH4	chr1:76262630-76378923:+	0.26	4.49	9.06E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs1498568	chr15:24594887	PWRN1	chr15:24778839-24832924:+	0.2	3.62	0.000321	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.28	7.37	7.08E-13	Height	
LGG	cis	1	rs1498718	chr3:134205920	CEP63	chr3:134204575-134293852:+	0.19	3.54	0.000442	Height	
LGG	cis	1	rs1499503	chr3:65658302	MAGI1	chr3:65339907-66024509:-	0.14	3.65	0.000291	Age-related hearing impairment (interaction)	
LGG	cis	1	rs1499613	chr7:65730860	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs1499614	chr7:65730798	CCT6P1	chr7:65216092-65228661:+	0.25	4.51	8.18E-6	Diabetic kidney disease	
LGG	cis	1	rs1501550	chr1:211168759	KCNH1	chr1:210851657-211307457:-	-0.21	-3.92	0.000102	Circulating vasoactive peptide levels	
LGG	cis	1	rs1501908	chr5:156398169	TIMD4	chr5:156346293-156390266:-	0.23	4.66	4.07E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs1502006	chr16:55610366	LPCAT2	chr16:55542913-55620581:+	-0.09	-3.58	0.000379	Thyroid hormone levels	
LGG	cis	1	rs1505572	chr1:31864721	ZCCHC17	chr1:31769842-31837780:+	-0.16	-3.94	9.33E-5	Schizophrenia	
LGG	cis	1	rs1507098	chr8:83073160	FABP4	chr8:82390732-82395473:-	0.19	3.72	0.000222	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs150835	chr6:52888138	ICK	chr6:52866098-52926600:-	0.19	3.53	0.000457	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs1509460	chr5:42433819	HMGCS1	chr5:43289494-43313595:-	-0.14	-3.62	0.000328	Systemic lupus erythematosus	
LGG	cis	1	rs1511218	chr2:160906390	LY75	chr2:160625141-160761262:-	0.13	3.68	0.000254	Idiopathic membranous nephropathy	
LGG	cis	1	rs151222	chr16:20674492	ACSM5	chr16:20420856-20452278:+	0.26	4.26	2.47E-5	Schizophrenia	
LGG	cis	1	rs1512268	chr8:23526463	NKX3-1	chr8:23536207-23540450:-	0.22	4.47	9.93E-6	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs151317012	chr4:106806194	GSTCD	chr4:106629941-106768881:+	0.35	3.74	0.000207	Post bronchodilator FEV1	
LGG	cis	1	rs1517700	chr11:114621985	C11orf71	chr11:114262170-114271255:-	0.21	4.41	1.27E-5	Urinary albumin excretion	
LGG	cis	1	rs1519466	chr9:111860797	C9orf5	chr9:111777416-111882225:-	-0.19	-4.12	4.38E-5	Information processing speed	
LGG	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.44	-10.51	1.92E-23	Ankylosing spondylitis	
LGG	cis	1	rs151964	chr5:96123666	ERAP2	chr5:96211644-96255398:+	0.33	5.72	1.89E-8	Ankylosing spondylitis	
LGG	cis	1	rs1520884	chr11:18309700	GTF2H1	chr11:18343816-18388590:+	-0.41	-7.64	1.18E-13	Pancreatic cancer	
LGG	cis	1	rs1520884	chr11:18309700	LDHC	chr11:18433853-18472792:+	-0.22	-4.07	5.56E-5	Pancreatic cancer	
LGG	cis	1	rs1522106	chr4:56307214	TMEM165	chr4:56262090-56292342:+	0.15	4.37	1.52E-5	Personality dimensions	
LGG	cis	1	rs1522108	chr4:56380733	TMEM165	chr4:56262090-56292342:+	-0.17	-4.94	1.08E-6	Personality dimensions	
LGG	cis	1	rs1522110	chr4:56380283	TMEM165	chr4:56262090-56292342:+	-0.17	-5.07	5.56E-7	Personality dimensions	
LGG	cis	1	rs1522111	chr4:56329563	TMEM165	chr4:56262090-56292342:+	-0.17	-4.99	8.22E-7	Personality dimensions	
LGG	cis	1	rs1523435	chr3:186436306	KNG1	chr3:186435120-186461741:+	-0.15	-3.47	0.000574	Adiponectin levels	
LGG	cis	1	rs1524976	chr3:65486388	MAGI1	chr3:65339907-66024509:-	-0.2	-4.02	6.86E-5	PR interval	
LGG	cis	1	rs1527243	chr2:123291022	MKI67IP	chr2:122484522-122494503:-	-0.18	-3.57	0.000394	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs1528229	chr2:188154489	CALCRL	chr2:188207851-188313021:-	0.22	5.36	1.28E-7	Coronary heart disease	
LGG	cis	1	rs1528233	chr2:188207245	CALCRL	chr2:188207851-188313021:-	0.22	5.46	7.6E-8	Coronary heart disease	
LGG	cis	1	rs1528402	chr2:27857517	PPM1G	chr2:27604062-27632496:-	0.14	4.37	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs1528402	chr2:27857517	SNX17	chr2:27593363-27599994:+	-0.12	-3.59	0.000362	Oral cavity cancer	
LGG	cis	1	rs1528404	chr2:27846603	PPM1G	chr2:27604062-27632496:-	-0.13	-4.04	6.1E-5	Oral cavity cancer	
LGG	cis	1	rs1528404	chr2:27846603	SNX17	chr2:27593363-27599994:+	0.11	3.48	0.00055	Oral cavity cancer	
LGG	cis	1	rs1529467	chr5:126728697	FLJ44606	chr5:126381051-126409172:-	0.28	3.78	0.000176	IgG glycosylation	
LGG	cis	1	rs1531378	chr2:166897248	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531378	chr2:166897248	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531379	chr2:166897226	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531379	chr2:166897226	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531380	chr2:166897217	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531380	chr2:166897217	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1531462	chr8:76752790	HNF4G	chr8:76320183-76479059:+	-0.29	-3.57	0.000388	Hippocampal atrophy	
LGG	cis	1	rs1532423	chr8:86268313	LRRCC1	chr8:86019377-86058312:+	0.22	4.75	2.65E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs1533040	chr9:15638364	CER1	chr9:14719734-14722715:-	-0.17	-3.72	0.000225	Body mass index	
LGG	cis	1	rs1533267	chr7:143766440	OR2A9P	chr7:143991573-143997832:+;chr7	-0.17	-3.45	0.0006	Obesity-related traits	
LGG	cis	1	rs1533268	chr7:143766358	OR2A9P	chr7:143991573-143997832:+;chr7	-0.17	-3.45	0.0006	Obesity-related traits	
LGG	cis	1	rs1533825	chr11:214163	PSMD13	chr11:236808-252984:+	0.22	4.67	3.89E-6	Menarche (age at onset)	
LGG	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.6	1.52E-13	Height	
LGG	cis	1	rs1534025	chr3:134313304	CEP63	chr3:134204575-134293852:+	-0.21	-3.8	0.000161	Height	
LGG	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.3	7.81	3.56E-14	Height	
LGG	cis	1	rs1534026	chr3:134284767	CEP63	chr3:134204575-134293852:+	0.2	3.74	0.000209	Height	
LGG	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.4	7.2	2.22E-12	Metabolite levels	
LGG	cis	1	rs1534471	chr2:73647508	NAT8	chr2:73867850-73869537:-	0.28	4.54	6.99E-6	Metabolite levels	
LGG	cis	1	rs1535277	chr6:26567802	BTN2A3	chr6:26422317-26431927:+	0.13	3.65	0.00029	Educational attainment	
LGG	cis	1	rs1535277	chr6:26567802	HMGN4	chr6:26538572-26547162:+	-0.18	-4.6	5.34E-6	Educational attainment	
LGG	cis	1	rs1538767	chr3:195007852	ACAP2	chr3:194995475-195163817:-	-0.35	-8.53	1.85E-16	Body mass index	
LGG	cis	1	rs1540651	chr7:65650121	ASL	chr7:65540776-65558321:+	0.22	5.61	3.39E-8	Aortic root size	
LGG	cis	1	rs1540927	chr20:33931344	CPNE1	chr20:34213968-34262539:-	0.26	5.76	1.45E-8	Height	
LGG	cis	1	rs1540927	chr20:33931344	GDF5	chr20:33897002-34042568:-	-0.37	-7.37	7.24E-13	Height	
LGG	cis	1	rs1540927	chr20:33931344	UQCC	chr20:33890383-33999833:-	0.24	5.23	2.54E-7	Height	
LGG	cis	1	rs1541306	chr11:71708013	FAM86C	chr11:71498557-71512276:+	0.43	4.56	6.36E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1541424	chr7:26557421	KIAA0087	chr7:26572740-26578444:-	0.19	3.61	0.000336	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1545762	chr1:150128425	RPRD2	chr1:150336990-150449039:+	-0.15	-3.74	0.000207	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs1546059	chr7:65654709	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs1546977	chr6:84314423	SNAP91	chr6:84262607-84419127:-	-0.08	-3.9	0.000108	Schizophrenia	
LGG	cis	1	rs1549588	chr2:166901064	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1549588	chr2:166901064	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1550381	chr2:26266946	GPR113	chr2:26531041-26569685:-	-0.24	-3.81	0.000157	Gut microbiome composition (summer)	
LGG	cis	1	rs1550382	chr2:26266877	GPR113	chr2:26531041-26569685:-	-0.24	-3.8	0.000161	Gut microbiome composition (summer)	
LGG	cis	1	rs1552994	chr1:152171461	FLG	chr1:152274651-152297679:-	0.4	6.34	5.08E-10	Inflammatory skin disease	
LGG	cis	1	rs1553174	chr7:65731194	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs1553398	chr7:25620958	SNX10	chr7:26331515-26413937:+	-0.24	-3.67	0.000269	Preeclampsia	
LGG	cis	1	rs1553399	chr7:25620866	SNX10	chr7:26331515-26413937:+	-0.24	-3.67	0.000269	Preeclampsia	
LGG	cis	1	rs1553609	chr7:66197139	ASL	chr7:65540776-65558321:+	-0.19	-4.86	1.55E-6	Aortic root size	
LGG	cis	1	rs1553609	chr7:66197139	TYW1	chr7:66461817-66704496:+	0.17	3.68	0.000254	Aortic root size	
LGG	cis	1	rs1553610	chr7:66197233	ASL	chr7:65540776-65558321:+	-0.19	-4.98	9.03E-7	Aortic root size	
LGG	cis	1	rs1553610	chr7:66197233	TYW1	chr7:66461817-66704496:+	0.17	3.58	0.00038	Aortic root size	
LGG	cis	1	rs1553749	chr17:46441441	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs1553753	chr17:46420806	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs1554664	chr3:65501649	MAGI1	chr3:65339907-66024509:-	-0.2	-3.99	7.76E-5	PR interval	
LGG	cis	1	rs1555337	chr20:61863641	BIRC7	chr20:61867276-61871853:+	-0.38	-4.73	2.92E-6	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs1555337	chr20:61863641	NKAIN4	chr20:61872137-61885892:-	-0.33	-5.51	5.84E-8	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs1556562	chr1:93034023	EVI5	chr1:92974255-93257961:-	0.29	7.11	3.99E-12	Cholesterol, total	
LGG	cis	1	rs1557503	chr22:51013072	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs1558377	chr4:17650758	MED28	chr4:17616273-17629791:+	0.2	4.27	2.39E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1558378	chr4:17650351	MED28	chr4:17616273-17629791:+	0.2	4.27	2.39E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.8	15.16	7.21E-43	Type 2 diabetes	
LGG	cis	1	rs1559282	chr5:56099375	MIER3	chr5:56215429-56267501:-	0.16	3.56	0.000406	Type 2 diabetes	
LGG	cis	1	rs1560868	chr2:26281459	GPR113	chr2:26531041-26569685:-	0.23	3.55	0.000429	Gut microbiome composition (summer)	
LGG	cis	1	rs1561288	chr2:25369002	POMC	chr2:25383722-25391559:-	0.17	3.65	0.000295	Body mass index	
LGG	cis	1	rs1561328	chr2:86272758	IMMT	chr2:86371056-86422893:-	0.3	3.58	0.000381	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs1561328	chr2:86272758	LOC90784	chr2:86247339-86250991:-	-0.49	-5.34	1.45E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs1561962	chr9:100546219	C9orf156	chr9:100666772-100684852:-	0.18	3.87	0.000122	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs1563736	chr3:48436794	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs1563736	chr3:48436794	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs15637	chr17:61772050	FTSJ3	chr17:61896795-61905031:-	0.45	9.21	9.8E-19	Body mass index	
LGG	cis	1	rs15637	chr17:61772050	SMARCD2	chr17:61909441-61920351:-	0.21	4.72	3.1E-6	Body mass index	
LGG	cis	1	rs156407	chr7:23315639	GPNMB	chr7:23286316-23314728:+	-0.22	-4.86	1.59E-6	Parkinson's disease	
LGG	cis	1	rs156407	chr7:23315639	NUPL2	chr7:23221446-23240629:+	-0.39	-9.72	1.58E-20	Parkinson's disease	
LGG	cis	1	rs156421	chr7:23312487	GPNMB	chr7:23286316-23314728:+	-0.22	-4.9	1.33E-6	Parkinson's disease	
LGG	cis	1	rs156421	chr7:23312487	NUPL2	chr7:23221446-23240629:+	-0.38	-9.61	3.92E-20	Parkinson's disease	
LGG	cis	1	rs156425	chr7:23309119	GPNMB	chr7:23286316-23314728:+	0.22	4.92	1.16E-6	Parkinson's disease	
LGG	cis	1	rs156425	chr7:23309119	NUPL2	chr7:23221446-23240629:+	0.37	9.34	3.29E-19	Parkinson's disease	
LGG	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs1565531	chr7:65663113	ASL	chr7:65540776-65558321:+	0.22	5.65	2.75E-8	Aortic root size	
LGG	cis	1	rs1565679	chr12:89927081	GALNT4	chr12:89913192-89919777:-	-0.17	-4.66	4.0E-6	Schizophrenia	
LGG	cis	1	rs1565679	chr12:89927081	POC1B	chr12:89813501-89919777:-	-0.17	-3.68	0.000256	Schizophrenia	
LGG	cis	1	rs1567337	chr5:115514834	COMMD10	chr5:115420727-115628978:+	0.23	4.47	9.71E-6	Metabolite levels  (X-11787)	
LGG	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.34	-8.08	4.9E-15	Blood metabolite levels	
LGG	cis	1	rs15676	chr9:131572027	LRRC8A	chr9:131644391-131680315:+	-0.19	-4.23	2.8E-5	Blood metabolite levels	
LGG	cis	1	rs1567865	chr20:47881967	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.9	0.000108	Height	
LGG	cis	1	rs1568657	chr15:83726179	C15orf40	chr15:83657724-83680393:-	0.31	4.31	1.96E-5	Kawasaki disease	
LGG	cis	1	rs1569716	chr22:38998519	LOC646851	chr22:38974125-39052634:-	0.24	7.53	2.43E-13	Resting heart rate	
LGG	cis	1	rs1570004	chr20:33958253	CPNE1	chr20:34213968-34262539:-	0.26	5.75	1.57E-8	Height	
LGG	cis	1	rs1570004	chr20:33958253	GDF5	chr20:33897002-34042568:-	-0.37	-7.38	6.93E-13	Height	
LGG	cis	1	rs1570004	chr20:33958253	UQCC	chr20:33890383-33999833:-	0.24	5.21	2.83E-7	Height	
LGG	cis	1	rs1570836	chr1:92972457	EVI5	chr1:92974255-93257961:-	-0.29	-7.12	3.73E-12	Cholesterol, total	
LGG	cis	1	rs1570837	chr1:93006816	EVI5	chr1:92974255-93257961:-	-0.3	-7.41	5.66E-13	Cholesterol, total	
LGG	cis	1	rs1570979	chr13:24441561	RNF17	chr13:25338301-25454056:+	-0.31	-3.53	0.000458	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs1573502	chr11:71747428	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1573897	chr1:247215054	ZNF670	chr1:247200087-247242069:-	-0.21	-4.82	1.88E-6	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.53	-10.72	3.2E-24	Response to antipsychotic treatment	
LGG	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.5	-10.05	1.0E-21	Response to antipsychotic treatment	
LGG	cis	1	rs15870	chr14:55619311	FBXO34	chr14:55738021-55893431:+	0.14	4.31	1.97E-5	Protein biomarker	
LGG	cis	1	rs1588635	chr9:100537802	C9orf156	chr9:100666772-100684852:-	0.18	3.79	0.000172	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs1590973	chr9:99246159	CDC14B	chr9:99262397-99382112:-	-0.29	-5.21	2.85E-7	Height	
LGG	cis	1	rs1590973	chr9:99246159	HABP4	chr9:99212414-99253617:+	-0.23	-5.08	5.39E-7	Height	
LGG	cis	1	rs1590973	chr9:99246159	SLC35D2	chr9:99075727-99145992:-	-0.16	-3.63	0.000319	Height	
LGG	cis	1	rs1592917	chr5:115569414	COMMD10	chr5:115420727-115628978:+	0.46	5.65	2.71E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1599280	chr6:56792576	BEND6	chr6:56819773-56892138:+	-0.34	-6	3.88E-9	Menarche (age at onset)	
LGG	cis	1	rs1599280	chr6:56792576	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.01	6.95E-5	Menarche (age at onset)	
LGG	cis	1	rs1599281	chr6:56789311	BEND6	chr6:56819773-56892138:+	0.3	4.97	9.21E-7	Menarche (age at onset)	
LGG	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.47	11.27	2.27E-26	Multiple sclerosis	
LGG	cis	1	rs1599932	chr12:58177943	TSFM	chr12:58176536-58191367:+	-0.46	-8.79	2.47E-17	Multiple sclerosis	
LGG	cis	1	rs1599932	chr12:58177943	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-3.69	0.000247	Multiple sclerosis	
LGG	cis	1	rs160208	chr3:12159294	TIMP4	chr3:12194573-12200647:-	-0.3	-4.03	6.35E-5	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs160214	chr3:12168910	TIMP4	chr3:12194573-12200647:-	-0.3	-4.06	5.72E-5	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs160633	chr7:65528228	CCT6P1	chr7:65216092-65228661:+	0.25	4.4	1.34E-5	Diabetic kidney disease	
LGG	cis	1	rs160634	chr7:65528664	CCT6P1	chr7:65216092-65228661:+	-0.22	-4	7.33E-5	Diabetic kidney disease	
LGG	cis	1	rs160634	chr7:65528664	LOC493754	chr7:65993446-66057363:-	-0.28	-3.72	0.00022	Diabetic kidney disease	
LGG	cis	1	rs160637	chr7:65584318	CCT6P1	chr7:65216092-65228661:+	0.25	4.6	5.49E-6	Diabetic kidney disease	
LGG	cis	1	rs160639	chr7:65579987	CCT6P1	chr7:65216092-65228661:+	0.25	4.6	5.49E-6	Diabetic kidney disease	
LGG	cis	1	rs160642	chr7:65558373	CCT6P1	chr7:65216092-65228661:+	0.26	4.79	2.23E-6	Diabetic kidney disease	
LGG	cis	1	rs160643	chr7:65558222	CCT6P1	chr7:65216092-65228661:+	0.23	4.7	3.39E-6	Diabetic kidney disease	
LGG	cis	1	rs160644	chr7:65558186	CCT6P1	chr7:65216092-65228661:+	0.26	4.79	2.23E-6	Diabetic kidney disease	
LGG	cis	1	rs160646	chr7:65556280	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.13E-6	Diabetic kidney disease	
LGG	cis	1	rs160648	chr7:65543384	CCT6P1	chr7:65216092-65228661:+	0.26	4.55	6.65E-6	Diabetic kidney disease	
LGG	cis	1	rs160652	chr7:65538431	CCT6P1	chr7:65216092-65228661:+	0.26	4.55	6.92E-6	Diabetic kidney disease	
LGG	cis	1	rs160655	chr7:65533214	CCT6P1	chr7:65216092-65228661:+	0.25	4.52	7.82E-6	Diabetic kidney disease	
LGG	cis	1	rs1606803	chr2:88933316	EIF2AK3	chr2:88856261-88926994:-	0.16	3.72	0.000226	Height	
LGG	cis	1	rs1607908	chr3:41905196	ULK4	chr3:41288091-42003660:-	0.77	15.13	1.03E-42	Diastolic blood pressure	
LGG	cis	1	rs1609268	chr2:188205598	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.65E-7	Coronary heart disease	
LGG	cis	1	rs1609810	chr9:123642351	LOC253039	chr9:123605320-123616644:+	-0.66	-11.66	6.4E-28	Rheumatoid arthritis	
LGG	cis	1	rs1609810	chr9:123642351	PSMD5	chr9:123578334-123605206:-	-0.35	-6.38	4.12E-10	Rheumatoid arthritis	
LGG	cis	1	rs1609810	chr9:123642351	TRAF1	chr9:123664672-123691479:-	0.18	3.93	9.57E-5	Rheumatoid arthritis	
LGG	cis	1	rs1612028	chr10:73805290	ASCC1	chr10:73856278-73976892:-	0.14	4.1	4.79E-5	Smoking behavior	
LGG	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.79	-15.53	1.49E-44	Diastolic blood pressure	
LGG	cis	1	rs1613759	chr3:41906183	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1614182	chr1:159004526	IFI16	chr1:158969758-159024943:+	-0.17	-3.8	0.000165	Obesity-related traits	
LGG	cis	1	rs1615243	chr3:41965234	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs1615543	chr3:41906404	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1628874	chr3:41955714	ULK4	chr3:41288091-42003660:-	-0.78	-15.42	4.72E-44	Diastolic blood pressure	
LGG	cis	1	rs1629460	chr3:41927449	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs163030	chr5:76781471	WDR41	chr5:76728069-76788332:-	0.19	3.63	0.000316	Caudate nucleus volume	
LGG	cis	1	rs1630642	chr10:73804620	ASCC1	chr10:73856278-73976892:-	-0.14	-4.03	6.38E-5	Smoking behavior	
LGG	cis	1	rs1632282	chr2:188208012	CALCRL	chr2:188207851-188313021:-	0.21	5.15	3.77E-7	Coronary heart disease	
LGG	cis	1	rs1633256	chr1:159002557	IFI16	chr1:158969758-159024943:+	-0.19	-4.21	2.98E-5	Obesity-related traits	
LGG	cis	1	rs1633262	chr1:159004888	IFI16	chr1:158969758-159024943:+	-0.17	-3.78	0.000174	Obesity-related traits	
LGG	cis	1	rs1633265	chr1:159005727	IFI16	chr1:158969758-159024943:+	-0.17	-3.75	0.0002	Obesity-related traits	
LGG	cis	1	rs1633360	chr12:58108052	FAM119B	chr12:58166383-58176323:+	-0.36	-8.78	2.81E-17	Rheumatoid arthritis	
LGG	cis	1	rs1633360	chr12:58108052	TSFM	chr12:58176536-58191367:+	0.24	4.53	7.57E-6	Rheumatoid arthritis	
LGG	cis	1	rs1634409	chr17:18836177	FAM18B	chr17:18684582-18710026:+	-0.2	-5.18	3.3E-7	Educational attainment (years of education)	
LGG	cis	1	rs1634409	chr17:18836177	FBXW10	chr17:18647326-18682661:+	-0.19	-4.29	2.16E-5	Educational attainment (years of education)	
LGG	cis	1	rs1634411	chr17:18833810	FAM18B	chr17:18684582-18710026:+	-0.19	-5.06	5.83E-7	Educational attainment (years of education)	
LGG	cis	1	rs1634411	chr17:18833810	FBXW10	chr17:18647326-18682661:+	-0.19	-4.27	2.36E-5	Educational attainment (years of education)	
LGG	cis	1	rs1638676	chr3:47327651	NRADDP	chr3:47053032-47054957:+	-0.23	-4.02	6.85E-5	Colorectal cancer	
LGG	cis	1	rs1638731	chr7:66144679	CCT6P1	chr7:65216092-65228661:+	0.22	3.99	7.47E-5	Gout	
LGG	cis	1	rs1638734	chr7:66097539	CCT6P1	chr7:65216092-65228661:+	0.2	3.6	0.000344	Diabetic kidney disease	
LGG	cis	1	rs164106	chr17:74290566	QRICH2	chr17:74270130-74303761:-	-0.17	-4.48	9.41E-6	White matter hyperintensities in ischemic stroke	
LGG	cis	1	rs164252	chr5:112791801	SRP19	chr5:112196993-112228774:+	-0.31	-3.91	0.000107	F-cell distribution	
LGG	cis	1	rs164636	chr3:52265259	GLYCTK	chr3:52321836-52329271:+	0.34	3.48	0.000545	Waist-hip ratio	
LGG	cis	1	rs1659685	chr2:27420690	SLC5A6	chr2:27422459-27435071:-	0.3	6.24	9.71E-10	Blood metabolite levels	
LGG	cis	1	rs1659695	chr2:27406944	SLC5A6	chr2:27422459-27435071:-	0.3	6.21	1.15E-9	Blood metabolite levels	
LGG	cis	1	rs1665362	chr4:1726367	TMEM129	chr4:1717680-1723084:-	-0.18	-3.88	0.000117	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs1665364	chr4:1727206	TMEM129	chr4:1717680-1723084:-	0.17	3.65	0.000293	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs1665366	chr4:1728381	TMEM129	chr4:1717680-1723084:-	0.19	4.08	5.32E-5	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs1665982	chr3:47905079	NME6	chr3:48335591-48342886:-	0.24	4.48	9.14E-6	Educational attainment (years of education)	
LGG	cis	1	rs166663	chr7:23316742	GPNMB	chr7:23286316-23314728:+	-0.21	-4.54	6.95E-6	Parkinson's disease	
LGG	cis	1	rs166663	chr7:23316742	NUPL2	chr7:23221446-23240629:+	-0.4	-9.85	5.31E-21	Parkinson's disease	
LGG	cis	1	rs166870	chr15:80069762	MTHFS	chr15:80137320-80189370:-	0.2	3.68	0.000257	Disease-free survival in breast cancer	
LGG	cis	1	rs1678542	chr12:57968715	FAM119B	chr12:58166383-58176323:+	-0.27	-6.7	5.55E-11	Rheumatoid arthritis	
LGG	cis	1	rs1678542	chr12:57968715	TSFM	chr12:58176536-58191367:+	0.21	4.18	3.45E-5	Rheumatoid arthritis	
LGG	cis	1	rs1678618	chr10:73806288	ASCC1	chr10:73856278-73976892:-	-0.14	-4.1	4.85E-5	Smoking behavior	
LGG	cis	1	rs167890	chr13:111449115	ANKRD10	chr13:111530888-111567416:-	-0.23	-3.49	0.000531	Obesity-related traits	
LGG	cis	1	rs1679381	chr12:75946124	GLIPR1L2	chr12:75784889-75825591:+	-0.29	-5.02	7.24E-7	Polycystic ovary syndrome	
LGG	cis	1	rs1679709	chr6:28228342	ZNF165	chr6:28046572-28057338:+	0.32	4.71	3.24E-6	Depression	
LGG	cis	1	rs1679709	chr6:28228342	ZNF187	chr6:28234788-28245978:+	0.26	4.52	7.75E-6	Depression	
LGG	cis	1	rs1679709	chr6:28228342	ZNF389	chr6:28129551-28137375:+	-0.43	-6.84	2.41E-11	Depression	
LGG	cis	1	rs1679709	chr6:28228342	ZSCAN12	chr6:28346770-28367544:-	0.33	4.67	3.91E-6	Depression	
LGG	cis	1	rs1679709	chr6:28228342	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.31	2.01E-5	Depression	
LGG	cis	1	rs1679732	chr6:28221264	ZNF165	chr6:28046572-28057338:+	0.32	4.71	3.24E-6	Depression	
LGG	cis	1	rs1679732	chr6:28221264	ZNF187	chr6:28234788-28245978:+	0.26	4.52	7.75E-6	Depression	
LGG	cis	1	rs1679732	chr6:28221264	ZNF389	chr6:28129551-28137375:+	-0.43	-6.84	2.41E-11	Depression	
LGG	cis	1	rs1679732	chr6:28221264	ZSCAN12	chr6:28346770-28367544:-	0.33	4.67	3.91E-6	Depression	
LGG	cis	1	rs1679732	chr6:28221264	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.31	2.01E-5	Depression	
LGG	cis	1	rs16823014	chr2:169817713	ABCB11	chr2:169779449-169887833:-	0.33	3.49	0.000529	Egg allergy	
LGG	cis	1	rs1682361	chr3:136734014	PCCB	chr3:135969167-136056737:+	0.23	4.84	1.7E-6	Schizophrenia	
LGG	cis	1	rs16832155	chr2:190749841	ORMDL1	chr2:190634994-190649097:-	0.34	5.17	3.37E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs16832158	chr2:190758688	ORMDL1	chr2:190634994-190649097:-	0.34	5.2	2.92E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.82	12.1	1.08E-29	Rheumatoid arthritis	
LGG	cis	1	rs16839793	chr3:132622657	NPHP3	chr3:132363641-132441276:-	-0.17	-3.92	0.000102	Number of pregnancies	
LGG	cis	1	rs16840074	chr1:150683156	ARNT	chr1:150782186-150849186:-	0.24	4	7.43E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs16843590	chr2:242298228	ANO7	chr2:242127924-242164791:+	0.38	6.33	5.67E-10	Prostate cancer	
LGG	cis	1	rs16844002	chr3:128053487	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.95	9.03E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs16844002	chr3:128053487	LOC90246	chr3:128226678-128229427:+	-0.29	-3.75	0.000199	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs16844715	chr2:160915106	LY75	chr2:160625141-160761262:-	-0.13	-3.71	0.000235	Idiopathic membranous nephropathy	
LGG	cis	1	rs16847897	chr3:169568116	LRRC34	chr3:169511266-169530720:-	0.27	4.65	4.31E-6	Glioma (high-grade)	
LGG	cis	1	rs1684942	chr3:47900703	NME6	chr3:48335591-48342886:-	-0.23	-4.58	5.81E-6	Educational attainment (years of education)	
LGG	cis	1	rs16851607	chr3:128570263	RAB43	chr3:128806418-128880029:-	0.31	3.69	0.000249	Dental caries	
LGG	cis	1	rs16851720	chr3:141463298	RNF7	chr3:141457051-141465242:+	0.17	3.85	0.000132	Hepatitis C induced liver fibrosis	
LGG	cis	1	rs16854186	chr1:179473704	C1orf125	chr1:179335107-179523868:+	0.66	8.22	1.86E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs16870629	chr5:1015063	NKD2	chr5:1009168-1038925:+	-0.15	-3.6	0.000355	QT interval	
LGG	cis	1	rs16872094	chr5:42015691	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.0003	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs16872100	chr5:42016983	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.000302	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs16873899	chr7:25615915	SNX10	chr7:26331515-26413937:+	-0.23	-3.67	0.000264	Preeclampsia	
LGG	cis	1	rs16873909	chr7:25617723	SNX10	chr7:26331515-26413937:+	-0.24	-3.67	0.000269	Preeclampsia	
LGG	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.53	-11.29	1.93E-26	Response to antipsychotic treatment	
LGG	cis	1	rs16879114	chr7:33257641	BBS9	chr7:33169152-33645680:+	0.42	5.76	1.46E-8	Smooth-surface caries	
LGG	cis	1	rs16887244	chr8:38031345	LSM1	chr8:38020861-38034169:-	-0.18	-3.91	0.000107	Schizophrenia	
LGG	cis	1	rs16891378	chr6:26188864	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.3	2.04E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891378	chr6:26188864	HIST1H3E	chr6:26224427-26226589:+	0.63	10.64	6.49E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891397	chr6:26200256	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.2	3.2E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891397	chr6:26200256	HIST1H3E	chr6:26224427-26226589:+	0.64	10.81	1.46E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891401	chr6:26202337	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.22	2.96E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891401	chr6:26202337	HIST1H3E	chr6:26224427-26226589:+	0.65	10.86	9.19E-25	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891405	chr6:26204506	HIST1H2AE	chr6:26217148-26217711:+	-0.29	-4.05	5.88E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs16891405	chr6:26204506	HIST1H3E	chr6:26224427-26226589:+	0.65	10.76	2.28E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs16894959	chr6:34825662	C6orf106	chr6:34555066-34664625:-	0.25	4.89	1.39E-6	Pubertal anthropometrics	
LGG	cis	1	rs16895513	chr8:98326973	HRSP12	chr8:99114567-99129418:-	0.14	3.46	0.000581	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs16895514	chr8:98327059	HRSP12	chr8:99114567-99129418:-	0.16	3.76	0.000188	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs16895516	chr8:98327181	HRSP12	chr8:99114567-99129418:-	0.15	3.55	0.000418	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs16899276	chr5:81165704	ATG10	chr5:81267844-81551211:+	0.28	4.4	1.35E-5	Cognitive function	
LGG	cis	1	rs16916041	chr10:63146547	C10orf107	chr10:63422719-63526089:+	-0.29	-4.01	6.95E-5	Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	
LGG	cis	1	rs16929097	chr9:12521826	MPDZ	chr9:13105709-13279563:-	0.53	7.02	7.27E-12	Asthma (childhood onset)	
LGG	cis	1	rs16944254	chr15:90898527	IQGAP1	chr15:90931473-91045475:+	0.13	4.06	5.79E-5	Rheumatoid arthritis	
LGG	cis	1	rs16945428	chr16:77316260	ADAMTS18	chr16:77316026-77469011:-	-0.28	-4.13	4.35E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs16945470	chr16:77329408	ADAMTS18	chr16:77316026-77469011:-	0.36	4.13	4.22E-5	White matter integrity	
LGG	cis	1	rs16947005	chr17:61702989	DDX42	chr17:61851567-61896676:+	0.17	3.8	0.000163	Body mass index	
LGG	cis	1	rs16947005	chr17:61702989	FTSJ3	chr17:61896795-61905031:-	-0.42	-8.57	1.35E-16	Body mass index	
LGG	cis	1	rs16947005	chr17:61702989	SMARCD2	chr17:61909441-61920351:-	-0.2	-4.41	1.27E-5	Body mass index	
LGG	cis	1	rs16947014	chr17:61719032	DDX42	chr17:61851567-61896676:+	-0.17	-3.8	0.000161	Body mass index	
LGG	cis	1	rs16947014	chr17:61719032	FTSJ3	chr17:61896795-61905031:-	0.41	8.31	9.43E-16	Body mass index	
LGG	cis	1	rs16947014	chr17:61719032	SMARCD2	chr17:61909441-61920351:-	0.19	4.19	3.35E-5	Body mass index	
LGG	cis	1	rs16947042	chr17:61766457	FTSJ3	chr17:61896795-61905031:-	0.44	9.03	3.79E-18	Body mass index	
LGG	cis	1	rs16947042	chr17:61766457	SMARCD2	chr17:61909441-61920351:-	0.21	4.73	2.96E-6	Body mass index	
LGG	cis	1	rs16948048	chr17:47440466	GNGT2	chr17:47283597-47286743:-	-0.11	-3.9	0.000108	Diastolic blood pressure	
LGG	cis	1	rs16948098	chr15:44219607	ADAL	chr15:43622872-43646094:+	-0.59	-5.11	4.68E-7	Serum albumin level	
LGG	cis	1	rs16948098	chr15:44219607	STRC	chr15:43891762-43924561:-	0.38	4.7	3.35E-6	Serum albumin level	
LGG	cis	1	rs16952848	chr18:44597829	HDHD2	chr18:44633782-44676871:-	0.47	4.73	2.88E-6	Sitting height ratio	
LGG	cis	1	rs16955397	chr17:46394330	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs16955471	chr17:53058807	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs16955471	chr17:53058807	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs16957524	chr16:67798005	LRRC36	chr16:67360747-67419108:+	0.42	4.23	2.74E-5	Crohn's disease	
LGG	cis	1	rs16957524	chr16:67798005	RANBP10	chr16:67757006-67840555:-	-0.28	-3.6	0.000353	Crohn's disease	
LGG	cis	1	rs16957590	chr16:67934725	LRRC36	chr16:67360747-67419108:+	-0.48	-4.52	7.75E-6	Crohn's disease	
LGG	cis	1	rs16957590	chr16:67934725	RANBP10	chr16:67757006-67840555:-	0.32	3.8	0.000164	Crohn's disease	
LGG	cis	1	rs16958432	chr18:44631773	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs16958440	chr18:44632884	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs16958445	chr15:74176557	CD276	chr15:73976622-74006859:+	0.32	3.51	0.000482	Exfoliation glaucoma or exfoliation syndrome	
LGG	cis	1	rs16958445	chr15:74176557	EDC3	chr15:74922900-74988386:-	0.43	3.98	7.91E-5	Exfoliation glaucoma or exfoliation syndrome	
LGG	cis	1	rs16958445	chr15:74176557	SCAMP2	chr15:75136073-75165670:-	0.29	3.48	0.000545	Exfoliation glaucoma or exfoliation syndrome	
LGG	cis	1	rs16958445	chr15:74176557	UBL7	chr15:74738318-74753529:-	0.4	3.67	0.00027	Exfoliation glaucoma or exfoliation syndrome	
LGG	cis	1	rs16958701	chr18:44655241	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs16969790	chr16:20265733	ACSM1	chr16:20634559-20709066:-	0.34	3.49	0.000531	Body mass index	
LGG	cis	1	rs16971217	chr17:33944055	PEX12	chr17:33901815-33905656:-	-0.23	-4.09	5.02E-5	Platelet count	
LGG	cis	1	rs16971227	chr17:33949222	PEX12	chr17:33901815-33905656:-	-0.22	-3.93	9.58E-5	Platelet count	
LGG	cis	1	rs16973222	chr15:82228120	FAM154B	chr15:82555152-82577265:+	0.35	3.87	0.000126	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs16973225	chr15:82229999	FAM154B	chr15:82555152-82577265:+	0.35	3.87	0.000126	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs16973500	chr16:71965196	DHODH	chr16:72042643-72058954:+	0.25	3.79	0.00017	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs16973500	chr16:71965196	HP	chr16:72088508-72094957:+	0.36	4.69	3.6E-6	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs16973500	chr16:71965196	HPR	chr16:72097125-72111144:+	0.39	5.55	4.57E-8	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs16973500	chr16:71965196	KIAA0174	chr16:71924472-71962906:+	0.23	3.55	0.000423	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs16973500	chr16:71965196	TXNL4B	chr16:72072001-72128215:-	0.32	4.05	5.89E-5	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs16973500	chr16:71965196	ZNF19	chr16:71507976-71523254:-	0.32	4.65	4.26E-6	Attention deficit hyperactivity disorder and conduct disorder;Response to anti-TNF therapy in rheumatoid arthritis	
LGG	cis	1	rs1697845	chr5:75922504	F2RL2	chr5:75911308-75919240:-	-0.21	-4.53	7.45E-6	Hearing impairment	
LGG	cis	1	rs1697978	chr5:642829	SDHA	chr5:218356-256812:+	0.19	4.36	1.61E-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs16980665	chr20:55624075	CTCFL	chr20:56063880-56100708:-	-0.26	-3.76	0.000188	Response to citalopram treatment	
LGG	cis	1	rs16981031	chr19:49497453	RUVBL2	chr19:49496819-49519182:+	-0.22	-3.78	0.000174	Follicule stimulating hormone	
LGG	cis	1	rs1699379	chr4:129992337	C4orf33	chr4:130014829-130033842:+	-0.58	-9.83	6.1E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1699389	chr4:130004079	C4orf33	chr4:130014829-130033842:+	-0.6	-9.95	2.34E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1699391	chr4:130005096	C4orf33	chr4:130014829-130033842:+	-0.6	-9.95	2.34E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1699393	chr4:130019352	C4orf33	chr4:130014829-130033842:+	-0.54	-8.87	1.37E-17	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.55	-9.24	7.35E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs16995592	chr20:49524451	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs16997087	chr20:16054982	SNRPB2	chr20:16710629-16722037:+	-0.25	-3.78	0.000177	Brain connectivity	
LGG	cis	1	rs1700490	chr5:176402401	FGFR4	chr5:176513921-176525124:+	0.22	5.95	5.19E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs17006610	chr3:20152563	EFHB	chr3:19920968-19988501:-	0.33	4.45	1.07E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs17006623	chr3:20161043	EFHB	chr3:19920968-19988501:-	0.34	4.52	7.69E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs1701750	chr7:65467145	CCT6P1	chr7:65216092-65228661:+	0.26	4.74	2.82E-6	Diabetic kidney disease	
LGG	cis	1	rs1701758	chr7:65470201	CCT6P1	chr7:65216092-65228661:+	0.26	4.74	2.82E-6	Diabetic kidney disease	
LGG	cis	1	rs17027011	chr2:86406556	LOC90784	chr2:86247339-86250991:-	-0.4	-4.32	1.86E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs17030284	chr2:105380921	MRPS9	chr2:105654483-105716417:+	0.25	4.26	2.43E-5	Pancreatic cancer	
LGG	cis	1	rs17030292	chr2:105383596	MRPS9	chr2:105654483-105716417:+	-0.25	-4.19	3.24E-5	Pancreatic cancer	
LGG	cis	1	rs17030308	chr2:105385872	MRPS9	chr2:105654483-105716417:+	-0.25	-4.19	3.24E-5	Pancreatic cancer	
LGG	cis	1	rs17030309	chr2:105391328	MRPS9	chr2:105654483-105716417:+	-0.23	-3.84	0.000138	Pancreatic cancer	
LGG	cis	1	rs17030651	chr1:113239382	ST7L	chr1:113066142-113162405:-	0.24	5.56	4.5E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs17030651	chr1:113239382	WNT2B	chr1:113010040-113063908:+	0.2	3.96	8.59E-5	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs17035960	chr4:106531846	GSTCD	chr4:106629941-106768881:+	0.3	3.6	0.000353	Post bronchodilator FEV1	
LGG	cis	1	rs17036023	chr1:117129711	TRIM45	chr1:117653677-117664414:-	0.25	4.03	6.52E-5	Asthma (childhood onset)	
LGG	cis	1	rs17036258	chr4:106737382	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000564	Post bronchodilator FEV1	
LGG	cis	1	rs17036308	chr4:106749593	GSTCD	chr4:106629941-106768881:+	0.3	3.59	0.000367	Post bronchodilator FEV1	
LGG	cis	1	rs17036971	chr2:48035993	FBXO11	chr2:48034061-48132814:-	0.24	4.33	1.8E-5	Schizophrenia	
LGG	cis	1	rs17037021	chr2:48088412	FBXO11	chr2:48034061-48132814:-	0.23	4.13	4.19E-5	Schizophrenia	
LGG	cis	1	rs17037040	chr2:48119446	FBXO11	chr2:48034061-48132814:-	0.25	4.6	5.31E-6	Schizophrenia	
LGG	cis	1	rs17037055	chr2:48143149	FBXO11	chr2:48034061-48132814:-	0.23	4.09	4.98E-5	Schizophrenia	
LGG	cis	1	rs17037062	chr2:48145347	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs17037064	chr2:48147589	FBXO11	chr2:48034061-48132814:-	0.23	4.09	4.98E-5	Schizophrenia	
LGG	cis	1	rs17037066	chr2:48148572	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs17040322	chr2:26351274	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs17040870	chr12:109085410	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs17040915	chr12:109115844	SELPLG	chr12:109015682-109027670:-	0.21	3.67	0.000266	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs17045711	chr2:54476678	C2orf73	chr2:54558071-54588714:+	0.33	4.8	2.09E-6	Telomere length	
LGG	cis	1	rs17045711	chr2:54476678	TSPYL6	chr2:54480315-54483409:-	-0.46	-5.58	3.99E-8	Telomere length	
LGG	cis	1	rs17052727	chr3:53070914	RFT1	chr3:53122503-53164470:-	0.3	3.61	0.000335	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs17053637	chr5:156011426	SGCD	chr5:155135063-156194796:+	0.3	4.68	3.74E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs17058743	chr3:58009372	DNAH12	chr3:57327727-57530071:-	-0.21	-3.7	0.000242	Optic cup area	
LGG	cis	1	rs17061431	chr3:41792655	ULK4	chr3:41288091-42003660:-	0.74	14.51	6.11E-40	Diastolic blood pressure	
LGG	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.74	14.34	3.22E-39	Diastolic blood pressure	
LGG	cis	1	rs1706249	chr2:188153718	CALCRL	chr2:188207851-188313021:-	0.22	5.36	1.28E-7	Coronary heart disease	
LGG	cis	1	rs1706252	chr2:188156578	CALCRL	chr2:188207851-188313021:-	-0.23	-5.53	5.08E-8	Coronary heart disease	
LGG	cis	1	rs1706261	chr2:188204916	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.65E-7	Coronary heart disease	
LGG	cis	1	rs1706262	chr2:188203848	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.66E-7	Coronary heart disease	
LGG	cis	1	rs1706276	chr2:188206664	CALCRL	chr2:188207851-188313021:-	0.21	5.21	2.82E-7	Coronary heart disease	
LGG	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs17064124	chr3:41890803	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs17070580	chr6:109738714	AKD1	chr6:109814059-110012415:-	0.3	6.26	8.51E-10	Height	
LGG	cis	1	rs17070580	chr6:109738714	FIG4	chr6:110012424-110146634:+	0.16	3.59	0.000366	Height	
LGG	cis	1	rs17070580	chr6:109738714	MICAL1	chr6:109765268-109787171:-	0.33	7.84	2.85E-14	Height	
LGG	cis	1	rs17070580	chr6:109738714	ZBTB24	chr6:109783719-109804440:-	0.2	3.96	8.72E-5	Height	
LGG	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.92	1.17E-6	Body mass index	
LGG	cis	1	rs1707321	chr1:46505309	MUTYH	chr1:45794915-45806142:-	0.14	5.1	4.96E-7	Body mass index	
LGG	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.73	2.89E-6	Body mass index	
LGG	cis	1	rs1707335	chr1:46571921	MUTYH	chr1:45794915-45806142:-	0.14	5.09	5.17E-7	Body mass index	
LGG	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.57	6.16E-6	Body mass index	
LGG	cis	1	rs1707336	chr1:46493460	MUTYH	chr1:45794915-45806142:-	0.13	4.85	1.7E-6	Body mass index	
LGG	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.99	8.24E-7	Body mass index	
LGG	cis	1	rs1707340	chr1:46514942	MUTYH	chr1:45794915-45806142:-	0.14	5.06	5.97E-7	Body mass index	
LGG	cis	1	rs17085889	chr4:56402115	TMEM165	chr4:56262090-56292342:+	0.18	5.24	2.41E-7	Personality dimensions	
LGG	cis	1	rs17092215	chr20:33595913	PROCR	chr20:33758727-33765164:+	-0.3	-5.73	1.74E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17092297	chr20:33703134	PROCR	chr20:33758727-33765164:+	0.31	5.99	3.98E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17093141	chr14:74326903	LIN52	chr14:74551656-74667117:+	0.37	4.88	1.47E-6	Morning vs. evening chronotype	
LGG	cis	1	rs17093474	chr14:74342413	LIN52	chr14:74551656-74667117:+	0.34	4.54	7.23E-6	Morning vs. evening chronotype	
LGG	cis	1	rs17093474	chr14:74342413	PTGR2	chr14:74318534-74352166:+	-0.22	-3.52	0.000468	Morning vs. evening chronotype	
LGG	cis	1	rs17094021	chr14:74394295	LIN52	chr14:74551656-74667117:+	0.36	4.72	3.13E-6	Morning vs. evening chronotype	
LGG	cis	1	rs17096228	chr14:74558669	LIN52	chr14:74551656-74667117:+	0.49	11.51	2.6E-27	Common traits (Other)	
LGG	cis	1	rs17101854	chr14:64906265	WDR89	chr14:64063758-64108591:-	0.42	4.05	5.83E-5	Cognitive performance	
LGG	cis	1	rs17102362	chr10:92673370	RPP30	chr10:92631474-92668312:+	0.19	3.73	0.00021	Economic and political preferences (time)	
LGG	cis	1	rs17103138	chr10:123913330	NSMCE4A	chr10:123716609-123734731:-	0.26	4.26	2.47E-5	Myopia (pathological)	
LGG	cis	1	rs17109512	chr10:100127551	PYROXD2	chr10:100143323-100174978:-	0.3	3.94	9.21E-5	Aspartate aminotransferase	
LGG	cis	1	rs17111376	chr5:150226899	LOC134466	chr5:150310000-150326146:-	0.4	4.63	4.71E-6	Crohn's disease	
LGG	cis	1	rs17112431	chr14:20957490	TMEM55B	chr14:20926012-20929637:-	0.21	3.63	0.000316	Response to antipsychotic therapy (extrapyramidal side effects)	
LGG	cis	1	rs17112901	chr10:102066185	BLOC1S2	chr10:102033713-102046439:-	0.33	4.93	1.14E-6	Obesity-related traits	
LGG	cis	1	rs17113137	chr10:102241998	HIF1AN	chr10:102295641-102313680:+	0.18	3.64	0.000304	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs17113137	chr10:102241998	NDUFB8	chr10:102283497-102289636:-	0.15	4.3	2.02E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs17113137	chr10:102241998	WNT8B	chr10:102222812-102243397:+	0.51	8.67	6.39E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs17113138	chr5:151731277	NMUR2	chr5:151771102-151784840:-	-0.22	-3.85	0.000135	Optic nerve measurement (cup area)	
LGG	cis	1	rs17113145	chr5:151733056	NMUR2	chr5:151771102-151784840:-	-0.23	-3.85	0.000135	Optic nerve measurement (cup area)	
LGG	cis	1	rs17114359	chr21:43510437	C21orf128	chr21:43522244-43528644:-	0.53	10.4	5.05E-23	IgG glycosylation	
LGG	cis	1	rs17115100	chr10:104591393	SFXN2	chr10:104474298-104498946:+	-0.32	-3.99	7.65E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs17115231	chr12:75933675	GLIPR1L2	chr12:75784889-75825591:+	-0.3	-5.26	2.21E-7	Polycystic ovary syndrome	
LGG	cis	1	rs17118403	chr12:56630067	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs17118409	chr12:56630764	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs17118439	chr12:56667604	IL23A	chr12:56732663-56734193:+	-0.56	-4.96	9.73E-7	Psoriasis vulgaris	
LGG	cis	1	rs17121651	chr14:50097172	RPL36AL	chr14:50085407-50087349:-	0.32	8.35	7.25E-16	Carotid intima media thickness	
LGG	cis	1	rs17122979	chr12:48813697	VDR	chr12:48235322-48298814:-	0.22	3.62	0.000327	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs17124700	chr14:88905629	KCNK10	chr14:88646454-88793256:-	-0.18	-3.57	0.000386	Coronary artery calcification	
LGG	cis	1	rs17124700	chr14:88905629	SPATA7	chr14:88852012-88904802:+	-0.49	-8.81	2.23E-17	Coronary artery calcification	
LGG	cis	1	rs17126877	chr10:111672786	PDCD4	chr10:112631596-112659763:+	0.21	3.48	0.000536	Biliary atresia	
LGG	cis	1	rs17126931	chr10:111754633	PDCD4	chr10:112631596-112659763:+	0.24	3.83	0.000146	Biliary atresia	
LGG	cis	1	rs1712790	chr11:114621469	C11orf71	chr11:114262170-114271255:-	-0.22	-4.57	6.05E-6	Urinary albumin excretion	
LGG	cis	1	rs17128050	chr14:55343879	GCH1	chr14:55308724-55369542:-	0.27	4.45	1.07E-5	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs17138884	chr5:115425628	COMMD10	chr5:115420727-115628978:+	0.45	5.79	1.26E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17138917	chr5:115469316	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139192	chr5:115561710	COMMD10	chr5:115420727-115628978:+	0.48	5.98	4.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139193	chr5:115562073	COMMD10	chr5:115420727-115628978:+	0.48	5.98	4.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139224	chr5:115568193	COMMD10	chr5:115420727-115628978:+	0.48	5.87	8.18E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139265	chr5:115578810	COMMD10	chr5:115420727-115628978:+	0.42	5.19	3.11E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139314	chr5:115607127	COMMD10	chr5:115420727-115628978:+	0.46	5.75	1.58E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17139457	chr5:115640603	COMMD10	chr5:115420727-115628978:+	-0.44	-5.52	5.65E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs17140062	chr10:17202840	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.55	6.79E-6	Homocysteine levels	
LGG	cis	1	rs17149161	chr7:75978229	POR	chr7:75544420-75616172:+	0.19	3.91	0.000105	Multiple sclerosis	
LGG	cis	1	rs17149161	chr7:75978229	SRCRB4D	chr7:76018647-76039012:-	0.26	5.96	4.77E-9	Multiple sclerosis	
LGG	cis	1	rs17149161	chr7:75978229	UPK3B	chr7:76139745-76157197:+	-0.24	-4.51	8.06E-6	Multiple sclerosis	
LGG	cis	1	rs1715235	chr7:65488394	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.56E-6	Diabetic kidney disease	
LGG	cis	1	rs17154671	chr5:125908203	ALDH7A1	chr5:125878918-125931082:-	0.45	5.52	5.49E-8	Osteoporosis	
LGG	cis	1	rs17154676	chr5:125912120	ALDH7A1	chr5:125878918-125931082:-	0.46	5.41	1.01E-7	Osteoporosis	
LGG	cis	1	rs17155886	chr10:1145182	IDI2	chr10:1064847-1071799:-	0.33	4.12	4.49E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs17161966	chr11:71815308	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.33E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs17161991	chr11:71839960	FAM86C	chr11:71498557-71512276:+	-0.45	-4.28	2.29E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs17164747	chr4:260587	ZNF718	chr4:53272-156488:+	0.26	5.14	3.92E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs17164979	chr5:126731831	FLJ44606	chr5:126381051-126409172:-	0.26	3.48	0.00055	IgG glycosylation	
LGG	cis	1	rs1716642	chr3:41965865	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.79	-15.61	6.77E-45	Diastolic blood pressure	
LGG	cis	1	rs1716651	chr3:41975099	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs1716657	chr3:41918456	ULK4	chr3:41288091-42003660:-	-0.76	-14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1716660	chr3:41929960	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.78	-15.47	3.04E-44	Diastolic blood pressure	
LGG	cis	1	rs1716664	chr3:41948378	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs1716668	chr3:41907850	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1716669	chr3:41908681	ULK4	chr3:41288091-42003660:-	0.77	15.13	1.03E-42	Diastolic blood pressure	
LGG	cis	1	rs1716676	chr3:41903208	ULK4	chr3:41288091-42003660:-	0.76	14.89	1.18E-41	Diastolic blood pressure	
LGG	cis	1	rs1716683	chr3:41923074	ULK4	chr3:41288091-42003660:-	-0.77	-15	3.75E-42	Diastolic blood pressure	
LGG	cis	1	rs1716685	chr3:41925301	ULK4	chr3:41288091-42003660:-	0.76	14.92	9.24E-42	Diastolic blood pressure	
LGG	cis	1	rs1716688	chr3:41926546	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs1716690	chr3:41922102	ULK4	chr3:41288091-42003660:-	-0.77	-15	3.75E-42	Diastolic blood pressure	
LGG	cis	1	rs1716692	chr3:41983786	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs1716693	chr3:41985600	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs1716696	chr3:41935811	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs17168107	chr7:96614137	ASNS	chr7:97481443-97501854:-	0.35	3.62	0.00033	Ossification of the posterior longitudinal ligament of the spine	
LGG	cis	1	rs17169807	chr7:33181238	BBS9	chr7:33169152-33645680:+	0.43	5.54	4.84E-8	Smooth-surface caries	
LGG	cis	1	rs17169808	chr7:33181349	BBS9	chr7:33169152-33645680:+	0.43	5.54	4.84E-8	Smooth-surface caries	
LGG	cis	1	rs1716984	chr3:41965532	ULK4	chr3:41288091-42003660:-	-0.77	-15.34	1.18E-43	Diastolic blood pressure	
LGG	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.79	-15.64	5.03E-45	Diastolic blood pressure	
LGG	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.79	-15.61	6.77E-45	Diastolic blood pressure	
LGG	cis	1	rs1716997	chr3:41924333	ULK4	chr3:41288091-42003660:-	-0.77	-15	3.75E-42	Diastolic blood pressure	
LGG	cis	1	rs1716999	chr3:41930041	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs1717000	chr3:41930219	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs1717001	chr3:41934949	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.77	15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs17170099	chr7:33235552	BBS9	chr7:33169152-33645680:+	0.41	5.76	1.45E-8	Smooth-surface caries	
LGG	cis	1	rs1717009	chr3:41946308	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs17170105	chr7:33236176	BBS9	chr7:33169152-33645680:+	0.43	5.69	2.16E-8	Smooth-surface caries	
LGG	cis	1	rs1717011	chr3:41980199	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs17170120	chr7:33263143	BBS9	chr7:33169152-33645680:+	0.42	5.67	2.4E-8	Smooth-surface caries	
LGG	cis	1	rs17170131	chr7:33277778	BBS9	chr7:33169152-33645680:+	0.43	5.81	1.12E-8	Smooth-surface caries	
LGG	cis	1	rs17170138	chr7:33289041	BBS9	chr7:33169152-33645680:+	0.44	6.2	1.17E-9	Smooth-surface caries	
LGG	cis	1	rs17170140	chr7:33292381	BBS9	chr7:33169152-33645680:+	-0.33	-4.8	2.06E-6	Smooth-surface caries	
LGG	cis	1	rs17170143	chr7:33297580	BBS9	chr7:33169152-33645680:+	0.48	6.53	1.66E-10	Smooth-surface caries	
LGG	cis	1	rs1717014	chr3:41917395	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs17170155	chr7:33314323	BBS9	chr7:33169152-33645680:+	0.47	6.47	2.43E-10	Smooth-surface caries	
LGG	cis	1	rs17170167	chr7:33328636	BBS9	chr7:33169152-33645680:+	0.47	6.46	2.58E-10	Smooth-surface caries	
LGG	cis	1	rs17170169	chr7:33329731	BBS9	chr7:33169152-33645680:+	0.47	6.46	2.58E-10	Smooth-surface caries	
LGG	cis	1	rs17170178	chr7:33349225	BBS9	chr7:33169152-33645680:+	0.43	5.71	1.92E-8	Smooth-surface caries	
LGG	cis	1	rs1717017	chr3:41915616	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.78	15.47	3.04E-44	Diastolic blood pressure	
LGG	cis	1	rs1717021	chr3:41983860	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs1717024	chr3:41984888	ULK4	chr3:41288091-42003660:-	-0.74	-14.77	3.97E-41	Diastolic blood pressure	
LGG	cis	1	rs1717027	chr3:41987920	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs1717031	chr3:41905791	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs1717033	chr3:41910216	ULK4	chr3:41288091-42003660:-	0.77	15.24	3.32E-43	Diastolic blood pressure	
LGG	cis	1	rs17213965	chr16:15881967	NDE1	chr16:15737124-15820206:+	0.17	3.47	0.00057	Waist-hip ratio	
LGG	cis	1	rs17214441	chr2:207683777	MDH1B	chr2:207598943-207630050:-	0.33	4.86	1.61E-6	Episodic memory	
LGG	cis	1	rs17216620	chr8:58169412	C8orf71	chr8:58192102-58197288:+	0.35	6.14	1.66E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17216648	chr8:58169429	C8orf71	chr8:58192102-58197288:+	0.35	6.14	1.66E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17216711	chr8:58170856	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17216957	chr8:58179893	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17217033	chr8:58180061	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17217047	chr8:58180296	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.61E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17217082	chr8:58180918	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17223420	chr12:983720	RAD52	chr12:1021255-1099219:-	-0.19	-3.95	8.93E-5	Colorectal cancer	
LGG	cis	1	rs1723267	chr7:65473314	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.58E-6	Diabetic kidney disease	
LGG	cis	1	rs1723269	chr7:65472786	CCT6P1	chr7:65216092-65228661:+	0.27	4.85	1.64E-6	Diabetic kidney disease	
LGG	cis	1	rs1723270	chr7:65469830	CCT6P1	chr7:65216092-65228661:+	0.26	4.72	3.09E-6	Diabetic kidney disease	
LGG	cis	1	rs17237094	chr12:48952456	ZNF641	chr12:48735912-48745021:-	0.23	3.58	0.000381	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs17246007	chr14:65865671	LOC645431	chr14:65877313-65879335:-	0.51	7.15	3.13E-12	Ischemic stroke	
LGG	cis	1	rs17246035	chr14:65874130	LOC645431	chr14:65877313-65879335:-	-0.5	-6.79	3.35E-11	Ischemic stroke	
LGG	cis	1	rs17246042	chr14:65874330	LOC645431	chr14:65877313-65879335:-	-0.5	-7.04	6.37E-12	Ischemic stroke	
LGG	cis	1	rs17246259	chr14:66075327	LOC645431	chr14:65877313-65879335:-	-0.46	-6.31	6.4E-10	Ischemic stroke	
LGG	cis	1	rs172722	chr6:160754202	SLC22A3	chr6:160769425-160876013:+	0.35	6.07	2.49E-9	Waist circumference	
LGG	cis	1	rs1728667	chr2:188153421	CALCRL	chr2:188207851-188313021:-	0.23	5.5	5.96E-8	Coronary heart disease	
LGG	cis	1	rs1728668	chr2:188153662	CALCRL	chr2:188207851-188313021:-	0.23	5.5	5.96E-8	Coronary heart disease	
LGG	cis	1	rs1728669	chr2:188153875	CALCRL	chr2:188207851-188313021:-	0.23	5.5	5.96E-8	Coronary heart disease	
LGG	cis	1	rs1728670	chr2:188154357	CALCRL	chr2:188207851-188313021:-	0.22	5.36	1.28E-7	Coronary heart disease	
LGG	cis	1	rs1728673	chr2:188156452	CALCRL	chr2:188207851-188313021:-	0.22	5.45	7.87E-8	Coronary heart disease	
LGG	cis	1	rs1728680	chr2:188193463	CALCRL	chr2:188207851-188313021:-	0.22	5.37	1.21E-7	Coronary heart disease	
LGG	cis	1	rs1728690	chr2:188206953	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.65E-7	Coronary heart disease	
LGG	cis	1	rs1729245	chr2:233424891	EIF4E2	chr2:233415357-233448349:+	0.21	3.59	0.000364	Height	
LGG	cis	1	rs17293608	chr10:1056252	C10orf110	chr10:1068577-1090141:+	0.31	5.6	3.58E-8	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs17304569	chr19:24240905	LOC100101266	chr19:24344995-24346249:-	0.25	4.22	2.95E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs17305573	chr20:33180152	NCOA6	chr20:33302579-33413433:-	0.25	3.47	0.00057	Melanoma	
LGG	cis	1	rs17310467	chr20:33545616	PROCR	chr20:33758727-33765164:+	-0.33	-5.85	9.16E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17317888	chr20:33594959	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.84E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17319967	chr20:33693650	GDF5	chr20:33897002-34042568:-	0.28	3.57	0.000385	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17319967	chr20:33693650	PROCR	chr20:33758727-33765164:+	-0.33	-6.11	2.06E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17323433	chr5:93551028	FAM172A	chr5:92953432-93447404:-	-0.29	-3.97	8.24E-5	Diabetic retinopathy	
LGG	cis	1	rs17327139	chr5:112710785	SRP19	chr5:112196993-112228774:+	0.29	3.57	0.000391	F-cell distribution	
LGG	cis	1	rs17333948	chr4:183933386	CDKN2AIP	chr4:184365789-184369049:+	-0.37	-3.84	0.00014	Neuroticism	
LGG	cis	1	rs17341301	chr2:160902420	LY75	chr2:160625141-160761262:-	0.13	3.76	0.000191	Idiopathic membranous nephropathy	
LGG	cis	1	rs17347505	chr7:23915283	C7orf46	chr7:23719749-23742268:+	0.2	4.24	2.62E-5	Schizophrenia	
LGG	cis	1	rs17347692	chr7:23918367	C7orf46	chr7:23719749-23742268:+	0.21	4.43	1.18E-5	Schizophrenia	
LGG	cis	1	rs17347733	chr7:23918510	C7orf46	chr7:23719749-23742268:+	0.2	4.39	1.4E-5	Schizophrenia	
LGG	cis	1	rs173509	chr5:126725641	FLJ44606	chr5:126381051-126409172:-	0.28	3.88	0.000119	IgG glycosylation	
LGG	cis	1	rs17374749	chr3:136768010	PCCB	chr3:135969167-136056737:+	-0.24	-4.36	1.55E-5	Anxiety in major depressive disorder	
LGG	cis	1	rs17376207	chr5:93545524	FAM172A	chr5:92953432-93447404:-	0.28	3.91	0.000106	Diabetic retinopathy	
LGG	cis	1	rs17376456	chr5:93557702	FAM172A	chr5:92953432-93447404:-	0.3	4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs1737944	chr17:18840433	FAM18B	chr17:18684582-18710026:+	-0.18	-4.73	3.0E-6	Educational attainment (years of education)	
LGG	cis	1	rs1737944	chr17:18840433	FBXW10	chr17:18647326-18682661:+	-0.2	-4.51	8.09E-6	Educational attainment (years of education)	
LGG	cis	1	rs1737947	chr17:18831432	FAM18B	chr17:18684582-18710026:+	0.15	3.57	0.000393	Pancreatic cancer	
LGG	cis	1	rs1737947	chr17:18831432	PRPSAP2	chr17:18759663-18834580:+	-0.2	-5.42	9.61E-8	Pancreatic cancer	
LGG	cis	1	rs17382723	chr2:242053546	MTERFD2	chr2:242034545-242041747:-	-0.24	-4	7.41E-5	Height	
LGG	cis	1	rs17386555	chr2:242371825	ANO7	chr2:242127924-242164791:+	0.38	6.59	1.1E-10	Prostate cancer	
LGG	cis	1	rs17386695	chr2:242379751	ANO7	chr2:242127924-242164791:+	-0.39	-6.85	2.24E-11	Prostate cancer	
LGG	cis	1	rs1739377	chr6:126012236	HEY2	chr6:126068780-126082414:+	0.16	3.48	0.000543	Endometrial cancer	
LGG	cis	1	rs17396122	chr2:48220336	FOXN2	chr2:48541795-48606434:+	0.29	5.37	1.21E-7	Schizophrenia	
LGG	cis	1	rs17396440	chr2:48270256	FOXN2	chr2:48541795-48606434:+	0.3	5.75	1.6E-8	Schizophrenia	
LGG	cis	1	rs17401737	chr20:33552642	PROCR	chr20:33758727-33765164:+	-0.33	-5.82	1.04E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs17407324	chr4:10273043	SLC2A9	chr4:9827850-10041872:-	-0.23	-5.33	1.52E-7	Schizophrenia (age at onset)	
LGG	cis	1	rs17407555	chr4:10274994	SLC2A9	chr4:9827850-10041872:-	0.23	5.39	1.1E-7	Schizophrenia (age at onset)	
LGG	cis	1	rs17425307	chr8:21190781	PIWIL2	chr8:22132810-22213584:+	-0.15	-3.56	0.000409	Sitting height ratio	
LGG	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.74	23.81	7.41E-84	Carotid intima media thickness	
LGG	cis	1	rs17442031	chr12:17502531	LMO3	chr12:16701307-16762758:-	0.14	3.49	0.000526	Life satisfaction	
LGG	cis	1	rs17446828	chr5:151731007	NMUR2	chr5:151771102-151784840:-	-0.23	-3.82	0.000149	Optic nerve measurement (cup area)	
LGG	cis	1	rs17450788	chr19:22224755	ZNF257	chr19:22235266-22273901:+	0.56	9	4.87E-18	Body mass index (change over time)	
LGG	cis	1	rs17450853	chr6:56788004	BEND6	chr6:56819773-56892138:+	-0.32	-5.8	1.19E-8	Menarche (age at onset)	
LGG	cis	1	rs17450853	chr6:56788004	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.89	0.000113	Menarche (age at onset)	
LGG	cis	1	rs174551	chr11:61573684	FADS1	chr11:61567103-61584529:-	-0.21	-4.86	1.59E-6	LDL cholesterol	
LGG	cis	1	rs17505772	chr13:31456002	C13orf33	chr13:31480312-31499708:+	0.44	5.92	6.01E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs17505830	chr7:117998621	ANKRD7	chr7:117864712-117882782:+	0.22	3.74	0.000207	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs17507481	chr4:17620066	MED28	chr4:17616273-17629791:+	0.21	4.53	7.43E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs17513752	chr19:30290811	CCNE1	chr19:30302901-30315218:+	0.21	4.59	5.57E-6	Bladder cancer	
LGG	cis	1	rs17515241	chr7:74132014	STAG3L2	chr7:74298846-74306731:-	0.27	3.97	8.39E-5	Menarche (age at onset)	
LGG	cis	1	rs1752435	chr14:59946094	C14orf149	chr14:59939406-59951126:-	-0.43	-4.69	3.47E-6	Schizophrenia	
LGG	cis	1	rs1752435	chr14:59946094	JKAMP	chr14:59951161-59972080:+	0.5	4.88	1.4E-6	Schizophrenia	
LGG	cis	1	rs17534004	chr13:31469665	C13orf33	chr13:31480312-31499708:+	0.34	4.81	2.04E-6	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs17534109	chr13:31470937	C13orf33	chr13:31480312-31499708:+	-0.34	-4.85	1.69E-6	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs17534137	chr13:31471920	C13orf33	chr13:31480312-31499708:+	0.44	6.06	2.78E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs17538840	chr2:61077817	AHSA2	chr2:61404553-61414058:+	0.23	5.77	1.44E-8	Inflammatory skin disease	
LGG	cis	1	rs17538840	chr2:61077817	C2orf74	chr2:61372243-61391964:+	-0.3	-5.02	7.26E-7	Inflammatory skin disease	
LGG	cis	1	rs175425	chr14:75626131	ACYP1	chr14:75519930-75530736:-	0.15	3.87	0.000123	Height	
LGG	cis	1	rs175425	chr14:75626131	EIF2B2	chr14:75469612-75476292:+	-0.18	-3.54	0.000446	Height	
LGG	cis	1	rs175426	chr14:75624134	ACYP1	chr14:75519930-75530736:-	0.15	3.98	8.09E-5	Height	
LGG	cis	1	rs175436	chr14:75608683	ACYP1	chr14:75519930-75530736:-	0.15	3.98	7.79E-5	Height	
LGG	cis	1	rs175442	chr14:75603564	ACYP1	chr14:75519930-75530736:-	0.15	4.07	5.53E-5	Height	
LGG	cis	1	rs175443	chr14:75601963	ACYP1	chr14:75519930-75530736:-	0.15	4.06	5.78E-5	Height	
LGG	cis	1	rs175449	chr14:75590846	ACYP1	chr14:75519930-75530736:-	0.15	4.06	5.59E-5	Height	
LGG	cis	1	rs17546473	chr17:33285996	RAD51L3	chr17:33426811-33448541:-	-0.31	-3.81	0.000159	Night sleep phenotypes	
LGG	cis	1	rs17548631	chr22:24144125	C22orf43	chr22:23950640-23974487:-	-0.32	-4.45	1.06E-5	IgG glycosylation	
LGG	cis	1	rs17548631	chr22:24144125	DERL3	chr22:24176691-24181315:-	0.31	5.59	3.87E-8	IgG glycosylation	
LGG	cis	1	rs175492	chr14:75545220	ACYP1	chr14:75519930-75530736:-	-0.15	-4.17	3.6E-5	Height	
LGG	cis	1	rs17549954	chr17:61707032	DDX42	chr17:61851567-61896676:+	-0.17	-3.95	8.87E-5	Body mass index	
LGG	cis	1	rs17549954	chr17:61707032	FTSJ3	chr17:61896795-61905031:-	0.41	8.23	1.72E-15	Body mass index	
LGG	cis	1	rs17549954	chr17:61707032	SMARCD2	chr17:61909441-61920351:-	0.17	3.71	0.000235	Body mass index	
LGG	cis	1	rs175512	chr14:75523382	ACYP1	chr14:75519930-75530736:-	0.15	4.06	5.68E-5	Height	
LGG	cis	1	rs17551370	chr5:110404185	TSLP	chr5:110405778-110413722:+	-0.32	-4.46	1.03E-5	Eosinophil counts	
LGG	cis	1	rs17566701	chr7:66193183	ASL	chr7:65540776-65558321:+	-0.2	-5	8.13E-7	Aortic root size	
LGG	cis	1	rs17566701	chr7:66193183	TYW1	chr7:66461817-66704496:+	0.19	3.91	0.000107	Aortic root size	
LGG	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.56	-9.34	3.42E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.53	8.82	1.99E-17	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.54	-9.05	3.38E-18	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs17583830	chr6:107778358	QRSL1	chr6:107077441-107116290:+	-0.32	-3.61	0.000335	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs17584024	chr7:117998472	ANKRD7	chr7:117864712-117882782:+	0.22	3.84	0.000139	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs17584115	chr7:117998812	ANKRD7	chr7:117864712-117882782:+	0.22	3.81	0.000157	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs17584143	chr7:118000283	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs17584359	chr7:118006306	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.82	0.00015	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs17584578	chr2:86307624	LOC90784	chr2:86247339-86250991:-	0.4	4.11	4.58E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs17592784	chr4:42471181	SHISA3	chr4:42399856-42404503:+	0.29	4.44	1.12E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.54	-12.37	9.1E-31	Forced vital capacity	
LGG	cis	1	rs17598927	chr6:26184640	HIST1H2AE	chr6:26217148-26217711:+	0.33	4.48	9.27E-6	Renal underexcretion gout;Gout	
LGG	cis	1	rs17598927	chr6:26184640	HIST1H3E	chr6:26224427-26226589:+	-0.51	-7.81	3.61E-14	Renal underexcretion gout;Gout	
LGG	cis	1	rs17599764	chr13:31469580	C13orf33	chr13:31480312-31499708:+	0.44	5.93	5.69E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs17600551	chr15:85319258	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.35	1.66E-5	Schizophrenia	
LGG	cis	1	rs17600551	chr15:85319258	LOC388152	chr15:84867600-84898920:-	-0.29	-5.47	7.21E-8	Schizophrenia	
LGG	cis	1	rs17600551	chr15:85319258	WDR73	chr15:85186012-85197524:-	-0.19	-3.47	0.000573	Schizophrenia	
LGG	cis	1	rs17601029	chr15:85347709	GOLGA6L5	chr15:85047738-85060078:-	-0.19	-4.2	3.18E-5	Schizophrenia	
LGG	cis	1	rs17601029	chr15:85347709	LOC388152	chr15:84867600-84898920:-	-0.29	-5.33	1.47E-7	Schizophrenia	
LGG	cis	1	rs1760621	chr1:183156006	LAMC2	chr1:183155174-183214262:+	0.27	5.42	9.55E-8	Hypertriglyceridemia	
LGG	cis	1	rs1760624	chr1:183158552	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs17612	chr9:123725926	TRAF1	chr9:123664672-123691479:-	0.36	4.16	3.77E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs17615788	chr8:21814739	XPO7	chr8:21777180-21864095:+	0.15	3.53	0.000463	Mean corpuscular volume	
LGG	cis	1	rs17628883	chr4:171009009	AADAT	chr4:170981374-171011372:-	-0.31	-3.92	0.000102	Thyroid hormone levels	
LGG	cis	1	rs17628895	chr4:171021185	AADAT	chr4:170981374-171011372:-	-0.32	-4.08	5.36E-5	Thyroid hormone levels	
LGG	cis	1	rs17628931	chr4:171030807	AADAT	chr4:170981374-171011372:-	-0.32	-4.13	4.3E-5	Thyroid hormone levels	
LGG	cis	1	rs17630450	chr4:42449681	SHISA3	chr4:42399856-42404503:+	-0.3	-4.66	4.04E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs17630526	chr4:42461004	SHISA3	chr4:42399856-42404503:+	0.26	3.88	0.000121	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs17630562	chr4:42468448	SHISA3	chr4:42399856-42404503:+	0.29	4.53	7.29E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs17630758	chr22:24136542	C22orf43	chr22:23950640-23974487:-	0.3	4.28	2.29E-5	IgG glycosylation	
LGG	cis	1	rs17630758	chr22:24136542	DERL3	chr22:24176691-24181315:-	-0.3	-5.46	7.49E-8	IgG glycosylation	
LGG	cis	1	rs17632	chr20:47713063	ARFGEF2	chr20:47538275-47653229:+	0.11	4.11	4.64E-5	Anger	
LGG	cis	1	rs17632	chr20:47713063	CSE1L	chr20:47662838-47713484:+	0.18	4.98	9.01E-7	Anger	
LGG	cis	1	rs17645523	chr15:50882645	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs17645649	chr15:50900370	SPPL2A	chr15:50999739-51057910:-	0.12	4.02	6.65E-5	QT interval	
LGG	cis	1	rs17645826	chr15:50950141	SPPL2A	chr15:50999739-51057910:-	0.13	4.23	2.83E-5	QT interval	
LGG	cis	1	rs17646946	chr1:152062767	HRNR	chr1:152184558-152196669:-	0.27	3.74	0.000202	Common traits (Other)	
LGG	cis	1	rs17661933	chr19:50534520	SIGLEC16	chr19:50472912-50479075:+	-0.45	-6.49	2.06E-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LGG	cis	1	rs17668704	chr16:72257699	DHODH	chr16:72042643-72058954:+	0.21	4.52	7.72E-6	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs17669480	chr10:102066065	BLOC1S2	chr10:102033713-102046439:-	-0.32	-4.7	3.35E-6	Obesity-related traits	
LGG	cis	1	rs17671194	chr15:40667539	C15orf23	chr15:40674922-40686488:+	1.04	18.05	3.21E-56	Heschl's gyrus morphology	
LGG	cis	1	rs17671194	chr15:40667539	IVD	chr15:40697686-40713512:+	-0.34	-3.91	0.000104	Heschl's gyrus morphology	
LGG	cis	1	rs17671250	chr15:40673124	C15orf23	chr15:40674922-40686488:+	-0.84	-14.81	2.59E-41	Heschl's gyrus morphology	
LGG	cis	1	rs17671250	chr15:40673124	IVD	chr15:40697686-40713512:+	0.43	5.45	8.0E-8	Heschl's gyrus morphology	
LGG	cis	1	rs17674998	chr17:41879544	VAT1	chr17:41166622-41174459:-	-0.18	-3.92	0.000103	Triglycerides	
LGG	cis	1	rs17675122	chr17:41886190	VAT1	chr17:41166622-41174459:-	-0.17	-3.54	0.000441	Triglycerides	
LGG	cis	1	rs17677510	chr7:29182574	CPVL	chr7:29035249-29234892:-	-0.22	-3.89	0.000112	Diabetes related insulin traits	
LGG	cis	1	rs1768208	chr3:39523003	RPSA	chr3:39448204-39454030:+	0.25	5.83	9.97E-9	Corticobasal degeneration;Progressive supranuclear palsy	
LGG	cis	1	rs17685143	chr6:56774788	BEND6	chr6:56819773-56892138:+	-0.3	-5.36	1.3E-7	Menarche (age at onset)	
LGG	cis	1	rs17685143	chr6:56774788	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.78	0.000174	Menarche (age at onset)	
LGG	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.87	1.52E-6	Body mass index	
LGG	cis	1	rs1768803	chr1:46546208	MUTYH	chr1:45794915-45806142:-	0.14	5.22	2.69E-7	Body mass index	
LGG	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.84	1.71E-6	Body mass index	
LGG	cis	1	rs1768816	chr1:46528599	MUTYH	chr1:45794915-45806142:-	0.14	5.29	1.86E-7	Body mass index	
LGG	cis	1	rs17691170	chr3:121357626	IQCB1	chr3:121488610-121553926:-	0.35	6.6	1.06E-10	Cognitive performance	
LGG	cis	1	rs17693816	chr9:26783300	LRRC19	chr9:26993143-27005691:-	-0.23	-4	7.23E-5	Smoking behavior	
LGG	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.28	7.24	1.79E-12	Height	
LGG	cis	1	rs17694011	chr3:134213981	CEP63	chr3:134204575-134293852:+	0.19	3.57	0.000398	Height	
LGG	cis	1	rs17694493	chr9:22041998	MTAP	chr9:21802635-22029593:+	0.27	4.3	2.1E-5	Prostate cancer	
LGG	cis	1	rs17698817	chr14:88822976	KCNK10	chr14:88646454-88793256:-	-0.18	-3.46	0.000595	Coronary artery calcification	
LGG	cis	1	rs17698817	chr14:88822976	SPATA7	chr14:88852012-88904802:+	-0.43	-7.48	3.34E-13	Coronary artery calcification	
LGG	cis	1	rs17707196	chr2:188201216	CALCRL	chr2:188207851-188313021:-	-0.21	-5.05	6.17E-7	Coronary heart disease	
LGG	cis	1	rs17712049	chr7:48266195	ABCA13	chr7:48211057-48687091:+	-0.44	-5.98	4.2E-9	Refractive astigmatism	
LGG	cis	1	rs17712926	chr16:77319037	ADAMTS18	chr16:77316026-77469011:-	-0.31	-4.53	7.46E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17712956	chr16:77322254	ADAMTS18	chr16:77316026-77469011:-	-0.31	-4.56	6.56E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17712992	chr16:77326391	ADAMTS18	chr16:77316026-77469011:-	-0.27	-4	7.37E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17713035	chr16:77330423	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17713119	chr16:77336426	ADAMTS18	chr16:77316026-77469011:-	-0.25	-3.71	0.000227	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17713396	chr2:227201	FAM150B	chr2:279563-288308:-	-0.34	-6.31	6.21E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs17713396	chr2:227201	SNTG2	chr2:946555-1371382:+	0.19	3.46	0.000598	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs17713729	chr2:249092	FAM150B	chr2:279563-288308:-	-0.33	-6.23	9.88E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs17713729	chr2:249092	SNTG2	chr2:946555-1371382:+	0.23	4.21	3.04E-5	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs17714252	chr2:285471	FAM150B	chr2:279563-288308:-	-0.33	-6.21	1.15E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs17714252	chr2:285471	SNTG2	chr2:946555-1371382:+	0.19	3.55	0.000417	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs1772408	chr1:159005649	IFI16	chr1:158969758-159024943:+	-0.17	-3.85	0.000136	Obesity-related traits	
LGG	cis	1	rs1772415	chr1:159002778	IFI16	chr1:158969758-159024943:+	-0.19	-4.17	3.61E-5	Obesity-related traits	
LGG	cis	1	rs17727568	chr5:150244688	LOC134466	chr5:150310000-150326146:-	0.49	5.19	3.1E-7	Crohn's disease	
LGG	cis	1	rs17742905	chr17:41891143	VAT1	chr17:41166622-41174459:-	-0.17	-3.62	0.000331	Triglycerides	
LGG	cis	1	rs17745344	chr17:53048319	TOM1L1	chr17:52978052-53039328:+	-0.19	-5.38	1.13E-7	Breast cancer	
LGG	cis	1	rs17746014	chr10:102315354	HIF1AN	chr10:102295641-102313680:+	0.21	3.94	9.49E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs17746014	chr10:102315354	NDUFB8	chr10:102283497-102289636:-	0.17	4.63	4.68E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs17746014	chr10:102315354	WNT8B	chr10:102222812-102243397:+	0.49	7.68	8.71E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1775148	chr1:205757824	PM20D1	chr1:205797154-205819245:-	-0.49	-9.05	3.27E-18	Prostate cancer	
LGG	cis	1	rs1775148	chr1:205757824	RAB7L1	chr1:205737115-205744610:-	0.17	4.15	3.99E-5	Prostate cancer	
LGG	cis	1	rs1775151	chr1:205745684	PM20D1	chr1:205797154-205819245:-	-0.38	-6.38	4.21E-10	Parkinson's disease	
LGG	cis	1	rs17752459	chr6:56798755	BEND6	chr6:56819773-56892138:+	-0.33	-5.88	7.48E-9	Menarche (age at onset)	
LGG	cis	1	rs17752459	chr6:56798755	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.05	5.85E-5	Menarche (age at onset)	
LGG	cis	1	rs17754780	chr6:126664333	CENPW	chr6:126661253-126804465:+	-0.15	-3.91	0.000105	Type 1 diabetes	
LGG	cis	1	rs17755571	chr9:26783388	LRRC19	chr9:26993143-27005691:-	-0.24	-4.06	5.75E-5	Smoking behavior	
LGG	cis	1	rs17756240	chr4:57355192	SRP72	chr4:57333762-57369846:+	-0.36	-4.72	3.04E-6	Airflow obstruction	
LGG	cis	1	rs17756804	chr2:188163250	CALCRL	chr2:188207851-188313021:-	-0.22	-5.19	3.07E-7	Coronary heart disease	
LGG	cis	1	rs17769663	chr16:77318839	ADAMTS18	chr16:77316026-77469011:-	-0.32	-4.67	3.93E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17769712	chr16:77322499	ADAMTS18	chr16:77316026-77469011:-	0.31	4.53	7.46E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17769748	chr16:77327417	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17769754	chr16:77327861	ADAMTS18	chr16:77316026-77469011:-	0.29	4.23	2.82E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17769760	chr16:77329400	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17769766	chr16:77329464	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs17772064	chr14:88822871	SPATA7	chr14:88852012-88904802:+	-0.45	-8.3	1.04E-15	Coronary artery calcification	
LGG	cis	1	rs17772222	chr14:88826482	SPATA7	chr14:88852012-88904802:+	0.46	8.07	5.51E-15	Coronary artery calcification	
LGG	cis	1	rs17772288	chr14:88827366	KCNK10	chr14:88646454-88793256:-	-0.17	-3.5	0.000513	Coronary artery calcification	
LGG	cis	1	rs17772288	chr14:88827366	SPATA7	chr14:88852012-88904802:+	-0.44	-7.91	1.69E-14	Coronary artery calcification	
LGG	cis	1	rs17779494	chr15:43579223	STRC	chr15:43891762-43924561:-	-0.24	-5.23	2.56E-7	Lung cancer	
LGG	cis	1	rs17779494	chr15:43579223	TGM5	chr15:43525375-43559055:-	0.2	3.66	0.000285	Lung cancer	
LGG	cis	1	rs17780080	chr17:30343146	LRRC37B	chr17:30335037-30380517:+	0.26	5.43	8.77E-8	Height	
LGG	cis	1	rs17780086	chr17:30343282	LRRC37B	chr17:30335037-30380517:+	0.26	5.43	8.77E-8	Height	
LGG	cis	1	rs1778508	chr6:28229881	ZNF165	chr6:28046572-28057338:+	0.32	4.71	3.24E-6	Depression	
LGG	cis	1	rs1778508	chr6:28229881	ZNF187	chr6:28234788-28245978:+	0.26	4.52	7.75E-6	Depression	
LGG	cis	1	rs1778508	chr6:28229881	ZNF389	chr6:28129551-28137375:+	-0.43	-6.84	2.41E-11	Depression	
LGG	cis	1	rs1778508	chr6:28229881	ZSCAN12	chr6:28346770-28367544:-	0.33	4.67	3.91E-6	Depression	
LGG	cis	1	rs1778508	chr6:28229881	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.31	2.01E-5	Depression	
LGG	cis	1	rs1778511	chr6:28229411	ZNF165	chr6:28046572-28057338:+	0.32	4.71	3.24E-6	Depression	
LGG	cis	1	rs1778511	chr6:28229411	ZNF187	chr6:28234788-28245978:+	0.26	4.52	7.75E-6	Depression	
LGG	cis	1	rs1778511	chr6:28229411	ZNF389	chr6:28129551-28137375:+	-0.43	-6.84	2.41E-11	Depression	
LGG	cis	1	rs1778511	chr6:28229411	ZSCAN12	chr6:28346770-28367544:-	0.33	4.67	3.91E-6	Depression	
LGG	cis	1	rs1778511	chr6:28229411	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.31	2.01E-5	Depression	
LGG	cis	1	rs17790938	chr20:49509184	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs1779410	chr1:205248759	TMEM81	chr1:205052258-205053588:-	-0.21	-4.48	9.4E-6	Mean platelet volume	
LGG	cis	1	rs17799244	chr14:90760040	C14orf102	chr14:90744398-90798279:-	-0.22	-3.86	0.00013	Longevity	
LGG	cis	1	rs17799244	chr14:90760040	PSMC1	chr14:90722894-90738964:+	-0.17	-3.64	0.000296	Longevity	
LGG	cis	1	rs17800886	chr5:150309539	LOC134466	chr5:150310000-150326146:-	0.53	6.07	2.58E-9	Crohn's disease	
LGG	cis	1	rs17800987	chr5:150323428	LOC134466	chr5:150310000-150326146:-	0.52	5.8	1.19E-8	Crohn's disease	
LGG	cis	1	rs17805326	chr8:58169533	C8orf71	chr8:58192102-58197288:+	0.36	6.35	4.96E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17805332	chr8:58169798	C8orf71	chr8:58192102-58197288:+	0.35	6.16	1.55E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17805549	chr8:58179653	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17805602	chr8:58179915	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17805656	chr8:58180318	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.61E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17816781	chr8:58186161	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs17818028	chr17:53062755	TOM1L1	chr17:52978052-53039328:+	0.18	5.3	1.78E-7	Breast cancer	
LGG	cis	1	rs17818399	chr2:46826026	ATP6V1E2	chr2:46738988-46769696:-	-0.19	-4.1	4.81E-5	Height	
LGG	cis	1	rs17818399	chr2:46826026	CRIPT	chr2:46844325-46852880:+	0.41	9.17	1.3E-18	Height	
LGG	cis	1	rs17818399	chr2:46826026	PIGF	chr2:46808414-46844251:-	0.16	3.74	0.000206	Height	
LGG	cis	1	rs17826448	chr14:65852017	AKAP5	chr14:64932217-64941220:+	0.15	3.57	0.000386	Ischemic stroke	
LGG	cis	1	rs17826448	chr14:65852017	LOC645431	chr14:65877313-65879335:-	0.44	6.59	1.14E-10	Ischemic stroke	
LGG	cis	1	rs17826466	chr14:65852170	LOC645431	chr14:65877313-65879335:-	-0.43	-6.07	2.58E-9	Ischemic stroke	
LGG	cis	1	rs17826580	chr14:65915262	LOC645431	chr14:65877313-65879335:-	-0.52	-7.16	2.89E-12	Ischemic stroke	
LGG	cis	1	rs17826724	chr14:66068320	LOC645431	chr14:65877313-65879335:-	-0.45	-6.18	1.33E-9	Ischemic stroke	
LGG	cis	1	rs17826736	chr14:66082202	LOC645431	chr14:65877313-65879335:-	-0.45	-6.14	1.71E-9	Ischemic stroke	
LGG	cis	1	rs17826790	chr14:66103427	LOC645431	chr14:65877313-65879335:-	-0.48	-6.57	1.28E-10	Ischemic stroke	
LGG	cis	1	rs17826796	chr14:66104187	LOC645431	chr14:65877313-65879335:-	-0.49	-6.78	3.38E-11	Ischemic stroke	
LGG	cis	1	rs17826820	chr14:66113837	LOC645431	chr14:65877313-65879335:-	-0.49	-6.63	8.86E-11	Ischemic stroke	
LGG	cis	1	rs17831161	chr2:160909360	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs17831191	chr2:160911332	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs17831251	chr2:160914156	LY75	chr2:160625141-160761262:-	0.13	3.68	0.000254	Idiopathic membranous nephropathy	
LGG	cis	1	rs1783521	chr11:64106291	C11orf20	chr11:64067863-64072238:+	0.18	3.95	8.98E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs1783521	chr11:64106291	CCDC88B	chr11:64107695-64125005:+	-0.12	-4.54	6.97E-6	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs1783521	chr11:64106291	PPP1R14B	chr11:64011953-64014413:-	-0.13	-3.86	0.000126	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs17836662	chr22:50672154	MLC1	chr22:50497820-50524358:-	0.1	3.65	0.000293	Obesity-related traits	
LGG	cis	1	rs17839567	chr16:31057945	MYST1	chr16:31128985-31142713:+	0.15	4.31	1.95E-5	Response to metformin (IC50)	
LGG	cis	1	rs17839567	chr16:31057945	PRSS53	chr16:31094747-31106276:-	-0.17	-4.81	2.03E-6	Response to metformin (IC50)	
LGG	cis	1	rs1783961	chr11:71576095	FAM86C	chr11:71498557-71512276:+	-0.49	-5.01	7.71E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs17839695	chr5:126732812	FLJ44606	chr5:126381051-126409172:-	0.28	3.75	0.000196	IgG glycosylation	
LGG	cis	1	rs17848459	chr22:51012311	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs17860606	chr6:170099561	C6orf70	chr6:170151721-170181617:+	-0.18	-3.51	0.000493	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs17860606	chr6:170099561	PHF10	chr6:170104004-170124106:-	-0.23	-3.47	0.000561	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs17860606	chr6:170099561	WDR27	chr6:169857307-170102159:-	-0.41	-9.37	2.63E-19	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs17862920	chr2:234827995	USP40	chr2:234384166-234475428:-	-0.23	-3.63	0.000309	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs1791544	chr11:71784957	FAM86C	chr11:71498557-71512276:+	0.39	4.19	3.32E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1792379	chr11:114627619	C11orf71	chr11:114262170-114271255:-	0.21	4.35	1.64E-5	Urinary albumin excretion	
LGG	cis	1	rs1795379	chr12:75941042	GLIPR1L2	chr12:75784889-75825591:+	-0.36	-6.12	1.95E-9	Polycystic ovary syndrome	
LGG	cis	1	rs1796220	chr7:66062100	CCT6P1	chr7:65216092-65228661:+	0.23	4.1	4.76E-5	Diabetic kidney disease	
LGG	cis	1	rs1796228	chr7:66033084	CCT6P1	chr7:65216092-65228661:+	0.22	4.05	6.01E-5	Diabetic kidney disease	
LGG	cis	1	rs1799945	chr6:26091179	HIST1H3E	chr6:26224427-26226589:+	0.31	4.26	2.41E-5	Systolic blood pressure;Hypertension;Diastolic blood pressure;Iron status biomarkers	
LGG	cis	1	rs1799958	chr12:121176083	SPPL3	chr12:121201036-121342151:-	-0.23	-3.99	7.69E-5	Urinary metabolites (H-NMR features)	
LGG	cis	1	rs1800615	chr1:15832281	AGMAT	chr1:15899152-15911605:-	0.19	5.45	7.85E-8	Glomerular filtration rate (creatinine)	
LGG	cis	1	rs1800615	chr1:15832281	CASP9	chr1:15817324-15851384:-	0.2	4.3	2.11E-5	Glomerular filtration rate (creatinine)	
LGG	cis	1	rs1800662	chr10:102289078	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1800662	chr10:102289078	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1800662	chr10:102289078	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs1802236	chr12:56679751	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs180515	chr17:58024275	DHX40P1	chr17:58053385-58096336:-	0.39	7.66	1.01E-13	Multiple sclerosis	
LGG	cis	1	rs1806606	chr1:202442385	UBE2T	chr1:202300786-202311094:-	-0.13	-4.12	4.4E-5	Sex ratio	
LGG	cis	1	rs1807782	chr2:103033147	IL18R1	chr2:102927962-103015215:+	-0.37	-5.92	5.93E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1807782	chr2:103033147	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.18	3.2E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1808579	chr18:21104888	C18orf8	chr18:21083462-21111742:+	0.2	3.91	0.000105	Body mass index	
LGG	cis	1	rs1808579	chr18:21104888	NPC1	chr18:21108363-21166581:-	0.13	3.73	0.000213	Body mass index	
LGG	cis	1	rs1810563	chr1:12054030	MIIP	chr1:12079512-12092106:+	-0.09	-3.5	0.000513	Platelet count	
LGG	cis	1	rs1813615	chr5:42018896	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.000302	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs1813616	chr5:42019034	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.000302	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.28	7.2	2.35E-12	Height	
LGG	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.27	7.05	6.29E-12	Height	
LGG	cis	1	rs1814337	chr3:134200682	CEP63	chr3:134204575-134293852:+	0.19	3.47	0.00056	Height	
LGG	cis	1	rs1815787	chr11:116921397	SIDT2	chr11:117049939-117068161:+	0.31	3.77	0.000182	Subjective well-being	
LGG	cis	1	rs1816256	chr5:150272853	LOC134466	chr5:150310000-150326146:-	0.41	4.66	4.0E-6	Crohn's disease	
LGG	cis	1	rs1818426	chr4:25286293	ANAPC4	chr4:25378848-25420119:+	-0.32	-5.1	4.78E-7	Cannabis dependence	
LGG	cis	1	rs1818426	chr4:25286293	PI4K2B	chr4:25162285-25280831:+	-0.3	-5.18	3.26E-7	Cannabis dependence	
LGG	cis	1	rs1818462	chr1:202459114	PTPN7	chr1:202116143-202130709:-	-0.11	-3.47	0.000561	Sex ratio	
LGG	cis	1	rs1818462	chr1:202459114	UBE2T	chr1:202300786-202311094:-	-0.13	-3.92	0.000101	Sex ratio	
LGG	cis	1	rs1818950	chr15:84722521	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.54	4.91E-8	Schizophrenia	
LGG	cis	1	rs1818950	chr15:84722521	LOC388152	chr15:84867600-84898920:-	-0.32	-6.33	5.62E-10	Schizophrenia	
LGG	cis	1	rs1820682	chr5:150262142	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs1823874	chr15:100357435	C15orf51	chr15:100330361-100347132:-	-0.43	-9.19	1.09E-18	IgG glycosylation	
LGG	cis	1	rs182988	chr5:112813566	SRP19	chr5:112196993-112228774:+	-0.28	-3.58	0.000373	F-cell distribution	
LGG	cis	1	rs1830074	chr7:6718674	PMS2CL	chr7:6749757-6793492:+	-0.42	-10.18	3.17E-22	Body mass index	
LGG	cis	1	rs1830074	chr7:6718674	RSPH10B2	chr7:6793740-6838396:+;chr7	-0.21	-3.97	8.18E-5	Body mass index	
LGG	cis	1	rs1830074	chr7:6718674	ZNF12	chr7:6728064-6746566:-	-0.18	-4.41	1.25E-5	Body mass index	
LGG	cis	1	rs1832719	chr1:202447026	UBE2T	chr1:202300786-202311094:-	-0.13	-4	7.41E-5	Sex ratio	
LGG	cis	1	rs1833176	chr7:33341979	BBS9	chr7:33169152-33645680:+	0.46	6.3	6.72E-10	Smooth-surface caries	
LGG	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.8	15.29	1.88E-43	Type 2 diabetes	
LGG	cis	1	rs1833896	chr5:56097669	MIER3	chr5:56215429-56267501:-	0.16	3.51	0.000497	Type 2 diabetes	
LGG	cis	1	rs1834839	chr2:166885888	SCN2A	chr2:166095912-166248818:+	0.09	3.58	0.000381	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1834839	chr2:166885888	TTC21B	chr2:166713988-166810348:-	0.13	3.92	0.000101	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1834840	chr2:166885720	SCN2A	chr2:166095912-166248818:+	0.09	3.58	0.000381	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1834840	chr2:166885720	TTC21B	chr2:166713988-166810348:-	0.13	3.92	0.000101	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs183618	chr17:53235974	COX11	chr17:53029259-53046064:-	0.41	8.45	3.23E-16	Menarche (age at onset)	
LGG	cis	1	rs1836860	chr3:186436604	KNG1	chr3:186435120-186461741:+	0.15	3.48	0.000551	Adiponectin levels	
LGG	cis	1	rs1839622	chr12:7334534	PEX5	chr12:7341759-7371167:+	0.33	7.2	2.24E-12	IgG glycosylation	
LGG	cis	1	rs1839972	chr15:90891354	IQGAP1	chr15:90931473-91045475:+	0.12	3.92	0.000102	Rheumatoid arthritis	
LGG	cis	1	rs1839972	chr15:90891354	TTLL13	chr15:90792764-90815443:+	0.19	3.48	0.000552	Rheumatoid arthritis	
LGG	cis	1	rs1841547	chr2:166886819	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000401	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1841547	chr2:166886819	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.35E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs1843200	chr3:136766976	PCCB	chr3:135969167-136056737:+	0.23	4.07	5.38E-5	Anxiety in major depressive disorder	
LGG	cis	1	rs1848093	chr15:84755527	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.57	4.18E-8	Schizophrenia	
LGG	cis	1	rs1848093	chr15:84755527	LOC388152	chr15:84867600-84898920:-	-0.32	-6.4	3.63E-10	Schizophrenia	
LGG	cis	1	rs1849004	chr19:22142455	ZNF257	chr19:22235266-22273901:+	0.57	9.03	4.07E-18	Body mass index (change over time)	
LGG	cis	1	rs1851664	chr3:186436503	KNG1	chr3:186435120-186461741:+	-0.15	-3.47	0.000571	Adiponectin levels	
LGG	cis	1	rs1851665	chr3:186436398	KNG1	chr3:186435120-186461741:+	-0.15	-3.47	0.000574	Adiponectin levels	
LGG	cis	1	rs185336	chr5:112739836	SRP19	chr5:112196993-112228774:+	0.3	3.66	0.000278	F-cell distribution	
LGG	cis	1	rs1854774	chr4:129988405	C4orf33	chr4:130014829-130033842:+	-0.58	-9.53	7.46E-20	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs1854779	chr1:152880672	SMCP	chr1:152850798-152857515:+	-0.33	-5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs185538822	chr4:106803682	GSTCD	chr4:106629941-106768881:+	0.35	3.74	0.000204	Post bronchodilator FEV1	
LGG	cis	1	rs1856859	chr6:151860110	C6orf97	chr6:151815175-151942327:+	-0.27	-4.35	1.68E-5	Bone mineral density (spine)	
LGG	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.49	-10.13	5.19E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1858482	chr1:152306921	HRNR	chr1:152184558-152196669:-	0.54	7.96	1.21E-14	Atopic dermatitis	
LGG	cis	1	rs1858821	chr22:31676454	LIMK2	chr22:31608250-31676064:+	0.27	5.65	2.78E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs1859690	chr7:99227172	CYP3A5	chr7:99245818-99332821:-	0.39	3.94	9.34E-5	Blood metabolite levels	
LGG	cis	1	rs1860596	chr4:17660082	MED28	chr4:17616273-17629791:+	0.2	4.19	3.38E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1860597	chr4:17657650	MED28	chr4:17616273-17629791:+	0.18	3.94	9.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1861243	chr2:39956836	THUMPD2	chr2:39963200-40006416:-	-0.32	-5.82	1.05E-8	Personality dimensions	
LGG	cis	1	rs1861246	chr2:102966783	IL18R1	chr2:102927962-103015215:+	-0.39	-6.25	9.12E-10	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1861246	chr2:102966783	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.31	1.62E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs1861444	chr2:37464511	CEBPZ	chr2:37428778-37458740:-	0.19	5.11	4.63E-7	Chronic lymphocytic leukemia	
LGG	cis	1	rs1861612	chr2:230522398	DNER	chr2:230222346-230579286:-	0.29	6.61	9.78E-11	Type 2 diabetes	
LGG	cis	1	rs1861662	chr16:50107383	HEATR3	chr16:50099881-50139373:+	0.3	4.1	4.89E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs1862228	chr5:78314051	BHMT	chr5:78407604-78428112:+	-0.18	-3.6	0.000355	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.8	15.29	1.88E-43	Type 2 diabetes	
LGG	cis	1	rs1862619	chr5:56098256	MIER3	chr5:56215429-56267501:-	0.16	3.51	0.000497	Type 2 diabetes	
LGG	cis	1	rs186378	chr7:65582058	CCT6P1	chr7:65216092-65228661:+	0.25	4.6	5.49E-6	Diabetic kidney disease	
LGG	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.27	7.15	3.13E-12	Height	
LGG	cis	1	rs1863998	chr5:150271753	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs1864367	chr3:53111704	RFT1	chr3:53122503-53164470:-	-0.49	-10.48	2.54E-23	Height	
LGG	cis	1	rs1864395	chr10:43655697	CSGALNACT2	chr10:43633934-43680747:+	-0.34	-8.06	5.71E-15	Hirschsprung disease	
LGG	cis	1	rs1864399	chr10:43610455	CSGALNACT2	chr10:43633934-43680747:+	-0.36	-8.73	3.97E-17	Hirschsprung disease	
LGG	cis	1	rs1864410	chr10:43575625	CSGALNACT2	chr10:43633934-43680747:+	-0.23	-5.34	1.41E-7	Hirschsprung disease	
LGG	cis	1	rs1865687	chr2:25112885	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs186595	chr11:108251211	ATM	chr11:108093559-108239826:+	-0.11	-3.46	0.000598	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs1866295	chr12:104186946	NT5DC3	chr12:104164231-104234975:-	-0.22	-4.6	5.4E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs1867146	chr15:75354971	PPCDC	chr15:75315927-75343066:+	0.25	5.2	2.97E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs1869365	chr17:40293865	DHX58	chr17:40253422-40264751:-	-0.21	-4.25	2.51E-5	Fibrinogen levels	
LGG	cis	1	rs1869596	chr1:110624104	ALX3	chr1:110602998-110613322:-	-0.29	-6.69	6.04E-11	Blood metabolite levels	
LGG	cis	1	rs1869596	chr1:110624104	FAM40A	chr1:110574199-110597424:+	0.11	3.99	7.75E-5	Blood metabolite levels	
LGG	cis	1	rs1871045	chr19:45326768	PVRL2	chr19:45349393-45392485:+	-0.14	-4.03	6.52E-5	Waist-to-hip circumference ratio (interaction)	
LGG	cis	1	rs1872329	chr2:54471823	C2orf73	chr2:54558071-54588714:+	0.33	4.74	2.84E-6	Telomere length	
LGG	cis	1	rs1872329	chr2:54471823	TSPYL6	chr2:54480315-54483409:-	-0.47	-5.62	3.24E-8	Telomere length	
LGG	cis	1	rs1872992	chr12:26457190	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.31	1.94E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs1873494	chr7:65649899	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs187455071	chr4:106805884	GSTCD	chr4:106629941-106768881:+	0.35	3.74	0.000207	Post bronchodilator FEV1	
LGG	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.29	7.44	4.6E-13	Height	
LGG	cis	1	rs1874883	chr3:134205071	CEP63	chr3:134204575-134293852:+	0.19	3.46	0.000593	Height	
LGG	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.47	11.44	5.2E-27	Multiple sclerosis	
LGG	cis	1	rs1875124	chr12:58196802	TSFM	chr12:58176536-58191367:+	-0.46	-8.78	2.71E-17	Multiple sclerosis	
LGG	cis	1	rs1875124	chr12:58196802	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-3.63	0.000308	Multiple sclerosis	
LGG	cis	1	rs1876673	chr5:115450773	COMMD10	chr5:115420727-115628978:+	0.45	5.51	5.9E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1876674	chr5:115450969	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs1877316	chr17:61766880	DDX42	chr17:61851567-61896676:+	-0.16	-3.56	0.000405	Body mass index	
LGG	cis	1	rs1877316	chr17:61766880	FTSJ3	chr17:61896795-61905031:-	0.41	8.46	3.04E-16	Body mass index	
LGG	cis	1	rs1877316	chr17:61766880	SMARCD2	chr17:61909441-61920351:-	0.18	4.13	4.2E-5	Body mass index	
LGG	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs1880376	chr3:134270347	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs1880377	chr3:134270468	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.4	7.19	2.49E-12	Metabolite levels	
LGG	cis	1	rs1881245	chr2:73649928	NAT8	chr2:73867850-73869537:-	0.27	4.56	6.46E-6	Metabolite levels	
LGG	cis	1	rs1881284	chr2:188157329	CALCRL	chr2:188207851-188313021:-	0.22	5.35	1.32E-7	Coronary heart disease	
LGG	cis	1	rs1881285	chr2:188157332	CALCRL	chr2:188207851-188313021:-	0.22	5.4	1.06E-7	Coronary heart disease	
LGG	cis	1	rs1882099	chr4:1352685	CRIPAK	chr4:1385340-1389782:+	0.27	5.82	1.04E-8	Systolic blood pressure	
LGG	cis	1	rs1882655	chr7:66147057	CCT6P1	chr7:65216092-65228661:+	-0.22	-3.99	7.47E-5	Gout	
LGG	cis	1	rs1884946	chr6:26545308	BTN2A3	chr6:26422317-26431927:+	0.12	3.54	0.000445	Educational attainment	
LGG	cis	1	rs1884946	chr6:26545308	HMGN4	chr6:26538572-26547162:+	-0.21	-5.39	1.08E-7	Educational attainment	
LGG	cis	1	rs1884948	chr6:26567988	BTN2A3	chr6:26422317-26431927:+	0.13	3.63	0.000315	Educational attainment	
LGG	cis	1	rs1884948	chr6:26567988	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.55E-6	Educational attainment	
LGG	cis	1	rs1884949	chr6:26568067	BTN2A3	chr6:26422317-26431927:+	0.13	3.63	0.000315	Educational attainment	
LGG	cis	1	rs1884949	chr6:26568067	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.55E-6	Educational attainment	
LGG	cis	1	rs1885708	chr14:102960164	ANKRD9	chr14:102973198-102976128:-	0.19	4.44	1.14E-5	QT interval	
LGG	cis	1	rs1886242	chr6:35117656	TCP11	chr6:35085849-35109187:-	0.32	5.33	1.51E-7	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs1886682	chr1:92977275	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs1886683	chr1:92976023	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs1886972	chr13:24436230	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs188759	chr4:25234122	ANAPC4	chr4:25378848-25420119:+	0.3	4.68	3.71E-6	Cannabis dependence	
LGG	cis	1	rs188759	chr4:25234122	PI4K2B	chr4:25162285-25280831:+	0.27	4.71	3.19E-6	Cannabis dependence	
LGG	cis	1	rs1888997	chr20:25298988	ABHD12	chr20:25275380-25371477:-	-0.27	-7.35	8.36E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888997	chr20:25298988	FAM182A	chr20:26035250-26067552:+	0.56	11.06	1.54E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888997	chr20:25298988	FAM182B	chr20:25744102-25848786:-	-0.21	-4.74	2.75E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888998	chr20:25291826	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888998	chr20:25291826	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888998	chr20:25291826	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888999	chr20:25291848	ABHD12	chr20:25275380-25371477:-	0.26	7.12	3.96E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888999	chr20:25291848	FAM182A	chr20:26035250-26067552:+	-0.56	-11.08	1.31E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1888999	chr20:25291848	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.13E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1889899	chr9:26789940	LRRC19	chr9:26993143-27005691:-	-0.24	-4.15	3.98E-5	Smoking behavior	
LGG	cis	1	rs1890875	chr1:202531366	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs1891969	chr1:114185855	BCL2L15	chr1:114419437-114430169:-	0.16	4.52	7.67E-6	Bacteremia	
LGG	cis	1	rs189218934	chr15:78903987	CHRNA5	chr15:78857906-78886458:+	0.33	5.14	3.96E-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs1892846	chr22:22186479	CCDC116	chr22:21987086-21991615:+	0.17	3.7	0.000236	Multiple sclerosis	
LGG	cis	1	rs1892848	chr22:22186562	CCDC116	chr22:21987086-21991615:+	0.17	3.7	0.000236	Multiple sclerosis	
LGG	cis	1	rs1892894	chr11:120254684	TMEM136	chr11:120196016-120204388:+	0.19	4.37	1.51E-5	Intraocular pressure	
LGG	cis	1	rs1896707	chr5:150245129	LOC134466	chr5:150310000-150326146:-	0.41	4.66	3.99E-6	Crohn's disease	
LGG	cis	1	rs1896708	chr5:150245076	LOC134466	chr5:150310000-150326146:-	0.43	4.8	2.09E-6	Crohn's disease	
LGG	cis	1	rs1896709	chr5:150245032	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs1899782	chr3:4223456	SUMF1	chr3:3823036-4508954:-	-0.16	-3.53	0.000449	Periodontitis (DPAL)	
LGG	cis	1	rs1900120	chr14:76626516	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs1900122	chr14:76629517	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs1900125	chr14:76657470	ESRRB	chr14:76837690-76968178:+	-0.4	-6.46	2.54E-10	Blood pressure	
LGG	cis	1	rs190113	chr10:64488223	ADO	chr10:64564516-64568238:+	-0.17	-4.45	1.05E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs1903330	chr6:56776985	BEND6	chr6:56819773-56892138:+	0.3	5.45	8.2E-8	Menarche (age at onset)	
LGG	cis	1	rs1903330	chr6:56776985	KIAA1586	chr6:56911384-56920021:+	0.15	3.94	9.24E-5	Menarche (age at onset)	
LGG	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs1905552	chr15:46644080	SPATA5L1	chr15:45694519-45713614:+	-0.2	-3.67	0.000266	Prostate cancer	
LGG	cis	1	rs1911155	chr15:84787635	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.52	5.63E-8	Schizophrenia	
LGG	cis	1	rs1911155	chr15:84787635	LOC388152	chr15:84867600-84898920:-	-0.33	-6.59	1.13E-10	Schizophrenia	
LGG	cis	1	rs1911155	chr15:84787635	UBE2Q2P1	chr15:85070427-85114026:-	0.15	3.53	0.000462	Schizophrenia	
LGG	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.49	-10.07	8.35E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1912154	chr17:46443594	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs1915146	chr10:126846214	OAT	chr10:126085872-126107519:-	0.14	3.99	7.65E-5	Menarche (age at onset)	
LGG	cis	1	rs1916284	chr3:57394766	ASB14	chr3:57302379-57326686:-	0.15	3.47	0.000573	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.68E-13	Height	
LGG	cis	1	rs1917130	chr3:134313773	CEP63	chr3:134204575-134293852:+	-0.21	-3.76	0.00019	Height	
LGG	cis	1	rs1917531	chr3:65503221	MAGI1	chr3:65339907-66024509:-	-0.2	-4.07	5.56E-5	PR interval	
LGG	cis	1	rs1918689	chr2:84906853	DNAH6	chr2:84743579-85046711:+	-0.19	-3.58	0.000376	Hypospadias	
LGG	cis	1	rs1918690	chr2:84906915	DNAH6	chr2:84743579-85046711:+	-0.19	-3.59	0.000365	Hypospadias	
LGG	cis	1	rs1918902	chr2:188091511	CALCRL	chr2:188207851-188313021:-	-0.21	-4.95	1.05E-6	Coronary heart disease	
LGG	cis	1	rs1919125	chr2:27801403	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs1919125	chr2:27801403	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs1919126	chr2:27801418	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs1919126	chr2:27801418	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs1920120	chr3:169502180	LOC100128164	chr3:169661774-169684522:-	-0.2	-3.71	0.000233	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920120	chr3:169502180	LRRC34	chr3:169511266-169530720:-	-0.29	-5.23	2.47E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920122	chr3:169506141	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.48	0.000553	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920122	chr3:169506141	LRRC34	chr3:169511266-169530720:-	-0.29	-5.15	3.8E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920123	chr3:169506173	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.48	0.000553	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920123	chr3:169506173	LRRC34	chr3:169511266-169530720:-	-0.29	-5.15	3.8E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1920592	chr12:114705586	PLBD2	chr12:113796371-113827458:+	0.17	3.85	0.000132	Schizophrenia	
LGG	cis	1	rs1920650	chr3:160335588	TRIM59	chr3:160153292-160167626:-	0.1	3.61	0.000343	Primary biliary cirrhosis	
LGG	cis	1	rs1923539	chr10:81694950	SFTPD	chr10:81697498-81708861:-	0.48	10.05	9.51E-22	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs1928020	chr13:36695968	SOHLH2	chr13:36742347-36871992:-	0.38	5.81	1.15E-8	Optic cup area	
LGG	cis	1	rs1930961	chr22:25875265	ADRBK2	chr22:25960861-26125256:+	-0.25	-4.43	1.17E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs1930961	chr22:25875265	CRYBB2	chr22:25615612-25627836:+	0.61	7.89	2.0E-14	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs1935	chr10:64927823	NRBF2	chr10:64893007-64914785:+	-0.22	-5.37	1.24E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1935	chr10:64927823	REEP3	chr10:65281123-65381971:+	0.14	4.14	4.09E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs1936365	chr6:28268452	ZNF165	chr6:28046572-28057338:+	0.3	4.56	6.5E-6	Depression	
LGG	cis	1	rs1936365	chr6:28268452	ZNF187	chr6:28234788-28245978:+	0.28	5.08	5.46E-7	Depression	
LGG	cis	1	rs1936365	chr6:28268452	ZNF389	chr6:28129551-28137375:+	-0.4	-6.65	7.63E-11	Depression	
LGG	cis	1	rs1936365	chr6:28268452	ZSCAN12	chr6:28346770-28367544:-	0.33	4.78	2.3E-6	Depression	
LGG	cis	1	rs1936365	chr6:28268452	ZSCAN23	chr6:28393287-28411279:-	-0.18	-4.26	2.46E-5	Depression	
LGG	cis	1	rs1939242	chr11:71753582	FAM86C	chr11:71498557-71512276:+	0.45	4.64	4.49E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1939245	chr11:71742532	FAM86C	chr11:71498557-71512276:+	0.47	4.62	5.0E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1939247	chr11:71740521	FAM86C	chr11:71498557-71512276:+	0.49	4.86	1.61E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs1941746	chr11:65502413	DKFZp761E198	chr11:65543380-65547822:-	0.26	3.62	0.000322	Atopic dermatitis	
LGG	cis	1	rs194577	chr7:117993966	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000179	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs194579	chr7:117994536	ANKRD7	chr7:117864712-117882782:+	0.21	3.63	0.000315	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs194582	chr7:117995340	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000179	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs1949510	chr2:17778129	GEN1	chr2:17935162-17966632:+	0.26	4.09	5.08E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs1950500	chr14:24830850	ADCY4	chr14:24787571-24804277:-	-0.15	-3.93	9.54E-5	Height	
LGG	cis	1	rs1950500	chr14:24830850	TGM1	chr14:24718322-24732416:-	-0.14	-3.49	0.000521	Height	
LGG	cis	1	rs1952012	chr14:50098896	RPL36AL	chr14:50085407-50087349:-	0.31	8.09	4.59E-15	Carotid intima media thickness	
LGG	cis	1	rs1953126	chr9:123640500	LOC253039	chr9:123605320-123616644:+	-0.66	-11.58	1.43E-27	Rheumatoid arthritis	
LGG	cis	1	rs1953126	chr9:123640500	PSMD5	chr9:123578334-123605206:-	-0.35	-6.26	8.27E-10	Rheumatoid arthritis	
LGG	cis	1	rs1953126	chr9:123640500	TRAF1	chr9:123664672-123691479:-	0.19	4.02	6.6E-5	Rheumatoid arthritis	
LGG	cis	1	rs1953417	chr14:65878909	LOC645431	chr14:65877313-65879335:-	-0.52	-7.21	2.1E-12	Ischemic stroke	
LGG	cis	1	rs1953600	chr10:81911725	ANXA11	chr10:81914880-81965433:-	-0.15	-5.14	3.93E-7	Sarcoidosis	
LGG	cis	1	rs1953600	chr10:81911725	PLAC9	chr10:81892258-81904784:+	-0.24	-6.31	6.29E-10	Sarcoidosis	
LGG	cis	1	rs1955599	chr14:88825132	SPATA7	chr14:88852012-88904802:+	-0.44	-7.7	7.6E-14	Coronary artery calcification	
LGG	cis	1	rs1955600	chr14:88825384	SPATA7	chr14:88852012-88904802:+	-0.44	-7.7	7.6E-14	Coronary artery calcification	
LGG	cis	1	rs1957543	chr14:81777074	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs1957544	chr14:81773268	STON2	chr14:81727000-81893748:-	-0.14	-3.61	0.000332	Obesity-related traits	
LGG	cis	1	rs1957545	chr14:81772981	STON2	chr14:81727000-81893748:-	-0.14	-3.61	0.000332	Obesity-related traits	
LGG	cis	1	rs1957548	chr14:81781835	STON2	chr14:81727000-81893748:-	-0.14	-3.53	0.000454	Obesity-related traits	
LGG	cis	1	rs1957977	chr14:50090603	RPL36AL	chr14:50085407-50087349:-	0.34	8.88	1.29E-17	Carotid intima media thickness	
LGG	cis	1	rs1958560	chr14:66036795	FUT8	chr14:65877840-66209961:+	0.12	3.59	0.00037	Menarche (age at onset)	
LGG	cis	1	rs1961778	chr8:58168756	C8orf71	chr8:58192102-58197288:+	0.36	6.23	9.78E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.5	-10.33	9.14E-23	Response to antipsychotic treatment	
LGG	cis	1	rs1964692	chr7:65454183	CCT6P1	chr7:65216092-65228661:+	0.26	4.75	2.66E-6	Diabetic kidney disease	
LGG	cis	1	rs1966423	chr2:202216661	ALS2CR12	chr2:202153148-202222101:-	-0.2	-4.02	6.61E-5	Basal cell carcinoma	
LGG	cis	1	rs1966423	chr2:202216661	ALS2CR4	chr2:202484907-202508224:-	0.2	5.53	5.12E-8	Basal cell carcinoma	
LGG	cis	1	rs1966423	chr2:202216661	PPIL3	chr2:201735680-201753999:-	-0.19	-4.03	6.57E-5	Basal cell carcinoma	
LGG	cis	1	rs1966839	chr7:50627101	FIGNL1	chr7:50511834-50518088:-	-0.22	-5.19	3.16E-7	Malaria	
LGG	cis	1	rs1968186	chr16:50125512	HEATR3	chr16:50099881-50139373:+	0.3	4.08	5.21E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs1968225	chr7:65874773	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs1971762	chr12:54058238	PRR13	chr12:53835433-53840426:+	-0.12	-3.49	0.00053	Height	
LGG	cis	1	rs1971898	chr15:90890836	IQGAP1	chr15:90931473-91045475:+	0.12	3.71	0.000229	Rheumatoid arthritis	
LGG	cis	1	rs1972669	chr2:27767107	PPM1G	chr2:27604062-27632496:-	0.14	4.39	1.4E-5	Oral cavity cancer	
LGG	cis	1	rs1972669	chr2:27767107	SNX17	chr2:27593363-27599994:+	-0.12	-3.65	0.000288	Oral cavity cancer	
LGG	cis	1	rs1974624	chr4:17650281	MED28	chr4:17616273-17629791:+	0.2	4.36	1.55E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs1975174	chr19:22515251	ZNF257	chr19:22235266-22273901:+	0.2	3.54	0.000433	Telomere length	
LGG	cis	1	rs1975174	chr19:22515251	ZNF98	chr19:22573899-22605148:-	0.16	3.76	0.000191	Telomere length	
LGG	cis	1	rs1975957	chr1:150104269	RPRD2	chr1:150336990-150449039:+	-0.15	-3.7	0.000243	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs1976053	chr17:65833002	LOC440461	chr17:66194801-66196436:+	0.28	4.59	5.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs1976054	chr17:65833224	LOC440461	chr17:66194801-66196436:+	0.26	4.23	2.78E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs1977447	chr9:131868196	CRAT	chr9:131857075-131873070:-	-0.21	-3.64	0.000303	Blood metabolite ratios	
LGG	cis	1	rs1978968	chr22:18448113	PEX26	chr22:18560686-18572206:+	0.15	3.63	0.000316	Presence of antiphospholipid antibodies	
LGG	cis	1	rs1979214	chr2:70137498	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.53	7.52E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs1979755	chr2:42708405	HAAO	chr2:42994230-43019751:-	-0.12	-3.59	0.00036	Body mass index	
LGG	cis	1	rs1979823	chr7:65704613	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.38	1.43E-5	Diabetic kidney disease	
LGG	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-0.93	-13.17	3.99E-34	Schizophrenia	
LGG	cis	1	rs1981798	chr7:65954903	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs1981898	chr14:76175565	TTLL5	chr14:76127621-76421421:+	0.24	5.34	1.4E-7	Large artery stroke	
LGG	cis	1	rs1982861	chr3:49577665	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.53	7.36E-6	Menarche (age at onset)	
LGG	cis	1	rs1982861	chr3:49577665	GMPPB	chr3:49758932-49761384:-	-0.23	-4.51	8.15E-6	Menarche (age at onset)	
LGG	cis	1	rs1984598	chr2:242284824	ANO7	chr2:242127924-242164791:+	0.34	6.2	1.19E-9	Prostate cancer	
LGG	cis	1	rs1986074	chr15:50857452	SPPL2A	chr15:50999739-51057910:-	0.13	4.14	4.08E-5	QT interval	
LGG	cis	1	rs1986557	chr4:283118	ZNF718	chr4:53272-156488:+	0.23	4.61	5.07E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs198806	chr6:26133616	BTN3A2	chr6:26365398-26378546:+	0.23	4.72	3.09E-6	Schizophrenia	
LGG	cis	1	rs198811	chr6:26128446	BTN3A2	chr6:26365398-26378546:+	-0.21	-4.39	1.42E-5	Schizophrenia	
LGG	cis	1	rs1988934	chr5:42150885	C5orf51	chr5:41904470-41921737:+	-0.27	-3.49	0.000518	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs1990674	chr17:53061075	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs1990674	chr17:53061075	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs199347	chr7:23293746	GPNMB	chr7:23286316-23314728:+	-0.23	-5.19	3.03E-7	Parkinson's disease	
LGG	cis	1	rs199347	chr7:23293746	NUPL2	chr7:23221446-23240629:+	-0.39	-9.81	7.4E-21	Parkinson's disease	
LGG	cis	1	rs199348	chr7:23293098	GPNMB	chr7:23286316-23314728:+	-0.22	-4.9	1.29E-6	Parkinson's disease	
LGG	cis	1	rs199348	chr7:23293098	NUPL2	chr7:23221446-23240629:+	-0.37	-9.19	1.14E-18	Parkinson's disease	
LGG	cis	1	rs199351	chr7:23300049	GPNMB	chr7:23286316-23314728:+	-0.23	-4.97	9.49E-7	Parkinson's disease	
LGG	cis	1	rs199351	chr7:23300049	NUPL2	chr7:23221446-23240629:+	-0.38	-9.36	2.88E-19	Parkinson's disease	
LGG	cis	1	rs199357	chr7:23288309	GPNMB	chr7:23286316-23314728:+	0.23	5.2	2.88E-7	Parkinson's disease	
LGG	cis	1	rs199357	chr7:23288309	NUPL2	chr7:23221446-23240629:+	0.38	9.4	2.13E-19	Parkinson's disease	
LGG	cis	1	rs1993901	chr17:20938791	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.76	14.03	7.94E-38	Diastolic blood pressure	
LGG	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.49	-10.07	8.35E-22	Response to antipsychotic treatment	
LGG	cis	1	rs1995689	chr1:212869847	BATF3	chr1:212859760-212873327:-	0.19	4.11	4.67E-5	Leprosy	
LGG	cis	1	rs1997392	chr3:169509652	LOC100128164	chr3:169661774-169684522:-	0.19	3.5	0.000511	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1997392	chr3:169509652	LRRC34	chr3:169511266-169530720:-	0.28	5.09	5.15E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs1998035	chr14:66126230	LOC645431	chr14:65877313-65879335:-	-0.47	-6.31	6.33E-10	Ischemic stroke	
LGG	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.51	-10.56	1.26E-23	Response to antipsychotic treatment	
LGG	cis	1	rs2000614	chr11:116915742	SIDT2	chr11:117049939-117068161:+	0.31	3.77	0.000182	Protein quantitative trait loci	
LGG	cis	1	rs2000615	chr11:116915819	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs2000616	chr11:116916529	SIDT2	chr11:117049939-117068161:+	0.31	3.77	0.000182	Protein quantitative trait loci	
LGG	cis	1	rs2000999	chr16:72108093	HP	chr16:72088508-72094957:+	1	19.76	2.34E-64	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2000999	chr16:72108093	HPR	chr16:72097125-72111144:+	1.02	24.68	4.73E-88	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2000999	chr16:72108093	TXNL4B	chr16:72072001-72128215:-	0.74	12.37	9.09E-31	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2002895	chr12:101728166	UTP20	chr12:101673905-101780397:+	-0.15	-3.59	0.000362	Alcohol dependence (age at onset)	
LGG	cis	1	rs2003284	chr10:102202338	HIF1AN	chr10:102295641-102313680:+	0.19	3.77	0.000181	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2003284	chr10:102202338	NDUFB8	chr10:102283497-102289636:-	0.16	4.64	4.47E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2003284	chr10:102202338	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.08E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2003301	chr7:66147656	ASL	chr7:65540776-65558321:+	0.19	4.83	1.82E-6	Aortic root size	
LGG	cis	1	rs2003301	chr7:66147656	TYW1	chr7:66461817-66704496:+	-0.17	-3.69	0.00025	Aortic root size	
LGG	cis	1	rs2004711	chr5:150225068	LOC134466	chr5:150310000-150326146:-	0.4	4.61	5.17E-6	Crohn's disease	
LGG	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.52	-11.29	2.02E-26	Forced vital capacity	
LGG	cis	1	rs2006893	chr22:22128678	CCDC116	chr22:21987086-21991615:+	0.19	4.06	5.71E-5	Multiple sclerosis	
LGG	cis	1	rs2007981	chr19:18567555	LRRC25	chr19:18501955-18508421:-	-0.17	-5.85	9.22E-9	Breast cancer	
LGG	cis	1	rs2009756	chr17:20901464	USP22	chr17:20902908-20947073:-	-0.2	-4.41	1.29E-5	Blood trace element (Se levels)	
LGG	cis	1	rs2011013	chr15:84625766	LOC388152	chr15:84867600-84898920:-	0.21	3.95	8.87E-5	Sitting height ratio	
LGG	cis	1	rs2011064	chr15:50957625	SPPL2A	chr15:50999739-51057910:-	0.12	3.63	0.000309	QT interval	
LGG	cis	1	rs2011105	chr5:42019110	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.000302	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs2011331	chr1:152286002	HRNR	chr1:152184558-152196669:-	-0.51	-8.08	4.99E-15	Atopic dermatitis	
LGG	cis	1	rs2012353	chr19:32899293	DPY19L3	chr19:32896677-32975236:+	0.14	3.74	0.000204	Bipolar disorder	
LGG	cis	1	rs2013288	chr17:61785904	DDX42	chr17:61851567-61896676:+	-0.17	-3.86	0.000129	Body mass index	
LGG	cis	1	rs2013288	chr17:61785904	FTSJ3	chr17:61896795-61905031:-	0.4	8.16	2.8E-15	Body mass index	
LGG	cis	1	rs2013288	chr17:61785904	SMARCD2	chr17:61909441-61920351:-	0.18	4.06	5.73E-5	Body mass index	
LGG	cis	1	rs2014252	chr2:27462405	SLC5A6	chr2:27422459-27435071:-	-0.3	-6.22	1.05E-9	Blood metabolite levels	
LGG	cis	1	rs2014355	chr12:121175524	SPPL3	chr12:121201036-121342151:-	-0.25	-4.24	2.72E-5	Urinary metabolites (H-NMR features)	
LGG	cis	1	rs2014521	chr17:40283413	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs2014521	chr17:40283413	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs2015454	chr2:111872148	ACOXL	chr2:111490150-111875799:+	-0.21	-3.62	0.000329	Chronic lymphocytic leukemia	
LGG	cis	1	rs2017962	chr19:22208751	ZNF208	chr19:22115760-22193745:-	0.21	3.51	0.000483	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2017962	chr19:22208751	ZNF257	chr19:22235266-22273901:+	0.4	7.13	3.7E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2018368	chr11:10740366	RNF141	chr11:10533225-10562774:-	0.13	3.74	0.000206	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2019097	chr2:202193463	ALS2CR12	chr2:202153148-202222101:-	0.29	3.58	0.000373	Rheumatoid arthritis	
LGG	cis	1	rs2019097	chr2:202193463	PPIL3	chr2:201735680-201753999:-	-0.83	-11.94	5.02E-29	Rheumatoid arthritis	
LGG	cis	1	rs2020010	chr1:202510881	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs2020854	chr12:56743367	IL23A	chr12:56732663-56734193:+	0.56	5.56	4.47E-8	Psoriasis vulgaris	
LGG	cis	1	rs2020927	chr9:107553185	NIPSNAP3B	chr9:107526451-107553175:+	0.46	8.59	1.17E-16	Gout	
LGG	cis	1	rs2022002	chr1:158587143	KIRREL	chr1:157963063-158065842:+	-0.12	-3.64	0.000301	Other erythrocyte phenotypes	
LGG	cis	1	rs2023786	chr7:23915153	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.84E-5	Schizophrenia	
LGG	cis	1	rs2023787	chr7:23915140	C7orf46	chr7:23719749-23742268:+	0.2	4.24	2.62E-5	Schizophrenia	
LGG	cis	1	rs2024959	chr20:47695391	ARFGEF2	chr20:47538275-47653229:+	0.11	4.07	5.47E-5	Anger	
LGG	cis	1	rs2024959	chr20:47695391	CSE1L	chr20:47662838-47713484:+	0.19	5.04	6.45E-7	Anger	
LGG	cis	1	rs2027003	chr20:25350498	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027003	chr20:25350498	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027003	chr20:25350498	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027004	chr20:25350618	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027004	chr20:25350618	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027004	chr20:25350618	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2027299	chr6:126685827	CENPW	chr6:126661253-126804465:+	-0.15	-3.83	0.000145	Type 1 diabetes	
LGG	cis	1	rs2027349	chr1:150039678	RPRD2	chr1:150336990-150449039:+	-0.15	-3.88	0.000119	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs2027760	chr11:73036481	RELT	chr11:73087405-73108518:+	0.32	3.69	0.000245	Pulmonary function (interaction)	
LGG	cis	1	rs2027761	chr11:73036179	RELT	chr11:73087405-73108518:+	0.32	3.69	0.000245	Pulmonary function (interaction)	
LGG	cis	1	rs2028299	chr15:90374257	AP3S2	chr15:90373832-90456222:-	-0.48	-9.2	1.0E-18	Type 2 diabetes	
LGG	cis	1	rs2028669	chr1:202517364	UBE2T	chr1:202300786-202311094:-	-0.13	-3.87	0.000123	Sex ratio	
LGG	cis	1	rs2030732	chr3:65465766	MAGI1	chr3:65339907-66024509:-	-0.2	-4.17	3.65E-5	PR interval	
LGG	cis	1	rs2030973	chr1:202307863	UBE2T	chr1:202300786-202311094:-	-0.13	-4.01	7.12E-5	Sex ratio	
LGG	cis	1	rs2031494	chr1:92965969	EVI5	chr1:92974255-93257961:-	-0.29	-6.95	1.18E-11	Cholesterol, total	
LGG	cis	1	rs2031532	chr13:50080847	SETDB2	chr13:50018429-50069138:+	0.21	4.44	1.1E-5	Cardiac hypertrophy	
LGG	cis	1	rs2032843	chr17:46847524	SNF8	chr17:47007461-47022154:-	-0.16	-4.11	4.62E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs2032844	chr17:46847364	SNF8	chr17:47007461-47022154:-	-0.16	-4.17	3.63E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs2034897	chr5:110441561	TSLP	chr5:110405778-110413722:+	-0.32	-4.58	5.78E-6	Eosinophil counts	
LGG	cis	1	rs2034899	chr5:78316188	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000486	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs2034900	chr5:78315964	BHMT	chr5:78407604-78428112:+	0.17	3.51	0.000487	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs2036264	chr7:65799904	ASL	chr7:65540776-65558321:+	0.22	5.57	4.26E-8	Aortic root size	
LGG	cis	1	rs2036402	chr5:156464242	TIMD4	chr5:156346293-156390266:-	-0.25	-4.51	8.26E-6	Hypertriglyceridemia	
LGG	cis	1	rs2036534	chr15:78826948	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.73	4.73E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2037150	chr17:45328718	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs2037670	chr3:65488142	MAGI1	chr3:65339907-66024509:-	0.22	4.25	2.61E-5	PR interval	
LGG	cis	1	rs2037965	chr3:128025044	EEFSEC	chr3:127872313-128127488:+	0.21	3.94	9.25E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2037965	chr3:128025044	LOC90246	chr3:128226678-128229427:+	0.28	3.56	0.000402	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2038227	chr16:539140	DECR2	chr16:451858-462486:+	-0.17	-3.78	0.000177	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs2039800	chr1:150095754	RPRD2	chr1:150336990-150449039:+	-0.14	-3.7	0.000244	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs2040533	chr22:31679110	LIMK2	chr22:31608250-31676064:+	0.28	5.86	8.68E-9	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2041756	chr2:103049910	IL18R1	chr2:102927962-103015215:+	0.36	5.82	1.05E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2041756	chr2:103049910	IL1RL1	chr2:102927962-102968497:+	0.36	5.22	2.64E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2041837	chr2:37468564	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.98	8.91E-7	Chronic lymphocytic leukemia	
LGG	cis	1	rs2041840	chr2:37467264	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.66	4.09E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2042133	chr7:65931922	ASL	chr7:65540776-65558321:+	-0.22	-5.57	4.26E-8	Aortic root size	
LGG	cis	1	rs2042495	chr2:160084263	CCDC148	chr2:159028479-159313214:-	-0.26	-3.64	0.000303	Sudden cardiac arrest	
LGG	cis	1	rs2042497	chr2:160085788	CCDC148	chr2:159028479-159313214:-	-0.26	-3.64	0.000303	Sudden cardiac arrest	
LGG	cis	1	rs2042947	chr19:12693103	MAN2B1	chr19:12757322-12777591:-	0.14	4.63	4.75E-6	Bipolar disorder	
LGG	cis	1	rs2045554	chr3:48494542	ATRIP	chr3:48488141-48507708:+	-0.19	-4.66	4.15E-6	Longevity	
LGG	cis	1	rs2045554	chr3:48494542	TREX1	chr3:48501186-48509043:+	0.42	10.9	6.12E-25	Longevity	
LGG	cis	1	rs2046323	chr17:65849927	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs2049693	chr2:188112036	CALCRL	chr2:188207851-188313021:-	-0.21	-5.04	6.51E-7	Coronary heart disease	
LGG	cis	1	rs2052187	chr17:65834737	LOC440461	chr17:66194801-66196436:+	0.27	4.5	8.67E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs2053367	chr2:26293413	GPR113	chr2:26531041-26569685:-	-0.23	-3.71	0.00023	Gut microbiome composition (summer)	
LGG	cis	1	rs2054463	chr17:20919705	USP22	chr17:20902908-20947073:-	-0.2	-4.57	6.16E-6	Blood trace element (Se levels)	
LGG	cis	1	rs2054711	chr8:21818060	XPO7	chr8:21777180-21864095:+	0.16	3.57	0.000391	Mean corpuscular volume	
LGG	cis	1	rs2055127	chr1:235598973	B3GALNT2	chr1:235610533-235667781:-	-0.26	-6.76	3.83E-11	Adiposity	
LGG	cis	1	rs2055127	chr1:235598973	TBCE	chr1:235530728-235612280:+	-0.18	-3.73	0.00021	Adiposity	
LGG	cis	1	rs2055619	chr5:176415964	FGFR4	chr5:176513921-176525124:+	0.22	5.92	6.12E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs2055682	chr7:66260289	ASL	chr7:65540776-65558321:+	-0.2	-5.1	4.98E-7	Aortic root size	
LGG	cis	1	rs2055682	chr7:66260289	TYW1	chr7:66461817-66704496:+	0.18	3.86	0.000131	Aortic root size	
LGG	cis	1	rs2056458	chr17:46458003	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000515	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs2056486	chr2:73717567	ALMS1P	chr2:73872046-73912692:+	0.4	7.16	3.01E-12	Metabolite levels	
LGG	cis	1	rs2056486	chr2:73717567	NAT8	chr2:73867850-73869537:-	0.28	4.58	6.03E-6	Metabolite levels	
LGG	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs2056603	chr3:134312749	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs2056604	chr3:134312648	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs2058059	chr7:72311817	TRIM50	chr7:72726535-72742085:-	-0.2	-3.49	0.000533	Subcutaneous adipose tissue	
LGG	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.54	-7.9	1.83E-14	Subcutaneous adipose tissue	
LGG	cis	1	rs2058337	chr4:17678649	LAP3	chr4:17578927-17609590:+	-0.14	-3.78	0.000177	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2058338	chr4:17678600	LAP3	chr4:17578927-17609590:+	0.15	4.04	6.16E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2058339	chr4:17678456	LAP3	chr4:17578927-17609590:+	-0.14	-3.84	0.000142	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2058350	chr12:3913427	PARP11	chr12:3918027-3982608:-	-0.26	-5.22	2.62E-7	Cognitive performance	
LGG	cis	1	rs2058620	chr2:39970583	THUMPD2	chr2:39963200-40006416:-	0.41	7.93	1.5E-14	Personality dimensions	
LGG	cis	1	rs2058622	chr2:102985424	IL18R1	chr2:102927962-103015215:+	-0.36	-5.64	2.8E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058622	chr2:102985424	IL1RL1	chr2:102927962-102968497:+	-0.35	-4.92	1.16E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058623	chr2:102986170	IL18R1	chr2:102927962-103015215:+	-0.36	-5.64	2.8E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058623	chr2:102986170	IL1RL1	chr2:102927962-102968497:+	-0.35	-4.92	1.16E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058660	chr2:103054449	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058660	chr2:103054449	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2058813	chr16:50129454	HEATR3	chr16:50099881-50139373:+	-0.33	-6.7	5.63E-11	Testicular germ cell tumor	
LGG	cis	1	rs20598	chr7:117965959	ANKRD7	chr7:117864712-117882782:+	0.22	3.73	0.000215	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2060222	chr5:138308466	FAM53C	chr5:137673224-137685416:+	0.19	3.57	0.000387	Age-related hearing impairment (interaction)	
LGG	cis	1	rs2060222	chr5:138308466	SIL1	chr5:138282412-138534065:-	0.14	4.03	6.51E-5	Age-related hearing impairment (interaction)	
LGG	cis	1	rs2061164	chr11:18329006	GTF2H1	chr11:18343816-18388590:+	0.42	7.81	3.47E-14	Pancreatic cancer	
LGG	cis	1	rs2061164	chr11:18329006	LDHC	chr11:18433853-18472792:+	0.22	4.04	6.1E-5	Pancreatic cancer	
LGG	cis	1	rs2062340	chr2:54480245	C2orf73	chr2:54558071-54588714:+	0.34	4.9	1.29E-6	Telomere length	
LGG	cis	1	rs2062340	chr2:54480245	TSPYL6	chr2:54480315-54483409:-	-0.48	-5.74	1.62E-8	Telomere length	
LGG	cis	1	rs2064088	chr22:39053382	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs2066089	chr20:16056180	SNRPB2	chr20:16710629-16722037:+	0.25	3.66	0.000283	Brain connectivity	
LGG	cis	1	rs2066558	chr13:50610595	EBPL	chr13:50234811-50265623:-	-0.16	-3.49	0.000528	Height	
LGG	cis	1	rs2066575	chr13:50656582	EBPL	chr13:50234811-50265623:-	-0.17	-3.73	0.000213	Height	
LGG	cis	1	rs2066587	chr13:50685954	EBPL	chr13:50234811-50265623:-	-0.19	-4.1	4.91E-5	Height	
LGG	cis	1	rs2066720	chr9:107554069	NIPSNAP3B	chr9:107526451-107553175:+	-0.46	-8.59	1.17E-16	Gout	
LGG	cis	1	rs2066808	chr12:56737973	IL23A	chr12:56732663-56734193:+	0.59	5.94	5.55E-9	Psoriasis vulgaris	
LGG	cis	1	rs2066818	chr12:56753822	IL23A	chr12:56732663-56734193:+	0.58	5.02	7.32E-7	Psoriasis vulgaris	
LGG	cis	1	rs2066819	chr12:56750204	IL23A	chr12:56732663-56734193:+	0.58	5.02	7.32E-7	Psoriasis vulgaris	
LGG	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.46	-11.16	6.42E-26	Multiple sclerosis	
LGG	cis	1	rs2069502	chr12:58144665	TSFM	chr12:58176536-58191367:+	0.45	8.6	1.06E-16	Multiple sclerosis	
LGG	cis	1	rs2069940	chr20:33759272	PROCR	chr20:33758727-33765164:+	-0.35	-6.27	7.89E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs2070180	chr3:121351338	IQCB1	chr3:121488610-121553926:-	-0.35	-6.45	2.67E-10	Cognitive performance	
LGG	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.46	11.11	9.87E-26	Multiple sclerosis	
LGG	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.45	-8.58	1.29E-16	Multiple sclerosis	
LGG	cis	1	rs2072293	chr14:74537885	LIN52	chr14:74551656-74667117:+	0.46	10.53	1.6E-23	Common traits (Other)	
LGG	cis	1	rs2072435	chr7:75959188	POR	chr7:75544420-75616172:+	0.19	3.92	9.96E-5	Multiple sclerosis	
LGG	cis	1	rs2072435	chr7:75959188	SRCRB4D	chr7:76018647-76039012:-	0.26	5.99	4.01E-9	Multiple sclerosis	
LGG	cis	1	rs2072435	chr7:75959188	UPK3B	chr7:76139745-76157197:+	-0.24	-4.5	8.35E-6	Multiple sclerosis	
LGG	cis	1	rs2072794	chr22:39150543	LOC646851	chr22:38974125-39052634:-	0.24	6.97	1.05E-11	Resting heart rate	
LGG	cis	1	rs2072795	chr22:39064209	LOC646851	chr22:38974125-39052634:-	-0.22	-6.71	5.54E-11	Resting heart rate	
LGG	cis	1	rs2072796	chr22:39064230	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs2072798	chr22:39148483	LOC646851	chr22:38974125-39052634:-	0.25	7.48	3.38E-13	Resting heart rate	
LGG	cis	1	rs2072883	chr22:43435668	TTLL1	chr22:43435524-43485434:-	-0.23	-4.79	2.17E-6	Schizophrenia	
LGG	cis	1	rs2073294	chr14:66082493	LOC645431	chr14:65877313-65879335:-	-0.48	-6.48	2.18E-10	Ischemic stroke	
LGG	cis	1	rs2073333	chr14:94844562	PPP4R4	chr14:94640649-94746072:+	-0.12	-3.84	0.000139	Metabolite levels	
LGG	cis	1	rs2073604	chr22:51008925	CPT1B	chr22:51007291-51017096:-	-0.31	-6.02	3.36E-9	Narcolepsy	
LGG	cis	1	rs2073605	chr22:51008850	CPT1B	chr22:51007291-51017096:-	-0.31	-6.17	1.44E-9	Narcolepsy	
LGG	cis	1	rs2073857	chr22:31658281	LIMK2	chr22:31608250-31676064:+	0.27	5.66	2.53E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2074018	chr11:2309634	C11orf21	chr11:2317507-2323143:-	0.32	4.21	3.01E-5	Obesity-related traits	
LGG	cis	1	rs2074771	chr2:242350944	SEPT2	chr2:242254723-242293439:+	0.53	7.7	7.69E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs2075184	chr2:103080592	IL18R1	chr2:102927962-103015215:+	-0.39	-6.19	1.3E-9	Pediatric autoimmune diseases	
LGG	cis	1	rs2075184	chr2:103080592	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.45	7.89E-8	Pediatric autoimmune diseases	
LGG	cis	1	rs2075555	chr17:48274291	SGCA	chr17:48243366-48253292:+	0.45	6.49	2.06E-10	Breast cancer	
LGG	cis	1	rs2075603	chr14:55609955	FBXO34	chr14:55738021-55893431:+	0.15	4.47	9.53E-6	Protein biomarker	
LGG	cis	1	rs2075678	chr20:47701339	ARFGEF2	chr20:47538275-47653229:+	0.11	4.07	5.38E-5	Anger	
LGG	cis	1	rs2075678	chr20:47701339	CSE1L	chr20:47662838-47713484:+	0.2	5.32	1.6E-7	Anger	
LGG	cis	1	rs2076028	chr22:39150450	LOC646851	chr22:38974125-39052634:-	0.25	7.21	2.16E-12	Resting heart rate	
LGG	cis	1	rs2077593	chr7:65892530	ASL	chr7:65540776-65558321:+	-0.21	-5.37	1.25E-7	Aortic root size	
LGG	cis	1	rs2077654	chr11:17427901	ABCC8	chr11:17414433-17498449:-	0.19	3.64	0.000307	Gout	
LGG	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.27	-7.47	3.6E-13	Homocysteine levels	
LGG	cis	1	rs2077808	chr1:45988115	MMACHC	chr1:45965856-45976737:+	0.26	5.57	4.24E-8	Homocysteine levels	
LGG	cis	1	rs2077808	chr1:45988115	MUTYH	chr1:45794915-45806142:-	0.13	4.4	1.32E-5	Homocysteine levels	
LGG	cis	1	rs2078089	chr19:22209753	ZNF208	chr19:22115760-22193745:-	0.21	3.51	0.000483	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2078089	chr19:22209753	ZNF257	chr19:22235266-22273901:+	0.4	7.13	3.7E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2078803	chr22:31652852	LIMK2	chr22:31608250-31676064:+	0.26	5.54	4.98E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2079005	chr17:41865627	VAT1	chr17:41166622-41174459:-	-0.2	-4.21	3.08E-5	Triglycerides	
LGG	cis	1	rs2080303	chr2:202165206	ALS2CR12	chr2:202153148-202222101:-	-0.29	-5.44	8.36E-8	Basal cell carcinoma	
LGG	cis	1	rs2080303	chr2:202165206	ALS2CR4	chr2:202484907-202508224:-	0.17	4.13	4.34E-5	Basal cell carcinoma	
LGG	cis	1	rs2080303	chr2:202165206	PPIL3	chr2:201735680-201753999:-	-0.25	-4.92	1.16E-6	Basal cell carcinoma	
LGG	cis	1	rs2081302	chr2:23945355	LOC375190	chr2:24299728-24397519:+	0.19	4.33	1.84E-5	Obesity-related traits	
LGG	cis	1	rs208346	chr7:2799686	AMZ1	chr7:2719163-2755069:+	0.12	3.5	0.000509	Loneliness (linear analysis)	
LGG	cis	1	rs2083634	chr4:129976478	C4orf33	chr4:130014829-130033842:+	-0.6	-10	1.51E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs2083729	chr15:45935159	SPATA5L1	chr15:45694519-45713614:+	0.28	4.28	2.29E-5	Obesity-related traits	
LGG	cis	1	rs2083731	chr15:75368538	PPCDC	chr15:75315927-75343066:+	0.23	4.95	1.01E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs2087017	chr3:113842013	KIAA1407	chr3:113682986-113775460:-	-0.15	-4.03	6.35E-5	Personality dimensions	
LGG	cis	1	rs2087647	chr7:65593188	ASL	chr7:65540776-65558321:+	0.21	5.44	8.56E-8	Aortic root size	
LGG	cis	1	rs2089162	chr15:78739763	CHRNA5	chr15:78857906-78886458:+	-0.64	-11.83	1.34E-28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2092982	chr22:50282204	ALG12	chr22:50296856-50312106:-	-0.27	-5.53	5.31E-8	Schizophrenia	
LGG	cis	1	rs2092990	chr20:3346338	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs2093395	chr6:41155026	LOC221442	chr6:41068773-41108567:+	-0.19	-5.11	4.7E-7	Alzheimer's disease (late onset)	
LGG	cis	1	rs2093396	chr6:41155000	LOC221442	chr6:41068773-41108567:+	0.19	4.98	8.88E-7	Alzheimer's disease (late onset)	
LGG	cis	1	rs2093761	chr1:207786542	CR1	chr1:207669473-207815109:+	-0.38	-6.48	2.17E-10	Alzheimer's disease (late onset)	
LGG	cis	1	rs2098297	chr14:75619118	ACYP1	chr14:75519930-75530736:-	0.13	3.62	0.00032	Height	
LGG	cis	1	rs2098297	chr14:75619118	EIF2B2	chr14:75469612-75476292:+	-0.2	-3.88	0.000118	Height	
LGG	cis	1	rs2098297	chr14:75619118	MLH3	chr14:75480467-75518235:-	-0.2	-3.57	0.000393	Height	
LGG	cis	1	rs2099880	chr15:45935074	SPATA5L1	chr15:45694519-45713614:+	0.28	4.28	2.29E-5	Obesity-related traits	
LGG	cis	1	rs2103876	chr1:12053100	MIIP	chr1:12079512-12092106:+	0.09	3.56	0.000401	Platelet count	
LGG	cis	1	rs2106186	chr7:127241352	GCC1	chr7:127220683-127225654:-	0.32	5.25	2.25E-7	Type 2 diabetes	
LGG	cis	1	rs2106187	chr7:127241353	GCC1	chr7:127220683-127225654:-	0.32	5.29	1.82E-7	Type 2 diabetes	
LGG	cis	1	rs2106346	chr9:135784169	C9orf98	chr9:135600965-135754198:-	0.35	9.36	2.86E-19	Psoriasis	
LGG	cis	1	rs2106346	chr9:135784169	GFI1B	chr9:135854098-135867083:+	-0.2	-3.6	0.000349	Psoriasis	
LGG	cis	1	rs2106747	chr7:23911499	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.8E-5	Schizophrenia	
LGG	cis	1	rs2106748	chr7:23911313	C7orf46	chr7:23719749-23742268:+	0.19	4.13	4.18E-5	Schizophrenia	
LGG	cis	1	rs2108622	chr19:15990431	CYP4F11	chr19:16023180-16045676:-	-0.22	-4.57	6.08E-6	Acenocoumarol maintenance dosage;Vitamin E levels;Circulating phylloquinone levels;Metabolite levels;Response to Vitamin E supplementation;Warfarin maintenance dose	
LGG	cis	1	rs2109065	chr19:45695610	GEMIN7	chr19:45582518-45594782:+	-0.12	-3.66	0.000277	Quantitative traits	
LGG	cis	1	rs2109522	chr4:17658645	MED28	chr4:17616273-17629791:+	0.18	3.94	9.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2110073	chr12:7075882	EMG1	chr12:7079944-7105520:+	0.24	3.89	0.000115	Red blood cell fatty acid levels	
LGG	cis	1	rs2110734	chr2:103052206	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2110734	chr2:103052206	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2110735	chr2:103050925	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2110735	chr2:103050925	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.81	14.55	3.92E-40	Type 2 diabetes	
LGG	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.85	16.35	2.83E-48	Type 2 diabetes	
LGG	cis	1	rs2113079	chr5:56157951	MIER3	chr5:56215429-56267501:-	0.17	3.74	0.000204	Type 2 diabetes	
LGG	cis	1	rs2113422	chr2:23939007	LOC375190	chr2:24299728-24397519:+	0.21	5.07	5.77E-7	Obesity-related traits	
LGG	cis	1	rs2113423	chr2:23942287	LOC375190	chr2:24299728-24397519:+	0.22	5.15	3.71E-7	Obesity-related traits	
LGG	cis	1	rs2114760	chr2:166887283	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000401	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2114760	chr2:166887283	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.35E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2115069	chr5:150252365	LOC134466	chr5:150310000-150326146:-	0.42	4.76	2.54E-6	Crohn's disease	
LGG	cis	1	rs2115671	chr15:50956432	SPPL2A	chr15:50999739-51057910:-	0.13	4.19	3.34E-5	QT interval	
LGG	cis	1	rs211718	chr1:76106675	MSH4	chr1:76262630-76378923:+	0.23	4.22	2.89E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs211723	chr1:76103030	MSH4	chr1:76262630-76378923:+	-0.27	-4.61	5.19E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs2120019	chr15:75334184	PPCDC	chr15:75315927-75343066:+	0.26	5.65	2.68E-8	Blood trace element (Zn levels)	
LGG	cis	1	rs2121067	chr14:76617651	ESRRB	chr14:76837690-76968178:+	0.44	6.96	1.13E-11	Blood pressure	
LGG	cis	1	rs2121070	chr14:76650764	ESRRB	chr14:76837690-76968178:+	0.43	7.11	4.18E-12	Blood pressure	
LGG	cis	1	rs2121071	chr14:76665477	ESRRB	chr14:76837690-76968178:+	0.42	6.78	3.42E-11	Blood pressure	
LGG	cis	1	rs2121075	chr14:76675540	ESRRB	chr14:76837690-76968178:+	0.42	6.72	5.1E-11	Blood pressure	
LGG	cis	1	rs2121077	chr14:76676355	ESRRB	chr14:76837690-76968178:+	-0.42	-6.43	3.04E-10	Blood pressure	
LGG	cis	1	rs2122517	chr10:111754787	ADD3	chr10:111756108-111895320:+	0.18	4.08	5.25E-5	Biliary atresia	
LGG	cis	1	rs2123694	chr2:108857505	SULT1C2	chr2:108905095-108926370:+	0.62	9.85	5.03E-21	Blood pressure	
LGG	cis	1	rs2123694	chr2:108857505	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.07	5.45E-5	Blood pressure	
LGG	cis	1	rs2125211	chr4:103559876	UBE2D3	chr4:103715547-103790032:-	0.18	3.63	0.000308	Primary biliary cirrhosis	
LGG	cis	1	rs2126129	chr2:212548	FAM150B	chr2:279563-288308:-	-0.31	-5.8	1.19E-8	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs2126152	chr2:166896143	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2126152	chr2:166896143	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2127093	chr17:20919703	USP22	chr17:20902908-20947073:-	-0.19	-4.33	1.79E-5	Blood trace element (Se levels)	
LGG	cis	1	rs2127094	chr17:20925319	USP22	chr17:20902908-20947073:-	-0.19	-4.33	1.8E-5	Blood trace element (Se levels)	
LGG	cis	1	rs2127905	chr11:117026374	SIDT2	chr11:117049939-117068161:+	0.31	3.67	0.000268	Protein quantitative trait loci	
LGG	cis	1	rs2128792	chr17:65857177	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs2130221	chr2:179750087	CCDC141	chr2:179697347-179914786:-	-0.34	-5.2	2.94E-7	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.27	-7.9	1.84E-14	Kawasaki disease	
LGG	cis	1	rs2131877	chr3:194858374	ACAP2	chr3:194995475-195163817:-	0.25	5.07	5.7E-7	Non-small cell lung cancer	
LGG	cis	1	rs2133134	chr1:76179587	MSH4	chr1:76262630-76378923:+	0.25	4.39	1.39E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs2134055	chr2:48073011	FBXO11	chr2:48034061-48132814:-	0.23	4.14	4.01E-5	Schizophrenia	
LGG	cis	1	rs2134265	chr15:63398196	LACTB	chr15:63414032-63434254:+	0.22	4.43	1.18E-5	HDL cholesterol	
LGG	cis	1	rs2134688	chr1:150816886	ARNT	chr1:150782186-150849186:-	-0.23	-4.16	3.7E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs2134688	chr1:150816886	OAZ3	chr1:151735445-151743805:+	-0.29	-3.7	0.000239	Congenital left-sided heart lesions	
LGG	cis	1	rs2135509	chr4:17917818	DCAF16	chr4:17802280-17812381:-	-0.15	-3.67	0.000268	Height	
LGG	cis	1	rs2137435	chr1:202499321	UBE2T	chr1:202300786-202311094:-	-0.13	-3.86	0.000131	Sex ratio	
LGG	cis	1	rs2140195	chr2:73702344	ALMS1P	chr2:73872046-73912692:+	0.39	7.16	3.02E-12	Metabolite levels	
LGG	cis	1	rs2140195	chr2:73702344	NAT8	chr2:73867850-73869537:-	0.28	4.62	4.84E-6	Metabolite levels	
LGG	cis	1	rs2140270	chr3:49439440	AMIGO3	chr3:49754268-49757238:-	0.18	4.28	2.3E-5	Menarche (age at onset)	
LGG	cis	1	rs2140270	chr3:49439440	GMPPB	chr3:49758932-49761384:-	0.22	4.33	1.82E-5	Menarche (age at onset)	
LGG	cis	1	rs2140270	chr3:49439440	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.53	0.000458	Menarche (age at onset)	
LGG	cis	1	rs2140270	chr3:49439440	TREX1	chr3:48501186-48509043:+	0.24	5.08	5.31E-7	Menarche (age at onset)	
LGG	cis	1	rs214034	chr2:17988658	SMC6	chr2:17845080-17981462:-	-0.17	-4.21	3.1E-5	Response to amphetamines	
LGG	cis	1	rs2141595	chr3:169503432	LRRC34	chr3:169511266-169530720:-	-0.29	-5.14	4.07E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs2141924	chr7:66186246	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2143062	chr6:27353852	ZNF391	chr6:27356524-27369227:+	0.3	7.15	3.12E-12	Glomerular filtration rate (creatinine)	
LGG	cis	1	rs2143178	chr22:39660829	APOBEC3C	chr22:39410265-39414823:+	0.15	3.77	0.000183	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs2143290	chr1:169088679	NME7	chr1:169101771-169337186:-	-0.29	-4.33	1.79E-5	QT interval	
LGG	cis	1	rs2143346	chr6:26198449	HIST1H2AE	chr6:26217148-26217711:+	0.3	4.2	3.21E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs2143346	chr6:26198449	HIST1H3E	chr6:26224427-26226589:+	-0.64	-10.65	5.64E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs2143347	chr6:26198494	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs2143347	chr6:26198494	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs2147712	chr14:50091684	RPL36AL	chr14:50085407-50087349:-	0.34	8.89	1.21E-17	Carotid intima media thickness	
LGG	cis	1	rs2147972	chr14:55598030	FBXO34	chr14:55738021-55893431:+	0.15	4.51	8.21E-6	Protein biomarker	
LGG	cis	1	rs2148501	chr14:70366409	COX16	chr14:70791799-70826444:-	-0.21	-3.92	0.000103	Red blood cell traits	
LGG	cis	1	rs2148501	chr14:70366409	SLC39A9	chr14:69865407-69929105:+	-0.22	-3.97	8.16E-5	Red blood cell traits	
LGG	cis	1	rs2149423	chr13:36772381	SOHLH2	chr13:36742347-36871992:-	0.36	6.52	1.75E-10	Glucose homeostasis traits	
LGG	cis	1	rs2152375	chr14:65915778	LOC645431	chr14:65877313-65879335:-	-0.52	-6.96	1.09E-11	Ischemic stroke	
LGG	cis	1	rs2152916	chr10:97392265	TCTN3	chr10:97423154-97453900:-	0.18	3.48	0.000538	Blood metabolite levels	
LGG	cis	1	rs2153904	chr1:205642790	PM20D1	chr1:205797154-205819245:-	-0.39	-5.68	2.34E-8	Prostate-specific antigen levels	
LGG	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.46	-12.19	4.75E-30	Eye color traits	
LGG	cis	1	rs2154536	chr21:38492147	TTC3	chr21:38445571-38575406:+	0.12	3.99	7.64E-5	Eye color traits	
LGG	cis	1	rs2155098	chr11:94322052	MRE11A	chr11:94150469-94227040:-	-0.14	-3.53	0.000449	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs2155583	chr11:116915217	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs2156257	chr6:163100710	PACRG	chr6:163148164-163736523:+	0.41	5.62	3.26E-8	Body mass index	
LGG	cis	1	rs2157710	chr22:23457486	RTDR1	chr22:23401594-23484241:-	-0.15	-3.47	0.000558	Bone mineral density	
LGG	cis	1	rs2158100	chr17:18811479	FAM18B	chr17:18684582-18710026:+	0.15	3.52	0.000478	Pancreatic cancer	
LGG	cis	1	rs2158100	chr17:18811479	PRPSAP2	chr17:18759663-18834580:+	-0.2	-5.46	7.6E-8	Pancreatic cancer	
LGG	cis	1	rs2158428	chr5:130751481	SLC22A5	chr5:131705401-131731302:+	-0.27	-4.7	3.31E-6	Life satisfaction	
LGG	cis	1	rs2159324	chr19:45695738	GEMIN7	chr19:45582518-45594782:+	-0.13	-3.9	0.000107	Quantitative traits	
LGG	cis	1	rs2159400	chr3:47375890	NRADDP	chr3:47053032-47054957:+	0.22	3.75	0.0002	Colorectal cancer	
LGG	cis	1	rs2159583	chr4:17658838	MED28	chr4:17616273-17629791:+	0.18	3.94	9.26E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2159584	chr4:17620568	MED28	chr4:17616273-17629791:+	0.21	4.5	8.69E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2160232	chr2:103046880	IL18R1	chr2:102927962-103015215:+	-0.37	-5.92	6.06E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2160232	chr2:103046880	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.18	3.29E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2160392	chr2:37527393	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.93	1.15E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2160393	chr2:37516950	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.93	1.13E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2160395	chr2:37479862	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.72	3.03E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2160908	chr22:37586792	C1QTNF6	chr22:37576206-37594341:-	-0.21	-5.14	3.95E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2163167	chr3:53131772	RFT1	chr3:53122503-53164470:-	-0.46	-9.87	4.42E-21	Height	
LGG	cis	1	rs216345	chr9:33799370	NUDT2	chr9:34329504-34343695:+	-0.19	-4.8	2.13E-6	Bipolar disorder	
LGG	cis	1	rs2163846	chr19:22505844	ZNF257	chr19:22235266-22273901:+	0.2	3.59	0.000359	Telomere length	
LGG	cis	1	rs2164879	chr2:86261579	LOC90784	chr2:86247339-86250991:-	-0.47	-5.04	6.43E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs2165295	chr15:67027320	SMAD6	chr15:66994674-67074335:+	-0.19	-3.55	0.00042	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs2166580	chr4:1743169	TMEM129	chr4:1717680-1723084:-	-0.17	-3.57	0.000387	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.53	-11.3	1.75E-26	Response to antipsychotic treatment	
LGG	cis	1	rs2169748	chr2:28957753	FAM179A	chr2:29204164-29275094:+	0.19	3.6	0.000344	Body mass index	
LGG	cis	1	rs2169748	chr2:28957753	TRMT61B	chr2:29072690-29093175:-	0.52	10.77	1.96E-24	Body mass index	
LGG	cis	1	rs2169751	chr2:28966758	FAM179A	chr2:29204164-29275094:+	-0.19	-3.71	0.000229	Body mass index	
LGG	cis	1	rs2169751	chr2:28966758	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.66	5.06E-24	Body mass index	
LGG	cis	1	rs217181	chr16:72114002	HP	chr16:72088508-72094957:+	0.27	4.17	3.57E-5	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs217181	chr16:72114002	HPR	chr16:72097125-72111144:+	0.22	3.78	0.000179	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs2172252	chr3:49678307	MST1R	chr3:49924438-49941306:-	-0.2	-3.89	0.000115	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs2172252	chr3:49678307	RBM6	chr3:49977592-50137484:+	0.16	4.46	1.01E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs2172252	chr3:49678307	SEMA3F	chr3:50192848-50226507:+	0.19	4.35	1.66E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs217295	chr6:84383958	SNAP91	chr6:84262607-84419127:-	-0.07	-3.69	0.000247	Schizophrenia	
LGG	cis	1	rs217297	chr6:84380923	SNAP91	chr6:84262607-84419127:-	0.07	3.77	0.000186	Schizophrenia	
LGG	cis	1	rs217308	chr6:84369869	SNAP91	chr6:84262607-84419127:-	-0.07	-3.7	0.000241	Schizophrenia	
LGG	cis	1	rs217309	chr6:84365449	SNAP91	chr6:84262607-84419127:-	-0.07	-3.66	0.000275	Schizophrenia	
LGG	cis	1	rs217310	chr6:84364565	SNAP91	chr6:84262607-84419127:-	-0.07	-3.69	0.000247	Schizophrenia	
LGG	cis	1	rs217311	chr6:84364140	SNAP91	chr6:84262607-84419127:-	-0.07	-3.69	0.000246	Schizophrenia	
LGG	cis	1	rs217327	chr6:84348594	SNAP91	chr6:84262607-84419127:-	-0.07	-3.47	0.000558	Schizophrenia	
LGG	cis	1	rs217333	chr6:84343891	SNAP91	chr6:84262607-84419127:-	-0.07	-3.48	0.000554	Schizophrenia	
LGG	cis	1	rs217335	chr6:84342142	SNAP91	chr6:84262607-84419127:-	-0.07	-3.79	0.000171	Schizophrenia	
LGG	cis	1	rs217343	chr6:84336742	SNAP91	chr6:84262607-84419127:-	-0.07	-3.84	0.000138	Schizophrenia	
LGG	cis	1	rs2174608	chr15:50871993	SPPL2A	chr15:50999739-51057910:-	0.12	3.96	8.66E-5	QT interval	
LGG	cis	1	rs2175082	chr9:15641279	CER1	chr9:14719734-14722715:-	0.19	4.1	4.74E-5	Body mass index	
LGG	cis	1	rs2175366	chr19:22128279	ZNF208	chr19:22115760-22193745:-	0.22	3.65	0.000291	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2175366	chr19:22128279	ZNF257	chr19:22235266-22273901:+	0.4	7.12	3.84E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2175416	chr2:160904021	LY75	chr2:160625141-160761262:-	0.13	3.68	0.000254	Idiopathic membranous nephropathy	
LGG	cis	1	rs2177129	chr4:56365414	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs2177268	chr3:49439725	AMIGO3	chr3:49754268-49757238:-	0.18	4.28	2.3E-5	Menarche (age at onset)	
LGG	cis	1	rs2177268	chr3:49439725	GMPPB	chr3:49758932-49761384:-	0.22	4.33	1.82E-5	Menarche (age at onset)	
LGG	cis	1	rs2177268	chr3:49439725	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.53	0.000458	Menarche (age at onset)	
LGG	cis	1	rs2177268	chr3:49439725	TREX1	chr3:48501186-48509043:+	0.24	5.08	5.31E-7	Menarche (age at onset)	
LGG	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs2177601	chr3:134245434	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs2177685	chr3:65491171	MAGI1	chr3:65339907-66024509:-	0.22	4.22	2.88E-5	PR interval	
LGG	cis	1	rs2177703	chr7:65391717	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs2179142	chr22:39037954	LOC646851	chr22:38974125-39052634:-	0.23	7.11	4.11E-12	Resting heart rate	
LGG	cis	1	rs2181043	chr10:17217803	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.38	1.48E-5	Homocysteine levels	
LGG	cis	1	rs2182712	chr20:6368089	CRLS1	chr20:5986739-6020694:+	-0.18	-3.5	0.000502	Metabolite levels  (X-11787)	
LGG	cis	1	rs2184000	chr20:25395878	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2184000	chr20:25395878	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2184000	chr20:25395878	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2184602	chr14:65915672	LOC645431	chr14:65877313-65879335:-	-0.52	-7.16	2.89E-12	Ischemic stroke	
LGG	cis	1	rs2186369	chr22:24170996	C22orf43	chr22:23950640-23974487:-	-0.29	-4.06	5.77E-5	IgG glycosylation	
LGG	cis	1	rs2186369	chr22:24170996	DERL3	chr22:24176691-24181315:-	0.28	5.19	3.05E-7	IgG glycosylation	
LGG	cis	1	rs2186637	chr11:71570115	FAM86C	chr11:71498557-71512276:+	-0.43	-4.5	8.43E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2188654	chr7:118179073	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000174	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2189125	chr7:118007075	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2192233	chr7:118074563	ANKRD7	chr7:117864712-117882782:+	-0.23	-3.95	9.1E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2195144	chr2:166909751	SCN2A	chr2:166095912-166248818:+	0.09	3.61	0.000337	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2195144	chr2:166909751	TTC21B	chr2:166713988-166810348:-	0.13	3.91	0.000104	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2197089	chr8:19826373	LPL	chr8:19796582-19824769:+	-0.2	-3.66	0.000279	Metabolic syndrome (bivariate traits)	
LGG	cis	1	rs2198042	chr4:129885499	C4orf33	chr4:130014829-130033842:+	0.55	8.8	2.27E-17	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs2198463	chr2:108875093	SULT1C2	chr2:108905095-108926370:+	0.62	9.8	7.75E-21	Blood pressure	
LGG	cis	1	rs2198463	chr2:108875093	SULT1C4	chr2:108994421-109004270:+	-0.22	-4.39	1.4E-5	Blood pressure	
LGG	cis	1	rs2205802	chr22:39046327	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs2208331	chr6:26507319	HMGN4	chr6:26538572-26547162:+	-0.2	-5.15	3.72E-7	Educational attainment	
LGG	cis	1	rs2212361	chr11:94312323	MRE11A	chr11:94150469-94227040:-	-0.14	-3.71	0.000232	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs2214363	chr7:118001244	ANKRD7	chr7:117864712-117882782:+	0.22	3.72	0.000224	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2214366	chr7:118023272	ANKRD7	chr7:117864712-117882782:+	0.22	3.79	0.000168	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs2215450	chr4:17675394	LAP3	chr4:17578927-17609590:+	-0.14	-3.96	8.76E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2217266	chr5:150272621	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs2219078	chr2:108875198	SULT1C2	chr2:108905095-108926370:+	0.62	9.95	2.19E-21	Blood pressure	
LGG	cis	1	rs2219078	chr2:108875198	SULT1C4	chr2:108994421-109004270:+	-0.21	-4.24	2.7E-5	Blood pressure	
LGG	cis	1	rs2221593	chr1:212873431	BATF3	chr1:212859760-212873327:-	0.18	3.86	0.000129	Leprosy	
LGG	cis	1	rs2221720	chr11:34754921	APIP	chr11:34896714-34937939:-	-0.18	-4.12	4.44E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs2224380	chr6:26553943	BTN2A3	chr6:26422317-26431927:+	0.13	3.69	0.000252	Educational attainment	
LGG	cis	1	rs2224380	chr6:26553943	HMGN4	chr6:26538572-26547162:+	-0.19	-4.93	1.15E-6	Educational attainment	
LGG	cis	1	rs222451	chr6:52909609	ICK	chr6:52866098-52926600:-	0.21	3.66	0.000283	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs222453	chr6:52896853	ICK	chr6:52866098-52926600:-	0.21	3.8	0.000165	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs222458	chr6:52890625	ICK	chr6:52866098-52926600:-	0.22	3.89	0.000113	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs222459	chr6:52889384	ICK	chr6:52866098-52926600:-	0.22	3.89	0.000113	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs2224949	chr14:50096560	RPL36AL	chr14:50085407-50087349:-	-0.31	-8.15	3.05E-15	Carotid intima media thickness	
LGG	cis	1	rs2225056	chr14:70366705	COX16	chr14:70791799-70826444:-	-0.21	-3.91	0.000106	Red blood cell traits	
LGG	cis	1	rs2225056	chr14:70366705	SLC39A9	chr14:69865407-69929105:+	-0.21	-3.93	9.6E-5	Red blood cell traits	
LGG	cis	1	rs2227336	chr17:38174855	GSDMA	chr17:38119226-38134019:+	-0.71	-15.37	7.97E-44	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs2228479	chr16:89985940	LOC100130015	chr16:90106171-90114181:-	0.28	3.86	0.000126	Skin colour saturation	
LGG	cis	1	rs2228479	chr16:89985940	MC1R	chr16:89984287-89987384:+	0.31	4.92	1.16E-6	Skin colour saturation	
LGG	cis	1	rs2229238	chr1:154437896	NUP210L	chr1:153965170-154127592:-	-0.27	-4.07	5.5E-5	Coronary heart disease	
LGG	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.15	3.46	0.000581	Homocysteine levels	
LGG	cis	1	rs2229496	chr1:152882610	SMCP	chr1:152850798-152857515:+	-0.33	-5.1	4.88E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2233925	chr1:212870292	BATF3	chr1:212859760-212873327:-	0.19	4.11	4.67E-5	Leprosy	
LGG	cis	1	rs2235230	chr22:39124467	LOC646851	chr22:38974125-39052634:-	-0.23	-6.79	3.21E-11	Resting heart rate	
LGG	cis	1	rs2235649	chr16:1837406	C16orf73	chr16:1883984-1934295:-	0.26	4.25	2.58E-5	Blood metabolite levels	
LGG	cis	1	rs2235649	chr16:1837406	FAHD1	chr16:1877225-1890201:+	-0.19	-3.57	0.000396	Blood metabolite levels	
LGG	cis	1	rs2236087	chr20:3255905	ITPA	chr20:3190056-3204504:+	-0.36	-8.42	4.12E-16	IFN-related cytopenia	
LGG	cis	1	rs2236089	chr20:3257194	ITPA	chr20:3190056-3204504:+	-0.35	-8.37	5.99E-16	IFN-related cytopenia	
LGG	cis	1	rs2236092	chr20:3258188	ITPA	chr20:3190056-3204504:+	-0.35	-8.36	6.4E-16	IFN-related cytopenia	
LGG	cis	1	rs2236098	chr20:3267133	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs2236104	chr20:3277602	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs2236106	chr20:3278410	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs2236107	chr20:3285821	ITPA	chr20:3190056-3204504:+	-0.36	-8.42	4.07E-16	IFN-related cytopenia	
LGG	cis	1	rs2236108	chr20:3286331	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs2236117	chr20:3302021	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs2236118	chr20:3302058	ITPA	chr20:3190056-3204504:+	-0.38	-9.18	1.22E-18	IFN-related cytopenia	
LGG	cis	1	rs2236122	chr20:3305240	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs2236123	chr20:3305305	ITPA	chr20:3190056-3204504:+	0.36	8.63	8.52E-17	IFN-related cytopenia	
LGG	cis	1	rs2236246	chr14:104379206	KLC1	chr14:104029299-104167887:+	0.13	3.52	0.000475	Bipolar disorder	
LGG	cis	1	rs2236246	chr14:104379206	TDRD9	chr14:104394817-104519002:+	-0.21	-4.33	1.8E-5	Bipolar disorder	
LGG	cis	1	rs2236247	chr14:104378087	EIF5	chr14:103800493-103811359:+	-0.19	-3.58	0.00038	Bipolar disorder	
LGG	cis	1	rs2236247	chr14:104378087	KLC1	chr14:104029299-104167887:+	-0.18	-5.17	3.4E-7	Bipolar disorder	
LGG	cis	1	rs2236247	chr14:104378087	TDRD9	chr14:104394817-104519002:+	0.19	3.82	0.000151	Bipolar disorder	
LGG	cis	1	rs2239557	chr14:74551970	LIN52	chr14:74551656-74667117:+	0.49	11.51	2.6E-27	Common traits (Other)	
LGG	cis	1	rs2240009	chr17:40283142	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs2240009	chr17:40283142	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs2240010	chr17:40278081	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs2240010	chr17:40278081	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs2240335	chr1:17674537	PADI4	chr1:17634690-17690495:+	0.22	4.81	2.01E-6	Rheumatoid arthritis	
LGG	cis	1	rs224048	chr10:64491549	ADO	chr10:64564516-64568238:+	-0.17	-4.46	1.03E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224052	chr10:64494174	ADO	chr10:64564516-64568238:+	-0.17	-4.46	1.03E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224057	chr10:64497768	ADO	chr10:64564516-64568238:+	-0.17	-4.46	1.03E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224058	chr10:64498865	ADO	chr10:64564516-64568238:+	0.18	4.67	3.86E-6	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224071	chr10:64508475	ADO	chr10:64564516-64568238:+	0.17	4.52	7.73E-6	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs2241106	chr1:156218910	BGLAP	chr1:156182784-156213112:+	0.22	4.66	4.12E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2241106	chr1:156218910	CCT3	chr1:156278752-156308195:-	-0.14	-3.48	0.000542	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2241389	chr19:6693317	GPR108	chr19:6729927-6737633:-	-0.27	-3.76	0.00019	Complement C3 and C4 levels	
LGG	cis	1	rs2241390	chr19:6693240	GPR108	chr19:6729927-6737633:-	-0.27	-3.75	0.000195	Complement C3 and C4 levels	
LGG	cis	1	rs224139	chr10:64473716	ADO	chr10:64564516-64568238:+	-0.18	-4.59	5.66E-6	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224148	chr10:64486639	ADO	chr10:64564516-64568238:+	-0.17	-4.45	1.05E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224149	chr10:64487073	ADO	chr10:64564516-64568238:+	-0.17	-4.45	1.05E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs224150	chr10:64488087	ADO	chr10:64564516-64568238:+	-0.17	-4.45	1.05E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs2241784	chr3:51418348	HEMK1	chr3:50606583-50622419:+	0.19	3.56	0.000408	Melanoma	
LGG	cis	1	rs2241878	chr2:234183718	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.17	3.6E-5	Crohn's disease	
LGG	cis	1	rs2241879	chr2:234183468	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.2	3.14E-5	Crohn's disease	
LGG	cis	1	rs2241880	chr2:234183368	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.2	3.14E-5	Crohn's disease	
LGG	cis	1	rs2242050	chr10:102059329	BLOC1S2	chr10:102033713-102046439:-	-0.32	-4.73	2.95E-6	Obesity-related traits	
LGG	cis	1	rs2242073	chr2:208994045	CRYGA	chr2:209025465-209028297:-	-0.23	-3.51	0.000485	Attention deficit hyperactivity disorder	
LGG	cis	1	rs2242150	chr3:48505964	ATRIP	chr3:48488141-48507708:+	-0.22	-5.53	5.21E-8	Longevity	
LGG	cis	1	rs2242150	chr3:48505964	TREX1	chr3:48501186-48509043:+	0.4	10.18	3.38E-22	Longevity	
LGG	cis	1	rs2242471	chr4:76878716	NAAA	chr4:76831809-76862166:-	0.46	11.06	1.47E-25	Longevity	
LGG	cis	1	rs2242473	chr4:76878956	NAAA	chr4:76831809-76862166:-	0.46	11.03	1.92E-25	Longevity	
LGG	cis	1	rs2242474	chr4:76878982	NAAA	chr4:76831809-76862166:-	0.46	11.06	1.47E-25	Longevity	
LGG	cis	1	rs2242482	chr13:50655879	EBPL	chr13:50234811-50265623:-	-0.17	-3.63	0.000308	Height	
LGG	cis	1	rs224329	chr20:34019579	CPNE1	chr20:34213968-34262539:-	-0.26	-5.49	6.4E-8	Height	
LGG	cis	1	rs224329	chr20:34019579	GDF5	chr20:33897002-34042568:-	0.36	7.02	7.57E-12	Height	
LGG	cis	1	rs224329	chr20:34019579	UQCC	chr20:33890383-33999833:-	-0.27	-5.71	2.0E-8	Height	
LGG	cis	1	rs224333	chr20:34023962	CPNE1	chr20:34213968-34262539:-	-0.27	-5.73	1.72E-8	Height	
LGG	cis	1	rs224333	chr20:34023962	GDF5	chr20:33897002-34042568:-	0.35	6.81	2.87E-11	Height	
LGG	cis	1	rs224333	chr20:34023962	UQCC	chr20:33890383-33999833:-	-0.26	-5.62	3.19E-8	Height	
LGG	cis	1	rs2243480	chr7:65599196	CCT6P1	chr7:65216092-65228661:+	0.22	3.78	0.000179	Diabetic kidney disease	
LGG	cis	1	rs2244526	chr1:169586946	SCYL3	chr1:169821804-169863076:-	0.31	4.3	2.07E-5	Late-onset Alzheimer's disease	
LGG	cis	1	rs2245715	chr15:43818052	ADAL	chr15:43622872-43646094:+	-0.64	-8.37	6.17E-16	Tumor biomarkers	
LGG	cis	1	rs2245715	chr15:43818052	CCNDBP1	chr15:43477466-43488228:+	-0.22	-3.51	0.000483	Tumor biomarkers	
LGG	cis	1	rs2245715	chr15:43818052	LCMT2	chr15:43619976-43622891:-	-0.33	-4.36	1.61E-5	Tumor biomarkers	
LGG	cis	1	rs2245715	chr15:43818052	STRC	chr15:43891762-43924561:-	0.38	6.94	1.26E-11	Tumor biomarkers	
LGG	cis	1	rs2246833	chr10:91005854	LIPA	chr10:90973328-91174382:-	0.19	5.34	1.46E-7	Fibrinogen levels	
LGG	cis	1	rs2246942	chr10:91004886	LIPA	chr10:90973328-91174382:-	0.19	5.31	1.68E-7	Fibrinogen levels	
LGG	cis	1	rs2248393	chr20:33926103	CPNE1	chr20:34213968-34262539:-	-0.27	-5.86	8.44E-9	Height	
LGG	cis	1	rs2248393	chr20:33926103	GDF5	chr20:33897002-34042568:-	0.38	7.48	3.47E-13	Height	
LGG	cis	1	rs2248393	chr20:33926103	UQCC	chr20:33890383-33999833:-	-0.23	-5.06	5.91E-7	Height	
LGG	cis	1	rs2249811	chr1:202531741	UBE2T	chr1:202300786-202311094:-	0.12	3.75	0.000201	Sex ratio	
LGG	cis	1	rs2250644	chr10:91008879	LIPA	chr10:90973328-91174382:-	0.19	5.33	1.51E-7	Fibrinogen levels	
LGG	cis	1	rs2250752	chr12:51106091	ATF1	chr12:51157819-51214906:+	-0.21	-4.41	1.29E-5	Fibrinogen	
LGG	cis	1	rs2250752	chr12:51106091	LETMD1	chr12:51442084-51454206:+	0.16	4	7.41E-5	Fibrinogen	
LGG	cis	1	rs2250752	chr12:51106091	SLC11A2	chr12:51373319-51422058:-	0.17	3.83	0.000144	Fibrinogen	
LGG	cis	1	rs2250866	chr11:71804513	FAM86C	chr11:71498557-71512276:+	0.44	5.07	5.59E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2251603	chr12:51049653	ATF1	chr12:51157819-51214906:+	0.19	4.1	4.81E-5	Fibrinogen	
LGG	cis	1	rs2251603	chr12:51049653	LETMD1	chr12:51442084-51454206:+	-0.16	-4	7.28E-5	Fibrinogen	
LGG	cis	1	rs2251603	chr12:51049653	SLC11A2	chr12:51373319-51422058:-	-0.18	-3.93	9.68E-5	Fibrinogen	
LGG	cis	1	rs2251844	chr15:43836478	ADAL	chr15:43622872-43646094:+	-0.6	-7.95	1.31E-14	Tumor biomarkers	
LGG	cis	1	rs2251844	chr15:43836478	LCMT2	chr15:43619976-43622891:-	-0.28	-3.75	0.000201	Tumor biomarkers	
LGG	cis	1	rs2251844	chr15:43836478	STRC	chr15:43891762-43924561:-	0.38	7.16	3.06E-12	Tumor biomarkers	
LGG	cis	1	rs2251963	chr1:158582543	KIRREL	chr1:157963063-158065842:+	-0.12	-3.61	0.000337	Other erythrocyte phenotypes	
LGG	cis	1	rs2251964	chr1:158582552	KIRREL	chr1:157963063-158065842:+	-0.12	-3.61	0.000337	Other erythrocyte phenotypes	
LGG	cis	1	rs2252259	chr20:47662823	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.47E-5	Anger	
LGG	cis	1	rs2252259	chr20:47662823	CSE1L	chr20:47662838-47713484:+	-0.19	-5.04	6.45E-7	Anger	
LGG	cis	1	rs2252589	chr12:51041957	ATF1	chr12:51157819-51214906:+	-0.2	-4.28	2.24E-5	Fibrinogen	
LGG	cis	1	rs2252589	chr12:51041957	LETMD1	chr12:51442084-51454206:+	0.16	3.86	0.00013	Fibrinogen	
LGG	cis	1	rs2252589	chr12:51041957	SLC11A2	chr12:51373319-51422058:-	0.17	3.76	0.000192	Fibrinogen	
LGG	cis	1	rs2253209	chr3:53115160	RFT1	chr3:53122503-53164470:-	-0.47	-10.06	8.78E-22	Height	
LGG	cis	1	rs2253656	chr3:53119099	RFT1	chr3:53122503-53164470:-	-0.47	-10.06	8.78E-22	Height	
LGG	cis	1	rs2253685	chr3:53119703	RFT1	chr3:53122503-53164470:-	-0.47	-10.05	1.02E-21	Height	
LGG	cis	1	rs2253796	chr3:53120098	RFT1	chr3:53122503-53164470:-	-0.47	-10.05	1.02E-21	Height	
LGG	cis	1	rs2253826	chr1:202408800	UBE2T	chr1:202300786-202311094:-	-0.13	-3.84	0.000139	Sex ratio	
LGG	cis	1	rs2254230	chr9:131905177	CRAT	chr9:131857075-131873070:-	-0.21	-3.89	0.000112	Blood metabolite ratios	
LGG	cis	1	rs2254537	chr10:113917085	ZDHHC6	chr10:114190060-114207306:-	0.24	4.64	4.48E-6	HDL cholesterol	
LGG	cis	1	rs2255042	chr15:43834318	ADAL	chr15:43622872-43646094:+	0.63	8.33	8.17E-16	Tumor biomarkers	
LGG	cis	1	rs2255042	chr15:43834318	LCMT2	chr15:43619976-43622891:-	0.3	3.95	9.03E-5	Tumor biomarkers	
LGG	cis	1	rs2255042	chr15:43834318	STRC	chr15:43891762-43924561:-	-0.37	-6.88	1.82E-11	Tumor biomarkers	
LGG	cis	1	rs2255051	chr15:43846161	ADAL	chr15:43622872-43646094:+	-0.6	-8.02	8.02E-15	Tumor biomarkers	
LGG	cis	1	rs2255051	chr15:43846161	LCMT2	chr15:43619976-43622891:-	-0.28	-3.75	0.000198	Tumor biomarkers	
LGG	cis	1	rs2255051	chr15:43846161	STRC	chr15:43891762-43924561:-	0.39	7.22	2.05E-12	Tumor biomarkers	
LGG	cis	1	rs2255070	chr6:26501777	HMGN4	chr6:26538572-26547162:+	-0.2	-5.04	6.54E-7	Educational attainment	
LGG	cis	1	rs2255400	chr10:113936244	ZDHHC6	chr10:114190060-114207306:-	0.25	4.7	3.46E-6	HDL cholesterol	
LGG	cis	1	rs2255440	chr15:43830467	ADAL	chr15:43622872-43646094:+	-0.62	-8.16	2.85E-15	Tumor biomarkers	
LGG	cis	1	rs2255440	chr15:43830467	CCNDBP1	chr15:43477466-43488228:+	-0.22	-3.56	0.000408	Tumor biomarkers	
LGG	cis	1	rs2255440	chr15:43830467	LCMT2	chr15:43619976-43622891:-	-0.31	-4.08	5.27E-5	Tumor biomarkers	
LGG	cis	1	rs2255440	chr15:43830467	STRC	chr15:43891762-43924561:-	0.39	7.27	1.46E-12	Tumor biomarkers	
LGG	cis	1	rs2257420	chr20:25275890	ABHD12	chr20:25275380-25371477:-	0.27	7.29	1.23E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257420	chr20:25275890	FAM182A	chr20:26035250-26067552:+	-0.55	-10.74	2.6E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257420	chr20:25275890	FAM182B	chr20:25744102-25848786:-	0.21	4.83	1.85E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257432	chr20:25271086	ABHD12	chr20:25275380-25371477:-	0.26	7.1	4.42E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257432	chr20:25271086	FAM182A	chr20:26035250-26067552:+	-0.54	-10.62	7.19E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257432	chr20:25271086	FAM182B	chr20:25744102-25848786:-	0.21	4.7	3.33E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257496	chr20:25279315	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257496	chr20:25279315	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257496	chr20:25279315	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257790	chr7:65600450	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs2257808	chr20:25266450	ABHD12	chr20:25275380-25371477:-	0.26	7.03	6.76E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257808	chr20:25266450	FAM182A	chr20:26035250-26067552:+	-0.54	-10.64	6.3E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257808	chr20:25266450	FAM182B	chr20:25744102-25848786:-	0.21	4.66	4.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257809	chr20:25266476	ABHD12	chr20:25275380-25371477:-	0.26	7.03	6.76E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257809	chr20:25266476	FAM182A	chr20:26035250-26067552:+	-0.54	-10.64	6.3E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257809	chr20:25266476	FAM182B	chr20:25744102-25848786:-	0.21	4.66	4.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257982	chr20:25269630	ABHD12	chr20:25275380-25371477:-	0.26	7.05	5.99E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257982	chr20:25269630	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.96E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257982	chr20:25269630	FAM182B	chr20:25744102-25848786:-	0.21	4.66	4.11E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257985	chr20:25269743	ABHD12	chr20:25275380-25371477:-	0.26	7.06	5.9E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257985	chr20:25269743	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	7.08E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257985	chr20:25269743	FAM182B	chr20:25744102-25848786:-	0.21	4.67	3.87E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257988	chr20:25270003	ABHD12	chr20:25275380-25371477:-	0.26	7.06	5.9E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257988	chr20:25270003	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	7.08E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257988	chr20:25270003	FAM182B	chr20:25744102-25848786:-	0.21	4.67	3.87E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257991	chr20:25270339	ABHD12	chr20:25275380-25371477:-	-0.26	-6.95	1.13E-11	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257991	chr20:25270339	FAM182A	chr20:26035250-26067552:+	0.54	10.72	3.13E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2257991	chr20:25270339	FAM182B	chr20:25744102-25848786:-	-0.21	-4.65	4.36E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258066	chr20:25271326	ABHD12	chr20:25275380-25371477:-	0.26	7.1	4.42E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258066	chr20:25271326	FAM182A	chr20:26035250-26067552:+	-0.54	-10.62	7.19E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258066	chr20:25271326	FAM182B	chr20:25744102-25848786:-	0.21	4.7	3.33E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258135	chr20:25272323	ABHD12	chr20:25275380-25371477:-	0.26	7.06	5.78E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258135	chr20:25272323	FAM182A	chr20:26035250-26067552:+	-0.54	-10.67	4.89E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258135	chr20:25272323	FAM182B	chr20:25744102-25848786:-	0.21	4.66	4.05E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258201	chr20:25272490	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258201	chr20:25272490	FAM182A	chr20:26035250-26067552:+	-0.54	-10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258201	chr20:25272490	FAM182B	chr20:25744102-25848786:-	0.21	4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258483	chr8:133925659	TG	chr8:133879205-134147141:+	-0.22	-3.92	0.000101	Vitiligo	
LGG	cis	1	rs2258563	chr20:25273435	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258563	chr20:25273435	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258563	chr20:25273435	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258617	chr20:25274318	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258617	chr20:25274318	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258617	chr20:25274318	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258719	chr20:25275843	ABHD12	chr20:25275380-25371477:-	0.27	7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258719	chr20:25275843	FAM182A	chr20:26035250-26067552:+	-0.56	-11.09	1.19E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258719	chr20:25275843	FAM182B	chr20:25744102-25848786:-	0.22	5	7.88E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258769	chr20:25276680	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258769	chr20:25276680	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258769	chr20:25276680	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258879	chr20:25279213	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258879	chr20:25279213	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258879	chr20:25279213	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258884	chr20:25279539	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258884	chr20:25279539	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2258884	chr20:25279539	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259837	chr20:25280205	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259837	chr20:25280205	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259837	chr20:25280205	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259873	chr20:25280781	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259873	chr20:25280781	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259873	chr20:25280781	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259926	chr20:25281733	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259926	chr20:25281733	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259926	chr20:25281733	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259928	chr20:25281834	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259928	chr20:25281834	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259928	chr20:25281834	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259956	chr20:25282433	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259956	chr20:25282433	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	6.83E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2259956	chr20:25282433	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2260160	chr15:43895643	ADAL	chr15:43622872-43646094:+	-0.59	-7.77	4.54E-14	Tumor biomarkers	
LGG	cis	1	rs2260160	chr15:43895643	LCMT2	chr15:43619976-43622891:-	-0.27	-3.58	0.000377	Tumor biomarkers	
LGG	cis	1	rs2260160	chr15:43895643	STRC	chr15:43891762-43924561:-	0.4	7.44	4.61E-13	Tumor biomarkers	
LGG	cis	1	rs2262909	chr19:22135270	ZNF208	chr19:22115760-22193745:-	0.22	3.55	0.000416	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2262909	chr19:22135270	ZNF257	chr19:22235266-22273901:+	0.39	6.79	3.27E-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2266967	chr22:22156789	CCDC116	chr22:21987086-21991615:+	0.17	3.58	0.000378	Multiple sclerosis	
LGG	cis	1	rs2267002	chr22:23456702	RTDR1	chr22:23401594-23484241:-	-0.17	-3.95	8.87E-5	Bone mineral density	
LGG	cis	1	rs2267003	chr22:23457098	RTDR1	chr22:23401594-23484241:-	-0.16	-3.61	0.000341	Bone mineral density	
LGG	cis	1	rs2267393	chr22:39101619	LOC646851	chr22:38974125-39052634:-	0.25	7.5	3.01E-13	Resting heart rate	
LGG	cis	1	rs2267394	chr22:39101633	LOC646851	chr22:38974125-39052634:-	0.25	7.5	3.01E-13	Resting heart rate	
LGG	cis	1	rs2267395	chr22:39113903	LOC646851	chr22:38974125-39052634:-	0.25	7.6	1.51E-13	Resting heart rate	
LGG	cis	1	rs2268206	chr21:31039378	USP16	chr21:30396938-30426805:+	0.28	3.58	0.000377	Hyperactive-impulsive symptoms	
LGG	cis	1	rs2268617	chr14:75608728	ACYP1	chr14:75519930-75530736:-	-0.14	-3.69	0.000246	Height	
LGG	cis	1	rs2268617	chr14:75608728	EIF2B2	chr14:75469612-75476292:+	0.2	3.86	0.000127	Height	
LGG	cis	1	rs2268617	chr14:75608728	MLH3	chr14:75480467-75518235:-	0.21	3.59	0.000364	Height	
LGG	cis	1	rs2268957	chr14:66113233	LOC645431	chr14:65877313-65879335:-	0.49	6.67	6.78E-11	Ischemic stroke	
LGG	cis	1	rs2268958	chr14:66128238	LOC645431	chr14:65877313-65879335:-	-0.48	-6.26	8.28E-10	Ischemic stroke	
LGG	cis	1	rs2268960	chr14:66145500	LOC645431	chr14:65877313-65879335:-	-0.44	-6.07	2.56E-9	Ischemic stroke	
LGG	cis	1	rs2269186	chr14:104379912	KLC1	chr14:104029299-104167887:+	-0.13	-3.58	0.000375	Bipolar disorder	
LGG	cis	1	rs2269186	chr14:104379912	TDRD9	chr14:104394817-104519002:+	0.21	4.29	2.13E-5	Bipolar disorder	
LGG	cis	1	rs2269381	chr22:51020069	CPT1B	chr22:51007291-51017096:-	-0.34	-6.15	1.61E-9	Narcolepsy	
LGG	cis	1	rs2269382	chr22:51018911	CPT1B	chr22:51007291-51017096:-	-0.36	-6.45	2.72E-10	Narcolepsy	
LGG	cis	1	rs2269384	chr22:51011115	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs2269385	chr22:51010939	CPT1B	chr22:51007291-51017096:-	-0.32	-6.27	7.74E-10	Narcolepsy	
LGG	cis	1	rs2269558	chr16:682250	PIGQ	chr16:617032-634108:+	-0.25	-7.38	6.97E-13	Height	
LGG	cis	1	rs2269558	chr16:682250	WFIKKN1	chr16:679239-684116:+	0.45	9.69	1.94E-20	Height	
LGG	cis	1	rs2270291	chr1:156244992	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2270291	chr1:156244992	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2270297	chr2:102992675	IL18R1	chr2:102927962-103015215:+	-0.38	-6.04	3.02E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2270297	chr2:102992675	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.25	2.31E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2270861	chr12:101736381	UTP20	chr12:101673905-101780397:+	-0.16	-3.52	0.000475	Alcohol dependence (age at onset)	
LGG	cis	1	rs227087	chr11:108244114	ATM	chr11:108093559-108239826:+	-0.11	-3.48	0.000544	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs227094	chr11:108233800	ATM	chr11:108093559-108239826:+	-0.11	-3.48	0.000552	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs2271357	chr8:10683623	RP1L1	chr8:10463862-10512617:-	-0.21	-3.8	0.000162	Triglycerides	
LGG	cis	1	rs2272006	chr3:41997059	ULK4	chr3:41288091-42003660:-	-0.79	-15.87	4.21E-46	Diastolic blood pressure	
LGG	cis	1	rs2272007	chr3:41996136	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs2272129	chr2:103040249	IL18R1	chr2:102927962-103015215:+	-0.37	-5.79	1.27E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2272129	chr2:103040249	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.18	3.16E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs2272390	chr2:202195311	PPIL3	chr2:201735680-201753999:-	-0.91	-11.8	1.84E-28	Rheumatoid arthritis	
LGG	cis	1	rs2272563	chr11:236871	PSMD13	chr11:236808-252984:+	-0.24	-5.27	2.1E-7	Menarche (age at onset)	
LGG	cis	1	rs2272565	chr11:244414	PSMD13	chr11:236808-252984:+	-0.21	-4.74	2.74E-6	Menarche (age at onset)	
LGG	cis	1	rs2273145	chr20:47839591	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.28	2.25E-5	Height	
LGG	cis	1	rs2273610	chr14:104387642	TDRD9	chr14:104394817-104519002:+	0.23	4.6	5.51E-6	Bipolar disorder	
LGG	cis	1	rs2273653	chr20:47770756	ARFGEF2	chr20:47538275-47653229:+	0.11	4.02	6.7E-5	Anger	
LGG	cis	1	rs2273653	chr20:47770756	CSE1L	chr20:47662838-47713484:+	0.19	5.21	2.74E-7	Anger	
LGG	cis	1	rs2273694	chr10:102256496	NDUFB8	chr10:102283497-102289636:-	0.16	4.37	1.54E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2273694	chr10:102256496	WNT8B	chr10:102222812-102243397:+	0.49	8.23	1.75E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2273695	chr10:102259568	NDUFB8	chr10:102283497-102289636:-	0.16	4.46	9.98E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2273695	chr10:102259568	WNT8B	chr10:102222812-102243397:+	0.49	8.22	1.77E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2273832	chr1:156233143	BGLAP	chr1:156182784-156213112:+	0.24	4.9	1.3E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2273832	chr1:156233143	CCT3	chr1:156278752-156308195:-	-0.14	-3.52	0.000468	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2273833	chr1:156233189	BGLAP	chr1:156182784-156213112:+	0.24	5.01	7.56E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2273833	chr1:156233189	CCT3	chr1:156278752-156308195:-	-0.14	-3.53	0.000449	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.46	11.06	1.54E-25	Longevity	
LGG	cis	1	rs2274273	chr14:55614636	FBXO34	chr14:55738021-55893431:+	-0.13	-4.09	5.13E-5	Protein biomarker	
LGG	cis	1	rs2274292	chr13:96295321	UGGT2	chr13:96453838-96705736:-	-0.25	-4.13	4.29E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.62	5.0E-6	Body mass index	
LGG	cis	1	rs2275426	chr1:46487552	MUTYH	chr1:45794915-45806142:-	0.14	5.01	7.43E-7	Body mass index	
LGG	cis	1	rs2276014	chr11:64081445	C11orf20	chr11:64067863-64072238:+	-0.31	-4.65	4.32E-6	Mean platelet volume	
LGG	cis	1	rs2276547	chr2:28975107	FAM179A	chr2:29204164-29275094:+	-0.18	-3.56	0.0004	Body mass index	
LGG	cis	1	rs2276547	chr2:28975107	TRMT61B	chr2:29072690-29093175:-	-0.52	-10.74	2.53E-24	Body mass index	
LGG	cis	1	rs2276654	chr2:97492479	FAM178B	chr2:97541620-97652301:-	-0.15	-3.66	0.00028	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs2276834	chr3:52325759	GNL3	chr3:52719936-52728508:+	-0.16	-3.46	0.000577	Electroencephalogram traits	
LGG	cis	1	rs227731	chr17:54773238	DGKE	chr17:54911460-54946034:+	0.1	3.62	0.000325	Orofacial clefts	
LGG	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.64	-11.54	1.98E-27	Cholesterol, total	
LGG	cis	1	rs2277869	chr12:1016910	RAD52	chr12:1021255-1099219:-	-0.19	-3.8	0.000163	Colorectal cancer	
LGG	cis	1	rs2277870	chr1:156246792	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2277870	chr1:156246792	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2277871	chr1:156246742	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2277871	chr1:156246742	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2278086	chr2:86281905	LOC90784	chr2:86247339-86250991:-	-0.5	-5.34	1.4E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs2278161	chr18:72176083	CNDP2	chr18:72163597-72188356:+	0.25	5.75	1.61E-8	Refractive error	
LGG	cis	1	rs2278162	chr18:72175814	CNDP2	chr18:72163597-72188356:+	0.25	5.75	1.61E-8	Refractive error	
LGG	cis	1	rs2278238	chr19:18576484	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.05E-8	Breast cancer	
LGG	cis	1	rs2278842	chr10:102056745	BLOC1S2	chr10:102033713-102046439:-	-0.34	-4.78	2.35E-6	Obesity-related traits	
LGG	cis	1	rs2279077	chr3:48474249	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.18E-5	Longevity	
LGG	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.43	-11.2	4.57E-26	Longevity	
LGG	cis	1	rs2279144	chr19:39201781	LGALS4	chr19:39292312-39303740:-	-0.15	-3.49	0.000523	Heart rate	
LGG	cis	1	rs2279154	chr15:74023017	CLK3	chr15:74890843-74922541:+	0.21	3.54	0.000439	Bipolar disorder	
LGG	cis	1	rs2279155	chr15:74023137	CLK3	chr15:74890843-74922541:+	0.21	3.54	0.000439	Bipolar disorder	
LGG	cis	1	rs2279241	chr3:138121198	MRAS	chr3:138066625-138124376:+	-0.19	-3.49	0.000535	Coronary artery disease;Coronary heart disease	
LGG	cis	1	rs2279256	chr10:1132852	IDI2	chr10:1064847-1071799:-	0.33	3.83	0.000142	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs2279581	chr15:40300092	EIF2AK4	chr15:40226347-40327797:+	0.25	3.55	0.000425	Response to haloperidol in psychosis	
LGG	cis	1	rs2279741	chr3:159744261	IL12A	chr3:159706629-159713805:+	-0.21	-4.06	5.79E-5	Primary biliary cirrhosis	
LGG	cis	1	rs2280017	chr16:15151361	RRN3	chr16:15153881-15188158:-	0.13	3.82	0.000149	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
LGG	cis	1	rs2280018	chr16:15150833	RRN3	chr16:15153881-15188158:-	-0.12	-3.79	0.000168	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
LGG	cis	1	rs2280141	chr10:124193181	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.38	1.43E-5	Height	
LGG	cis	1	rs2280670	chr3:119217312	KTELC1	chr3:119187785-119213552:+	-0.19	-3.49	0.000531	Arthritis (juvenile idiopathic)	
LGG	cis	1	rs2281006	chr1:171110869	FMO3	chr1:171060018-171086957:+	-0.37	-6.28	7.57E-10	Blood metabolite levels	
LGG	cis	1	rs2281019	chr22:39064378	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs2281020	chr22:39064406	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs2281021	chr22:39064667	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs2281494	chr20:3235494	ITPA	chr20:3190056-3204504:+	-0.36	-8.46	3.12E-16	IFN-related cytopenia	
LGG	cis	1	rs2281497	chr20:3258874	ITPA	chr20:3190056-3204504:+	-0.35	-8.25	1.46E-15	IFN-related cytopenia	
LGG	cis	1	rs2281500	chr20:3262824	ITPA	chr20:3190056-3204504:+	-0.37	-8.77	2.84E-17	IFN-related cytopenia	
LGG	cis	1	rs2281503	chr20:3263636	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs2283792	chr22:22131125	CCDC116	chr22:21987086-21991615:+	0.18	3.77	0.000185	Multiple sclerosis	
LGG	cis	1	rs2283879	chr22:31638448	LIMK2	chr22:31608250-31676064:+	0.26	5.37	1.21E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2283881	chr22:31638932	LIMK2	chr22:31608250-31676064:+	0.26	5.36	1.31E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2284033	chr22:37534034	CYTH4	chr22:37678495-37711388:+	-0.1	-3.75	0.000195	Asthma	
LGG	cis	1	rs2284073	chr22:39105948	LOC646851	chr22:38974125-39052634:-	0.25	7.51	2.74E-13	Resting heart rate	
LGG	cis	1	rs2285657	chr17:40272594	DHX58	chr17:40253422-40264751:-	-0.19	-3.98	8.02E-5	Fibrinogen levels	
LGG	cis	1	rs2285810	chr12:112699540	TMEM116	chr12:112369103-112450989:-	0.15	3.61	0.000336	Oral cavity and pharyngeal cancer	
LGG	cis	1	rs228590	chr11:108096141	ATM	chr11:108093559-108239826:+	-0.11	-3.47	0.000572	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs228591	chr11:108097333	ATM	chr11:108093559-108239826:+	-0.12	-3.6	0.000351	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs228598	chr11:108107497	ATM	chr11:108093559-108239826:+	-0.11	-3.46	0.000581	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs2286614	chr11:64068310	C11orf20	chr11:64067863-64072238:+	-0.32	-4.77	2.39E-6	Mean platelet volume	
LGG	cis	1	rs2286684	chr7:66129830	ASL	chr7:65540776-65558321:+	0.19	4.95	1.01E-6	Aortic root size	
LGG	cis	1	rs2286684	chr7:66129830	TYW1	chr7:66461817-66704496:+	-0.17	-3.57	0.000393	Aortic root size	
LGG	cis	1	rs2286771	chr4:17643848	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2287670	chr19:33095057	C19orf40	chr19:33463148-33467955:+	0.2	3.69	0.000248	Eosinophilic esophagitis	
LGG	cis	1	rs2287670	chr19:33095057	PDCD5	chr19:33072104-33078322:+	-0.17	-4.21	2.99E-5	Eosinophilic esophagitis	
LGG	cis	1	rs2287680	chr19:33608566	GPATCH1	chr19:33571786-33621318:+	-0.19	-5.01	7.68E-7	Bone properties (heel)	
LGG	cis	1	rs2287680	chr19:33608566	RHPN2	chr19:33469499-33555824:-	0.26	5.95	5.06E-9	Bone properties (heel)	
LGG	cis	1	rs2287754	chr19:49496494	RUVBL2	chr19:49496819-49519182:+	-0.23	-4.37	1.54E-5	Follicule stimulating hormone	
LGG	cis	1	rs2287838	chr19:9959014	ZNF266	chr19:9523272-9546234:-	-0.17	-4.27	2.32E-5	Sleep duration	
LGG	cis	1	rs2287997	chr16:72140553	HP	chr16:72088508-72094957:+	0.99	19.35	2.07E-62	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2287997	chr16:72140553	HPR	chr16:72097125-72111144:+	1.01	24	8.5E-85	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2287997	chr16:72140553	TXNL4B	chr16:72072001-72128215:-	0.73	12.2	4.3E-30	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs2288012	chr16:58327646	PRSS54	chr16:58313902-58328951:-	0.34	6.36	4.59E-10	Systemic lupus erythematosus	
LGG	cis	1	rs2288073	chr2:24413298	C2orf84	chr2:24397531-24414566:+	-0.23	-4.42	1.23E-5	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs2288073	chr2:24413298	LOC375190	chr2:24299728-24397519:+	0.3	6.76	3.94E-11	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs2288111	chr2:160084534	CCDC148	chr2:159028479-159313214:-	-0.26	-3.6	0.000348	Sudden cardiac arrest	
LGG	cis	1	rs2288871	chr19:41917868	ATP5SL	chr19:41937224-41945810:-	0.17	4.81	1.97E-6	Height	
LGG	cis	1	rs2289022	chr2:26350136	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs2289130	chr18:44626630	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs2289131	chr18:44602864	HDHD2	chr18:44633782-44676871:-	0.39	4	7.39E-5	Sitting height ratio	
LGG	cis	1	rs2289132	chr18:44602292	HDHD2	chr18:44633782-44676871:-	0.39	4	7.39E-5	Sitting height ratio	
LGG	cis	1	rs2289329	chr15:40705159	C15orf23	chr15:40674922-40686488:+	-0.17	-3.46	0.000578	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs2289329	chr15:40705159	DISP2	chr15:40650434-40663256:+	0.19	4.38	1.45E-5	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs2289329	chr15:40705159	IVD	chr15:40697686-40713512:+	0.33	5.87	8.0E-9	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs2289472	chr2:234182240	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.2	3.14E-5	Crohn's disease	
LGG	cis	1	rs2289474	chr2:234181848	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.2	3.14E-5	Crohn's disease	
LGG	cis	1	rs2289836	chr14:76640125	ESRRB	chr14:76837690-76968178:+	-0.44	-6.98	9.58E-12	Blood pressure	
LGG	cis	1	rs2290402	chr4:941518	SLC26A1	chr4:972864-987224:-	0.24	5.35	1.36E-7	Type 2 diabetes	
LGG	cis	1	rs2290822	chr3:48473204	ATRIP	chr3:48488141-48507708:+	0.18	4.51	8.04E-6	Longevity	
LGG	cis	1	rs2290822	chr3:48473204	TREX1	chr3:48501186-48509043:+	-0.43	-11.11	9.43E-26	Longevity	
LGG	cis	1	rs2290850	chr11:47807774	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs2290850	chr11:47807774	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs2290850	chr11:47807774	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs2290911	chr2:224919	FAM150B	chr2:279563-288308:-	-0.33	-6.14	1.75E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs2290911	chr2:224919	SNTG2	chr2:946555-1371382:+	0.2	3.75	0.0002	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs2291036	chr17:20922702	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs2291361	chr12:56717805	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs2291447	chr17:43212963	ACBD4	chr17:43209967-43221541:+	0.13	3.6	0.000349	Economic and political preferences	
LGG	cis	1	rs2291542	chr3:49751585	MST1R	chr3:49924438-49941306:-	0.24	4.65	4.27E-6	Resting heart rate	
LGG	cis	1	rs2292174	chr15:50924956	SPPL2A	chr15:50999739-51057910:-	0.13	4.07	5.38E-5	QT interval	
LGG	cis	1	rs2292239	chr12:56482180	ERBB3	chr12:56473892-56497127:+	0.24	5.34	1.43E-7	Cognitive function	
LGG	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.78	16.68	7.82E-50	Cognitive function	
LGG	cis	1	rs2292255	chr5:176334195	FGFR4	chr5:176513921-176525124:+	0.22	6.05	2.89E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs2292256	chr5:176333126	FGFR4	chr5:176513921-176525124:+	0.22	6.12	1.86E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs2292489	chr1:202536848	UBE2T	chr1:202300786-202311094:-	-0.13	-3.87	0.000123	Sex ratio	
LGG	cis	1	rs2292573	chr11:78053139	NARS2	chr11:78147017-78285909:-	-0.18	-3.45	0.0006	Testicular germ cell tumor	
LGG	cis	1	rs2292626	chr10:124186714	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.28	2.23E-5	Height	
LGG	cis	1	rs2293167	chr11:211644	PSMD13	chr11:236808-252984:+	0.21	4.56	6.55E-6	Menarche (age at onset)	
LGG	cis	1	rs2293551	chr1:202408594	PTPN7	chr1:202116143-202130709:-	-0.12	-3.53	0.000459	Sex ratio	
LGG	cis	1	rs2293551	chr1:202408594	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.49E-5	Sex ratio	
LGG	cis	1	rs2293552	chr1:202408751	PTPN7	chr1:202116143-202130709:-	-0.12	-3.53	0.000459	Sex ratio	
LGG	cis	1	rs2293552	chr1:202408751	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.49E-5	Sex ratio	
LGG	cis	1	rs2294008	chr8:143761931	LY6K	chr8:143781529-143785582:+	0.31	5.88	7.79E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2294008	chr8:143761931	PSCA	chr8:143761875-143764142:+	0.36	6.23	9.94E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2294010	chr8:143762430	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2294010	chr8:143762430	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2294010	chr8:143762430	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2294296	chr22:39053049	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs2295028	chr20:47582958	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.1	4.93E-5	Anger	
LGG	cis	1	rs2295028	chr20:47582958	CSE1L	chr20:47662838-47713484:+	-0.18	-4.98	8.71E-7	Anger	
LGG	cis	1	rs2295135	chr14:88894210	KCNK10	chr14:88646454-88793256:-	-0.17	-3.45	0.000599	Coronary artery calcification	
LGG	cis	1	rs2295135	chr14:88894210	SPATA7	chr14:88852012-88904802:+	-0.48	-8.51	2.19E-16	Coronary artery calcification	
LGG	cis	1	rs2295408	chr22:50261051	ALG12	chr22:50296856-50312106:-	-0.27	-5.34	1.43E-7	Schizophrenia	
LGG	cis	1	rs2295409	chr22:50261060	ALG12	chr22:50296856-50312106:-	-0.27	-5.34	1.43E-7	Schizophrenia	
LGG	cis	1	rs2295700	chr20:33591627	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.01E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs2295714	chr20:47739814	ARFGEF2	chr20:47538275-47653229:+	0.1	3.81	0.000156	Anger	
LGG	cis	1	rs2295714	chr20:47739814	CSE1L	chr20:47662838-47713484:+	0.17	4.72	3.04E-6	Anger	
LGG	cis	1	rs2295770	chr10:102239829	HIF1AN	chr10:102295641-102313680:+	0.19	3.79	0.00017	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295770	chr10:102239829	NDUFB8	chr10:102283497-102289636:-	0.16	4.63	4.63E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295770	chr10:102239829	WNT8B	chr10:102222812-102243397:+	0.52	8.8	2.36E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295772	chr10:102265183	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.00031	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295772	chr10:102265183	NDUFB8	chr10:102283497-102289636:-	0.17	4.75	2.74E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295772	chr10:102265183	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295773	chr10:102265815	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.00031	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295773	chr10:102265815	NDUFB8	chr10:102283497-102289636:-	0.17	4.75	2.74E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295773	chr10:102265815	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295774	chr10:102265847	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.15E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295774	chr10:102265847	SEC31B	chr10:102246403-102289636:-	-0.11	-3.47	0.000559	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295774	chr10:102265847	WNT8B	chr10:102222812-102243397:+	0.5	8.12	3.69E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295776	chr10:102295629	HIF1AN	chr10:102295641-102313680:+	0.19	3.69	0.000251	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295776	chr10:102295629	NDUFB8	chr10:102283497-102289636:-	0.17	4.8	2.08E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295776	chr10:102295629	WNT8B	chr10:102222812-102243397:+	0.49	8	8.83E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295779	chr10:102296061	HIF1AN	chr10:102295641-102313680:+	0.18	3.49	0.000525	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295779	chr10:102296061	NDUFB8	chr10:102283497-102289636:-	0.16	4.51	8.3E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295779	chr10:102296061	WNT8B	chr10:102222812-102243397:+	0.49	7.94	1.36E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295780	chr10:102305965	HIF1AN	chr10:102295641-102313680:+	0.18	3.46	0.00058	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295780	chr10:102305965	NDUFB8	chr10:102283497-102289636:-	0.17	4.76	2.61E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295780	chr10:102305965	WNT8B	chr10:102222812-102243397:+	0.49	7.9	1.83E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2295888	chr20:33722863	PROCR	chr20:33758727-33765164:+	-0.33	-6.07	2.56E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs2296375	chr1:156309372	BGLAP	chr1:156182784-156213112:+	0.24	4.85	1.64E-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2296375	chr1:156309372	CCT3	chr1:156278752-156308195:-	-0.17	-4.03	6.51E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs2296691	chr10:97370989	TCTN3	chr10:97423154-97453900:-	0.2	4	7.19E-5	Blood metabolite levels	
LGG	cis	1	rs2296747	chr6:33744882	LEMD2	chr6:33738991-33756906:-	-0.15	-4.8	2.08E-6	Crohn's disease	
LGG	cis	1	rs2296748	chr6:33745071	LEMD2	chr6:33738991-33756906:-	-0.14	-4.65	4.3E-6	Crohn's disease	
LGG	cis	1	rs2297407	chr9:107554521	NIPSNAP3B	chr9:107526451-107553175:+	-0.47	-8.66	7.06E-17	Gout	
LGG	cis	1	rs2297496	chr20:25295787	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2297496	chr20:25295787	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2297496	chr20:25295787	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2297497	chr20:25297909	ABHD12	chr20:25275380-25371477:-	-0.26	-7.06	5.75E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2297497	chr20:25297909	FAM182A	chr20:26035250-26067552:+	0.55	10.81	1.38E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2297497	chr20:25297909	FAM182B	chr20:25744102-25848786:-	-0.21	-4.74	2.75E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2298074	chr10:102247526	NDUFB8	chr10:102283497-102289636:-	0.16	4.48	9.28E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2298074	chr10:102247526	WNT8B	chr10:102222812-102243397:+	0.53	8.88	1.29E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2298075	chr10:102247408	HIF1AN	chr10:102295641-102313680:+	0.18	3.62	0.000324	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2298075	chr10:102247408	NDUFB8	chr10:102283497-102289636:-	0.15	4.36	1.59E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2298075	chr10:102247408	WNT8B	chr10:102222812-102243397:+	0.52	8.77	2.91E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2298456	chr11:71730715	FAM86C	chr11:71498557-71512276:+	-0.47	-4.7	3.46E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2298457	chr11:71734211	FAM86C	chr11:71498557-71512276:+	0.5	4.88	1.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2298771	chr2:166892788	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2298771	chr2:166892788	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2300601	chr14:75639571	EIF2B2	chr14:75469612-75476292:+	0.25	4.78	2.27E-6	Height	
LGG	cis	1	rs2300601	chr14:75639571	MLH3	chr14:75480467-75518235:-	0.23	3.95	9.1E-5	Height	
LGG	cis	1	rs2300867	chr14:66129154	LOC645431	chr14:65877313-65879335:-	-0.5	-6.72	4.93E-11	Ischemic stroke	
LGG	cis	1	rs2300871	chr14:66147694	LOC645431	chr14:65877313-65879335:-	0.48	6.77	3.76E-11	Ischemic stroke	
LGG	cis	1	rs2300872	chr14:66147761	LOC645431	chr14:65877313-65879335:-	-0.47	-6.15	1.57E-9	Ischemic stroke	
LGG	cis	1	rs2301907	chr7:74114847	STAG3L2	chr7:74298846-74306731:-	-0.26	-3.79	0.000172	Menarche (age at onset)	
LGG	cis	1	rs2302138	chr14:74363305	LIN52	chr14:74551656-74667117:+	0.34	4.43	1.16E-5	Morning vs. evening chronotype	
LGG	cis	1	rs2302138	chr14:74363305	VSX2	chr14:74706175-74729434:+	-0.31	-3.5	0.000508	Morning vs. evening chronotype	
LGG	cis	1	rs2302139	chr14:74362935	LIN52	chr14:74551656-74667117:+	0.3	3.94	9.41E-5	Morning vs. evening chronotype	
LGG	cis	1	rs2302139	chr14:74362935	PTGR2	chr14:74318534-74352166:+	-0.23	-3.57	0.000393	Morning vs. evening chronotype	
LGG	cis	1	rs2302278	chr3:47361082	NRADDP	chr3:47053032-47054957:+	0.2	3.51	0.000498	Colorectal cancer	
LGG	cis	1	rs2302507	chr3:37144535	LRRFIP2	chr3:37094117-37217851:-	0.15	3.58	0.00038	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs2302772	chr19:32902050	DPY19L3	chr19:32896677-32975236:+	0.13	3.59	0.000366	Bipolar disorder	
LGG	cis	1	rs2302772	chr19:32902050	ZNF507	chr19:32836514-32878571:+	0.13	3.56	0.000401	Bipolar disorder	
LGG	cis	1	rs2302773	chr19:32927311	ZNF507	chr19:32836514-32878571:+	0.13	3.76	0.00019	Bipolar disorder	
LGG	cis	1	rs2303100	chr19:9968434	ZNF266	chr19:9523272-9546234:-	-0.16	-4.08	5.31E-5	Sleep duration	
LGG	cis	1	rs2303339	chr2:86346180	IMMT	chr2:86371056-86422893:-	-0.31	-3.52	0.000471	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs2303339	chr2:86346180	LOC90784	chr2:86247339-86250991:-	0.4	4.08	5.32E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs2303340	chr2:86333193	LOC90784	chr2:86247339-86250991:-	-0.43	-4.42	1.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs2303695	chr19:18562624	LRRC25	chr19:18501955-18508421:-	-0.17	-5.84	9.38E-9	Breast cancer	
LGG	cis	1	rs2303697	chr19:18546678	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.04E-8	Breast cancer	
LGG	cis	1	rs2304389	chr9:101068580	TDRD7	chr9:100174302-100258403:+	0.18	3.49	0.00052	Schizophrenia	
LGG	cis	1	rs2304390	chr9:101068649	TDRD7	chr9:100174302-100258403:+	0.18	3.51	0.000497	Schizophrenia	
LGG	cis	1	rs2304687	chr2:55138282	MTIF2	chr2:55463758-55496384:-	0.33	3.53	0.000454	Refractive astigmatism	
LGG	cis	1	rs2305008	chr11:120319064	TMEM136	chr11:120196016-120204388:+	0.19	4.47	9.65E-6	Intraocular pressure	
LGG	cis	1	rs2305010	chr11:120330149	TMEM136	chr11:120196016-120204388:+	-0.2	-4.7	3.45E-6	Intraocular pressure	
LGG	cis	1	rs2305188	chr4:1739592	TMEM129	chr4:1717680-1723084:-	-0.17	-3.71	0.00023	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs2305815	chr1:150956947	ARNT	chr1:150782186-150849186:-	0.25	4	7.37E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs2305815	chr1:150956947	OAZ3	chr1:151735445-151743805:+	0.36	4.15	3.9E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs2306641	chr8:21833965	XPO7	chr8:21777180-21864095:+	-0.18	-4.04	6.15E-5	Mean corpuscular volume	
LGG	cis	1	rs2306693	chr12:56680531	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs2306694	chr12:56680636	IL23A	chr12:56732663-56734193:+	-0.53	-4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs2306940	chr1:113241052	ST7L	chr1:113066142-113162405:-	0.25	5.92	6.14E-9	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs2306940	chr1:113241052	WNT2B	chr1:113010040-113063908:+	0.19	3.8	0.000162	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs2307021	chr3:49765483	MST1R	chr3:49924438-49941306:-	0.25	4.72	3.06E-6	Resting heart rate	
LGG	cis	1	rs2310997	chr3:48678011	SLC26A6	chr3:48663158-48672926:-	0.22	3.65	0.000292	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs2310997	chr3:48678011	TREX1	chr3:48501186-48509043:+	-0.27	-3.95	9.12E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs2310997	chr3:48678011	USP4	chr3:49314577-49377536:-	0.37	4.69	3.55E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs2312236	chr1:166794217	MAEL	chr1:166958519-166991447:+	0.32	3.85	0.000135	Post-traumatic stress disorder	
LGG	cis	1	rs2312462	chr3:49601255	APEH	chr3:49711435-49720933:+	0.17	3.49	0.000518	Menarche (age at onset)	
LGG	cis	1	rs2312462	chr3:49601255	NCKIPSD	chr3:48711280-48723334:-	0.19	4.47	9.87E-6	Menarche (age at onset)	
LGG	cis	1	rs2315281	chr19:19480099	GMIP	chr19:19740286-19754455:-	-0.13	-3.82	0.000153	Schizophrenia	
LGG	cis	1	rs2315281	chr19:19480099	TSSK6	chr19:19623230-19626469:-	-0.2	-4.29	2.17E-5	Schizophrenia	
LGG	cis	1	rs2315556	chr4:17670861	LAP3	chr4:17578927-17609590:+	-0.14	-3.78	0.000179	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2315560	chr4:17677305	LAP3	chr4:17578927-17609590:+	-0.14	-3.82	0.00015	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2315561	chr4:17679695	LAP3	chr4:17578927-17609590:+	-0.13	-3.76	0.000191	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2317384	chr17:45329770	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs2317385	chr17:45329682	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs2318119	chr1:158569874	KIRREL	chr1:157963063-158065842:+	-0.13	-3.86	0.000128	Other erythrocyte phenotypes	
LGG	cis	1	rs2318763	chr1:150115974	RPRD2	chr1:150336990-150449039:+	0.16	3.89	0.000116	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs2319458	chr22:50236306	ALG12	chr22:50296856-50312106:-	0.27	5.38	1.17E-7	Schizophrenia	
LGG	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.5	-10.16	3.95E-22	Response to antipsychotic treatment	
LGG	cis	1	rs2326387	chr6:126680489	CENPW	chr6:126661253-126804465:+	-0.15	-3.83	0.000145	Type 1 diabetes	
LGG	cis	1	rs2326680	chr20:5942955	MCM8	chr20:5931298-5975829:+	-0.33	-8.39	5.33E-16	HIV-1 viral setpoint	
LGG	cis	1	rs2329340	chr7:50620229	FIGNL1	chr7:50511834-50518088:-	-0.21	-5.08	5.5E-7	Malaria	
LGG	cis	1	rs2329341	chr7:50620275	FIGNL1	chr7:50511834-50518088:-	-0.21	-5.08	5.5E-7	Malaria	
LGG	cis	1	rs2329342	chr7:50624971	FIGNL1	chr7:50511834-50518088:-	0.22	5.19	3.16E-7	Malaria	
LGG	cis	1	rs2336723	chr3:53106047	RFT1	chr3:53122503-53164470:-	-0.49	-10.47	2.75E-23	Height	
LGG	cis	1	rs2338555	chr1:152309380	HRNR	chr1:152184558-152196669:-	-0.54	-8.12	3.74E-15	Atopic dermatitis	
LGG	cis	1	rs2338556	chr1:152309427	HRNR	chr1:152184558-152196669:-	-0.54	-8.12	3.74E-15	Atopic dermatitis	
LGG	cis	1	rs2342310	chr17:41866199	VAT1	chr17:41166622-41174459:-	-0.19	-4.11	4.55E-5	Triglycerides	
LGG	cis	1	rs2344180	chr5:150267357	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs2344181	chr5:150262574	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs2345001	chr5:150266518	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs2346676	chr16:67223803	CENPT	chr16:67862064-67881361:-	-0.18	-3.53	0.000446	HDL cholesterol	
LGG	cis	1	rs2348114	chr2:201582193	PPIL3	chr2:201735680-201753999:-	0.41	5.09	5.2E-7	Intelligence	
LGG	cis	1	rs2349075	chr2:202223566	ALS2CR12	chr2:202153148-202222101:-	-0.19	-3.79	0.000169	Basal cell carcinoma	
LGG	cis	1	rs2349075	chr2:202223566	ALS2CR4	chr2:202484907-202508224:-	0.19	5.03	7.04E-7	Basal cell carcinoma	
LGG	cis	1	rs2349075	chr2:202223566	PPIL3	chr2:201735680-201753999:-	-0.2	-4.12	4.41E-5	Basal cell carcinoma	
LGG	cis	1	rs2351706	chr15:90384115	AP3S2	chr15:90373832-90456222:-	-0.49	-9.39	2.25E-19	Type 2 diabetes	
LGG	cis	1	rs2351707	chr15:90384045	AP3S2	chr15:90373832-90456222:-	-0.48	-9.24	7.21E-19	Type 2 diabetes	
LGG	cis	1	rs2353605	chr4:219538	ZNF718	chr4:53272-156488:+	0.24	4.76	2.59E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.26	-7.19	2.4E-12	Homocysteine levels	
LGG	cis	1	rs2356559	chr1:45981512	MMACHC	chr1:45965856-45976737:+	0.26	5.41	9.69E-8	Homocysteine levels	
LGG	cis	1	rs2356559	chr1:45981512	MUTYH	chr1:45794915-45806142:-	0.15	5.05	6.28E-7	Homocysteine levels	
LGG	cis	1	rs2358628	chr14:74631757	LIN52	chr14:74551656-74667117:+	-0.45	-10.07	8.12E-22	Common traits (Other)	
LGG	cis	1	rs2358633	chr14:74647418	LIN52	chr14:74551656-74667117:+	-0.46	-10.49	2.25E-23	Common traits (Other)	
LGG	cis	1	rs2359155	chr19:21671869	ZNF493	chr19:21579921-21610294:+	-0.13	-3.63	0.000314	Pain	
LGG	cis	1	rs2359811	chr19:22152876	ZNF257	chr19:22235266-22273901:+	0.54	8.47	2.91E-16	Body mass index (change over time)	
LGG	cis	1	rs2359820	chr19:22208114	ZNF257	chr19:22235266-22273901:+	0.56	8.99	5.45E-18	Body mass index (change over time)	
LGG	cis	1	rs2359821	chr19:22208314	ZNF208	chr19:22115760-22193745:-	0.21	3.51	0.000483	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2359821	chr19:22208314	ZNF257	chr19:22235266-22273901:+	0.4	7.13	3.7E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2360977	chr14:76654481	ESRRB	chr14:76837690-76968178:+	0.43	7.02	7.52E-12	Blood pressure	
LGG	cis	1	rs236104	chr20:5958960	MCM8	chr20:5931298-5975829:+	-0.33	-8.36	6.35E-16	HIV-1 viral setpoint	
LGG	cis	1	rs236114	chr20:5935385	CRLS1	chr20:5986739-6020694:+	0.2	3.48	0.000536	Menopause (age at onset)	
LGG	cis	1	rs236121	chr20:5972594	MCM8	chr20:5931298-5975829:+	-0.33	-8.39	5.11E-16	HIV-1 viral setpoint	
LGG	cis	1	rs2361453	chr1:202336314	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs2361453	chr1:202336314	UBE2T	chr1:202300786-202311094:-	-0.13	-3.98	7.82E-5	Sex ratio	
LGG	cis	1	rs2362450	chr3:48461313	ATRIP	chr3:48488141-48507708:+	0.17	4.14	4.09E-5	Longevity	
LGG	cis	1	rs2362450	chr3:48461313	TREX1	chr3:48501186-48509043:+	-0.44	-11.48	3.32E-27	Longevity	
LGG	cis	1	rs2362452	chr3:48418214	ATRIP	chr3:48488141-48507708:+	-0.17	-4.21	3.01E-5	Longevity	
LGG	cis	1	rs2362452	chr3:48418214	TREX1	chr3:48501186-48509043:+	0.4	10.27	1.5E-22	Longevity	
LGG	cis	1	rs2362826	chr3:37203360	LRRFIP2	chr3:37094117-37217851:-	0.16	3.72	0.000219	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs2363731	chr2:88521793	FABP1	chr2:88422510-88427578:-	-0.31	-4.28	2.21E-5	Plasma clusterin levels	
LGG	cis	1	rs2363731	chr2:88521793	THNSL2	chr2:88469835-88486145:+	-0.58	-8.69	5.36E-17	Plasma clusterin levels	
LGG	cis	1	rs2363736	chr11:71656967	FAM86C	chr11:71498557-71512276:+	0.43	4.64	4.5E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2364143	chr5:78316227	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000486	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs2364328	chr17:20939409	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs2364332	chr17:20909288	USP22	chr17:20902908-20947073:-	-0.2	-4.59	5.75E-6	Blood trace element (Se levels)	
LGG	cis	1	rs2364333	chr17:20909210	USP22	chr17:20902908-20947073:-	-0.2	-4.57	6.16E-6	Blood trace element (Se levels)	
LGG	cis	1	rs2365468	chr17:65841318	LOC440461	chr17:66194801-66196436:+	0.27	4.52	7.72E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs2365764	chr17:65857714	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs236702	chr20:57687831	GNASAS	chr20:57393974-57425958:-	0.51	4.06	5.75E-5	Attention function in attention deficit hyperactive disorder	
LGG	cis	1	rs236704	chr20:57688159	GNASAS	chr20:57393974-57425958:-	0.53	4.16	3.74E-5	Attention function in attention deficit hyperactive disorder	
LGG	cis	1	rs2367725	chr1:44215828	ARTN	chr1:44398992-44402911:+	-0.16	-4.02	6.6E-5	Aging (time to event)	
LGG	cis	1	rs2368984	chr14:104372055	KLC1	chr14:104029299-104167887:+	-0.16	-4.33	1.79E-5	Bipolar disorder	
LGG	cis	1	rs2368984	chr14:104372055	TDRD9	chr14:104394817-104519002:+	0.2	4.05	6.03E-5	Bipolar disorder	
LGG	cis	1	rs236918	chr11:117091609	SIDT2	chr11:117049939-117068161:+	-0.34	-4.02	6.66E-5	Protein quantitative trait loci	
LGG	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs2370578	chr3:134199612	CEP63	chr3:134204575-134293852:+	0.2	3.66	0.000275	Height	
LGG	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.27	7.14	3.36E-12	Height	
LGG	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.28	7.12	3.89E-12	Height	
LGG	cis	1	rs2371454	chr12:56647243	IL23A	chr12:56732663-56734193:+	-0.53	-4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs2371494	chr12:56728000	IL23A	chr12:56732663-56734193:+	0.59	5.94	5.47E-9	Psoriasis vulgaris	
LGG	cis	1	rs2371623	chr3:41761083	ULK4	chr3:41288091-42003660:-	0.72	13.82	6.14E-37	Diastolic blood pressure	
LGG	cis	1	rs2371627	chr3:41839219	ULK4	chr3:41288091-42003660:-	0.78	15.42	4.73E-44	Diastolic blood pressure	
LGG	cis	1	rs2373000	chr2:37592628	QPCT	chr2:37571753-37600464:+	-0.14	-3.6	0.000344	Schizophrenia	
LGG	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs2373865	chr3:134291556	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs237711	chr20:47926856	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.02	6.81E-5	Height	
LGG	cis	1	rs237741	chr20:47903680	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.96	8.69E-5	Height	
LGG	cis	1	rs237743	chr20:47903019	ARFGEF2	chr20:47538275-47653229:+	0.14	3.96	8.69E-5	Height	
LGG	cis	1	rs2377784	chr1:31860936	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.79	0.000169	Schizophrenia	
LGG	cis	1	rs2377785	chr1:31855683	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.82	0.000153	Schizophrenia	
LGG	cis	1	rs2378078	chr20:32714728	NCOA6	chr20:33302579-33413433:-	-0.14	-3.57	0.000391	Tanning;Skin sensitivity to sun;Red vs. non-red hair color;Freckles;Burning and freckling	
LGG	cis	1	rs238150	chr20:47851919	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.92	0.000101	Height	
LGG	cis	1	rs238164	chr20:47844341	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.94	9.2E-5	Height	
LGG	cis	1	rs238174	chr20:47879109	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.93	9.73E-5	Height	
LGG	cis	1	rs238198	chr20:47899060	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.96	8.69E-5	Height	
LGG	cis	1	rs238200	chr20:47899652	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.92	0.000102	Height	
LGG	cis	1	rs238217	chr20:47871439	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.97	8.12E-5	Height	
LGG	cis	1	rs2384207	chr12:113607502	C12orf52	chr12:113623555-113630119:+	-0.21	-3.7	0.00024	Response to fenofibrate (adiponectin levels)	
LGG	cis	1	rs2384321	chr2:26290054	GPR113	chr2:26531041-26569685:-	-0.22	-3.49	0.000522	Gut microbiome composition (summer)	
LGG	cis	1	rs2384322	chr2:26291146	GPR113	chr2:26531041-26569685:-	-0.22	-3.48	0.000551	Gut microbiome composition (summer)	
LGG	cis	1	rs2384323	chr2:26306473	GPR113	chr2:26531041-26569685:-	-0.23	-3.62	0.000329	Gut microbiome composition (summer)	
LGG	cis	1	rs2384654	chr2:27847364	PPM1G	chr2:27604062-27632496:-	0.13	4.15	3.99E-5	Oral cavity cancer	
LGG	cis	1	rs2386661	chr10:5670275	ASB13	chr10:5680820-5708558:-	0.17	4.43	1.15E-5	Breast cancer	
LGG	cis	1	rs2387299	chr10:1163427	IDI2	chr10:1064847-1071799:-	0.33	4.01	6.96E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs2387880	chr20:25377787	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387880	chr20:25377787	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387880	chr20:25377787	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387881	chr20:25378172	ABHD12	chr20:25275380-25371477:-	-0.27	-7.37	7.29E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387881	chr20:25378172	FAM182A	chr20:26035250-26067552:+	0.55	10.72	3.03E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387881	chr20:25378172	FAM182B	chr20:25744102-25848786:-	-0.22	-4.88	1.43E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387884	chr20:25379069	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387884	chr20:25379069	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2387884	chr20:25379069	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2390321	chr2:166886515	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000411	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2390321	chr2:166886515	TTC21B	chr2:166713988-166810348:-	0.13	3.93	9.83E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2390322	chr2:166886675	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000411	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2390322	chr2:166886675	TTC21B	chr2:166713988-166810348:-	0.13	3.93	9.83E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2390847	chr7:23911701	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.84E-5	Schizophrenia	
LGG	cis	1	rs2391159	chr1:92971951	EVI5	chr1:92974255-93257961:-	-0.29	-6.94	1.24E-11	Cholesterol, total	
LGG	cis	1	rs2391160	chr1:92992797	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs2392229	chr7:33173539	BBS9	chr7:33169152-33645680:+	0.43	5.54	4.92E-8	Smooth-surface caries	
LGG	cis	1	rs2392639	chr7:105534421	CDHR3	chr7:105517264-105676876:+	0.22	5.23	2.54E-7	Obesity-related traits	
LGG	cis	1	rs2393593	chr6:26285683	HIST1H3E	chr6:26224427-26226589:+	0.24	4.94	1.08E-6	Educational attainment	
LGG	cis	1	rs2393670	chr6:26535541	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs2393670	chr6:26535541	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs2393725	chr12:121192619	SPPL3	chr12:121201036-121342151:-	0.27	3.83	0.000142	Quantitative traits	
LGG	cis	1	rs2393969	chr10:65140440	NRBF2	chr10:64893007-64914785:+	-0.22	-5.07	5.72E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2393969	chr10:65140440	REEP3	chr10:65281123-65381971:+	0.14	4	7.26E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2395400	chr6:33770076	LEMD2	chr6:33738991-33756906:-	0.18	5.07	5.71E-7	Body mass index	
LGG	cis	1	rs2395449	chr6:33728755	BAK1	chr6:33540324-33548070:-	-0.16	-3.71	0.000233	Crohn's disease	
LGG	cis	1	rs2395449	chr6:33728755	LEMD2	chr6:33738991-33756906:-	-0.14	-4.46	1.0E-5	Crohn's disease	
LGG	cis	1	rs2401195	chr21:44466887	NDUFV3	chr21:44313378-44329772:+	0.28	4.36	1.58E-5	Information processing speed	
LGG	cis	1	rs2403083	chr8:86108149	LRRCC1	chr8:86019377-86058312:+	0.45	9.35	3.11E-19	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs2407987	chr12:89932593	GALNT4	chr12:89913192-89919777:-	-0.16	-4.62	4.83E-6	Schizophrenia	
LGG	cis	1	rs2407987	chr12:89932593	POC1B	chr12:89813501-89919777:-	-0.17	-3.63	0.000307	Schizophrenia	
LGG	cis	1	rs2411984	chr17:47445751	GNGT2	chr17:47283597-47286743:-	-0.11	-3.52	0.000474	Sex hormone-binding globulin levels	
LGG	cis	1	rs2412459	chr15:40295959	EIF2AK4	chr15:40226347-40327797:+	0.27	3.82	0.000149	Response to haloperidol in psychosis	
LGG	cis	1	rs2413047	chr22:31666026	LIMK2	chr22:31608250-31676064:+	0.27	5.77	1.42E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2413049	chr22:31686144	LIMK2	chr22:31608250-31676064:+	0.28	5.86	8.34E-9	Paclitaxel-induced neuropathy	
LGG	cis	1	rs2413544	chr22:39059404	LOC646851	chr22:38974125-39052634:-	0.22	6.66	7.31E-11	Resting heart rate	
LGG	cis	1	rs2413545	chr22:39092524	LOC646851	chr22:38974125-39052634:-	0.22	6.56	1.34E-10	Resting heart rate	
LGG	cis	1	rs2413546	chr22:39107001	LOC646851	chr22:38974125-39052634:-	0.22	6.62	9.52E-11	Resting heart rate	
LGG	cis	1	rs2413547	chr22:39107338	LOC646851	chr22:38974125-39052634:-	0.22	6.62	9.52E-11	Resting heart rate	
LGG	cis	1	rs2413583	chr22:39659773	APOBEC3C	chr22:39410265-39414823:+	0.15	3.78	0.000174	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs2413740	chr22:43419325	TTLL1	chr22:43435524-43485434:-	-0.18	-3.68	0.000258	Schizophrenia	
LGG	cis	1	rs2414060	chr15:50873262	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs2414468	chr15:56527277	TEX9	chr15:56657644-56738071:+	-0.23	-3.47	0.000571	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs2415253	chr15:75375699	PPCDC	chr15:75315927-75343066:+	0.24	5.22	2.62E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs2415255	chr15:75332412	PPCDC	chr15:75315927-75343066:+	0.26	5.65	2.68E-8	Blood trace element (Zn levels)	
LGG	cis	1	rs2416257	chr5:110435490	TSLP	chr5:110405778-110413722:+	-0.32	-4.56	6.38E-6	Eosinophil counts	
LGG	cis	1	rs2419604	chr10:113944271	ZDHHC6	chr10:114190060-114207306:-	0.25	4.69	3.53E-6	HDL cholesterol	
LGG	cis	1	rs2420168	chr7:65630631	ASL	chr7:65540776-65558321:+	0.22	5.55	4.79E-8	Aortic root size	
LGG	cis	1	rs2420170	chr7:65656053	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs2420171	chr7:65637760	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.27	2.36E-5	Diabetic kidney disease	
LGG	cis	1	rs2420591	chr7:65912381	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs2420824	chr7:66131116	ASL	chr7:65540776-65558321:+	0.19	4.9	1.29E-6	Aortic root size	
LGG	cis	1	rs2420824	chr7:66131116	TYW1	chr7:66461817-66704496:+	-0.17	-3.67	0.000269	Aortic root size	
LGG	cis	1	rs2420903	chr10:122802506	WDR11	chr10:122610695-122669035:+	-0.17	-3.79	0.000167	HIV-1 viral setpoint	
LGG	cis	1	rs2421016	chr10:124167512	PLEKHA1	chr10:124134220-124191866:+	-0.14	-4.97	9.28E-7	Height	
LGG	cis	1	rs2421017	chr10:124148167	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.13	4.33E-5	Height	
LGG	cis	1	rs2421021	chr10:124157046	PLEKHA1	chr10:124134220-124191866:+	-0.11	-3.98	7.96E-5	Height	
LGG	cis	1	rs2421143	chr10:124737546	PSTK	chr10:124739556-124749906:+	0.15	3.46	0.000595	Migraine without aura	
LGG	cis	1	rs2421155	chr10:124725481	PSTK	chr10:124739556-124749906:+	0.15	3.48	0.000537	Migraine without aura	
LGG	cis	1	rs2421158	chr10:124721098	PSTK	chr10:124739556-124749906:+	0.15	3.58	0.000378	Migraine without aura	
LGG	cis	1	rs2421332	chr2:61876965	C2orf74	chr2:61372243-61391964:+	-0.2	-3.58	0.000373	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs2421555	chr2:73816955	ALMS1P	chr2:73872046-73912692:+	0.38	6.82	2.66E-11	Metabolite levels	
LGG	cis	1	rs2421555	chr2:73816955	NAT8	chr2:73867850-73869537:-	0.28	4.53	7.56E-6	Metabolite levels	
LGG	cis	1	rs2421992	chr1:172241251	DNM3	chr1:171810621-172387567:+	0.1	3.5	0.000517	Height	
LGG	cis	1	rs242271	chr6:88082029	C6orf163	chr6:88057220-88075180:+	0.21	3.81	0.000159	Depressive episodes in bipolar disorder	
LGG	cis	1	rs242271	chr6:88082029	C6orf164	chr6:88032306-88109459:+	-0.2	-3.46	0.000587	Depressive episodes in bipolar disorder	
LGG	cis	1	rs2424700	chr20:25266513	ABHD12	chr20:25275380-25371477:-	0.26	7.03	6.76E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424700	chr20:25266513	FAM182A	chr20:26035250-26067552:+	-0.54	-10.64	6.3E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424700	chr20:25266513	FAM182B	chr20:25744102-25848786:-	0.21	4.66	4.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424704	chr20:25273929	ABHD12	chr20:25275380-25371477:-	0.27	7.29	1.23E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424704	chr20:25273929	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	4.04E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424704	chr20:25273929	FAM182B	chr20:25744102-25848786:-	0.22	4.86	1.61E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424710	chr20:25283886	ABHD12	chr20:25275380-25371477:-	0.27	7.38	6.89E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424710	chr20:25283886	FAM182A	chr20:26035250-26067552:+	-0.56	-11.04	1.91E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424710	chr20:25283886	FAM182B	chr20:25744102-25848786:-	0.21	4.82	1.94E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424712	chr20:25416942	ABHD12	chr20:25275380-25371477:-	0.27	7.38	6.64E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424712	chr20:25416942	FAM182A	chr20:26035250-26067552:+	-0.55	-10.73	2.96E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424712	chr20:25416942	FAM182B	chr20:25744102-25848786:-	0.22	4.91	1.27E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424713	chr20:25418482	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.03E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424713	chr20:25418482	FAM182A	chr20:26035250-26067552:+	-0.56	-11.09	1.18E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424713	chr20:25418482	FAM182B	chr20:25744102-25848786:-	0.22	4.99	8.29E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424716	chr20:25423538	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.21E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424716	chr20:25423538	FAM182A	chr20:26035250-26067552:+	-0.56	-11.04	1.77E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2424716	chr20:25423538	FAM182B	chr20:25744102-25848786:-	0.22	4.94	1.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2425065	chr20:33926268	CPNE1	chr20:34213968-34262539:-	-0.27	-5.79	1.27E-8	Height	
LGG	cis	1	rs2425065	chr20:33926268	GDF5	chr20:33897002-34042568:-	0.38	7.48	3.39E-13	Height	
LGG	cis	1	rs2425065	chr20:33926268	UQCC	chr20:33890383-33999833:-	-0.23	-5	7.99E-7	Height	
LGG	cis	1	rs2425066	chr20:33927006	CPNE1	chr20:34213968-34262539:-	-0.26	-5.76	1.45E-8	Height	
LGG	cis	1	rs2425066	chr20:33927006	GDF5	chr20:33897002-34042568:-	0.37	7.37	7.24E-13	Height	
LGG	cis	1	rs2425066	chr20:33927006	UQCC	chr20:33890383-33999833:-	-0.24	-5.23	2.54E-7	Height	
LGG	cis	1	rs2426106	chr20:47639464	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.5E-5	Anger	
LGG	cis	1	rs2426106	chr20:47639464	CSE1L	chr20:47662838-47713484:+	-0.18	-4.93	1.15E-6	Anger	
LGG	cis	1	rs2426109	chr20:47662627	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.12	4.42E-5	Anger	
LGG	cis	1	rs2426109	chr20:47662627	CSE1L	chr20:47662838-47713484:+	-0.19	-5.08	5.42E-7	Anger	
LGG	cis	1	rs2426112	chr20:47690139	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.47E-5	Anger	
LGG	cis	1	rs2426112	chr20:47690139	CSE1L	chr20:47662838-47713484:+	-0.19	-5.04	6.45E-7	Anger	
LGG	cis	1	rs2426113	chr20:47690189	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.47E-5	Anger	
LGG	cis	1	rs2426113	chr20:47690189	CSE1L	chr20:47662838-47713484:+	-0.19	-5.04	6.45E-7	Anger	
LGG	cis	1	rs2426116	chr20:47693047	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.47E-5	Anger	
LGG	cis	1	rs2426116	chr20:47693047	CSE1L	chr20:47662838-47713484:+	-0.19	-5.04	6.45E-7	Anger	
LGG	cis	1	rs2430494	chr2:37463620	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.6	5.32E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2431349	chr5:75921330	F2RL2	chr5:75911308-75919240:-	-0.18	-3.75	0.000199	Hearing impairment	
LGG	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.63E-47	Type 2 diabetes	
LGG	cis	1	rs2435356	chr10:43583150	CSGALNACT2	chr10:43633934-43680747:+	0.25	5.58	4.05E-8	Hirschsprung disease	
LGG	cis	1	rs2435357	chr10:43582056	CSGALNACT2	chr10:43633934-43680747:+	-0.23	-5.43	9.1E-8	Hirschsprung disease	
LGG	cis	1	rs2435362	chr10:43578779	CSGALNACT2	chr10:43633934-43680747:+	-0.22	-5.16	3.62E-7	Hirschsprung disease	
LGG	cis	1	rs2439391	chr15:67019313	SMAD6	chr15:66994674-67074335:+	-0.19	-3.61	0.000336	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs244286	chr17:53232594	COX11	chr17:53029259-53046064:-	-0.4	-8.23	1.65E-15	Menarche (age at onset)	
LGG	cis	1	rs244288	chr17:53231841	COX11	chr17:53029259-53046064:-	-0.4	-8.25	1.43E-15	Menarche (age at onset)	
LGG	cis	1	rs244289	chr17:53231788	COX11	chr17:53029259-53046064:-	-0.4	-8.24	1.52E-15	Menarche (age at onset)	
LGG	cis	1	rs244291	chr17:53231137	COX11	chr17:53029259-53046064:-	-0.4	-8.17	2.71E-15	Menarche (age at onset)	
LGG	cis	1	rs244292	chr17:53230734	COX11	chr17:53029259-53046064:-	-0.4	-8.24	1.52E-15	Menarche (age at onset)	
LGG	cis	1	rs244293	chr17:53230722	COX11	chr17:53029259-53046064:-	-0.4	-8.2	2.12E-15	Menarche (age at onset)	
LGG	cis	1	rs244295	chr17:53242899	COX11	chr17:53029259-53046064:-	-0.4	-8.25	1.44E-15	Menarche (age at onset)	
LGG	cis	1	rs244296	chr17:53242878	COX11	chr17:53029259-53046064:-	-0.4	-8.25	1.44E-15	Menarche (age at onset)	
LGG	cis	1	rs244299	chr17:53240266	COX11	chr17:53029259-53046064:-	0.4	8.25	1.46E-15	Menarche (age at onset)	
LGG	cis	1	rs244316	chr17:53215223	COX11	chr17:53029259-53046064:-	-0.39	-7.98	1.04E-14	Menarche (age at onset)	
LGG	cis	1	rs2444043	chr15:55534342	RAB27A	chr15:55495802-55582001:-	-0.14	-3.66	0.000278	Fractional exhaled nitric oxide levels	
LGG	cis	1	rs2447196	chr15:43893818	ADAL	chr15:43622872-43646094:+	0.59	7.74	5.9E-14	Tumor biomarkers	
LGG	cis	1	rs2447196	chr15:43893818	LCMT2	chr15:43619976-43622891:-	0.29	3.8	0.000161	Tumor biomarkers	
LGG	cis	1	rs2447196	chr15:43893818	STRC	chr15:43891762-43924561:-	-0.38	-6.9	1.6E-11	Tumor biomarkers	
LGG	cis	1	rs2447208	chr15:43933895	ADAL	chr15:43622872-43646094:+	-0.59	-7.62	1.33E-13	Tumor biomarkers	
LGG	cis	1	rs2447208	chr15:43933895	LCMT2	chr15:43619976-43622891:-	-0.29	-3.77	0.000184	Tumor biomarkers	
LGG	cis	1	rs2447208	chr15:43933895	STRC	chr15:43891762-43924561:-	0.38	6.96	1.12E-11	Tumor biomarkers	
LGG	cis	1	rs2447211	chr15:43936351	ADAL	chr15:43622872-43646094:+	-0.61	-7.79	4.09E-14	Tumor biomarkers	
LGG	cis	1	rs2447211	chr15:43936351	LCMT2	chr15:43619976-43622891:-	-0.29	-3.7	0.000237	Tumor biomarkers	
LGG	cis	1	rs2447211	chr15:43936351	STRC	chr15:43891762-43924561:-	0.39	6.96	1.11E-11	Tumor biomarkers	
LGG	cis	1	rs2448707	chr6:49446951	CENPQ	chr6:49431096-49460820:+	0.23	5.08	5.28E-7	Folate pathway vitamin levels	
LGG	cis	1	rs2455219	chr5:75922581	F2RL2	chr5:75911308-75919240:-	-0.2	-4.24	2.68E-5	Hearing impairment	
LGG	cis	1	rs2455331	chr5:643593	SDHA	chr5:218356-256812:+	0.18	4.14	4.02E-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs2455601	chr11:8899400	C11orf17	chr11:8932701-8941624:+	-0.19	-3.47	0.000575	Schizophrenia	
LGG	cis	1	rs2456173	chr5:176514595	FGFR4	chr5:176513921-176525124:+	-0.18	-3.95	8.84E-5	Height	
LGG	cis	1	rs2460254	chr11:71570110	FAM86C	chr11:71498557-71512276:+	-0.45	-4.73	2.98E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2460422	chr7:65601505	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs2460882	chr12:53787953	PRR13	chr12:53835433-53840426:+	-0.15	-3.53	0.000461	Percentage gas trapping	
LGG	cis	1	rs2462569	chr7:65474846	CCT6P1	chr7:65216092-65228661:+	-0.27	-4.98	8.75E-7	Diabetic kidney disease	
LGG	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.44	-10.51	1.92E-23	Ankylosing spondylitis	
LGG	cis	1	rs246454	chr5:96123264	ERAP2	chr5:96211644-96255398:+	0.33	5.72	1.89E-8	Ankylosing spondylitis	
LGG	cis	1	rs2465120	chr7:65620974	CCT6P1	chr7:65216092-65228661:+	0.24	4.4	1.31E-5	Diabetic kidney disease	
LGG	cis	1	rs2469081	chr15:67022403	SMAD6	chr15:66994674-67074335:+	-0.19	-3.6	0.000356	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs2469090	chr15:67019948	SMAD6	chr15:66994674-67074335:+	-0.2	-3.64	0.000298	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs2470134	chr15:43849886	ADAL	chr15:43622872-43646094:+	0.59	7.42	5.22E-13	Tumor biomarkers	
LGG	cis	1	rs2470134	chr15:43849886	LCMT2	chr15:43619976-43622891:-	0.27	3.52	0.000465	Tumor biomarkers	
LGG	cis	1	rs2470134	chr15:43849886	STRC	chr15:43891762-43924561:-	-0.4	-7.13	3.62E-12	Tumor biomarkers	
LGG	cis	1	rs2471851	chr11:113301069	TTC12	chr11:113185251-113244016:+	0.26	5.67	2.38E-8	Select biomarker traits	
LGG	cis	1	rs2471854	chr11:113299639	TTC12	chr11:113185251-113244016:+	-0.27	-5.94	5.52E-9	Select biomarker traits	
LGG	cis	1	rs2471857	chr11:113298339	TTC12	chr11:113185251-113244016:+	-0.28	-6.09	2.32E-9	Select biomarker traits	
LGG	cis	1	rs2471884	chr11:117010320	SIDT2	chr11:117049939-117068161:+	0.35	4.31	2.0E-5	Protein quantitative trait loci	
LGG	cis	1	rs2472476	chr9:107531956	NIPSNAP3A	chr9:107509969-107535189:+	0.15	3.93	9.54E-5	Obesity-related traits	
LGG	cis	1	rs2472478	chr9:107531361	NIPSNAP3A	chr9:107509969-107535189:+	0.15	3.93	9.54E-5	Obesity-related traits	
LGG	cis	1	rs2474777	chr20:25272633	ABHD12	chr20:25275380-25371477:-	0.27	7.12	3.87E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2474777	chr20:25272633	FAM182A	chr20:26035250-26067552:+	-0.49	-9.23	8.04E-19	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2474777	chr20:25272633	FAM182B	chr20:25744102-25848786:-	0.19	4.2	3.17E-5	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2479868	chr1:158580069	KIRREL	chr1:157963063-158065842:+	-0.11	-3.53	0.000453	Other erythrocyte phenotypes	
LGG	cis	1	rs2482427	chr9:107532425	NIPSNAP3A	chr9:107509969-107535189:+	0.15	3.94	9.3E-5	Obesity-related traits	
LGG	cis	1	rs2482911	chr20:25395528	ABHD12	chr20:25275380-25371477:-	-0.27	-7.38	6.89E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482911	chr20:25395528	FAM182A	chr20:26035250-26067552:+	0.56	11.04	1.91E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482911	chr20:25395528	FAM182B	chr20:25744102-25848786:-	-0.21	-4.82	1.94E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482919	chr20:25299756	ABHD12	chr20:25275380-25371477:-	-0.27	-7.38	6.8E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482919	chr20:25299756	FAM182A	chr20:26035250-26067552:+	0.56	11	2.7E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482919	chr20:25299756	FAM182B	chr20:25744102-25848786:-	-0.22	-4.88	1.45E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482927	chr20:25327151	ABHD12	chr20:25275380-25371477:-	-0.27	-7.25	1.6E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482927	chr20:25327151	FAM182A	chr20:26035250-26067552:+	0.56	11.06	1.54E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482927	chr20:25327151	FAM182B	chr20:25744102-25848786:-	-0.22	-4.9	1.31E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482928	chr20:25331530	ABHD12	chr20:25275380-25371477:-	-0.27	-7.22	1.96E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482928	chr20:25331530	FAM182A	chr20:26035250-26067552:+	0.56	11.12	8.72E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482928	chr20:25331530	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.49E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482930	chr20:25334115	ABHD12	chr20:25275380-25371477:-	-0.27	-7.35	8.36E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482930	chr20:25334115	FAM182A	chr20:26035250-26067552:+	0.56	11.06	1.54E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482930	chr20:25334115	FAM182B	chr20:25744102-25848786:-	-0.21	-4.74	2.75E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482931	chr20:25334445	ABHD12	chr20:25275380-25371477:-	-0.27	-7.38	6.8E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482931	chr20:25334445	FAM182A	chr20:26035250-26067552:+	0.56	11	2.7E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482931	chr20:25334445	FAM182B	chr20:25744102-25848786:-	-0.22	-4.88	1.45E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482937	chr20:25340786	ABHD12	chr20:25275380-25371477:-	-0.27	-7.38	6.89E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482937	chr20:25340786	FAM182A	chr20:26035250-26067552:+	0.56	11.04	1.91E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482937	chr20:25340786	FAM182B	chr20:25744102-25848786:-	-0.21	-4.82	1.94E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482940	chr20:25349830	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482940	chr20:25349830	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482940	chr20:25349830	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482941	chr20:25361216	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482941	chr20:25361216	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482941	chr20:25361216	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482943	chr20:25380593	ABHD12	chr20:25275380-25371477:-	-0.27	-7.37	7.47E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482943	chr20:25380593	FAM182A	chr20:26035250-26067552:+	0.57	11.41	6.57E-27	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2482943	chr20:25380593	FAM182B	chr20:25744102-25848786:-	-0.22	-4.93	1.14E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.71	3.18E-6	Body mass index	
LGG	cis	1	rs2486447	chr1:46545724	MUTYH	chr1:45794915-45806142:-	0.14	5.28	1.98E-7	Body mass index	
LGG	cis	1	rs2487715	chr9:107532394	NIPSNAP3A	chr9:107509969-107535189:+	0.16	4.23	2.82E-5	Obesity-related traits	
LGG	cis	1	rs2489034	chr10:102319192	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.000312	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489034	chr10:102319192	NDUFB8	chr10:102283497-102289636:-	0.16	4.25	2.59E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489034	chr10:102319192	WNT8B	chr10:102222812-102243397:+	0.5	7.9	1.84E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489035	chr10:102319395	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.000312	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489035	chr10:102319395	NDUFB8	chr10:102283497-102289636:-	0.16	4.25	2.59E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489035	chr10:102319395	WNT8B	chr10:102222812-102243397:+	0.5	7.9	1.84E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489036	chr10:102319581	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.000312	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489036	chr10:102319581	NDUFB8	chr10:102283497-102289636:-	0.16	4.25	2.59E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489036	chr10:102319581	WNT8B	chr10:102222812-102243397:+	0.5	7.9	1.84E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489037	chr10:102319918	NDUFB8	chr10:102283497-102289636:-	-0.15	-4.06	5.79E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489037	chr10:102319918	WNT8B	chr10:102222812-102243397:+	-0.5	-7.91	1.72E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489039	chr10:102328036	NDUFB8	chr10:102283497-102289636:-	0.15	4.17	3.67E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489039	chr10:102328036	WNT8B	chr10:102222812-102243397:+	0.49	7.85	2.62E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489040	chr10:102331298	NDUFB8	chr10:102283497-102289636:-	0.16	4.41	1.3E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489040	chr10:102331298	WNT8B	chr10:102222812-102243397:+	0.49	8.13	3.45E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489043	chr10:102334327	NDUFB8	chr10:102283497-102289636:-	0.16	4.38	1.47E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489043	chr10:102334327	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.29E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489045	chr10:102344754	NDUFB8	chr10:102283497-102289636:-	0.17	4.6	5.44E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489045	chr10:102344754	WNT8B	chr10:102222812-102243397:+	0.5	8.25	1.41E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489046	chr10:102346282	NDUFB8	chr10:102283497-102289636:-	0.14	3.85	0.000134	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489046	chr10:102346282	WNT8B	chr10:102222812-102243397:+	0.46	7.62	1.29E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489047	chr10:102347028	NDUFB8	chr10:102283497-102289636:-	0.14	3.81	0.000155	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489047	chr10:102347028	WNT8B	chr10:102222812-102243397:+	0.45	7.38	6.74E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489048	chr10:102348497	NDUFB8	chr10:102283497-102289636:-	0.16	4.34	1.71E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489048	chr10:102348497	WNT8B	chr10:102222812-102243397:+	0.49	8.01	8.59E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489049	chr10:102350732	NDUFB8	chr10:102283497-102289636:-	0.13	3.75	0.000196	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489049	chr10:102350732	WNT8B	chr10:102222812-102243397:+	0.44	7.28	1.36E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489050	chr10:102350898	NDUFB8	chr10:102283497-102289636:-	0.16	4.32	1.93E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489050	chr10:102350898	WNT8B	chr10:102222812-102243397:+	0.5	8.09	4.78E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489051	chr10:102351785	HIF1AN	chr10:102295641-102313680:+	-0.18	-3.59	0.000362	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489051	chr10:102351785	NDUFB8	chr10:102283497-102289636:-	-0.14	-3.98	7.98E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489051	chr10:102351785	WNT8B	chr10:102222812-102243397:+	-0.48	-8.11	4.2E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489053	chr10:102353341	NDUFB8	chr10:102283497-102289636:-	0.13	3.55	0.00043	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2489053	chr10:102353341	WNT8B	chr10:102222812-102243397:+	0.44	7.13	3.71E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2492859	chr6:34645266	C6orf106	chr6:34555066-34664625:-	0.29	5.61	3.37E-8	Pubertal anthropometrics	
LGG	cis	1	rs2494112	chr1:201787833	LMOD1	chr1:201865585-201915716:-	-0.22	-4.68	3.68E-6	Body mass index	
LGG	cis	1	rs2494112	chr1:201787833	SHISA4	chr1:201858032-201861426:+	-0.3	-7.62	1.29E-13	Body mass index	
LGG	cis	1	rs2495732	chr10:102357780	NDUFB8	chr10:102283497-102289636:-	0.15	4.02	6.84E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495732	chr10:102357780	WNT8B	chr10:102222812-102243397:+	0.48	7.71	7.09E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495734	chr10:102338686	NDUFB8	chr10:102283497-102289636:-	0.16	4.5	8.57E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495734	chr10:102338686	WNT8B	chr10:102222812-102243397:+	0.48	7.94	1.36E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495736	chr10:102338410	NDUFB8	chr10:102283497-102289636:-	0.16	4.46	1.0E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495736	chr10:102338410	WNT8B	chr10:102222812-102243397:+	0.5	8.17	2.7E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495737	chr10:102338344	NDUFB8	chr10:102283497-102289636:-	0.16	4.44	1.09E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495737	chr10:102338344	WNT8B	chr10:102222812-102243397:+	0.48	7.83	3.05E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495739	chr10:102335507	NDUFB8	chr10:102283497-102289636:-	0.16	4.49	9.06E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495739	chr10:102335507	WNT8B	chr10:102222812-102243397:+	0.48	7.91	1.71E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495741	chr10:102331795	NDUFB8	chr10:102283497-102289636:-	0.16	4.4	1.33E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495741	chr10:102331795	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.03E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495742	chr10:102331364	NDUFB8	chr10:102283497-102289636:-	0.17	4.61	5.16E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495742	chr10:102331364	WNT8B	chr10:102222812-102243397:+	0.5	8.17	2.67E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495743	chr10:102329739	NDUFB8	chr10:102283497-102289636:-	0.16	4.29	2.18E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495743	chr10:102329739	WNT8B	chr10:102222812-102243397:+	0.51	8.27	1.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495745	chr10:102329075	HIF1AN	chr10:102295641-102313680:+	0.18	3.47	0.000559	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495745	chr10:102329075	NDUFB8	chr10:102283497-102289636:-	0.15	4.05	5.96E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495745	chr10:102329075	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.09E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495747	chr10:102328247	NDUFB8	chr10:102283497-102289636:-	0.14	3.96	8.47E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495747	chr10:102328247	WNT8B	chr10:102222812-102243397:+	0.47	7.56	1.93E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495750	chr10:102327708	NDUFB8	chr10:102283497-102289636:-	0.17	4.44	1.11E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495750	chr10:102327708	WNT8B	chr10:102222812-102243397:+	0.5	7.85	2.65E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495751	chr10:102327260	NDUFB8	chr10:102283497-102289636:-	0.15	4.17	3.67E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495751	chr10:102327260	WNT8B	chr10:102222812-102243397:+	0.49	7.85	2.62E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495752	chr10:102326115	NDUFB8	chr10:102283497-102289636:-	0.16	4.24	2.64E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495752	chr10:102326115	WNT8B	chr10:102222812-102243397:+	0.49	7.82	3.34E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495753	chr10:102325640	NDUFB8	chr10:102283497-102289636:-	0.17	4.53	7.53E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495753	chr10:102325640	WNT8B	chr10:102222812-102243397:+	0.5	7.82	3.15E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495754	chr10:102324812	HIF1AN	chr10:102295641-102313680:+	0.19	3.48	0.000537	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495754	chr10:102324812	NDUFB8	chr10:102283497-102289636:-	0.16	4.25	2.54E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495754	chr10:102324812	WNT8B	chr10:102222812-102243397:+	0.49	7.77	4.79E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495755	chr10:102324649	NDUFB8	chr10:102283497-102289636:-	0.17	4.64	4.52E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495755	chr10:102324649	WNT8B	chr10:102222812-102243397:+	0.5	7.84	2.84E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495758	chr10:102321900	NDUFB8	chr10:102283497-102289636:-	0.17	4.64	4.52E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495758	chr10:102321900	WNT8B	chr10:102222812-102243397:+	0.5	7.84	2.84E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495759	chr10:102320363	NDUFB8	chr10:102283497-102289636:-	0.17	4.52	7.89E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495759	chr10:102320363	WNT8B	chr10:102222812-102243397:+	0.49	7.54	2.37E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495760	chr10:102318771	NDUFB8	chr10:102283497-102289636:-	0.18	4.71	3.19E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2495760	chr10:102318771	WNT8B	chr10:102222812-102243397:+	0.51	7.97	1.13E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2500404	chr20:25359758	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500404	chr20:25359758	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500404	chr20:25359758	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500405	chr20:25360826	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500405	chr20:25360826	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500405	chr20:25360826	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500418	chr20:25382268	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.48E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500418	chr20:25382268	FAM182A	chr20:26035250-26067552:+	0.55	10.95	4.23E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500418	chr20:25382268	FAM182B	chr20:25744102-25848786:-	-0.22	-5.01	7.45E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500424	chr20:25391969	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500424	chr20:25391969	FAM182A	chr20:26035250-26067552:+	0.56	10.98	3.04E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500424	chr20:25391969	FAM182B	chr20:25744102-25848786:-	-0.22	-4.96	9.92E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500432	chr20:25290512	ABHD12	chr20:25275380-25371477:-	0.26	7.02	7.42E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500432	chr20:25290512	FAM182A	chr20:26035250-26067552:+	-0.55	-10.88	7.53E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500432	chr20:25290512	FAM182B	chr20:25744102-25848786:-	0.21	4.83	1.81E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500436	chr20:25406366	ABHD12	chr20:25275380-25371477:-	-0.27	-7.25	1.62E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500436	chr20:25406366	FAM182A	chr20:26035250-26067552:+	0.56	11.1	1.08E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500436	chr20:25406366	FAM182B	chr20:25744102-25848786:-	-0.22	-4.84	1.76E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500443	chr20:25331442	ABHD12	chr20:25275380-25371477:-	-0.27	-7.22	1.96E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500443	chr20:25331442	FAM182A	chr20:26035250-26067552:+	0.56	11.12	8.72E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500443	chr20:25331442	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.49E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500446	chr20:25339664	ABHD12	chr20:25275380-25371477:-	-0.27	-7.35	8.36E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500446	chr20:25339664	FAM182A	chr20:26035250-26067552:+	0.56	11.06	1.54E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500446	chr20:25339664	FAM182B	chr20:25744102-25848786:-	-0.21	-4.74	2.75E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500448	chr20:25404027	ABHD12	chr20:25275380-25371477:-	-0.27	-7.28	1.31E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500448	chr20:25404027	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.7E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2500448	chr20:25404027	FAM182B	chr20:25744102-25848786:-	-0.22	-4.97	9.44E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2501962	chr6:49453636	CENPQ	chr6:49431096-49460820:+	0.23	5.15	3.81E-7	Folate pathway vitamin levels	
LGG	cis	1	rs2501963	chr6:49454281	CENPQ	chr6:49431096-49460820:+	0.23	5.12	4.3E-7	Folate pathway vitamin levels	
LGG	cis	1	rs2505998	chr10:43570925	CSGALNACT2	chr10:43633934-43680747:+	-0.23	-5.39	1.11E-7	Hirschsprung disease	
LGG	cis	1	rs2506006	chr10:43581501	CSGALNACT2	chr10:43633934-43680747:+	-0.23	-5.24	2.33E-7	Hirschsprung disease	
LGG	cis	1	rs2508858	chr11:71805405	FAM86C	chr11:71498557-71512276:+	-0.47	-4.6	5.3E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2510340	chr18:21142438	C18orf8	chr18:21083462-21111742:+	0.2	3.94	9.21E-5	Body mass index	
LGG	cis	1	rs2511075	chr11:71780257	FAM86C	chr11:71498557-71512276:+	0.51	4.98	8.95E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2511076	chr11:71783827	FAM86C	chr11:71498557-71512276:+	0.5	4.92	1.19E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2511079	chr11:71804154	FAM86C	chr11:71498557-71512276:+	0.46	4.6	5.45E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2511114	chr11:71792147	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2511116	chr11:71802160	FAM86C	chr11:71498557-71512276:+	0.44	4.43	1.18E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2513093	chr11:116806687	SIDT2	chr11:117049939-117068161:+	0.31	3.59	0.000359	Protein quantitative trait loci	
LGG	cis	1	rs2513095	chr11:116806269	SIDT2	chr11:117049939-117068161:+	0.31	3.6	0.000351	Protein quantitative trait loci	
LGG	cis	1	rs2518490	chr1:158584675	KIRREL	chr1:157963063-158065842:+	-0.12	-3.65	0.000295	Other erythrocyte phenotypes	
LGG	cis	1	rs2518491	chr1:158585230	KIRREL	chr1:157963063-158065842:+	-0.12	-3.66	0.000279	Other erythrocyte phenotypes	
LGG	cis	1	rs2518806	chr22:18976603	DGCR6	chr22:18893541-18899600:+	0.21	4.85	1.67E-6	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs2524005	chr6:29899677	HCG2P7	chr6:29866808-29870429:+	0.56	8.03	7.13E-15	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2524005	chr6:29899677	HCG4	chr6:29758809-29760850:-	-0.65	-9.81	7.35E-21	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2524005	chr6:29899677	HCG4P6	chr6:29867168-29911213:-	0.42	5.65	2.7E-8	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2524005	chr6:29899677	HLA-G	chr6:29794756-29977731:+	-0.24	-3.93	9.63E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2524005	chr6:29899677	HLA-J	chr6:29973748-29977731:+	0.27	4.01	6.9E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs2524005	chr6:29899677	HLA-L	chr6:30227339-30234728:+	-0.21	-3.5	0.000506	Bipolar disorder and schizophrenia	
LGG	cis	1	rs252716	chr5:110425063	TSLP	chr5:110405778-110413722:+	0.29	5.55	4.72E-8	Eosinophilic esophagitis	
LGG	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.84	16.02	9.2E-47	Type 2 diabetes	
LGG	cis	1	rs252887	chr5:56166188	MIER3	chr5:56215429-56267501:-	0.18	3.92	0.000101	Type 2 diabetes	
LGG	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.85	15.81	8.03E-46	Type 2 diabetes	
LGG	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.82	15.46	3.38E-44	Type 2 diabetes	
LGG	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.86	15.46	3.32E-44	Type 2 diabetes	
LGG	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.83	-15.52	1.66E-44	Type 2 diabetes	
LGG	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.63E-47	Type 2 diabetes	
LGG	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.84	16.19	1.46E-47	Type 2 diabetes	
LGG	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.84	16.19	1.46E-47	Type 2 diabetes	
LGG	cis	1	rs2533288	chr7:66056711	CCT6P1	chr7:65216092-65228661:+	0.23	4.1	4.76E-5	Diabetic kidney disease	
LGG	cis	1	rs2540226	chr2:39959060	THUMPD2	chr2:39963200-40006416:-	-0.43	-8.53	1.83E-16	Personality dimensions	
LGG	cis	1	rs2540227	chr2:39957578	THUMPD2	chr2:39963200-40006416:-	0.44	8.59	1.16E-16	Personality dimensions	
LGG	cis	1	rs2540648	chr22:18967349	DGCR5	chr22:18958027-19018742:+	-0.3	-4.36	1.59E-5	Blood metabolite ratios	
LGG	cis	1	rs2540977	chr2:37462228	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.8	2.16E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2541161	chr9:131884802	CRAT	chr9:131857075-131873070:-	-0.21	-3.83	0.000143	Blood metabolite ratios	
LGG	cis	1	rs2541164	chr9:131876908	CRAT	chr9:131857075-131873070:-	0.21	3.91	0.000106	Blood metabolite ratios	
LGG	cis	1	rs2543376	chr14:76609923	ESRRB	chr14:76837690-76968178:+	0.47	7.55	2.11E-13	Blood pressure	
LGG	cis	1	rs2543382	chr14:76624887	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.99E-13	Blood pressure	
LGG	cis	1	rs2543383	chr14:76626703	ESRRB	chr14:76837690-76968178:+	0.45	7.47	3.66E-13	Blood pressure	
LGG	cis	1	rs2543384	chr14:76627301	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs2543387	chr14:76629046	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs2544414	chr4:106757561	INTS12	chr4:106603787-106629881:-	-0.35	-3.64	0.000297	Lung function (FEV1)	
LGG	cis	1	rs2544418	chr4:106741974	INTS12	chr4:106603787-106629881:-	-0.31	-3.53	0.000461	Lung function (FEV1)	
LGG	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.84	16.2	1.29E-47	Type 2 diabetes	
LGG	cis	1	rs2548664	chr5:56133555	MIER3	chr5:56215429-56267501:-	0.16	3.46	0.000584	Type 2 diabetes	
LGG	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.84	16.2	1.29E-47	Type 2 diabetes	
LGG	cis	1	rs2548665	chr5:56131805	MIER3	chr5:56215429-56267501:-	0.16	3.46	0.000584	Type 2 diabetes	
LGG	cis	1	rs2549803	chr5:96174929	ERAP1	chr5:96096515-96149837:-	-0.35	-7.82	3.34E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs255857	chr5:112743066	SRP19	chr5:112196993-112228774:+	0.3	3.7	0.000237	F-cell distribution	
LGG	cis	1	rs255859	chr5:112743480	SRP19	chr5:112196993-112228774:+	0.3	3.7	0.000237	F-cell distribution	
LGG	cis	1	rs2562456	chr19:21666210	ZNF493	chr19:21579921-21610294:+	0.13	3.63	0.000311	Pain	
LGG	cis	1	rs2564921	chr3:53125585	RFT1	chr3:53122503-53164470:-	0.48	10.17	3.46E-22	Height	
LGG	cis	1	rs2564926	chr3:53094730	ITIH4	chr3:52847007-52866554:-	0.22	3.52	0.00048	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs2564940	chr3:53107569	RFT1	chr3:53122503-53164470:-	-0.47	-10.09	7.0E-22	Height	
LGG	cis	1	rs2564956	chr3:53070462	ITIH4	chr3:52847007-52866554:-	-0.18	-4.87	1.53E-6	Ulcerative colitis	
LGG	cis	1	rs2564956	chr3:53070462	RFT1	chr3:53122503-53164470:-	-0.2	-3.97	8.12E-5	Ulcerative colitis	
LGG	cis	1	rs256572	chr2:190717867	ASNSD1	chr2:190526125-190535556:+	-0.25	-4.13	4.32E-5	Subcutaneous adipose tissue	
LGG	cis	1	rs256572	chr2:190717867	ORMDL1	chr2:190634994-190649097:-	0.26	5.62	3.14E-8	Subcutaneous adipose tissue	
LGG	cis	1	rs2570916	chr1:159012646	IFI16	chr1:158969758-159024943:+	-0.17	-3.77	0.000183	Obesity-related traits	
LGG	cis	1	rs2572910	chr8:143770135	C8orf55	chr8:143808621-143818350:+	0.17	3.57	0.000391	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2572910	chr8:143770135	LY6K	chr8:143781529-143785582:+	0.35	6.74	4.32E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2572910	chr8:143770135	PSCA	chr8:143761875-143764142:+	0.34	5.93	5.64E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2573346	chr10:81918041	ANXA11	chr10:81914880-81965433:-	0.16	5.43	8.85E-8	Sarcoidosis	
LGG	cis	1	rs2573346	chr10:81918041	PLAC9	chr10:81892258-81904784:+	0.24	6.21	1.14E-9	Sarcoidosis	
LGG	cis	1	rs257389	chr5:130744263	SLC22A5	chr5:131705401-131731302:+	-0.21	-3.72	0.000226	Life satisfaction	
LGG	cis	1	rs257390	chr5:130740617	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.52	7.61E-6	Life satisfaction	
LGG	cis	1	rs2574985	chr10:52129486	SGMS1	chr10:52065346-52384923:-	0.15	3.49	0.000526	Subjective well-being	
LGG	cis	1	rs2581782	chr3:53122257	RFT1	chr3:53122503-53164470:-	-0.48	-10.27	1.56E-22	Height	
LGG	cis	1	rs2581783	chr3:53122258	RFT1	chr3:53122503-53164470:-	-0.47	-10.11	5.81E-22	Height	
LGG	cis	1	rs2581786	chr3:53126143	RFT1	chr3:53122503-53164470:-	-0.46	-9.79	8.58E-21	Height	
LGG	cis	1	rs2581787	chr3:53127677	RFT1	chr3:53122503-53164470:-	-0.46	-9.8	8.04E-21	Height	
LGG	cis	1	rs2581794	chr3:53036206	RFT1	chr3:53122503-53164470:-	-0.28	-5.45	7.79E-8	Schizophrenia	
LGG	cis	1	rs2581800	chr3:53109352	RFT1	chr3:53122503-53164470:-	-0.5	-10.67	4.62E-24	Height	
LGG	cis	1	rs2581817	chr3:53071797	ITIH4	chr3:52847007-52866554:-	-0.17	-4.79	2.17E-6	Ulcerative colitis	
LGG	cis	1	rs2581817	chr3:53071797	RFT1	chr3:53122503-53164470:-	-0.2	-4.01	7.15E-5	Ulcerative colitis	
LGG	cis	1	rs2585179	chr8:143774193	C8orf55	chr8:143808621-143818350:+	0.16	3.54	0.000439	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2585179	chr8:143774193	LY6K	chr8:143781529-143785582:+	0.35	6.68	6.52E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2585179	chr8:143774193	PSCA	chr8:143761875-143764142:+	0.34	5.96	4.74E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2587949	chr3:4223616	SUMF1	chr3:3823036-4508954:-	-0.16	-3.52	0.000478	Periodontitis (DPAL)	
LGG	cis	1	rs2591092	chr14:76630133	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs2591094	chr14:76632335	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs259346	chr1:95728746	RWDD3	chr1:95583479-95712773:+	0.3	4.51	8.17E-6	Stearic acid (18:0) plasma levels	
LGG	cis	1	rs259354	chr1:95718205	RWDD3	chr1:95583479-95712773:+	-0.27	-4.51	8.25E-6	Stearic acid (18:0) plasma levels	
LGG	cis	1	rs2595500	chr11:6963165	ZNF215	chr11:6947654-7005861:+	0.21	4.42	1.21E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs2595501	chr11:6955340	ZNF215	chr11:6947654-7005861:+	-0.22	-4.21	3.09E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs2614811	chr15:43913487	ADAL	chr15:43622872-43646094:+	-0.6	-7.66	1.02E-13	Tumor biomarkers	
LGG	cis	1	rs2614811	chr15:43913487	LCMT2	chr15:43619976-43622891:-	-0.27	-3.48	0.000547	Tumor biomarkers	
LGG	cis	1	rs2614811	chr15:43913487	STRC	chr15:43891762-43924561:-	0.4	7.17	2.84E-12	Tumor biomarkers	
LGG	cis	1	rs2617170	chr12:10560957	KLRC2	chr12:10579193-10588592:-	-0.26	-5.56	4.5E-8	Behcet's disease	
LGG	cis	1	rs2617170	chr12:10560957	KLRC4	chr12:10559985-10562356:-	0.14	3.53	0.000454	Behcet's disease	
LGG	cis	1	rs2617170	chr12:10560957	KLRK1	chr12:10524953-10562745:-	0.18	4.22	2.95E-5	Behcet's disease	
LGG	cis	1	rs2617433	chr5:96176441	ERAP1	chr5:96096515-96149837:-	-0.35	-7.79	3.88E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs2625667	chr3:41900951	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs2625668	chr3:41905930	ULK4	chr3:41288091-42003660:-	0.76	14.86	1.69E-41	Diastolic blood pressure	
LGG	cis	1	rs2628313	chr17:53235352	COX11	chr17:53029259-53046064:-	-0.4	-8.23	1.76E-15	Menarche (age at onset)	
LGG	cis	1	rs2628314	chr17:53235182	COX11	chr17:53029259-53046064:-	-0.4	-8.16	2.92E-15	Menarche (age at onset)	
LGG	cis	1	rs2629447	chr12:56700809	IL23A	chr12:56732663-56734193:+	-0.57	-5.82	1.05E-8	Psoriasis vulgaris	
LGG	cis	1	rs2629540	chr10:126426148	METTL10	chr10:126447406-126480439:-	0.37	8.16	2.82E-15	Cocaine dependence	
LGG	cis	1	rs2630	chr15:50849399	SPPL2A	chr15:50999739-51057910:-	0.13	4.31	1.93E-5	QT interval	
LGG	cis	1	rs2637678	chr6:116787378	FAM26F	chr6:116782556-116784933:+	0.16	4.17	3.61E-5	Ulcerative colitis	
LGG	cis	1	rs2638090	chr11:6955142	ZNF215	chr11:6947654-7005861:+	-0.22	-4.21	3.09E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs2638092	chr11:6961746	ZNF215	chr11:6947654-7005861:+	-0.23	-4.54	6.93E-6	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs2643623	chr12:56689725	IL23A	chr12:56732663-56734193:+	-0.57	-5.82	1.05E-8	Psoriasis vulgaris	
LGG	cis	1	rs2643626	chr12:56726518	IL23A	chr12:56732663-56734193:+	-0.53	-5.34	1.42E-7	Psoriasis vulgaris	
LGG	cis	1	rs2644128	chr1:201793440	LMOD1	chr1:201865585-201915716:-	0.2	4.29	2.11E-5	Body mass index	
LGG	cis	1	rs2644128	chr1:201793440	SHISA4	chr1:201858032-201861426:+	0.3	7.68	8.88E-14	Body mass index	
LGG	cis	1	rs2647597	chr11:5375761	FAM160A2	chr11:6232565-6255941:-	0.21	4.13	4.19E-5	Fetal hemoglobin levels	
LGG	cis	1	rs2648337	chr3:12162280	TIMP4	chr3:12194573-12200647:-	-0.3	-4.06	5.72E-5	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.44	-10.53	1.64E-23	Ankylosing spondylitis	
LGG	cis	1	rs26510	chr5:96125910	ERAP2	chr5:96211644-96255398:+	0.33	5.71	1.95E-8	Ankylosing spondylitis	
LGG	cis	1	rs2651829	chr11:2308304	C11orf21	chr11:2317507-2323143:-	0.31	4.23	2.81E-5	Obesity-related traits	
LGG	cis	1	rs2652816	chr15:63403368	LACTB	chr15:63414032-63434254:+	0.2	4.13	4.32E-5	HDL cholesterol	
LGG	cis	1	rs2652832	chr15:63396928	LACTB	chr15:63414032-63434254:+	0.22	4.53	7.48E-6	HDL cholesterol	
LGG	cis	1	rs2652833	chr15:63396885	LACTB	chr15:63414032-63434254:+	0.22	4.58	5.83E-6	HDL cholesterol	
LGG	cis	1	rs2652834	chr15:63396867	LACTB	chr15:63414032-63434254:+	0.22	4.58	5.91E-6	HDL cholesterol	
LGG	cis	1	rs2652835	chr15:63396408	LACTB	chr15:63414032-63434254:+	0.22	4.63	4.65E-6	HDL cholesterol	
LGG	cis	1	rs2652838	chr15:63396088	LACTB	chr15:63414032-63434254:+	0.22	4.63	4.65E-6	HDL cholesterol	
LGG	cis	1	rs2652840	chr15:63393220	LACTB	chr15:63414032-63434254:+	0.21	4.19	3.33E-5	HDL cholesterol	
LGG	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.57	-9.46	1.3E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs2656056	chr15:78722519	CHRNA5	chr15:78857906-78886458:+	0.27	4.06	5.63E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2656803	chr12:55426569	ITGA7	chr12:56078356-56106089:-	-0.16	-3.49	0.000535	IgG glycosylation	
LGG	cis	1	rs2659889	chr7:66217112	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.22E-6	Aortic root size	
LGG	cis	1	rs2659889	chr7:66217112	TYW1	chr7:66461817-66704496:+	0.18	3.77	0.000184	Aortic root size	
LGG	cis	1	rs2659903	chr7:66180931	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2659906	chr7:66165310	ASL	chr7:65540776-65558321:+	-0.19	-4.94	1.06E-6	Aortic root size	
LGG	cis	1	rs2659906	chr7:66165310	TYW1	chr7:66461817-66704496:+	0.17	3.58	0.000375	Aortic root size	
LGG	cis	1	rs2659909	chr7:66160279	ASL	chr7:65540776-65558321:+	-0.19	-4.9	1.34E-6	Aortic root size	
LGG	cis	1	rs2659909	chr7:66160279	TYW1	chr7:66461817-66704496:+	0.17	3.69	0.000253	Aortic root size	
LGG	cis	1	rs2659911	chr7:66158420	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2659912	chr7:66157999	ASL	chr7:65540776-65558321:+	-0.2	-4.98	8.88E-7	Aortic root size	
LGG	cis	1	rs2659912	chr7:66157999	TYW1	chr7:66461817-66704496:+	0.16	3.5	0.000501	Aortic root size	
LGG	cis	1	rs2659913	chr7:66157336	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2659915	chr7:66153101	ASL	chr7:65540776-65558321:+	-0.18	-4.6	5.44E-6	Aortic root size	
LGG	cis	1	rs2659915	chr7:66153101	TYW1	chr7:66461817-66704496:+	0.19	4.1	4.81E-5	Aortic root size	
LGG	cis	1	rs2665826	chr17:61944924	DDX42	chr17:61851567-61896676:+	-0.16	-3.71	0.000235	Body mass index	
LGG	cis	1	rs2665826	chr17:61944924	FTSJ3	chr17:61896795-61905031:-	0.41	8.36	6.52E-16	Body mass index	
LGG	cis	1	rs2665826	chr17:61944924	SMARCD2	chr17:61909441-61920351:-	0.18	4.18	3.48E-5	Body mass index	
LGG	cis	1	rs2666428	chr1:226589709	CDC42BPA	chr1:227177567-227505826:-	-0.12	-3.52	0.000469	Melanoma	
LGG	cis	1	rs2667011	chr2:160867059	LY75	chr2:160625141-160761262:-	-0.16	-3.88	0.000119	Bilirubin levels	
LGG	cis	1	rs2675680	chr10:75658864	FUT11	chr10:75532049-75535974:+	0.12	3.99	7.62E-5	Inflammatory bowel disease	
LGG	cis	1	rs267736	chr1:150945607	ARNT	chr1:150782186-150849186:-	0.28	4.85	1.66E-6	Congenital left-sided heart lesions	
LGG	cis	1	rs267736	chr1:150945607	CDC42SE1	chr1:151023449-151032125:-	0.22	3.47	0.000571	Congenital left-sided heart lesions	
LGG	cis	1	rs267736	chr1:150945607	OAZ3	chr1:151735445-151743805:+	0.3	3.75	0.000197	Congenital left-sided heart lesions	
LGG	cis	1	rs2683695	chr3:41914928	ULK4	chr3:41288091-42003660:-	0.77	15.24	3.32E-43	Diastolic blood pressure	
LGG	cis	1	rs2683696	chr3:41914898	ULK4	chr3:41288091-42003660:-	0.77	15.09	1.49E-42	Diastolic blood pressure	
LGG	cis	1	rs2684898	chr12:51046825	ATF1	chr12:51157819-51214906:+	-0.2	-4.34	1.76E-5	Fibrinogen	
LGG	cis	1	rs2684898	chr12:51046825	LETMD1	chr12:51442084-51454206:+	0.15	3.82	0.00015	Fibrinogen	
LGG	cis	1	rs2684898	chr12:51046825	SLC11A2	chr12:51373319-51422058:-	0.17	3.72	0.000225	Fibrinogen	
LGG	cis	1	rs2684900	chr12:51019556	ATF1	chr12:51157819-51214906:+	-0.21	-4.58	5.79E-6	Fibrinogen	
LGG	cis	1	rs2684900	chr12:51019556	LETMD1	chr12:51442084-51454206:+	0.15	3.66	0.000279	Fibrinogen	
LGG	cis	1	rs2684900	chr12:51019556	SLC11A2	chr12:51373319-51422058:-	0.16	3.6	0.000355	Fibrinogen	
LGG	cis	1	rs2687723	chr3:127865559	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.55E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2687730	chr3:127915457	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.6E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2687818	chr8:133928876	TG	chr8:133879205-134147141:+	-0.22	-3.91	0.000106	Vitiligo	
LGG	cis	1	rs2687821	chr8:133926295	TG	chr8:133879205-134147141:+	-0.22	-3.92	0.000101	Vitiligo	
LGG	cis	1	rs2687822	chr8:133925914	TG	chr8:133879205-134147141:+	-0.22	-3.92	0.000101	Vitiligo	
LGG	cis	1	rs2687824	chr8:133925209	TG	chr8:133879205-134147141:+	0.21	3.82	0.00015	Vitiligo	
LGG	cis	1	rs2687826	chr8:133925027	TG	chr8:133879205-134147141:+	-0.23	-4.06	5.81E-5	Vitiligo	
LGG	cis	1	rs2687827	chr8:133924681	TG	chr8:133879205-134147141:+	-0.22	-3.86	0.000126	Vitiligo	
LGG	cis	1	rs2687829	chr8:133923009	TG	chr8:133879205-134147141:+	-0.22	-3.92	0.000101	Vitiligo	
LGG	cis	1	rs2687830	chr8:133922627	TG	chr8:133879205-134147141:+	-0.22	-3.89	0.000113	Vitiligo	
LGG	cis	1	rs2687831	chr8:133922144	TG	chr8:133879205-134147141:+	-0.22	-3.89	0.000113	Vitiligo	
LGG	cis	1	rs2687832	chr8:133922097	TG	chr8:133879205-134147141:+	-0.22	-3.89	0.000113	Vitiligo	
LGG	cis	1	rs2687833	chr8:133921893	TG	chr8:133879205-134147141:+	-0.22	-3.89	0.000113	Vitiligo	
LGG	cis	1	rs2687834	chr8:133921827	TG	chr8:133879205-134147141:+	-0.21	-3.82	0.000153	Vitiligo	
LGG	cis	1	rs2688608	chr10:75658349	FUT11	chr10:75532049-75535974:+	0.12	4.12	4.4E-5	Inflammatory bowel disease	
LGG	cis	1	rs2688610	chr10:75654931	FUT11	chr10:75532049-75535974:+	-0.14	-4.83	1.86E-6	Inflammatory bowel disease	
LGG	cis	1	rs2695782	chr12:56722830	IL23A	chr12:56732663-56734193:+	-0.62	-6.14	1.66E-9	Psoriasis vulgaris	
LGG	cis	1	rs2695788	chr12:56697110	IL23A	chr12:56732663-56734193:+	-0.57	-5.81	1.11E-8	Psoriasis vulgaris	
LGG	cis	1	rs2695789	chr12:56694261	IL23A	chr12:56732663-56734193:+	-0.57	-5.82	1.05E-8	Psoriasis vulgaris	
LGG	cis	1	rs26962	chr5:112737010	SRP19	chr5:112196993-112228774:+	0.3	3.7	0.000237	F-cell distribution	
LGG	cis	1	rs26980	chr5:112770027	SRP19	chr5:112196993-112228774:+	0.33	4.02	6.66E-5	F-cell distribution	
LGG	cis	1	rs26984	chr5:112774425	SRP19	chr5:112196993-112228774:+	0.34	4.06	5.62E-5	F-cell distribution	
LGG	cis	1	rs26986	chr5:112777570	SRP19	chr5:112196993-112228774:+	0.34	4.03	6.36E-5	F-cell distribution	
LGG	cis	1	rs2699352	chr13:103903542	C13orf39	chr13:103338099-103356652:-	0.22	3.45	0.000601	Prostate cancer	
LGG	cis	1	rs2700479	chr12:51020471	ATF1	chr12:51157819-51214906:+	-0.21	-4.58	5.79E-6	Fibrinogen	
LGG	cis	1	rs2700479	chr12:51020471	LETMD1	chr12:51442084-51454206:+	0.15	3.66	0.000279	Fibrinogen	
LGG	cis	1	rs2700479	chr12:51020471	SLC11A2	chr12:51373319-51422058:-	0.16	3.6	0.000355	Fibrinogen	
LGG	cis	1	rs2700482	chr12:51083265	ATF1	chr12:51157819-51214906:+	-0.21	-4.52	7.69E-6	Fibrinogen	
LGG	cis	1	rs2700482	chr12:51083265	LETMD1	chr12:51442084-51454206:+	0.15	3.7	0.000237	Fibrinogen	
LGG	cis	1	rs2700482	chr12:51083265	SLC11A2	chr12:51373319-51422058:-	0.16	3.62	0.000327	Fibrinogen	
LGG	cis	1	rs2700485	chr12:51103992	ATF1	chr12:51157819-51214906:+	-0.21	-4.41	1.29E-5	Fibrinogen	
LGG	cis	1	rs2700485	chr12:51103992	LETMD1	chr12:51442084-51454206:+	0.16	4	7.41E-5	Fibrinogen	
LGG	cis	1	rs2700485	chr12:51103992	SLC11A2	chr12:51373319-51422058:-	0.17	3.83	0.000144	Fibrinogen	
LGG	cis	1	rs2705123	chr12:48878792	VDR	chr12:48235322-48298814:-	-0.23	-3.63	0.000311	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2705126	chr12:48882562	VDR	chr12:48235322-48298814:-	-0.22	-3.53	0.000458	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2705141	chr12:48924427	VDR	chr12:48235322-48298814:-	0.26	3.74	0.000208	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2705142	chr12:48923291	VDR	chr12:48235322-48298814:-	-0.26	-3.81	0.000155	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2705154	chr12:48907793	VDR	chr12:48235322-48298814:-	-0.23	-3.53	0.000461	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2707828	chr7:66171377	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2707830	chr7:66167645	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2707831	chr7:66062511	CCT6P1	chr7:65216092-65228661:+	0.23	4.1	4.76E-5	Diabetic kidney disease	
LGG	cis	1	rs2707832	chr7:66136549	CCT6P1	chr7:65216092-65228661:+	0.22	4.05	5.84E-5	Gout	
LGG	cis	1	rs2707836	chr7:66160435	ASL	chr7:65540776-65558321:+	-0.19	-4.94	1.06E-6	Aortic root size	
LGG	cis	1	rs2707836	chr7:66160435	TYW1	chr7:66461817-66704496:+	0.17	3.58	0.000375	Aortic root size	
LGG	cis	1	rs2707838	chr7:66159201	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs2707840	chr7:66158015	CCT6P1	chr7:65216092-65228661:+	0.22	4.03	6.37E-5	Gout	
LGG	cis	1	rs2707844	chr7:66059509	CCT6P1	chr7:65216092-65228661:+	0.23	4.1	4.76E-5	Diabetic kidney disease	
LGG	cis	1	rs2707845	chr7:66198798	ASL	chr7:65540776-65558321:+	-0.19	-4.86	1.55E-6	Aortic root size	
LGG	cis	1	rs2707845	chr7:66198798	TYW1	chr7:66461817-66704496:+	0.17	3.68	0.000254	Aortic root size	
LGG	cis	1	rs2707850	chr7:66203870	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.24E-6	Aortic root size	
LGG	cis	1	rs2707850	chr7:66203870	TYW1	chr7:66461817-66704496:+	0.18	3.76	0.000192	Aortic root size	
LGG	cis	1	rs2707854	chr7:66212597	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.22E-6	Aortic root size	
LGG	cis	1	rs2707854	chr7:66212597	TYW1	chr7:66461817-66704496:+	0.18	3.76	0.00019	Aortic root size	
LGG	cis	1	rs2707856	chr7:66211010	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.23E-6	Aortic root size	
LGG	cis	1	rs2707856	chr7:66211010	TYW1	chr7:66461817-66704496:+	0.18	3.76	0.000193	Aortic root size	
LGG	cis	1	rs2710331	chr3:52837855	ITIH4	chr3:52847007-52866554:-	0.25	6.5	1.96E-10	Bipolar disorder	
LGG	cis	1	rs2710331	chr3:52837855	TMEM110	chr3:52867139-52931547:-	0.16	3.63	0.000319	Bipolar disorder	
LGG	cis	1	rs2714470	chr2:37486527	CEBPZ	chr2:37428778-37458740:-	-0.18	-4.73	2.92E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs2715131	chr7:50749079	FIGNL1	chr7:50511834-50518088:-	0.17	3.71	0.000231	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs2715133	chr7:50749425	FIGNL1	chr7:50511834-50518088:-	0.18	3.87	0.000125	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs271621	chr19:18631332	LRRC25	chr19:18501955-18508421:-	-0.16	-5.74	1.64E-8	Breast cancer	
LGG	cis	1	rs271623	chr19:18628947	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.05E-8	Breast cancer	
LGG	cis	1	rs271624	chr19:18627953	LRRC25	chr19:18501955-18508421:-	-0.17	-5.75	1.6E-8	Breast cancer	
LGG	cis	1	rs2717562	chr8:143776668	C8orf55	chr8:143808621-143818350:+	0.16	3.46	0.000583	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2717562	chr8:143776668	LY6K	chr8:143781529-143785582:+	0.35	6.56	1.4E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2717562	chr8:143776668	PSCA	chr8:143761875-143764142:+	0.33	5.82	1.09E-8	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2729780	chr15:63404639	LACTB	chr15:63414032-63434254:+	0.2	4.18	3.52E-5	HDL cholesterol	
LGG	cis	1	rs2729781	chr15:63404265	LACTB	chr15:63414032-63434254:+	0.2	4.09	5.07E-5	HDL cholesterol	
LGG	cis	1	rs2729782	chr15:63403354	LACTB	chr15:63414032-63434254:+	0.2	4.13	4.32E-5	HDL cholesterol	
LGG	cis	1	rs2729783	chr15:63403316	LACTB	chr15:63414032-63434254:+	0.18	3.69	0.000248	HDL cholesterol	
LGG	cis	1	rs2729784	chr15:63402735	LACTB	chr15:63414032-63434254:+	0.2	4.09	5.07E-5	HDL cholesterol	
LGG	cis	1	rs2729785	chr15:63402574	LACTB	chr15:63414032-63434254:+	0.2	4.09	5.07E-5	HDL cholesterol	
LGG	cis	1	rs2729788	chr15:63400378	LACTB	chr15:63414032-63434254:+	0.2	4.18	3.51E-5	HDL cholesterol	
LGG	cis	1	rs2729830	chr15:63395812	LACTB	chr15:63414032-63434254:+	0.22	4.56	6.51E-6	HDL cholesterol	
LGG	cis	1	rs2729833	chr15:63397044	LACTB	chr15:63414032-63434254:+	0.21	4.39	1.37E-5	HDL cholesterol	
LGG	cis	1	rs2731006	chr12:43160825	PPHLN1	chr12:42632249-42853517:+	0.24	3.51	0.000485	Panic disorder	
LGG	cis	1	rs2731073	chr12:48919556	VDR	chr12:48235322-48298814:-	-0.24	-3.62	0.00032	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2731434	chr12:51109875	ATF1	chr12:51157819-51214906:+	-0.21	-4.38	1.45E-5	Fibrinogen	
LGG	cis	1	rs2731434	chr12:51109875	LETMD1	chr12:51442084-51454206:+	0.16	4.01	6.95E-5	Fibrinogen	
LGG	cis	1	rs2731434	chr12:51109875	SLC11A2	chr12:51373319-51422058:-	0.17	3.8	0.000164	Fibrinogen	
LGG	cis	1	rs2731439	chr12:51060350	ATF1	chr12:51157819-51214906:+	-0.2	-4.3	2.07E-5	Fibrinogen	
LGG	cis	1	rs2731439	chr12:51060350	LETMD1	chr12:51442084-51454206:+	0.16	3.93	9.78E-5	Fibrinogen	
LGG	cis	1	rs2731439	chr12:51060350	SLC11A2	chr12:51373319-51422058:-	0.17	3.76	0.000191	Fibrinogen	
LGG	cis	1	rs2731440	chr12:51057627	ATF1	chr12:51157819-51214906:+	-0.2	-4.32	1.85E-5	Fibrinogen	
LGG	cis	1	rs2731440	chr12:51057627	LETMD1	chr12:51442084-51454206:+	0.16	3.85	0.000131	Fibrinogen	
LGG	cis	1	rs2731440	chr12:51057627	SLC11A2	chr12:51373319-51422058:-	0.17	3.72	0.000219	Fibrinogen	
LGG	cis	1	rs2731442	chr12:51054655	ATF1	chr12:51157819-51214906:+	-0.2	-4.3	2.03E-5	Fibrinogen	
LGG	cis	1	rs2731442	chr12:51054655	LETMD1	chr12:51442084-51454206:+	0.15	3.84	0.000141	Fibrinogen	
LGG	cis	1	rs2731442	chr12:51054655	SLC11A2	chr12:51373319-51422058:-	0.17	3.72	0.000218	Fibrinogen	
LGG	cis	1	rs2731443	chr12:51094138	ATF1	chr12:51157819-51214906:+	-0.21	-4.37	1.54E-5	Fibrinogen	
LGG	cis	1	rs2731443	chr12:51094138	LETMD1	chr12:51442084-51454206:+	0.16	3.86	0.000128	Fibrinogen	
LGG	cis	1	rs2731443	chr12:51094138	SLC11A2	chr12:51373319-51422058:-	0.17	3.7	0.00024	Fibrinogen	
LGG	cis	1	rs2734839	chr11:113286490	TTC12	chr11:113185251-113244016:+	-0.32	-9.7	1.77E-20	Information processing speed	
LGG	cis	1	rs2736345	chr8:11352485	FAM66A	chr8:12219528-12279968:+	0.23	4.1	4.78E-5	Systemic lupus erythematosus	
LGG	cis	1	rs2736371	chr8:11105529	C8orf12	chr8:11225911-11296166:+	0.15	4.05	5.93E-5	Retinal vascular caliber	
LGG	cis	1	rs2736552	chr11:5385545	FAM160A2	chr11:6232565-6255941:-	0.2	4	7.44E-5	Fetal hemoglobin levels	
LGG	cis	1	rs2739053	chr8:133922871	TG	chr8:133879205-134147141:+	-0.21	-3.84	0.000141	Vitiligo	
LGG	cis	1	rs2739054	chr8:133926921	TG	chr8:133879205-134147141:+	-0.22	-3.86	0.000126	Vitiligo	
LGG	cis	1	rs2739330	chr22:24295286	DDT	chr22:24237099-24322019:-	0.58	15.64	5.12E-45	Liver enzyme levels (gamma-glutamyl transferase)	
LGG	cis	1	rs2739330	chr22:24295286	DDTL	chr22:24309026-24314747:+	0.39	8.92	9.13E-18	Liver enzyme levels (gamma-glutamyl transferase)	
LGG	cis	1	rs2739330	chr22:24295286	GSTT1	chr22:24376141-24384284:-	0.83	18.29	2.32E-57	Liver enzyme levels (gamma-glutamyl transferase)	
LGG	cis	1	rs2739330	chr22:24295286	GSTT2	chr22:24322314-24326104:+;chr22	-0.98	-23.86	4.2E-84	Liver enzyme levels (gamma-glutamyl transferase)	
LGG	cis	1	rs2739330	chr22:24295286	LOC391322	chr22:24373117-24374043:+	0.78	18.83	6.4E-60	Liver enzyme levels (gamma-glutamyl transferase)	
LGG	cis	1	rs2740544	chr13:50617640	EBPL	chr13:50234811-50265623:-	-0.16	-3.5	0.000499	Height	
LGG	cis	1	rs2741852	chr1:202404277	UBE2T	chr1:202300786-202311094:-	-0.13	-3.84	0.000139	Sex ratio	
LGG	cis	1	rs27421	chr5:130743771	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.62	5.0E-6	Life satisfaction	
LGG	cis	1	rs2742234	chr10:43612609	CSGALNACT2	chr10:43633934-43680747:+	0.33	8.15	3.0E-15	Hirschsprung disease	
LGG	cis	1	rs2744800	chr1:41156009	LOC100130557	chr1:41154752-41157933:-	0.25	3.53	0.000459	Depressive and manic episodes in bipolar disorder	
LGG	cis	1	rs2744947	chr6:34657809	C6orf106	chr6:34555066-34664625:-	0.29	5.64	2.92E-8	Pubertal anthropometrics	
LGG	cis	1	rs2744954	chr6:34621470	C6orf106	chr6:34555066-34664625:-	0.29	5.61	3.34E-8	Pubertal anthropometrics	
LGG	cis	1	rs2744955	chr6:34618958	C6orf106	chr6:34555066-34664625:-	0.29	5.64	2.92E-8	Pubertal anthropometrics	
LGG	cis	1	rs2744956	chr6:34618937	C6orf106	chr6:34555066-34664625:-	0.28	5.49	6.29E-8	Pubertal anthropometrics	
LGG	cis	1	rs2744972	chr6:34659054	C6orf106	chr6:34555066-34664625:-	0.28	5.5	6.26E-8	Pubertal anthropometrics	
LGG	cis	1	rs2747725	chr6:126012397	HEY2	chr6:126068780-126082414:+	0.18	4.01	6.89E-5	Endometrial cancer	
LGG	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.43	-10.34	8.34E-23	Ankylosing spondylitis	
LGG	cis	1	rs27529	chr5:96126308	ERAP2	chr5:96211644-96255398:+	0.33	5.81	1.11E-8	Ankylosing spondylitis	
LGG	cis	1	rs27663	chr5:130741438	SLC22A5	chr5:131705401-131731302:+	-0.25	-4.47	9.8E-6	Life satisfaction	
LGG	cis	1	rs2766690	chr14:100682154	CCDC85C	chr14:99977604-100070727:-	0.15	3.51	0.000486	Electroencephalographic traits in alcoholism	
LGG	cis	1	rs2766692	chr14:100684192	CCDC85C	chr14:99977604-100070727:-	-0.16	-3.76	0.000192	Electroencephalographic traits in alcoholism	
LGG	cis	1	rs27708	chr5:130743541	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.63	4.68E-6	Life satisfaction	
LGG	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.45	10.79	1.7E-24	Ankylosing spondylitis	
LGG	cis	1	rs27710	chr5:96126197	ERAP2	chr5:96211644-96255398:+	-0.32	-5.65	2.74E-8	Ankylosing spondylitis	
LGG	cis	1	rs2779116	chr1:158585415	KIRREL	chr1:157963063-158065842:+	-0.12	-3.62	0.00032	Other erythrocyte phenotypes	
LGG	cis	1	rs2780885	chr1:65331372	JAK1	chr1:65298906-65432619:-	-0.33	-7.06	5.53E-12	Diabetic kidney disease	
LGG	cis	1	rs2780885	chr1:65331372	RAVER2	chr1:65210778-65298912:+	-0.2	-4.4	1.33E-5	Diabetic kidney disease	
LGG	cis	1	rs2780902	chr1:65329100	JAK1	chr1:65298906-65432619:-	0.35	7.45	4.23E-13	Diabetic kidney disease	
LGG	cis	1	rs2780902	chr1:65329100	RAVER2	chr1:65210778-65298912:+	0.21	4.74	2.85E-6	Diabetic kidney disease	
LGG	cis	1	rs27873	chr5:130731151	SLC22A5	chr5:131705401-131731302:+	-0.22	-3.89	0.000116	Life satisfaction	
LGG	cis	1	rs2789679	chr10:81907884	ANXA11	chr10:81914880-81965433:-	0.15	5.21	2.75E-7	Sarcoidosis	
LGG	cis	1	rs2789679	chr10:81907884	PLAC9	chr10:81892258-81904784:+	0.24	6.31	6.18E-10	Sarcoidosis	
LGG	cis	1	rs2791603	chr3:195142939	ACAP2	chr3:194995475-195163817:-	0.36	8.36	6.51E-16	Body mass index	
LGG	cis	1	rs2792735	chr10:113921825	ZDHHC6	chr10:114190060-114207306:-	0.25	4.75	2.65E-6	HDL cholesterol	
LGG	cis	1	rs2792736	chr10:113921159	ZDHHC6	chr10:114190060-114207306:-	0.25	4.83	1.82E-6	HDL cholesterol	
LGG	cis	1	rs2799077	chr6:28234597	ZNF165	chr6:28046572-28057338:+	-0.32	-4.71	3.24E-6	Depression	
LGG	cis	1	rs2799077	chr6:28234597	ZNF187	chr6:28234788-28245978:+	-0.27	-4.54	7.07E-6	Depression	
LGG	cis	1	rs2799077	chr6:28234597	ZNF389	chr6:28129551-28137375:+	0.43	6.89	1.71E-11	Depression	
LGG	cis	1	rs2799077	chr6:28234597	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.69	3.49E-6	Depression	
LGG	cis	1	rs2799077	chr6:28234597	ZSCAN23	chr6:28393287-28411279:-	0.18	4.28	2.23E-5	Depression	
LGG	cis	1	rs2799079	chr6:28235176	ZNF165	chr6:28046572-28057338:+	-0.32	-4.72	3.08E-6	Depression	
LGG	cis	1	rs2799079	chr6:28235176	ZNF187	chr6:28234788-28245978:+	-0.27	-4.75	2.65E-6	Depression	
LGG	cis	1	rs2799079	chr6:28235176	ZNF389	chr6:28129551-28137375:+	0.4	6.5	1.96E-10	Depression	
LGG	cis	1	rs2799079	chr6:28235176	ZSCAN12	chr6:28346770-28367544:-	-0.32	-4.55	6.67E-6	Depression	
LGG	cis	1	rs2799079	chr6:28235176	ZSCAN23	chr6:28393287-28411279:-	0.19	4.39	1.41E-5	Depression	
LGG	cis	1	rs2802727	chr1:243483326	SDCCAG8	chr1:243419320-243663392:+	0.27	4.43	1.14E-5	Obesity (early onset extreme)	
LGG	cis	1	rs2803608	chr10:113916302	ZDHHC6	chr10:114190060-114207306:-	0.24	4.63	4.74E-6	HDL cholesterol	
LGG	cis	1	rs2805591	chr10:98812283	FRAT2	chr10:99092254-99094458:-	0.24	3.61	0.000338	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs280603	chr4:129915063	C4orf33	chr4:130014829-130033842:+	-0.59	-9.83	5.99E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.59	-9.93	2.61E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs2811381	chr3:127997912	EEFSEC	chr3:127872313-128127488:+	0.23	4.07	5.37E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811387	chr3:128015178	EEFSEC	chr3:127872313-128127488:+	0.21	3.97	8.18E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811390	chr3:128021481	EEFSEC	chr3:127872313-128127488:+	0.21	3.94	9.25E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811390	chr3:128021481	LOC90246	chr3:128226678-128229427:+	0.28	3.56	0.000402	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811391	chr3:128022368	EEFSEC	chr3:127872313-128127488:+	0.21	3.94	9.25E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811391	chr3:128022368	LOC90246	chr3:128226678-128229427:+	0.28	3.56	0.000402	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811392	chr3:128023976	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000183	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811392	chr3:128023976	LOC90246	chr3:128226678-128229427:+	0.29	3.59	0.000365	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811393	chr3:128023999	EEFSEC	chr3:127872313-128127488:+	0.21	3.91	0.000103	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811393	chr3:128023999	LOC90246	chr3:128226678-128229427:+	0.29	3.73	0.000211	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811396	chr3:127987356	EEFSEC	chr3:127872313-128127488:+	0.2	3.79	0.000172	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811397	chr3:128027237	EEFSEC	chr3:127872313-128127488:+	0.21	3.94	9.25E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811397	chr3:128027237	LOC90246	chr3:128226678-128229427:+	0.28	3.56	0.000402	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811414	chr3:127991177	EEFSEC	chr3:127872313-128127488:+	0.2	3.55	0.00042	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811416	chr3:127991938	EEFSEC	chr3:127872313-128127488:+	0.27	4.78	2.36E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811511	chr3:127912988	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.97	8.21E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811518	chr3:128013645	EEFSEC	chr3:127872313-128127488:+	0.2	3.72	0.00022	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811518	chr3:128013645	LOC90246	chr3:128226678-128229427:+	0.28	3.63	0.00031	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811519	chr3:128012876	EEFSEC	chr3:127872313-128127488:+	0.2	3.72	0.00022	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811519	chr3:128012876	LOC90246	chr3:128226678-128229427:+	0.28	3.63	0.00031	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811522	chr3:128011423	EEFSEC	chr3:127872313-128127488:+	0.21	3.92	0.000102	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811522	chr3:128011423	LOC90246	chr3:128226678-128229427:+	0.29	3.71	0.000227	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811523	chr3:128011397	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.91	0.000107	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811523	chr3:128011397	LOC90246	chr3:128226678-128229427:+	-0.29	-3.72	0.000226	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811525	chr3:127999430	EEFSEC	chr3:127872313-128127488:+	0.23	4.35	1.67E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811526	chr3:127995718	EEFSEC	chr3:127872313-128127488:+	0.23	4.24	2.65E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811526	chr3:127995718	LOC90246	chr3:128226678-128229427:+	0.28	3.48	0.000544	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811527	chr3:127994604	EEFSEC	chr3:127872313-128127488:+	0.23	4.28	2.24E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811528	chr3:127994436	EEFSEC	chr3:127872313-128127488:+	0.23	4.07	5.37E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811530	chr3:127993166	EEFSEC	chr3:127872313-128127488:+	0.22	4.05	5.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811533	chr3:127991729	EEFSEC	chr3:127872313-128127488:+	0.22	4.04	6.17E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811533	chr3:127991729	LOC90246	chr3:128226678-128229427:+	0.29	3.58	0.000372	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811534	chr3:127991108	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811534	chr3:127991108	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811536	chr3:127988919	EEFSEC	chr3:127872313-128127488:+	0.21	3.76	0.000193	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811537	chr3:127987924	EEFSEC	chr3:127872313-128127488:+	-0.2	-3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811537	chr3:127987924	LOC90246	chr3:128226678-128229427:+	-0.28	-3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811539	chr3:127986473	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.07	5.5E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811539	chr3:127986473	LOC90246	chr3:128226678-128229427:+	-0.29	-3.7	0.000243	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811541	chr3:127984794	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811541	chr3:127984794	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811542	chr3:127983800	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811542	chr3:127983800	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811543	chr3:127983796	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811543	chr3:127983796	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811544	chr3:127983495	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811544	chr3:127983495	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811545	chr3:127983148	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811545	chr3:127983148	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2811549	chr3:127938708	EEFSEC	chr3:127872313-128127488:+	0.2	3.71	0.000232	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2812222	chr13:50714998	EBPL	chr13:50234811-50265623:-	-0.16	-3.45	0.000601	Height	
LGG	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs2814993	chr6:34618893	C6orf106	chr6:34555066-34664625:-	-0.28	-5.55	4.8E-8	Pubertal anthropometrics	
LGG	cis	1	rs2814994	chr6:34620153	C6orf106	chr6:34555066-34664625:-	0.28	5.47	7.18E-8	Pubertal anthropometrics	
LGG	cis	1	rs2814996	chr6:34621314	C6orf106	chr6:34555066-34664625:-	0.29	5.61	3.34E-8	Pubertal anthropometrics	
LGG	cis	1	rs2815005	chr6:34638847	C6orf106	chr6:34555066-34664625:-	0.29	5.64	2.92E-8	Pubertal anthropometrics	
LGG	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.1E-25	Response to antipsychotic treatment	
LGG	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs2820292	chr1:201784287	LMOD1	chr1:201865585-201915716:-	-0.21	-4.51	8.15E-6	Body mass index	
LGG	cis	1	rs2820292	chr1:201784287	SHISA4	chr1:201858032-201861426:+	-0.28	-7.1	4.31E-12	Body mass index	
LGG	cis	1	rs282802	chr15:80072820	MTHFS	chr15:80137320-80189370:-	0.18	3.54	0.00044	Disease-free survival in breast cancer	
LGG	cis	1	rs282804	chr15:80071108	MTHFS	chr15:80137320-80189370:-	-0.18	-3.5	0.000501	Disease-free survival in breast cancer	
LGG	cis	1	rs2832183	chr21:30482150	RWDD2B	chr21:30378082-30391685:-	0.23	3.98	7.99E-5	Dental caries	
LGG	cis	1	rs2832184	chr21:30483265	RWDD2B	chr21:30378082-30391685:-	0.22	3.88	0.000118	Dental caries	
LGG	cis	1	rs2832185	chr21:30483761	RWDD2B	chr21:30378082-30391685:-	0.22	3.74	0.000207	Dental caries	
LGG	cis	1	rs2832189	chr21:30487414	RWDD2B	chr21:30378082-30391685:-	0.22	3.82	0.000149	Dental caries	
LGG	cis	1	rs2832190	chr21:30488226	RWDD2B	chr21:30378082-30391685:-	0.22	3.82	0.000149	Dental caries	
LGG	cis	1	rs2832191	chr21:30489300	RWDD2B	chr21:30378082-30391685:-	0.23	3.96	8.45E-5	Dental caries	
LGG	cis	1	rs2833888	chr21:33927560	TCP10L	chr21:33947152-33957845:-	-0.35	-6.35	5.03E-10	Gastritis	
LGG	cis	1	rs2833889	chr21:33927768	TCP10L	chr21:33947152-33957845:-	0.34	6.15	1.56E-9	Gastritis	
LGG	cis	1	rs2833890	chr21:33927886	TCP10L	chr21:33947152-33957845:-	0.34	6.34	5.19E-10	Gastritis	
LGG	cis	1	rs2834288	chr21:35264397	ATP5O	chr21:35275758-35288158:-	-0.15	-4.29	2.13E-5	Gut microbiota (bacterial taxa)	
LGG	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.46	-12.19	4.75E-30	Eye color traits	
LGG	cis	1	rs2835607	chr21:38491973	TTC3	chr21:38445571-38575406:+	0.12	3.99	7.64E-5	Eye color traits	
LGG	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.46	-12.19	4.75E-30	Eye color traits	
LGG	cis	1	rs2835608	chr21:38493455	TTC3	chr21:38445571-38575406:+	0.12	3.99	7.64E-5	Eye color traits	
LGG	cis	1	rs28360523	chr6:52877181	ICK	chr6:52866098-52926600:-	-0.22	-3.9	0.000109	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs28360546	chr6:163210973	PACRG	chr6:163148164-163736523:+	0.4	5.42	9.28E-8	Body mass index	
LGG	cis	1	rs28362672	chr2:70056866	SNRNP27	chr2:70121090-70132348:+	-0.18	-3.48	0.000553	Colorectal or endometrial cancer	
LGG	cis	1	rs28365850	chr14:35591316	KIAA0391	chr14:35591776-35786673:+	0.23	3.64	0.000307	Atopic dermatitis	
LGG	cis	1	rs28367503	chr16:67854534	LRRC36	chr16:67360747-67419108:+	0.49	4.52	7.87E-6	Crohn's disease	
LGG	cis	1	rs28367503	chr16:67854534	RANBP10	chr16:67757006-67840555:-	-0.31	-3.6	0.000355	Crohn's disease	
LGG	cis	1	rs2836950	chr21:40604429	HMGN1	chr21:40714247-40721270:-	0.16	4.03	6.54E-5	Menarche (age at onset)	
LGG	cis	1	rs2836950	chr21:40604429	WRB	chr21:40752213-40769814:+	-0.19	-3.76	0.00019	Menarche (age at onset)	
LGG	cis	1	rs28372828	chr1:156253031	BGLAP	chr1:156182784-156213112:+	0.26	5.34	1.43E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs28372828	chr1:156253031	CCT3	chr1:156278752-156308195:-	-0.16	-3.92	0.000101	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs28374715	chr15:41563950	NDUFAF1	chr15:41679553-41694642:-	-0.19	-3.54	0.000433	Ulcerative colitis	
LGG	cis	1	rs28374715	chr15:41563950	RPAP1	chr15:41809377-41836464:-	-0.24	-4.21	3.02E-5	Ulcerative colitis	
LGG	cis	1	rs28374891	chr4:120183550	MYOZ2	chr4:120056939-120108935:+	0.23	4.48	9.46E-6	Corneal astigmatism	
LGG	cis	1	rs2838009	chr21:42694284	FAM3B	chr21:42676177-42729654:+	-0.44	-8.19	2.31E-15	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LGG	cis	1	rs28380602	chr15:24778146	PWRN1	chr15:24778839-24832924:+	0.21	4.49	8.82E-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs2838517	chr21:45613825	PWP2	chr21:45527208-45551062:+	0.22	4.12	4.51E-5	Inflammatory bowel disease	
LGG	cis	1	rs28391259	chr4:107014012	NPNT	chr4:106816605-106892827:+	-0.22	-4.7	3.42E-6	Airflow obstruction	
LGG	cis	1	rs2839181	chr21:47685939	C21orf56	chr21:47581063-47604373:-	-0.26	-5.67	2.46E-8	Testicular germ cell tumor	
LGG	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.23	-5.5	6.01E-8	Testicular germ cell tumor	
LGG	cis	1	rs2839181	chr21:47685939	FTCD	chr21:47556177-47575481:-	-0.18	-4.09	5.13E-5	Testicular germ cell tumor	
LGG	cis	1	rs2839186	chr21:47690068	C21orf56	chr21:47581063-47604373:-	-0.21	-4.52	7.82E-6	Testicular germ cell tumor	
LGG	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.24	-5.8	1.21E-8	Testicular germ cell tumor	
LGG	cis	1	rs2839337	chr21:47987167	C21orf56	chr21:47581063-47604373:-	0.18	3.58	0.000375	Lymphocyte counts	
LGG	cis	1	rs2839434	chr21:43418905	C21orf121	chr21:43442113-43445060:+	0.26	4.24	2.69E-5	Hand grip strength	
LGG	cis	1	rs2839465	chr21:43511232	C21orf128	chr21:43522244-43528644:-	0.52	10.37	6.3E-23	IgG glycosylation	
LGG	cis	1	rs2839466	chr21:43512324	C21orf128	chr21:43522244-43528644:-	-0.5	-10.15	4.13E-22	IgG glycosylation	
LGG	cis	1	rs2839467	chr21:43513200	C21orf128	chr21:43522244-43528644:-	-0.55	-10.86	9.43E-25	IgG glycosylation	
LGG	cis	1	rs2839618	chr21:44433454	NDUFV3	chr21:44313378-44329772:+	0.3	4.67	3.95E-6	Information processing speed	
LGG	cis	1	rs2839627	chr21:44448718	NDUFV3	chr21:44313378-44329772:+	-0.26	-3.99	7.54E-5	Information processing speed	
LGG	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs28409322	chr3:134252385	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs28416696	chr2:54484326	C2orf73	chr2:54558071-54588714:+	0.33	4.86	1.62E-6	Telomere length	
LGG	cis	1	rs28416696	chr2:54484326	TSPYL6	chr2:54480315-54483409:-	-0.47	-5.67	2.43E-8	Telomere length	
LGG	cis	1	rs28419773	chr4:120211061	MYOZ2	chr4:120056939-120108935:+	0.22	4.19	3.33E-5	Corneal astigmatism	
LGG	cis	1	rs28427293	chr9:26785289	LRRC19	chr9:26993143-27005691:-	-0.24	-4.12	4.37E-5	Smoking behavior	
LGG	cis	1	rs2842992	chr6:160071159	MRPL18	chr6:160211022-160219460:+	-0.19	-3.46	0.00058	Age-related macular degeneration (GA)	
LGG	cis	1	rs2843409	chr1:202359976	UBE2T	chr1:202300786-202311094:-	0.13	3.85	0.000134	Sex ratio	
LGG	cis	1	rs28434757	chr22:18451554	PEX26	chr22:18560686-18572206:+	-0.14	-3.52	0.000477	Presence of antiphospholipid antibodies	
LGG	cis	1	rs28436199	chr17:18751730	FAM18B	chr17:18684582-18710026:+	-0.17	-4.47	9.53E-6	Educational attainment (years of education)	
LGG	cis	1	rs28436199	chr17:18751730	FBXW10	chr17:18647326-18682661:+	-0.2	-4.53	7.28E-6	Educational attainment (years of education)	
LGG	cis	1	rs28437878	chr15:78807872	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.5	2.02E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs28448438	chr4:56416665	TMEM165	chr4:56262090-56292342:+	0.17	4.85	1.68E-6	Personality dimensions	
LGG	cis	1	rs28456975	chr15:24824729	PWRN1	chr15:24778839-24832924:+	0.25	4.42	1.22E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs28458334	chr6:160753363	SLC22A3	chr6:160769425-160876013:+	0.34	5.92	5.92E-9	Waist circumference	
LGG	cis	1	rs2845857	chr11:71715215	FAM86C	chr11:71498557-71512276:+	0.51	5.09	5.1E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs28463311	chr17:61919643	DDX42	chr17:61851567-61896676:+	-0.16	-3.72	0.000219	Body mass index	
LGG	cis	1	rs28463311	chr17:61919643	FTSJ3	chr17:61896795-61905031:-	0.41	8.24	1.6E-15	Body mass index	
LGG	cis	1	rs28463311	chr17:61919643	SMARCD2	chr17:61909441-61920351:-	0.18	4.05	6.04E-5	Body mass index	
LGG	cis	1	rs28463765	chr4:56412434	TMEM165	chr4:56262090-56292342:+	0.17	4.98	9.01E-7	Personality dimensions	
LGG	cis	1	rs28469723	chr20:33700717	PROCR	chr20:33758727-33765164:+	-0.36	-6.54	1.57E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs28477407	chr14:55344901	GCH1	chr14:55308724-55369542:-	-0.3	-5.05	6.3E-7	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs28480159	chr4:17685707	LAP3	chr4:17578927-17609590:+	-0.13	-3.64	0.000306	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28480159	chr4:17685707	MED28	chr4:17616273-17629791:+	0.16	3.5	0.000514	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28485881	chr17:80690014	FN3KRP	chr17:80674582-80685889:+	-0.34	-6.87	1.94E-11	Glycated hemoglobin levels	
LGG	cis	1	rs28494067	chr15:50908272	SPPL2A	chr15:50999739-51057910:-	0.12	3.95	8.79E-5	QT interval	
LGG	cis	1	rs28497813	chr4:17685503	LAP3	chr4:17578927-17609590:+	-0.13	-3.64	0.000306	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28497813	chr4:17685503	MED28	chr4:17616273-17629791:+	0.16	3.5	0.000514	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28501187	chr4:17643620	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28501387	chr14:81772667	STON2	chr14:81727000-81893748:-	-0.14	-3.61	0.000332	Obesity-related traits	
LGG	cis	1	rs28502530	chr14:65850968	LOC645431	chr14:65877313-65879335:-	-0.4	-5.8	1.21E-8	Ischemic stroke	
LGG	cis	1	rs28504107	chr11:71832519	FAM86C	chr11:71498557-71512276:+	-0.47	-4.62	4.96E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs28512382	chr10:1092195	C10orf110	chr10:1068577-1090141:+	0.29	5.37	1.21E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs28514423	chr4:56429239	TMEM165	chr4:56262090-56292342:+	0.17	5.14	3.93E-7	Personality dimensions	
LGG	cis	1	rs28517362	chr6:151876387	C6orf97	chr6:151815175-151942327:+	0.26	4.21	3.06E-5	Bone mineral density (spine)	
LGG	cis	1	rs28522614	chr10:102323141	HIF1AN	chr10:102295641-102313680:+	0.2	3.65	0.000291	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs28522614	chr10:102323141	NDUFB8	chr10:102283497-102289636:-	0.16	4.31	1.96E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs28522614	chr10:102323141	WNT8B	chr10:102222812-102243397:+	0.48	7.4	6.15E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs2852634	chr1:158585355	KIRREL	chr1:157963063-158065842:+	-0.12	-3.66	0.000279	Other erythrocyte phenotypes	
LGG	cis	1	rs2852635	chr1:158586277	KIRREL	chr1:157963063-158065842:+	-0.12	-3.66	0.000279	Other erythrocyte phenotypes	
LGG	cis	1	rs2853579	chr9:107591272	LOC286367	chr9:107536633-107540044:+	0.16	3.68	0.000263	Myopia (pathological)	
LGG	cis	1	rs28539246	chr17:29226630	SUZ12P	chr17:29035714-29097067:+	-0.24	-6.67	6.78E-11	Height	
LGG	cis	1	rs28540190	chr19:49135043	SEC1	chr19:49141296-49185501:+	-0.69	-8.32	8.59E-16	Elevated serum carcinoembryonic antigen levels	
LGG	cis	1	rs2854218	chr17:61942940	DDX42	chr17:61851567-61896676:+	-0.16	-3.46	0.000583	Body mass index	
LGG	cis	1	rs2854218	chr17:61942940	FTSJ3	chr17:61896795-61905031:-	0.42	8.37	6.07E-16	Body mass index	
LGG	cis	1	rs2854218	chr17:61942940	SMARCD2	chr17:61909441-61920351:-	0.19	4.16	3.81E-5	Body mass index	
LGG	cis	1	rs2854219	chr17:61942682	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000273	Body mass index	
LGG	cis	1	rs2854219	chr17:61942682	FTSJ3	chr17:61896795-61905031:-	0.4	8.22	1.89E-15	Body mass index	
LGG	cis	1	rs2854219	chr17:61942682	SMARCD2	chr17:61909441-61920351:-	0.18	3.95	9.12E-5	Body mass index	
LGG	cis	1	rs2854223	chr17:61939014	FTSJ3	chr17:61896795-61905031:-	0.42	8.76	3.17E-17	Body mass index	
LGG	cis	1	rs2854223	chr17:61939014	SMARCD2	chr17:61909441-61920351:-	0.2	4.61	5.19E-6	Body mass index	
LGG	cis	1	rs28542689	chr8:10813054	RP1L1	chr8:10463862-10512617:-	-0.29	-3.71	0.000234	Asthma and hay fever	
LGG	cis	1	rs28545485	chr4:17645376	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2855036	chr11:5272682	HBG2	chr11:5269502-5667011:-	0.3	5	8.09E-7	Hemoglobin levels	
LGG	cis	1	rs2855039	chr11:5271671	HBG2	chr11:5269502-5667011:-	0.29	4.82	1.96E-6	Hemoglobin levels	
LGG	cis	1	rs2855121	chr11:5277291	HBG2	chr11:5269502-5667011:-	0.29	4.82	1.92E-6	Hemoglobin levels	
LGG	cis	1	rs28552744	chr4:17620165	MED28	chr4:17616273-17629791:+	0.2	4.24	2.64E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28558133	chr6:26531433	BTN2A3	chr6:26422317-26431927:+	0.12	3.54	0.000443	Educational attainment	
LGG	cis	1	rs28558133	chr6:26531433	HMGN4	chr6:26538572-26547162:+	-0.19	-4.96	9.67E-7	Educational attainment	
LGG	cis	1	rs28558726	chr17:53058676	STXBP4	chr17:53046126-53241449:+	-0.16	-3.69	0.000249	Breast cancer	
LGG	cis	1	rs28558726	chr17:53058676	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	1.0E-7	Breast cancer	
LGG	cis	1	rs28562777	chr19:32900819	DPY19L3	chr19:32896677-32975236:+	0.13	3.51	0.000481	Bipolar disorder	
LGG	cis	1	rs28564902	chr4:56479491	SRD5A3	chr4:56212409-56237866:+	-0.17	-3.66	0.000276	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs28567450	chr6:34747409	C6orf106	chr6:34555066-34664625:-	0.25	4.98	8.72E-7	Pubertal anthropometrics	
LGG	cis	1	rs2856	chr20:25433536	ABHD12	chr20:25275380-25371477:-	0.27	7.32	9.94E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2856	chr20:25433536	FAM182A	chr20:26035250-26067552:+	-0.55	-10.82	1.27E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs2856	chr20:25433536	FAM182B	chr20:25744102-25848786:-	0.21	4.72	3.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs28572116	chr4:56424344	TMEM165	chr4:56262090-56292342:+	0.17	4.92	1.16E-6	Personality dimensions	
LGG	cis	1	rs28572537	chr19:18552208	LRRC25	chr19:18501955-18508421:-	-0.16	-5.48	6.74E-8	Breast cancer	
LGG	cis	1	rs28572537	chr19:18552208	SSBP4	chr19:18530221-18545371:+	-0.12	-3.57	0.000394	Breast cancer	
LGG	cis	1	rs2857891	chr11:6962957	ZNF215	chr11:6947654-7005861:+	-0.22	-4.36	1.57E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs28582059	chr4:56408404	TMEM165	chr4:56262090-56292342:+	0.17	5.18	3.32E-7	Personality dimensions	
LGG	cis	1	rs2859817	chr2:166909832	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs2859817	chr2:166909832	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs28599680	chr16:29860685	LOC440356	chr16:29875004-29879374:+	-0.25	-4.09	4.95E-5	Multiple sclerosis	
LGG	cis	1	rs2859998	chr8:59324162	UBXN2B	chr8:59323823-59364059:+	-0.21	-5.49	6.61E-8	Narcolepsy with cataplexy	
LGG	cis	1	rs28602663	chr1:76235355	MSH4	chr1:76262630-76378923:+	0.25	4.44	1.11E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs28602670	chr15:78768167	CHRNA5	chr15:78857906-78886458:+	-0.28	-4.22	2.85E-5	Post bronchodilator FEV1	
LGG	cis	1	rs28625349	chr15:24832473	PWRN1	chr15:24778839-24832924:+	0.25	4.4	1.36E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs28626045	chr14:75589195	ACYP1	chr14:75519930-75530736:-	-0.14	-3.85	0.000136	Height	
LGG	cis	1	rs28626045	chr14:75589195	EIF2B2	chr14:75469612-75476292:+	0.18	3.51	0.000493	Height	
LGG	cis	1	rs28627084	chr15:74023638	CLK3	chr15:74890843-74922541:+	0.22	3.6	0.000348	Bipolar disorder	
LGG	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.52	11.16	6.18E-26	Forced vital capacity	
LGG	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.51	11.08	1.29E-25	Forced vital capacity	
LGG	cis	1	rs2862985	chr10:102062809	BLOC1S2	chr10:102033713-102046439:-	-0.3	-4.22	2.9E-5	Obesity-related traits	
LGG	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.52	-11.32	1.44E-26	Forced vital capacity	
LGG	cis	1	rs28660389	chr1:150019327	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs28664971	chr17:28437410	EFCAB5	chr17:28256874-28435469:+	0.23	6.16	1.51E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs28670674	chr4:56407103	TMEM165	chr4:56262090-56292342:+	0.18	5.06	5.9E-7	Personality dimensions	
LGG	cis	1	rs28672356	chr19:32907843	DPY19L3	chr19:32896677-32975236:+	0.14	3.68	0.000255	Bipolar disorder	
LGG	cis	1	rs28672356	chr19:32907843	ZNF507	chr19:32836514-32878571:+	0.14	3.71	0.000228	Bipolar disorder	
LGG	cis	1	rs28675843	chr3:128575353	RAB43	chr3:128806418-128880029:-	0.32	3.75	0.000197	Dental caries	
LGG	cis	1	rs2867898	chr20:37690952	DHX35	chr20:37591000-37668363:+	-0.19	-4.29	2.13E-5	Dialysis-related mortality	
LGG	cis	1	rs28693609	chr4:17645233	MED28	chr4:17616273-17629791:+	0.19	4.05	5.95E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28694035	chr3:128575365	RAB43	chr3:128806418-128880029:-	0.32	3.75	0.000197	Dental caries	
LGG	cis	1	rs2869548	chr15:78922638	CHRNA5	chr15:78857906-78886458:+	-0.62	-11.57	1.54E-27	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2869716	chr20:47779340	ARFGEF2	chr20:47538275-47653229:+	0.11	4.16	3.75E-5	Anger	
LGG	cis	1	rs2869716	chr20:47779340	CSE1L	chr20:47662838-47713484:+	0.2	5.35	1.38E-7	Anger	
LGG	cis	1	rs2870024	chr20:49538921	SNAI1	chr20:48599527-48605418:+	-0.27	-3.48	0.000542	Prostate cancer	
LGG	cis	1	rs2870025	chr20:49539058	SNAI1	chr20:48599527-48605418:+	-0.27	-3.48	0.000542	Prostate cancer	
LGG	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.76	14.03	7.94E-38	Diastolic blood pressure	
LGG	cis	1	rs28715816	chr15:24824508	PWRN1	chr15:24778839-24832924:+	0.25	4.43	1.18E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs28718130	chr15:50909489	SPPL2A	chr15:50999739-51057910:-	0.12	3.95	8.79E-5	QT interval	
LGG	cis	1	rs28729153	chr19:32907578	DPY19L3	chr19:32896677-32975236:+	0.13	3.51	0.000483	Bipolar disorder	
LGG	cis	1	rs28729153	chr19:32907578	ZNF507	chr19:32836514-32878571:+	0.14	3.79	0.00017	Bipolar disorder	
LGG	cis	1	rs2872958	chr4:17665032	LAP3	chr4:17578927-17609590:+	-0.13	-3.54	0.000435	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs2872958	chr4:17665032	MED28	chr4:17616273-17629791:+	0.17	3.58	0.000379	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.79	15.24	3.28E-43	Diastolic blood pressure	
LGG	cis	1	rs2874121	chr17:61731024	DDX42	chr17:61851567-61896676:+	-0.16	-3.7	0.000238	Body mass index	
LGG	cis	1	rs2874121	chr17:61731024	FTSJ3	chr17:61896795-61905031:-	0.41	8.37	6.04E-16	Body mass index	
LGG	cis	1	rs2874121	chr17:61731024	SMARCD2	chr17:61909441-61920351:-	0.18	4.15	3.97E-5	Body mass index	
LGG	cis	1	rs28753817	chr1:150018373	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs28755797	chr3:41774446	ULK4	chr3:41288091-42003660:-	0.7	12.56	1.41E-31	Diastolic blood pressure	
LGG	cis	1	rs28786136	chr15:24832114	PWRN1	chr15:24778839-24832924:+	0.25	4.36	1.59E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs2878677	chr1:12053264	MIIP	chr1:12079512-12092106:+	-0.09	-3.81	0.000156	Platelet count	
LGG	cis	1	rs2880329	chr17:41866168	VAT1	chr17:41166622-41174459:-	-0.19	-4.11	4.55E-5	Triglycerides	
LGG	cis	1	rs2880791	chr5:150267376	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs28817917	chr15:50965846	SPPL2A	chr15:50999739-51057910:-	0.13	4.1	4.83E-5	QT interval	
LGG	cis	1	rs2881863	chr2:48073815	FBXO11	chr2:48034061-48132814:-	0.23	4.14	4.01E-5	Schizophrenia	
LGG	cis	1	rs28824259	chr3:48425675	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs28824259	chr3:48425675	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs2882667	chr5:138314106	FAM53C	chr5:137673224-137685416:+	0.2	3.7	0.000242	Age-related hearing impairment (interaction)	
LGG	cis	1	rs2882667	chr5:138314106	SIL1	chr5:138282412-138534065:-	0.14	4.05	6.01E-5	Age-related hearing impairment (interaction)	
LGG	cis	1	rs28827279	chr11:118700763	PHLDB1	chr11:118477213-118528741:+	-0.22	-3.59	0.000364	Vitiligo	
LGG	cis	1	rs28854485	chr3:101628537	CEP97	chr3:101443494-101486181:+	0.12	3.62	0.000327	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs28854485	chr3:101628537	LOC285359	chr3:101431278-101432259:+	-0.25	-5.37	1.22E-7	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs2885510	chr3:48418226	ATRIP	chr3:48488141-48507708:+	-0.19	-4.84	1.75E-6	Longevity	
LGG	cis	1	rs2885510	chr3:48418226	TREX1	chr3:48501186-48509043:+	0.39	9.77	1.04E-20	Longevity	
LGG	cis	1	rs2885880	chr11:71655847	FAM86C	chr11:71498557-71512276:+	0.43	4.64	4.5E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.28	7.22	1.94E-12	Height	
LGG	cis	1	rs28897193	chr4:107005529	NPNT	chr4:106816605-106892827:+	-0.22	-4.81	2.02E-6	Airflow obstruction	
LGG	cis	1	rs2889873	chr20:33646841	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.87E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs2891490	chr2:26325927	GPR113	chr2:26531041-26569685:-	-0.24	-3.78	0.000177	Gut microbiome composition (summer)	
LGG	cis	1	rs2899462	chr15:50939254	SPPL2A	chr15:50999739-51057910:-	0.13	4.08	5.27E-5	QT interval	
LGG	cis	1	rs2899832	chr14:35740941	KIAA0391	chr14:35591776-35786673:+	-0.31	-5.56	4.34E-8	Response to zileuton treatment in asthma (FEV1 change interaction)	
LGG	cis	1	rs2901354	chr10:124733038	PSTK	chr10:124739556-124749906:+	0.15	3.47	0.000564	Migraine without aura	
LGG	cis	1	rs2901438	chr2:73665656	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.63E-12	Metabolite levels	
LGG	cis	1	rs2901438	chr2:73665656	NAT8	chr2:73867850-73869537:-	0.26	4.36	1.6E-5	Metabolite levels	
LGG	cis	1	rs2904804	chr10:5009759	AKR1C1	chr10:4934796-5020157:+	-0.17	-3.68	0.000254	Economic and political preferences (immigration/crime)	
LGG	cis	1	rs2905425	chr19:19475717	GMIP	chr19:19740286-19754455:-	-0.14	-4.02	6.66E-5	Schizophrenia	
LGG	cis	1	rs2905425	chr19:19475717	TSSK6	chr19:19623230-19626469:-	-0.2	-4.21	3.09E-5	Schizophrenia	
LGG	cis	1	rs2905426	chr19:19478022	GMIP	chr19:19740286-19754455:-	-0.14	-3.98	7.92E-5	Schizophrenia	
LGG	cis	1	rs2905426	chr19:19478022	TSSK6	chr19:19623230-19626469:-	-0.19	-3.97	8.2E-5	Schizophrenia	
LGG	cis	1	rs2905427	chr19:19478023	GMIP	chr19:19740286-19754455:-	-0.14	-3.98	7.92E-5	Schizophrenia	
LGG	cis	1	rs2905427	chr19:19478023	TSSK6	chr19:19623230-19626469:-	-0.19	-3.97	8.2E-5	Schizophrenia	
LGG	cis	1	rs2911130	chr5:96183427	ERAP1	chr5:96096515-96149837:-	-0.35	-7.98	1.05E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs2911131	chr5:96185949	ERAP1	chr5:96096515-96149837:-	0.34	7.67	9.51E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs2911132	chr5:96186988	ERAP1	chr5:96096515-96149837:-	-0.34	-7.69	8.26E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs2911140	chr5:96179943	ERAP1	chr5:96096515-96149837:-	-0.35	-7.8	3.64E-14	Urate levels (BMI interaction)	
LGG	cis	1	rs2916068	chr19:19516433	GMIP	chr19:19740286-19754455:-	0.12	3.65	0.000292	Schizophrenia	
LGG	cis	1	rs2916068	chr19:19516433	TSSK6	chr19:19623230-19626469:-	0.2	4.23	2.83E-5	Schizophrenia	
LGG	cis	1	rs2919009	chr10:122591373	WDR11	chr10:122610695-122669035:+	0.24	4.57	6.19E-6	Obesity-related traits	
LGG	cis	1	rs2920280	chr8:143761144	LY6K	chr8:143781529-143785582:+	0.35	6.41	3.37E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920280	chr8:143761144	PSCA	chr8:143761875-143764142:+	0.4	6.82	2.75E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920282	chr8:143757763	LY6K	chr8:143781529-143785582:+	0.32	5.9	6.85E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920282	chr8:143757763	PSCA	chr8:143761875-143764142:+	0.35	6.11	2.03E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920292	chr8:143765699	LY6K	chr8:143781529-143785582:+	0.33	6.33	5.41E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920292	chr8:143765699	PSCA	chr8:143761875-143764142:+	0.34	6.04	3.04E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920293	chr8:143765414	C8orf55	chr8:143808621-143818350:+	0.17	3.64	0.000307	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920293	chr8:143765414	LY6K	chr8:143781529-143785582:+	0.33	6.39	3.78E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920293	chr8:143765414	PSCA	chr8:143761875-143764142:+	0.34	6.06	2.72E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920294	chr8:143765326	C8orf55	chr8:143808621-143818350:+	0.17	3.64	0.000307	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920294	chr8:143765326	LY6K	chr8:143781529-143785582:+	0.33	6.39	3.78E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920294	chr8:143765326	PSCA	chr8:143761875-143764142:+	0.34	6.06	2.72E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920295	chr8:143764937	C8orf55	chr8:143808621-143818350:+	0.17	3.7	0.000236	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920295	chr8:143764937	LY6K	chr8:143781529-143785582:+	0.33	6.41	3.47E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920295	chr8:143764937	PSCA	chr8:143761875-143764142:+	0.34	6.01	3.6E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920296	chr8:143763109	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920296	chr8:143763109	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920296	chr8:143763109	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920297	chr8:143763083	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920297	chr8:143763083	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920297	chr8:143763083	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920298	chr8:143763043	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920298	chr8:143763043	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920298	chr8:143763043	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2920781	chr15:43924682	ADAL	chr15:43622872-43646094:+	-0.61	-7.79	3.94E-14	Tumor biomarkers	
LGG	cis	1	rs2920781	chr15:43924682	LCMT2	chr15:43619976-43622891:-	-0.29	-3.75	0.000195	Tumor biomarkers	
LGG	cis	1	rs2920781	chr15:43924682	STRC	chr15:43891762-43924561:-	0.4	7.19	2.4E-12	Tumor biomarkers	
LGG	cis	1	rs2927072	chr15:43922398	ADAL	chr15:43622872-43646094:+	-0.61	-7.8	3.84E-14	Tumor biomarkers	
LGG	cis	1	rs2927072	chr15:43922398	LCMT2	chr15:43619976-43622891:-	-0.29	-3.74	0.000208	Tumor biomarkers	
LGG	cis	1	rs2927072	chr15:43922398	STRC	chr15:43891762-43924561:-	0.39	6.99	8.93E-12	Tumor biomarkers	
LGG	cis	1	rs2929282	chr15:44245931	ADAL	chr15:43622872-43646094:+	-0.46	-3.99	7.52E-5	Triglycerides	
LGG	cis	1	rs2929282	chr15:44245931	STRC	chr15:43891762-43924561:-	0.41	5.01	7.75E-7	Triglycerides	
LGG	cis	1	rs2932538	chr1:113216543	ST7L	chr1:113066142-113162405:-	-0.3	-7.92	1.55E-14	Systolic blood pressure;Hypertension;Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs2935183	chr17:45607572	C17orf57	chr17:45401142-45518675:+	-0.15	-3.64	0.000296	Multiple sclerosis or amyotrophic lateral sclerosis	
LGG	cis	1	rs2935183	chr17:45607572	LOC100272146	chr17:45500843-45504056:+	-0.15	-3.71	0.000234	Multiple sclerosis or amyotrophic lateral sclerosis	
LGG	cis	1	rs2938670	chr15:78740688	CHRNA5	chr15:78857906-78886458:+	-0.62	-11.91	6.5E-29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2941484	chr8:76478768	HNF4G	chr8:76320183-76479059:+	0.18	3.86	0.00013	Urate levels	
LGG	cis	1	rs2941509	chr17:37921194	GSDMB	chr17:38060850-38074903:-	0.23	3.61	0.000336	Systemic lupus erythematosus	
LGG	cis	1	rs2942895	chr2:101297172	AFF3	chr2:100163718-100759037:-	-0.18	-3.48	0.00055	Alzheimer disease and age of onset	
LGG	cis	1	rs2945232	chr8:8098038	FLJ10661	chr8:8086092-8102386:+	-0.61	-14.35	3.07E-39	Schizophrenia	
LGG	cis	1	rs2951363	chr7:143754724	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.61	0.000339	Obesity-related traits	
LGG	cis	1	rs2951364	chr7:143754483	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.67	0.000271	Obesity-related traits	
LGG	cis	1	rs2951368	chr7:143752821	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.67	0.000271	Obesity-related traits	
LGG	cis	1	rs2951369	chr7:143752638	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.67	0.000271	Obesity-related traits	
LGG	cis	1	rs2951372	chr7:143749503	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.64	0.000304	Obesity-related traits	
LGG	cis	1	rs295428	chr3:47359262	NRADDP	chr3:47053032-47054957:+	-0.22	-3.78	0.000177	Colorectal cancer	
LGG	cis	1	rs295442	chr3:47335881	NRADDP	chr3:47053032-47054957:+	-0.24	-4.21	3.02E-5	Colorectal cancer	
LGG	cis	1	rs295449	chr3:47375955	NRADDP	chr3:47053032-47054957:+	-0.22	-3.79	0.000172	Colorectal cancer	
LGG	cis	1	rs295458	chr3:47385585	NRADDP	chr3:47053032-47054957:+	-0.22	-3.77	0.000184	Colorectal cancer	
LGG	cis	1	rs295461	chr3:47368010	NRADDP	chr3:47053032-47054957:+	-0.22	-3.79	0.000172	Colorectal cancer	
LGG	cis	1	rs2955077	chr3:127958869	EEFSEC	chr3:127872313-128127488:+	0.2	3.59	0.000358	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955078	chr3:127959186	EEFSEC	chr3:127872313-128127488:+	0.2	3.59	0.000358	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955079	chr3:127959824	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955080	chr3:127959865	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955081	chr3:127960299	EEFSEC	chr3:127872313-128127488:+	0.2	3.59	0.000358	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955082	chr3:127960334	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955083	chr3:127961178	EEFSEC	chr3:127872313-128127488:+	0.2	3.55	0.000416	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955085	chr3:127962757	EEFSEC	chr3:127872313-128127488:+	0.2	3.59	0.000358	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955086	chr3:127963191	EEFSEC	chr3:127872313-128127488:+	0.2	3.73	0.000212	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955088	chr3:127963710	EEFSEC	chr3:127872313-128127488:+	0.2	3.75	0.0002	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955089	chr3:127969330	EEFSEC	chr3:127872313-128127488:+	0.21	3.79	0.000168	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955089	chr3:127969330	LOC90246	chr3:128226678-128229427:+	0.28	3.47	0.000576	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955090	chr3:127969371	EEFSEC	chr3:127872313-128127488:+	0.21	3.79	0.000168	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955090	chr3:127969371	LOC90246	chr3:128226678-128229427:+	0.28	3.47	0.000576	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955091	chr3:127971361	EEFSEC	chr3:127872313-128127488:+	0.24	4.58	5.99E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955095	chr3:127977665	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.19	3.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955095	chr3:127977665	LOC90246	chr3:128226678-128229427:+	-0.3	-3.76	0.000188	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955096	chr3:127977866	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.76	0.000193	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955099	chr3:127979654	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955099	chr3:127979654	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955100	chr3:127993325	EEFSEC	chr3:127872313-128127488:+	0.23	4.22	2.94E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955100	chr3:127993325	LOC90246	chr3:128226678-128229427:+	0.28	3.53	0.000453	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955101	chr3:128009612	EEFSEC	chr3:127872313-128127488:+	0.22	4.15	3.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955101	chr3:128009612	LOC90246	chr3:128226678-128229427:+	0.28	3.57	0.000391	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955126	chr3:127926254	EEFSEC	chr3:127872313-128127488:+	0.24	4.44	1.1E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955129	chr3:127929207	EEFSEC	chr3:127872313-128127488:+	0.24	4.31	2.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955130	chr3:127937814	EEFSEC	chr3:127872313-128127488:+	0.22	4.03	6.42E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2955245	chr17:61979845	FTSJ3	chr17:61896795-61905031:-	-0.28	-5.27	2.08E-7	Height	
LGG	cis	1	rs2955245	chr17:61979845	TCAM1P	chr17:61934376-61941738:+	0.21	3.84	0.00014	Height	
LGG	cis	1	rs2956716	chr12:48856183	VDR	chr12:48235322-48298814:-	-0.22	-3.48	0.000548	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs2960821	chr7:25606956	SNX10	chr7:26331515-26413937:+	0.28	4.18	3.4E-5	Preeclampsia	
LGG	cis	1	rs2961102	chr7:65424658	CCT6P1	chr7:65216092-65228661:+	0.27	4.97	9.37E-7	Diabetic kidney disease	
LGG	cis	1	rs2961115	chr7:143753371	OR2A9P	chr7:143991573-143997832:+;chr7	-0.18	-3.67	0.000271	Obesity-related traits	
LGG	cis	1	rs2961144	chr7:143747870	OR2A9P	chr7:143991573-143997832:+;chr7	0.17	3.49	0.000525	Obesity-related traits	
LGG	cis	1	rs2965188	chr19:19522557	GMIP	chr19:19740286-19754455:-	0.13	3.83	0.000143	Schizophrenia	
LGG	cis	1	rs2965188	chr19:19522557	TSSK6	chr19:19623230-19626469:-	0.2	4.34	1.74E-5	Schizophrenia	
LGG	cis	1	rs2965198	chr19:19473030	GMIP	chr19:19740286-19754455:-	-0.13	-3.75	0.000196	Schizophrenia	
LGG	cis	1	rs2965198	chr19:19473030	TSSK6	chr19:19623230-19626469:-	-0.19	-3.93	9.56E-5	Schizophrenia	
LGG	cis	1	rs2976388	chr8:143760256	LY6K	chr8:143781529-143785582:+	0.34	6.25	8.99E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976388	chr8:143760256	PSCA	chr8:143761875-143764142:+	0.39	6.85	2.27E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976392	chr8:143762932	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976392	chr8:143762932	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976392	chr8:143762932	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976394	chr8:143763622	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.00034	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976394	chr8:143763622	LY6K	chr8:143781529-143785582:+	0.33	6.24	9.62E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976394	chr8:143763622	PSCA	chr8:143761875-143764142:+	0.34	6.09	2.28E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976396	chr8:143764001	C8orf55	chr8:143808621-143818350:+	-0.2	-4.25	2.57E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976396	chr8:143764001	LY6K	chr8:143781529-143785582:+	-0.35	-6.65	8.04E-11	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976396	chr8:143764001	PSCA	chr8:143761875-143764142:+	-0.37	-6.57	1.32E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976398	chr8:143764879	C8orf55	chr8:143808621-143818350:+	0.17	3.64	0.000307	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976398	chr8:143764879	LY6K	chr8:143781529-143785582:+	0.33	6.39	3.78E-10	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2976398	chr8:143764879	PSCA	chr8:143761875-143764142:+	0.34	6.06	2.72E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2977993	chr9:131608786	ENDOG	chr9:131580779-131584954:+	0.36	8.62	9.36E-17	Schizophrenia	
LGG	cis	1	rs2977993	chr9:131608786	LRRC8A	chr9:131644391-131680315:+	0.19	4.11	4.67E-5	Schizophrenia	
LGG	cis	1	rs2978982	chr8:143763490	C8orf55	chr8:143808621-143818350:+	0.17	3.61	0.000342	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2978982	chr8:143763490	LY6K	chr8:143781529-143785582:+	0.33	6.23	1.0E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2978982	chr8:143763490	PSCA	chr8:143761875-143764142:+	0.34	6.08	2.37E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LGG	cis	1	rs2985684	chr14:50101682	RPL36AL	chr14:50085407-50087349:-	0.31	8.09	4.59E-15	Carotid intima media thickness	
LGG	cis	1	rs2985687	chr14:50100386	RPL36AL	chr14:50085407-50087349:-	0.31	8.09	4.59E-15	Carotid intima media thickness	
LGG	cis	1	rs2985696	chr14:50094913	RPL36AL	chr14:50085407-50087349:-	0.33	8.66	6.65E-17	Carotid intima media thickness	
LGG	cis	1	rs2985697	chr14:50092902	RPL36AL	chr14:50085407-50087349:-	0.33	8.66	6.66E-17	Carotid intima media thickness	
LGG	cis	1	rs2999061	chr3:127993623	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.38	1.45E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999062	chr3:127993606	EEFSEC	chr3:127872313-128127488:+	0.23	4.22	2.94E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999062	chr3:127993606	LOC90246	chr3:128226678-128229427:+	0.28	3.53	0.000453	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999065	chr3:127981438	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999065	chr3:127981438	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999066	chr3:127980286	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999066	chr3:127980286	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999067	chr3:127978531	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999067	chr3:127978531	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999068	chr3:127977978	EEFSEC	chr3:127872313-128127488:+	0.2	3.78	0.000176	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999068	chr3:127977978	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.00036	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999069	chr3:127971609	EEFSEC	chr3:127872313-128127488:+	0.21	3.9	0.000108	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999069	chr3:127971609	LOC90246	chr3:128226678-128229427:+	0.29	3.68	0.000263	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999070	chr3:127964651	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999071	chr3:127963615	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999072	chr3:127962876	EEFSEC	chr3:127872313-128127488:+	0.2	3.59	0.000358	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999073	chr3:127962329	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999076	chr3:127958692	EEFSEC	chr3:127872313-128127488:+	0.21	3.87	0.000122	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999077	chr3:127958414	EEFSEC	chr3:127872313-128127488:+	0.2	3.66	0.000274	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999079	chr3:127957232	EEFSEC	chr3:127872313-128127488:+	0.2	3.77	0.000181	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999084	chr3:127952488	EEFSEC	chr3:127872313-128127488:+	0.2	3.85	0.000134	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999085	chr3:127951559	EEFSEC	chr3:127872313-128127488:+	0.2	3.85	0.000134	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999086	chr3:127951248	EEFSEC	chr3:127872313-128127488:+	0.2	3.85	0.000134	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999089	chr3:127935159	EEFSEC	chr3:127872313-128127488:+	0.22	4	7.39E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs2999090	chr3:127931340	EEFSEC	chr3:127872313-128127488:+	-0.25	-4.47	9.57E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs3002142	chr1:222788062	TAF1A	chr1:222731244-222763255:-	0.24	3.6	0.000346	LDL peak particle diameter (total fat intake interaction)	
LGG	cis	1	rs3002702	chr20:25268920	ABHD12	chr20:25275380-25371477:-	0.26	7.06	5.9E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3002702	chr20:25268920	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	7.08E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3002702	chr20:25268920	FAM182B	chr20:25744102-25848786:-	0.21	4.67	3.87E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3007030	chr14:50086563	RPL36AL	chr14:50085407-50087349:-	0.33	8.79	2.59E-17	Carotid intima media thickness	
LGG	cis	1	rs3007031	chr14:50102269	RPL36AL	chr14:50085407-50087349:-	0.3	7.94	1.37E-14	Carotid intima media thickness	
LGG	cis	1	rs3008607	chr1:222785692	TAF1A	chr1:222731244-222763255:-	0.25	3.65	0.000288	LDL peak particle diameter (total fat intake interaction)	
LGG	cis	1	rs3010562	chr6:167765251	TTLL2	chr6:167738574-167772990:+	0.26	4.64	4.58E-6	Gut microbiome composition (summer and winter)	
LGG	cis	1	rs3018301	chr11:71792071	FAM86C	chr11:71498557-71512276:+	0.38	4.12	4.38E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs3018302	chr11:71790942	FAM86C	chr11:71498557-71512276:+	0.5	4.88	1.43E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.44	-10.51	1.92E-23	Ankylosing spondylitis	
LGG	cis	1	rs30187	chr5:96124330	ERAP2	chr5:96211644-96255398:+	0.33	5.72	1.89E-8	Ankylosing spondylitis	
LGG	cis	1	rs3021	chr20:47874005	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.13	4.31E-5	Height	
LGG	cis	1	rs302660	chr11:87885448	RAB38	chr11:87846431-87908599:-	0.33	7.79	3.92E-14	Frontotemporal dementia	
LGG	cis	1	rs302662	chr11:87881236	RAB38	chr11:87846431-87908599:-	0.33	7.79	3.99E-14	Frontotemporal dementia	
LGG	cis	1	rs302663	chr11:87880759	RAB38	chr11:87846431-87908599:-	0.33	7.79	3.99E-14	Frontotemporal dementia	
LGG	cis	1	rs302668	chr11:87876911	RAB38	chr11:87846431-87908599:-	0.33	7.74	5.62E-14	Frontotemporal dementia	
LGG	cis	1	rs30378	chr5:96121994	ERAP1	chr5:96096515-96149837:-	-0.44	-10.41	4.45E-23	Ankylosing spondylitis	
LGG	cis	1	rs30378	chr5:96121994	ERAP2	chr5:96211644-96255398:+	0.33	5.73	1.8E-8	Ankylosing spondylitis	
LGG	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.44	-10.55	1.31E-23	Ankylosing spondylitis	
LGG	cis	1	rs30379	chr5:96122260	ERAP2	chr5:96211644-96255398:+	0.33	5.77	1.38E-8	Ankylosing spondylitis	
LGG	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.44	-10.55	1.31E-23	Ankylosing spondylitis	
LGG	cis	1	rs30380	chr5:96122281	ERAP2	chr5:96211644-96255398:+	0.33	5.77	1.38E-8	Ankylosing spondylitis	
LGG	cis	1	rs30736	chr5:130724240	SLC22A5	chr5:131705401-131731302:+	-0.25	-4.44	1.13E-5	Life satisfaction	
LGG	cis	1	rs307567	chr3:12166424	TIMP4	chr3:12194573-12200647:-	-0.3	-4.04	6.1E-5	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs307571	chr3:12126112	TIMP4	chr3:12194573-12200647:-	-0.29	-3.87	0.000121	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs307594	chr3:12106191	TIMP4	chr3:12194573-12200647:-	0.28	3.81	0.00016	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs308969	chr3:12177083	TIMP4	chr3:12194573-12200647:-	-0.45	-5.1	4.94E-7	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs308971	chr3:12116620	TIMP4	chr3:12194573-12200647:-	-0.29	-3.89	0.000113	Fasting insulin-related traits (interaction with BMI)	
LGG	cis	1	rs3091497	chr20:47645427	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.42E-5	Anger	
LGG	cis	1	rs3091497	chr20:47645427	CSE1L	chr20:47662838-47713484:+	-0.19	-5.2	2.99E-7	Anger	
LGG	cis	1	rs3091529	chr20:47647068	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.09	5.12E-5	Anger	
LGG	cis	1	rs3091529	chr20:47647068	CSE1L	chr20:47662838-47713484:+	-0.18	-5	7.98E-7	Anger	
LGG	cis	1	rs3091866	chr20:47648353	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.5E-5	Anger	
LGG	cis	1	rs3091866	chr20:47648353	CSE1L	chr20:47662838-47713484:+	-0.18	-4.93	1.15E-6	Anger	
LGG	cis	1	rs3092039	chr20:47678770	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.12	4.46E-5	Anger	
LGG	cis	1	rs3092039	chr20:47678770	CSE1L	chr20:47662838-47713484:+	-0.18	-4.99	8.44E-7	Anger	
LGG	cis	1	rs3092374	chr20:47663944	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.15	3.97E-5	Anger	
LGG	cis	1	rs3092374	chr20:47663944	CSE1L	chr20:47662838-47713484:+	-0.19	-5.22	2.62E-7	Anger	
LGG	cis	1	rs3092411	chr20:47690591	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.07	5.47E-5	Anger	
LGG	cis	1	rs3092411	chr20:47690591	CSE1L	chr20:47662838-47713484:+	-0.19	-5.04	6.45E-7	Anger	
LGG	cis	1	rs3092720	chr20:47640466	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.03	6.34E-5	Anger	
LGG	cis	1	rs3092720	chr20:47640466	CSE1L	chr20:47662838-47713484:+	-0.18	-4.9	1.33E-6	Anger	
LGG	cis	1	rs3093253	chr13:113774092	F7	chr13:113760105-113774994:+	-0.28	-3.56	0.000405	End-stage coagulation	
LGG	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.84	16.2	1.29E-47	Type 2 diabetes	
LGG	cis	1	rs3099459	chr5:56137170	MIER3	chr5:56215429-56267501:-	0.16	3.46	0.000584	Type 2 diabetes	
LGG	cis	1	rs3099555	chr4:1725651	TMEM129	chr4:1717680-1723084:-	-0.18	-3.8	0.00016	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.59	-9.91	3.05E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs310124	chr1:153020275	LOR	chr1:153232179-153234598:+	-0.16	-3.64	0.000305	Inflammatory skin disease	
LGG	cis	1	rs3101443	chr15:43912372	ADAL	chr15:43622872-43646094:+	-0.58	-7.48	3.45E-13	Tumor biomarkers	
LGG	cis	1	rs3101443	chr15:43912372	STRC	chr15:43891762-43924561:-	0.41	7.46	3.88E-13	Tumor biomarkers	
LGG	cis	1	rs3101852	chr15:50848370	SPPL2A	chr15:50999739-51057910:-	-0.13	-4.15	3.89E-5	QT interval	
LGG	cis	1	rs3101853	chr15:50848382	SPPL2A	chr15:50999739-51057910:-	-0.13	-4.28	2.26E-5	QT interval	
LGG	cis	1	rs3101855	chr15:50859874	SPPL2A	chr15:50999739-51057910:-	0.13	4.19	3.36E-5	QT interval	
LGG	cis	1	rs310213	chr1:65318351	JAK1	chr1:65298906-65432619:-	-0.33	-7.15	3.12E-12	Diabetic kidney disease	
LGG	cis	1	rs310213	chr1:65318351	RAVER2	chr1:65210778-65298912:+	-0.2	-4.59	5.66E-6	Diabetic kidney disease	
LGG	cis	1	rs310215	chr1:65316988	JAK1	chr1:65298906-65432619:-	-0.33	-7.14	3.37E-12	Diabetic kidney disease	
LGG	cis	1	rs310215	chr1:65316988	RAVER2	chr1:65210778-65298912:+	-0.21	-4.74	2.82E-6	Diabetic kidney disease	
LGG	cis	1	rs310216	chr1:65316675	JAK1	chr1:65298906-65432619:-	-0.34	-7.18	2.57E-12	Diabetic kidney disease	
LGG	cis	1	rs310216	chr1:65316675	RAVER2	chr1:65210778-65298912:+	-0.21	-4.62	4.9E-6	Diabetic kidney disease	
LGG	cis	1	rs310219	chr1:65315298	JAK1	chr1:65298906-65432619:-	-0.33	-7.18	2.56E-12	Diabetic kidney disease	
LGG	cis	1	rs310219	chr1:65315298	RAVER2	chr1:65210778-65298912:+	-0.21	-4.78	2.31E-6	Diabetic kidney disease	
LGG	cis	1	rs310225	chr1:65324683	JAK1	chr1:65298906-65432619:-	-0.35	-7.48	3.57E-13	Diabetic kidney disease	
LGG	cis	1	rs310225	chr1:65324683	RAVER2	chr1:65210778-65298912:+	-0.21	-4.72	3.12E-6	Diabetic kidney disease	
LGG	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.55	-9.34	3.31E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs3105590	chr15:50864145	SPPL2A	chr15:50999739-51057910:-	0.13	4.13	4.32E-5	QT interval	
LGG	cis	1	rs3105591	chr15:50869042	SPPL2A	chr15:50999739-51057910:-	0.12	3.86	0.000127	QT interval	
LGG	cis	1	rs3105593	chr15:50845018	SPPL2A	chr15:50999739-51057910:-	0.12	4	7.26E-5	QT interval	
LGG	cis	1	rs3106351	chr2:188202989	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.66E-7	Coronary heart disease	
LGG	cis	1	rs3106352	chr2:188202673	CALCRL	chr2:188207851-188313021:-	0.21	5.22	2.65E-7	Coronary heart disease	
LGG	cis	1	rs3109878	chr15:50836243	SPPL2A	chr15:50999739-51057910:-	0.13	4.1	4.9E-5	QT interval	
LGG	cis	1	rs3109879	chr15:50837618	SPPL2A	chr15:50999739-51057910:-	0.14	4.45	1.08E-5	QT interval	
LGG	cis	1	rs3109880	chr15:50837812	SPPL2A	chr15:50999739-51057910:-	0.14	4.51	8.08E-6	QT interval	
LGG	cis	1	rs3109881	chr15:50839272	SPPL2A	chr15:50999739-51057910:-	0.14	4.56	6.42E-6	QT interval	
LGG	cis	1	rs3109888	chr15:50860694	SPPL2A	chr15:50999739-51057910:-	0.13	4.19	3.36E-5	QT interval	
LGG	cis	1	rs3109892	chr15:50877011	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs3109894	chr15:50878574	GABPB1	chr15:50569390-50647605:-	-0.11	-3.53	0.000461	QT interval	
LGG	cis	1	rs3109894	chr15:50878574	USP8	chr15:50716579-50793276:+	-0.14	-3.63	0.00031	QT interval	
LGG	cis	1	rs3109895	chr15:50880560	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs3113489	chr4:129961179	C4orf33	chr4:130014829-130033842:+	-0.57	-9.35	3.03E-19	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs3115231	chr4:25230152	ANAPC4	chr4:25378848-25420119:+	0.21	3.86	0.000126	Cannabis dependence	
LGG	cis	1	rs3115231	chr4:25230152	PI4K2B	chr4:25162285-25280831:+	0.26	5.28	1.93E-7	Cannabis dependence	
LGG	cis	1	rs3115232	chr4:25270011	ANAPC4	chr4:25378848-25420119:+	0.31	4.95	1.03E-6	Cannabis dependence	
LGG	cis	1	rs3115232	chr4:25270011	PI4K2B	chr4:25162285-25280831:+	0.29	5.1	4.81E-7	Cannabis dependence	
LGG	cis	1	rs3118181	chr1:183166970	LAMC2	chr1:183155174-183214262:+	0.27	5.41	9.62E-8	Hypertriglyceridemia	
LGG	cis	1	rs3118625	chr9:131873256	CRAT	chr9:131857075-131873070:-	-0.21	-3.64	0.000303	Blood metabolite ratios	
LGG	cis	1	rs3118632	chr9:131901284	CRAT	chr9:131857075-131873070:-	-0.21	-3.81	0.000156	Blood metabolite ratios	
LGG	cis	1	rs3120034	chr1:183167051	LAMC2	chr1:183155174-183214262:+	0.27	5.35	1.37E-7	Hypertriglyceridemia	
LGG	cis	1	rs3120662	chr1:152302865	HRNR	chr1:152184558-152196669:-	-0.54	-8.05	6.15E-15	Atopic dermatitis	
LGG	cis	1	rs3121446	chr6:107140866	QRSL1	chr6:107077441-107116290:+	-0.19	-3.82	0.00015	Daytime sleep phenotypes	
LGG	cis	1	rs3124510	chr9:131899690	CRAT	chr9:131857075-131873070:-	-0.23	-4.3	2.07E-5	Blood metabolite ratios	
LGG	cis	1	rs3124511	chr9:131901458	CRAT	chr9:131857075-131873070:-	-0.22	-3.98	7.77E-5	Blood metabolite ratios	
LGG	cis	1	rs3124512	chr9:131903881	CRAT	chr9:131857075-131873070:-	-0.22	-4.05	5.9E-5	Blood metabolite ratios	
LGG	cis	1	rs3124513	chr9:131904593	CRAT	chr9:131857075-131873070:-	-0.2	-3.65	0.000295	Blood metabolite ratios	
LGG	cis	1	rs3124514	chr9:131904608	CRAT	chr9:131857075-131873070:-	-0.2	-3.65	0.000295	Blood metabolite ratios	
LGG	cis	1	rs3126085	chr1:152300817	HRNR	chr1:152184558-152196669:-	-0.53	-7.95	1.29E-14	Atopic dermatitis	
LGG	cis	1	rs3126092	chr1:152307955	HRNR	chr1:152184558-152196669:-	-0.54	-7.98	1.06E-14	Atopic dermatitis	
LGG	cis	1	rs3126095	chr1:152309683	HRNR	chr1:152184558-152196669:-	-0.53	-7.89	2.0E-14	Atopic dermatitis	
LGG	cis	1	rs3127661	chr6:107141927	QRSL1	chr6:107077441-107116290:+	-0.18	-3.57	0.000388	Daytime sleep phenotypes	
LGG	cis	1	rs3131573	chr15:50869601	SPPL2A	chr15:50999739-51057910:-	0.12	4.04	6.28E-5	QT interval	
LGG	cis	1	rs3131577	chr15:50863516	SPPL2A	chr15:50999739-51057910:-	0.12	4	7.43E-5	QT interval	
LGG	cis	1	rs3131578	chr15:50861470	SPPL2A	chr15:50999739-51057910:-	-0.14	-4.59	5.54E-6	QT interval	
LGG	cis	1	rs3131580	chr15:50854926	SPPL2A	chr15:50999739-51057910:-	0.13	4.19	3.36E-5	QT interval	
LGG	cis	1	rs3131582	chr15:50879670	SPPL2A	chr15:50999739-51057910:-	0.12	4.04	6.26E-5	QT interval	
LGG	cis	1	rs3131584	chr15:50847401	SPPL2A	chr15:50999739-51057910:-	0.13	4.26	2.49E-5	QT interval	
LGG	cis	1	rs3131585	chr15:50845796	SPPL2A	chr15:50999739-51057910:-	0.13	4.19	3.38E-5	QT interval	
LGG	cis	1	rs3131586	chr15:50845236	SPPL2A	chr15:50999739-51057910:-	0.13	4.2	3.21E-5	QT interval	
LGG	cis	1	rs3131587	chr15:50845101	SPPL2A	chr15:50999739-51057910:-	0.14	4.4	1.32E-5	QT interval	
LGG	cis	1	rs3131589	chr15:50841053	SPPL2A	chr15:50999739-51057910:-	0.14	4.54	7.06E-6	QT interval	
LGG	cis	1	rs3131590	chr15:50840955	SPPL2A	chr15:50999739-51057910:-	0.14	4.44	1.11E-5	QT interval	
LGG	cis	1	rs3131596	chr15:50877575	SPPL2A	chr15:50999739-51057910:-	0.13	4.14	4.14E-5	QT interval	
LGG	cis	1	rs313533	chr4:25273174	ANAPC4	chr4:25378848-25420119:+	0.31	4.95	1.03E-6	Cannabis dependence	
LGG	cis	1	rs313533	chr4:25273174	PI4K2B	chr4:25162285-25280831:+	0.29	5.1	4.81E-7	Cannabis dependence	
LGG	cis	1	rs313536	chr4:25255947	ANAPC4	chr4:25378848-25420119:+	0.31	4.93	1.12E-6	Cannabis dependence	
LGG	cis	1	rs313536	chr4:25255947	PI4K2B	chr4:25162285-25280831:+	0.29	5.11	4.68E-7	Cannabis dependence	
LGG	cis	1	rs313538	chr4:25264754	ANAPC4	chr4:25378848-25420119:+	0.31	4.93	1.12E-6	Cannabis dependence	
LGG	cis	1	rs313538	chr4:25264754	PI4K2B	chr4:25162285-25280831:+	0.29	5.11	4.68E-7	Cannabis dependence	
LGG	cis	1	rs313539	chr4:25264018	ANAPC4	chr4:25378848-25420119:+	0.31	4.93	1.12E-6	Cannabis dependence	
LGG	cis	1	rs313539	chr4:25264018	PI4K2B	chr4:25162285-25280831:+	0.29	5.11	4.68E-7	Cannabis dependence	
LGG	cis	1	rs313553	chr4:25244743	ANAPC4	chr4:25378848-25420119:+	0.27	4.26	2.47E-5	Cannabis dependence	
LGG	cis	1	rs313553	chr4:25244743	PI4K2B	chr4:25162285-25280831:+	0.25	4.37	1.5E-5	Cannabis dependence	
LGG	cis	1	rs313569	chr4:25219566	ANAPC4	chr4:25378848-25420119:+	0.3	4.74	2.84E-6	Cannabis dependence	
LGG	cis	1	rs313569	chr4:25219566	PI4K2B	chr4:25162285-25280831:+	0.28	4.87	1.48E-6	Cannabis dependence	
LGG	cis	1	rs313574	chr4:25215493	ANAPC4	chr4:25378848-25420119:+	0.32	4.93	1.13E-6	Cannabis dependence	
LGG	cis	1	rs313574	chr4:25215493	PI4K2B	chr4:25162285-25280831:+	0.29	4.97	9.26E-7	Cannabis dependence	
LGG	cis	1	rs313579	chr4:25221774	ANAPC4	chr4:25378848-25420119:+	0.31	4.81	2.01E-6	Cannabis dependence	
LGG	cis	1	rs313579	chr4:25221774	PI4K2B	chr4:25162285-25280831:+	0.28	4.86	1.57E-6	Cannabis dependence	
LGG	cis	1	rs313798	chr7:65493031	CCT6P1	chr7:65216092-65228661:+	0.27	4.84	1.71E-6	Diabetic kidney disease	
LGG	cis	1	rs313799	chr7:65494330	CCT6P1	chr7:65216092-65228661:+	0.27	4.85	1.65E-6	Diabetic kidney disease	
LGG	cis	1	rs313802	chr7:65516373	CCT6P1	chr7:65216092-65228661:+	0.26	4.7	3.37E-6	Diabetic kidney disease	
LGG	cis	1	rs313803	chr7:65514731	CCT6P1	chr7:65216092-65228661:+	0.26	4.7	3.37E-6	Diabetic kidney disease	
LGG	cis	1	rs313807	chr7:65499481	CCT6P1	chr7:65216092-65228661:+	0.26	4.58	5.9E-6	Diabetic kidney disease	
LGG	cis	1	rs313809	chr7:65499983	CCT6P1	chr7:65216092-65228661:+	0.26	4.58	5.9E-6	Diabetic kidney disease	
LGG	cis	1	rs3138137	chr12:56116981	RDH5	chr12:56114151-56118525:+	-0.18	-4.54	7.12E-6	Refractive error	
LGG	cis	1	rs313813	chr7:65503500	CCT6P1	chr7:65216092-65228661:+	0.26	4.71	3.16E-6	Diabetic kidney disease	
LGG	cis	1	rs3138144	chr12:56114769	RDH5	chr12:56114151-56118525:+	-0.18	-4.52	7.67E-6	Refractive error	
LGG	cis	1	rs313814	chr7:65503293	CCT6P1	chr7:65216092-65228661:+	0.26	4.71	3.16E-6	Diabetic kidney disease	
LGG	cis	1	rs313820	chr7:65574466	CCT6P1	chr7:65216092-65228661:+	0.25	4.53	7.52E-6	Diabetic kidney disease	
LGG	cis	1	rs313824	chr7:65581207	CCT6P1	chr7:65216092-65228661:+	0.25	4.6	5.49E-6	Diabetic kidney disease	
LGG	cis	1	rs313831	chr7:65551226	CCT6P1	chr7:65216092-65228661:+	0.24	4.38	1.47E-5	Diabetic kidney disease	
LGG	cis	1	rs313832	chr7:65550891	CCT6P1	chr7:65216092-65228661:+	0.24	4.38	1.47E-5	Diabetic kidney disease	
LGG	cis	1	rs316161	chr6:160753983	SLC22A3	chr6:160769425-160876013:+	0.35	6.07	2.49E-9	Waist circumference	
LGG	cis	1	rs316163	chr6:160752478	SLC22A3	chr6:160769425-160876013:+	0.35	6.07	2.49E-9	Waist circumference	
LGG	cis	1	rs316167	chr6:160754752	SLC22A3	chr6:160769425-160876013:+	-0.31	-5.42	9.2E-8	Waist circumference	
LGG	cis	1	rs316168	chr6:160755057	SLC22A3	chr6:160769425-160876013:+	0.34	6.02	3.41E-9	Waist circumference	
LGG	cis	1	rs316169	chr6:160755657	SLC22A3	chr6:160769425-160876013:+	0.33	5.72	1.87E-8	Waist circumference	
LGG	cis	1	rs316170	chr6:160756037	SLC22A3	chr6:160769425-160876013:+	-0.33	-5.89	7.12E-9	Waist circumference	
LGG	cis	1	rs316304	chr7:65616894	CCT6P1	chr7:65216092-65228661:+	0.24	4.4	1.31E-5	Diabetic kidney disease	
LGG	cis	1	rs316307	chr7:65570171	CCT6P1	chr7:65216092-65228661:+	0.25	4.53	7.26E-6	Diabetic kidney disease	
LGG	cis	1	rs316312	chr7:65596491	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316313	chr7:65593548	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316315	chr7:65591205	CCT6P1	chr7:65216092-65228661:+	-0.23	-4.52	7.66E-6	Diabetic kidney disease	
LGG	cis	1	rs316317	chr7:65613637	CCT6P1	chr7:65216092-65228661:+	0.24	4.4	1.31E-5	Diabetic kidney disease	
LGG	cis	1	rs316318	chr7:65612904	CCT6P1	chr7:65216092-65228661:+	0.24	4.4	1.31E-5	Diabetic kidney disease	
LGG	cis	1	rs316321	chr7:65611613	CCT6P1	chr7:65216092-65228661:+	0.24	4.4	1.31E-5	Diabetic kidney disease	
LGG	cis	1	rs316322	chr7:65611233	CCT6P1	chr7:65216092-65228661:+	0.24	4.23	2.73E-5	Diabetic kidney disease	
LGG	cis	1	rs316325	chr7:65609518	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316326	chr7:65609453	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316327	chr7:65609201	CCT6P1	chr7:65216092-65228661:+	-0.23	-4.26	2.47E-5	Diabetic kidney disease	
LGG	cis	1	rs316329	chr7:65608416	CCT6P1	chr7:65216092-65228661:+	0.23	4.27	2.36E-5	Diabetic kidney disease	
LGG	cis	1	rs316330	chr7:65605372	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316331	chr7:65604622	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316332	chr7:65604299	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs316334	chr7:65602126	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs317186	chr11:89095733	NOX4	chr11:89057524-89322779:-	0.34	3.69	0.000251	Homocysteine levels	
LGG	cis	1	rs3176766	chr19:10449778	ICAM3	chr19:10444452-10450345:-	-0.31	-5.88	7.38E-9	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs3176767	chr19:10449751	ICAM3	chr19:10444452-10450345:-	-0.31	-5.83	9.91E-9	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs3176768	chr19:10449665	ICAM3	chr19:10444452-10450345:-	0.28	5.25	2.29E-7	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs3177243	chr22:24179922	C22orf43	chr22:23950640-23974487:-	-0.3	-4.09	5.11E-5	IgG glycosylation	
LGG	cis	1	rs3177243	chr22:24179922	DERL3	chr22:24176691-24181315:-	0.3	5.32	1.59E-7	IgG glycosylation	
LGG	cis	1	rs3180872	chr22:51017394	CPT1B	chr22:51007291-51017096:-	-0.34	-6.73	4.77E-11	Narcolepsy	
LGG	cis	1	rs31872	chr5:140372222	PCDHA13	chr5:140261854-140391929:+	-0.2	-3.63	0.000315	Visceral adipose tissue adjusted for BMI	
LGG	cis	1	rs319680	chr3:47898307	NME6	chr3:48335591-48342886:-	-0.21	-4.16	3.79E-5	Educational attainment (years of education)	
LGG	cis	1	rs319690	chr3:47927484	NME6	chr3:48335591-48342886:-	-0.23	-4.77	2.47E-6	Blood pressure	
LGG	cis	1	rs3197999	chr3:49721532	MST1R	chr3:49924438-49941306:-	-0.22	-4.25	2.58E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs3197999	chr3:49721532	RBM6	chr3:49977592-50137484:+	0.15	4.09	4.99E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs3197999	chr3:49721532	SEMA3F	chr3:50192848-50226507:+	0.19	4.24	2.67E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs3204270	chr17:79682051	ARL16	chr17:79648234-79650954:-	-0.63	-8.21	2.03E-15	Dental caries	
LGG	cis	1	rs3206817	chr17:65892834	LOC440461	chr17:66194801-66196436:+	0.28	4.61	5.06E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs3208509	chr1:150129335	RPRD2	chr1:150336990-150449039:+	-0.15	-3.71	0.000231	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs3213445	chr22:51015838	CPT1B	chr22:51007291-51017096:-	-0.32	-6.32	5.88E-10	Narcolepsy	
LGG	cis	1	rs3213446	chr22:51015674	CPT1B	chr22:51007291-51017096:-	-0.32	-6.34	5.19E-10	Narcolepsy	
LGG	cis	1	rs3213762	chr17:38178627	GSDMA	chr17:38119226-38134019:+	-0.71	-15.15	7.8E-43	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs3214041	chr3:48454468	ATRIP	chr3:48488141-48507708:+	0.18	4.42	1.2E-5	Longevity	
LGG	cis	1	rs3214041	chr3:48454468	TREX1	chr3:48501186-48509043:+	-0.42	-10.92	5.51E-25	Longevity	
LGG	cis	1	rs321622	chr4:48024380	CNGA1	chr4:47937996-48018610:-	0.58	12.13	8.35E-30	Renal underexcretion gout;Gout	
LGG	cis	1	rs3218036	chr19:30305684	CCNE1	chr19:30302901-30315218:+	0.22	4.76	2.57E-6	Bladder cancer	
LGG	cis	1	rs327511	chr7:127257261	GCC1	chr7:127220683-127225654:-	0.24	4.27	2.33E-5	Type 2 diabetes	
LGG	cis	1	rs327512	chr7:127257251	GCC1	chr7:127220683-127225654:-	0.24	4.27	2.33E-5	Type 2 diabetes	
LGG	cis	1	rs3310	chr20:3237232	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.84	16.02	9.2E-47	Type 2 diabetes	
LGG	cis	1	rs33322	chr5:56175226	MIER3	chr5:56215429-56267501:-	0.18	3.92	0.000101	Type 2 diabetes	
LGG	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.84	16.19	1.46E-47	Type 2 diabetes	
LGG	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.84	16.2	1.29E-47	Type 2 diabetes	
LGG	cis	1	rs33326	chr5:56142601	MIER3	chr5:56215429-56267501:-	0.16	3.46	0.000584	Type 2 diabetes	
LGG	cis	1	rs335472	chr5:176984163	DOK3	chr5:176928915-176937427:-	-0.2	-3.72	0.000219	Alzheimer disease and age of onset	
LGG	cis	1	rs33936662	chr6:52878654	ICK	chr6:52866098-52926600:-	-0.23	-4.13	4.29E-5	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs33988592	chr3:121415610	IQCB1	chr3:121488610-121553926:-	0.37	6.82	2.7E-11	Cognitive performance	
LGG	cis	1	rs33993216	chr10:17204139	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.79	2.18E-6	Homocysteine levels	
LGG	cis	1	rs33998546	chr3:127831038	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.15	3.92E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs33999310	chr3:52883332	ABHD14B	chr3:52002527-52017425:-	0.22	3.54	0.000436	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs34010330	chr19:18559657	LRRC25	chr19:18501955-18508421:-	-0.17	-5.96	4.88E-9	Breast cancer	
LGG	cis	1	rs34010330	chr19:18559657	SSBP4	chr19:18530221-18545371:+	-0.12	-3.57	0.000398	Breast cancer	
LGG	cis	1	rs34013242	chr5:93507947	FAM172A	chr5:92953432-93447404:-	-0.3	-4.08	5.35E-5	Diabetic retinopathy	
LGG	cis	1	rs34029977	chr7:118018673	ANKRD7	chr7:117864712-117882782:+	0.22	3.82	0.000149	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs34030940	chr1:31857202	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.66	0.000276	Schizophrenia	
LGG	cis	1	rs34031278	chr16:77327792	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs34042070	chr16:72101525	HP	chr16:72088508-72094957:+	0.99	18.93	2.02E-60	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs34042070	chr16:72101525	HPR	chr16:72097125-72111144:+	1.02	23.73	1.68E-83	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs34042070	chr16:72101525	TXNL4B	chr16:72072001-72128215:-	0.74	12.2	4.24E-30	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs34052221	chr6:163160803	PACRG	chr6:163148164-163736523:+	0.44	5.91	6.26E-9	Body mass index	
LGG	cis	1	rs34053335	chr11:5386200	FAM160A2	chr11:6232565-6255941:-	0.2	4	7.44E-5	Fetal hemoglobin levels	
LGG	cis	1	rs34055941	chr9:131895076	CRAT	chr9:131857075-131873070:-	0.2	3.65	0.000288	Blood metabolite ratios	
LGG	cis	1	rs34066731	chr6:163011047	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs34068652	chr5:93563319	FAM172A	chr5:92953432-93447404:-	-0.3	-4.03	6.43E-5	Diabetic retinopathy	
LGG	cis	1	rs34086988	chr3:121352745	IQCB1	chr3:121488610-121553926:-	0.35	6.57	1.25E-10	Cognitive performance	
LGG	cis	1	rs34087092	chr8:126504762	TRIB1	chr8:126442563-126450642:+	-0.22	-4.05	5.92E-5	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs34088794	chr15:40665420	C15orf23	chr15:40674922-40686488:+	1.02	17.48	1.5E-53	Heschl's gyrus morphology	
LGG	cis	1	rs34088794	chr15:40665420	IVD	chr15:40697686-40713512:+	-0.33	-3.78	0.000174	Heschl's gyrus morphology	
LGG	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.67	3.94E-6	Body mass index	
LGG	cis	1	rs34102169	chr1:46424864	MUTYH	chr1:45794915-45806142:-	0.13	4.82	1.89E-6	Body mass index	
LGG	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.5	-10.28	1.34E-22	Response to antipsychotic treatment	
LGG	cis	1	rs34117728	chr5:156433497	TIMD4	chr5:156346293-156390266:-	-0.26	-4.72	3.15E-6	Hypertriglyceridemia	
LGG	cis	1	rs34121720	chr3:53072167	RFT1	chr3:53122503-53164470:-	0.31	3.56	0.000407	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs34123137	chr2:234167881	ATG16L1	chr2:234160217-234204319:+	-0.17	-4.11	4.66E-5	Crohn's disease	
LGG	cis	1	rs34127220	chr16:29842891	LOC440356	chr16:29875004-29879374:+	-0.24	-3.98	8.08E-5	Multiple sclerosis	
LGG	cis	1	rs34128973	chr11:47851376	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000365	Subjective well-being	
LGG	cis	1	rs34128973	chr11:47851376	MTCH2	chr11:47638859-47664206:-	0.25	4.81	2.03E-6	Subjective well-being	
LGG	cis	1	rs34128973	chr11:47851376	PSMC3	chr11:47440320-47448024:-	0.15	3.71	0.000235	Subjective well-being	
LGG	cis	1	rs34136756	chr7:65381256	CCT6P1	chr7:65216092-65228661:+	0.25	4.63	4.77E-6	Diabetic kidney disease	
LGG	cis	1	rs34138336	chr6:163144929	PACRG	chr6:163148164-163736523:+	0.45	6.01	3.69E-9	Body mass index	
LGG	cis	1	rs34138960	chr15:78831668	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.58	1.25E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34156253	chr5:150226230	LOC134466	chr5:150310000-150326146:-	0.39	4.5	8.38E-6	Crohn's disease	
LGG	cis	1	rs34171762	chr19:18559410	LRRC25	chr19:18501955-18508421:-	-0.16	-5.73	1.71E-8	Breast cancer	
LGG	cis	1	rs34174370	chr3:127849744	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34174778	chr20:33544277	PROCR	chr20:33758727-33765164:+	-0.33	-5.85	9.16E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs34177053	chr6:163007772	PACRG	chr6:163148164-163736523:+	0.29	4.43	1.19E-5	Body mass index	
LGG	cis	1	rs34180169	chr6:52879537	ICK	chr6:52866098-52926600:-	-0.23	-4.13	4.29E-5	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs34182248	chr17:45321359	ITGB3	chr17:45331208-45421658:+	-0.22	-4.53	7.37E-6	Body mass index	
LGG	cis	1	rs34192067	chr7:65887657	CCT6P1	chr7:65216092-65228661:+	0.23	4.2	3.12E-5	Diabetic kidney disease	
LGG	cis	1	rs34192365	chr6:163012382	PACRG	chr6:163148164-163736523:+	0.29	4.29	2.14E-5	Body mass index	
LGG	cis	1	rs34193460	chr7:65393110	CCT6P1	chr7:65216092-65228661:+	0.26	4.73	2.92E-6	Diabetic kidney disease	
LGG	cis	1	rs34221813	chr1:211595896	C1orf97	chr1:211556097-211605876:+	0.2	3.49	0.000518	Educational attainment (years of education)	
LGG	cis	1	rs34228187	chr3:127816433	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.21	2.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34228197	chr6:163008232	PACRG	chr6:163148164-163736523:+	0.29	4.43	1.19E-5	Body mass index	
LGG	cis	1	rs34230359	chr5:156449561	TIMD4	chr5:156346293-156390266:-	-0.25	-4.65	4.22E-6	Hypertriglyceridemia	
LGG	cis	1	rs34237279	chr15:75361121	PPCDC	chr15:75315927-75343066:+	0.23	4.93	1.11E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs34245511	chr12:50573433	C12orf62	chr12:50505900-50514234:+	0.14	3.74	0.000207	Colorectal cancer	
LGG	cis	1	rs34256197	chr19:18606472	LRRC25	chr19:18501955-18508421:-	-0.16	-5.67	2.41E-8	Breast cancer	
LGG	cis	1	rs34275373	chr5:125915744	ALDH7A1	chr5:125878918-125931082:-	0.46	5.46	7.68E-8	Osteoporosis	
LGG	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.5	-10.32	1.01E-22	Response to antipsychotic treatment	
LGG	cis	1	rs34285687	chr6:52875329	ICK	chr6:52866098-52926600:-	-0.23	-4.13	4.29E-5	Staphylococcus aureus nasal carriage (intermittent)	
LGG	cis	1	rs34286592	chr16:29820480	LOC440356	chr16:29875004-29879374:+	-0.23	-3.69	0.000249	Multiple sclerosis	
LGG	cis	1	rs34292685	chr11:64049021	C11orf20	chr11:64067863-64072238:+	-0.32	-4.77	2.4E-6	Mean platelet volume	
LGG	cis	1	rs34304649	chr9:99247301	CDC14B	chr9:99262397-99382112:-	-0.29	-5.21	2.85E-7	Height	
LGG	cis	1	rs34304649	chr9:99247301	HABP4	chr9:99212414-99253617:+	-0.23	-5.08	5.39E-7	Height	
LGG	cis	1	rs34304649	chr9:99247301	SLC35D2	chr9:99075727-99145992:-	-0.16	-3.63	0.000319	Height	
LGG	cis	1	rs34307072	chr12:104196304	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.77	2.41E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs34324835	chr7:74132305	STAG3L2	chr7:74298846-74306731:-	-0.27	-3.99	7.61E-5	Menarche (age at onset)	
LGG	cis	1	rs34329423	chr1:31857177	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.66	0.000276	Schizophrenia	
LGG	cis	1	rs34333482	chr6:116855952	FAM26F	chr6:116782556-116784933:+	0.18	4.79	2.17E-6	Pelvic organ prolapse (moderate/severe)	
LGG	cis	1	rs34344888	chr14:23387585	HAUS4	chr14:23415438-23426335:-	-0.34	-8.96	7.04E-18	Educational attainment (years of education)	
LGG	cis	1	rs34344888	chr14:23387585	PSMB5	chr14:23495061-23504429:-	-0.15	-3.77	0.000185	Educational attainment (years of education)	
LGG	cis	1	rs34344906	chr6:162993378	PACRG	chr6:163148164-163736523:+	0.33	4.78	2.27E-6	Body mass index	
LGG	cis	1	rs34361144	chr5:112734005	SRP19	chr5:112196993-112228774:+	0.3	3.7	0.000237	F-cell distribution	
LGG	cis	1	rs34371402	chr16:77316410	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.18	3.38E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs34373625	chr10:4981201	AKR1C2	chr10:4964715-5060207:-	0.36	4.84	1.76E-6	Height	
LGG	cis	1	rs34385765	chr1:207993637	CD46	chr1:207925402-207968857:+	-0.24	-7.16	2.91E-12	Schizophrenia	
LGG	cis	1	rs34398656	chr6:162999612	PACRG	chr6:163148164-163736523:+	0.3	4.57	6.09E-6	Body mass index	
LGG	cis	1	rs34403909	chr3:127810445	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34409160	chr2:28943865	FAM179A	chr2:29204164-29275094:+	0.18	3.59	0.000368	Body mass index	
LGG	cis	1	rs34409160	chr2:28943865	TRMT61B	chr2:29072690-29093175:-	0.52	10.88	7.91E-25	Body mass index	
LGG	cis	1	rs34409737	chr5:156457857	TIMD4	chr5:156346293-156390266:-	-0.25	-4.45	1.05E-5	Hypertriglyceridemia	
LGG	cis	1	rs34409786	chr3:127888175	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34418448	chr1:211570581	C1orf97	chr1:211556097-211605876:+	0.2	3.57	0.000388	Educational attainment (years of education)	
LGG	cis	1	rs34421316	chr21:43513989	C21orf128	chr21:43522244-43528644:-	0.57	11.41	6.74E-27	IgG glycosylation	
LGG	cis	1	rs34428306	chr1:152184316	FLG	chr1:152274651-152297679:-	0.4	6.4	3.66E-10	Inflammatory skin disease	
LGG	cis	1	rs34434809	chr10:17187634	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.7	3.31E-6	Homocysteine levels	
LGG	cis	1	rs34443622	chr6:163208214	PACRG	chr6:163148164-163736523:+	0.4	5.48	6.71E-8	Body mass index	
LGG	cis	1	rs34453673	chr5:434722	EXOC3	chr5:443334-467407:+	-0.23	-5.36	1.27E-7	Cystic fibrosis severity	
LGG	cis	1	rs3448	chr3:49396751	AMIGO3	chr3:49754268-49757238:-	-0.19	-4.5	8.5E-6	Menarche (age at onset)	
LGG	cis	1	rs3448	chr3:49396751	GMPPB	chr3:49758932-49761384:-	-0.23	-4.51	7.99E-6	Menarche (age at onset)	
LGG	cis	1	rs3448	chr3:49396751	TREX1	chr3:48501186-48509043:+	-0.25	-5.15	3.69E-7	Menarche (age at onset)	
LGG	cis	1	rs34492688	chr17:45321622	ITGB3	chr17:45331208-45421658:+	-0.22	-4.47	9.78E-6	Body mass index	
LGG	cis	1	rs34493921	chr1:175122759	TNN	chr1:175036994-175117202:+	-0.18	-3.7	0.00024	Alcohol dependence	
LGG	cis	1	rs34500464	chr10:17191996	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.68	3.66E-6	Homocysteine levels	
LGG	cis	1	rs34504566	chr16:77327637	ADAMTS18	chr16:77316026-77469011:-	-0.32	-4.54	7.03E-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs34529418	chr7:65403209	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs34530577	chr3:53103796	RFT1	chr3:53122503-53164470:-	-0.47	-9.93	2.6E-21	Height	
LGG	cis	1	rs34538248	chr13:31468796	C13orf33	chr13:31480312-31499708:+	0.43	5.9	6.89E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs34539248	chr5:112697365	SRP19	chr5:112196993-112228774:+	0.29	3.54	0.000444	F-cell distribution	
LGG	cis	1	rs34558323	chr10:17184228	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.29	2.15E-5	Homocysteine levels	
LGG	cis	1	rs34560516	chr7:65404092	CCT6P1	chr7:65216092-65228661:+	0.27	4.97	9.37E-7	Diabetic kidney disease	
LGG	cis	1	rs34562493	chr3:127817022	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34570071	chr15:85280212	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.35	1.62E-5	Schizophrenia	
LGG	cis	1	rs34570071	chr15:85280212	LOC388152	chr15:84867600-84898920:-	-0.3	-5.55	4.61E-8	Schizophrenia	
LGG	cis	1	rs34570071	chr15:85280212	WDR73	chr15:85186012-85197524:-	-0.19	-3.56	0.000408	Schizophrenia	
LGG	cis	1	rs34575783	chr15:63397686	LACTB	chr15:63414032-63434254:+	0.22	4.42	1.19E-5	HDL cholesterol	
LGG	cis	1	rs34577383	chr7:65385726	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs34580798	chr20:47899957	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.08	5.29E-5	Height	
LGG	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.51	-10.37	6.21E-23	Response to antipsychotic treatment	
LGG	cis	1	rs34583567	chr15:67983281	IQCH	chr15:67547188-67794139:+	0.13	3.78	0.000177	Motion sickness	
LGG	cis	1	rs34586537	chr2:70163316	SNRNP27	chr2:70121090-70132348:+	0.2	4.57	6.24E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs34587942	chr2:70081501	SNRNP27	chr2:70121090-70132348:+	-0.18	-3.64	0.000304	Colorectal or endometrial cancer	
LGG	cis	1	rs34591938	chr6:163087003	PACRG	chr6:163148164-163736523:+	0.41	5.58	4.03E-8	Body mass index	
LGG	cis	1	rs34593101	chr1:152881350	LCE1C	chr1:152777311-152779107:-	-0.35	-4.18	3.38E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34593101	chr1:152881350	LCE1E	chr1:152758753-152760898:+	-0.35	-4.09	5.13E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34593101	chr1:152881350	SMCP	chr1:152850798-152857515:+	-0.4	-5.31	1.63E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34594856	chr6:163051845	PACRG	chr6:163148164-163736523:+	0.36	4.88	1.43E-6	Body mass index	
LGG	cis	1	rs34599045	chr1:152886874	LCE1C	chr1:152777311-152779107:-	-0.31	-3.86	0.000131	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34599045	chr1:152886874	LCE1E	chr1:152758753-152760898:+	-0.32	-3.85	0.000133	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34599045	chr1:152886874	SMCP	chr1:152850798-152857515:+	-0.38	-5.22	2.58E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs34616626	chr8:58184650	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs34618077	chr10:71216134	TSPAN15	chr10:71211226-71267423:+	0.27	4.49	8.91E-6	Age-related hearing impairment (interaction)	
LGG	cis	1	rs34619021	chr6:163029767	PACRG	chr6:163148164-163736523:+	0.31	4.5	8.32E-6	Body mass index	
LGG	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.49	-10.07	8.35E-22	Response to antipsychotic treatment	
LGG	cis	1	rs34629498	chr19:23060720	ZNF492	chr19:22817126-22850472:+	-0.22	-4.4	1.35E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs34637087	chr6:163004064	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs34637256	chr7:65360131	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs34638686	chr3:48682658	USP4	chr3:49314577-49377536:-	0.35	4.3	2.07E-5	Educational attainment (years of education)	
LGG	cis	1	rs34645895	chr20:25368373	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs34645895	chr20:25368373	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs34645895	chr20:25368373	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs34653853	chr6:163114362	PACRG	chr6:163148164-163736523:+	0.42	5.65	2.76E-8	Body mass index	
LGG	cis	1	rs34655790	chr6:163202739	PACRG	chr6:163148164-163736523:+	0.38	5.36	1.3E-7	Body mass index	
LGG	cis	1	rs346785	chr17:74283769	FAM100B	chr17:74261286-74267379:+	0.13	3.53	0.000459	White matter hyperintensities in ischemic stroke	
LGG	cis	1	rs346785	chr17:74283769	QRICH2	chr17:74270130-74303761:-	0.16	4.36	1.57E-5	White matter hyperintensities in ischemic stroke	
LGG	cis	1	rs34684276	chr15:78813155	CHRNA5	chr15:78857906-78886458:+	-0.69	-13.48	1.91E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Nicotine dependence	
LGG	cis	1	rs34697913	chr6:163000187	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs34702770	chr7:65344823	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs34703416	chr7:65300642	CCT6P1	chr7:65216092-65228661:+	0.26	4.84	1.73E-6	Diabetic kidney disease	
LGG	cis	1	rs34709844	chr3:127818869	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34714518	chr6:163080778	PACRG	chr6:163148164-163736523:+	0.41	5.46	7.73E-8	Body mass index	
LGG	cis	1	rs34725898	chr6:163127302	PACRG	chr6:163148164-163736523:+	0.44	5.82	1.06E-8	Body mass index	
LGG	cis	1	rs34746918	chr19:18539744	LRRC25	chr19:18501955-18508421:-	-0.16	-5.75	1.55E-8	Breast cancer	
LGG	cis	1	rs34746918	chr19:18539744	SSBP4	chr19:18530221-18545371:+	-0.12	-3.51	0.000493	Breast cancer	
LGG	cis	1	rs34751999	chr15:84758419	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.57	4.18E-8	Schizophrenia	
LGG	cis	1	rs34751999	chr15:84758419	LOC388152	chr15:84867600-84898920:-	-0.32	-6.4	3.63E-10	Schizophrenia	
LGG	cis	1	rs34756085	chr5:93556294	FAM172A	chr5:92953432-93447404:-	-0.3	-4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs34758895	chr17:37925468	GSDMB	chr17:38060850-38074903:-	-0.22	-3.49	0.00053	Systemic lupus erythematosus	
LGG	cis	1	rs34762726	chr3:49689210	MST1R	chr3:49924438-49941306:-	-0.2	-3.84	0.000139	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs34762726	chr3:49689210	RBM6	chr3:49977592-50137484:+	0.16	4.52	7.65E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs34762726	chr3:49689210	SEMA3F	chr3:50192848-50226507:+	0.2	4.48	9.11E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs34773528	chr6:163088796	PACRG	chr6:163148164-163736523:+	0.41	5.51	5.69E-8	Body mass index	
LGG	cis	1	rs34774661	chr22:50267508	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs34804433	chr20:47896187	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs34812189	chr6:56806727	BEND6	chr6:56819773-56892138:+	-0.34	-5.85	8.89E-9	Menarche (age at onset)	
LGG	cis	1	rs34812189	chr6:56806727	KIAA1586	chr6:56911384-56920021:+	-0.16	-4.28	2.28E-5	Menarche (age at onset)	
LGG	cis	1	rs34815098	chr7:65292254	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs34817706	chr3:127861058	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.55E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34837468	chr1:41141660	LOC100130557	chr1:41154752-41157933:-	0.26	3.58	0.000373	Depressive and manic episodes in bipolar disorder	
LGG	cis	1	rs34847072	chr5:437862	EXOC3	chr5:443334-467407:+	-0.23	-5.25	2.31E-7	Cystic fibrosis severity	
LGG	cis	1	rs34847140	chr7:117991638	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000179	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs34848593	chr1:113240106	ST7L	chr1:113066142-113162405:-	0.25	5.75	1.61E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs34848593	chr1:113240106	WNT2B	chr1:113010040-113063908:+	0.19	3.9	0.00011	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs34849118	chr2:240919912	NDUFA10	chr2:240900158-240964798:-	0.41	7.84	2.85E-14	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.5	-10.25	1.82E-22	Response to antipsychotic treatment	
LGG	cis	1	rs34854140	chr5:93538169	FAM172A	chr5:92953432-93447404:-	-0.28	-3.91	0.000106	Diabetic retinopathy	
LGG	cis	1	rs34864242	chr22:24175440	C22orf43	chr22:23950640-23974487:-	-0.29	-4.18	3.47E-5	IgG glycosylation	
LGG	cis	1	rs34864242	chr22:24175440	DERL3	chr22:24176691-24181315:-	0.28	5.18	3.17E-7	IgG glycosylation	
LGG	cis	1	rs34865093	chr5:156424767	TIMD4	chr5:156346293-156390266:-	-0.24	-4.45	1.06E-5	Hypertriglyceridemia	
LGG	cis	1	rs34872586	chr17:65863466	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs34878079	chr2:29248199	TRMT61B	chr2:29072690-29093175:-	0.23	4.4	1.31E-5	Diastolic blood pressure (alcohol consumption interaction)	
LGG	cis	1	rs34900908	chr15:85257599	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.31	1.93E-5	Schizophrenia	
LGG	cis	1	rs34900908	chr15:85257599	LOC388152	chr15:84867600-84898920:-	-0.31	-5.75	1.55E-8	Schizophrenia	
LGG	cis	1	rs34900908	chr15:85257599	WDR73	chr15:85186012-85197524:-	-0.19	-3.52	0.000464	Schizophrenia	
LGG	cis	1	rs34910028	chr11:47758449	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs34910028	chr11:47758449	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs34910028	chr11:47758449	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs34918316	chr6:163005386	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs34931503	chr6:163003876	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs34933526	chr7:65383199	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs34949904	chr22:24695298	POM121L9P	chr22:24647589-24661490:+	-0.26	-5.5	6.07E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs34950347	chr7:33308522	BBS9	chr7:33169152-33645680:+	0.47	6.52	1.75E-10	Smooth-surface caries	
LGG	cis	1	rs34955225	chr3:127825078	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs34964872	chr14:104448435	TDRD9	chr14:104394817-104519002:+	0.23	4.6	5.27E-6	Bipolar disorder	
LGG	cis	1	rs34970380	chr7:65431493	CCT6P1	chr7:65216092-65228661:+	0.27	4.97	9.37E-7	Diabetic kidney disease	
LGG	cis	1	rs34974928	chr7:65364006	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs35005608	chr11:107478873	LOC643923	chr11:107462471-107463949:+	-0.43	-7.98	1.06E-14	Common traits (Other)	
LGG	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.59	9.6	4.2E-20	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs35017019	chr6:162982581	PACRG	chr6:163148164-163736523:+	0.33	4.83	1.85E-6	Body mass index	
LGG	cis	1	rs35021112	chr7:118198815	ANKRD7	chr7:117864712-117882782:+	0.2	3.48	0.000549	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs35025342	chr6:151876661	C6orf97	chr6:151815175-151942327:+	0.26	4.2	3.23E-5	Bone mineral density (spine)	
LGG	cis	1	rs35033009	chr1:31857236	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.66	0.000276	Schizophrenia	
LGG	cis	1	rs35044651	chr6:163004142	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs35046236	chr7:65408613	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs35056702	chr6:109736326	AKD1	chr6:109814059-110012415:-	-0.29	-5.89	6.99E-9	Height	
LGG	cis	1	rs35056702	chr6:109736326	MICAL1	chr6:109765268-109787171:-	-0.32	-7.58	1.77E-13	Height	
LGG	cis	1	rs35056702	chr6:109736326	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.65	0.000288	Height	
LGG	cis	1	rs35058610	chr7:65390925	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.55	-12.45	4.0E-31	Forced vital capacity	
LGG	cis	1	rs35062783	chr10:17202869	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.55	6.79E-6	Homocysteine levels	
LGG	cis	1	rs35092540	chr6:163090778	PACRG	chr6:163148164-163736523:+	0.41	5.51	5.84E-8	Body mass index	
LGG	cis	1	rs35102841	chr3:186649683	ST6GAL1	chr3:186648516-186796339:+	-0.26	-4.37	1.55E-5	Drug-induced liver injury (flucloxacillin)	
LGG	cis	1	rs35103567	chr6:163183400	PACRG	chr6:163148164-163736523:+	0.4	5.51	5.83E-8	Body mass index	
LGG	cis	1	rs35106985	chr10:102307542	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs35106985	chr10:102307542	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs35106985	chr10:102307542	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs35115612	chr5:125926839	ALDH7A1	chr5:125878918-125931082:-	0.47	5.79	1.29E-8	Osteoporosis	
LGG	cis	1	rs35126854	chr6:163012443	PACRG	chr6:163148164-163736523:+	0.29	4.43	1.19E-5	Body mass index	
LGG	cis	1	rs35130019	chr17:37983142	GSDMB	chr17:38060850-38074903:-	-0.23	-3.57	0.000399	Systemic lupus erythematosus	
LGG	cis	1	rs35141484	chr4:39088341	PDS5A	chr4:39824484-39979576:-	-0.41	-4.02	6.86E-5	Asthma (childhood onset)	
LGG	cis	1	rs35141484	chr4:39088341	UBE2K	chr4:39699664-39784408:+	-0.57	-5.81	1.13E-8	Asthma (childhood onset)	
LGG	cis	1	rs35141484	chr4:39088341	UGDH	chr4:39500375-39529211:-	-0.44	-3.67	0.000272	Asthma (childhood onset)	
LGG	cis	1	rs35145572	chr3:127847418	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.21	2.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35149210	chr7:65929925	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs35159031	chr5:156475430	TIMD4	chr5:156346293-156390266:-	-0.25	-4.46	1.03E-5	Hypertriglyceridemia	
LGG	cis	1	rs35160687	chr2:86472114	LOC90784	chr2:86247339-86250991:-	0.16	3.48	0.00055	Night sleep phenotypes	
LGG	cis	1	rs35184505	chr5:93561535	FAM172A	chr5:92953432-93447404:-	-0.3	-4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs35184688	chr17:40272406	DHX58	chr17:40253422-40264751:-	-0.19	-3.98	8.02E-5	Fibrinogen levels	
LGG	cis	1	rs35202312	chr6:56788937	BEND6	chr6:56819773-56892138:+	-0.3	-5.42	9.24E-8	Menarche (age at onset)	
LGG	cis	1	rs35202312	chr6:56788937	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.78	0.000174	Menarche (age at onset)	
LGG	cis	1	rs35203738	chr7:74105196	STAG3L2	chr7:74298846-74306731:-	-0.25	-3.65	0.000292	Menarche (age at onset)	
LGG	cis	1	rs35212593	chr15:78831826	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.62	9.45E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35237539	chr17:33929582	PEX12	chr17:33901815-33905656:-	-0.21	-3.91	0.000105	Platelet count	
LGG	cis	1	rs35243555	chr17:65876477	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs35283677	chr7:65359233	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs35296483	chr16:77327018	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs35297609	chr15:84772896	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.58	4.08E-8	Schizophrenia	
LGG	cis	1	rs35297609	chr15:84772896	LOC388152	chr15:84867600-84898920:-	-0.33	-6.55	1.48E-10	Schizophrenia	
LGG	cis	1	rs35297609	chr15:84772896	UBE2Q2P1	chr15:85070427-85114026:-	0.14	3.47	0.000568	Schizophrenia	
LGG	cis	1	rs35300242	chr2:234168790	ATG16L1	chr2:234160217-234204319:+	-0.17	-4.11	4.66E-5	Crohn's disease	
LGG	cis	1	rs35303215	chr22:24801535	POM121L9P	chr22:24647589-24661490:+	-0.27	-5.35	1.33E-7	Gut microbiome composition (summer)	
LGG	cis	1	rs35309034	chr8:126498265	TRIB1	chr8:126442563-126450642:+	-0.23	-4.24	2.65E-5	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs35316992	chr15:85248133	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.29	2.16E-5	Schizophrenia	
LGG	cis	1	rs35316992	chr15:85248133	LOC388152	chr15:84867600-84898920:-	-0.31	-5.76	1.51E-8	Schizophrenia	
LGG	cis	1	rs35316992	chr15:85248133	WDR73	chr15:85186012-85197524:-	-0.19	-3.45	0.000599	Schizophrenia	
LGG	cis	1	rs35324226	chr15:24609999	PWRN1	chr15:24778839-24832924:+	0.2	3.59	0.000366	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs35328831	chr13:26780341	RNF6	chr13:26706253-26796508:-	0.16	3.51	0.000488	Type 2 diabetes	
LGG	cis	1	rs35332070	chr19:23034266	ZNF492	chr19:22817126-22850472:+	-0.21	-4.23	2.83E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs35332498	chr1:211559243	C1orf97	chr1:211556097-211605876:+	0.2	3.54	0.000431	Educational attainment (years of education)	
LGG	cis	1	rs35341640	chr17:18818228	PRPSAP2	chr17:18759663-18834580:+	-0.2	-5.5	6.01E-8	Pancreatic cancer	
LGG	cis	1	rs35341640	chr17:18818228	TRIM16L	chr17:18601311-18639431:+	-0.16	-3.52	0.000466	Pancreatic cancer	
LGG	cis	1	rs353464	chr5:176403023	FGFR4	chr5:176513921-176525124:+	0.22	5.88	7.47E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs353467	chr5:176445698	FGFR4	chr5:176513921-176525124:+	0.22	5.92	6.05E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs353468	chr5:176445494	FGFR4	chr5:176513921-176525124:+	0.22	5.92	6.05E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs353478	chr5:176370988	FGFR4	chr5:176513921-176525124:+	0.22	5.96	4.77E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs353490	chr5:176433063	FGFR4	chr5:176513921-176525124:+	0.21	5.84	9.48E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs353493	chr5:176432585	FGFR4	chr5:176513921-176525124:+	0.22	5.92	6.12E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs35365094	chr11:34767790	APIP	chr11:34896714-34937939:-	0.18	4.12	4.41E-5	Systemic lupus erythematosus and Systemic sclerosis	
LGG	cis	1	rs35382009	chr7:117991641	ANKRD7	chr7:117864712-117882782:+	0.21	3.7	0.000238	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs35382680	chr4:42462886	SHISA3	chr4:42399856-42404503:+	0.26	3.88	0.000121	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs35383933	chr6:163002869	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs35387764	chr20:47902841	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs35391607	chr7:65360829	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs35395156	chr15:67962763	IQCH	chr15:67547188-67794139:+	0.13	3.73	0.000217	Motion sickness	
LGG	cis	1	rs35396113	chr7:65495461	CCT6P1	chr7:65216092-65228661:+	0.27	4.83	1.81E-6	Diabetic kidney disease	
LGG	cis	1	rs354033	chr7:149289464	ZNF746	chr7:149169884-149194898:-	-0.18	-3.63	0.000313	Multiple sclerosis	
LGG	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.5	-10.32	1.01E-22	Response to antipsychotic treatment	
LGG	cis	1	rs35421223	chr3:127829879	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.07	5.4E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35421653	chr7:65363429	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs35424047	chr6:163029715	PACRG	chr6:163148164-163736523:+	0.31	4.5	8.32E-6	Body mass index	
LGG	cis	1	rs35432774	chr7:65393019	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs35435780	chr17:79579602	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs35435780	chr17:79579602	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs35437840	chr3:127825306	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35449999	chr6:163023465	PACRG	chr6:163148164-163736523:+	0.3	4.41	1.26E-5	Body mass index	
LGG	cis	1	rs35454259	chr6:27254475	BTN3A2	chr6:26365398-26378546:+	-0.34	-5.98	4.41E-9	Schizophrenia	
LGG	cis	1	rs35454259	chr6:27254475	ZNF165	chr6:28046572-28057338:+	-0.2	-3.47	0.000566	Schizophrenia	
LGG	cis	1	rs35454259	chr6:27254475	ZNF389	chr6:28129551-28137375:+	0.21	4.01	6.9E-5	Schizophrenia	
LGG	cis	1	rs35457602	chr16:77327520	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs35461422	chr3:186649678	ST6GAL1	chr3:186648516-186796339:+	-0.26	-4.37	1.55E-5	Drug-induced liver injury (flucloxacillin)	
LGG	cis	1	rs35464459	chr10:4964640	AKR1C2	chr10:4964715-5060207:-	0.43	5.73	1.71E-8	Height	
LGG	cis	1	rs35468197	chr10:4978256	AKR1C2	chr10:4964715-5060207:-	0.36	4.84	1.7E-6	Height	
LGG	cis	1	rs35468353	chr16:31056433	MYST1	chr16:31128985-31142713:+	0.15	4.27	2.38E-5	Response to metformin (IC50)	
LGG	cis	1	rs35468353	chr16:31056433	PRSS53	chr16:31094747-31106276:-	-0.17	-4.72	3.06E-6	Response to metformin (IC50)	
LGG	cis	1	rs35506374	chr20:47927883	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.17	3.65E-5	Height	
LGG	cis	1	rs35507120	chr3:53053924	RFT1	chr3:53122503-53164470:-	0.31	3.53	0.000459	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs35513231	chr1:211619503	C1orf97	chr1:211556097-211605876:+	0.2	3.55	0.000428	Educational attainment (years of education)	
LGG	cis	1	rs35515217	chr3:127813811	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.07	5.4E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35522482	chr22:39063015	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs35524990	chr15:85258203	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.31	1.93E-5	Schizophrenia	
LGG	cis	1	rs35524990	chr15:85258203	LOC388152	chr15:84867600-84898920:-	-0.31	-5.75	1.55E-8	Schizophrenia	
LGG	cis	1	rs35524990	chr15:85258203	WDR73	chr15:85186012-85197524:-	-0.19	-3.52	0.000464	Schizophrenia	
LGG	cis	1	rs35526714	chr12:56634639	IL23A	chr12:56732663-56734193:+	0.54	4.64	4.5E-6	Psoriasis vulgaris	
LGG	cis	1	rs35527216	chr6:56791278	BEND6	chr6:56819773-56892138:+	-0.34	-6.15	1.62E-9	Menarche (age at onset)	
LGG	cis	1	rs35527216	chr6:56791278	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.11	4.58E-5	Menarche (age at onset)	
LGG	cis	1	rs35531186	chr3:127841060	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35542501	chr7:65431215	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs35547195	chr7:118007795	ANKRD7	chr7:117864712-117882782:+	0.22	3.86	0.000126	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs35552264	chr20:33544973	PROCR	chr20:33758727-33765164:+	-0.33	-5.85	9.15E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs35559419	chr16:77330324	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs35564624	chr6:151876494	C6orf97	chr6:151815175-151942327:+	0.26	4.21	3.06E-5	Bone mineral density (spine)	
LGG	cis	1	rs35565791	chr22:39063011	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs35568473	chr5:112734881	SRP19	chr5:112196993-112228774:+	0.3	3.66	0.000281	F-cell distribution	
LGG	cis	1	rs35575481	chr6:163007746	PACRG	chr6:163148164-163736523:+	0.29	4.29	2.14E-5	Body mass index	
LGG	cis	1	rs35576914	chr3:53092270	RFT1	chr3:53122503-53164470:-	0.31	3.46	0.000592	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs35577967	chr15:75354621	PPCDC	chr15:75315927-75343066:+	0.25	5.24	2.35E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs35583420	chr6:163214327	PACRG	chr6:163148164-163736523:+	0.41	5.6	3.57E-8	Body mass index	
LGG	cis	1	rs35593345	chr6:163174981	PACRG	chr6:163148164-163736523:+	0.44	5.87	7.96E-9	Body mass index	
LGG	cis	1	rs35602488	chr3:94246319	STX19	chr3:93733215-93747454:-	0.68	9.94	2.51E-21	Blood pressure measurement (high sodium intervention)	
LGG	cis	1	rs35608327	chr15:90369204	AP3S2	chr15:90373832-90456222:-	-0.48	-9.16	1.4E-18	Type 2 diabetes	
LGG	cis	1	rs35610147	chr1:31857206	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.66	0.000276	Schizophrenia	
LGG	cis	1	rs35624992	chr11:47615798	ACP2	chr11:47260854-47270457:-	0.16	3.48	0.000538	Subjective well-being	
LGG	cis	1	rs35624992	chr11:47615798	MTCH2	chr11:47638859-47664206:-	0.25	4.84	1.75E-6	Subjective well-being	
LGG	cis	1	rs35624992	chr11:47615798	PSMC3	chr11:47440320-47448024:-	0.15	3.8	0.000164	Subjective well-being	
LGG	cis	1	rs35628132	chr4:122955788	SPATA5	chr4:123844225-124240602:+	0.16	3.71	0.000231	Emphysema imaging phenotypes	
LGG	cis	1	rs35630683	chr15:85349231	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.27	2.4E-5	Schizophrenia	
LGG	cis	1	rs35630683	chr15:85349231	LOC388152	chr15:84867600-84898920:-	-0.29	-5.41	9.99E-8	Schizophrenia	
LGG	cis	1	rs35630683	chr15:85349231	WDR73	chr15:85186012-85197524:-	-0.19	-3.52	0.000468	Schizophrenia	
LGG	cis	1	rs35630951	chr10:17215649	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.5	8.57E-6	Homocysteine levels	
LGG	cis	1	rs35632377	chr5:156436252	TIMD4	chr5:156346293-156390266:-	-0.26	-4.71	3.3E-6	Hypertriglyceridemia	
LGG	cis	1	rs35635311	chr12:75712220	KRR1	chr12:75891421-75905418:-	0.25	3.58	0.000373	Coronary artery calcification	
LGG	cis	1	rs35643470	chr4:120184948	MYOZ2	chr4:120056939-120108935:+	0.22	4.27	2.31E-5	Corneal astigmatism	
LGG	cis	1	rs35646895	chr13:31469604	C13orf33	chr13:31480312-31499708:+	0.44	5.93	5.69E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs35648189	chr15:84740748	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.57	4.18E-8	Schizophrenia	
LGG	cis	1	rs35648189	chr15:84740748	LOC388152	chr15:84867600-84898920:-	-0.32	-6.4	3.63E-10	Schizophrenia	
LGG	cis	1	rs35658069	chr15:84780146	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.58	3.97E-8	Schizophrenia	
LGG	cis	1	rs35658069	chr15:84780146	LOC388152	chr15:84867600-84898920:-	-0.33	-6.45	2.64E-10	Schizophrenia	
LGG	cis	1	rs35682316	chr7:29181260	CPVL	chr7:29035249-29234892:-	-0.21	-3.83	0.000143	Diabetes related insulin traits	
LGG	cis	1	rs35696109	chr5:115527756	COMMD10	chr5:115420727-115628978:+	0.46	5.52	5.44E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs35704663	chr17:45327321	ITGB3	chr17:45331208-45421658:+	-0.24	-4.75	2.63E-6	Body mass index	
LGG	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs35718987	chr3:134272783	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs35723993	chr6:163008197	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs35724792	chr3:127809616	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35726233	chr15:85337800	GOLGA6L5	chr15:85047738-85060078:-	-0.19	-4.2	3.14E-5	Schizophrenia	
LGG	cis	1	rs35726233	chr15:85337800	LOC388152	chr15:84867600-84898920:-	-0.29	-5.44	8.31E-8	Schizophrenia	
LGG	cis	1	rs35726233	chr15:85337800	WDR73	chr15:85186012-85197524:-	-0.19	-3.45	0.0006	Schizophrenia	
LGG	cis	1	rs35735127	chr7:65300423	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs35736167	chr15:75332002	PPCDC	chr15:75315927-75343066:+	0.27	5.67	2.43E-8	Blood trace element (Zn levels)	
LGG	cis	1	rs35754151	chr6:163074867	PACRG	chr6:163148164-163736523:+	0.37	5.14	4.03E-7	Body mass index	
LGG	cis	1	rs35759030	chr20:47858290	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.11	4.54E-5	Height	
LGG	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.51	-10.25	1.78E-22	Response to antipsychotic treatment	
LGG	cis	1	rs35767091	chr4:56346723	TMEM165	chr4:56262090-56292342:+	-0.17	-4.99	8.22E-7	Personality dimensions	
LGG	cis	1	rs35771425	chr1:211609768	C1orf97	chr1:211556097-211605876:+	0.2	3.49	0.000518	Educational attainment (years of education)	
LGG	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.51	-10.37	6.63E-23	Response to antipsychotic treatment	
LGG	cis	1	rs35808647	chr15:85377441	GOLGA6L5	chr15:85047738-85060078:-	-0.17	-3.61	0.000338	Schizophrenia	
LGG	cis	1	rs35808647	chr15:85377441	LOC388152	chr15:84867600-84898920:-	-0.27	-4.74	2.75E-6	Schizophrenia	
LGG	cis	1	rs35818596	chr6:163001874	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs35820085	chr7:65442758	CCT6P1	chr7:65216092-65228661:+	0.27	4.98	9.04E-7	Diabetic kidney disease	
LGG	cis	1	rs35820211	chr6:163046252	PACRG	chr6:163148164-163736523:+	0.35	4.93	1.15E-6	Body mass index	
LGG	cis	1	rs35825738	chr7:65318027	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs35835884	chr10:127708468	UROS	chr10:127477148-127511837:-	-0.15	-5.02	7.12E-7	Visceral fat	
LGG	cis	1	rs35858501	chr13:31472120	C13orf33	chr13:31480312-31499708:+	0.44	6.06	2.78E-9	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs35868174	chr5:156425303	TIMD4	chr5:156346293-156390266:-	-0.24	-4.45	1.06E-5	Hypertriglyceridemia	
LGG	cis	1	rs35902101	chr11:47795169	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs35902101	chr11:47795169	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs35902101	chr11:47795169	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs35911566	chr6:162994154	PACRG	chr6:163148164-163736523:+	0.33	4.78	2.27E-6	Body mass index	
LGG	cis	1	rs35923019	chr3:186651388	ST6GAL1	chr3:186648516-186796339:+	-0.25	-4.24	2.66E-5	Drug-induced liver injury (flucloxacillin)	
LGG	cis	1	rs35924034	chr16:77330312	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.29E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs35934224	chr22:19872645	TBX1	chr22:19744226-19771110:+	0.33	4.87	1.52E-6	Glaucoma (primary open-angle)	
LGG	cis	1	rs35934224	chr22:19872645	TXNRD2	chr22:19863040-19929359:-	-0.25	-4.86	1.62E-6	Glaucoma (primary open-angle)	
LGG	cis	1	rs35947214	chr3:127833231	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs35955426	chr13:31471381	C13orf33	chr13:31480312-31499708:+	0.43	5.81	1.1E-8	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs35960805	chr15:85343980	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.24	2.67E-5	Schizophrenia	
LGG	cis	1	rs35960805	chr15:85343980	LOC388152	chr15:84867600-84898920:-	-0.29	-5.44	8.2E-8	Schizophrenia	
LGG	cis	1	rs35960997	chr22:30692301	CCDC157	chr22:30752627-30772816:+	0.36	4.83	1.8E-6	Coronary artery calcification	
LGG	cis	1	rs35977534	chr5:176335231	FGFR4	chr5:176513921-176525124:+	0.22	6.12	1.86E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs35988617	chr3:121432902	IQCB1	chr3:121488610-121553926:-	0.37	6.82	2.7E-11	Cognitive performance	
LGG	cis	1	rs36000835	chr10:4979788	AKR1C2	chr10:4964715-5060207:-	0.37	4.96	9.59E-7	Height	
LGG	cis	1	rs36004835	chr15:67951542	IQCH	chr15:67547188-67794139:+	0.13	3.77	0.000181	Motion sickness	
LGG	cis	1	rs36007635	chr6:163009335	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs36016605	chr20:47896145	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.48E-5	Height	
LGG	cis	1	rs36033484	chr7:65390558	CCT6P1	chr7:65216092-65228661:+	0.26	4.73	2.92E-6	Diabetic kidney disease	
LGG	cis	1	rs36033486	chr15:85319692	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.35	1.66E-5	Schizophrenia	
LGG	cis	1	rs36033486	chr15:85319692	LOC388152	chr15:84867600-84898920:-	-0.29	-5.47	7.21E-8	Schizophrenia	
LGG	cis	1	rs36033486	chr15:85319692	WDR73	chr15:85186012-85197524:-	-0.19	-3.47	0.000573	Schizophrenia	
LGG	cis	1	rs36035949	chr6:109736614	AKD1	chr6:109814059-110012415:-	-0.31	-6.39	3.93E-10	Height	
LGG	cis	1	rs36035949	chr6:109736614	MICAL1	chr6:109765268-109787171:-	-0.33	-7.76	4.89E-14	Height	
LGG	cis	1	rs36035949	chr6:109736614	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.57	0.000385	Height	
LGG	cis	1	rs36042757	chr6:163004744	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs36044436	chr7:74089819	STAG3L2	chr7:74298846-74306731:-	-0.25	-3.65	0.000292	Menarche (age at onset)	
LGG	cis	1	rs36059338	chr3:127815927	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.25	2.61E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs36068983	chr7:65408991	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs36071027	chr5:158444274	EBF1	chr5:158122924-158526788:-	0.22	3.81	0.000156	Carotid intima media thickness	
LGG	cis	1	rs36096746	chr10:4975353	AKR1C2	chr10:4964715-5060207:-	0.37	5.14	3.89E-7	Height	
LGG	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.5	-10.27	1.46E-22	Response to antipsychotic treatment	
LGG	cis	1	rs36107456	chr6:162997399	PACRG	chr6:163148164-163736523:+	0.3	4.57	6.09E-6	Body mass index	
LGG	cis	1	rs36113695	chr6:163004733	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs36116701	chr15:63397494	LACTB	chr15:63414032-63434254:+	0.22	4.42	1.19E-5	HDL cholesterol	
LGG	cis	1	rs3612	chr17:20905084	USP22	chr17:20902908-20947073:-	-0.2	-4.44	1.09E-5	Blood trace element (Se levels)	
LGG	cis	1	rs36207871	chr12:56684496	IL23A	chr12:56732663-56734193:+	-0.57	-5.77	1.37E-8	Inflammatory skin disease	
LGG	cis	1	rs36216559	chr2:262335	FAM150B	chr2:279563-288308:-	-0.34	-6.51	1.85E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs36216559	chr2:262335	SNTG2	chr2:946555-1371382:+	0.2	3.71	0.000227	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs365132	chr5:176378574	FGFR4	chr5:176513921-176525124:+	0.22	6.01	3.72E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs36611	chr5:112755990	SRP19	chr5:112196993-112228774:+	0.34	4.06	5.7E-5	F-cell distribution	
LGG	cis	1	rs36613	chr5:112758471	SRP19	chr5:112196993-112228774:+	0.34	4.06	5.8E-5	F-cell distribution	
LGG	cis	1	rs368123	chr6:160719593	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs370278	chr6:160726284	SLC22A3	chr6:160769425-160876013:+	0.35	5.99	4.17E-9	Waist circumference	
LGG	cis	1	rs370301	chr6:160738743	SLC22A3	chr6:160769425-160876013:+	0.36	6.25	8.83E-10	Waist circumference	
LGG	cis	1	rs370586	chr6:160719569	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs371025208	chr20:43928602	SLPI	chr20:43880879-43883206:-	-0.25	-3.65	0.00029	Parental longevity (mother's age at death)	
LGG	cis	1	rs371674	chr21:42695445	FAM3B	chr21:42676177-42729654:+	0.45	8.42	4.11E-16	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LGG	cis	1	rs3731714	chr2:202060820	ALS2CR12	chr2:202153148-202222101:-	-0.24	-4.09	5.02E-5	Trans fatty acid levels	
LGG	cis	1	rs3731714	chr2:202060820	CASP10	chr2:202047621-202094110:+	0.15	3.62	0.000331	Trans fatty acid levels	
LGG	cis	1	rs3731714	chr2:202060820	PPIL3	chr2:201735680-201753999:-	0.28	5.19	3.07E-7	Trans fatty acid levels	
LGG	cis	1	rs3731896	chr2:220146402	RESP18	chr2:220192132-220197899:-	-0.23	-4.85	1.66E-6	Educational attainment	
LGG	cis	1	rs3732276	chr2:242343404	SEPT2	chr2:242254723-242293439:+	0.54	7.85	2.65E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs3732408	chr3:121421179	IQCB1	chr3:121488610-121553926:-	0.37	6.82	2.7E-11	Cognitive performance	
LGG	cis	1	rs3733418	chr4:165878335	C4orf39	chr4:165878100-165880273:+	-0.34	-4.26	2.4E-5	Obesity-related traits	
LGG	cis	1	rs3733419	chr4:165878170	C4orf39	chr4:165878100-165880273:+	-0.32	-4.14	4.16E-5	Obesity-related traits	
LGG	cis	1	rs3734030	chr5:156939880	ADAM19	chr5:156822542-157002768:-	0.17	3.57	0.000399	Pulmonary function;Pulmonary function (interaction)	
LGG	cis	1	rs3734266	chr6:34823187	TCP11	chr6:35085849-35109187:-	0.32	3.54	0.000441	Systemic lupus erythematosus	
LGG	cis	1	rs3734530	chr6:26195408	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs3734530	chr6:26195408	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs3735148	chr7:65971009	ASL	chr7:65540776-65558321:+	-0.22	-5.54	4.96E-8	Aortic root size	
LGG	cis	1	rs3736544	chr4:56309992	TMEM165	chr4:56262090-56292342:+	-0.17	-4.88	1.43E-6	Personality dimensions	
LGG	cis	1	rs3736582	chr10:124742895	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs3736583	chr10:124742792	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs3736584	chr10:124742683	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs3736585	chr10:124742586	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs3736781	chr6:26505362	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.89E-7	Educational attainment	
LGG	cis	1	rs3736782	chr6:26505403	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.89E-7	Educational attainment	
LGG	cis	1	rs3737628	chr1:1722932	MMP23B	chr1:1567560-1570029:+	-0.18	-4.56	6.42E-6	Body mass index	
LGG	cis	1	rs3737628	chr1:1722932	SLC35E2	chr1:1590990-1677431:-	0.15	4.18	3.43E-5	Body mass index	
LGG	cis	1	rs3738000	chr3:130947435	NUDT16P1	chr3:131080689-131083965:+	0.16	4.32	1.89E-5	Carotid intima media thickness	
LGG	cis	1	rs3738483	chr1:150801466	ARNT	chr1:150782186-150849186:-	-0.23	-4.12	4.47E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs3738483	chr1:150801466	OAZ3	chr1:151735445-151743805:+	-0.27	-3.55	0.000425	Congenital left-sided heart lesions	
LGG	cis	1	rs3738848	chr2:73761881	ALMS1P	chr2:73872046-73912692:+	0.39	6.93	1.32E-11	Metabolite levels	
LGG	cis	1	rs3738848	chr2:73761881	NAT8	chr2:73867850-73869537:-	0.27	4.42	1.23E-5	Metabolite levels	
LGG	cis	1	rs3739821	chr9:130702477	PIP5KL1	chr9:130683809-130693076:-	-0.27	-5.45	8.05E-8	Glaucoma (primary angle closure)	
LGG	cis	1	rs3739847	chr9:131911574	CRAT	chr9:131857075-131873070:-	-0.21	-3.81	0.000157	Blood metabolite ratios	
LGG	cis	1	rs3740711	chr11:18379839	GTF2H1	chr11:18343816-18388590:+	0.39	7.41	5.39E-13	Pancreatic cancer	
LGG	cis	1	rs3742320	chr13:33164418	N4BP2L2	chr13:33006930-33112936:-	0.25	5.8	1.17E-8	Body mass index	
LGG	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.44	-10.32	9.88E-23	IgG glycosylation	
LGG	cis	1	rs3742566	chr14:55595839	FBXO34	chr14:55738021-55893431:+	0.14	4.37	1.51E-5	Protein biomarker	
LGG	cis	1	rs3742773	chr14:75579643	ACYP1	chr14:75519930-75530736:-	-0.14	-3.76	0.000188	Height	
LGG	cis	1	rs3742778	chr14:75538217	ACYP1	chr14:75519930-75530736:-	0.14	3.84	0.000139	Height	
LGG	cis	1	rs3742778	chr14:75538217	EIF2B2	chr14:75469612-75476292:+	-0.19	-3.69	0.000251	Height	
LGG	cis	1	rs3742778	chr14:75538217	MLH3	chr14:75480467-75518235:-	-0.21	-3.71	0.000234	Height	
LGG	cis	1	rs3742780	chr14:75505008	EIF2B2	chr14:75469612-75476292:+	0.19	3.7	0.000235	Height	
LGG	cis	1	rs3742780	chr14:75505008	MLH3	chr14:75480467-75518235:-	0.21	3.55	0.000427	Height	
LGG	cis	1	rs3745565	chr19:6690982	GPR108	chr19:6729927-6737633:-	-0.26	-3.68	0.000255	Complement C3 and C4 levels	
LGG	cis	1	rs3745566	chr19:6690966	GPR108	chr19:6729927-6737633:-	0.27	3.8	0.000162	Complement C3 and C4 levels	
LGG	cis	1	rs3745567	chr19:6690771	GPR108	chr19:6729927-6737633:-	0.3	4.33	1.83E-5	Complement C3 and C4 levels	
LGG	cis	1	rs3745734	chr19:49134388	SEC1	chr19:49141296-49185501:+	-0.69	-8.32	8.59E-16	Elevated serum carcinoembryonic antigen levels	
LGG	cis	1	rs3745859	chr19:39196745	LGALS4	chr19:39292312-39303740:-	-0.15	-3.61	0.000343	Heart rate	
LGG	cis	1	rs3745937	chr19:42071289	CEACAM21	chr19:42055886-42093196:+	0.65	16.74	4.16E-50	Schizophrenia	
LGG	cis	1	rs3746016	chr19:32877259	ZNF507	chr19:32836514-32878571:+	0.12	3.55	0.000427	Bipolar disorder	
LGG	cis	1	rs3747113	chr22:24717518	POM121L9P	chr22:24647589-24661490:+	0.26	5.53	5.3E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs3747170	chr22:39067331	LOC646851	chr22:38974125-39052634:-	0.22	6.78	3.36E-11	Resting heart rate	
LGG	cis	1	rs3747172	chr22:39067524	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs3747174	chr22:39069181	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs374748	chr5:127699375	FLJ33630	chr5:127276135-127419299:-	0.28	3.89	0.000112	Obesity (extreme)	
LGG	cis	1	rs3748656	chr1:113236681	ST7L	chr1:113066142-113162405:-	0.24	5.72	1.84E-8	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs3748656	chr1:113236681	WNT2B	chr1:113010040-113063908:+	0.19	3.9	0.00011	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs3748682	chr1:38279987	INPP5B	chr1:38326369-38412729:-	0.2	5.46	7.52E-8	Hypothyroidism	
LGG	cis	1	rs3749237	chr3:49770032	MST1R	chr3:49924438-49941306:-	0.24	4.58	5.91E-6	Resting heart rate	
LGG	cis	1	rs3749237	chr3:49770032	RBM6	chr3:49977592-50137484:+	-0.13	-3.51	0.000498	Resting heart rate	
LGG	cis	1	rs3749591	chr4:120214030	MYOZ2	chr4:120056939-120108935:+	0.24	4.49	8.95E-6	Corneal astigmatism	
LGG	cis	1	rs3750626	chr10:102266316	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.00031	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750626	chr10:102266316	NDUFB8	chr10:102283497-102289636:-	0.17	4.75	2.74E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750626	chr10:102266316	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750627	chr10:102275642	HIF1AN	chr10:102295641-102313680:+	0.2	3.75	0.000201	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750627	chr10:102275642	NDUFB8	chr10:102283497-102289636:-	0.17	4.76	2.53E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750627	chr10:102275642	WNT8B	chr10:102222812-102243397:+	0.48	7.91	1.68E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750629	chr10:102275727	NDUFB8	chr10:102283497-102289636:-	0.15	4.15	3.87E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750629	chr10:102275727	WNT8B	chr10:102222812-102243397:+	0.48	7.94	1.39E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750630	chr10:102275780	HIF1AN	chr10:102295641-102313680:+	0.19	3.65	0.00029	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750630	chr10:102275780	NDUFB8	chr10:102283497-102289636:-	0.17	4.73	2.99E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750630	chr10:102275780	WNT8B	chr10:102222812-102243397:+	0.48	7.81	3.54E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750633	chr10:102308214	NDUFB8	chr10:102283497-102289636:-	0.16	4.58	5.84E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750633	chr10:102308214	WNT8B	chr10:102222812-102243397:+	0.47	7.84	2.91E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750719	chr10:102248950	NDUFB8	chr10:102283497-102289636:-	0.17	4.75	2.68E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750719	chr10:102248950	WNT8B	chr10:102222812-102243397:+	0.52	8.79	2.44E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750720	chr10:102248884	NDUFB8	chr10:102283497-102289636:-	0.17	4.77	2.49E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750720	chr10:102248884	WNT8B	chr10:102222812-102243397:+	0.52	8.92	9.3E-18	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3750908	chr11:71822401	FAM86C	chr11:71498557-71512276:+	-0.47	-4.57	6.25E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs3751972	chr17:26206414	C17orf108	chr17:26205341-26220409:-	0.32	8.21	1.94E-15	Fractional exhaled nitric oxide (childhood)	
LGG	cis	1	rs3751972	chr17:26206414	NOS2	chr17:26083793-26220409:-	-0.62	-10.66	5.28E-24	Fractional exhaled nitric oxide (childhood)	
LGG	cis	1	rs3752749	chr4:1737262	TMEM129	chr4:1717680-1723084:-	-0.17	-3.61	0.000336	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs3752950	chr10:17203356	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.69	3.56E-6	Homocysteine levels	
LGG	cis	1	rs3753908	chr1:202511295	UBE2T	chr1:202300786-202311094:-	-0.12	-3.74	0.000209	Sex ratio	
LGG	cis	1	rs3754210	chr1:150954261	ARNT	chr1:150782186-150849186:-	0.23	4.07	5.5E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs3754210	chr1:150954261	OAZ3	chr1:151735445-151743805:+	0.3	3.8	0.000161	Congenital left-sided heart lesions	
LGG	cis	1	rs3754439	chr1:110615094	ALX3	chr1:110602998-110613322:-	-0.31	-7.14	3.31E-12	Blood metabolite levels	
LGG	cis	1	rs3754439	chr1:110615094	FAM40A	chr1:110574199-110597424:+	0.1	3.54	0.000442	Blood metabolite levels	
LGG	cis	1	rs3754440	chr1:110613674	ALX3	chr1:110602998-110613322:-	-0.33	-7.5	3.0E-13	Blood metabolite levels	
LGG	cis	1	rs3754440	chr1:110613674	FAM40A	chr1:110574199-110597424:+	0.11	3.67	0.00027	Blood metabolite levels	
LGG	cis	1	rs3754482	chr1:212873557	BATF3	chr1:212859760-212873327:-	0.2	4.18	3.41E-5	Leprosy	
LGG	cis	1	rs3755267	chr2:103038587	IL18R1	chr2:102927962-103015215:+	0.36	5.64	2.92E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3755267	chr2:103038587	IL1RL1	chr2:102927962-102968497:+	0.35	4.92	1.19E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3755274	chr2:103002395	IL18R1	chr2:102927962-103015215:+	-0.37	-5.98	4.4E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3755274	chr2:103002395	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.21	2.81E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3757135	chr6:26200707	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.23	2.79E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs3757135	chr6:26200707	HIST1H3E	chr6:26224427-26226589:+	0.65	10.84	1.11E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs3759470	chr13:26798892	RNF6	chr13:26706253-26796508:-	0.15	3.46	0.000581	Type 2 diabetes	
LGG	cis	1	rs3761117	chr20:25388070	ABHD12	chr20:25275380-25371477:-	-0.28	-7.6	1.48E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3761117	chr20:25388070	FAM182A	chr20:26035250-26067552:+	0.55	10.78	1.79E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3761117	chr20:25388070	FAM182B	chr20:25744102-25848786:-	-0.21	-4.81	1.99E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3761430	chr22:31538002	C22orf30	chr22:32072242-32146120:-	0.28	4.11	4.55E-5	Age-related hearing impairment	
LGG	cis	1	rs3761454	chr22:39066820	LOC646851	chr22:38974125-39052634:-	0.22	6.78	3.36E-11	Resting heart rate	
LGG	cis	1	rs3763695	chr10:102269206	HIF1AN	chr10:102295641-102313680:+	0.19	3.58	0.000377	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3763695	chr10:102269206	NDUFB8	chr10:102283497-102289636:-	0.17	4.73	2.96E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3763695	chr10:102269206	WNT8B	chr10:102222812-102243397:+	0.49	8.06	6.07E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs376440	chr6:160727941	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs3764419	chr17:29164023	SUZ12P	chr17:29035714-29097067:+	-0.25	-6.75	4.27E-11	Height	
LGG	cis	1	rs3764617	chr19:49497123	RUVBL2	chr19:49496819-49519182:+	-0.21	-3.59	0.000371	Follicule stimulating hormone	
LGG	cis	1	rs3764619	chr19:49497277	RUVBL2	chr19:49496819-49519182:+	-0.22	-3.78	0.000174	Follicule stimulating hormone	
LGG	cis	1	rs3767395	chr1:202536140	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs3767397	chr1:202534389	UBE2T	chr1:202300786-202311094:-	-0.12	-3.74	0.000209	Sex ratio	
LGG	cis	1	rs3767404	chr1:202519900	UBE2T	chr1:202300786-202311094:-	0.13	4.07	5.55E-5	Sex ratio	
LGG	cis	1	rs3767405	chr1:202516875	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs3767406	chr1:202512246	UBE2T	chr1:202300786-202311094:-	0.12	3.71	0.00023	Sex ratio	
LGG	cis	1	rs3767408	chr1:202498111	UBE2T	chr1:202300786-202311094:-	-0.12	-3.72	0.000222	Sex ratio	
LGG	cis	1	rs3767411	chr1:202471315	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs3767411	chr1:202471315	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.68E-5	Sex ratio	
LGG	cis	1	rs3767412	chr1:202462023	UBE2T	chr1:202300786-202311094:-	-0.14	-4.13	4.29E-5	Sex ratio	
LGG	cis	1	rs3767421	chr1:202432160	UBE2T	chr1:202300786-202311094:-	0.14	4.3	2.03E-5	Sex ratio	
LGG	cis	1	rs3767425	chr1:202413840	UBE2T	chr1:202300786-202311094:-	-0.13	-3.99	7.73E-5	Sex ratio	
LGG	cis	1	rs3768486	chr1:110123971	SYPL2	chr1:110009100-110024763:+	-0.21	-3.84	0.000137	Major depressive disorder	
LGG	cis	1	rs3768547	chr1:212871081	BATF3	chr1:212859760-212873327:-	0.17	3.77	0.000185	Leprosy	
LGG	cis	1	rs3769143	chr2:27450724	SLC5A6	chr2:27422459-27435071:-	0.31	6.21	1.11E-9	Blood metabolite levels	
LGG	cis	1	rs3769825	chr2:202111380	CASP10	chr2:202047621-202094110:+	0.14	4.05	5.96E-5	Chronic lymphocytic leukemia	
LGG	cis	1	rs3769825	chr2:202111380	PPIL3	chr2:201735680-201753999:-	-0.17	-3.62	0.000329	Chronic lymphocytic leukemia	
LGG	cis	1	rs3770066	chr2:86392350	LOC90784	chr2:86247339-86250991:-	-0.39	-4.15	3.85E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs3770087	chr2:86267068	LOC90784	chr2:86247339-86250991:-	-0.47	-5.04	6.43E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs3770090	chr2:86263288	LOC90784	chr2:86247339-86250991:-	-0.47	-5.04	6.43E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs3770752	chr2:37576136	CEBPZ	chr2:37428778-37458740:-	0.17	4.17	3.59E-5	Schizophrenia	
LGG	cis	1	rs3770752	chr2:37576136	QPCT	chr2:37571753-37600464:+	0.15	3.77	0.000184	Schizophrenia	
LGG	cis	1	rs3771170	chr2:102985980	IL18R1	chr2:102927962-103015215:+	-0.36	-5.64	2.88E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3771170	chr2:102985980	IL1RL1	chr2:102927962-102968497:+	-0.35	-4.95	1.02E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3771175	chr2:102960210	IL18R1	chr2:102927962-103015215:+	0.46	6.26	8.59E-10	Asthma	
LGG	cis	1	rs3771180	chr2:102953617	IL18R1	chr2:102927962-103015215:+	-0.5	-6.89	1.72E-11	Asthma	
LGG	cis	1	rs3771180	chr2:102953617	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.97	8.14E-5	Asthma	
LGG	cis	1	rs3771531	chr2:70164034	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.35	1.68E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs3771564	chr2:242355701	ANO7	chr2:242127924-242164791:+	0.37	6.47	2.37E-10	Prostate cancer	
LGG	cis	1	rs3771570	chr2:242382864	ANO7	chr2:242127924-242164791:+	0.41	7.01	8.07E-12	Prostate cancer	
LGG	cis	1	rs377197	chr6:160720991	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs3772128	chr3:121345094	IQCB1	chr3:121488610-121553926:-	0.36	6.71	5.42E-11	Cognitive performance	
LGG	cis	1	rs3772130	chr3:121344140	IQCB1	chr3:121488610-121553926:-	0.36	6.77	3.64E-11	Cognitive performance	
LGG	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.74	13.72	1.65E-36	Diastolic blood pressure	
LGG	cis	1	rs3774808	chr3:48481647	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.19E-5	Longevity	
LGG	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.43	-11.2	4.54E-26	Longevity	
LGG	cis	1	rs3778483	chr6:46627100	SLC25A27	chr6:46620679-46645925:+	-0.19	-6.94	1.22E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs3778483	chr6:46627100	TDRD6	chr6:46655866-46670149:+	0.27	6.81	2.77E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs3778909	chr7:66255646	ASL	chr7:65540776-65558321:+	-0.19	-4.82	1.96E-6	Aortic root size	
LGG	cis	1	rs3778909	chr7:66255646	TYW1	chr7:66461817-66704496:+	0.17	3.65	0.000285	Aortic root size	
LGG	cis	1	rs3781001	chr10:127706028	UROS	chr10:127477148-127511837:-	-0.15	-5.08	5.42E-7	Visceral fat	
LGG	cis	1	rs3781663	chr11:69999252	FADD	chr11:70049269-70053508:+	0.14	3.74	0.000208	Survival in rectal cancer	
LGG	cis	1	rs3781684	chr11:76823484	CAPN5	chr11:76777992-76837196:+	0.33	3.67	0.000272	Cognitive performance	
LGG	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.45	10.96	3.76E-25	Multiple sclerosis	
LGG	cis	1	rs3782130	chr12:58161898	TSFM	chr12:58176536-58191367:+	-0.45	-8.58	1.22E-16	Multiple sclerosis	
LGG	cis	1	rs3783637	chr14:55348118	GCH1	chr14:55308724-55369542:-	-0.28	-4.51	8.23E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs3783638	chr14:55348373	GCH1	chr14:55308724-55369542:-	0.29	4.9	1.33E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs3788042	chr21:44442388	NDUFV3	chr21:44313378-44329772:+	0.27	4.28	2.27E-5	Information processing speed	
LGG	cis	1	rs3788332	chr22:22171567	CCDC116	chr22:21987086-21991615:+	0.19	4.04	6.32E-5	Multiple sclerosis	
LGG	cis	1	rs3788544	chr22:39064966	LOC646851	chr22:38974125-39052634:-	0.22	6.62	9.68E-11	Resting heart rate	
LGG	cis	1	rs3788545	chr22:39065172	LOC646851	chr22:38974125-39052634:-	0.23	6.9	1.59E-11	Resting heart rate	
LGG	cis	1	rs3790012	chr13:36773489	SOHLH2	chr13:36742347-36871992:-	0.36	6.59	1.15E-10	Glucose homeostasis traits	
LGG	cis	1	rs3791220	chr2:227066	FAM150B	chr2:279563-288308:-	-0.34	-6.49	2.07E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791220	chr2:227066	SNTG2	chr2:946555-1371382:+	0.2	3.64	0.000299	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791221	chr2:226933	FAM150B	chr2:279563-288308:-	-0.33	-6.4	3.54E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791221	chr2:226933	SNTG2	chr2:946555-1371382:+	0.2	3.69	0.00025	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791223	chr2:222336	FAM150B	chr2:279563-288308:-	-0.32	-6.05	2.94E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791223	chr2:222336	SNTG2	chr2:946555-1371382:+	0.2	3.73	0.000216	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791224	chr2:221981	FAM150B	chr2:279563-288308:-	-0.32	-6.03	3.14E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3791224	chr2:221981	SNTG2	chr2:946555-1371382:+	0.2	3.74	0.000208	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3792112	chr2:234176609	ATG16L1	chr2:234160217-234204319:+	-0.17	-4.07	5.4E-5	Crohn's disease	
LGG	cis	1	rs3793079	chr6:33767788	BAK1	chr6:33540324-33548070:-	-0.15	-3.57	0.000396	Crohn's disease	
LGG	cis	1	rs3793079	chr6:33767788	LEMD2	chr6:33738991-33756906:-	-0.14	-4.52	7.82E-6	Crohn's disease	
LGG	cis	1	rs3793706	chr10:102269085	NDUFB8	chr10:102283497-102289636:-	-0.15	-4.2	3.12E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793706	chr10:102269085	WNT8B	chr10:102222812-102243397:+	-0.48	-8.04	6.58E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793771	chr10:102222957	HIF1AN	chr10:102295641-102313680:+	0.18	3.62	0.000328	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793771	chr10:102222957	NDUFB8	chr10:102283497-102289636:-	0.16	4.42	1.22E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793771	chr10:102222957	WNT8B	chr10:102222812-102243397:+	0.51	8.64	8.16E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793772	chr10:102222825	HIF1AN	chr10:102295641-102313680:+	0.2	3.93	9.86E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793772	chr10:102222825	NDUFB8	chr10:102283497-102289636:-	0.16	4.73	2.9E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793772	chr10:102222825	WNT8B	chr10:102222812-102243397:+	0.49	8.39	5.13E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs3793938	chr11:71823133	FAM86C	chr11:71498557-71512276:+	-0.46	-4.41	1.28E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs3794695	chr16:72097827	HP	chr16:72088508-72094957:+	1	19.35	1.98E-62	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs3794695	chr16:72097827	HPR	chr16:72097125-72111144:+	1.03	24.34	2.1E-86	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs3794695	chr16:72097827	TXNL4B	chr16:72072001-72128215:-	0.75	12.38	7.68E-31	Haptoglobin levels;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs3795432	chr1:31829873	ZCCHC17	chr1:31769842-31837780:+	0.16	3.95	8.92E-5	Schizophrenia	
LGG	cis	1	rs3795819	chr1:113234179	RHOC	chr1:113243749-113250025:-	0.12	3.6	0.000348	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs3795819	chr1:113234179	ST7L	chr1:113066142-113162405:-	-0.23	-5.37	1.2E-7	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs3795819	chr1:113234179	WNT2B	chr1:113010040-113063908:+	-0.19	-3.88	0.000121	Diastolic blood pressure;Blood pressure	
LGG	cis	1	rs3796352	chr3:52913279	GLT8D1	chr3:52728505-52740048:-	0.28	3.66	0.000276	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs3796352	chr3:52913279	RFT1	chr3:53122503-53164470:-	0.31	3.5	0.000504	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs3796689	chr4:185649866	MLF1IP	chr4:185615220-185655286:-	-0.26	-7.51	2.82E-13	Kawasaki disease	
LGG	cis	1	rs3798867	chr6:84331841	SNAP91	chr6:84262607-84419127:-	0.08	4.05	5.92E-5	Schizophrenia	
LGG	cis	1	rs3798869	chr6:84328660	SNAP91	chr6:84262607-84419127:-	-0.07	-3.83	0.000144	Schizophrenia	
LGG	cis	1	rs3800457	chr6:34663598	C6orf106	chr6:34555066-34664625:-	-0.29	-5.61	3.37E-8	Pubertal anthropometrics	
LGG	cis	1	rs3800812	chr7:66223461	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.22E-6	Aortic root size	
LGG	cis	1	rs3800812	chr7:66223461	TYW1	chr7:66461817-66704496:+	0.18	3.77	0.000184	Aortic root size	
LGG	cis	1	rs380143	chr6:160731356	SLC22A3	chr6:160769425-160876013:+	0.35	6.11	2.09E-9	Waist circumference	
LGG	cis	1	rs3803538	chr15:90891771	IQGAP1	chr15:90931473-91045475:+	0.12	3.78	0.000175	Rheumatoid arthritis	
LGG	cis	1	rs3803539	chr15:90891982	IQGAP1	chr15:90931473-91045475:+	0.15	4.32	1.86E-5	Rheumatoid arthritis	
LGG	cis	1	rs3805108	chr3:183691650	ABCC5	chr3:183637726-183735727:-	0.11	3.57	0.000386	Anterior chamber depth	
LGG	cis	1	rs3805152	chr4:56359658	TMEM165	chr4:56262090-56292342:+	-0.17	-4.95	1.01E-6	Personality dimensions	
LGG	cis	1	rs3805154	chr4:56363927	TMEM165	chr4:56262090-56292342:+	-0.17	-4.92	1.18E-6	Personality dimensions	
LGG	cis	1	rs3805157	chr4:56364103	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs3805174	chr4:79511363	ANXA3	chr4:79472742-79531602:+	-0.29	-6.79	3.17E-11	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs3805383	chr4:56475338	SRD5A3	chr4:56212409-56237866:+	-0.17	-3.6	0.000347	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs3805389	chr4:56482750	SRD5A3	chr4:56212409-56237866:+	-0.19	-4	7.22E-5	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs3806108	chr6:33767579	BAK1	chr6:33540324-33548070:-	-0.15	-3.57	0.000396	Crohn's disease	
LGG	cis	1	rs3806108	chr6:33767579	LEMD2	chr6:33738991-33756906:-	-0.14	-4.52	7.82E-6	Crohn's disease	
LGG	cis	1	rs3806407	chr1:156251742	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806407	chr1:156251742	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806408	chr1:156252137	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806408	chr1:156252137	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806409	chr1:156252291	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806409	chr1:156252291	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs3806689	chr3:186435077	KNG1	chr3:186435120-186461741:+	-0.15	-3.49	0.000535	Adiponectin levels	
LGG	cis	1	rs3806988	chr6:49431569	CENPQ	chr6:49431096-49460820:+	-0.23	-5.25	2.27E-7	Folate pathway vitamin levels	
LGG	cis	1	rs3809861	chr17:45330066	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs3809862	chr17:45330428	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs3809868	chr17:45750596	C17orf57	chr17:45401142-45518675:+	-0.15	-3.65	0.000291	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs3809868	chr17:45750596	LOC100272146	chr17:45500843-45504056:+	-0.15	-3.79	0.000167	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs3810174	chr19:41904165	ATP5SL	chr19:41937224-41945810:-	0.16	4.61	5.13E-6	Height	
LGG	cis	1	rs3810174	chr19:41904165	B9D2	chr19:41860322-41870078:-	-0.1	-3.48	0.000556	Height	
LGG	cis	1	rs3810175	chr19:41904396	ATP5SL	chr19:41937224-41945810:-	-0.18	-5.07	5.77E-7	Height	
LGG	cis	1	rs3810175	chr19:41904396	B9D2	chr19:41860322-41870078:-	0.1	3.53	0.000461	Height	
LGG	cis	1	rs3810176	chr19:49496786	RUVBL2	chr19:49496819-49519182:+	0.2	3.63	0.000314	Follicule stimulating hormone	
LGG	cis	1	rs3810429	chr19:18543270	LRRC25	chr19:18501955-18508421:-	-0.16	-5.67	2.46E-8	Breast cancer	
LGG	cis	1	rs3810610	chr22:22115498	CCDC116	chr22:21987086-21991615:+	0.17	3.58	0.00038	Multiple sclerosis	
LGG	cis	1	rs381262	chr20:47933479	ARFGEF2	chr20:47538275-47653229:+	-0.12	-3.6	0.000357	Height	
LGG	cis	1	rs381262	chr20:47933479	CSE1L	chr20:47662838-47713484:+	-0.16	-3.57	0.000389	Height	
LGG	cis	1	rs3812719	chr2:166909559	SCN2A	chr2:166095912-166248818:+	-0.09	-3.46	0.000597	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs3812719	chr2:166909559	TTC21B	chr2:166713988-166810348:-	-0.13	-3.77	0.000186	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.39	-6.97	1.01E-11	Metabolite levels	
LGG	cis	1	rs3813227	chr2:73651967	NAT8	chr2:73867850-73869537:-	-0.26	-4.38	1.46E-5	Metabolite levels	
LGG	cis	1	rs3814184	chr10:69966251	PBLD	chr10:70042417-70092684:-	0.42	7.3	1.17E-12	Optic nerve measurement (disc area)	
LGG	cis	1	rs3814486	chr8:58191226	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs3814721	chr11:71709272	FAM86C	chr11:71498557-71512276:+	0.51	5.11	4.69E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs3814855	chr14:88933360	KCNK10	chr14:88646454-88793256:-	-0.19	-3.8	0.000165	Coronary artery calcification	
LGG	cis	1	rs3814855	chr14:88933360	SPATA7	chr14:88852012-88904802:+	-0.52	-9.48	1.13E-19	Coronary artery calcification	
LGG	cis	1	rs3815413	chr4:17654648	MED28	chr4:17616273-17629791:+	0.2	4.2	3.15E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3815414	chr4:17606659	MED28	chr4:17616273-17629791:+	-0.18	-3.83	0.000143	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3815700	chr19:33093252	C19orf40	chr19:33463148-33467955:+	0.21	3.79	0.000169	Eosinophilic esophagitis	
LGG	cis	1	rs3815700	chr19:33093252	PDCD5	chr19:33072104-33078322:+	-0.17	-4.21	3.05E-5	Eosinophilic esophagitis	
LGG	cis	1	rs3815824	chr16:29852860	LOC440356	chr16:29875004-29879374:+	-0.25	-3.99	7.5E-5	Multiple sclerosis	
LGG	cis	1	rs3816037	chr19:41918009	ATP5SL	chr19:41937224-41945810:-	0.17	4.88	1.41E-6	Height	
LGG	cis	1	rs3817181	chr17:61776538	DDX42	chr17:61851567-61896676:+	-0.16	-3.71	0.000235	Body mass index	
LGG	cis	1	rs3817181	chr17:61776538	FTSJ3	chr17:61896795-61905031:-	0.42	8.42	4.29E-16	Body mass index	
LGG	cis	1	rs3817181	chr17:61776538	SMARCD2	chr17:61909441-61920351:-	0.17	3.8	0.00016	Body mass index	
LGG	cis	1	rs3818262	chr20:47741556	ARFGEF2	chr20:47538275-47653229:+	0.11	3.98	7.91E-5	Anger	
LGG	cis	1	rs3818262	chr20:47741556	CSE1L	chr20:47662838-47713484:+	0.18	4.94	1.07E-6	Anger	
LGG	cis	1	rs3818361	chr1:207784968	CR1	chr1:207669473-207815109:+	-0.38	-6.64	8.34E-11	Alzheimer's disease (late onset)	
LGG	cis	1	rs3819787	chr1:71443066	PTGER3	chr1:71318036-71513491:-	0.16	3.82	0.000148	IgG glycosylation	
LGG	cis	1	rs3819788	chr1:71443083	PTGER3	chr1:71318036-71513491:-	0.16	3.79	0.000167	IgG glycosylation	
LGG	cis	1	rs3820136	chr1:152884438	SMCP	chr1:152850798-152857515:+	-0.33	-5.04	6.64E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3820541	chr1:150848681	ARNT	chr1:150782186-150849186:-	0.24	3.82	0.000149	Congenital left-sided heart lesions	
LGG	cis	1	rs3820541	chr1:150848681	OAZ3	chr1:151735445-151743805:+	0.31	3.5	0.000506	Congenital left-sided heart lesions	
LGG	cis	1	rs3820543	chr1:150812858	ARNT	chr1:150782186-150849186:-	0.22	3.58	0.00038	Congenital left-sided heart lesions	
LGG	cis	1	rs3820543	chr1:150812858	OAZ3	chr1:151735445-151743805:+	0.3	3.55	0.000422	Congenital left-sided heart lesions	
LGG	cis	1	rs3821301	chr2:160087535	CCDC148	chr2:159028479-159313214:-	-0.26	-3.56	0.000411	Sudden cardiac arrest	
LGG	cis	1	rs3821383	chr3:169489946	LOC100128164	chr3:169661774-169684522:-	-0.2	-3.57	0.000397	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs3821383	chr3:169489946	LRRC34	chr3:169511266-169530720:-	-0.29	-5.11	4.68E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs3821815	chr3:186434262	KNG1	chr3:186435120-186461741:+	-0.15	-3.49	0.000528	Adiponectin levels	
LGG	cis	1	rs3823114	chr6:49431720	CENPQ	chr6:49431096-49460820:+	-0.23	-5.11	4.61E-7	Folate pathway vitamin levels	
LGG	cis	1	rs3824754	chr10:104614350	SFXN2	chr10:104474298-104498946:+	-0.28	-3.51	0.000496	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs3824755	chr10:104595849	SFXN2	chr10:104474298-104498946:+	-0.3	-3.97	8.35E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LGG	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.49	11.73	3.41E-28	Multiple sclerosis	
LGG	cis	1	rs3825079	chr12:58203354	TSFM	chr12:58176536-58191367:+	-0.45	-8.39	5.34E-16	Multiple sclerosis	
LGG	cis	1	rs3825079	chr12:58203354	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-3.5	0.000511	Multiple sclerosis	
LGG	cis	1	rs3825253	chr12:109109281	SELPLG	chr12:109015682-109027670:-	-0.2	-3.53	0.000461	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs3825611	chr14:55348837	GCH1	chr14:55308724-55369542:-	-0.29	-4.8	2.13E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs3825613	chr14:55593172	FBXO34	chr14:55738021-55893431:+	0.15	4.51	8.21E-6	Protein biomarker	
LGG	cis	1	rs3826061	chr16:88927221	GALNS	chr16:88880143-88923374:-	-0.25	-6.04	2.99E-9	Parkinson disease and lewy body pathology	
LGG	cis	1	rs3826061	chr16:88927221	TRAPPC2L	chr16:88922628-88927591:+	-0.43	-12.79	1.6E-32	Parkinson disease and lewy body pathology	
LGG	cis	1	rs3826331	chr17:38150492	GSDMA	chr17:38119226-38134019:+	0.69	14.69	9.65E-41	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs3826656	chr19:51726613	CLEC11A	chr19:51226605-51228979:+	0.18	3.97	8.4E-5	Alzheimer's disease	
LGG	cis	1	rs3827066	chr20:44586023	WFDC3	chr20:44402847-44420547:-	-0.5	-7.69	8.39E-14	Abdominal aortic aneurysm	
LGG	cis	1	rs3827066	chr20:44586023	ZSWIM1	chr20:44509848-44513904:+	0.24	4.33	1.78E-5	Abdominal aortic aneurysm	
LGG	cis	1	rs3827316	chr22:23468538	RTDR1	chr22:23401594-23484241:-	-0.16	-3.73	0.000211	Bone mineral density	
LGG	cis	1	rs3827357	chr22:39079413	LOC646851	chr22:38974125-39052634:-	0.22	6.69	6.22E-11	Resting heart rate	
LGG	cis	1	rs3828165	chr2:220889	FAM150B	chr2:279563-288308:-	-0.33	-6.19	1.3E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3828165	chr2:220889	SNTG2	chr2:946555-1371382:+	0.2	3.66	0.00028	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs3828267	chr2:190531615	ORMDL1	chr2:190634994-190649097:-	0.35	5.13	4.19E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs3828996	chr7:33195526	BBS9	chr7:33169152-33645680:+	0.46	5.96	4.83E-9	Smooth-surface caries	
LGG	cis	1	rs3829218	chr11:58331309	ZFP91-CNTF	chr11:58346587-58393203:+	0.35	5.82	1.05E-8	Lymphoma	
LGG	cis	1	rs3829251	chr11:71194559	KRTAP5-9	chr11:71259466-71260653:+	0.28	4.54	7.02E-6	Vitamin D levels	
LGG	cis	1	rs3829640	chr18:72174980	CNDP2	chr18:72163597-72188356:+	0.25	5.71	1.92E-8	Refractive error	
LGG	cis	1	rs383402	chr7:65586653	CCT6P1	chr7:65216092-65228661:+	-0.26	-4.79	2.18E-6	Diabetic kidney disease	
LGG	cis	1	rs384156	chr6:160745751	SLC22A3	chr6:160769425-160876013:+	0.34	5.69	2.22E-8	Waist circumference	
LGG	cis	1	rs3845340	chr1:152889661	SMCP	chr1:152850798-152857515:+	-0.31	-4.67	3.85E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.28	7.32	1.05E-12	Height	
LGG	cis	1	rs3846055	chr3:134203973	CEP63	chr3:134204575-134293852:+	0.19	3.48	0.000544	Height	
LGG	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.29	7.64	1.12E-13	Height	
LGG	cis	1	rs3846056	chr3:134227292	CEP63	chr3:134204575-134293852:+	0.2	3.77	0.000182	Height	
LGG	cis	1	rs3846357	chr4:17635887	MED28	chr4:17616273-17629791:+	0.2	4.22	2.89E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3846966	chr7:74113141	STAG3L2	chr7:74298846-74306731:-	-0.26	-3.88	0.00012	Menarche (age at onset)	
LGG	cis	1	rs3847669	chr12:75949158	GLIPR1L2	chr12:75784889-75825591:+	-0.35	-6.01	3.68E-9	Polycystic ovary syndrome	
LGG	cis	1	rs3848129	chr15:50892064	SPPL2A	chr15:50999739-51057910:-	0.12	3.84	0.000137	QT interval	
LGG	cis	1	rs3848130	chr15:50892111	SPPL2A	chr15:50999739-51057910:-	0.12	4.04	6.26E-5	QT interval	
LGG	cis	1	rs3850304	chr14:59895019	C14orf149	chr14:59939406-59951126:-	-0.44	-4.78	2.38E-6	Schizophrenia	
LGG	cis	1	rs3850304	chr14:59895019	JKAMP	chr14:59951161-59972080:+	0.41	4.01	7.01E-5	Schizophrenia	
LGG	cis	1	rs3850838	chr1:150065378	RPRD2	chr1:150336990-150449039:+	-0.15	-3.78	0.000173	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs3851050	chr10:81882370	SFTPD	chr10:81697498-81708861:-	0.16	3.47	0.000559	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs3851296	chr1:205253839	TMEM81	chr1:205052258-205053588:-	-0.21	-4.51	8.09E-6	Mean platelet volume	
LGG	cis	1	rs3856807	chr3:12527600	TSEN2	chr3:12525931-12581122:+	0.31	3.59	0.000361	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs3857067	chr4:95026434	SMARCAD1	chr4:95128759-95212441:+	0.11	3.45	0.000599	QT interval	
LGG	cis	1	rs3857422	chr5:150268609	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs3857688	chr7:66127806	ASL	chr7:65540776-65558321:+	0.19	4.95	1.01E-6	Aortic root size	
LGG	cis	1	rs3857688	chr7:66127806	TYW1	chr7:66461817-66704496:+	-0.17	-3.57	0.000393	Aortic root size	
LGG	cis	1	rs3858534	chr12:75947084	GLIPR1L2	chr12:75784889-75825591:+	-0.34	-5.93	5.73E-9	Polycystic ovary syndrome	
LGG	cis	1	rs3860055	chr2:17775828	GEN1	chr2:17935162-17966632:+	0.26	4.09	5.08E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs3860444	chr2:103007623	IL18R1	chr2:102927962-103015215:+	-0.38	-6.14	1.71E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3860444	chr2:103007623	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.35	1.34E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs3862356	chr11:89150372	NOX4	chr11:89057524-89322779:-	0.34	3.85	0.000136	Homocysteine levels	
LGG	cis	1	rs3866330	chr3:49582994	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.52	7.72E-6	Menarche (age at onset)	
LGG	cis	1	rs3866330	chr3:49582994	GMPPB	chr3:49758932-49761384:-	-0.23	-4.58	5.96E-6	Menarche (age at onset)	
LGG	cis	1	rs3870339	chr3:49536863	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.14	4.02E-5	Menarche (age at onset)	
LGG	cis	1	rs3870339	chr3:49536863	GMPPB	chr3:49758932-49761384:-	-0.22	-4.34	1.71E-5	Menarche (age at onset)	
LGG	cis	1	rs3870339	chr3:49536863	NCKIPSD	chr3:48711280-48723334:-	0.15	3.49	0.00052	Menarche (age at onset)	
LGG	cis	1	rs3870341	chr3:49584745	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.52	7.72E-6	Menarche (age at onset)	
LGG	cis	1	rs3870341	chr3:49584745	GMPPB	chr3:49758932-49761384:-	-0.23	-4.58	5.96E-6	Menarche (age at onset)	
LGG	cis	1	rs38752	chr7:111078912	IMMP2L	chr7:110303110-111202538:-	0.19	3.7	0.000237	Schizophrenia	
LGG	cis	1	rs387676	chr7:65598220	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs3885839	chr7:65290403	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs3886589	chr11:71669487	FAM86C	chr11:71498557-71512276:+	0.5	4.92	1.18E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs3890604	chr3:41760625	ULK4	chr3:41288091-42003660:-	0.74	14.31	4.61E-39	Diastolic blood pressure	
LGG	cis	1	rs3891585	chr2:66756976	MEIS1	chr2:66662532-66799890:+	0.18	4.27	2.37E-5	PR interval	
LGG	cis	1	rs3892761	chr12:54070445	PRR13	chr12:53835433-53840426:+	-0.13	-3.65	0.000292	Height	
LGG	cis	1	rs389404	chr19:6693387	GPR108	chr19:6729927-6737633:-	-0.25	-3.61	0.00034	Complement C3 and C4 levels	
LGG	cis	1	rs3900064	chr5:150264414	LOC134466	chr5:150310000-150326146:-	-0.39	-4.49	8.72E-6	Crohn's disease	
LGG	cis	1	rs3901668	chr1:202501761	UBE2T	chr1:202300786-202311094:-	-0.14	-4.23	2.76E-5	Sex ratio	
LGG	cis	1	rs3905330	chr3:49550774	AMIGO3	chr3:49754268-49757238:-	-0.19	-4.46	1.01E-5	Menarche (age at onset)	
LGG	cis	1	rs3905330	chr3:49550774	GMPPB	chr3:49758932-49761384:-	-0.23	-4.52	7.61E-6	Menarche (age at onset)	
LGG	cis	1	rs3906527	chr5:150266392	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs3906528	chr5:150266718	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs3910272	chr2:26287842	GPR113	chr2:26531041-26569685:-	-0.22	-3.49	0.000522	Gut microbiome composition (summer)	
LGG	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.57	-9.54	6.49E-20	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs3916	chr12:121177272	SPPL3	chr12:121201036-121342151:-	-0.22	-3.78	0.000175	Urinary metabolites (H-NMR features)	
LGG	cis	1	rs3925724	chr1:150080265	RPRD2	chr1:150336990-150449039:+	-0.15	-3.77	0.000182	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs3931020	chr1:75235317	CRYZ	chr1:75171175-75199092:-	-0.21	-5.1	4.96E-7	Resistin levels	
LGG	cis	1	rs393271	chr6:160742239	SLC22A3	chr6:160769425-160876013:+	0.36	6.08	2.4E-9	Waist circumference	
LGG	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.28	7.37	7.08E-13	Height	
LGG	cis	1	rs3932818	chr3:134206069	CEP63	chr3:134204575-134293852:+	0.19	3.54	0.000442	Height	
LGG	cis	1	rs3933453	chr4:17636319	MED28	chr4:17616273-17629791:+	0.22	4.59	5.6E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.79	-15.64	5.03E-45	Diastolic blood pressure	
LGG	cis	1	rs3935543	chr17:79579874	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs3935543	chr17:79579874	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs3935969	chr17:65881959	LOC440461	chr17:66194801-66196436:+	0.26	4.31	1.99E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs3942852	chr11:48115089	AGBL2	chr11:47681145-47736302:-	-0.24	-4.19	3.32E-5	Acute lymphoblastic leukemia (childhood)	
LGG	cis	1	rs3943299	chr17:20920611	USP22	chr17:20902908-20947073:-	-0.2	-4.54	7.0E-6	Blood trace element (Se levels)	
LGG	cis	1	rs394463	chr6:160732925	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs39474	chr7:118128820	ANKRD7	chr7:117864712-117882782:+	0.22	3.82	0.000153	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs39481	chr7:118134635	ANKRD7	chr7:117864712-117882782:+	0.22	3.82	0.000153	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs39485	chr7:118143329	ANKRD7	chr7:117864712-117882782:+	0.21	3.75	0.000199	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs39486	chr7:118144823	ANKRD7	chr7:117864712-117882782:+	0.21	3.67	0.000269	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs39489	chr7:118151455	ANKRD7	chr7:117864712-117882782:+	0.23	4.06	5.78E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs3960018	chr15:90383307	AP3S2	chr15:90373832-90456222:-	-0.49	-9.39	2.25E-19	Type 2 diabetes	
LGG	cis	1	rs396007	chr5:176518426	FGFR4	chr5:176513921-176525124:+	-0.17	-3.67	0.000268	Height	
LGG	cis	1	rs396508	chr16:20682354	ACSM5	chr16:20420856-20452278:+	0.13	3.53	0.000457	Schizophrenia	
LGG	cis	1	rs397119	chr20:25440187	ABHD12	chr20:25275380-25371477:-	0.26	7.12	3.97E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs397119	chr20:25440187	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	2.98E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs397119	chr20:25440187	FAM182B	chr20:25744102-25848786:-	0.21	4.81	1.99E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3976455	chr16:29861447	LOC440356	chr16:29875004-29879374:+	-0.25	-4.12	4.53E-5	Multiple sclerosis	
LGG	cis	1	rs398036	chr20:25439850	ABHD12	chr20:25275380-25371477:-	0.26	7.12	3.83E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs398036	chr20:25439850	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	2.99E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs398036	chr20:25439850	FAM182B	chr20:25744102-25848786:-	0.21	4.8	2.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs3981131	chr7:65951677	ASL	chr7:65540776-65558321:+	-0.22	-5.66	2.62E-8	Aortic root size	
LGG	cis	1	rs3981351	chr10:115515120	CASP7	chr10:115438935-115490662:+	0.42	9.93	2.77E-21	Obesity-related traits	
LGG	cis	1	rs39841	chr5:96120170	ERAP1	chr5:96096515-96149837:-	-0.4	-9.05	3.27E-18	Inflammatory skin disease	
LGG	cis	1	rs39841	chr5:96120170	ERAP2	chr5:96211644-96255398:+	0.4	6.82	2.63E-11	Inflammatory skin disease	
LGG	cis	1	rs399367	chr6:160719030	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs3999544	chr6:26285867	HIST1H3E	chr6:26224427-26226589:+	0.24	4.94	1.08E-6	Educational attainment	
LGG	cis	1	rs401166	chr20:25446308	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs401166	chr20:25446308	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs401166	chr20:25446308	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs401882	chr6:160723541	SLC22A3	chr6:160769425-160876013:+	0.34	5.91	6.27E-9	Waist circumference	
LGG	cis	1	rs402051	chr6:160730132	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs402387	chr6:160723397	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	4.96E-9	Waist circumference	
LGG	cis	1	rs402418	chr7:65509469	CCT6P1	chr7:65216092-65228661:+	0.26	4.71	3.16E-6	Diabetic kidney disease	
LGG	cis	1	rs402511	chr5:176434440	FGFR4	chr5:176513921-176525124:+	0.22	5.92	6.12E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs4037	chr10:97365820	TCTN3	chr10:97423154-97453900:-	0.19	3.84	0.000138	Blood metabolite levels	
LGG	cis	1	rs4038129	chr2:17774746	GEN1	chr2:17935162-17966632:+	0.26	4.2	3.23E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs4038130	chr2:17774912	GEN1	chr2:17935162-17966632:+	-0.26	-4.2	3.23E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs40396	chr5:130708044	SLC22A5	chr5:131705401-131731302:+	-0.25	-4.37	1.53E-5	Life satisfaction	
LGG	cis	1	rs404394	chr20:25447896	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs404394	chr20:25447896	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs404394	chr20:25447896	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4045344	chr5:595870	SDHA	chr5:218356-256812:+	-0.2	-4.38	1.45E-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs405137	chr6:160731591	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs4058847	chr1:150058727	RPRD2	chr1:150336990-150449039:+	-0.15	-3.86	0.000127	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs406151	chr6:160717711	SLC22A3	chr6:160769425-160876013:+	0.34	5.92	6.16E-9	Waist circumference	
LGG	cis	1	rs406900	chr6:88085447	C6orf163	chr6:88057220-88075180:+	0.2	3.58	0.000385	Depressive episodes in bipolar disorder	
LGG	cis	1	rs407133	chr21:46571889	LOC642852	chr21:46707967-46717268:+	-0.16	-3.48	0.00055	Body mass index	
LGG	cis	1	rs4073405	chr11:45323853	PEX16	chr11:45931221-45939674:-	-0.14	-4.15	3.87E-5	Schizophrenia	
LGG	cis	1	rs4073405	chr11:45323853	SLC35C1	chr11:45825623-45834566:+	-0.17	-3.5	0.000504	Schizophrenia	
LGG	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.15	4.23	2.79E-5	Body mass index	
LGG	cis	1	rs4073846	chr1:46462881	MUTYH	chr1:45794915-45806142:-	-0.13	-4.77	2.46E-6	Body mass index	
LGG	cis	1	rs4074170	chr17:28381141	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4074232	chr11:977682	MUC6	chr11:1012824-1036706:-	-0.17	-3.7	0.000241	Alzheimer's disease (late onset)	
LGG	cis	1	rs4074493	chr1:231172281	FAM89A	chr1:231154704-231175995:-	0.28	4.79	2.17E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4074494	chr1:231172249	FAM89A	chr1:231154704-231175995:-	0.26	4.67	3.95E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4074915	chr17:79579230	PDE6G	chr17:79617489-79623607:-	0.23	5.98	4.19E-9	Eye color traits	
LGG	cis	1	rs4074915	chr17:79579230	TSPAN10	chr17:79609349-79615778:+	-0.68	-17.39	3.82E-53	Eye color traits	
LGG	cis	1	rs4074916	chr17:79579248	PDE6G	chr17:79617489-79623607:-	0.23	5.99	4.09E-9	Eye color traits	
LGG	cis	1	rs4074916	chr17:79579248	TSPAN10	chr17:79609349-79615778:+	-0.68	-17.45	1.99E-53	Eye color traits	
LGG	cis	1	rs4075623	chr17:28386526	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4075892	chr1:231171807	FAM89A	chr1:231154704-231175995:-	0.27	4.61	5.22E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.72	3.13E-6	Body mass index	
LGG	cis	1	rs4076006	chr1:46438076	MUTYH	chr1:45794915-45806142:-	0.13	4.96	9.68E-7	Body mass index	
LGG	cis	1	rs4076054	chr11:2231341	C11orf21	chr11:2317507-2323143:-	0.26	4.52	7.86E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs4077341	chr8:22962348	TNFRSF10C	chr8:22941868-22974948:+	-0.18	-4.15	3.94E-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score)	
LGG	cis	1	rs4077468	chr1:205914757	PM20D1	chr1:205797154-205819245:-	0.32	5.92	6.11E-9	Cystic fibrosis-related diabetes	
LGG	cis	1	rs4077469	chr1:205914885	PM20D1	chr1:205797154-205819245:-	0.32	5.92	6.11E-9	Cystic fibrosis-related diabetes	
LGG	cis	1	rs4077515	chr9:139266496	C8G	chr9:139839698-139841426:+	0.17	3.51	0.000497	IgA nephropathy;Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs409035	chr20:5943649	MCM8	chr20:5931298-5975829:+	-0.33	-8.39	5.33E-16	HIV-1 viral setpoint	
LGG	cis	1	rs409131	chr4:25213025	ANAPC4	chr4:25378848-25420119:+	0.32	4.92	1.18E-6	Cannabis dependence	
LGG	cis	1	rs409131	chr4:25213025	PI4K2B	chr4:25162285-25280831:+	0.29	5	7.84E-7	Cannabis dependence	
LGG	cis	1	rs409610	chr6:160718264	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs410118	chr6:160728440	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs410128	chr7:65603173	CCT6P1	chr7:65216092-65228661:+	0.24	4.23	2.77E-5	Diabetic kidney disease	
LGG	cis	1	rs410569	chr6:160735746	SLC22A3	chr6:160769425-160876013:+	0.36	6.33	5.58E-10	Waist circumference	
LGG	cis	1	rs412128	chr6:160728678	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs4121395	chr11:71669242	FAM86C	chr11:71498557-71512276:+	0.5	4.92	1.18E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs41258306	chr9:123716103	TRAF1	chr9:123664672-123691479:-	0.35	4.05	5.86E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41265383	chr6:170068025	WDR27	chr6:169857307-170102159:-	-0.41	-9.5	8.94E-20	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs41266807	chr6:26199822	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.2	3.2E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs41266807	chr6:26199822	HIST1H3E	chr6:26224427-26226589:+	0.64	10.81	1.46E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs41266839	chr6:26409890	BTN3A2	chr6:26365398-26378546:+	-0.95	-10.73	2.83E-24	Schizophrenia	
LGG	cis	1	rs41266959	chr2:242275579	ANO7	chr2:242127924-242164791:+	0.4	6.59	1.14E-10	Prostate cancer	
LGG	cis	1	rs41277668	chr13:96295824	UGGT2	chr13:96453838-96705736:-	-0.27	-4.45	1.05E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs41280035	chr22:38054038	LGALS1	chr22:38071613-38075807:+	-0.19	-4.98	8.72E-7	Fat distribution (HIV)	
LGG	cis	1	rs41294396	chr11:64078581	C11orf20	chr11:64067863-64072238:+	-0.32	-4.7	3.36E-6	Mean platelet volume	
LGG	cis	1	rs4129956	chr4:302008	ZNF718	chr4:53272-156488:+	0.27	5.33	1.5E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs4130590	chr9:130107964	RPL12	chr9:130209955-130213684:-	-0.18	-4.76	2.55E-6	Bipolar disorder	
LGG	cis	1	rs4130590	chr9:130107964	SLC2A8	chr9:130159465-130170161:+	0.22	4.76	2.56E-6	Bipolar disorder	
LGG	cis	1	rs41312871	chr9:123733630	TRAF1	chr9:123664672-123691479:-	0.27	3.45	0.000602	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41312901	chr9:123726029	TRAF1	chr9:123664672-123691479:-	0.35	4.05	5.86E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41312903	chr9:123725776	TRAF1	chr9:123664672-123691479:-	0.35	4.05	5.86E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41312907	chr9:123725524	TRAF1	chr9:123664672-123691479:-	0.34	4.17	3.66E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41313597	chr9:123723050	TRAF1	chr9:123664672-123691479:-	0.36	4.16	3.77E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41313609	chr9:123721649	TRAF1	chr9:123664672-123691479:-	0.36	4.16	3.77E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs41313623	chr9:123718563	TRAF1	chr9:123664672-123691479:-	0.35	4.05	5.86E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs4131712	chr17:46394172	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs4133914	chr17:20922023	USP22	chr17:20902908-20947073:-	-0.2	-4.54	7.0E-6	Blood trace element (Se levels)	
LGG	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	4.07E-7	Body mass index	
LGG	cis	1	rs4134386	chr1:46395089	MUTYH	chr1:45794915-45806142:-	0.13	4.84	1.78E-6	Body mass index	
LGG	cis	1	rs41363748	chr12:56696056	IL23A	chr12:56732663-56734193:+	-0.56	-4.9	1.29E-6	Psoriasis vulgaris	
LGG	cis	1	rs41392645	chr12:56696742	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs414013	chr6:88085866	C6orf163	chr6:88057220-88075180:+	0.2	3.68	0.000258	Depressive episodes in bipolar disorder	
LGG	cis	1	rs41411047	chr3:149592911	C3orf16	chr3:149478892-149510610:-	0.31	3.94	9.41E-5	Myocardial infarction	
LGG	cis	1	rs414130	chr6:160719280	SLC22A3	chr6:160769425-160876013:+	0.34	5.83	1.01E-8	Waist circumference	
LGG	cis	1	rs4141404	chr22:31675185	LIMK2	chr22:31608250-31676064:+	0.27	5.65	2.78E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs41423244	chr12:56693520	IL23A	chr12:56732663-56734193:+	-0.53	-4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs41433250	chr13:31495835	HMGB1	chr13:31032881-31191510:-	0.46	4.21	2.99E-5	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	cis	1	rs41433250	chr13:31495835	HSPH1	chr13:31710765-31736502:-	0.47	4.54	7.06E-6	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	cis	1	rs41433250	chr13:31495835	KATNAL1	chr13:30776768-30881584:-	0.44	4.3	2.07E-5	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	cis	1	rs41433250	chr13:31495835	USPL1	chr13:31191830-31233686:+	0.66	6.35	4.91E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	cis	1	rs4144081	chr2:70155482	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.32	1.92E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4144422	chr10:92645687	RPP30	chr10:92631474-92668312:+	0.18	3.76	0.000192	Economic and political preferences (time)	
LGG	cis	1	rs4144743	chr17:45323125	ITGB3	chr17:45331208-45421658:+	-0.2	-4.2	3.15E-5	Body mass index	
LGG	cis	1	rs4144744	chr17:45323262	ITGB3	chr17:45331208-45421658:+	-0.21	-4.29	2.17E-5	Body mass index	
LGG	cis	1	rs4144745	chr17:45323349	ITGB3	chr17:45331208-45421658:+	-0.21	-4.29	2.17E-5	Body mass index	
LGG	cis	1	rs4144746	chr17:45323355	ITGB3	chr17:45331208-45421658:+	-0.21	-4.29	2.17E-5	Body mass index	
LGG	cis	1	rs414475	chr5:112808617	SRP19	chr5:112196993-112228774:+	-0.34	-4.13	4.34E-5	F-cell distribution	
LGG	cis	1	rs4144937	chr6:46628516	SLC25A27	chr6:46620679-46645925:+	-0.19	-6.9	1.62E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs4144937	chr6:46628516	TDRD6	chr6:46655866-46670149:+	0.27	6.74	4.55E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs4145008	chr7:65647511	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs4146894	chr10:124155381	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.26	2.44E-5	Height	
LGG	cis	1	rs4148571	chr3:183720576	ABCC5	chr3:183637726-183735727:-	0.11	3.64	0.000297	Anterior chamber depth	
LGG	cis	1	rs4148575	chr3:183702275	ABCC5	chr3:183637726-183735727:-	0.11	3.62	0.000324	Anterior chamber depth	
LGG	cis	1	rs4149308	chr9:107589630	LOC286367	chr9:107536633-107540044:+	0.15	3.52	0.000472	Myopia (pathological)	
LGG	cis	1	rs4149309	chr9:107589580	LOC286367	chr9:107536633-107540044:+	0.15	3.52	0.000472	Myopia (pathological)	
LGG	cis	1	rs4149327	chr9:107555711	NIPSNAP3B	chr9:107526451-107553175:+	0.4	6.59	1.15E-10	Gout	
LGG	cis	1	rs4149334	chr9:107552695	NIPSNAP3B	chr9:107526451-107553175:+	0.44	7.86	2.43E-14	Gout	
LGG	cis	1	rs4149420	chr2:108913090	SULT1C2	chr2:108905095-108926370:+	0.99	17.72	1.14E-54	Lobe size	
LGG	cis	1	rs4149423	chr2:108916044	SULT1C2	chr2:108905095-108926370:+	0.95	17.75	7.89E-55	Lobe size	
LGG	cis	1	rs4149468	chr7:65825690	CCT6P1	chr7:65216092-65228661:+	0.23	4.21	3.06E-5	Diabetic kidney disease	
LGG	cis	1	rs4149547	chr2:240933308	NDUFA10	chr2:240900158-240964798:-	0.43	8.32	8.96E-16	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs4149551	chr2:240921463	NDUFA10	chr2:240900158-240964798:-	0.41	8.06	5.92E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs4149556	chr2:240915307	NDUFA10	chr2:240900158-240964798:-	0.41	7.95	1.32E-14	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs4150550	chr11:18350898	GTF2H1	chr11:18343816-18388590:+	0.42	7.91	1.69E-14	Pancreatic cancer	
LGG	cis	1	rs4150550	chr11:18350898	LDHC	chr11:18433853-18472792:+	0.2	3.77	0.000187	Pancreatic cancer	
LGG	cis	1	rs4150562	chr11:18354995	GTF2H1	chr11:18343816-18388590:+	0.42	7.95	1.26E-14	Pancreatic cancer	
LGG	cis	1	rs4150562	chr11:18354995	LDHC	chr11:18433853-18472792:+	0.19	3.52	0.000471	Pancreatic cancer	
LGG	cis	1	rs4150564	chr11:18355308	GTF2H1	chr11:18343816-18388590:+	0.42	7.91	1.76E-14	Pancreatic cancer	
LGG	cis	1	rs4150564	chr11:18355308	LDHC	chr11:18433853-18472792:+	0.21	3.98	8.06E-5	Pancreatic cancer	
LGG	cis	1	rs4150566	chr11:18355599	GTF2H1	chr11:18343816-18388590:+	0.43	8.06	5.93E-15	Pancreatic cancer	
LGG	cis	1	rs4150566	chr11:18355599	LDHC	chr11:18433853-18472792:+	0.21	3.94	9.15E-5	Pancreatic cancer	
LGG	cis	1	rs4150575	chr11:18356466	GTF2H1	chr11:18343816-18388590:+	0.42	8	8.89E-15	Pancreatic cancer	
LGG	cis	1	rs4150575	chr11:18356466	LDHC	chr11:18433853-18472792:+	0.2	3.79	0.000167	Pancreatic cancer	
LGG	cis	1	rs4150579	chr11:18357180	GTF2H1	chr11:18343816-18388590:+	-0.4	-7.54	2.32E-13	Pancreatic cancer	
LGG	cis	1	rs4150610	chr11:18364140	GTF2H1	chr11:18343816-18388590:+	0.41	7.69	7.95E-14	Pancreatic cancer	
LGG	cis	1	rs4150610	chr11:18364140	LDHC	chr11:18433853-18472792:+	0.2	3.78	0.000176	Pancreatic cancer	
LGG	cis	1	rs4150612	chr11:18364358	GTF2H1	chr11:18343816-18388590:+	0.4	7.54	2.33E-13	Pancreatic cancer	
LGG	cis	1	rs4150612	chr11:18364358	LDHC	chr11:18433853-18472792:+	0.19	3.59	0.000364	Pancreatic cancer	
LGG	cis	1	rs4150615	chr11:18365028	GTF2H1	chr11:18343816-18388590:+	-0.39	-7.15	3.08E-12	Pancreatic cancer	
LGG	cis	1	rs4150622	chr11:18365710	GTF2H1	chr11:18343816-18388590:+	0.41	7.89	1.94E-14	Pancreatic cancer	
LGG	cis	1	rs4150622	chr11:18365710	LDHC	chr11:18433853-18472792:+	0.2	3.78	0.000176	Pancreatic cancer	
LGG	cis	1	rs4150641	chr11:18370739	GTF2H1	chr11:18343816-18388590:+	0.41	7.79	4.07E-14	Pancreatic cancer	
LGG	cis	1	rs4150641	chr11:18370739	LDHC	chr11:18433853-18472792:+	0.2	3.71	0.000228	Pancreatic cancer	
LGG	cis	1	rs4150650	chr11:18374279	GTF2H1	chr11:18343816-18388590:+	0.41	7.72	6.68E-14	Pancreatic cancer	
LGG	cis	1	rs4150651	chr11:18374425	GTF2H1	chr11:18343816-18388590:+	0.41	7.72	6.68E-14	Pancreatic cancer	
LGG	cis	1	rs4150655	chr11:18375164	GTF2H1	chr11:18343816-18388590:+	-0.41	-7.77	4.48E-14	Pancreatic cancer	
LGG	cis	1	rs4150655	chr11:18375164	LDHC	chr11:18433853-18472792:+	-0.2	-3.83	0.000146	Pancreatic cancer	
LGG	cis	1	rs4150661	chr11:18379629	GTF2H1	chr11:18343816-18388590:+	0.39	7.33	9.65E-13	Pancreatic cancer	
LGG	cis	1	rs4150661	chr11:18379629	LDHC	chr11:18433853-18472792:+	0.2	3.67	0.000274	Pancreatic cancer	
LGG	cis	1	rs4150673	chr11:18383449	GTF2H1	chr11:18343816-18388590:+	0.4	7.5	3.12E-13	Pancreatic cancer	
LGG	cis	1	rs415897	chr6:160739505	SLC22A3	chr6:160769425-160876013:+	-0.35	-6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs416131	chr6:167406544	RNASET2	chr6:167343008-167412795:-	0.08	3.7	0.000241	Crohn's disease	
LGG	cis	1	rs416451	chr5:75922072	F2RL2	chr5:75911308-75919240:-	-0.2	-4.29	2.14E-5	Hearing impairment	
LGG	cis	1	rs41945	chr7:117961810	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.92	9.93E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41950	chr7:117964293	ANKRD7	chr7:117864712-117882782:+	0.23	4	7.37E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41953	chr7:117965390	ANKRD7	chr7:117864712-117882782:+	0.23	3.99	7.57E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41955	chr7:117970074	ANKRD7	chr7:117864712-117882782:+	0.22	3.84	0.000137	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41956	chr7:117970264	ANKRD7	chr7:117864712-117882782:+	0.23	3.99	7.57E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41957	chr7:117972595	ANKRD7	chr7:117864712-117882782:+	0.23	3.99	7.57E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs419603	chr7:65597341	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs41961	chr7:117975259	ANKRD7	chr7:117864712-117882782:+	0.22	3.84	0.000137	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41970	chr7:117980884	ANKRD7	chr7:117864712-117882782:+	0.23	3.99	7.57E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41977	chr7:117984592	ANKRD7	chr7:117864712-117882782:+	0.21	3.63	0.000309	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41978	chr7:117984828	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000174	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41982	chr7:117986026	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000174	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41984	chr7:117987631	ANKRD7	chr7:117864712-117882782:+	0.22	3.78	0.000174	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41986	chr7:117988236	ANKRD7	chr7:117864712-117882782:+	0.21	3.63	0.000309	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41987	chr7:117989233	ANKRD7	chr7:117864712-117882782:+	0.21	3.63	0.000309	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41988	chr7:117989281	ANKRD7	chr7:117864712-117882782:+	-0.23	-3.98	8.04E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41991	chr7:117989739	ANKRD7	chr7:117864712-117882782:+	0.22	3.87	0.000125	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41993	chr7:117990723	ANKRD7	chr7:117864712-117882782:+	0.22	3.79	0.000172	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41994	chr7:117991231	ANKRD7	chr7:117864712-117882782:+	0.22	3.79	0.000172	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41995	chr7:117991339	ANKRD7	chr7:117864712-117882782:+	0.22	3.73	0.000211	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41996	chr7:117991556	ANKRD7	chr7:117864712-117882782:+	0.21	3.68	0.000262	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs41997	chr7:117991895	ANKRD7	chr7:117864712-117882782:+	0.21	3.67	0.000274	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs420259	chr16:23634026	COG7	chr16:23399816-23464503:-	-0.2	-3.53	0.000461	Bipolar disorder	
LGG	cis	1	rs420259	chr16:23634026	DCTN5	chr16:23652807-23681182:+	-0.16	-3.54	0.000441	Bipolar disorder	
LGG	cis	1	rs420259	chr16:23634026	EARS2	chr16:23533335-23568696:-	0.24	5.64	2.86E-8	Bipolar disorder	
LGG	cis	1	rs421147	chr19:6691424	GPR108	chr19:6729927-6737633:-	-0.25	-3.66	0.000284	Complement C3 and C4 levels	
LGG	cis	1	rs421515	chr5:112808643	SRP19	chr5:112196993-112228774:+	-0.34	-4.13	4.34E-5	F-cell distribution	
LGG	cis	1	rs422164	chr7:65586605	CCT6P1	chr7:65216092-65228661:+	0.25	4.55	6.72E-6	Diabetic kidney disease	
LGG	cis	1	rs422292	chr6:160719491	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs42234	chr7:117970148	ANKRD7	chr7:117864712-117882782:+	0.23	3.99	7.57E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs422421	chr5:176517326	FGFR4	chr5:176513921-176525124:+	-0.17	-3.68	0.00026	Height	
LGG	cis	1	rs422424	chr20:25445446	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422424	chr20:25445446	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422424	chr20:25445446	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422844	chr20:25445591	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422844	chr20:25445591	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422844	chr20:25445591	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs422973	chr6:160717911	SLC22A3	chr6:160769425-160876013:+	0.34	5.92	6.02E-9	Waist circumference	
LGG	cis	1	rs4233708	chr2:26291345	GPR113	chr2:26531041-26569685:-	-0.24	-3.76	0.000191	Gut microbiome composition (summer)	
LGG	cis	1	rs4233709	chr2:26291493	GPR113	chr2:26531041-26569685:-	0.23	3.69	0.00025	Gut microbiome composition (summer)	
LGG	cis	1	rs4233710	chr2:26291565	GPR113	chr2:26531041-26569685:-	-0.22	-3.48	0.000551	Gut microbiome composition (summer)	
LGG	cis	1	rs4233937	chr2:66752251	MEIS1	chr2:66662532-66799890:+	-0.18	-4.23	2.73E-5	PR interval	
LGG	cis	1	rs4235388	chr4:17682030	LAP3	chr4:17578927-17609590:+	-0.13	-3.71	0.000232	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.52	11.1	1.06E-25	Forced vital capacity	
LGG	cis	1	rs42376	chr7:117981820	ANKRD7	chr7:117864712-117882782:+	0.21	3.73	0.000217	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4239227	chr17:28389103	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4241407	chr3:49600319	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.2	3.12E-5	Menarche (age at onset)	
LGG	cis	1	rs4241407	chr3:49600319	GMPPB	chr3:49758932-49761384:-	-0.22	-4.32	1.9E-5	Menarche (age at onset)	
LGG	cis	1	rs4241407	chr3:49600319	NCKIPSD	chr3:48711280-48723334:-	0.15	3.6	0.000345	Menarche (age at onset)	
LGG	cis	1	rs4243954	chr11:5372006	FAM160A2	chr11:6232565-6255941:-	0.18	3.53	0.000461	Fetal hemoglobin levels	
LGG	cis	1	rs4243956	chr11:5374236	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4243957	chr11:5374268	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4243959	chr11:5374330	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4244172	chr1:248466838	OR2L13	chr1:248100493-248264223:+	0.21	3.71	0.000227	Common traits (Other)	
LGG	cis	1	rs4244172	chr1:248466838	OR2L2	chr1:248201474-248202606:+	0.2	3.54	0.000442	Common traits (Other)	
LGG	cis	1	rs4244174	chr1:248467956	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000457	Common traits (Other)	
LGG	cis	1	rs4244176	chr1:248468231	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000457	Common traits (Other)	
LGG	cis	1	rs4244178	chr1:248468441	OR2L13	chr1:248100493-248264223:+	0.2	3.55	0.000415	Common traits (Other)	
LGG	cis	1	rs4244179	chr1:248470984	OR2L13	chr1:248100493-248264223:+	0.2	3.55	0.000415	Common traits (Other)	
LGG	cis	1	rs4244180	chr1:248471033	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000448	Common traits (Other)	
LGG	cis	1	rs4244182	chr1:248471174	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000448	Common traits (Other)	
LGG	cis	1	rs4244183	chr1:248471222	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000448	Common traits (Other)	
LGG	cis	1	rs4244338	chr10:102272802	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000218	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4244338	chr10:102272802	NDUFB8	chr10:102283497-102289636:-	0.18	4.89	1.4E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4244338	chr10:102272802	WNT8B	chr10:102222812-102243397:+	0.49	7.95	1.26E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4245707	chr1:202391419	PTPN7	chr1:202116143-202130709:-	-0.11	-3.48	0.000538	Sex ratio	
LGG	cis	1	rs4245707	chr1:202391419	UBE2T	chr1:202300786-202311094:-	-0.13	-3.95	8.87E-5	Sex ratio	
LGG	cis	1	rs424573	chr4:25212808	ANAPC4	chr4:25378848-25420119:+	-0.26	-4.19	3.29E-5	Cannabis dependence	
LGG	cis	1	rs424573	chr4:25212808	PI4K2B	chr4:25162285-25280831:+	-0.24	-4.35	1.65E-5	Cannabis dependence	
LGG	cis	1	rs4245924	chr4:108946378	SGMS2	chr4:108745721-108836200:+	-0.26	-3.59	0.00036	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs4246215	chr11:61564299	FADS1	chr11:61567103-61584529:-	-0.21	-4.88	1.41E-6	Phospholipid levels (plasma);Platelet count;Red blood cell fatty acid levels;Trans fatty acid levels;Inflammatory bowel disease	
LGG	cis	1	rs4253417	chr4:187199005	KLKB1	chr4:187148672-187179624:+	-0.16	-3.54	0.000442	Venous thromboembolism	
LGG	cis	1	rs4253766	chr22:46623905	PKDREJ	chr22:46651561-46659219:-	-0.59	-7.32	1.02E-12	Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs4253772	chr22:46627603	PKDREJ	chr22:46651561-46659219:-	-0.58	-6.98	9.46E-12	Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs4256490	chr7:1890764	FTSJ2	chr7:2273928-2281833:-	0.22	4.86	1.6E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4260737	chr6:163137746	PACRG	chr6:163148164-163736523:+	0.45	6.01	3.69E-9	Body mass index	
LGG	cis	1	rs4261259	chr11:18737952	LDHC	chr11:18433853-18472792:+	-0.24	-4.13	4.26E-5	Diabetic kidney disease	
LGG	cis	1	rs4261510	chr15:90890606	IQGAP1	chr15:90931473-91045475:+	0.15	4.3	2.06E-5	Rheumatoid arthritis	
LGG	cis	1	rs4261589	chr17:46501437	HOXB2	chr17:46620021-46622393:-	-0.2	-3.74	0.000206	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs4261589	chr17:46501437	HOXB3	chr17:46626233-46667631:-	-0.18	-3.56	0.000408	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs4263408	chr4:39785276	RPL9	chr4:39455747-39460568:-	-0.41	-7.93	1.54E-14	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs4264132	chr11:18739075	LDHC	chr11:18433853-18472792:+	0.22	3.76	0.000192	Diabetic kidney disease	
LGG	cis	1	rs42648	chr7:89977760	GTPBP10	chr7:89969690-90016650:+	0.17	4.18	3.44E-5	Homocysteine levels	
LGG	cis	1	rs42649	chr7:89977789	GTPBP10	chr7:89969690-90016650:+	0.17	4.19	3.33E-5	Homocysteine levels	
LGG	cis	1	rs4265148	chr8:10816503	RP1L1	chr8:10463862-10512617:-	-0.29	-3.68	0.000257	Asthma and hay fever	
LGG	cis	1	rs42656	chr7:89981636	GTPBP10	chr7:89969690-90016650:+	0.16	3.84	0.000138	Homocysteine levels	
LGG	cis	1	rs42658	chr7:89981915	GTPBP10	chr7:89969690-90016650:+	0.18	4.4	1.35E-5	Homocysteine levels	
LGG	cis	1	rs4267943	chr6:49439805	CENPQ	chr6:49431096-49460820:+	0.23	5.09	5.04E-7	Folate pathway vitamin levels	
LGG	cis	1	rs4268415	chr10:4983590	AKR1C2	chr10:4964715-5060207:-	0.3	4.04	6.32E-5	Height	
LGG	cis	1	rs4270120	chr15:45936234	SPATA5L1	chr15:45694519-45713614:+	0.29	4.4	1.34E-5	Obesity-related traits	
LGG	cis	1	rs427044	chr7:65508545	CCT6P1	chr7:65216092-65228661:+	0.26	4.71	3.16E-6	Diabetic kidney disease	
LGG	cis	1	rs4271550	chr15:45936266	SPATA5L1	chr15:45694519-45713614:+	0.29	4.38	1.48E-5	Obesity-related traits	
LGG	cis	1	rs4271626	chr17:65930133	LOC440461	chr17:66194801-66196436:+	0.3	4.97	9.17E-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs4279493	chr7:66226620	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.22E-6	Aortic root size	
LGG	cis	1	rs4279493	chr7:66226620	TYW1	chr7:66461817-66704496:+	0.18	3.77	0.000184	Aortic root size	
LGG	cis	1	rs4279530	chr7:118070771	ANKRD7	chr7:117864712-117882782:+	-0.24	-4.26	2.44E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4280164	chr14:24771285	DHRS1	chr14:24759806-24769039:-	0.27	4.18	3.5E-5	Parent of origin effect on language impairment (paternal)	
LGG	cis	1	rs4280164	chr14:24771285	RABGGTA	chr14:24734746-24740803:-	-0.24	-4.37	1.52E-5	Parent of origin effect on language impairment (paternal)	
LGG	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.44	-10.62	7.44E-24	Longevity	
LGG	cis	1	rs4283605	chr3:49678651	MST1R	chr3:49924438-49941306:-	-0.2	-3.88	0.00012	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs4283605	chr3:49678651	RBM6	chr3:49977592-50137484:+	0.16	4.52	7.81E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs4283605	chr3:49678651	SEMA3F	chr3:50192848-50226507:+	0.2	4.41	1.25E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs4283834	chr5:115521463	COMMD10	chr5:115420727-115628978:+	0.47	5.93	5.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs4285028	chr3:121660664	GOLGB1	chr3:121382050-121468602:-	0.17	3.59	0.000364	Multiple sclerosis	
LGG	cis	1	rs4285028	chr3:121660664	IQCB1	chr3:121488610-121553926:-	-0.19	-3.77	0.000183	Multiple sclerosis	
LGG	cis	1	rs4286306	chr2:69885647	GFPT1	chr2:69546905-69614382:-	0.15	3.47	0.000562	Serum thyroid-stimulating hormone levels	
LGG	cis	1	rs4286716	chr5:115519697	COMMD10	chr5:115420727-115628978:+	-0.46	-5.68	2.37E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs4291211	chr7:135335373	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.1	4.74E-5	Red blood cell traits	
LGG	cis	1	rs4291212	chr7:135335465	SLC13A4	chr7:135365993-135412933:-	-0.27	-3.92	0.000102	Red blood cell traits	
LGG	cis	1	rs4294134	chr7:135293128	PL-5283	chr7:135347221-135378160:+	0.43	8.59	1.13E-16	Paget's disease	
LGG	cis	1	rs4294134	chr7:135293128	SLC13A4	chr7:135365993-135412933:-	-0.35	-5.05	6.19E-7	Paget's disease	
LGG	cis	1	rs429671	chr6:160718312	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs4297570	chr13:36755179	SOHLH2	chr13:36742347-36871992:-	-0.38	-6.95	1.2E-11	Glucose homeostasis traits	
LGG	cis	1	rs4298932	chr11:5374188	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4300412	chr11:5393589	FAM160A2	chr11:6232565-6255941:-	0.19	3.81	0.000155	Fetal hemoglobin levels	
LGG	cis	1	rs4304115	chr5:110403346	TSLP	chr5:110405778-110413722:+	-0.31	-4.44	1.11E-5	Eosinophil counts	
LGG	cis	1	rs4304957	chr14:76647572	ESRRB	chr14:76837690-76968178:+	0.45	7.45	4.16E-13	Blood pressure	
LGG	cis	1	rs4306162	chr1:248468509	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000457	Common traits (Other)	
LGG	cis	1	rs4306312	chr11:5393165	FAM160A2	chr11:6232565-6255941:-	0.19	3.79	0.000167	Fetal hemoglobin levels	
LGG	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs4309773	chr3:134277301	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs4310508	chr10:65138573	NRBF2	chr10:64893007-64914785:+	-0.22	-5.16	3.52E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4310508	chr10:65138573	REEP3	chr10:65281123-65381971:+	0.13	3.68	0.000262	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs431076	chr7:65600320	CCT6P1	chr7:65216092-65228661:+	0.24	4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs4311997	chr10:124179299	PLEKHA1	chr10:124134220-124191866:+	-0.13	-4.43	1.16E-5	Height	
LGG	cis	1	rs431318	chr7:65511597	CCT6P1	chr7:65216092-65228661:+	0.26	4.69	3.57E-6	Diabetic kidney disease	
LGG	cis	1	rs431328	chr19:22222236	ZNF257	chr19:22235266-22273901:+	0.38	6.81	2.83E-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4316926	chr2:66749108	MEIS1	chr2:66662532-66799890:+	-0.18	-4.1	4.76E-5	PR interval	
LGG	cis	1	rs4318247	chr17:65882172	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.84	16.14	2.5E-47	Type 2 diabetes	
LGG	cis	1	rs43184	chr5:56141777	MIER3	chr5:56215429-56267501:-	0.16	3.5	0.000501	Type 2 diabetes	
LGG	cis	1	rs4322591	chr14:75600697	ACYP1	chr14:75519930-75530736:-	-0.15	-3.99	7.72E-5	Height	
LGG	cis	1	rs4322591	chr14:75600697	EIF2B2	chr14:75469612-75476292:+	0.19	3.8	0.000165	Height	
LGG	cis	1	rs4322591	chr14:75600697	MLH3	chr14:75480467-75518235:-	0.21	3.58	0.000384	Height	
LGG	cis	1	rs4323544	chr9:123647377	LOC253039	chr9:123605320-123616644:+	-0.66	-11.73	3.51E-28	Rheumatoid arthritis	
LGG	cis	1	rs4323544	chr9:123647377	PSMD5	chr9:123578334-123605206:-	-0.35	-6.51	1.9E-10	Rheumatoid arthritis	
LGG	cis	1	rs4323544	chr9:123647377	TRAF1	chr9:123664672-123691479:-	0.18	3.94	9.35E-5	Rheumatoid arthritis	
LGG	cis	1	rs4327428	chr3:45809329	CCR2	chr3:46395235-46402412:+	-0.25	-3.53	0.000462	Blood metabolite levels	
LGG	cis	1	rs4327428	chr3:45809329	CXCR6	chr3:45984973-45989845:+	-0.27	-3.68	0.000259	Blood metabolite levels	
LGG	cis	1	rs4328498	chr17:28344276	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.98	4.42E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4332428	chr10:4965434	AKR1C2	chr10:4964715-5060207:-	0.39	5.37	1.22E-7	Height	
LGG	cis	1	rs433406	chr11:131371019	NTM	chr11:131240371-132206715:+	-0.14	-3.83	0.000143	Male fertility	
LGG	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs4334685	chr3:134304335	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs433598	chr16:20680206	ACSM1	chr16:20634559-20709066:-	0.18	3.58	0.000383	Schizophrenia	
LGG	cis	1	rs433598	chr16:20680206	ACSM5	chr16:20420856-20452278:+	-0.13	-3.57	0.000399	Schizophrenia	
LGG	cis	1	rs4338555	chr11:71755696	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs433992	chr6:160738830	SLC22A3	chr6:160769425-160876013:+	0.36	6.25	8.83E-10	Waist circumference	
LGG	cis	1	rs434012	chr6:160738800	SLC22A3	chr6:160769425-160876013:+	0.36	6.25	8.83E-10	Waist circumference	
LGG	cis	1	rs4341440	chr10:4965293	AKR1C2	chr10:4964715-5060207:-	0.41	5.57	4.2E-8	Height	
LGG	cis	1	rs4341511	chr11:18736627	LDHC	chr11:18433853-18472792:+	0.21	3.54	0.000434	Diabetic kidney disease	
LGG	cis	1	rs4342423	chr6:33732679	BAK1	chr6:33540324-33548070:-	-0.15	-3.51	0.000486	Crohn's disease	
LGG	cis	1	rs4342423	chr6:33732679	LEMD2	chr6:33738991-33756906:-	-0.14	-4.4	1.32E-5	Crohn's disease	
LGG	cis	1	rs4344199	chr9:99549449	FAM22G	chr9:99690592-99704572:+	0.45	3.71	0.000229	Height	
LGG	cis	1	rs434434	chr5:176516953	FGFR4	chr5:176513921-176525124:+	-0.17	-3.87	0.000124	Height	
LGG	cis	1	rs4344684	chr15:63397318	LACTB	chr15:63414032-63434254:+	0.22	4.58	5.83E-6	HDL cholesterol	
LGG	cis	1	rs4346380	chr2:242263223	ANO7	chr2:242127924-242164791:+	0.39	6.36	4.51E-10	Prostate cancer	
LGG	cis	1	rs4347419	chr11:5374786	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4350617	chr17:28423088	EFCAB5	chr17:28256874-28435469:+	0.23	6.07	2.5E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs435294	chr6:160717708	SLC22A3	chr6:160769425-160876013:+	0.34	5.92	6.16E-9	Waist circumference	
LGG	cis	1	rs4353250	chr11:18323517	GTF2H1	chr11:18343816-18388590:+	0.41	7.64	1.17E-13	Pancreatic cancer	
LGG	cis	1	rs4353250	chr11:18323517	LDHC	chr11:18433853-18472792:+	0.22	4.05	5.89E-5	Pancreatic cancer	
LGG	cis	1	rs435542	chr6:160723324	SLC22A3	chr6:160769425-160876013:+	0.34	5.91	6.27E-9	Waist circumference	
LGG	cis	1	rs4358460	chr4:111382685	ENPEP	chr4:111397229-111484491:+	0.23	5.12	4.34E-7	Blood pressure	
LGG	cis	1	rs436039	chr19:22214873	ZNF208	chr19:22115760-22193745:-	0.21	3.51	0.000483	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs436039	chr19:22214873	ZNF257	chr19:22235266-22273901:+	0.4	7.13	3.7E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs436041	chr19:6692796	GPR108	chr19:6729927-6737633:-	-0.25	-3.63	0.000316	Complement C3 and C4 levels	
LGG	cis	1	rs4360553	chr1:248467092	OR2L13	chr1:248100493-248264223:+	0.2	3.52	0.000478	Common traits (Other)	
LGG	cis	1	rs4360555	chr1:248468591	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000457	Common traits (Other)	
LGG	cis	1	rs436348	chr6:160729705	SLC22A3	chr6:160769425-160876013:+	0.35	6.12	1.95E-9	Waist circumference	
LGG	cis	1	rs4363822	chr15:67992583	IQCH	chr15:67547188-67794139:+	0.13	3.62	0.000322	Motion sickness	
LGG	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.3	7.72	6.48E-14	Height	
LGG	cis	1	rs4367113	chr3:134287975	CEP63	chr3:134204575-134293852:+	0.21	3.9	0.000108	Height	
LGG	cis	1	rs4367688	chr9:135791103	C9orf98	chr9:135600965-135754198:-	0.33	8.55	1.6E-16	Psoriasis	
LGG	cis	1	rs4367688	chr9:135791103	GFI1B	chr9:135854098-135867083:+	-0.21	-3.53	0.000459	Psoriasis	
LGG	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs4368544	chr3:134300014	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs4369438	chr11:5374743	FAM160A2	chr11:6232565-6255941:-	0.2	4.07	5.53E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4370169	chr4:42473094	SHISA3	chr4:42399856-42404503:+	0.3	4.59	5.58E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs4372295	chr1:248464871	OR2L13	chr1:248100493-248264223:+	0.2	3.63	0.000312	Common traits (Other)	
LGG	cis	1	rs4372836	chr2:28973883	FAM179A	chr2:29204164-29275094:+	-0.2	-3.86	0.000129	Body mass index	
LGG	cis	1	rs4372836	chr2:28973883	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.74	2.64E-24	Body mass index	
LGG	cis	1	rs437298	chr1:76113770	MSH4	chr1:76262630-76378923:+	-0.26	-4.64	4.56E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4374747	chr5:156426239	TIMD4	chr5:156346293-156390266:-	-0.25	-4.58	5.91E-6	Hypertriglyceridemia	
LGG	cis	1	rs4375281	chr1:92987575	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs437539	chr6:160725560	SLC22A3	chr6:160769425-160876013:+	0.35	5.99	4.17E-9	Waist circumference	
LGG	cis	1	rs4375701	chr17:45712218	C17orf57	chr17:45401142-45518675:+	0.14	3.56	0.000411	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4375701	chr17:45712218	LOC100272146	chr17:45500843-45504056:+	0.14	3.64	0.000299	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.08	5.49E-7	Body mass index	
LGG	cis	1	rs4376778	chr1:46288846	MUTYH	chr1:45794915-45806142:-	0.14	5.15	3.86E-7	Body mass index	
LGG	cis	1	rs4378192	chr1:231173379	FAM89A	chr1:231154704-231175995:-	0.27	4.7	3.39E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs437889	chr7:65509234	CCT6P1	chr7:65216092-65228661:+	0.26	4.71	3.16E-6	Diabetic kidney disease	
LGG	cis	1	rs4379723	chr10:64963449	NRBF2	chr10:64893007-64914785:+	-0.22	-5.27	2.0E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4379723	chr10:64963449	REEP3	chr10:65281123-65381971:+	0.14	4.15	3.96E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4381823	chr2:48047335	FBXO11	chr2:48034061-48132814:-	0.23	4.19	3.37E-5	Schizophrenia	
LGG	cis	1	rs4385200	chr5:130487658	LYRM7	chr5:130506641-130541119:+	-0.23	-3.49	0.000517	Diisocyanate-induced asthma	
LGG	cis	1	rs438703	chr19:6692790	GPR108	chr19:6729927-6737633:-	-0.25	-3.63	0.000316	Complement C3 and C4 levels	
LGG	cis	1	rs4394010	chr4:129894649	C4orf33	chr4:130014829-130033842:+	0.59	9.95	2.24E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs4397735	chr10:4965543	AKR1C2	chr10:4964715-5060207:-	0.43	5.76	1.48E-8	Height	
LGG	cis	1	rs4398671	chr5:115557842	COMMD10	chr5:115420727-115628978:+	0.48	5.98	4.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs4399232	chr10:64999490	NRBF2	chr10:64893007-64914785:+	-0.22	-5.29	1.87E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4399232	chr10:64999490	REEP3	chr10:65281123-65381971:+	0.14	4.2	3.13E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4400351	chr8:98325837	HRSP12	chr8:99114567-99129418:-	0.15	3.56	0.0004	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs4400684	chr10:65012687	NRBF2	chr10:64893007-64914785:+	-0.23	-5.52	5.53E-8	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4400684	chr10:65012687	REEP3	chr10:65281123-65381971:+	0.13	3.73	0.00021	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs440429	chr6:160726192	SLC22A3	chr6:160769425-160876013:+	0.35	5.99	4.17E-9	Waist circumference	
LGG	cis	1	rs4407214	chr2:29118258	TRMT61B	chr2:29072690-29093175:-	0.45	8.57	1.38E-16	Breast cancer (estrogen-receptor negative);Breast cancer	
LGG	cis	1	rs4408846	chr3:41753679	ULK4	chr3:41288091-42003660:-	0.71	12.9	5.49E-33	Diastolic blood pressure	
LGG	cis	1	rs441109	chr1:76120430	MSH4	chr1:76262630-76378923:+	-0.24	-4.3	2.02E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4417886	chr3:20108511	EFHB	chr3:19920968-19988501:-	0.39	5.13	4.13E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.3	7.79	4.13E-14	Height	
LGG	cis	1	rs4417907	chr3:134291363	CEP63	chr3:134204575-134293852:+	0.2	3.68	0.000262	Height	
LGG	cis	1	rs441810	chr21:42698907	FAM3B	chr21:42676177-42729654:+	0.44	8.2	2.12E-15	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LGG	cis	1	rs4420500	chr15:78962964	ADAMTS7	chr15:79051546-79103773:-	0.21	4.62	4.88E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs4420500	chr15:78962964	CHRNA5	chr15:78857906-78886458:+	-0.33	-5.91	6.25E-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs442309	chr10:64490495	ADO	chr10:64564516-64568238:+	-0.17	-4.46	1.03E-5	Vogt-Koyanagi-Harada syndrome	
LGG	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.6	1.56E-13	Height	
LGG	cis	1	rs4423809	chr3:134300107	CEP63	chr3:134204575-134293852:+	-0.2	-3.69	0.000245	Height	
LGG	cis	1	rs442426	chr6:160721106	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs4424652	chr11:18737095	LDHC	chr11:18433853-18472792:+	0.22	3.89	0.000114	Diabetic kidney disease	
LGG	cis	1	rs442856	chr5:176517292	FGFR4	chr5:176513921-176525124:+	-0.16	-3.52	0.000478	Height	
LGG	cis	1	rs4430369	chr1:248464330	OR2L13	chr1:248100493-248264223:+	0.21	3.75	0.000195	Common traits (Other)	
LGG	cis	1	rs4430369	chr1:248464330	OR2L2	chr1:248201474-248202606:+	0.2	3.48	0.000553	Common traits (Other)	
LGG	cis	1	rs4430933	chr2:66749610	MEIS1	chr2:66662532-66799890:+	0.19	4.36	1.57E-5	PR interval	
LGG	cis	1	rs4431687	chr9:130111697	SLC2A8	chr9:130159465-130170161:+	-0.27	-5.51	5.65E-8	Metabolite levels (HVA)	
LGG	cis	1	rs4433986	chr2:66760311	MEIS1	chr2:66662532-66799890:+	-0.18	-4.21	3.09E-5	PR interval	
LGG	cis	1	rs4439540	chr11:5372147	FAM160A2	chr11:6232565-6255941:-	0.18	3.6	0.000344	Fetal hemoglobin levels	
LGG	cis	1	rs4441659	chr3:108851791	MORC1	chr3:108677089-108836993:-	0.37	6.68	6.4E-11	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs4442739	chr14:76647645	ESRRB	chr14:76837690-76968178:+	0.45	7.42	5.15E-13	Blood pressure	
LGG	cis	1	rs4449196	chr20:49521655	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs4449693	chr7:1884630	FTSJ2	chr7:2273928-2281833:-	0.22	4.72	3.04E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4452748	chr7:50625056	FIGNL1	chr7:50511834-50518088:-	0.22	5.19	3.16E-7	Malaria	
LGG	cis	1	rs4457616	chr1:248492198	OR2L13	chr1:248100493-248264223:+	0.2	3.48	0.000542	Common traits (Other)	
LGG	cis	1	rs4457616	chr1:248492198	OR2L2	chr1:248201474-248202606:+	0.2	3.49	0.000528	Common traits (Other)	
LGG	cis	1	rs4460622	chr1:231173033	FAM89A	chr1:231154704-231175995:-	0.27	4.7	3.39E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4462380	chr11:5393523	FAM160A2	chr11:6232565-6255941:-	0.19	3.81	0.000155	Fetal hemoglobin levels	
LGG	cis	1	rs4462662	chr17:20961579	USP22	chr17:20902908-20947073:-	-0.18	-4.01	7.11E-5	Blood trace element (Se levels)	
LGG	cis	1	rs446272	chr5:112801861	SRP19	chr5:112196993-112228774:+	-0.34	-4.13	4.34E-5	F-cell distribution	
LGG	cis	1	rs4465649	chr17:28394747	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.87	7.87E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4465650	chr17:28396721	EFCAB5	chr17:28256874-28435469:+	0.21	5.64	2.94E-8	Coffee consumption (cups per day)	
LGG	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.59	-9.96	2.14E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs4466067	chr4:79502569	ANXA3	chr4:79472742-79531602:+	0.32	7.4	6.04E-13	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs446809	chr6:160737581	SLC22A3	chr6:160769425-160876013:+	-0.34	-5.86	8.57E-9	Waist circumference	
LGG	cis	1	rs446887	chr6:160716588	SLC22A3	chr6:160769425-160876013:+	0.34	5.92	6.02E-9	Waist circumference	
LGG	cis	1	rs4469291	chr6:49440614	CENPQ	chr6:49431096-49460820:+	-0.23	-5.02	7.29E-7	Folate pathway vitamin levels	
LGG	cis	1	rs4474293	chr1:248470438	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000448	Common traits (Other)	
LGG	cis	1	rs447722	chr20:25443510	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs447722	chr20:25443510	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs447722	chr20:25443510	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4478072	chr3:53106125	RFT1	chr3:53122503-53164470:-	0.28	3.47	0.000573	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs448396	chr20:25440269	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs448396	chr20:25440269	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs448396	chr20:25440269	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4489133	chr6:163137793	PACRG	chr6:163148164-163736523:+	0.45	6.01	3.69E-9	Body mass index	
LGG	cis	1	rs4489592	chr1:248470697	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000454	Common traits (Other)	
LGG	cis	1	rs4490383	chr3:48484683	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.85E-6	Longevity	
LGG	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.43	-11.08	1.32E-25	Longevity	
LGG	cis	1	rs449043	chr21:42700410	FAM3B	chr21:42676177-42729654:+	-0.48	-8.9	1.05E-17	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LGG	cis	1	rs4490669	chr6:56789465	BEND6	chr6:56819773-56892138:+	-0.32	-5.78	1.32E-8	Menarche (age at onset)	
LGG	cis	1	rs4490669	chr6:56789465	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.89	0.000114	Menarche (age at onset)	
LGG	cis	1	rs449303	chr14:60605788	MNAT1	chr14:61201470-61435396:+	0.24	3.51	0.000486	Age-related hearing impairment (interaction)	
LGG	cis	1	rs4497901	chr2:239969	FAM150B	chr2:279563-288308:-	-0.32	-6.17	1.45E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs4497901	chr2:239969	SNTG2	chr2:946555-1371382:+	0.2	3.79	0.000171	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs4498009	chr3:134198008	CEP63	chr3:134204575-134293852:+	0.2	3.66	0.000275	Height	
LGG	cis	1	rs4508046	chr1:248488988	OR2L13	chr1:248100493-248264223:+	0.19	3.46	0.00059	Common traits (Other)	
LGG	cis	1	rs4509126	chr6:170068058	WDR27	chr6:169857307-170102159:-	-0.4	-9.04	3.53E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4509958	chr15:50894175	SPPL2A	chr15:50999739-51057910:-	0.12	4.04	6.26E-5	QT interval	
LGG	cis	1	rs4510228	chr2:17774685	GEN1	chr2:17935162-17966632:+	0.26	4.2	3.23E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs4510229	chr2:17774701	GEN1	chr2:17935162-17966632:+	0.26	4.14	4.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs4512750	chr10:135358664	CYP2E1	chr10:135340867-135374724:+	0.19	3.51	0.000483	Obesity-related traits	
LGG	cis	1	rs451396	chr7:65484074	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.56E-6	Diabetic kidney disease	
LGG	cis	1	rs4520133	chr8:98326013	HRSP12	chr8:99114567-99129418:-	0.16	3.83	0.000146	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs4521419	chr4:108914578	SGMS2	chr4:108745721-108836200:+	0.26	3.61	0.000341	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs4523473	chr1:152881430	SMCP	chr1:152850798-152857515:+	-0.33	-5.07	5.56E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4525554	chr17:30312819	LRRC37B	chr17:30335037-30380517:+	0.25	5.38	1.14E-7	Height	
LGG	cis	1	rs452788	chr6:160735328	SLC22A3	chr6:160769425-160876013:+	0.35	6.07	2.51E-9	Waist circumference	
LGG	cis	1	rs4531856	chr19:18388383	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.39	1.41E-5	Waist-to-hip ratio adjusted for body mass index	
LGG	cis	1	rs4531962	chr2:190526683	ORMDL1	chr2:190634994-190649097:-	0.36	5.26	2.19E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs453329	chr20:25440593	ABHD12	chr20:25275380-25371477:-	0.26	7.15	3.08E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs453329	chr20:25440593	FAM182A	chr20:26035250-26067552:+	-0.57	-11.19	4.68E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs453329	chr20:25440593	FAM182B	chr20:25744102-25848786:-	0.22	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4533340	chr17:28277951	EFCAB5	chr17:28256874-28435469:+	0.23	6.02	3.39E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.3	-7.82	3.22E-14	Height	
LGG	cis	1	rs4535272	chr3:134299916	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000206	Height	
LGG	cis	1	rs4538777	chr7:33271122	BBS9	chr7:33169152-33645680:+	0.43	5.74	1.62E-8	Smooth-surface caries	
LGG	cis	1	rs4538799	chr7:118066964	ANKRD7	chr7:117864712-117882782:+	-0.23	-4	7.24E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4541130	chr17:45321037	ITGB3	chr17:45331208-45421658:+	-0.23	-4.72	3.15E-6	Body mass index	
LGG	cis	1	rs454422	chr20:5943693	MCM8	chr20:5931298-5975829:+	-0.33	-8.39	5.33E-16	HIV-1 viral setpoint	
LGG	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.07	5.54E-7	Body mass index	
LGG	cis	1	rs4545281	chr1:46360054	MUTYH	chr1:45794915-45806142:-	0.13	4.57	6.05E-6	Body mass index	
LGG	cis	1	rs45469101	chr20:61875007	BIRC7	chr20:61867276-61871853:+	0.34	4.27	2.35E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs45469101	chr20:61875007	NKAIN4	chr20:61872137-61885892:-	0.3	5.11	4.71E-7	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs45472399	chr10:17209967	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.53	7.58E-6	Homocysteine levels	
LGG	cis	1	rs4547912	chr5:93571190	FAM172A	chr5:92953432-93447404:-	-0.3	-3.68	0.00026	Diabetic retinopathy	
LGG	cis	1	rs4548056	chr7:65298873	CCT6P1	chr7:65216092-65228661:+	0.25	4.59	5.59E-6	Diabetic kidney disease	
LGG	cis	1	rs4549034	chr2:28972579	FAM179A	chr2:29204164-29275094:+	-0.2	-3.86	0.000129	Body mass index	
LGG	cis	1	rs4549034	chr2:28972579	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.74	2.64E-24	Body mass index	
LGG	cis	1	rs4549329	chr4:239785	ZNF718	chr4:53272-156488:+	0.24	4.77	2.44E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs4553671	chr17:46848272	SNF8	chr17:47007461-47022154:-	-0.16	-4.09	5.04E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs45559033	chr14:74341124	LIN52	chr14:74551656-74667117:+	0.37	4.74	2.8E-6	Morning vs. evening chronotype	
LGG	cis	1	rs4558891	chr4:122957871	SPATA5	chr4:123844225-124240602:+	0.15	3.59	0.00037	Emphysema imaging phenotypes	
LGG	cis	1	rs4559448	chr1:76203456	MSH4	chr1:76262630-76378923:+	0.24	4.42	1.24E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4560537	chr5:150262586	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs4560868	chr9:115985499	CDC26	chr9:116029290-116037869:-	0.6	14.21	1.27E-38	Hematology traits	
LGG	cis	1	rs45615636	chr10:17210591	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.48	9.18E-6	Homocysteine levels	
LGG	cis	1	rs4563674	chr5:126727209	FLJ44606	chr5:126381051-126409172:-	0.29	3.99	7.6E-5	IgG glycosylation	
LGG	cis	1	rs4569324	chr17:65872750	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs4572812	chr3:134291177	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs4575590	chr17:28361969	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4579248	chr5:150268151	LOC134466	chr5:150310000-150326146:-	0.49	5.3	1.75E-7	Crohn's disease	
LGG	cis	1	rs4579792	chr1:248463742	OR2L13	chr1:248100493-248264223:+	-0.2	-3.66	0.000277	Common traits (Other)	
LGG	cis	1	rs458055	chr5:112799883	SRP19	chr5:112196993-112228774:+	-0.34	-4.13	4.34E-5	F-cell distribution	
LGG	cis	1	rs4580704	chr4:56326707	TMEM165	chr4:56262090-56292342:+	0.18	5.2	2.92E-7	Personality dimensions	
LGG	cis	1	rs4581755	chr17:28427898	EFCAB5	chr17:28256874-28435469:+	0.23	6.08	2.48E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs4582105	chr4:246342	ZNF718	chr4:53272-156488:+	0.26	5.12	4.5E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs458291	chr7:65520479	CCT6P1	chr7:65216092-65228661:+	0.26	4.7	3.37E-6	Diabetic kidney disease	
LGG	cis	1	rs4586057	chr10:92632899	RPP30	chr10:92631474-92668312:+	0.17	3.49	0.000527	Economic and political preferences (time)	
LGG	cis	1	rs4589143	chr1:248470446	OR2L13	chr1:248100493-248264223:+	0.2	3.55	0.000415	Common traits (Other)	
LGG	cis	1	rs4592586	chr14:81692293	STON2	chr14:81727000-81893748:-	0.19	3.5	0.000515	IgG glycosylation	
LGG	cis	1	rs4593512	chr8:98326152	HRSP12	chr8:99114567-99129418:-	0.16	3.83	0.000146	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs4595427	chr10:65012944	NRBF2	chr10:64893007-64914785:+	-0.23	-5.52	5.53E-8	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4595427	chr10:65012944	REEP3	chr10:65281123-65381971:+	0.13	3.73	0.00021	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4595905	chr19:18547305	LRRC25	chr19:18501955-18508421:-	-0.16	-5.7	2.04E-8	Breast cancer	
LGG	cis	1	rs4597652	chr22:50270570	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs4601204	chr7:1890925	FTSJ2	chr7:2273928-2281833:-	0.22	4.86	1.6E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4603880	chr22:31744721	LIMK2	chr22:31608250-31676064:+	-0.25	-5.31	1.71E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs4604732	chr1:247623872	C1orf150	chr1:247670394-247739846:+	0.29	4.74	2.74E-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
LGG	cis	1	rs4604805	chr10:102261409	WNT8B	chr10:102222812-102243397:+	0.44	7.5	3.01E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4604928	chr11:117044203	SIDT2	chr11:117049939-117068161:+	0.32	3.8	0.000162	Protein quantitative trait loci	
LGG	cis	1	rs4605213	chr17:49244747	NME1-NME2	chr17:49230920-49249104:+	0.26	6.37	4.34E-10	Height	
LGG	cis	1	rs4605213	chr17:49244747	UTP18	chr17:49337897-49375290:+	-0.18	-4.05	5.87E-5	Height	
LGG	cis	1	rs4606360	chr1:173699007	DARS2	chr1:173793958-173827682:+	-0.24	-6.15	1.59E-9	Subjective well-being	
LGG	cis	1	rs4606360	chr1:173699007	SERPINC1	chr1:173872943-173886516:-	0.22	3.94	9.35E-5	Subjective well-being	
LGG	cis	1	rs4606360	chr1:173699007	SLC9A11	chr1:173469604-173572233:-	0.23	5.14	4.07E-7	Subjective well-being	
LGG	cis	1	rs4609941	chr18:44645491	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs4611808	chr3:51469107	HEMK1	chr3:50606583-50622419:+	0.22	3.55	0.000423	Melanoma	
LGG	cis	1	rs4613123	chr17:20929295	USP22	chr17:20902908-20947073:-	-0.19	-4.4	1.34E-5	Blood trace element (Se levels)	
LGG	cis	1	rs461866	chr5:112231450	SRP19	chr5:112196993-112228774:+	-0.19	-3.48	0.000546	Attention deficit hyperactivity disorder	
LGG	cis	1	rs4623374	chr8:10816520	RP1L1	chr8:10463862-10512617:-	-0.3	-3.76	0.00019	Asthma and hay fever	
LGG	cis	1	rs4625780	chr17:30249214	LRRC37B	chr17:30335037-30380517:+	0.21	4.62	4.81E-6	Height	
LGG	cis	1	rs4626559	chr8:10816487	RP1L1	chr8:10463862-10512617:-	-0.29	-3.7	0.000238	Asthma and hay fever	
LGG	cis	1	rs4628178	chr7:33273638	BBS9	chr7:33169152-33645680:+	0.43	5.81	1.12E-8	Smooth-surface caries	
LGG	cis	1	rs462853	chr7:65558167	CCT6P1	chr7:65216092-65228661:+	0.26	4.79	2.23E-6	Diabetic kidney disease	
LGG	cis	1	rs4628584	chr10:4972697	AKR1C2	chr10:4964715-5060207:-	0.4	5.45	8.01E-8	Height	
LGG	cis	1	rs4629607	chr5:44857467	MRPS30	chr5:44809027-44815614:+	-0.18	-3.74	0.000204	Schizophrenia	
LGG	cis	1	rs4639966	chr11:118573519	IFT46	chr11:118415259-118436750:-	-0.23	-4.03	6.48E-5	Systemic lupus erythematosus	
LGG	cis	1	rs4639966	chr11:118573519	PHLDB1	chr11:118477213-118528741:+	0.28	4.76	2.5E-6	Systemic lupus erythematosus	
LGG	cis	1	rs4640348	chr2:28965479	FAM179A	chr2:29204164-29275094:+	-0.19	-3.68	0.000261	Body mass index	
LGG	cis	1	rs4640348	chr2:28965479	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.69	4.0E-24	Body mass index	
LGG	cis	1	rs4642241	chr4:17617111	MED28	chr4:17616273-17629791:+	0.21	4.43	1.14E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4643294	chr15:85250253	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.31	1.93E-5	Schizophrenia	
LGG	cis	1	rs4643294	chr15:85250253	LOC388152	chr15:84867600-84898920:-	-0.31	-5.75	1.55E-8	Schizophrenia	
LGG	cis	1	rs4643294	chr15:85250253	WDR73	chr15:85186012-85197524:-	-0.19	-3.52	0.000464	Schizophrenia	
LGG	cis	1	rs4643578	chr2:190526684	ORMDL1	chr2:190634994-190649097:-	0.36	5.26	2.19E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs4644	chr14:55604935	FBXO34	chr14:55738021-55893431:+	0.15	4.47	9.53E-6	Protein biomarker	
LGG	cis	1	rs4645525	chr8:10816174	RP1L1	chr8:10463862-10512617:-	-0.28	-3.59	0.000364	Asthma and hay fever	
LGG	cis	1	rs4646457	chr7:99245080	CYP3A5	chr7:99245818-99332821:-	0.36	3.88	0.000117	Blood metabolite levels	
LGG	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.45	11.05	1.73E-25	Multiple sclerosis	
LGG	cis	1	rs4646536	chr12:58157988	TSFM	chr12:58176536-58191367:+	-0.44	-8.55	1.57E-16	Multiple sclerosis	
LGG	cis	1	rs4646961	chr1:76217169	MSH4	chr1:76262630-76378923:+	0.23	4.28	2.24E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4647277	chr3:37058509	LRRFIP2	chr3:37094117-37217851:-	0.17	3.87	0.000124	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs464895	chr7:65527106	CCT6P1	chr7:65216092-65228661:+	0.25	4.38	1.48E-5	Diabetic kidney disease	
LGG	cis	1	rs465359	chr7:65558164	CCT6P1	chr7:65216092-65228661:+	0.26	4.79	2.23E-6	Diabetic kidney disease	
LGG	cis	1	rs4654863	chr1:20902244	CDA	chr1:20915444-20945398:+	-0.18	-3.55	0.000423	Age-related hearing impairment (interaction)	
LGG	cis	1	rs4658552	chr1:243412936	SDCCAG8	chr1:243419320-243663392:+	0.17	3.99	7.7E-5	Educational attainment	
LGG	cis	1	rs4658875	chr1:231168994	FAM89A	chr1:231154704-231175995:-	-0.25	-4.47	9.56E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.28	7.95	1.33E-14	Homocysteine levels	
LGG	cis	1	rs4660306	chr1:45978675	MMACHC	chr1:45965856-45976737:+	-0.27	-5.74	1.65E-8	Homocysteine levels	
LGG	cis	1	rs4660306	chr1:45978675	MUTYH	chr1:45794915-45806142:-	-0.13	-4.56	6.34E-6	Homocysteine levels	
LGG	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.17	-5	8.18E-7	Body mass index	
LGG	cis	1	rs4660317	chr1:46326226	MUTYH	chr1:45794915-45806142:-	0.14	5.17	3.37E-7	Body mass index	
LGG	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.95	1.02E-6	Body mass index	
LGG	cis	1	rs4660319	chr1:46341623	MUTYH	chr1:45794915-45806142:-	0.14	5.16	3.52E-7	Body mass index	
LGG	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.37	1.24E-7	Body mass index	
LGG	cis	1	rs4660321	chr1:46366760	MUTYH	chr1:45794915-45806142:-	0.13	4.99	8.3E-7	Body mass index	
LGG	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.15	3.71E-7	Body mass index	
LGG	cis	1	rs4660898	chr1:46402171	MUTYH	chr1:45794915-45806142:-	0.13	4.97	9.12E-7	Body mass index	
LGG	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.87	1.52E-6	Body mass index	
LGG	cis	1	rs4660910	chr1:46548402	MUTYH	chr1:45794915-45806142:-	0.14	5.22	2.69E-7	Body mass index	
LGG	cis	1	rs4664308	chr2:160917497	LY75	chr2:160625141-160761262:-	0.13	3.51	0.000481	Idiopathic membranous nephropathy	
LGG	cis	1	rs4665147	chr2:160917062	LY75	chr2:160625141-160761262:-	0.13	3.51	0.000481	Idiopathic membranous nephropathy	
LGG	cis	1	rs4665238	chr2:23942446	LOC375190	chr2:24299728-24397519:+	0.22	5.15	3.71E-7	Obesity-related traits	
LGG	cis	1	rs4665298	chr2:26256378	GPR113	chr2:26531041-26569685:-	-0.24	-3.86	0.000131	Gut microbiome composition (summer)	
LGG	cis	1	rs4665299	chr2:26256840	GPR113	chr2:26531041-26569685:-	-0.23	-3.66	0.000278	Gut microbiome composition (summer)	
LGG	cis	1	rs4665304	chr2:26313406	GPR113	chr2:26531041-26569685:-	-0.24	-3.87	0.000123	Gut microbiome composition (summer)	
LGG	cis	1	rs4665305	chr2:26313524	GPR113	chr2:26531041-26569685:-	-0.24	-3.81	0.000155	Gut microbiome composition (summer)	
LGG	cis	1	rs4665306	chr2:26319124	GPR113	chr2:26531041-26569685:-	-0.23	-3.75	0.000196	Gut microbiome composition (summer)	
LGG	cis	1	rs4665308	chr2:26330514	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs4665309	chr2:26335502	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs4665381	chr2:27757150	PPM1G	chr2:27604062-27632496:-	0.13	4.16	3.83E-5	Oral cavity cancer	
LGG	cis	1	rs4665381	chr2:27757150	SNX17	chr2:27593363-27599994:+	-0.12	-3.62	0.000323	Oral cavity cancer	
LGG	cis	1	rs4665809	chr2:26251361	GPR113	chr2:26531041-26569685:-	0.23	3.68	0.000255	Gut microbiome composition (summer)	
LGG	cis	1	rs4665811	chr2:26260017	GPR113	chr2:26531041-26569685:-	-0.24	-3.74	0.000206	Gut microbiome composition (summer)	
LGG	cis	1	rs4665816	chr2:26305094	GPR113	chr2:26531041-26569685:-	-0.24	-3.81	0.000156	Gut microbiome composition (summer)	
LGG	cis	1	rs4665817	chr2:26305167	GPR113	chr2:26531041-26569685:-	-0.23	-3.51	0.000491	Gut microbiome composition (summer)	
LGG	cis	1	rs4665819	chr2:26309073	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs4665820	chr2:26309150	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs4665821	chr2:26309949	GPR113	chr2:26531041-26569685:-	-0.23	-3.7	0.000242	Gut microbiome composition (summer)	
LGG	cis	1	rs4665823	chr2:26312723	GPR113	chr2:26531041-26569685:-	-0.23	-3.7	0.000242	Gut microbiome composition (summer)	
LGG	cis	1	rs4665958	chr2:27443196	SLC5A6	chr2:27422459-27435071:-	-0.3	-6.24	9.71E-10	Blood metabolite levels	
LGG	cis	1	rs4666007	chr2:27856495	PPM1G	chr2:27604062-27632496:-	0.14	4.37	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs4666007	chr2:27856495	SNX17	chr2:27593363-27599994:+	-0.12	-3.59	0.000362	Oral cavity cancer	
LGG	cis	1	rs4666009	chr2:27857992	PPM1G	chr2:27604062-27632496:-	0.12	3.92	9.99E-5	Oral cavity cancer	
LGG	cis	1	rs4666009	chr2:27857992	SNX17	chr2:27593363-27599994:+	-0.12	-3.54	0.000433	Oral cavity cancer	
LGG	cis	1	rs4666118	chr2:28951698	FAM179A	chr2:29204164-29275094:+	-0.2	-3.91	0.000107	Body mass index	
LGG	cis	1	rs4666118	chr2:28951698	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.74	2.5E-24	Body mass index	
LGG	cis	1	rs4666119	chr2:28975690	TRMT61B	chr2:29072690-29093175:-	-0.52	-10.93	4.72E-25	Body mass index	
LGG	cis	1	rs4667160	chr2:188166881	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.09E-8	Coronary heart disease	
LGG	cis	1	rs4667304	chr2:190587103	ASNSD1	chr2:190526125-190535556:+	-0.33	-3.53	0.000452	Subcutaneous adipose tissue	
LGG	cis	1	rs4667304	chr2:190587103	ORMDL1	chr2:190634994-190649097:-	0.39	5.38	1.13E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs4667503	chr2:166917408	TTC21B	chr2:166713988-166810348:-	0.12	3.66	0.000279	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667861	chr2:166888236	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000401	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667861	chr2:166888236	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.35E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667862	chr2:166888439	SCN2A	chr2:166095912-166248818:+	-0.09	-3.66	0.00028	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667862	chr2:166888439	TTC21B	chr2:166713988-166810348:-	-0.14	-3.97	8.28E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667865	chr2:166906782	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667865	chr2:166906782	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667867	chr2:166916043	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4667867	chr2:166916043	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4669418	chr2:9823870	KIDINS220	chr2:8865690-8977755:-	0.13	3.51	0.000497	Mammographic density	
LGG	cis	1	rs466983	chr7:65520496	CCT6P1	chr7:65216092-65228661:+	0.27	4.84	1.75E-6	Diabetic kidney disease	
LGG	cis	1	rs4671459	chr2:63392872	TMEM17	chr2:62727356-62762780:-	-0.18	-3.48	0.000544	Subjective well-being	
LGG	cis	1	rs4671460	chr2:63397203	TMEM17	chr2:62727356-62762780:-	-0.19	-3.49	0.000522	Subjective well-being	
LGG	cis	1	rs4674372	chr2:220141963	RESP18	chr2:220192132-220197899:-	0.19	4.23	2.77E-5	Educational attainment	
LGG	cis	1	rs4675310	chr2:203880834	WDR12	chr2:203745324-203776949:-	-0.21	-3.47	0.000568	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs4675811	chr2:242402062	ANO7	chr2:242127924-242164791:+	0.36	6.63	9.14E-11	Prostate cancer	
LGG	cis	1	rs4677834	chr3:195093631	ACAP2	chr3:194995475-195163817:-	0.36	8.43	3.96E-16	Body mass index	
LGG	cis	1	rs4679868	chr3:159724154	IL12A	chr3:159706629-159713805:+	0.2	3.88	0.000118	Primary biliary cirrhosis	
LGG	cis	1	rs4683948	chr3:101650188	CEP97	chr3:101443494-101486181:+	0.11	3.56	0.00041	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs4683948	chr3:101650188	LOC285359	chr3:101431278-101432259:+	-0.22	-4.84	1.77E-6	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs4683950	chr3:101653958	LOC285359	chr3:101431278-101432259:+	-0.2	-4.34	1.72E-5	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs4687697	chr3:53090490	ITIH1	chr3:52811608-52826077:+	-0.17	-3.47	0.000563	Ulcerative colitis	
LGG	cis	1	rs4687697	chr3:53090490	ITIH4	chr3:52847007-52866554:-	0.18	4.95	1.01E-6	Ulcerative colitis	
LGG	cis	1	rs4687697	chr3:53090490	RFT1	chr3:53122503-53164470:-	0.21	4.09	4.97E-5	Ulcerative colitis	
LGG	cis	1	rs4687701	chr3:53121276	RFT1	chr3:53122503-53164470:-	0.38	8.02	8.01E-15	Height	
LGG	cis	1	rs4687721	chr3:51598254	HEMK1	chr3:50606583-50622419:+	0.23	3.99	7.61E-5	Melanoma	
LGG	cis	1	rs4688011	chr3:119227247	KTELC1	chr3:119187785-119213552:+	-0.19	-3.59	0.000367	Arthritis (juvenile idiopathic)	
LGG	cis	1	rs4688013	chr3:119229486	KTELC1	chr3:119187785-119213552:+	-0.19	-3.59	0.000361	Arthritis (juvenile idiopathic)	
LGG	cis	1	rs4688240	chr3:65522392	MAGI1	chr3:65339907-66024509:-	0.17	3.5	0.000511	PR interval	
LGG	cis	1	rs4688570	chr3:65466168	MAGI1	chr3:65339907-66024509:-	-0.21	-4.31	1.99E-5	PR interval	
LGG	cis	1	rs4690909	chr4:159629151	ETFDH	chr4:159593277-159629839:+	0.29	5.95	5.11E-9	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs4692790	chr4:171012708	AADAT	chr4:170981374-171011372:-	-0.31	-4.01	7.09E-5	Thyroid hormone levels	
LGG	cis	1	rs4692791	chr4:171012741	AADAT	chr4:170981374-171011372:-	-0.31	-4.01	7.09E-5	Thyroid hormone levels	
LGG	cis	1	rs4692792	chr4:171016540	AADAT	chr4:170981374-171011372:-	-0.31	-4.03	6.37E-5	Thyroid hormone levels	
LGG	cis	1	rs4692793	chr4:171018383	AADAT	chr4:170981374-171011372:-	-0.35	-4.5	8.65E-6	Thyroid hormone levels	
LGG	cis	1	rs4692801	chr4:171051123	AADAT	chr4:170981374-171011372:-	-0.28	-3.48	0.000538	Thyroid hormone levels	
LGG	cis	1	rs4693089	chr4:84373622	AGPAT9	chr4:84457261-84527025:+	0.14	3.91	0.000107	Menopause (age at onset)	
LGG	cis	1	rs4693089	chr4:84373622	MRPS18C	chr4:84377118-84389352:+	-0.36	-8.1	4.3E-15	Menopause (age at onset)	
LGG	cis	1	rs469727	chr5:112242968	SRP19	chr5:112196993-112228774:+	0.21	3.88	0.000119	Attention deficit hyperactivity disorder	
LGG	cis	1	rs4697559	chr4:25289580	ANAPC4	chr4:25378848-25420119:+	-0.32	-5.1	4.78E-7	Cannabis dependence	
LGG	cis	1	rs4697559	chr4:25289580	PI4K2B	chr4:25162285-25280831:+	-0.3	-5.18	3.26E-7	Cannabis dependence	
LGG	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.44	-10.42	4.14E-23	Ankylosing spondylitis	
LGG	cis	1	rs469758	chr5:96121715	ERAP2	chr5:96211644-96255398:+	0.33	5.73	1.73E-8	Ankylosing spondylitis	
LGG	cis	1	rs4698198	chr4:17656536	MED28	chr4:17616273-17629791:+	0.18	3.96	8.72E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4698199	chr4:17656738	MED28	chr4:17616273-17629791:+	0.18	3.96	8.72E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4698200	chr4:17657051	MED28	chr4:17616273-17629791:+	0.18	3.97	8.29E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs469827	chr5:112242139	SRP19	chr5:112196993-112228774:+	-0.2	-3.63	0.000311	Attention deficit hyperactivity disorder	
LGG	cis	1	rs4698634	chr4:17630192	MED28	chr4:17616273-17629791:+	-0.18	-3.92	9.97E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4698635	chr4:17630242	MED28	chr4:17616273-17629791:+	0.2	4.33	1.84E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4698641	chr4:17642630	MED28	chr4:17616273-17629791:+	0.2	4.36	1.55E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs4698775	chr4:110590479	PLA2G12A	chr4:110631146-110651242:-	-0.18	-3.58	0.000382	Age-related macular degeneration	
LGG	cis	1	rs470119	chr22:50966914	CPT1B	chr22:51007291-51017096:-	-0.11	-3.82	0.000153	Mean corpuscular hemoglobin	
LGG	cis	1	rs470119	chr22:50966914	TYMP	chr22:50964184-50968514:-	-0.15	-4.94	1.07E-6	Mean corpuscular hemoglobin	
LGG	cis	1	rs4702718	chr5:10671040	DAP	chr5:10679343-10761387:-	0.16	4.15	3.9E-5	Obesity-related traits	
LGG	cis	1	rs470360	chr11:65500530	DKFZp761E198	chr11:65543380-65547822:-	0.26	3.62	0.000322	Atopic dermatitis	
LGG	cis	1	rs4704296	chr5:75502410	F2R	chr5:76011868-76031594:+	-0.18	-4.02	6.84E-5	Migraine - clinic-based	
LGG	cis	1	rs4704727	chr5:156380067	TIMD4	chr5:156346293-156390266:-	-0.21	-4.13	4.29E-5	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs4704729	chr5:156424516	TIMD4	chr5:156346293-156390266:-	-0.24	-4.45	1.06E-5	Hypertriglyceridemia	
LGG	cis	1	rs4704825	chr5:156382308	TIMD4	chr5:156346293-156390266:-	-0.23	-4.77	2.39E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.52	-11.14	7.67E-26	Response to antipsychotic treatment	
LGG	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.52	-11.09	1.19E-25	Response to antipsychotic treatment	
LGG	cis	1	rs4711346	chr6:33730996	LEMD2	chr6:33738991-33756906:-	0.18	5.18	3.31E-7	Body mass index	
LGG	cis	1	rs4711351	chr6:33754592	BAK1	chr6:33540324-33548070:-	-0.15	-3.46	0.00058	Crohn's disease	
LGG	cis	1	rs4711351	chr6:33754592	LEMD2	chr6:33738991-33756906:-	-0.15	-4.63	4.75E-6	Crohn's disease	
LGG	cis	1	rs471144	chr1:152454255	FLG	chr1:152274651-152297679:-	-0.39	-3.93	9.6E-5	Inflammatory skin disease	
LGG	cis	1	rs4713006	chr6:26519872	BTN2A3	chr6:26422317-26431927:+	0.12	3.46	0.000591	Educational attainment	
LGG	cis	1	rs4713006	chr6:26519872	HMGN4	chr6:26538572-26547162:+	-0.2	-5.28	1.97E-7	Educational attainment	
LGG	cis	1	rs4713008	chr6:26538268	BTN2A3	chr6:26422317-26431927:+	0.12	3.52	0.000472	Educational attainment	
LGG	cis	1	rs4713008	chr6:26538268	HMGN4	chr6:26538572-26547162:+	-0.2	-5.12	4.37E-7	Educational attainment	
LGG	cis	1	rs4713682	chr6:33757047	LEMD2	chr6:33738991-33756906:-	-0.15	-4.73	3.01E-6	Crohn's disease	
LGG	cis	1	rs4713684	chr6:33766488	BAK1	chr6:33540324-33548070:-	-0.15	-3.61	0.000336	Crohn's disease	
LGG	cis	1	rs4713684	chr6:33766488	LEMD2	chr6:33738991-33756906:-	-0.14	-4.34	1.7E-5	Crohn's disease	
LGG	cis	1	rs4713	chr9:131910805	CRAT	chr9:131857075-131873070:-	-0.2	-3.64	0.000304	Blood metabolite ratios	
LGG	cis	1	rs471490	chr6:160718711	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs4715129	chr6:49415043	CENPQ	chr6:49431096-49460820:+	-0.22	-4.87	1.47E-6	Folate pathway vitamin levels	
LGG	cis	1	rs4715130	chr6:49416825	CENPQ	chr6:49431096-49460820:+	-0.23	-5.1	4.98E-7	Folate pathway vitamin levels	
LGG	cis	1	rs471584	chr11:64149252	C11orf20	chr11:64067863-64072238:+	-0.22	-3.73	0.000216	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs4716375	chr6:170071218	WDR27	chr6:169857307-170102159:-	-0.41	-9.37	2.55E-19	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4716378	chr6:170086568	C6orf70	chr6:170151721-170181617:+	-0.18	-3.45	0.000599	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4716378	chr6:170086568	WDR27	chr6:169857307-170102159:-	-0.41	-9.2	1.05E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4716380	chr6:170090399	WDR27	chr6:169857307-170102159:-	-0.4	-9.04	3.6E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4717292	chr7:65895598	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs4717300	chr7:65947380	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs4717310	chr7:66161007	ASL	chr7:65540776-65558321:+	-0.19	-4.83	1.82E-6	Aortic root size	
LGG	cis	1	rs4717310	chr7:66161007	TYW1	chr7:66461817-66704496:+	0.17	3.69	0.00025	Aortic root size	
LGG	cis	1	rs4717319	chr7:66242593	ASL	chr7:65540776-65558321:+	-0.19	-4.82	1.95E-6	Aortic root size	
LGG	cis	1	rs4717319	chr7:66242593	TYW1	chr7:66461817-66704496:+	0.17	3.66	0.000285	Aortic root size	
LGG	cis	1	rs4718269	chr7:65200778	CCT6P1	chr7:65216092-65228661:+	-0.27	-5.06	5.82E-7	Diabetic kidney disease	
LGG	cis	1	rs4718270	chr7:65202407	CCT6P1	chr7:65216092-65228661:+	0.27	4.87	1.5E-6	Diabetic kidney disease	
LGG	cis	1	rs4718307	chr7:65610988	ASL	chr7:65540776-65558321:+	0.22	5.58	4.07E-8	Aortic root size	
LGG	cis	1	rs4718309	chr7:65627764	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.28	2.24E-5	Diabetic kidney disease	
LGG	cis	1	rs4718315	chr7:65648541	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs4718316	chr7:65648731	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs4718317	chr7:65648901	CCT6P1	chr7:65216092-65228661:+	-0.22	-3.93	9.75E-5	Diabetic kidney disease	
LGG	cis	1	rs4718333	chr7:65772758	CCT6P1	chr7:65216092-65228661:+	-0.23	-4.17	3.55E-5	Diabetic kidney disease	
LGG	cis	1	rs4718334	chr7:65789454	CCT6P1	chr7:65216092-65228661:+	-0.21	-3.87	0.000125	Diabetic kidney disease	
LGG	cis	1	rs4718343	chr7:65874288	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs4718344	chr7:65874381	ASL	chr7:65540776-65558321:+	-0.22	-5.58	4.04E-8	Aortic root size	
LGG	cis	1	rs4718357	chr7:65960878	ASL	chr7:65540776-65558321:+	-0.22	-5.55	4.64E-8	Aortic root size	
LGG	cis	1	rs4719319	chr7:1888094	FTSJ2	chr7:2273928-2281833:-	0.21	4.71	3.19E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4721121	chr7:1892565	FTSJ2	chr7:2273928-2281833:-	0.17	3.78	0.000176	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4721122	chr7:1893311	FTSJ2	chr7:2273928-2281833:-	0.19	4.12	4.41E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs4722286	chr7:23913624	C7orf46	chr7:23719749-23742268:+	-0.18	-3.96	8.51E-5	Schizophrenia	
LGG	cis	1	rs472415	chr11:83267166	CCDC90B	chr11:82972506-82997414:-	0.23	5.61	3.36E-8	Subcortical brain region volumes	
LGG	cis	1	rs4727443	chr7:99593346	EPO	chr7:100318423-100321321:+	0.21	4.64	4.55E-6	Interstitial lung disease	
LGG	cis	1	rs4727443	chr7:99593346	TRIM4	chr7:99488037-99517154:-	-0.24	-5.1	4.77E-7	Interstitial lung disease	
LGG	cis	1	rs4727865	chr7:118005595	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.75	0.000197	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4727867	chr7:118051152	ANKRD7	chr7:117864712-117882782:+	-0.23	-4.04	6.11E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4728142	chr7:128573967	IRF5	chr7:128577769-128590086:+	0.1	4.06	5.7E-5	Systemic lupus erythematosus;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs473005	chr4:56288125	TMEM165	chr4:56262090-56292342:+	-0.16	-4.91	1.27E-6	Personality dimensions	
LGG	cis	1	rs4730119	chr7:105535800	CDHR3	chr7:105517264-105676876:+	0.23	5.42	9.56E-8	Obesity-related traits	
LGG	cis	1	rs473073	chr10:131429646	MGMT	chr10:131265454-131565783:+	0.23	6.27	7.8E-10	Response to temozolomide	
LGG	cis	1	rs4730871	chr7:118079738	ANKRD7	chr7:117864712-117882782:+	-0.23	-4.01	7.08E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs4731207	chr7:124396645	POT1	chr7:124462441-124570037:-	0.15	3.54	0.000442	Cutaneous malignant melanoma	
LGG	cis	1	rs473188	chr11:116812029	SIDT2	chr11:117049939-117068161:+	0.32	3.85	0.000135	Protein quantitative trait loci	
LGG	cis	1	rs4733384	chr8:29985381	MBOAT4	chr8:29989188-30002200:-	0.34	3.82	0.000151	Migraine	
LGG	cis	1	rs4734494	chr8:101917721	YWHAZ	chr8:101930804-101965623:-	-0.16	-4.01	7.16E-5	Attention deficit hyperactivity disorder and conduct disorder	
LGG	cis	1	rs4734495	chr8:101917817	YWHAZ	chr8:101930804-101965623:-	-0.15	-3.82	0.000148	Attention deficit hyperactivity disorder and conduct disorder	
LGG	cis	1	rs473771	chr10:131408155	MGMT	chr10:131265454-131565783:+	0.23	6.1	2.19E-9	Response to temozolomide	
LGG	cis	1	rs4740619	chr9:15634326	CER1	chr9:14719734-14722715:-	-0.15	-3.47	0.000576	Body mass index	
LGG	cis	1	rs4740620	chr9:15638387	CER1	chr9:14719734-14722715:-	-0.17	-3.72	0.000225	Body mass index	
LGG	cis	1	rs4740621	chr9:15640404	CER1	chr9:14719734-14722715:-	-0.17	-3.67	0.000265	Body mass index	
LGG	cis	1	rs4741524	chr9:15634249	CER1	chr9:14719734-14722715:-	-0.17	-3.8	0.000165	Body mass index	
LGG	cis	1	rs4742711	chr9:100780790	C9orf156	chr9:100666772-100684852:-	0.21	3.86	0.000128	Coronary heart disease	
LGG	cis	1	rs4743130	chr9:100546040	C9orf156	chr9:100666772-100684852:-	0.18	3.79	0.000168	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs4743131	chr9:100554907	C9orf156	chr9:100666772-100684852:-	0.19	3.93	9.88E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs4743150	chr9:100740124	C9orf156	chr9:100666772-100684852:-	0.2	3.74	0.000203	Coronary heart disease	
LGG	cis	1	rs4743197	chr9:101067734	TDRD7	chr9:100174302-100258403:+	0.18	3.49	0.000523	Schizophrenia	
LGG	cis	1	rs4743199	chr9:101067992	TDRD7	chr9:100174302-100258403:+	0.18	3.49	0.000523	Schizophrenia	
LGG	cis	1	rs474617	chr6:160700441	SLC22A3	chr6:160769425-160876013:+	0.31	5.26	2.17E-7	Waist circumference	
LGG	cis	1	rs4750759	chr10:131436603	MGMT	chr10:131265454-131565783:+	-0.24	-6.47	2.43E-10	Response to temozolomide	
LGG	cis	1	rs4752797	chr11:47874364	MTCH2	chr11:47638859-47664206:-	0.22	4.23	2.81E-5	Subjective well-being	
LGG	cis	1	rs4752856	chr11:47648042	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000364	Subjective well-being	
LGG	cis	1	rs4752856	chr11:47648042	MTCH2	chr11:47638859-47664206:-	0.27	5.21	2.84E-7	Subjective well-being	
LGG	cis	1	rs4752856	chr11:47648042	PSMC3	chr11:47440320-47448024:-	0.16	3.97	8.32E-5	Subjective well-being	
LGG	cis	1	rs4752857	chr11:47655752	MTCH2	chr11:47638859-47664206:-	0.25	4.86	1.58E-6	Subjective well-being	
LGG	cis	1	rs4752857	chr11:47655752	PSMC3	chr11:47440320-47448024:-	0.15	3.59	0.000358	Subjective well-being	
LGG	cis	1	rs4752873	chr11:47857520	ACP2	chr11:47260854-47270457:-	0.16	3.53	0.000456	Subjective well-being	
LGG	cis	1	rs4752873	chr11:47857520	MTCH2	chr11:47638859-47664206:-	0.25	4.79	2.26E-6	Subjective well-being	
LGG	cis	1	rs4752873	chr11:47857520	PSMC3	chr11:47440320-47448024:-	0.15	3.78	0.000178	Subjective well-being	
LGG	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.51	-11.06	1.59E-25	Forced vital capacity	
LGG	cis	1	rs4759042	chr12:57377347	GEFT	chr12:58003963-58011025:+	-0.18	-4	7.29E-5	Migraine	
LGG	cis	1	rs4759229	chr12:56474480	ERBB3	chr12:56473892-56497127:+	-0.27	-5.93	5.79E-9	Cognitive function	
LGG	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.81	-17.03	1.95E-51	Cognitive function	
LGG	cis	1	rs4760355	chr12:57725197	TSFM	chr12:58176536-58191367:+	-0.23	-3.65	0.000291	Triglycerides	
LGG	cis	1	rs4761832	chr12:51694278	LETMD1	chr12:51442084-51454206:+	-0.18	-3.73	0.000216	Aging (time to death)	
LGG	cis	1	rs4762016	chr12:51694156	LETMD1	chr12:51442084-51454206:+	0.17	3.47	0.000558	Aging (time to death)	
LGG	cis	1	rs4763555	chr12:10721456	KLRA1	chr12:10741078-10752434:-	0.13	3.46	0.000582	Cognitive function	
LGG	cis	1	rs4763555	chr12:10721456	KLRC2	chr12:10579193-10588592:-	-0.22	-4.5	8.36E-6	Cognitive function	
LGG	cis	1	rs4763879	chr12:9910164	CLECL1	chr12:9868457-9885860:-	-0.44	-10.43	3.78E-23	Type 1 diabetes	
LGG	cis	1	rs4764124	chr12:14966604	C12orf60	chr12:14956506-14976789:+	-0.34	-6.79	3.26E-11	Pubertal anthropometrics	
LGG	cis	1	rs4764124	chr12:14966604	C12orf69	chr12:14957584-14967116:-	-0.23	-3.89	0.000113	Pubertal anthropometrics	
LGG	cis	1	rs4764124	chr12:14966604	ERP27	chr12:15066977-15091463:-	-0.19	-4.29	2.19E-5	Pubertal anthropometrics	
LGG	cis	1	rs4766646	chr12:110398145	GLTP	chr12:110288749-110318293:-	-0.18	-4.87	1.48E-6	Metabolite levels (MHPG)	
LGG	cis	1	rs4766646	chr12:110398145	TRPV4	chr12:110220894-110271212:-	-0.17	-3.76	0.000192	Metabolite levels (MHPG)	
LGG	cis	1	rs4768	chr3:49758764	MST1R	chr3:49924438-49941306:-	0.25	4.83	1.81E-6	Resting heart rate	
LGG	cis	1	rs476940	chr11:96026842	CCDC82	chr11:96085930-96123083:-	-0.17	-3.61	0.00034	Corneal astigmatism	
LGG	cis	1	rs477046	chr11:83324190	CCDC90B	chr11:82972506-82997414:-	0.25	5.93	5.67E-9	Subcortical brain region volumes	
LGG	cis	1	rs4770506	chr13:24434703	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs4770507	chr13:24434744	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs4770509	chr13:24438643	RNF17	chr13:25338301-25454056:+	-0.31	-3.53	0.000458	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs4775893	chr15:50898695	SPPL2A	chr15:50999739-51057910:-	0.11	3.72	0.000226	QT interval	
LGG	cis	1	rs4775897	chr15:50944066	SPPL2A	chr15:50999739-51057910:-	0.12	4.02	6.68E-5	QT interval	
LGG	cis	1	rs477612	chr11:96026835	CCDC82	chr11:96085930-96123083:-	-0.17	-3.61	0.00034	Corneal astigmatism	
LGG	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.22	6	3.87E-9	Response to temozolomide	
LGG	cis	1	rs4778656	chr15:82222597	FAM154B	chr15:82555152-82577265:+	-0.33	-3.61	0.00034	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs477895	chr11:64048912	C11orf20	chr11:64067863-64072238:+	0.27	4.44	1.11E-5	Mean platelet volume	
LGG	cis	1	rs478048	chr11:83324320	CCDC90B	chr11:82972506-82997414:-	-0.23	-5.55	4.78E-8	Subcortical brain region volumes	
LGG	cis	1	rs4785202	chr16:50095995	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs4785203	chr16:50096065	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs4785204	chr16:50103734	HEATR3	chr16:50099881-50139373:+	-0.29	-3.98	8.01E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs4785379	chr16:50089373	HEATR3	chr16:50099881-50139373:+	-0.31	-4.14	4.12E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs4785381	chr16:50133789	HEATR3	chr16:50099881-50139373:+	0.32	6.41	3.4E-10	Testicular germ cell tumor	
LGG	cis	1	rs4785382	chr16:50142220	HEATR3	chr16:50099881-50139373:+	0.31	6.23	1.01E-9	Testicular germ cell tumor	
LGG	cis	1	rs4787480	chr16:29857316	LOC440356	chr16:29875004-29879374:+	-0.25	-4.02	6.66E-5	Multiple sclerosis	
LGG	cis	1	rs4787484	chr16:29906546	BOLA2	chr16:29454226-29466285:-;chr16	-0.19	-4	7.36E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs4787484	chr16:29906546	LOC440356	chr16:29875004-29879374:+	-0.25	-5.14	4.07E-7	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs4787491	chr16:30015337	TBX6	chr16:30097117-30103208:-	0.22	4.8	2.13E-6	Body mass index	
LGG	cis	1	rs4788187	chr16:29845685	LOC440356	chr16:29875004-29879374:+	0.26	4.3	2.04E-5	Multiple sclerosis	
LGG	cis	1	rs4788188	chr16:29860863	LOC440356	chr16:29875004-29879374:+	-0.28	-4.66	4.1E-6	Multiple sclerosis	
LGG	cis	1	rs4788196	chr16:29967434	PPP4C	chr16:30087341-30096688:+	-0.09	-3.53	0.000455	Pubertal anthropometrics	
LGG	cis	1	rs4788196	chr16:29967434	TBX6	chr16:30097117-30103208:-	0.17	3.72	0.000218	Pubertal anthropometrics	
LGG	cis	1	rs4788815	chr16:71634811	PHLPP2	chr16:71671739-71757715:-	-0.14	-4.74	2.81E-6	Metabolite levels	
LGG	cis	1	rs478946	chr11:83297563	CCDC90B	chr11:82972506-82997414:-	0.24	5.67	2.41E-8	Subcortical brain region volumes	
LGG	cis	1	rs4790908	chr17:65852907	LOC440461	chr17:66194801-66196436:+	0.26	4.32	1.91E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs4791212	chr17:65975385	LOC440461	chr17:66194801-66196436:+	0.28	4.75	2.72E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs4791299	chr17:65930937	LOC440461	chr17:66194801-66196436:+	0.29	4.84	1.74E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs4793035	chr17:41887753	VAT1	chr17:41166622-41174459:-	-0.16	-3.46	0.00058	Triglycerides	
LGG	cis	1	rs4794016	chr17:45725931	C17orf57	chr17:45401142-45518675:+	-0.15	-3.64	0.0003	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4794016	chr17:45725931	LOC100272146	chr17:45500843-45504056:+	-0.15	-3.75	0.000199	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4794048	chr17:45763073	C17orf57	chr17:45401142-45518675:+	0.16	3.91	0.000106	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4794048	chr17:45763073	LOC100272146	chr17:45500843-45504056:+	0.14	3.54	0.000435	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs4794202	chr17:45930539	LRRC46	chr17:45909100-45914690:+	-0.38	-6.87	1.96E-11	Alzheimer's disease (cognitive decline)	
LGG	cis	1	rs4794202	chr17:45930539	SCRN2	chr17:45915049-45918699:-	-0.32	-7.4	5.85E-13	Alzheimer's disease (cognitive decline)	
LGG	cis	1	rs479478	chr10:131428959	MGMT	chr10:131265454-131565783:+	0.23	6.13	1.8E-9	Response to temozolomide	
LGG	cis	1	rs4794823	chr17:38166265	GSDMA	chr17:38119226-38134019:+	-0.72	-15.76	1.35E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4794824	chr17:38179290	GSDMA	chr17:38119226-38134019:+	-0.7	-15.21	4.41E-43	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4795412	chr17:38150604	GSDMA	chr17:38119226-38134019:+	-0.72	-16.01	1.01E-46	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4795415	chr17:38157995	GSDMA	chr17:38119226-38134019:+	-0.72	-15.66	3.99E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4795416	chr17:38158133	GSDMA	chr17:38119226-38134019:+	-0.72	-15.66	3.99E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4795418	chr17:38164851	GSDMA	chr17:38119226-38134019:+	-0.72	-15.76	1.35E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs4795525	chr17:28388487	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs479879	chr10:105945985	C10orf79	chr10:105889647-105992120:-	0.19	5.07	5.53E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs479994	chr1:183161729	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs480132	chr1:183161779	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs4803463	chr19:41911040	ATP5SL	chr19:41937224-41945810:-	0.16	4.42	1.22E-5	Height	
LGG	cis	1	rs4803463	chr19:41911040	B9D2	chr19:41860322-41870078:-	-0.11	-3.63	0.000317	Height	
LGG	cis	1	rs4803463	chr19:41911040	EXOSC5	chr19:41892278-41903256:-	-0.12	-3.66	0.000283	Height	
LGG	cis	1	rs4803465	chr19:41918158	ATP5SL	chr19:41937224-41945810:-	-0.17	-4.56	6.41E-6	Height	
LGG	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.62	16.4	1.55E-48	Schizophrenia	
LGG	cis	1	rs480643	chr10:131400308	MGMT	chr10:131265454-131565783:+	0.24	6.33	5.43E-10	Response to temozolomide	
LGG	cis	1	rs4808133	chr19:18608518	LRRC25	chr19:18501955-18508421:-	-0.16	-5.61	3.4E-8	Breast cancer	
LGG	cis	1	rs4808134	chr19:18608579	LRRC25	chr19:18501955-18508421:-	-0.16	-5.61	3.4E-8	Breast cancer	
LGG	cis	1	rs4808136	chr19:18618867	LRRC25	chr19:18501955-18508421:-	0.17	5.93	5.62E-9	Breast cancer	
LGG	cis	1	rs4808200	chr19:19554803	GMIP	chr19:19740286-19754455:-	0.13	3.93	9.87E-5	Schizophrenia	
LGG	cis	1	rs4808200	chr19:19554803	TSSK6	chr19:19623230-19626469:-	0.17	3.67	0.000273	Schizophrenia	
LGG	cis	1	rs4808801	chr19:18571141	LRRC25	chr19:18501955-18508421:-	-0.16	-5.77	1.39E-8	Breast cancer	
LGG	cis	1	rs4808804	chr19:18585325	LRRC25	chr19:18501955-18508421:-	-0.16	-5.62	3.19E-8	Breast cancer	
LGG	cis	1	rs4809219	chr20:62303115	LIME1	chr20:62367053-62370459:+	-0.15	-3.53	0.000449	Atopic dermatitis	
LGG	cis	1	rs4810055	chr20:55623058	CTCFL	chr20:56063880-56100708:-	0.25	3.63	0.000313	Response to citalopram treatment	
LGG	cis	1	rs4810486	chr20:44766403	CD40	chr20:44746906-44758384:+	-0.2	-4.32	1.92E-5	Kawasaki disease	
LGG	cis	1	rs4810486	chr20:44766403	WFDC3	chr20:44402847-44420547:-	0.3	4.4	1.32E-5	Kawasaki disease	
LGG	cis	1	rs4810909	chr20:47621372	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.09	5.0E-5	Anger	
LGG	cis	1	rs4810909	chr20:47621372	CSE1L	chr20:47662838-47713484:+	-0.2	-5.33	1.53E-7	Anger	
LGG	cis	1	rs4812048	chr20:57587771	TH1L	chr20:57556311-57570186:+	-0.26	-4.52	7.9E-6	Mean platelet volume	
LGG	cis	1	rs4813001	chr20:44762857	CD40	chr20:44746906-44758384:+	-0.21	-4.45	1.08E-5	Kawasaki disease	
LGG	cis	1	rs4813001	chr20:44762857	WFDC3	chr20:44402847-44420547:-	0.32	4.59	5.58E-6	Kawasaki disease	
LGG	cis	1	rs4813002	chr20:44763187	CD40	chr20:44746906-44758384:+	-0.21	-4.46	1.01E-5	Kawasaki disease	
LGG	cis	1	rs4813002	chr20:44763187	WFDC3	chr20:44402847-44420547:-	0.32	4.65	4.3E-6	Kawasaki disease	
LGG	cis	1	rs4813003	chr20:44763284	CD40	chr20:44746906-44758384:+	-0.2	-4.4	1.32E-5	Kawasaki disease	
LGG	cis	1	rs4813003	chr20:44763284	WFDC3	chr20:44402847-44420547:-	0.31	4.59	5.59E-6	Kawasaki disease	
LGG	cis	1	rs4813562	chr20:25352588	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813562	chr20:25352588	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813562	chr20:25352588	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813563	chr20:25365340	ABHD12	chr20:25275380-25371477:-	-0.27	-7.31	1.09E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813563	chr20:25365340	FAM182A	chr20:26035250-26067552:+	0.56	11.01	2.49E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813563	chr20:25365340	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.52E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813566	chr20:25386465	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813566	chr20:25386465	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4813566	chr20:25386465	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815404	chr20:25301845	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815404	chr20:25301845	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.69E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815404	chr20:25301845	FAM182B	chr20:25744102-25848786:-	-0.21	-4.76	2.53E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815405	chr20:25317492	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815405	chr20:25317492	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815405	chr20:25317492	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815406	chr20:25341316	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.17E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815406	chr20:25341316	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.25E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815406	chr20:25341316	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.49E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815407	chr20:25341478	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.05E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815407	chr20:25341478	FAM182A	chr20:26035250-26067552:+	0.56	11.02	2.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815407	chr20:25341478	FAM182B	chr20:25744102-25848786:-	-0.21	-4.83	1.82E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815408	chr20:25346678	ABHD12	chr20:25275380-25371477:-	-0.27	-7.31	1.09E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815408	chr20:25346678	FAM182A	chr20:26035250-26067552:+	0.56	11.01	2.49E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815408	chr20:25346678	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.52E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815409	chr20:25346697	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815409	chr20:25346697	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815409	chr20:25346697	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815411	chr20:25350223	ABHD12	chr20:25275380-25371477:-	-0.28	-7.62	1.31E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815411	chr20:25350223	FAM182A	chr20:26035250-26067552:+	0.54	10.69	4.05E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815411	chr20:25350223	FAM182B	chr20:25744102-25848786:-	-0.22	-4.97	9.24E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815412	chr20:25350325	ABHD12	chr20:25275380-25371477:-	0.27	7.33	9.56E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815412	chr20:25350325	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	4.11E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815412	chr20:25350325	FAM182B	chr20:25744102-25848786:-	0.21	4.74	2.75E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815417	chr20:25379526	ABHD12	chr20:25275380-25371477:-	-0.27	-7.62	1.36E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815417	chr20:25379526	FAM182A	chr20:26035250-26067552:+	0.53	10.55	1.37E-23	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815417	chr20:25379526	FAM182B	chr20:25744102-25848786:-	-0.21	-4.81	1.98E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815418	chr20:25382211	ABHD12	chr20:25275380-25371477:-	-0.28	-7.66	9.86E-14	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815418	chr20:25382211	FAM182A	chr20:26035250-26067552:+	0.54	10.68	4.47E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815418	chr20:25382211	FAM182B	chr20:25744102-25848786:-	-0.22	-4.94	1.06E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815420	chr20:25383979	ABHD12	chr20:25275380-25371477:-	-0.27	-7.34	8.87E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815420	chr20:25383979	FAM182A	chr20:26035250-26067552:+	0.54	10.49	2.23E-23	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815420	chr20:25383979	FAM182B	chr20:25744102-25848786:-	-0.22	-4.86	1.59E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815421	chr20:25386509	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815421	chr20:25386509	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815421	chr20:25386509	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815424	chr20:25390284	ABHD12	chr20:25275380-25371477:-	-0.27	-7.31	1.09E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815424	chr20:25390284	FAM182A	chr20:26035250-26067552:+	0.56	11.01	2.49E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815424	chr20:25390284	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.52E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815426	chr20:25405186	ABHD12	chr20:25275380-25371477:-	-0.27	-7.5	2.93E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815426	chr20:25405186	FAM182A	chr20:26035250-26067552:+	0.55	10.73	2.8E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4815426	chr20:25405186	FAM182B	chr20:25744102-25848786:-	-0.22	-4.88	1.41E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs4820043	chr22:31647094	LIMK2	chr22:31608250-31676064:+	0.26	5.33	1.54E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs482013	chr11:71803962	FAM86C	chr11:71498557-71512276:+	0.44	4.43	1.18E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4820294	chr22:38071043	LGALS1	chr22:38071613-38075807:+	-0.18	-4.9	1.29E-6	Fat distribution (HIV)	
LGG	cis	1	rs4820345	chr22:39091151	LOC646851	chr22:38974125-39052634:-	0.22	6.56	1.41E-10	Resting heart rate	
LGG	cis	1	rs4820539	chr22:23477970	RTDR1	chr22:23401594-23484241:-	0.16	3.7	0.000241	Bone mineral density	
LGG	cis	1	rs4820834	chr22:30751627	CCDC157	chr22:30752627-30772816:+	0.4	5.59	3.86E-8	Coronary artery calcification	
LGG	cis	1	rs4820963	chr22:31698166	LIMK2	chr22:31608250-31676064:+	0.27	5.55	4.68E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs4821798	chr22:39021165	LOC646851	chr22:38974125-39052634:-	0.25	7.56	1.94E-13	Resting heart rate	
LGG	cis	1	rs4821808	chr22:39065739	LOC646851	chr22:38974125-39052634:-	0.22	6.73	4.68E-11	Resting heart rate	
LGG	cis	1	rs4821809	chr22:39065743	LOC646851	chr22:38974125-39052634:-	0.22	6.73	4.68E-11	Resting heart rate	
LGG	cis	1	rs4821810	chr22:39072098	LOC646851	chr22:38974125-39052634:-	0.25	7.8	3.69E-14	Resting heart rate	
LGG	cis	1	rs4821811	chr22:39075145	LOC646851	chr22:38974125-39052634:-	0.22	6.59	1.13E-10	Resting heart rate	
LGG	cis	1	rs4821812	chr22:39075235	LOC646851	chr22:38974125-39052634:-	0.22	6.69	6.22E-11	Resting heart rate	
LGG	cis	1	rs4821816	chr22:39113134	LOC646851	chr22:38974125-39052634:-	0.25	7.6	1.51E-13	Resting heart rate	
LGG	cis	1	rs4822357	chr22:23473231	RTDR1	chr22:23401594-23484241:-	-0.19	-4.27	2.31E-5	Bone mineral density	
LGG	cis	1	rs4822358	chr22:23474795	RTDR1	chr22:23401594-23484241:-	-0.16	-3.78	0.000175	Bone mineral density	
LGG	cis	1	rs4822360	chr22:23482460	RTDR1	chr22:23401594-23484241:-	-0.15	-3.49	0.000521	Bone mineral density	
LGG	cis	1	rs4822361	chr22:23482718	RTDR1	chr22:23401594-23484241:-	0.16	3.74	0.000203	Bone mineral density	
LGG	cis	1	rs4822362	chr22:23482744	RTDR1	chr22:23401594-23484241:-	-0.16	-3.69	0.000248	Bone mineral density	
LGG	cis	1	rs4823086	chr22:30688659	CCDC157	chr22:30752627-30772816:+	0.37	4.84	1.77E-6	Coronary artery calcification	
LGG	cis	1	rs4823087	chr22:30693581	CCDC157	chr22:30752627-30772816:+	0.36	4.81	1.98E-6	Coronary artery calcification	
LGG	cis	1	rs4824106	chr22:50267822	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs4824112	chr22:50284345	ALG12	chr22:50296856-50312106:-	0.24	4.68	3.72E-6	Schizophrenia	
LGG	cis	1	rs4824112	chr22:50284345	CRELD2	chr22:50312283-50321186:+	0.17	3.62	0.000328	Schizophrenia	
LGG	cis	1	rs483783	chr1:183162152	LAMC2	chr1:183155174-183214262:+	0.28	5.5	5.97E-8	Hypertriglyceridemia	
LGG	cis	1	rs4838890	chr1:110616679	ALX3	chr1:110602998-110613322:-	-0.29	-6.63	9.01E-11	Blood metabolite levels	
LGG	cis	1	rs4838890	chr1:110616679	FAM40A	chr1:110574199-110597424:+	0.12	4.23	2.81E-5	Blood metabolite levels	
LGG	cis	1	rs483905	chr11:96023427	CCDC82	chr11:96085930-96123083:-	-0.16	-3.48	0.000537	Corneal astigmatism	
LGG	cis	1	rs4839103	chr1:110620701	ALX3	chr1:110602998-110613322:-	-0.27	-6.15	1.59E-9	Blood metabolite levels	
LGG	cis	1	rs4839103	chr1:110620701	FAM40A	chr1:110574199-110597424:+	0.12	4.22	2.92E-5	Blood metabolite levels	
LGG	cis	1	rs4840351	chr8:8573148	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.03	6.88E-7	Obesity-related traits	
LGG	cis	1	rs4840352	chr8:8573508	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.93	1.13E-6	Obesity-related traits	
LGG	cis	1	rs4841016	chr8:8572561	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.01	7.51E-7	Obesity-related traits	
LGG	cis	1	rs4841017	chr8:8577093	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.8	2.13E-6	Obesity-related traits	
LGG	cis	1	rs4842658	chr12:89853408	GALNT4	chr12:89913192-89919777:-	-0.15	-4.31	1.98E-5	Schizophrenia	
LGG	cis	1	rs4842658	chr12:89853408	POC1B	chr12:89813501-89919777:-	-0.17	-3.55	0.000429	Schizophrenia	
LGG	cis	1	rs4842660	chr12:89928313	GALNT4	chr12:89913192-89919777:-	-0.16	-4.62	4.83E-6	Schizophrenia	
LGG	cis	1	rs4842660	chr12:89928313	POC1B	chr12:89813501-89919777:-	-0.17	-3.63	0.000307	Schizophrenia	
LGG	cis	1	rs484538	chr1:71442683	PTGER3	chr1:71318036-71513491:-	0.15	3.61	0.000337	IgG glycosylation	
LGG	cis	1	rs4846083	chr1:12045555	MIIP	chr1:12079512-12092106:+	0.09	3.55	0.000418	Platelet count	
LGG	cis	1	rs4846085	chr1:12050634	MIIP	chr1:12079512-12092106:+	0.09	3.55	0.000416	Platelet count	
LGG	cis	1	rs484675	chr1:71442737	PTGER3	chr1:71318036-71513491:-	0.15	3.61	0.000337	IgG glycosylation	
LGG	cis	1	rs4847181	chr1:93028792	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs484953	chr11:96018862	CCDC82	chr11:96085930-96123083:-	-0.16	-3.51	0.000485	Corneal astigmatism	
LGG	cis	1	rs4851575	chr2:103025203	IL18R1	chr2:102927962-103015215:+	-0.4	-6.35	4.93E-10	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4851575	chr2:103025203	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.43	9.07E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4851584	chr2:103060313	IL18R1	chr2:102927962-103015215:+	-0.36	-5.69	2.16E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4851584	chr2:103060313	IL1RL1	chr2:102927962-102968497:+	-0.35	-5.08	5.28E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4851588	chr2:103073505	IL18R1	chr2:102927962-103015215:+	-0.39	-6.21	1.16E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4851588	chr2:103073505	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.44	8.34E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs4852375	chr2:70125988	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.46	1.01E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs4853036	chr2:70059824	SNRNP27	chr2:70121090-70132348:+	-0.19	-3.82	0.000153	Colorectal or endometrial cancer	
LGG	cis	1	rs4853634	chr2:190779231	ORMDL1	chr2:190634994-190649097:-	0.34	5.09	5.05E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs4854058	chr2:240923677	NDUFA10	chr2:240900158-240964798:-	0.42	8.18	2.5E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs4855579	chr3:108857881	MORC1	chr3:108677089-108836993:-	-0.36	-6.79	3.23E-11	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs4855581	chr3:108860645	MORC1	chr3:108677089-108836993:-	-0.39	-6.32	5.94E-10	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs4855695	chr3:108851484	MORC1	chr3:108677089-108836993:-	-0.25	-6.07	2.62E-9	Colorectal cancer (diet interaction)	
LGG	cis	1	rs4855696	chr3:108852822	MORC1	chr3:108677089-108836993:-	-0.39	-6.96	1.13E-11	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.22	6	3.82E-9	Response to temozolomide	
LGG	cis	1	rs485842	chr11:96023214	CCDC82	chr11:96085930-96123083:-	-0.16	-3.48	0.000537	Corneal astigmatism	
LGG	cis	1	rs4858793	chr3:48415007	ATRIP	chr3:48488141-48507708:+	-0.2	-4.88	1.46E-6	Longevity	
LGG	cis	1	rs4858793	chr3:48415007	TREX1	chr3:48501186-48509043:+	0.35	8.83	1.89E-17	Longevity	
LGG	cis	1	rs4858817	chr3:48416756	ATRIP	chr3:48488141-48507708:+	-0.18	-4.48	9.39E-6	Longevity	
LGG	cis	1	rs4858817	chr3:48416756	TREX1	chr3:48501186-48509043:+	0.39	9.93	2.76E-21	Longevity	
LGG	cis	1	rs4858888	chr3:47405305	NBEAL2	chr3:47021173-47051193:+	0.13	3.67	0.000272	Colorectal cancer	
LGG	cis	1	rs4858888	chr3:47405305	NRADDP	chr3:47053032-47054957:+	0.23	4	7.23E-5	Colorectal cancer	
LGG	cis	1	rs4859413	chr4:76898250	NAAA	chr4:76831809-76862166:-	0.45	11.07	1.4E-25	Longevity	
LGG	cis	1	rs4859581	chr4:76906974	NAAA	chr4:76831809-76862166:-	-0.46	-11.4	7.21E-27	Longevity	
LGG	cis	1	rs4859582	chr4:76907213	NAAA	chr4:76831809-76862166:-	-0.46	-11.23	3.37E-26	Longevity	
LGG	cis	1	rs4862357	chr4:185220362	C4orf41	chr4:184580446-184634744:+	0.17	3.81	0.000154	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	
LGG	cis	1	rs4862406	chr4:185629339	CCDC111	chr4:185570767-185616112:+	-0.16	-3.55	0.00043	Kawasaki disease	
LGG	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.26	7.46	3.94E-13	Kawasaki disease	
LGG	cis	1	rs486301	chr15:43836949	ADAL	chr15:43622872-43646094:+	-0.6	-8.02	7.77E-15	Tumor biomarkers	
LGG	cis	1	rs486301	chr15:43836949	LCMT2	chr15:43619976-43622891:-	-0.28	-3.79	0.000171	Tumor biomarkers	
LGG	cis	1	rs486301	chr15:43836949	STRC	chr15:43891762-43924561:-	0.38	7.14	3.44E-12	Tumor biomarkers	
LGG	cis	1	rs4864998	chr4:56332606	TMEM165	chr4:56262090-56292342:+	-0.17	-4.95	1.01E-6	Personality dimensions	
LGG	cis	1	rs4865008	chr4:56410855	TMEM165	chr4:56262090-56292342:+	0.17	5.02	7.37E-7	Personality dimensions	
LGG	cis	1	rs4865010	chr4:56414962	TMEM165	chr4:56262090-56292342:+	0.15	4.4	1.35E-5	Personality dimensions	
LGG	cis	1	rs4865463	chr4:1742400	TMEM129	chr4:1717680-1723084:-	-0.18	-3.87	0.000125	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs4865467	chr4:1745500	TMEM129	chr4:1717680-1723084:-	0.18	3.89	0.000113	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs4868110	chr5:171164168	NEURL1B	chr5:172068276-172118531:+	0.16	3.47	0.000575	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs4868111	chr5:171166875	NEURL1B	chr5:172068276-172118531:+	-0.16	-3.53	0.000457	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-1.03	-31.32	3.98E-119	Pediatric autoimmune diseases	
LGG	cis	1	rs4870040	chr6:151872090	C6orf97	chr6:151815175-151942327:+	0.25	4.13	4.31E-5	Bone mineral density (spine)	
LGG	cis	1	rs4870041	chr6:151872324	C6orf97	chr6:151815175-151942327:+	0.25	4.11	4.71E-5	Bone mineral density (spine)	
LGG	cis	1	rs4870941	chr8:126498828	TRIB1	chr8:126442563-126450642:+	-0.23	-4.18	3.48E-5	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs4871	chr6:26545632	BTN2A3	chr6:26422317-26431927:+	0.12	3.57	0.000396	Educational attainment	
LGG	cis	1	rs4871	chr6:26545632	HMGN4	chr6:26538572-26547162:+	-0.2	-5.31	1.69E-7	Educational attainment	
LGG	cis	1	rs4872175	chr8:23534802	NKX3-1	chr8:23536207-23540450:-	0.2	3.94	9.28E-5	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs488483	chr11:60592227	CCDC86	chr11:60609429-60618561:+	0.22	3.9	0.00011	Wegener's granulomatosis	
LGG	cis	1	rs488483	chr11:60592227	GPR44	chr11:60618398-60623444:-	0.25	4.43	1.14E-5	Wegener's granulomatosis	
LGG	cis	1	rs4886018	chr13:52990717	CKAP2	chr13:53029495-53050763:+	-0.29	-8.56	1.49E-16	Lewy body disease	
LGG	cis	1	rs4886018	chr13:52990717	NEK3	chr13:52706780-52733996:-	0.26	8.06	6.02E-15	Lewy body disease	
LGG	cis	1	rs4886018	chr13:52990717	TPTE2P3	chr13:53063128-53161224:+	-0.17	-4.11	4.58E-5	Lewy body disease	
LGG	cis	1	rs4886018	chr13:52990717	VPS36	chr13:52986739-53024763:-	0.16	4.38	1.45E-5	Lewy body disease	
LGG	cis	1	rs4886615	chr15:75131661	MPI	chr15:75182410-75190565:+	0.28	6.02	3.35E-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	
LGG	cis	1	rs4886755	chr15:76298132	NRG4	chr15:76235385-76352069:-	0.17	3.74	0.000208	Urate levels in obese individuals	
LGG	cis	1	rs4887036	chr15:74023853	CLK3	chr15:74890843-74922541:+	0.22	3.6	0.000348	Bipolar disorder	
LGG	cis	1	rs4887039	chr15:74023864	CLK3	chr15:74890843-74922541:+	0.22	3.6	0.000348	Bipolar disorder	
LGG	cis	1	rs4887045	chr15:74024059	CLK3	chr15:74890843-74922541:+	0.22	3.6	0.000348	Bipolar disorder	
LGG	cis	1	rs4887067	chr15:78886947	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.36	5.76E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs4887114	chr15:74029846	CLK3	chr15:74890843-74922541:+	0.23	3.79	0.000169	Bipolar disorder	
LGG	cis	1	rs488799	chr11:71561686	FAM86C	chr11:71498557-71512276:+	-0.5	-5.18	3.25E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4889609	chr16:31026427	MYST1	chr16:31128985-31142713:+	0.14	3.99	7.49E-5	Response to metformin (IC50)	
LGG	cis	1	rs4889609	chr16:31026427	PRSS53	chr16:31094747-31106276:-	-0.16	-4.44	1.09E-5	Response to metformin (IC50)	
LGG	cis	1	rs4889792	chr17:77839845	NPTX1	chr17:78440633-78450404:-	0.19	3.72	0.00022	Electroencephalogram traits	
LGG	cis	1	rs4889911	chr17:77839811	NPTX1	chr17:78440633-78450404:-	0.19	3.72	0.00022	Electroencephalogram traits	
LGG	cis	1	rs4895807	chr6:126686513	CENPW	chr6:126661253-126804465:+	-0.15	-3.89	0.000116	Type 1 diabetes	
LGG	cis	1	rs4899544	chr14:75546556	ACYP1	chr14:75519930-75530736:-	-0.13	-3.55	0.000428	Height	
LGG	cis	1	rs4899546	chr14:75594946	ACYP1	chr14:75519930-75530736:-	-0.15	-4.02	6.6E-5	Height	
LGG	cis	1	rs4899546	chr14:75594946	EIF2B2	chr14:75469612-75476292:+	0.19	3.67	0.00027	Height	
LGG	cis	1	rs4899586	chr14:76660856	ESRRB	chr14:76837690-76968178:+	0.43	6.99	9.09E-12	Blood pressure	
LGG	cis	1	rs490234	chr9:128303734	FAM125B	chr9:129089128-129273699:+	0.12	3.51	0.000483	Mean arterial pressure	
LGG	cis	1	rs4902765	chr14:70368337	COX16	chr14:70791799-70826444:-	-0.2	-3.64	0.000302	Red blood cell traits	
LGG	cis	1	rs4902765	chr14:70368337	SLC39A9	chr14:69865407-69929105:+	-0.2	-3.76	0.000193	Red blood cell traits	
LGG	cis	1	rs4903201	chr14:74659690	C14orf45	chr14:74486059-74549566:+	-0.14	-3.73	0.000216	Common traits (Other)	
LGG	cis	1	rs4903201	chr14:74659690	LIN52	chr14:74551656-74667117:+	-0.49	-11.22	3.56E-26	Common traits (Other)	
LGG	cis	1	rs4903202	chr14:74660302	C14orf45	chr14:74486059-74549566:+	-0.14	-3.72	0.000218	Common traits (Other)	
LGG	cis	1	rs4903202	chr14:74660302	LIN52	chr14:74551656-74667117:+	-0.49	-11.21	3.93E-26	Common traits (Other)	
LGG	cis	1	rs4903203	chr14:74660508	C14orf45	chr14:74486059-74549566:+	-0.14	-3.72	0.000218	Common traits (Other)	
LGG	cis	1	rs4903203	chr14:74660508	LIN52	chr14:74551656-74667117:+	-0.49	-11.21	3.93E-26	Common traits (Other)	
LGG	cis	1	rs4903275	chr14:75512509	EIF2B2	chr14:75469612-75476292:+	0.19	3.7	0.00024	Height	
LGG	cis	1	rs4903275	chr14:75512509	MLH3	chr14:75480467-75518235:-	0.21	3.6	0.000347	Height	
LGG	cis	1	rs4903279	chr14:75546583	ACYP1	chr14:75519930-75530736:-	-0.13	-3.55	0.000428	Height	
LGG	cis	1	rs4903281	chr14:75554361	ACYP1	chr14:75519930-75530736:-	-0.14	-3.58	0.000371	Height	
LGG	cis	1	rs4903281	chr14:75554361	EIF2B2	chr14:75469612-75476292:+	0.18	3.46	0.000595	Height	
LGG	cis	1	rs4903281	chr14:75554361	MLH3	chr14:75480467-75518235:-	0.2	3.46	0.000594	Height	
LGG	cis	1	rs4903284	chr14:75592483	ACYP1	chr14:75519930-75530736:-	-0.14	-3.7	0.000241	Height	
LGG	cis	1	rs4903284	chr14:75592483	EIF2B2	chr14:75469612-75476292:+	0.2	3.9	0.00011	Height	
LGG	cis	1	rs4903284	chr14:75592483	MLH3	chr14:75480467-75518235:-	0.2	3.49	0.000521	Height	
LGG	cis	1	rs4903289	chr14:75623988	ACYP1	chr14:75519930-75530736:-	0.13	3.58	0.000377	Height	
LGG	cis	1	rs4903386	chr14:76669658	ESRRB	chr14:76837690-76968178:+	0.43	6.79	3.35E-11	Blood pressure	
LGG	cis	1	rs4903977	chr14:81772095	STON2	chr14:81727000-81893748:-	-0.14	-3.59	0.000361	Obesity-related traits	
LGG	cis	1	rs4903979	chr14:81778158	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs4903980	chr14:81778263	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs4905941	chr14:100725438	CCDC85C	chr14:99977604-100070727:-	-0.15	-3.53	0.000457	Electroencephalographic traits in alcoholism	
LGG	cis	1	rs4906205	chr14:102932447	ANKRD9	chr14:102973198-102976128:-	0.19	4.55	6.77E-6	QT interval	
LGG	cis	1	rs4910553	chr11:5372658	FAM160A2	chr11:6232565-6255941:-	0.18	3.6	0.000344	Fetal hemoglobin levels	
LGG	cis	1	rs4910755	chr11:5372751	FAM160A2	chr11:6232565-6255941:-	0.2	3.93	9.71E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4910772	chr11:5389544	FAM160A2	chr11:6232565-6255941:-	0.2	4.03	6.48E-5	Fetal hemoglobin levels	
LGG	cis	1	rs4910774	chr11:5392544	FAM160A2	chr11:6232565-6255941:-	0.18	3.57	0.000386	Fetal hemoglobin levels	
LGG	cis	1	rs4910775	chr11:5392805	FAM160A2	chr11:6232565-6255941:-	0.18	3.68	0.000261	Fetal hemoglobin levels	
LGG	cis	1	rs4910776	chr11:5392884	FAM160A2	chr11:6232565-6255941:-	0.18	3.68	0.000261	Fetal hemoglobin levels	
LGG	cis	1	rs4911178	chr20:33952620	CPNE1	chr20:34213968-34262539:-	0.25	5.52	5.47E-8	Height	
LGG	cis	1	rs4911178	chr20:33952620	GDF5	chr20:33897002-34042568:-	-0.39	-7.68	8.47E-14	Height	
LGG	cis	1	rs4911178	chr20:33952620	UQCC	chr20:33890383-33999833:-	0.22	4.83	1.84E-6	Height	
LGG	cis	1	rs4911180	chr20:33972948	CPNE1	chr20:34213968-34262539:-	0.28	5.96	4.91E-9	Height	
LGG	cis	1	rs4911180	chr20:33972948	GDF5	chr20:33897002-34042568:-	-0.39	-7.56	2.0E-13	Height	
LGG	cis	1	rs4911180	chr20:33972948	UQCC	chr20:33890383-33999833:-	0.24	5.16	3.65E-7	Height	
LGG	cis	1	rs4911491	chr20:33947285	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs4911491	chr20:33947285	GDF5	chr20:33897002-34042568:-	-0.38	-7.48	3.39E-13	Height	
LGG	cis	1	rs4911491	chr20:33947285	UQCC	chr20:33890383-33999833:-	0.23	5	7.99E-7	Height	
LGG	cis	1	rs4911492	chr20:33951799	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs4911492	chr20:33951799	GDF5	chr20:33897002-34042568:-	-0.38	-7.48	3.39E-13	Height	
LGG	cis	1	rs4911492	chr20:33951799	UQCC	chr20:33890383-33999833:-	0.23	5	7.99E-7	Height	
LGG	cis	1	rs4911494	chr20:33971914	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs4911494	chr20:33971914	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs4911494	chr20:33971914	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs4911496	chr20:33972053	CPNE1	chr20:34213968-34262539:-	-0.26	-5.57	4.1E-8	Height	
LGG	cis	1	rs4911496	chr20:33972053	GDF5	chr20:33897002-34042568:-	0.37	7.28	1.3E-12	Height	
LGG	cis	1	rs4911496	chr20:33972053	UQCC	chr20:33890383-33999833:-	-0.23	-4.89	1.35E-6	Height	
LGG	cis	1	rs4916124	chr1:248466495	OR2L13	chr1:248100493-248264223:+	0.21	3.72	0.000222	Common traits (Other)	
LGG	cis	1	rs4916125	chr1:248466583	OR2L13	chr1:248100493-248264223:+	0.21	3.72	0.000222	Common traits (Other)	
LGG	cis	1	rs4916128	chr1:248466706	OR2L13	chr1:248100493-248264223:+	0.21	3.72	0.000222	Common traits (Other)	
LGG	cis	1	rs4917385	chr10:105003721	AS3MT	chr10:104613967-104661653:+	-0.22	-4.18	3.5E-5	Systemic lupus erythematosus	
LGG	cis	1	rs4917385	chr10:105003721	C10orf32	chr10:104613967-104624718:+	-0.18	-3.69	0.000253	Systemic lupus erythematosus	
LGG	cis	1	rs4917385	chr10:105003721	NT5C2	chr10:104845940-104953056:-	-0.15	-3.46	0.000578	Systemic lupus erythematosus	
LGG	cis	1	rs4917385	chr10:105003721	TMEM180	chr10:104221170-104238858:+	-0.16	-3.52	0.000479	Systemic lupus erythematosus	
LGG	cis	1	rs4917901	chr10:102201773	HIF1AN	chr10:102295641-102313680:+	0.19	3.77	0.000181	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4917901	chr10:102201773	NDUFB8	chr10:102283497-102289636:-	0.16	4.64	4.47E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4917901	chr10:102201773	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.08E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4918722	chr10:113947040	ZDHHC6	chr10:114190060-114207306:-	0.25	4.57	6.07E-6	HDL cholesterol	
LGG	cis	1	rs4919464	chr10:102221195	HIF1AN	chr10:102295641-102313680:+	0.2	3.84	0.000141	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919464	chr10:102221195	NDUFB8	chr10:102283497-102289636:-	0.17	4.84	1.73E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919464	chr10:102221195	WNT8B	chr10:102222812-102243397:+	0.51	8.58	1.24E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919465	chr10:102221703	HIF1AN	chr10:102295641-102313680:+	0.2	3.84	0.000141	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919465	chr10:102221703	NDUFB8	chr10:102283497-102289636:-	0.17	4.84	1.73E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919465	chr10:102221703	WNT8B	chr10:102222812-102243397:+	0.51	8.58	1.24E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919466	chr10:102241213	HIF1AN	chr10:102295641-102313680:+	0.18	3.63	0.000317	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919466	chr10:102241213	NDUFB8	chr10:102283497-102289636:-	0.15	4.27	2.3E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919466	chr10:102241213	WNT8B	chr10:102222812-102243397:+	0.52	8.82	1.98E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919468	chr10:102288343	HIF1AN	chr10:102295641-102313680:+	0.19	3.55	0.000428	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919468	chr10:102288343	NDUFB8	chr10:102283497-102289636:-	0.18	5.05	6.38E-7	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919468	chr10:102288343	WNT8B	chr10:102222812-102243397:+	0.5	8.21	2.04E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919469	chr10:102298855	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.000278	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919469	chr10:102298855	NDUFB8	chr10:102283497-102289636:-	0.17	4.71	3.29E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919469	chr10:102298855	WNT8B	chr10:102222812-102243397:+	0.49	8.1	4.46E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919470	chr10:102298920	NDUFB8	chr10:102283497-102289636:-	0.17	4.74	2.81E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919470	chr10:102298920	WNT8B	chr10:102222812-102243397:+	0.54	8.78	2.78E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919471	chr10:102299239	HIF1AN	chr10:102295641-102313680:+	0.19	3.53	0.000459	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919471	chr10:102299239	NDUFB8	chr10:102283497-102289636:-	0.16	4.47	9.54E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919471	chr10:102299239	WNT8B	chr10:102222812-102243397:+	0.5	8.1	4.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919472	chr10:102315864	HIF1AN	chr10:102295641-102313680:+	0.21	3.94	9.49E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919472	chr10:102315864	NDUFB8	chr10:102283497-102289636:-	0.17	4.63	4.68E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919472	chr10:102315864	WNT8B	chr10:102222812-102243397:+	0.49	7.68	8.71E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs4919690	chr10:104616500	AS3MT	chr10:104613967-104661653:+	0.76	17.35	6.2E-53	Arsenic metabolism	
LGG	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.4	8.4	4.68E-16	Arsenic metabolism	
LGG	cis	1	rs4920657	chr2:190707167	ORMDL1	chr2:190634994-190649097:-	0.32	5.01	7.75E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs4920660	chr2:190744666	ASNSD1	chr2:190526125-190535556:+	-0.31	-3.67	0.00027	Subcutaneous adipose tissue	
LGG	cis	1	rs4920660	chr2:190744666	ORMDL1	chr2:190634994-190649097:-	0.33	5.19	3.16E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs4921542	chr8:17205577	MTMR7	chr8:17154308-17271040:-	-0.31	-4.39	1.4E-5	Creutzfeldt-Jakob disease (variant)	
LGG	cis	1	rs4921799	chr8:17507964	MTUS1	chr8:17501304-17658426:-	0.18	5.11	4.55E-7	Adenocarcinoma;Lung cancer	
LGG	cis	1	rs4924935	chr17:18753870	FAM18B	chr17:18684582-18710026:+	-0.15	-3.5	0.000511	Pancreatic cancer	
LGG	cis	1	rs4924935	chr17:18753870	PRPSAP2	chr17:18759663-18834580:+	0.21	5.42	9.54E-8	Pancreatic cancer	
LGG	cis	1	rs4925166	chr17:18210810	LOC220594	chr17:18414577-18445234:-	-0.24	-4.95	1.01E-6	Multiple sclerosis	
LGG	cis	1	rs4925166	chr17:18210810	SHMT1	chr17:18231195-18266856:-	0.13	3.91	0.000103	Multiple sclerosis	
LGG	cis	1	rs4925540	chr1:247214878	ZNF670	chr1:247200087-247242069:-	-0.23	-5.2	2.91E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs492607	chr11:83295311	CCDC90B	chr11:82972506-82997414:-	0.25	5.84	9.25E-9	Subcortical brain region volumes	
LGG	cis	1	rs4926407	chr1:150087824	RPRD2	chr1:150336990-150449039:+	-0.15	-3.95	9.07E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs4926408	chr1:150106226	RPRD2	chr1:150336990-150449039:+	-0.15	-3.7	0.000243	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs4926409	chr1:150110435	RPRD2	chr1:150336990-150449039:+	-0.15	-3.7	0.000243	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs4929949	chr11:8604593	STK33	chr11:8413418-8615775:-	-0.21	-5.81	1.14E-8	Body mass index	
LGG	cis	1	rs4929949	chr11:8604593	TRIM66	chr11:8633586-8693413:-	0.17	3.95	8.94E-5	Body mass index	
LGG	cis	1	rs4929983	chr11:2024579	LOC100133545	chr11:2004440-2011150:-	-0.13	-3.63	0.000313	DNA methylation (variation);DNA methylation (parent-of-origin)	
LGG	cis	1	rs4930103	chr11:2024544	LOC100133545	chr11:2004440-2011150:-	-0.13	-3.65	0.000293	DNA methylation (variation);DNA methylation (parent-of-origin)	
LGG	cis	1	rs493065	chr11:71796929	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4932143	chr15:90372067	AP3S2	chr15:90373832-90456222:-	-0.48	-9.07	2.97E-18	Type 2 diabetes	
LGG	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.5	-9.76	1.11E-20	Type 2 diabetes	
LGG	cis	1	rs4932237	chr15:90164185	CRTC3	chr15:91073198-91188576:+	0.34	3.54	0.00044	Obesity-related traits	
LGG	cis	1	rs4935575	chr10:52006165	FAM21A	chr10:51827684-51893268:+	-0.59	-6.62	9.18E-11	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs4936444	chr11:118743338	PHLDB1	chr11:118477213-118528741:+	0.19	3.72	0.000226	Primary biliary cirrhosis	
LGG	cis	1	rs4938804	chr11:120273865	TMEM136	chr11:120196016-120204388:+	0.2	4.59	5.71E-6	Intraocular pressure	
LGG	cis	1	rs4938805	chr11:120274211	TMEM136	chr11:120196016-120204388:+	-0.2	-4.65	4.25E-6	Intraocular pressure	
LGG	cis	1	rs4938808	chr11:120336902	TMEM136	chr11:120196016-120204388:+	0.19	4.45	1.09E-5	Intraocular pressure	
LGG	cis	1	rs493888	chr11:133832473	LOC283174	chr11:133766330-133771635:-	-0.25	-3.48	0.000556	Migraine	
LGG	cis	1	rs494003	chr11:65542298	RNASEH2C	chr11:65485146-65488409:-	-0.2	-4.61	5.2E-6	Systemic lupus erythematosus	
LGG	cis	1	rs494003	chr11:65542298	SNX32	chr11:65601410-65621170:+	0.22	4.8	2.11E-6	Systemic lupus erythematosus	
LGG	cis	1	rs4943821	chr11:71813747	FAM86C	chr11:71498557-71512276:+	-0.45	-4.45	1.05E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4944140	chr11:76818662	CAPN5	chr11:76777992-76837196:+	0.33	3.74	0.000208	Cognitive performance	
LGG	cis	1	rs4944232	chr11:71642258	FAM86C	chr11:71498557-71512276:+	-0.49	-4.95	1.02E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4944242	chr11:71667141	FAM86C	chr11:71498557-71512276:+	0.52	5.12	4.39E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4944258	chr11:71743393	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4945340	chr11:71619100	FAM86C	chr11:71498557-71512276:+	0.43	4.67	3.98E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4945426	chr11:71748146	FAM86C	chr11:71498557-71512276:+	-0.43	-4.32	1.92E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4945434	chr11:71759087	FAM86C	chr11:71498557-71512276:+	-0.43	-4.27	2.32E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4945435	chr11:71759219	FAM86C	chr11:71498557-71512276:+	0.51	5.08	5.41E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4947015	chr6:110052515	AKD1	chr6:109814059-110012415:-	-0.29	-3.57	0.000386	Hematological parameters	
LGG	cis	1	rs4947019	chr6:110090049	AKD1	chr6:109814059-110012415:-	-0.29	-3.56	0.000408	Hematological parameters	
LGG	cis	1	rs4947534	chr7:56079094	GBAS	chr7:56032296-56067871:+	-0.22	-4.59	5.53E-6	Blood metabolite levels;Amino acid levels	
LGG	cis	1	rs4947534	chr7:56079094	ZNF713	chr7:55955162-56008433:+	-0.21	-4.93	1.15E-6	Blood metabolite levels;Amino acid levels	
LGG	cis	1	rs4948102	chr7:56097265	GBAS	chr7:56032296-56067871:+	-0.24	-5.07	5.54E-7	Plasma homocysteine levels (post-methionine load test)	
LGG	cis	1	rs4948102	chr7:56097265	ZNF713	chr7:55955162-56008433:+	-0.22	-5.01	7.68E-7	Plasma homocysteine levels (post-methionine load test)	
LGG	cis	1	rs4949371	chr1:31735880	ZCCHC17	chr1:31769842-31837780:+	-0.17	-3.98	7.82E-5	Schizophrenia	
LGG	cis	1	rs4949391	chr1:31833706	ZCCHC17	chr1:31769842-31837780:+	0.16	3.97	8.37E-5	Schizophrenia	
LGG	cis	1	rs4949674	chr1:76213715	MSH4	chr1:76262630-76378923:+	0.24	4.35	1.63E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4949872	chr1:76131392	MSH4	chr1:76262630-76378923:+	0.26	4.56	6.54E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4949874	chr1:76161889	MSH4	chr1:76262630-76378923:+	0.23	4.27	2.39E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4949875	chr1:76173080	MSH4	chr1:76262630-76378923:+	0.25	4.4	1.31E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4949876	chr1:76173377	MSH4	chr1:76262630-76378923:+	0.23	4.16	3.83E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4949879	chr1:76237143	MSH4	chr1:76262630-76378923:+	0.24	4.23	2.77E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs4950848	chr1:202356174	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000534	Sex ratio	
LGG	cis	1	rs4950848	chr1:202356174	UBE2T	chr1:202300786-202311094:-	-0.13	-3.97	8.27E-5	Sex ratio	
LGG	cis	1	rs4950849	chr1:202408518	PTPN7	chr1:202116143-202130709:-	-0.12	-3.53	0.000459	Sex ratio	
LGG	cis	1	rs4950849	chr1:202408518	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.49E-5	Sex ratio	
LGG	cis	1	rs4951261	chr1:205717823	PM20D1	chr1:205797154-205819245:-	0.41	7.64	1.17E-13	Menarche (age at onset)	
LGG	cis	1	rs4951261	chr1:205717823	RAB7L1	chr1:205737115-205744610:-	-0.16	-4.15	3.97E-5	Menarche (age at onset)	
LGG	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.29	7.8	3.87E-14	Height	
LGG	cis	1	rs4955485	chr3:134295843	CEP63	chr3:134204575-134293852:+	0.19	3.58	0.000375	Height	
LGG	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.3	7.81	3.56E-14	Height	
LGG	cis	1	rs4955555	chr3:134286427	CEP63	chr3:134204575-134293852:+	0.2	3.74	0.000209	Height	
LGG	cis	1	rs4955676	chr3:169568492	LRRC34	chr3:169511266-169530720:-	-0.27	-4.6	5.36E-6	Glioma (high-grade)	
LGG	cis	1	rs4955677	chr3:169568510	LRRC34	chr3:169511266-169530720:-	-0.27	-4.6	5.36E-6	Glioma (high-grade)	
LGG	cis	1	rs4955678	chr3:169574912	LRRC34	chr3:169511266-169530720:-	-0.29	-4.84	1.78E-6	Glioma (high-grade)	
LGG	cis	1	rs495567	chr11:71795488	FAM86C	chr11:71498557-71512276:+	0.43	4.56	6.38E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs4956034	chr4:108944846	SGMS2	chr4:108745721-108836200:+	0.26	3.56	0.0004	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs495681	chr2:166876829	SCN2A	chr2:166095912-166248818:+	-0.09	-3.55	0.000415	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs495681	chr2:166876829	TTC21B	chr2:166713988-166810348:-	-0.13	-3.77	0.000184	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs4958422	chr5:150186734	LOC134466	chr5:150310000-150326146:-	0.38	3.98	7.97E-5	Crohn's disease	
LGG	cis	1	rs4958424	chr5:150225036	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs4958426	chr5:150278346	LOC134466	chr5:150310000-150326146:-	0.45	4.78	2.35E-6	Crohn's disease	
LGG	cis	1	rs4958842	chr5:150224877	LOC134466	chr5:150310000-150326146:-	0.47	5.15	3.76E-7	Crohn's disease	
LGG	cis	1	rs4958843	chr5:150224924	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs4958848	chr5:150271122	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs4958852	chr5:150330631	LOC134466	chr5:150310000-150326146:-	0.5	5.26	2.19E-7	Crohn's disease	
LGG	cis	1	rs4959677	chr6:2500820	C6orf195	chr6:2622972-2635298:-	-0.23	-4.48	9.38E-6	Orthostatic hypotension	
LGG	cis	1	rs4964794	chr12:104194418	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.73	2.92E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs4964805	chr12:104192824	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.64	4.57E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs4964806	chr12:104192760	NT5DC3	chr12:104164231-104234975:-	-0.23	-4.67	3.88E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs496584	chr15:43831923	ADAL	chr15:43622872-43646094:+	-0.56	-7.17	2.78E-12	Tumor biomarkers	
LGG	cis	1	rs496584	chr15:43831923	STRC	chr15:43891762-43924561:-	0.38	7.03	7.08E-12	Tumor biomarkers	
LGG	cis	1	rs4968361	chr17:57502828	DHX40P1	chr17:58053385-58096336:-	0.38	5.28	1.95E-7	Schizophrenia	
LGG	cis	1	rs4970696	chr1:92968853	EVI5	chr1:92974255-93257961:-	-0.29	-6.91	1.48E-11	Cholesterol, total	
LGG	cis	1	rs4970698	chr1:92972933	EVI5	chr1:92974255-93257961:-	-0.29	-7.08	4.99E-12	Cholesterol, total	
LGG	cis	1	rs4970705	chr1:92971828	EVI5	chr1:92974255-93257961:-	0.3	7.31	1.07E-12	Cholesterol, total	
LGG	cis	1	rs4970708	chr1:92986514	EVI5	chr1:92974255-93257961:-	-0.29	-7.23	1.87E-12	Cholesterol, total	
LGG	cis	1	rs4970709	chr1:92988592	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs4970710	chr1:92988717	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs4970712	chr1:92993547	EVI5	chr1:92974255-93257961:-	0.26	6.79	3.17E-11	Cholesterol, total	
LGG	cis	1	rs4970941	chr1:151068546	LYSMD1	chr1:151132225-151138424:-	-0.18	-4.12	4.44E-5	Body mass index	
LGG	cis	1	rs4970941	chr1:151068546	MRPL9	chr1:151732125-151736040:-	-0.14	-3.64	0.000302	Body mass index	
LGG	cis	1	rs4970941	chr1:151068546	PSMD4	chr1:151227197-151239952:+	-0.13	-3.49	0.000536	Body mass index	
LGG	cis	1	rs4971316	chr1:247210903	ZNF670	chr1:247200087-247242069:-	-0.22	-5.11	4.55E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs4971319	chr1:247211565	ZNF670	chr1:247200087-247242069:-	-0.22	-5.11	4.55E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs4972909	chr2:230521863	DNER	chr2:230222346-230579286:-	0.29	6.38	3.99E-10	Type 2 diabetes	
LGG	cis	1	rs4972910	chr2:230521908	DNER	chr2:230222346-230579286:-	0.29	6.38	3.99E-10	Type 2 diabetes	
LGG	cis	1	rs4973215	chr2:230521476	DNER	chr2:230222346-230579286:-	0.28	6.15	1.6E-9	Type 2 diabetes	
LGG	cis	1	rs4973991	chr3:41927273	ULK4	chr3:41288091-42003660:-	-0.77	-15.06	2.05E-42	Diastolic blood pressure	
LGG	cis	1	rs4974105	chr3:51369574	HEMK1	chr3:50606583-50622419:+	0.22	3.75	0.000198	Melanoma	
LGG	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.27	7.27	1.38E-12	Height	
LGG	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.28	7.16	3.03E-12	Height	
LGG	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.28	7.12	3.89E-12	Height	
LGG	cis	1	rs4974559	chr4:1380848	CRIPAK	chr4:1385340-1389782:+	-0.23	-5.33	1.46E-7	Systolic blood pressure	
LGG	cis	1	rs4975193	chr4:129980630	C4orf33	chr4:130014829-130033842:+	-0.58	-9.84	5.71E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs4975194	chr4:129982377	C4orf33	chr4:130014829-130033842:+	-0.58	-9.83	6.1E-21	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs4980171	chr10:124743200	PSTK	chr10:124739556-124749906:+	0.16	3.71	0.000233	Migraine without aura	
LGG	cis	1	rs4980239	chr10:124741184	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs4985813	chr17:20901001	USP22	chr17:20902908-20947073:-	-0.21	-4.77	2.42E-6	Blood trace element (Se levels)	
LGG	cis	1	rs4985820	chr17:20931660	USP22	chr17:20902908-20947073:-	-0.19	-4.35	1.63E-5	Blood trace element (Se levels)	
LGG	cis	1	rs4985953	chr17:20897584	USP22	chr17:20902908-20947073:-	-0.2	-4.75	2.66E-6	Blood trace element (Se levels)	
LGG	cis	1	rs4985954	chr17:20897952	USP22	chr17:20902908-20947073:-	-0.22	-5.02	7.42E-7	Blood trace element (Se levels)	
LGG	cis	1	rs4985955	chr17:20898014	USP22	chr17:20902908-20947073:-	0.23	5.45	8.15E-8	Blood trace element (Se levels)	
LGG	cis	1	rs4985962	chr17:20916035	USP22	chr17:20902908-20947073:-	-0.2	-4.57	6.16E-6	Blood trace element (Se levels)	
LGG	cis	1	rs498872	chr11:118477367	PHLDB1	chr11:118477213-118528741:+	0.32	7.26	1.52E-12	Glioma	
LGG	cis	1	rs4992989	chr15:24821481	PWRN1	chr15:24778839-24832924:+	0.26	4.39	1.4E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs4993024	chr11:18736877	LDHC	chr11:18433853-18472792:+	0.22	3.83	0.000143	Diabetic kidney disease	
LGG	cis	1	rs499425	chr11:64105929	C11orf20	chr11:64067863-64072238:+	-0.18	-3.77	0.00018	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs499425	chr11:64105929	CAPN1	chr11:64948772-64979476:+	0.14	3.48	0.000542	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs499425	chr11:64105929	CCDC88B	chr11:64107695-64125005:+	0.11	4.5	8.6E-6	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs499425	chr11:64105929	PPP1R14B	chr11:64011953-64014413:-	0.13	3.99	7.76E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs5000249	chr17:46497380	HOXB2	chr17:46620021-46622393:-	-0.19	-3.6	0.000348	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs5000249	chr17:46497380	HOXB3	chr17:46626233-46667631:-	-0.17	-3.47	0.000558	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs500059	chr11:83283859	CCDC90B	chr11:82972506-82997414:-	-0.22	-5.08	5.29E-7	Subcortical brain region volumes	
LGG	cis	1	rs500199	chr6:160701403	SLC22A3	chr6:160769425-160876013:+	0.31	5.35	1.37E-7	Waist circumference	
LGG	cis	1	rs5003261	chr4:207023	ZNF718	chr4:53272-156488:+	0.28	5.49	6.61E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs500571	chr11:83305542	CCDC90B	chr11:82972506-82997414:-	0.24	5.71	2.0E-8	Subcortical brain region volumes	
LGG	cis	1	rs5005801	chr17:20944154	USP22	chr17:20902908-20947073:-	-0.2	-4.66	4.05E-6	Blood trace element (Se levels)	
LGG	cis	1	rs5006656	chr2:166888768	SCN2A	chr2:166095912-166248818:+	0.09	3.56	0.000401	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs5006656	chr2:166888768	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.35E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs5006882	chr11:5373334	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5006883	chr11:5373311	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5006884	chr11:5373251	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5006886	chr11:5373170	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5006887	chr11:5373129	FAM160A2	chr11:6232565-6255941:-	0.2	3.96	8.45E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5006889	chr11:5373104	FAM160A2	chr11:6232565-6255941:-	0.2	4	7.29E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5011018	chr10:4967006	AKR1C2	chr10:4964715-5060207:-	0.39	5.31	1.67E-7	Height	
LGG	cis	1	rs501220	chr6:25873025	BTN3A2	chr6:26365398-26378546:+	-0.46	-6.46	2.5E-10	Homocysteine levels	
LGG	cis	1	rs5024038	chr11:5373738	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5024039	chr11:5373728	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5024040	chr11:5373724	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5024042	chr11:5373562	FAM160A2	chr11:6232565-6255941:-	0.2	4.01	7.06E-5	Fetal hemoglobin levels	
LGG	cis	1	rs5024798	chr13:24440203	RNF17	chr13:25338301-25454056:+	-0.31	-3.53	0.000458	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs5027032	chr11:89168756	NOX4	chr11:89057524-89322779:-	0.36	3.86	0.000127	Homocysteine levels	
LGG	cis	1	rs502822	chr11:96022489	CCDC82	chr11:96085930-96123083:-	-0.16	-3.48	0.000537	Corneal astigmatism	
LGG	cis	1	rs5029970	chr3:186434491	KNG1	chr3:186435120-186461741:+	-0.15	-3.49	0.000535	Adiponectin levels	
LGG	cis	1	rs503660	chr10:131418999	MGMT	chr10:131265454-131565783:+	0.22	6	3.8E-9	Response to temozolomide	
LGG	cis	1	rs504059	chr2:166861725	SCN2A	chr2:166095912-166248818:+	-0.09	-3.52	0.000465	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs504059	chr2:166861725	TTC21B	chr2:166713988-166810348:-	-0.13	-3.75	0.000196	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs505111	chr6:160701424	SLC22A3	chr6:160769425-160876013:+	-0.3	-5.06	5.92E-7	Waist circumference	
LGG	cis	1	rs505564	chr11:83277912	CCDC90B	chr11:82972506-82997414:-	0.22	5.22	2.68E-7	Subcortical brain region volumes	
LGG	cis	1	rs505621	chr11:83277927	CCDC90B	chr11:82972506-82997414:-	0.24	5.59	3.86E-8	Subcortical brain region volumes	
LGG	cis	1	rs505998	chr11:83315597	CCDC90B	chr11:82972506-82997414:-	0.24	5.69	2.24E-8	Subcortical brain region volumes	
LGG	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.22	6.02	3.49E-9	Response to temozolomide	
LGG	cis	1	rs507193	chr2:166876837	SCN2A	chr2:166095912-166248818:+	-0.09	-3.53	0.000457	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs507193	chr2:166876837	TTC21B	chr2:166713988-166810348:-	-0.13	-3.84	0.000142	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.23	-6.04	3.11E-9	Response to temozolomide	
LGG	cis	1	rs508585	chr2:166883632	SCN2A	chr2:166095912-166248818:+	-0.09	-3.51	0.000495	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs508585	chr2:166883632	TTC21B	chr2:166713988-166810348:-	-0.13	-3.73	0.000214	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs508970	chr11:60906450	CD5	chr11:60869930-60895321:+	-0.22	-5.05	6.16E-7	Rheumatoid arthritis	
LGG	cis	1	rs510615	chr6:160722449	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs510642	chr1:183162776	LAMC2	chr1:183155174-183214262:+	0.27	5.41	9.65E-8	Hypertriglyceridemia	
LGG	cis	1	rs510988	chr11:116813804	SIDT2	chr11:117049939-117068161:+	0.31	3.56	0.000413	Protein quantitative trait loci	
LGG	cis	1	rs511676	chr11:116824884	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs512129	chr1:168688580	SELL	chr1:169659810-169680837:-	0.2	4.09	5.04E-5	QT interval	
LGG	cis	1	rs512140	chr6:84230653	SNAP91	chr6:84262607-84419127:-	0.09	4.2	3.23E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.21	5.74	1.66E-8	Response to temozolomide	
LGG	cis	1	rs515358	chr11:71562302	FAM86C	chr11:71498557-71512276:+	-0.45	-4.61	5.09E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs515910	chr10:105966404	C10orf79	chr10:105889647-105992120:-	0.18	5	7.86E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs516647	chr1:71444149	PTGER3	chr1:71318036-71513491:-	0.16	3.86	0.000126	IgG glycosylation	
LGG	cis	1	rs516704	chr10:131419879	MGMT	chr10:131265454-131565783:+	0.23	6.15	1.59E-9	Response to temozolomide	
LGG	cis	1	rs517837	chr11:71802359	FAM86C	chr11:71498557-71512276:+	0.44	4.43	1.18E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs520025	chr11:71562832	FAM86C	chr11:71498557-71512276:+	-0.5	-5.18	3.25E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs522372	chr1:183157449	LAMC2	chr1:183155174-183214262:+	-0.27	-5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs522891	chr10:131430916	MGMT	chr10:131265454-131565783:+	-0.23	-6.27	8.15E-10	Response to temozolomide	
LGG	cis	1	rs523494	chr11:83312379	CCDC90B	chr11:82972506-82997414:-	0.24	5.69	2.24E-8	Subcortical brain region volumes	
LGG	cis	1	rs527154	chr10:105943683	C10orf79	chr10:105889647-105992120:-	0.18	5.03	6.99E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs528953	chr1:168691851	SELL	chr1:169659810-169680837:-	0.2	4.26	2.47E-5	QT interval	
LGG	cis	1	rs529522	chr11:71580562	FAM86C	chr11:71498557-71512276:+	-0.44	-4.68	3.73E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs530466	chr10:131427717	MGMT	chr10:131265454-131565783:+	0.23	6.19	1.26E-9	Response to temozolomide	
LGG	cis	1	rs530612	chr18:6942997	ARHGAP28	chr18:6788493-6915710:+	0.28	3.88	0.000121	Sudden cardiac arrest	
LGG	cis	1	rs531326	chr11:71570656	FAM86C	chr11:71498557-71512276:+	-0.44	-4.48	9.47E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.21	-5.6	3.56E-8	Response to temozolomide	
LGG	cis	1	rs531706	chr1:168692137	SELL	chr1:169659810-169680837:-	0.2	4.26	2.47E-5	QT interval	
LGG	cis	1	rs533619	chr1:168685805	SELL	chr1:169659810-169680837:-	0.2	4	7.3E-5	QT interval	
LGG	cis	1	rs533928	chr1:150884271	ARNT	chr1:150782186-150849186:-	-0.28	-4.79	2.2E-6	Congenital left-sided heart lesions	
LGG	cis	1	rs533928	chr1:150884271	OAZ3	chr1:151735445-151743805:+	-0.32	-3.94	9.33E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs536744	chr2:166881890	SCN2A	chr2:166095912-166248818:+	-0.09	-3.53	0.000455	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs536744	chr2:166881890	TTC21B	chr2:166713988-166810348:-	-0.13	-3.83	0.000147	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs538969	chr10:131410608	MGMT	chr10:131265454-131565783:+	0.23	6.1	2.1E-9	Response to temozolomide	
LGG	cis	1	rs539598	chr11:96026074	CCDC82	chr11:96085930-96123083:-	-0.17	-3.65	0.00029	Corneal astigmatism	
LGG	cis	1	rs541022	chr11:71783056	FAM86C	chr11:71498557-71512276:+	0.52	5.12	4.39E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs541667	chr1:71444634	PTGER3	chr1:71318036-71513491:-	0.16	3.86	0.000126	IgG glycosylation	
LGG	cis	1	rs542752	chr11:71810644	FAM86C	chr11:71498557-71512276:+	-0.47	-4.44	1.09E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs543725	chr11:57483039	TIMM10	chr11:57295936-57298232:-	-0.16	-4	7.42E-5	Schizophrenia	
LGG	cis	1	rs544271	chr6:160702685	SLC22A3	chr6:160769425-160876013:+	0.31	5.31	1.67E-7	Waist circumference	
LGG	cis	1	rs544352	chr1:183157546	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs545238	chr2:166867933	SCN2A	chr2:166095912-166248818:+	-0.09	-3.7	0.000243	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs545238	chr2:166867933	TTC21B	chr2:166713988-166810348:-	-0.13	-3.87	0.000122	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs545833	chr1:168689940	SELL	chr1:169659810-169680837:-	0.19	3.99	7.63E-5	QT interval	
LGG	cis	1	rs546183	chr1:183157753	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs547905	chr1:183157924	LAMC2	chr1:183155174-183214262:+	0.26	5.28	1.92E-7	Hypertriglyceridemia	
LGG	cis	1	rs548127	chr11:71575294	FAM86C	chr11:71498557-71512276:+	0.46	4.63	4.77E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.23	6.15	1.6E-9	Response to temozolomide	
LGG	cis	1	rs548756	chr11:114428866	C11orf71	chr11:114262170-114271255:-	-0.17	-3.55	0.000427	Ulcerative colitis	
LGG	cis	1	rs548961	chr11:71793887	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs549844	chr1:183158143	LAMC2	chr1:183155174-183214262:+	-0.27	-5.32	1.59E-7	Hypertriglyceridemia	
LGG	cis	1	rs550213	chr17:30317518	LRRC37B	chr17:30335037-30380517:+	0.23	5.06	6.03E-7	Height	
LGG	cis	1	rs550230	chr11:71602222	FAM86C	chr11:71498557-71512276:+	-0.48	-5.26	2.18E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs551569	chr1:183158293	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs552585	chr11:96021945	CCDC82	chr11:96085930-96123083:-	-0.16	-3.48	0.000537	Corneal astigmatism	
LGG	cis	1	rs552966	chr11:71788217	FAM86C	chr11:71498557-71512276:+	0.41	4.32	1.89E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs553371	chr10:131413676	MGMT	chr10:131265454-131565783:+	0.23	6.23	1.01E-9	Response to temozolomide	
LGG	cis	1	rs553989	chr3:47400328	NRADDP	chr3:47053032-47054957:+	0.24	4.12	4.36E-5	Colorectal cancer	
LGG	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.23	6.27	7.78E-10	Response to temozolomide	
LGG	cis	1	rs555	chr4:17625658	MED28	chr4:17616273-17629791:+	0.2	4.25	2.54E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs556199	chr11:83276006	CCDC90B	chr11:82972506-82997414:-	0.22	5.34	1.46E-7	Subcortical brain region volumes	
LGG	cis	1	rs556292	chr10:105961957	C10orf79	chr10:105889647-105992120:-	0.18	5.06	5.89E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs55634485	chr2:242268994	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs556357	chr11:60593329	CCDC86	chr11:60609429-60618561:+	0.21	3.72	0.00022	Wegener's granulomatosis	
LGG	cis	1	rs556357	chr11:60593329	GPR44	chr11:60618398-60623444:-	0.24	4.16	3.68E-5	Wegener's granulomatosis	
LGG	cis	1	rs55638051	chr4:25207995	ANAPC4	chr4:25378848-25420119:+	0.3	4.76	2.55E-6	Cannabis dependence	
LGG	cis	1	rs55638051	chr4:25207995	PI4K2B	chr4:25162285-25280831:+	0.27	4.65	4.25E-6	Cannabis dependence	
LGG	cis	1	rs55638051	chr4:25207995	SEL1L3	chr4:25749050-25864610:-	0.26	3.61	0.000333	Cannabis dependence	
LGG	cis	1	rs55645375	chr2:242269024	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs55645543	chr4:122607178	ANXA5	chr4:122589153-122618147:-	-0.28	-3.75	0.000198	Age at smoking initiation in chronic obstructive pulmonary disease	
LGG	cis	1	rs55645900	chr21:43515728	C21orf128	chr21:43522244-43528644:-	0.58	11.47	3.93E-27	IgG glycosylation	
LGG	cis	1	rs55647342	chr1:150029936	RPRD2	chr1:150336990-150449039:+	0.16	3.92	0.000101	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs55647424	chr16:50092495	HEATR3	chr16:50099881-50139373:+	-0.31	-4.14	4.12E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs55674647	chr17:61794195	DDX42	chr17:61851567-61896676:+	-0.16	-3.57	0.000397	Body mass index	
LGG	cis	1	rs55674647	chr17:61794195	FTSJ3	chr17:61896795-61905031:-	0.42	8.21	1.96E-15	Body mass index	
LGG	cis	1	rs55674647	chr17:61794195	SMARCD2	chr17:61909441-61920351:-	0.19	4.11	4.66E-5	Body mass index	
LGG	cis	1	rs55675294	chr3:128043050	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.95	9.03E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55675294	chr3:128043050	LOC90246	chr3:128226678-128229427:+	-0.29	-3.75	0.000199	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55683820	chr10:111665376	PDCD4	chr10:112631596-112659763:+	0.21	3.48	0.000536	Biliary atresia	
LGG	cis	1	rs55684215	chr3:127812792	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55696836	chr20:33549887	PROCR	chr20:33758727-33765164:+	-0.33	-5.82	1.04E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs55707752	chr16:50133570	HEATR3	chr16:50099881-50139373:+	-0.32	-4.16	3.83E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs55721100	chr12:109122654	SELPLG	chr12:109015682-109027670:-	0.21	3.67	0.000266	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs55722539	chr14:88878035	SPATA7	chr14:88852012-88904802:+	-0.48	-8.61	9.78E-17	Coronary artery calcification	
LGG	cis	1	rs55734215	chr20:33585437	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.01E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs55737734	chr7:86884337	CROT	chr7:86974951-87029112:+	0.33	4.29	2.2E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs55744181	chr14:81777794	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs55744319	chr19:15981821	CYP4F11	chr19:16023180-16045676:-	-0.21	-4.42	1.23E-5	Acenocoumarol maintenance dosage;Vitamin E levels;Circulating phylloquinone levels;Metabolite levels;Response to Vitamin E supplementation;Warfarin maintenance dose	
LGG	cis	1	rs55753056	chr2:243929	FAM150B	chr2:279563-288308:-	-0.32	-6.04	3.13E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs55753056	chr2:243929	SNTG2	chr2:946555-1371382:+	0.21	3.87	0.000124	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs55756843	chr12:109092796	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs55762931	chr3:127847675	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.16	3.7E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55775340	chr6:33751784	LEMD2	chr6:33738991-33756906:-	0.19	5.65	2.75E-8	Body mass index	
LGG	cis	1	rs55781439	chr10:111670220	ADD3	chr10:111756108-111895320:+	0.16	3.52	0.000474	Biliary atresia	
LGG	cis	1	rs55781567	chr15:78857986	CHRNA5	chr15:78857906-78886458:+	-0.67	-13	2.09E-33	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55786720	chr6:56783647	BEND6	chr6:56819773-56892138:+	-0.3	-5.4	1.07E-7	Menarche (age at onset)	
LGG	cis	1	rs55786720	chr6:56783647	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.71	0.000231	Menarche (age at onset)	
LGG	cis	1	rs55787104	chr8:58178519	C8orf71	chr8:58192102-58197288:+	0.35	6.13	1.84E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs55788133	chr15:40664239	C15orf23	chr15:40674922-40686488:+	1.02	17.48	1.5E-53	Heschl's gyrus morphology	
LGG	cis	1	rs55788133	chr15:40664239	IVD	chr15:40697686-40713512:+	-0.33	-3.78	0.000174	Heschl's gyrus morphology	
LGG	cis	1	rs55791720	chr12:1066834	RAD52	chr12:1021255-1099219:-	0.14	4	7.25E-5	Lung cancer	
LGG	cis	1	rs55805894	chr2:105380420	MRPS9	chr2:105654483-105716417:+	-0.25	-4.19	3.24E-5	Pancreatic cancer	
LGG	cis	1	rs558104	chr11:83276244	CCDC90B	chr11:82972506-82997414:-	0.24	5.69	2.22E-8	Subcortical brain region volumes	
LGG	cis	1	rs55822577	chr6:163069710	PACRG	chr6:163148164-163736523:+	0.36	4.96	9.79E-7	Body mass index	
LGG	cis	1	rs55827077	chr17:45331083	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs55829345	chr7:33250729	BBS9	chr7:33169152-33645680:+	0.41	5.38	1.18E-7	Smooth-surface caries	
LGG	cis	1	rs55835850	chr2:28949296	FAM179A	chr2:29204164-29275094:+	0.19	3.66	0.000277	Body mass index	
LGG	cis	1	rs55835850	chr2:28949296	TRMT61B	chr2:29072690-29093175:-	0.51	10.68	4.26E-24	Body mass index	
LGG	cis	1	rs55840906	chr1:150003117	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs55842567	chr5:437586	EXOC3	chr5:443334-467407:+	-0.23	-5.25	2.31E-7	Cystic fibrosis severity	
LGG	cis	1	rs55847707	chr6:163003414	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs55856327	chr17:33279125	RAD51L3	chr17:33426811-33448541:-	-0.31	-3.81	0.000159	Night sleep phenotypes	
LGG	cis	1	rs55865959	chr7:33293479	BBS9	chr7:33169152-33645680:+	0.45	6.33	5.63E-10	Smooth-surface caries	
LGG	cis	1	rs55868506	chr17:61851686	DDX42	chr17:61851567-61896676:+	-0.16	-3.62	0.000329	Body mass index	
LGG	cis	1	rs55868506	chr17:61851686	FTSJ3	chr17:61896795-61905031:-	0.41	8.46	2.98E-16	Body mass index	
LGG	cis	1	rs55868506	chr17:61851686	SMARCD2	chr17:61909441-61920351:-	0.19	4.29	2.14E-5	Body mass index	
LGG	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.21	-5.72	1.9E-8	Response to temozolomide	
LGG	cis	1	rs55879323	chr1:152168740	FLG	chr1:152274651-152297679:-	-0.45	-8.38	5.51E-16	Inflammatory skin disease	
LGG	cis	1	rs55879323	chr1:152168740	HRNR	chr1:152184558-152196669:-	0.56	10.3	1.13E-22	Inflammatory skin disease	
LGG	cis	1	rs55895244	chr7:65387678	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs55896768	chr17:65913358	LOC440461	chr17:66194801-66196436:+	0.29	4.81	1.98E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs55905547	chr20:57589995	TH1L	chr20:57556311-57570186:+	-0.28	-4.92	1.21E-6	Mean platelet volume	
LGG	cis	1	rs55909363	chr20:33549407	PROCR	chr20:33758727-33765164:+	-0.33	-5.82	1.04E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs55912359	chr1:114167099	BCL2L15	chr1:114419437-114430169:-	0.16	4.64	4.47E-6	Bacteremia	
LGG	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.3	7.81	3.56E-14	Height	
LGG	cis	1	rs55913793	chr3:134285968	CEP63	chr3:134204575-134293852:+	0.2	3.74	0.000209	Height	
LGG	cis	1	rs55918911	chr1:150012168	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs55925538	chr3:128042877	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.8	0.00016	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55925538	chr3:128042877	LOC90246	chr3:128226678-128229427:+	-0.29	-3.61	0.000342	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55934422	chr7:33333896	BBS9	chr7:33169152-33645680:+	0.46	6.29	7.15E-10	Smooth-surface caries	
LGG	cis	1	rs55936726	chr2:258210	FAM150B	chr2:279563-288308:-	-0.34	-6.3	6.67E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs55936726	chr2:258210	SNTG2	chr2:946555-1371382:+	0.21	3.86	0.000128	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs55939327	chr4:17642937	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs55939964	chr17:65869297	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs55942649	chr1:179482604	C1orf125	chr1:179335107-179523868:+	0.46	6.07	2.59E-9	Multiple sclerosis (age of onset)	
LGG	cis	1	rs55944282	chr8:58180821	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs55946144	chr20:33629610	PROCR	chr20:33758727-33765164:+	-0.3	-5.75	1.6E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs55946380	chr2:268293	FAM150B	chr2:279563-288308:-	-0.34	-6.47	2.45E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs55946380	chr2:268293	SNTG2	chr2:946555-1371382:+	0.2	3.72	0.000225	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs559476	chr1:183160704	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs559555	chr2:31810974	NLRC4	chr2:32449518-32490801:-	0.13	4.2	3.11E-5	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs55957623	chr1:152223196	HRNR	chr1:152184558-152196669:-	-0.58	-8.09	4.58E-15	Atopic dermatitis	
LGG	cis	1	rs55958006	chr8:10812144	RP1L1	chr8:10463862-10512617:-	-0.29	-3.7	0.000243	Asthma and hay fever	
LGG	cis	1	rs55961005	chr1:211567891	C1orf97	chr1:211556097-211605876:+	0.2	3.52	0.000468	Educational attainment (years of education)	
LGG	cis	1	rs55962648	chr7:65625751	ASL	chr7:65540776-65558321:+	0.22	5.55	4.79E-8	Aortic root size	
LGG	cis	1	rs55966740	chr13:50147394	CDADC1	chr13:49822103-49867619:+	-0.28	-3.53	0.000447	Multiple sclerosis	
LGG	cis	1	rs55971458	chr17:28427016	EFCAB5	chr17:28256874-28435469:+	0.23	6.07	2.5E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs55972015	chr11:71642576	FAM86C	chr11:71498557-71512276:+	0.54	5.45	7.91E-8	Severe influenza A (H1N1) infection	
LGG	cis	1	rs55974734	chr4:25198059	ANAPC4	chr4:25378848-25420119:+	0.31	4.83	1.86E-6	Cannabis dependence	
LGG	cis	1	rs55974734	chr4:25198059	PI4K2B	chr4:25162285-25280831:+	0.28	4.79	2.23E-6	Cannabis dependence	
LGG	cis	1	rs55974734	chr4:25198059	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000436	Cannabis dependence	
LGG	cis	1	rs55979739	chr16:31049155	MYST1	chr16:31128985-31142713:+	0.15	4.1	4.81E-5	Response to metformin (IC50)	
LGG	cis	1	rs55979739	chr16:31049155	PRSS53	chr16:31094747-31106276:-	-0.16	-4.4	1.32E-5	Response to metformin (IC50)	
LGG	cis	1	rs55989768	chr3:128043004	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.95	9.03E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs55989768	chr3:128043004	LOC90246	chr3:128226678-128229427:+	-0.29	-3.75	0.000199	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs559928	chr11:64150370	C11orf20	chr11:64067863-64072238:+	-0.22	-3.8	0.000165	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs55998153	chr1:179453824	C1orf125	chr1:179335107-179523868:+	0.64	8.01	8.4E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs56000731	chr3:128647141	RAB43	chr3:128806418-128880029:-	0.32	3.74	0.000209	Dental caries	
LGG	cis	1	rs56003071	chr3:128596048	RAB43	chr3:128806418-128880029:-	0.34	4.07	5.46E-5	Dental caries	
LGG	cis	1	rs56004802	chr10:1159187	IDI2	chr10:1064847-1071799:-	0.35	4.2	3.2E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs56015036	chr10:17226767	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.4	1.35E-5	Homocysteine levels	
LGG	cis	1	rs56015123	chr15:50977228	SPPL2A	chr15:50999739-51057910:-	0.13	4.26	2.49E-5	QT interval	
LGG	cis	1	rs56016656	chr7:65383481	CCT6P1	chr7:65216092-65228661:+	0.26	4.73	2.92E-6	Diabetic kidney disease	
LGG	cis	1	rs56020497	chr20:33166470	NCOA6	chr20:33302579-33413433:-	0.25	3.47	0.00057	Melanoma	
LGG	cis	1	rs56030203	chr6:56783857	BEND6	chr6:56819773-56892138:+	-0.3	-5.4	1.07E-7	Menarche (age at onset)	
LGG	cis	1	rs56030203	chr6:56783857	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.71	0.000231	Menarche (age at onset)	
LGG	cis	1	rs56040780	chr16:28861881	EIF3C	chr16:28722782-28747052:+;chr16	0.21	3.83	0.000147	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.36	7.02	7.43E-12	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs56040780	chr16:28861881	SULT1A1	chr16:28616918-28634866:-	-0.17	-4.3	2.05E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs56040780	chr16:28861881	SULT1A2	chr16:28603266-28608391:-	0.18	4.07	5.47E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs56040780	chr16:28861881	TUFM	chr16:28853732-28857729:-	0.16	4.42	1.22E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs56042615	chr5:437667	EXOC3	chr5:443334-467407:+	-0.23	-5.25	2.31E-7	Cystic fibrosis severity	
LGG	cis	1	rs56046246	chr5:93531545	FAM172A	chr5:92953432-93447404:-	-0.3	-4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs56052835	chr2:242243251	ANO7	chr2:242127924-242164791:+	0.39	6.64	8.43E-11	Prostate cancer	
LGG	cis	1	rs56057198	chr17:61733332	DDX42	chr17:61851567-61896676:+	-0.16	-3.6	0.000356	Body mass index	
LGG	cis	1	rs56057198	chr17:61733332	FTSJ3	chr17:61896795-61905031:-	0.42	8.24	1.52E-15	Body mass index	
LGG	cis	1	rs56057198	chr17:61733332	SMARCD2	chr17:61909441-61920351:-	0.19	4.02	6.84E-5	Body mass index	
LGG	cis	1	rs56060232	chr14:104386165	TDRD9	chr14:104394817-104519002:+	0.22	4.51	8.0E-6	Bipolar disorder	
LGG	cis	1	rs56060450	chr7:135331777	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs56063711	chr3:128585715	RAB43	chr3:128806418-128880029:-	0.35	4.15	3.96E-5	Dental caries	
LGG	cis	1	rs56069965	chr15:50966973	SPPL2A	chr15:50999739-51057910:-	0.13	4.1	4.88E-5	QT interval	
LGG	cis	1	rs56076132	chr7:33257440	BBS9	chr7:33169152-33645680:+	0.43	5.81	1.12E-8	Smooth-surface caries	
LGG	cis	1	rs56077333	chr15:78899003	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.43	3.02E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs560777	chr11:71770602	FAM86C	chr11:71498557-71512276:+	-0.48	-4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs56080544	chr15:50950970	SPPL2A	chr15:50999739-51057910:-	0.13	4.13	4.33E-5	QT interval	
LGG	cis	1	rs56098064	chr14:50105849	RPL36AL	chr14:50085407-50087349:-	0.31	8.22	1.89E-15	Carotid intima media thickness	
LGG	cis	1	rs56100812	chr1:202365422	UBE2T	chr1:202300786-202311094:-	-0.13	-4.12	4.51E-5	Sex ratio	
LGG	cis	1	rs56104203	chr2:86336256	LOC90784	chr2:86247339-86250991:-	-0.42	-4.39	1.37E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs56104584	chr5:437542	EXOC3	chr5:443334-467407:+	-0.23	-5.25	2.31E-7	Cystic fibrosis severity	
LGG	cis	1	rs56105592	chr2:17779641	GEN1	chr2:17935162-17966632:+	0.27	4.23	2.8E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs56118429	chr15:50923849	SPPL2A	chr15:50999739-51057910:-	0.12	3.99	7.6E-5	QT interval	
LGG	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.76	13.97	1.36E-37	Diastolic blood pressure	
LGG	cis	1	rs561241	chr13:113760034	F7	chr13:113760105-113774994:+	-0.33	-4.24	2.73E-5	End-stage coagulation	
LGG	cis	1	rs56125600	chr1:150012917	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs56127630	chr3:49438036	AMIGO3	chr3:49754268-49757238:-	0.19	4.39	1.41E-5	Menarche (age at onset)	
LGG	cis	1	rs56127630	chr3:49438036	GMPPB	chr3:49758932-49761384:-	0.22	4.26	2.42E-5	Menarche (age at onset)	
LGG	cis	1	rs56127630	chr3:49438036	TREX1	chr3:48501186-48509043:+	0.24	4.95	1.04E-6	Menarche (age at onset)	
LGG	cis	1	rs56131635	chr20:47774343	ARFGEF2	chr20:47538275-47653229:+	0.11	4.05	5.97E-5	Anger	
LGG	cis	1	rs56131635	chr20:47774343	CSE1L	chr20:47662838-47713484:+	0.19	5.05	6.09E-7	Anger	
LGG	cis	1	rs56145559	chr2:73623439	ALMS1P	chr2:73872046-73912692:+	0.4	7.2	2.35E-12	Schizophrenia	
LGG	cis	1	rs56145559	chr2:73623439	NAT8	chr2:73867850-73869537:-	0.26	4.28	2.29E-5	Schizophrenia	
LGG	cis	1	rs56148300	chr17:65892752	LOC440461	chr17:66194801-66196436:+	0.29	4.73	2.95E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.4	7.19	2.37E-12	Metabolite levels	
LGG	cis	1	rs56154726	chr2:73721767	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.59E-5	Metabolite levels	
LGG	cis	1	rs56156035	chr2:242205955	ANO7	chr2:242127924-242164791:+	0.37	6.37	4.44E-10	Prostate cancer	
LGG	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.76	13.97	1.36E-37	Diastolic blood pressure	
LGG	cis	1	rs56159542	chr19:19682971	TSSK6	chr19:19623230-19626469:-	-0.2	-3.67	0.000265	Attention deficit hyperactivity disorder symptom score	
LGG	cis	1	rs56167434	chr2:282137	FAM150B	chr2:279563-288308:-	-0.35	-6.57	1.25E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs56167434	chr2:282137	SNTG2	chr2:946555-1371382:+	0.21	3.86	0.000127	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs56167534	chr5:110431551	TSLP	chr5:110405778-110413722:+	-0.31	-4.42	1.24E-5	Eosinophil counts	
LGG	cis	1	rs56168206	chr8:58184485	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs56188926	chr1:150073256	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.77	12.8	1.43E-32	Diastolic blood pressure	
LGG	cis	1	rs562179	chr11:116805204	SIDT2	chr11:117049939-117068161:+	0.31	3.56	0.000402	Protein quantitative trait loci	
LGG	cis	1	rs56221251	chr5:151733019	NMUR2	chr5:151771102-151784840:-	-0.23	-3.85	0.000135	Optic nerve measurement (cup area)	
LGG	cis	1	rs56222556	chr2:242364119	ANO7	chr2:242127924-242164791:+	0.4	6.87	2.01E-11	Prostate cancer	
LGG	cis	1	rs56224502	chr7:118015311	ANKRD7	chr7:117864712-117882782:+	0.22	3.81	0.000156	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs56227395	chr2:54487496	C2orf73	chr2:54558071-54588714:+	0.32	4.8	2.1E-6	Telomere length	
LGG	cis	1	rs56227395	chr2:54487496	TSPYL6	chr2:54480315-54483409:-	-0.44	-5.51	5.8E-8	Telomere length	
LGG	cis	1	rs56234712	chr16:67241754	CENPT	chr16:67862064-67881361:-	-0.18	-3.67	0.000268	HDL cholesterol	
LGG	cis	1	rs56234712	chr16:67241754	CES2	chr16:66968347-66978992:+	-0.33	-3.65	0.000292	HDL cholesterol	
LGG	cis	1	rs562469	chr11:71569843	FAM86C	chr11:71498557-71512276:+	-0.46	-4.6	5.46E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs56255635	chr8:58178264	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs56257941	chr11:65505641	DKFZp761E198	chr11:65543380-65547822:-	-0.29	-3.65	0.000289	Atopic dermatitis	
LGG	cis	1	rs56265469	chr12:101732655	UTP20	chr12:101673905-101780397:+	-0.16	-3.52	0.000475	Alcohol dependence (age at onset)	
LGG	cis	1	rs56278218	chr15:84626694	LOC388152	chr15:84867600-84898920:-	0.2	3.85	0.000134	Sitting height ratio	
LGG	cis	1	rs56280226	chr17:28429575	EFCAB5	chr17:28256874-28435469:+	0.23	6.08	2.46E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs56287882	chr3:128030343	EEFSEC	chr3:127872313-128127488:+	-0.2	-3.68	0.000255	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs56291018	chr7:65390339	CCT6P1	chr7:65216092-65228661:+	0.26	4.73	2.92E-6	Diabetic kidney disease	
LGG	cis	1	rs56293318	chr11:89178524	NOX4	chr11:89057524-89322779:-	0.35	3.84	0.00014	Homocysteine levels	
LGG	cis	1	rs56297666	chr2:160902023	LY75	chr2:160625141-160761262:-	0.13	3.72	0.000221	Idiopathic membranous nephropathy	
LGG	cis	1	rs563026	chr1:183161037	LAMC2	chr1:183155174-183214262:+	-0.27	-5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs56306402	chr20:33937704	CPNE1	chr20:34213968-34262539:-	0.27	5.83	9.87E-9	Height	
LGG	cis	1	rs56306402	chr20:33937704	GDF5	chr20:33897002-34042568:-	-0.38	-7.37	7.5E-13	Height	
LGG	cis	1	rs56306402	chr20:33937704	UQCC	chr20:33890383-33999833:-	0.25	5.32	1.57E-7	Height	
LGG	cis	1	rs56308330	chr4:17643050	MED28	chr4:17616273-17629791:+	0.19	4.05	5.95E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs56314138	chr3:121356656	IQCB1	chr3:121488610-121553926:-	0.36	6.67	7.1E-11	Cognitive performance	
LGG	cis	1	rs56317427	chr10:81861934	PLAC9	chr10:81892258-81904784:+	-0.46	-6.57	1.26E-10	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs56317427	chr10:81861934	SFTPA2	chr10:81315609-81320163:-	-0.35	-3.75	0.000195	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs56321614	chr2:268191	FAM150B	chr2:279563-288308:-	-0.34	-6.46	2.56E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs56321614	chr2:268191	SNTG2	chr2:946555-1371382:+	0.2	3.63	0.000313	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs56328893	chr3:128041830	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.93	9.81E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs56328893	chr3:128041830	LOC90246	chr3:128226678-128229427:+	-0.28	-3.54	0.000435	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs56335217	chr20:47871197	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.13	4.31E-5	Height	
LGG	cis	1	rs56337141	chr16:50092690	HEATR3	chr16:50099881-50139373:+	-0.31	-4.14	4.12E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs56343904	chr7:33341350	BBS9	chr7:33169152-33645680:+	0.46	6.29	7.15E-10	Smooth-surface caries	
LGG	cis	1	rs56344560	chr8:58180626	C8orf71	chr8:58192102-58197288:+	0.35	6.12	1.9E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs56348638	chr17:53064550	STXBP4	chr17:53046126-53241449:+	-0.16	-3.69	0.000251	Breast cancer	
LGG	cis	1	rs56348638	chr17:53064550	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.32	1.56E-7	Breast cancer	
LGG	cis	1	rs56349882	chr1:150129998	RPRD2	chr1:150336990-150449039:+	0.16	3.99	7.58E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs56350499	chr8:58178139	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs56363214	chr2:242227157	ANO7	chr2:242127924-242164791:+	0.38	6.51	1.82E-10	Prostate cancer	
LGG	cis	1	rs56363533	chr20:33626005	PROCR	chr20:33758727-33765164:+	-0.31	-5.85	9.22E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs56364559	chr7:77480561	PTPN12	chr7:77166773-77269388:+	-0.2	-4.37	1.54E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs56367205	chr7:86893151	CROT	chr7:86974951-87029112:+	0.33	4.29	2.2E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs56373916	chr15:84626741	LOC388152	chr15:84867600-84898920:-	0.2	3.8	0.000161	Sitting height ratio	
LGG	cis	1	rs56383420	chr2:242219281	ANO7	chr2:242127924-242164791:+	0.37	6.29	7.07E-10	Prostate cancer	
LGG	cis	1	rs56383601	chr17:61929968	DDX42	chr17:61851567-61896676:+	-0.16	-3.72	0.000224	Body mass index	
LGG	cis	1	rs56383601	chr17:61929968	FTSJ3	chr17:61896795-61905031:-	0.41	8.32	8.98E-16	Body mass index	
LGG	cis	1	rs56383601	chr17:61929968	SMARCD2	chr17:61909441-61920351:-	0.18	4.05	5.97E-5	Body mass index	
LGG	cis	1	rs56390833	chr15:78877381	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.58	6.93E-36	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs56392198	chr1:179451124	C1orf125	chr1:179335107-179523868:+	0.64	8.01	8.4E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs56393562	chr17:65933918	LOC440461	chr17:66194801-66196436:+	0.29	4.9	1.28E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs56394211	chr10:17186447	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.33	1.79E-5	Homocysteine levels	
LGG	cis	1	rs56397023	chr5:125915779	ALDH7A1	chr5:125878918-125931082:-	0.46	5.56	4.45E-8	Osteoporosis	
LGG	cis	1	rs56400413	chr7:77340821	PTPN12	chr7:77166773-77269388:+	-0.17	-3.79	0.000171	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs56404791	chr17:65893019	LOC440461	chr17:66194801-66196436:+	0.29	4.81	1.98E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs564170	chr11:71569979	FAM86C	chr11:71498557-71512276:+	-0.43	-4.5	8.43E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs565348	chr2:166873299	SCN2A	chr2:166095912-166248818:+	-0.1	-3.75	0.000195	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs565348	chr2:166873299	TTC21B	chr2:166713988-166810348:-	-0.14	-4.04	6.24E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.23	6.27	7.78E-10	Response to temozolomide	
LGG	cis	1	rs566529	chr2:234756811	TRPM8	chr2:234826043-234928165:+	0.27	4.76	2.57E-6	Migraine	
LGG	cis	1	rs566625	chr1:183161441	LAMC2	chr1:183155174-183214262:+	0.28	5.53	5.3E-8	Hypertriglyceridemia	
LGG	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.39	7.07	5.42E-12	Metabolite levels	
LGG	cis	1	rs56672945	chr2:73622663	NAT8	chr2:73867850-73869537:-	0.25	4.16	3.79E-5	Metabolite levels	
LGG	cis	1	rs56682209	chr2:48108186	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs56740825	chr8:58175617	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs567652	chr2:166861478	SCN2A	chr2:166095912-166248818:+	-0.09	-3.46	0.000594	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs567652	chr2:166861478	TTC21B	chr2:166713988-166810348:-	-0.14	-4.03	6.51E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.23	6.27	7.78E-10	Response to temozolomide	
LGG	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.78	15.15	8.08E-43	Diastolic blood pressure	
LGG	cis	1	rs56791846	chr2:179745089	CCDC141	chr2:179697347-179914786:-	-0.38	-5.49	6.51E-8	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs568129	chr6:84229114	SNAP91	chr6:84262607-84419127:-	-0.1	-4.73	2.89E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs56818101	chr2:17776053	GEN1	chr2:17935162-17966632:+	0.28	4.25	2.53E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs568328	chr10:13081704	CCDC3	chr10:12938625-13141713:-	-0.22	-3.5	0.000516	Coronary artery aneurysm in Kawasaki disease	
LGG	cis	1	rs56850662	chr3:128061922	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.17	3.63E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs56850662	chr3:128061922	LOC90246	chr3:128226678-128229427:+	-0.29	-3.64	0.000301	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.43	-8.73	3.91E-17	Crohn's disease	
LGG	cis	1	rs568617	chr11:65653242	FIBP	chr11:65651212-65656010:-	0.24	5.87	8.15E-9	Crohn's disease	
LGG	cis	1	rs568617	chr11:65653242	SNX32	chr11:65601410-65621170:+	0.41	9.93	2.59E-21	Crohn's disease	
LGG	cis	1	rs56864281	chr15:85357649	GOLGA6L5	chr15:85047738-85060078:-	-0.19	-4.05	5.88E-5	Schizophrenia	
LGG	cis	1	rs56864281	chr15:85357649	LOC388152	chr15:84867600-84898920:-	-0.29	-5.38	1.14E-7	Schizophrenia	
LGG	cis	1	rs56864281	chr15:85357649	UBE2Q2P1	chr15:85070427-85114026:-	0.15	3.48	0.000553	Schizophrenia	
LGG	cis	1	rs56864281	chr15:85357649	WDR73	chr15:85186012-85197524:-	-0.19	-3.47	0.000558	Schizophrenia	
LGG	cis	1	rs56884994	chr1:247211057	ZNF670	chr1:247200087-247242069:-	-0.22	-5.17	3.49E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs56922390	chr17:38157021	GSDMA	chr17:38119226-38134019:+	-0.72	-15.66	3.99E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.23	6.1	2.19E-9	Response to temozolomide	
LGG	cis	1	rs569557	chr13:113769917	F7	chr13:113760105-113774994:+	-0.29	-3.88	0.000118	End-stage coagulation	
LGG	cis	1	rs56974987	chr4:17627856	MED28	chr4:17616273-17629791:+	0.2	4.19	3.27E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs569856	chr10:105942304	C10orf79	chr10:105889647-105992120:-	0.18	4.9	1.3E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs56985706	chr7:65394562	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs56987357	chr14:88824363	SPATA7	chr14:88852012-88904802:+	-0.44	-7.63	1.21E-13	Coronary artery calcification	
LGG	cis	1	rs569967	chr10:105942337	C10orf79	chr10:105889647-105992120:-	0.18	4.9	1.3E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs57001853	chr5:150272452	LOC134466	chr5:150310000-150326146:-	0.4	4.57	6.06E-6	Crohn's disease	
LGG	cis	1	rs57002197	chr15:50873760	SPPL2A	chr15:50999739-51057910:-	0.12	4.04	6.28E-5	QT interval	
LGG	cis	1	rs570021	chr1:71445390	PTGER3	chr1:71318036-71513491:-	0.16	3.86	0.000126	IgG glycosylation	
LGG	cis	1	rs57012661	chr14:66172750	LOC645431	chr14:65877313-65879335:-	-0.46	-6.27	7.85E-10	Ischemic stroke	
LGG	cis	1	rs57025426	chr10:102205868	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs57025426	chr10:102205868	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs57025426	chr10:102205868	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs57057549	chr7:65405738	CCT6P1	chr7:65216092-65228661:+	0.27	4.97	9.37E-7	Diabetic kidney disease	
LGG	cis	1	rs57060498	chr2:54479230	C2orf73	chr2:54558071-54588714:+	0.32	4.64	4.42E-6	Telomere length	
LGG	cis	1	rs57060498	chr2:54479230	TSPYL6	chr2:54480315-54483409:-	-0.46	-5.57	4.18E-8	Telomere length	
LGG	cis	1	rs57064725	chr15:78833036	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.65	7.86E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs57083693	chr12:101742180	UTP20	chr12:101673905-101780397:+	-0.16	-3.48	0.000542	Alcohol dependence (age at onset)	
LGG	cis	1	rs57137641	chr12:56741228	IL23A	chr12:56732663-56734193:+	0.55	5.03	6.83E-7	Psoriasis vulgaris	
LGG	cis	1	rs57185954	chr17:46844961	SNF8	chr17:47007461-47022154:-	-0.16	-4.05	6.01E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs57186557	chr8:58177277	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs57196672	chr2:242235193	ANO7	chr2:242127924-242164791:+	0.4	6.64	8.48E-11	Prostate cancer	
LGG	cis	1	rs57201867	chr14:66093872	LOC645431	chr14:65877313-65879335:-	-0.5	-6.63	9.14E-11	Ischemic stroke	
LGG	cis	1	rs57261109	chr8:58172152	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs57279772	chr12:56698960	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs573418	chr1:168690634	SELL	chr1:169659810-169680837:-	0.19	3.99	7.63E-5	QT interval	
LGG	cis	1	rs57378064	chr8:58169844	C8orf71	chr8:58192102-58197288:+	0.34	6	3.83E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs573890	chr11:108251363	ATM	chr11:108093559-108239826:+	0.11	3.47	0.000573	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs57406211	chr5:150170966	LOC134466	chr5:150310000-150326146:-	0.39	4.2	3.12E-5	Crohn's disease	
LGG	cis	1	rs57411618	chr17:28273052	EFCAB5	chr17:28256874-28435469:+	0.23	6.1	2.14E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs57415683	chr13:36684221	SOHLH2	chr13:36742347-36871992:-	0.39	5.88	7.62E-9	Optic cup area	
LGG	cis	1	rs5743004	chr2:190667190	ORMDL1	chr2:190634994-190649097:-	-0.28	-3.63	0.000313	Subcutaneous adipose tissue	
LGG	cis	1	rs5743030	chr2:190678545	ASNSD1	chr2:190526125-190535556:+	-0.38	-4.34	1.73E-5	Subcutaneous adipose tissue	
LGG	cis	1	rs5743030	chr2:190678545	ORMDL1	chr2:190634994-190649097:-	0.33	4.9	1.28E-6	Subcutaneous adipose tissue	
LGG	cis	1	rs5743044	chr2:190683265	ASNSD1	chr2:190526125-190535556:+	-0.38	-4.23	2.78E-5	Subcutaneous adipose tissue	
LGG	cis	1	rs5743044	chr2:190683265	ORMDL1	chr2:190634994-190649097:-	0.35	5.02	7.16E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs5743100	chr2:190705853	ASNSD1	chr2:190526125-190535556:+	-0.4	-4.18	3.5E-5	Subcutaneous adipose tissue	
LGG	cis	1	rs5743100	chr2:190705853	ORMDL1	chr2:190634994-190649097:-	0.37	5.01	7.55E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs5743112	chr2:190708982	ASNSD1	chr2:190526125-190535556:+	-0.31	-3.5	0.000508	Subcutaneous adipose tissue	
LGG	cis	1	rs5743112	chr2:190708982	ORMDL1	chr2:190634994-190649097:-	0.35	5.26	2.13E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs5743117	chr2:190714245	ORMDL1	chr2:190634994-190649097:-	0.35	5.25	2.24E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs5743202	chr2:190742666	ORMDL1	chr2:190634994-190649097:-	0.34	5.13	4.1E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs5743208	chr2:190743048	ORMDL1	chr2:190634994-190649097:-	-0.33	-5.19	3.07E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs57434520	chr5:115648765	COMMD10	chr5:115420727-115628978:+	0.41	5.94	5.3E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs57479675	chr3:41798038	ULK4	chr3:41288091-42003660:-	0.77	15.19	5.54E-43	Diastolic blood pressure	
LGG	cis	1	rs5749806	chr22:22106618	CCDC116	chr22:21987086-21991615:+	0.18	3.75	0.000197	Multiple sclerosis	
LGG	cis	1	rs5749986	chr22:22157661	CCDC116	chr22:21987086-21991615:+	-0.17	-3.62	0.000328	Multiple sclerosis	
LGG	cis	1	rs5750621	chr22:38956166	LOC646851	chr22:38974125-39052634:-	0.22	6.69	5.93E-11	Resting heart rate	
LGG	cis	1	rs5750622	chr22:38956464	LOC646851	chr22:38974125-39052634:-	0.22	6.69	5.93E-11	Resting heart rate	
LGG	cis	1	rs5750626	chr22:38977890	LOC646851	chr22:38974125-39052634:-	0.22	6.47	2.43E-10	Resting heart rate	
LGG	cis	1	rs5750627	chr22:38982321	LOC646851	chr22:38974125-39052634:-	0.25	7.62	1.31E-13	Resting heart rate	
LGG	cis	1	rs5750630	chr22:38985818	LOC646851	chr22:38974125-39052634:-	0.21	6.35	4.97E-10	Resting heart rate	
LGG	cis	1	rs5750633	chr22:38993467	LOC646851	chr22:38974125-39052634:-	0.24	7.49	3.3E-13	Resting heart rate	
LGG	cis	1	rs5750649	chr22:39036769	LOC646851	chr22:38974125-39052634:-	0.24	7.47	3.62E-13	Resting heart rate	
LGG	cis	1	rs5750652	chr22:39048316	LOC646851	chr22:38974125-39052634:-	0.24	7.47	3.62E-13	Resting heart rate	
LGG	cis	1	rs5750659	chr22:39068789	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs5750662	chr22:39072472	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs5750664	chr22:39072769	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs5750668	chr22:39079964	LOC646851	chr22:38974125-39052634:-	0.23	6.82	2.61E-11	Resting heart rate	
LGG	cis	1	rs5750669	chr22:39080638	LOC646851	chr22:38974125-39052634:-	0.22	6.72	5.04E-11	Resting heart rate	
LGG	cis	1	rs5750671	chr22:39094619	LOC646851	chr22:38974125-39052634:-	0.25	7.65	1.1E-13	Resting heart rate	
LGG	cis	1	rs5750672	chr22:39104168	LOC646851	chr22:38974125-39052634:-	-0.22	-6.58	1.19E-10	Resting heart rate	
LGG	cis	1	rs5750673	chr22:39110124	LOC646851	chr22:38974125-39052634:-	0.22	6.6	1.09E-10	Resting heart rate	
LGG	cis	1	rs5750677	chr22:39147715	LOC646851	chr22:38974125-39052634:-	0.25	7.61	1.45E-13	Resting heart rate	
LGG	cis	1	rs5751255	chr22:42648408	C22orf32	chr22:42475699-42480287:+	0.17	4.77	2.39E-6	Cognitive function	
LGG	cis	1	rs5751255	chr22:42648408	CYP2D6	chr22:42522502-42526883:-	-0.26	-7.67	9.29E-14	Cognitive function	
LGG	cis	1	rs5751255	chr22:42648408	LOC339674	chr22:42120359-42354945:+	0.13	3.9	0.000111	Cognitive function	
LGG	cis	1	rs5751255	chr22:42648408	NAGA	chr22:42454339-42466846:-	0.1	3.64	0.000305	Cognitive function	
LGG	cis	1	rs57512806	chr2:17776078	GEN1	chr2:17935162-17966632:+	0.27	4.22	2.94E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs57514701	chr10:1146169	IDI2	chr10:1064847-1071799:-	0.33	4.01	6.96E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs5751589	chr22:23475762	RTDR1	chr22:23401594-23484241:-	0.17	3.91	0.000107	Bone mineral density	
LGG	cis	1	rs5753521	chr22:31638027	LIMK2	chr22:31608250-31676064:+	0.26	5.4	1.03E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs5753543	chr22:31685458	LIMK2	chr22:31608250-31676064:+	0.28	5.86	8.34E-9	Paclitaxel-induced neuropathy	
LGG	cis	1	rs5754074	chr22:32805015	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.49	6.3E-8	IgG glycosylation	
LGG	cis	1	rs57542652	chr2:228088	FAM150B	chr2:279563-288308:-	-0.34	-6.32	5.97E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs57542652	chr2:228088	SNTG2	chr2:946555-1371382:+	0.19	3.55	0.000415	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs575474	chr1:183158599	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs5756813	chr22:38175477	GALR3	chr22:38219389-38221502:+	0.23	5.16	3.61E-7	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs5756813	chr22:38175477	GCAT	chr22:38203955-38213183:+	-0.17	-3.53	0.000452	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs5756813	chr22:38175477	TRIOBP	chr22:38082344-38172562:+	-0.21	-5.15	3.73E-7	Optic cup area;Vertical cup-disc ratio	
LGG	cis	1	rs5757141	chr22:38957483	LOC646851	chr22:38974125-39052634:-	0.22	6.73	4.85E-11	Resting heart rate	
LGG	cis	1	rs5757162	chr22:38993370	LOC646851	chr22:38974125-39052634:-	0.22	6.55	1.5E-10	Resting heart rate	
LGG	cis	1	rs5757166	chr22:38995385	LOC646851	chr22:38974125-39052634:-	0.24	7.52	2.67E-13	Resting heart rate	
LGG	cis	1	rs5757181	chr22:39013522	LOC646851	chr22:38974125-39052634:-	0.22	6.52	1.71E-10	Resting heart rate	
LGG	cis	1	rs5757187	chr22:39021522	LOC646851	chr22:38974125-39052634:-	-0.22	-6.74	4.42E-11	Resting heart rate	
LGG	cis	1	rs5757193	chr22:39034867	LOC646851	chr22:38974125-39052634:-	-0.22	-6.7	5.84E-11	Resting heart rate	
LGG	cis	1	rs5757196	chr22:39039855	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757200	chr22:39043491	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757203	chr22:39044152	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757204	chr22:39046700	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757208	chr22:39049230	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757211	chr22:39051705	LOC646851	chr22:38974125-39052634:-	0.21	6.52	1.71E-10	Resting heart rate	
LGG	cis	1	rs5757213	chr22:39053888	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs5757226	chr22:39070550	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs5757231	chr22:39071658	LOC646851	chr22:38974125-39052634:-	-0.23	-6.81	2.93E-11	Resting heart rate	
LGG	cis	1	rs5757232	chr22:39071677	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs5757234	chr22:39072686	LOC646851	chr22:38974125-39052634:-	0.25	7.8	3.69E-14	Resting heart rate	
LGG	cis	1	rs5757253	chr22:39104320	LOC646851	chr22:38974125-39052634:-	0.25	7.58	1.74E-13	Resting heart rate	
LGG	cis	1	rs57576577	chr16:31036367	MYST1	chr16:31128985-31142713:+	0.14	4.03	6.55E-5	Response to metformin (IC50)	
LGG	cis	1	rs57576577	chr16:31036367	PRSS53	chr16:31094747-31106276:-	-0.16	-4.5	8.69E-6	Response to metformin (IC50)	
LGG	cis	1	rs5757673	chr22:39837920	TAB1	chr22:39745954-39833132:+	-0.17	-3.66	0.000275	Post bronchodilator FEV1	
LGG	cis	1	rs5758659	chr22:42622003	C22orf32	chr22:42475699-42480287:+	0.18	5	7.91E-7	Cognitive function	
LGG	cis	1	rs5758659	chr22:42622003	CYP2D6	chr22:42522502-42526883:-	-0.25	-7.48	3.37E-13	Cognitive function	
LGG	cis	1	rs5758659	chr22:42622003	FAM109B	chr22:42470255-42475441:+	0.11	3.47	0.000569	Cognitive function	
LGG	cis	1	rs5758659	chr22:42622003	LOC339674	chr22:42120359-42354945:+	0.13	3.85	0.000134	Cognitive function	
LGG	cis	1	rs5758659	chr22:42622003	NAGA	chr22:42454339-42466846:-	0.1	3.76	0.000192	Cognitive function	
LGG	cis	1	rs5758660	chr22:42623718	C22orf32	chr22:42475699-42480287:+	0.17	4.8	2.07E-6	Cognitive function	
LGG	cis	1	rs5758660	chr22:42623718	CYP2D6	chr22:42522502-42526883:-	-0.26	-7.66	9.93E-14	Cognitive function	
LGG	cis	1	rs5758660	chr22:42623718	LOC339674	chr22:42120359-42354945:+	0.13	3.81	0.000155	Cognitive function	
LGG	cis	1	rs5758660	chr22:42623718	NAGA	chr22:42454339-42466846:-	0.1	3.71	0.000232	Cognitive function	
LGG	cis	1	rs5758677	chr22:42643039	C22orf32	chr22:42475699-42480287:+	0.17	4.78	2.29E-6	Cognitive function	
LGG	cis	1	rs5758677	chr22:42643039	CYP2D6	chr22:42522502-42526883:-	-0.26	-7.66	9.84E-14	Cognitive function	
LGG	cis	1	rs5758677	chr22:42643039	LOC339674	chr22:42120359-42354945:+	0.13	3.8	0.00016	Cognitive function	
LGG	cis	1	rs5758677	chr22:42643039	NAGA	chr22:42454339-42466846:-	0.1	3.65	0.000286	Cognitive function	
LGG	cis	1	rs5759113	chr22:43443952	TTLL1	chr22:43435524-43485434:-	-0.21	-4.32	1.85E-5	Schizophrenia	
LGG	cis	1	rs5759595	chr22:23471624	RTDR1	chr22:23401594-23484241:-	-0.17	-3.84	0.000138	Bone mineral density	
LGG	cis	1	rs5759596	chr22:23475750	RTDR1	chr22:23401594-23484241:-	-0.17	-3.85	0.000136	Bone mineral density	
LGG	cis	1	rs5760216	chr22:24539734	SUSD2	chr22:24577444-24585074:+	0.5	5.84	9.52E-9	Amyotrophic lateral sclerosis	
LGG	cis	1	rs5760220	chr22:24542480	SUSD2	chr22:24577444-24585074:+	0.51	5.92	6.2E-9	Amyotrophic lateral sclerosis	
LGG	cis	1	rs5760229	chr22:24560254	SUSD2	chr22:24577444-24585074:+	0.52	6.17	1.47E-9	Amyotrophic lateral sclerosis	
LGG	cis	1	rs57624567	chr8:58176995	C8orf71	chr8:58192102-58197288:+	0.36	6.16	1.53E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs5762788	chr22:29174770	XBP1	chr22:29190549-29196560:-	-0.17	-3.59	0.000363	Esophageal squamous cell carcinoma;Esophageal cancer (squamous cell)	
LGG	cis	1	rs5763766	chr22:30491512	THOC5	chr22:29904157-29949736:-	0.36	3.7	0.000244	LDL cholesterol	
LGG	cis	1	rs576526	chr1:71446134	PTGER3	chr1:71318036-71513491:-	0.16	3.85	0.000135	IgG glycosylation	
LGG	cis	1	rs576663	chr11:65498942	DKFZp761E198	chr11:65543380-65547822:-	0.26	3.62	0.000322	Atopic dermatitis	
LGG	cis	1	rs576779	chr4:56274307	TMEM165	chr4:56262090-56292342:+	-0.17	-5.01	7.48E-7	Personality dimensions	
LGG	cis	1	rs57690120	chr20:33731437	PROCR	chr20:33758727-33765164:+	-0.32	-6	3.84E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs5769760	chr22:50259696	ALG12	chr22:50296856-50312106:-	-0.26	-5.21	2.79E-7	Schizophrenia	
LGG	cis	1	rs5769764	chr22:50270784	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs5769765	chr22:50271176	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs576982	chr15:78870803	CHRNA5	chr15:78857906-78886458:+	-0.36	-5.62	3.15E-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs57699322	chr3:128065313	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.19	3.36E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs57699322	chr3:128065313	LOC90246	chr3:128226678-128229427:+	-0.3	-3.73	0.000213	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs5770728	chr22:50259984	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs5770741	chr22:50270215	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs5770742	chr22:50270309	ALG12	chr22:50296856-50312106:-	-0.27	-5.38	1.13E-7	Schizophrenia	
LGG	cis	1	rs5770755	chr22:50280136	ALG12	chr22:50296856-50312106:-	-0.27	-5.42	9.15E-8	Schizophrenia	
LGG	cis	1	rs5770911	chr22:51011241	CPT1B	chr22:51007291-51017096:-	-0.33	-5.92	5.92E-9	Narcolepsy	
LGG	cis	1	rs5770917	chr22:51017353	CPT1B	chr22:51007291-51017096:-	-0.31	-5.83	1.02E-8	Narcolepsy	
LGG	cis	1	rs5770922	chr22:51023408	CPT1B	chr22:51007291-51017096:-	-0.34	-6.16	1.5E-9	Narcolepsy	
LGG	cis	1	rs5770924	chr22:51024542	CPT1B	chr22:51007291-51017096:-	-0.34	-6.16	1.5E-9	Narcolepsy	
LGG	cis	1	rs577227	chr10:131404528	MGMT	chr10:131265454-131565783:+	0.23	6.09	2.3E-9	Response to temozolomide	
LGG	cis	1	rs577306	chr2:166871905	SCN2A	chr2:166095912-166248818:+	-0.09	-3.7	0.000243	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs577306	chr2:166871905	TTC21B	chr2:166713988-166810348:-	-0.13	-3.87	0.000122	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs57735707	chr3:128065815	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.17	3.57E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs57735707	chr3:128065815	LOC90246	chr3:128226678-128229427:+	-0.29	-3.52	0.000468	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs57804141	chr3:129962512	COL6A4P2	chr3:129931663-129992648:+	0.31	5.37	1.21E-7	Response to amphetamines	
LGG	cis	1	rs578056	chr11:65514874	RNASEH2C	chr11:65485146-65488409:-	-0.21	-4.84	1.75E-6	Systemic lupus erythematosus	
LGG	cis	1	rs578056	chr11:65514874	SNX32	chr11:65601410-65621170:+	0.23	4.83	1.79E-6	Systemic lupus erythematosus	
LGG	cis	1	rs57844481	chr14:76684493	ESRRB	chr14:76837690-76968178:+	-0.42	-6.38	4.18E-10	Blood pressure	
LGG	cis	1	rs57870697	chr12:56752874	IL23A	chr12:56732663-56734193:+	0.58	5.02	7.32E-7	Psoriasis vulgaris	
LGG	cis	1	rs57877016	chr11:76834174	CAPN5	chr11:76777992-76837196:+	0.31	3.52	0.000467	Cognitive performance	
LGG	cis	1	rs57894940	chr19:30293462	CCNE1	chr19:30302901-30315218:+	-0.19	-3.98	7.98E-5	Bladder cancer	
LGG	cis	1	rs57912102	chr19:22136043	ZNF257	chr19:22235266-22273901:+	0.56	9.01	4.69E-18	Body mass index (change over time)	
LGG	cis	1	rs57916046	chr7:19800542	TMEM196	chr7:19758939-19813216:-	0.2	3.61	0.000337	Thyroid stimulating hormone	
LGG	cis	1	rs57928699	chr18:44645593	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs57941207	chr8:58169821	C8orf71	chr8:58192102-58197288:+	0.37	6.3	6.77E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs57961439	chr11:76819171	CAPN5	chr11:76777992-76837196:+	0.33	3.74	0.000208	Cognitive performance	
LGG	cis	1	rs57970196	chr14:55600405	FBXO34	chr14:55738021-55893431:+	0.15	4.51	8.21E-6	Protein biomarker	
LGG	cis	1	rs579807	chr11:96026073	CCDC82	chr11:96085930-96123083:-	-0.17	-3.65	0.00029	Corneal astigmatism	
LGG	cis	1	rs57994353	chr9:139356987	C8G	chr9:139839698-139841426:+	0.2	3.9	0.000109	cutaneous squamous cell carcinoma	
LGG	cis	1	rs58053450	chr8:58173348	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs58057481	chr2:48106382	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs58062456	chr7:65394852	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs58069930	chr16:50067031	HEATR3	chr16:50099881-50139373:+	-0.3	-4.12	4.49E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs580705	chr11:114430047	C11orf71	chr11:114262170-114271255:-	-0.17	-3.51	0.000483	Ulcerative colitis	
LGG	cis	1	rs580745	chr10:131414401	MGMT	chr10:131265454-131565783:+	0.23	6.09	2.29E-9	Response to temozolomide	
LGG	cis	1	rs58088385	chr20:33748229	PROCR	chr20:33758727-33765164:+	-0.36	-6.37	4.26E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs58115860	chr14:66057626	LOC645431	chr14:65877313-65879335:-	-0.48	-6.34	5.2E-10	Ischemic stroke	
LGG	cis	1	rs58122682	chr17:65876915	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs581686	chr10:105983356	C10orf79	chr10:105889647-105992120:-	0.2	5.25	2.21E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs58183575	chr8:83072464	FABP4	chr8:82390732-82395473:-	0.19	3.82	0.000153	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs58189451	chr6:149921388	RAET1G	chr6:150238014-150244214:-	0.25	4.27	2.38E-5	Lung cancer	
LGG	cis	1	rs58189451	chr6:149921388	ULBP1	chr6:150285143-150294844:+	0.18	3.57	0.000396	Lung cancer	
LGG	cis	1	rs58189451	chr6:149921388	ULBP2	chr6:150263136-150270366:+	0.16	3.5	0.000504	Lung cancer	
LGG	cis	1	rs58204112	chr14:74359417	LIN52	chr14:74551656-74667117:+	0.38	4.77	2.49E-6	Morning vs. evening chronotype	
LGG	cis	1	rs58328848	chr9:123729962	TRAF1	chr9:123664672-123691479:-	0.34	4.11	4.69E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs583583	chr1:147083114	ACP6	chr1:147119168-147142634:-	0.54	10.45	3.17E-23	Schizophrenia (negative symptoms)	
LGG	cis	1	rs58363453	chr5:42393364	C5orf51	chr5:41904470-41921737:+	-0.28	-3.52	0.000477	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs58365910	chr15:78849034	CHRNA5	chr15:78857906-78886458:+	-0.67	-12.97	2.75E-33	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs58371676	chr8:58189382	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs58382845	chr8:58169851	C8orf71	chr8:58192102-58197288:+	0.37	6.3	6.77E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs583905	chr11:118695908	MPZL3	chr11:118100337-118123011:-	-0.23	-3.57	0.00039	Vitiligo	
LGG	cis	1	rs58416181	chr15:85264461	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.28	2.25E-5	Schizophrenia	
LGG	cis	1	rs58416181	chr15:85264461	LOC388152	chr15:84867600-84898920:-	-0.3	-5.55	4.77E-8	Schizophrenia	
LGG	cis	1	rs58416181	chr15:85264461	WDR73	chr15:85186012-85197524:-	-0.2	-3.6	0.000353	Schizophrenia	
LGG	cis	1	rs58426216	chr1:150124615	RPRD2	chr1:150336990-150449039:+	0.16	3.98	8.0E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs584309	chr10:105956776	C10orf79	chr10:105889647-105992120:-	0.18	4.83	1.84E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs58436485	chr15:90900633	IQGAP1	chr15:90931473-91045475:+	0.15	4.5	8.31E-6	Rheumatoid arthritis	
LGG	cis	1	rs584438	chr17:38599172	IGFBP4	chr17:38599676-38613981:+	-0.14	-3.57	0.000385	Height	
LGG	cis	1	rs584440	chr18:6940522	ARHGAP28	chr18:6788493-6915710:+	0.26	3.58	0.000381	Sudden cardiac arrest	
LGG	cis	1	rs58453750	chr2:17778329	GEN1	chr2:17935162-17966632:+	0.27	4.23	2.8E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs58461606	chr2:267367	FAM150B	chr2:279563-288308:-	-0.34	-6.55	1.49E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs58461606	chr2:267367	SNTG2	chr2:946555-1371382:+	0.2	3.65	0.000292	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs585228	chr11:71773289	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs58550767	chr7:33194004	BBS9	chr7:33169152-33645680:+	0.46	5.96	4.83E-9	Smooth-surface caries	
LGG	cis	1	rs58551145	chr17:65837235	LOC440461	chr17:66194801-66196436:+	0.27	4.52	7.86E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs58552166	chr2:48112019	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs58565853	chr11:78036707	NARS2	chr11:78147017-78285909:-	-0.19	-3.63	0.00031	Testicular germ cell tumor	
LGG	cis	1	rs58591218	chr19:32890782	ZNF507	chr19:32836514-32878571:+	0.13	3.56	0.000407	Bipolar disorder	
LGG	cis	1	rs58601355	chr4:120186367	MYOZ2	chr4:120056939-120108935:+	0.22	4.21	3.05E-5	Corneal astigmatism	
LGG	cis	1	rs58602070	chr14:65849242	LOC645431	chr14:65877313-65879335:-	-0.42	-5.94	5.36E-9	Ischemic stroke	
LGG	cis	1	rs58603761	chr2:73726605	ALMS1P	chr2:73872046-73912692:+	0.4	7.2	2.3E-12	Metabolite levels	
LGG	cis	1	rs58603761	chr2:73726605	NAT8	chr2:73867850-73869537:-	0.28	4.6	5.49E-6	Metabolite levels	
LGG	cis	1	rs58608483	chr8:58195269	C8orf71	chr8:58192102-58197288:+	0.34	5.8	1.18E-8	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs58660500	chr3:53086573	RFT1	chr3:53122503-53164470:-	0.31	3.47	0.000572	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs58669269	chr7:65951953	CCT6P1	chr7:65216092-65228661:+	0.22	3.95	9.01E-5	Diabetic kidney disease	
LGG	cis	1	rs58717741	chr5:150284936	LOC134466	chr5:150310000-150326146:-	0.52	5.84	9.3E-9	Crohn's disease	
LGG	cis	1	rs58734583	chr5:93532155	FAM172A	chr5:92953432-93447404:-	-0.28	-3.91	0.000106	Diabetic retinopathy	
LGG	cis	1	rs58749629	chr20:44571317	WFDC3	chr20:44402847-44420547:-	-0.5	-7.52	2.63E-13	Abdominal aortic aneurysm	
LGG	cis	1	rs58749629	chr20:44571317	ZSWIM1	chr20:44509848-44513904:+	0.21	3.85	0.000136	Abdominal aortic aneurysm	
LGG	cis	1	rs58852079	chr12:56706922	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs58865519	chr10:46010891	ALOX5	chr10:45869629-45941561:+	-0.1	-3.69	0.000245	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs58865519	chr10:46010891	FAM21C	chr10:46222667-46288411:+	-0.19	-3.49	0.000521	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs588918	chr11:116856642	SIDT2	chr11:117049939-117068161:+	0.31	3.63	0.000312	Protein quantitative trait loci	
LGG	cis	1	rs58947041	chr8:58188934	C8orf71	chr8:58192102-58197288:+	0.35	6.12	1.93E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs58986862	chr3:128061689	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.17	3.63E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs58986862	chr3:128061689	LOC90246	chr3:128226678-128229427:+	-0.29	-3.64	0.000301	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs58991229	chr11:71839878	FAM86C	chr11:71498557-71512276:+	-0.43	-4.11	4.65E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs59043219	chr1:209970610	IRF6	chr1:209961262-209979482:-	-0.33	-6.3	6.56E-10	Alzheimer's disease (APOE e4 interaction)	
LGG	cis	1	rs59043558	chr5:150334662	LOC134466	chr5:150310000-150326146:-	0.42	4.56	6.48E-6	Crohn's disease	
LGG	cis	1	rs59044152	chr17:41888747	VAT1	chr17:41166622-41174459:-	-0.16	-3.47	0.000557	Triglycerides	
LGG	cis	1	rs59048466	chr9:114283836	PTGR1	chr9:114312003-114362135:-	-0.37	-5.34	1.4E-7	Menarche (age at onset)	
LGG	cis	1	rs59048466	chr9:114283836	ZNF483	chr9:114287447-114340124:+	0.23	3.53	0.000454	Menarche (age at onset)	
LGG	cis	1	rs59065735	chr3:128595566	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs59071610	chr8:58186301	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59075362	chr7:33307876	BBS9	chr7:33169152-33645680:+	0.46	6.35	4.9E-10	Smooth-surface caries	
LGG	cis	1	rs59104589	chr2:242237902	ANO7	chr2:242127924-242164791:+	0.24	5.38	1.18E-7	Fibrinogen levels	
LGG	cis	1	rs59117465	chr14:66052472	LOC645431	chr14:65877313-65879335:-	-0.48	-6.21	1.16E-9	Ischemic stroke	
LGG	cis	1	rs59150578	chr11:18340862	GTF2H1	chr11:18343816-18388590:+	0.43	8.01	8.2E-15	Pancreatic cancer	
LGG	cis	1	rs59150578	chr11:18340862	LDHC	chr11:18433853-18472792:+	0.2	3.67	0.000273	Pancreatic cancer	
LGG	cis	1	rs591784	chr10:105936290	C10orf79	chr10:105889647-105992120:-	0.19	5.1	4.98E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs59203167	chr1:248014245	TRIM58	chr1:248020501-248043436:+	-0.47	-4.26	2.46E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs59204447	chr14:66106727	LOC645431	chr14:65877313-65879335:-	-0.49	-6.63	8.86E-11	Ischemic stroke	
LGG	cis	1	rs59226697	chr22:25870037	CRYBB2	chr22:25615612-25627836:+	0.55	5.77	1.44E-8	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs59227481	chr12:110007993	KCTD10	chr12:109886460-109915155:-	-0.21	-4.57	6.08E-6	Age-related nuclear cataracts	
LGG	cis	1	rs59228675	chr4:42452756	SHISA3	chr4:42399856-42404503:+	0.27	4.18	3.38E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs59244622	chr2:97501632	FAM178B	chr2:97541620-97652301:-	-0.15	-3.67	0.000272	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs59248873	chr7:1888185	FTSJ2	chr7:2273928-2281833:-	0.18	4.02	6.75E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs59274738	chr17:28437635	EFCAB5	chr17:28256874-28435469:+	0.22	5.94	5.34E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs59275611	chr8:58195191	C8orf71	chr8:58192102-58197288:+	0.37	6.24	9.34E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59295315	chr12:56708576	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs592955	chr11:108156473	ATM	chr11:108093559-108239826:+	-0.11	-3.5	0.000504	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs593126	chr15:45935777	SPATA5L1	chr15:45694519-45713614:+	0.28	4.26	2.45E-5	Obesity-related traits	
LGG	cis	1	rs593151	chr10:105935979	C10orf79	chr10:105889647-105992120:-	0.19	5.1	4.98E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs59321715	chr5:150313480	LOC134466	chr5:150310000-150326146:-	0.46	4.66	4.02E-6	Crohn's disease	
LGG	cis	1	rs59343240	chr16:67850529	LRRC36	chr16:67360747-67419108:+	0.49	4.52	7.87E-6	Crohn's disease	
LGG	cis	1	rs59343240	chr16:67850529	RANBP10	chr16:67757006-67840555:-	-0.31	-3.6	0.000355	Crohn's disease	
LGG	cis	1	rs59343384	chr11:71828038	FAM86C	chr11:71498557-71512276:+	-0.44	-4.41	1.29E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs59352627	chr6:39363489	KCNK5	chr6:39156748-39197251:-	0.31	3.66	0.000284	Obesity-related traits	
LGG	cis	1	rs59363432	chr14:74397545	LIN52	chr14:74551656-74667117:+	0.36	4.68	3.8E-6	Morning vs. evening chronotype	
LGG	cis	1	rs59376497	chr16:67681170	LRRC36	chr16:67360747-67419108:+	0.48	4.42	1.23E-5	Crohn's disease	
LGG	cis	1	rs59376497	chr16:67681170	RANBP10	chr16:67757006-67840555:-	-0.31	-3.6	0.00035	Crohn's disease	
LGG	cis	1	rs59377495	chr10:1157019	IDI2	chr10:1064847-1071799:-	0.34	4.14	4.15E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs59383954	chr8:58189689	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs593982	chr11:65513107	DKFZp761E198	chr11:65543380-65547822:-	0.26	3.62	0.000322	Atopic dermatitis	
LGG	cis	1	rs594074	chr6:6552994	LY86	chr6:6588934-6655216:+	0.11	4.83	1.81E-6	Diabetic kidney disease	
LGG	cis	1	rs59428599	chr10:4970849	AKR1C2	chr10:4964715-5060207:-	0.38	5.06	6.0E-7	Height	
LGG	cis	1	rs59446325	chr7:33223425	BBS9	chr7:33169152-33645680:+	0.44	5.76	1.5E-8	Smooth-surface caries	
LGG	cis	1	rs59468948	chr1:156288058	BGLAP	chr1:156182784-156213112:+	0.25	5.23	2.51E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs59468948	chr1:156288058	CCT3	chr1:156278752-156308195:-	-0.16	-4	7.43E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs59472588	chr5:93511981	FAM172A	chr5:92953432-93447404:-	-0.31	-4.29	2.13E-5	Diabetic retinopathy	
LGG	cis	1	rs59496049	chr2:242260756	ANO7	chr2:242127924-242164791:+	0.34	6.14	1.73E-9	Prostate cancer	
LGG	cis	1	rs595018	chr11:60592276	CCDC86	chr11:60609429-60618561:+	0.21	3.63	0.000318	Wegener's granulomatosis	
LGG	cis	1	rs595018	chr11:60592276	GPR44	chr11:60618398-60623444:-	0.25	4.33	1.82E-5	Wegener's granulomatosis	
LGG	cis	1	rs59531858	chr5:150247063	LOC134466	chr5:150310000-150326146:-	0.5	5.35	1.37E-7	Crohn's disease	
LGG	cis	1	rs59536819	chr2:242272388	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs59538106	chr11:121956831	LOC399959	chr11:121959811-122238467:-	-0.18	-3.47	0.000564	Cardiovascular disease risk factors	
LGG	cis	1	rs59549824	chr8:58186205	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59561356	chr14:66020022	LOC645431	chr14:65877313-65879335:-	-0.47	-6.34	5.19E-10	Ischemic stroke	
LGG	cis	1	rs59607464	chr1:150130081	RPRD2	chr1:150336990-150449039:+	0.16	3.93	9.67E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs59626664	chr12:56636975	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs596629	chr11:71562576	FAM86C	chr11:71498557-71512276:+	-0.49	-5.01	7.46E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs59663729	chr5:110433789	TSLP	chr5:110405778-110413722:+	-0.31	-4.46	1.04E-5	Eosinophil counts	
LGG	cis	1	rs59676254	chr14:65942840	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.24E-12	Ischemic stroke	
LGG	cis	1	rs59682951	chr17:18800766	FAM18B	chr17:18684582-18710026:+	-0.18	-4.67	3.81E-6	Educational attainment (years of education)	
LGG	cis	1	rs59682951	chr17:18800766	FBXW10	chr17:18647326-18682661:+	-0.2	-4.46	1.01E-5	Educational attainment (years of education)	
LGG	cis	1	rs59685862	chr14:66080130	LOC645431	chr14:65877313-65879335:-	-0.49	-6.64	8.14E-11	Ischemic stroke	
LGG	cis	1	rs59708460	chr8:58196526	C8orf71	chr8:58192102-58197288:+	0.38	6.32	6.05E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59715748	chr5:150189287	LOC134466	chr5:150310000-150326146:-	0.38	3.98	7.97E-5	Crohn's disease	
LGG	cis	1	rs59784306	chr20:61859596	BIRC7	chr20:61867276-61871853:+	0.34	4.44	1.09E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs59784306	chr20:61859596	NKAIN4	chr20:61872137-61885892:-	0.26	4.58	5.88E-6	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs59794892	chr7:65415873	CCT6P1	chr7:65216092-65228661:+	0.25	4.75	2.69E-6	Diabetic kidney disease	
LGG	cis	1	rs59797486	chr8:58174435	C8orf71	chr8:58192102-58197288:+	0.36	6.33	5.65E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59804446	chr4:56429541	TMEM165	chr4:56262090-56292342:+	0.17	4.93	1.14E-6	Personality dimensions	
LGG	cis	1	rs59808242	chr5:130754894	SLC22A5	chr5:131705401-131731302:+	-0.26	-4.68	3.7E-6	Life satisfaction	
LGG	cis	1	rs59811639	chr12:56695954	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs59822422	chr14:65889566	LOC645431	chr14:65877313-65879335:-	-0.52	-7.24	1.8E-12	Ischemic stroke	
LGG	cis	1	rs59843034	chr8:58195756	C8orf71	chr8:58192102-58197288:+	0.38	6.28	7.25E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs59918529	chr3:158452705	RARRES1	chr3:158414899-158450275:-	0.22	3.48	0.000553	Tetralogy of Fallot	
LGG	cis	1	rs59921977	chr14:66018659	LOC645431	chr14:65877313-65879335:-	-0.48	-6.39	3.8E-10	Ischemic stroke	
LGG	cis	1	rs59925331	chr17:38169273	GSDMA	chr17:38119226-38134019:+	-0.72	-15.76	1.35E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs5992928	chr22:18451438	PEX26	chr22:18560686-18572206:+	-0.14	-3.54	0.000431	Presence of antiphospholipid antibodies	
LGG	cis	1	rs59937473	chr2:271797	FAM150B	chr2:279563-288308:-	-0.34	-6.47	2.43E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs59937473	chr2:271797	SNTG2	chr2:946555-1371382:+	0.2	3.62	0.000331	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs59947468	chr2:86289436	LOC90784	chr2:86247339-86250991:-	-0.47	-4.9	1.31E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs59950564	chr17:65860859	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs599558	chr11:108177538	ATM	chr11:108093559-108239826:+	-0.11	-3.47	0.000557	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs5995610	chr22:39064681	LOC646851	chr22:38974125-39052634:-	0.22	6.61	1.01E-10	Resting heart rate	
LGG	cis	1	rs5996946	chr22:25875988	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.14	4.15E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs5996946	chr22:25875988	CRYBB2	chr22:25615612-25627836:+	0.66	8.3	1.05E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs59980321	chr5:150241813	LOC134466	chr5:150310000-150326146:-	0.43	4.84	1.77E-6	Crohn's disease	
LGG	cis	1	rs5998432	chr22:32745916	SLC5A4	chr22:32614465-32651318:-	-0.54	-6.44	2.8E-10	Cerebrospinal T-tau levels	
LGG	cis	1	rs59989824	chr7:118175322	ANKRD7	chr7:117864712-117882782:+	0.21	3.76	0.000193	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs5999515	chr22:22145101	CCDC116	chr22:21987086-21991615:+	-0.18	-3.76	0.000194	Multiple sclerosis	
LGG	cis	1	rs5999521	chr22:22146399	CCDC116	chr22:21987086-21991615:+	0.17	3.75	0.000195	Multiple sclerosis	
LGG	cis	1	rs5999750	chr22:22188009	CCDC116	chr22:21987086-21991615:+	0.17	3.65	0.000288	Multiple sclerosis	
LGG	cis	1	rs6001173	chr22:39015302	LOC646851	chr22:38974125-39052634:-	0.25	7.67	9.49E-14	Resting heart rate	
LGG	cis	1	rs6001175	chr22:39018334	LOC646851	chr22:38974125-39052634:-	0.24	7.42	5.2E-13	Resting heart rate	
LGG	cis	1	rs6001182	chr22:39047443	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs6001184	chr22:39052116	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs6001185	chr22:39052155	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs6001188	chr22:39062194	LOC646851	chr22:38974125-39052634:-	0.22	6.63	8.79E-11	Resting heart rate	
LGG	cis	1	rs6001191	chr22:39074452	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs6001204	chr22:39100239	LOC646851	chr22:38974125-39052634:-	0.25	7.58	1.74E-13	Resting heart rate	
LGG	cis	1	rs6001214	chr22:39149155	LOC646851	chr22:38974125-39052634:-	0.25	7.65	1.06E-13	Resting heart rate	
LGG	cis	1	rs600329	chr11:108163733	ATM	chr11:108093559-108239826:+	-0.11	-3.53	0.000457	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6003518	chr22:23471533	RTDR1	chr22:23401594-23484241:-	-0.17	-3.86	0.000129	Bone mineral density	
LGG	cis	1	rs6003958	chr22:24264089	DDT	chr22:24237099-24322019:-	-0.41	-7.98	1.04E-14	S-phenylmercapturic acid levels in smokers	
LGG	cis	1	rs6003958	chr22:24264089	DDTL	chr22:24309026-24314747:+	-0.29	-5.32	1.58E-7	S-phenylmercapturic acid levels in smokers	
LGG	cis	1	rs6003958	chr22:24264089	GSTT1	chr22:24376141-24384284:-	-0.8	-13.42	3.44E-35	S-phenylmercapturic acid levels in smokers	
LGG	cis	1	rs6003958	chr22:24264089	GSTT2	chr22:24322314-24326104:+;chr22	0.7	10.98	3.25E-25	S-phenylmercapturic acid levels in smokers	
LGG	cis	1	rs6003958	chr22:24264089	LOC391322	chr22:24373117-24374043:+	-0.74	-13.52	1.29E-35	S-phenylmercapturic acid levels in smokers	
LGG	cis	1	rs60043652	chr2:17778944	GEN1	chr2:17935162-17966632:+	0.26	4.09	5.08E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs6004654	chr22:25855204	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.29	2.15E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004654	chr22:25855204	CRYBB2	chr22:25615612-25627836:+	0.67	8.6	1.07E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004655	chr22:25855629	ADRBK2	chr22:25960861-26125256:+	-0.25	-4.39	1.42E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004655	chr22:25855629	CRYBB2	chr22:25615612-25627836:+	0.67	8.65	7.59E-17	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004657	chr22:25855714	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.28	2.29E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004657	chr22:25855714	CRYBB2	chr22:25615612-25627836:+	0.66	8.5	2.25E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004658	chr22:25856231	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.16	3.69E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004658	chr22:25856231	CRYBB2	chr22:25615612-25627836:+	0.67	8.57	1.35E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004659	chr22:25856411	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.16	3.69E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004659	chr22:25856411	CRYBB2	chr22:25615612-25627836:+	0.67	8.57	1.35E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004662	chr22:25862124	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.22	2.96E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004662	chr22:25862124	CRYBB2	chr22:25615612-25627836:+	0.65	8.23	1.68E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004667	chr22:25874464	ADRBK2	chr22:25960861-26125256:+	0.24	4.16	3.73E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004667	chr22:25874464	CRYBB2	chr22:25615612-25627836:+	-0.64	-8.24	1.52E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004668	chr22:25874502	ADRBK2	chr22:25960861-26125256:+	0.24	4.26	2.44E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004668	chr22:25874502	CRYBB2	chr22:25615612-25627836:+	-0.64	-8.26	1.41E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004669	chr22:25875803	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.14	4.15E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004669	chr22:25875803	CRYBB2	chr22:25615612-25627836:+	0.66	8.3	1.05E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004671	chr22:25879474	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.13	4.19E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004671	chr22:25879474	CRYBB2	chr22:25615612-25627836:+	0.66	8.33	8.14E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004672	chr22:25881013	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.13	4.19E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004672	chr22:25881013	CRYBB2	chr22:25615612-25627836:+	0.66	8.33	8.14E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004673	chr22:25885353	ADRBK2	chr22:25960861-26125256:+	-0.22	-4	7.23E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004673	chr22:25885353	CRYBB2	chr22:25615612-25627836:+	0.61	7.85	2.55E-14	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004675	chr22:25889385	ADRBK2	chr22:25960861-26125256:+	-0.22	-3.85	0.000134	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6004675	chr22:25889385	CRYBB2	chr22:25615612-25627836:+	0.66	8.28	1.21E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs600931	chr11:108117335	ATM	chr11:108093559-108239826:+	-0.11	-3.49	0.000519	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6009823	chr22:50086334	TUBGCP6	chr22:50656118-50683400:-	0.15	3.89	0.000115	Natriuretic peptide levels	
LGG	cis	1	rs6009824	chr22:50086373	TUBGCP6	chr22:50656118-50683400:-	0.15	3.89	0.000115	Natriuretic peptide levels	
LGG	cis	1	rs60111824	chr7:6774135	C7orf28B	chr7:6838572-6865861:-	-0.35	-3.61	0.000338	Ejection fraction in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs60111824	chr7:6774135	PMS2CL	chr7:6749757-6793492:+	-0.42	-5.91	6.25E-9	Ejection fraction in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6011691	chr20:61867454	BIRC7	chr20:61867276-61871853:+	0.34	4.46	1.01E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs6011691	chr20:61867454	NKAIN4	chr20:61872137-61885892:-	0.27	4.74	2.78E-6	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs60118201	chr2:48076288	FBXO11	chr2:48034061-48132814:-	0.23	4.14	4.01E-5	Schizophrenia	
LGG	cis	1	rs6012564	chr20:47541600	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs6012564	chr20:47541600	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs6012617	chr20:47837126	ARFGEF2	chr20:47538275-47653229:+	0.14	4.17	3.64E-5	Height	
LGG	cis	1	rs60134818	chr5:150261043	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs60149603	chr2:285421	FAM150B	chr2:279563-288308:-	-0.33	-6.14	1.73E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60149603	chr2:285421	SNTG2	chr2:946555-1371382:+	0.21	3.7	0.000238	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60178264	chr4:17685308	LAP3	chr4:17578927-17609590:+	-0.13	-3.62	0.000328	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs60178264	chr4:17685308	MED28	chr4:17616273-17629791:+	0.16	3.48	0.000553	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs60179239	chr7:135333028	SLC13A4	chr7:135365993-135412933:-	-0.27	-3.97	8.27E-5	Red blood cell traits	
LGG	cis	1	rs601923	chr5:176417386	FGFR4	chr5:176513921-176525124:+	0.21	5.73	1.79E-8	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs601934	chr1:71444355	PTGER3	chr1:71318036-71513491:-	0.16	3.86	0.000126	IgG glycosylation	
LGG	cis	1	rs60209440	chr2:242260340	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.36E-10	Prostate cancer	
LGG	cis	1	rs60228288	chr18:44640412	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs60231757	chr8:58169937	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs60253563	chr6:170083019	C6orf70	chr6:170151721-170181617:+	-0.18	-3.45	0.000599	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs60253563	chr6:170083019	WDR27	chr6:169857307-170102159:-	-0.41	-9.2	1.05E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs60268357	chr7:33317767	BBS9	chr7:33169152-33645680:+	0.47	6.47	2.43E-10	Smooth-surface caries	
LGG	cis	1	rs60277994	chr7:25622565	SNX10	chr7:26331515-26413937:+	-0.24	-3.67	0.000269	Preeclampsia	
LGG	cis	1	rs6028335	chr20:37845477	DHX35	chr20:37591000-37668363:+	-0.32	-6.26	8.3E-10	Alcohol and nictotine co-dependence	
LGG	cis	1	rs6030712	chr20:35637398	RPN2	chr20:35807456-35870023:+	-0.16	-3.55	0.000423	Height	
LGG	cis	1	rs60310240	chr14:88822709	KCNK10	chr14:88646454-88793256:-	-0.17	-3.49	0.000518	Coronary artery calcification	
LGG	cis	1	rs60310240	chr14:88822709	SPATA7	chr14:88852012-88904802:+	-0.45	-8.04	6.95E-15	Coronary artery calcification	
LGG	cis	1	rs60326618	chr7:66166358	CCT6P1	chr7:65216092-65228661:+	0.22	4.04	6.14E-5	Gout	
LGG	cis	1	rs6032755	chr20:44921676	WFDC3	chr20:44402847-44420547:-	0.23	4.31	2.02E-5	IgG glycosylation	
LGG	cis	1	rs6037086	chr20:25306338	ABHD12	chr20:25275380-25371477:-	-0.27	-7.38	6.8E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037086	chr20:25306338	FAM182A	chr20:26035250-26067552:+	0.56	11	2.7E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037086	chr20:25306338	FAM182B	chr20:25744102-25848786:-	-0.22	-4.88	1.45E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037095	chr20:25335687	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037095	chr20:25335687	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.69E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037095	chr20:25335687	FAM182B	chr20:25744102-25848786:-	-0.21	-4.76	2.53E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037099	chr20:25356876	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037099	chr20:25356876	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037099	chr20:25356876	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037105	chr20:25374199	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037105	chr20:25374199	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037105	chr20:25374199	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037121	chr20:25428311	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037121	chr20:25428311	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037121	chr20:25428311	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6037526	chr20:3251248	ITPA	chr20:3190056-3204504:+	-0.35	-8.37	5.99E-16	IFN-related cytopenia	
LGG	cis	1	rs6037532	chr20:3267911	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6037533	chr20:3268817	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6037535	chr20:3270621	ITPA	chr20:3190056-3204504:+	-0.36	-8.58	1.27E-16	IFN-related cytopenia	
LGG	cis	1	rs6037538	chr20:3282978	ITPA	chr20:3190056-3204504:+	-0.36	-8.66	7.0E-17	IFN-related cytopenia	
LGG	cis	1	rs6037547	chr20:3299228	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs6037551	chr20:3306690	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.37E-17	IFN-related cytopenia	
LGG	cis	1	rs6037553	chr20:3313884	ITPA	chr20:3190056-3204504:+	-0.36	-8.58	1.27E-16	IFN-related cytopenia	
LGG	cis	1	rs6037554	chr20:3315613	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6037556	chr20:3317890	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6037560	chr20:3323055	ITPA	chr20:3190056-3204504:+	-0.36	-8.5	2.28E-16	IFN-related cytopenia	
LGG	cis	1	rs6037562	chr20:3326141	ITPA	chr20:3190056-3204504:+	-0.36	-8.39	5.38E-16	IFN-related cytopenia	
LGG	cis	1	rs6037567	chr20:3332160	ITPA	chr20:3190056-3204504:+	-0.36	-8.39	5.38E-16	IFN-related cytopenia	
LGG	cis	1	rs6037579	chr20:3347980	ITPA	chr20:3190056-3204504:+	-0.36	-8.39	5.28E-16	IFN-related cytopenia	
LGG	cis	1	rs6037583	chr20:3360632	ITPA	chr20:3190056-3204504:+	-0.35	-8.3	1.03E-15	IFN-related cytopenia	
LGG	cis	1	rs6037590	chr20:3374085	ITPA	chr20:3190056-3204504:+	-0.36	-8.59	1.12E-16	IFN-related cytopenia	
LGG	cis	1	rs60399786	chr3:128062070	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.17	3.63E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs60399786	chr3:128062070	LOC90246	chr3:128226678-128229427:+	-0.29	-3.64	0.000301	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs60422392	chr18:44621473	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs60425110	chr15:75333000	PPCDC	chr15:75315927-75343066:+	0.27	5.67	2.43E-8	Blood trace element (Zn levels)	
LGG	cis	1	rs6042	chr13:113770068	F7	chr13:113760105-113774994:+	-0.27	-3.64	0.000296	End-stage coagulation	
LGG	cis	1	rs60432293	chr17:65860407	LOC440461	chr17:66194801-66196436:+	0.26	4.28	2.21E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs60454728	chr8:58173781	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs60479377	chr2:86283948	LOC90784	chr2:86247339-86250991:-	-0.47	-4.9	1.31E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs60484953	chr2:221560	FAM150B	chr2:279563-288308:-	-0.33	-6.18	1.31E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60484953	chr2:221560	SNTG2	chr2:946555-1371382:+	0.2	3.66	0.000277	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60491621	chr7:33248293	BBS9	chr7:33169152-33645680:+	0.42	5.65	2.72E-8	Smooth-surface caries	
LGG	cis	1	rs6050542	chr20:25318879	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050542	chr20:25318879	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050542	chr20:25318879	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050544	chr20:25320228	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050544	chr20:25320228	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.69E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050544	chr20:25320228	FAM182B	chr20:25744102-25848786:-	-0.21	-4.76	2.53E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050547	chr20:25326012	ABHD12	chr20:25275380-25371477:-	-0.26	-7.19	2.43E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050547	chr20:25326012	FAM182A	chr20:26035250-26067552:+	0.54	10.7	3.61E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050547	chr20:25326012	FAM182B	chr20:25744102-25848786:-	-0.21	-4.79	2.23E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050555	chr20:25328543	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.27E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050555	chr20:25328543	FAM182A	chr20:26035250-26067552:+	0.55	10.62	7.75E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050555	chr20:25328543	FAM182B	chr20:25744102-25848786:-	-0.2	-4.39	1.38E-5	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050559	chr20:25329915	ABHD12	chr20:25275380-25371477:-	0.27	7.23	1.81E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050559	chr20:25329915	FAM182A	chr20:26035250-26067552:+	-0.56	-11.07	1.35E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050559	chr20:25329915	FAM182B	chr20:25744102-25848786:-	0.2	4.54	7.04E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050561	chr20:25334855	ABHD12	chr20:25275380-25371477:-	-0.28	-7.59	1.64E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050561	chr20:25334855	FAM182A	chr20:26035250-26067552:+	0.54	10.65	5.56E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050561	chr20:25334855	FAM182B	chr20:25744102-25848786:-	-0.21	-4.79	2.23E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050562	chr20:25336186	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050562	chr20:25336186	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.69E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050562	chr20:25336186	FAM182B	chr20:25744102-25848786:-	-0.21	-4.76	2.53E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050564	chr20:25344231	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050564	chr20:25344231	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050564	chr20:25344231	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050565	chr20:25347563	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050565	chr20:25347563	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050565	chr20:25347563	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050566	chr20:25351071	ABHD12	chr20:25275380-25371477:-	-0.27	-7.31	1.09E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050566	chr20:25351071	FAM182A	chr20:26035250-26067552:+	0.56	11.01	2.49E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050566	chr20:25351071	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.52E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050573	chr20:25366065	ABHD12	chr20:25275380-25371477:-	0.27	7.36	7.6E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050573	chr20:25366065	FAM182A	chr20:26035250-26067552:+	-0.54	-10.59	9.87E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050573	chr20:25366065	FAM182B	chr20:25744102-25848786:-	0.22	4.96	9.61E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050590	chr20:25384994	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050590	chr20:25384994	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050590	chr20:25384994	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050598	chr20:25397257	ABHD12	chr20:25275380-25371477:-	0.28	7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050598	chr20:25397257	FAM182A	chr20:26035250-26067552:+	-0.54	-10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050598	chr20:25397257	FAM182B	chr20:25744102-25848786:-	0.22	4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050599	chr20:25400240	ABHD12	chr20:25275380-25371477:-	-0.27	-7.5	2.95E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050599	chr20:25400240	FAM182A	chr20:26035250-26067552:+	0.55	10.72	3.04E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050599	chr20:25400240	FAM182B	chr20:25744102-25848786:-	-0.22	-4.89	1.38E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050602	chr20:25401203	ABHD12	chr20:25275380-25371477:-	-0.27	-7.5	2.95E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050602	chr20:25401203	FAM182A	chr20:26035250-26067552:+	0.55	10.72	3.04E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050602	chr20:25401203	FAM182B	chr20:25744102-25848786:-	-0.22	-4.89	1.38E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050609	chr20:25411751	ABHD12	chr20:25275380-25371477:-	-0.27	-7.53	2.51E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050609	chr20:25411751	FAM182A	chr20:26035250-26067552:+	0.54	10.7	3.81E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050609	chr20:25411751	FAM182B	chr20:25744102-25848786:-	-0.22	-4.94	1.07E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050617	chr20:25421648	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050617	chr20:25421648	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050617	chr20:25421648	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050626	chr20:25428261	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050626	chr20:25428261	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050626	chr20:25428261	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050629	chr20:25430680	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050629	chr20:25430680	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050629	chr20:25430680	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050630	chr20:25430745	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050630	chr20:25430745	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050630	chr20:25430745	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050631	chr20:25431749	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.21E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050631	chr20:25431749	FAM182A	chr20:26035250-26067552:+	-0.56	-11.04	1.77E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050631	chr20:25431749	FAM182B	chr20:25744102-25848786:-	0.22	4.94	1.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050632	chr20:25432601	ABHD12	chr20:25275380-25371477:-	0.27	7.53	2.45E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050632	chr20:25432601	FAM182A	chr20:26035250-26067552:+	-0.54	-10.69	3.9E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6050632	chr20:25432601	FAM182B	chr20:25744102-25848786:-	0.22	4.95	1.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6051080	chr20:25975674	FAM182A	chr20:26035250-26067552:+	-0.2	-3.48	0.00054	Colorectal or endometrial cancer	
LGG	cis	1	rs6051080	chr20:25975674	FAM182B	chr20:25744102-25848786:-	0.42	9.41	1.97E-19	Colorectal or endometrial cancer	
LGG	cis	1	rs60512868	chr3:48483445	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.85E-6	Longevity	
LGG	cis	1	rs60512868	chr3:48483445	TREX1	chr3:48501186-48509043:+	-0.43	-11.08	1.32E-25	Longevity	
LGG	cis	1	rs6051672	chr20:3224819	ITPA	chr20:3190056-3204504:+	-0.37	-8.89	1.16E-17	IFN-related cytopenia	
LGG	cis	1	rs6051702	chr20:3251924	ITPA	chr20:3190056-3204504:+	-0.35	-8.37	5.99E-16	IFN-related cytopenia	
LGG	cis	1	rs6051703	chr20:3252347	ITPA	chr20:3190056-3204504:+	-0.35	-8.36	6.61E-16	IFN-related cytopenia	
LGG	cis	1	rs6051705	chr20:3253143	ITPA	chr20:3190056-3204504:+	-0.35	-8.36	6.61E-16	IFN-related cytopenia	
LGG	cis	1	rs6051708	chr20:3262493	ITPA	chr20:3190056-3204504:+	-0.38	-9.11	2.14E-18	IFN-related cytopenia	
LGG	cis	1	rs6051709	chr20:3263685	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051712	chr20:3265029	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051713	chr20:3265779	ITPA	chr20:3190056-3204504:+	0.37	8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051715	chr20:3266548	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051716	chr20:3267736	ITPA	chr20:3190056-3204504:+	-0.36	-8.42	4.12E-16	IFN-related cytopenia	
LGG	cis	1	rs6051718	chr20:3270370	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.37E-17	IFN-related cytopenia	
LGG	cis	1	rs6051722	chr20:3274435	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs6051723	chr20:3278512	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.37E-17	IFN-related cytopenia	
LGG	cis	1	rs6051724	chr20:3279338	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051732	chr20:3294182	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.37E-17	IFN-related cytopenia	
LGG	cis	1	rs6051736	chr20:3296898	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs6051737	chr20:3296992	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051745	chr20:3307243	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs6051747	chr20:3307945	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6051751	chr20:3310049	ITPA	chr20:3190056-3204504:+	-0.37	-8.86	1.53E-17	IFN-related cytopenia	
LGG	cis	1	rs6051753	chr20:3315513	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.32E-17	IFN-related cytopenia	
LGG	cis	1	rs6051762	chr20:3321590	ITPA	chr20:3190056-3204504:+	-0.35	-8.07	5.63E-15	IFN-related cytopenia	
LGG	cis	1	rs6051763	chr20:3321616	ITPA	chr20:3190056-3204504:+	-0.36	-8.5	2.28E-16	IFN-related cytopenia	
LGG	cis	1	rs6051764	chr20:3321807	ITPA	chr20:3190056-3204504:+	0.31	7.61	1.39E-13	IFN-related cytopenia	
LGG	cis	1	rs6051779	chr20:3333449	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6051790	chr20:3342994	ITPA	chr20:3190056-3204504:+	-0.35	-8.23	1.65E-15	IFN-related cytopenia	
LGG	cis	1	rs6051792	chr20:3343519	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6051806	chr20:3350319	ITPA	chr20:3190056-3204504:+	-0.36	-8.4	4.92E-16	IFN-related cytopenia	
LGG	cis	1	rs6051807	chr20:3350485	ITPA	chr20:3190056-3204504:+	-0.34	-7.95	1.27E-14	IFN-related cytopenia	
LGG	cis	1	rs6051808	chr20:3350697	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6051809	chr20:3352551	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6051810	chr20:3355384	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs6051827	chr20:3372007	ITPA	chr20:3190056-3204504:+	-0.36	-8.47	2.81E-16	IFN-related cytopenia	
LGG	cis	1	rs6051831	chr20:3373712	ITPA	chr20:3190056-3204504:+	0.34	7.97	1.13E-14	IFN-related cytopenia	
LGG	cis	1	rs6051838	chr20:3389012	ITPA	chr20:3190056-3204504:+	-0.36	-8.59	1.15E-16	IFN-related cytopenia	
LGG	cis	1	rs6053815	chr20:5970438	MCM8	chr20:5931298-5975829:+	-0.32	-8.26	1.4E-15	HIV-1 viral setpoint	
LGG	cis	1	rs6053816	chr20:5970750	MCM8	chr20:5931298-5975829:+	-0.33	-8.39	5.11E-16	HIV-1 viral setpoint	
LGG	cis	1	rs60554055	chr14:66068285	LOC645431	chr14:65877313-65879335:-	-0.46	-6.25	8.77E-10	Ischemic stroke	
LGG	cis	1	rs60555365	chr1:211590328	C1orf97	chr1:211556097-211605876:+	0.2	3.49	0.000518	Educational attainment (years of education)	
LGG	cis	1	rs60563713	chr5:78313516	BHMT	chr5:78407604-78428112:+	-0.18	-3.6	0.000355	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs6058352	chr20:30269179	BCL2L1	chr20:30252263-30311729:-	0.16	3.51	0.000483	Subcortical brain region volumes	
LGG	cis	1	rs6058352	chr20:30269179	COX4I2	chr20:30225691-30232800:+	0.19	4.33	1.78E-5	Subcortical brain region volumes	
LGG	cis	1	rs6058352	chr20:30269179	DUSP15	chr20:30435441-30458479:-	0.17	4.3	2.04E-5	Subcortical brain region volumes	
LGG	cis	1	rs6058352	chr20:30269179	FRG1B	chr20:29611879-29653908:+	0.2	3.66	0.000275	Subcortical brain region volumes	
LGG	cis	1	rs6058465	chr20:30397691	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6058465	chr20:30397691	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6058465	chr20:30397691	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6058465	chr20:30397691	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs6058468	chr20:30406448	BCL2L1	chr20:30252263-30311729:-	0.17	3.72	0.000223	Subcortical brain region volumes	
LGG	cis	1	rs6058468	chr20:30406448	COX4I2	chr20:30225691-30232800:+	0.2	4.55	6.87E-6	Subcortical brain region volumes	
LGG	cis	1	rs6058468	chr20:30406448	DUSP15	chr20:30435441-30458479:-	0.17	4.23	2.82E-5	Subcortical brain region volumes	
LGG	cis	1	rs6058468	chr20:30406448	FRG1B	chr20:29611879-29653908:+	0.21	3.81	0.000154	Subcortical brain region volumes	
LGG	cis	1	rs6060222	chr20:33682570	GDF5	chr20:33897002-34042568:-	0.26	3.58	0.00038	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060222	chr20:33682570	PROCR	chr20:33758727-33765164:+	-0.32	-6.19	1.3E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060230	chr20:33689308	GDF5	chr20:33897002-34042568:-	-0.27	-3.6	0.000348	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060230	chr20:33689308	PROCR	chr20:33758727-33765164:+	0.31	5.99	4.14E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060235	chr20:33691652	GDF5	chr20:33897002-34042568:-	0.28	3.57	0.000385	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060235	chr20:33691652	PROCR	chr20:33758727-33765164:+	-0.33	-6.11	2.06E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060236	chr20:33692618	GDF5	chr20:33897002-34042568:-	0.28	3.57	0.000385	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060236	chr20:33692618	PROCR	chr20:33758727-33765164:+	-0.33	-6.11	2.06E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060244	chr20:33699435	PROCR	chr20:33758727-33765164:+	0.36	6.92	1.39E-11	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060245	chr20:33699625	PROCR	chr20:33758727-33765164:+	-0.36	-6.54	1.57E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060246	chr20:33701107	PROCR	chr20:33758727-33765164:+	-0.35	-6.4	3.61E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6060401	chr20:34005214	CPNE1	chr20:34213968-34262539:-	0.26	5.6	3.63E-8	Height	
LGG	cis	1	rs6060401	chr20:34005214	GDF5	chr20:33897002-34042568:-	-0.36	-6.99	8.84E-12	Height	
LGG	cis	1	rs6060401	chr20:34005214	UQCC	chr20:33890383-33999833:-	0.24	5.02	7.2E-7	Height	
LGG	cis	1	rs6060402	chr20:34005240	CPNE1	chr20:34213968-34262539:-	0.26	5.5	6.05E-8	Height	
LGG	cis	1	rs6060402	chr20:34005240	GDF5	chr20:33897002-34042568:-	-0.36	-6.92	1.37E-11	Height	
LGG	cis	1	rs6060402	chr20:34005240	UQCC	chr20:33890383-33999833:-	0.24	5.21	2.8E-7	Height	
LGG	cis	1	rs60604866	chr2:242352257	ANO7	chr2:242127924-242164791:+	0.38	6.54	1.5E-10	Prostate cancer	
LGG	cis	1	rs6060599	chr20:30257754	COX4I2	chr20:30225691-30232800:+	0.19	4.35	1.68E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060599	chr20:30257754	DUSP15	chr20:30435441-30458479:-	0.17	4.18	3.45E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060599	chr20:30257754	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000115	Subcortical brain region volumes	
LGG	cis	1	rs6060621	chr20:30261562	COX4I2	chr20:30225691-30232800:+	0.18	4.22	2.96E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060621	chr20:30261562	DUSP15	chr20:30435441-30458479:-	0.17	4.25	2.57E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060621	chr20:30261562	FRG1B	chr20:29611879-29653908:+	0.2	3.74	0.000207	Subcortical brain region volumes	
LGG	cis	1	rs6060716	chr20:30274847	BCL2L1	chr20:30252263-30311729:-	0.16	3.51	0.000483	Subcortical brain region volumes	
LGG	cis	1	rs6060716	chr20:30274847	COX4I2	chr20:30225691-30232800:+	0.19	4.33	1.78E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060716	chr20:30274847	DUSP15	chr20:30435441-30458479:-	0.17	4.3	2.04E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060716	chr20:30274847	FRG1B	chr20:29611879-29653908:+	0.2	3.66	0.000275	Subcortical brain region volumes	
LGG	cis	1	rs6060857	chr20:30300222	BCL2L1	chr20:30252263-30311729:-	0.15	3.46	0.000579	Subcortical brain region volumes	
LGG	cis	1	rs6060857	chr20:30300222	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.33E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060857	chr20:30300222	DUSP15	chr20:30435441-30458479:-	0.17	4.22	2.89E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060857	chr20:30300222	FRG1B	chr20:29611879-29653908:+	0.21	3.87	0.000126	Subcortical brain region volumes	
LGG	cis	1	rs6060915	chr20:30330306	BCL2L1	chr20:30252263-30311729:-	0.16	3.6	0.000354	Subcortical brain region volumes	
LGG	cis	1	rs6060915	chr20:30330306	COX4I2	chr20:30225691-30232800:+	0.19	4.39	1.4E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060915	chr20:30330306	DUSP15	chr20:30435441-30458479:-	0.16	3.97	8.22E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060915	chr20:30330306	FRG1B	chr20:29611879-29653908:+	0.2	3.62	0.000327	Subcortical brain region volumes	
LGG	cis	1	rs6060919	chr20:30331922	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6060919	chr20:30331922	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060919	chr20:30331922	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060919	chr20:30331922	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs6060922	chr20:30333909	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6060922	chr20:30333909	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060922	chr20:30333909	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060922	chr20:30333909	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs6060932	chr20:30350545	BCL2L1	chr20:30252263-30311729:-	0.16	3.53	0.000463	Subcortical brain region volumes	
LGG	cis	1	rs6060932	chr20:30350545	COX4I2	chr20:30225691-30232800:+	0.19	4.41	1.28E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060932	chr20:30350545	DUSP15	chr20:30435441-30458479:-	0.17	4.23	2.74E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060932	chr20:30350545	FRG1B	chr20:29611879-29653908:+	0.21	3.9	0.00011	Subcortical brain region volumes	
LGG	cis	1	rs6060933	chr20:30351903	BCL2L1	chr20:30252263-30311729:-	0.16	3.51	0.000497	Subcortical brain region volumes	
LGG	cis	1	rs6060933	chr20:30351903	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.32E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060933	chr20:30351903	DUSP15	chr20:30435441-30458479:-	0.17	4.25	2.56E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060933	chr20:30351903	FRG1B	chr20:29611879-29653908:+	0.21	3.88	0.000118	Subcortical brain region volumes	
LGG	cis	1	rs6060944	chr20:30372114	BCL2L1	chr20:30252263-30311729:-	0.16	3.51	0.000497	Subcortical brain region volumes	
LGG	cis	1	rs6060944	chr20:30372114	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.32E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060944	chr20:30372114	DUSP15	chr20:30435441-30458479:-	0.17	4.25	2.56E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060944	chr20:30372114	FRG1B	chr20:29611879-29653908:+	0.21	3.88	0.000118	Subcortical brain region volumes	
LGG	cis	1	rs6060950	chr20:30378031	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6060950	chr20:30378031	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060950	chr20:30378031	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060950	chr20:30378031	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs6060962	chr20:30397847	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6060962	chr20:30397847	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060962	chr20:30397847	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6060962	chr20:30397847	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs606329	chr6:160718764	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs6063352	chr20:47718594	ARFGEF2	chr20:47538275-47653229:+	0.11	4.03	6.59E-5	Anger	
LGG	cis	1	rs6063352	chr20:47718594	CSE1L	chr20:47662838-47713484:+	0.19	5.04	6.66E-7	Anger	
LGG	cis	1	rs6063353	chr20:47719810	ARFGEF2	chr20:47538275-47653229:+	0.11	4.03	6.59E-5	Anger	
LGG	cis	1	rs6063353	chr20:47719810	CSE1L	chr20:47662838-47713484:+	0.19	5.04	6.66E-7	Anger	
LGG	cis	1	rs6063354	chr20:47719949	ARFGEF2	chr20:47538275-47653229:+	0.11	4.03	6.59E-5	Anger	
LGG	cis	1	rs6063354	chr20:47719949	CSE1L	chr20:47662838-47713484:+	0.19	5.04	6.66E-7	Anger	
LGG	cis	1	rs6063360	chr20:47748375	ARFGEF2	chr20:47538275-47653229:+	0.11	3.98	7.91E-5	Anger	
LGG	cis	1	rs6063360	chr20:47748375	CSE1L	chr20:47662838-47713484:+	0.18	4.94	1.07E-6	Anger	
LGG	cis	1	rs6063361	chr20:47757963	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs6063361	chr20:47757963	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs6065094	chr20:37453194	ACTR5	chr20:37377097-37401089:+	-0.21	-4.48	9.37E-6	Schizophrenia	
LGG	cis	1	rs60651159	chr8:58174074	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs60652129	chr2:207649313	MDH1B	chr2:207598943-207630050:-	0.35	5.31	1.65E-7	Episodic memory	
LGG	cis	1	rs6065945	chr20:44921631	WFDC3	chr20:44402847-44420547:-	0.23	4.34	1.77E-5	IgG glycosylation	
LGG	cis	1	rs6066968	chr20:47727341	ARFGEF2	chr20:47538275-47653229:+	0.11	4.02	6.74E-5	Anger	
LGG	cis	1	rs6066968	chr20:47727341	CSE1L	chr20:47662838-47713484:+	0.18	5	7.87E-7	Anger	
LGG	cis	1	rs6066975	chr20:47750377	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.16	3.68E-5	Anger	
LGG	cis	1	rs6066975	chr20:47750377	CSE1L	chr20:47662838-47713484:+	-0.19	-4.98	8.63E-7	Anger	
LGG	cis	1	rs6066977	chr20:47755075	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.31E-5	Anger	
LGG	cis	1	rs6066977	chr20:47755075	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.07E-7	Anger	
LGG	cis	1	rs6066978	chr20:47755742	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs6066978	chr20:47755742	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs6066982	chr20:47763558	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs6066982	chr20:47763558	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs60683927	chr7:65394768	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs6070692	chr20:57586374	TH1L	chr20:57556311-57570186:+	-0.26	-4.38	1.45E-5	Mean platelet volume	
LGG	cis	1	rs6070696	chr20:57597645	TH1L	chr20:57556311-57570186:+	-0.27	-4.97	9.16E-7	Mean platelet volume	
LGG	cis	1	rs6070697	chr20:57599402	TH1L	chr20:57556311-57570186:+	-0.28	-4.86	1.57E-6	Mean platelet volume	
LGG	cis	1	rs60710459	chr2:48687857	FOXN2	chr2:48541795-48606434:+	0.28	5.75	1.58E-8	Schizophrenia	
LGG	cis	1	rs60719662	chr6:163006643	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs6074022	chr20:44740196	CD40	chr20:44746906-44758384:+	0.22	5.47	7.27E-8	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis	
LGG	cis	1	rs607446	chr11:71789252	FAM86C	chr11:71498557-71512276:+	0.5	4.92	1.19E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs607484	chr1:168687512	SELL	chr1:169659810-169680837:-	-0.19	-3.99	7.47E-5	QT interval	
LGG	cis	1	rs60750097	chr12:101743608	UTP20	chr12:101673905-101780397:+	-0.16	-3.48	0.000542	Alcohol dependence (age at onset)	
LGG	cis	1	rs607541	chr15:45934869	SPATA5L1	chr15:45694519-45713614:+	0.28	4.33	1.82E-5	Obesity-related traits	
LGG	cis	1	rs607594	chr15:45934840	SPATA5L1	chr15:45694519-45713614:+	0.28	4.33	1.82E-5	Obesity-related traits	
LGG	cis	1	rs6076336	chr20:25319212	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076336	chr20:25319212	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076336	chr20:25319212	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076339	chr20:25348712	ABHD12	chr20:25275380-25371477:-	-0.28	-7.67	9.08E-14	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076339	chr20:25348712	FAM182A	chr20:26035250-26067552:+	0.54	10.61	8.42E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076339	chr20:25348712	FAM182B	chr20:25744102-25848786:-	-0.22	-5	7.81E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076345	chr20:25381895	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076345	chr20:25381895	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6076345	chr20:25381895	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs608086	chr11:108185023	ATM	chr11:108093559-108239826:+	-0.11	-3.46	0.000589	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6083804	chr20:25317060	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083804	chr20:25317060	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083804	chr20:25317060	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083805	chr20:25317356	ABHD12	chr20:25275380-25371477:-	-0.27	-7.29	1.22E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083805	chr20:25317356	FAM182A	chr20:26035250-26067552:+	0.56	11.05	1.69E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083805	chr20:25317356	FAM182B	chr20:25744102-25848786:-	-0.21	-4.76	2.53E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083809	chr20:25329309	ABHD12	chr20:25275380-25371477:-	-0.27	-7.46	4.07E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083809	chr20:25329309	FAM182A	chr20:26035250-26067552:+	0.54	10.72	3.18E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083809	chr20:25329309	FAM182B	chr20:25744102-25848786:-	-0.21	-4.81	2.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083813	chr20:25337671	ABHD12	chr20:25275380-25371477:-	-0.28	-7.59	1.64E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083813	chr20:25337671	FAM182A	chr20:26035250-26067552:+	0.54	10.65	5.56E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083813	chr20:25337671	FAM182B	chr20:25744102-25848786:-	-0.21	-4.79	2.23E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083825	chr20:25366424	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083825	chr20:25366424	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083825	chr20:25366424	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083828	chr20:25369918	ABHD12	chr20:25275380-25371477:-	-0.28	-7.6	1.49E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083828	chr20:25369918	FAM182A	chr20:26035250-26067552:+	0.55	10.95	3.96E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083828	chr20:25369918	FAM182B	chr20:25744102-25848786:-	-0.22	-4.86	1.55E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083844	chr20:25386832	ABHD12	chr20:25275380-25371477:-	-0.28	-7.6	1.55E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083844	chr20:25386832	FAM182A	chr20:26035250-26067552:+	0.53	10.45	3.32E-23	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083844	chr20:25386832	FAM182B	chr20:25744102-25848786:-	-0.22	-4.89	1.38E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083856	chr20:25407585	ABHD12	chr20:25275380-25371477:-	-0.27	-7.27	1.39E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083856	chr20:25407585	FAM182A	chr20:26035250-26067552:+	0.56	11.07	1.35E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083856	chr20:25407585	FAM182B	chr20:25744102-25848786:-	-0.22	-4.89	1.38E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083862	chr20:25411086	ABHD12	chr20:25275380-25371477:-	-0.28	-7.66	9.75E-14	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083862	chr20:25411086	FAM182A	chr20:26035250-26067552:+	0.51	9.74	1.34E-20	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6083862	chr20:25411086	FAM182B	chr20:25744102-25848786:-	-0.19	-4.28	2.29E-5	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs60843830	chr2:286756	FAM150B	chr2:279563-288308:-	-0.33	-6.13	1.85E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60843830	chr2:286756	SNTG2	chr2:946555-1371382:+	0.21	3.73	0.000214	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.39	7.07	5.42E-12	Metabolite levels	
LGG	cis	1	rs60844734	chr2:73623205	NAT8	chr2:73867850-73869537:-	0.25	4.16	3.79E-5	Metabolite levels	
LGG	cis	1	rs60854219	chr18:44646664	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs60866116	chr20:33726150	PROCR	chr20:33758727-33765164:+	-0.32	-6.02	3.38E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs60871858	chr7:33258937	BBS9	chr7:33169152-33645680:+	0.42	5.76	1.46E-8	Smooth-surface caries	
LGG	cis	1	rs6087698	chr20:33948919	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6087698	chr20:33948919	GDF5	chr20:33897002-34042568:-	-0.38	-7.48	3.39E-13	Height	
LGG	cis	1	rs6087698	chr20:33948919	UQCC	chr20:33890383-33999833:-	0.23	5	7.99E-7	Height	
LGG	cis	1	rs6087702	chr20:33995945	CPNE1	chr20:34213968-34262539:-	0.26	5.66	2.55E-8	Height	
LGG	cis	1	rs6087702	chr20:33995945	GDF5	chr20:33897002-34042568:-	-0.37	-7.33	9.25E-13	Height	
LGG	cis	1	rs6087702	chr20:33995945	UQCC	chr20:33890383-33999833:-	0.23	5.06	5.96E-7	Height	
LGG	cis	1	rs6087703	chr20:33996433	CPNE1	chr20:34213968-34262539:-	0.26	5.73	1.79E-8	Height	
LGG	cis	1	rs6087703	chr20:33996433	GDF5	chr20:33897002-34042568:-	-0.37	-7.36	7.83E-13	Height	
LGG	cis	1	rs6087703	chr20:33996433	UQCC	chr20:33890383-33999833:-	0.24	5.11	4.69E-7	Height	
LGG	cis	1	rs6087704	chr20:34001058	CPNE1	chr20:34213968-34262539:-	0.26	5.73	1.79E-8	Height	
LGG	cis	1	rs6087704	chr20:34001058	GDF5	chr20:33897002-34042568:-	-0.37	-7.36	7.83E-13	Height	
LGG	cis	1	rs6087704	chr20:34001058	UQCC	chr20:33890383-33999833:-	0.24	5.11	4.69E-7	Height	
LGG	cis	1	rs6087705	chr20:34001250	CPNE1	chr20:34213968-34262539:-	0.26	5.66	2.64E-8	Height	
LGG	cis	1	rs6087705	chr20:34001250	GDF5	chr20:33897002-34042568:-	-0.37	-7.36	7.65E-13	Height	
LGG	cis	1	rs6087705	chr20:34001250	UQCC	chr20:33890383-33999833:-	0.23	5.01	7.5E-7	Height	
LGG	cis	1	rs6087771	chr20:30306724	BCL2L1	chr20:30252263-30311729:-	0.16	3.49	0.000517	Subcortical brain region volumes	
LGG	cis	1	rs6087771	chr20:30306724	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.35E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087771	chr20:30306724	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.41E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087771	chr20:30306724	FRG1B	chr20:29611879-29653908:+	0.21	3.89	0.000114	Subcortical brain region volumes	
LGG	cis	1	rs6087779	chr20:30370566	BCL2L1	chr20:30252263-30311729:-	0.16	3.51	0.000497	Subcortical brain region volumes	
LGG	cis	1	rs6087779	chr20:30370566	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.32E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087779	chr20:30370566	DUSP15	chr20:30435441-30458479:-	0.17	4.25	2.56E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087779	chr20:30370566	FRG1B	chr20:29611879-29653908:+	0.21	3.88	0.000118	Subcortical brain region volumes	
LGG	cis	1	rs6087782	chr20:30391580	BCL2L1	chr20:30252263-30311729:-	0.15	3.45	0.000601	Subcortical brain region volumes	
LGG	cis	1	rs6087782	chr20:30391580	COX4I2	chr20:30225691-30232800:+	0.19	4.44	1.09E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087782	chr20:30391580	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.5E-5	Subcortical brain region volumes	
LGG	cis	1	rs6087782	chr20:30391580	FRG1B	chr20:29611879-29653908:+	0.22	4.1	4.93E-5	Subcortical brain region volumes	
LGG	cis	1	rs6088799	chr20:33934301	CPNE1	chr20:34213968-34262539:-	0.27	5.86	8.52E-9	Height	
LGG	cis	1	rs6088799	chr20:33934301	GDF5	chr20:33897002-34042568:-	-0.38	-7.45	4.28E-13	Height	
LGG	cis	1	rs6088799	chr20:33934301	UQCC	chr20:33890383-33999833:-	0.23	4.97	9.08E-7	Height	
LGG	cis	1	rs6088812	chr20:33974163	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6088812	chr20:33974163	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6088812	chr20:33974163	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6088813	chr20:33975181	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6088813	chr20:33975181	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6088813	chr20:33975181	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6088815	chr20:33976474	CPNE1	chr20:34213968-34262539:-	0.27	5.77	1.4E-8	Height	
LGG	cis	1	rs6088815	chr20:33976474	GDF5	chr20:33897002-34042568:-	-0.37	-7.32	1.04E-12	Height	
LGG	cis	1	rs6088815	chr20:33976474	UQCC	chr20:33890383-33999833:-	0.24	5.2	2.87E-7	Height	
LGG	cis	1	rs6088816	chr20:33982435	CPNE1	chr20:34213968-34262539:-	0.27	5.86	8.29E-9	Height	
LGG	cis	1	rs6088816	chr20:33982435	GDF5	chr20:33897002-34042568:-	-0.38	-7.42	5.05E-13	Height	
LGG	cis	1	rs6088816	chr20:33982435	UQCC	chr20:33890383-33999833:-	0.23	4.98	8.86E-7	Height	
LGG	cis	1	rs6088820	chr20:33987298	CPNE1	chr20:34213968-34262539:-	0.27	5.77	1.4E-8	Height	
LGG	cis	1	rs6088820	chr20:33987298	GDF5	chr20:33897002-34042568:-	-0.37	-7.32	1.04E-12	Height	
LGG	cis	1	rs6088820	chr20:33987298	UQCC	chr20:33890383-33999833:-	0.24	5.2	2.87E-7	Height	
LGG	cis	1	rs6088821	chr20:33987576	CPNE1	chr20:34213968-34262539:-	0.27	5.83	9.87E-9	Height	
LGG	cis	1	rs6088821	chr20:33987576	GDF5	chr20:33897002-34042568:-	-0.37	-7.34	8.8E-13	Height	
LGG	cis	1	rs6088821	chr20:33987576	UQCC	chr20:33890383-33999833:-	0.24	5.25	2.26E-7	Height	
LGG	cis	1	rs6088823	chr20:33994265	CPNE1	chr20:34213968-34262539:-	0.26	5.73	1.79E-8	Height	
LGG	cis	1	rs6088823	chr20:33994265	GDF5	chr20:33897002-34042568:-	-0.37	-7.36	7.83E-13	Height	
LGG	cis	1	rs6088823	chr20:33994265	UQCC	chr20:33890383-33999833:-	0.24	5.11	4.69E-7	Height	
LGG	cis	1	rs6088825	chr20:33995972	CPNE1	chr20:34213968-34262539:-	0.26	5.76	1.52E-8	Height	
LGG	cis	1	rs6088825	chr20:33995972	GDF5	chr20:33897002-34042568:-	-0.38	-7.44	4.52E-13	Height	
LGG	cis	1	rs6088825	chr20:33995972	UQCC	chr20:33890383-33999833:-	0.22	4.84	1.76E-6	Height	
LGG	cis	1	rs6091233	chr20:49511907	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs6091236	chr20:49516995	SNAI1	chr20:48599527-48605418:+	-0.26	-3.49	0.000533	Prostate cancer	
LGG	cis	1	rs6091237	chr20:49525987	SNAI1	chr20:48599527-48605418:+	-0.27	-3.58	0.000376	Prostate cancer	
LGG	cis	1	rs609181	chr11:71569672	FAM86C	chr11:71498557-71512276:+	-0.45	-4.53	7.51E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs609261	chr11:108158134	ATM	chr11:108093559-108239826:+	-0.11	-3.53	0.000457	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs60927973	chr14:65897331	LOC645431	chr14:65877313-65879335:-	-0.52	-6.96	1.09E-11	Ischemic stroke	
LGG	cis	1	rs60936033	chr14:65856983	LOC645431	chr14:65877313-65879335:-	-0.43	-6.08	2.35E-9	Ischemic stroke	
LGG	cis	1	rs60942639	chr14:66107636	LOC645431	chr14:65877313-65879335:-	-0.5	-6.63	9.14E-11	Ischemic stroke	
LGG	cis	1	rs6094272	chr20:44918218	WFDC3	chr20:44402847-44420547:-	0.22	4.12	4.47E-5	IgG glycosylation	
LGG	cis	1	rs6095357	chr20:47523865	ARFGEF2	chr20:47538275-47653229:+	-0.1	-3.47	0.000565	Schizophrenia	
LGG	cis	1	rs6095357	chr20:47523865	CSE1L	chr20:47662838-47713484:+	-0.17	-4.51	8.25E-6	Schizophrenia	
LGG	cis	1	rs60957376	chr15:85280792	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.41	1.26E-5	Schizophrenia	
LGG	cis	1	rs60957376	chr15:85280792	LOC388152	chr15:84867600-84898920:-	-0.3	-5.63	3.07E-8	Schizophrenia	
LGG	cis	1	rs60957376	chr15:85280792	WDR73	chr15:85186012-85197524:-	-0.19	-3.58	0.000374	Schizophrenia	
LGG	cis	1	rs60967688	chr17:28437052	EFCAB5	chr17:28256874-28435469:+	0.22	6.01	3.68E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs60982898	chr6:49385806	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs610041	chr11:71797968	FAM86C	chr11:71498557-71512276:+	0.48	4.65	4.34E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs61013045	chr2:105370775	MRPS9	chr2:105654483-105716417:+	-0.24	-3.88	0.000119	Pancreatic cancer	
LGG	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.52	-11.28	2.05E-26	Forced vital capacity	
LGG	cis	1	rs61038704	chr14:66172300	LOC645431	chr14:65877313-65879335:-	-0.47	-6.16	1.53E-9	Ischemic stroke	
LGG	cis	1	rs61044849	chr3:128065466	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.17	3.57E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs61044849	chr3:128065466	LOC90246	chr3:128226678-128229427:+	-0.29	-3.52	0.000468	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6107033	chr20:25363591	ABHD12	chr20:25275380-25371477:-	-0.28	-7.67	9.08E-14	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107033	chr20:25363591	FAM182A	chr20:26035250-26067552:+	0.54	10.61	8.42E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107033	chr20:25363591	FAM182B	chr20:25744102-25848786:-	-0.22	-5	7.81E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107045	chr20:25441936	ABHD12	chr20:25275380-25371477:-	0.27	7.26	1.54E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107045	chr20:25441936	FAM182A	chr20:26035250-26067552:+	-0.56	-11.15	7.11E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107045	chr20:25441936	FAM182B	chr20:25744102-25848786:-	0.22	4.85	1.65E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107046	chr20:25442049	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.3E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107046	chr20:25442049	FAM182A	chr20:26035250-26067552:+	-0.57	-11.21	4.07E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107046	chr20:25442049	FAM182B	chr20:25744102-25848786:-	0.22	4.88	1.44E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107047	chr20:25442097	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.3E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107047	chr20:25442097	FAM182A	chr20:26035250-26067552:+	-0.57	-11.21	4.07E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6107047	chr20:25442097	FAM182B	chr20:25744102-25848786:-	0.22	4.88	1.44E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.19	3.06E-7	Body mass index	
LGG	cis	1	rs61102033	chr1:46382441	MUTYH	chr1:45794915-45806142:-	0.14	5.04	6.47E-7	Body mass index	
LGG	cis	1	rs61132622	chr5:93539684	FAM172A	chr5:92953432-93447404:-	-0.28	-3.91	0.000106	Diabetic retinopathy	
LGG	cis	1	rs61138004	chr3:20145855	EFHB	chr3:19920968-19988501:-	0.38	4.98	8.61E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs61142792	chr5:176983463	DOK3	chr5:176928915-176937427:-	0.22	3.89	0.000116	Alzheimer disease and age of onset	
LGG	cis	1	rs6115140	chr20:25285507	ABHD12	chr20:25275380-25371477:-	0.27	7.38	6.89E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115140	chr20:25285507	FAM182A	chr20:26035250-26067552:+	-0.56	-11.04	1.91E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115140	chr20:25285507	FAM182B	chr20:25744102-25848786:-	0.21	4.82	1.94E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115146	chr20:25304507	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115146	chr20:25304507	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115146	chr20:25304507	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115153	chr20:25325567	ABHD12	chr20:25275380-25371477:-	-0.27	-7.46	4.07E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115153	chr20:25325567	FAM182A	chr20:26035250-26067552:+	0.54	10.72	3.18E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115153	chr20:25325567	FAM182B	chr20:25744102-25848786:-	-0.21	-4.81	2.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115159	chr20:25350944	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115159	chr20:25350944	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115159	chr20:25350944	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115168	chr20:25372891	ABHD12	chr20:25275380-25371477:-	-0.28	-7.64	1.18E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115168	chr20:25372891	FAM182A	chr20:26035250-26067552:+	0.54	10.66	5.34E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115168	chr20:25372891	FAM182B	chr20:25744102-25848786:-	-0.22	-4.87	1.54E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115182	chr20:25410259	ABHD12	chr20:25275380-25371477:-	-0.27	-7.53	2.5E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115182	chr20:25410259	FAM182A	chr20:26035250-26067552:+	0.54	10.71	3.51E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115182	chr20:25410259	FAM182B	chr20:25744102-25848786:-	-0.22	-4.93	1.1E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115191	chr20:25440478	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.3E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115191	chr20:25440478	FAM182A	chr20:26035250-26067552:+	-0.57	-11.21	4.07E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6115191	chr20:25440478	FAM182B	chr20:25744102-25848786:-	0.22	4.88	1.44E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6119650	chr20:30258480	COX4I2	chr20:30225691-30232800:+	0.18	4.23	2.85E-5	Subcortical brain region volumes	
LGG	cis	1	rs6119650	chr20:30258480	DUSP15	chr20:30435441-30458479:-	0.17	4.26	2.43E-5	Subcortical brain region volumes	
LGG	cis	1	rs6119650	chr20:30258480	FRG1B	chr20:29611879-29653908:+	0.2	3.72	0.000226	Subcortical brain region volumes	
LGG	cis	1	rs6119652	chr20:30259445	COX4I2	chr20:30225691-30232800:+	0.19	4.31	1.94E-5	Subcortical brain region volumes	
LGG	cis	1	rs6119652	chr20:30259445	DUSP15	chr20:30435441-30458479:-	0.17	4.21	3.03E-5	Subcortical brain region volumes	
LGG	cis	1	rs6119652	chr20:30259445	FRG1B	chr20:29611879-29653908:+	0.21	3.9	0.000109	Subcortical brain region volumes	
LGG	cis	1	rs61204066	chr15:78815298	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.72	5.06E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6120849	chr20:33730387	EDEM2	chr20:33703160-33865928:-	-0.15	-4.04	6.25E-5	Protein C levels	
LGG	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.63	-11.02	2.12E-25	Triglycerides	
LGG	cis	1	rs6121038	chr20:30254773	COX4I2	chr20:30225691-30232800:+	0.2	4.72	3.12E-6	Subcortical brain region volumes	
LGG	cis	1	rs6121038	chr20:30254773	DUSP15	chr20:30435441-30458479:-	0.16	4.04	6.19E-5	Subcortical brain region volumes	
LGG	cis	1	rs6121038	chr20:30254773	FRG1B	chr20:29611879-29653908:+	0.21	3.94	9.48E-5	Subcortical brain region volumes	
LGG	cis	1	rs6121172	chr20:30296095	COX4I2	chr20:30225691-30232800:+	0.19	4.4	1.31E-5	Subcortical brain region volumes	
LGG	cis	1	rs6121172	chr20:30296095	DUSP15	chr20:30435441-30458479:-	0.17	4.13	4.18E-5	Subcortical brain region volumes	
LGG	cis	1	rs6121172	chr20:30296095	FRG1B	chr20:29611879-29653908:+	0.21	3.81	0.000155	Subcortical brain region volumes	
LGG	cis	1	rs61212428	chr8:58173963	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6121243	chr20:30415094	BCL2L1	chr20:30252263-30311729:-	0.16	3.56	0.000411	Subcortical brain region volumes	
LGG	cis	1	rs6121243	chr20:30415094	COX4I2	chr20:30225691-30232800:+	0.2	4.53	7.56E-6	Subcortical brain region volumes	
LGG	cis	1	rs6121243	chr20:30415094	DUSP15	chr20:30435441-30458479:-	0.17	4.31	1.97E-5	Subcortical brain region volumes	
LGG	cis	1	rs6121243	chr20:30415094	FRG1B	chr20:29611879-29653908:+	0.21	3.88	0.000117	Subcortical brain region volumes	
LGG	cis	1	rs6122763	chr20:47797653	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.14	4.14E-5	Anger	
LGG	cis	1	rs6122763	chr20:47797653	CSE1L	chr20:47662838-47713484:+	-0.19	-5.11	4.68E-7	Anger	
LGG	cis	1	rs6124684	chr20:43721493	STK4	chr20:43595120-43708591:+	0.14	3.65	0.000291	Bipolar disorder	
LGG	cis	1	rs6125539	chr20:47703810	ARFGEF2	chr20:47538275-47653229:+	0.12	4.29	2.16E-5	Anger	
LGG	cis	1	rs6125539	chr20:47703810	CSE1L	chr20:47662838-47713484:+	0.2	5.36	1.28E-7	Anger	
LGG	cis	1	rs6125540	chr20:47704039	ARFGEF2	chr20:47538275-47653229:+	0.11	4.07	5.59E-5	Anger	
LGG	cis	1	rs6125540	chr20:47704039	CSE1L	chr20:47662838-47713484:+	0.17	4.55	6.84E-6	Anger	
LGG	cis	1	rs6125576	chr20:47776919	ARFGEF2	chr20:47538275-47653229:+	0.11	4.16	3.75E-5	Anger	
LGG	cis	1	rs6125576	chr20:47776919	CSE1L	chr20:47662838-47713484:+	0.2	5.35	1.38E-7	Anger	
LGG	cis	1	rs61270113	chr5:150226263	LOC134466	chr5:150310000-150326146:-	0.39	4.5	8.38E-6	Crohn's disease	
LGG	cis	1	rs6127911	chr20:55616909	CTCFL	chr20:56063880-56100708:-	0.25	3.71	0.000227	Response to citalopram treatment	
LGG	cis	1	rs6127914	chr20:55623806	CTCFL	chr20:56063880-56100708:-	0.27	3.93	9.56E-5	Response to citalopram treatment	
LGG	cis	1	rs61312893	chr17:45325023	ITGB3	chr17:45331208-45421658:+	-0.22	-4.57	6.14E-6	Body mass index	
LGG	cis	1	rs61315421	chr14:66076603	LOC645431	chr14:65877313-65879335:-	-0.49	-6.43	3.04E-10	Ischemic stroke	
LGG	cis	1	rs61316646	chr18:44610670	HDHD2	chr18:44633782-44676871:-	0.4	4.09	5.05E-5	Sitting height ratio	
LGG	cis	1	rs6132835	chr20:25434667	ABHD12	chr20:25275380-25371477:-	0.26	7.14	3.44E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6132835	chr20:25434667	FAM182A	chr20:26035250-26067552:+	-0.55	-10.83	1.17E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6132835	chr20:25434667	FAM182B	chr20:25744102-25848786:-	0.21	4.81	2.03E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6133036	chr20:3349682	ITPA	chr20:3190056-3204504:+	-0.35	-8.28	1.19E-15	IFN-related cytopenia	
LGG	cis	1	rs61360320	chr17:61800392	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs61360320	chr17:61800392	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs61360320	chr17:61800392	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs61378129	chr13:36684353	SOHLH2	chr13:36742347-36871992:-	0.39	5.88	7.62E-9	Optic cup area	
LGG	cis	1	rs6138572	chr20:25435934	ABHD12	chr20:25275380-25371477:-	0.27	7.24	1.69E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6138572	chr20:25435934	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	3.15E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6138572	chr20:25435934	FAM182B	chr20:25744102-25848786:-	0.22	4.98	8.86E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6138575	chr20:25438952	ABHD12	chr20:25275380-25371477:-	0.27	7.24	1.69E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6138575	chr20:25438952	FAM182A	chr20:26035250-26067552:+	-0.57	-11.24	3.15E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6138575	chr20:25438952	FAM182B	chr20:25744102-25848786:-	0.22	4.98	8.86E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6139064	chr20:3277050	ITPA	chr20:3190056-3204504:+	-0.37	-8.75	3.55E-17	IFN-related cytopenia	
LGG	cis	1	rs6139068	chr20:3284393	ITPA	chr20:3190056-3204504:+	-0.37	-8.87	1.37E-17	IFN-related cytopenia	
LGG	cis	1	rs6139088	chr20:3329063	ITPA	chr20:3190056-3204504:+	-0.36	-8.39	5.38E-16	IFN-related cytopenia	
LGG	cis	1	rs6139103	chr20:3361140	ITPA	chr20:3190056-3204504:+	-0.36	-8.41	4.6E-16	IFN-related cytopenia	
LGG	cis	1	rs61394483	chr6:33751945	LEMD2	chr6:33738991-33756906:-	0.18	5.4	1.04E-7	Body mass index	
LGG	cis	1	rs6141546	chr20:33949282	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6141546	chr20:33949282	GDF5	chr20:33897002-34042568:-	-0.38	-7.48	3.39E-13	Height	
LGG	cis	1	rs6141546	chr20:33949282	UQCC	chr20:33890383-33999833:-	0.23	5	7.99E-7	Height	
LGG	cis	1	rs6141548	chr20:33971085	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6141548	chr20:33971085	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6141548	chr20:33971085	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6141549	chr20:33974051	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6141549	chr20:33974051	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6141549	chr20:33974051	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6141	chr3:184090266	CLCN2	chr3:184064340-184079391:-	0.12	3.56	0.00041	Platelet count;Diisocyanate-induced asthma	
LGG	cis	1	rs6142358	chr20:33960308	CPNE1	chr20:34213968-34262539:-	-0.26	-5.54	5.04E-8	Height	
LGG	cis	1	rs6142358	chr20:33960308	GDF5	chr20:33897002-34042568:-	0.38	7.56	1.96E-13	Height	
LGG	cis	1	rs6142358	chr20:33960308	UQCC	chr20:33890383-33999833:-	-0.21	-4.53	7.41E-6	Height	
LGG	cis	1	rs6142359	chr20:33960450	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6142359	chr20:33960450	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6142359	chr20:33960450	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6142360	chr20:33960486	CPNE1	chr20:34213968-34262539:-	0.26	5.6	3.48E-8	Height	
LGG	cis	1	rs6142360	chr20:33960486	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.96E-13	Height	
LGG	cis	1	rs6142360	chr20:33960486	PROCR	chr20:33758727-33765164:+	0.13	3.51	0.000494	Height	
LGG	cis	1	rs6142360	chr20:33960486	UQCC	chr20:33890383-33999833:-	0.24	5.18	3.22E-7	Height	
LGG	cis	1	rs6142369	chr20:33973315	CPNE1	chr20:34213968-34262539:-	0.27	5.83	9.87E-9	Height	
LGG	cis	1	rs6142369	chr20:33973315	GDF5	chr20:33897002-34042568:-	-0.37	-7.34	8.8E-13	Height	
LGG	cis	1	rs6142369	chr20:33973315	UQCC	chr20:33890383-33999833:-	0.24	5.25	2.26E-7	Height	
LGG	cis	1	rs6142370	chr20:33973378	CPNE1	chr20:34213968-34262539:-	0.27	5.79	1.27E-8	Height	
LGG	cis	1	rs6142370	chr20:33973378	GDF5	chr20:33897002-34042568:-	-0.38	-7.46	3.98E-13	Height	
LGG	cis	1	rs6142370	chr20:33973378	UQCC	chr20:33890383-33999833:-	0.23	4.93	1.13E-6	Height	
LGG	cis	1	rs6142373	chr20:33983314	CPNE1	chr20:34213968-34262539:-	0.27	5.77	1.4E-8	Height	
LGG	cis	1	rs6142373	chr20:33983314	GDF5	chr20:33897002-34042568:-	-0.37	-7.32	1.04E-12	Height	
LGG	cis	1	rs6142373	chr20:33983314	UQCC	chr20:33890383-33999833:-	0.24	5.2	2.87E-7	Height	
LGG	cis	1	rs6142374	chr20:33985568	CPNE1	chr20:34213968-34262539:-	0.27	5.83	9.87E-9	Height	
LGG	cis	1	rs6142374	chr20:33985568	GDF5	chr20:33897002-34042568:-	-0.37	-7.34	8.8E-13	Height	
LGG	cis	1	rs6142374	chr20:33985568	UQCC	chr20:33890383-33999833:-	0.24	5.25	2.26E-7	Height	
LGG	cis	1	rs6142376	chr20:33992761	CPNE1	chr20:34213968-34262539:-	0.27	5.86	8.29E-9	Height	
LGG	cis	1	rs6142376	chr20:33992761	GDF5	chr20:33897002-34042568:-	-0.38	-7.42	5.05E-13	Height	
LGG	cis	1	rs6142376	chr20:33992761	UQCC	chr20:33890383-33999833:-	0.23	4.98	8.86E-7	Height	
LGG	cis	1	rs6142379	chr20:33999267	CPNE1	chr20:34213968-34262539:-	0.26	5.73	1.79E-8	Height	
LGG	cis	1	rs6142379	chr20:33999267	GDF5	chr20:33897002-34042568:-	-0.37	-7.36	7.83E-13	Height	
LGG	cis	1	rs6142379	chr20:33999267	UQCC	chr20:33890383-33999833:-	0.24	5.11	4.69E-7	Height	
LGG	cis	1	rs61424916	chr2:105390188	MRPS9	chr2:105654483-105716417:+	-0.25	-4.19	3.24E-5	Pancreatic cancer	
LGG	cis	1	rs61457790	chr3:20136186	EFHB	chr3:19920968-19988501:-	0.39	5.14	4.02E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs61505517	chr5:176982391	DOK3	chr5:176928915-176937427:-	0.22	3.89	0.000116	Alzheimer disease and age of onset	
LGG	cis	1	rs61508494	chr14:55587297	FBXO34	chr14:55738021-55893431:+	0.14	4.15	3.96E-5	Protein biomarker	
LGG	cis	1	rs6151429	chr22:51063477	ARSA	chr22:51063450-51066607:-	-0.61	-8.51	2.11E-16	Blood metabolite levels	
LGG	cis	1	rs61517255	chr10:17208918	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.47	9.85E-6	Homocysteine levels	
LGG	cis	1	rs61524473	chr15:45646283	GATM	chr15:45653324-45670980:-	-0.25	-4.58	6.0E-6	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs61524473	chr15:45646283	SPATA5L1	chr15:45694519-45713614:+	0.59	11.37	9.12E-27	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs61530785	chr5:150261364	LOC134466	chr5:150310000-150326146:-	0.47	5.13	4.09E-7	Crohn's disease	
LGG	cis	1	rs61558956	chr3:158452655	RARRES1	chr3:158414899-158450275:-	0.23	3.52	0.000479	Tetralogy of Fallot	
LGG	cis	1	rs615695	chr11:103068444	DYNC2H1	chr11:102980160-103350591:+	0.18	3.58	0.000376	Spine bone mineral density and alcohol drinking	
LGG	cis	1	rs616147	chr3:39534481	RPSA	chr3:39448204-39454030:+	0.22	5.09	4.99E-7	Corticobasal degeneration;Progressive supranuclear palsy	
LGG	cis	1	rs61662306	chr6:33746697	LEMD2	chr6:33738991-33756906:-	0.19	5.67	2.46E-8	Body mass index	
LGG	cis	1	rs61675148	chr22:32746276	SLC5A4	chr22:32614465-32651318:-	-0.52	-6.24	9.23E-10	Cerebrospinal T-tau levels	
LGG	cis	1	rs617219	chr5:78429594	DMGDH	chr5:78293430-78365449:-	-0.18	-3.84	0.000139	Betaine levels in individuals undergoing cardiac evaluation	
LGG	cis	1	rs61733801	chr8:58192513	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs61744385	chr3:41756986	ULK4	chr3:41288091-42003660:-	0.71	12.94	3.55E-33	Diastolic blood pressure	
LGG	cis	1	rs61744388	chr3:41756965	ULK4	chr3:41288091-42003660:-	0.71	12.94	3.55E-33	Diastolic blood pressure	
LGG	cis	1	rs61776516	chr1:12047028	MIIP	chr1:12079512-12092106:+	0.09	3.53	0.000452	Platelet count	
LGG	cis	1	rs61780780	chr1:31864183	ZCCHC17	chr1:31769842-31837780:+	-0.16	-4.02	6.73E-5	Schizophrenia	
LGG	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.02	7.37E-7	Body mass index	
LGG	cis	1	rs61783200	chr1:46297403	MUTYH	chr1:45794915-45806142:-	0.14	5.02	7.23E-7	Body mass index	
LGG	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.17	-5	8.18E-7	Body mass index	
LGG	cis	1	rs61783220	chr1:46335312	MUTYH	chr1:45794915-45806142:-	0.14	5.17	3.37E-7	Body mass index	
LGG	cis	1	rs61792114	chr4:289139	ZNF718	chr4:53272-156488:+	0.23	4.65	4.24E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61792116	chr4:301077	ZNF718	chr4:53272-156488:+	0.28	5.38	1.15E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61794996	chr4:209328	ZNF718	chr4:53272-156488:+	0.26	4.99	8.48E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61794997	chr4:222103	ZNF718	chr4:53272-156488:+	0.28	5.41	9.74E-8	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61795001	chr4:242057	ZNF718	chr4:53272-156488:+	0.28	5.3	1.71E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61795002	chr4:242797	ZNF718	chr4:53272-156488:+	0.25	4.88	1.43E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61795006	chr4:253601	ZNF718	chr4:53272-156488:+	0.24	4.67	3.92E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61795007	chr4:255264	ZNF718	chr4:53272-156488:+	0.24	4.67	3.92E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs61806716	chr1:153649147	S100A13	chr1:153591280-153606568:-	-0.19	-3.87	0.000122	Multiple myeloma (IgH translocation)	
LGG	cis	1	rs61806716	chr1:153649147	S100A1	chr1:153600873-153604513:+	-0.29	-4.21	3.04E-5	Multiple myeloma (IgH translocation)	
LGG	cis	1	rs61819219	chr1:151084375	LYSMD1	chr1:151132225-151138424:-	-0.18	-4.03	6.37E-5	Body mass index	
LGG	cis	1	rs61819219	chr1:151084375	MRPL9	chr1:151732125-151736040:-	-0.13	-3.49	0.000517	Body mass index	
LGG	cis	1	rs61826828	chr1:174015261	DARS2	chr1:173793958-173827682:+	-0.17	-3.54	0.000441	Schizophrenia	
LGG	cis	1	rs61826828	chr1:174015261	RC3H1	chr1:173900354-173962210:-	-0.19	-3.65	0.000293	Schizophrenia	
LGG	cis	1	rs61826828	chr1:174015261	SERPINC1	chr1:173872943-173886516:-	0.47	7.29	1.23E-12	Schizophrenia	
LGG	cis	1	rs61833916	chr1:243469946	SDCCAG8	chr1:243419320-243663392:+	-0.29	-4.69	3.53E-6	Obesity (early onset extreme)	
LGG	cis	1	rs61835260	chr1:227703336	JMJD4	chr1:227918891-227923112:-	0.23	3.75	0.000198	Height	
LGG	cis	1	rs61852630	chr1:247210193	ZNF670	chr1:247200087-247242069:-	-0.22	-5.11	4.55E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs61852637	chr1:247219636	ZNF670	chr1:247200087-247242069:-	-0.22	-4.96	9.59E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs61854764	chr10:69965475	PBLD	chr10:70042417-70092684:-	0.42	7.37	7.35E-13	Optic nerve measurement (disc area)	
LGG	cis	1	rs61871790	chr10:97391223	TCTN3	chr10:97423154-97453900:-	0.18	3.45	0.000601	Blood metabolite levels	
LGG	cis	1	rs61871792	chr10:97397586	TCTN3	chr10:97423154-97453900:-	0.17	3.46	0.000582	Blood metabolite levels	
LGG	cis	1	rs61871793	chr10:97407738	TCTN3	chr10:97423154-97453900:-	0.18	3.6	0.000345	Blood metabolite levels	
LGG	cis	1	rs61877775	chr11:521462	HRAS	chr11:532243-535550:-	-0.2	-3.47	0.000562	Body mass index	
LGG	cis	1	rs61879300	chr11:22117880	FANCF	chr11:22644079-22647387:-	0.21	3.5	0.00051	Parkinson's disease	
LGG	cis	1	rs61886892	chr11:18738575	LDHC	chr11:18433853-18472792:+	-0.23	-4.05	6.01E-5	Diabetic kidney disease	
LGG	cis	1	rs61931739	chr12:34089973	SYT10	chr12:33528348-33592754:-	-0.16	-3.91	0.000105	Morning vs. evening chronotype	
LGG	cis	1	rs61971377	chr13:109511305	FAM155A	chr13:107820880-108519460:-	0.18	3.74	0.000206	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)	
LGG	cis	1	rs61977049	chr14:88827000	SPATA7	chr14:88852012-88904802:+	-0.45	-7.91	1.74E-14	Coronary artery calcification	
LGG	cis	1	rs61977058	chr14:88881915	KCNK10	chr14:88646454-88793256:-	-0.18	-3.67	0.000267	Coronary artery calcification	
LGG	cis	1	rs61977058	chr14:88881915	SPATA7	chr14:88852012-88904802:+	-0.49	-8.79	2.52E-17	Coronary artery calcification	
LGG	cis	1	rs61995742	chr12:48954030	ZNF641	chr12:48735912-48745021:-	0.24	3.7	0.000237	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs619972	chr11:108169619	ATM	chr11:108093559-108239826:+	-0.12	-3.54	0.000436	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs61998258	chr8:58192284	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs61998259	chr8:58192290	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs62017189	chr15:50922032	SPPL2A	chr15:50999739-51057910:-	0.12	3.99	7.54E-5	QT interval	
LGG	cis	1	rs62017206	chr15:50955626	SPPL2A	chr15:50999739-51057910:-	0.13	4.18	3.39E-5	QT interval	
LGG	cis	1	rs62017210	chr15:50960620	SPPL2A	chr15:50999739-51057910:-	0.13	4.24	2.65E-5	QT interval	
LGG	cis	1	rs62019464	chr15:85294469	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.42	1.22E-5	Schizophrenia	
LGG	cis	1	rs62019464	chr15:85294469	LOC388152	chr15:84867600-84898920:-	-0.3	-5.64	2.95E-8	Schizophrenia	
LGG	cis	1	rs62019464	chr15:85294469	WDR73	chr15:85186012-85197524:-	-0.19	-3.57	0.000385	Schizophrenia	
LGG	cis	1	rs62019469	chr15:85321220	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.35	1.66E-5	Schizophrenia	
LGG	cis	1	rs62019469	chr15:85321220	LOC388152	chr15:84867600-84898920:-	-0.29	-5.47	7.21E-8	Schizophrenia	
LGG	cis	1	rs62019469	chr15:85321220	WDR73	chr15:85186012-85197524:-	-0.19	-3.47	0.000573	Schizophrenia	
LGG	cis	1	rs62021219	chr15:85256159	GOLGA6L5	chr15:85047738-85060078:-	-0.2	-4.31	1.93E-5	Schizophrenia	
LGG	cis	1	rs62021219	chr15:85256159	LOC388152	chr15:84867600-84898920:-	-0.31	-5.75	1.55E-8	Schizophrenia	
LGG	cis	1	rs62021219	chr15:85256159	WDR73	chr15:85186012-85197524:-	-0.19	-3.52	0.000464	Schizophrenia	
LGG	cis	1	rs62026530	chr15:84775840	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.58	4.08E-8	Schizophrenia	
LGG	cis	1	rs62026530	chr15:84775840	LOC388152	chr15:84867600-84898920:-	-0.33	-6.55	1.48E-10	Schizophrenia	
LGG	cis	1	rs62026530	chr15:84775840	UBE2Q2P1	chr15:85070427-85114026:-	0.14	3.47	0.000568	Schizophrenia	
LGG	cis	1	rs62056375	chr16:29857901	LOC440356	chr16:29875004-29879374:+	-0.24	-3.74	0.000204	Multiple sclerosis	
LGG	cis	1	rs62064823	chr17:33288103	RAD51L3	chr17:33426811-33448541:-	-0.31	-3.8	0.000161	Night sleep phenotypes	
LGG	cis	1	rs62070270	chr17:28263980	EFCAB5	chr17:28256874-28435469:+	0.22	6.01	3.65E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs62070312	chr17:28438877	EFCAB5	chr17:28256874-28435469:+	0.22	5.94	5.39E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs62084208	chr17:65827443	LOC440461	chr17:66194801-66196436:+	0.28	4.59	5.62E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084210	chr17:65828710	LOC440461	chr17:66194801-66196436:+	0.26	4.25	2.56E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084213	chr17:65842016	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084214	chr17:65843325	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084238	chr17:65856573	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.84E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084240	chr17:65859233	LOC440461	chr17:66194801-66196436:+	0.27	4.52	7.86E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084246	chr17:65867911	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084248	chr17:65874541	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084249	chr17:65874998	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62084251	chr17:65878736	LOC440461	chr17:66194801-66196436:+	0.28	4.55	6.9E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62085992	chr17:65923083	LOC440461	chr17:66194801-66196436:+	0.28	4.57	6.27E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62085993	chr17:65923152	LOC440461	chr17:66194801-66196436:+	0.29	4.9	1.28E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs62096106	chr18:59838919	ZCCHC2	chr18:60190658-60253962:+	0.31	3.62	0.000319	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)	
LGG	cis	1	rs62096463	chr18:44628928	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs62096464	chr18:44629207	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs62096466	chr18:44636171	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs62096468	chr18:44637566	HDHD2	chr18:44633782-44676871:-	0.41	4.02	6.72E-5	Sitting height ratio	
LGG	cis	1	rs62096469	chr18:44638298	HDHD2	chr18:44633782-44676871:-	0.41	4.33	1.78E-5	Sitting height ratio	
LGG	cis	1	rs62096470	chr18:44641466	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs62096471	chr18:44643814	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs62096474	chr18:44647504	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs62096476	chr18:44658621	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs62096478	chr18:44662409	HDHD2	chr18:44633782-44676871:-	0.44	4.61	5.17E-6	Sitting height ratio	
LGG	cis	1	rs62103177	chr18:77624479	HSBP1L1	chr18:77724582-77730820:+	0.28	5.49	6.31E-8	Opioid sensitivity	
LGG	cis	1	rs62104473	chr19:30289779	CCNE1	chr19:30302901-30315218:+	-0.22	-4.51	8.23E-6	Bladder cancer	
LGG	cis	1	rs62107762	chr19:15982538	CYP4F11	chr19:16023180-16045676:-	-0.22	-4.43	1.16E-5	Acenocoumarol maintenance dosage;Vitamin E levels;Circulating phylloquinone levels;Metabolite levels;Response to Vitamin E supplementation;Warfarin maintenance dose	
LGG	cis	1	rs62112907	chr19:22209569	ZNF257	chr19:22235266-22273901:+	0.56	8.99	5.45E-18	Body mass index (change over time)	
LGG	cis	1	rs62112917	chr19:22226580	ZNF257	chr19:22235266-22273901:+	0.6	9.4	2.14E-19	Body mass index (change over time)	
LGG	cis	1	rs62114497	chr2:214837	FAM150B	chr2:279563-288308:-	-0.31	-5.77	1.44E-8	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114501	chr2:231741	FAM150B	chr2:279563-288308:-	-0.33	-6.29	7.1E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114501	chr2:231741	SNTG2	chr2:946555-1371382:+	0.2	3.64	0.0003	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114505	chr2:242426	FAM150B	chr2:279563-288308:-	-0.32	-6.1	2.17E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114505	chr2:242426	SNTG2	chr2:946555-1371382:+	0.21	3.79	0.000172	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114544	chr2:269679	FAM150B	chr2:279563-288308:-	-0.34	-6.47	2.45E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114544	chr2:269679	SNTG2	chr2:946555-1371382:+	0.2	3.72	0.000225	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114548	chr2:274672	FAM150B	chr2:279563-288308:-	-0.34	-6.41	3.37E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114548	chr2:274672	SNTG2	chr2:946555-1371382:+	0.2	3.57	0.000395	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs62114762	chr19:24233868	LOC100101266	chr19:24344995-24346249:-	0.27	4.32	1.9E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs62117633	chr19:24219474	LOC100101266	chr19:24344995-24346249:-	0.26	4.15	3.94E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs62120832	chr19:23064264	ZNF492	chr19:22817126-22850472:+	-0.22	-4.36	1.56E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs62132091	chr2:17770276	GEN1	chr2:17935162-17966632:+	0.26	4.16	3.8E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132092	chr2:17770893	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132093	chr2:17771207	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132125	chr2:17776997	GEN1	chr2:17935162-17966632:+	0.26	4.09	5.08E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132127	chr2:17778708	GEN1	chr2:17935162-17966632:+	0.27	4.23	2.8E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132129	chr2:17778782	GEN1	chr2:17935162-17966632:+	0.3	4.37	1.53E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132133	chr2:17780483	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132135	chr2:17783190	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132137	chr2:17784194	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132138	chr2:17784781	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132139	chr2:17785987	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132140	chr2:17786559	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132141	chr2:17786758	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132142	chr2:17788469	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132143	chr2:17788743	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132144	chr2:17788790	GEN1	chr2:17935162-17966632:+	0.31	4.48	9.46E-6	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132145	chr2:17789253	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132146	chr2:17790133	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132147	chr2:17790876	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132148	chr2:17791048	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132150	chr2:17792359	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132151	chr2:17792698	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62132152	chr2:17794404	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133576	chr2:17795297	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133577	chr2:17798777	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133578	chr2:17799575	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133579	chr2:17800196	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133583	chr2:17805779	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133584	chr2:17805944	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133586	chr2:17806579	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133587	chr2:17806654	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133588	chr2:17807469	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133589	chr2:17807626	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62133590	chr2:17811126	GEN1	chr2:17935162-17966632:+	0.38	5.31	1.63E-7	Psychosis and Alzheimer's disease	
LGG	cis	1	rs62136864	chr2:46829124	ATP6V1E2	chr2:46738988-46769696:-	-0.2	-4.23	2.73E-5	Height	
LGG	cis	1	rs62136864	chr2:46829124	CRIPT	chr2:46844325-46852880:+	0.4	8.96	7.04E-18	Height	
LGG	cis	1	rs62136864	chr2:46829124	PIGF	chr2:46808414-46844251:-	0.15	3.71	0.000228	Height	
LGG	cis	1	rs62139200	chr2:54475507	C2orf73	chr2:54558071-54588714:+	0.33	4.78	2.36E-6	Telomere length	
LGG	cis	1	rs62139200	chr2:54475507	TSPYL6	chr2:54480315-54483409:-	-0.46	-5.47	7.12E-8	Telomere length	
LGG	cis	1	rs62139251	chr2:54478605	C2orf73	chr2:54558071-54588714:+	0.35	5.02	7.1E-7	Telomere length	
LGG	cis	1	rs62139251	chr2:54478605	TSPYL6	chr2:54480315-54483409:-	-0.48	-5.64	2.83E-8	Telomere length	
LGG	cis	1	rs62139254	chr2:54480336	C2orf73	chr2:54558071-54588714:+	0.34	4.9	1.29E-6	Telomere length	
LGG	cis	1	rs62139254	chr2:54480336	TSPYL6	chr2:54480315-54483409:-	-0.48	-5.74	1.62E-8	Telomere length	
LGG	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.4	7.19	2.37E-12	Metabolite levels	
LGG	cis	1	rs62151652	chr2:73700131	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.59E-5	Metabolite levels	
LGG	cis	1	rs62152790	chr2:97478579	FAM178B	chr2:97541620-97652301:-	-0.15	-3.59	0.000361	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs62152793	chr2:97484948	FAM178B	chr2:97541620-97652301:-	-0.15	-3.66	0.00028	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs62152794	chr2:97485110	FAM178B	chr2:97541620-97652301:-	-0.14	-3.59	0.000365	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs62152834	chr2:97504863	FAM178B	chr2:97541620-97652301:-	-0.15	-3.78	0.000175	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs62157778	chr2:88934090	EIF2AK3	chr2:88856261-88926994:-	0.16	3.69	0.000248	Height	
LGG	cis	1	rs62172508	chr2:188084469	CALCRL	chr2:188207851-188313021:-	-0.21	-5.04	6.43E-7	Coronary heart disease	
LGG	cis	1	rs62172509	chr2:188084535	CALCRL	chr2:188207851-188313021:-	-0.21	-4.95	1.05E-6	Coronary heart disease	
LGG	cis	1	rs62172510	chr2:188093671	CALCRL	chr2:188207851-188313021:-	-0.21	-5.05	6.33E-7	Coronary heart disease	
LGG	cis	1	rs62172533	chr2:188131585	CALCRL	chr2:188207851-188313021:-	-0.21	-5.16	3.57E-7	Coronary heart disease	
LGG	cis	1	rs62172550	chr2:188146887	CALCRL	chr2:188207851-188313021:-	-0.21	-5.07	5.72E-7	Coronary heart disease	
LGG	cis	1	rs62175515	chr2:160909524	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs62175517	chr2:160911575	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs62177297	chr2:179751771	CCDC141	chr2:179697347-179914786:-	-0.38	-5.53	5.19E-8	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs62184315	chr2:190771945	ASNSD1	chr2:190526125-190535556:+	-0.21	-3.61	0.000342	Alcohol dependence (age at onset)	
LGG	cis	1	rs62184315	chr2:190771945	ORMDL1	chr2:190634994-190649097:-	0.2	4.59	5.58E-6	Alcohol dependence (age at onset)	
LGG	cis	1	rs62186400	chr2:242226700	ANO7	chr2:242127924-242164791:+	0.38	6.51	1.82E-10	Prostate cancer	
LGG	cis	1	rs62186411	chr2:242236667	ANO7	chr2:242127924-242164791:+	0.39	6.58	1.18E-10	Prostate cancer	
LGG	cis	1	rs62186422	chr2:242249499	ANO7	chr2:242127924-242164791:+	0.39	6.64	8.43E-11	Prostate cancer	
LGG	cis	1	rs62190367	chr2:242376276	ANO7	chr2:242127924-242164791:+	0.39	6.87	1.98E-11	Prostate cancer	
LGG	cis	1	rs62190370	chr2:242384194	ANO7	chr2:242127924-242164791:+	0.41	7.01	8.07E-12	Prostate cancer	
LGG	cis	1	rs62192854	chr2:208992553	CRYGA	chr2:209025465-209028297:-	-0.26	-3.86	0.000127	Attention deficit hyperactivity disorder	
LGG	cis	1	rs62193171	chr2:242276523	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs62193175	chr2:242284405	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs62193197	chr2:242294301	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.39E-10	Prostate cancer	
LGG	cis	1	rs62193202	chr2:242303717	ANO7	chr2:242127924-242164791:+	0.38	6.33	5.67E-10	Prostate cancer	
LGG	cis	1	rs62193204	chr2:242315443	ANO7	chr2:242127924-242164791:+	0.37	6.43	3.01E-10	Prostate cancer	
LGG	cis	1	rs62193205	chr2:242316512	ANO7	chr2:242127924-242164791:+	0.38	6.54	1.58E-10	Prostate cancer	
LGG	cis	1	rs62193207	chr2:242318501	ANO7	chr2:242127924-242164791:+	0.37	6.43	3.01E-10	Prostate cancer	
LGG	cis	1	rs62193208	chr2:242322430	ANO7	chr2:242127924-242164791:+	0.38	6.52	1.79E-10	Prostate cancer	
LGG	cis	1	rs62193210	chr2:242323616	ANO7	chr2:242127924-242164791:+	0.38	6.53	1.64E-10	Prostate cancer	
LGG	cis	1	rs62193221	chr2:242354632	ANO7	chr2:242127924-242164791:+	0.39	6.82	2.69E-11	Prostate cancer	
LGG	cis	1	rs62193256	chr2:242362168	ANO7	chr2:242127924-242164791:+	0.4	6.87	2.01E-11	Prostate cancer	
LGG	cis	1	rs62211529	chr20:33959315	CPNE1	chr20:34213968-34262539:-	0.27	5.84	9.75E-9	Height	
LGG	cis	1	rs62211529	chr20:33959315	GDF5	chr20:33897002-34042568:-	-0.38	-7.35	8.38E-13	Height	
LGG	cis	1	rs62211529	chr20:33959315	UQCC	chr20:33890383-33999833:-	0.24	5.27	2.1E-7	Height	
LGG	cis	1	rs62212343	chr20:33196937	NCOA6	chr20:33302579-33413433:-	0.25	3.46	0.00059	Melanoma	
LGG	cis	1	rs62229266	chr21:37460271	SETD4	chr21:37406840-37451687:-	-0.41	-10.23	2.18E-22	Mitral valve prolapse	
LGG	cis	1	rs62236665	chr22:38059847	LGALS1	chr22:38071613-38075807:+	-0.19	-4.98	8.96E-7	Fat distribution (HIV)	
LGG	cis	1	rs62236667	chr22:38061520	LGALS1	chr22:38071613-38075807:+	-0.18	-4.95	1.02E-6	Fat distribution (HIV)	
LGG	cis	1	rs62236668	chr22:38063870	LGALS1	chr22:38071613-38075807:+	-0.18	-4.95	1.02E-6	Fat distribution (HIV)	
LGG	cis	1	rs62255273	chr3:65452827	MAGI1	chr3:65339907-66024509:-	0.22	4.63	4.74E-6	PR interval	
LGG	cis	1	rs62255276	chr3:65457776	MAGI1	chr3:65339907-66024509:-	0.22	4.64	4.51E-6	PR interval	
LGG	cis	1	rs62255277	chr3:65470507	MAGI1	chr3:65339907-66024509:-	0.22	4.62	4.91E-6	PR interval	
LGG	cis	1	rs62255278	chr3:65475846	MAGI1	chr3:65339907-66024509:-	0.23	4.68	3.73E-6	PR interval	
LGG	cis	1	rs62255280	chr3:65483527	MAGI1	chr3:65339907-66024509:-	0.21	4.23	2.77E-5	PR interval	
LGG	cis	1	rs62255282	chr3:65485422	MAGI1	chr3:65339907-66024509:-	0.22	4.29	2.17E-5	PR interval	
LGG	cis	1	rs62259933	chr3:49469703	AMIGO3	chr3:49754268-49757238:-	0.19	4.41	1.29E-5	Menarche (age at onset)	
LGG	cis	1	rs62259933	chr3:49469703	GMPPB	chr3:49758932-49761384:-	0.23	4.47	9.92E-6	Menarche (age at onset)	
LGG	cis	1	rs62259933	chr3:49469703	TREX1	chr3:48501186-48509043:+	0.26	5.36	1.3E-7	Menarche (age at onset)	
LGG	cis	1	rs62259944	chr3:49430883	AMIGO3	chr3:49754268-49757238:-	0.21	4.78	2.37E-6	Menarche (age at onset)	
LGG	cis	1	rs62259944	chr3:49430883	GMPPB	chr3:49758932-49761384:-	0.26	5.01	7.8E-7	Menarche (age at onset)	
LGG	cis	1	rs62259944	chr3:49430883	GPX1	chr3:49394611-49395791:-	0.1	3.57	0.000399	Menarche (age at onset)	
LGG	cis	1	rs62259944	chr3:49430883	TREX1	chr3:48501186-48509043:+	0.26	5.18	3.3E-7	Menarche (age at onset)	
LGG	cis	1	rs62259947	chr3:49439924	AMIGO3	chr3:49754268-49757238:-	0.21	4.67	3.83E-6	Menarche (age at onset)	
LGG	cis	1	rs62259947	chr3:49439924	GMPPB	chr3:49758932-49761384:-	0.25	4.84	1.78E-6	Menarche (age at onset)	
LGG	cis	1	rs62259947	chr3:49439924	TREX1	chr3:48501186-48509043:+	0.25	5.21	2.85E-7	Menarche (age at onset)	
LGG	cis	1	rs62261249	chr3:49594060	AMIGO3	chr3:49754268-49757238:-	0.22	4.89	1.35E-6	Menarche (age at onset)	
LGG	cis	1	rs62261249	chr3:49594060	GMPPB	chr3:49758932-49761384:-	0.26	5.02	7.41E-7	Menarche (age at onset)	
LGG	cis	1	rs622624	chr6:160716932	SLC22A3	chr6:160769425-160876013:+	0.34	5.82	1.07E-8	Waist circumference	
LGG	cis	1	rs62264483	chr3:119226831	KTELC1	chr3:119187785-119213552:+	-0.19	-3.57	0.000396	Arthritis (juvenile idiopathic)	
LGG	cis	1	rs62265556	chr3:94243253	STX19	chr3:93733215-93747454:-	0.7	10.14	4.75E-22	Blood pressure measurement (high sodium intervention)	
LGG	cis	1	rs62268732	chr3:121370455	IQCB1	chr3:121488610-121553926:-	0.36	6.6	1.07E-10	Cognitive performance	
LGG	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.28	7.24	1.79E-12	Height	
LGG	cis	1	rs62269547	chr3:134214042	CEP63	chr3:134204575-134293852:+	0.19	3.57	0.000398	Height	
LGG	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.6	1.56E-13	Height	
LGG	cis	1	rs62271513	chr3:134298412	CEP63	chr3:134204575-134293852:+	-0.2	-3.69	0.000245	Height	
LGG	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.6	1.56E-13	Height	
LGG	cis	1	rs62271514	chr3:134298554	CEP63	chr3:134204575-134293852:+	-0.2	-3.69	0.000245	Height	
LGG	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs62271515	chr3:134300507	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs62295634	chr4:17685346	LAP3	chr4:17578927-17609590:+	-0.13	-3.65	0.000296	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs62295634	chr4:17685346	MED28	chr4:17616273-17629791:+	0.17	3.51	0.000494	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs62321365	chr4:107013723	NPNT	chr4:106816605-106892827:+	-0.22	-4.63	4.68E-6	Airflow obstruction	
LGG	cis	1	rs62362510	chr5:76712907	WDR41	chr5:76728069-76788332:-	0.26	3.56	0.000413	Morning vs. evening chronotype	
LGG	cis	1	rs62384189	chr5:115510391	COMMD10	chr5:115420727-115628978:+	0.48	5.99	4.16E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384212	chr5:115521667	COMMD10	chr5:115420727-115628978:+	0.47	5.93	5.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384213	chr5:115526795	COMMD10	chr5:115420727-115628978:+	0.46	5.52	5.44E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384215	chr5:115528198	COMMD10	chr5:115420727-115628978:+	0.46	5.68	2.31E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384231	chr5:115530304	COMMD10	chr5:115420727-115628978:+	0.47	5.96	4.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384233	chr5:115533597	COMMD10	chr5:115420727-115628978:+	0.47	5.96	4.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384235	chr5:115534234	COMMD10	chr5:115420727-115628978:+	0.46	5.68	2.31E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384236	chr5:115534637	COMMD10	chr5:115420727-115628978:+	0.46	5.68	2.31E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384237	chr5:115540222	COMMD10	chr5:115420727-115628978:+	0.47	5.85	9.2E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384238	chr5:115542531	COMMD10	chr5:115420727-115628978:+	0.45	5.45	7.88E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384253	chr5:115563415	COMMD10	chr5:115420727-115628978:+	0.48	5.89	7.15E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384468	chr5:115623850	COMMD10	chr5:115420727-115628978:+	0.45	5.55	4.79E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384469	chr5:115624964	COMMD10	chr5:115420727-115628978:+	0.4	5.17	3.36E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384471	chr5:115631273	COMMD10	chr5:115420727-115628978:+	0.4	5.14	4.05E-7	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384476	chr5:115649509	COMMD10	chr5:115420727-115628978:+	0.45	5.53	5.11E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384493	chr5:115673448	COMMD10	chr5:115420727-115628978:+	0.48	5.79	1.28E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384678	chr5:115422688	COMMD10	chr5:115420727-115628978:+	0.47	5.89	7.01E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384697	chr5:115438284	COMMD10	chr5:115420727-115628978:+	0.47	5.94	5.28E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384700	chr5:115443805	COMMD10	chr5:115420727-115628978:+	0.46	5.88	7.68E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62384714	chr5:115452597	COMMD10	chr5:115420727-115628978:+	0.46	5.64	2.94E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62385177	chr5:115480480	COMMD10	chr5:115420727-115628978:+	0.46	5.89	7.34E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62385980	chr5:115592908	COMMD10	chr5:115420727-115628978:+	0.47	5.78	1.29E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62385993	chr5:115602254	COMMD10	chr5:115420727-115628978:+	0.46	5.75	1.58E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs62391527	chr5:125904970	ALDH7A1	chr5:125878918-125931082:-	0.43	4.93	1.13E-6	Osteoporosis	
LGG	cis	1	rs62391531	chr5:125914726	ALDH7A1	chr5:125878918-125931082:-	0.46	5.58	4.01E-8	Osteoporosis	
LGG	cis	1	rs62402013	chr6:26915000	C6orf41	chr6:26924772-26991752:+	-0.22	-3.91	0.000105	Schizophrenia	
LGG	cis	1	rs62402365	chr6:46318800	ENPP5	chr6:46127762-46138717:-	0.15	3.61	0.000335	Body mass index	
LGG	cis	1	rs62404566	chr6:35118432	TCP11	chr6:35085849-35109187:-	-0.32	-5.39	1.12E-7	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs624159	chr10:105939451	C10orf79	chr10:105889647-105992120:-	0.18	4.85	1.66E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs62447152	chr7:48200018	ABCA13	chr7:48211057-48687091:+	0.46	6.34	5.07E-10	Refractive astigmatism	
LGG	cis	1	rs62447153	chr7:48200023	ABCA13	chr7:48211057-48687091:+	0.46	6.34	5.07E-10	Refractive astigmatism	
LGG	cis	1	rs62454590	chr7:25610880	SNX10	chr7:26331515-26413937:+	-0.24	-3.67	0.000269	Preeclampsia	
LGG	cis	1	rs62454591	chr7:25621380	SNX10	chr7:26331515-26413937:+	-0.23	-3.6	0.000344	Preeclampsia	
LGG	cis	1	rs62454592	chr7:25621383	SNX10	chr7:26331515-26413937:+	-0.23	-3.6	0.000344	Preeclampsia	
LGG	cis	1	rs62460739	chr7:77406747	PTPN12	chr7:77166773-77269388:+	-0.18	-3.95	9.02E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs62460740	chr7:77409439	PTPN12	chr7:77166773-77269388:+	-0.17	-3.75	0.000197	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs62466793	chr7:66191517	ASL	chr7:65540776-65558321:+	-0.2	-4.97	9.17E-7	Aortic root size	
LGG	cis	1	rs62466793	chr7:66191517	TYW1	chr7:66461817-66704496:+	0.17	3.53	0.000455	Aortic root size	
LGG	cis	1	rs62466794	chr7:66191579	ASL	chr7:65540776-65558321:+	-0.19	-4.86	1.57E-6	Aortic root size	
LGG	cis	1	rs62466794	chr7:66191579	TYW1	chr7:66461817-66704496:+	0.17	3.64	0.000305	Aortic root size	
LGG	cis	1	rs62508972	chr8:98327596	HRSP12	chr8:99114567-99129418:-	0.15	3.61	0.000331	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs62573369	chr9:88878971	C9orf153	chr9:88835181-88874519:-	0.25	3.51	0.000496	Diisocyanate-induced asthma	
LGG	cis	1	rs62578379	chr9:123669709	TRAF1	chr9:123664672-123691479:-	0.4	4.57	6.15E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578381	chr9:123677967	TRAF1	chr9:123664672-123691479:-	0.4	4.57	6.15E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578383	chr9:123690582	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578393	chr9:123691750	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578394	chr9:123695233	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578395	chr9:123698332	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578397	chr9:123700338	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578400	chr9:123700496	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578404	chr9:123705850	TRAF1	chr9:123664672-123691479:-	0.38	5.25	2.28E-7	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578405	chr9:123709795	TRAF1	chr9:123664672-123691479:-	0.38	4.28	2.21E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs62578417	chr9:123727440	TRAF1	chr9:123664672-123691479:-	0.36	4.16	3.77E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs625917	chr1:183157991	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs631389	chr1:71446353	PTGER3	chr1:71318036-71513491:-	0.16	3.82	0.000153	IgG glycosylation	
LGG	cis	1	rs633554	chr6:84265708	SNAP91	chr6:84262607-84419127:-	-0.09	-4.61	5.14E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs634368	chr11:83324911	CCDC90B	chr11:82972506-82997414:-	0.2	4.86	1.61E-6	Subcortical brain region volumes	
LGG	cis	1	rs635442	chr11:71570982	FAM86C	chr11:71498557-71512276:+	-0.46	-4.6	5.49E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs636736	chr11:118705145	PHLDB1	chr11:118477213-118528741:+	-0.22	-3.63	0.000309	Vitiligo	
LGG	cis	1	rs637064	chr11:108140909	ATM	chr11:108093559-108239826:+	-0.11	-3.48	0.000538	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs638781	chr1:183157358	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs638893	chr11:118698537	PHLDB1	chr11:118477213-118528741:+	-0.22	-3.59	0.000364	Vitiligo	
LGG	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.43	-8.71	4.6E-17	Crohn's disease	
LGG	cis	1	rs641018	chr11:65655393	FIBP	chr11:65651212-65656010:-	0.23	5.75	1.6E-8	Crohn's disease	
LGG	cis	1	rs641018	chr11:65655393	SNX32	chr11:65601410-65621170:+	0.41	9.91	3.07E-21	Crohn's disease	
LGG	cis	1	rs641605	chr11:108101919	ATM	chr11:108093559-108239826:+	-0.11	-3.46	0.000581	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs641823	chr11:103066027	DYNC2H1	chr11:102980160-103350591:+	0.21	4.02	6.63E-5	Spine bone mineral density and alcohol drinking	
LGG	cis	1	rs6421571	chr11:118743772	PHLDB1	chr11:118477213-118528741:+	0.19	3.75	0.0002	Primary biliary cirrhosis	
LGG	cis	1	rs6422512	chr1:93024844	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs6425323	chr1:175125036	TNN	chr1:175036994-175117202:+	-0.17	-3.55	0.000415	Alcohol dependence	
LGG	cis	1	rs642573	chr11:71780854	FAM86C	chr11:71498557-71512276:+	0.54	5.35	1.34E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6425747	chr1:31869978	ZCCHC17	chr1:31769842-31837780:+	-0.18	-4.21	3.07E-5	Schizophrenia	
LGG	cis	1	rs6427950	chr1:202472066	PTPN7	chr1:202116143-202130709:-	-0.11	-3.49	0.000528	Sex ratio	
LGG	cis	1	rs6427950	chr1:202472066	UBE2T	chr1:202300786-202311094:-	-0.13	-3.96	8.68E-5	Sex ratio	
LGG	cis	1	rs6427952	chr1:202492418	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.000229	Sex ratio	
LGG	cis	1	rs6428476	chr1:89126005	CCBL2	chr1:89401456-89458643:-	0.54	12.58	1.21E-31	Height	
LGG	cis	1	rs6429082	chr1:235600129	B3GALNT2	chr1:235610533-235667781:-	0.24	6.02	3.36E-9	Adiposity	
LGG	cis	1	rs6429082	chr1:235600129	TBCE	chr1:235530728-235612280:+	0.18	3.68	0.000262	Adiposity	
LGG	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.25	-7.02	7.33E-12	Homocysteine levels	
LGG	cis	1	rs6429569	chr1:46001330	MMACHC	chr1:45965856-45976737:+	0.23	4.81	1.97E-6	Homocysteine levels	
LGG	cis	1	rs6429569	chr1:46001330	MUTYH	chr1:45794915-45806142:-	0.13	4.26	2.43E-5	Homocysteine levels	
LGG	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.15	3.84	0.00014	Body mass index	
LGG	cis	1	rs6429582	chr1:46321843	MUTYH	chr1:45794915-45806142:-	-0.13	-4.32	1.93E-5	Body mass index	
LGG	cis	1	rs6431654	chr2:234161769	ATG16L1	chr2:234160217-234204319:+	-0.19	-4.55	6.85E-6	Crohn's disease	
LGG	cis	1	rs6432858	chr2:166889943	SCN2A	chr2:166095912-166248818:+	0.09	3.59	0.000364	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6432858	chr2:166889943	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.16E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6432859	chr2:166896287	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6432859	chr2:166896287	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6432860	chr2:166897864	SCN2A	chr2:166095912-166248818:+	0.09	3.64	0.000301	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6432860	chr2:166897864	TTC21B	chr2:166713988-166810348:-	0.14	3.98	7.83E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6435079	chr2:202200331	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.99	7.64E-5	Basal cell carcinoma	
LGG	cis	1	rs6435079	chr2:202200331	ALS2CR4	chr2:202484907-202508224:-	0.19	5.07	5.57E-7	Basal cell carcinoma	
LGG	cis	1	rs6435079	chr2:202200331	PPIL3	chr2:201735680-201753999:-	-0.2	-4.05	5.86E-5	Basal cell carcinoma	
LGG	cis	1	rs643507	chr18:2946291	METTL4	chr18:2537525-2571489:-	-0.31	-3.59	0.000369	Body mass index in asthmatics	
LGG	cis	1	rs6435081	chr2:202220623	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.97	8.32E-5	Basal cell carcinoma	
LGG	cis	1	rs6435081	chr2:202220623	ALS2CR4	chr2:202484907-202508224:-	0.19	5.16	3.64E-7	Basal cell carcinoma	
LGG	cis	1	rs6435081	chr2:202220623	PPIL3	chr2:201735680-201753999:-	-0.2	-4.07	5.48E-5	Basal cell carcinoma	
LGG	cis	1	rs6437827	chr3:108849373	MORC1	chr3:108677089-108836993:-	-0.39	-6.96	1.13E-11	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs6439116	chr3:127849067	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6439124	chr3:128007466	EEFSEC	chr3:127872313-128127488:+	0.22	4.15	3.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6439124	chr3:128007466	LOC90246	chr3:128226678-128229427:+	0.28	3.57	0.000391	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs6439484	chr3:134249899	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs6439487	chr3:134260860	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs6439649	chr3:136371691	PCCB	chr3:135969167-136056737:+	-0.21	-4.42	1.22E-5	Schizophrenia	
LGG	cis	1	rs6441286	chr3:159728878	IL12A	chr3:159706629-159713805:+	-0.21	-4.04	6.32E-5	Primary biliary cirrhosis	
LGG	cis	1	rs6442117	chr3:48419897	ATRIP	chr3:48488141-48507708:+	-0.2	-5.06	5.89E-7	Longevity	
LGG	cis	1	rs6442117	chr3:48419897	TREX1	chr3:48501186-48509043:+	0.39	9.75	1.18E-20	Longevity	
LGG	cis	1	rs6442118	chr3:48440047	ATRIP	chr3:48488141-48507708:+	0.18	4.33	1.82E-5	Longevity	
LGG	cis	1	rs6442118	chr3:48440047	TREX1	chr3:48501186-48509043:+	-0.42	-10.87	8.46E-25	Longevity	
LGG	cis	1	rs6442119	chr3:48440178	ATRIP	chr3:48488141-48507708:+	0.17	4.13	4.25E-5	Longevity	
LGG	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.43	-11.09	1.15E-25	Longevity	
LGG	cis	1	rs6442120	chr3:48464503	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.16E-5	Longevity	
LGG	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.43	-11.19	4.66E-26	Longevity	
LGG	cis	1	rs6442123	chr3:48500286	ATRIP	chr3:48488141-48507708:+	0.2	4.9	1.31E-6	Longevity	
LGG	cis	1	rs6442123	chr3:48500286	TREX1	chr3:48501186-48509043:+	-0.42	-10.83	1.14E-24	Longevity	
LGG	cis	1	rs6443245	chr3:9636660	RPUSD3	chr3:9879534-9885702:-	-0.17	-3.72	0.000222	Daytime sleep phenotypes	
LGG	cis	1	rs6443924	chr3:183679532	ABCC5	chr3:183637726-183735727:-	0.11	3.53	0.000456	Anterior chamber depth	
LGG	cis	1	rs6443926	chr3:183706630	ABCC5	chr3:183637726-183735727:-	0.11	3.6	0.000347	Anterior chamber depth	
LGG	cis	1	rs6443927	chr3:183718864	ABCC5	chr3:183637726-183735727:-	0.12	3.75	0.000198	Anterior chamber depth	
LGG	cis	1	rs644493	chr15:45935816	SPATA5L1	chr15:45694519-45713614:+	0.28	4.26	2.45E-5	Obesity-related traits	
LGG	cis	1	rs6445358	chr3:52308845	GNL3	chr3:52719936-52728508:+	-0.17	-3.58	0.000376	Electroencephalogram traits	
LGG	cis	1	rs6445622	chr3:51356823	HEMK1	chr3:50606583-50622419:+	0.22	3.75	0.000198	Melanoma	
LGG	cis	1	rs6446262	chr3:49401153	AMIGO3	chr3:49754268-49757238:-	-0.21	-4.86	1.58E-6	Menarche (age at onset)	
LGG	cis	1	rs6446262	chr3:49401153	GMPPB	chr3:49758932-49761384:-	-0.26	-4.97	9.32E-7	Menarche (age at onset)	
LGG	cis	1	rs6446262	chr3:49401153	TREX1	chr3:48501186-48509043:+	-0.26	-5.3	1.75E-7	Menarche (age at onset)	
LGG	cis	1	rs6446268	chr3:49445695	AMIGO3	chr3:49754268-49757238:-	0.18	4.04	6.31E-5	Menarche (age at onset)	
LGG	cis	1	rs6446268	chr3:49445695	GMPPB	chr3:49758932-49761384:-	0.21	4.08	5.32E-5	Menarche (age at onset)	
LGG	cis	1	rs6446268	chr3:49445695	NCKIPSD	chr3:48711280-48723334:-	-0.16	-3.65	0.000291	Menarche (age at onset)	
LGG	cis	1	rs6446268	chr3:49445695	TREX1	chr3:48501186-48509043:+	0.23	4.86	1.59E-6	Menarche (age at onset)	
LGG	cis	1	rs6446275	chr3:49466871	AMIGO3	chr3:49754268-49757238:-	0.19	4.41	1.29E-5	Menarche (age at onset)	
LGG	cis	1	rs6446275	chr3:49466871	GMPPB	chr3:49758932-49761384:-	0.23	4.47	9.92E-6	Menarche (age at onset)	
LGG	cis	1	rs6446275	chr3:49466871	TREX1	chr3:48501186-48509043:+	0.26	5.36	1.3E-7	Menarche (age at onset)	
LGG	cis	1	rs6449319	chr4:17640283	MED28	chr4:17616273-17629791:+	0.21	4.44	1.13E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.82	15.42	5.13E-44	Type 2 diabetes	
LGG	cis	1	rs6450408	chr5:56098146	MIER3	chr5:56215429-56267501:-	0.17	3.67	0.000271	Type 2 diabetes	
LGG	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.81	15.59	8.19E-45	Type 2 diabetes	
LGG	cis	1	rs6453209	chr5:75495849	F2R	chr5:76011868-76031594:+	0.19	4.15	3.94E-5	Migraine - clinic-based	
LGG	cis	1	rs6453424	chr5:78315367	BHMT	chr5:78407604-78428112:+	0.17	3.55	0.00043	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.52	10.93	4.87E-25	Response to antipsychotic treatment	
LGG	cis	1	rs645485	chr11:108168863	ATM	chr11:108093559-108239826:+	-0.12	-3.49	0.000534	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6456733	chr6:26566804	BTN2A3	chr6:26422317-26431927:+	0.13	3.72	0.000225	Educational attainment	
LGG	cis	1	rs6456733	chr6:26566804	HMGN4	chr6:26538572-26547162:+	-0.18	-4.6	5.49E-6	Educational attainment	
LGG	cis	1	rs6456734	chr6:26566965	BTN2A3	chr6:26422317-26431927:+	0.13	3.72	0.000225	Educational attainment	
LGG	cis	1	rs6456734	chr6:26566965	HMGN4	chr6:26538572-26547162:+	-0.18	-4.6	5.49E-6	Educational attainment	
LGG	cis	1	rs6457805	chr6:35120443	TCP11	chr6:35085849-35109187:-	-0.34	-5.62	3.13E-8	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs6458307	chr6:42731115	GNMT	chr6:42928500-42931617:+	0.18	3.68	0.000258	Bipolar disorder	
LGG	cis	1	rs6458690	chr6:49411619	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.15E-6	Folate pathway vitamin levels	
LGG	cis	1	rs6458694	chr6:49445306	CENPQ	chr6:49431096-49460820:+	-0.23	-5.06	6.08E-7	Folate pathway vitamin levels	
LGG	cis	1	rs6459657	chr6:170136454	WDR27	chr6:169857307-170102159:-	-0.36	-7.99	9.46E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6460260	chr7:65215455	CCT6P1	chr7:65216092-65228661:+	-0.27	-4.87	1.5E-6	Diabetic kidney disease	
LGG	cis	1	rs6460261	chr7:65215580	CCT6P1	chr7:65216092-65228661:+	-0.27	-4.87	1.5E-6	Diabetic kidney disease	
LGG	cis	1	rs6460274	chr7:65628484	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.28	2.24E-5	Diabetic kidney disease	
LGG	cis	1	rs6460292	chr7:65810075	ASL	chr7:65540776-65558321:+	0.22	5.57	4.31E-8	Aortic root size	
LGG	cis	1	rs6460295	chr7:65882728	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs6460296	chr7:65895139	ASL	chr7:65540776-65558321:+	-0.22	-5.57	4.26E-8	Aortic root size	
LGG	cis	1	rs646153	chr11:64089588	C11orf20	chr11:64067863-64072238:+	0.2	4.23	2.79E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs646153	chr11:64089588	CCDC88B	chr11:64107695-64125005:+	-0.11	-4.39	1.38E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs646153	chr11:64089588	PPP1R14B	chr11:64011953-64014413:-	-0.14	-4.17	3.63E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs6464573	chr7:143748098	OR2A9P	chr7:143991573-143997832:+;chr7	0.17	3.57	0.000394	Obesity-related traits	
LGG	cis	1	rs6465750	chr7:99235522	CYP3A5	chr7:99245818-99332821:-	0.42	4.23	2.76E-5	Blood metabolite levels	
LGG	cis	1	rs6466656	chr7:118042177	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.85	0.000133	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs6468131	chr8:29981020	MBOAT4	chr8:29989188-30002200:-	-0.34	-3.99	7.73E-5	Migraine	
LGG	cis	1	rs6468544	chr8:98329765	HRSP12	chr8:99114567-99129418:-	-0.15	-3.66	0.000281	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs6477733	chr9:99625063	FAM22G	chr9:99690592-99704572:+	0.43	3.77	0.000182	Height	
LGG	cis	1	rs6477998	chr9:115997249	CDC26	chr9:116029290-116037869:-	0.45	9.92	2.96E-21	Hematology traits	
LGG	cis	1	rs6478484	chr9:123652380	LOC253039	chr9:123605320-123616644:+	-0.67	-12.03	2.1E-29	Rheumatoid arthritis	
LGG	cis	1	rs6478484	chr9:123652380	PSMD5	chr9:123578334-123605206:-	-0.36	-6.65	7.64E-11	Rheumatoid arthritis	
LGG	cis	1	rs6478484	chr9:123652380	TRAF1	chr9:123664672-123691479:-	0.18	3.97	8.42E-5	Rheumatoid arthritis	
LGG	cis	1	rs6478486	chr9:123655329	LOC253039	chr9:123605320-123616644:+	-0.66	-11.81	1.67E-28	Rheumatoid arthritis	
LGG	cis	1	rs6478486	chr9:123655329	PSMD5	chr9:123578334-123605206:-	-0.36	-6.55	1.42E-10	Rheumatoid arthritis	
LGG	cis	1	rs6478486	chr9:123655329	TRAF1	chr9:123664672-123691479:-	0.18	4	7.32E-5	Rheumatoid arthritis	
LGG	cis	1	rs6478867	chr9:131903923	CRAT	chr9:131857075-131873070:-	-0.19	-3.52	0.000471	Blood metabolite ratios	
LGG	cis	1	rs6480314	chr10:69967447	PBLD	chr10:70042417-70092684:-	-0.37	-6.7	5.88E-11	Optic nerve measurement (disc area)	
LGG	cis	1	rs648541	chr11:114429934	C11orf71	chr11:114262170-114271255:-	-0.17	-3.51	0.000483	Ulcerative colitis	
LGG	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.53	-11.74	3.27E-28	Forced vital capacity	
LGG	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.57	12.85	8.51E-33	Forced vital capacity	
LGG	cis	1	rs6487679	chr12:9371332	LOC642846	chr12:9436253-9466684:+	0.31	6.12	1.88E-9	Non-alcoholic fatty liver disease histology (AST)	
LGG	cis	1	rs6489785	chr12:121363724	SPPL3	chr12:121201036-121342151:-	0.2	3.55	0.000418	Longevity	
LGG	cis	1	rs6492925	chr15:40304170	EIF2AK4	chr15:40226347-40327797:+	0.28	3.95	8.8E-5	Response to haloperidol in psychosis	
LGG	cis	1	rs649338	chr11:118705654	PHLDB1	chr11:118477213-118528741:+	-0.23	-3.82	0.000151	Vitiligo	
LGG	cis	1	rs6495706	chr15:34976870	C15orf24	chr15:34376226-34394053:-	-0.2	-3.5	0.000515	Congenital left-sided heart lesions	
LGG	cis	1	rs6495706	chr15:34976870	C15orf29	chr15:34432876-34502297:-	-0.18	-3.49	0.000523	Congenital left-sided heart lesions	
LGG	cis	1	rs649587	chr6:160718374	SLC22A3	chr6:160769425-160876013:+	0.34	5.95	5.17E-9	Waist circumference	
LGG	cis	1	rs6496044	chr15:86067306	KLHL25	chr15:86302561-86338189:-	-0.13	-3.55	0.000421	Interstitial lung disease	
LGG	cis	1	rs6496044	chr15:86067306	WDR73	chr15:85186012-85197524:-	-0.19	-4.01	7.12E-5	Interstitial lung disease	
LGG	cis	1	rs6496609	chr15:90379632	AP3S2	chr15:90373832-90456222:-	-0.48	-9.25	6.98E-19	Type 2 diabetes	
LGG	cis	1	rs6496665	chr15:90891615	IQGAP1	chr15:90931473-91045475:+	0.12	3.92	0.000102	Rheumatoid arthritis	
LGG	cis	1	rs6496666	chr15:90891662	IQGAP1	chr15:90931473-91045475:+	0.14	4.26	2.48E-5	Rheumatoid arthritis	
LGG	cis	1	rs6496667	chr15:90893668	IQGAP1	chr15:90931473-91045475:+	0.13	4	7.36E-5	Rheumatoid arthritis	
LGG	cis	1	rs6496668	chr15:90893704	IQGAP1	chr15:90931473-91045475:+	0.15	4.54	7.17E-6	Rheumatoid arthritis	
LGG	cis	1	rs6496669	chr15:90895265	IQGAP1	chr15:90931473-91045475:+	-0.14	-4.29	2.16E-5	Rheumatoid arthritis	
LGG	cis	1	rs6499188	chr16:68674788	ZFP90	chr16:68564048-68601038:+	-0.24	-4.08	5.34E-5	Ulcerative colitis	
LGG	cis	1	rs6499766	chr16:55604128	IRX6	chr16:55358471-55364671:+	0.19	3.73	0.00021	Thyroid hormone levels	
LGG	cis	1	rs6499946	chr16:58326610	PRSS54	chr16:58313902-58328951:-	-0.36	-6.81	2.9E-11	Systemic lupus erythematosus	
LGG	cis	1	rs650173	chr11:108174173	ATM	chr11:108093559-108239826:+	-0.12	-3.57	0.000393	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6502674	chr17:18776897	FAM18B	chr17:18684582-18710026:+	-0.15	-3.64	0.000302	Pancreatic cancer	
LGG	cis	1	rs6502674	chr17:18776897	PRPSAP2	chr17:18759663-18834580:+	0.2	5.41	1.01E-7	Pancreatic cancer	
LGG	cis	1	rs6502674	chr17:18776897	TRIM16L	chr17:18601311-18639431:+	0.16	3.55	0.000422	Pancreatic cancer	
LGG	cis	1	rs6502677	chr17:18803658	FAM18B	chr17:18684582-18710026:+	-0.18	-4.72	3.04E-6	Educational attainment (years of education)	
LGG	cis	1	rs6502677	chr17:18803658	FBXW10	chr17:18647326-18682661:+	-0.2	-4.5	8.58E-6	Educational attainment (years of education)	
LGG	cis	1	rs6503530	chr17:38161823	GSDMA	chr17:38119226-38134019:+	-0.72	-15.76	1.35E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs6503703	chr17:40592207	HSD17B1	chr17:40703984-40707224:+	-0.17	-3.49	0.000525	Crohn's disease	
LGG	cis	1	rs6504167	chr17:61693194	DDX42	chr17:61851567-61896676:+	-0.16	-3.62	0.000327	Body mass index	
LGG	cis	1	rs6504167	chr17:61693194	FTSJ3	chr17:61896795-61905031:-	0.42	8.57	1.31E-16	Body mass index	
LGG	cis	1	rs6504167	chr17:61693194	SMARCD2	chr17:61909441-61920351:-	0.2	4.37	1.54E-5	Body mass index	
LGG	cis	1	rs6504168	chr17:61697469	DDX42	chr17:61851567-61896676:+	-0.16	-3.61	0.000339	Body mass index	
LGG	cis	1	rs6504168	chr17:61697469	FTSJ3	chr17:61896795-61905031:-	0.41	8.46	3.17E-16	Body mass index	
LGG	cis	1	rs6504168	chr17:61697469	SMARCD2	chr17:61909441-61920351:-	0.19	4.23	2.82E-5	Body mass index	
LGG	cis	1	rs6504169	chr17:61709145	DDX42	chr17:61851567-61896676:+	-0.17	-3.81	0.000154	Body mass index	
LGG	cis	1	rs6504169	chr17:61709145	FTSJ3	chr17:61896795-61905031:-	0.41	8.29	1.1E-15	Body mass index	
LGG	cis	1	rs6504169	chr17:61709145	SMARCD2	chr17:61909441-61920351:-	0.18	4.07	5.46E-5	Body mass index	
LGG	cis	1	rs6504170	chr17:61709168	DDX42	chr17:61851567-61896676:+	-0.16	-3.66	0.000281	Body mass index	
LGG	cis	1	rs6504170	chr17:61709168	FTSJ3	chr17:61896795-61905031:-	0.42	8.65	7.32E-17	Body mass index	
LGG	cis	1	rs6504170	chr17:61709168	SMARCD2	chr17:61909441-61920351:-	0.19	4.3	2.05E-5	Body mass index	
LGG	cis	1	rs6504171	chr17:61710010	FTSJ3	chr17:61896795-61905031:-	0.44	9.04	3.54E-18	Body mass index	
LGG	cis	1	rs6504171	chr17:61710010	SMARCD2	chr17:61909441-61920351:-	0.21	4.73	2.95E-6	Body mass index	
LGG	cis	1	rs6504173	chr17:61735056	FTSJ3	chr17:61896795-61905031:-	0.44	9.07	2.85E-18	Body mass index	
LGG	cis	1	rs6504173	chr17:61735056	SMARCD2	chr17:61909441-61920351:-	0.2	4.58	5.88E-6	Body mass index	
LGG	cis	1	rs6504182	chr17:61823672	FTSJ3	chr17:61896795-61905031:-	0.43	9.04	3.74E-18	Body mass index	
LGG	cis	1	rs6504182	chr17:61823672	SMARCD2	chr17:61909441-61920351:-	0.2	4.6	5.48E-6	Body mass index	
LGG	cis	1	rs6504203	chr17:46454675	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000504	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs6504542	chr17:65836642	LOC440461	chr17:66194801-66196436:+	0.26	4.23	2.78E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs6504543	chr17:65837659	LOC440461	chr17:66194801-66196436:+	0.27	4.52	7.72E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs6504548	chr17:65886048	LOC440461	chr17:66194801-66196436:+	0.27	4.42	1.21E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs6504549	chr17:65888784	LOC440461	chr17:66194801-66196436:+	0.27	4.49	9.03E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs6504555	chr17:65940727	LOC440461	chr17:66194801-66196436:+	-0.29	-4.77	2.47E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs6504661	chr17:48580126	MYCBPAP	chr17:48585745-48608861:+	0.28	5.47	7.03E-8	Visceral fat	
LGG	cis	1	rs6504948	chr17:53049987	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs6504948	chr17:53049987	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs6504949	chr17:53050133	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs6504949	chr17:53050133	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs6504950	chr17:53056471	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs6504950	chr17:53056471	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs6504951	chr17:53056975	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs6504951	chr17:53056975	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs6505152	chr17:28331466	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs6505158	chr17:28403348	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.99	4.17E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs650619	chr11:65506483	DKFZp761E198	chr11:65543380-65547822:-	0.26	3.62	0.000329	Atopic dermatitis	
LGG	cis	1	rs6508977	chr19:41909346	ATP5SL	chr19:41937224-41945810:-	0.16	4.38	1.43E-5	Height	
LGG	cis	1	rs6508977	chr19:41909346	B9D2	chr19:41860322-41870078:-	-0.11	-3.6	0.000347	Height	
LGG	cis	1	rs6508977	chr19:41909346	EXOSC5	chr19:41892278-41903256:-	-0.12	-3.65	0.000294	Height	
LGG	cis	1	rs6511313	chr19:22215905	ZNF257	chr19:22235266-22273901:+	0.52	8.19	2.3E-15	Body mass index (change over time)	
LGG	cis	1	rs6512577	chr20:47865784	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.13	4.31E-5	Height	
LGG	cis	1	rs6515651	chr20:25414539	ABHD12	chr20:25275380-25371477:-	-0.26	-7.2	2.21E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6515651	chr20:25414539	FAM182A	chr20:26035250-26067552:+	0.56	11.04	1.77E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6515651	chr20:25414539	FAM182B	chr20:25744102-25848786:-	-0.22	-4.94	1.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs6515773	chr20:3174105	ITPA	chr20:3190056-3204504:+	0.14	3.59	0.00036	Night sleep phenotypes	
LGG	cis	1	rs6516891	chr21:30483070	RWDD2B	chr21:30378082-30391685:-	0.22	3.88	0.000118	Dental caries	
LGG	cis	1	rs6518986	chr22:22185347	CCDC116	chr22:21987086-21991615:+	0.17	3.72	0.000226	Multiple sclerosis	
LGG	cis	1	rs6519119	chr22:38989007	LOC646851	chr22:38974125-39052634:-	0.22	6.55	1.5E-10	Resting heart rate	
LGG	cis	1	rs6519120	chr22:38991393	LOC646851	chr22:38974125-39052634:-	-0.25	-7.42	5.17E-13	Resting heart rate	
LGG	cis	1	rs6519124	chr22:39045099	LOC646851	chr22:38974125-39052634:-	0.24	7.47	3.62E-13	Resting heart rate	
LGG	cis	1	rs6519611	chr22:25845855	ADRBK2	chr22:25960861-26125256:+	-0.23	-4.11	4.54E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6519611	chr22:25845855	CRYBB2	chr22:25615612-25627836:+	0.65	8.45	3.33E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs652753	chr1:183156569	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.44	-10.62	7.44E-24	Longevity	
LGG	cis	1	rs6533804	chr4:79510973	ANXA3	chr4:79472742-79531602:+	-0.33	-7.76	5.11E-14	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs6536365	chr4:159632293	ETFDH	chr4:159593277-159629839:+	-0.35	-7.31	1.09E-12	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs6537825	chr1:114948281	AP4B1	chr1:114437677-114447741:-	0.21	3.75	0.000201	Autism	
LGG	cis	1	rs6537837	chr1:110119732	SYPL2	chr1:110009100-110024763:+	-0.21	-3.73	0.000214	Major depressive disorder	
LGG	cis	1	rs6538188	chr12:89857138	GALNT4	chr12:89913192-89919777:-	-0.16	-4.34	1.69E-5	Schizophrenia	
LGG	cis	1	rs6538188	chr12:89857138	POC1B	chr12:89813501-89919777:-	-0.17	-3.54	0.000431	Schizophrenia	
LGG	cis	1	rs654005	chr11:108155397	ATM	chr11:108093559-108239826:+	-0.12	-3.63	0.00031	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs6542334	chr2:111907214	ACOXL	chr2:111490150-111875799:+	-0.21	-3.76	0.000194	Chronic lymphocytic leukemia	
LGG	cis	1	rs6543134	chr2:103050458	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6543134	chr2:103050458	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6543141	chr2:103076351	IL18R1	chr2:102927962-103015215:+	-0.38	-6.15	1.57E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6543141	chr2:103076351	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.41	1.01E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6543268	chr2:105370105	MRPS9	chr2:105654483-105716417:+	-0.24	-3.94	9.49E-5	Pancreatic cancer	
LGG	cis	1	rs6544065	chr2:37497417	CEBPZ	chr2:37428778-37458740:-	-0.19	-4.89	1.39E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs6545883	chr2:61772257	AHSA2	chr2:61404553-61414058:+	-0.26	-8.38	5.72E-16	Tuberculosis	
LGG	cis	1	rs6545883	chr2:61772257	C2orf74	chr2:61372243-61391964:+	0.32	7	8.34E-12	Tuberculosis	
LGG	cis	1	rs6545946	chr2:62713533	EHBP1	chr2:62901013-63273619:+	0.21	3.65	0.000293	Crohn's disease	
LGG	cis	1	rs6546553	chr2:70111711	SNRNP27	chr2:70121090-70132348:+	-0.17	-3.78	0.000178	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6546556	chr2:70139001	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.35	1.64E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6546558	chr2:70145717	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.46	1.01E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6546559	chr2:70145833	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.5	8.49E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6546726	chr2:26275116	GPR113	chr2:26531041-26569685:-	-0.23	-3.76	0.000191	Gut microbiome composition (summer)	
LGG	cis	1	rs6546727	chr2:26275282	GPR113	chr2:26531041-26569685:-	-0.23	-3.63	0.000309	Gut microbiome composition (summer)	
LGG	cis	1	rs6546728	chr2:26276531	GPR113	chr2:26531041-26569685:-	-0.23	-3.53	0.000455	Gut microbiome composition (summer)	
LGG	cis	1	rs6546736	chr2:26293878	GPR113	chr2:26531041-26569685:-	0.23	3.72	0.000219	Gut microbiome composition (summer)	
LGG	cis	1	rs6546744	chr2:26302161	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs6546766	chr2:26328680	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs6546767	chr2:26328746	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs6546768	chr2:26328800	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs6546835	chr2:73664715	ALMS1P	chr2:73872046-73912692:+	0.4	7.15	3.12E-12	Metabolite levels	
LGG	cis	1	rs6546835	chr2:73664715	NAT8	chr2:73867850-73869537:-	0.27	4.42	1.21E-5	Metabolite levels	
LGG	cis	1	rs6546836	chr2:73677833	ALMS1P	chr2:73872046-73912692:+	0.4	7.15	3.17E-12	Metabolite levels	
LGG	cis	1	rs6546836	chr2:73677833	NAT8	chr2:73867850-73869537:-	0.27	4.43	1.16E-5	Metabolite levels	
LGG	cis	1	rs6546837	chr2:73677898	ALMS1P	chr2:73872046-73912692:+	0.4	7.14	3.31E-12	Metabolite levels	
LGG	cis	1	rs6546837	chr2:73677898	NAT8	chr2:73867850-73869537:-	0.27	4.52	7.83E-6	Metabolite levels	
LGG	cis	1	rs6546838	chr2:73679280	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.61E-12	Metabolite levels	
LGG	cis	1	rs6546838	chr2:73679280	NAT8	chr2:73867850-73869537:-	0.27	4.47	9.87E-6	Metabolite levels	
LGG	cis	1	rs6546839	chr2:73680508	ALMS1P	chr2:73872046-73912692:+	0.4	7.14	3.31E-12	Metabolite levels	
LGG	cis	1	rs6546839	chr2:73680508	NAT8	chr2:73867850-73869537:-	0.27	4.52	7.83E-6	Metabolite levels	
LGG	cis	1	rs6547734	chr2:27830990	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs6547734	chr2:27830990	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs6547741	chr2:27855924	PPM1G	chr2:27604062-27632496:-	0.14	4.37	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs6547741	chr2:27855924	SNX17	chr2:27593363-27599994:+	-0.12	-3.59	0.000362	Oral cavity cancer	
LGG	cis	1	rs6547872	chr2:28978074	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.77	1.93E-24	Body mass index	
LGG	cis	1	rs6554106	chr4:54292791	RPL21P44	chr4:54851668-54853449:-	0.21	3.58	0.000377	DNA methylation (variation)	
LGG	cis	1	rs6554286	chr4:56400304	TMEM165	chr4:56262090-56292342:+	0.17	5.03	6.79E-7	Personality dimensions	
LGG	cis	1	rs6563380	chr13:36770422	SOHLH2	chr13:36742347-36871992:-	0.37	6.56	1.34E-10	Glucose homeostasis traits	
LGG	cis	1	rs656640	chr11:71781710	FAM86C	chr11:71498557-71512276:+	0.51	4.98	8.95E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.43	-8.71	4.6E-17	Crohn's disease	
LGG	cis	1	rs656980	chr11:65656282	FIBP	chr11:65651212-65656010:-	0.23	5.75	1.6E-8	Crohn's disease	
LGG	cis	1	rs656980	chr11:65656282	SNX32	chr11:65601410-65621170:+	0.41	9.91	3.07E-21	Crohn's disease	
LGG	cis	1	rs6573006	chr14:55610432	FBXO34	chr14:55738021-55893431:+	0.13	4.06	5.66E-5	Protein biomarker	
LGG	cis	1	rs6573333	chr14:61308337	C14orf135	chr14:60558629-60635851:+	0.55	5.89	7.16E-9	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	DHRS7	chr14:60611502-60636561:-	0.57	5.44	8.33E-8	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	HIF1A	chr14:62162119-62214977:+	0.42	4.72	3.04E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	MNAT1	chr14:61201470-61435396:+	0.68	7.07	5.35E-12	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	PPM1A	chr14:60712470-60765803:+	0.51	6.56	1.37E-10	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	SLC38A6	chr14:61447880-61550450:+	0.38	4.06	5.79E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	SNAPC1	chr14:62229075-62263145:+	0.53	4.71	3.26E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6573333	chr14:61308337	TRMT5	chr14:61438169-61447782:-	0.47	5.2	2.94E-7	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6574278	chr14:76663838	ESRRB	chr14:76837690-76968178:+	0.42	6.78	3.42E-11	Blood pressure	
LGG	cis	1	rs6574639	chr14:81771541	STON2	chr14:81727000-81893748:-	-0.14	-3.59	0.000364	Obesity-related traits	
LGG	cis	1	rs6574641	chr14:81774111	STON2	chr14:81727000-81893748:-	-0.15	-3.64	0.000304	Obesity-related traits	
LGG	cis	1	rs6574642	chr14:81774316	STON2	chr14:81727000-81893748:-	-0.15	-3.64	0.000304	Obesity-related traits	
LGG	cis	1	rs6574643	chr14:81774402	STON2	chr14:81727000-81893748:-	-0.15	-3.64	0.000304	Obesity-related traits	
LGG	cis	1	rs6574644	chr14:81778644	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs6578999	chr11:2231774	C11orf21	chr11:2317507-2323143:-	0.26	4.51	8.2E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs6579000	chr11:2232042	C11orf21	chr11:2317507-2323143:-	0.26	4.49	9.04E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs6579001	chr11:2232056	C11orf21	chr11:2317507-2323143:-	0.26	4.49	9.04E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs6579208	chr20:33598612	PROCR	chr20:33758727-33765164:+	-0.31	-5.85	9.17E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6579210	chr20:33605802	PROCR	chr20:33758727-33765164:+	-0.31	-5.85	9.17E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6579211	chr20:33605857	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.84E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs6579234	chr20:33983485	CPNE1	chr20:34213968-34262539:-	0.27	5.77	1.4E-8	Height	
LGG	cis	1	rs6579234	chr20:33983485	GDF5	chr20:33897002-34042568:-	-0.37	-7.32	1.04E-12	Height	
LGG	cis	1	rs6579234	chr20:33983485	UQCC	chr20:33890383-33999833:-	0.24	5.2	2.87E-7	Height	
LGG	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.62	-10.97	3.46E-25	Cholesterol, total	
LGG	cis	1	rs6579803	chr5:150255559	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs6579804	chr5:150255931	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs6579806	chr5:150271084	LOC134466	chr5:150310000-150326146:-	0.4	4.55	6.88E-6	Crohn's disease	
LGG	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.47	11.59	1.28E-27	Multiple sclerosis	
LGG	cis	1	rs6581155	chr12:58178162	TSFM	chr12:58176536-58191367:+	-0.44	-8.52	1.9E-16	Multiple sclerosis	
LGG	cis	1	rs6584379	chr10:102224490	HIF1AN	chr10:102295641-102313680:+	0.19	3.74	0.000203	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584379	chr10:102224490	NDUFB8	chr10:102283497-102289636:-	0.16	4.6	5.51E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584379	chr10:102224490	WNT8B	chr10:102222812-102243397:+	0.52	8.82	2.05E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584383	chr10:102303065	HIF1AN	chr10:102295641-102313680:+	0.19	3.6	0.000347	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584383	chr10:102303065	NDUFB8	chr10:102283497-102289636:-	0.17	4.66	4.11E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584383	chr10:102303065	WNT8B	chr10:102222812-102243397:+	0.46	7.29	1.23E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs6584962	chr10:111689904	ADD3	chr10:111756108-111895320:+	0.15	3.6	0.000355	Biliary atresia	
LGG	cis	1	rs6585827	chr10:124165615	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.1	4.93E-5	Height	
LGG	cis	1	rs658661	chr11:71559269	FAM86C	chr11:71498557-71512276:+	-0.47	-4.83	1.82E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6587109	chr17:20917818	USP22	chr17:20902908-20947073:-	-0.19	-4.42	1.23E-5	Blood trace element (Se levels)	
LGG	cis	1	rs6587115	chr17:20960911	USP22	chr17:20902908-20947073:-	-0.18	-4.17	3.65E-5	Blood trace element (Se levels)	
LGG	cis	1	rs6587711	chr1:152887237	SMCP	chr1:152850798-152857515:+	-0.33	-5.07	5.74E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6589589	chr11:116932428	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs6589810	chr11:120233908	TMEM136	chr11:120196016-120204388:+	0.22	4.97	9.23E-7	Intraocular pressure	
LGG	cis	1	rs6589811	chr11:120235703	TMEM136	chr11:120196016-120204388:+	0.2	4.56	6.33E-6	Intraocular pressure	
LGG	cis	1	rs6589812	chr11:120278359	TMEM136	chr11:120196016-120204388:+	0.2	4.49	8.7E-6	Intraocular pressure	
LGG	cis	1	rs6589813	chr11:120293490	TMEM136	chr11:120196016-120204388:+	0.2	4.59	5.52E-6	Intraocular pressure	
LGG	cis	1	rs6589964	chr11:122870683	UBASH3B	chr11:122526398-122685186:+	0.14	3.48	0.000551	Menarche (age at onset)	
LGG	cis	1	rs6592448	chr11:71670044	FAM86C	chr11:71498557-71512276:+	-0.47	-4.67	3.86E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6592450	chr11:71671166	FAM86C	chr11:71498557-71512276:+	0.4	4.36	1.56E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6592453	chr11:71683231	FAM86C	chr11:71498557-71512276:+	0.49	4.81	2.06E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6592455	chr11:71689541	FAM86C	chr11:71498557-71512276:+	-0.44	-4.35	1.64E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs659307	chr1:183163078	LAMC2	chr1:183155174-183214262:+	0.27	5.5	6.07E-8	Hypertriglyceridemia	
LGG	cis	1	rs6593585	chr1:76140273	MSH4	chr1:76262630-76378923:+	0.23	4.24	2.71E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs6594906	chr5:115171435	ATG12	chr5:115165818-115177520:-	0.19	4.13	4.23E-5	IgG glycosylation	
LGG	cis	1	rs659513	chr11:71812411	FAM86C	chr11:71498557-71512276:+	-0.5	-4.87	1.53E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6595767	chr5:126734267	FLJ44606	chr5:126381051-126409172:-	0.27	3.7	0.000241	IgG glycosylation	
LGG	cis	1	rs6595769	chr5:126734365	FLJ44606	chr5:126381051-126409172:-	0.28	3.82	0.000153	IgG glycosylation	
LGG	cis	1	rs6597965	chr11:964476	MUC6	chr11:1012824-1036706:-	-0.18	-3.93	9.61E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs6597972	chr11:928402	MUC6	chr11:1012824-1036706:-	-0.19	-4.06	5.6E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs6598060	chr11:243987	PSMD13	chr11:236808-252984:+	-0.24	-5.27	2.08E-7	Menarche (age at onset)	
LGG	cis	1	rs6598061	chr11:243853	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs6598062	chr11:243712	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs6598063	chr11:243672	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs6598065	chr11:243211	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs6598066	chr11:243185	PSMD13	chr11:236808-252984:+	-0.22	-4.78	2.37E-6	Menarche (age at onset)	
LGG	cis	1	rs6598069	chr11:240664	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs6598074	chr11:219398	PSMD13	chr11:236808-252984:+	-0.22	-4.73	2.91E-6	Menarche (age at onset)	
LGG	cis	1	rs6598266	chr15:100299239	ADAMTS17	chr15:100511643-100882183:-	-0.27	-3.62	0.000329	Major depressive disorder	
LGG	cis	1	rs6598266	chr15:100299239	C15orf51	chr15:100330361-100347132:-	0.31	4.47	9.64E-6	Major depressive disorder	
LGG	cis	1	rs6598267	chr15:100299295	ADAMTS17	chr15:100511643-100882183:-	0.28	3.6	0.000356	Major depressive disorder	
LGG	cis	1	rs6598267	chr15:100299295	C15orf51	chr15:100330361-100347132:-	-0.33	-4.63	4.58E-6	Major depressive disorder	
LGG	cis	1	rs6598268	chr15:100299300	ADAMTS17	chr15:100511643-100882183:-	0.28	3.62	0.000331	Major depressive disorder	
LGG	cis	1	rs6598268	chr15:100299300	C15orf51	chr15:100330361-100347132:-	-0.33	-4.62	4.9E-6	Major depressive disorder	
LGG	cis	1	rs6598269	chr15:100299380	ADAMTS17	chr15:100511643-100882183:-	0.27	3.54	0.000431	Major depressive disorder	
LGG	cis	1	rs6598269	chr15:100299380	C15orf51	chr15:100330361-100347132:-	-0.33	-4.66	4.06E-6	Major depressive disorder	
LGG	cis	1	rs6598270	chr15:100299596	ADAMTS17	chr15:100511643-100882183:-	0.27	3.54	0.000431	Major depressive disorder	
LGG	cis	1	rs6598270	chr15:100299596	C15orf51	chr15:100330361-100347132:-	-0.33	-4.66	4.06E-6	Major depressive disorder	
LGG	cis	1	rs6598271	chr15:100299633	ADAMTS17	chr15:100511643-100882183:-	0.28	3.63	0.000308	Major depressive disorder	
LGG	cis	1	rs6598271	chr15:100299633	C15orf51	chr15:100330361-100347132:-	-0.33	-4.62	4.93E-6	Major depressive disorder	
LGG	cis	1	rs6598272	chr15:100299673	ADAMTS17	chr15:100511643-100882183:-	0.28	3.66	0.000279	Major depressive disorder	
LGG	cis	1	rs6598272	chr15:100299673	C15orf51	chr15:100330361-100347132:-	-0.33	-4.68	3.66E-6	Major depressive disorder	
LGG	cis	1	rs6598955	chr1:26619649	UBXN11	chr1:26608773-26644756:-	0.12	4.41	1.29E-5	Obesity-related traits	
LGG	cis	1	rs6598955	chr1:26619649	ZNF593	chr1:26496388-26497362:+	0.14	4.43	1.15E-5	Obesity-related traits	
LGG	cis	1	rs6599170	chr3:41772718	ULK4	chr3:41288091-42003660:-	0.72	14.12	3.18E-38	Diastolic blood pressure	
LGG	cis	1	rs6599175	chr3:41786009	ULK4	chr3:41288091-42003660:-	-0.75	-14.87	1.5E-41	Diastolic blood pressure	
LGG	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.77	-15.08	1.66E-42	Diastolic blood pressure	
LGG	cis	1	rs6599178	chr3:41842129	ULK4	chr3:41288091-42003660:-	0.77	15.31	1.49E-43	Diastolic blood pressure	
LGG	cis	1	rs6599179	chr3:41855284	ULK4	chr3:41288091-42003660:-	0.77	15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs6599318	chr4:243968	ZNF718	chr4:53272-156488:+	0.26	5.12	4.5E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs6599388	chr4:939087	SLC26A1	chr4:972864-987224:-	0.17	4.6	5.34E-6	Parkinson's disease	
LGG	cis	1	rs6599639	chr10:124743751	PSTK	chr10:124739556-124749906:+	0.16	3.71	0.000228	Migraine without aura	
LGG	cis	1	rs6601540	chr8:10816873	RP1L1	chr8:10463862-10512617:-	-0.29	-3.67	0.000271	Asthma and hay fever	
LGG	cis	1	rs6603033	chr15:83335875	FAM154B	chr15:82555152-82577265:+	0.21	4.41	1.29E-5	Schizophrenia	
LGG	cis	1	rs6603033	chr15:83335875	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.19	4.64	4.43E-6	Schizophrenia	
LGG	cis	1	rs6603975	chr1:92951239	EVI5	chr1:92974255-93257961:-	-0.29	-6.56	1.4E-10	Cholesterol, total	
LGG	cis	1	rs6603979	chr1:92979354	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs6603981	chr1:92993807	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs6603982	chr1:92994033	EVI5	chr1:92974255-93257961:-	-0.29	-7.32	9.91E-13	Cholesterol, total	
LGG	cis	1	rs6603984	chr1:93011572	EVI5	chr1:92974255-93257961:-	-0.29	-7.17	2.74E-12	Cholesterol, total	
LGG	cis	1	rs6603985	chr1:93017159	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs6603987	chr1:93019313	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs6603990	chr1:93030735	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.4E-13	Cholesterol, total	
LGG	cis	1	rs660602	chr1:183162774	LAMC2	chr1:183155174-183214262:+	0.27	5.41	9.65E-8	Hypertriglyceridemia	
LGG	cis	1	rs661242	chr11:71579229	FAM86C	chr11:71498557-71512276:+	-0.45	-4.66	4.01E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs662545	chr11:83267886	CCDC90B	chr11:82972506-82997414:-	0.24	5.6	3.54E-8	Subcortical brain region volumes	
LGG	cis	1	rs664172	chr15:78862762	CHRNA5	chr15:78857906-78886458:+	-0.36	-5.55	4.65E-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs66477954	chr8:58187810	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs66479724	chr8:58188309	C8orf71	chr8:58192102-58197288:+	0.34	5.91	6.41E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6648	chr20:47895242	ARFGEF2	chr20:47538275-47653229:+	-0.14	-3.92	0.000101	Height	
LGG	cis	1	rs66495524	chr8:58187365	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6650153	chr10:5019320	AKR1C2	chr10:4964715-5060207:-	0.33	4.25	2.6E-5	Height	
LGG	cis	1	rs6650178	chr11:114629786	C11orf71	chr11:114262170-114271255:-	-0.2	-4.21	3.0E-5	Urinary albumin excretion	
LGG	cis	1	rs66529337	chr6:163005662	PACRG	chr6:163148164-163736523:+	0.3	4.54	7.06E-6	Body mass index	
LGG	cis	1	rs66534347	chr2:240899346	NDUFA10	chr2:240900158-240964798:-	0.41	7.92	1.66E-14	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs66534429	chr6:163003322	PACRG	chr6:163148164-163736523:+	0.3	4.57	6.09E-6	Body mass index	
LGG	cis	1	rs6656432	chr1:93029453	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs6656450	chr1:151089602	LYSMD1	chr1:151132225-151138424:-	-0.18	-4.06	5.74E-5	Body mass index	
LGG	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.17	-5	8.18E-7	Body mass index	
LGG	cis	1	rs6656992	chr1:46333068	MUTYH	chr1:45794915-45806142:-	0.14	5.17	3.37E-7	Body mass index	
LGG	cis	1	rs6658708	chr1:202322113	UBE2T	chr1:202300786-202311094:-	-0.13	-4.04	6.14E-5	Sex ratio	
LGG	cis	1	rs665885	chr6:160702859	SLC22A3	chr6:160769425-160876013:+	0.31	5.35	1.37E-7	Waist circumference	
LGG	cis	1	rs6659039	chr1:248465689	OR2L13	chr1:248100493-248264223:+	0.21	3.74	0.000207	Common traits (Other)	
LGG	cis	1	rs66594243	chr6:163169024	PACRG	chr6:163148164-163736523:+	0.44	5.94	5.26E-9	Body mass index	
LGG	cis	1	rs66597435	chr12:50945269	ATF1	chr12:51157819-51214906:+	-0.2	-4.29	2.15E-5	Fibrinogen	
LGG	cis	1	rs66597435	chr12:50945269	LETMD1	chr12:51442084-51454206:+	0.15	3.73	0.000214	Fibrinogen	
LGG	cis	1	rs66597435	chr12:50945269	SLC11A2	chr12:51373319-51422058:-	0.17	3.71	0.000227	Fibrinogen	
LGG	cis	1	rs66598018	chr2:61878318	C2orf74	chr2:61372243-61391964:+	0.2	3.48	0.00055	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs6659824	chr1:175125378	TNN	chr1:175036994-175117202:+	-0.17	-3.54	0.000439	Alcohol dependence	
LGG	cis	1	rs6660565	chr1:171261193	FMO4	chr1:171283486-171311222:+	-0.19	-4.45	1.06E-5	Sudden cardiac arrest	
LGG	cis	1	rs6661134	chr1:93010908	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.46E-13	Cholesterol, total	
LGG	cis	1	rs6661764	chr1:207808385	CR1	chr1:207669473-207815109:+	0.19	3.65	0.000291	LDL cholesterol	
LGG	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.95	9.98E-7	Body mass index	
LGG	cis	1	rs6661910	chr1:46290632	MUTYH	chr1:45794915-45806142:-	0.14	5.09	5.06E-7	Body mass index	
LGG	cis	1	rs6661970	chr1:202520925	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs66624122	chr10:4981039	AKR1C2	chr10:4964715-5060207:-	0.36	4.84	1.76E-6	Height	
LGG	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.73	2.89E-6	Body mass index	
LGG	cis	1	rs6662641	chr1:46571509	MUTYH	chr1:45794915-45806142:-	0.14	5.09	5.17E-7	Body mass index	
LGG	cis	1	rs66629800	chr5:112712238	SRP19	chr5:112196993-112228774:+	0.28	3.48	0.000539	F-cell distribution	
LGG	cis	1	rs66644594	chr12:50932983	ATF1	chr12:51157819-51214906:+	-0.21	-4.34	1.72E-5	Fibrinogen	
LGG	cis	1	rs66644594	chr12:50932983	LETMD1	chr12:51442084-51454206:+	0.15	3.61	0.000342	Fibrinogen	
LGG	cis	1	rs66644594	chr12:50932983	SLC11A2	chr12:51373319-51422058:-	0.17	3.68	0.000261	Fibrinogen	
LGG	cis	1	rs6664760	chr1:3648268	LRRC47	chr1:3696784-3713068:-	-0.26	-3.46	0.000593	Visceral adipose tissue adjusted for BMI	
LGG	cis	1	rs66651343	chr15:43558004	STRC	chr15:43891762-43924561:-	0.26	5.49	6.62E-8	Lung cancer	
LGG	cis	1	rs66651343	chr15:43558004	TGM5	chr15:43525375-43559055:-	-0.2	-3.68	0.00026	Lung cancer	
LGG	cis	1	rs666581	chr5:42152335	C5orf51	chr5:41904470-41921737:+	-0.29	-3.79	0.00017	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs6665949	chr1:31862537	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.81	0.000155	Schizophrenia	
LGG	cis	1	rs6666690	chr1:248465323	OR2L13	chr1:248100493-248264223:+	0.2	3.62	0.000323	Common traits (Other)	
LGG	cis	1	rs6666959	chr1:150088955	RPRD2	chr1:150336990-150449039:+	-0.15	-3.95	9.07E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs66672857	chr8:58179817	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.3	1.79E-7	Body mass index	
LGG	cis	1	rs6668284	chr1:46354510	MUTYH	chr1:45794915-45806142:-	0.13	4.93	1.15E-6	Body mass index	
LGG	cis	1	rs6668386	chr1:12047233	MIIP	chr1:12079512-12092106:+	0.09	3.52	0.000467	Platelet count	
LGG	cis	1	rs666845	chr11:83277544	CCDC90B	chr11:82972506-82997414:-	0.22	5.22	2.68E-7	Subcortical brain region volumes	
LGG	cis	1	rs6669008	chr1:114166561	BCL2L15	chr1:114419437-114430169:-	0.17	4.63	4.74E-6	Bacteremia	
LGG	cis	1	rs6669236	chr1:227813909	JMJD4	chr1:227918891-227923112:-	0.27	4.63	4.6E-6	Height	
LGG	cis	1	rs6669236	chr1:227813909	SNAP47	chr1:227916240-227968932:+	-0.2	-3.82	0.000153	Height	
LGG	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	3.88E-7	Body mass index	
LGG	cis	1	rs6669522	chr1:46397941	MUTYH	chr1:45794915-45806142:-	0.13	4.98	8.99E-7	Body mass index	
LGG	cis	1	rs6671789	chr1:248482931	OR2L13	chr1:248100493-248264223:+	0.19	3.46	0.00059	Common traits (Other)	
LGG	cis	1	rs6672180	chr1:76123973	MSH4	chr1:76262630-76378923:+	0.23	4.28	2.25E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs6672267	chr1:12054911	MIIP	chr1:12079512-12092106:+	0.09	3.67	0.000267	Platelet count	
LGG	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.08	5.49E-7	Body mass index	
LGG	cis	1	rs6672898	chr1:46290588	MUTYH	chr1:45794915-45806142:-	0.14	5.15	3.86E-7	Body mass index	
LGG	cis	1	rs66731170	chr8:58187895	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs66738981	chr17:45325538	ITGB3	chr17:45331208-45421658:+	-0.23	-4.62	4.98E-6	Body mass index	
LGG	cis	1	rs6674970	chr1:151116279	LYSMD1	chr1:151132225-151138424:-	-0.18	-4.12	4.37E-5	Body mass index	
LGG	cis	1	rs667538	chr6:160738920	SLC22A3	chr6:160769425-160876013:+	-0.35	-6.01	3.69E-9	Waist circumference	
LGG	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.89	1.36E-6	Body mass index	
LGG	cis	1	rs6675726	chr1:46560643	MUTYH	chr1:45794915-45806142:-	0.14	5.04	6.41E-7	Body mass index	
LGG	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.33	1.51E-7	Body mass index	
LGG	cis	1	rs6675946	chr1:46371774	MUTYH	chr1:45794915-45806142:-	0.13	4.98	8.85E-7	Body mass index	
LGG	cis	1	rs6676190	chr1:151079317	LYSMD1	chr1:151132225-151138424:-	-0.17	-4.01	6.97E-5	Body mass index	
LGG	cis	1	rs6676190	chr1:151079317	MRPL9	chr1:151732125-151736040:-	-0.13	-3.46	0.000595	Body mass index	
LGG	cis	1	rs6676190	chr1:151079317	PSMD4	chr1:151227197-151239952:+	-0.13	-3.47	0.000558	Body mass index	
LGG	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.15	3.71E-7	Body mass index	
LGG	cis	1	rs6677007	chr1:46400590	MUTYH	chr1:45794915-45806142:-	0.13	4.97	9.05E-7	Body mass index	
LGG	cis	1	rs6677097	chr1:175123897	TNN	chr1:175036994-175117202:+	-0.17	-3.54	0.000432	Alcohol dependence	
LGG	cis	1	rs66775662	chr6:151876216	C6orf97	chr6:151815175-151942327:+	0.26	4.24	2.72E-5	Bone mineral density (spine)	
LGG	cis	1	rs66789102	chr6:163104432	PACRG	chr6:163148164-163736523:+	0.41	5.63	3.12E-8	Body mass index	
LGG	cis	1	rs6678964	chr1:95694268	RWDD3	chr1:95583479-95712773:+	0.24	4.28	2.29E-5	Stearic acid (18:0) plasma levels	
LGG	cis	1	rs6679073	chr1:205756484	PM20D1	chr1:205797154-205819245:-	-0.46	-8.05	6.27E-15	Prostate-specific antigen levels	
LGG	cis	1	rs6679145	chr1:156256000	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6679145	chr1:156256000	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6679552	chr1:202449586	UBE2T	chr1:202300786-202311094:-	-0.13	-3.95	9.01E-5	Sex ratio	
LGG	cis	1	rs66796009	chr8:58174529	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs66797613	chr10:1090469	C10orf110	chr10:1068577-1090141:+	0.29	5.36	1.3E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.02	7.37E-7	Body mass index	
LGG	cis	1	rs6680380	chr1:46300189	MUTYH	chr1:45794915-45806142:-	0.14	5.02	7.23E-7	Body mass index	
LGG	cis	1	rs6681020	chr1:175125264	TNN	chr1:175036994-175117202:+	-0.17	-3.54	0.000439	Alcohol dependence	
LGG	cis	1	rs6681423	chr1:248482834	OR2L13	chr1:248100493-248264223:+	0.19	3.46	0.00059	Common traits (Other)	
LGG	cis	1	rs6682784	chr1:202313978	UBE2T	chr1:202300786-202311094:-	-0.13	-3.81	0.000155	Sex ratio	
LGG	cis	1	rs6682956	chr1:110130264	SYPL2	chr1:110009100-110024763:+	-0.22	-3.91	0.000105	Major depressive disorder	
LGG	cis	1	rs6683533	chr1:175125440	TNN	chr1:175036994-175117202:+	-0.17	-3.54	0.000433	Alcohol dependence	
LGG	cis	1	rs6683717	chr1:248476792	OR2L13	chr1:248100493-248264223:+	0.2	3.5	0.000501	Common traits (Other)	
LGG	cis	1	rs66840104	chr8:58190001	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6684514	chr1:156255456	BGLAP	chr1:156182784-156213112:+	0.26	5.41	9.65E-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6684514	chr1:156255456	CCT3	chr1:156278752-156308195:-	-0.16	-3.93	9.68E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6685373	chr1:202314199	UBE2T	chr1:202300786-202311094:-	-0.13	-4.01	7.12E-5	Sex ratio	
LGG	cis	1	rs6686532	chr1:220606775	MOSC2	chr1:220921676-220957594:+	0.23	3.52	0.000468	Fat distribution (HIV)	
LGG	cis	1	rs6686643	chr1:165616588	MGST3	chr1:165600450-165624853:+	0.25	6.99	8.76E-12	Total ventricular volume	
LGG	cis	1	rs66870803	chr8:58180022	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs66871576	chr14:55629050	FBXO34	chr14:55738021-55893431:+	0.15	4.62	4.93E-6	Protein biomarker	
LGG	cis	1	rs6687454	chr1:149999764	RPRD2	chr1:150336990-150449039:+	0.16	3.98	7.91E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs66885174	chr10:4975650	AKR1C2	chr10:4964715-5060207:-	0.4	5.44	8.61E-8	Height	
LGG	cis	1	rs66886949	chr8:58187613	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6689375	chr1:227721627	JMJD4	chr1:227918891-227923112:-	0.23	3.89	0.000113	Height	
LGG	cis	1	rs6689375	chr1:227721627	SNAP47	chr1:227916240-227968932:+	-0.18	-3.52	0.000466	Height	
LGG	cis	1	rs6690764	chr1:92976590	EVI5	chr1:92974255-93257961:-	-0.29	-7.27	1.4E-12	Cholesterol, total	
LGG	cis	1	rs6692187	chr1:93035020	EVI5	chr1:92974255-93257961:-	-0.3	-7.37	7.53E-13	Cholesterol, total	
LGG	cis	1	rs6692376	chr1:227716069	JMJD4	chr1:227918891-227923112:-	0.22	3.73	0.000211	Height	
LGG	cis	1	rs66936919	chr8:58172868	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6695144	chr1:202489218	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.2	2.86E-7	Body mass index	
LGG	cis	1	rs6695809	chr1:46285461	MUTYH	chr1:45794915-45806142:-	0.14	5.3	1.78E-7	Body mass index	
LGG	cis	1	rs6696239	chr1:227750068	JMJD4	chr1:227918891-227923112:-	0.25	4.26	2.42E-5	Height	
LGG	cis	1	rs6696239	chr1:227750068	SNAP47	chr1:227916240-227968932:+	-0.19	-3.8	0.000164	Height	
LGG	cis	1	rs66965793	chr1:156285814	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.79E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs66965793	chr1:156285814	CCT3	chr1:156278752-156308195:-	-0.16	-3.99	7.54E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6696611	chr1:202493689	UBE2T	chr1:202300786-202311094:-	-0.12	-3.64	0.000304	Sex ratio	
LGG	cis	1	rs66968227	chr11:64070930	C11orf20	chr11:64067863-64072238:+	-0.32	-4.81	1.98E-6	Mean platelet volume	
LGG	cis	1	rs6697735	chr1:248465315	OR2L13	chr1:248100493-248264223:+	0.2	3.62	0.000323	Common traits (Other)	
LGG	cis	1	rs66978370	chr5:93553633	FAM172A	chr5:92953432-93447404:-	-0.29	-3.97	8.24E-5	Diabetic retinopathy	
LGG	cis	1	rs6698409	chr1:227768358	JMJD4	chr1:227918891-227923112:-	0.25	4.26	2.42E-5	Height	
LGG	cis	1	rs6698409	chr1:227768358	SNAP47	chr1:227916240-227968932:+	-0.19	-3.8	0.000164	Height	
LGG	cis	1	rs6698579	chr1:31861710	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.79	0.000172	Schizophrenia	
LGG	cis	1	rs66987356	chr3:127841098	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.07	5.4E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6699417	chr1:89123443	CCBL2	chr1:89401456-89458643:-	-0.53	-12.4	6.85E-31	Height	
LGG	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	3.9E-7	Body mass index	
LGG	cis	1	rs6700597	chr1:46284246	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.06E-7	Body mass index	
LGG	cis	1	rs6700792	chr1:231170013	FAM89A	chr1:231154704-231175995:-	-0.27	-4.67	3.94E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6701037	chr1:175120079	TNN	chr1:175036994-175117202:+	0.18	3.71	0.000234	Alcohol dependence	
LGG	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.06	5.88E-7	Body mass index	
LGG	cis	1	rs6701614	chr1:46309420	MUTYH	chr1:45794915-45806142:-	0.14	5.13	4.18E-7	Body mass index	
LGG	cis	1	rs6701713	chr1:207786289	CR1	chr1:207669473-207815109:+	-0.38	-6.64	8.34E-11	Alzheimer's disease (late onset)	
LGG	cis	1	rs6702010	chr1:175123858	TNN	chr1:175036994-175117202:+	-0.17	-3.58	0.000377	Alcohol dependence	
LGG	cis	1	rs67025553	chr6:163011552	PACRG	chr6:163148164-163736523:+	0.29	4.29	2.14E-5	Body mass index	
LGG	cis	1	rs6702653	chr1:227703919	JMJD4	chr1:227918891-227923112:-	0.22	3.63	0.000316	Height	
LGG	cis	1	rs67034206	chr1:156270260	BGLAP	chr1:156182784-156213112:+	0.25	5.33	1.52E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs67034206	chr1:156270260	CCT3	chr1:156278752-156308195:-	-0.16	-4.02	6.66E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs67039591	chr8:58174553	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs67042566	chr6:163006541	PACRG	chr6:163148164-163736523:+	0.3	4.47	9.91E-6	Body mass index	
LGG	cis	1	rs67046187	chr6:163068532	PACRG	chr6:163148164-163736523:+	0.36	4.96	9.94E-7	Body mass index	
LGG	cis	1	rs6704770	chr2:232109816	HTR2B	chr2:231972952-231989824:-	0.45	7.31	1.09E-12	Food antigen IgG levels	
LGG	cis	1	rs6704930	chr2:26325705	GPR113	chr2:26531041-26569685:-	-0.24	-3.82	0.00015	Gut microbiome composition (summer)	
LGG	cis	1	rs6705001	chr2:103076210	IL18R1	chr2:102927962-103015215:+	-0.38	-6.15	1.57E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6705001	chr2:103076210	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.41	1.01E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6705330	chr2:203662197	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.4	7.22	2.04E-12	Metabolite levels	
LGG	cis	1	rs6705489	chr2:73648811	NAT8	chr2:73867850-73869537:-	0.26	4.31	2.0E-5	Metabolite levels	
LGG	cis	1	rs6706610	chr2:27778091	PPM1G	chr2:27604062-27632496:-	0.14	4.36	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs6706610	chr2:27778091	SNX17	chr2:27593363-27599994:+	-0.12	-3.63	0.000314	Oral cavity cancer	
LGG	cis	1	rs67073037	chr2:29119585	TRMT61B	chr2:29072690-29093175:-	0.45	8.57	1.38E-16	Breast cancer (estrogen-receptor negative);Breast cancer	
LGG	cis	1	rs6707458	chr2:160914540	LY75	chr2:160625141-160761262:-	0.13	3.63	0.000312	Idiopathic membranous nephropathy	
LGG	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.39	7.12	3.81E-12	Metabolite levels	
LGG	cis	1	rs6707722	chr2:73654363	NAT8	chr2:73867850-73869537:-	0.27	4.44	1.12E-5	Metabolite levels	
LGG	cis	1	rs6707813	chr2:173923137	ZAK	chr2:173940565-174132736:+	0.16	3.52	0.000469	Parental longevity (mother's age at death)	
LGG	cis	1	rs6707848	chr2:28988083	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.89	7.03E-25	Body mass index	
LGG	cis	1	rs67080286	chr17:45322248	ITGB3	chr17:45331208-45421658:+	-0.21	-4.37	1.55E-5	Body mass index	
LGG	cis	1	rs6708328	chr2:24412413	C2orf84	chr2:24397531-24414566:+	0.24	4.59	5.6E-6	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs6708328	chr2:24412413	LOC375190	chr2:24299728-24397519:+	-0.3	-6.85	2.27E-11	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs6708373	chr2:234172846	ATG16L1	chr2:234160217-234204319:+	-0.18	-4.14	4.09E-5	Crohn's disease	
LGG	cis	1	rs67094146	chr6:163145412	PACRG	chr6:163148164-163736523:+	0.42	6.04	3.09E-9	Body mass index	
LGG	cis	1	rs6709534	chr2:217334	FAM150B	chr2:279563-288308:-	-0.31	-5.85	9.16E-9	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs6709534	chr2:217334	SNTG2	chr2:946555-1371382:+	0.2	3.69	0.000248	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs6709595	chr2:26259885	GPR113	chr2:26531041-26569685:-	-0.24	-3.88	0.000119	Gut microbiome composition (summer)	
LGG	cis	1	rs67096506	chr8:58195655	C8orf71	chr8:58192102-58197288:+	0.38	6.34	5.28E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs67098772	chr14:55595242	FBXO34	chr14:55738021-55893431:+	0.15	4.51	8.21E-6	Protein biomarker	
LGG	cis	1	rs6710438	chr2:73820108	ALMS1P	chr2:73872046-73912692:+	-0.41	-7.31	1.09E-12	Metabolite levels	
LGG	cis	1	rs6710438	chr2:73820108	NAT8	chr2:73867850-73869537:-	-0.26	-4.23	2.82E-5	Metabolite levels	
LGG	cis	1	rs67105789	chr8:58192002	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6710959	chr2:28958603	FAM179A	chr2:29204164-29275094:+	-0.19	-3.71	0.000229	Body mass index	
LGG	cis	1	rs6710959	chr2:28958603	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.66	5.06E-24	Body mass index	
LGG	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.39	7	8.28E-12	Metabolite levels	
LGG	cis	1	rs6711033	chr2:73746643	NAT8	chr2:73867850-73869537:-	0.27	4.43	1.15E-5	Metabolite levels	
LGG	cis	1	rs6711127	chr2:202213515	PPIL3	chr2:201735680-201753999:-	-0.9	-11.75	2.8E-28	Rheumatoid arthritis	
LGG	cis	1	rs6711312	chr2:232122348	HTR2B	chr2:231972952-231989824:-	0.44	7.16	2.95E-12	Food antigen IgG levels	
LGG	cis	1	rs67113930	chr2:179741348	CCDC141	chr2:179697347-179914786:-	-0.33	-5.12	4.38E-7	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.82	-12.1	1.08E-29	Rheumatoid arthritis	
LGG	cis	1	rs6712370	chr2:69855094	GFPT1	chr2:69546905-69614382:-	-0.16	-3.56	0.000406	Serum thyroid-stimulating hormone levels	
LGG	cis	1	rs6713618	chr2:103048437	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6713618	chr2:103048437	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6714736	chr2:202214148	ALS2CR12	chr2:202153148-202222101:-	0.21	4.03	6.41E-5	Basal cell carcinoma	
LGG	cis	1	rs6714736	chr2:202214148	ALS2CR4	chr2:202484907-202508224:-	-0.2	-5.21	2.79E-7	Basal cell carcinoma	
LGG	cis	1	rs6714736	chr2:202214148	PPIL3	chr2:201735680-201753999:-	0.19	3.89	0.000116	Basal cell carcinoma	
LGG	cis	1	rs67150649	chr5:93292377	FAM172A	chr5:92953432-93447404:-	-0.33	-4.7	3.39E-6	Diabetic retinopathy	
LGG	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.79	-11.78	2.23E-28	Rheumatoid arthritis	
LGG	cis	1	rs6715380	chr2:202214505	PPIL3	chr2:201735680-201753999:-	-0.88	-11.53	2.24E-27	Rheumatoid arthritis	
LGG	cis	1	rs6715819	chr2:73772309	ALMS1P	chr2:73872046-73912692:+	0.38	6.63	9.14E-11	Metabolite levels	
LGG	cis	1	rs6715819	chr2:73772309	NAT8	chr2:73867850-73869537:-	0.26	4.1	4.79E-5	Metabolite levels	
LGG	cis	1	rs6716784	chr2:103048467	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6716784	chr2:103048467	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs671681	chr11:71782812	FAM86C	chr11:71498557-71512276:+	0.51	4.98	8.95E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6716937	chr2:70127229	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.35	1.69E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs67173199	chr3:186432858	KNG1	chr3:186435120-186461741:+	-0.16	-3.55	0.000418	Adiponectin levels	
LGG	cis	1	rs6717980	chr2:27452784	SLC5A6	chr2:27422459-27435071:-	-0.3	-6.24	9.71E-10	Blood metabolite levels	
LGG	cis	1	rs67180937	chr1:222823743	HHIPL2	chr1:222695602-222721444:-	0.2	3.56	0.000404	Coronary artery disease	
LGG	cis	1	rs6718128	chr2:27833752	PPM1G	chr2:27604062-27632496:-	-0.13	-4.07	5.49E-5	Oral cavity cancer	
LGG	cis	1	rs6718128	chr2:27833752	SNX17	chr2:27593363-27599994:+	0.12	3.68	0.000258	Oral cavity cancer	
LGG	cis	1	rs67188507	chr8:58187492	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6719462	chr2:166895226	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000348	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6719462	chr2:166895226	TTC21B	chr2:166713988-166810348:-	0.13	3.91	0.000107	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6719686	chr2:160908292	LY75	chr2:160625141-160761262:-	0.13	3.67	0.000267	Idiopathic membranous nephropathy	
LGG	cis	1	rs6719899	chr2:166895573	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6719899	chr2:166895573	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs67200948	chr5:126731136	FLJ44606	chr5:126381051-126409172:-	0.26	3.48	0.000553	IgG glycosylation	
LGG	cis	1	rs6720314	chr2:26334852	GPR113	chr2:26531041-26569685:-	-0.23	-3.52	0.000472	Gut microbiome composition (summer)	
LGG	cis	1	rs67205460	chr10:1090366	C10orf110	chr10:1068577-1090141:+	0.29	5.36	1.3E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs672059	chr1:183162539	LAMC2	chr1:183155174-183214262:+	0.28	5.59	3.82E-8	Hypertriglyceridemia	
LGG	cis	1	rs6720763	chr2:167992286	XIRP2	chr2:167744997-168116259:+	0.33	4.87	1.54E-6	Atopic dermatitis	
LGG	cis	1	rs6720809	chr2:88528943	FABP1	chr2:88422510-88427578:-	-0.3	-4.21	2.99E-5	Plasma clusterin levels	
LGG	cis	1	rs6720809	chr2:88528943	THNSL2	chr2:88469835-88486145:+	-0.57	-8.38	5.56E-16	Plasma clusterin levels	
LGG	cis	1	rs672119	chr1:183162506	LAMC2	chr1:183155174-183214262:+	0.28	5.59	3.82E-8	Hypertriglyceridemia	
LGG	cis	1	rs67214274	chr20:47898561	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs6721891	chr2:70146121	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.23	2.83E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6722069	chr2:88533151	FABP1	chr2:88422510-88427578:-	-0.31	-4.32	1.92E-5	Plasma clusterin levels	
LGG	cis	1	rs6722069	chr2:88533151	THNSL2	chr2:88469835-88486145:+	-0.57	-8.37	6.25E-16	Plasma clusterin levels	
LGG	cis	1	rs67236942	chr8:58176525	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs67237174	chr8:58175776	C8orf71	chr8:58192102-58197288:+	0.35	6.1	2.11E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6724025	chr2:86200835	LOC90784	chr2:86247339-86250991:-	-0.39	-4.35	1.63E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs6724253	chr2:232121998	HTR2B	chr2:231972952-231989824:-	0.44	7.16	2.95E-12	Food antigen IgG levels	
LGG	cis	1	rs67243305	chr8:58174958	C8orf71	chr8:58192102-58197288:+	0.36	6.21	1.12E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6724782	chr2:73679990	ALMS1P	chr2:73872046-73912692:+	0.4	7.14	3.31E-12	Metabolite levels	
LGG	cis	1	rs6724782	chr2:73679990	NAT8	chr2:73867850-73869537:-	0.27	4.52	7.83E-6	Metabolite levels	
LGG	cis	1	rs6725425	chr2:70150674	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.33	1.84E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs67257959	chr19:17158145	HAUS8	chr19:17160573-17186343:-	-0.11	-3.73	0.000214	Selective IgA deficiency	
LGG	cis	1	rs6727306	chr2:102981644	IL18R1	chr2:102927962-103015215:+	-0.36	-5.6	3.54E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6727306	chr2:102981644	IL1RL1	chr2:102927962-102968497:+	-0.34	-4.86	1.59E-6	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6729080	chr2:26301282	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs6729553	chr2:84909835	DNAH6	chr2:84743579-85046711:+	-0.19	-3.59	0.000365	Hypospadias	
LGG	cis	1	rs6729757	chr2:26285102	GPR113	chr2:26531041-26569685:-	-0.23	-3.73	0.000212	Gut microbiome composition (summer)	
LGG	cis	1	rs6729760	chr2:70161032	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.41	1.26E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6730503	chr2:37528478	CEBPZ	chr2:37428778-37458740:-	0.19	4.86	1.61E-6	Chronic lymphocytic leukemia	
LGG	cis	1	rs67308532	chr5:125908599	ALDH7A1	chr5:125878918-125931082:-	0.46	5.48	6.69E-8	Osteoporosis	
LGG	cis	1	rs6732426	chr2:43587504	LOC100129726	chr2:43454350-43455994:+	0.15	3.88	0.000117	Hair morphology	
LGG	cis	1	rs6732655	chr2:166895066	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Epilepsy	
LGG	cis	1	rs6732655	chr2:166895066	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Epilepsy	
LGG	cis	1	rs6732789	chr2:166895203	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000348	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6732789	chr2:166895203	TTC21B	chr2:166713988-166810348:-	0.13	3.91	0.000107	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs67344620	chr8:58187537	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6735104	chr2:166907971	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6735104	chr2:166907971	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6736360	chr2:190748749	ORMDL1	chr2:190634994-190649097:-	0.34	5.17	3.37E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs6736408	chr2:70137774	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.35	1.64E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6736711	chr2:25116456	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.38	6.91	1.46E-11	Metabolite levels	
LGG	cis	1	rs6736866	chr2:73661986	NAT8	chr2:73867850-73869537:-	0.25	4.06	5.66E-5	Metabolite levels	
LGG	cis	1	rs6737085	chr2:202221441	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.92	0.000103	Basal cell carcinoma	
LGG	cis	1	rs6737085	chr2:202221441	ALS2CR4	chr2:202484907-202508224:-	0.19	5.11	4.65E-7	Basal cell carcinoma	
LGG	cis	1	rs6737085	chr2:202221441	PPIL3	chr2:201735680-201753999:-	-0.2	-4.06	5.62E-5	Basal cell carcinoma	
LGG	cis	1	rs67375757	chr20:47916295	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs6737668	chr2:103093081	IL18R1	chr2:102927962-103015215:+	-0.4	-6.24	9.7E-10	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6737668	chr2:103093081	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.36	1.28E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6737921	chr2:27839107	PPM1G	chr2:27604062-27632496:-	0.13	4.12	4.37E-5	Oral cavity cancer	
LGG	cis	1	rs6737921	chr2:27839107	SNX17	chr2:27593363-27599994:+	-0.11	-3.49	0.000526	Oral cavity cancer	
LGG	cis	1	rs67384205	chr8:58180348	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.61E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6738490	chr2:234161583	ATG16L1	chr2:234160217-234204319:+	-0.16	-3.83	0.000147	Crohn's disease	
LGG	cis	1	rs67385415	chr8:21853733	XPO7	chr8:21777180-21864095:+	0.18	4.04	6.22E-5	Mean corpuscular volume	
LGG	cis	1	rs67385638	chr11:5290370	HBG2	chr11:5269502-5667011:-	0.28	4.5	8.38E-6	Hemoglobin levels	
LGG	cis	1	rs67388517	chr8:58176617	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6739061	chr2:26256147	GPR113	chr2:26531041-26569685:-	-0.24	-3.8	0.000161	Gut microbiome composition (summer)	
LGG	cis	1	rs6739780	chr2:70138111	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.35	1.64E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs67401267	chr22:30750209	CCDC157	chr22:30752627-30772816:+	0.39	5.39	1.11E-7	Coronary artery calcification	
LGG	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.39	7.12	3.81E-12	Metabolite levels	
LGG	cis	1	rs6740223	chr2:73653332	NAT8	chr2:73867850-73869537:-	0.27	4.44	1.12E-5	Metabolite levels	
LGG	cis	1	rs6740641	chr2:54482989	C2orf73	chr2:54558071-54588714:+	0.35	4.98	8.65E-7	Telomere length	
LGG	cis	1	rs6740641	chr2:54482989	TSPYL6	chr2:54480315-54483409:-	-0.46	-5.51	5.74E-8	Telomere length	
LGG	cis	1	rs67411574	chr17:18797337	FAM18B	chr17:18684582-18710026:+	-0.18	-4.81	1.97E-6	Educational attainment (years of education)	
LGG	cis	1	rs67411574	chr17:18797337	FBXW10	chr17:18647326-18682661:+	-0.2	-4.58	5.95E-6	Educational attainment (years of education)	
LGG	cis	1	rs6741449	chr2:70156589	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.26	2.48E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6742276	chr2:61768745	AHSA2	chr2:61404553-61414058:+	-0.29	-9.46	1.28E-19	Tuberculosis	
LGG	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.4	8.55	1.57E-16	Tuberculosis	
LGG	cis	1	rs67426384	chr16:77326168	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs6743139	chr2:87018452	LOC285074	chr2:87257799-87303536:-	-0.2	-3.46	0.000581	Progressive supranuclear palsy	
LGG	cis	1	rs674343	chr1:183162052	LAMC2	chr1:183155174-183214262:+	0.27	5.33	1.53E-7	Hypertriglyceridemia	
LGG	cis	1	rs67445790	chr6:151876730	C6orf97	chr6:151815175-151942327:+	0.26	4.2	3.23E-5	Bone mineral density (spine)	
LGG	cis	1	rs6744707	chr2:105371087	MRPS9	chr2:105654483-105716417:+	-0.23	-3.85	0.000136	Pancreatic cancer	
LGG	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.39	6.78	3.42E-11	Metabolite levels	
LGG	cis	1	rs6745368	chr2:73809974	NAT8	chr2:73867850-73869537:-	0.25	4.07	5.43E-5	Metabolite levels	
LGG	cis	1	rs674568	chr15:45936587	SPATA5L1	chr15:45694519-45713614:+	0.29	4.43	1.16E-5	Obesity-related traits	
LGG	cis	1	rs6746271	chr2:103052995	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6746271	chr2:103052995	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6746608	chr2:111892984	ACOXL	chr2:111490150-111875799:+	0.2	3.46	0.000588	Chronic lymphocytic leukemia	
LGG	cis	1	rs67466576	chr10:4977394	AKR1C2	chr10:4964715-5060207:-	0.38	5.24	2.38E-7	Height	
LGG	cis	1	rs674735	chr11:71560580	FAM86C	chr11:71498557-71512276:+	-0.49	-5.1	4.98E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs67487119	chr6:163102657	PACRG	chr6:163148164-163736523:+	0.41	5.62	3.26E-8	Body mass index	
LGG	cis	1	rs6749052	chr2:27772879	PPM1G	chr2:27604062-27632496:-	0.14	4.36	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs6749052	chr2:27772879	SNX17	chr2:27593363-27599994:+	-0.12	-3.63	0.000314	Oral cavity cancer	
LGG	cis	1	rs6749125	chr2:84907368	DNAH6	chr2:84743579-85046711:+	0.19	3.56	0.000414	Hypospadias	
LGG	cis	1	rs6749855	chr2:26255263	GPR113	chr2:26531041-26569685:-	-0.23	-3.64	0.000299	Gut microbiome composition (summer)	
LGG	cis	1	rs6750020	chr2:102994714	IL18R1	chr2:102927962-103015215:+	-0.38	-6.04	3.02E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6750020	chr2:102994714	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.25	2.31E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6750488	chr2:70146125	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.23	2.83E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs67505314	chr10:17240134	TRDMT1	chr10:17184983-17243681:-	-0.22	-4.51	8.17E-6	Homocysteine levels	
LGG	cis	1	rs6750681	chr2:26329677	GPR113	chr2:26531041-26569685:-	-0.23	-3.66	0.000275	Gut microbiome composition (summer)	
LGG	cis	1	rs6750765	chr2:86300308	IMMT	chr2:86371056-86422893:-	0.32	3.54	0.000443	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs6750765	chr2:86300308	LOC90784	chr2:86247339-86250991:-	-0.4	-3.96	8.45E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs6750943	chr2:27777904	PPM1G	chr2:27604062-27632496:-	0.14	4.36	1.55E-5	Oral cavity cancer	
LGG	cis	1	rs6750943	chr2:27777904	SNX17	chr2:27593363-27599994:+	-0.12	-3.63	0.000314	Oral cavity cancer	
LGG	cis	1	rs675185	chr11:71775572	FAM86C	chr11:71498557-71512276:+	0.49	4.85	1.67E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6752050	chr2:242228780	ANO7	chr2:242127924-242164791:+	0.39	6.51	1.87E-10	Prostate cancer	
LGG	cis	1	rs6752107	chr2:234161448	ATG16L1	chr2:234160217-234204319:+	-0.17	-3.95	8.92E-5	Crohn's disease	
LGG	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.39	-7	8.47E-12	Metabolite levels	
LGG	cis	1	rs6753344	chr2:73653138	NAT8	chr2:73867850-73869537:-	-0.26	-4.31	1.95E-5	Metabolite levels	
LGG	cis	1	rs6753355	chr2:166900606	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs6753355	chr2:166900606	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs67536397	chr7:65947917	CCT6P1	chr7:65216092-65228661:+	0.22	3.95	9.01E-5	Diabetic kidney disease	
LGG	cis	1	rs6753717	chr2:102993161	IL18R1	chr2:102927962-103015215:+	-0.38	-6.04	3.02E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6753717	chr2:102993161	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.25	2.31E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs675413	chr15:45936745	SPATA5L1	chr15:45694519-45713614:+	0.29	4.46	1.04E-5	Obesity-related traits	
LGG	cis	1	rs67544533	chr15:75361539	PPCDC	chr15:75315927-75343066:+	0.23	4.94	1.06E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs67546820	chr8:58168567	C8orf71	chr8:58192102-58197288:+	0.36	6.23	9.78E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6754896	chr2:70138170	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.35	1.64E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.38	6.87	1.95E-11	Metabolite levels	
LGG	cis	1	rs6755217	chr2:73641285	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.61E-5	Metabolite levels	
LGG	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.39	6.97	1.03E-11	Metabolite levels	
LGG	cis	1	rs6755241	chr2:73641364	NAT8	chr2:73867850-73869537:-	0.25	4.11	4.6E-5	Metabolite levels	
LGG	cis	1	rs6755786	chr2:103048103	IL18R1	chr2:102927962-103015215:+	-0.37	-5.89	7.07E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6755786	chr2:103048103	IL1RL1	chr2:102927962-102968497:+	-0.36	-5.23	2.57E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs6756238	chr2:27841305	PPM1G	chr2:27604062-27632496:-	0.13	4.12	4.37E-5	Oral cavity cancer	
LGG	cis	1	rs6756238	chr2:27841305	SNX17	chr2:27593363-27599994:+	-0.11	-3.49	0.000526	Oral cavity cancer	
LGG	cis	1	rs6756987	chr2:73687077	ALMS1P	chr2:73872046-73912692:+	0.4	7.14	3.31E-12	Metabolite levels	
LGG	cis	1	rs6756987	chr2:73687077	NAT8	chr2:73867850-73869537:-	0.27	4.52	7.83E-6	Metabolite levels	
LGG	cis	1	rs67575175	chr3:127880226	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.13	4.34E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6758089	chr2:188191834	CALCRL	chr2:188207851-188313021:-	0.22	5.36	1.3E-7	Coronary heart disease	
LGG	cis	1	rs675876	chr15:45936856	SPATA5L1	chr15:45694519-45713614:+	0.29	4.37	1.51E-5	Obesity-related traits	
LGG	cis	1	rs6759004	chr2:202004676	CFLAR	chr2:201980816-202029001:+	-0.28	-5.76	1.5E-8	Triptolide cytotoxicity	
LGG	cis	1	rs6759004	chr2:202004676	NDUFB3	chr2:201936462-201950471:+	-0.19	-3.66	0.00028	Triptolide cytotoxicity	
LGG	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-0.86	-15.91	2.73E-46	Triptolide cytotoxicity	
LGG	cis	1	rs67594249	chr8:58180521	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.61E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6759836	chr2:160912802	LY75	chr2:160625141-160761262:-	0.13	3.68	0.000254	Idiopathic membranous nephropathy	
LGG	cis	1	rs6759924	chr2:160912747	LY75	chr2:160625141-160761262:-	0.13	3.61	0.00034	Idiopathic membranous nephropathy	
LGG	cis	1	rs67600807	chr17:38001559	GSDMB	chr17:38060850-38074903:-	-0.23	-3.58	0.000385	Systemic lupus erythematosus	
LGG	cis	1	rs6761514	chr2:202227549	ALS2CR12	chr2:202153148-202222101:-	-0.23	-4.57	6.11E-6	Basal cell carcinoma	
LGG	cis	1	rs6761514	chr2:202227549	ALS2CR4	chr2:202484907-202508224:-	0.18	4.94	1.07E-6	Basal cell carcinoma	
LGG	cis	1	rs6761514	chr2:202227549	PPIL3	chr2:201735680-201753999:-	-0.18	-3.86	0.00013	Basal cell carcinoma	
LGG	cis	1	rs67615769	chr17:45325478	ITGB3	chr17:45331208-45421658:+	-0.23	-4.59	5.71E-6	Body mass index	
LGG	cis	1	rs6761757	chr2:166895502	TTC21B	chr2:166713988-166810348:-	0.13	3.82	0.000153	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs67630725	chr8:58185580	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs6763088	chr3:134254989	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.62	1.32E-13	Height	
LGG	cis	1	rs6763093	chr3:134254995	CEP63	chr3:134204575-134293852:+	-0.21	-3.84	0.00014	Height	
LGG	cis	1	rs6763829	chr3:41897046	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs67640320	chr14:52511596	GNG2	chr14:52313952-52436517:+	0.16	3.6	0.000355	Pulmonary function	
LGG	cis	1	rs6764184	chr3:58006266	DNAH12	chr3:57327727-57530071:-	0.2	3.6	0.00035	Optic cup area	
LGG	cis	1	rs67646369	chr6:163003233	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs6765233	chr3:128002850	EEFSEC	chr3:127872313-128127488:+	0.22	3.98	7.81E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs67652499	chr20:47926691	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.18	3.49E-5	Height	
LGG	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.45E-12	Height	
LGG	cis	1	rs6765505	chr3:134208132	CEP63	chr3:134204575-134293852:+	0.19	3.59	0.000365	Height	
LGG	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.29	7.63	1.22E-13	Height	
LGG	cis	1	rs6766818	chr3:134226159	CEP63	chr3:134204575-134293852:+	0.21	3.78	0.000178	Height	
LGG	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.3	7.73	6.02E-14	Height	
LGG	cis	1	rs6766897	chr3:134191303	CEP63	chr3:134204575-134293852:+	0.23	4.09	4.98E-5	Height	
LGG	cis	1	rs6767013	chr3:183680102	ABCC5	chr3:183637726-183735727:-	0.11	3.56	0.000401	Anterior chamber depth	
LGG	cis	1	rs6767049	chr3:20220712	KAT2B	chr3:20081524-20195894:+	-0.17	-3.85	0.000132	Temperament (bipolar disorder)	
LGG	cis	1	rs67674204	chr3:127824778	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6768014	chr3:128592457	RAB43	chr3:128806418-128880029:-	0.3	3.46	0.000579	Dental caries	
LGG	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.78	15.11	1.27E-42	Diastolic blood pressure	
LGG	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.78	15.03	2.7E-42	Diastolic blood pressure	
LGG	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.77	14.75	4.99E-41	Diastolic blood pressure	
LGG	cis	1	rs6768627	chr3:46895376	CCDC12	chr3:46963220-47018270:-	0.21	3.49	0.000527	Microalbuminuria	
LGG	cis	1	rs67696450	chr10:1090684	C10orf110	chr10:1068577-1090141:+	0.29	5.36	1.3E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.3	7.72	6.48E-14	Height	
LGG	cis	1	rs6769885	chr3:134286913	CEP63	chr3:134204575-134293852:+	0.21	3.9	0.000108	Height	
LGG	cis	1	rs6770152	chr3:53100214	ITIH4	chr3:52847007-52866554:-	-0.17	-4.64	4.49E-6	Ulcerative colitis	
LGG	cis	1	rs6770152	chr3:53100214	RFT1	chr3:53122503-53164470:-	-0.21	-4.18	3.44E-5	Ulcerative colitis	
LGG	cis	1	rs67701624	chr12:50928938	ATF1	chr12:51157819-51214906:+	-0.2	-4.33	1.78E-5	Fibrinogen	
LGG	cis	1	rs67701624	chr12:50928938	LETMD1	chr12:51442084-51454206:+	0.15	3.58	0.000373	Fibrinogen	
LGG	cis	1	rs67701624	chr12:50928938	SLC11A2	chr12:51373319-51422058:-	0.17	3.69	0.000252	Fibrinogen	
LGG	cis	1	rs6770470	chr3:48435123	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.15E-5	Longevity	
LGG	cis	1	rs6770470	chr3:48435123	TREX1	chr3:48501186-48509043:+	-0.42	-10.82	1.24E-24	Longevity	
LGG	cis	1	rs67705655	chr8:58177688	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6770670	chr3:49686682	MST1R	chr3:49924438-49941306:-	-0.2	-3.84	0.000139	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs6770670	chr3:49686682	RBM6	chr3:49977592-50137484:+	0.16	4.52	7.65E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs6770670	chr3:49686682	SEMA3F	chr3:50192848-50226507:+	0.2	4.48	9.11E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs6771941	chr3:20157077	EFHB	chr3:19920968-19988501:-	0.24	3.56	0.000414	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6771941	chr3:20157077	KAT2B	chr3:20081524-20195894:+	-0.18	-3.56	0.000401	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6772407	chr3:128044372	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.95	9.03E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6772407	chr3:128044372	LOC90246	chr3:128226678-128229427:+	-0.29	-3.75	0.000199	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6772548	chr3:37075934	LRRFIP2	chr3:37094117-37217851:-	0.16	3.83	0.000143	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs677279	chr11:71770469	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs67728539	chr7:65378124	CCT6P1	chr7:65216092-65228661:+	0.25	4.59	5.64E-6	Diabetic kidney disease	
LGG	cis	1	rs67728756	chr8:27078358	STMN4	chr8:27093816-27115903:-	0.17	4.03	6.36E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs6772896	chr3:134203347	CEP63	chr3:134204575-134293852:+	0.2	3.66	0.000275	Height	
LGG	cis	1	rs67733885	chr20:47896557	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs6774367	chr3:20163077	EFHB	chr3:19920968-19988501:-	0.32	4.34	1.71E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs67747005	chr6:163150845	PACRG	chr6:163148164-163736523:+	0.4	5.78	1.3E-8	Body mass index	
LGG	cis	1	rs6774724	chr3:49381911	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.53	7.29E-6	Menarche (age at onset)	
LGG	cis	1	rs6774724	chr3:49381911	GMPPB	chr3:49758932-49761384:-	-0.25	-4.83	1.85E-6	Menarche (age at onset)	
LGG	cis	1	rs6774724	chr3:49381911	TREX1	chr3:48501186-48509043:+	-0.27	-5.5	6.06E-8	Menarche (age at onset)	
LGG	cis	1	rs67766926	chr2:61163581	AHSA2	chr2:61404553-61414058:+	-0.24	-5.82	1.07E-8	Inflammatory skin disease	
LGG	cis	1	rs67766926	chr2:61163581	C2orf74	chr2:61372243-61391964:+	0.35	5.83	9.83E-9	Inflammatory skin disease	
LGG	cis	1	rs6776700	chr3:48496758	ATRIP	chr3:48488141-48507708:+	0.19	4.76	2.51E-6	Longevity	
LGG	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.42	-10.94	4.53E-25	Longevity	
LGG	cis	1	rs6778057	chr3:128647823	RAB43	chr3:128806418-128880029:-	0.32	3.74	0.000209	Dental caries	
LGG	cis	1	rs677977	chr1:147083744	ACP6	chr1:147119168-147142634:-	-0.54	-10.55	1.31E-23	Schizophrenia (negative symptoms)	
LGG	cis	1	rs67805055	chr14:55587552	FBXO34	chr14:55738021-55893431:+	0.15	4.59	5.63E-6	Protein biomarker	
LGG	cis	1	rs6781326	chr3:41777028	ULK4	chr3:41288091-42003660:-	0.74	14.32	3.93E-39	Diastolic blood pressure	
LGG	cis	1	rs678170	chr11:114431956	C11orf71	chr11:114262170-114271255:-	-0.19	-3.95	9.12E-5	Ulcerative colitis	
LGG	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.8	3.87E-14	Height	
LGG	cis	1	rs6782563	chr3:134295959	CEP63	chr3:134204575-134293852:+	-0.19	-3.58	0.000375	Height	
LGG	cis	1	rs678292	chr10:105957561	C10orf79	chr10:105889647-105992120:-	0.18	4.89	1.35E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs6783001	chr3:41862232	ULK4	chr3:41288091-42003660:-	0.77	15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs6783003	chr3:49524778	AMIGO3	chr3:49754268-49757238:-	0.21	4.78	2.3E-6	Menarche (age at onset)	
LGG	cis	1	rs6783003	chr3:49524778	GMPPB	chr3:49758932-49761384:-	0.26	4.98	8.61E-7	Menarche (age at onset)	
LGG	cis	1	rs6783253	chr3:127851561	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs67840803	chr6:163049048	PACRG	chr6:163148164-163736523:+	0.35	4.88	1.43E-6	Body mass index	
LGG	cis	1	rs6784159	chr3:127843378	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.15	3.92E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6784322	chr3:48422235	ATRIP	chr3:48488141-48507708:+	0.21	5.26	2.19E-7	Longevity	
LGG	cis	1	rs6784322	chr3:48422235	TREX1	chr3:48501186-48509043:+	-0.4	-10.19	2.9E-22	Longevity	
LGG	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.28	-7.5	2.98E-13	Height	
LGG	cis	1	rs6785027	chr3:134211649	CEP63	chr3:134204575-134293852:+	-0.2	-3.69	0.000247	Height	
LGG	cis	1	rs6785045	chr3:49435243	AMIGO3	chr3:49754268-49757238:-	0.18	4.28	2.3E-5	Menarche (age at onset)	
LGG	cis	1	rs6785045	chr3:49435243	GMPPB	chr3:49758932-49761384:-	0.22	4.33	1.82E-5	Menarche (age at onset)	
LGG	cis	1	rs6785045	chr3:49435243	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.53	0.000458	Menarche (age at onset)	
LGG	cis	1	rs6785045	chr3:49435243	TREX1	chr3:48501186-48509043:+	0.24	5.08	5.31E-7	Menarche (age at onset)	
LGG	cis	1	rs67854568	chr5:126731721	FLJ44606	chr5:126381051-126409172:-	0.26	3.54	0.000436	IgG glycosylation	
LGG	cis	1	rs6785535	chr3:127834695	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs678629	chr1:168691900	SELL	chr1:169659810-169680837:-	0.2	4.03	6.57E-5	QT interval	
LGG	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.29	7.77	4.63E-14	Height	
LGG	cis	1	rs6787371	chr3:134254991	CEP63	chr3:134204575-134293852:+	0.2	3.69	0.000254	Height	
LGG	cis	1	rs6787614	chr3:127817478	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6789043	chr3:37025867	LRRFIP2	chr3:37094117-37217851:-	0.17	3.92	0.0001	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs6789094	chr3:128591267	RAB43	chr3:128806418-128880029:-	0.32	3.74	0.000209	Dental caries	
LGG	cis	1	rs6789260	chr3:41776350	ULK4	chr3:41288091-42003660:-	0.7	12.56	1.42E-31	Diastolic blood pressure	
LGG	cis	1	rs67895971	chr8:58177994	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs6790466	chr3:134197740	CEP63	chr3:134204575-134293852:+	0.2	3.66	0.000275	Height	
LGG	cis	1	rs6790732	chr3:41864872	ULK4	chr3:41288091-42003660:-	0.77	15.3	1.69E-43	Diastolic blood pressure	
LGG	cis	1	rs67913746	chr8:58177825	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6791806	chr3:41889995	ULK4	chr3:41288091-42003660:-	0.76	15.06	2.0E-42	Diastolic blood pressure	
LGG	cis	1	rs67923812	chr17:45326151	ITGB3	chr17:45331208-45421658:+	-0.24	-4.78	2.27E-6	Body mass index	
LGG	cis	1	rs67927699	chr2:61187415	AHSA2	chr2:61404553-61414058:+	-0.25	-7.73	6.27E-14	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs67927699	chr2:61187415	C2orf74	chr2:61372243-61391964:+	0.3	6.13	1.79E-9	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs6793295	chr3:169518455	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.5	0.000511	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs6793295	chr3:169518455	LRRC34	chr3:169511266-169530720:-	-0.28	-5.09	5.15E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.8	3.87E-14	Height	
LGG	cis	1	rs6793487	chr3:134299426	CEP63	chr3:134204575-134293852:+	-0.19	-3.58	0.000375	Height	
LGG	cis	1	rs67940364	chr3:127833353	EEFSEC	chr3:127872313-128127488:+	-0.23	-4.31	1.97E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6794591	chr3:128031219	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.91	0.000103	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6794591	chr3:128031219	LOC90246	chr3:128226678-128229427:+	-0.29	-3.73	0.000211	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6794875	chr3:48455626	ATRIP	chr3:48488141-48507708:+	0.18	4.36	1.59E-5	Longevity	
LGG	cis	1	rs6794875	chr3:48455626	TREX1	chr3:48501186-48509043:+	-0.43	-11.24	3.07E-26	Longevity	
LGG	cis	1	rs679515	chr1:207750568	CR1	chr1:207669473-207815109:+	-0.36	-6.03	3.16E-9	Alzheimer's disease in APOE e4+ carriers	
LGG	cis	1	rs6795293	chr3:128592669	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs6796031	chr3:128593259	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs6796210	chr3:41851718	ULK4	chr3:41288091-42003660:-	0.77	15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs6796491	chr3:48430465	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs6796491	chr3:48430465	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs6797165	chr3:41887777	ULK4	chr3:41288091-42003660:-	0.77	15.14	9.32E-43	Diastolic blood pressure	
LGG	cis	1	rs6797834	chr3:127856400	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.98	8.01E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6798749	chr3:128056897	EEFSEC	chr3:127872313-128127488:+	0.22	4.25	2.59E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6798749	chr3:128056897	LOC90246	chr3:128226678-128229427:+	0.28	3.59	0.000363	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs679926	chr11:71769936	FAM86C	chr11:71498557-71512276:+	-0.48	-4.72	3.06E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs6800225	chr3:127862178	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.55E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs68005215	chr10:4977435	AKR1C2	chr10:4964715-5060207:-	0.38	5.3	1.71E-7	Height	
LGG	cis	1	rs6800554	chr3:37143879	LRRFIP2	chr3:37094117-37217851:-	-0.16	-3.61	0.000333	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.29	7.63	1.23E-13	Height	
LGG	cis	1	rs6800862	chr3:134228628	CEP63	chr3:134204575-134293852:+	0.19	3.62	0.00033	Height	
LGG	cis	1	rs6800	chr1:156262653	BGLAP	chr1:156182784-156213112:+	0.25	5.3	1.74E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs6800	chr1:156262653	CCT3	chr1:156278752-156308195:-	-0.16	-4.1	4.76E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs680113	chr11:108165406	ATM	chr11:108093559-108239826:+	-0.11	-3.53	0.000457	Response to metformin in type 2 diabetes (glycemic);Response to metformin	
LGG	cis	1	rs68012338	chr17:46856405	SNF8	chr17:47007461-47022154:-	-0.15	-3.86	0.000128	Schizophrenia or bipolar disorder	
LGG	cis	1	rs6801343	chr3:41767234	ULK4	chr3:41288091-42003660:-	0.73	14.02	8.76E-38	Diastolic blood pressure	
LGG	cis	1	rs68014903	chr20:47912039	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.12	4.51E-5	Height	
LGG	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.29	7.76	4.83E-14	Height	
LGG	cis	1	rs6801596	chr3:134252114	CEP63	chr3:134204575-134293852:+	0.2	3.65	0.000295	Height	
LGG	cis	1	rs6802340	chr3:41894034	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.27	7.1	4.44E-12	Height	
LGG	cis	1	rs6802685	chr3:40007027	ZNF620	chr3:40547530-40559197:+	-0.34	-4.11	4.55E-5	Information processing speed	
LGG	cis	1	rs6802849	chr3:183698943	ABCC5	chr3:183637726-183735727:-	0.11	3.5	0.000502	Anterior chamber depth	
LGG	cis	1	rs6803560	chr3:41824480	ULK4	chr3:41288091-42003660:-	0.76	15.01	3.52E-42	Diastolic blood pressure	
LGG	cis	1	rs68035691	chr5:126730533	FLJ44606	chr5:126381051-126409172:-	0.26	3.48	0.000553	IgG glycosylation	
LGG	cis	1	rs6803652	chr3:41824556	ULK4	chr3:41288091-42003660:-	0.76	15.01	3.52E-42	Diastolic blood pressure	
LGG	cis	1	rs68045643	chr6:163029709	PACRG	chr6:163148164-163736523:+	0.31	4.56	6.57E-6	Body mass index	
LGG	cis	1	rs6804655	chr3:49738945	MST1R	chr3:49924438-49941306:-	0.26	4.9	1.34E-6	Resting heart rate	
LGG	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.29	7.64	1.12E-13	Height	
LGG	cis	1	rs6804770	chr3:134230234	CEP63	chr3:134204575-134293852:+	0.2	3.77	0.000182	Height	
LGG	cis	1	rs6804774	chr3:48430617	ATRIP	chr3:48488141-48507708:+	0.18	4.41	1.27E-5	Longevity	
LGG	cis	1	rs6804774	chr3:48430617	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	1.0E-24	Longevity	
LGG	cis	1	rs6805582	chr3:128029008	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.94	9.25E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6805582	chr3:128029008	LOC90246	chr3:128226678-128229427:+	-0.28	-3.56	0.000402	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6805609	chr3:49471522	AMIGO3	chr3:49754268-49757238:-	0.21	4.92	1.19E-6	Menarche (age at onset)	
LGG	cis	1	rs6805609	chr3:49471522	CCDC71	chr3:49199969-49203785:-	0.19	3.6	0.000351	Menarche (age at onset)	
LGG	cis	1	rs6805609	chr3:49471522	GMPPB	chr3:49758932-49761384:-	0.26	5.12	4.4E-7	Menarche (age at onset)	
LGG	cis	1	rs6805609	chr3:49471522	QRICH1	chr3:49067144-49131504:-	0.2	3.66	0.000275	Menarche (age at onset)	
LGG	cis	1	rs6805609	chr3:49471522	TREX1	chr3:48501186-48509043:+	0.27	5.85	8.97E-9	Menarche (age at onset)	
LGG	cis	1	rs6805621	chr3:128029204	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.91	0.000103	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6805621	chr3:128029204	LOC90246	chr3:128226678-128229427:+	-0.29	-3.73	0.000211	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.78	15.03	2.7E-42	Diastolic blood pressure	
LGG	cis	1	rs6805913	chr3:183662924	ABCC5	chr3:183637726-183735727:-	0.11	3.46	0.000598	Anterior chamber depth	
LGG	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.28	-7.5	3.08E-13	Height	
LGG	cis	1	rs6806417	chr3:134211446	CEP63	chr3:134204575-134293852:+	-0.2	-3.76	0.000188	Height	
LGG	cis	1	rs680668	chr6:84229366	SNAP91	chr6:84262607-84419127:-	-0.1	-4.73	2.89E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs6807015	chr3:41754514	ULK4	chr3:41288091-42003660:-	0.71	12.89	6.02E-33	Diastolic blood pressure	
LGG	cis	1	rs68076606	chr8:58191271	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6808835	chr3:46449864	CCR5	chr3:46411633-46417690:+	0.18	4.05	5.93E-5	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LGG	cis	1	rs6808835	chr3:46449864	LTF	chr3:46477497-46526724:-	0.31	4.47	9.57E-6	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LGG	cis	1	rs68088462	chr15:63397617	LACTB	chr15:63414032-63434254:+	0.21	4.37	1.52E-5	HDL cholesterol	
LGG	cis	1	rs6810006	chr3:127856058	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.16	3.7E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6810060	chr3:48434748	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.15E-5	Longevity	
LGG	cis	1	rs6810060	chr3:48434748	TREX1	chr3:48501186-48509043:+	-0.42	-10.82	1.24E-24	Longevity	
LGG	cis	1	rs68112919	chr8:58188247	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6811520	chr4:56315178	TMEM165	chr4:56262090-56292342:+	-0.17	-4.84	1.74E-6	Personality dimensions	
LGG	cis	1	rs6811887	chr4:17640858	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6812042	chr4:56396079	TMEM165	chr4:56262090-56292342:+	-0.17	-4.92	1.19E-6	Personality dimensions	
LGG	cis	1	rs68141011	chr6:28217797	ZNF165	chr6:28046572-28057338:+	-0.33	-4.8	2.15E-6	Depression	
LGG	cis	1	rs68141011	chr6:28217797	ZNF187	chr6:28234788-28245978:+	-0.28	-4.71	3.28E-6	Depression	
LGG	cis	1	rs68141011	chr6:28217797	ZNF389	chr6:28129551-28137375:+	0.43	6.85	2.23E-11	Depression	
LGG	cis	1	rs68141011	chr6:28217797	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.67	3.91E-6	Depression	
LGG	cis	1	rs68141011	chr6:28217797	ZSCAN23	chr6:28393287-28411279:-	0.18	4.16	3.77E-5	Depression	
LGG	cis	1	rs68144677	chr6:163149024	PACRG	chr6:163148164-163736523:+	0.45	6.01	3.69E-9	Body mass index	
LGG	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.5	-10.05	1.02E-21	Response to antipsychotic treatment	
LGG	cis	1	rs6818286	chr4:42456438	SHISA3	chr4:42399856-42404503:+	0.26	3.88	0.000121	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6818639	chr4:17633049	MED28	chr4:17616273-17629791:+	0.2	4.22	2.89E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs68189316	chr7:65409169	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs6819493	chr4:42458627	SHISA3	chr4:42399856-42404503:+	0.26	3.88	0.000121	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs6819660	chr4:56374577	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs6822866	chr4:171027704	AADAT	chr4:170981374-171011372:-	0.28	3.89	0.000116	Thyroid hormone levels	
LGG	cis	1	rs6823347	chr4:106962725	NPNT	chr4:106816605-106892827:+	-0.24	-5.1	4.83E-7	Airflow obstruction	
LGG	cis	1	rs6824057	chr4:56367278	TMEM165	chr4:56262090-56292342:+	-0.17	-4.95	1.01E-6	Personality dimensions	
LGG	cis	1	rs6825911	chr4:111381638	ENPEP	chr4:111397229-111484491:+	0.22	4.95	1.03E-6	Blood pressure	
LGG	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.44	-10.62	7.24E-24	Longevity	
LGG	cis	1	rs6828499	chr4:171017475	AADAT	chr4:170981374-171011372:-	-0.35	-4.52	7.63E-6	Thyroid hormone levels	
LGG	cis	1	rs6830485	chr4:108963382	SGMS2	chr4:108745721-108836200:+	0.25	3.46	0.000586	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs6831256	chr4:3473139	LRPAP1	chr4:3514290-3534224:-	0.13	3.48	0.000545	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs683125	chr11:83276245	CCDC90B	chr11:82972506-82997414:-	0.24	5.69	2.22E-8	Subcortical brain region volumes	
LGG	cis	1	rs6832503	chr4:48028442	CNGA1	chr4:47937996-48018610:-	-0.59	-12.22	3.71E-30	Renal underexcretion gout;Gout	
LGG	cis	1	rs683250	chr11:83276168	CCDC90B	chr11:82972506-82997414:-	0.23	5.39	1.1E-7	Subcortical brain region volumes	
LGG	cis	1	rs6832769	chr4:56298194	TMEM165	chr4:56262090-56292342:+	-0.18	-5.25	2.23E-7	Personality dimensions	
LGG	cis	1	rs6833988	chr4:10295586	SLC2A9	chr4:9827850-10041872:-	0.22	5.23	2.54E-7	Schizophrenia (age at onset)	
LGG	cis	1	rs6834676	chr4:56298414	TMEM165	chr4:56262090-56292342:+	-0.17	-4.84	1.77E-6	Personality dimensions	
LGG	cis	1	rs6837710	chr4:56374455	TMEM165	chr4:56262090-56292342:+	-0.17	-4.95	1.01E-6	Personality dimensions	
LGG	cis	1	rs6837898	chr4:120179154	MYOZ2	chr4:120056939-120108935:+	0.23	4.46	1.01E-5	Corneal astigmatism	
LGG	cis	1	rs6841898	chr4:24578097	DHX15	chr4:24529089-24586184:-	0.25	3.46	0.000595	Myopia (pathological)	
LGG	cis	1	rs6846238	chr4:17629939	MED28	chr4:17616273-17629791:+	0.2	4.3	2.05E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6846579	chr4:107011756	NPNT	chr4:106816605-106892827:+	-0.22	-4.65	4.27E-6	Airflow obstruction	
LGG	cis	1	rs6848360	chr4:17634442	MED28	chr4:17616273-17629791:+	0.21	4.49	8.9E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6849704	chr4:17652031	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6849889	chr4:120186348	MYOZ2	chr4:120056939-120108935:+	0.22	4.25	2.53E-5	Corneal astigmatism	
LGG	cis	1	rs6851838	chr4:56420747	TMEM165	chr4:56262090-56292342:+	0.17	5.17	3.48E-7	Personality dimensions	
LGG	cis	1	rs685289	chr6:160747902	SLC22A3	chr6:160769425-160876013:+	0.35	6.07	2.49E-9	Waist circumference	
LGG	cis	1	rs6853192	chr4:56409254	TMEM165	chr4:56262090-56292342:+	0.17	5.18	3.22E-7	Personality dimensions	
LGG	cis	1	rs685395	chr11:103067460	DYNC2H1	chr11:102980160-103350591:+	-0.2	-3.75	0.000195	Spine bone mineral density and alcohol drinking	
LGG	cis	1	rs6854733	chr4:17640526	MED28	chr4:17616273-17629791:+	0.19	4.02	6.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6862814	chr5:150245259	LOC134466	chr5:150310000-150326146:-	0.42	4.77	2.43E-6	Crohn's disease	
LGG	cis	1	rs686441	chr10:105950233	C10orf79	chr10:105889647-105992120:-	0.17	4.8	2.1E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs6867042	chr5:93555761	FAM172A	chr5:92953432-93447404:-	-0.3	-4.04	6.23E-5	Diabetic retinopathy	
LGG	cis	1	rs6867113	chr5:115543623	COMMD10	chr5:115420727-115628978:+	-0.19	-3.63	0.000312	Metabolite levels  (X-11787)	
LGG	cis	1	rs6869774	chr5:110467086	TSLP	chr5:110405778-110413722:+	-0.28	-4.26	2.5E-5	Eosinophil counts	
LGG	cis	1	rs6870097	chr5:151734471	NMUR2	chr5:151771102-151784840:-	-0.24	-4.03	6.41E-5	Optic nerve measurement (cup area)	
LGG	cis	1	rs6870356	chr5:110467237	TSLP	chr5:110405778-110413722:+	-0.31	-4.82	1.9E-6	Eosinophil counts	
LGG	cis	1	rs6870816	chr5:151734701	NMUR2	chr5:151771102-151784840:-	-0.23	-4.02	6.74E-5	Optic nerve measurement (cup area)	
LGG	cis	1	rs6874202	chr5:156391628	TIMD4	chr5:156346293-156390266:-	-0.23	-4.85	1.7E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs6874392	chr5:126726738	FLJ44606	chr5:126381051-126409172:-	0.29	3.99	7.6E-5	IgG glycosylation	
LGG	cis	1	rs6874560	chr5:150182713	LOC134466	chr5:150310000-150326146:-	0.38	4	7.41E-5	Crohn's disease	
LGG	cis	1	rs6875011	chr5:150182710	LOC134466	chr5:150310000-150326146:-	0.38	3.99	7.58E-5	Crohn's disease	
LGG	cis	1	rs687557	chr10:105989509	C10orf79	chr10:105889647-105992120:-	0.19	5.18	3.18E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.43	8.78	2.8E-17	Crohn's disease	
LGG	cis	1	rs687672	chr11:65649984	FIBP	chr11:65651212-65656010:-	-0.24	-5.94	5.4E-9	Crohn's disease	
LGG	cis	1	rs687672	chr11:65649984	SNX32	chr11:65601410-65621170:+	-0.41	-9.91	3.21E-21	Crohn's disease	
LGG	cis	1	rs6876972	chr5:115642519	COMMD10	chr5:115420727-115628978:+	0.43	5.41	9.68E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs6877621	chr5:78314379	BHMT	chr5:78407604-78428112:+	-0.18	-3.6	0.000355	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs6878680	chr5:156387137	TIMD4	chr5:156346293-156390266:-	-0.24	-4.9	1.3E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs6880213	chr5:115447414	COMMD10	chr5:115420727-115628978:+	0.46	5.88	7.68E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs6880889	chr5:115167896	ATG12	chr5:115165818-115177520:-	-0.18	-4.01	7.13E-5	IgG glycosylation	
LGG	cis	1	rs6882076	chr5:156390297	TIMD4	chr5:156346293-156390266:-	-0.23	-4.85	1.7E-6	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs6885032	chr5:172983279	LOC285593	chr5:173006646-173012074:+	0.25	4.62	4.88E-6	Height	
LGG	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.84	16.02	8.78E-47	Type 2 diabetes	
LGG	cis	1	rs6886034	chr5:115543761	COMMD10	chr5:115420727-115628978:+	0.19	3.69	0.000247	Metabolite levels  (X-11787)	
LGG	cis	1	rs6886255	chr5:176718361	MXD3	chr5:176732501-176739292:-	-0.14	-3.79	0.00017	Migraine without aura	
LGG	cis	1	rs6886621	chr5:115543792	COMMD10	chr5:115420727-115628978:+	0.18	3.5	0.000503	Metabolite levels  (X-11787)	
LGG	cis	1	rs6887276	chr5:127378294	FLJ33630	chr5:127276135-127419299:-	-0.26	-6.18	1.37E-9	Height	
LGG	cis	1	rs6887546	chr5:156009046	SGCD	chr5:155135063-156194796:+	0.29	4.5	8.31E-6	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs688967	chr15:45936127	SPATA5L1	chr15:45694519-45713614:+	0.29	4.41	1.25E-5	Obesity-related traits	
LGG	cis	1	rs6890695	chr5:130888424	SLC22A5	chr5:131705401-131731302:+	0.24	4.22	2.88E-5	Alzheimer's disease in APOE e4- carriers	
LGG	cis	1	rs6896780	chr5:151735124	NMUR2	chr5:151771102-151784840:-	-0.23	-4.02	6.74E-5	Optic nerve measurement (cup area)	
LGG	cis	1	rs6897290	chr5:126730705	FLJ44606	chr5:126381051-126409172:-	0.26	3.61	0.000339	IgG glycosylation	
LGG	cis	1	rs6898413	chr5:173927	AHRR	chr5:304292-438403:+	0.47	3.82	0.000148	Asthma (childhood onset)	
LGG	cis	1	rs6900902	chr6:105235757	HACE1	chr6:105175968-105307794:-	-0.15	-3.64	0.000306	Thyroid stimulating hormone	
LGG	cis	1	rs6901575	chr6:28250984	ZNF165	chr6:28046572-28057338:+	-0.32	-4.67	3.9E-6	Depression	
LGG	cis	1	rs6901575	chr6:28250984	ZNF187	chr6:28234788-28245978:+	-0.27	-4.55	6.88E-6	Depression	
LGG	cis	1	rs6901575	chr6:28250984	ZNF389	chr6:28129551-28137375:+	0.43	6.82	2.68E-11	Depression	
LGG	cis	1	rs6901575	chr6:28250984	ZSCAN12	chr6:28346770-28367544:-	-0.33	-4.63	4.69E-6	Depression	
LGG	cis	1	rs6901575	chr6:28250984	ZSCAN23	chr6:28393287-28411279:-	0.18	4.31	1.99E-5	Depression	
LGG	cis	1	rs6903973	chr6:26499942	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.76E-7	Educational attainment	
LGG	cis	1	rs6904133	chr6:151881805	C6orf97	chr6:151815175-151942327:+	0.28	4.43	1.17E-5	Bone mineral density (spine)	
LGG	cis	1	rs6904601	chr6:170131905	WDR27	chr6:169857307-170102159:-	-0.36	-8.13	3.49E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6904991	chr6:33732262	BAK1	chr6:33540324-33548070:-	-0.15	-3.51	0.000486	Crohn's disease	
LGG	cis	1	rs6904991	chr6:33732262	LEMD2	chr6:33738991-33756906:-	-0.14	-4.4	1.32E-5	Crohn's disease	
LGG	cis	1	rs6905391	chr6:28262686	ZNF165	chr6:28046572-28057338:+	-0.3	-4.45	1.05E-5	Depression	
LGG	cis	1	rs6905391	chr6:28262686	ZNF187	chr6:28234788-28245978:+	-0.28	-4.89	1.37E-6	Depression	
LGG	cis	1	rs6905391	chr6:28262686	ZNF389	chr6:28129551-28137375:+	0.41	6.62	9.16E-11	Depression	
LGG	cis	1	rs6905391	chr6:28262686	ZSCAN12	chr6:28346770-28367544:-	-0.32	-4.6	5.44E-6	Depression	
LGG	cis	1	rs6905391	chr6:28262686	ZSCAN23	chr6:28393287-28411279:-	0.18	4.17	3.61E-5	Depression	
LGG	cis	1	rs6907898	chr6:126666416	CENPW	chr6:126661253-126804465:+	-0.15	-3.92	0.000103	Type 1 diabetes	
LGG	cis	1	rs6910233	chr6:33534726	BAK1	chr6:33540324-33548070:-	0.18	4.34	1.73E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs6910899	chr6:26524339	BTN2A3	chr6:26422317-26431927:+	0.12	3.47	0.000575	Educational attainment	
LGG	cis	1	rs6910899	chr6:26524339	HMGN4	chr6:26538572-26547162:+	-0.2	-5.27	2.02E-7	Educational attainment	
LGG	cis	1	rs6912959	chr6:170126224	WDR27	chr6:169857307-170102159:-	-0.35	-7.8	3.66E-14	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6913799	chr6:151988829	C6orf97	chr6:151815175-151942327:+	0.32	4.69	3.55E-6	Breast cancer	
LGG	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs6915267	chr6:151977085	C6orf97	chr6:151815175-151942327:+	0.34	5.04	6.58E-7	Breast cancer	
LGG	cis	1	rs6917747	chr6:160402705	WTAP	chr6:160148129-160177349:+	0.26	3.86	0.00013	Brain lesion load	
LGG	cis	1	rs6918586	chr6:26097384	BTN3A2	chr6:26365398-26378546:+	-0.21	-4.29	2.12E-5	Schizophrenia	
LGG	cis	1	rs6919397	chr6:126659043	CENPW	chr6:126661253-126804465:+	-0.14	-3.67	0.000274	Type 1 diabetes	
LGG	cis	1	rs6920075	chr6:33731797	BAK1	chr6:33540324-33548070:-	-0.15	-3.49	0.000536	Crohn's disease	
LGG	cis	1	rs6920075	chr6:33731797	LEMD2	chr6:33738991-33756906:-	-0.14	-4.39	1.41E-5	Crohn's disease	
LGG	cis	1	rs6921487	chr6:33749293	LEMD2	chr6:33738991-33756906:-	0.18	5.5	6.06E-8	Body mass index	
LGG	cis	1	rs6922313	chr6:24438719	MRS2	chr6:24403153-24425809:+	-0.21	-3.48	0.000554	Liver enzyme levels	
LGG	cis	1	rs6922824	chr6:26553815	BTN2A3	chr6:26422317-26431927:+	-0.13	-3.65	0.000289	Educational attainment	
LGG	cis	1	rs6922824	chr6:26553815	HMGN4	chr6:26538572-26547162:+	0.19	4.93	1.13E-6	Educational attainment	
LGG	cis	1	rs6923124	chr6:49419864	CENPQ	chr6:49431096-49460820:+	-0.22	-4.92	1.18E-6	Folate pathway vitamin levels	
LGG	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.53	11.35	1.11E-26	Response to antipsychotic treatment	
LGG	cis	1	rs6923339	chr6:170128033	WDR27	chr6:169857307-170102159:-	-0.35	-7.8	3.66E-14	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6924838	chr6:26571756	BTN2A3	chr6:26422317-26431927:+	0.13	3.57	0.000386	Educational attainment	
LGG	cis	1	rs6924838	chr6:26571756	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.47E-6	Educational attainment	
LGG	cis	1	rs6925273	chr6:33732448	LEMD2	chr6:33738991-33756906:-	-0.14	-4.42	1.19E-5	Crohn's disease	
LGG	cis	1	rs6925703	chr6:26521589	BTN2A3	chr6:26422317-26431927:+	0.12	3.46	0.000579	Educational attainment	
LGG	cis	1	rs6925703	chr6:26521589	HMGN4	chr6:26538572-26547162:+	-0.2	-5.15	3.69E-7	Educational attainment	
LGG	cis	1	rs6925895	chr6:26572165	BTN2A3	chr6:26422317-26431927:+	0.13	3.57	0.000386	Educational attainment	
LGG	cis	1	rs6925895	chr6:26572165	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.47E-6	Educational attainment	
LGG	cis	1	rs6926629	chr6:26499903	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.83E-7	Educational attainment	
LGG	cis	1	rs6927188	chr6:42912589	CUL7	chr6:43005356-43021654:-	0.15	3.5	0.00051	Diabetic kidney disease	
LGG	cis	1	rs6927188	chr6:42912589	GNMT	chr6:42928500-42931617:+	0.41	8.66	6.74E-17	Diabetic kidney disease	
LGG	cis	1	rs6927188	chr6:42912589	PEX6	chr6:42931613-42946981:-	-0.48	-9.07	2.86E-18	Diabetic kidney disease	
LGG	cis	1	rs6927188	chr6:42912589	RPL7L1	chr6:42847671-42857596:+	0.13	3.64	0.0003	Diabetic kidney disease	
LGG	cis	1	rs6928	chr22:22115004	CCDC116	chr22:21987086-21991615:+	0.19	3.95	9.09E-5	Multiple sclerosis	
LGG	cis	1	rs6929299	chr6:161032089	MRPL18	chr6:160211022-160219460:+	-0.18	-3.94	9.25E-5	Lipoprotein (a) levels	
LGG	cis	1	rs6930076	chr6:88088654	C6orf163	chr6:88057220-88075180:+	0.21	3.84	0.000139	Depressive episodes in bipolar disorder	
LGG	cis	1	rs6930120	chr6:26555484	BTN2A3	chr6:26422317-26431927:+	0.13	3.69	0.000252	Educational attainment	
LGG	cis	1	rs6930120	chr6:26555484	HMGN4	chr6:26538572-26547162:+	-0.19	-4.93	1.15E-6	Educational attainment	
LGG	cis	1	rs6930201	chr6:33738749	LEMD2	chr6:33738991-33756906:-	0.18	5.36	1.28E-7	Body mass index	
LGG	cis	1	rs6930201	chr6:33738749	RGL2	chr6:33259438-33266738:-	0.14	3.5	0.000515	Body mass index	
LGG	cis	1	rs6932156	chr6:26571506	BTN2A3	chr6:26422317-26431927:+	0.13	3.57	0.000386	Educational attainment	
LGG	cis	1	rs6932156	chr6:26571506	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.47E-6	Educational attainment	
LGG	cis	1	rs6932590	chr6:27248931	BTN3A2	chr6:26365398-26378546:+	-0.29	-5.1	4.77E-7	Schizophrenia	
LGG	cis	1	rs6932590	chr6:27248931	ZNF389	chr6:28129551-28137375:+	0.2	3.85	0.000136	Schizophrenia	
LGG	cis	1	rs6933094	chr6:150297603	ULBP1	chr6:150285143-150294844:+	0.4	3.8	0.000163	Radiation response	
LGG	cis	1	rs6933094	chr6:150297603	ULBP2	chr6:150263136-150270366:+	0.37	3.89	0.000114	Radiation response	
LGG	cis	1	rs6933174	chr6:33751003	LEMD2	chr6:33738991-33756906:-	0.18	5.4	1.04E-7	Body mass index	
LGG	cis	1	rs6933176	chr6:26540178	BTN2A3	chr6:26422317-26431927:+	0.12	3.55	0.000418	Educational attainment	
LGG	cis	1	rs6933176	chr6:26540178	HMGN4	chr6:26538572-26547162:+	-0.2	-5.12	4.37E-7	Educational attainment	
LGG	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.37	8.2	2.19E-15	Response to antipsychotic treatment	
LGG	cis	1	rs6933568	chr6:33751261	LEMD2	chr6:33738991-33756906:-	0.19	5.44	8.37E-8	Body mass index	
LGG	cis	1	rs6933607	chr6:33743997	LEMD2	chr6:33738991-33756906:-	0.19	5.67	2.46E-8	Body mass index	
LGG	cis	1	rs6934171	chr6:46316742	ENPP5	chr6:46127762-46138717:-	0.15	3.61	0.000336	Body mass index	
LGG	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.5	-10.24	1.98E-22	Response to antipsychotic treatment	
LGG	cis	1	rs6936177	chr6:34783717	C6orf106	chr6:34555066-34664625:-	0.25	4.98	8.72E-7	Pubertal anthropometrics	
LGG	cis	1	rs6938239	chr6:34683635	C6orf106	chr6:34555066-34664625:-	-0.28	-5.43	8.85E-8	Pubertal anthropometrics	
LGG	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.43	-8.73	3.91E-17	Crohn's disease	
LGG	cis	1	rs693824	chr11:65654783	FIBP	chr11:65651212-65656010:-	0.24	5.87	8.15E-9	Crohn's disease	
LGG	cis	1	rs693824	chr11:65654783	SNX32	chr11:65601410-65621170:+	0.41	9.93	2.59E-21	Crohn's disease	
LGG	cis	1	rs6940053	chr6:26562122	BTN2A3	chr6:26422317-26431927:+	0.13	3.71	0.000232	Educational attainment	
LGG	cis	1	rs6940053	chr6:26562122	HMGN4	chr6:26538572-26547162:+	-0.18	-4.49	8.73E-6	Educational attainment	
LGG	cis	1	rs6940188	chr6:26562029	BTN2A3	chr6:26422317-26431927:+	0.13	3.71	0.000232	Educational attainment	
LGG	cis	1	rs6940188	chr6:26562029	HMGN4	chr6:26538572-26547162:+	-0.18	-4.49	8.73E-6	Educational attainment	
LGG	cis	1	rs6940353	chr6:33752550	LEMD2	chr6:33738991-33756906:-	0.18	5.4	1.04E-7	Body mass index	
LGG	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.49	-10.22	2.37E-22	Response to antipsychotic treatment	
LGG	cis	1	rs6941766	chr6:170131653	WDR27	chr6:169857307-170102159:-	-0.36	-8.13	3.49E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6942231	chr6:105191814	HACE1	chr6:105175968-105307794:-	-0.15	-3.61	0.000335	Thyroid stimulating hormone	
LGG	cis	1	rs6942255	chr6:107555018	PDSS2	chr6:107473761-107780779:-	-0.22	-4.28	2.25E-5	Coffee consumption	
LGG	cis	1	rs6942332	chr6:170131934	WDR27	chr6:169857307-170102159:-	-0.37	-8.23	1.66E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs6945843	chr7:65734783	ASL	chr7:65540776-65558321:+	0.22	5.53	5.2E-8	Aortic root size	
LGG	cis	1	rs6946143	chr7:65579722	ASL	chr7:65540776-65558321:+	-0.18	-4.63	4.71E-6	Aortic root size	
LGG	cis	1	rs694739	chr11:64097233	C11orf20	chr11:64067863-64072238:+	0.18	3.88	0.000117	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs694739	chr11:64097233	CCDC88B	chr11:64107695-64125005:+	-0.11	-4.21	3.05E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs694739	chr11:64097233	PPP1R14B	chr11:64011953-64014413:-	-0.14	-4.13	4.25E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LGG	cis	1	rs6948433	chr7:118030666	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.74	0.000206	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs6949812	chr7:65387101	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs6949897	chr7:50621920	FIGNL1	chr7:50511834-50518088:-	-0.21	-5.14	4.03E-7	Malaria	
LGG	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.43	-8.76	3.22E-17	Crohn's disease	
LGG	cis	1	rs694994	chr11:65653309	FIBP	chr11:65651212-65656010:-	0.24	5.93	5.68E-9	Crohn's disease	
LGG	cis	1	rs694994	chr11:65653309	SNX32	chr11:65601410-65621170:+	0.41	9.89	3.74E-21	Crohn's disease	
LGG	cis	1	rs6952244	chr7:33290258	BBS9	chr7:33169152-33645680:+	0.44	6.2	1.17E-9	Smooth-surface caries	
LGG	cis	1	rs6952407	chr7:66045512	ASL	chr7:65540776-65558321:+	0.2	5.16	3.57E-7	Cotinine glucuronidation	
LGG	cis	1	rs6952407	chr7:66045512	LOC493754	chr7:65993446-66057363:-	0.18	3.65	0.000288	Cotinine glucuronidation	
LGG	cis	1	rs6952808	chr7:1886535	FTSJ2	chr7:2273928-2281833:-	0.17	3.63	0.000316	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6953693	chr7:1886388	FTSJ2	chr7:2273928-2281833:-	0.19	4.18	3.51E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6954521	chr7:1886865	FTSJ2	chr7:2273928-2281833:-	0.21	4.71	3.19E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6954673	chr7:1886937	FTSJ2	chr7:2273928-2281833:-	0.21	4.71	3.19E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6956179	chr7:65806659	ASL	chr7:65540776-65558321:+	0.21	5.48	6.95E-8	Aortic root size	
LGG	cis	1	rs6957199	chr7:65978519	ASL	chr7:65540776-65558321:+	-0.22	-5.55	4.64E-8	Aortic root size	
LGG	cis	1	rs6957894	chr7:1887362	FTSJ2	chr7:2273928-2281833:-	0.18	4.01	6.94E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6958271	chr7:65979331	ASL	chr7:65540776-65558321:+	-0.22	-5.5	6.23E-8	Aortic root size	
LGG	cis	1	rs6958277	chr7:65979349	ASL	chr7:65540776-65558321:+	-0.22	-5.5	6.23E-8	Aortic root size	
LGG	cis	1	rs6958289	chr7:65657111	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.23	2.77E-5	Diabetic kidney disease	
LGG	cis	1	rs6958420	chr7:65751171	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.29	2.12E-5	Diabetic kidney disease	
LGG	cis	1	rs6958484	chr7:65599446	ASL	chr7:65540776-65558321:+	0.21	5.44	8.56E-8	Aortic root size	
LGG	cis	1	rs6958520	chr7:66151453	ASL	chr7:65540776-65558321:+	-0.19	-4.94	1.06E-6	Aortic root size	
LGG	cis	1	rs6958520	chr7:66151453	TYW1	chr7:66461817-66704496:+	0.17	3.58	0.000375	Aortic root size	
LGG	cis	1	rs6959002	chr7:65650496	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs6959273	chr7:118041733	ANKRD7	chr7:117864712-117882782:+	0.21	3.63	0.000315	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs6960169	chr7:50751829	FIGNL1	chr7:50511834-50518088:-	0.17	3.74	0.000205	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs6960419	chr7:2595406	C7orf27	chr7:2577511-2595146:-	-0.16	-3.7	0.00024	Obesity-related traits	
LGG	cis	1	rs696092	chr2:188210214	CALCRL	chr2:188207851-188313021:-	0.22	5.46	7.62E-8	Coronary heart disease	
LGG	cis	1	rs6961155	chr7:65933295	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs6961717	chr7:65587537	ASL	chr7:65540776-65558321:+	0.21	5.4	1.06E-7	Aortic root size	
LGG	cis	1	rs6961990	chr7:65888570	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs6962965	chr7:26568001	KIAA0087	chr7:26572740-26578444:-	0.19	3.79	0.000169	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs6963495	chr7:105166853	RINT1	chr7:105172532-105208124:+	-0.3	-4.91	1.21E-6	Bipolar disorder (body mass index interaction)	
LGG	cis	1	rs6963646	chr7:65685767	ASL	chr7:65540776-65558321:+	0.22	5.6	3.61E-8	Aortic root size	
LGG	cis	1	rs6964245	chr7:65718717	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.42	1.23E-5	Diabetic kidney disease	
LGG	cis	1	rs6964530	chr7:65718851	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.43	1.17E-5	Diabetic kidney disease	
LGG	cis	1	rs6964833	chr7:74101909	STAG3L2	chr7:74298846-74306731:-	-0.24	-3.62	0.000329	Menarche (age at onset)	
LGG	cis	1	rs6966322	chr7:65646754	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.27	2.36E-5	Diabetic kidney disease	
LGG	cis	1	rs6966675	chr7:2596989	C7orf27	chr7:2577511-2595146:-	-0.15	-3.52	0.000467	Obesity-related traits	
LGG	cis	1	rs6967152	chr7:74099317	STAG3L2	chr7:74298846-74306731:-	-0.24	-3.59	0.000369	Menarche (age at onset)	
LGG	cis	1	rs6967740	chr7:105540774	CDHR3	chr7:105517264-105676876:+	0.22	5.02	7.15E-7	Obesity-related traits	
LGG	cis	1	rs6970030	chr7:65968679	ASL	chr7:65540776-65558321:+	-0.22	-5.55	4.64E-8	Aortic root size	
LGG	cis	1	rs6970243	chr7:65388490	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs6973114	chr7:33256744	BBS9	chr7:33169152-33645680:+	0.42	5.77	1.39E-8	Smooth-surface caries	
LGG	cis	1	rs6973552	chr7:33294271	BBS9	chr7:33169152-33645680:+	0.45	6.33	5.63E-10	Smooth-surface caries	
LGG	cis	1	rs6974373	chr7:99590893	EPO	chr7:100318423-100321321:+	0.21	4.59	5.54E-6	Interstitial lung disease	
LGG	cis	1	rs6974373	chr7:99590893	TRIM4	chr7:99488037-99517154:-	-0.24	-5.23	2.49E-7	Interstitial lung disease	
LGG	cis	1	rs697451	chr1:202480085	UBE2T	chr1:202300786-202311094:-	-0.12	-3.7	0.000242	Sex ratio	
LGG	cis	1	rs6974723	chr7:65637939	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.27	2.36E-5	Diabetic kidney disease	
LGG	cis	1	rs6975195	chr7:66124774	ASL	chr7:65540776-65558321:+	0.19	4.95	1.01E-6	Aortic root size	
LGG	cis	1	rs6975195	chr7:66124774	TYW1	chr7:66461817-66704496:+	-0.17	-3.57	0.000393	Aortic root size	
LGG	cis	1	rs6975251	chr7:135328689	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs6976053	chr7:100512119	UFSP1	chr7:100486346-100487339:-	-0.28	-6.12	1.92E-9	Plasminogen activator inhibitor type 1 levels (PAI-1)	
LGG	cis	1	rs6976501	chr7:50760220	FIGNL1	chr7:50511834-50518088:-	0.17	3.75	0.000197	Fasting glucose-related traits (interaction with BMI)	
LGG	cis	1	rs6977733	chr7:1886725	FTSJ2	chr7:2273928-2281833:-	-0.2	-4.41	1.29E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6978048	chr7:1886872	FTSJ2	chr7:2273928-2281833:-	0.21	4.71	3.19E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs6979382	chr7:65886375	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs6979391	chr7:135328873	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs6979439	chr7:135329004	SLC13A4	chr7:135365993-135412933:-	-0.27	-4.01	6.98E-5	Red blood cell traits	
LGG	cis	1	rs6979663	chr7:118050881	ANKRD7	chr7:117864712-117882782:+	-0.23	-4.04	6.11E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs6982751	chr8:10813474	RP1L1	chr8:10463862-10512617:-	-0.29	-3.73	0.000218	Asthma and hay fever	
LGG	cis	1	rs6982769	chr8:10688400	RP1L1	chr8:10463862-10512617:-	-0.21	-3.88	0.000119	Triglycerides	
LGG	cis	1	rs6982927	chr8:10813598	RP1L1	chr8:10463862-10512617:-	-0.29	-3.73	0.000218	Asthma and hay fever	
LGG	cis	1	rs698405	chr5:112243527	SRP19	chr5:112196993-112228774:+	-0.21	-3.72	0.000222	Attention deficit hyperactivity disorder	
LGG	cis	1	rs698406	chr7:127255285	GCC1	chr7:127220683-127225654:-	0.3	4.94	1.08E-6	Type 2 diabetes	
LGG	cis	1	rs6984388	chr8:10685669	RP1L1	chr8:10463862-10512617:-	-0.21	-3.76	0.000189	Triglycerides	
LGG	cis	1	rs698500	chr15:83237769	FAM154B	chr15:82555152-82577265:+	-0.2	-4.19	3.35E-5	Schizophrenia	
LGG	cis	1	rs698500	chr15:83237769	GOLGA6L9	chr15:82711895-82731584:+;chr15	-0.17	-4.14	4.1E-5	Schizophrenia	
LGG	cis	1	rs698582	chr2:188227921	CALCRL	chr2:188207851-188313021:-	-0.22	-5.27	2.02E-7	Coronary heart disease	
LGG	cis	1	rs698588	chr2:188214924	CALCRL	chr2:188207851-188313021:-	-0.2	-4.94	1.09E-6	Coronary heart disease	
LGG	cis	1	rs698590	chr2:188214823	CALCRL	chr2:188207851-188313021:-	0.21	5.06	6.03E-7	Coronary heart disease	
LGG	cis	1	rs698592	chr2:188214239	CALCRL	chr2:188207851-188313021:-	-0.21	-5.01	7.43E-7	Coronary heart disease	
LGG	cis	1	rs698593	chr2:188213235	CALCRL	chr2:188207851-188313021:-	-0.2	-4.92	1.19E-6	Coronary heart disease	
LGG	cis	1	rs6987199	chr8:10688661	RP1L1	chr8:10463862-10512617:-	-0.2	-3.72	0.000224	Triglycerides	
LGG	cis	1	rs6987200	chr8:10688666	RP1L1	chr8:10463862-10512617:-	-0.21	-3.75	0.000196	Triglycerides	
LGG	cis	1	rs6987435	chr8:58177334	C8orf71	chr8:58192102-58197288:+	0.35	6.03	3.25E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs698833	chr2:44735438	SLC3A1	chr2:44502597-44547959:+	0.19	4.51	8.08E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LGG	cis	1	rs698834	chr2:44736957	SLC3A1	chr2:44502597-44547959:+	0.2	4.64	4.55E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LGG	cis	1	rs6989060	chr8:58178989	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs6991083	chr8:83078757	FABP4	chr8:82390732-82395473:-	-0.19	-3.73	0.000213	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs6991499	chr8:10688997	RP1L1	chr8:10463862-10512617:-	0.2	3.74	0.000207	Triglycerides	
LGG	cis	1	rs6991526	chr8:10689050	RP1L1	chr8:10463862-10512617:-	-0.2	-3.73	0.000214	Triglycerides	
LGG	cis	1	rs6997458	chr8:86274030	LRRCC1	chr8:86019377-86058312:+	0.21	4.46	1.03E-5	Blood trace element (Zn levels)	
LGG	cis	1	rs7000939	chr8:10688874	RP1L1	chr8:10463862-10512617:-	-0.21	-3.77	0.000186	Triglycerides	
LGG	cis	1	rs7004438	chr8:8574379	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.98	8.84E-7	Obesity-related traits	
LGG	cis	1	rs7005380	chr8:120953873	DSCC1	chr8:120846182-120868170:-	-0.32	-7.6	1.49E-13	Interstitial lung disease	
LGG	cis	1	rs7006612	chr8:10813636	RP1L1	chr8:10463862-10512617:-	-0.29	-3.73	0.000218	Asthma and hay fever	
LGG	cis	1	rs7007040	chr8:83053718	FABP4	chr8:82390732-82395473:-	-0.21	-4.1	4.92E-5	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.64	15.69	2.95E-45	Bone mineral density	
LGG	cis	1	rs7007805	chr8:58179327	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7014273	chr8:67358694	ADHFE1	chr8:67344718-67381042:+	0.3	7.1	4.54E-12	Blood metabolite levels	
LGG	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.64	15.61	6.59E-45	Bone mineral density	
LGG	cis	1	rs7018067	chr8:74013420	C8orf84	chr8:73976779-74005507:-	0.25	5.27	2.0E-7	Crohn's disease	
LGG	cis	1	rs7018	chr20:25278261	ABHD12	chr20:25275380-25371477:-	0.27	7.31	1.09E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7018	chr20:25278261	FAM182A	chr20:26035250-26067552:+	-0.56	-11.01	2.49E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7018	chr20:25278261	FAM182B	chr20:25744102-25848786:-	0.22	4.87	1.52E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7019033	chr9:100793176	C9orf156	chr9:100666772-100684852:-	0.2	3.6	0.000347	Coronary heart disease	
LGG	cis	1	rs7019	chr20:25278278	ABHD12	chr20:25275380-25371477:-	0.27	7.45	4.33E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7019	chr20:25278278	FAM182A	chr20:26035250-26067552:+	-0.56	-11.01	2.35E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7019	chr20:25278278	FAM182B	chr20:25744102-25848786:-	0.22	4.86	1.56E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7020689	chr9:22972985	CDKN2B	chr9:22002906-22009312:-	-0.36	-4.21	3.06E-5	Cannabis use (initiation)	
LGG	cis	1	rs7020976	chr9:100547972	C9orf156	chr9:100666772-100684852:-	0.18	3.84	0.000142	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7020	chr20:25278600	ABHD12	chr20:25275380-25371477:-	0.27	7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7020	chr20:25278600	FAM182A	chr20:26035250-26067552:+	-0.55	-10.74	2.57E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7020	chr20:25278600	FAM182B	chr20:25744102-25848786:-	0.23	5.1	4.96E-7	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7021449	chr9:131899312	CRAT	chr9:131857075-131873070:-	0.2	3.7	0.00024	Blood metabolite ratios	
LGG	cis	1	rs7021576	chr9:100540541	C9orf156	chr9:100666772-100684852:-	0.19	3.88	0.000118	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7022397	chr9:116007677	CDC26	chr9:116029290-116037869:-	-0.58	-13.71	1.84E-36	Hematology traits	
LGG	cis	1	rs7023900	chr9:131891152	CRAT	chr9:131857075-131873070:-	0.2	3.65	0.000288	Blood metabolite ratios	
LGG	cis	1	rs7024214	chr9:99239173	CDC14B	chr9:99262397-99382112:-	-0.29	-5.21	2.85E-7	Height	
LGG	cis	1	rs7024214	chr9:99239173	HABP4	chr9:99212414-99253617:+	-0.23	-5.08	5.39E-7	Height	
LGG	cis	1	rs7024214	chr9:99239173	SLC35D2	chr9:99075727-99145992:-	-0.16	-3.63	0.000319	Height	
LGG	cis	1	rs7026073	chr9:38040672	SHB	chr9:37915896-38069210:-	0.15	3.48	0.000551	Brain structure	
LGG	cis	1	rs7027030	chr9:100550455	C9orf156	chr9:100666772-100684852:-	0.18	3.82	0.000148	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7028436	chr9:21682141	MTAP	chr9:21802635-22029593:+	-0.2	-3.6	0.000354	Pediatric bone mineral content (radius)	
LGG	cis	1	rs7028661	chr9:100538470	C9orf156	chr9:100666772-100684852:-	0.19	3.89	0.000116	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7028950	chr9:21682260	KLHL9	chr9:21324054-21335429:-	-0.22	-4.36	1.58E-5	Pediatric bone mineral content (radius)	
LGG	cis	1	rs7028950	chr9:21682260	MTAP	chr9:21802635-22029593:+	-0.32	-5.82	1.06E-8	Pediatric bone mineral content (radius)	
LGG	cis	1	rs7029536	chr9:130110411	RPL12	chr9:130209955-130213684:-	0.15	3.73	0.000215	Metabolite levels (HVA)	
LGG	cis	1	rs7029536	chr9:130110411	SLC2A8	chr9:130159465-130170161:+	-0.26	-5.3	1.74E-7	Metabolite levels (HVA)	
LGG	cis	1	rs7030241	chr9:100550375	C9orf156	chr9:100666772-100684852:-	0.18	3.73	0.00021	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7030256	chr9:100535203	C9orf156	chr9:100666772-100684852:-	0.18	3.87	0.000122	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7030280	chr9:100535267	C9orf156	chr9:100666772-100684852:-	0.19	4.1	4.75E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7032019	chr9:100548144	C9orf156	chr9:100666772-100684852:-	0.18	3.84	0.000142	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7032164	chr9:114054001	PTGR1	chr9:114312003-114362135:-	-0.28	-3.58	0.000372	Menarche (age at onset)	
LGG	cis	1	rs7036114	chr9:131893406	CRAT	chr9:131857075-131873070:-	0.2	3.65	0.000288	Blood metabolite ratios	
LGG	cis	1	rs7037140	chr9:123656327	LOC253039	chr9:123605320-123616644:+	-0.66	-11.85	1.11E-28	Rheumatoid arthritis	
LGG	cis	1	rs7037140	chr9:123656327	PSMD5	chr9:123578334-123605206:-	-0.36	-6.6	1.08E-10	Rheumatoid arthritis	
LGG	cis	1	rs7037140	chr9:123656327	TRAF1	chr9:123664672-123691479:-	0.18	3.92	0.000103	Rheumatoid arthritis	
LGG	cis	1	rs7037163	chr9:131894340	CRAT	chr9:131857075-131873070:-	0.21	3.86	0.000129	Blood metabolite ratios	
LGG	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.43	-10.5	2.12E-23	Multiple sclerosis	
LGG	cis	1	rs703842	chr12:58162739	TSFM	chr12:58176536-58191367:+	0.45	8.76	3.2E-17	Multiple sclerosis	
LGG	cis	1	rs7038769	chr9:116007583	CDC26	chr9:116029290-116037869:-	-0.58	-13.71	1.84E-36	Hematology traits	
LGG	cis	1	rs7042681	chr9:38040828	SHB	chr9:37915896-38069210:-	0.15	3.48	0.000551	Brain structure	
LGG	cis	1	rs7045138	chr9:100591463	C9orf156	chr9:100666772-100684852:-	0.26	5.92	6.03E-9	Thyroid hormone levels	
LGG	cis	1	rs7045881	chr9:26935996	LRRC19	chr9:26993143-27005691:-	-0.64	-8.09	4.58E-15	Schizophrenia	
LGG	cis	1	rs705696	chr12:56480648	ERBB3	chr12:56473892-56497127:+	0.27	5.74	1.68E-8	Cognitive function	
LGG	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.8	16.44	1.1E-48	Cognitive function	
LGG	cis	1	rs705731	chr1:202298894	UBE2T	chr1:202300786-202311094:-	0.12	3.7	0.000238	Sex ratio	
LGG	cis	1	rs705735	chr1:202313481	UBE2T	chr1:202300786-202311094:-	0.13	3.84	0.000136	Sex ratio	
LGG	cis	1	rs705736	chr1:202442082	UBE2T	chr1:202300786-202311094:-	-0.13	-3.99	7.47E-5	Sex ratio	
LGG	cis	1	rs705742	chr1:202461982	UBE2T	chr1:202300786-202311094:-	-0.13	-3.79	0.00017	Sex ratio	
LGG	cis	1	rs705743	chr1:202474799	UBE2T	chr1:202300786-202311094:-	-0.13	-3.82	0.000148	Sex ratio	
LGG	cis	1	rs7061710	chr1:171080615	FMO3	chr1:171060018-171086957:+	-0.32	-5.48	6.7E-8	Blood metabolite levels	
LGG	cis	1	rs7067773	chr10:52005271	FAM21A	chr10:51827684-51893268:+	0.53	6.42	3.3E-10	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7070296	chr10:65070438	NRBF2	chr10:64893007-64914785:+	-0.23	-5.48	6.8E-8	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7070296	chr10:65070438	REEP3	chr10:65281123-65381971:+	0.14	3.92	9.91E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7070776	chr10:102264672	HIF1AN	chr10:102295641-102313680:+	0.19	3.58	0.000381	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7070776	chr10:102264672	NDUFB8	chr10:102283497-102289636:-	0.16	4.54	7.05E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7070776	chr10:102264672	WNT8B	chr10:102222812-102243397:+	0.48	7.79	3.92E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7071271	chr10:102264824	HIF1AN	chr10:102295641-102313680:+	0.19	3.63	0.00031	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7071271	chr10:102264824	NDUFB8	chr10:102283497-102289636:-	0.17	4.75	2.74E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7071271	chr10:102264824	WNT8B	chr10:102222812-102243397:+	0.48	7.87	2.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7072204	chr10:124195485	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.26	2.45E-5	Height	
LGG	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.4	12.56	1.39E-31	Metabolite levels	
LGG	cis	1	rs7072554	chr10:1090988	C10orf110	chr10:1068577-1090141:+	0.25	5	8.11E-7	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs7072634	chr10:17240918	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.73	2.96E-6	Homocysteine levels	
LGG	cis	1	rs7073497	chr10:100153688	PYROXD2	chr10:100143323-100174978:-	0.31	3.86	0.000127	Aspartate aminotransferase	
LGG	cis	1	rs7073586	chr10:102307671	NDUFB8	chr10:102283497-102289636:-	0.14	4	7.21E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7073586	chr10:102307671	WNT8B	chr10:102222812-102243397:+	0.45	7.37	7.36E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7073746	chr10:64904071	NRBF2	chr10:64893007-64914785:+	-0.22	-5.19	3.13E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7073746	chr10:64904071	REEP3	chr10:65281123-65381971:+	0.14	4	7.38E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7075188	chr10:1088746	C10orf110	chr10:1068577-1090141:+	-0.22	-4.5	8.64E-6	Response to angiotensin II receptor blocker therapy	
LGG	cis	1	rs7077415	chr10:52005293	FAM21A	chr10:51827684-51893268:+	-0.52	-5.79	1.24E-8	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7078003	chr10:99359412	C10orf62	chr10:99349484-99350690:+	-0.23	-3.47	0.000563	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs7078012	chr10:81705433	SFTPD	chr10:81697498-81708861:-	0.36	5.78	1.33E-8	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs7078799	chr10:102301447	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7078799	chr10:102301447	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7078799	chr10:102301447	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079136	chr10:102292709	HIF1AN	chr10:102295641-102313680:+	0.19	3.73	0.000214	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079136	chr10:102292709	NDUFB8	chr10:102283497-102289636:-	0.18	4.88	1.41E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079136	chr10:102292709	WNT8B	chr10:102222812-102243397:+	0.49	7.93	1.45E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079713	chr10:111755416	ADD3	chr10:111756108-111895320:+	0.17	3.97	8.14E-5	Biliary atresia	
LGG	cis	1	rs7079756	chr10:102302105	HIF1AN	chr10:102295641-102313680:+	0.18	3.45	0.000604	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079756	chr10:102302105	NDUFB8	chr10:102283497-102289636:-	0.17	4.63	4.66E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079756	chr10:102302105	WNT8B	chr10:102222812-102243397:+	0.45	7.31	1.09E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7079976	chr10:124172108	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.35	1.69E-5	Height	
LGG	cis	1	rs7080356	chr10:102266735	HIF1AN	chr10:102295641-102313680:+	0.19	3.57	0.000398	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7080356	chr10:102266735	NDUFB8	chr10:102283497-102289636:-	0.16	4.5	8.51E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7080356	chr10:102266735	WNT8B	chr10:102222812-102243397:+	0.48	7.8	3.79E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7082376	chr10:17232223	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.46	1.02E-5	Homocysteine levels	
LGG	cis	1	rs7084476	chr10:17211383	TRDMT1	chr10:17184983-17243681:-	-0.2	-4.24	2.64E-5	Homocysteine levels	
LGG	cis	1	rs7084810	chr10:102297546	HIF1AN	chr10:102295641-102313680:+	0.2	3.75	0.000196	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7084810	chr10:102297546	NDUFB8	chr10:102283497-102289636:-	0.18	4.87	1.51E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7084810	chr10:102297546	WNT8B	chr10:102222812-102243397:+	0.49	8.02	8.07E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7085439	chr10:102210100	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7085439	chr10:102210100	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7085439	chr10:102210100	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7086046	chr10:46076235	ALOX5	chr10:45869629-45941561:+	0.09	3.82	0.000149	HDL cholesterol;Cholesterol, total	
LGG	cis	1	rs7086205	chr10:104202729	AS3MT	chr10:104613967-104661653:+	-0.31	-5.06	5.85E-7	Social autistic-like traits	
LGG	cis	1	rs7088512	chr10:102303498	HIF1AN	chr10:102295641-102313680:+	0.19	3.6	0.000357	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7088512	chr10:102303498	NDUFB8	chr10:102283497-102289636:-	0.17	4.61	5.18E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7088512	chr10:102303498	WNT8B	chr10:102222812-102243397:+	0.47	7.53	2.5E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7088827	chr10:102303865	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7088827	chr10:102303865	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7088827	chr10:102303865	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7090431	chr10:102261753	NDUFB8	chr10:102283497-102289636:-	0.16	4.44	1.13E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7090431	chr10:102261753	WNT8B	chr10:102222812-102243397:+	0.5	8.26	1.37E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7091404	chr10:124745458	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs7095889	chr10:124744265	PSTK	chr10:124739556-124749906:+	0.16	3.6	0.000354	Migraine without aura	
LGG	cis	1	rs709592	chr17:38175553	GSDMA	chr17:38119226-38134019:+	-0.71	-15.37	7.97E-44	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs7095944	chr10:126302936	METTL10	chr10:126447406-126480439:-	-0.19	-5	8.07E-7	Asthma	
LGG	cis	1	rs709595	chr7:65817333	ASL	chr7:65540776-65558321:+	-0.22	-5.52	5.55E-8	Aortic root size	
LGG	cis	1	rs709597	chr7:65825983	ASL	chr7:65540776-65558321:+	0.22	5.65	2.67E-8	Aortic root size	
LGG	cis	1	rs709597	chr7:65825983	STAG3L4	chr7:66767616-66786512:+	0.16	3.48	0.000553	Aortic root size	
LGG	cis	1	rs709607	chr7:65449541	CCT6P1	chr7:65216092-65228661:+	-0.25	-4.56	6.33E-6	Diabetic kidney disease	
LGG	cis	1	rs7096568	chr10:92641636	RPP30	chr10:92631474-92668312:+	0.18	3.59	0.000368	Economic and political preferences (time)	
LGG	cis	1	rs7096692	chr10:17180828	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.34	1.71E-5	Homocysteine levels	
LGG	cis	1	rs7097701	chr10:124171857	PLEKHA1	chr10:124134220-124191866:+	-0.12	-4.35	1.69E-5	Height	
LGG	cis	1	rs7097	chr13:28197436	POLR1D	chr13:28194895-28241547:+	0.16	3.55	0.000424	Large B-cell lymphoma	
LGG	cis	1	rs709937	chr2:233744021	C2orf82	chr2:233734994-233741107:+	-0.37	-7.21	2.1E-12	Schizophrenia	
LGG	cis	1	rs7099913	chr10:102314777	HIF1AN	chr10:102295641-102313680:+	0.2	3.75	0.000198	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7099913	chr10:102314777	NDUFB8	chr10:102283497-102289636:-	0.17	4.49	8.85E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7099913	chr10:102314777	WNT8B	chr10:102222812-102243397:+	0.46	7.27	1.41E-12	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7099965	chr10:102301165	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7099965	chr10:102301165	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7099965	chr10:102301165	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7100163	chr10:17181177	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.42	1.24E-5	Homocysteine levels	
LGG	cis	1	rs7100386	chr10:102301417	HIF1AN	chr10:102295641-102313680:+	0.19	3.66	0.00028	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7100386	chr10:102301417	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7100386	chr10:102301417	WNT8B	chr10:102222812-102243397:+	0.47	7.65	1.1E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7100697	chr10:124745323	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs7101415	chr11:120239088	TMEM136	chr11:120196016-120204388:+	0.21	4.83	1.8E-6	Intraocular pressure	
LGG	cis	1	rs7101701	chr11:71762155	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7103210	chr11:71648966	FAM86C	chr11:71498557-71512276:+	0.52	5.2	2.89E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7104639	chr11:120239456	TMEM136	chr11:120196016-120204388:+	0.2	4.64	4.57E-6	Intraocular pressure	
LGG	cis	1	rs7104764	chr11:229977	PSMD13	chr11:236808-252984:+	-0.24	-5.21	2.79E-7	Menarche (age at onset)	
LGG	cis	1	rs7105178	chr11:64145109	C11orf20	chr11:64067863-64072238:+	-0.22	-3.67	0.000267	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7105282	chr11:47805614	ACP2	chr11:47260854-47270457:-	0.17	3.53	0.000456	Subjective well-being	
LGG	cis	1	rs7105282	chr11:47805614	MTCH2	chr11:47638859-47664206:-	0.24	4.72	3.07E-6	Subjective well-being	
LGG	cis	1	rs7105282	chr11:47805614	PSMC3	chr11:47440320-47448024:-	0.15	3.57	0.000391	Subjective well-being	
LGG	cis	1	rs7105681	chr11:73059341	RELT	chr11:73087405-73108518:+	0.32	3.8	0.000165	Pulmonary function (interaction)	
LGG	cis	1	rs7106748	chr11:71645803	FAM86C	chr11:71498557-71512276:+	0.52	5.12	4.39E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7107129	chr11:76821280	CAPN5	chr11:76777992-76837196:+	0.33	3.67	0.000272	Cognitive performance	
LGG	cis	1	rs7107211	chr11:120262922	TMEM136	chr11:120196016-120204388:+	0.21	4.88	1.42E-6	Intraocular pressure	
LGG	cis	1	rs7107356	chr11:47676170	MADD	chr11:47290927-47351582:+	-0.1	-3.71	0.00023	Neuroticism	
LGG	cis	1	rs7107356	chr11:47676170	MTCH2	chr11:47638859-47664206:-	-0.17	-3.46	0.000594	Neuroticism	
LGG	cis	1	rs710865	chr1:19568972	KIAA0090	chr1:19544585-19578046:-	-0.3	-9.99	1.66E-21	Brain structure	
LGG	cis	1	rs710866	chr1:19568722	KIAA0090	chr1:19544585-19578046:-	-0.3	-9.91	3.16E-21	Brain structure	
LGG	cis	1	rs7109474	chr11:2233219	C11orf21	chr11:2317507-2323143:-	0.26	4.48	9.43E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs7111	chr15:90373873	AP3S2	chr15:90373832-90456222:-	-0.48	-9.2	1.0E-18	Type 2 diabetes	
LGG	cis	1	rs7112513	chr11:117037361	SIDT2	chr11:117049939-117068161:+	0.37	4.6	5.3E-6	Protein quantitative trait loci	
LGG	cis	1	rs7112865	chr11:45326538	PEX16	chr11:45931221-45939674:-	0.13	4.13	4.3E-5	Schizophrenia	
LGG	cis	1	rs7112865	chr11:45326538	SLC35C1	chr11:45825623-45834566:+	0.18	3.66	0.000279	Schizophrenia	
LGG	cis	1	rs7113549	chr11:71829967	FAM86C	chr11:71498557-71512276:+	-0.45	-4.45	1.07E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7113565	chr11:5386911	FAM160A2	chr11:6232565-6255941:-	0.2	4	7.44E-5	Fetal hemoglobin levels	
LGG	cis	1	rs7114252	chr11:71237606	KRTAP5-9	chr11:71259466-71260653:+	0.26	4.21	3.05E-5	Vitamin D levels	
LGG	cis	1	rs7114963	chr11:116875983	SIDT2	chr11:117049939-117068161:+	0.31	3.62	0.000321	Protein quantitative trait loci	
LGG	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.52	-11.28	2.05E-26	Forced vital capacity	
LGG	cis	1	rs7116108	chr11:89144965	NOX4	chr11:89057524-89322779:-	0.37	3.96	8.68E-5	Homocysteine levels	
LGG	cis	1	rs7116495	chr11:71762085	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7117063	chr11:120238824	TMEM136	chr11:120196016-120204388:+	0.2	4.58	5.94E-6	Intraocular pressure	
LGG	cis	1	rs7117321	chr11:120239051	TMEM136	chr11:120196016-120204388:+	0.2	4.58	5.94E-6	Intraocular pressure	
LGG	cis	1	rs7117560	chr11:5371393	FAM160A2	chr11:6232565-6255941:-	0.18	3.6	0.000344	Fetal hemoglobin levels	
LGG	cis	1	rs7119	chr15:77777632	SGK269	chr15:77400471-77577333:-	0.18	4.58	5.91E-6	Type 2 diabetes	
LGG	cis	1	rs7120029	chr11:71198957	KRTAP5-9	chr11:71259466-71260653:+	0.3	4.76	2.53E-6	Vitamin D levels	
LGG	cis	1	rs7120333	chr11:47817441	ACP2	chr11:47260854-47270457:-	0.17	3.59	0.000365	Subjective well-being	
LGG	cis	1	rs7120333	chr11:47817441	MTCH2	chr11:47638859-47664206:-	0.25	4.81	2.03E-6	Subjective well-being	
LGG	cis	1	rs7120333	chr11:47817441	PSMC3	chr11:47440320-47448024:-	0.15	3.71	0.000235	Subjective well-being	
LGG	cis	1	rs712039	chr17:35850553	TADA2A	chr17:35766981-35837224:+	-0.19	-3.67	0.000271	Tuberculosis	
LGG	cis	1	rs7121260	chr11:71700566	FAM86C	chr11:71498557-71512276:+	0.48	4.91	1.23E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7121347	chr11:116867209	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs7121446	chr11:121954657	LOC399959	chr11:121959811-122238467:-	-0.18	-3.65	0.000291	Cardiovascular disease risk factors	
LGG	cis	1	rs7122539	chr11:66662731	C11orf80	chr11:66512207-66610987:+	-0.2	-4.29	2.16E-5	HIV-1 susceptibility	
LGG	cis	1	rs7122539	chr11:66662731	LRFN4	chr11:66624589-66627945:+	-0.15	-3.68	0.000255	HIV-1 susceptibility	
LGG	cis	1	rs7122539	chr11:66662731	PC	chr11:66615997-66725847:-	-0.21	-4.98	8.94E-7	HIV-1 susceptibility	
LGG	cis	1	rs7122539	chr11:66662731	RAB1B	chr11:66036056-66044961:+	-0.17	-3.93	9.8E-5	HIV-1 susceptibility	
LGG	cis	1	rs7122944	chr11:117034619	SIDT2	chr11:117049939-117068161:+	0.33	3.85	0.000136	Protein quantitative trait loci	
LGG	cis	1	rs7123312	chr11:2232359	C11orf21	chr11:2317507-2323143:-	0.26	4.51	8.23E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs7123517	chr11:117027755	SIDT2	chr11:117049939-117068161:+	0.33	3.85	0.000136	Protein quantitative trait loci	
LGG	cis	1	rs7124000	chr11:71754338	FAM86C	chr11:71498557-71512276:+	0.48	4.78	2.31E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7124442	chr11:27677041	LIN7C	chr11:27515971-27528326:-	-0.2	-3.59	0.000362	Body mass index;Weight	
LGG	cis	1	rs7125020	chr11:70001534	FADD	chr11:70049269-70053508:+	0.14	3.75	0.000199	Survival in rectal cancer	
LGG	cis	1	rs7126328	chr11:120244577	TMEM136	chr11:120196016-120204388:+	0.2	4.54	7.25E-6	Intraocular pressure	
LGG	cis	1	rs712697	chr7:127247132	GCC1	chr7:127220683-127225654:-	0.31	5.2	2.98E-7	Type 2 diabetes	
LGG	cis	1	rs712698	chr7:127249098	GCC1	chr7:127220683-127225654:-	0.31	5.2	2.98E-7	Type 2 diabetes	
LGG	cis	1	rs712700	chr7:127250907	GCC1	chr7:127220683-127225654:-	0.32	5.31	1.7E-7	Type 2 diabetes	
LGG	cis	1	rs712701	chr7:127251188	GCC1	chr7:127220683-127225654:-	0.32	5.36	1.25E-7	Type 2 diabetes	
LGG	cis	1	rs712703	chr7:127257498	GCC1	chr7:127220683-127225654:-	-0.27	-4.63	4.66E-6	Type 2 diabetes	
LGG	cis	1	rs712704	chr7:127258208	GCC1	chr7:127220683-127225654:-	-0.38	-6.15	1.59E-9	Type 2 diabetes	
LGG	cis	1	rs7127865	chr11:71747781	FAM86C	chr11:71498557-71512276:+	0.48	4.77	2.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7127900	chr11:2233574	C11orf21	chr11:2317507-2323143:-	0.26	4.49	9.09E-6	Prostate cancer (early onset);Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs7128029	chr11:244141	PSMD13	chr11:236808-252984:+	-0.22	-4.97	9.24E-7	Menarche (age at onset)	
LGG	cis	1	rs7128044	chr11:244115	PSMD13	chr11:236808-252984:+	-0.22	-4.97	9.24E-7	Menarche (age at onset)	
LGG	cis	1	rs7128317	chr11:71701367	FAM86C	chr11:71498557-71512276:+	-0.52	-5.05	6.34E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7129556	chr11:77300048	AQP11	chr11:77300436-77320691:+	-0.24	-4.26	2.42E-5	Weight loss (gastric bypass surgery)	
LGG	cis	1	rs7130165	chr11:5387695	FAM160A2	chr11:6232565-6255941:-	0.19	3.87	0.000121	Fetal hemoglobin levels	
LGG	cis	1	rs71301804	chr3:53073314	RFT1	chr3:53122503-53164470:-	0.31	3.56	0.000407	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs71301808	chr3:53085577	RFT1	chr3:53122503-53164470:-	0.31	3.51	0.000487	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs71301809	chr3:53090312	RFT1	chr3:53122503-53164470:-	0.31	3.46	0.000592	Immune reponse to smallpox (secreted IL-2)	
LGG	cis	1	rs7130284	chr11:89148372	NOX4	chr11:89057524-89322779:-	0.32	3.77	0.000184	Homocysteine levels	
LGG	cis	1	rs7130829	chr11:71237702	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.4	1.33E-5	Vitamin D levels	
LGG	cis	1	rs7131367	chr11:5392106	FAM160A2	chr11:6232565-6255941:-	0.18	3.68	0.000261	Fetal hemoglobin levels	
LGG	cis	1	rs7131597	chr11:120303939	TMEM136	chr11:120196016-120204388:+	0.2	4.67	3.87E-6	Intraocular pressure	
LGG	cis	1	rs7131696	chr12:121459344	SPPL3	chr12:121201036-121342151:-	0.3	4.19	3.37E-5	Type 2 diabetes	
LGG	cis	1	rs713219	chr9:131900920	CRAT	chr9:131857075-131873070:-	0.21	3.78	0.000177	Blood metabolite ratios	
LGG	cis	1	rs7132434	chr12:26472562	BHLHE41	chr12:26272961-26278003:-	0.13	3.86	0.000128	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs71327718	chr3:125592857	LOC100125556	chr3:125635444-125648865:+	0.78	9.71	1.64E-20	Metabolite levels (HVA/5-HIAA ratio)	
LGG	cis	1	rs7137121	chr12:89841834	GALNT4	chr12:89913192-89919777:-	-0.15	-4.07	5.41E-5	Schizophrenia	
LGG	cis	1	rs7137121	chr12:89841834	POC1B	chr12:89813501-89919777:-	-0.17	-3.56	0.000405	Schizophrenia	
LGG	cis	1	rs7137828	chr12:111932800	ALDH2	chr12:112204346-112247782:+	-0.13	-3.78	0.000174	Glaucoma (primary open-angle)	
LGG	cis	1	rs713835	chr22:38064650	LGALS1	chr22:38071613-38075807:+	-0.18	-4.95	1.02E-6	Fat distribution (HIV)	
LGG	cis	1	rs71391092	chr16:74567075	LOC283922	chr16:74366304-74402153:-	-0.25	-3.88	0.00012	Schizophrenia	
LGG	cis	1	rs71396107	chr16:77336556	ADAMTS18	chr16:77316026-77469011:-	-0.3	-4.37	1.5E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs7139978	chr13:38196963	ALG5	chr13:37523910-37573504:-	-0.23	-5.01	7.79E-7	Life satisfaction	
LGG	cis	1	rs7139978	chr13:38196963	EXOSC8	chr13:37574678-37583749:+	-0.18	-4.87	1.52E-6	Life satisfaction	
LGG	cis	1	rs7139978	chr13:38196963	FAM48A	chr13:37583453-37633850:-	-0.15	-3.72	0.000224	Life satisfaction	
LGG	cis	1	rs7139978	chr13:38196963	RFXAP	chr13:37393339-37403740:+	-0.18	-3.83	0.000142	Life satisfaction	
LGG	cis	1	rs7140261	chr14:65973956	LOC645431	chr14:65877313-65879335:-	-0.47	-6.16	1.48E-9	Ischemic stroke	
LGG	cis	1	rs7140872	chr14:55612744	FBXO34	chr14:55738021-55893431:+	0.14	4.31	1.97E-5	Protein biomarker	
LGG	cis	1	rs7141319	chr14:55336360	GCH1	chr14:55308724-55369542:-	-0.3	-5.03	6.94E-7	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs714191	chr22:29145411	HSCB	chr22:29138043-29153488:+	0.2	3.9	0.00011	Breast size	
LGG	cis	1	rs7142235	chr14:75559963	ACYP1	chr14:75519930-75530736:-	-0.14	-3.86	0.000127	Height	
LGG	cis	1	rs7142457	chr14:50097862	RPL36AL	chr14:50085407-50087349:-	0.31	8.09	4.59E-15	Carotid intima media thickness	
LGG	cis	1	rs7142704	chr14:55630603	FBXO34	chr14:55738021-55893431:+	0.14	4.2	3.17E-5	Protein biomarker	
LGG	cis	1	rs71436418	chr13:31455888	C13orf33	chr13:31480312-31499708:+	0.42	5.76	1.49E-8	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs7143682	chr14:104413455	TDRD9	chr14:104394817-104519002:+	0.23	4.6	5.39E-6	Bipolar disorder	
LGG	cis	1	rs7144423	chr14:35572547	KIAA0391	chr14:35591776-35786673:+	0.23	3.65	0.000291	Atopic dermatitis	
LGG	cis	1	rs7145159	chr14:75583268	ACYP1	chr14:75519930-75530736:-	-0.14	-3.71	0.000231	Height	
LGG	cis	1	rs7145159	chr14:75583268	EIF2B2	chr14:75469612-75476292:+	0.18	3.55	0.00043	Height	
LGG	cis	1	rs7145574	chr14:65884402	LOC645431	chr14:65877313-65879335:-	-0.52	-7.17	2.84E-12	Ischemic stroke	
LGG	cis	1	rs7145588	chr14:88826796	SPATA7	chr14:88852012-88904802:+	-0.45	-7.91	1.74E-14	Coronary artery calcification	
LGG	cis	1	rs7147118	chr14:75610170	ACYP1	chr14:75519930-75530736:-	-0.15	-4.02	6.76E-5	Height	
LGG	cis	1	rs7147118	chr14:75610170	EIF2B2	chr14:75469612-75476292:+	0.19	3.64	0.000297	Height	
LGG	cis	1	rs7147118	chr14:75610170	MLH3	chr14:75480467-75518235:-	0.2	3.55	0.00043	Height	
LGG	cis	1	rs7148538	chr14:74392342	LIN52	chr14:74551656-74667117:+	0.38	4.83	1.85E-6	Morning vs. evening chronotype	
LGG	cis	1	rs71488545	chr11:5388739	FAM160A2	chr11:6232565-6255941:-	0.19	3.67	0.000271	Fetal hemoglobin levels	
LGG	cis	1	rs714909	chr22:31741067	LIMK2	chr22:31608250-31676064:+	-0.25	-5.31	1.68E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs7152001	chr14:67461348	PIGH	chr14:68056023-68067017:-	0.26	3.5	0.000516	Depression (quantitative trait)	
LGG	cis	1	rs71523144	chr1:169590416	SCYL3	chr1:169821804-169863076:-	-0.27	-4.03	6.49E-5	Late-onset Alzheimer's disease	
LGG	cis	1	rs7153097	chr14:81772203	STON2	chr14:81727000-81893748:-	-0.14	-3.59	0.000361	Obesity-related traits	
LGG	cis	1	rs7153160	chr14:74509377	LIN52	chr14:74551656-74667117:+	0.45	10.38	5.72E-23	Common traits (Other)	
LGG	cis	1	rs7153538	chr14:81779507	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs7153587	chr14:74509660	LIN52	chr14:74551656-74667117:+	0.45	10.38	5.72E-23	Common traits (Other)	
LGG	cis	1	rs7153679	chr14:66012954	LOC645431	chr14:65877313-65879335:-	-0.45	-6.02	3.48E-9	Ischemic stroke	
LGG	cis	1	rs7154309	chr14:81782933	STON2	chr14:81727000-81893748:-	-0.14	-3.67	0.000269	Obesity-related traits	
LGG	cis	1	rs71550519	chr6:56780272	BEND6	chr6:56819773-56892138:+	-0.31	-5.44	8.61E-8	Menarche (age at onset)	
LGG	cis	1	rs71550519	chr6:56780272	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.81	0.000159	Menarche (age at onset)	
LGG	cis	1	rs715510	chr22:31690528	LIMK2	chr22:31608250-31676064:+	0.28	5.86	8.34E-9	Paclitaxel-induced neuropathy	
LGG	cis	1	rs7155454	chr14:65502239	RAB15	chr14:65412532-65438875:-	0.12	3.69	0.000246	Red blood cell traits	
LGG	cis	1	rs7155930	chr14:81776026	STON2	chr14:81727000-81893748:-	-0.14	-3.56	0.000404	Obesity-related traits	
LGG	cis	1	rs7156105	chr14:75541954	ACYP1	chr14:75519930-75530736:-	-0.15	-3.92	0.000102	Height	
LGG	cis	1	rs7156105	chr14:75541954	EIF2B2	chr14:75469612-75476292:+	0.18	3.46	0.000595	Height	
LGG	cis	1	rs7156105	chr14:75541954	MLH3	chr14:75480467-75518235:-	0.21	3.58	0.000378	Height	
LGG	cis	1	rs7156146	chr14:81776297	STON2	chr14:81727000-81893748:-	-0.15	-3.75	0.000201	Obesity-related traits	
LGG	cis	1	rs7156251	chr14:81776179	STON2	chr14:81727000-81893748:-	-0.14	-3.56	0.000404	Obesity-related traits	
LGG	cis	1	rs7156328	chr14:75532941	ACYP1	chr14:75519930-75530736:-	-0.13	-3.54	0.000432	Height	
LGG	cis	1	rs7156328	chr14:75532941	MLH3	chr14:75480467-75518235:-	0.2	3.52	0.000468	Height	
LGG	cis	1	rs71564866	chr6:56771207	BEND6	chr6:56819773-56892138:+	-0.3	-5.36	1.3E-7	Menarche (age at onset)	
LGG	cis	1	rs71564866	chr6:56771207	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.78	0.000174	Menarche (age at onset)	
LGG	cis	1	rs71564868	chr6:56798441	BEND6	chr6:56819773-56892138:+	-0.33	-5.88	7.48E-9	Menarche (age at onset)	
LGG	cis	1	rs71564868	chr6:56798441	KIAA1586	chr6:56911384-56920021:+	-0.15	-4.05	5.85E-5	Menarche (age at onset)	
LGG	cis	1	rs71567659	chr6:163001736	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs7157566	chr14:74649129	LIN52	chr14:74551656-74667117:+	-0.47	-10.85	9.62E-25	Common traits (Other)	
LGG	cis	1	rs7157940	chr14:94563193	IFI27L1	chr14:94547639-94569059:+	0.14	3.58	0.000377	Anthropometric traits	
LGG	cis	1	rs71586101	chr5:125908586	ALDH7A1	chr5:125878918-125931082:-	0.46	5.48	6.69E-8	Osteoporosis	
LGG	cis	1	rs7160110	chr14:55594635	FBXO34	chr14:55738021-55893431:+	0.13	4.1	4.86E-5	Protein biomarker	
LGG	cis	1	rs7162175	chr15:90897473	IQGAP1	chr15:90931473-91045475:+	0.16	4.58	5.96E-6	Rheumatoid arthritis	
LGG	cis	1	rs7162243	chr15:90892631	IQGAP1	chr15:90931473-91045475:+	0.14	4.44	1.1E-5	Rheumatoid arthritis	
LGG	cis	1	rs7162900	chr15:75368017	PPCDC	chr15:75315927-75343066:+	0.24	5.18	3.17E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs7163730	chr15:78814681	CHRNA5	chr15:78857906-78886458:+	-0.45	-6.9	1.61E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7164132	chr15:40675155	C15orf23	chr15:40674922-40686488:+	1.01	18.62	6.13E-59	Heschl's gyrus morphology	
LGG	cis	1	rs7164132	chr15:40675155	IVD	chr15:40697686-40713512:+	-0.38	-4.59	5.59E-6	Heschl's gyrus morphology	
LGG	cis	1	rs71642219	chr1:28259338	RPA2	chr1:28218049-28241236:-	0.23	6.13	1.78E-9	Corneal astigmatism	
LGG	cis	1	rs7164594	chr15:78803057	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.76	3.98E-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7166691	chr15:100300260	ADAMTS17	chr15:100511643-100882183:-	0.28	3.62	0.00033	Major depressive disorder	
LGG	cis	1	rs7166691	chr15:100300260	C15orf51	chr15:100330361-100347132:-	-0.33	-4.59	5.67E-6	Major depressive disorder	
LGG	cis	1	rs7166991	chr15:40671957	C15orf23	chr15:40674922-40686488:+	0.99	18.18	7.38E-57	Heschl's gyrus morphology	
LGG	cis	1	rs7166991	chr15:40671957	IVD	chr15:40697686-40713512:+	-0.36	-4.44	1.1E-5	Heschl's gyrus morphology	
LGG	cis	1	rs7167138	chr15:50958998	SPPL2A	chr15:50999739-51057910:-	0.13	4.09	5.1E-5	QT interval	
LGG	cis	1	rs7167285	chr15:75368769	PPCDC	chr15:75315927-75343066:+	0.24	5.18	3.17E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs716822	chr4:171007504	AADAT	chr4:170981374-171011372:-	-0.29	-3.6	0.000346	Thyroid hormone levels	
LGG	cis	1	rs7168539	chr15:100295200	C15orf51	chr15:100330361-100347132:-	-0.3	-4.03	6.34E-5	Major depressive disorder	
LGG	cis	1	rs7168680	chr15:75369212	PPCDC	chr15:75315927-75343066:+	0.24	5.18	3.17E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs7169404	chr15:40675443	C15orf23	chr15:40674922-40686488:+	1.01	18.62	6.13E-59	Heschl's gyrus morphology	
LGG	cis	1	rs7169404	chr15:40675443	IVD	chr15:40697686-40713512:+	-0.38	-4.59	5.59E-6	Heschl's gyrus morphology	
LGG	cis	1	rs7170930	chr15:66580853	TIPIN	chr15:66629008-66649054:-	-0.63	-7.16	2.97E-12	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs7171869	chr15:78900909	CHRNA5	chr15:78857906-78886458:+	0.33	5.19	3.13E-7	Post bronchodilator FEV1	
LGG	cis	1	rs7172118	chr15:78862453	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.42	3.39E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7173833	chr15:75369618	PPCDC	chr15:75315927-75343066:+	0.21	4.55	6.8E-6	Blood trace element (Zn levels)	
LGG	cis	1	rs7174348	chr15:78792439	CHRNA5	chr15:78857906-78886458:+	-0.27	-4.14	4.05E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7175720	chr15:75348962	PPCDC	chr15:75315927-75343066:+	-0.26	-5.43	8.76E-8	Blood trace element (Zn levels)	
LGG	cis	1	rs717593	chr20:33652964	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.0E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7177486	chr15:90897109	IQGAP1	chr15:90931473-91045475:+	0.15	4.5	8.31E-6	Rheumatoid arthritis	
LGG	cis	1	rs7178496	chr15:90896959	IQGAP1	chr15:90931473-91045475:+	0.13	4.05	6.06E-5	Rheumatoid arthritis	
LGG	cis	1	rs7178663	chr15:90897058	IQGAP1	chr15:90931473-91045475:+	0.15	4.5	8.31E-6	Rheumatoid arthritis	
LGG	cis	1	rs7180201	chr15:24832671	PWRN1	chr15:24778839-24832924:+	-0.26	-4.54	6.94E-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7181141	chr15:63398552	LACTB	chr15:63414032-63434254:+	0.22	4.45	1.05E-5	HDL cholesterol	
LGG	cis	1	rs7181245	chr15:78814389	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.58	1.21E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7181447	chr15:78814567	CHRNA5	chr15:78857906-78886458:+	-0.44	-6.58	1.21E-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7182154	chr15:100300253	ADAMTS17	chr15:100511643-100882183:-	0.28	3.57	0.000397	Major depressive disorder	
LGG	cis	1	rs7182154	chr15:100300253	C15orf51	chr15:100330361-100347132:-	-0.33	-4.61	5.04E-6	Major depressive disorder	
LGG	cis	1	rs7182544	chr15:90897480	IQGAP1	chr15:90931473-91045475:+	0.13	4.05	6.06E-5	Rheumatoid arthritis	
LGG	cis	1	rs7182618	chr15:63398622	LACTB	chr15:63414032-63434254:+	0.21	4.4	1.34E-5	HDL cholesterol	
LGG	cis	1	rs718314	chr12:26453283	BHLHE41	chr12:26272961-26278003:-	-0.15	-4.31	1.94E-5	Waist-hip ratio;Renal cell carcinoma	
LGG	cis	1	rs718444	chr13:33147052	N4BP2L2	chr13:33006930-33112936:-	0.28	6.43	3.05E-10	Body mass index	
LGG	cis	1	rs7186227	chr16:55609568	LPCAT2	chr16:55542913-55620581:+	-0.09	-3.58	0.000379	Thyroid hormone levels	
LGG	cis	1	rs7186908	chr16:72220373	DHODH	chr16:72042643-72058954:+	0.36	7	8.48E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7186983	chr16:50098852	HEATR3	chr16:50099881-50139373:+	-0.3	-4.12	4.51E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs7187350	chr16:50099036	HEATR3	chr16:50099881-50139373:+	-0.3	-4.12	4.51E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs7189550	chr16:29911260	BOLA2	chr16:29454226-29466285:-;chr16	0.19	4.35	1.63E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7189550	chr16:29911260	LOC440356	chr16:29875004-29879374:+	0.26	5.5	6.17E-8	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7189750	chr16:29911416	BOLA2	chr16:29454226-29466285:-;chr16	-0.19	-4.28	2.29E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7189750	chr16:29911416	LOC440356	chr16:29875004-29879374:+	-0.27	-5.66	2.54E-8	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7191384	chr16:50104234	HEATR3	chr16:50099881-50139373:+	-0.3	-4.05	5.87E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs7191700	chr16:11406803	C16orf75	chr16:11343506-11445617:+	0.18	4.97	9.24E-7	Multiple sclerosis	
LGG	cis	1	rs7192208	chr16:77329641	ADAMTS18	chr16:77316026-77469011:-	0.36	4.12	4.41E-5	White matter integrity	
LGG	cis	1	rs7193487	chr16:50093406	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs7195415	chr16:67689057	LRRC36	chr16:67360747-67419108:+	0.47	4.54	7.2E-6	Crohn's disease	
LGG	cis	1	rs7195415	chr16:67689057	RANBP10	chr16:67757006-67840555:-	-0.34	-4.25	2.6E-5	Crohn's disease	
LGG	cis	1	rs7200950	chr16:67689752	LRRC36	chr16:67360747-67419108:+	0.47	4.54	7.2E-6	Crohn's disease	
LGG	cis	1	rs7200950	chr16:67689752	RANBP10	chr16:67757006-67840555:-	-0.34	-4.25	2.6E-5	Crohn's disease	
LGG	cis	1	rs7201519	chr16:29859977	LOC440356	chr16:29875004-29879374:+	-0.25	-4.09	4.95E-5	Multiple sclerosis	
LGG	cis	1	rs720475	chr7:144074929	ARHGEF5	chr7:144052489-144077724:+	0.25	4.86	1.57E-6	Breast cancer	
LGG	cis	1	rs7204827	chr16:4467533	CORO7	chr16:4390253-4466962:-	0.57	14.07	4.98E-38	Schizophrenia	
LGG	cis	1	rs7204827	chr16:4467533	NMRAL1	chr16:4511696-4526307:-	-0.41	-8.46	3.2E-16	Schizophrenia	
LGG	cis	1	rs7205409	chr16:642610	PIGQ	chr16:617032-634108:+	-0.26	-7.74	5.69E-14	Height	
LGG	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.45	9.71	1.68E-20	Height	
LGG	cis	1	rs7207021	chr17:28400516	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.98	4.2E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs7207724	chr17:20924236	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7207826	chr17:46500673	HOXB2	chr17:46620021-46622393:-	-0.19	-3.74	0.000209	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7207826	chr17:46500673	HOXB3	chr17:46626233-46667631:-	-0.18	-3.53	0.000452	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7208170	chr17:45330759	ITGB3	chr17:45331208-45421658:+	-0.24	-4.76	2.55E-6	Body mass index	
LGG	cis	1	rs7208663	chr17:65885171	LOC440461	chr17:66194801-66196436:+	0.26	4.24	2.64E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7209043	chr17:46495951	HOXB2	chr17:46620021-46622393:-	-0.19	-3.72	0.000221	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7209043	chr17:46495951	HOXB3	chr17:46626233-46667631:-	-0.18	-3.54	0.000445	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7209180	chr17:79581519	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs7209180	chr17:79581519	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs7209435	chr17:61712964	FTSJ3	chr17:61896795-61905031:-	0.44	9.04	3.54E-18	Body mass index	
LGG	cis	1	rs7209435	chr17:61712964	SMARCD2	chr17:61909441-61920351:-	0.21	4.73	2.95E-6	Body mass index	
LGG	cis	1	rs7209675	chr17:65831258	LOC440461	chr17:66194801-66196436:+	0.25	4.12	4.4E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7209758	chr17:61913621	DDX42	chr17:61851567-61896676:+	-0.16	-3.61	0.000343	Body mass index	
LGG	cis	1	rs7209758	chr17:61913621	FTSJ3	chr17:61896795-61905031:-	0.4	8.27	1.26E-15	Body mass index	
LGG	cis	1	rs7209758	chr17:61913621	SMARCD2	chr17:61909441-61920351:-	0.2	4.49	9.05E-6	Body mass index	
LGG	cis	1	rs7210027	chr17:65977053	LOC440461	chr17:66194801-66196436:+	-0.29	-4.87	1.49E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7210445	chr17:46401318	HOXB2	chr17:46620021-46622393:-	-0.18	-3.51	0.000491	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7210708	chr17:46444610	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7210738	chr17:45757598	C17orf57	chr17:45401142-45518675:+	-0.15	-3.65	0.000291	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs7210738	chr17:45757598	LOC100272146	chr17:45500843-45504056:+	-0.15	-3.79	0.000167	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs7211094	chr17:20923750	USP22	chr17:20902908-20947073:-	0.2	4.67	3.95E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7211213	chr17:61769456	FTSJ3	chr17:61896795-61905031:-	0.44	9.1	2.31E-18	Body mass index	
LGG	cis	1	rs7211213	chr17:61769456	SMARCD2	chr17:61909441-61920351:-	0.2	4.49	9.01E-6	Body mass index	
LGG	cis	1	rs7212293	chr17:65847325	LOC440461	chr17:66194801-66196436:+	0.28	4.7	3.41E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7212497	chr17:28335949	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs7213129	chr17:79581573	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs7213129	chr17:79581573	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs7214085	chr17:38169095	GSDMA	chr17:38119226-38134019:+	-0.72	-15.78	1.08E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs7214312	chr17:61870863	DDX42	chr17:61851567-61896676:+	-0.16	-3.62	0.000331	Body mass index	
LGG	cis	1	rs7214312	chr17:61870863	FTSJ3	chr17:61896795-61905031:-	0.41	8.41	4.38E-16	Body mass index	
LGG	cis	1	rs7214312	chr17:61870863	SMARCD2	chr17:61909441-61920351:-	0.19	4.32	1.87E-5	Body mass index	
LGG	cis	1	rs7214589	chr17:46401400	HOXB2	chr17:46620021-46622393:-	-0.19	-3.59	0.000369	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7214758	chr17:65880538	LOC440461	chr17:66194801-66196436:+	0.28	4.51	8.17E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7214921	chr17:40294025	DHX58	chr17:40253422-40264751:-	-0.19	-3.94	9.31E-5	Fibrinogen levels	
LGG	cis	1	rs7215147	chr17:30266711	LRRC37B	chr17:30335037-30380517:+	0.21	4.83	1.86E-6	Height	
LGG	cis	1	rs7215369	chr17:20916856	USP22	chr17:20902908-20947073:-	-0.19	-4.36	1.59E-5	Blood trace element (Se levels)	
LGG	cis	1	rs7216064	chr17:65898809	LOC440461	chr17:66194801-66196436:+	0.3	4.97	9.17E-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7216449	chr17:20930876	USP22	chr17:20902908-20947073:-	0.2	4.63	4.59E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7216786	chr17:20931064	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7216798	chr17:61740963	FTSJ3	chr17:61896795-61905031:-	0.43	8.99	5.24E-18	Body mass index	
LGG	cis	1	rs7216798	chr17:61740963	SMARCD2	chr17:61909441-61920351:-	0.2	4.51	8.06E-6	Body mass index	
LGG	cis	1	rs7216978	chr17:20926294	USP22	chr17:20902908-20947073:-	-0.2	-4.62	4.9E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7217025	chr17:46447390	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7217982	chr17:61832150	DDX42	chr17:61851567-61896676:+	-0.16	-3.7	0.000236	Body mass index	
LGG	cis	1	rs7217982	chr17:61832150	FTSJ3	chr17:61896795-61905031:-	0.41	8.38	5.52E-16	Body mass index	
LGG	cis	1	rs7217982	chr17:61832150	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.53E-5	Body mass index	
LGG	cis	1	rs7218345	chr17:46502917	HOXB2	chr17:46620021-46622393:-	-0.19	-3.74	0.000208	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7218345	chr17:46502917	HOXB3	chr17:46626233-46667631:-	-0.18	-3.58	0.00038	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7218524	chr17:45326565	ITGB3	chr17:45331208-45421658:+	-0.24	-4.75	2.63E-6	Body mass index	
LGG	cis	1	rs7219021	chr17:46840541	SNF8	chr17:47007461-47022154:-	-0.14	-3.72	0.000221	Schizophrenia or bipolar disorder	
LGG	cis	1	rs7219220	chr17:40294280	DHX58	chr17:40253422-40264751:-	-0.19	-3.93	9.9E-5	Fibrinogen levels	
LGG	cis	1	rs7219244	chr17:20926595	USP22	chr17:20902908-20947073:-	-0.19	-4.4	1.34E-5	Blood trace element (Se levels)	
LGG	cis	1	rs7219816	chr17:46393794	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7219874	chr17:53065807	STXBP4	chr17:53046126-53241449:+	-0.16	-3.64	0.000306	Breast cancer	
LGG	cis	1	rs7219874	chr17:53065807	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.42	9.12E-8	Breast cancer	
LGG	cis	1	rs7220821	chr17:61704147	DDX42	chr17:61851567-61896676:+	-0.16	-3.55	0.00042	Body mass index	
LGG	cis	1	rs7220821	chr17:61704147	FTSJ3	chr17:61896795-61905031:-	0.43	8.89	1.15E-17	Body mass index	
LGG	cis	1	rs7220821	chr17:61704147	SMARCD2	chr17:61909441-61920351:-	0.2	4.42	1.2E-5	Body mass index	
LGG	cis	1	rs7220892	chr17:61908316	DDX42	chr17:61851567-61896676:+	-0.16	-3.61	0.000343	Body mass index	
LGG	cis	1	rs7220892	chr17:61908316	FTSJ3	chr17:61896795-61905031:-	0.4	8.27	1.26E-15	Body mass index	
LGG	cis	1	rs7220892	chr17:61908316	SMARCD2	chr17:61909441-61920351:-	0.2	4.49	9.05E-6	Body mass index	
LGG	cis	1	rs7221223	chr17:53059007	TOM1L1	chr17:52978052-53039328:+	-0.19	-5.42	9.47E-8	Breast cancer	
LGG	cis	1	rs7221651	chr17:65832390	LOC440461	chr17:66194801-66196436:+	-0.25	-4.18	3.48E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7221743	chr17:28407876	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.98	4.34E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs7221770	chr17:46399835	HOXB2	chr17:46620021-46622393:-	-0.18	-3.51	0.000486	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7222060	chr17:61868279	DDX42	chr17:61851567-61896676:+	-0.16	-3.62	0.000331	Body mass index	
LGG	cis	1	rs7222060	chr17:61868279	FTSJ3	chr17:61896795-61905031:-	0.41	8.41	4.38E-16	Body mass index	
LGG	cis	1	rs7222060	chr17:61868279	SMARCD2	chr17:61909441-61920351:-	0.19	4.32	1.87E-5	Body mass index	
LGG	cis	1	rs7222197	chr17:53047499	STXBP4	chr17:53046126-53241449:+	0.15	3.54	0.000436	Breast cancer	
LGG	cis	1	rs7222197	chr17:53047499	TOM1L1	chr17:52978052-53039328:+	0.18	5.47	7.04E-8	Breast cancer	
LGG	cis	1	rs7222241	chr17:79574714	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs7222241	chr17:79574714	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs7222308	chr17:28277041	EFCAB5	chr17:28256874-28435469:+	0.23	6.06	2.66E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs7222452	chr17:46409991	HOXB2	chr17:46620021-46622393:-	-0.18	-3.47	0.000558	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7223003	chr17:45324293	ITGB3	chr17:45331208-45421658:+	-0.21	-4.35	1.64E-5	Body mass index	
LGG	cis	1	rs7223231	chr17:18811846	FAM18B	chr17:18684582-18710026:+	-0.19	-4.96	9.77E-7	Educational attainment (years of education)	
LGG	cis	1	rs7223231	chr17:18811846	FBXW10	chr17:18647326-18682661:+	-0.19	-4.27	2.4E-5	Educational attainment (years of education)	
LGG	cis	1	rs7223257	chr17:61787684	FTSJ3	chr17:61896795-61905031:-	0.26	5.31	1.68E-7	Height	
LGG	cis	1	rs7223257	chr17:61787684	TCAM1P	chr17:61934376-61941738:+	-0.2	-3.86	0.00013	Height	
LGG	cis	1	rs7223412	chr17:61808172	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs7223412	chr17:61808172	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs7223412	chr17:61808172	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs7223613	chr17:79574803	PDE6G	chr17:79617489-79623607:-	0.23	5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs7223613	chr17:79574803	TSPAN10	chr17:79609349-79615778:+	-0.68	-17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs7223672	chr17:61720565	DDX42	chr17:61851567-61896676:+	-0.17	-3.8	0.000164	Body mass index	
LGG	cis	1	rs7223672	chr17:61720565	FTSJ3	chr17:61896795-61905031:-	0.41	8.33	8.38E-16	Body mass index	
LGG	cis	1	rs7223672	chr17:61720565	SMARCD2	chr17:61909441-61920351:-	0.19	4.18	3.39E-5	Body mass index	
LGG	cis	1	rs7223786	chr17:28332107	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs7223813	chr17:65945840	LOC440461	chr17:66194801-66196436:+	0.3	4.98	8.67E-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7223930	chr17:65842186	LOC440461	chr17:66194801-66196436:+	0.26	4.28	2.21E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7223966	chr17:61893398	DDX42	chr17:61851567-61896676:+	-0.16	-3.63	0.00031	Body mass index	
LGG	cis	1	rs7223966	chr17:61893398	FTSJ3	chr17:61896795-61905031:-	0.39	8.01	8.42E-15	Body mass index	
LGG	cis	1	rs7223966	chr17:61893398	SMARCD2	chr17:61909441-61920351:-	0.2	4.39	1.38E-5	Body mass index	
LGG	cis	1	rs7224737	chr17:40289364	DHX58	chr17:40253422-40264751:-	0.19	3.9	0.000109	Fibrinogen levels	
LGG	cis	1	rs7224737	chr17:40289364	HSPB9	chr17:40274756-40275371:+	0.16	3.56	0.000411	Fibrinogen levels	
LGG	cis	1	rs7224923	chr17:65842265	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7224990	chr17:45326878	ITGB3	chr17:45331208-45421658:+	-0.24	-4.75	2.63E-6	Body mass index	
LGG	cis	1	rs7225608	chr17:40298326	DHX58	chr17:40253422-40264751:-	-0.21	-4.25	2.51E-5	Fibrinogen levels	
LGG	cis	1	rs7226229	chr17:20924077	USP22	chr17:20902908-20947073:-	-0.2	-4.57	6.19E-6	Blood trace element (Se levels)	
LGG	cis	1	rs7226599	chr18:74491132	ZNF236	chr18:74536116-74682680:+	-0.12	-3.48	0.000539	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
LGG	cis	1	rs723937	chr11:120312746	TMEM136	chr11:120196016-120204388:+	0.21	4.9	1.31E-6	Intraocular pressure	
LGG	cis	1	rs7246657	chr19:37747108	WDR87	chr19:38375472-38397317:-	-0.25	-3.93	9.74E-5	Coronary artery calcification	
LGG	cis	1	rs7246657	chr19:37747108	ZNF781	chr19:38158650-38183216:-	-0.26	-4.59	5.73E-6	Coronary artery calcification	
LGG	cis	1	rs7246967	chr19:23056346	ZNF492	chr19:22817126-22850472:+	-0.22	-4.44	1.12E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs7247420	chr19:33096786	C19orf40	chr19:33463148-33467955:+	0.21	3.8	0.000161	Eosinophilic esophagitis	
LGG	cis	1	rs7247420	chr19:33096786	PDCD5	chr19:33072104-33078322:+	-0.16	-3.84	0.000142	Eosinophilic esophagitis	
LGG	cis	1	rs7247513	chr19:12691185	MAN2B1	chr19:12757322-12777591:-	0.14	4.84	1.75E-6	Bipolar disorder	
LGG	cis	1	rs7248273	chr19:33096816	C19orf40	chr19:33463148-33467955:+	0.2	3.7	0.000243	Eosinophilic esophagitis	
LGG	cis	1	rs7248273	chr19:33096816	PDCD5	chr19:33072104-33078322:+	-0.16	-3.91	0.000103	Eosinophilic esophagitis	
LGG	cis	1	rs7248470	chr19:53013539	ZNF808	chr19:53030909-53067717:+	0.3	3.51	0.000495	Longitudinal alcohol consumption	
LGG	cis	1	rs7248845	chr19:33096718	C19orf40	chr19:33463148-33467955:+	0.21	3.88	0.000116	Eosinophilic esophagitis	
LGG	cis	1	rs7248845	chr19:33096718	PDCD5	chr19:33072104-33078322:+	-0.16	-3.88	0.000118	Eosinophilic esophagitis	
LGG	cis	1	rs7250300	chr19:10448660	ICAM3	chr19:10444452-10450345:-	-0.3	-5.53	5.12E-8	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs7251653	chr19:18608283	LRRC25	chr19:18501955-18508421:-	-0.16	-5.69	2.15E-8	Breast cancer	
LGG	cis	1	rs7252707	chr19:18612257	LRRC25	chr19:18501955-18508421:-	-0.17	-5.79	1.23E-8	Breast cancer	
LGG	cis	1	rs7252848	chr19:18612351	LRRC25	chr19:18501955-18508421:-	-0.16	-5.79	1.24E-8	Breast cancer	
LGG	cis	1	rs725309	chr3:48418708	ATRIP	chr3:48488141-48507708:+	-0.2	-5.05	6.15E-7	Longevity	
LGG	cis	1	rs725309	chr3:48418708	TREX1	chr3:48501186-48509043:+	0.38	9.68	2.1E-20	Longevity	
LGG	cis	1	rs725310	chr3:48418571	ATRIP	chr3:48488141-48507708:+	-0.19	-4.71	3.21E-6	Longevity	
LGG	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.39	9.87	4.56E-21	Longevity	
LGG	cis	1	rs7253326	chr19:53009541	ZNF808	chr19:53030909-53067717:+	0.29	3.52	0.000472	Longitudinal alcohol consumption	
LGG	cis	1	rs7254041	chr19:10448636	ICAM3	chr19:10444452-10450345:-	-0.3	-5.53	5.12E-8	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs7254349	chr19:24230343	LOC100101266	chr19:24344995-24346249:-	0.27	4.31	2.01E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7255436	chr19:8433196	RPS28	chr19:8386384-8387278:+	-0.25	-4.39	1.36E-5	HDL cholesterol	
LGG	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.65	16.73	4.53E-50	Schizophrenia	
LGG	cis	1	rs7257127	chr19:23056699	ZNF492	chr19:22817126-22850472:+	-0.21	-4.23	2.82E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs7257871	chr19:10449252	ICAM3	chr19:10444452-10450345:-	-0.3	-5.53	5.12E-8	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs7258015	chr19:10449358	ICAM3	chr19:10444452-10450345:-	-0.3	-5.62	3.26E-8	Systemic lupus erythematosus or rheumatoid arthritis	
LGG	cis	1	rs7258465	chr19:18533642	LRRC25	chr19:18501955-18508421:-	-0.17	-5.82	1.04E-8	Breast cancer	
LGG	cis	1	rs7258465	chr19:18533642	SSBP4	chr19:18530221-18545371:+	-0.12	-3.58	0.000383	Breast cancer	
LGG	cis	1	rs725908	chr20:33968067	CPNE1	chr20:34213968-34262539:-	0.26	5.59	3.75E-8	Height	
LGG	cis	1	rs725908	chr20:33968067	GDF5	chr20:33897002-34042568:-	-0.38	-7.45	4.22E-13	Height	
LGG	cis	1	rs725908	chr20:33968067	PROCR	chr20:33758727-33765164:+	0.13	3.51	0.000497	Height	
LGG	cis	1	rs725908	chr20:33968067	UQCC	chr20:33890383-33999833:-	0.24	5.19	3.02E-7	Height	
LGG	cis	1	rs7259376	chr19:22507705	ZNF257	chr19:22235266-22273901:+	-0.21	-3.91	0.000107	Telomere length	
LGG	cis	1	rs7259376	chr19:22507705	ZNF98	chr19:22573899-22605148:-	-0.14	-3.48	0.000551	Telomere length	
LGG	cis	1	rs7260482	chr19:45143942	PVR	chr19:45147098-45169426:+	0.13	3.49	0.000534	Multiple sclerosis	
LGG	cis	1	rs7260598	chr19:24222786	LOC100101266	chr19:24344995-24346249:-	-0.27	-4.39	1.4E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs7260624	chr19:33096562	C19orf40	chr19:33463148-33467955:+	0.21	3.88	0.000117	Eosinophilic esophagitis	
LGG	cis	1	rs7260624	chr19:33096562	PDCD5	chr19:33072104-33078322:+	-0.16	-3.92	0.000101	Eosinophilic esophagitis	
LGG	cis	1	rs7261167	chr20:33576205	PROCR	chr20:33758727-33765164:+	-0.3	-5.94	5.4E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7261312	chr20:33684909	GDF5	chr20:33897002-34042568:-	0.27	3.73	0.00021	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7261312	chr20:33684909	PROCR	chr20:33758727-33765164:+	-0.3	-5.93	5.64E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72627117	chr14:74355233	LIN52	chr14:74551656-74667117:+	0.37	4.66	4.17E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627119	chr14:74356274	LIN52	chr14:74551656-74667117:+	0.37	4.66	4.17E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627120	chr14:74363480	LIN52	chr14:74551656-74667117:+	0.34	4.43	1.16E-5	Morning vs. evening chronotype	
LGG	cis	1	rs72627120	chr14:74363480	VSX2	chr14:74706175-74729434:+	-0.31	-3.5	0.000508	Morning vs. evening chronotype	
LGG	cis	1	rs72627122	chr14:74368236	LIN52	chr14:74551656-74667117:+	0.35	4.55	6.8E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627122	chr14:74368236	VSX2	chr14:74706175-74729434:+	-0.31	-3.47	0.000575	Morning vs. evening chronotype	
LGG	cis	1	rs72627123	chr14:74368331	LIN52	chr14:74551656-74667117:+	0.35	4.55	6.8E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627123	chr14:74368331	VSX2	chr14:74706175-74729434:+	-0.31	-3.47	0.000575	Morning vs. evening chronotype	
LGG	cis	1	rs72627124	chr14:74369128	LIN52	chr14:74551656-74667117:+	0.38	4.84	1.78E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627125	chr14:74369623	LIN52	chr14:74551656-74667117:+	0.38	4.84	1.78E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627126	chr14:74370024	LIN52	chr14:74551656-74667117:+	0.38	4.83	1.79E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627127	chr14:74370098	LIN52	chr14:74551656-74667117:+	0.38	4.84	1.78E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627129	chr14:74374805	LIN52	chr14:74551656-74667117:+	0.38	4.84	1.78E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627130	chr14:74374897	LIN52	chr14:74551656-74667117:+	0.38	4.84	1.78E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72627138	chr14:74401900	LIN52	chr14:74551656-74667117:+	0.35	4.51	7.95E-6	Morning vs. evening chronotype	
LGG	cis	1	rs72628223	chr16:77327815	ADAMTS18	chr16:77316026-77469011:-	0.35	3.8	0.000163	White matter integrity	
LGG	cis	1	rs7263203	chr20:33773375	PROCR	chr20:33758727-33765164:+	-0.36	-6.52	1.78E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7263253	chr20:33649376	PROCR	chr20:33758727-33765164:+	-0.32	-5.73	1.74E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72632952	chr11:8917976	C11orf17	chr11:8932701-8941624:+	-0.19	-3.61	0.00034	Schizophrenia	
LGG	cis	1	rs72644213	chr10:81783660	LOC219347	chr10:81805991-81838949:-	0.55	9.36	2.91E-19	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs72650885	chr8:58175131	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72650887	chr8:58177343	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72650892	chr8:58179714	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72650899	chr8:58180525	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.61E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72650900	chr8:58185675	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72652905	chr8:58188355	C8orf71	chr8:58192102-58197288:+	0.35	6.09	2.3E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs72652906	chr8:58188360	C8orf71	chr8:58192102-58197288:+	0.35	6.09	2.3E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7265317	chr20:33768523	PROCR	chr20:33758727-33765164:+	-0.36	-6.52	1.78E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72669978	chr4:106520852	GSTCD	chr4:106629941-106768881:+	0.29	3.46	0.000593	Post bronchodilator FEV1	
LGG	cis	1	rs72673831	chr4:106733380	GSTCD	chr4:106629941-106768881:+	0.31	3.49	0.000528	Post bronchodilator FEV1	
LGG	cis	1	rs72673832	chr4:106738760	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000564	Post bronchodilator FEV1	
LGG	cis	1	rs72673834	chr4:106739374	GSTCD	chr4:106629941-106768881:+	0.31	3.47	0.000564	Post bronchodilator FEV1	
LGG	cis	1	rs72677306	chr4:106997678	NPNT	chr4:106816605-106892827:+	-0.23	-4.86	1.59E-6	Airflow obstruction	
LGG	cis	1	rs7267979	chr20:25298087	ABHD12	chr20:25275380-25371477:-	0.26	6.95	1.13E-11	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7267979	chr20:25298087	FAM182A	chr20:26035250-26067552:+	-0.56	-11.08	1.25E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7267979	chr20:25298087	FAM182B	chr20:25744102-25848786:-	0.21	4.63	4.72E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7268053	chr20:25328286	ABHD12	chr20:25275380-25371477:-	-0.27	-7.46	4.07E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7268053	chr20:25328286	FAM182A	chr20:26035250-26067552:+	0.54	10.72	3.18E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7268053	chr20:25328286	FAM182B	chr20:25744102-25848786:-	-0.21	-4.81	2.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7268447	chr20:33649593	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.0E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72686191	chr1:76218319	MSH4	chr1:76262630-76378923:+	0.26	4.53	7.35E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7269138	chr20:33570007	PROCR	chr20:33758727-33765164:+	-0.31	-5.97	4.6E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72692857	chr1:150001632	RPRD2	chr1:150336990-150449039:+	0.14	3.48	0.00055	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692861	chr1:150005225	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692865	chr1:150015166	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692866	chr1:150017234	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692869	chr1:150019036	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692896	chr1:150048871	RPRD2	chr1:150336990-150449039:+	0.15	3.62	0.000323	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692897	chr1:150049934	RPRD2	chr1:150336990-150449039:+	0.16	3.91	0.000106	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72692901	chr1:150056510	RPRD2	chr1:150336990-150449039:+	0.16	3.91	0.000103	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694906	chr1:150065287	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694908	chr1:150068071	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694917	chr1:150076613	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694918	chr1:150076663	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694919	chr1:150076808	RPRD2	chr1:150336990-150449039:+	0.16	3.82	0.000148	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694927	chr1:150080659	RPRD2	chr1:150336990-150449039:+	0.16	3.87	0.000125	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694943	chr1:150111980	RPRD2	chr1:150336990-150449039:+	0.14	3.49	0.000525	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694954	chr1:150123762	RPRD2	chr1:150336990-150449039:+	0.16	3.77	0.000183	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs72694957	chr1:150135291	RPRD2	chr1:150336990-150449039:+	0.16	3.64	0.000299	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs726967	chr4:56421713	TMEM165	chr4:56262090-56292342:+	0.17	4.97	9.29E-7	Personality dimensions	
LGG	cis	1	rs72696952	chr1:152172694	HRNR	chr1:152184558-152196669:-	-0.59	-8.26	1.36E-15	Atopic dermatitis	
LGG	cis	1	rs72696963	chr1:152181189	HRNR	chr1:152184558-152196669:-	-0.58	-8.01	8.34E-15	Atopic dermatitis	
LGG	cis	1	rs72696969	chr1:152196339	HRNR	chr1:152184558-152196669:-	-0.58	-8.01	8.52E-15	Atopic dermatitis	
LGG	cis	1	rs72696989	chr1:152248674	HRNR	chr1:152184558-152196669:-	-0.57	-7.99	1.0E-14	Atopic dermatitis	
LGG	cis	1	rs72697000	chr1:152276772	HRNR	chr1:152184558-152196669:-	-0.55	-7.68	8.56E-14	Atopic dermatitis	
LGG	cis	1	rs72698044	chr1:165627540	ALDH9A1	chr1:165631449-165667900:-	0.22	3.58	0.000381	Parental extreme longevity (95 years and older)	
LGG	cis	1	rs72698906	chr1:152307184	HRNR	chr1:152184558-152196669:-	-0.55	-7.77	4.75E-14	Atopic dermatitis	
LGG	cis	1	rs7270326	chr20:33693582	GDF5	chr20:33897002-34042568:-	0.27	3.73	0.00021	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7270326	chr20:33693582	PROCR	chr20:33758727-33765164:+	-0.3	-5.93	5.64E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7270354	chr20:44607661	WFDC3	chr20:44402847-44420547:-	-0.48	-7.36	7.86E-13	Abdominal aortic aneurysm	
LGG	cis	1	rs7270354	chr20:44607661	ZSWIM1	chr20:44509848-44513904:+	0.2	3.78	0.000173	Abdominal aortic aneurysm	
LGG	cis	1	rs7271729	chr20:33610992	PROCR	chr20:33758727-33765164:+	-0.33	-5.86	8.28E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72717411	chr5:429124	EXOC3	chr5:443334-467407:+	-0.24	-5.51	5.83E-8	Cystic fibrosis severity	
LGG	cis	1	rs72717412	chr5:429381	EXOC3	chr5:443334-467407:+	-0.24	-5.6	3.54E-8	Cystic fibrosis severity	
LGG	cis	1	rs72717414	chr5:429818	EXOC3	chr5:443334-467407:+	-0.24	-5.53	5.08E-8	Cystic fibrosis severity	
LGG	cis	1	rs72718804	chr14:55630610	FBXO34	chr14:55738021-55893431:+	0.15	4.59	5.55E-6	Protein biomarker	
LGG	cis	1	rs7272164	chr20:47766197	ARFGEF2	chr20:47538275-47653229:+	0.11	4	7.16E-5	Anger	
LGG	cis	1	rs7272164	chr20:47766197	CSE1L	chr20:47662838-47713484:+	0.18	4.97	9.32E-7	Anger	
LGG	cis	1	rs7273734	chr20:33599403	PROCR	chr20:33758727-33765164:+	-0.31	-5.84	9.37E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs72741611	chr9:89571627	ISCA1	chr9:88879464-88897490:-	0.29	3.48	0.000543	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy	
LGG	cis	1	rs72743233	chr1:211556996	C1orf97	chr1:211556097-211605876:+	0.21	3.6	0.000346	Educational attainment (years of education)	
LGG	cis	1	rs7274581	chr20:55018260	CASS4	chr20:54987168-55034396:+	0.29	4.19	3.32E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs72748633	chr5:42014597	C5orf51	chr5:41904470-41921737:+	-0.31	-3.76	0.000187	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs72748635	chr5:42015409	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.0003	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs72748636	chr5:42015558	C5orf51	chr5:41904470-41921737:+	-0.29	-3.65	0.000286	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs7274866	chr20:33608616	PROCR	chr20:33758727-33765164:+	-0.31	-5.93	5.72E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs727563	chr22:41867377	MEI1	chr22:42095518-42195459:+	-0.27	-5.37	1.24E-7	Crohn's disease;Inflammatory bowel disease	
LGG	cis	1	rs727563	chr22:41867377	TNFRSF13C	chr22:42321036-42322821:-	-0.18	-3.46	0.000593	Crohn's disease;Inflammatory bowel disease	
LGG	cis	1	rs727563	chr22:41867377	XPNPEP3	chr22:41253094-41363888:+	-0.19	-3.47	0.000561	Crohn's disease;Inflammatory bowel disease	
LGG	cis	1	rs72761021	chr1:248012975	TRIM58	chr1:248020501-248043436:+	-0.47	-4.3	2.1E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs7276302	chr21:45614159	PWP2	chr21:45527208-45551062:+	0.22	3.98	7.84E-5	Inflammatory bowel disease	
LGG	cis	1	rs72768397	chr1:247219411	ZNF670	chr1:247200087-247242069:-	-0.22	-5.01	7.46E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs727694	chr8:21849962	XPO7	chr8:21777180-21864095:+	0.17	3.96	8.47E-5	Mean corpuscular volume	
LGG	cis	1	rs72772787	chr1:248016378	TRIM58	chr1:248020501-248043436:+	-0.49	-4.34	1.74E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs72782294	chr2:28953390	FAM179A	chr2:29204164-29275094:+	0.19	3.71	0.000229	Body mass index	
LGG	cis	1	rs72782294	chr2:28953390	TRMT61B	chr2:29072690-29093175:-	0.51	10.66	5.06E-24	Body mass index	
LGG	cis	1	rs72796115	chr16:50077722	HEATR3	chr16:50099881-50139373:+	-0.3	-4.11	4.63E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72796149	chr16:50114885	HEATR3	chr16:50099881-50139373:+	-0.3	-4.08	5.21E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72796151	chr16:50117077	HEATR3	chr16:50099881-50139373:+	-0.3	-4.08	5.21E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72796155	chr16:50121763	HEATR3	chr16:50099881-50139373:+	-0.3	-4.08	5.21E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72796159	chr16:50126320	HEATR3	chr16:50099881-50139373:+	-0.3	-4.08	5.21E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72796169	chr16:50132067	HEATR3	chr16:50099881-50139373:+	-0.3	-3.98	8.08E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs72800847	chr16:31022639	PRSS53	chr16:31094747-31106276:-	-0.17	-4.54	7.01E-6	Response to metformin (IC50)	
LGG	cis	1	rs72801605	chr16:77326515	ADAMTS18	chr16:77316026-77469011:-	-0.29	-4.19	3.3E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	
LGG	cis	1	rs72811623	chr2:97496473	FAM178B	chr2:97541620-97652301:-	-0.15	-3.64	0.0003	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs72823473	chr17:45321775	ITGB3	chr17:45331208-45421658:+	-0.21	-4.3	2.07E-5	Body mass index	
LGG	cis	1	rs72823474	chr17:45321776	ITGB3	chr17:45331208-45421658:+	-0.21	-4.37	1.55E-5	Body mass index	
LGG	cis	1	rs72823619	chr2:102924615	IL18R1	chr2:102927962-103015215:+	-0.49	-6.59	1.14E-10	Asthma	
LGG	cis	1	rs72823619	chr2:102924615	IL1R1	chr2:102686836-102796333:+	-0.21	-3.51	0.000489	Asthma	
LGG	cis	1	rs72823619	chr2:102924615	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.82	0.000151	Asthma	
LGG	cis	1	rs72823621	chr2:102925435	IL18R1	chr2:102927962-103015215:+	-0.49	-6.56	1.34E-10	Asthma	
LGG	cis	1	rs72823621	chr2:102925435	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.9	0.000108	Asthma	
LGG	cis	1	rs72823632	chr2:102931534	IL18R1	chr2:102927962-103015215:+	-0.49	-6.7	5.74E-11	Asthma	
LGG	cis	1	rs72823632	chr2:102931534	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.85	0.000132	Asthma	
LGG	cis	1	rs72823635	chr2:102931612	IL18R1	chr2:102927962-103015215:+	-0.49	-6.7	5.74E-11	Asthma	
LGG	cis	1	rs72823635	chr2:102931612	IL1RL1	chr2:102927962-102968497:+	-0.32	-3.85	0.000132	Asthma	
LGG	cis	1	rs72823646	chr2:102954213	IL18R1	chr2:102927962-103015215:+	-0.5	-6.89	1.72E-11	Asthma	
LGG	cis	1	rs72823646	chr2:102954213	IL1RL1	chr2:102927962-102968497:+	-0.33	-3.97	8.14E-5	Asthma	
LGG	cis	1	rs72825746	chr17:30364610	LRRC37B	chr17:30335037-30380517:+	0.27	5.55	4.6E-8	Height	
LGG	cis	1	rs72830442	chr2:105375329	MRPS9	chr2:105654483-105716417:+	-0.23	-3.85	0.000136	Pancreatic cancer	
LGG	cis	1	rs72831853	chr17:46842575	SNF8	chr17:47007461-47022154:-	-0.15	-4.03	6.48E-5	Schizophrenia or bipolar disorder	
LGG	cis	1	rs72840063	chr2:85550396	RETSAT	chr2:85569079-85581821:-	0.15	4.1	4.75E-5	Ear protrusion	
LGG	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-0.94	-10.6	8.97E-24	Schizophrenia	
LGG	cis	1	rs72845397	chr11:6950903	ZNF215	chr11:6947654-7005861:+	-0.22	-4.22	2.91E-5	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs72848797	chr17:61934664	DDX42	chr17:61851567-61896676:+	-0.16	-3.72	0.000224	Body mass index	
LGG	cis	1	rs72848797	chr17:61934664	FTSJ3	chr17:61896795-61905031:-	0.41	8.32	8.98E-16	Body mass index	
LGG	cis	1	rs72848797	chr17:61934664	SMARCD2	chr17:61909441-61920351:-	0.18	4.05	5.97E-5	Body mass index	
LGG	cis	1	rs7285549	chr22:25874580	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.14	4.16E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs7285549	chr22:25874580	CRYBB2	chr22:25615612-25627836:+	0.66	8.31	9.21E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs728615	chr10:81848089	PLAC9	chr10:81892258-81904784:+	-0.47	-6.67	6.76E-11	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs728615	chr10:81848089	SFTPA2	chr10:81315609-81320163:-	-0.34	-3.72	0.000218	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs728616	chr10:81847914	PLAC9	chr10:81892258-81904784:+	-0.47	-6.69	5.94E-11	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs728616	chr10:81847914	SFTPA2	chr10:81315609-81320163:-	-0.32	-3.53	0.000452	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs72872548	chr11:5289139	HBG2	chr11:5269502-5667011:-	0.28	4.48	9.16E-6	Hemoglobin levels	
LGG	cis	1	rs72872744	chr2:48704719	FOXN2	chr2:48541795-48606434:+	0.28	5.74	1.64E-8	Schizophrenia	
LGG	cis	1	rs7289577	chr22:39042214	LOC646851	chr22:38974125-39052634:-	0.22	6.56	1.34E-10	Resting heart rate	
LGG	cis	1	rs72896770	chr2:188139930	CALCRL	chr2:188207851-188313021:-	-0.22	-5.21	2.82E-7	Coronary heart disease	
LGG	cis	1	rs7289855	chr22:39042221	LOC646851	chr22:38974125-39052634:-	0.22	6.6	1.06E-10	Resting heart rate	
LGG	cis	1	rs7291412	chr22:46459132	LOC100271722	chr22:46435789-46440748:-	0.41	8.04	6.66E-15	Subjective well-being	
LGG	cis	1	rs7291867	chr22:38062112	LGALS1	chr22:38071613-38075807:+	-0.19	-5.03	7.04E-7	Fat distribution (HIV)	
LGG	cis	1	rs72922733	chr11:65520746	RNASEH2C	chr11:65485146-65488409:-	-0.2	-4.61	5.07E-6	Systemic lupus erythematosus	
LGG	cis	1	rs72922733	chr11:65520746	SNX32	chr11:65601410-65621170:+	0.23	4.71	3.25E-6	Systemic lupus erythematosus	
LGG	cis	1	rs72924202	chr11:64133228	C11orf20	chr11:64067863-64072238:+	0.23	3.77	0.000185	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs72926038	chr11:64142391	C11orf20	chr11:64067863-64072238:+	0.24	3.94	9.17E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs72926046	chr11:64143387	C11orf20	chr11:64067863-64072238:+	0.24	3.94	9.45E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs72926050	chr11:64143574	C11orf20	chr11:64067863-64072238:+	0.24	3.94	9.45E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs72932725	chr2:203649341	WDR12	chr2:203745324-203776949:-	0.21	3.52	0.000463	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932731	chr2:203650410	WDR12	chr2:203745324-203776949:-	0.21	3.49	0.000522	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932737	chr2:203654540	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932741	chr2:203661048	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932745	chr2:203662888	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932746	chr2:203663498	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932752	chr2:203667526	WDR12	chr2:203745324-203776949:-	0.21	3.5	0.000499	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72932776	chr2:203688300	WDR12	chr2:203745324-203776949:-	0.21	3.46	0.000585	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs72934944	chr2:202190610	ALS2CR12	chr2:202153148-202222101:-	0.29	3.52	0.000478	Rheumatoid arthritis	
LGG	cis	1	rs72934944	chr2:202190610	PPIL3	chr2:201735680-201753999:-	-0.85	-12.09	1.2E-29	Rheumatoid arthritis	
LGG	cis	1	rs72934960	chr2:202204749	PPIL3	chr2:201735680-201753999:-	-0.9	-11.81	1.63E-28	Rheumatoid arthritis	
LGG	cis	1	rs72934973	chr2:202213934	PPIL3	chr2:201735680-201753999:-	-0.9	-11.75	2.8E-28	Rheumatoid arthritis	
LGG	cis	1	rs72934999	chr2:202223524	PPIL3	chr2:201735680-201753999:-	-0.88	-11.52	2.32E-27	Rheumatoid arthritis	
LGG	cis	1	rs72937106	chr2:202225520	PPIL3	chr2:201735680-201753999:-	-0.88	-11.52	2.32E-27	Rheumatoid arthritis	
LGG	cis	1	rs72937118	chr2:202229527	PPIL3	chr2:201735680-201753999:-	-0.88	-11.43	5.44E-27	Rheumatoid arthritis	
LGG	cis	1	rs72937120	chr2:202232611	PPIL3	chr2:201735680-201753999:-	-0.88	-11.43	5.44E-27	Rheumatoid arthritis	
LGG	cis	1	rs72939875	chr6:107676435	QRSL1	chr6:107077441-107116290:+	0.33	3.46	0.00058	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs72939877	chr6:107676966	QRSL1	chr6:107077441-107116290:+	0.34	3.54	0.000437	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs72950839	chr2:113846794	RABL2A	chr2:114384817-114400974:+	0.2	3.46	0.00059	Stroke	
LGG	cis	1	rs72950861	chr2:113855124	RABL2A	chr2:114384817-114400974:+	0.2	3.46	0.000597	Stroke	
LGG	cis	1	rs72963846	chr11:94307762	MRE11A	chr11:94150469-94227040:-	-0.14	-3.65	0.00029	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs72963850	chr11:94310732	MRE11A	chr11:94150469-94227040:-	-0.14	-3.65	0.000293	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs72963868	chr11:94317709	MRE11A	chr11:94150469-94227040:-	-0.14	-3.69	0.000253	Attention deficit hyperactivity disorder symptoms (interaction)	
LGG	cis	1	rs7297610	chr12:69824024	YEATS4	chr12:69753532-69784575:+	0.42	4.8	2.15E-6	Response to diuretic therapy	
LGG	cis	1	rs7298108	chr12:9376168	LOC642846	chr12:9436253-9466684:+	-0.31	-6.16	1.54E-9	Non-alcoholic fatty liver disease histology (AST)	
LGG	cis	1	rs73002111	chr2:242277833	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.38E-10	Prostate cancer	
LGG	cis	1	rs73002147	chr2:242302934	ANO7	chr2:242127924-242164791:+	0.38	6.33	5.67E-10	Prostate cancer	
LGG	cis	1	rs73004354	chr2:242356239	ANO7	chr2:242127924-242164791:+	0.4	6.87	2.01E-11	Prostate cancer	
LGG	cis	1	rs73004382	chr2:242382192	ANO7	chr2:242127924-242164791:+	0.41	7.01	8.07E-12	Prostate cancer	
LGG	cis	1	rs73005500	chr11:118697375	MPZL3	chr11:118100337-118123011:-	0.25	3.76	0.000191	Vitiligo	
LGG	cis	1	rs73008453	chr6:163013384	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs73015655	chr3:158451882	RARRES1	chr3:158414899-158450275:-	0.22	3.47	0.000564	Tetralogy of Fallot	
LGG	cis	1	rs73016459	chr6:163066323	PACRG	chr6:163148164-163736523:+	0.36	4.96	9.94E-7	Body mass index	
LGG	cis	1	rs73018141	chr2:242221570	ANO7	chr2:242127924-242164791:+	0.38	6.51	1.81E-10	Prostate cancer	
LGG	cis	1	rs73020143	chr2:242261240	ANO7	chr2:242127924-242164791:+	0.39	6.56	1.36E-10	Prostate cancer	
LGG	cis	1	rs73034216	chr19:32883416	ZNF507	chr19:32836514-32878571:+	0.13	3.77	0.000186	Bipolar disorder	
LGG	cis	1	rs73035012	chr6:162997279	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs73035021	chr6:163000716	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs73035023	chr6:163000927	PACRG	chr6:163148164-163736523:+	0.3	4.44	1.1E-5	Body mass index	
LGG	cis	1	rs73035025	chr6:163000988	PACRG	chr6:163148164-163736523:+	0.3	4.5	8.6E-6	Body mass index	
LGG	cis	1	rs73036735	chr1:179426268	C1orf125	chr1:179335107-179523868:+	0.65	8.01	8.11E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs73036771	chr1:179463925	C1orf125	chr1:179335107-179523868:+	0.64	8.01	8.59E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs73038113	chr3:20139025	EFHB	chr3:19920968-19988501:-	0.38	4.96	9.5E-7	Bipolar disorder and schizophrenia	
LGG	cis	1	rs73038541	chr1:179479775	C1orf125	chr1:179335107-179523868:+	0.46	6.07	2.59E-9	Multiple sclerosis (age of onset)	
LGG	cis	1	rs7303	chr14:75520065	EIF2B2	chr14:75469612-75476292:+	0.19	3.6	0.000348	Height	
LGG	cis	1	rs7303	chr14:75520065	MLH3	chr14:75480467-75518235:-	0.21	3.62	0.000328	Height	
LGG	cis	1	rs730543	chr20:47635715	ARFGEF2	chr20:47538275-47653229:+	-0.11	-4.02	6.82E-5	Anger	
LGG	cis	1	rs730543	chr20:47635715	CSE1L	chr20:47662838-47713484:+	-0.18	-4.82	1.9E-6	Anger	
LGG	cis	1	rs730547	chr17:33112106	LIG3	chr17:33307538-33332088:+	0.16	3.46	0.000585	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs7305655	chr12:51005289	ATF1	chr12:51157819-51214906:+	0.21	4.56	6.61E-6	Fibrinogen	
LGG	cis	1	rs7305655	chr12:51005289	LETMD1	chr12:51442084-51454206:+	-0.15	-3.66	0.000276	Fibrinogen	
LGG	cis	1	rs7305655	chr12:51005289	SLC11A2	chr12:51373319-51422058:-	-0.16	-3.64	0.000304	Fibrinogen	
LGG	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.71	12.97	2.65E-33	Diastolic blood pressure	
LGG	cis	1	rs73069394	chr3:41787233	ULK4	chr3:41288091-42003660:-	0.74	14.35	2.98E-39	Diastolic blood pressure	
LGG	cis	1	rs73069396	chr3:41787236	ULK4	chr3:41288091-42003660:-	0.74	14.35	2.98E-39	Diastolic blood pressure	
LGG	cis	1	rs73070048	chr2:207641394	MDH1B	chr2:207598943-207630050:-	0.33	6.05	2.88E-9	Episodic memory	
LGG	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.76	14.83	2.28E-41	Diastolic blood pressure	
LGG	cis	1	rs73074358	chr3:48427247	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs73074358	chr3:48427247	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs73077367	chr3:41851959	ULK4	chr3:41288091-42003660:-	0.76	14.56	3.72E-40	Diastolic blood pressure	
LGG	cis	1	rs7307815	chr12:50922710	ATF1	chr12:51157819-51214906:+	-0.21	-4.38	1.42E-5	Fibrinogen	
LGG	cis	1	rs7307815	chr12:50922710	LETMD1	chr12:51442084-51454206:+	0.14	3.52	0.000477	Fibrinogen	
LGG	cis	1	rs7307815	chr12:50922710	SLC11A2	chr12:51373319-51422058:-	0.17	3.7	0.000242	Fibrinogen	
LGG	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.76	13.79	8.6E-37	Diastolic blood pressure	
LGG	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.79	15.23	3.61E-43	Diastolic blood pressure	
LGG	cis	1	rs73079851	chr1:212872852	BATF3	chr1:212859760-212873327:-	0.19	4.11	4.61E-5	Leprosy	
LGG	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.75	13.76	1.18E-36	Diastolic blood pressure	
LGG	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.75	13.76	1.18E-36	Diastolic blood pressure	
LGG	cis	1	rs73088137	chr3:49448423	AMIGO3	chr3:49754268-49757238:-	0.2	4.57	6.3E-6	Menarche (age at onset)	
LGG	cis	1	rs73088137	chr3:49448423	GMPPB	chr3:49758932-49761384:-	0.25	4.74	2.79E-6	Menarche (age at onset)	
LGG	cis	1	rs73088137	chr3:49448423	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.49	0.000533	Menarche (age at onset)	
LGG	cis	1	rs73088137	chr3:49448423	TREX1	chr3:48501186-48509043:+	0.25	5.2	2.94E-7	Menarche (age at onset)	
LGG	cis	1	rs7309927	chr12:1000185	RAD52	chr12:1021255-1099219:-	-0.18	-3.63	0.000314	Colorectal cancer	
LGG	cis	1	rs7310615	chr12:111865049	ALDH2	chr12:112204346-112247782:+	-0.13	-3.98	7.85E-5	Fibrinogen levels	
LGG	cis	1	rs731152	chr17:40279680	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs731152	chr17:40279680	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs73116394	chr2:242367915	SEPT2	chr2:242254723-242293439:+	0.54	7.89	1.97E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs73116396	chr2:242368693	SEPT2	chr2:242254723-242293439:+	0.54	7.89	1.97E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs7312329	chr12:3970007	PARP11	chr12:3918027-3982608:-	-0.23	-4.82	1.93E-6	Cognitive performance	
LGG	cis	1	rs73140069	chr7:75986790	POR	chr7:75544420-75616172:+	0.19	3.97	8.39E-5	Multiple sclerosis	
LGG	cis	1	rs73140069	chr7:75986790	SRCRB4D	chr7:76018647-76039012:-	0.27	5.99	4.09E-9	Multiple sclerosis	
LGG	cis	1	rs73140069	chr7:75986790	UPK3B	chr7:76139745-76157197:+	-0.24	-4.47	9.52E-6	Multiple sclerosis	
LGG	cis	1	rs73142121	chr7:65311206	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs73142122	chr7:65311298	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs73142162	chr7:65374296	CCT6P1	chr7:65216092-65228661:+	0.27	4.99	8.28E-7	Diabetic kidney disease	
LGG	cis	1	rs73142166	chr7:65375832	CCT6P1	chr7:65216092-65228661:+	0.27	4.87	1.5E-6	Diabetic kidney disease	
LGG	cis	1	rs7314929	chr12:89870785	GALNT4	chr12:89913192-89919777:-	-0.16	-4.34	1.69E-5	Schizophrenia	
LGG	cis	1	rs7314929	chr12:89870785	POC1B	chr12:89813501-89919777:-	-0.17	-3.54	0.000431	Schizophrenia	
LGG	cis	1	rs73150014	chr7:65450919	CCT6P1	chr7:65216092-65228661:+	0.27	4.98	9.01E-7	Diabetic kidney disease	
LGG	cis	1	rs73155068	chr3:149536209	C3orf16	chr3:149478892-149510610:-	-0.32	-3.54	0.000432	Myocardial infarction	
LGG	cis	1	rs73159739	chr12:101735192	UTP20	chr12:101673905-101780397:+	-0.19	-3.94	9.51E-5	Alcohol dependence (age at onset)	
LGG	cis	1	rs73168721	chr22:32793641	RFPL3S	chr22:32755895-32767063:-	-0.25	-5.62	3.19E-8	IgG glycosylation	
LGG	cis	1	rs73168729	chr22:32796718	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.46	7.69E-8	IgG glycosylation	
LGG	cis	1	rs7319041	chr13:40345356	COG6	chr13:40229764-40365802:+	-0.27	-5.74	1.68E-8	Rheumatoid arthritis	
LGG	cis	1	rs73192052	chr12:104190854	NT5DC3	chr12:104164231-104234975:-	-0.22	-4.46	1.03E-5	Attention deficit hyperactivity disorder	
LGG	cis	1	rs73192053	chr12:104190855	NT5DC3	chr12:104164231-104234975:-	-0.22	-4.6	5.4E-6	Attention deficit hyperactivity disorder	
LGG	cis	1	rs73192978	chr3:127868275	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.55E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73192979	chr3:127868321	EEFSEC	chr3:127872313-128127488:+	-0.22	-3.99	7.55E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs731945	chr19:18567039	LRRC25	chr19:18501955-18508421:-	0.11	3.77	0.000184	Self-reported allergy	
LGG	cis	1	rs73194650	chr7:86957971	CROT	chr7:86974951-87029112:+	0.38	4.9	1.32E-6	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs73197383	chr3:128030474	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.88	0.000121	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73197388	chr3:128043920	EEFSEC	chr3:127872313-128127488:+	-0.21	-3.8	0.00016	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73197388	chr3:128043920	LOC90246	chr3:128226678-128229427:+	-0.29	-3.61	0.000342	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73198875	chr3:128540286	RAB43	chr3:128806418-128880029:-	0.33	3.49	0.000525	Dental caries	
LGG	cis	1	rs73201462	chr3:128059293	EEFSEC	chr3:127872313-128127488:+	-0.24	-4.36	1.62E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73201462	chr3:128059293	LOC90246	chr3:128226678-128229427:+	-0.28	-3.49	0.000519	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7320598	chr13:40345466	COG6	chr13:40229764-40365802:+	-0.27	-5.69	2.2E-8	Rheumatoid arthritis	
LGG	cis	1	rs73212041	chr7:86878952	CROT	chr7:86974951-87029112:+	0.31	4.09	5.05E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs73212049	chr7:86885478	CROT	chr7:86974951-87029112:+	0.33	4.29	2.2E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs73212060	chr7:86906513	CROT	chr7:86974951-87029112:+	0.33	4.29	2.2E-5	Bipolar disorder or major depressive disorder (combined)	
LGG	cis	1	rs732172	chr16:31050033	MYST1	chr16:31128985-31142713:+	0.15	4.13	4.31E-5	Response to metformin (IC50)	
LGG	cis	1	rs732172	chr16:31050033	PRSS53	chr16:31094747-31106276:-	-0.16	-4.41	1.25E-5	Response to metformin (IC50)	
LGG	cis	1	rs732173	chr16:31050023	MYST1	chr16:31128985-31142713:+	0.15	4.1	4.79E-5	Response to metformin (IC50)	
LGG	cis	1	rs732173	chr16:31050023	PRSS53	chr16:31094747-31106276:-	-0.17	-4.44	1.11E-5	Response to metformin (IC50)	
LGG	cis	1	rs73224414	chr4:10297679	SLC2A9	chr4:9827850-10041872:-	0.22	5.22	2.68E-7	Schizophrenia (age at onset)	
LGG	cis	1	rs73224437	chr4:10329825	SLC2A9	chr4:9827850-10041872:-	0.22	4.95	1.05E-6	Schizophrenia (age at onset)	
LGG	cis	1	rs73235570	chr4:42453332	SHISA3	chr4:42399856-42404503:+	0.27	4.18	3.38E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs73235575	chr4:42465992	SHISA3	chr4:42399856-42404503:+	0.28	4.33	1.82E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs73235579	chr4:42476027	SHISA3	chr4:42399856-42404503:+	0.29	4.53	7.29E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs73235581	chr4:42478158	SHISA3	chr4:42399856-42404503:+	0.29	4.49	8.96E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs73235582	chr4:42479980	SHISA3	chr4:42399856-42404503:+	0.29	4.46	9.98E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs7323755	chr13:45900267	GTF2F2	chr13:45694631-45858237:+	0.34	3.79	0.00017	Myopia (pathological)	
LGG	cis	1	rs73239429	chr8:27079082	STMN4	chr8:27093816-27115903:-	0.2	4.65	4.37E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs73242910	chr6:170114670	PHF10	chr6:170104004-170124106:-	-0.23	-3.5	0.00051	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs73242910	chr6:170114670	WDR27	chr6:169857307-170102159:-	-0.38	-8.74	3.63E-17	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs73242927	chr6:170129573	WDR27	chr6:169857307-170102159:-	-0.36	-8.13	3.49E-15	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7324410	chr13:24437465	RNF17	chr13:25338301-25454056:+	-0.31	-3.53	0.000458	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs7324557	chr13:24296862	PCOTH	chr13:24463028-24466241:+	0.35	7.46	3.85E-13	Visceral adipose tissue adjusted for BMI	
LGG	cis	1	rs73252544	chr4:25192550	ANAPC4	chr4:25378848-25420119:+	0.31	4.85	1.69E-6	Cannabis dependence	
LGG	cis	1	rs73252544	chr4:25192550	PI4K2B	chr4:25162285-25280831:+	0.28	4.81	2.04E-6	Cannabis dependence	
LGG	cis	1	rs73252544	chr4:25192550	SEL1L3	chr4:25749050-25864610:-	0.26	3.49	0.000533	Cannabis dependence	
LGG	cis	1	rs73252547	chr4:25197417	ANAPC4	chr4:25378848-25420119:+	0.31	4.83	1.86E-6	Cannabis dependence	
LGG	cis	1	rs73252547	chr4:25197417	PI4K2B	chr4:25162285-25280831:+	0.28	4.79	2.23E-6	Cannabis dependence	
LGG	cis	1	rs73252547	chr4:25197417	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000436	Cannabis dependence	
LGG	cis	1	rs73252548	chr4:25198127	ANAPC4	chr4:25378848-25420119:+	0.31	4.83	1.86E-6	Cannabis dependence	
LGG	cis	1	rs73252548	chr4:25198127	PI4K2B	chr4:25162285-25280831:+	0.28	4.79	2.23E-6	Cannabis dependence	
LGG	cis	1	rs73252548	chr4:25198127	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000436	Cannabis dependence	
LGG	cis	1	rs73252549	chr4:25198785	ANAPC4	chr4:25378848-25420119:+	0.31	4.83	1.86E-6	Cannabis dependence	
LGG	cis	1	rs73252549	chr4:25198785	PI4K2B	chr4:25162285-25280831:+	0.28	4.79	2.23E-6	Cannabis dependence	
LGG	cis	1	rs73252549	chr4:25198785	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000436	Cannabis dependence	
LGG	cis	1	rs73252550	chr4:25199142	ANAPC4	chr4:25378848-25420119:+	0.31	4.83	1.86E-6	Cannabis dependence	
LGG	cis	1	rs73252550	chr4:25199142	PI4K2B	chr4:25162285-25280831:+	0.28	4.79	2.23E-6	Cannabis dependence	
LGG	cis	1	rs73252550	chr4:25199142	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000436	Cannabis dependence	
LGG	cis	1	rs73252551	chr4:25200063	ANAPC4	chr4:25378848-25420119:+	0.31	4.87	1.51E-6	Cannabis dependence	
LGG	cis	1	rs73252551	chr4:25200063	PI4K2B	chr4:25162285-25280831:+	0.28	4.83	1.83E-6	Cannabis dependence	
LGG	cis	1	rs73252551	chr4:25200063	SEL1L3	chr4:25749050-25864610:-	0.26	3.54	0.000435	Cannabis dependence	
LGG	cis	1	rs73252553	chr4:25201318	ANAPC4	chr4:25378848-25420119:+	0.31	4.79	2.19E-6	Cannabis dependence	
LGG	cis	1	rs73252553	chr4:25201318	PI4K2B	chr4:25162285-25280831:+	0.28	4.85	1.62E-6	Cannabis dependence	
LGG	cis	1	rs73252553	chr4:25201318	SEL1L3	chr4:25749050-25864610:-	0.26	3.51	0.000491	Cannabis dependence	
LGG	cis	1	rs73252555	chr4:25207397	ANAPC4	chr4:25378848-25420119:+	0.3	4.76	2.55E-6	Cannabis dependence	
LGG	cis	1	rs73252555	chr4:25207397	PI4K2B	chr4:25162285-25280831:+	0.27	4.65	4.25E-6	Cannabis dependence	
LGG	cis	1	rs73252555	chr4:25207397	SEL1L3	chr4:25749050-25864610:-	0.26	3.61	0.000333	Cannabis dependence	
LGG	cis	1	rs73252556	chr4:25207533	ANAPC4	chr4:25378848-25420119:+	0.3	4.76	2.55E-6	Cannabis dependence	
LGG	cis	1	rs73252556	chr4:25207533	PI4K2B	chr4:25162285-25280831:+	0.27	4.65	4.25E-6	Cannabis dependence	
LGG	cis	1	rs73252556	chr4:25207533	SEL1L3	chr4:25749050-25864610:-	0.26	3.61	0.000333	Cannabis dependence	
LGG	cis	1	rs73252557	chr4:25208462	ANAPC4	chr4:25378848-25420119:+	0.3	4.76	2.55E-6	Cannabis dependence	
LGG	cis	1	rs73252557	chr4:25208462	PI4K2B	chr4:25162285-25280831:+	0.27	4.65	4.25E-6	Cannabis dependence	
LGG	cis	1	rs73252557	chr4:25208462	SEL1L3	chr4:25749050-25864610:-	0.26	3.61	0.000333	Cannabis dependence	
LGG	cis	1	rs73268512	chr14:66088905	LOC645431	chr14:65877313-65879335:-	-0.47	-6.51	1.81E-10	Ischemic stroke	
LGG	cis	1	rs73268521	chr14:66093243	LOC645431	chr14:65877313-65879335:-	-0.49	-6.63	8.67E-11	Ischemic stroke	
LGG	cis	1	rs73280512	chr14:55337129	GCH1	chr14:55308724-55369542:-	-0.29	-4.62	4.86E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs73282209	chr5:150174959	LOC134466	chr5:150310000-150326146:-	0.39	4.29	2.15E-5	Crohn's disease	
LGG	cis	1	rs73282213	chr14:65852139	LOC645431	chr14:65877313-65879335:-	-0.46	-6.18	1.35E-9	Ischemic stroke	
LGG	cis	1	rs73282223	chr14:65854555	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs73282230	chr14:65856015	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs73282232	chr14:65856077	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs73282234	chr5:150195924	LOC134466	chr5:150310000-150326146:-	0.46	4.74	2.78E-6	Crohn's disease	
LGG	cis	1	rs73282255	chr5:150223647	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs73282260	chr14:65858964	LOC645431	chr14:65877313-65879335:-	-0.5	-6.76	3.99E-11	Ischemic stroke	
LGG	cis	1	rs73284121	chr14:65936936	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.24E-12	Ischemic stroke	
LGG	cis	1	rs73284126	chr5:150261307	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs73284133	chr14:65946612	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.24E-12	Ischemic stroke	
LGG	cis	1	rs73284141	chr5:150266086	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs732856	chr22:38060691	LGALS1	chr22:38071613-38075807:+	0.19	5.08	5.43E-7	Fat distribution (HIV)	
LGG	cis	1	rs73286118	chr14:66034821	LOC645431	chr14:65877313-65879335:-	-0.46	-6.11	2.07E-9	Ischemic stroke	
LGG	cis	1	rs73286169	chr14:66078448	LOC645431	chr14:65877313-65879335:-	-0.49	-6.65	7.96E-11	Ischemic stroke	
LGG	cis	1	rs73286173	chr14:66079540	LOC645431	chr14:65877313-65879335:-	-0.47	-6.51	1.81E-10	Ischemic stroke	
LGG	cis	1	rs73287472	chr12:11557133	MAGOHB	chr12:10756794-10766183:-	0.31	3.75	0.000195	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs73287473	chr12:11557259	MAGOHB	chr12:10756794-10766183:-	0.31	3.75	0.000195	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs73287479	chr12:11557486	MAGOHB	chr12:10756794-10766183:-	0.32	3.9	0.000111	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs73287481	chr12:11557536	MAGOHB	chr12:10756794-10766183:-	0.31	3.75	0.000195	Response to gemcitabine in pancreatic cancer	
LGG	cis	1	rs73301712	chr14:59898245	C14orf149	chr14:59939406-59951126:-	-0.46	-5.13	4.11E-7	Schizophrenia	
LGG	cis	1	rs73301712	chr14:59898245	JKAMP	chr14:59951161-59972080:+	0.36	3.54	0.000443	Schizophrenia	
LGG	cis	1	rs73301725	chr14:59902159	C14orf149	chr14:59939406-59951126:-	-0.48	-5.28	1.96E-7	Schizophrenia	
LGG	cis	1	rs73301725	chr14:59902159	JKAMP	chr14:59951161-59972080:+	0.38	3.67	0.000267	Schizophrenia	
LGG	cis	1	rs73301741	chr14:59908444	C14orf149	chr14:59939406-59951126:-	-0.47	-5.23	2.46E-7	Schizophrenia	
LGG	cis	1	rs73301741	chr14:59908444	JKAMP	chr14:59951161-59972080:+	0.39	3.78	0.000173	Schizophrenia	
LGG	cis	1	rs73301746	chr14:59908485	C14orf149	chr14:59939406-59951126:-	-0.47	-5.23	2.46E-7	Schizophrenia	
LGG	cis	1	rs73301746	chr14:59908485	JKAMP	chr14:59951161-59972080:+	0.39	3.78	0.000173	Schizophrenia	
LGG	cis	1	rs73305083	chr20:57684987	GNASAS	chr20:57393974-57425958:-	-0.47	-3.76	0.00019	Attention function in attention deficit hyperactive disorder	
LGG	cis	1	rs73307384	chr7:33268540	BBS9	chr7:33169152-33645680:+	0.43	5.8	1.17E-8	Smooth-surface caries	
LGG	cis	1	rs73307385	chr7:33268681	BBS9	chr7:33169152-33645680:+	0.43	5.8	1.17E-8	Smooth-surface caries	
LGG	cis	1	rs73307386	chr7:33270220	BBS9	chr7:33169152-33645680:+	0.43	5.8	1.17E-8	Smooth-surface caries	
LGG	cis	1	rs73307399	chr7:33287106	BBS9	chr7:33169152-33645680:+	0.44	6.2	1.17E-9	Smooth-surface caries	
LGG	cis	1	rs73307400	chr7:33287183	BBS9	chr7:33169152-33645680:+	0.44	6.2	1.17E-9	Smooth-surface caries	
LGG	cis	1	rs73309316	chr7:33300514	BBS9	chr7:33169152-33645680:+	0.47	6.49	2.14E-10	Smooth-surface caries	
LGG	cis	1	rs73309318	chr7:33301042	BBS9	chr7:33169152-33645680:+	0.47	6.41	3.36E-10	Smooth-surface caries	
LGG	cis	1	rs73309326	chr7:33306345	BBS9	chr7:33169152-33645680:+	0.46	6.35	4.9E-10	Smooth-surface caries	
LGG	cis	1	rs73309328	chr7:33306989	BBS9	chr7:33169152-33645680:+	0.46	6.35	4.9E-10	Smooth-surface caries	
LGG	cis	1	rs73309405	chr7:33180947	BBS9	chr7:33169152-33645680:+	0.44	5.6	3.51E-8	Smooth-surface caries	
LGG	cis	1	rs73309423	chr7:33197066	BBS9	chr7:33169152-33645680:+	0.46	5.96	4.83E-9	Smooth-surface caries	
LGG	cis	1	rs7331003	chr13:44230253	C13orf31	chr13:44453420-44468067:+	-0.1	-3.53	0.000452	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs73313121	chr7:33329691	BBS9	chr7:33169152-33645680:+	0.47	6.46	2.58E-10	Smooth-surface caries	
LGG	cis	1	rs73313138	chr7:33350809	BBS9	chr7:33169152-33645680:+	0.44	5.88	7.77E-9	Smooth-surface caries	
LGG	cis	1	rs73317492	chr7:33208414	BBS9	chr7:33169152-33645680:+	0.44	5.87	8.19E-9	Smooth-surface caries	
LGG	cis	1	rs73319406	chr7:33226844	BBS9	chr7:33169152-33645680:+	0.44	5.76	1.5E-8	Smooth-surface caries	
LGG	cis	1	rs73319407	chr7:33228807	BBS9	chr7:33169152-33645680:+	0.43	5.74	1.64E-8	Smooth-surface caries	
LGG	cis	1	rs7332115	chr13:33147548	N4BP2L2	chr13:33006930-33112936:-	0.28	6.34	5.27E-10	Body mass index	
LGG	cis	1	rs7332189	chr13:36755610	SOHLH2	chr13:36742347-36871992:-	-0.37	-6.72	4.99E-11	Glucose homeostasis traits	
LGG	cis	1	rs7332763	chr13:33147888	N4BP2L2	chr13:33006930-33112936:-	0.28	6.36	4.73E-10	Body mass index	
LGG	cis	1	rs7332932	chr13:36755636	SOHLH2	chr13:36742347-36871992:-	-0.37	-6.72	4.99E-11	Glucose homeostasis traits	
LGG	cis	1	rs733318	chr2:190724141	ORMDL1	chr2:190634994-190649097:-	0.35	5.25	2.32E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7333720	chr13:98005152	OXGR1	chr13:97637973-97646604:-	0.29	3.54	0.000434	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score)	
LGG	cis	1	rs73337598	chr17:61732576	DDX42	chr17:61851567-61896676:+	-0.16	-3.61	0.000344	Body mass index	
LGG	cis	1	rs73337598	chr17:61732576	FTSJ3	chr17:61896795-61905031:-	0.42	8.67	6.34E-17	Body mass index	
LGG	cis	1	rs73337598	chr17:61732576	SMARCD2	chr17:61909441-61920351:-	0.19	4.27	2.35E-5	Body mass index	
LGG	cis	1	rs73343315	chr5:125904762	ALDH7A1	chr5:125878918-125931082:-	0.44	4.96	9.93E-7	Osteoporosis	
LGG	cis	1	rs73343333	chr5:125913560	ALDH7A1	chr5:125878918-125931082:-	0.45	5.47	7.07E-8	Osteoporosis	
LGG	cis	1	rs73348070	chr5:127893533	FBN2	chr5:127593602-127873916:-	0.42	4.88	1.43E-6	Multiple system atrophy	
LGG	cis	1	rs7335094	chr13:44223936	C13orf31	chr13:44453420-44468067:+	-0.1	-3.61	0.000332	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs73352808	chr17:65875157	LOC440461	chr17:66194801-66196436:+	0.25	4.06	5.68E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs7340989	chr4:107148720	NPNT	chr4:106816605-106892827:+	-0.23	-5	7.82E-7	Airflow obstruction	
LGG	cis	1	rs73412140	chr6:33757014	LEMD2	chr6:33738991-33756906:-	0.19	5.49	6.33E-8	Body mass index	
LGG	cis	1	rs7343481	chr20:25300113	ABHD12	chr20:25275380-25371477:-	-0.27	-7.32	1.01E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7343481	chr20:25300113	FAM182A	chr20:26035250-26067552:+	0.54	10.64	6.29E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7343481	chr20:25300113	FAM182B	chr20:25744102-25848786:-	-0.21	-4.77	2.46E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs734559	chr18:72179579	CNDP2	chr18:72163597-72188356:+	0.24	5.62	3.21E-8	Refractive error	
LGG	cis	1	rs734809	chr22:32808998	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.52	5.49E-8	IgG glycosylation	
LGG	cis	1	rs73532987	chr9:123730300	TRAF1	chr9:123664672-123691479:-	0.34	4.11	4.69E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs73539529	chr11:71815596	FAM86C	chr11:71498557-71512276:+	-0.46	-4.41	1.29E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs73539532	chr11:71815684	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.33E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs73543609	chr11:71816619	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.33E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs73543633	chr11:71828844	FAM86C	chr11:71498557-71512276:+	-0.47	-4.56	6.48E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7355157	chr1:110129835	SYPL2	chr1:110009100-110024763:+	-0.22	-3.91	0.000105	Major depressive disorder	
LGG	cis	1	rs735531	chr20:33947730	CPNE1	chr20:34213968-34262539:-	0.27	5.83	9.87E-9	Height	
LGG	cis	1	rs735531	chr20:33947730	GDF5	chr20:33897002-34042568:-	-0.38	-7.37	7.5E-13	Height	
LGG	cis	1	rs735531	chr20:33947730	UQCC	chr20:33890383-33999833:-	0.25	5.32	1.57E-7	Height	
LGG	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.3	7.71	7.11E-14	Height	
LGG	cis	1	rs7356093	chr3:134238753	CEP63	chr3:134204575-134293852:+	0.2	3.7	0.000239	Height	
LGG	cis	1	rs7356941	chr6:107794473	QRSL1	chr6:107077441-107116290:+	0.31	3.54	0.000445	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs735765	chr6:28170297	ZNF187	chr6:28234788-28245978:+	-0.21	-3.46	0.000592	Depression	
LGG	cis	1	rs735765	chr6:28170297	ZNF389	chr6:28129551-28137375:+	0.43	6.54	1.57E-10	Depression	
LGG	cis	1	rs735765	chr6:28170297	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.58	5.96E-6	Depression	
LGG	cis	1	rs735765	chr6:28170297	ZSCAN23	chr6:28393287-28411279:-	0.17	3.92	0.000103	Depression	
LGG	cis	1	rs73591706	chr8:58195633	C8orf71	chr8:58192102-58197288:+	0.38	6.34	5.28E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73591936	chr16:67761825	LRRC36	chr16:67360747-67419108:+	0.48	4.47	9.81E-6	Crohn's disease	
LGG	cis	1	rs73591936	chr16:67761825	RANBP10	chr16:67757006-67840555:-	-0.33	-3.92	9.97E-5	Crohn's disease	
LGG	cis	1	rs7359276	chr15:78892661	CHRNA5	chr15:78857906-78886458:+	0.34	5.43	8.91E-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs73607863	chr8:58170178	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73607871	chr8:58173007	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73607874	chr8:58173433	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73607875	chr8:58173522	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73609747	chr8:58189104	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73609760	chr8:58192170	C8orf71	chr8:58192102-58197288:+	0.34	5.87	8.14E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73609762	chr8:58192695	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs73609764	chr8:58192971	C8orf71	chr8:58192102-58197288:+	0.36	6.18	1.33E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs736408	chr3:52835354	GNL3	chr3:52719936-52728508:+	-0.19	-3.9	0.00011	Bipolar disorder	
LGG	cis	1	rs736408	chr3:52835354	ITIH4	chr3:52847007-52866554:-	0.23	5.78	1.32E-8	Bipolar disorder	
LGG	cis	1	rs7364180	chr22:42218856	NAGA	chr22:42454339-42466846:-	-0.12	-3.88	0.000121	Alzheimer's disease biomarkers	
LGG	cis	1	rs7366341	chr1:202333695	UBE2T	chr1:202300786-202311094:-	-0.13	-3.88	0.000119	Sex ratio	
LGG	cis	1	rs736678	chr17:30347423	LRRC37B	chr17:30335037-30380517:+	0.26	5.48	6.81E-8	Height	
LGG	cis	1	rs73688093	chr7:33281750	BBS9	chr7:33169152-33645680:+	0.45	6.26	8.58E-10	Smooth-surface caries	
LGG	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.29	7.77	4.63E-14	Height	
LGG	cis	1	rs7371896	chr3:134249769	CEP63	chr3:134204575-134293852:+	0.2	3.69	0.000254	Height	
LGG	cis	1	rs7371	chr1:110135308	SYPL2	chr1:110009100-110024763:+	-0.24	-4.07	5.42E-5	Major depressive disorder	
LGG	cis	1	rs73721606	chr7:135335678	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.05	6.04E-5	Red blood cell traits	
LGG	cis	1	rs7372217	chr3:41990122	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs7373998	chr3:128008223	EEFSEC	chr3:127872313-128127488:+	0.22	4.15	3.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7373998	chr3:128008223	LOC90246	chr3:128226678-128229427:+	0.28	3.57	0.000391	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs7374158	chr3:134270156	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs7374227	chr3:128001515	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.15	3.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7374227	chr3:128001515	LOC90246	chr3:128226678-128229427:+	-0.28	-3.57	0.000391	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.3	7.67	9.08E-14	Height	
LGG	cis	1	rs7374325	chr3:134275601	CEP63	chr3:134204575-134293852:+	0.22	3.92	0.000101	Height	
LGG	cis	1	rs7374952	chr3:128001367	EEFSEC	chr3:127872313-128127488:+	-0.22	-4.15	3.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7374952	chr3:128001367	LOC90246	chr3:128226678-128229427:+	-0.28	-3.57	0.000391	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs737684	chr22:31659827	LIMK2	chr22:31608250-31676064:+	0.27	5.77	1.42E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs737887	chr22:31696615	LIMK2	chr22:31608250-31676064:+	0.27	5.55	4.68E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs738093	chr19:32930507	ZNF507	chr19:32836514-32878571:+	0.13	3.74	0.000208	Bipolar disorder	
LGG	cis	1	rs738711	chr22:50282603	ALG12	chr22:50296856-50312106:-	-0.27	-5.53	5.31E-8	Schizophrenia	
LGG	cis	1	rs73903009	chr20:33678732	PROCR	chr20:33758727-33765164:+	-0.3	-5.77	1.42E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73903017	chr20:33724758	PROCR	chr20:33758727-33765164:+	-0.32	-6.02	3.38E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73903019	chr20:33727779	PROCR	chr20:33758727-33765164:+	-0.32	-6.01	3.71E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73905019	chr20:33560314	GDF5	chr20:33897002-34042568:-	0.28	3.56	0.0004	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73905019	chr20:33560314	PROCR	chr20:33758727-33765164:+	-0.33	-5.96	4.71E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73905041	chr20:33592148	PROCR	chr20:33758727-33765164:+	-0.31	-5.83	1.01E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs73909829	chr20:49526297	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs73909831	chr20:49526485	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs739139	chr22:38067011	LGALS1	chr22:38071613-38075807:+	-0.18	-4.95	1.02E-6	Fat distribution (HIV)	
LGG	cis	1	rs73915969	chr20:57684738	GNASAS	chr20:57393974-57425958:-	-0.47	-3.76	0.00019	Attention function in attention deficit hyperactive disorder	
LGG	cis	1	rs73915970	chr20:57684761	GNASAS	chr20:57393974-57425958:-	-0.49	-3.73	0.000211	Attention function in attention deficit hyperactive disorder	
LGG	cis	1	rs73921003	chr2:17775205	GEN1	chr2:17935162-17966632:+	0.26	4.09	5.08E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs739337	chr8:17202871	MTMR7	chr8:17154308-17271040:-	0.29	3.54	0.000445	Creutzfeldt-Jakob disease (variant)	
LGG	cis	1	rs7394190	chr10:75421648	NUDT13	chr10:74870210-74891580:+	-0.24	-4.24	2.63E-5	Atrial fibrillation	
LGG	cis	1	rs7394449	chr11:962190	MUC6	chr11:1012824-1036706:-	-0.18	-3.96	8.61E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs7395213	chr11:87869579	RAB38	chr11:87846431-87908599:-	-0.33	-7.72	6.71E-14	Frontotemporal dementia	
LGG	cis	1	rs7395328	chr11:242624	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs7395632	chr11:958789	MUC6	chr11:1012824-1036706:-	0.18	3.95	9.13E-5	Alzheimer's disease (late onset)	
LGG	cis	1	rs7395691	chr11:985006	MUC6	chr11:1012824-1036706:-	-0.17	-3.61	0.00034	Alzheimer's disease (late onset)	
LGG	cis	1	rs739622	chr7:25618185	SNX10	chr7:26331515-26413937:+	-0.23	-3.67	0.000264	Preeclampsia	
LGG	cis	1	rs7396366	chr11:986185	MUC6	chr11:1012824-1036706:-	-0.17	-3.61	0.000333	Alzheimer's disease (late onset)	
LGG	cis	1	rs739636	chr17:40281063	DHX58	chr17:40253422-40264751:-	-0.21	-4.35	1.66E-5	Fibrinogen levels	
LGG	cis	1	rs739637	chr17:40280944	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs739637	chr17:40280944	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs7396798	chr11:970510	MUC6	chr11:1012824-1036706:-	-0.17	-3.7	0.000241	Alzheimer's disease (late onset)	
LGG	cis	1	rs73979024	chr2:190536755	ORMDL1	chr2:190634994-190649097:-	0.4	5.59	3.72E-8	Subcutaneous adipose tissue	
LGG	cis	1	rs73985728	chr2:207668245	MDH1B	chr2:207598943-207630050:-	0.32	4.95	1.05E-6	Episodic memory	
LGG	cis	1	rs74019800	chr16:58159888	C16orf80	chr16:58147497-58163296:-	-0.31	-3.51	0.000492	Telomere length	
LGG	cis	1	rs7402778	chr15:24774948	PWRN1	chr15:24778839-24832924:+	0.24	4.08	5.18E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7402804	chr15:24836600	PWRN1	chr15:24778839-24832924:+	0.25	4.33	1.83E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7402908	chr15:24836980	PWRN1	chr15:24778839-24832924:+	0.25	4.36	1.56E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7403037	chr15:24818497	PWRN1	chr15:24778839-24832924:+	-0.25	-4.34	1.72E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7406003	chr17:79597597	PDE6G	chr17:79617489-79623607:-	-0.23	-5.94	5.52E-9	Eye color traits	
LGG	cis	1	rs7406003	chr17:79597597	TSPAN10	chr17:79609349-79615778:+	0.68	17.35	6.36E-53	Eye color traits	
LGG	cis	1	rs74071851	chr14:88882202	KCNK10	chr14:88646454-88793256:-	-0.18	-3.46	0.000593	Coronary artery calcification	
LGG	cis	1	rs74071851	chr14:88882202	SPATA7	chr14:88852012-88904802:+	-0.48	-8.39	5.2E-16	Coronary artery calcification	
LGG	cis	1	rs74117831	chr10:1145707	IDI2	chr10:1064847-1071799:-	0.33	4.01	6.96E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs74117848	chr10:1160974	IDI2	chr10:1064847-1071799:-	0.34	4.07	5.55E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs74117849	chr10:1165425	IDI2	chr10:1064847-1071799:-	0.36	4.23	2.84E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs74117850	chr10:1165777	IDI2	chr10:1064847-1071799:-	0.36	4.23	2.84E-5	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs74120451	chr10:1126866	IDI2	chr10:1064847-1071799:-	0.3	3.63	0.000311	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs7412746	chr1:150860471	ARNT	chr1:150782186-150849186:-	-0.25	-6.75	4.08E-11	Melanoma	
LGG	cis	1	rs74140304	chr1:227730539	JMJD4	chr1:227918891-227923112:-	0.22	3.71	0.000232	Height	
LGG	cis	1	rs74140304	chr1:227730539	SNAP47	chr1:227916240-227968932:+	-0.18	-3.49	0.000521	Height	
LGG	cis	1	rs74152845	chr1:248013317	TRIM58	chr1:248020501-248043436:+	-0.45	-4.07	5.49E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs74152846	chr1:248013318	TRIM58	chr1:248020501-248043436:+	-0.45	-4.07	5.49E-5	Response to serotonin reuptake inhibitors in major depressive disorder	
LGG	cis	1	rs7418348	chr1:227720778	JMJD4	chr1:227918891-227923112:-	-0.23	-4.17	3.61E-5	Height	
LGG	cis	1	rs7419837	chr2:70146625	SNRNP27	chr2:70121090-70132348:+	-0.19	-4.33	1.84E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs74210981	chr10:102287520	NDUFB8	chr10:102283497-102289636:-	0.18	5.08	5.36E-7	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs74210981	chr10:102287520	WNT8B	chr10:102222812-102243397:+	0.51	8.23	1.65E-15	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7425670	chr2:88522028	FABP1	chr2:88422510-88427578:-	-0.31	-4.36	1.56E-5	Plasma clusterin levels	
LGG	cis	1	rs7425670	chr2:88522028	THNSL2	chr2:88469835-88486145:+	-0.58	-8.73	4.0E-17	Plasma clusterin levels	
LGG	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.58	1.73E-13	Height	
LGG	cis	1	rs7426847	chr3:134267519	CEP63	chr3:134204575-134293852:+	-0.21	-3.81	0.000156	Height	
LGG	cis	1	rs7427165	chr3:121364624	IQCB1	chr3:121488610-121553926:-	0.34	6.18	1.31E-9	Cognitive performance	
LGG	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.3	7.76	5.11E-14	Height	
LGG	cis	1	rs7427492	chr3:134261654	CEP63	chr3:134204575-134293852:+	0.21	3.75	0.000199	Height	
LGG	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs7428326	chr3:134251184	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs7428	chr2:85545490	RETSAT	chr2:85569079-85581821:-	-0.14	-3.91	0.000104	Ear protrusion	
LGG	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.49	3.17E-13	Height	
LGG	cis	1	rs7429866	chr3:134236306	CEP63	chr3:134204575-134293852:+	-0.21	-3.76	0.00019	Height	
LGG	cis	1	rs7429990	chr3:47901803	NME6	chr3:48335591-48342886:-	-0.22	-4.26	2.41E-5	Educational attainment (years of education)	
LGG	cis	1	rs74322175	chr9:123695650	TRAF1	chr9:123664672-123691479:-	0.4	4.59	5.66E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.3	7.67	9.08E-14	Height	
LGG	cis	1	rs7432268	chr3:134242051	CEP63	chr3:134204575-134293852:+	0.22	3.92	0.000101	Height	
LGG	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.29	7.6	1.48E-13	Height	
LGG	cis	1	rs7433663	chr3:134235790	CEP63	chr3:134204575-134293852:+	0.21	3.92	0.000102	Height	
LGG	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs7433991	chr3:134312292	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs743479	chr21:45611950	PWP2	chr21:45527208-45551062:+	0.21	3.89	0.000113	Inflammatory bowel disease	
LGG	cis	1	rs7436021	chr4:76905472	NAAA	chr4:76831809-76862166:-	-0.46	-11.12	8.73E-26	Longevity	
LGG	cis	1	rs74363821	chr6:26189524	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs74363821	chr6:26189524	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs743776	chr22:37551487	PDXP	chr22:38054737-38062939:+	0.1	3.6	0.000344	Rheumatoid arthritis;Type 1 diabetes autoantibodies	
LGG	cis	1	rs743777	chr22:37551607	PDXP	chr22:38054737-38062939:+	-0.11	-3.95	8.98E-5	Rheumatoid arthritis;Type 1 diabetes autoantibodies	
LGG	cis	1	rs74403477	chr1:179424380	C1orf125	chr1:179335107-179523868:+	0.65	7.81	3.44E-14	Multiple sclerosis (age of onset)	
LGG	cis	1	rs744051	chr12:56667298	IL23A	chr12:56732663-56734193:+	-0.53	-4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs74414802	chr2:48060876	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.55E-5	Schizophrenia	
LGG	cis	1	rs7443669	chr5:115527611	COMMD10	chr5:115420727-115628978:+	0.47	5.96	4.83E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7444	chr22:21976934	CCDC116	chr22:21987086-21991615:+	-0.41	-7.48	3.38E-13	Systemic lupus erythematosus	
LGG	cis	1	rs7444	chr22:21976934	YDJC	chr22:21982378-21984340:-	0.34	7.49	3.19E-13	Systemic lupus erythematosus	
LGG	cis	1	rs7445050	chr5:75495349	F2R	chr5:76011868-76031594:+	0.19	4.22	2.88E-5	Migraine - clinic-based	
LGG	cis	1	rs74471041	chr3:49542543	AMIGO3	chr3:49754268-49757238:-	0.19	4.41	1.29E-5	Menarche (age at onset)	
LGG	cis	1	rs74471041	chr3:49542543	GMPPB	chr3:49758932-49761384:-	0.23	4.47	9.92E-6	Menarche (age at onset)	
LGG	cis	1	rs74496027	chr12:56726340	IL23A	chr12:56732663-56734193:+	0.55	5.03	6.83E-7	Psoriasis vulgaris	
LGG	cis	1	rs74529341	chr10:92646725	RPP30	chr10:92631474-92668312:+	0.22	4.09	5.11E-5	Economic and political preferences (time)	
LGG	cis	1	rs74543591	chr20:33658658	PROCR	chr20:33758727-33765164:+	-0.32	-5.64	2.93E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs74544416	chr8:82657745	CHMP4C	chr8:82644688-82671746:+	-0.48	-4.79	2.18E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs74546828	chr8:58171678	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7456042	chr7:65299778	CCT6P1	chr7:65216092-65228661:+	0.26	4.8	2.11E-6	Diabetic kidney disease	
LGG	cis	1	rs74589786	chr20:61860939	BIRC7	chr20:61867276-61871853:+	0.41	5.1	4.74E-7	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs74589786	chr20:61860939	NKAIN4	chr20:61872137-61885892:-	0.32	5.36	1.25E-7	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs7459736	chr8:83062665	FABP4	chr8:82390732-82395473:-	0.19	3.82	0.000149	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs74599371	chr20:33561495	GDF5	chr20:33897002-34042568:-	0.28	3.49	0.000526	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs74599371	chr20:33561495	PROCR	chr20:33758727-33765164:+	-0.33	-5.94	5.28E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs74604451	chr4:42474633	SHISA3	chr4:42399856-42404503:+	0.29	4.53	7.29E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs74607112	chr2:86305534	LOC90784	chr2:86247339-86250991:-	-0.44	-4.54	6.94E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs74611500	chr14:66009789	LOC645431	chr14:65877313-65879335:-	-0.46	-6.13	1.83E-9	Ischemic stroke	
LGG	cis	1	rs74617736	chr14:55620919	FBXO34	chr14:55738021-55893431:+	0.13	4.02	6.69E-5	Protein biomarker	
LGG	cis	1	rs74626382	chr20:33746668	PROCR	chr20:33758727-33765164:+	-0.37	-6.43	3.07E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs74638829	chr11:65495571	DKFZp761E198	chr11:65543380-65547822:-	-0.29	-3.66	0.000282	Atopic dermatitis	
LGG	cis	1	rs74650218	chr10:102293830	HIF1AN	chr10:102295641-102313680:+	0.19	3.6	0.000348	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs74650218	chr10:102293830	NDUFB8	chr10:102283497-102289636:-	0.17	4.7	3.42E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs74650218	chr10:102293830	WNT8B	chr10:102222812-102243397:+	0.49	7.94	1.41E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs74673257	chr12:56638077	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs74703215	chr4:171014283	AADAT	chr4:170981374-171011372:-	-0.31	-3.94	9.19E-5	Thyroid hormone levels	
LGG	cis	1	rs74703743	chr2:190792622	ORMDL1	chr2:190634994-190649097:-	0.33	5.26	2.19E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7475154	chr10:131440584	MGMT	chr10:131265454-131565783:+	-0.24	-6.38	4.13E-10	Response to temozolomide	
LGG	cis	1	rs74752617	chr13:24435981	RNF17	chr13:25338301-25454056:+	0.31	3.5	0.0005	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs74758321	chr8:82667320	CHMP4C	chr8:82644688-82671746:+	-0.48	-4.78	2.35E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs747692	chr6:33737436	LEMD2	chr6:33738991-33756906:-	0.19	5.56	4.49E-8	Body mass index	
LGG	cis	1	rs747695	chr6:33736672	LEMD2	chr6:33738991-33756906:-	-0.14	-4.57	6.15E-6	Crohn's disease	
LGG	cis	1	rs7477246	chr10:102261538	HIF1AN	chr10:102295641-102313680:+	0.18	3.47	0.00057	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7477246	chr10:102261538	NDUFB8	chr10:102283497-102289636:-	0.17	4.65	4.23E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7477246	chr10:102261538	WNT8B	chr10:102222812-102243397:+	0.5	8.35	6.94E-16	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7478880	chr11:120261791	TMEM136	chr11:120196016-120204388:+	0.21	4.76	2.58E-6	Intraocular pressure	
LGG	cis	1	rs7481993	chr11:237875	PSMD13	chr11:236808-252984:+	-0.22	-4.9	1.33E-6	Menarche (age at onset)	
LGG	cis	1	rs7482591	chr11:245861	PSMD13	chr11:236808-252984:+	-0.21	-4.75	2.65E-6	Menarche (age at onset)	
LGG	cis	1	rs74827261	chr2:48127260	FBXO11	chr2:48034061-48132814:-	0.22	3.98	8.09E-5	Schizophrenia	
LGG	cis	1	rs7483122	chr11:5373006	FAM160A2	chr11:6232565-6255941:-	0.19	3.76	0.00019	Fetal hemoglobin levels	
LGG	cis	1	rs74834639	chr4:42475170	SHISA3	chr4:42399856-42404503:+	0.29	4.53	7.29E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs7483725	chr11:114626598	C11orf71	chr11:114262170-114271255:-	-0.19	-4.11	4.61E-5	Urinary albumin excretion	
LGG	cis	1	rs7483951	chr11:231758	PSMD13	chr11:236808-252984:+	-0.24	-5.21	2.79E-7	Menarche (age at onset)	
LGG	cis	1	rs748404	chr15:43559231	STRC	chr15:43891762-43924561:-	0.25	5.39	1.08E-7	Lung cancer	
LGG	cis	1	rs748404	chr15:43559231	TGM5	chr15:43525375-43559055:-	-0.2	-3.65	0.00029	Lung cancer	
LGG	cis	1	rs74872801	chr2:48092665	FBXO11	chr2:48034061-48132814:-	0.23	4.13	4.19E-5	Schizophrenia	
LGG	cis	1	rs74897112	chr2:48115952	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs74900588	chr6:170102180	WDR27	chr6:169857307-170102159:-	-0.38	-8.65	7.34E-17	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs74900896	chr1:63609189	ITGB3BP	chr1:63906462-63988835:-	-0.2	-3.56	0.000403	Brain imaging	
LGG	cis	1	rs749050	chr10:97376115	TCTN3	chr10:97423154-97453900:-	0.18	3.53	0.000462	Blood metabolite levels	
LGG	cis	1	rs74925218	chr15:78796732	CHRNA5	chr15:78857906-78886458:+	-0.3	-4.45	1.04E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs7492600	chr14:55336875	GCH1	chr14:55308724-55369542:-	-0.29	-5.01	7.61E-7	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs7493394	chr14:55617755	FBXO34	chr14:55738021-55893431:+	0.14	4.31	1.97E-5	Protein biomarker	
LGG	cis	1	rs74933964	chr13:98005634	OXGR1	chr13:97637973-97646604:-	0.32	3.72	0.000225	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score)	
LGG	cis	1	rs74941093	chr2:48070817	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.55E-5	Schizophrenia	
LGG	cis	1	rs7494918	chr15:24833624	PWRN1	chr15:24778839-24832924:+	0.25	4.33	1.83E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs7495122	chr15:24833611	PWRN1	chr15:24778839-24832924:+	0.25	4.33	1.83E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs74955473	chr5:150174558	LOC134466	chr5:150310000-150326146:-	0.4	4.28	2.28E-5	Crohn's disease	
LGG	cis	1	rs74957607	chr2:207583731	MDH1B	chr2:207598943-207630050:-	0.39	5.78	1.32E-8	Episodic memory	
LGG	cis	1	rs7496954	chr15:83345536	FAM154B	chr15:82555152-82577265:+	0.21	4.44	1.13E-5	Schizophrenia	
LGG	cis	1	rs7496954	chr15:83345536	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.17	4.18	3.46E-5	Schizophrenia	
LGG	cis	1	rs74975304	chr6:110094039	AKD1	chr6:109814059-110012415:-	-0.29	-3.47	0.000575	Hematological parameters	
LGG	cis	1	rs74984113	chr4:250522	ZNF718	chr4:53272-156488:+	0.27	5.18	3.32E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs74984740	chr2:17796007	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs7503168	chr17:33885904	PEX12	chr17:33901815-33905656:-	-0.24	-4.33	1.84E-5	Platelet count	
LGG	cis	1	rs7503679	chr17:79583843	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs7503679	chr17:79583843	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs75037501	chr8:58170136	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs750450	chr2:26324631	GPR113	chr2:26531041-26569685:-	-0.23	-3.63	0.000309	Gut microbiome composition (summer)	
LGG	cis	1	rs750451	chr2:26324241	GPR113	chr2:26531041-26569685:-	-0.24	-3.84	0.000137	Gut microbiome composition (summer)	
LGG	cis	1	rs750452	chr2:26324995	GPR113	chr2:26531041-26569685:-	-0.23	-3.71	0.000235	Gut microbiome composition (summer)	
LGG	cis	1	rs7506045	chr18:11987272	AFG3L2	chr18:12329108-12377194:-	0.36	4.48	9.43E-6	Stroke	
LGG	cis	1	rs75063298	chr10:102213600	HIF1AN	chr10:102295641-102313680:+	0.19	3.71	0.00023	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs75063298	chr10:102213600	NDUFB8	chr10:102283497-102289636:-	0.16	4.62	4.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs75063298	chr10:102213600	WNT8B	chr10:102222812-102243397:+	0.51	8.7	5.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs75071288	chr5:150224379	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs75080838	chr5:115557467	COMMD10	chr5:115420727-115628978:+	0.46	5.56	4.46E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs751075	chr3:51377300	HEMK1	chr3:50606583-50622419:+	0.22	3.69	0.000253	Melanoma	
LGG	cis	1	rs751096	chr6:33742838	LEMD2	chr6:33738991-33756906:-	-0.19	-5.57	4.18E-8	Body mass index	
LGG	cis	1	rs751096	chr6:33742838	RGL2	chr6:33259438-33266738:-	-0.15	-3.72	0.000223	Body mass index	
LGG	cis	1	rs7511706	chr1:248467360	OR2L13	chr1:248100493-248264223:+	0.2	3.53	0.000457	Common traits (Other)	
LGG	cis	1	rs751187	chr1:59477391	DAB1	chr1:57463579-59012446:-	-0.2	-3.54	0.000434	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LGG	cis	1	rs7511962	chr1:247212122	ZNF670	chr1:247200087-247242069:-	-0.22	-5.11	4.57E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs7512150	chr1:247212326	ZNF670	chr1:247200087-247242069:-	-0.22	-5.12	4.39E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs7512413	chr1:175124789	TNN	chr1:175036994-175117202:+	-0.17	-3.55	0.000415	Alcohol dependence	
LGG	cis	1	rs7512552	chr1:150265704	MRPS21	chr1:150266269-150280818:+	-0.21	-6.14	1.73E-9	Atopic dermatitis	
LGG	cis	1	rs75128809	chr21:43418210	C21orf121	chr21:43442113-43445060:+	0.27	4.4	1.31E-5	Hand grip strength	
LGG	cis	1	rs7513161	chr1:248453422	OR2L13	chr1:248100493-248264223:+	0.21	3.75	0.000201	Common traits (Other)	
LGG	cis	1	rs7513559	chr1:76173744	MSH4	chr1:76262630-76378923:+	0.26	4.59	5.53E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7514749	chr1:175122123	TNN	chr1:175036994-175117202:+	-0.18	-3.7	0.00024	Alcohol dependence	
LGG	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.47	7.23E-8	Body mass index	
LGG	cis	1	rs7515491	chr1:46355079	MUTYH	chr1:45794915-45806142:-	0.13	4.78	2.3E-6	Body mass index	
LGG	cis	1	rs7515577	chr1:93009438	EVI5	chr1:92974255-93257961:-	-0.32	-7.5	3.0E-13	Cholesterol, total	
LGG	cis	1	rs75159543	chr15:40665228	C15orf23	chr15:40674922-40686488:+	1.02	17.48	1.5E-53	Heschl's gyrus morphology	
LGG	cis	1	rs75159543	chr15:40665228	IVD	chr15:40697686-40713512:+	-0.33	-3.78	0.000174	Heschl's gyrus morphology	
LGG	cis	1	rs7516226	chr1:76234257	MSH4	chr1:76262630-76378923:+	0.25	4.42	1.2E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs75165171	chr20:33651453	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.0E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs75167249	chr19:22128655	ZNF257	chr19:22235266-22273901:+	0.56	8.84	1.68E-17	Body mass index (change over time)	
LGG	cis	1	rs7517189	chr1:152881746	SMCP	chr1:152850798-152857515:+	0.33	5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs751728	chr6:33764033	LEMD2	chr6:33738991-33756906:-	-0.15	-4.8	2.09E-6	Crohn's disease	
LGG	cis	1	rs7517319	chr1:248466408	OR2L13	chr1:248100493-248264223:+	0.21	3.72	0.000222	Common traits (Other)	
LGG	cis	1	rs75178169	chr2:190568752	ORMDL1	chr2:190634994-190649097:-	0.38	5.41	1.0E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7517	chr1:150596411	ARNT	chr1:150782186-150849186:-	-0.24	-4.47	9.8E-6	Congenital left-sided heart lesions	
LGG	cis	1	rs7518038	chr1:76154430	MSH4	chr1:76262630-76378923:+	0.24	4.24	2.66E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs75181745	chr2:88520408	FABP1	chr2:88422510-88427578:-	-0.31	-4.28	2.29E-5	Plasma clusterin levels	
LGG	cis	1	rs75181745	chr2:88520408	THNSL2	chr2:88469835-88486145:+	-0.58	-8.67	6.57E-17	Plasma clusterin levels	
LGG	cis	1	rs7518935	chr1:202503549	UBE2T	chr1:202300786-202311094:-	-0.12	-3.56	0.000405	Sex ratio	
LGG	cis	1	rs75192006	chr13:96303624	UGGT2	chr13:96453838-96705736:-	-0.26	-4.38	1.47E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs7519795	chr1:247212126	ZNF670	chr1:247200087-247242069:-	-0.22	-5.11	4.57E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs7519918	chr1:150013019	RPRD2	chr1:150336990-150449039:+	-0.15	-3.85	0.000134	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7520516	chr1:150659695	ARNT	chr1:150782186-150849186:-	-0.23	-3.94	9.24E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs7520930	chr1:150037560	RPRD2	chr1:150336990-150449039:+	-0.15	-3.9	0.000109	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.86	1.58E-6	Body mass index	
LGG	cis	1	rs7522601	chr1:46419021	MUTYH	chr1:45794915-45806142:-	0.13	4.97	9.48E-7	Body mass index	
LGG	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.23	6.14	1.69E-9	Homocysteine levels	
LGG	cis	1	rs7522705	chr1:45992300	MMACHC	chr1:45965856-45976737:+	-0.27	-5.8	1.21E-8	Homocysteine levels	
LGG	cis	1	rs7522705	chr1:45992300	MUTYH	chr1:45794915-45806142:-	-0.12	-3.92	0.000101	Homocysteine levels	
LGG	cis	1	rs7522948	chr1:156275308	BGLAP	chr1:156182784-156213112:+	0.24	4.97	9.23E-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs7522948	chr1:156275308	CCT3	chr1:156278752-156308195:-	-0.15	-3.6	0.000351	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LGG	cis	1	rs7522991	chr1:202492151	UBE2T	chr1:202300786-202311094:-	-0.12	-3.74	0.000209	Sex ratio	
LGG	cis	1	rs7523273	chr1:207977083	CD46	chr1:207925402-207968857:+	-0.24	-7.1	4.31E-12	Schizophrenia	
LGG	cis	1	rs7524467	chr1:76194054	MSH4	chr1:76262630-76378923:+	0.24	4.31	2.0E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.14	3.9E-7	Body mass index	
LGG	cis	1	rs7524495	chr1:46266932	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.06E-7	Body mass index	
LGG	cis	1	rs7525344	chr1:248467565	OR2L13	chr1:248100493-248264223:+	-0.2	-3.52	0.00047	Common traits (Other)	
LGG	cis	1	rs752590	chr2:113972945	DDX11L2	chr2:114356606-114359153:-	-0.23	-3.53	0.000452	Mucinous ovarian carcinoma	
LGG	cis	1	rs752621	chr17:61901880	DDX42	chr17:61851567-61896676:+	-0.16	-3.73	0.000214	Body mass index	
LGG	cis	1	rs752621	chr17:61901880	FTSJ3	chr17:61896795-61905031:-	0.41	8.22	1.84E-15	Body mass index	
LGG	cis	1	rs752621	chr17:61901880	SMARCD2	chr17:61909441-61920351:-	0.18	4.05	5.91E-5	Body mass index	
LGG	cis	1	rs75265219	chr12:56640341	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7527822	chr1:248467301	OR2L13	chr1:248100493-248264223:+	0.19	3.45	0.0006	Common traits (Other)	
LGG	cis	1	rs75278386	chr15:40678312	C15orf23	chr15:40674922-40686488:+	1.02	18.84	5.28E-60	Heschl's gyrus morphology	
LGG	cis	1	rs75278386	chr15:40678312	IVD	chr15:40697686-40713512:+	-0.39	-4.74	2.87E-6	Heschl's gyrus morphology	
LGG	cis	1	rs75286527	chr2:48119837	FBXO11	chr2:48034061-48132814:-	0.23	4.13	4.19E-5	Schizophrenia	
LGG	cis	1	rs75287019	chr20:33721261	PROCR	chr20:33758727-33765164:+	-0.37	-6.88	1.85E-11	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7528862	chr1:152881689	SMCP	chr1:152850798-152857515:+	-0.33	-5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7529204	chr1:150845380	ARNT	chr1:150782186-150849186:-	0.24	3.82	0.000149	Congenital left-sided heart lesions	
LGG	cis	1	rs7529204	chr1:150845380	OAZ3	chr1:151735445-151743805:+	0.31	3.5	0.000506	Congenital left-sided heart lesions	
LGG	cis	1	rs75294883	chr5:150196503	LOC134466	chr5:150310000-150326146:-	0.43	4.3	2.04E-5	Crohn's disease	
LGG	cis	1	rs75307886	chr2:48053913	FBXO11	chr2:48034061-48132814:-	0.23	4.16	3.68E-5	Schizophrenia	
LGG	cis	1	rs7530922	chr1:150023407	RPRD2	chr1:150336990-150449039:+	-0.16	-4.06	5.78E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs75309929	chr2:88524377	FABP1	chr2:88422510-88427578:-	-0.31	-4.27	2.37E-5	Plasma clusterin levels	
LGG	cis	1	rs75309929	chr2:88524377	THNSL2	chr2:88469835-88486145:+	-0.58	-8.69	5.35E-17	Plasma clusterin levels	
LGG	cis	1	rs7531202	chr1:110616474	ALX3	chr1:110602998-110613322:-	-0.29	-6.64	8.47E-11	Blood metabolite levels	
LGG	cis	1	rs7531202	chr1:110616474	FAM40A	chr1:110574199-110597424:+	0.12	4.12	4.44E-5	Blood metabolite levels	
LGG	cis	1	rs753129	chr4:56668431	EXOC1	chr4:56719816-56771244:+	0.21	3.54	0.000441	Psychosis in Alzheimer's disease	
LGG	cis	1	rs7532615	chr1:121172840	HIST2H2BA	chr1:120906034-120914842:+	-0.16	-3.57	0.000392	Hip geometry	
LGG	cis	1	rs7532835	chr1:202518291	UBE2T	chr1:202300786-202311094:-	-0.12	-3.71	0.00023	Sex ratio	
LGG	cis	1	rs7533434	chr1:212871752	BATF3	chr1:212859760-212873327:-	0.2	4.21	3.04E-5	Leprosy	
LGG	cis	1	rs7533623	chr1:110616475	ALX3	chr1:110602998-110613322:-	-0.31	-7.25	1.68E-12	Blood metabolite levels	
LGG	cis	1	rs7533623	chr1:110616475	FAM40A	chr1:110574199-110597424:+	0.1	3.64	0.000302	Blood metabolite levels	
LGG	cis	1	rs75336711	chr4:171020067	AADAT	chr4:170981374-171011372:-	-0.35	-4.5	8.65E-6	Thyroid hormone levels	
LGG	cis	1	rs7533888	chr1:76160449	MSH4	chr1:76262630-76378923:+	0.23	4.27	2.39E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7534086	chr1:202453155	UBE2T	chr1:202300786-202311094:-	-0.13	-4.09	5.07E-5	Sex ratio	
LGG	cis	1	rs7534271	chr1:47693981	FOXE3	chr1:47881744-47883723:+	0.2	4.53	7.28E-6	Body mass index	
LGG	cis	1	rs7534392	chr1:31863595	ZCCHC17	chr1:31769842-31837780:+	-0.16	-3.91	0.000104	Schizophrenia	
LGG	cis	1	rs7534465	chr1:31863663	ZCCHC17	chr1:31769842-31837780:+	-0.16	-3.9	0.000109	Schizophrenia	
LGG	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.27	-7.47	3.6E-13	Homocysteine levels	
LGG	cis	1	rs7534467	chr1:45988691	MMACHC	chr1:45965856-45976737:+	0.26	5.57	4.24E-8	Homocysteine levels	
LGG	cis	1	rs7534467	chr1:45988691	MUTYH	chr1:45794915-45806142:-	0.13	4.4	1.32E-5	Homocysteine levels	
LGG	cis	1	rs7534624	chr1:22494627	HSPC157	chr1:22351707-22357713:+	0.14	4.02	6.87E-5	Obesity-related traits	
LGG	cis	1	rs7534754	chr1:76185308	MSH4	chr1:76262630-76378923:+	0.24	4.35	1.62E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7535032	chr1:150947745	ARNT	chr1:150782186-150849186:-	0.23	4.13	4.2E-5	Congenital left-sided heart lesions	
LGG	cis	1	rs7535306	chr1:152883680	SMCP	chr1:152850798-152857515:+	-0.33	-5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.26	-7.53	2.5E-13	Homocysteine levels	
LGG	cis	1	rs7536557	chr1:45992114	MMACHC	chr1:45965856-45976737:+	0.25	5.47	7.06E-8	Homocysteine levels	
LGG	cis	1	rs7536557	chr1:45992114	MUTYH	chr1:45794915-45806142:-	0.13	4.41	1.27E-5	Homocysteine levels	
LGG	cis	1	rs7536700	chr1:153640827	S100A13	chr1:153591280-153606568:-	-0.19	-3.87	0.000123	Multiple myeloma (IgH translocation)	
LGG	cis	1	rs7536700	chr1:153640827	S100A1	chr1:153600873-153604513:+	-0.3	-4.34	1.69E-5	Multiple myeloma (IgH translocation)	
LGG	cis	1	rs7537507	chr1:110131105	SYPL2	chr1:110009100-110024763:+	-0.22	-3.72	0.00022	Major depressive disorder	
LGG	cis	1	rs7538893	chr1:227728803	JMJD4	chr1:227918891-227923112:-	0.22	3.71	0.000232	Height	
LGG	cis	1	rs7538893	chr1:227728803	SNAP47	chr1:227916240-227968932:+	-0.18	-3.49	0.000521	Height	
LGG	cis	1	rs7539232	chr1:152881802	SMCP	chr1:152850798-152857515:+	-0.33	-5.11	4.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7539624	chr1:223906827	FAM177B	chr1:222910558-222924001:+	0.18	3.83	0.000146	Schizophrenia	
LGG	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.17	-5.19	3.15E-7	Body mass index	
LGG	cis	1	rs7539932	chr1:46292354	MUTYH	chr1:45794915-45806142:-	0.14	5.1	4.92E-7	Body mass index	
LGG	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.17	-5	8.18E-7	Body mass index	
LGG	cis	1	rs7540325	chr1:46338217	MUTYH	chr1:45794915-45806142:-	0.14	5.17	3.37E-7	Body mass index	
LGG	cis	1	rs75408336	chr1:179459485	C1orf125	chr1:179335107-179523868:+	0.64	8.19	2.24E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs7540847	chr1:150026823	RPRD2	chr1:150336990-150449039:+	0.15	3.7	0.000238	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7541230	chr1:207957555	CD46	chr1:207925402-207968857:+	-0.25	-7.38	6.94E-13	Schizophrenia	
LGG	cis	1	rs75439527	chr2:48388666	FOXN2	chr2:48541795-48606434:+	0.29	5.67	2.38E-8	Schizophrenia	
LGG	cis	1	rs75444304	chr15:90894246	IQGAP1	chr15:90931473-91045475:+	0.13	3.97	8.11E-5	Rheumatoid arthritis	
LGG	cis	1	rs7545413	chr1:152883608	SMCP	chr1:152850798-152857515:+	-0.33	-5.14	3.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7545520	chr1:152883711	SMCP	chr1:152850798-152857515:+	-0.33	-5.14	3.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7546304	chr1:151114484	LYSMD1	chr1:151132225-151138424:-	-0.17	-3.99	7.75E-5	Body mass index	
LGG	cis	1	rs7546304	chr1:151114484	MRPL9	chr1:151732125-151736040:-	-0.13	-3.48	0.000553	Body mass index	
LGG	cis	1	rs7546342	chr1:247213292	ZNF670	chr1:247200087-247242069:-	-0.22	-5.17	3.49E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs75478457	chr15:82226478	FAM154B	chr15:82555152-82577265:+	0.35	3.87	0.000126	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs7548962	chr1:76139266	MSH4	chr1:76262630-76378923:+	0.23	4.22	2.94E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs75491762	chr11:89150645	NOX4	chr11:89057524-89322779:-	0.37	3.96	8.68E-5	Homocysteine levels	
LGG	cis	1	rs7549410	chr1:247214167	ZNF670	chr1:247200087-247242069:-	-0.23	-5.2	2.91E-7	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs7549475	chr1:227774700	JMJD4	chr1:227918891-227923112:-	-0.25	-4.14	4.01E-5	Height	
LGG	cis	1	rs7550323	chr1:150027004	RPRD2	chr1:150336990-150449039:+	0.16	3.92	0.000101	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7550350	chr1:150003513	RPRD2	chr1:150336990-150449039:+	-0.15	-3.83	0.000144	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.18	-5.27	2.06E-7	Body mass index	
LGG	cis	1	rs7550746	chr1:46351719	MUTYH	chr1:45794915-45806142:-	0.13	4.81	2.04E-6	Body mass index	
LGG	cis	1	rs7551345	chr1:31831870	ZCCHC17	chr1:31769842-31837780:+	-0.18	-4.57	6.28E-6	Schizophrenia	
LGG	cis	1	rs7551874	chr1:12048130	MIIP	chr1:12079512-12092106:+	0.09	3.53	0.000447	Platelet count	
LGG	cis	1	rs7552404	chr1:76135946	MSH4	chr1:76262630-76378923:+	0.25	4.49	8.96E-6	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs7553330	chr1:180956015	STX6	chr1:180913175-180992046:-	-0.13	-3.51	0.000498	Progressive supranuclear palsy	
LGG	cis	1	rs75535620	chr20:33601498	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.84E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7553622	chr1:150064762	RPRD2	chr1:150336990-150449039:+	-0.15	-3.78	0.000173	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs75537616	chr20:33592588	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.01E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs75542230	chr2:48057288	FBXO11	chr2:48034061-48132814:-	0.23	4.16	3.68E-5	Schizophrenia	
LGG	cis	1	rs755495	chr6:33734128	LEMD2	chr6:33738991-33756906:-	-0.18	-5.26	2.1E-7	Body mass index	
LGG	cis	1	rs755496	chr6:33734376	LEMD2	chr6:33738991-33756906:-	-0.14	-4.33	1.84E-5	Crohn's disease	
LGG	cis	1	rs755587	chr20:47720957	ARFGEF2	chr20:47538275-47653229:+	0.11	4.06	5.63E-5	Anger	
LGG	cis	1	rs755587	chr20:47720957	CSE1L	chr20:47662838-47713484:+	0.18	4.92	1.18E-6	Anger	
LGG	cis	1	rs755589	chr20:47721385	ARFGEF2	chr20:47538275-47653229:+	0.11	4.05	5.84E-5	Anger	
LGG	cis	1	rs755589	chr20:47721385	CSE1L	chr20:47662838-47713484:+	0.19	5.14	4.04E-7	Anger	
LGG	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.16	4.51	8.06E-6	Body mass index	
LGG	cis	1	rs7556436	chr1:46363880	MUTYH	chr1:45794915-45806142:-	-0.13	-4.58	5.95E-6	Body mass index	
LGG	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.71	3.29E-6	Body mass index	
LGG	cis	1	rs7556615	chr1:46461369	MUTYH	chr1:45794915-45806142:-	0.13	4.95	1.04E-6	Body mass index	
LGG	cis	1	rs7556629	chr1:202483678	UBE2T	chr1:202300786-202311094:-	-0.12	-3.75	0.0002	Sex ratio	
LGG	cis	1	rs7557535	chr2:242206555	ANO7	chr2:242127924-242164791:+	0.37	6.37	4.44E-10	Prostate cancer	
LGG	cis	1	rs75580831	chr2:48379382	FOXN2	chr2:48541795-48606434:+	0.29	5.68	2.32E-8	Schizophrenia	
LGG	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.39	6.79	3.21E-11	Metabolite levels	
LGG	cis	1	rs7558944	chr2:73810909	NAT8	chr2:73867850-73869537:-	0.26	4.15	3.95E-5	Metabolite levels	
LGG	cis	1	rs7559479	chr2:103068787	IL18R1	chr2:102927962-103015215:+	-0.37	-5.81	1.1E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs7559479	chr2:103068787	IL1RL1	chr2:102927962-102968497:+	-0.34	-4.96	9.68E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs75598973	chr12:56746558	IL23A	chr12:56732663-56734193:+	0.56	4.91	1.22E-6	Psoriasis vulgaris	
LGG	cis	1	rs7560327	chr2:190772522	ORMDL1	chr2:190634994-190649097:-	0.34	5.11	4.74E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7560328	chr2:202164837	ALS2CR12	chr2:202153148-202222101:-	-0.37	-7.54	2.35E-13	Melanoma;Esophageal squamous cell carcinoma	
LGG	cis	1	rs75607323	chr2:207635770	MDH1B	chr2:207598943-207630050:-	0.33	4.84	1.74E-6	Episodic memory	
LGG	cis	1	rs75610822	chr12:48948898	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs7561149	chr2:179689856	CCDC141	chr2:179697347-179914786:-	0.17	3.5	0.000512	QT interval	
LGG	cis	1	rs7561487	chr2:103077894	IL18R1	chr2:102927962-103015215:+	-0.39	-6.19	1.3E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs7561487	chr2:103077894	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.45	7.89E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs7562170	chr2:28943516	FAM179A	chr2:29204164-29275094:+	0.19	3.7	0.00024	Body mass index	
LGG	cis	1	rs7562170	chr2:28943516	TRMT61B	chr2:29072690-29093175:-	0.51	10.61	8.46E-24	Body mass index	
LGG	cis	1	rs75635914	chr20:33555815	PROCR	chr20:33758727-33765164:+	-0.33	-5.8	1.21E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs75648520	chr20:33724221	PROCR	chr20:33758727-33765164:+	-0.37	-6.61	9.74E-11	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.4	7.12	3.92E-12	Metabolite levels	
LGG	cis	1	rs7564890	chr2:73641853	NAT8	chr2:73867850-73869537:-	0.26	4.25	2.56E-5	Metabolite levels	
LGG	cis	1	rs75657440	chr2:48121131	FBXO11	chr2:48034061-48132814:-	0.23	4.13	4.19E-5	Schizophrenia	
LGG	cis	1	rs7566279	chr2:281178	FAM150B	chr2:279563-288308:-	-0.35	-6.7	5.77E-11	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs7566279	chr2:281178	SNTG2	chr2:946555-1371382:+	0.2	3.59	0.000368	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs756631	chr22:23463183	RTDR1	chr22:23401594-23484241:-	-0.16	-3.75	0.000196	Bone mineral density	
LGG	cis	1	rs7567549	chr2:84906264	DNAH6	chr2:84743579-85046711:+	-0.19	-3.65	0.000295	Hypospadias	
LGG	cis	1	rs756769	chr9:135774059	C9orf98	chr9:135600965-135754198:-	0.34	9.27	5.72E-19	Psoriasis	
LGG	cis	1	rs756769	chr9:135774059	GFI1B	chr9:135854098-135867083:+	-0.2	-3.57	0.000389	Psoriasis	
LGG	cis	1	rs7569147	chr2:167989691	XIRP2	chr2:167744997-168116259:+	-0.3	-4.37	1.53E-5	Atopic dermatitis	
LGG	cis	1	rs756920	chr11:2310870	C11orf21	chr11:2317507-2323143:-	0.32	4.41	1.27E-5	Obesity-related traits	
LGG	cis	1	rs7571716	chr2:233441420	EIF4E2	chr2:233415357-233448349:+	0.21	3.54	0.000436	Height	
LGG	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.62E-12	Metabolite levels	
LGG	cis	1	rs7572722	chr2:73724675	NAT8	chr2:73867850-73869537:-	0.26	4.29	2.13E-5	Metabolite levels	
LGG	cis	1	rs7573118	chr2:26308086	GPR113	chr2:26531041-26569685:-	-0.23	-3.74	0.000204	Gut microbiome composition (summer)	
LGG	cis	1	rs7573442	chr2:70154037	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.5	8.49E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs7574618	chr2:166899878	SCN2A	chr2:166095912-166248818:+	0.09	3.62	0.00033	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7574618	chr2:166899878	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs75754909	chr12:56726349	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.39	7.11	4.01E-12	Metabolite levels	
LGG	cis	1	rs7576245	chr2:73829678	NAT8	chr2:73867850-73869537:-	0.26	4.37	1.5E-5	Metabolite levels	
LGG	cis	1	rs7577262	chr2:234818869	USP40	chr2:234384166-234475428:-	-0.2	-3.46	0.000585	Blood pressure measurement (cold pressor test)	
LGG	cis	1	rs75774363	chr5:150223722	LOC134466	chr5:150310000-150326146:-	0.41	4.62	4.96E-6	Crohn's disease	
LGG	cis	1	rs7577696	chr2:32278782	NLRC4	chr2:32449518-32490801:-	-0.12	-4.19	3.26E-5	Inflammatory biomarkers	
LGG	cis	1	rs7578199	chr2:242192848	SEPT2	chr2:242254723-242293439:+	0.29	5.9	6.8E-9	Chronic lymphocytic leukemia	
LGG	cis	1	rs7578456	chr2:202235348	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.4	1.31E-5	Basal cell carcinoma	
LGG	cis	1	rs7578456	chr2:202235348	ALS2CR4	chr2:202484907-202508224:-	0.17	4.69	3.5E-6	Basal cell carcinoma	
LGG	cis	1	rs7578456	chr2:202235348	PPIL3	chr2:201735680-201753999:-	-0.19	-3.98	7.87E-5	Basal cell carcinoma	
LGG	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.51	-10.81	1.43E-24	Body mass index	
LGG	cis	1	rs757978	chr2:242371101	SEPT2	chr2:242254723-242293439:+	0.53	7.6	1.48E-13	Chronic lymphocytic leukemia	
LGG	cis	1	rs75800624	chr18:44633605	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs7580240	chr2:29114372	TRMT61B	chr2:29072690-29093175:-	0.45	8.76	3.13E-17	Breast cancer (estrogen-receptor negative);Breast cancer	
LGG	cis	1	rs7580482	chr2:166903445	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7580482	chr2:166903445	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7580558	chr2:242060296	KIF1A	chr2:241653185-241759624:-	0.2	3.69	0.000246	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LGG	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.39	7.07	5.24E-12	Metabolite levels	
LGG	cis	1	rs7580825	chr2:73635148	NAT8	chr2:73867850-73869537:-	0.26	4.22	2.87E-5	Metabolite levels	
LGG	cis	1	rs7581224	chr2:84709215	DNAH6	chr2:84743579-85046711:+	0.42	10.54	1.47E-23	Coronary artery calcification	
LGG	cis	1	rs75824542	chr14:74523047	LIN52	chr14:74551656-74667117:+	0.46	10.52	1.8E-23	Common traits (Other)	
LGG	cis	1	rs75824619	chr20:61856471	BIRC7	chr20:61867276-61871853:+	0.41	5.1	4.84E-7	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs75824619	chr20:61856471	NKAIN4	chr20:61872137-61885892:-	0.32	5.35	1.32E-7	Response to cytadine analogues (cytosine arabinoside)	
LGG	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.4	7.15	3.07E-12	Metabolite levels	
LGG	cis	1	rs7582606	chr2:73813945	NAT8	chr2:73867850-73869537:-	0.26	4.22	2.94E-5	Metabolite levels	
LGG	cis	1	rs758324	chr5:131109545	P4HA2	chr5:131528306-131563556:-	0.15	3.52	0.000473	Alzheimer's disease in APOE e4- carriers	
LGG	cis	1	rs758324	chr5:131109545	SLC22A5	chr5:131705401-131731302:+	0.28	4.8	2.08E-6	Alzheimer's disease in APOE e4- carriers	
LGG	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.4	7.17	2.74E-12	Metabolite levels	
LGG	cis	1	rs7583255	chr2:73797996	NAT8	chr2:73867850-73869537:-	0.27	4.31	1.94E-5	Metabolite levels	
LGG	cis	1	rs75838545	chr1:150024854	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs7584535	chr2:232106857	HTR2B	chr2:231972952-231989824:-	0.44	7.17	2.8E-12	Food antigen IgG levels	
LGG	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.39	7.16	2.93E-12	Metabolite levels	
LGG	cis	1	rs7584575	chr2:73666402	NAT8	chr2:73867850-73869537:-	0.27	4.43	1.17E-5	Metabolite levels	
LGG	cis	1	rs7585004	chr2:73666645	ALMS1P	chr2:73872046-73912692:+	0.38	6.92	1.46E-11	Metabolite levels	
LGG	cis	1	rs7585004	chr2:73666645	NAT8	chr2:73867850-73869537:-	0.25	4.14	4.03E-5	Metabolite levels	
LGG	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.4	7.17	2.74E-12	Metabolite levels	
LGG	cis	1	rs7586463	chr2:73798476	NAT8	chr2:73867850-73869537:-	0.27	4.31	1.94E-5	Metabolite levels	
LGG	cis	1	rs75866240	chr20:33558839	PROCR	chr20:33758727-33765164:+	-0.33	-5.8	1.21E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7586879	chr2:25116977	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs7588761	chr2:48150587	FBXO11	chr2:48034061-48132814:-	0.25	4.46	1.01E-5	Schizophrenia	
LGG	cis	1	rs7588802	chr2:26277789	GPR113	chr2:26531041-26569685:-	-0.23	-3.64	0.000299	Gut microbiome composition (summer)	
LGG	cis	1	rs75888794	chr20:33702998	PROCR	chr20:33758727-33765164:+	-0.36	-6.54	1.57E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs758944	chr7:75953297	POR	chr7:75544420-75616172:+	0.19	3.92	0.000102	Multiple sclerosis	
LGG	cis	1	rs758944	chr7:75953297	SRCRB4D	chr7:76018647-76039012:-	0.28	6.31	6.28E-10	Multiple sclerosis	
LGG	cis	1	rs758944	chr7:75953297	UPK3B	chr7:76139745-76157197:+	-0.23	-4.42	1.2E-5	Multiple sclerosis	
LGG	cis	1	rs7589728	chr2:88518440	FABP1	chr2:88422510-88427578:-	-0.31	-4.27	2.31E-5	Plasma clusterin levels	
LGG	cis	1	rs7589728	chr2:88518440	THNSL2	chr2:88469835-88486145:+	-0.59	-8.68	6.04E-17	Plasma clusterin levels	
LGG	cis	1	rs7590071	chr2:240900947	NDUFA10	chr2:240900158-240964798:-	0.42	8.19	2.32E-15	Odorant perception (isobutyraldehyde)	
LGG	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	0.52	8.79	2.53E-17	Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs7591472	chr2:201889751	NDUFB3	chr2:201936462-201950471:+	-0.2	-3.95	9.06E-5	Triptolide cytotoxicity	
LGG	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-0.9	-17.76	7.18E-55	Triptolide cytotoxicity	
LGG	cis	1	rs7591782	chr2:179693013	CCDC141	chr2:179697347-179914786:-	0.18	3.76	0.000187	QT interval	
LGG	cis	1	rs75919582	chr7:139054919	C7orf55	chr7:139025897-139030539:+	-0.2	-4.26	2.42E-5	Diisocyanate-induced asthma	
LGG	cis	1	rs75921373	chr6:26191843	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.24	2.66E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs75921373	chr6:26191843	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	3.94E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs75927128	chr14:65895320	LOC645431	chr14:65877313-65879335:-	-0.52	-6.96	1.09E-11	Ischemic stroke	
LGG	cis	1	rs7592764	chr2:240448167	HDAC4	chr2:239969865-240323346:-	-0.26	-4.18	3.49E-5	Blood pressure (smoking interaction)	
LGG	cis	1	rs7593448	chr2:27449293	SLC5A6	chr2:27422459-27435071:-	-0.31	-6.21	1.11E-9	Blood metabolite levels	
LGG	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.4	7.21	2.1E-12	Metabolite levels	
LGG	cis	1	rs7594511	chr2:73681639	NAT8	chr2:73867850-73869537:-	0.25	4.15	3.93E-5	Metabolite levels	
LGG	cis	1	rs7594645	chr2:207646674	MDH1B	chr2:207598943-207630050:-	0.33	4.99	8.22E-7	Episodic memory	
LGG	cis	1	rs7595075	chr2:264019	FAM150B	chr2:279563-288308:-	-0.34	-6.49	2.11E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs7595075	chr2:264019	SNTG2	chr2:946555-1371382:+	0.2	3.64	0.000299	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs7595154	chr2:166886112	SCN2A	chr2:166095912-166248818:+	0.09	3.58	0.000381	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7595154	chr2:166886112	TTC21B	chr2:166713988-166810348:-	0.13	3.92	0.000101	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7596362	chr2:61204688	AHSA2	chr2:61404553-61414058:+	-0.24	-7.45	4.17E-13	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7596362	chr2:61204688	C2orf74	chr2:61372243-61391964:+	0.31	6.31	6.31E-10	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7598283	chr2:70128717	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.53	7.52E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.4	7.18	2.67E-12	Metabolite levels	
LGG	cis	1	rs7598396	chr2:73652628	NAT8	chr2:73867850-73869537:-	0.26	4.21	3.08E-5	Metabolite levels	
LGG	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.39	6.96	1.06E-11	Metabolite levels	
LGG	cis	1	rs7598419	chr2:73798223	NAT8	chr2:73867850-73869537:-	0.26	4.31	1.95E-5	Metabolite levels	
LGG	cis	1	rs7598759	chr2:232321956	C2orf52	chr2:232373137-232379050:-	-0.22	-4.26	2.46E-5	Noise-induced hearing loss	
LGG	cis	1	rs7598876	chr2:28974466	FAM179A	chr2:29204164-29275094:+	-0.19	-3.73	0.00021	Body mass index	
LGG	cis	1	rs7598876	chr2:28974466	TRMT61B	chr2:29072690-29093175:-	-0.52	-10.8	1.54E-24	Body mass index	
LGG	cis	1	rs7599132	chr2:26279810	GPR113	chr2:26531041-26569685:-	0.22	3.53	0.000461	Gut microbiome composition (summer)	
LGG	cis	1	rs7600330	chr2:179689985	CCDC141	chr2:179697347-179914786:-	0.17	3.5	0.000512	QT interval	
LGG	cis	1	rs7601520	chr2:166893081	SCN2A	chr2:166095912-166248818:+	0.09	3.6	0.000347	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7601520	chr2:166893081	TTC21B	chr2:166713988-166810348:-	0.13	3.95	8.88E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7601738	chr2:242375813	SEPT2	chr2:242254723-242293439:+	-0.52	-7.67	9.61E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs76023408	chr8:58193345	C8orf71	chr8:58192102-58197288:+	0.36	6.22	1.05E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs76024966	chr7:75995021	POR	chr7:75544420-75616172:+	0.2	4.04	6.12E-5	Multiple sclerosis	
LGG	cis	1	rs76024966	chr7:75995021	SRCRB4D	chr7:76018647-76039012:-	0.26	5.81	1.15E-8	Multiple sclerosis	
LGG	cis	1	rs76024966	chr7:75995021	UPK3B	chr7:76139745-76157197:+	-0.25	-4.74	2.81E-6	Multiple sclerosis	
LGG	cis	1	rs76029311	chr4:171001269	AADAT	chr4:170981374-171011372:-	-0.3	-3.7	0.000236	Thyroid hormone levels	
LGG	cis	1	rs7603153	chr2:25116966	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs7603250	chr2:103068834	IL18R1	chr2:102927962-103015215:+	-0.37	-5.98	4.34E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs7603250	chr2:103068834	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.33	1.48E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs7604682	chr2:73788026	ALMS1P	chr2:73872046-73912692:+	0.39	7.06	5.55E-12	Metabolite levels	
LGG	cis	1	rs7604682	chr2:73788026	NAT8	chr2:73867850-73869537:-	0.28	4.58	5.92E-6	Metabolite levels	
LGG	cis	1	rs7604798	chr2:27824940	PPM1G	chr2:27604062-27632496:-	0.13	4.26	2.43E-5	Oral cavity cancer	
LGG	cis	1	rs7604798	chr2:27824940	SNX17	chr2:27593363-27599994:+	-0.12	-3.61	0.000335	Oral cavity cancer	
LGG	cis	1	rs760554	chr22:25872592	ADRBK2	chr22:25960861-26125256:+	-0.25	-4.47	9.64E-6	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs760554	chr22:25872592	CRYBB2	chr22:25615612-25627836:+	0.62	7.89	1.93E-14	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs760555	chr22:25872837	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.11	4.68E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs760555	chr22:25872837	CRYBB2	chr22:25615612-25627836:+	0.64	8.17	2.65E-15	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs7605824	chr2:280819	FAM150B	chr2:279563-288308:-	0.34	6.53	1.7E-10	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs7605824	chr2:280819	SNTG2	chr2:946555-1371382:+	-0.2	-3.75	0.000202	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs76068439	chr10:1121018	IDI2	chr10:1064847-1071799:-	0.32	3.51	0.000493	Chronic kidney disease;Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs7606888	chr2:166889476	SCN2A	chr2:166095912-166248818:+	0.09	3.59	0.000364	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7606888	chr2:166889476	TTC21B	chr2:166713988-166810348:-	0.14	3.97	8.16E-5	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs7607014	chr2:73730174	ALMS1P	chr2:73872046-73912692:+	-0.37	-6.77	3.64E-11	Metabolite levels	
LGG	cis	1	rs7607014	chr2:73730174	NAT8	chr2:73867850-73869537:-	-0.26	-4.26	2.47E-5	Metabolite levels	
LGG	cis	1	rs76081054	chr2:86285037	LOC90784	chr2:86247339-86250991:-	-0.47	-4.9	1.31E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs7608185	chr2:25115432	ADCY3	chr2:25042041-25142055:-	-0.18	-4.07	5.58E-5	Body mass index	
LGG	cis	1	rs7608623	chr2:23948953	C2orf84	chr2:24397531-24414566:+	-0.18	-3.76	0.00019	Obesity-related traits	
LGG	cis	1	rs7608623	chr2:23948953	LOC375190	chr2:24299728-24397519:+	0.23	5.36	1.27E-7	Obesity-related traits	
LGG	cis	1	rs7608697	chr2:61204641	AHSA2	chr2:61404553-61414058:+	-0.24	-7.43	5.0E-13	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7608697	chr2:61204641	C2orf74	chr2:61372243-61391964:+	0.31	6.22	1.04E-9	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7608910	chr2:61204856	AHSA2	chr2:61404553-61414058:+	0.25	7.46	4.06E-13	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7608910	chr2:61204856	C2orf74	chr2:61372243-61391964:+	-0.3	-5.97	4.55E-9	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs761025	chr20:25426968	ABHD12	chr20:25275380-25371477:-	0.26	7.2	2.21E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs761025	chr20:25426968	FAM182A	chr20:26035250-26067552:+	-0.56	-11.04	1.77E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs761025	chr20:25426968	FAM182B	chr20:25744102-25848786:-	0.22	4.94	1.08E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs76108580	chr7:99495732	TRIM4	chr7:99488037-99517154:-	-0.37	-3.46	0.000592	Dehydroepiandrosterone sulphate levels;Metabolic traits	
LGG	cis	1	rs76112204	chr5:115618889	COMMD10	chr5:115420727-115628978:+	0.45	5.49	6.61E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7611238	chr3:195072918	ACAP2	chr3:194995475-195163817:-	-0.36	-8.72	4.16E-17	Body mass index	
LGG	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs7611611	chr3:134307877	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs7611828	chr3:134250325	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs7612710	chr3:65476581	MAGI1	chr3:65339907-66024509:-	0.22	4.57	6.26E-6	PR interval	
LGG	cis	1	rs7613282	chr3:47389409	NRADDP	chr3:47053032-47054957:+	0.24	4.11	4.56E-5	Colorectal cancer	
LGG	cis	1	rs7613491	chr3:49508976	AMIGO3	chr3:49754268-49757238:-	0.21	4.8	2.08E-6	Menarche (age at onset)	
LGG	cis	1	rs7613491	chr3:49508976	GMPPB	chr3:49758932-49761384:-	0.26	4.97	9.09E-7	Menarche (age at onset)	
LGG	cis	1	rs7614727	chr3:52295895	GNL3	chr3:52719936-52728508:+	-0.17	-3.65	0.000288	Electroencephalogram traits	
LGG	cis	1	rs76151170	chr12:56659320	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.33E-6	Psoriasis vulgaris	
LGG	cis	1	rs7615952	chr3:125649403	ALG1L	chr3:125648118-125655882:-	0.35	4.48	9.43E-6	Blood pressure (smoking interaction)	
LGG	cis	1	rs7615952	chr3:125649403	LOC100125556	chr3:125635444-125648865:+	-0.69	-10.12	5.28E-22	Blood pressure (smoking interaction)	
LGG	cis	1	rs7616044	chr3:125649354	ALG1L	chr3:125648118-125655882:-	-0.34	-4.35	1.67E-5	Blood pressure (smoking interaction)	
LGG	cis	1	rs7616044	chr3:125649354	LOC100125556	chr3:125635444-125648865:+	0.71	10.51	1.89E-23	Blood pressure (smoking interaction)	
LGG	cis	1	rs7616844	chr3:41874343	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs7617397	chr3:41959037	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs761879	chr22:50241210	ALG12	chr22:50296856-50312106:-	-0.26	-5.29	1.86E-7	Schizophrenia	
LGG	cis	1	rs76191812	chr20:33563911	PROCR	chr20:33758727-33765164:+	-0.33	-5.84	9.45E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.25	6.05	2.87E-9	Height	
LGG	cis	1	rs7619451	chr3:134233238	CEP63	chr3:134204575-134293852:+	0.21	3.63	0.000318	Height	
LGG	cis	1	rs76194	chr19:18630580	LRRC25	chr19:18501955-18508421:-	-0.16	-5.74	1.64E-8	Breast cancer	
LGG	cis	1	rs7619789	chr3:49476263	AMIGO3	chr3:49754268-49757238:-	-0.18	-4.14	4.02E-5	Menarche (age at onset)	
LGG	cis	1	rs7619789	chr3:49476263	GMPPB	chr3:49758932-49761384:-	-0.22	-4.34	1.71E-5	Menarche (age at onset)	
LGG	cis	1	rs7619789	chr3:49476263	NCKIPSD	chr3:48711280-48723334:-	0.15	3.49	0.00052	Menarche (age at onset)	
LGG	cis	1	rs7619789	chr3:49476263	TREX1	chr3:48501186-48509043:+	-0.26	-5.45	8.18E-8	Menarche (age at onset)	
LGG	cis	1	rs7620350	chr3:183710053	ABCC5	chr3:183637726-183735727:-	0.11	3.51	0.000487	Anterior chamber depth	
LGG	cis	1	rs7622259	chr3:41881351	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs7624372	chr3:41881107	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs7625734	chr3:169508915	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.52	0.000474	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs7625734	chr3:169508915	LRRC34	chr3:169511266-169530720:-	-0.28	-5.08	5.39E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs7625821	chr3:51513236	HEMK1	chr3:50606583-50622419:+	0.19	3.49	0.000525	Melanoma	
LGG	cis	1	rs762676	chr22:51017794	CPT1B	chr22:51007291-51017096:-	-0.34	-6.73	4.66E-11	Narcolepsy	
LGG	cis	1	rs762677	chr22:51017713	CPT1B	chr22:51007291-51017096:-	-0.34	-6.73	4.77E-11	Narcolepsy	
LGG	cis	1	rs76270388	chr8:58195605	C8orf71	chr8:58192102-58197288:+	0.38	6.34	5.28E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs76272943	chr15:82237819	FAM154B	chr15:82555152-82577265:+	0.33	3.62	0.000329	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs76277863	chr15:40649863	C15orf23	chr15:40674922-40686488:+	0.99	16.95	4.55E-51	Heschl's gyrus morphology	
LGG	cis	1	rs76277863	chr15:40649863	IVD	chr15:40697686-40713512:+	-0.33	-3.88	0.000117	Heschl's gyrus morphology	
LGG	cis	1	rs7629072	chr3:52305633	GNL3	chr3:52719936-52728508:+	-0.17	-3.67	0.000269	Electroencephalogram traits	
LGG	cis	1	rs76292674	chr5:115625260	COMMD10	chr5:115420727-115628978:+	0.45	5.65	2.72E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs763014	chr16:675680	PIGQ	chr16:617032-634108:+	-0.26	-7.5	3.01E-13	Height	
LGG	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.45	9.77	1.05E-20	Height	
LGG	cis	1	rs7630741	chr3:48419723	ATRIP	chr3:48488141-48507708:+	0.2	4.99	8.52E-7	Longevity	
LGG	cis	1	rs7630741	chr3:48419723	TREX1	chr3:48501186-48509043:+	-0.4	-10.29	1.34E-22	Longevity	
LGG	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.61	1.41E-13	Height	
LGG	cis	1	rs7630874	chr3:134293291	CEP63	chr3:134204575-134293852:+	-0.21	-3.74	0.000207	Height	
LGG	cis	1	rs7631057	chr3:41817951	ULK4	chr3:41288091-42003660:-	0.77	15.04	2.61E-42	Diastolic blood pressure	
LGG	cis	1	rs7631605	chr3:37234589	LRRFIP2	chr3:37094117-37217851:-	0.15	3.52	0.000465	Cerebrospinal P-tau181p levels	
LGG	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.75	14.09	4.32E-38	Diastolic blood pressure	
LGG	cis	1	rs7632670	chr3:183713877	ABCC5	chr3:183637726-183735727:-	0.11	3.51	0.000488	Anterior chamber depth	
LGG	cis	1	rs76329209	chr6:26196430	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs76329209	chr6:26196430	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs7633265	chr3:195048814	ACAP2	chr3:194995475-195163817:-	-0.37	-8.92	9.41E-18	Body mass index	
LGG	cis	1	rs7633750	chr3:169509244	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.55	0.000427	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs7633750	chr3:169509244	LRRC34	chr3:169511266-169530720:-	-0.29	-5.26	2.13E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs7634345	chr3:195073403	ACAP2	chr3:194995475-195163817:-	-0.38	-9.04	3.51E-18	Body mass index	
LGG	cis	1	rs7634377	chr3:48421258	ATRIP	chr3:48488141-48507708:+	0.2	4.99	8.5E-7	Longevity	
LGG	cis	1	rs7634377	chr3:48421258	TREX1	chr3:48501186-48509043:+	-0.4	-10.29	1.32E-22	Longevity	
LGG	cis	1	rs7635522	chr3:48423656	ATRIP	chr3:48488141-48507708:+	0.17	4.21	3.07E-5	Longevity	
LGG	cis	1	rs7635522	chr3:48423656	TREX1	chr3:48501186-48509043:+	-0.43	-10.99	2.79E-25	Longevity	
LGG	cis	1	rs7636044	chr3:48484560	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.85E-6	Longevity	
LGG	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.43	-11.08	1.32E-25	Longevity	
LGG	cis	1	rs76363448	chr20:33655535	PROCR	chr20:33758727-33765164:+	-0.32	-5.64	2.93E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7636782	chr3:48421387	ATRIP	chr3:48488141-48507708:+	0.18	4.35	1.67E-5	Longevity	
LGG	cis	1	rs7636782	chr3:48421387	TREX1	chr3:48501186-48509043:+	-0.42	-10.71	3.27E-24	Longevity	
LGG	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.3	7.73	6.07E-14	Height	
LGG	cis	1	rs7637227	chr3:134244155	CEP63	chr3:134204575-134293852:+	0.22	3.95	9.14E-5	Height	
LGG	cis	1	rs7637230	chr3:101663555	LOC285359	chr3:101431278-101432259:+	-0.19	-4.29	2.19E-5	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs7638995	chr3:69173375	ARL6IP5	chr3:69134090-69155237:+	0.2	3.9	0.00011	Alzheimer's disease (late onset)	
LGG	cis	1	rs76393969	chr4:171032231	AADAT	chr4:170981374-171011372:-	-0.28	-3.5	0.00051	Thyroid hormone levels	
LGG	cis	1	rs76414143	chr5:115625396	COMMD10	chr5:115420727-115628978:+	0.45	5.65	2.72E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs76430365	chr12:56699993	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs76433514	chr5:150306532	LOC134466	chr5:150310000-150326146:-	0.53	5.88	7.72E-9	Crohn's disease	
LGG	cis	1	rs76435840	chr11:58285981	ZFP91-CNTF	chr11:58346587-58393203:+	0.35	5.83	1.02E-8	Lymphoma	
LGG	cis	1	rs7644148	chr3:49545241	AMIGO3	chr3:49754268-49757238:-	0.19	4.41	1.29E-5	Menarche (age at onset)	
LGG	cis	1	rs7644148	chr3:49545241	GMPPB	chr3:49758932-49761384:-	0.23	4.47	9.92E-6	Menarche (age at onset)	
LGG	cis	1	rs76449411	chr2:17799354	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.3	7.96	1.21E-14	Height	
LGG	cis	1	rs76454304	chr20:49513290	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.74	13.83	5.92E-37	Diastolic blood pressure	
LGG	cis	1	rs76466034	chr12:56719450	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs7646881	chr3:158453279	RARRES1	chr3:158414899-158450275:-	0.23	3.5	0.0005	Tetralogy of Fallot	
LGG	cis	1	rs76471037	chr3:41799414	ULK4	chr3:41288091-42003660:-	0.76	15.08	1.66E-42	Diastolic blood pressure	
LGG	cis	1	rs76472382	chr14:59954385	C14orf149	chr14:59939406-59951126:-	-0.42	-4.32	1.92E-5	Schizophrenia	
LGG	cis	1	rs76472382	chr14:59954385	JKAMP	chr14:59951161-59972080:+	0.52	4.87	1.51E-6	Schizophrenia	
LGG	cis	1	rs76473275	chr1:243460555	SDCCAG8	chr1:243419320-243663392:+	-0.27	-4.45	1.08E-5	Obesity (early onset extreme)	
LGG	cis	1	rs76475039	chr1:179476763	C1orf125	chr1:179335107-179523868:+	0.66	8.22	1.86E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs7647973	chr3:49510931	AMIGO3	chr3:49754268-49757238:-	0.21	4.7	3.46E-6	Menarche (age at onset)	
LGG	cis	1	rs7647973	chr3:49510931	GMPPB	chr3:49758932-49761384:-	0.26	4.95	1.0E-6	Menarche (age at onset)	
LGG	cis	1	rs7647973	chr3:49510931	KLHDC8B	chr3:49209068-49213918:+	0.18	3.47	0.000565	Menarche (age at onset)	
LGG	cis	1	rs764813	chr22:50286172	ALG12	chr22:50296856-50312106:-	0.28	5.6	3.66E-8	Schizophrenia	
LGG	cis	1	rs76482184	chr12:109084848	SELPLG	chr12:109015682-109027670:-	0.2	3.54	0.000432	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs7648357	chr3:41849670	ULK4	chr3:41288091-42003660:-	0.77	14.87	1.51E-41	Diastolic blood pressure	
LGG	cis	1	rs7648578	chr3:41858731	ULK4	chr3:41288091-42003660:-	0.77	15.21	4.24E-43	Diastolic blood pressure	
LGG	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs7648990	chr3:134244390	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs7648995	chr3:49438803	AMIGO3	chr3:49754268-49757238:-	0.18	4.28	2.3E-5	Menarche (age at onset)	
LGG	cis	1	rs7648995	chr3:49438803	GMPPB	chr3:49758932-49761384:-	0.22	4.33	1.82E-5	Menarche (age at onset)	
LGG	cis	1	rs7648995	chr3:49438803	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.53	0.000458	Menarche (age at onset)	
LGG	cis	1	rs7648995	chr3:49438803	TREX1	chr3:48501186-48509043:+	0.24	5.08	5.31E-7	Menarche (age at onset)	
LGG	cis	1	rs7650227	chr3:41794937	ULK4	chr3:41288091-42003660:-	0.75	14.77	3.98E-41	Diastolic blood pressure	
LGG	cis	1	rs76507298	chr20:33623522	PROCR	chr20:33758727-33765164:+	-0.32	-5.65	2.68E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7651407	chr3:48443816	ATRIP	chr3:48488141-48507708:+	0.18	4.42	1.22E-5	Longevity	
LGG	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.42	-10.91	5.63E-25	Longevity	
LGG	cis	1	rs7651757	chr3:195077305	ACAP2	chr3:194995475-195163817:-	-0.35	-8.41	4.44E-16	Body mass index	
LGG	cis	1	rs7653691	chr3:48419689	ATRIP	chr3:48488141-48507708:+	-0.2	-5.07	5.77E-7	Longevity	
LGG	cis	1	rs7653691	chr3:48419689	TREX1	chr3:48501186-48509043:+	0.39	9.75	1.19E-20	Longevity	
LGG	cis	1	rs76542740	chr15:43891512	ADAL	chr15:43622872-43646094:+	-0.61	-7.75	5.24E-14	Tumor biomarkers	
LGG	cis	1	rs76542740	chr15:43891512	LCMT2	chr15:43619976-43622891:-	-0.29	-3.71	0.000234	Tumor biomarkers	
LGG	cis	1	rs76542740	chr15:43891512	STRC	chr15:43891762-43924561:-	0.38	6.89	1.74E-11	Tumor biomarkers	
LGG	cis	1	rs76548544	chr5:150223515	LOC134466	chr5:150310000-150326146:-	0.41	4.65	4.25E-6	Crohn's disease	
LGG	cis	1	rs76552490	chr11:212015	PSMD13	chr11:236808-252984:+	0.22	4.62	4.91E-6	Menarche (age at onset)	
LGG	cis	1	rs765527	chr19:22129555	ZNF208	chr19:22115760-22193745:-	-0.23	-3.77	0.000186	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs765527	chr19:22129555	ZNF257	chr19:22235266-22273901:+	-0.41	-7.09	4.66E-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs76553384	chr14:74383679	LIN52	chr14:74551656-74667117:+	0.38	4.83	1.81E-6	Morning vs. evening chronotype	
LGG	cis	1	rs7655841	chr4:129890790	C4orf33	chr4:130014829-130033842:+	0.56	9.11	2.16E-18	Chronic obstructive pulmonary disease (moderate to severe)	
LGG	cis	1	rs7656037	chr4:39717965	RPL9	chr4:39455747-39460568:-	-0.4	-7.77	4.64E-14	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs76568228	chr12:48949457	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs7657746	chr4:123161619	KIAA1109	chr4:123091758-123283905:+	0.13	3.69	0.000249	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs7657962	chr4:106966715	NPNT	chr4:106816605-106892827:+	-0.23	-4.97	9.09E-7	Airflow obstruction	
LGG	cis	1	rs76579763	chr14:59935971	C14orf149	chr14:59939406-59951126:-	-0.44	-4.6	5.37E-6	Schizophrenia	
LGG	cis	1	rs76579763	chr14:59935971	JKAMP	chr14:59951161-59972080:+	0.48	4.57	6.25E-6	Schizophrenia	
LGG	cis	1	rs7659194	chr4:120207147	MYOZ2	chr4:120056939-120108935:+	0.22	4.23	2.74E-5	Corneal astigmatism	
LGG	cis	1	rs76594057	chr18:44637272	HDHD2	chr18:44633782-44676871:-	0.4	4.07	5.39E-5	Sitting height ratio	
LGG	cis	1	rs7659718	chr4:17638020	MED28	chr4:17616273-17629791:+	0.21	4.49	8.9E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs76609693	chr2:48381731	FOXN2	chr2:48541795-48606434:+	0.29	5.67	2.44E-8	Schizophrenia	
LGG	cis	1	rs7661070	chr4:39724365	RPL9	chr4:39455747-39460568:-	-0.41	-7.89	1.96E-14	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs76648234	chr20:33689941	PROCR	chr20:33758727-33765164:+	-0.34	-5.98	4.37E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7665590	chr4:99796784	EIF4E	chr4:99799607-99851786:-	-0.2	-4.31	1.96E-5	Primary biliary cirrhosis	
LGG	cis	1	rs7665727	chr4:277057	ZNF718	chr4:53272-156488:+	0.26	5.15	3.72E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs76670717	chr4:171008689	AADAT	chr4:170981374-171011372:-	-0.31	-3.92	0.000102	Thyroid hormone levels	
LGG	cis	1	rs7667849	chr4:56388199	TMEM165	chr4:56262090-56292342:+	0.17	4.93	1.1E-6	Personality dimensions	
LGG	cis	1	rs7667930	chr4:42436737	SHISA3	chr4:42399856-42404503:+	0.3	4.4	1.34E-5	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs7668147	chr4:56339384	TMEM165	chr4:56262090-56292342:+	-0.17	-5.09	5.18E-7	Personality dimensions	
LGG	cis	1	rs76683169	chr10:102358397	NDUFB8	chr10:102283497-102289636:-	0.14	3.63	0.000309	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs76683169	chr10:102358397	WNT8B	chr10:102222812-102243397:+	0.44	6.52	1.7E-10	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs76688555	chr2:190747415	ORMDL1	chr2:190634994-190649097:-	0.34	5.17	3.37E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs766903	chr12:51703834	LETMD1	chr12:51442084-51454206:+	-0.18	-3.64	0.000305	Aging (time to death)	
LGG	cis	1	rs7669892	chr4:309253	ZNF718	chr4:53272-156488:+	-0.15	-3.71	0.000228	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs76701316	chr9:123708273	TRAF1	chr9:123664672-123691479:-	0.39	4.42	1.2E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs7670225	chr4:56368018	TMEM165	chr4:56262090-56292342:+	-0.17	-4.99	8.22E-7	Personality dimensions	
LGG	cis	1	rs7671752	chr4:17661398	LAP3	chr4:17578927-17609590:+	-0.13	-3.63	0.000307	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7671752	chr4:17661398	MED28	chr4:17616273-17629791:+	0.18	3.74	0.000203	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs76722536	chr6:26192946	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.28	2.25E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs76722536	chr6:26192946	HIST1H3E	chr6:26224427-26226589:+	0.64	10.64	6.06E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs7673500	chr4:17621383	MED28	chr4:17616273-17629791:+	0.22	4.64	4.38E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7673908	chr4:56394819	TMEM165	chr4:56262090-56292342:+	0.16	4.87	1.51E-6	Personality dimensions	
LGG	cis	1	rs76745316	chr12:56627652	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7674560	chr4:263319	ZNF718	chr4:53272-156488:+	0.23	4.6	5.27E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs767471	chr6:26557854	BTN2A3	chr6:26422317-26431927:+	0.13	3.69	0.000252	Educational attainment	
LGG	cis	1	rs767471	chr6:26557854	HMGN4	chr6:26538572-26547162:+	-0.19	-4.93	1.15E-6	Educational attainment	
LGG	cis	1	rs76753180	chr5:130763701	SLC22A5	chr5:131705401-131731302:+	-0.27	-4.76	2.53E-6	Life satisfaction	
LGG	cis	1	rs7677248	chr4:106960497	NPNT	chr4:106816605-106892827:+	0.24	5.18	3.29E-7	Airflow obstruction	
LGG	cis	1	rs7677526	chr4:56349908	TMEM165	chr4:56262090-56292342:+	-0.18	-5.14	3.93E-7	Personality dimensions	
LGG	cis	1	rs76784350	chr2:27764278	PPM1G	chr2:27604062-27632496:-	0.13	4.3	2.09E-5	Oral cavity cancer	
LGG	cis	1	rs76784350	chr2:27764278	SNX17	chr2:27593363-27599994:+	-0.12	-3.73	0.000212	Oral cavity cancer	
LGG	cis	1	rs7678847	chr4:106987426	NPNT	chr4:106816605-106892827:+	-0.22	-4.78	2.34E-6	Airflow obstruction	
LGG	cis	1	rs7679218	chr4:79506864	ANXA3	chr4:79472742-79531602:+	-0.31	-7.2	2.27E-12	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs76796947	chr5:115501040	COMMD10	chr5:115420727-115628978:+	0.47	5.95	5.04E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs76800049	chr2:48051171	FBXO11	chr2:48034061-48132814:-	0.23	4.19	3.37E-5	Schizophrenia	
LGG	cis	1	rs7682402	chr4:1743343	TMEM129	chr4:1717680-1723084:-	-0.18	-3.84	0.000138	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs7682502	chr4:79504121	ANXA3	chr4:79472742-79531602:+	-0.31	-7.29	1.28E-12	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs76827709	chr2:48115942	FBXO11	chr2:48034061-48132814:-	0.23	4.17	3.62E-5	Schizophrenia	
LGG	cis	1	rs7683399	chr4:79510367	ANXA3	chr4:79472742-79531602:+	-0.31	-7.17	2.71E-12	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs76837345	chr8:82668818	CHMP4C	chr8:82644688-82671746:+	-0.5	-4.75	2.69E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs76850134	chr20:33671725	PROCR	chr20:33758727-33765164:+	-0.32	-5.64	2.93E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs768618	chr22:50286827	ALG12	chr22:50296856-50312106:-	0.28	5.6	3.66E-8	Schizophrenia	
LGG	cis	1	rs768619	chr22:50287266	ALG12	chr22:50296856-50312106:-	0.28	5.6	3.66E-8	Schizophrenia	
LGG	cis	1	rs7686546	chr4:240614	ZNF718	chr4:53272-156488:+	0.28	5.32	1.54E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs76872831	chr5:150171559	LOC134466	chr5:150310000-150326146:-	0.39	4.22	2.95E-5	Crohn's disease	
LGG	cis	1	rs76873509	chr8:38021982	LSM1	chr8:38020861-38034169:-	-0.18	-3.82	0.000151	Schizophrenia	
LGG	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.38	-7.39	6.39E-13	Plasma amyloid beta peptide concentrations (ABx-40)	
LGG	cis	1	rs76882722	chr12:48950252	ZNF641	chr12:48735912-48745021:-	0.26	3.86	0.000127	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs76886731	chr2:102945416	IL18R1	chr2:102927962-103015215:+	-0.57	-12.17	5.84E-30	Leprosy	
LGG	cis	1	rs76886731	chr2:102945416	IL1RL1	chr2:102927962-102968497:+	-0.52	-9.59	4.52E-20	Leprosy	
LGG	cis	1	rs76901676	chr1:179452520	C1orf125	chr1:179335107-179523868:+	0.64	8.01	8.4E-15	Multiple sclerosis (age of onset)	
LGG	cis	1	rs76917914	chr9:100771440	C9orf156	chr9:100666772-100684852:-	0.22	3.92	0.000103	Coronary heart disease	
LGG	cis	1	rs7692069	chr4:106959289	NPNT	chr4:106816605-106892827:+	-0.24	-5.22	2.62E-7	Airflow obstruction	
LGG	cis	1	rs7694020	chr4:17682597	LAP3	chr4:17578927-17609590:+	-0.13	-3.51	0.000483	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs76944716	chr8:58191643	C8orf71	chr8:58192102-58197288:+	0.36	5.99	3.99E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs76951621	chr2:48049944	FBXO11	chr2:48034061-48132814:-	0.23	4.19	3.37E-5	Schizophrenia	
LGG	cis	1	rs7697889	chr4:17617961	MED28	chr4:17616273-17629791:+	0.22	4.61	5.06E-6	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs76994419	chr15:40714150	C15orf23	chr15:40674922-40686488:+	1.04	16.21	1.2E-47	Heschl's gyrus morphology	
LGG	cis	1	rs7701475	chr5:171161824	NEURL1B	chr5:172068276-172118531:+	-0.16	-3.45	0.000603	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs77022811	chr2:190793046	ORMDL1	chr2:190634994-190649097:-	0.34	4.97	9.05E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs77032009	chr12:56679971	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs7703937	chr5:151729454	NMUR2	chr5:151771102-151784840:-	-0.23	-3.85	0.000133	Optic nerve measurement (cup area)	
LGG	cis	1	rs7704555	chr5:173000002	LOC285593	chr5:173006646-173012074:+	0.27	4.91	1.25E-6	Height	
LGG	cis	1	rs7705093	chr5:96290647	ERAP2	chr5:96211644-96255398:+	1.08	35.1	5.75E-136	Birdshot chorioretinopathy	
LGG	cis	1	rs7705542	chr5:150228318	LOC134466	chr5:150310000-150326146:-	0.41	4.72	3.11E-6	Crohn's disease	
LGG	cis	1	rs7705658	chr5:78315305	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000486	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs77068811	chr7:135334571	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.05	6.04E-5	Red blood cell traits	
LGG	cis	1	rs77078697	chr4:252048	ZNF718	chr4:53272-156488:+	0.24	4.67	3.92E-6	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs7709377	chr5:115540573	COMMD10	chr5:115420727-115628978:+	0.19	3.63	0.000312	Metabolite levels  (X-11787)	
LGG	cis	1	rs7709388	chr5:150246539	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs7709464	chr5:150269441	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7709472	chr5:78315151	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000497	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs7709650	chr5:150246685	LOC134466	chr5:150310000-150326146:-	0.42	4.77	2.48E-6	Crohn's disease	
LGG	cis	1	rs7709757	chr5:78315329	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000486	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs7710178	chr5:156013831	SGCD	chr5:155135063-156194796:+	0.28	4.22	2.93E-5	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs7712015	chr5:110428781	TSLP	chr5:110405778-110413722:+	-0.31	-4.42	1.22E-5	Eosinophil counts	
LGG	cis	1	rs77120900	chr8:58170368	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs77120931	chr12:56646213	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7713025	chr5:110416223	TSLP	chr5:110405778-110413722:+	0.29	4.18	3.49E-5	Eosinophil counts	
LGG	cis	1	rs77131854	chr12:56664231	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs77135258	chr7:33293116	BBS9	chr7:33169152-33645680:+	0.44	6.16	1.48E-9	Smooth-surface caries	
LGG	cis	1	rs7714415	chr5:150270292	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7714584	chr5:150270420	LOC134466	chr5:150310000-150326146:-	0.41	4.66	4.03E-6	Crohn's disease	
LGG	cis	1	rs77148055	chr5:115509920	COMMD10	chr5:115420727-115628978:+	0.46	5.7	2.04E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7715981	chr5:150258107	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7716600	chr5:44875005	MRPS30	chr5:44809027-44815614:+	-0.21	-3.82	0.000152	Breast cancer	
LGG	cis	1	rs7716903	chr5:150258574	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7718874	chr5:176358065	FGFR4	chr5:176513921-176525124:+	0.22	6.13	1.83E-9	Menopause (age at onset);Menarche and menopause (age at onset)	
LGG	cis	1	rs7719994	chr5:156430076	TIMD4	chr5:156346293-156390266:-	-0.26	-4.79	2.19E-6	Hypertriglyceridemia	
LGG	cis	1	rs77234191	chr4:258294	ZNF718	chr4:53272-156488:+	0.27	5.21	2.72E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs7724036	chr5:150284808	LOC134466	chr5:150310000-150326146:-	-0.44	-5.29	1.86E-7	Crohn's disease	
LGG	cis	1	rs77245075	chr2:17810302	GEN1	chr2:17935162-17966632:+	0.38	5.31	1.63E-7	Psychosis and Alzheimer's disease	
LGG	cis	1	rs7724558	chr5:150328866	LOC134466	chr5:150310000-150326146:-	0.49	5.22	2.66E-7	Crohn's disease	
LGG	cis	1	rs77246794	chr2:48144876	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs7726556	chr5:156478780	TIMD4	chr5:156346293-156390266:-	-0.24	-4.44	1.14E-5	Hypertriglyceridemia	
LGG	cis	1	rs7726839	chr5:618586	CEP72	chr5:612405-653664:+	-0.19	-3.75	0.000195	Obesity-related traits	
LGG	cis	1	rs7726839	chr5:618586	SLC9A3	chr5:473334-524549:-	0.16	3.56	0.000409	Obesity-related traits	
LGG	cis	1	rs7727038	chr5:131590257	SLC22A5	chr5:131705401-131731302:+	0.19	3.76	0.000193	Blood metabolite levels	
LGG	cis	1	rs7727544	chr5:131590534	SLC22A5	chr5:131705401-131731302:+	0.19	3.76	0.000193	Blood metabolite levels	
LGG	cis	1	rs7727882	chr5:115614507	CDO1	chr5:115140432-115152405:-	-0.25	-3.62	0.000324	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7727882	chr5:115614507	COMMD10	chr5:115420727-115628978:+	0.35	4.66	4.05E-6	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7729832	chr5:110428744	TSLP	chr5:110405778-110413722:+	0.31	4.45	1.08E-5	Eosinophil counts	
LGG	cis	1	rs77303550	chr16:72079657	HP	chr16:72088508-72094957:+	-0.25	-3.59	0.000362	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs77303550	chr16:72079657	HPR	chr16:72097125-72111144:+	-0.22	-3.57	0.000389	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs77314892	chr4:171013752	AADAT	chr4:170981374-171011372:-	-0.31	-3.94	9.19E-5	Thyroid hormone levels	
LGG	cis	1	rs7731821	chr5:110467918	TSLP	chr5:110405778-110413722:+	-0.3	-4.37	1.51E-5	Eosinophil counts	
LGG	cis	1	rs7732643	chr5:150261436	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7732945	chr5:150261601	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7733195	chr5:172994624	LOC285593	chr5:173006646-173012074:+	0.26	4.83	1.82E-6	Height	
LGG	cis	1	rs77341397	chr2:48124178	FBXO11	chr2:48034061-48132814:-	0.22	3.98	8.09E-5	Schizophrenia	
LGG	cis	1	rs77344981	chr19:6692145	GPR108	chr19:6729927-6737633:-	-0.27	-3.85	0.000136	Complement C3 and C4 levels	
LGG	cis	1	rs7734778	chr5:150256556	LOC134466	chr5:150310000-150326146:-	0.41	4.63	4.62E-6	Crohn's disease	
LGG	cis	1	rs7734910	chr5:176986300	DOK3	chr5:176928915-176937427:-	0.22	3.89	0.000116	Alzheimer disease and age of onset	
LGG	cis	1	rs7734928	chr5:150256613	LOC134466	chr5:150310000-150326146:-	0.42	4.78	2.28E-6	Crohn's disease	
LGG	cis	1	rs7736554	chr5:150258308	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs773664	chr12:56702176	IL23A	chr12:56732663-56734193:+	-0.57	-5.82	1.05E-8	Psoriasis vulgaris	
LGG	cis	1	rs7736873	chr5:150258482	LOC134466	chr5:150310000-150326146:-	0.4	4.64	4.46E-6	Crohn's disease	
LGG	cis	1	rs7737689	chr5:149396159	TIGD6	chr5:149372685-149380217:-	0.22	3.71	0.000235	HIV-1 control	
LGG	cis	1	rs77391665	chr1:150008584	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs77399357	chr2:48218576	FOXN2	chr2:48541795-48606434:+	0.31	5.74	1.63E-8	Schizophrenia	
LGG	cis	1	rs7740487	chr6:28216486	ZNF165	chr6:28046572-28057338:+	-0.33	-4.78	2.34E-6	Depression	
LGG	cis	1	rs7740487	chr6:28216486	ZNF187	chr6:28234788-28245978:+	-0.27	-4.65	4.26E-6	Depression	
LGG	cis	1	rs7740487	chr6:28216486	ZNF389	chr6:28129551-28137375:+	0.44	6.87	1.92E-11	Depression	
LGG	cis	1	rs7740487	chr6:28216486	ZSCAN12	chr6:28346770-28367544:-	-0.35	-4.8	2.12E-6	Depression	
LGG	cis	1	rs7740487	chr6:28216486	ZSCAN23	chr6:28393287-28411279:-	0.18	4.23	2.8E-5	Depression	
LGG	cis	1	rs7742626	chr6:136132496	C6orf217	chr6:135818939-136037192:+	0.19	3.89	0.000116	Phosphorus levels	
LGG	cis	1	rs774356	chr9:27559721	MOBKL2B	chr9:27325208-27529850:-	-0.22	-4.52	7.68E-6	Amyotrophic lateral sclerosis	
LGG	cis	1	rs77437249	chr20:33564738	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.01E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs77447765	chr12:56690662	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs7745098	chr6:135415004	ALDH8A1	chr6:135238529-135271244:-	-0.44	-11.7	4.81E-28	Hodgkin's lymphoma	
LGG	cis	1	rs7745098	chr6:135415004	HBS1L	chr6:135281517-135376036:-	-0.16	-3.77	0.00018	Hodgkin's lymphoma	
LGG	cis	1	rs7745311	chr6:107565060	PDSS2	chr6:107473761-107780779:-	-0.22	-4.18	3.39E-5	Coffee consumption	
LGG	cis	1	rs7746598	chr6:170084933	C6orf70	chr6:170151721-170181617:+	-0.18	-3.45	0.000599	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7746598	chr6:170084933	WDR27	chr6:169857307-170102159:-	-0.41	-9.2	1.05E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7747645	chr6:170070291	WDR27	chr6:169857307-170102159:-	-0.41	-9.5	8.94E-20	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.53	-11.28	2.08E-26	Response to antipsychotic treatment	
LGG	cis	1	rs7750918	chr6:49430082	CENPQ	chr6:49431096-49460820:+	-0.24	-5.21	2.85E-7	Folate pathway vitamin levels	
LGG	cis	1	rs77531164	chr15:40673466	C15orf23	chr15:40674922-40686488:+	1.01	18.62	6.13E-59	Heschl's gyrus morphology	
LGG	cis	1	rs77531164	chr15:40673466	IVD	chr15:40697686-40713512:+	-0.38	-4.59	5.59E-6	Heschl's gyrus morphology	
LGG	cis	1	rs7755323	chr6:33761159	LEMD2	chr6:33738991-33756906:-	0.18	5.5	6.06E-8	Body mass index	
LGG	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs77564939	chr5:115564294	COMMD10	chr5:115420727-115628978:+	0.47	5.91	6.57E-9	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs77584282	chr9:123672383	TRAF1	chr9:123664672-123691479:-	0.4	4.57	6.15E-6	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs7759001	chr6:27341409	ZNF391	chr6:27356524-27369227:+	0.3	7.41	5.71E-13	Glomerular filtration rate (creatinine)	
LGG	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.51	-10.33	8.84E-23	Response to antipsychotic treatment	
LGG	cis	1	rs77617771	chr9:123729896	TRAF1	chr9:123664672-123691479:-	0.35	4.06	5.83E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs7762018	chr6:170113244	WDR27	chr6:169857307-170102159:-	-0.39	-8.93	8.56E-18	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	cis	1	rs77622401	chr17:47946585	SPATA20	chr17:48620419-48633211:+	0.29	3.99	7.63E-5	Milk allergy	
LGG	cis	1	rs7762901	chr6:24449639	MRS2	chr6:24403153-24425809:+	-0.22	-3.48	0.000536	Liver enzyme levels	
LGG	cis	1	rs7764785	chr6:163009967	PACRG	chr6:163148164-163736523:+	0.29	4.35	1.68E-5	Body mass index	
LGG	cis	1	rs77665099	chr4:171024601	AADAT	chr4:170981374-171011372:-	-0.31	-4.13	4.29E-5	Thyroid hormone levels	
LGG	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs77673116	chr2:48128409	FBXO11	chr2:48034061-48132814:-	0.22	3.98	8.09E-5	Schizophrenia	
LGG	cis	1	rs776746	chr7:99270539	CYP3A5	chr7:99245818-99332821:-	-0.42	-4.24	2.67E-5	Blood metabolite levels	
LGG	cis	1	rs7769686	chr6:163199467	PACRG	chr6:163148164-163736523:+	0.38	5.36	1.3E-7	Body mass index	
LGG	cis	1	rs77698001	chr5:150250367	LOC134466	chr5:150310000-150326146:-	0.43	4.8	2.12E-6	Crohn's disease	
LGG	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.49	-10.06	9.1E-22	Response to antipsychotic treatment	
LGG	cis	1	rs7773987	chr6:135707486	AHI1	chr6:135605112-135818903:-	0.18	4	7.28E-5	Selective IgA deficiency	
LGG	cis	1	rs7773987	chr6:135707486	C6orf217	chr6:135818939-136037192:+	0.19	3.99	7.49E-5	Selective IgA deficiency	
LGG	cis	1	rs7776212	chr6:154071611	IPCEF1	chr6:154475620-154677900:-	-0.11	-3.59	0.00036	Coronary artery calcification	
LGG	cis	1	rs77763497	chr20:3250007	ITPA	chr20:3190056-3204504:+	-0.35	-8.36	6.61E-16	IFN-related cytopenia	
LGG	cis	1	rs77768890	chr12:56725121	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs7778911	chr7:65694506	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.38	1.43E-5	Diabetic kidney disease	
LGG	cis	1	rs77789667	chr14:59940418	C14orf149	chr14:59939406-59951126:-	-0.42	-4.45	1.08E-5	Schizophrenia	
LGG	cis	1	rs77789667	chr14:59940418	JKAMP	chr14:59951161-59972080:+	0.51	4.86	1.59E-6	Schizophrenia	
LGG	cis	1	rs7781698	chr7:65896312	ASL	chr7:65540776-65558321:+	-0.21	-5.27	2.04E-7	Aortic root size	
LGG	cis	1	rs77823122	chr8:58170161	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7782320	chr7:66177098	ASL	chr7:65540776-65558321:+	-0.19	-4.77	2.47E-6	Aortic root size	
LGG	cis	1	rs7782320	chr7:66177098	TYW1	chr7:66461817-66704496:+	0.17	3.68	0.000258	Aortic root size	
LGG	cis	1	rs7783613	chr7:65805261	ASL	chr7:65540776-65558321:+	0.22	5.57	4.26E-8	Aortic root size	
LGG	cis	1	rs778370	chr2:233743363	C2orf82	chr2:233734994-233741107:+	0.35	6.82	2.77E-11	Schizophrenia	
LGG	cis	1	rs778371	chr2:233743109	C2orf82	chr2:233734994-233741107:+	0.29	5.44	8.27E-8	Schizophrenia	
LGG	cis	1	rs7783924	chr7:66209057	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.24E-6	Aortic root size	
LGG	cis	1	rs7783924	chr7:66209057	TYW1	chr7:66461817-66704496:+	0.18	3.76	0.000192	Aortic root size	
LGG	cis	1	rs7784398	chr7:118082335	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.88	0.000117	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs77849630	chr5:115556900	COMMD10	chr5:115420727-115628978:+	0.47	5.75	1.59E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7785213	chr7:66138978	ASL	chr7:65540776-65558321:+	0.19	4.81	1.98E-6	Aortic root size	
LGG	cis	1	rs7785213	chr7:66138978	TYW1	chr7:66461817-66704496:+	-0.17	-3.69	0.000254	Aortic root size	
LGG	cis	1	rs77853814	chr12:56687572	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs77855653	chr4:171024744	AADAT	chr4:170981374-171011372:-	-0.31	-4.13	4.29E-5	Thyroid hormone levels	
LGG	cis	1	rs77856716	chr5:115565660	COMMD10	chr5:115420727-115628978:+	0.47	5.8	1.18E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs77857677	chr8:58170131	C8orf71	chr8:58192102-58197288:+	0.37	6.34	5.22E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7786410	chr7:55922323	PSPH	chr7:56078746-56184090:-	0.31	4.95	1.04E-6	Age-related hearing impairment	
LGG	cis	1	rs7786410	chr7:55922323	ZNF713	chr7:55955162-56008433:+	0.26	4.61	5.11E-6	Age-related hearing impairment	
LGG	cis	1	rs778679	chr7:65840911	CCT6P1	chr7:65216092-65228661:+	0.23	4.21	3.06E-5	Diabetic kidney disease	
LGG	cis	1	rs778685	chr7:65836176	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs778691	chr7:65873092	CCT6P1	chr7:65216092-65228661:+	0.23	4.2	3.12E-5	Diabetic kidney disease	
LGG	cis	1	rs778694	chr7:65871558	ASL	chr7:65540776-65558321:+	-0.22	-5.58	4.04E-8	Aortic root size	
LGG	cis	1	rs778696	chr7:65870813	ASL	chr7:65540776-65558321:+	-0.22	-5.58	4.04E-8	Aortic root size	
LGG	cis	1	rs778699	chr7:65868290	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs778704	chr7:65863467	CCT6P1	chr7:65216092-65228661:+	0.23	4.2	3.12E-5	Diabetic kidney disease	
LGG	cis	1	rs778706	chr7:65860424	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs778710	chr7:65854834	ASL	chr7:65540776-65558321:+	-0.22	-5.58	4.04E-8	Aortic root size	
LGG	cis	1	rs778722	chr7:65844828	ASL	chr7:65540776-65558321:+	-0.22	-5.49	6.55E-8	Aortic root size	
LGG	cis	1	rs7787230	chr7:65629099	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.28	2.24E-5	Diabetic kidney disease	
LGG	cis	1	rs778726	chr7:65828731	ASL	chr7:65540776-65558321:+	-0.22	-5.51	5.68E-8	Aortic root size	
LGG	cis	1	rs7787274	chr7:2275993	FTSJ2	chr7:2273928-2281833:-	0.3	6.97	1.01E-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LGG	cis	1	rs778729	chr7:65824419	CCT6P1	chr7:65216092-65228661:+	0.23	4.21	3.06E-5	Diabetic kidney disease	
LGG	cis	1	rs778758	chr2:61782161	AHSA2	chr2:61404553-61414058:+	-0.29	-9.28	5.64E-19	Tuberculosis	
LGG	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.39	8.24	1.62E-15	Tuberculosis	
LGG	cis	1	rs778762	chr2:61782921	AHSA2	chr2:61404553-61414058:+	-0.28	-8.91	1.01E-17	Tuberculosis	
LGG	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.38	8.17	2.62E-15	Tuberculosis	
LGG	cis	1	rs778763	chr2:61785639	AHSA2	chr2:61404553-61414058:+	-0.29	-9.26	6.41E-19	Tuberculosis	
LGG	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.38	8.2	2.14E-15	Tuberculosis	
LGG	cis	1	rs7788576	chr7:66148302	ASL	chr7:65540776-65558321:+	0.19	4.94	1.06E-6	Aortic root size	
LGG	cis	1	rs7788576	chr7:66148302	TYW1	chr7:66461817-66704496:+	-0.17	-3.58	0.000375	Aortic root size	
LGG	cis	1	rs7789184	chr7:66210195	ASL	chr7:65540776-65558321:+	-0.19	-4.91	1.24E-6	Aortic root size	
LGG	cis	1	rs7789184	chr7:66210195	TYW1	chr7:66461817-66704496:+	0.18	3.76	0.000192	Aortic root size	
LGG	cis	1	rs7789554	chr7:65946038	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs7789768	chr7:65938980	ASL	chr7:65540776-65558321:+	-0.22	-5.48	6.91E-8	Aortic root size	
LGG	cis	1	rs7789940	chr7:75951230	POR	chr7:75544420-75616172:+	0.18	3.71	0.000229	Multiple sclerosis	
LGG	cis	1	rs7789940	chr7:75951230	SRCRB4D	chr7:76018647-76039012:-	0.28	6.3	6.68E-10	Multiple sclerosis	
LGG	cis	1	rs7789940	chr7:75951230	UPK3B	chr7:76139745-76157197:+	-0.21	-3.9	0.000111	Multiple sclerosis	
LGG	cis	1	rs77906836	chr2:190768109	ORMDL1	chr2:190634994-190649097:-	0.34	5.09	5.05E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7792262	chr7:23915743	C7orf46	chr7:23719749-23742268:+	-0.2	-4.23	2.73E-5	Schizophrenia	
LGG	cis	1	rs7792391	chr7:65773429	CCT6P1	chr7:65216092-65228661:+	-0.23	-4.17	3.55E-5	Diabetic kidney disease	
LGG	cis	1	rs7792762	chr7:66004138	ASL	chr7:65540776-65558321:+	-0.2	-5.19	3.01E-7	Aortic root size	
LGG	cis	1	rs77930391	chr13:96297821	UGGT2	chr13:96453838-96705736:-	-0.26	-4.32	1.85E-5	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change)	
LGG	cis	1	rs77934397	chr2:190792255	ORMDL1	chr2:190634994-190649097:-	0.33	4.93	1.11E-6	Subcutaneous adipose tissue	
LGG	cis	1	rs7793667	chr7:33310619	BBS9	chr7:33169152-33645680:+	0.47	6.51	1.87E-10	Smooth-surface caries	
LGG	cis	1	rs7794661	chr7:65389730	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs7795242	chr7:65390094	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs77957229	chr6:26185226	HIST1H2AE	chr6:26217148-26217711:+	-0.32	-4.35	1.65E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs77957229	chr6:26185226	HIST1H3E	chr6:26224427-26226589:+	0.53	8.13	3.55E-15	Renal underexcretion gout;Gout	
LGG	cis	1	rs77961951	chr6:26186075	HIST1H2AE	chr6:26217148-26217711:+	-0.33	-4.44	1.1E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs77961951	chr6:26186075	HIST1H3E	chr6:26224427-26226589:+	0.54	8.16	2.78E-15	Renal underexcretion gout;Gout	
LGG	cis	1	rs7796393	chr7:118038928	ANKRD7	chr7:117864712-117882782:+	-0.21	-3.68	0.000256	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs7796922	chr7:33171110	BBS9	chr7:33169152-33645680:+	0.43	5.49	6.56E-8	Smooth-surface caries	
LGG	cis	1	rs7797626	chr7:118042798	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.87	0.000125	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs7798118	chr7:33311464	BBS9	chr7:33169152-33645680:+	0.47	6.51	1.87E-10	Smooth-surface caries	
LGG	cis	1	rs77981979	chr2:48209839	FOXN2	chr2:48541795-48606434:+	0.3	5.63	2.99E-8	Schizophrenia	
LGG	cis	1	rs7799006	chr7:2278226	FTSJ2	chr7:2273928-2281833:-	0.3	6.98	9.68E-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LGG	cis	1	rs7799346	chr7:33312020	BBS9	chr7:33169152-33645680:+	0.4	5.27	2.02E-7	Smooth-surface caries	
LGG	cis	1	rs78012445	chr6:26195080	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.24	2.66E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs78012445	chr6:26195080	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	3.94E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs7801282	chr7:65613687	ASL	chr7:65540776-65558321:+	0.22	5.58	4.07E-8	Aortic root size	
LGG	cis	1	rs78017006	chr11:5387289	FAM160A2	chr11:6232565-6255941:-	0.19	3.74	0.000203	Fetal hemoglobin levels	
LGG	cis	1	rs78022318	chr12:48949120	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs78027130	chr4:171019411	AADAT	chr4:170981374-171011372:-	-0.35	-4.55	6.75E-6	Thyroid hormone levels	
LGG	cis	1	rs78032512	chr11:76826173	CAPN5	chr11:76777992-76837196:+	0.35	3.78	0.000176	Cognitive performance	
LGG	cis	1	rs78032828	chr2:86309032	LOC90784	chr2:86247339-86250991:-	-0.4	-4.13	4.35E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs7804223	chr7:65664559	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.26	2.44E-5	Diabetic kidney disease	
LGG	cis	1	rs7805314	chr7:118076277	ANKRD7	chr7:117864712-117882782:+	-0.22	-3.89	0.000115	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs78055011	chr20:33618606	PROCR	chr20:33758727-33765164:+	-0.32	-5.65	2.68E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs78062696	chr2:48377720	FOXN2	chr2:48541795-48606434:+	0.29	5.68	2.32E-8	Schizophrenia	
LGG	cis	1	rs780672	chr10:73113246	SLC29A3	chr10:73079010-73123145:+	-0.16	-3.66	0.00028	Gestational age at birth (child effect)	
LGG	cis	1	rs780678	chr10:73114486	SLC29A3	chr10:73079010-73123145:+	-0.16	-3.91	0.000106	Gestational age at birth (child effect)	
LGG	cis	1	rs7806994	chr7:56139505	ZNF713	chr7:55955162-56008433:+	-0.3	-5.87	8.02E-9	PR interval in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs7808022	chr7:99220083	CYP3A5	chr7:99245818-99332821:-	0.39	3.9	0.00011	Blood metabolite levels	
LGG	cis	1	rs7808314	chr7:118092365	ANKRD7	chr7:117864712-117882782:+	-0.23	-4.06	5.7E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs7808472	chr7:33310348	BBS9	chr7:33169152-33645680:+	0.47	6.51	1.87E-10	Smooth-surface caries	
LGG	cis	1	rs7809235	chr7:33256416	BBS9	chr7:33169152-33645680:+	0.42	5.77	1.39E-8	Smooth-surface caries	
LGG	cis	1	rs7809366	chr7:33256372	BBS9	chr7:33169152-33645680:+	0.42	5.77	1.39E-8	Smooth-surface caries	
LGG	cis	1	rs7809399	chr7:33256429	BBS9	chr7:33169152-33645680:+	0.31	4.29	2.13E-5	Smooth-surface caries	
LGG	cis	1	rs7809615	chr7:99184778	CYP3A5	chr7:99245818-99332821:-	-0.32	-3.7	0.000238	Blood metabolite ratios	
LGG	cis	1	rs7810543	chr7:110894778	IMMP2L	chr7:110303110-111202538:-	-0.2	-3.79	0.000167	Schizophrenia	
LGG	cis	1	rs7810970	chr7:2276385	FTSJ2	chr7:2273928-2281833:-	0.3	6.99	8.75E-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LGG	cis	1	rs781142	chr7:65438778	CCT6P1	chr7:65216092-65228661:+	0.25	4.69	3.52E-6	Diabetic kidney disease	
LGG	cis	1	rs781149	chr7:65481284	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.56E-6	Diabetic kidney disease	
LGG	cis	1	rs781150	chr7:65480973	CCT6P1	chr7:65216092-65228661:+	0.27	4.84	1.71E-6	Diabetic kidney disease	
LGG	cis	1	rs781156	chr7:65479141	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.56E-6	Diabetic kidney disease	
LGG	cis	1	rs781157	chr7:65478311	CCT6P1	chr7:65216092-65228661:+	0.27	4.86	1.58E-6	Diabetic kidney disease	
LGG	cis	1	rs78121408	chr12:56684798	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs78128841	chr2:203663975	WDR12	chr2:203745324-203776949:-	0.21	3.58	0.000383	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs78149779	chr12:56694817	IL23A	chr12:56732663-56734193:+	0.52	4.75	2.64E-6	Psoriasis vulgaris	
LGG	cis	1	rs78153629	chr15:40673465	C15orf23	chr15:40674922-40686488:+	1.01	18.62	6.13E-59	Heschl's gyrus morphology	
LGG	cis	1	rs78153629	chr15:40673465	IVD	chr15:40697686-40713512:+	-0.38	-4.59	5.59E-6	Heschl's gyrus morphology	
LGG	cis	1	rs7815827	chr8:27077507	STMN4	chr8:27093816-27115903:-	0.17	4.05	5.96E-5	Bipolar disorder and schizophrenia	
LGG	cis	1	rs78172786	chr17:61847114	DDX42	chr17:61851567-61896676:+	-0.16	-3.57	0.000399	Body mass index	
LGG	cis	1	rs78172786	chr17:61847114	FTSJ3	chr17:61896795-61905031:-	0.41	8.32	8.61E-16	Body mass index	
LGG	cis	1	rs78172786	chr17:61847114	SMARCD2	chr17:61909441-61920351:-	0.17	3.8	0.000164	Body mass index	
LGG	cis	1	rs78177356	chr14:60008967	C14orf149	chr14:59939406-59951126:-	-0.43	-4.47	9.83E-6	Schizophrenia	
LGG	cis	1	rs78177356	chr14:60008967	JKAMP	chr14:59951161-59972080:+	0.45	4.21	3.0E-5	Schizophrenia	
LGG	cis	1	rs78186690	chr7:135334991	SLC13A4	chr7:135365993-135412933:-	-0.28	-4.05	6.04E-5	Red blood cell traits	
LGG	cis	1	rs7820159	chr8:8576215	FLJ10661	chr8:8086092-8102386:+	-0.25	-4.47	9.66E-6	Obesity-related traits	
LGG	cis	1	rs78202808	chr20:33667424	PROCR	chr20:33758727-33765164:+	-0.32	-6	3.91E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7821330	chr8:23522452	NKX3-1	chr8:23536207-23540450:-	0.22	4.59	5.64E-6	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs7822232	chr8:145145687	KIAA1875	chr8:145162629-145173218:+	-0.39	-7.55	2.11E-13	Blood metabolite levels	
LGG	cis	1	rs7824557	chr8:11104111	C8orf12	chr8:11225911-11296166:+	0.16	4.13	4.18E-5	Retinal vascular caliber	
LGG	cis	1	rs78267272	chr2:17790782	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs78275917	chr2:48147401	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs78285894	chr12:48948835	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs78300366	chr11:71205514	KRTAP5-9	chr11:71259466-71260653:+	0.28	4.38	1.43E-5	Vitamin D levels	
LGG	cis	1	rs7831583	chr8:98327878	HRSP12	chr8:99114567-99129418:-	0.15	3.61	0.000331	Antipsychotic-induced QTc interval prolongation	
LGG	cis	1	rs7833128	chr8:10684422	RP1L1	chr8:10463862-10512617:-	-0.21	-3.9	0.000111	Triglycerides	
LGG	cis	1	rs783396	chr6:106987370	QRSL1	chr6:107077441-107116290:+	-0.44	-4.91	1.27E-6	Stroke	
LGG	cis	1	rs783401	chr6:106985886	QRSL1	chr6:107077441-107116290:+	-0.42	-4.83	1.81E-6	Stroke	
LGG	cis	1	rs78343340	chr4:267437	ZNF718	chr4:53272-156488:+	0.26	5.15	3.72E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs78350765	chr12:48949043	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs783531	chr15:83249119	FAM154B	chr15:82555152-82577265:+	-0.19	-4.1	4.84E-5	Schizophrenia	
LGG	cis	1	rs783531	chr15:83249119	GOLGA6L9	chr15:82711895-82731584:+;chr15	-0.17	-4.17	3.57E-5	Schizophrenia	
LGG	cis	1	rs783540	chr15:83254708	FAM154B	chr15:82555152-82577265:+	0.2	4.2	3.16E-5	Schizophrenia	
LGG	cis	1	rs783540	chr15:83254708	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.18	4.65	4.18E-6	Schizophrenia	
LGG	cis	1	rs78362565	chr5:115564293	COMMD10	chr5:115420727-115628978:+	0.46	5.78	1.36E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7843479	chr8:21820813	XPO7	chr8:21777180-21864095:+	0.16	3.7	0.000241	Mean corpuscular volume	
LGG	cis	1	rs7843488	chr8:8576217	FLJ10661	chr8:8086092-8102386:+	-0.25	-4.48	9.28E-6	Obesity-related traits	
LGG	cis	1	rs78457084	chr12:109106800	SELPLG	chr12:109015682-109027670:-	0.2	3.55	0.000425	Low high density lipoprotein cholesterol levels	
LGG	cis	1	rs7846449	chr8:10684670	RP1L1	chr8:10463862-10512617:-	-0.21	-3.81	0.000158	Triglycerides	
LGG	cis	1	rs78465528	chr5:115474406	COMMD10	chr5:115420727-115628978:+	0.45	5.48	6.7E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs78472555	chr15:100267322	LYSMD4	chr15:100255906-100273626:-	0.21	4.24	2.7E-5	Post bronchodilator FEV1/FVC ratio in COPD	
LGG	cis	1	rs7847663	chr9:100544868	C9orf156	chr9:100666772-100684852:-	0.18	3.78	0.000174	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7849270	chr9:131874641	CRAT	chr9:131857075-131873070:-	0.22	3.99	7.67E-5	Blood metabolite ratios	
LGG	cis	1	rs7849585	chr9:139111870	QSOX2	chr9:139098182-139137687:-	0.28	5.39	1.1E-7	Height	
LGG	cis	1	rs78495928	chr12:56635080	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7850258	chr9:100549013	C9orf156	chr9:100666772-100684852:-	-0.16	-3.49	0.00052	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs7850685	chr9:100763890	C9orf156	chr9:100666772-100684852:-	-0.2	-3.71	0.000235	Coronary heart disease	
LGG	cis	1	rs78517863	chr6:151985574	C6orf97	chr6:151815175-151942327:+	0.42	6.06	2.66E-9	Breast cancer	
LGG	cis	1	rs7852169	chr9:114318394	PTGR1	chr9:114312003-114362135:-	-0.35	-4.95	1.02E-6	Menarche (age at onset)	
LGG	cis	1	rs7852169	chr9:114318394	ZNF483	chr9:114287447-114340124:+	0.23	3.58	0.000375	Menarche (age at onset)	
LGG	cis	1	rs7852872	chr9:119249339	PAPPA	chr9:118916071-119164599:+	0.17	3.61	0.000337	Hippocampal volume	
LGG	cis	1	rs78535412	chr2:48093156	FBXO11	chr2:48034061-48132814:-	0.23	4.13	4.19E-5	Schizophrenia	
LGG	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.99	8.6E-7	Body mass index	
LGG	cis	1	rs785464	chr1:46523089	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.02E-7	Body mass index	
LGG	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.84	1.78E-6	Body mass index	
LGG	cis	1	rs785471	chr1:46518677	MUTYH	chr1:45794915-45806142:-	0.14	5.04	6.68E-7	Body mass index	
LGG	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.63	4.67E-6	Body mass index	
LGG	cis	1	rs785479	chr1:46492144	MUTYH	chr1:45794915-45806142:-	0.13	4.93	1.12E-6	Body mass index	
LGG	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.83	1.82E-6	Body mass index	
LGG	cis	1	rs785481	chr1:46554518	MUTYH	chr1:45794915-45806142:-	0.14	5.08	5.5E-7	Body mass index	
LGG	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.84	1.77E-6	Body mass index	
LGG	cis	1	rs785485	chr1:46574424	MUTYH	chr1:45794915-45806142:-	0.14	4.88	1.45E-6	Body mass index	
LGG	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.92	1.21E-6	Body mass index	
LGG	cis	1	rs785488	chr1:46576095	MUTYH	chr1:45794915-45806142:-	0.14	5.01	7.44E-7	Body mass index	
LGG	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.92	1.21E-6	Body mass index	
LGG	cis	1	rs785489	chr1:46576390	MUTYH	chr1:45794915-45806142:-	0.14	5.01	7.44E-7	Body mass index	
LGG	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.95	1.01E-6	Body mass index	
LGG	cis	1	rs785491	chr1:46583418	MUTYH	chr1:45794915-45806142:-	0.14	4.93	1.14E-6	Body mass index	
LGG	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.71	3.28E-6	Body mass index	
LGG	cis	1	rs785492	chr1:46583607	MUTYH	chr1:45794915-45806142:-	0.14	4.98	8.78E-7	Body mass index	
LGG	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.86	1.59E-6	Body mass index	
LGG	cis	1	rs785494	chr1:46586626	MUTYH	chr1:45794915-45806142:-	0.14	4.94	1.09E-6	Body mass index	
LGG	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.15	-4.35	1.68E-5	Body mass index	
LGG	cis	1	rs785495	chr1:46587887	MUTYH	chr1:45794915-45806142:-	0.13	4.81	1.99E-6	Body mass index	
LGG	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.81	2.03E-6	Body mass index	
LGG	cis	1	rs785503	chr1:46595868	MUTYH	chr1:45794915-45806142:-	0.13	4.91	1.26E-6	Body mass index	
LGG	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.89	1.39E-6	Body mass index	
LGG	cis	1	rs785520	chr1:46568836	MUTYH	chr1:45794915-45806142:-	0.14	5.04	6.49E-7	Body mass index	
LGG	cis	1	rs7856392	chr9:101068967	TDRD7	chr9:100174302-100258403:+	0.18	3.55	0.000422	Schizophrenia	
LGG	cis	1	rs7857261	chr9:99219779	CDC14B	chr9:99262397-99382112:-	-0.26	-4.67	3.95E-6	Height	
LGG	cis	1	rs7857261	chr9:99219779	HABP4	chr9:99212414-99253617:+	-0.22	-4.89	1.39E-6	Height	
LGG	cis	1	rs7857261	chr9:99219779	SLC35D2	chr9:99075727-99145992:-	-0.15	-3.57	0.000391	Height	
LGG	cis	1	rs78604110	chr15:40681854	C15orf23	chr15:40674922-40686488:+	1.02	18.84	5.28E-60	Heschl's gyrus morphology	
LGG	cis	1	rs78604110	chr15:40681854	IVD	chr15:40697686-40713512:+	-0.39	-4.74	2.87E-6	Heschl's gyrus morphology	
LGG	cis	1	rs7861820	chr9:108936674	ZNF462	chr9:109625378-109773789:+	-0.11	-3.45	0.000601	Menarche and menopause (age at onset)	
LGG	cis	1	rs786425	chr12:124085502	ATP6V0A2	chr12:124196865-124246299:+	-0.23	-5.25	2.32E-7	Pubertal anthropometrics	
LGG	cis	1	rs786425	chr12:124085502	DDX55	chr12:124086672-124105483:+	0.31	8.11	3.95E-15	Pubertal anthropometrics	
LGG	cis	1	rs7864322	chr9:100548934	C9orf156	chr9:100666772-100684852:-	0.18	3.83	0.000143	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs78646493	chr2:86283195	LOC90784	chr2:86247339-86250991:-	-0.48	-5	8.1E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LGG	cis	1	rs7864754	chr9:139126120	QSOX2	chr9:139098182-139137687:-	0.26	5.04	6.61E-7	Height	
LGG	cis	1	rs78661157	chr2:48156721	FBXO11	chr2:48034061-48132814:-	0.24	4.22	2.87E-5	Schizophrenia	
LGG	cis	1	rs7867729	chr9:123723410	TRAF1	chr9:123664672-123691479:-	0.34	4.17	3.66E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs7867876	chr9:123723534	TRAF1	chr9:123664672-123691479:-	-0.36	-4.35	1.68E-5	Pre-treatment pain in head and neck squamous cell carcinoma	
LGG	cis	1	rs78679088	chr21:33910827	TCP10L	chr21:33947152-33957845:-	-0.37	-6.58	1.22E-10	Gastritis	
LGG	cis	1	rs7870753	chr9:99201585	CDC14B	chr9:99262397-99382112:-	-0.28	-5.15	3.79E-7	Height	
LGG	cis	1	rs7870753	chr9:99201585	HABP4	chr9:99212414-99253617:+	-0.23	-5.16	3.58E-7	Height	
LGG	cis	1	rs7870753	chr9:99201585	SLC35D2	chr9:99075727-99145992:-	-0.17	-3.86	0.00013	Height	
LGG	cis	1	rs78724141	chr8:82659661	CHMP4C	chr8:82644688-82671746:+	-0.48	-4.78	2.32E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7873102	chr9:38041142	SHB	chr9:37915896-38069210:-	0.15	3.58	0.000379	Brain structure	
LGG	cis	1	rs7873730	chr9:114303679	PTGR1	chr9:114312003-114362135:-	-0.37	-5.01	7.63E-7	Menarche (age at onset)	
LGG	cis	1	rs78740005	chr8:82659306	CHMP4C	chr8:82644688-82671746:+	-0.49	-4.81	1.97E-6	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs7877	chr1:171254890	FMO4	chr1:171283486-171311222:+	0.2	4.77	2.38E-6	Sudden cardiac arrest	
LGG	cis	1	rs78786946	chr11:76826756	CAPN5	chr11:76777992-76837196:+	0.33	3.72	0.00022	Cognitive performance	
LGG	cis	1	rs78797168	chr6:160459191	LOC729603	chr6:160514114-160517244:+	0.26	3.5	0.000504	Periodontitis (CDC/AAP)	
LGG	cis	1	rs78803505	chr7:65382572	CCT6P1	chr7:65216092-65228661:+	0.24	4.46	1.03E-5	Diabetic kidney disease	
LGG	cis	1	rs78836001	chr10:4981992	AKR1C2	chr10:4964715-5060207:-	0.37	4.96	9.59E-7	Height	
LGG	cis	1	rs78860779	chr20:49527371	SNAI1	chr20:48599527-48605418:+	-0.26	-3.47	0.000572	Prostate cancer	
LGG	cis	1	rs78867692	chr17:42263873	BRCA1	chr17:41196313-41322420:-	0.33	3.73	0.000213	Glycated hemoglobin levels	
LGG	cis	1	rs78867692	chr17:42263873	TMEM106A	chr17:41363894-41371589:+	0.3	4.66	4.05E-6	Glycated hemoglobin levels	
LGG	cis	1	rs78913826	chr3:101632638	CEP97	chr3:101443494-101486181:+	0.11	3.49	0.000527	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs78913826	chr3:101632638	LOC285359	chr3:101431278-101432259:+	-0.22	-4.92	1.17E-6	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs789208	chr10:105935096	C10orf79	chr10:105889647-105992120:-	0.18	5.01	7.7E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs7893456	chr10:5007862	AKR1C2	chr10:4964715-5060207:-	0.3	4.18	3.42E-5	Height	
LGG	cis	1	rs7894268	chr10:17199830	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.34	1.73E-5	Homocysteine levels	
LGG	cis	1	rs78953187	chr1:93000574	EVI5	chr1:92974255-93257961:-	-0.3	-7.39	6.35E-13	Cholesterol, total	
LGG	cis	1	rs78953746	chr8:58170608	C8orf71	chr8:58192102-58197288:+	0.36	6.21	1.11E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs78967641	chr20:33783053	PROCR	chr20:33758727-33765164:+	-0.37	-6.52	1.72E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs78974622	chr22:38059925	LGALS1	chr22:38071613-38075807:+	-0.19	-4.98	8.96E-7	Fat distribution (HIV)	
LGG	cis	1	rs7899096	chr10:113919125	ZDHHC6	chr10:114190060-114207306:-	0.25	4.88	1.47E-6	HDL cholesterol	
LGG	cis	1	rs7899351	chr10:116219491	CASP7	chr10:115438935-115490662:+	0.21	3.63	0.00031	Obesity-related traits	
LGG	cis	1	rs789970	chr10:105977721	C10orf79	chr10:105889647-105992120:-	0.19	5.27	2.07E-7	Attention deficit hyperactivity disorder	
LGG	cis	1	rs7900134	chr10:124744123	PSTK	chr10:124739556-124749906:+	0.16	3.68	0.000261	Migraine without aura	
LGG	cis	1	rs79021324	chr14:59941424	C14orf149	chr14:59939406-59951126:-	-0.42	-4.45	1.08E-5	Schizophrenia	
LGG	cis	1	rs79021324	chr14:59941424	JKAMP	chr14:59951161-59972080:+	0.51	4.86	1.59E-6	Schizophrenia	
LGG	cis	1	rs7902253	chr10:124739748	PSTK	chr10:124739556-124749906:+	0.15	3.46	0.000595	Migraine without aura	
LGG	cis	1	rs7903259	chr10:17259642	TRDMT1	chr10:17184983-17243681:-	-0.17	-3.59	0.000361	Cholesterol, total	
LGG	cis	1	rs7903402	chr10:17259772	TRDMT1	chr10:17184983-17243681:-	0.2	4.29	2.12E-5	Cholesterol, total	
LGG	cis	1	rs7903584	chr10:92667807	RPP30	chr10:92631474-92668312:+	0.19	3.68	0.000256	Economic and political preferences (time)	
LGG	cis	1	rs7904096	chr10:111755319	ADD3	chr10:111756108-111895320:+	0.17	3.99	7.55E-5	Biliary atresia	
LGG	cis	1	rs79044944	chr15:40676285	C15orf23	chr15:40674922-40686488:+	1.01	18.62	6.13E-59	Heschl's gyrus morphology	
LGG	cis	1	rs79044944	chr15:40676285	IVD	chr15:40697686-40713512:+	-0.38	-4.59	5.59E-6	Heschl's gyrus morphology	
LGG	cis	1	rs79048371	chr20:33731484	PROCR	chr20:33758727-33765164:+	-0.37	-6.58	1.2E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7905961	chr10:102297391	HIF1AN	chr10:102295641-102313680:+	0.19	3.6	0.000345	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7905961	chr10:102297391	NDUFB8	chr10:102283497-102289636:-	0.17	4.85	1.7E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7905961	chr10:102297391	WNT8B	chr10:102222812-102243397:+	0.48	7.84	2.9E-14	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs7908994	chr10:5008383	AKR1C2	chr10:4964715-5060207:-	0.28	3.87	0.000126	Height	
LGG	cis	1	rs79101914	chr12:56729739	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs7910668	chr10:15548925	ITGA8	chr10:15559088-15761770:-	-0.25	-3.81	0.000157	Parkinson's disease	
LGG	cis	1	rs7910927	chr10:65138910	NRBF2	chr10:64893007-64914785:+	-0.22	-5.16	3.52E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7910927	chr10:65138910	REEP3	chr10:65281123-65381971:+	0.13	3.68	0.000262	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7912093	chr10:17203934	TRDMT1	chr10:17184983-17243681:-	-0.23	-4.8	2.14E-6	Homocysteine levels	
LGG	cis	1	rs7912524	chr10:71098295	HK1	chr10:71029756-71161635:+	-0.11	-3.55	0.00042	Glycated hemoglobin levels	
LGG	cis	1	rs79139846	chr9:114309210	PTGR1	chr9:114312003-114362135:-	-0.43	-5.63	3.01E-8	Menarche (age at onset)	
LGG	cis	1	rs791583	chr6:160701935	SLC22A3	chr6:160769425-160876013:+	0.32	5.56	4.55E-8	Waist circumference	
LGG	cis	1	rs7916697	chr10:69991853	PBLD	chr10:70042417-70092684:-	-0.35	-7.25	1.68E-12	Optic disc area	
LGG	cis	1	rs7916697	chr10:69991853	SLC25A16	chr10:70242098-70287584:-	-0.15	-3.46	0.000589	Optic disc area	
LGG	cis	1	rs7917792	chr10:97365627	TCTN3	chr10:97423154-97453900:-	0.18	3.65	0.000287	Blood metabolite levels	
LGG	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.52	11.22	3.68E-26	Response to antipsychotic treatment	
LGG	cis	1	rs79197732	chr20:33562476	GDF5	chr20:33897002-34042568:-	0.28	3.49	0.000526	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs79197732	chr20:33562476	PROCR	chr20:33758727-33765164:+	-0.33	-5.94	5.28E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7920002	chr10:17259766	TRDMT1	chr10:17184983-17243681:-	0.2	4.29	2.12E-5	Cholesterol, total	
LGG	cis	1	rs7920112	chr10:17259863	TRDMT1	chr10:17184983-17243681:-	0.2	4.3	2.02E-5	Cholesterol, total	
LGG	cis	1	rs7921162	chr10:17229004	TRDMT1	chr10:17184983-17243681:-	-0.21	-4.28	2.29E-5	Homocysteine levels	
LGG	cis	1	rs7921185	chr10:4976430	AKR1C2	chr10:4964715-5060207:-	0.37	5.21	2.81E-7	Height	
LGG	cis	1	rs7923609	chr10:65133822	NRBF2	chr10:64893007-64914785:+	-0.22	-5.23	2.53E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7923609	chr10:65133822	REEP3	chr10:65281123-65381971:+	0.13	3.65	0.000289	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs7924963	chr11:120233536	TMEM136	chr11:120196016-120204388:+	0.2	4.63	4.76E-6	Intraocular pressure	
LGG	cis	1	rs79264785	chr6:26194121	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.31	1.99E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs79264785	chr6:26194121	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	4.07E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs7927771	chr11:47781306	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs7927771	chr11:47781306	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs7927771	chr11:47781306	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs792975	chr5:172271007	ERGIC1	chr5:172261223-172379683:+	0.23	4.38	1.45E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)	
LGG	cis	1	rs7929878	chr11:114628955	C11orf71	chr11:114262170-114271255:-	0.21	4.29	2.13E-5	Urinary albumin excretion	
LGG	cis	1	rs7930721	chr11:71737481	FAM86C	chr11:71498557-71512276:+	0.5	4.88	1.42E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs79311869	chr8:58195546	C8orf71	chr8:58192102-58197288:+	0.39	6.52	1.74E-10	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs79318564	chr15:84786150	GOLGA6L5	chr15:85047738-85060078:-	-0.24	-5.53	5.34E-8	Schizophrenia	
LGG	cis	1	rs79318564	chr15:84786150	LOC388152	chr15:84867600-84898920:-	-0.32	-6.39	3.86E-10	Schizophrenia	
LGG	cis	1	rs79318564	chr15:84786150	UBE2Q2P1	chr15:85070427-85114026:-	0.14	3.47	0.000564	Schizophrenia	
LGG	cis	1	rs7931941	chr11:71667604	FAM86C	chr11:71498557-71512276:+	0.39	4.23	2.82E-5	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7933086	chr11:120269308	TMEM136	chr11:120196016-120204388:+	-0.21	-4.76	2.59E-6	Intraocular pressure	
LGG	cis	1	rs7933295	chr11:5224738	TRIM78P	chr11:5664412-5687608:+	0.26	3.52	0.000474	HbA2 levels	
LGG	cis	1	rs79341738	chr20:33702104	PROCR	chr20:33758727-33765164:+	-0.36	-6.54	1.57E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs79366248	chr4:266659	ZNF718	chr4:53272-156488:+	0.26	5.14	3.92E-7	Immune response to smallpox vaccine (IL-6)	
LGG	cis	1	rs7937582	chr11:71744613	FAM86C	chr11:71498557-71512276:+	0.47	4.62	5.0E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7937612	chr11:120278688	TMEM136	chr11:120196016-120204388:+	0.2	4.49	8.7E-6	Intraocular pressure	
LGG	cis	1	rs7938380	chr11:64034866	C11orf20	chr11:64067863-64072238:+	-0.32	-4.86	1.59E-6	Mean platelet volume	
LGG	cis	1	rs79389870	chr2:48123895	FBXO11	chr2:48034061-48132814:-	0.22	3.98	8.09E-5	Schizophrenia	
LGG	cis	1	rs7939107	chr11:64034773	C11orf20	chr11:64067863-64072238:+	-0.32	-4.86	1.59E-6	Mean platelet volume	
LGG	cis	1	rs7939137	chr11:120343271	TMEM136	chr11:120196016-120204388:+	0.2	4.65	4.28E-6	Intraocular pressure	
LGG	cis	1	rs7940310	chr11:117024481	SIDT2	chr11:117049939-117068161:+	0.37	4.57	6.09E-6	Protein quantitative trait loci	
LGG	cis	1	rs79404901	chr5:115449332	COMMD10	chr5:115420727-115628978:+	0.46	5.64	2.94E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs7940866	chr11:130817579	SNX19	chr11:130745767-130786382:-	0.3	7.7	7.62E-14	Schizophrenia	
LGG	cis	1	rs79419293	chr2:190625076	ORMDL1	chr2:190634994-190649097:-	0.39	5.35	1.36E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs79436528	chr12:56686997	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs79438986	chr20:33702280	PROCR	chr20:33758727-33765164:+	-0.36	-6.39	3.89E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs79439610	chr20:33654689	PROCR	chr20:33758727-33765164:+	-0.32	-5.71	2.0E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs7944004	chr11:2311152	C11orf21	chr11:2317507-2323143:-	0.32	6.94	1.23E-11	Chronic lymphocytic leukemia	
LGG	cis	1	rs79442859	chr5:150171210	LOC134466	chr5:150310000-150326146:-	0.39	4.2	3.12E-5	Crohn's disease	
LGG	cis	1	rs79444544	chr2:190758532	ORMDL1	chr2:190634994-190649097:-	0.34	5.2	2.92E-7	Subcutaneous adipose tissue	
LGG	cis	1	rs7947143	chr11:64090422	C11orf20	chr11:64067863-64072238:+	-0.31	-4.63	4.72E-6	Mean platelet volume	
LGG	cis	1	rs7947378	chr11:18381327	GTF2H1	chr11:18343816-18388590:+	0.39	7.32	1.05E-12	Pancreatic cancer	
LGG	cis	1	rs7947378	chr11:18381327	LDHC	chr11:18433853-18472792:+	0.21	3.91	0.000107	Pancreatic cancer	
LGG	cis	1	rs79475579	chr11:58295900	ZFP91-CNTF	chr11:58346587-58393203:+	0.35	5.79	1.27E-8	Lymphoma	
LGG	cis	1	rs79477087	chr11:22116168	FANCF	chr11:22644079-22647387:-	0.21	3.47	0.000567	Parkinson's disease	
LGG	cis	1	rs7947730	chr11:47786184	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs7947730	chr11:47786184	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs7947730	chr11:47786184	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs7948821	chr11:71652485	FAM86C	chr11:71498557-71512276:+	0.52	5.12	4.39E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs79488685	chr4:171031611	AADAT	chr4:170981374-171011372:-	-0.28	-3.5	0.00051	Thyroid hormone levels	
LGG	cis	1	rs7948928	chr11:120273224	TMEM136	chr11:120196016-120204388:+	-0.21	-4.76	2.59E-6	Intraocular pressure	
LGG	cis	1	rs7949480	chr11:71697588	FAM86C	chr11:71498557-71512276:+	0.49	4.86	1.61E-6	Severe influenza A (H1N1) infection	
LGG	cis	1	rs7950364	chr11:116898886	SIDT2	chr11:117049939-117068161:+	0.3	3.54	0.000445	Protein quantitative trait loci	
LGG	cis	1	rs7951250	chr11:120309036	TMEM136	chr11:120196016-120204388:+	0.21	4.9	1.31E-6	Intraocular pressure	
LGG	cis	1	rs7951856	chr11:76822648	CAPN5	chr11:76777992-76837196:+	0.34	3.75	0.000201	Cognitive performance	
LGG	cis	1	rs7953249	chr12:121403724	HNF1A	chr12:121416549-121440312:+	0.3	5.98	4.4E-9	N-glycan levels;Chronic obstructive pulmonary disease-related biomarkers	
LGG	cis	1	rs7953615	chr12:89853694	GALNT4	chr12:89913192-89919777:-	-0.15	-4.31	1.98E-5	Schizophrenia	
LGG	cis	1	rs7953615	chr12:89853694	POC1B	chr12:89813501-89919777:-	-0.17	-3.55	0.000429	Schizophrenia	
LGG	cis	1	rs7954638	chr12:96314795	AMDHD1	chr12:96337071-96362369:+	0.33	6.31	6.14E-10	Metabolite levels (small molecules and protein measures)	
LGG	cis	1	rs79548696	chr3:41803385	ULK4	chr3:41288091-42003660:-	0.76	15.19	5.53E-43	Diastolic blood pressure	
LGG	cis	1	rs79561699	chr8:58170601	C8orf71	chr8:58192102-58197288:+	0.36	6.21	1.11E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs7957197	chr12:121460686	SPPL3	chr12:121201036-121342151:-	0.28	4.1	4.91E-5	Type 2 diabetes	
LGG	cis	1	rs79576418	chr19:30290890	CCNE1	chr19:30302901-30315218:+	-0.2	-4.29	2.11E-5	Bladder cancer	
LGG	cis	1	rs79579293	chr14:88822068	SPATA7	chr14:88852012-88904802:+	-0.43	-7.68	8.5E-14	Coronary artery calcification	
LGG	cis	1	rs79592437	chr2:48383328	FOXN2	chr2:48541795-48606434:+	0.28	5.61	3.44E-8	Schizophrenia	
LGG	cis	1	rs79603910	chr4:170999468	AADAT	chr4:170981374-171011372:-	-0.3	-3.7	0.000236	Thyroid hormone levels	
LGG	cis	1	rs7960884	chr12:31360640	DDX11	chr12:31226779-31257725:+	0.25	4.74	2.74E-6	Systolic blood pressure response to hydrochlorothiazide in hypertension	
LGG	cis	1	rs7961863	chr12:89893877	GALNT4	chr12:89913192-89919777:-	-0.18	-5.01	7.76E-7	Schizophrenia	
LGG	cis	1	rs7961863	chr12:89893877	POC1B	chr12:89813501-89919777:-	-0.19	-4.12	4.44E-5	Schizophrenia	
LGG	cis	1	rs79633844	chr2:203683990	WDR12	chr2:203745324-203776949:-	0.21	3.46	0.000596	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LGG	cis	1	rs79634040	chr11:71230169	KRTAP5-9	chr11:71259466-71260653:+	0.27	4.3	2.09E-5	Vitamin D levels	
LGG	cis	1	rs7963896	chr12:101734277	UTP20	chr12:101673905-101780397:+	-0.15	-3.61	0.000337	Alcohol dependence (age at onset)	
LGG	cis	1	rs79662097	chr2:48117374	FBXO11	chr2:48034061-48132814:-	0.22	4.05	6.02E-5	Schizophrenia	
LGG	cis	1	rs79677627	chr4:42479919	SHISA3	chr4:42399856-42404503:+	0.29	4.46	9.98E-6	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	cis	1	rs7968440	chr12:51134741	ATF1	chr12:51157819-51214906:+	-0.2	-4.39	1.4E-5	Fibrinogen	
LGG	cis	1	rs7968440	chr12:51134741	LETMD1	chr12:51442084-51454206:+	0.16	3.98	7.93E-5	Fibrinogen	
LGG	cis	1	rs7968440	chr12:51134741	SLC11A2	chr12:51373319-51422058:-	0.17	3.69	0.000245	Fibrinogen	
LGG	cis	1	rs7969761	chr12:355842	CCDC77	chr12:498516-551804:+	0.19	5	7.88E-7	Blood metabolite ratios	
LGG	cis	1	rs79716074	chr2:277003	FAM150B	chr2:279563-288308:-	-0.35	-6.63	9.04E-11	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs79716074	chr2:277003	SNTG2	chr2:946555-1371382:+	0.19	3.54	0.000435	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs79718165	chr12:56644251	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7973719	chr12:7334813	PEX5	chr12:7341759-7371167:+	0.33	7.22	1.95E-12	IgG glycosylation	
LGG	cis	1	rs79738251	chr2:17786558	GEN1	chr2:17935162-17966632:+	0.31	4.45	1.04E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs79750959	chr12:56702012	IL23A	chr12:56732663-56734193:+	0.53	4.78	2.32E-6	Psoriasis vulgaris	
LGG	cis	1	rs7975152	chr12:89893925	GALNT4	chr12:89913192-89919777:-	-0.18	-5.12	4.46E-7	Schizophrenia	
LGG	cis	1	rs7975152	chr12:89893925	POC1B	chr12:89813501-89919777:-	-0.19	-4.18	3.41E-5	Schizophrenia	
LGG	cis	1	rs79751662	chr4:171014655	AADAT	chr4:170981374-171011372:-	-0.35	-4.58	5.93E-6	Thyroid hormone levels	
LGG	cis	1	rs79770253	chr2:17784158	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs7977534	chr12:112717920	TMEM116	chr12:112369103-112450989:-	0.14	3.51	0.000484	Oral cavity and pharyngeal cancer	
LGG	cis	1	rs7977587	chr12:101734684	UTP20	chr12:101673905-101780397:+	-0.16	-3.52	0.000475	Alcohol dependence (age at onset)	
LGG	cis	1	rs7977690	chr12:51130414	ATF1	chr12:51157819-51214906:+	-0.21	-4.41	1.27E-5	Fibrinogen	
LGG	cis	1	rs7977690	chr12:51130414	LETMD1	chr12:51442084-51454206:+	0.16	3.88	0.000119	Fibrinogen	
LGG	cis	1	rs7977690	chr12:51130414	SLC11A2	chr12:51373319-51422058:-	0.17	3.66	0.000279	Fibrinogen	
LGG	cis	1	rs79780973	chr5:150174810	LOC134466	chr5:150310000-150326146:-	0.4	4.28	2.28E-5	Crohn's disease	
LGG	cis	1	rs7978454	chr12:124316876	DDX55	chr12:124086672-124105483:+	-0.17	-4.23	2.74E-5	IgG glycosylation	
LGG	cis	1	rs79792083	chr12:48949185	ZNF641	chr12:48735912-48745021:-	0.26	3.87	0.000124	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs7980501	chr12:3912972	PARP11	chr12:3918027-3982608:-	-0.26	-5.59	3.8E-8	Cognitive performance	
LGG	cis	1	rs7980799	chr12:33576990	SYT10	chr12:33528348-33592754:-	-0.15	-3.79	0.000169	Heart rate	
LGG	cis	1	rs79824801	chr12:56728137	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs79828515	chr2:48120866	FBXO11	chr2:48034061-48132814:-	0.23	4.1	4.84E-5	Schizophrenia	
LGG	cis	1	rs79831012	chr10:102237059	HIF1AN	chr10:102295641-102313680:+	0.18	3.57	0.00039	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs79831012	chr10:102237059	NDUFB8	chr10:102283497-102289636:-	0.15	4.31	1.96E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs79831012	chr10:102237059	WNT8B	chr10:102222812-102243397:+	0.51	8.73	3.9E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs79846980	chr19:22141343	ZNF257	chr19:22235266-22273901:+	0.57	8.97	6.38E-18	Body mass index (change over time)	
LGG	cis	1	rs798536	chr7:2766383	AMZ1	chr7:2719163-2755069:+	-0.16	-4.31	1.95E-5	Height	
LGG	cis	1	rs798540	chr7:2764130	AMZ1	chr7:2719163-2755069:+	-0.16	-4.36	1.57E-5	Height	
LGG	cis	1	rs798544	chr7:2763102	AMZ1	chr7:2719163-2755069:+	0.16	4.44	1.11E-5	Height	
LGG	cis	1	rs798545	chr7:2762386	AMZ1	chr7:2719163-2755069:+	-0.16	-4.4	1.3E-5	Height	
LGG	cis	1	rs798548	chr7:2760935	AMZ1	chr7:2719163-2755069:+	-0.16	-4.37	1.54E-5	Height	
LGG	cis	1	rs798550	chr7:2760609	AMZ1	chr7:2719163-2755069:+	-0.16	-4.37	1.5E-5	Height	
LGG	cis	1	rs798554	chr7:2759795	AMZ1	chr7:2719163-2755069:+	-0.16	-4.2	3.16E-5	Height	
LGG	cis	1	rs798559	chr7:2758341	AMZ1	chr7:2719163-2755069:+	-0.15	-4.09	4.94E-5	Height	
LGG	cis	1	rs798560	chr7:2758309	AMZ1	chr7:2719163-2755069:+	-0.16	-4.26	2.43E-5	Height	
LGG	cis	1	rs79868973	chr6:26189312	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.24	2.71E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs79868973	chr6:26189312	HIST1H3E	chr6:26224427-26226589:+	0.64	10.62	7.58E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs798719	chr4:1698183	TMEM129	chr4:1717680-1723084:-	-0.18	-4.01	7.14E-5	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798724	chr4:1704643	TMEM129	chr4:1717680-1723084:-	-0.18	-3.87	0.000123	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798741	chr4:1712413	TMEM129	chr4:1717680-1723084:-	-0.17	-3.65	0.000296	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798744	chr4:1714684	TMEM129	chr4:1717680-1723084:-	-0.19	-4.08	5.34E-5	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798754	chr4:1720757	TMEM129	chr4:1717680-1723084:-	-0.18	-3.86	0.000128	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798755	chr4:1720824	TMEM129	chr4:1717680-1723084:-	-0.18	-3.95	9.14E-5	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798756	chr4:1707447	TMEM129	chr4:1717680-1723084:-	-0.17	-3.77	0.000185	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798762	chr4:1731150	TMEM129	chr4:1717680-1723084:-	-0.18	-3.8	0.000162	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798766	chr4:1734239	TMEM129	chr4:1717680-1723084:-	0.17	3.66	0.00028	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs798767	chr4:1734281	TMEM129	chr4:1717680-1723084:-	-0.17	-3.71	0.000234	Urinary bladder cancer;Bladder cancer	
LGG	cis	1	rs79889615	chr5:115591292	COMMD10	chr5:115420727-115628978:+	0.46	5.71	2.0E-8	Asthma or chronic obstructive pulmonary disease	
LGG	cis	1	rs79890728	chr12:48952720	ZNF641	chr12:48735912-48745021:-	0.23	3.58	0.000381	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs7992643	chr13:100555038	CLYBL	chr13:100258936-100544823:+	-0.19	-4.19	3.36E-5	Attention deficit hyperactivity disorder	
LGG	cis	1	rs7992980	chr13:33181142	N4BP2L2	chr13:33006930-33112936:-	0.26	5.82	1.06E-8	Body mass index	
LGG	cis	1	rs7993214	chr13:40350912	COG6	chr13:40229764-40365802:+	0.28	6.02	3.44E-9	Rheumatoid arthritis	
LGG	cis	1	rs7998585	chr13:24435195	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs7999125	chr13:33145995	N4BP2L2	chr13:33006930-33112936:-	0.28	6.34	5.14E-10	Body mass index	
LGG	cis	1	rs79999461	chr7:117976981	ANKRD7	chr7:117864712-117882782:+	0.22	3.84	0.000137	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs8000149	chr13:50090025	RCBTB1	chr13:50106082-50159719:-	-0.16	-3.79	0.00017	Cardiac hypertrophy	
LGG	cis	1	rs8000149	chr13:50090025	SETDB2	chr13:50018429-50069138:+	-0.22	-4.85	1.66E-6	Cardiac hypertrophy	
LGG	cis	1	rs8002731	chr13:40362229	COG6	chr13:40229764-40365802:+	-0.28	-5.86	8.48E-9	Rheumatoid arthritis	
LGG	cis	1	rs8002861	chr13:44474517	C13orf31	chr13:44453420-44468067:+	-0.11	-3.99	7.57E-5	Leprosy	
LGG	cis	1	rs8002861	chr13:44474517	CCDC122	chr13:44410491-44453826:-	-0.21	-5.52	5.39E-8	Leprosy	
LGG	cis	1	rs8003506	chr14:75586288	EIF2B2	chr14:75469612-75476292:+	-0.25	-4.82	1.94E-6	Height	
LGG	cis	1	rs8003506	chr14:75586288	MLH3	chr14:75480467-75518235:-	-0.23	-3.89	0.000113	Height	
LGG	cis	1	rs8004018	chr14:55350696	GCH1	chr14:55308724-55369542:-	-0.29	-4.84	1.73E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs8005309	chr14:66056508	LOC645431	chr14:65877313-65879335:-	-0.48	-6.42	3.19E-10	Ischemic stroke	
LGG	cis	1	rs8005686	chr14:76633967	ESRRB	chr14:76837690-76968178:+	0.45	7.46	3.86E-13	Blood pressure	
LGG	cis	1	rs800586	chr8:116813905	TRPS1	chr8:116420725-116681228:-	-0.16	-3.95	9.14E-5	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs800588	chr8:116813143	TRPS1	chr8:116420725-116681228:-	0.16	3.79	0.000168	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs8006048	chr14:76683508	ESRRB	chr14:76837690-76968178:+	0.43	6.74	4.48E-11	Blood pressure	
LGG	cis	1	rs8006419	chr14:65500735	RAB15	chr14:65412532-65438875:-	-0.12	-3.76	0.00019	Red blood cell traits	
LGG	cis	1	rs80068722	chr14:65856111	LOC645431	chr14:65877313-65879335:-	-0.43	-5.98	4.35E-9	Ischemic stroke	
LGG	cis	1	rs80075680	chr5:150223737	LOC134466	chr5:150310000-150326146:-	0.4	4.59	5.51E-6	Crohn's disease	
LGG	cis	1	rs80076579	chr4:106991115	NPNT	chr4:106816605-106892827:+	-0.22	-4.78	2.34E-6	Airflow obstruction	
LGG	cis	1	rs80085676	chr2:242347907	SEPT2	chr2:242254723-242293439:+	0.54	7.86	2.53E-14	Chronic lymphocytic leukemia	
LGG	cis	1	rs80095925	chr6:26184942	HIST1H2AE	chr6:26217148-26217711:+	-0.33	-4.44	1.1E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs80095925	chr6:26184942	HIST1H3E	chr6:26224427-26226589:+	0.54	8.16	2.78E-15	Renal underexcretion gout;Gout	
LGG	cis	1	rs8010461	chr14:55351185	GCH1	chr14:55308724-55369542:-	-0.28	-4.52	7.69E-6	Rheumatoid arthritis;Obesity-related traits	
LGG	cis	1	rs8010545	chr14:81778787	STON2	chr14:81727000-81893748:-	-0.14	-3.55	0.000429	Obesity-related traits	
LGG	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.44	-10.18	3.18E-22	IgG glycosylation	
LGG	cis	1	rs80109502	chr20:33587596	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.9E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8011834	chr14:55625977	FBXO34	chr14:55738021-55893431:+	0.13	4.04	6.15E-5	Protein biomarker	
LGG	cis	1	rs80136244	chr2:48043974	FBXO11	chr2:48034061-48132814:-	0.23	4.19	3.37E-5	Schizophrenia	
LGG	cis	1	rs8014170	chr14:50071694	RPL36AL	chr14:50085407-50087349:-	0.33	8.7	4.99E-17	Carotid intima media thickness	
LGG	cis	1	rs80161161	chr2:17812016	GEN1	chr2:17935162-17966632:+	0.39	5.37	1.2E-7	Psychosis and Alzheimer's disease	
LGG	cis	1	rs8016982	chr14:81707057	STON2	chr14:81727000-81893748:-	-0.19	-5.61	3.3E-8	Schizophrenia	
LGG	cis	1	rs80170004	chr20:33551462	PROCR	chr20:33758727-33765164:+	-0.33	-5.82	1.04E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8017202	chr14:65854958	LOC645431	chr14:65877313-65879335:-	-0.43	-6.02	3.4E-9	Ischemic stroke	
LGG	cis	1	rs8017642	chr14:75590822	ACYP1	chr14:75519930-75530736:-	-0.14	-3.72	0.000223	Height	
LGG	cis	1	rs8017642	chr14:75590822	EIF2B2	chr14:75469612-75476292:+	0.18	3.58	0.000376	Height	
LGG	cis	1	rs8017980	chr14:102961341	ANKRD9	chr14:102973198-102976128:-	0.19	4.45	1.07E-5	QT interval	
LGG	cis	1	rs8018909	chr14:65960405	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.31E-12	Ischemic stroke	
LGG	cis	1	rs8019491	chr14:66168110	LOC645431	chr14:65877313-65879335:-	-0.45	-5.97	4.45E-9	Ischemic stroke	
LGG	cis	1	rs8020368	chr14:95943548	C14orf129	chr14:96829863-96853561:+	0.15	3.67	0.000271	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs8021692	chr14:104428576	TDRD9	chr14:104394817-104519002:+	0.24	4.62	4.96E-6	Bipolar disorder	
LGG	cis	1	rs8023482	chr15:40307095	EIF2AK4	chr15:40226347-40327797:+	0.31	4.06	5.79E-5	Response to haloperidol in psychosis	
LGG	cis	1	rs8023644	chr15:50937123	SPPL2A	chr15:50999739-51057910:-	0.12	3.99	7.7E-5	QT interval	
LGG	cis	1	rs8023776	chr15:90897952	AP3S2	chr15:90373832-90456222:-	-0.21	-3.57	0.00039	Rheumatoid arthritis	
LGG	cis	1	rs8023776	chr15:90897952	IQGAP1	chr15:90931473-91045475:+	-0.13	-4.2	3.14E-5	Rheumatoid arthritis	
LGG	cis	1	rs8024039	chr15:24826345	PWRN1	chr15:24778839-24832924:+	0.25	4.27	2.34E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs80259160	chr6:26190199	HIST1H2AE	chr6:26217148-26217711:+	-0.3	-4.24	2.66E-5	Renal underexcretion gout;Gout	
LGG	cis	1	rs80259160	chr6:26190199	HIST1H3E	chr6:26224427-26226589:+	0.64	10.69	3.94E-24	Renal underexcretion gout;Gout	
LGG	cis	1	rs80260495	chr2:17803101	GEN1	chr2:17935162-17966632:+	0.31	4.44	1.12E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs8026166	chr15:100299414	ADAMTS17	chr15:100511643-100882183:-	0.28	3.6	0.000356	Major depressive disorder	
LGG	cis	1	rs8026166	chr15:100299414	C15orf51	chr15:100330361-100347132:-	-0.33	-4.63	4.58E-6	Major depressive disorder	
LGG	cis	1	rs8026523	chr15:40654066	C15orf23	chr15:40674922-40686488:+	0.99	16.76	3.29E-50	Heschl's gyrus morphology	
LGG	cis	1	rs8026523	chr15:40654066	IVD	chr15:40697686-40713512:+	-0.34	-3.86	0.000128	Heschl's gyrus morphology	
LGG	cis	1	rs8026533	chr15:90893228	IQGAP1	chr15:90931473-91045475:+	0.12	3.87	0.000125	Rheumatoid arthritis	
LGG	cis	1	rs8027487	chr15:40654067	C15orf23	chr15:40674922-40686488:+	0.99	16.76	3.29E-50	Heschl's gyrus morphology	
LGG	cis	1	rs8027487	chr15:40654067	IVD	chr15:40697686-40713512:+	-0.34	-3.86	0.000128	Heschl's gyrus morphology	
LGG	cis	1	rs80276621	chr15:82231043	FAM154B	chr15:82555152-82577265:+	0.35	3.87	0.000126	Colorectal cancer (aspirin and/or NSAID use interaction)	
LGG	cis	1	rs80277764	chr20:33739456	PROCR	chr20:33758727-33765164:+	-0.37	-6.46	2.5E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8028182	chr15:75718669	MAN2C1	chr15:75648135-75660941:-	0.16	4.08	5.22E-5	Sudden cardiac arrest	
LGG	cis	1	rs80313145	chr6:26194965	HIST1H2AE	chr6:26217148-26217711:+	-0.28	-3.84	0.000139	Renal underexcretion gout;Gout	
LGG	cis	1	rs80313145	chr6:26194965	HIST1H3E	chr6:26224427-26226589:+	0.66	10.44	3.51E-23	Renal underexcretion gout;Gout	
LGG	cis	1	rs8031576	chr15:90380214	AP3S2	chr15:90373832-90456222:-	-0.48	-9.19	1.08E-18	Type 2 diabetes	
LGG	cis	1	rs80317430	chr12:56727705	IL23A	chr12:56732663-56734193:+	0.56	5.06	5.87E-7	Psoriasis vulgaris	
LGG	cis	1	rs8031915	chr15:91519291	RCCD1	chr15:91498106-91506353:+	0.18	3.69	0.000254	Type 2 diabetes	
LGG	cis	1	rs8031948	chr15:78816057	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.28	1.37E-34	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs8032104	chr15:63400584	LACTB	chr15:63414032-63434254:+	0.2	4.05	6.02E-5	HDL cholesterol	
LGG	cis	1	rs8032675	chr15:67959464	IQCH	chr15:67547188-67794139:+	0.13	3.61	0.000342	Motion sickness	
LGG	cis	1	rs8033837	chr15:75353975	PPCDC	chr15:75315927-75343066:+	0.25	5.26	2.13E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs8033938	chr15:40703114	C15orf23	chr15:40674922-40686488:+	1.01	18.4	6.93E-58	Heschl's gyrus morphology	
LGG	cis	1	rs8033938	chr15:40703114	IVD	chr15:40697686-40713512:+	-0.38	-4.6	5.4E-6	Heschl's gyrus morphology	
LGG	cis	1	rs8034191	chr15:78806023	CHRNA5	chr15:78857906-78886458:+	-0.67	-12.91	4.8E-33	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs8035675	chr15:67965581	IQCH	chr15:67547188-67794139:+	0.13	3.73	0.000217	Motion sickness	
LGG	cis	1	rs8036075	chr15:45934921	SPATA5L1	chr15:45694519-45713614:+	0.28	4.24	2.65E-5	Obesity-related traits	
LGG	cis	1	rs8036197	chr15:75370232	PPCDC	chr15:75315927-75343066:+	0.24	5.24	2.36E-7	Blood trace element (Zn levels)	
LGG	cis	1	rs8036588	chr15:50956834	SPPL2A	chr15:50999739-51057910:-	0.13	4.18	3.39E-5	QT interval	
LGG	cis	1	rs803688	chr15:83216793	FAM154B	chr15:82555152-82577265:+	-0.2	-4.15	3.99E-5	Schizophrenia	
LGG	cis	1	rs803688	chr15:83216793	GOLGA6L9	chr15:82711895-82731584:+;chr15	-0.18	-4.41	1.26E-5	Schizophrenia	
LGG	cis	1	rs8037254	chr15:91520099	RCCD1	chr15:91498106-91506353:+	0.17	3.59	0.000362	Type 2 diabetes	
LGG	cis	1	rs8040855	chr15:85699207	LOC388152	chr15:84867600-84898920:-	0.17	3.54	0.000438	Bulimia nervosa	
LGG	cis	1	rs8041847	chr15:78529575	WDR61	chr15:78575580-78591940:-	-0.2	-3.87	0.000124	Personality dimensions	
LGG	cis	1	rs8042680	chr15:91521337	RCCD1	chr15:91498106-91506353:+	-0.19	-3.96	8.59E-5	Type 2 diabetes	
LGG	cis	1	rs804280	chr8:11612698	FAM66A	chr8:12219528-12279968:+	0.24	4.73	2.98E-6	Myopia (pathological)	
LGG	cis	1	rs804280	chr8:11612698	NEIL2	chr8:11627172-11644854:+	0.2	4.26	2.45E-5	Myopia (pathological)	
LGG	cis	1	rs804281	chr8:11611865	FAM66A	chr8:12219528-12279968:+	0.26	4.93	1.14E-6	Myopia (pathological)	
LGG	cis	1	rs804281	chr8:11611865	NEIL2	chr8:11627172-11644854:+	0.2	4.18	3.47E-5	Myopia (pathological)	
LGG	cis	1	rs8042825	chr15:90897885	IQGAP1	chr15:90931473-91045475:+	-0.13	-4.02	6.77E-5	Rheumatoid arthritis	
LGG	cis	1	rs8042849	chr15:78817929	CHRNA5	chr15:78857906-78886458:+	0.65	12.73	2.88E-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs804292	chr8:11643915	NEIL2	chr8:11627172-11644854:+	0.23	4.13	4.18E-5	Alcohol dependence;Nicotine use	
LGG	cis	1	rs8046148	chr16:50142944	HEATR3	chr16:50099881-50139373:+	0.32	6.51	1.91E-10	Testicular germ cell tumor	
LGG	cis	1	rs8046697	chr16:75442144	CFDP1	chr16:75327609-75467387:-	-0.2	-4.97	9.27E-7	Migraine	
LGG	cis	1	rs8049439	chr16:28837515	EIF3C	chr16:28722782-28747052:+;chr16	0.21	3.97	8.39E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs8049439	chr16:28837515	EIF3CL	chr16:28699879-28747052:+;chr16	0.34	6.64	8.31E-11	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs8049439	chr16:28837515	SULT1A1	chr16:28616918-28634866:-	-0.16	-4.08	5.19E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs8049439	chr16:28837515	SULT1A2	chr16:28603266-28608391:-	0.15	3.49	0.000526	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs8049439	chr16:28837515	TUFM	chr16:28853732-28857729:-	0.15	4.21	3.02E-5	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LGG	cis	1	rs8049622	chr16:67800927	LRRC36	chr16:67360747-67419108:+	0.47	4.61	5.03E-6	Crohn's disease	
LGG	cis	1	rs8049622	chr16:67800927	RANBP10	chr16:67757006-67840555:-	-0.33	-4.12	4.5E-5	Crohn's disease	
LGG	cis	1	rs8051653	chr16:67848515	LRRC36	chr16:67360747-67419108:+	0.49	4.52	7.87E-6	Crohn's disease	
LGG	cis	1	rs8051653	chr16:67848515	RANBP10	chr16:67757006-67840555:-	-0.31	-3.6	0.000355	Crohn's disease	
LGG	cis	1	rs8052287	chr16:67865073	LRRC36	chr16:67360747-67419108:+	0.43	3.99	7.51E-5	Crohn's disease	
LGG	cis	1	rs8054034	chr16:67773652	LRRC36	chr16:67360747-67419108:+	0.48	4.47	9.81E-6	Crohn's disease	
LGG	cis	1	rs8054034	chr16:67773652	RANBP10	chr16:67757006-67840555:-	-0.33	-3.92	9.97E-5	Crohn's disease	
LGG	cis	1	rs8054842	chr16:672799	NARFL	chr16:779771-790997:-	0.13	3.66	0.000275	Height	
LGG	cis	1	rs8054842	chr16:672799	PIGQ	chr16:617032-634108:+	-0.26	-7.35	8.19E-13	Height	
LGG	cis	1	rs8054842	chr16:672799	WFIKKN1	chr16:679239-684116:+	0.45	9.71	1.64E-20	Height	
LGG	cis	1	rs8056208	chr16:50097104	HEATR3	chr16:50099881-50139373:+	-0.3	-4.12	4.51E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs8056893	chr16:68304392	NFATC3	chr16:68118654-68260837:+	0.18	4.11	4.7E-5	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine)	
LGG	cis	1	rs8056893	chr16:68304392	SLC7A6	chr16:68298423-68335722:+	0.23	4.52	7.8E-6	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine)	
LGG	cis	1	rs8058835	chr16:67814865	LRRC36	chr16:67360747-67419108:+	0.46	4.44	1.1E-5	Crohn's disease	
LGG	cis	1	rs8058835	chr16:67814865	RANBP10	chr16:67757006-67840555:-	-0.32	-3.95	9.01E-5	Crohn's disease	
LGG	cis	1	rs8060686	chr16:67911517	LRRC36	chr16:67360747-67419108:+	0.23	3.54	0.000434	HDL cholesterol;Metabolic syndrome	
LGG	cis	1	rs8060686	chr16:67911517	TSNAXIP1	chr16:67840977-67861970:+	0.16	3.85	0.000131	HDL cholesterol;Metabolic syndrome	
LGG	cis	1	rs8061384	chr16:67911874	LRRC36	chr16:67360747-67419108:+	0.48	4.52	7.75E-6	Crohn's disease	
LGG	cis	1	rs8061384	chr16:67911874	RANBP10	chr16:67757006-67840555:-	-0.32	-3.8	0.000164	Crohn's disease	
LGG	cis	1	rs806196	chr7:127248414	GCC1	chr7:127220683-127225654:-	0.31	5.2	2.98E-7	Type 2 diabetes	
LGG	cis	1	rs806214	chr7:127237003	GCC1	chr7:127220683-127225654:-	-0.36	-5.9	6.8E-9	Type 2 diabetes	
LGG	cis	1	rs806215	chr7:127237312	GCC1	chr7:127220683-127225654:-	-0.32	-5.34	1.45E-7	Type 2 diabetes	
LGG	cis	1	rs806216	chr7:127237862	GCC1	chr7:127220683-127225654:-	-0.34	-5.55	4.67E-8	Type 2 diabetes	
LGG	cis	1	rs806219	chr7:127240094	GCC1	chr7:127220683-127225654:-	0.31	5.12	4.35E-7	Type 2 diabetes	
LGG	cis	1	rs8063761	chr16:90027626	CDK10	chr16:89753076-89762771:+	0.11	3.58	0.000378	Squamous cell carcinoma	
LGG	cis	1	rs8063761	chr16:90027626	DEF8	chr16:90015151-90034467:+	0.18	3.99	7.48E-5	Squamous cell carcinoma	
LGG	cis	1	rs8064089	chr16:50094482	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs8064107	chr16:50094323	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs8064261	chr17:61705212	DDX42	chr17:61851567-61896676:+	-0.16	-3.65	0.000289	Body mass index	
LGG	cis	1	rs8064261	chr17:61705212	FTSJ3	chr17:61896795-61905031:-	0.41	8.5	2.25E-16	Body mass index	
LGG	cis	1	rs8064261	chr17:61705212	SMARCD2	chr17:61909441-61920351:-	0.19	4.24	2.67E-5	Body mass index	
LGG	cis	1	rs8064435	chr17:20917782	USP22	chr17:20902908-20947073:-	-0.2	-4.58	5.8E-6	Blood trace element (Se levels)	
LGG	cis	1	rs8065059	chr17:28417376	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.92	5.99E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs8065261	chr17:28418041	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.92	6.02E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs8065437	chr17:45721653	C17orf57	chr17:45401142-45518675:+	0.14	3.56	0.000411	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs8065437	chr17:45721653	LOC100272146	chr17:45500843-45504056:+	0.14	3.64	0.000299	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs8065669	chr17:45724996	C17orf57	chr17:45401142-45518675:+	0.16	3.96	8.77E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs8066156	chr17:30361629	LRRC37B	chr17:30335037-30380517:+	0.24	5.24	2.36E-7	Height	
LGG	cis	1	rs8066385	chr17:18761133	FAM18B	chr17:18684582-18710026:+	-0.17	-4.53	7.38E-6	Educational attainment (years of education)	
LGG	cis	1	rs8066385	chr17:18761133	FBXW10	chr17:18647326-18682661:+	-0.2	-4.44	1.13E-5	Educational attainment (years of education)	
LGG	cis	1	rs8066558	chr17:30272879	LRRC37B	chr17:30335037-30380517:+	0.24	5.35	1.35E-7	Height	
LGG	cis	1	rs8066719	chr17:61825764	DDX42	chr17:61851567-61896676:+	-0.16	-3.75	0.000194	Body mass index	
LGG	cis	1	rs8066719	chr17:61825764	FTSJ3	chr17:61896795-61905031:-	0.41	8.28	1.17E-15	Body mass index	
LGG	cis	1	rs8066719	chr17:61825764	SMARCD2	chr17:61909441-61920351:-	0.18	4.11	4.66E-5	Body mass index	
LGG	cis	1	rs8067064	chr17:61825984	DDX42	chr17:61851567-61896676:+	-0.16	-3.72	0.00022	Body mass index	
LGG	cis	1	rs8067064	chr17:61825984	FTSJ3	chr17:61896795-61905031:-	0.41	8.38	5.5E-16	Body mass index	
LGG	cis	1	rs8067064	chr17:61825984	SMARCD2	chr17:61909441-61920351:-	0.18	4.1	4.78E-5	Body mass index	
LGG	cis	1	rs8067431	chr17:61817048	DDX42	chr17:61851567-61896676:+	-0.17	-3.79	0.000171	Body mass index	
LGG	cis	1	rs8067431	chr17:61817048	FTSJ3	chr17:61896795-61905031:-	0.42	8.43	3.74E-16	Body mass index	
LGG	cis	1	rs8067431	chr17:61817048	SMARCD2	chr17:61909441-61920351:-	0.17	3.8	0.00016	Body mass index	
LGG	cis	1	rs8067892	chr17:65837983	LOC440461	chr17:66194801-66196436:+	0.26	4.28	2.21E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8067953	chr17:46429617	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs8068128	chr17:46405291	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs8068603	chr17:61755211	FTSJ3	chr17:61896795-61905031:-	0.44	9.06	3.13E-18	Body mass index	
LGG	cis	1	rs8068603	chr17:61755211	SMARCD2	chr17:61909441-61920351:-	0.2	4.5	8.49E-6	Body mass index	
LGG	cis	1	rs8069531	chr17:38009344	GSDMB	chr17:38060850-38074903:-	-0.22	-3.52	0.000472	Systemic lupus erythematosus	
LGG	cis	1	rs8069687	chr17:61883023	DDX42	chr17:61851567-61896676:+	0.16	3.62	0.000329	Body mass index	
LGG	cis	1	rs8069687	chr17:61883023	FTSJ3	chr17:61896795-61905031:-	-0.4	-8.31	9.54E-16	Body mass index	
LGG	cis	1	rs8069687	chr17:61883023	SMARCD2	chr17:61909441-61920351:-	-0.19	-4.35	1.63E-5	Body mass index	
LGG	cis	1	rs8070446	chr17:40285879	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs8070446	chr17:40285879	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs8070454	chr17:38160754	GSDMA	chr17:38119226-38134019:+	-0.72	-15.66	3.99E-45	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs8070650	chr17:61744040	DDX42	chr17:61851567-61896676:+	-0.16	-3.74	0.000205	Body mass index	
LGG	cis	1	rs8070650	chr17:61744040	FTSJ3	chr17:61896795-61905031:-	0.41	8.34	7.3E-16	Body mass index	
LGG	cis	1	rs8070650	chr17:61744040	SMARCD2	chr17:61909441-61920351:-	0.18	3.97	8.41E-5	Body mass index	
LGG	cis	1	rs8071463	chr17:65938655	LOC440461	chr17:66194801-66196436:+	-0.29	-4.69	3.52E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8071789	chr17:38006333	GSDMA	chr17:38119226-38134019:+	0.41	7.58	1.74E-13	Selective IgA deficiency	
LGG	cis	1	rs8071789	chr17:38006333	GSDMB	chr17:38060850-38074903:-	-0.13	-4.35	1.67E-5	Selective IgA deficiency	
LGG	cis	1	rs8071789	chr17:38006333	PGAP3	chr17:37827376-37844310:-	-0.18	-3.81	0.000156	Selective IgA deficiency	
LGG	cis	1	rs8072100	chr17:45674687	C17orf57	chr17:45401142-45518675:+	-0.16	-3.91	0.000106	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs8072100	chr17:45674687	LOC100272146	chr17:45500843-45504056:+	-0.14	-3.53	0.000463	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LGG	cis	1	rs8072215	chr17:40271970	DHX58	chr17:40253422-40264751:-	-0.21	-4.24	2.65E-5	Fibrinogen levels	
LGG	cis	1	rs8072225	chr17:65912960	LOC440461	chr17:66194801-66196436:+	0.29	4.85	1.69E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8073373	chr17:61703320	DDX42	chr17:61851567-61896676:+	-0.16	-3.55	0.00042	Body mass index	
LGG	cis	1	rs8073373	chr17:61703320	FTSJ3	chr17:61896795-61905031:-	0.43	8.89	1.15E-17	Body mass index	
LGG	cis	1	rs8073373	chr17:61703320	SMARCD2	chr17:61909441-61920351:-	0.2	4.42	1.2E-5	Body mass index	
LGG	cis	1	rs8074078	chr17:65838743	LOC440461	chr17:66194801-66196436:+	0.26	4.32	1.86E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8074443	chr17:46417813	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs8074708	chr17:40286354	DHX58	chr17:40253422-40264751:-	0.2	4.09	5.1E-5	Fibrinogen levels	
LGG	cis	1	rs8074708	chr17:40286354	HSPB9	chr17:40274756-40275371:+	0.17	3.7	0.000243	Fibrinogen levels	
LGG	cis	1	rs8074771	chr17:61735865	DDX42	chr17:61851567-61896676:+	-0.16	-3.74	0.000205	Body mass index	
LGG	cis	1	rs8074771	chr17:61735865	FTSJ3	chr17:61896795-61905031:-	0.41	8.34	7.3E-16	Body mass index	
LGG	cis	1	rs8074771	chr17:61735865	SMARCD2	chr17:61909441-61920351:-	0.18	3.97	8.41E-5	Body mass index	
LGG	cis	1	rs8075061	chr17:61804723	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs8075061	chr17:61804723	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs8075061	chr17:61804723	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs8075257	chr17:61728750	DDX42	chr17:61851567-61896676:+	-0.16	-3.58	0.000382	Body mass index	
LGG	cis	1	rs8075257	chr17:61728750	FTSJ3	chr17:61896795-61905031:-	0.42	8.66	6.67E-17	Body mass index	
LGG	cis	1	rs8075257	chr17:61728750	SMARCD2	chr17:61909441-61920351:-	0.19	4.34	1.7E-5	Body mass index	
LGG	cis	1	rs8075422	chr17:61804686	FTSJ3	chr17:61896795-61905031:-	0.43	9.04	3.74E-18	Body mass index	
LGG	cis	1	rs8075422	chr17:61804686	SMARCD2	chr17:61909441-61920351:-	0.2	4.6	5.48E-6	Body mass index	
LGG	cis	1	rs8075521	chr17:61804954	DDX42	chr17:61851567-61896676:+	-0.16	-3.67	0.000272	Body mass index	
LGG	cis	1	rs8075521	chr17:61804954	FTSJ3	chr17:61896795-61905031:-	0.41	8.47	2.86E-16	Body mass index	
LGG	cis	1	rs8075521	chr17:61804954	SMARCD2	chr17:61909441-61920351:-	0.19	4.25	2.56E-5	Body mass index	
LGG	cis	1	rs807624	chr2:15782471	DDX1	chr2:15731770-15771224:+	0.19	4.87	1.49E-6	Wilms tumor	
LGG	cis	1	rs8076336	chr17:18212614	TOP3A	chr17:18177235-18218321:-	0.17	6.03	3.16E-9	Parental longevity (combined parental age at death)	
LGG	cis	1	rs807669	chr22:19154522	SLC25A1	chr22:19163095-19166301:-	-0.24	-6.01	3.65E-9	Metabolite levels	
LGG	cis	1	rs807670	chr22:19154608	SLC25A1	chr22:19163095-19166301:-	-0.2	-5.22	2.64E-7	Metabolite levels	
LGG	cis	1	rs8076717	chr17:61850301	DDX42	chr17:61851567-61896676:+	0.15	3.47	0.000561	Body mass index	
LGG	cis	1	rs8076717	chr17:61850301	FTSJ3	chr17:61896795-61905031:-	-0.43	-8.73	4.08E-17	Body mass index	
LGG	cis	1	rs8076717	chr17:61850301	SMARCD2	chr17:61909441-61920351:-	-0.18	-4.03	6.45E-5	Body mass index	
LGG	cis	1	rs8077265	chr17:61732727	FTSJ3	chr17:61896795-61905031:-	0.44	9.04	3.74E-18	Body mass index	
LGG	cis	1	rs8077265	chr17:61732727	SMARCD2	chr17:61909441-61920351:-	0.2	4.57	6.31E-6	Body mass index	
LGG	cis	1	rs8077889	chr17:41878166	VAT1	chr17:41166622-41174459:-	0.17	3.81	0.000155	Triglycerides	
LGG	cis	1	rs807810	chr3:47403892	NRADDP	chr3:47053032-47054957:+	0.22	3.84	0.00014	Colorectal cancer	
LGG	cis	1	rs8078462	chr17:61857937	DDX42	chr17:61851567-61896676:+	-0.16	-3.62	0.000331	Body mass index	
LGG	cis	1	rs8078462	chr17:61857937	FTSJ3	chr17:61896795-61905031:-	0.41	8.41	4.38E-16	Body mass index	
LGG	cis	1	rs8078462	chr17:61857937	SMARCD2	chr17:61909441-61920351:-	0.19	4.32	1.87E-5	Body mass index	
LGG	cis	1	rs8078550	chr17:53053379	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs8078550	chr17:53053379	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs8078723	chr17:38166879	GSDMA	chr17:38119226-38134019:+	-0.72	-15.87	4.21E-46	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LGG	cis	1	rs8078862	chr17:61854068	DDX42	chr17:61851567-61896676:+	-0.16	-3.63	0.000312	Body mass index	
LGG	cis	1	rs8078862	chr17:61854068	FTSJ3	chr17:61896795-61905031:-	0.41	8.46	3.05E-16	Body mass index	
LGG	cis	1	rs8078862	chr17:61854068	SMARCD2	chr17:61909441-61920351:-	0.19	4.28	2.2E-5	Body mass index	
LGG	cis	1	rs807931	chr3:47389317	NRADDP	chr3:47053032-47054957:+	-0.23	-3.98	8.03E-5	Colorectal cancer	
LGG	cis	1	rs807936	chr3:47322496	NRADDP	chr3:47053032-47054957:+	-0.23	-4.02	6.85E-5	Colorectal cancer	
LGG	cis	1	rs8079754	chr17:65887896	LOC440461	chr17:66194801-66196436:+	0.27	4.5	8.35E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8080211	chr17:61729882	DDX42	chr17:61851567-61896676:+	-0.17	-3.77	0.000187	Body mass index	
LGG	cis	1	rs8080211	chr17:61729882	FTSJ3	chr17:61896795-61905031:-	0.41	8.04	6.98E-15	Body mass index	
LGG	cis	1	rs8080211	chr17:61729882	SMARCD2	chr17:61909441-61920351:-	0.18	3.96	8.54E-5	Body mass index	
LGG	cis	1	rs8080491	chr17:53049869	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs8080491	chr17:53049869	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs8081517	chr17:65845697	LOC440461	chr17:66194801-66196436:+	0.26	4.28	2.21E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8081541	chr17:61812483	DDX42	chr17:61851567-61896676:+	-0.16	-3.58	0.000377	Body mass index	
LGG	cis	1	rs8081541	chr17:61812483	FTSJ3	chr17:61896795-61905031:-	0.41	8.55	1.62E-16	Body mass index	
LGG	cis	1	rs8081541	chr17:61812483	SMARCD2	chr17:61909441-61920351:-	0.19	4.3	2.1E-5	Body mass index	
LGG	cis	1	rs8081612	chr17:61724695	FTSJ3	chr17:61896795-61905031:-	-0.43	-8.94	7.7E-18	Body mass index	
LGG	cis	1	rs8081612	chr17:61724695	SMARCD2	chr17:61909441-61920351:-	-0.21	-4.82	1.96E-6	Body mass index	
LGG	cis	1	rs8082471	chr17:53067993	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000268	Breast cancer	
LGG	cis	1	rs8082471	chr17:53067993	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.37	1.2E-7	Breast cancer	
LGG	cis	1	rs8082512	chr17:65837059	LOC440461	chr17:66194801-66196436:+	0.27	4.55	6.65E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs8084092	chr18:6945448	ARHGAP28	chr18:6788493-6915710:+	0.25	3.61	0.00034	Sudden cardiac arrest	
LGG	cis	1	rs808919	chr12:56647911	IL23A	chr12:56732663-56734193:+	-0.51	-5.2	2.9E-7	Psoriasis vulgaris	
LGG	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.17	-4.87	1.52E-6	Body mass index	
LGG	cis	1	rs809775	chr1:46538040	MUTYH	chr1:45794915-45806142:-	0.15	5.31	1.69E-7	Body mass index	
LGG	cis	1	rs8100042	chr19:22127841	ZNF257	chr19:22235266-22273901:+	0.55	8.94	8.05E-18	Body mass index (change over time)	
LGG	cis	1	rs8100168	chr19:33093084	C19orf40	chr19:33463148-33467955:+	0.22	3.87	0.000125	Eosinophilic esophagitis	
LGG	cis	1	rs8100168	chr19:33093084	PDCD5	chr19:33072104-33078322:+	-0.19	-4.31	2.01E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8101356	chr19:33093402	C19orf40	chr19:33463148-33467955:+	0.21	3.8	0.000161	Eosinophilic esophagitis	
LGG	cis	1	rs8101356	chr19:33093402	PDCD5	chr19:33072104-33078322:+	-0.17	-4.21	3.07E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8103622	chr19:18572834	LRRC25	chr19:18501955-18508421:-	-0.17	-6.02	3.48E-9	Breast cancer	
LGG	cis	1	rs8104328	chr19:33094371	C19orf40	chr19:33463148-33467955:+	0.21	3.8	0.000161	Eosinophilic esophagitis	
LGG	cis	1	rs8104328	chr19:33094371	PDCD5	chr19:33072104-33078322:+	-0.17	-4.21	2.99E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8104385	chr19:12700284	MAN2B1	chr19:12757322-12777591:-	0.15	4.95	1.02E-6	Bipolar disorder	
LGG	cis	1	rs8104559	chr19:22205167	ZNF257	chr19:22235266-22273901:+	0.55	8.86	1.5E-17	Body mass index (change over time)	
LGG	cis	1	rs8104726	chr19:33094675	C19orf40	chr19:33463148-33467955:+	0.2	3.7	0.000237	Eosinophilic esophagitis	
LGG	cis	1	rs8104726	chr19:33094675	PDCD5	chr19:33072104-33078322:+	-0.18	-4.3	2.04E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8104729	chr19:33093979	C19orf40	chr19:33463148-33467955:+	0.21	3.8	0.000161	Eosinophilic esophagitis	
LGG	cis	1	rs8104729	chr19:33093979	PDCD5	chr19:33072104-33078322:+	-0.17	-4.21	3.07E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8105895	chr19:22215457	ZNF257	chr19:22235266-22273901:+	0.56	8.99	5.45E-18	Body mass index (change over time)	
LGG	cis	1	rs8105994	chr19:18593553	LRRC25	chr19:18501955-18508421:-	-0.15	-5.39	1.1E-7	Breast cancer	
LGG	cis	1	rs8105994	chr19:18593553	SSBP4	chr19:18530221-18545371:+	-0.13	-3.9	0.00011	Breast cancer	
LGG	cis	1	rs8106929	chr19:52368467	ZNF577	chr19:52359056-52394145:-	-0.31	-5.42	9.33E-8	Breast cancer	
LGG	cis	1	rs8107367	chr19:18564705	LRRC25	chr19:18501955-18508421:-	-0.17	-5.83	9.84E-9	Breast cancer	
LGG	cis	1	rs8108840	chr19:33094452	C19orf40	chr19:33463148-33467955:+	0.23	3.91	0.000107	Eosinophilic esophagitis	
LGG	cis	1	rs8108840	chr19:33094452	PDCD5	chr19:33072104-33078322:+	-0.16	-3.63	0.000316	Eosinophilic esophagitis	
LGG	cis	1	rs8109573	chr19:18617151	LRRC25	chr19:18501955-18508421:-	-0.17	-5.95	5.04E-9	Breast cancer	
LGG	cis	1	rs8109768	chr19:33095463	C19orf40	chr19:33463148-33467955:+	0.2	3.65	0.000288	Eosinophilic esophagitis	
LGG	cis	1	rs8109768	chr19:33095463	PDCD5	chr19:33072104-33078322:+	-0.17	-4.19	3.25E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8109885	chr19:33095557	C19orf40	chr19:33463148-33467955:+	0.2	3.68	0.000256	Eosinophilic esophagitis	
LGG	cis	1	rs8109885	chr19:33095557	PDCD5	chr19:33072104-33078322:+	-0.17	-4.08	5.32E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8109990	chr19:33095636	C19orf40	chr19:33463148-33467955:+	0.2	3.68	0.000256	Eosinophilic esophagitis	
LGG	cis	1	rs8109990	chr19:33095636	PDCD5	chr19:33072104-33078322:+	-0.17	-4.08	5.32E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8110727	chr19:24230916	LOC100101266	chr19:24344995-24346249:-	0.25	3.97	8.27E-5	Response to taxane treatment (placlitaxel)	
LGG	cis	1	rs811115	chr3:47322133	NRADDP	chr3:47053032-47054957:+	-0.23	-4.02	6.85E-5	Colorectal cancer	
LGG	cis	1	rs8111708	chr19:18558876	LRRC25	chr19:18501955-18508421:-	-0.17	-5.96	4.88E-9	Breast cancer	
LGG	cis	1	rs8111708	chr19:18558876	SSBP4	chr19:18530221-18545371:+	-0.12	-3.57	0.000398	Breast cancer	
LGG	cis	1	rs8113165	chr19:33096316	C19orf40	chr19:33463148-33467955:+	0.18	3.59	0.000361	Eosinophilic esophagitis	
LGG	cis	1	rs8113165	chr19:33096316	PDCD5	chr19:33072104-33078322:+	-0.16	-4.23	2.8E-5	Eosinophilic esophagitis	
LGG	cis	1	rs8113312	chr19:23061182	ZNF492	chr19:22817126-22850472:+	-0.21	-4.19	3.37E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs8117100	chr20:33692261	GDF5	chr20:33897002-34042568:-	0.28	3.59	0.000369	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8117100	chr20:33692261	PROCR	chr20:33758727-33765164:+	-0.33	-6.07	2.63E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8117111	chr20:47884185	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.09	5.14E-5	Height	
LGG	cis	1	rs8117847	chr20:33642480	PROCR	chr20:33758727-33765164:+	-0.31	-5.85	9.17E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8118005	chr20:33636219	PROCR	chr20:33758727-33765164:+	-0.29	-5.54	5.06E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs811880	chr7:65818646	ASL	chr7:65540776-65558321:+	-0.22	-5.52	5.55E-8	Aortic root size	
LGG	cis	1	rs8118978	chr20:33574458	PROCR	chr20:33758727-33765164:+	-0.31	-5.84	9.66E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8119827	chr20:33726873	PROCR	chr20:33758727-33765164:+	-0.37	-6.71	5.32E-11	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8121957	chr20:33676109	PROCR	chr20:33758727-33765164:+	-0.3	-5.77	1.42E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8123289	chr20:3253831	ITPA	chr20:3190056-3204504:+	-0.34	-8.07	5.35E-15	IFN-related cytopenia	
LGG	cis	1	rs8123912	chr20:47863282	ARFGEF2	chr20:47538275-47653229:+	-0.14	-4.13	4.31E-5	Height	
LGG	cis	1	rs8123978	chr20:33598789	PROCR	chr20:33758727-33765164:+	-0.32	-5.72	1.84E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8124662	chr20:33639256	PROCR	chr20:33758727-33765164:+	-0.3	-5.78	1.32E-8	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs8125868	chr20:25324410	ABHD12	chr20:25275380-25371477:-	-0.26	-7.16	2.89E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs8125868	chr20:25324410	FAM182A	chr20:26035250-26067552:+	0.56	11.11	9.49E-26	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs8125868	chr20:25324410	FAM182B	chr20:25744102-25848786:-	-0.21	-4.78	2.29E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs8127691	chr21:45614860	PWP2	chr21:45527208-45551062:+	0.21	3.88	0.000119	Inflammatory bowel disease	
LGG	cis	1	rs8130986	chr21:44459743	NDUFV3	chr21:44313378-44329772:+	0.3	4.78	2.29E-6	Information processing speed	
LGG	cis	1	rs8131214	chr21:30483386	RWDD2B	chr21:30378082-30391685:-	0.22	3.82	0.00015	Dental caries	
LGG	cis	1	rs8133949	chr21:43421114	C21orf121	chr21:43442113-43445060:+	0.26	4.32	1.92E-5	Hand grip strength	
LGG	cis	1	rs8134050	chr21:44462363	NDUFV3	chr21:44313378-44329772:+	0.3	4.66	4.15E-6	Information processing speed	
LGG	cis	1	rs8137478	chr22:51017296	CPT1B	chr22:51007291-51017096:-	-0.35	-6.85	2.2E-11	Narcolepsy	
LGG	cis	1	rs8138799	chr22:24556902	SUSD2	chr22:24577444-24585074:+	0.46	5.68	2.26E-8	Amyotrophic lateral sclerosis	
LGG	cis	1	rs8138941	chr22:50290678	ALG12	chr22:50296856-50312106:-	0.27	5.54	5.03E-8	Schizophrenia	
LGG	cis	1	rs8138996	chr22:39047435	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs8140617	chr22:38970439	LOC646851	chr22:38974125-39052634:-	-0.22	-6.31	6.33E-10	Resting heart rate	
LGG	cis	1	rs8141797	chr22:24582041	SUSD2	chr22:24577444-24585074:+	-0.43	-5.85	8.98E-9	Amyotrophic lateral sclerosis	
LGG	cis	1	rs8142098	chr22:39058757	LOC646851	chr22:38974125-39052634:-	0.22	6.66	7.31E-11	Resting heart rate	
LGG	cis	1	rs8177876	chr16:81124275	GCSH	chr16:81115931-81129980:-	-0.32	-3.78	0.000175	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	
LGG	cis	1	rs8177876	chr16:81124275	PKD1L2	chr16:81134484-81253975:-	-0.32	-3.65	0.000294	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	
LGG	cis	1	rs8180040	chr3:47388947	NRADDP	chr3:47053032-47054957:+	-0.22	-3.89	0.000113	Colorectal cancer	
LGG	cis	1	rs8180991	chr8:126500350	TRIB1	chr8:126442563-126450642:+	-0.25	-4.66	4.16E-6	C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	
LGG	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.45	11.07	1.45E-25	Multiple sclerosis	
LGG	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.44	-8.35	7.17E-16	Multiple sclerosis	
LGG	cis	1	rs8184990	chr22:50273174	ALG12	chr22:50296856-50312106:-	-0.27	-5.37	1.22E-7	Schizophrenia	
LGG	cis	1	rs8192482	chr15:78886198	CHRNA5	chr15:78857906-78886458:+	-0.68	-13.34	7.62E-35	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs823144	chr1:205744546	PM20D1	chr1:205797154-205819245:-	-0.37	-6.26	8.23E-10	Parkinson's disease	
LGG	cis	1	rs823301	chr3:195123495	ACAP2	chr3:194995475-195163817:-	0.35	8.31	9.25E-16	Body mass index	
LGG	cis	1	rs823302	chr3:195104741	ACAP2	chr3:194995475-195163817:-	0.33	7.6	1.55E-13	Body mass index	
LGG	cis	1	rs823306	chr3:195108320	ACAP2	chr3:194995475-195163817:-	0.35	8.36	6.3E-16	Body mass index	
LGG	cis	1	rs823310	chr3:195127093	ACAP2	chr3:194995475-195163817:-	0.35	8.32	8.85E-16	Body mass index	
LGG	cis	1	rs823311	chr3:195141029	ACAP2	chr3:194995475-195163817:-	0.35	8.31	9.25E-16	Body mass index	
LGG	cis	1	rs823314	chr3:195132402	ACAP2	chr3:194995475-195163817:-	0.35	8.37	6.04E-16	Body mass index	
LGG	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.84	16.02	9.2E-47	Type 2 diabetes	
LGG	cis	1	rs832551	chr5:56180112	MIER3	chr5:56215429-56267501:-	0.18	3.92	0.000101	Type 2 diabetes	
LGG	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.83	15.86	5.07E-46	Type 2 diabetes	
LGG	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.82	15.51	1.87E-44	Type 2 diabetes	
LGG	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.85	16.31	4.25E-48	Type 2 diabetes	
LGG	cis	1	rs832565	chr5:56150803	MIER3	chr5:56215429-56267501:-	0.16	3.5	0.000501	Type 2 diabetes	
LGG	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.85	16.37	2.27E-48	Type 2 diabetes	
LGG	cis	1	rs832568	chr5:56153776	MIER3	chr5:56215429-56267501:-	0.17	3.66	0.000281	Type 2 diabetes	
LGG	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.85	16.37	2.27E-48	Type 2 diabetes	
LGG	cis	1	rs832569	chr5:56154584	MIER3	chr5:56215429-56267501:-	0.17	3.66	0.000281	Type 2 diabetes	
LGG	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.83	16.02	9.09E-47	Type 2 diabetes	
LGG	cis	1	rs832578	chr5:56164223	MIER3	chr5:56215429-56267501:-	0.17	3.71	0.000232	Type 2 diabetes	
LGG	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.84	16.02	9.2E-47	Type 2 diabetes	
LGG	cis	1	rs832582	chr5:56177743	MIER3	chr5:56215429-56267501:-	0.18	3.92	0.000101	Type 2 diabetes	
LGG	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.84	16.02	9.2E-47	Type 2 diabetes	
LGG	cis	1	rs832583	chr5:56178217	MIER3	chr5:56215429-56267501:-	0.18	3.92	0.000101	Type 2 diabetes	
LGG	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.83	-15.59	8.14E-45	Type 2 diabetes	
LGG	cis	1	rs835154	chr5:14876569	ANKH	chr5:14704910-14871887:-	-0.15	-3.65	0.000292	Blood metabolite levels	
LGG	cis	1	rs838705	chr2:234273242	USP40	chr2:234384166-234475428:-	-0.22	-5.29	1.83E-7	Calcium levels	
LGG	cis	1	rs8396	chr4:159630817	ETFDH	chr4:159593277-159629839:+	0.37	7.62	1.27E-13	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs840567	chr2:188174433	CALCRL	chr2:188207851-188313021:-	0.22	5.35	1.36E-7	Coronary heart disease	
LGG	cis	1	rs840569	chr2:188173125	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840570	chr2:188172677	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840571	chr2:188171676	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840572	chr2:188171253	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840574	chr2:188171068	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840576	chr2:188168350	CALCRL	chr2:188207851-188313021:-	0.22	5.39	1.11E-7	Coronary heart disease	
LGG	cis	1	rs840577	chr2:188168059	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840578	chr2:188167105	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840581	chr2:188190584	CALCRL	chr2:188207851-188313021:-	0.22	5.39	1.12E-7	Coronary heart disease	
LGG	cis	1	rs840583	chr2:188186320	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.31E-8	Coronary heart disease	
LGG	cis	1	rs840584	chr2:188186079	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.31E-8	Coronary heart disease	
LGG	cis	1	rs840586	chr2:188183918	CALCRL	chr2:188207851-188313021:-	0.22	5.35	1.36E-7	Coronary heart disease	
LGG	cis	1	rs840587	chr2:188183805	CALCRL	chr2:188207851-188313021:-	0.22	5.39	1.11E-7	Coronary heart disease	
LGG	cis	1	rs840589	chr2:188182527	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.31E-8	Coronary heart disease	
LGG	cis	1	rs840590	chr2:188181914	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840593	chr2:188181341	CALCRL	chr2:188207851-188313021:-	0.23	5.53	5.34E-8	Coronary heart disease	
LGG	cis	1	rs840595	chr2:188179494	CALCRL	chr2:188207851-188313021:-	0.22	5.37	1.23E-7	Coronary heart disease	
LGG	cis	1	rs840596	chr2:188178524	CALCRL	chr2:188207851-188313021:-	0.23	5.61	3.42E-8	Coronary heart disease	
LGG	cis	1	rs840597	chr2:188178480	CALCRL	chr2:188207851-188313021:-	0.22	5.39	1.11E-7	Coronary heart disease	
LGG	cis	1	rs840600	chr2:188159750	CALCRL	chr2:188207851-188313021:-	-0.23	-5.45	7.94E-8	Coronary heart disease	
LGG	cis	1	rs840603	chr2:188160901	CALCRL	chr2:188207851-188313021:-	0.22	5.36	1.29E-7	Coronary heart disease	
LGG	cis	1	rs840609	chr2:188199583	CALCRL	chr2:188207851-188313021:-	0.22	5.43	8.73E-8	Coronary heart disease	
LGG	cis	1	rs840611	chr2:188198446	CALCRL	chr2:188207851-188313021:-	0.22	5.38	1.14E-7	Coronary heart disease	
LGG	cis	1	rs840616	chr2:188196469	CALCRL	chr2:188207851-188313021:-	0.22	5.37	1.21E-7	Coronary heart disease	
LGG	cis	1	rs844479	chr2:188159178	CALCRL	chr2:188207851-188313021:-	-0.22	-5.31	1.68E-7	Coronary heart disease	
LGG	cis	1	rs848490	chr7:77555005	PTPN12	chr7:77166773-77269388:+	0.19	4.09	5.08E-5	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine)	
LGG	cis	1	rs853306	chr8:133931011	TG	chr8:133879205-134147141:+	-0.23	-4.2	3.21E-5	Vitiligo	
LGG	cis	1	rs853307	chr8:133930674	TG	chr8:133879205-134147141:+	-0.22	-3.99	7.77E-5	Vitiligo	
LGG	cis	1	rs853308	chr8:133929917	TG	chr8:133879205-134147141:+	-0.22	-3.96	8.5E-5	Vitiligo	
LGG	cis	1	rs853410	chr6:4058038	C6orf201	chr6:4079440-4130998:+	0.3	3.68	0.000259	Night sleep phenotypes	
LGG	cis	1	rs853676	chr6:28299687	ZNF165	chr6:28046572-28057338:+	-0.3	-4.37	1.51E-5	Depression	
LGG	cis	1	rs853676	chr6:28299687	ZNF187	chr6:28234788-28245978:+	-0.3	-5.23	2.48E-7	Depression	
LGG	cis	1	rs853676	chr6:28299687	ZNF389	chr6:28129551-28137375:+	0.42	6.75	4.24E-11	Depression	
LGG	cis	1	rs853676	chr6:28299687	ZSCAN12	chr6:28346770-28367544:-	-0.37	-5.19	3.11E-7	Depression	
LGG	cis	1	rs853676	chr6:28299687	ZSCAN23	chr6:28393287-28411279:-	0.17	4.02	6.61E-5	Depression	
LGG	cis	1	rs853678	chr6:28297313	ZNF165	chr6:28046572-28057338:+	-0.3	-4.46	1.03E-5	Depression	
LGG	cis	1	rs853678	chr6:28297313	ZNF187	chr6:28234788-28245978:+	-0.29	-5.19	3.02E-7	Depression	
LGG	cis	1	rs853678	chr6:28297313	ZNF389	chr6:28129551-28137375:+	0.41	6.75	4.09E-11	Depression	
LGG	cis	1	rs853678	chr6:28297313	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.86	1.55E-6	Depression	
LGG	cis	1	rs853678	chr6:28297313	ZSCAN23	chr6:28393287-28411279:-	0.16	3.92	0.0001	Depression	
LGG	cis	1	rs853679	chr6:28296863	ZNF165	chr6:28046572-28057338:+	-0.3	-4.46	1.03E-5	Depression	
LGG	cis	1	rs853679	chr6:28296863	ZNF187	chr6:28234788-28245978:+	-0.29	-5.19	3.02E-7	Depression	
LGG	cis	1	rs853679	chr6:28296863	ZNF389	chr6:28129551-28137375:+	0.41	6.75	4.09E-11	Depression	
LGG	cis	1	rs853679	chr6:28296863	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.86	1.55E-6	Depression	
LGG	cis	1	rs853679	chr6:28296863	ZSCAN23	chr6:28393287-28411279:-	0.16	3.92	0.0001	Depression	
LGG	cis	1	rs853685	chr6:28288785	ZNF165	chr6:28046572-28057338:+	-0.29	-4.37	1.5E-5	Depression	
LGG	cis	1	rs853685	chr6:28288785	ZNF187	chr6:28234788-28245978:+	-0.28	-4.85	1.63E-6	Depression	
LGG	cis	1	rs853685	chr6:28288785	ZNF389	chr6:28129551-28137375:+	0.42	6.81	2.92E-11	Depression	
LGG	cis	1	rs853685	chr6:28288785	ZSCAN12	chr6:28346770-28367544:-	-0.33	-4.65	4.35E-6	Depression	
LGG	cis	1	rs853685	chr6:28288785	ZSCAN23	chr6:28393287-28411279:-	0.18	4.21	2.98E-5	Depression	
LGG	cis	1	rs853694	chr6:28279100	ZNF165	chr6:28046572-28057338:+	-0.3	-4.43	1.18E-5	Depression	
LGG	cis	1	rs853694	chr6:28279100	ZNF187	chr6:28234788-28245978:+	-0.28	-4.85	1.69E-6	Depression	
LGG	cis	1	rs853694	chr6:28279100	ZNF389	chr6:28129551-28137375:+	0.42	6.76	3.87E-11	Depression	
LGG	cis	1	rs853694	chr6:28279100	ZSCAN12	chr6:28346770-28367544:-	-0.33	-4.66	4.08E-6	Depression	
LGG	cis	1	rs853694	chr6:28279100	ZSCAN23	chr6:28393287-28411279:-	0.18	4.22	2.92E-5	Depression	
LGG	cis	1	rs855865	chr1:159028378	IFI16	chr1:158969758-159024943:+	-0.17	-3.66	0.000276	Obesity-related traits	
LGG	cis	1	rs856053	chr1:159001504	IFI16	chr1:158969758-159024943:+	-0.2	-4.41	1.25E-5	Obesity-related traits	
LGG	cis	1	rs856054	chr1:159001521	IFI16	chr1:158969758-159024943:+	-0.16	-3.69	0.000246	Obesity-related traits	
LGG	cis	1	rs856055	chr1:159001593	IFI16	chr1:158969758-159024943:+	-0.19	-4.19	3.27E-5	Obesity-related traits	
LGG	cis	1	rs856056	chr1:159001709	IFI16	chr1:158969758-159024943:+	-0.19	-4.19	3.27E-5	Obesity-related traits	
LGG	cis	1	rs856057	chr1:159001735	IFI16	chr1:158969758-159024943:+	-0.19	-4.19	3.27E-5	Obesity-related traits	
LGG	cis	1	rs857684	chr1:158575729	KIRREL	chr1:157963063-158065842:+	-0.13	-3.77	0.00018	Other erythrocyte phenotypes	
LGG	cis	1	rs857685	chr1:158577109	KIRREL	chr1:157963063-158065842:+	-0.13	-3.85	0.000134	Other erythrocyte phenotypes	
LGG	cis	1	rs857721	chr1:158612548	KIRREL	chr1:157963063-158065842:+	0.13	3.82	0.000152	Other erythrocyte phenotypes	
LGG	cis	1	rs857725	chr1:158607935	KIRREL	chr1:157963063-158065842:+	-0.12	-3.65	0.000291	Other erythrocyte phenotypes	
LGG	cis	1	rs858239	chr7:23286315	GPNMB	chr7:23286316-23314728:+	-0.23	-5.1	4.82E-7	Parkinson's disease	
LGG	cis	1	rs858239	chr7:23286315	NUPL2	chr7:23221446-23240629:+	-0.39	-9.71	1.65E-20	Parkinson's disease	
LGG	cis	1	rs858240	chr7:23284237	GPNMB	chr7:23286316-23314728:+	-0.23	-5.03	6.84E-7	Parkinson's disease	
LGG	cis	1	rs858240	chr7:23284237	NUPL2	chr7:23221446-23240629:+	-0.4	-9.94	2.45E-21	Parkinson's disease	
LGG	cis	1	rs858744	chr2:188216783	CALCRL	chr2:188207851-188313021:-	-0.21	-5.07	5.58E-7	Coronary heart disease	
LGG	cis	1	rs858756	chr2:188233714	CALCRL	chr2:188207851-188313021:-	-0.22	-5.27	2.0E-7	Coronary heart disease	
LGG	cis	1	rs858758	chr2:188235258	CALCRL	chr2:188207851-188313021:-	-0.22	-5.27	2.0E-7	Coronary heart disease	
LGG	cis	1	rs858759	chr2:188235611	CALCRL	chr2:188207851-188313021:-	-0.22	-5.26	2.13E-7	Coronary heart disease	
LGG	cis	1	rs860475	chr8:133929799	TG	chr8:133879205-134147141:+	-0.22	-3.96	8.5E-5	Vitiligo	
LGG	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.83	-15.98	1.4E-46	Type 2 diabetes	
LGG	cis	1	rs860772	chr1:158576100	KIRREL	chr1:157963063-158065842:+	0.13	3.94	9.44E-5	Other erythrocyte phenotypes	
LGG	cis	1	rs860846	chr2:188234928	CALCRL	chr2:188207851-188313021:-	-0.22	-5.27	2.0E-7	Coronary heart disease	
LGG	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.83	15.72	2.22E-45	Type 2 diabetes	
LGG	cis	1	rs861283	chr5:56184610	MIER3	chr5:56215429-56267501:-	0.19	4.11	4.55E-5	Type 2 diabetes	
LGG	cis	1	rs861318	chr1:159002222	IFI16	chr1:158969758-159024943:+	-0.19	-4.19	3.27E-5	Obesity-related traits	
LGG	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.81	15.31	1.59E-43	Type 2 diabetes	
LGG	cis	1	rs863840	chr5:56128999	MIER3	chr5:56215429-56267501:-	0.18	3.97	8.42E-5	Type 2 diabetes	
LGG	cis	1	rs864091	chr8:133933290	TG	chr8:133879205-134147141:+	-0.23	-4.05	6.07E-5	Vitiligo	
LGG	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.84	15.77	1.29E-45	Type 2 diabetes	
LGG	cis	1	rs866222	chr5:56184444	MIER3	chr5:56215429-56267501:-	0.19	4.11	4.73E-5	Type 2 diabetes	
LGG	cis	1	rs867186	chr20:33764554	PROCR	chr20:33758727-33765164:+	0.35	6.41	3.35E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs867529	chr2:88913273	EIF2AK3	chr2:88856261-88926994:-	0.15	3.53	0.000461	Height	
LGG	cis	1	rs868530	chr5:156430916	TIMD4	chr5:156346293-156390266:-	-0.26	-4.75	2.61E-6	Hypertriglyceridemia	
LGG	cis	1	rs871130	chr12:56648777	IL23A	chr12:56732663-56734193:+	-0.46	-4.12	4.45E-5	Psoriasis vulgaris	
LGG	cis	1	rs871546	chr21:43413553	C21orf121	chr21:43442113-43445060:+	0.26	4.2	3.17E-5	Hand grip strength	
LGG	cis	1	rs873063	chr8:8572447	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.01	7.51E-7	Obesity-related traits	
LGG	cis	1	rs873064	chr8:8572380	FLJ10661	chr8:8086092-8102386:+	-0.27	-5.01	7.63E-7	Obesity-related traits	
LGG	cis	1	rs873457	chr1:12046334	MIIP	chr1:12079512-12092106:+	0.09	3.62	0.00033	Platelet count	
LGG	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.26	7.45	4.17E-13	Kawasaki disease	
LGG	cis	1	rs874610	chr9:100782695	C9orf156	chr9:100666772-100684852:-	0.21	3.84	0.000136	Coronary heart disease	
LGG	cis	1	rs875874	chr11:76834616	CAPN5	chr11:76777992-76837196:+	0.33	3.8	0.000165	Cognitive performance	
LGG	cis	1	rs875875	chr11:76834712	CAPN5	chr11:76777992-76837196:+	0.33	3.72	0.00022	Cognitive performance	
LGG	cis	1	rs8758	chr10:97366107	TCTN3	chr10:97423154-97453900:-	0.19	3.84	0.000138	Blood metabolite levels	
LGG	cis	1	rs875971	chr7:65617595	ASL	chr7:65540776-65558321:+	0.22	5.5	6.07E-8	Aortic root size	
LGG	cis	1	rs876402	chr14:75601862	ACYP1	chr14:75519930-75530736:-	0.14	3.74	0.000206	Height	
LGG	cis	1	rs876402	chr14:75601862	EIF2B2	chr14:75469612-75476292:+	-0.21	-4.16	3.71E-5	Height	
LGG	cis	1	rs876402	chr14:75601862	MLH3	chr14:75480467-75518235:-	-0.21	-3.62	0.000329	Height	
LGG	cis	1	rs876403	chr14:75602834	ACYP1	chr14:75519930-75530736:-	-0.15	-4	7.45E-5	Height	
LGG	cis	1	rs876403	chr14:75602834	EIF2B2	chr14:75469612-75476292:+	0.19	3.77	0.000186	Height	
LGG	cis	1	rs877636	chr12:56480583	ERBB3	chr12:56473892-56497127:+	-0.23	-5.02	7.13E-7	Cognitive function	
LGG	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.79	-16.88	9.12E-51	Cognitive function	
LGG	cis	1	rs878083	chr19:41897688	ATP5SL	chr19:41937224-41945810:-	0.16	4.69	3.59E-6	Height	
LGG	cis	1	rs878361	chr7:26557868	KIAA0087	chr7:26572740-26578444:-	0.18	3.47	0.000558	Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs880890	chr2:188184500	CALCRL	chr2:188207851-188313021:-	-0.24	-5.72	1.82E-8	Coronary heart disease	
LGG	cis	1	rs881375	chr9:123652898	LOC253039	chr9:123605320-123616644:+	-0.66	-11.87	9.96E-29	Rheumatoid arthritis	
LGG	cis	1	rs881375	chr9:123652898	PSMD5	chr9:123578334-123605206:-	-0.35	-6.52	1.78E-10	Rheumatoid arthritis	
LGG	cis	1	rs881375	chr9:123652898	TRAF1	chr9:123664672-123691479:-	0.18	4.01	7.16E-5	Rheumatoid arthritis	
LGG	cis	1	rs881802	chr7:118099945	ANKRD7	chr7:117864712-117882782:+	-0.2	-3.6	0.000353	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs881827	chr21:48019868	C21orf56	chr21:47581063-47604373:-	-0.19	-3.7	0.000243	Lymphocyte counts	
LGG	cis	1	rs882424	chr2:105370336	MRPS9	chr2:105654483-105716417:+	-0.24	-3.84	0.000142	Pancreatic cancer	
LGG	cis	1	rs883565	chr3:39055317	SCN11A	chr3:38887260-38992052:-	0.19	3.83	0.000142	Handedness	
LGG	cis	1	rs883648	chr8:8569521	FLJ10661	chr8:8086092-8102386:+	-0.27	-4.98	9.01E-7	Obesity-related traits	
LGG	cis	1	rs883838	chr9:135815474	C9orf98	chr9:135600965-135754198:-	0.34	9.11	2.08E-18	Psoriasis	
LGG	cis	1	rs883838	chr9:135815474	GFI1B	chr9:135854098-135867083:+	-0.21	-3.74	0.000208	Psoriasis	
LGG	cis	1	rs884247	chr14:65895706	LOC645431	chr14:65877313-65879335:-	-0.52	-7.16	2.89E-12	Ischemic stroke	
LGG	cis	1	rs884613	chr20:25288505	ABHD12	chr20:25275380-25371477:-	-0.27	-7.41	5.54E-13	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs884613	chr20:25288505	FAM182A	chr20:26035250-26067552:+	0.56	10.97	3.28E-25	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs884613	chr20:25288505	FAM182B	chr20:25744102-25848786:-	-0.22	-4.95	1.01E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.5	-10.32	9.57E-23	Response to antipsychotic treatment	
LGG	cis	1	rs885000	chr8:8568875	FLJ10661	chr8:8086092-8102386:+	-0.27	-5	7.83E-7	Obesity-related traits	
LGG	cis	1	rs885963	chr22:23460939	RTDR1	chr22:23401594-23484241:-	-0.16	-3.76	0.000194	Bone mineral density	
LGG	cis	1	rs885964	chr22:23461003	RTDR1	chr22:23401594-23484241:-	-0.16	-3.76	0.000194	Bone mineral density	
LGG	cis	1	rs885965	chr22:23461425	RTDR1	chr22:23401594-23484241:-	-0.16	-3.57	0.000392	Bone mineral density	
LGG	cis	1	rs889014	chr5:172984114	LOC285593	chr5:173006646-173012074:+	0.27	5.07	5.75E-7	Height	
LGG	cis	1	rs889312	chr5:56031884	C5orf35	chr5:56205103-56213010:+	0.34	6.55	1.44E-10	Breast cancer (early onset);Breast cancer	
LGG	cis	1	rs889398	chr16:69556715	PDXDC2	chr16:70010210-70099851:-	0.12	4.08	5.21E-5	Body mass index	
LGG	cis	1	rs889399	chr16:69556583	PDXDC2	chr16:70010210-70099851:-	0.12	4.06	5.69E-5	Body mass index	
LGG	cis	1	rs8897	chr3:49460407	AMIGO3	chr3:49754268-49757238:-	-0.2	-4.55	6.64E-6	Menarche (age at onset)	
LGG	cis	1	rs8897	chr3:49460407	GMPPB	chr3:49758932-49761384:-	-0.23	-4.54	7.19E-6	Menarche (age at onset)	
LGG	cis	1	rs8897	chr3:49460407	TREX1	chr3:48501186-48509043:+	-0.25	-5.34	1.42E-7	Menarche (age at onset)	
LGG	cis	1	rs891368	chr3:53123273	RFT1	chr3:53122503-53164470:-	-0.47	-10.06	8.66E-22	Height	
LGG	cis	1	rs891386	chr18:21103971	C18orf8	chr18:21083462-21111742:+	0.19	3.77	0.000186	Body mass index	
LGG	cis	1	rs892864	chr5:127835859	FBN2	chr5:127593602-127873916:-	0.43	4.96	9.73E-7	Multiple system atrophy	
LGG	cis	1	rs892974	chr3:49398514	AMIGO3	chr3:49754268-49757238:-	-0.21	-4.83	1.83E-6	Menarche (age at onset)	
LGG	cis	1	rs892974	chr3:49398514	GMPPB	chr3:49758932-49761384:-	-0.25	-4.91	1.25E-6	Menarche (age at onset)	
LGG	cis	1	rs892974	chr3:49398514	TREX1	chr3:48501186-48509043:+	-0.26	-5.32	1.59E-7	Menarche (age at onset)	
LGG	cis	1	rs894839	chr11:120337705	TMEM136	chr11:120196016-120204388:+	0.2	4.65	4.34E-6	Intraocular pressure	
LGG	cis	1	rs895959	chr12:122320352	PSMD9	chr12:122326646-122355770:+	-0.16	-3.68	0.000254	Urinary metabolites	
LGG	cis	1	rs897119	chr2:70160658	SNRNP27	chr2:70121090-70132348:+	-0.2	-4.51	8.09E-6	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs897120	chr2:70160982	SNRNP27	chr2:70121090-70132348:+	0.19	4.15	3.85E-5	Carotid plaque burden (smoking interaction)	
LGG	cis	1	rs897736	chr8:59306828	UBXN2B	chr8:59323823-59364059:+	-0.21	-3.79	0.000167	Gut microbiome composition (summer)	
LGG	cis	1	rs897737	chr8:59306803	UBXN2B	chr8:59323823-59364059:+	-0.21	-3.79	0.000167	Gut microbiome composition (summer)	
LGG	cis	1	rs898225	chr3:48413179	ATRIP	chr3:48488141-48507708:+	-0.2	-4.89	1.39E-6	Longevity	
LGG	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.38	9.42	1.73E-19	Longevity	
LGG	cis	1	rs899335	chr17:20898362	USP22	chr17:20902908-20947073:-	-0.22	-5.02	7.39E-7	Blood trace element (Se levels)	
LGG	cis	1	rs899336	chr17:20898393	USP22	chr17:20902908-20947073:-	-0.22	-5.07	5.76E-7	Blood trace element (Se levels)	
LGG	cis	1	rs905928	chr1:31863017	ZCCHC17	chr1:31769842-31837780:+	-0.15	-3.81	0.000155	Schizophrenia	
LGG	cis	1	rs906134	chr7:65444288	CCT6P1	chr7:65216092-65228661:+	0.27	4.97	9.37E-7	Diabetic kidney disease	
LGG	cis	1	rs907463	chr2:188185287	CALCRL	chr2:188207851-188313021:-	-0.21	-5.17	3.35E-7	Coronary heart disease	
LGG	cis	1	rs907611	chr11:1874072	LSP1	chr11:1874200-1913492:+	0.18	4.39	1.39E-5	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LGG	cis	1	rs907613	chr11:1874292	LSP1	chr11:1874200-1913492:+	0.18	4.39	1.41E-5	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LGG	cis	1	rs909341	chr20:62328742	LIME1	chr20:62367053-62370459:+	0.16	3.63	0.000314	Atopic dermatitis	
LGG	cis	1	rs909341	chr20:62328742	ZGPAT	chr20:62338794-62370459:+	-0.16	-4.27	2.33E-5	Atopic dermatitis	
LGG	cis	1	rs909847	chr1:71443127	PTGER3	chr1:71318036-71513491:-	0.16	3.79	0.000167	IgG glycosylation	
LGG	cis	1	rs909848	chr1:71443150	PTGER3	chr1:71318036-71513491:-	0.16	3.79	0.000167	IgG glycosylation	
LGG	cis	1	rs910316	chr14:75626042	ACYP1	chr14:75519930-75530736:-	-0.14	-3.72	0.000222	Height	
LGG	cis	1	rs910316	chr14:75626042	EIF2B2	chr14:75469612-75476292:+	0.23	4.41	1.28E-5	Height	
LGG	cis	1	rs910316	chr14:75626042	MLH3	chr14:75480467-75518235:-	0.21	3.67	0.000266	Height	
LGG	cis	1	rs910800	chr22:50278642	ALG12	chr22:50296856-50312106:-	-0.27	-5.53	5.31E-8	Schizophrenia	
LGG	cis	1	rs910873	chr20:33171772	NCOA6	chr20:33302579-33413433:-	0.25	3.47	0.00057	Melanoma	
LGG	cis	1	rs910997	chr20:25267301	ABHD12	chr20:25275380-25371477:-	0.26	7.06	5.9E-12	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs910997	chr20:25267301	FAM182A	chr20:26035250-26067552:+	-0.54	-10.63	7.08E-24	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs910997	chr20:25267301	FAM182B	chr20:25744102-25848786:-	0.21	4.67	3.87E-6	Liver enzyme levels (alkaline phosphatase)	
LGG	cis	1	rs911411	chr20:47718431	ARFGEF2	chr20:47538275-47653229:+	0.11	4.03	6.59E-5	Anger	
LGG	cis	1	rs911411	chr20:47718431	CSE1L	chr20:47662838-47713484:+	0.19	5.04	6.66E-7	Anger	
LGG	cis	1	rs913996	chr1:152884111	SMCP	chr1:152850798-152857515:+	-0.33	-5.14	3.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs916134	chr12:54069803	PRR13	chr12:53835433-53840426:+	-0.13	-3.58	0.000384	Height	
LGG	cis	1	rs916583	chr22:23469267	RTDR1	chr22:23401594-23484241:-	-0.17	-3.97	8.33E-5	Bone mineral density	
LGG	cis	1	rs916584	chr22:23469433	RTDR1	chr22:23401594-23484241:-	-0.17	-4.04	6.17E-5	Bone mineral density	
LGG	cis	1	rs916585	chr22:23469438	RTDR1	chr22:23401594-23484241:-	-0.17	-3.84	0.000137	Bone mineral density	
LGG	cis	1	rs917665	chr4:17668504	MED28	chr4:17616273-17629791:+	-0.19	-4.09	4.97E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs917761	chr7:117859053	ANKRD7	chr7:117864712-117882782:+	-0.24	-4.25	2.61E-5	Response to platinum-based chemotherapy in non-small-cell lung cancer	
LGG	cis	1	rs917911	chr12:9905851	CLECL1	chr12:9868457-9885860:-	0.45	10.53	1.6E-23	Type 1 diabetes	
LGG	cis	1	rs917962	chr2:39966594	THUMPD2	chr2:39963200-40006416:-	-0.43	-8.38	5.5E-16	Personality dimensions	
LGG	cis	1	rs917996	chr2:103082273	IL18R1	chr2:102927962-103015215:+	-0.39	-6.19	1.3E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs917996	chr2:103082273	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.45	7.89E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs917997	chr2:103070568	IL18R1	chr2:102927962-103015215:+	-0.38	-6.15	1.57E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs917997	chr2:103070568	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.41	1.01E-7	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs918814	chr2:23948466	LOC375190	chr2:24299728-24397519:+	0.21	5.07	5.57E-7	Obesity-related traits	
LGG	cis	1	rs9213	chr2:218386	FAM150B	chr2:279563-288308:-	-0.31	-5.79	1.25E-8	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs9213	chr2:218386	SNTG2	chr2:946555-1371382:+	0.19	3.5	0.000513	Spherical equivalent (joint main effects and education interaction)	
LGG	cis	1	rs921450	chr7:50623260	FIGNL1	chr7:50511834-50518088:-	0.22	5.21	2.79E-7	Malaria	
LGG	cis	1	rs921451	chr7:50623285	FIGNL1	chr7:50511834-50518088:-	-0.2	-4.69	3.47E-6	Malaria	
LGG	cis	1	rs921943	chr5:78316476	BHMT	chr5:78407604-78428112:+	-0.17	-3.51	0.000486	Blood trace element (Se levels);Blood and toenail selenium levels	
LGG	cis	1	rs922075	chr3:48489398	ATRIP	chr3:48488141-48507708:+	-0.19	-4.66	4.15E-6	Longevity	
LGG	cis	1	rs922075	chr3:48489398	TREX1	chr3:48501186-48509043:+	0.42	10.9	6.12E-25	Longevity	
LGG	cis	1	rs922227	chr2:166911942	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs922227	chr2:166911942	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs922483	chr8:11351912	FAM66A	chr8:12219528-12279968:+	0.22	4.06	5.76E-5	Systemic lupus erythematosus	
LGG	cis	1	rs924607	chr5:610093	SDHA	chr5:218356-256812:+	-0.18	-4.08	5.21E-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LGG	cis	1	rs925098	chr4:17919811	DCAF16	chr4:17802280-17812381:-	0.15	3.59	0.000358	Height	
LGG	cis	1	rs925410	chr2:160912652	LY75	chr2:160625141-160761262:-	-0.13	-3.64	0.000296	Idiopathic membranous nephropathy	
LGG	cis	1	rs925488	chr9:100546391	C9orf156	chr9:100666772-100684852:-	0.19	3.95	8.86E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs925489	chr9:100546600	C9orf156	chr9:100666772-100684852:-	0.18	3.79	0.00017	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs925532	chr1:202533880	UBE2T	chr1:202300786-202311094:-	-0.13	-4.03	6.51E-5	Sex ratio	
LGG	cis	1	rs925533	chr1:202534108	UBE2T	chr1:202300786-202311094:-	-0.13	-3.87	0.000123	Sex ratio	
LGG	cis	1	rs926299	chr22:39095698	LOC646851	chr22:38974125-39052634:-	0.25	7.65	1.1E-13	Resting heart rate	
LGG	cis	1	rs926391	chr20:37690485	DHX35	chr20:37591000-37668363:+	-0.19	-4.28	2.21E-5	Dialysis-related mortality	
LGG	cis	1	rs926392	chr20:37690464	DHX35	chr20:37591000-37668363:+	-0.17	-3.95	9.06E-5	Dialysis-related mortality	
LGG	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.8	14.62	1.9E-40	Type 2 diabetes	
LGG	cis	1	rs9288316	chr2:202163483	ALS2CR12	chr2:202153148-202222101:-	0.36	7.32	1.02E-12	Melanoma;Esophageal squamous cell carcinoma	
LGG	cis	1	rs9288887	chr3:108856292	MORC1	chr3:108677089-108836993:-	-0.39	-6.96	1.13E-11	Homeostasis model assessment of beta-cell function (interaction)	
LGG	cis	1	rs9289275	chr3:125648659	ALG1L	chr3:125648118-125655882:-	-0.33	-4.24	2.67E-5	Blood pressure (smoking interaction)	
LGG	cis	1	rs9289275	chr3:125648659	LOC100125556	chr3:125635444-125648865:+	0.71	10.53	1.67E-23	Blood pressure (smoking interaction)	
LGG	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.29	7.64	1.12E-13	Height	
LGG	cis	1	rs9289471	chr3:134230811	CEP63	chr3:134204575-134293852:+	0.2	3.77	0.000182	Height	
LGG	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.29	7.6	1.48E-13	Height	
LGG	cis	1	rs9289475	chr3:134236459	CEP63	chr3:134204575-134293852:+	0.21	3.92	0.000102	Height	
LGG	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.29	7.68	8.86E-14	Height	
LGG	cis	1	rs9289476	chr3:134237103	CEP63	chr3:134204575-134293852:+	0.19	3.6	0.000357	Height	
LGG	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.29	7.74	5.57E-14	Height	
LGG	cis	1	rs9289478	chr3:134268619	CEP63	chr3:134204575-134293852:+	0.2	3.6	0.000348	Height	
LGG	cis	1	rs929039	chr22:38071511	LGALS1	chr22:38071613-38075807:+	-0.18	-4.88	1.43E-6	Fat distribution (HIV)	
LGG	cis	1	rs9291659	chr4:17662360	LAP3	chr4:17578927-17609590:+	-0.13	-3.6	0.000357	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs9291659	chr4:17662360	MED28	chr4:17616273-17629791:+	0.17	3.73	0.000218	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs9291683	chr4:10324160	SLC2A9	chr4:9827850-10041872:-	-0.22	-6.07	2.61E-9	Bone mineral density	
LGG	cis	1	rs9292777	chr5:40437948	PTGER4	chr5:40680032-40693835:+	-0.15	-3.82	0.000152	Crohn's disease;Multiple sclerosis	
LGG	cis	1	rs9294377	chr6:88084839	C6orf163	chr6:88057220-88075180:+	0.21	3.76	0.000193	Depressive episodes in bipolar disorder	
LGG	cis	1	rs9295695	chr6:26528250	BTN2A3	chr6:26422317-26431927:+	-0.13	-3.63	0.000314	Educational attainment	
LGG	cis	1	rs9295695	chr6:26528250	HMGN4	chr6:26538572-26547162:+	0.19	4.81	2.04E-6	Educational attainment	
LGG	cis	1	rs9296295	chr6:39361854	KCNK5	chr6:39156748-39197251:-	0.31	3.65	0.00029	Obesity-related traits	
LGG	cis	1	rs9296404	chr6:42925803	GNMT	chr6:42928500-42931617:+	-0.57	-15.18	6.03E-43	Plasma homocysteine levels (post-methionine load test)	
LGG	cis	1	rs9296404	chr6:42925803	PEX6	chr6:42931613-42946981:-	0.68	16.84	1.43E-50	Plasma homocysteine levels (post-methionine load test)	
LGG	cis	1	rs9296504	chr6:46629505	SLC25A27	chr6:46620679-46645925:+	0.19	6.89	1.7E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9296504	chr6:46629505	TDRD6	chr6:46655866-46670149:+	-0.27	-6.7	5.83E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9296505	chr6:46629841	SLC25A27	chr6:46620679-46645925:+	0.19	6.88	1.77E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9296505	chr6:46629841	TDRD6	chr6:46655866-46670149:+	-0.27	-6.81	2.84E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9296616	chr6:49414235	CENPQ	chr6:49431096-49460820:+	-0.23	-5.1	4.98E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9296617	chr6:49428360	CENPQ	chr6:49431096-49460820:+	-0.23	-4.97	9.38E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9298383	chr8:83054885	FABP4	chr8:82390732-82395473:-	0.19	3.82	0.000149	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs929843	chr16:70045748	CLEC18A	chr16:69984626-69997887:+	-0.19	-3.91	0.000103	Menarche (age at onset)	
LGG	cis	1	rs929843	chr16:70045748	EXOSC6	chr16:70284134-70285833:-	-0.42	-7.35	8.3E-13	Menarche (age at onset)	
LGG	cis	1	rs929843	chr16:70045748	PDXDC2	chr16:70010210-70099851:-	-0.38	-11.45	4.48E-27	Menarche (age at onset)	
LGG	cis	1	rs9299894	chr11:89156698	NOX4	chr11:89057524-89322779:-	0.37	3.98	7.96E-5	Homocysteine levels	
LGG	cis	1	rs9299	chr17:46669430	CBX1	chr17:46147415-46178883:-	0.2	3.89	0.000116	Obesity	
LGG	cis	1	rs9303542	chr17:46411500	HOXB2	chr17:46620021-46622393:-	-0.18	-3.47	0.000558	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs930421	chr2:42981239	HAAO	chr2:42994230-43019751:-	0.15	4.13	4.34E-5	Attention deficit hyperactivity disorder	
LGG	cis	1	rs9306329	chr22:39072454	LOC646851	chr22:38974125-39052634:-	0.23	6.92	1.43E-11	Resting heart rate	
LGG	cis	1	rs9307050	chr4:76905649	NAAA	chr4:76831809-76862166:-	-0.46	-11.12	8.73E-26	Longevity	
LGG	cis	1	rs930734	chr1:202318316	UBE2T	chr1:202300786-202311094:-	0.13	3.92	0.000101	Sex ratio	
LGG	cis	1	rs9308731	chr2:111908262	ACOXL	chr2:111490150-111875799:+	-0.21	-3.77	0.00018	Chronic lymphocytic leukemia	
LGG	cis	1	rs9309331	chr2:61141615	AHSA2	chr2:61404553-61414058:+	-0.24	-6.03	3.19E-9	Inflammatory skin disease	
LGG	cis	1	rs9309331	chr2:61141615	C2orf74	chr2:61372243-61391964:+	0.31	5.26	2.18E-7	Inflammatory skin disease	
LGG	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.4	7.1	4.35E-12	Metabolite levels	
LGG	cis	1	rs9309473	chr2:73743982	NAT8	chr2:73867850-73869537:-	0.26	4.29	2.13E-5	Metabolite levels	
LGG	cis	1	rs931058	chr5:150333698	LOC134466	chr5:150310000-150326146:-	0.48	5.13	4.27E-7	Crohn's disease	
LGG	cis	1	rs9311171	chr3:37996477	SCN11A	chr3:38887260-38992052:-	-0.23	-3.84	0.000138	Prostate cancer	
LGG	cis	1	rs931127	chr11:65405300	SNX32	chr11:65601410-65621170:+	-0.14	-3.7	0.000239	Systemic lupus erythematosus	
LGG	cis	1	rs9311288	chr3:41804581	ULK4	chr3:41288091-42003660:-	0.78	15.52	1.76E-44	Diastolic blood pressure	
LGG	cis	1	rs9311423	chr3:48420308	ATRIP	chr3:48488141-48507708:+	0.2	4.99	8.5E-7	Longevity	
LGG	cis	1	rs9311423	chr3:48420308	TREX1	chr3:48501186-48509043:+	-0.4	-10.29	1.32E-22	Longevity	
LGG	cis	1	rs9311474	chr3:52338852	TMEM110	chr3:52867139-52931547:-	0.15	3.56	0.00041	Electroencephalogram traits	
LGG	cis	1	rs9311745	chr3:60001825	C3orf67	chr3:58711287-59035758:-	-0.49	-4.68	3.73E-6	Pit-and-Fissure caries	
LGG	cis	1	rs9312662	chr4:56386371	TMEM165	chr4:56262090-56292342:+	0.17	4.93	1.14E-6	Personality dimensions	
LGG	cis	1	rs931794	chr15:78826180	CHRNA5	chr15:78857906-78886458:+	0.69	13.63	4.3E-36	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs931812	chr8:101919321	YWHAZ	chr8:101930804-101965623:-	0.14	3.57	0.000386	Attention deficit hyperactivity disorder and conduct disorder	
LGG	cis	1	rs9320287	chr6:109744690	AKD1	chr6:109814059-110012415:-	-0.26	-5.26	2.14E-7	Height	
LGG	cis	1	rs9320287	chr6:109744690	MICAL1	chr6:109765268-109787171:-	-0.32	-7.48	3.35E-13	Height	
LGG	cis	1	rs9320287	chr6:109744690	SMPD2	chr6:109761931-109765121:+	0.19	3.82	0.000148	Height	
LGG	cis	1	rs9321490	chr6:135494875	ALDH8A1	chr6:135238529-135271244:-	-0.2	-4.05	5.91E-5	Multiple sclerosis	
LGG	cis	1	rs9322193	chr6:149919143	NUP43	chr6:150045453-150067688:-	-0.17	-3.79	0.00017	Lung cancer	
LGG	cis	1	rs9322193	chr6:149919143	RAET1G	chr6:150238014-150244214:-	0.28	4.93	1.11E-6	Lung cancer	
LGG	cis	1	rs9322193	chr6:149919143	ULBP1	chr6:150285143-150294844:+	0.18	3.58	0.000373	Lung cancer	
LGG	cis	1	rs9322817	chr6:105232233	HACE1	chr6:105175968-105307794:-	-0.15	-3.62	0.00033	Thyroid stimulating hormone	
LGG	cis	1	rs9324660	chr5:150257054	LOC134466	chr5:150310000-150326146:-	0.42	4.84	1.75E-6	Crohn's disease	
LGG	cis	1	rs9326314	chr11:101433161	TRPC6	chr11:101322296-101454659:-	-0.22	-4.1	4.9E-5	Menarche (age at onset)	
LGG	cis	1	rs932835	chr9:131887071	CRAT	chr9:131857075-131873070:-	0.2	3.65	0.000292	Blood metabolite ratios	
LGG	cis	1	rs9329165	chr8:8576642	FLJ10661	chr8:8086092-8102386:+	0.26	4.94	1.09E-6	Obesity-related traits	
LGG	cis	1	rs9329166	chr8:8576655	FLJ10661	chr8:8086092-8102386:+	-0.26	-4.83	1.86E-6	Obesity-related traits	
LGG	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.28	7.2	2.35E-12	Height	
LGG	cis	1	rs934624	chr15:50968906	SPPL2A	chr15:50999739-51057910:-	0.13	4.1	4.83E-5	QT interval	
LGG	cis	1	rs934625	chr15:50968756	SPPL2A	chr15:50999739-51057910:-	0.13	4.2	3.23E-5	QT interval	
LGG	cis	1	rs9348968	chr6:35117251	TCP11	chr6:35085849-35109187:-	-0.35	-5.94	5.29E-9	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs935334	chr14:76613678	ESRRB	chr14:76837690-76968178:+	0.42	6.8	3.1E-11	Blood pressure	
LGG	cis	1	rs9357010	chr6:26527945	HMGN4	chr6:26538572-26547162:+	-0.2	-5.27	2.06E-7	Educational attainment	
LGG	cis	1	rs9357037	chr6:27327349	ZNF391	chr6:27356524-27369227:+	0.3	7.45	4.15E-13	Glomerular filtration rate (creatinine)	
LGG	cis	1	rs936228	chr15:75132164	MPI	chr15:75182410-75190565:+	0.28	6.07	2.49E-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	
LGG	cis	1	rs936229	chr15:75132319	MPI	chr15:75182410-75190565:+	0.28	6.04	3.05E-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	
LGG	cis	1	rs9362395	chr6:87854341	C6orf163	chr6:88057220-88075180:+	-0.46	-5.14	4.04E-7	Schizophrenia	
LGG	cis	1	rs9362426	chr6:88089874	C6orf163	chr6:88057220-88075180:+	0.22	3.98	7.81E-5	Depressive episodes in bipolar disorder	
LGG	cis	1	rs9364554	chr6:160833664	SLC22A1	chr6:160542863-160579748:+	0.21	3.47	0.000574	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs936525	chr19:23056189	ZNF492	chr19:22817126-22850472:+	-0.21	-4.27	2.36E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs936526	chr19:23055987	ZNF492	chr19:22817126-22850472:+	-0.22	-4.44	1.12E-5	Bronchopulmonary dysplasia	
LGG	cis	1	rs9368849	chr6:35118236	TCP11	chr6:35085849-35109187:-	-0.35	-5.77	1.43E-8	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs937108	chr7:65428452	CCT6P1	chr7:65216092-65228661:+	0.25	4.62	4.81E-6	Diabetic kidney disease	
LGG	cis	1	rs9371221	chr6:151885986	C6orf97	chr6:151815175-151942327:+	0.29	4.64	4.57E-6	Bone mineral density (spine)	
LGG	cis	1	rs9371226	chr6:151986594	C6orf97	chr6:151815175-151942327:+	0.39	5.58	4.01E-8	Breast cancer	
LGG	cis	1	rs9371408	chr6:156266096	TFB1M	chr6:155578791-155635626:-	0.34	3.62	0.00032	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis	
LGG	cis	1	rs9371537	chr6:151872500	C6orf97	chr6:151815175-151942327:+	-0.25	-4.11	4.68E-5	Bone mineral density (spine)	
LGG	cis	1	rs9371538	chr6:151872963	C6orf211	chr6:151773422-151791232:+	0.25	3.67	0.000267	Bone mineral density (spine)	
LGG	cis	1	rs9371538	chr6:151872963	C6orf97	chr6:151815175-151942327:+	-0.24	-3.95	8.81E-5	Bone mineral density (spine)	
LGG	cis	1	rs9371547	chr6:151982089	C6orf97	chr6:151815175-151942327:+	0.34	5.08	5.3E-7	Breast cancer	
LGG	cis	1	rs9372149	chr6:107473218	PDSS2	chr6:107473761-107780779:-	-0.24	-4.33	1.83E-5	Childhood and early adolescence aggressive behavior	
LGG	cis	1	rs937495	chr7:65779798	ASL	chr7:65540776-65558321:+	0.22	5.57	4.26E-8	Aortic root size	
LGG	cis	1	rs9377228	chr6:149921998	NUP43	chr6:150045453-150067688:-	-0.18	-4.03	6.47E-5	Lung cancer	
LGG	cis	1	rs9377228	chr6:149921998	RAET1G	chr6:150238014-150244214:-	0.28	4.88	1.43E-6	Lung cancer	
LGG	cis	1	rs9377228	chr6:149921998	ULBP1	chr6:150285143-150294844:+	0.18	3.56	0.000406	Lung cancer	
LGG	cis	1	rs9377228	chr6:149921998	ULBP2	chr6:150263136-150270366:+	0.19	4.14	4.15E-5	Lung cancer	
LGG	cis	1	rs9377229	chr6:149928791	RAET1G	chr6:150238014-150244214:-	0.29	5.06	5.83E-7	Lung cancer	
LGG	cis	1	rs9377229	chr6:149928791	ULBP1	chr6:150285143-150294844:+	0.19	3.87	0.000123	Lung cancer	
LGG	cis	1	rs9377229	chr6:149928791	ULBP2	chr6:150263136-150270366:+	0.16	3.54	0.000445	Lung cancer	
LGG	cis	1	rs9380378	chr6:33765479	LEMD2	chr6:33738991-33756906:-	-0.14	-4.35	1.65E-5	Crohn's disease	
LGG	cis	1	rs9381040	chr6:41154650	LOC221442	chr6:41068773-41108567:+	0.18	4.96	9.85E-7	Alzheimer's disease (late onset)	
LGG	cis	1	rs9381469	chr6:46630068	SLC25A27	chr6:46620679-46645925:+	-0.19	-6.75	4.18E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9381469	chr6:46630068	TDRD6	chr6:46655866-46670149:+	0.28	6.93	1.36E-11	QRS complex (Sokolow-Lyon)	
LGG	cis	1	rs9383938	chr6:151987357	C6orf97	chr6:151815175-151942327:+	0.41	5.72	1.81E-8	Breast cancer	
LGG	cis	1	rs9388486	chr6:126661154	CENPW	chr6:126661253-126804465:+	0.14	3.58	0.000374	Type 1 diabetes	
LGG	cis	1	rs9388489	chr6:126698719	CENPW	chr6:126661253-126804465:+	0.16	4.11	4.67E-5	Type 1 diabetes	
LGG	cis	1	rs9388490	chr6:126704795	CENPW	chr6:126661253-126804465:+	-0.15	-3.89	0.000113	Type 1 diabetes	
LGG	cis	1	rs938875	chr15:67952922	IQCH	chr15:67547188-67794139:+	0.14	4.03	6.49E-5	Motion sickness	
LGG	cis	1	rs938878	chr15:67993366	IQCH	chr15:67547188-67794139:+	0.13	3.62	0.000322	Motion sickness	
LGG	cis	1	rs939337	chr3:183701147	ABCC5	chr3:183637726-183735727:-	0.11	3.5	0.000502	Anterior chamber depth	
LGG	cis	1	rs939338	chr3:183704068	ABCC5	chr3:183637726-183735727:-	-0.11	-3.47	0.000561	Anterior chamber depth	
LGG	cis	1	rs9393692	chr6:26276650	HIST1H3E	chr6:26224427-26226589:+	0.19	3.81	0.000159	Educational attainment	
LGG	cis	1	rs9393728	chr6:26509330	HMGN4	chr6:26538572-26547162:+	-0.2	-5.15	3.72E-7	Educational attainment	
LGG	cis	1	rs9393729	chr6:26514166	BTN2A3	chr6:26422317-26431927:+	0.12	3.46	0.000593	Educational attainment	
LGG	cis	1	rs9393729	chr6:26514166	HMGN4	chr6:26538572-26547162:+	-0.2	-5.28	1.97E-7	Educational attainment	
LGG	cis	1	rs9393731	chr6:26529374	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs9393731	chr6:26529374	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs9393732	chr6:26530898	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs9393732	chr6:26530898	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs9394159	chr6:33618162	ITPR3	chr6:33589161-33664346:+	0.17	4.09	5.05E-5	Graves' disease	
LGG	cis	1	rs9394166	chr6:33751122	LEMD2	chr6:33738991-33756906:-	-0.14	-4.59	5.53E-6	Crohn's disease	
LGG	cis	1	rs9394931	chr6:42873245	GNMT	chr6:42928500-42931617:+	0.34	7.92	1.55E-14	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
LGG	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.31	-6.36	4.67E-10	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
LGG	cis	1	rs9395174	chr6:46313100	ENPP5	chr6:46127762-46138717:-	0.15	3.48	0.000547	Body mass index	
LGG	cis	1	rs939558	chr3:41976040	ULK4	chr3:41288091-42003660:-	-0.78	-15.48	2.53E-44	Diastolic blood pressure	
LGG	cis	1	rs9397069	chr6:151980707	C6orf97	chr6:151815175-151942327:+	0.34	5.07	5.67E-7	Breast cancer	
LGG	cis	1	rs9397240	chr6:155648579	TFB1M	chr6:155578791-155635626:-	0.29	4.03	6.55E-5	Life satisfaction	
LGG	cis	1	rs9397424	chr6:151872791	C6orf97	chr6:151815175-151942327:+	0.26	4.18	3.4E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397425	chr6:151873024	C6orf97	chr6:151815175-151942327:+	0.26	4.27	2.39E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397427	chr6:151875034	C6orf97	chr6:151815175-151942327:+	0.26	4.26	2.46E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397428	chr6:151875080	C6orf97	chr6:151815175-151942327:+	0.27	4.34	1.71E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397429	chr6:151877569	C6orf97	chr6:151815175-151942327:+	0.28	4.43	1.17E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397431	chr6:151883930	C6orf97	chr6:151815175-151942327:+	0.28	4.43	1.17E-5	Bone mineral density (spine)	
LGG	cis	1	rs9397440	chr6:151978802	C6orf97	chr6:151815175-151942327:+	0.34	5.04	6.58E-7	Breast cancer	
LGG	cis	1	rs9397441	chr6:151982315	C6orf97	chr6:151815175-151942327:+	0.34	5.08	5.3E-7	Breast cancer	
LGG	cis	1	rs9398235	chr6:110732116	DDO	chr6:110713384-110736753:-	-0.34	-6.02	3.5E-9	Systemic lupus erythematosus	
LGG	cis	1	rs9399693	chr6:149933854	RAET1G	chr6:150238014-150244214:-	0.29	4.98	8.96E-7	Lung cancer	
LGG	cis	1	rs9399693	chr6:149933854	ULBP1	chr6:150285143-150294844:+	0.2	4.05	6.04E-5	Lung cancer	
LGG	cis	1	rs9399693	chr6:149933854	ULBP2	chr6:150263136-150270366:+	0.19	4.2	3.17E-5	Lung cancer	
LGG	cis	1	rs9400317	chr6:110007647	AKD1	chr6:109814059-110012415:-	-0.26	-3.77	0.000182	Response to hepatitis C treatment	
LGG	cis	1	rs940045	chr3:49449638	AMIGO3	chr3:49754268-49757238:-	-0.17	-3.93	9.75E-5	Menarche (age at onset)	
LGG	cis	1	rs940045	chr3:49449638	GMPPB	chr3:49758932-49761384:-	-0.21	-4.13	4.32E-5	Menarche (age at onset)	
LGG	cis	1	rs940045	chr3:49449638	NCKIPSD	chr3:48711280-48723334:-	0.16	3.74	0.000206	Menarche (age at onset)	
LGG	cis	1	rs940045	chr3:49449638	TREX1	chr3:48501186-48509043:+	-0.25	-5.17	3.38E-7	Menarche (age at onset)	
LGG	cis	1	rs940174	chr3:136309710	PCCB	chr3:135969167-136056737:+	0.21	4.21	3.01E-5	Schizophrenia	
LGG	cis	1	rs9410	chr4:159631991	ETFDH	chr4:159593277-159629839:+	-0.35	-7.31	1.06E-12	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs9419897	chr10:102246125	HIF1AN	chr10:102295641-102313680:+	0.18	3.61	0.000331	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9419897	chr10:102246125	NDUFB8	chr10:102283497-102289636:-	0.15	4.29	2.16E-5	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9419897	chr10:102246125	WNT8B	chr10:102222812-102243397:+	0.52	8.79	2.58E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420782	chr10:102235015	HIF1AN	chr10:102295641-102313680:+	0.19	3.77	0.000186	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420782	chr10:102235015	NDUFB8	chr10:102283497-102289636:-	0.16	4.52	7.76E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420782	chr10:102235015	WNT8B	chr10:102222812-102243397:+	0.51	8.75	3.31E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420785	chr10:102240451	HIF1AN	chr10:102295641-102313680:+	0.19	3.78	0.000174	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420785	chr10:102240451	NDUFB8	chr10:102283497-102289636:-	0.16	4.56	6.39E-6	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420785	chr10:102240451	WNT8B	chr10:102222812-102243397:+	0.52	8.81	2.08E-17	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420797	chr10:102331147	NDUFB8	chr10:102283497-102289636:-	0.12	3.6	0.000351	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420797	chr10:102331147	WNT8B	chr10:102222812-102243397:+	0.44	7.5	3.03E-13	Palmitoleic acid (16:1n-7) plasma levels	
LGG	cis	1	rs9420907	chr10:105676465	OBFC1	chr10:105637320-105678045:-	-0.24	-3.61	0.00034	Telomere length	
LGG	cis	1	rs9420	chr11:57510294	TIMM10	chr11:57295936-57298232:-	0.16	3.98	8.09E-5	Schizophrenia	
LGG	cis	1	rs942270	chr1:76177332	MSH4	chr1:76262630-76378923:+	0.25	4.34	1.73E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs9425766	chr1:173853127	DARS2	chr1:173793958-173827682:+	-0.2	-5.12	4.29E-7	Life satisfaction	
LGG	cis	1	rs9425766	chr1:173853127	SERPINC1	chr1:173872943-173886516:-	0.26	4.69	3.51E-6	Life satisfaction	
LGG	cis	1	rs9425766	chr1:173853127	SLC9A11	chr1:173469604-173572233:-	0.19	4.22	2.86E-5	Life satisfaction	
LGG	cis	1	rs942812	chr10:100153664	PYROXD2	chr10:100143323-100174978:-	0.31	3.86	0.000127	Aspartate aminotransferase	
LGG	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.84	1.77E-6	Body mass index	
LGG	cis	1	rs9429183	chr1:46524582	MUTYH	chr1:45794915-45806142:-	0.14	5.19	3.13E-7	Body mass index	
LGG	cis	1	rs943461	chr6:33769409	LEMD2	chr6:33738991-33756906:-	0.18	5.21	2.84E-7	Body mass index	
LGG	cis	1	rs943462	chr6:33769578	LEMD2	chr6:33738991-33756906:-	0.18	5.21	2.84E-7	Body mass index	
LGG	cis	1	rs943466	chr6:33731787	LEMD2	chr6:33738991-33756906:-	-0.16	-4.84	1.73E-6	Body mass index	
LGG	cis	1	rs943477	chr6:33750931	BAK1	chr6:33540324-33548070:-	-0.15	-3.46	0.00058	Crohn's disease	
LGG	cis	1	rs943477	chr6:33750931	LEMD2	chr6:33738991-33756906:-	-0.15	-4.63	4.75E-6	Crohn's disease	
LGG	cis	1	rs9436116	chr1:150454724	LOC728855	chr1:149576161-149672983:+;chr1	-0.17	-3.53	0.000448	Morning vs. evening chronotype	
LGG	cis	1	rs9436116	chr1:150454724	MRPS21	chr1:150266269-150280818:+	0.21	6.1	2.17E-9	Morning vs. evening chronotype	
LGG	cis	1	rs9439030	chr1:41146501	LOC100130557	chr1:41154752-41157933:-	0.25	3.49	0.00052	Depressive and manic episodes in bipolar disorder	
LGG	cis	1	rs9450662	chr6:88088593	C6orf163	chr6:88057220-88075180:+	0.22	3.95	8.8E-5	Depressive episodes in bipolar disorder	
LGG	cis	1	rs9457799	chr6:160408325	WTAP	chr6:160148129-160177349:+	0.25	3.75	0.000201	Brain lesion load	
LGG	cis	1	rs945961	chr20:33769926	PROCR	chr20:33758727-33765164:+	-0.36	-6.52	1.78E-10	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs9461010	chr6:24440206	MRS2	chr6:24403153-24425809:+	-0.21	-3.52	0.000479	Liver enzyme levels	
LGG	cis	1	rs9461259	chr6:26504835	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.89E-7	Educational attainment	
LGG	cis	1	rs9461271	chr6:26554968	BTN2A3	chr6:26422317-26431927:+	0.13	3.69	0.000252	Educational attainment	
LGG	cis	1	rs9461271	chr6:26554968	HMGN4	chr6:26538572-26547162:+	-0.19	-4.93	1.15E-6	Educational attainment	
LGG	cis	1	rs9462007	chr6:34715341	C6orf106	chr6:34555066-34664625:-	0.25	4.98	8.72E-7	Pubertal anthropometrics	
LGG	cis	1	rs9462016	chr6:34739790	C6orf106	chr6:34555066-34664625:-	0.25	4.98	8.7E-7	Pubertal anthropometrics	
LGG	cis	1	rs9463078	chr6:45181340	SUPT3H	chr6:44777054-45345670:-	-0.19	-4.55	6.65E-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	
LGG	cis	1	rs9463473	chr6:49380121	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.15E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9463474	chr6:49380199	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.15E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9463475	chr6:49380899	CENPQ	chr6:49431096-49460820:+	0.23	5.08	5.39E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9463477	chr6:49386446	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9463479	chr6:49393275	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9463480	chr6:49400795	CENPQ	chr6:49431096-49460820:+	-0.22	-4.94	1.07E-6	Folate pathway vitamin levels	
LGG	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.16	-4.62	5.0E-6	Body mass index	
LGG	cis	1	rs946529	chr1:46485548	MUTYH	chr1:45794915-45806142:-	0.14	5.01	7.43E-7	Body mass index	
LGG	cis	1	rs9467157	chr6:24440644	MRS2	chr6:24403153-24425809:+	-0.22	-3.6	0.000345	Liver enzyme levels	
LGG	cis	1	rs9467158	chr6:24441215	MRS2	chr6:24403153-24425809:+	-0.22	-3.53	0.000458	Liver enzyme levels	
LGG	cis	1	rs9467160	chr6:24441746	MRS2	chr6:24403153-24425809:+	-0.21	-3.56	0.000408	Liver enzyme levels	
LGG	cis	1	rs9467161	chr6:24441963	MRS2	chr6:24403153-24425809:+	-0.22	-3.46	0.000593	Liver enzyme levels	
LGG	cis	1	rs9467162	chr6:24442047	MRS2	chr6:24403153-24425809:+	-0.22	-3.46	0.000593	Liver enzyme levels	
LGG	cis	1	rs9467773	chr6:26498426	HMGN4	chr6:26538572-26547162:+	-0.19	-5.03	6.83E-7	Educational attainment	
LGG	cis	1	rs9467774	chr6:26505036	HMGN4	chr6:26538572-26547162:+	-0.2	-5.15	3.72E-7	Educational attainment	
LGG	cis	1	rs9467778	chr6:26534743	BTN2A3	chr6:26422317-26431927:+	0.12	3.53	0.000453	Educational attainment	
LGG	cis	1	rs9467778	chr6:26534743	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.3E-7	Educational attainment	
LGG	cis	1	rs9467779	chr6:26536687	BTN2A3	chr6:26422317-26431927:+	-0.13	-3.65	0.000292	Educational attainment	
LGG	cis	1	rs9467779	chr6:26536687	HMGN4	chr6:26538572-26547162:+	0.17	4.3	2.05E-5	Educational attainment	
LGG	cis	1	rs9467782	chr6:26542773	BTN2A3	chr6:26422317-26431927:+	0.12	3.59	0.000367	Educational attainment	
LGG	cis	1	rs9467782	chr6:26542773	HMGN4	chr6:26538572-26547162:+	-0.19	-5.08	5.47E-7	Educational attainment	
LGG	cis	1	rs9467783	chr6:26542894	BTN2A3	chr6:26422317-26431927:+	0.12	3.47	0.00056	Educational attainment	
LGG	cis	1	rs9467783	chr6:26542894	HMGN4	chr6:26538572-26547162:+	-0.19	-4.91	1.27E-6	Educational attainment	
LGG	cis	1	rs9467787	chr6:26556769	BTN2A3	chr6:26422317-26431927:+	0.13	3.69	0.000252	Educational attainment	
LGG	cis	1	rs9467787	chr6:26556769	HMGN4	chr6:26538572-26547162:+	-0.19	-4.93	1.15E-6	Educational attainment	
LGG	cis	1	rs9467791	chr6:26562486	BTN2A3	chr6:26422317-26431927:+	-0.14	-3.89	0.000112	Educational attainment	
LGG	cis	1	rs9467791	chr6:26562486	HMGN4	chr6:26538572-26547162:+	0.17	4.2	3.15E-5	Educational attainment	
LGG	cis	1	rs9467796	chr6:26568411	BTN2A3	chr6:26422317-26431927:+	0.13	3.63	0.000315	Educational attainment	
LGG	cis	1	rs9467796	chr6:26568411	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.55E-6	Educational attainment	
LGG	cis	1	rs9467797	chr6:26568473	BTN2A3	chr6:26422317-26431927:+	0.13	3.63	0.000315	Educational attainment	
LGG	cis	1	rs9467797	chr6:26568473	HMGN4	chr6:26538572-26547162:+	-0.18	-4.56	6.55E-6	Educational attainment	
LGG	cis	1	rs9468186	chr6:27626631	ZNF389	chr6:28129551-28137375:+	0.22	4.41	1.25E-5	Neuroticism	
LGG	cis	1	rs9468186	chr6:27626631	ZSCAN23	chr6:28393287-28411279:-	0.13	3.86	0.000127	Neuroticism	
LGG	cis	1	rs9469860	chr6:34724815	C6orf106	chr6:34555066-34664625:-	0.25	5.01	7.43E-7	Pubertal anthropometrics	
LGG	cis	1	rs9469890	chr6:34763982	C6orf106	chr6:34555066-34664625:-	0.25	4.98	8.72E-7	Pubertal anthropometrics	
LGG	cis	1	rs9471490	chr6:41153037	TREML2	chr6:41157552-41168925:-	-0.34	-3.58	0.000379	C-reactive protein	
LGG	cis	1	rs947211	chr1:205752665	PM20D1	chr1:205797154-205819245:-	-0.36	-6.09	2.33E-9	Parkinson's disease	
LGG	cis	1	rs9473549	chr6:49380020	CENPQ	chr6:49431096-49460820:+	-0.23	-5.14	4.02E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9473552	chr6:49387154	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9473553	chr6:49395977	CENPQ	chr6:49431096-49460820:+	-0.22	-4.93	1.11E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9473555	chr6:49409487	CENPQ	chr6:49431096-49460820:+	-0.22	-4.9	1.33E-6	Folate pathway vitamin levels	
LGG	cis	1	rs9473560	chr6:49427918	CENPQ	chr6:49431096-49460820:+	-0.23	-4.97	9.38E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9473561	chr6:49428755	CENPQ	chr6:49431096-49460820:+	-0.23	-5	7.88E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9473563	chr6:49453651	CENPQ	chr6:49431096-49460820:+	-0.24	-5.28	1.9E-7	Folate pathway vitamin levels	
LGG	cis	1	rs9475752	chr6:56780741	BEND6	chr6:56819773-56892138:+	-0.32	-5.84	9.49E-9	Menarche (age at onset)	
LGG	cis	1	rs9475752	chr6:56780741	KIAA1586	chr6:56911384-56920021:+	-0.14	-3.85	0.000131	Menarche (age at onset)	
LGG	cis	1	rs9479090	chr6:151989300	C6orf97	chr6:151815175-151942327:+	0.31	4.67	3.94E-6	Breast cancer	
LGG	cis	1	rs947932	chr11:71656705	FAM86C	chr11:71498557-71512276:+	0.52	5.12	4.39E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs9480933	chr6:109671391	AKD1	chr6:109814059-110012415:-	-0.29	-5.94	5.33E-9	Height	
LGG	cis	1	rs9480933	chr6:109671391	MICAL1	chr6:109765268-109787171:-	-0.32	-7.71	6.95E-14	Height	
LGG	cis	1	rs9480933	chr6:109671391	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.72	0.000224	Height	
LGG	cis	1	rs9480953	chr6:109739144	AKD1	chr6:109814059-110012415:-	-0.28	-5.86	8.63E-9	Height	
LGG	cis	1	rs9480953	chr6:109739144	MICAL1	chr6:109765268-109787171:-	-0.32	-7.58	1.69E-13	Height	
LGG	cis	1	rs9480953	chr6:109739144	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.62	0.000328	Height	
LGG	cis	1	rs9480955	chr6:109744533	AKD1	chr6:109814059-110012415:-	-0.26	-5.26	2.14E-7	Height	
LGG	cis	1	rs9480955	chr6:109744533	MICAL1	chr6:109765268-109787171:-	-0.32	-7.48	3.35E-13	Height	
LGG	cis	1	rs9480955	chr6:109744533	SMPD2	chr6:109761931-109765121:+	0.19	3.82	0.000148	Height	
LGG	cis	1	rs948562	chr11:58347765	ZFP91-CNTF	chr11:58346587-58393203:+	0.36	5.9	6.7E-9	Lymphoma	
LGG	cis	1	rs9486595	chr6:107675437	QRSL1	chr6:107077441-107116290:+	0.33	3.46	0.00058	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs9486596	chr6:107675921	QRSL1	chr6:107077441-107116290:+	0.33	3.47	0.000574	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs9486598	chr6:107682932	QRSL1	chr6:107077441-107116290:+	0.33	3.46	0.00058	Airway responsiveness in chronic obstructive pulmonary disease	
LGG	cis	1	rs9487094	chr6:109742015	AKD1	chr6:109814059-110012415:-	-0.28	-5.86	8.63E-9	Height	
LGG	cis	1	rs9487094	chr6:109742015	MICAL1	chr6:109765268-109787171:-	-0.32	-7.58	1.69E-13	Height	
LGG	cis	1	rs9487094	chr6:109742015	ZBTB24	chr6:109783719-109804440:-	-0.18	-3.62	0.000328	Height	
LGG	cis	1	rs9491624	chr6:126679106	CENPW	chr6:126661253-126804465:+	-0.15	-3.99	7.62E-5	Type 1 diabetes	
LGG	cis	1	rs949325	chr11:71729656	FAM86C	chr11:71498557-71512276:+	0.52	4.99	8.35E-7	Severe influenza A (H1N1) infection	
LGG	cis	1	rs9494145	chr6:135432552	ALDH8A1	chr6:135238529-135271244:-	-0.27	-4.83	1.85E-6	Fetal hemoglobin levels in sickle cell anemia;Platelet count;Mean platelet volume;Red blood cell traits	
LGG	cis	1	rs949848	chr8:58169125	C8orf71	chr8:58192102-58197288:+	0.35	6.15	1.58E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs950027	chr15:45801035	SPATA5L1	chr15:45694519-45713614:+	-0.29	-5.66	2.58E-8	Response to fenofibrate (adiponectin levels)	
LGG	cis	1	rs950169	chr15:84706461	GOLGA6L5	chr15:85047738-85060078:-	-0.23	-5.37	1.19E-7	Schizophrenia	
LGG	cis	1	rs950169	chr15:84706461	LOC388152	chr15:84867600-84898920:-	-0.32	-6.23	1.01E-9	Schizophrenia	
LGG	cis	1	rs950699	chr4:79505772	ANXA3	chr4:79472742-79531602:+	0.29	6.84	2.34E-11	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs950880	chr2:102932562	IL18R1	chr2:102927962-103015215:+	-0.34	-6.48	2.3E-10	Serum protein levels (sST2)	
LGG	cis	1	rs950880	chr2:102932562	IL1RL1	chr2:102927962-102968497:+	-0.37	-6.39	3.82E-10	Serum protein levels (sST2)	
LGG	cis	1	rs9510795	chr13:24216012	PCOTH	chr13:24463028-24466241:+	-0.19	-4.13	4.24E-5	Diabetic kidney disease	
LGG	cis	1	rs951084	chr1:227700252	JMJD4	chr1:227918891-227923112:-	0.22	3.71	0.00023	Height	
LGG	cis	1	rs9510907	chr13:24435564	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs9510908	chr13:24435768	RNF17	chr13:25338301-25454056:+	-0.32	-3.59	0.000363	3-hydroxypropylmercapturic acid levels in smokers	
LGG	cis	1	rs951366	chr1:205685352	PM20D1	chr1:205797154-205819245:-	-0.4	-7.6	1.55E-13	Menarche (age at onset)	
LGG	cis	1	rs951366	chr1:205685352	RAB7L1	chr1:205737115-205744610:-	0.16	4.13	4.34E-5	Menarche (age at onset)	
LGG	cis	1	rs9527	chr10:104623578	AS3MT	chr10:104613967-104661653:+	-0.76	-17.36	5.77E-53	Arsenic metabolism	
LGG	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.44	-9.15	1.55E-18	Arsenic metabolism	
LGG	cis	1	rs9531455	chr13:36685304	SOHLH2	chr13:36742347-36871992:-	0.39	5.88	7.62E-9	Optic cup area	
LGG	cis	1	rs9532430	chr13:40351341	COG6	chr13:40229764-40365802:+	0.27	5.8	1.22E-8	Rheumatoid arthritis	
LGG	cis	1	rs9532433	chr13:40352671	COG6	chr13:40229764-40365802:+	0.27	5.87	7.82E-9	Rheumatoid arthritis	
LGG	cis	1	rs9532434	chr13:40355913	COG6	chr13:40229764-40365802:+	0.27	5.79	1.25E-8	Rheumatoid arthritis	
LGG	cis	1	rs9533566	chr13:44224691	C13orf31	chr13:44453420-44468067:+	-0.1	-3.62	0.000328	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs9533572	chr13:44234265	C13orf31	chr13:44453420-44468067:+	-0.11	-3.81	0.000155	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs9546421	chr13:36690750	SOHLH2	chr13:36742347-36871992:-	0.39	5.82	1.08E-8	Optic cup area	
LGG	cis	1	rs9546430	chr13:36692673	SOHLH2	chr13:36742347-36871992:-	0.39	5.88	7.63E-9	Optic cup area	
LGG	cis	1	rs9546434	chr13:36694391	SOHLH2	chr13:36742347-36871992:-	0.39	5.88	7.63E-9	Optic cup area	
LGG	cis	1	rs9548932	chr13:40353230	COG6	chr13:40229764-40365802:+	0.27	5.75	1.6E-8	Rheumatoid arthritis	
LGG	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.52	10.66	5.08E-24	Response to antipsychotic treatment	
LGG	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.51	-10.32	1.02E-22	Response to antipsychotic treatment	
LGG	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.52	-10.47	2.76E-23	Response to antipsychotic treatment	
LGG	cis	1	rs9556710	chr13:98010406	OXGR1	chr13:97637973-97646604:-	0.32	3.94	9.51E-5	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score)	
LGG	cis	1	rs9559424	chr13:109506635	FAM155A	chr13:107820880-108519460:-	0.18	3.83	0.000147	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)	
LGG	cis	1	rs9559425	chr13:109507359	FAM155A	chr13:107820880-108519460:-	0.18	3.83	0.000146	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)	
LGG	cis	1	rs9559426	chr13:109507619	FAM155A	chr13:107820880-108519460:-	0.18	3.81	0.000156	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)	
LGG	cis	1	rs9559427	chr13:109512417	FAM155A	chr13:107820880-108519460:-	0.17	3.67	0.000272	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)	
LGG	cis	1	rs9568274	chr13:50179334	CDADC1	chr13:49822103-49867619:+	-0.28	-3.66	0.000284	Multiple sclerosis	
LGG	cis	1	rs9568281	chr13:50185204	CDADC1	chr13:49822103-49867619:+	-0.29	-3.71	0.000233	Multiple sclerosis	
LGG	cis	1	rs9568281	chr13:50185204	TRIM13	chr13:50571143-50592603:+	-0.28	-3.58	0.000384	Multiple sclerosis	
LGG	cis	1	rs9576321	chr13:38205546	ALG5	chr13:37523910-37573504:-	0.17	3.62	0.00032	Life satisfaction	
LGG	cis	1	rs9576321	chr13:38205546	EXOSC8	chr13:37574678-37583749:+	0.15	3.89	0.000113	Life satisfaction	
LGG	cis	1	rs9576322	chr13:38205561	ALG5	chr13:37523910-37573504:-	-0.2	-4.42	1.24E-5	Life satisfaction	
LGG	cis	1	rs9576322	chr13:38205561	EXOSC8	chr13:37574678-37583749:+	-0.15	-4.1	4.85E-5	Life satisfaction	
LGG	cis	1	rs957644	chr1:165616157	MGST3	chr1:165600450-165624853:+	0.25	6.93	1.29E-11	Total ventricular volume	
LGG	cis	1	rs958025	chr15:78759348	CHRNA5	chr15:78857906-78886458:+	-0.28	-4.22	2.85E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs958086	chr10:111752548	ADD3	chr10:111756108-111895320:+	0.17	3.74	0.000204	Biliary atresia	
LGG	cis	1	rs958283	chr6:151887150	C6orf97	chr6:151815175-151942327:+	0.29	4.62	4.82E-6	Bone mineral density (spine)	
LGG	cis	1	rs958550	chr7:65635679	CCT6P1	chr7:65216092-65228661:+	-0.19	-3.47	0.000573	Diabetic kidney disease	
LGG	cis	1	rs9591134	chr13:33148216	N4BP2L2	chr13:33006930-33112936:-	0.28	6.44	2.8E-10	Body mass index	
LGG	cis	1	rs9591143	chr13:33159438	N4BP2L2	chr13:33006930-33112936:-	0.25	5.8	1.17E-8	Body mass index	
LGG	cis	1	rs9591145	chr13:33161459	N4BP2L2	chr13:33006930-33112936:-	0.25	5.8	1.17E-8	Body mass index	
LGG	cis	1	rs9591165	chr13:33185153	N4BP2L2	chr13:33006930-33112936:-	0.25	5.87	8.14E-9	Body mass index	
LGG	cis	1	rs9594987	chr13:44230994	C13orf31	chr13:44453420-44468067:+	0.1	3.71	0.000233	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs9595905	chr13:33183403	N4BP2L2	chr13:33006930-33112936:-	0.25	5.91	6.38E-9	Body mass index	
LGG	cis	1	rs9595908	chr13:33184288	N4BP2L2	chr13:33006930-33112936:-	0.28	6.21	1.14E-9	Body mass index	
LGG	cis	1	rs959617	chr1:165616881	MGST3	chr1:165600450-165624853:+	0.24	6.84	2.29E-11	Total ventricular volume	
LGG	cis	1	rs9596219	chr13:50563447	EBPL	chr13:50234811-50265623:-	-0.17	-3.51	0.000487	Height	
LGG	cis	1	rs9603612	chr13:40334852	COG6	chr13:40229764-40365802:+	0.25	5.33	1.53E-7	Rheumatoid arthritis	
LGG	cis	1	rs9603616	chr13:40368069	COG6	chr13:40229764-40365802:+	-0.26	-5.46	7.61E-8	Rheumatoid arthritis	
LGG	cis	1	rs9604529	chr13:114622597	FLJ44054	chr13:114586610-114626485:+	0.23	3.49	0.000534	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs9604570	chr13:114631940	FLJ44054	chr13:114586610-114626485:+	0.31	4.39	1.39E-5	Response to tocilizumab in rheumatoid arthritis	
LGG	cis	1	rs9606830	chr22:31717799	LIMK2	chr22:31608250-31676064:+	-0.27	-5.59	3.78E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs9606831	chr22:31732512	LIMK2	chr22:31608250-31676064:+	-0.26	-5.37	1.22E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs9606944	chr22:32780126	RFPL3S	chr22:32755895-32767063:-	-0.25	-5.55	4.6E-8	IgG glycosylation	
LGG	cis	1	rs9606945	chr22:32780396	RFPL3S	chr22:32755895-32767063:-	-0.25	-5.55	4.6E-8	IgG glycosylation	
LGG	cis	1	rs9606947	chr22:32795285	RFPL3S	chr22:32755895-32767063:-	-0.25	-5.58	3.91E-8	IgG glycosylation	
LGG	cis	1	rs9606950	chr22:32806097	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.49	6.3E-8	IgG glycosylation	
LGG	cis	1	rs9607287	chr22:22163425	CCDC116	chr22:21987086-21991615:+	0.19	3.99	7.61E-5	Multiple sclerosis	
LGG	cis	1	rs9607566	chr22:39075434	LOC646851	chr22:38974125-39052634:-	0.22	6.69	6.22E-11	Resting heart rate	
LGG	cis	1	rs9609254	chr22:31705942	LIMK2	chr22:31608250-31676064:+	-0.27	-5.72	1.81E-8	Paclitaxel-induced neuropathy	
LGG	cis	1	rs9609264	chr22:31746719	LIMK2	chr22:31608250-31676064:+	-0.25	-5.25	2.29E-7	Paclitaxel-induced neuropathy	
LGG	cis	1	rs9609523	chr22:32781931	RFPL3S	chr22:32755895-32767063:-	-0.25	-5.55	4.6E-8	IgG glycosylation	
LGG	cis	1	rs9609527	chr22:32795751	RFPL3S	chr22:32755895-32767063:-	0.24	5.54	5.04E-8	IgG glycosylation	
LGG	cis	1	rs9609529	chr22:32800409	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.49	6.3E-8	IgG glycosylation	
LGG	cis	1	rs9609530	chr22:32800594	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.49	6.3E-8	IgG glycosylation	
LGG	cis	1	rs9609531	chr22:32801100	RFPL3S	chr22:32755895-32767063:-	-0.24	-5.49	6.3E-8	IgG glycosylation	
LGG	cis	1	rs9610986	chr22:39025277	LOC646851	chr22:38974125-39052634:-	0.22	6.6	1.07E-10	Resting heart rate	
LGG	cis	1	rs9610993	chr22:39042818	LOC646851	chr22:38974125-39052634:-	0.22	6.58	1.21E-10	Resting heart rate	
LGG	cis	1	rs9611267	chr22:40506004	SLC25A17	chr22:41165641-41215392:-	-0.22	-3.46	0.000583	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs9620326	chr22:24146629	C22orf43	chr22:23950640-23974487:-	0.31	4.33	1.79E-5	IgG glycosylation	
LGG	cis	1	rs9620326	chr22:24146629	DERL3	chr22:24176691-24181315:-	-0.29	-5.24	2.43E-7	IgG glycosylation	
LGG	cis	1	rs962221	chr1:92970770	EVI5	chr1:92974255-93257961:-	-0.29	-7.12	3.73E-12	Cholesterol, total	
LGG	cis	1	rs962222	chr1:92970953	EVI5	chr1:92974255-93257961:-	-0.29	-7.12	3.73E-12	Cholesterol, total	
LGG	cis	1	rs9622833	chr22:39000397	LOC646851	chr22:38974125-39052634:-	0.22	6.55	1.5E-10	Resting heart rate	
LGG	cis	1	rs9624326	chr22:24135043	C22orf43	chr22:23950640-23974487:-	-0.33	-4.71	3.24E-6	IgG glycosylation	
LGG	cis	1	rs9624326	chr22:24135043	DERL3	chr22:24176691-24181315:-	0.31	5.72	1.9E-8	IgG glycosylation	
LGG	cis	1	rs9624447	chr22:24681555	POM121L9P	chr22:24647589-24661490:+	-0.27	-5.65	2.77E-8	Gut microbiome composition (summer)	
LGG	cis	1	rs9624834	chr22:25846015	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.16	3.69E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9624834	chr22:25846015	CRYBB2	chr22:25615612-25627836:+	0.67	8.57	1.35E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9624835	chr22:25846021	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.16	3.69E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9624835	chr22:25846021	CRYBB2	chr22:25615612-25627836:+	0.67	8.57	1.35E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9624836	chr22:25846087	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.16	3.69E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9624836	chr22:25846087	CRYBB2	chr22:25615612-25627836:+	0.67	8.57	1.35E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9633950	chr11:120248249	TMEM136	chr11:120196016-120204388:+	0.2	4.56	6.49E-6	Intraocular pressure	
LGG	cis	1	rs9635251	chr14:65928468	LOC645431	chr14:65877313-65879335:-	-0.51	-7.07	5.24E-12	Ischemic stroke	
LGG	cis	1	rs9635324	chr15:40703211	C15orf23	chr15:40674922-40686488:+	-0.17	-3.51	0.000492	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs9635324	chr15:40703211	DISP2	chr15:40650434-40663256:+	0.18	4.33	1.83E-5	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs9635324	chr15:40703211	IVD	chr15:40697686-40713512:+	0.33	5.92	6.11E-9	Blood metabolite levels;Blood metabolite ratios	
LGG	cis	1	rs9646303	chr16:87461969	MAP1LC3B	chr16:87425801-87438379:+	-0.24	-3.72	0.00022	Major depressive disorder	
LGG	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.52	-11.1	1.09E-25	Response to antipsychotic treatment	
LGG	cis	1	rs9650139	chr8:58190508	C8orf71	chr8:58192102-58197288:+	0.36	6.17	1.41E-9	Developmental language disorder (linguistic errors)	
LGG	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.4	7.17	2.74E-12	Metabolite levels	
LGG	cis	1	rs9653557	chr2:73795962	NAT8	chr2:73867850-73869537:-	0.27	4.31	1.94E-5	Metabolite levels	
LGG	cis	1	rs965469	chr20:3381549	ITPA	chr20:3190056-3204504:+	-0.36	-8.58	1.24E-16	IFN-related cytopenia	
LGG	cis	1	rs965513	chr9:100556109	C9orf156	chr9:100666772-100684852:-	0.18	3.9	0.00011	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LGG	cis	1	rs9655613	chr7:151713518	LOC100128822	chr7:152161209-152162628:+	0.18	3.61	0.000339	Kidney function decline traits	
LGG	cis	1	rs9660992	chr1:205249450	TMEM81	chr1:205052258-205053588:-	-0.21	-4.48	9.4E-6	Mean platelet volume	
LGG	cis	1	rs9661504	chr1:205915667	PM20D1	chr1:205797154-205819245:-	0.29	5.1	4.95E-7	Cystic fibrosis-related diabetes	
LGG	cis	1	rs9662055	chr1:150018719	RPRD2	chr1:150336990-150449039:+	0.16	3.96	8.44E-5	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LGG	cis	1	rs9662166	chr1:76235906	MSH4	chr1:76262630-76378923:+	0.25	4.44	1.11E-5	Blood metabolite levels;Acylcarnitine levels	
LGG	cis	1	rs9662221	chr1:205915745	PM20D1	chr1:205797154-205819245:-	0.29	5.18	3.19E-7	Cystic fibrosis-related diabetes	
LGG	cis	1	rs9665626	chr10:104300638	SFXN2	chr10:104474298-104498946:+	0.27	3.69	0.000248	Schizophrenia	
LGG	cis	1	rs9665626	chr10:104300638	TMEM180	chr10:104221170-104238858:+	-0.36	-5.36	1.3E-7	Schizophrenia	
LGG	cis	1	rs9674872	chr17:79581931	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs9674872	chr17:79581931	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs9677476	chr2:232126290	HTR2B	chr2:231972952-231989824:-	-0.43	-6.97	1.0E-11	Food antigen IgG levels	
LGG	cis	1	rs9684708	chr4:56430381	TMEM165	chr4:56262090-56292342:+	0.17	5.02	7.34E-7	Personality dimensions	
LGG	cis	1	rs968567	chr11:61595564	C11orf66	chr11:61248592-61258399:+	-0.24	-4.18	3.53E-5	Blood metabolite levels;Rheumatoid arthritis;Glycerophospholipid levels	
LGG	cis	1	rs971572	chr1:184068508	TSEN15	chr1:184020811-184043341:+	0.28	6.19	1.24E-9	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs9715911	chr5:156394441	TIMD4	chr5:156346293-156390266:-	-0.2	-4.1	4.84E-5	Triglycerides;Cholesterol, total;LDL cholesterol	
LGG	cis	1	rs974495	chr3:49400482	AMIGO3	chr3:49754268-49757238:-	-0.19	-4.43	1.17E-5	Menarche (age at onset)	
LGG	cis	1	rs974495	chr3:49400482	GMPPB	chr3:49758932-49761384:-	-0.23	-4.53	7.49E-6	Menarche (age at onset)	
LGG	cis	1	rs974495	chr3:49400482	TREX1	chr3:48501186-48509043:+	-0.25	-5.34	1.42E-7	Menarche (age at onset)	
LGG	cis	1	rs9747164	chr17:61864787	DDX42	chr17:61851567-61896676:+	-0.16	-3.63	0.000308	Body mass index	
LGG	cis	1	rs9747164	chr17:61864787	FTSJ3	chr17:61896795-61905031:-	0.42	8.47	2.91E-16	Body mass index	
LGG	cis	1	rs9747164	chr17:61864787	SMARCD2	chr17:61909441-61920351:-	0.18	3.9	0.000111	Body mass index	
LGG	cis	1	rs9747349	chr17:79584297	PDE6G	chr17:79617489-79623607:-	-0.23	-5.98	4.22E-9	Eye color traits	
LGG	cis	1	rs9747349	chr17:79584297	TSPAN10	chr17:79609349-79615778:+	0.68	17.4	3.65E-53	Eye color traits	
LGG	cis	1	rs9748176	chr17:79584043	PDE6G	chr17:79617489-79623607:-	-0.23	-5.86	8.71E-9	Eye color traits	
LGG	cis	1	rs9748176	chr17:79584043	TSPAN10	chr17:79609349-79615778:+	0.68	17.26	1.56E-52	Eye color traits	
LGG	cis	1	rs9753608	chr20:47837206	ARFGEF2	chr20:47538275-47653229:+	-0.15	-4.28	2.25E-5	Height	
LGG	cis	1	rs975369	chr7:25612661	SNX10	chr7:26331515-26413937:+	-0.23	-3.59	0.000366	Preeclampsia	
LGG	cis	1	rs975459	chr6:151876909	C6orf97	chr6:151815175-151942327:+	0.26	4.2	3.23E-5	Bone mineral density (spine)	
LGG	cis	1	rs9767077	chr6:150109615	RAET1G	chr6:150238014-150244214:-	0.29	5.06	5.95E-7	Lung cancer	
LGG	cis	1	rs9767077	chr6:150109615	ULBP1	chr6:150285143-150294844:+	0.2	3.94	9.37E-5	Lung cancer	
LGG	cis	1	rs9767077	chr6:150109615	ULBP2	chr6:150263136-150270366:+	0.18	3.9	0.000108	Lung cancer	
LGG	cis	1	rs9769098	chr7:23916732	C7orf46	chr7:23719749-23742268:+	0.2	4.23	2.84E-5	Schizophrenia	
LGG	cis	1	rs9769882	chr7:65642925	CCT6P1	chr7:65216092-65228661:+	-0.24	-4.27	2.36E-5	Diabetic kidney disease	
LGG	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.52	11.09	1.2E-25	Forced vital capacity	
LGG	cis	1	rs9783347	chr11:18384938	GTF2H1	chr11:18343816-18388590:+	0.4	7.51	2.73E-13	Pancreatic cancer	
LGG	cis	1	rs9783386	chr11:18386625	GTF2H1	chr11:18343816-18388590:+	0.4	7.13	3.5E-12	Pancreatic cancer	
LGG	cis	1	rs9788179	chr12:51701155	LETMD1	chr12:51442084-51454206:+	-0.18	-3.63	0.000319	Aging (time to death)	
LGG	cis	1	rs9788682	chr15:78802586	CHRNA5	chr15:78857906-78886458:+	0.49	7.34	8.81E-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs9788721	chr15:78802869	CHRNA5	chr15:78857906-78886458:+	0.69	13.86	4.15E-37	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LGG	cis	1	rs9788767	chr15:24761453	PWRN1	chr15:24778839-24832924:+	0.23	3.86	0.000128	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs9789748	chr2:17801397	GEN1	chr2:17935162-17966632:+	0.31	4.46	1.01E-5	Psychosis and Alzheimer's disease	
LGG	cis	1	rs9791555	chr7:33245128	BBS9	chr7:33169152-33645680:+	0.42	5.65	2.72E-8	Smooth-surface caries	
LGG	cis	1	rs9791901	chr7:33240972	BBS9	chr7:33169152-33645680:+	0.43	5.69	2.16E-8	Smooth-surface caries	
LGG	cis	1	rs9793138	chr1:202339956	UBE2T	chr1:202300786-202311094:-	-0.14	-4.14	4.16E-5	Sex ratio	
LGG	cis	1	rs9795476	chr11:235894	PSMD13	chr11:236808-252984:+	-0.24	-5.21	2.79E-7	Menarche (age at onset)	
LGG	cis	1	rs9797279	chr17:20908325	USP22	chr17:20902908-20947073:-	-0.2	-4.57	6.16E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9797861	chr19:10743126	ANGPTL6	chr19:10203013-10213425:-	0.23	3.51	0.000496	Thrombosis	
LGG	cis	1	rs9797861	chr19:10743126	C19orf52	chr19:11039424-11040917:+	0.19	3.46	0.00059	Thrombosis	
LGG	cis	1	rs9804992	chr12:988894	RAD52	chr12:1021255-1099219:-	0.18	3.8	0.000162	Colorectal cancer	
LGG	cis	1	rs9805979	chr14:75566209	ACYP1	chr14:75519930-75530736:-	-0.14	-3.57	0.000397	Height	
LGG	cis	1	rs9805979	chr14:75566209	EIF2B2	chr14:75469612-75476292:+	0.18	3.52	0.00048	Height	
LGG	cis	1	rs9808651	chr21:40466468	ETS2	chr21:40177231-40196876:+	-0.21	-4.63	4.63E-6	Fibrinogen levels	
LGG	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.3	7.81	3.56E-14	Height	
LGG	cis	1	rs9809619	chr3:134280948	CEP63	chr3:134204575-134293852:+	0.2	3.74	0.000209	Height	
LGG	cis	1	rs9809843	chr3:48434398	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs9809843	chr3:48434398	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs9810077	chr3:195005422	ACAP2	chr3:194995475-195163817:-	-0.34	-8.23	1.64E-15	Body mass index	
LGG	cis	1	rs9810089	chr3:135807609	PCCB	chr3:135969167-136056737:+	-0.19	-3.92	9.93E-5	Gestational age at birth (child effect)	
LGG	cis	1	rs9810890	chr3:128652553	RAB43	chr3:128806418-128880029:-	0.32	3.69	0.00025	Dental caries	
LGG	cis	1	rs9811216	chr3:169487501	LRRC34	chr3:169511266-169530720:-	-0.31	-5.38	1.17E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.44	11.38	8.36E-27	Longevity	
LGG	cis	1	rs9812791	chr3:49682311	MST1R	chr3:49924438-49941306:-	-0.2	-3.84	0.000139	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9812791	chr3:49682311	RBM6	chr3:49977592-50137484:+	0.16	4.52	7.65E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9812791	chr3:49682311	SEMA3F	chr3:50192848-50226507:+	0.2	4.48	9.11E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9813712	chr3:129971101	COL6A4P2	chr3:129931663-129992648:+	0.3	5.32	1.6E-7	Response to amphetamines	
LGG	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.29	7.64	1.12E-13	Height	
LGG	cis	1	rs9813774	chr3:134227100	CEP63	chr3:134204575-134293852:+	0.2	3.77	0.000182	Height	
LGG	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.27	-6.9	1.62E-11	Height	
LGG	cis	1	rs9815103	chr3:48414215	ATRIP	chr3:48488141-48507708:+	0.19	4.75	2.62E-6	Longevity	
LGG	cis	1	rs9815103	chr3:48414215	TREX1	chr3:48501186-48509043:+	-0.39	-10.01	1.32E-21	Longevity	
LGG	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.75	13.61	5.15E-36	Diastolic blood pressure	
LGG	cis	1	rs9817615	chr3:48470756	ATRIP	chr3:48488141-48507708:+	0.18	4.51	8.04E-6	Longevity	
LGG	cis	1	rs9817615	chr3:48470756	TREX1	chr3:48501186-48509043:+	-0.43	-11.11	9.43E-26	Longevity	
LGG	cis	1	rs9817894	chr3:65465760	MAGI1	chr3:65339907-66024509:-	0.23	4.71	3.22E-6	PR interval	
LGG	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.78	15.16	7.18E-43	Diastolic blood pressure	
LGG	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.3	7.81	3.56E-14	Height	
LGG	cis	1	rs9819532	chr3:134288644	CEP63	chr3:134204575-134293852:+	0.2	3.74	0.000209	Height	
LGG	cis	1	rs9819628	chr3:20140837	EFHB	chr3:19920968-19988501:-	-0.36	-4.72	3.05E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs9819739	chr3:20140760	EFHB	chr3:19920968-19988501:-	0.35	4.68	3.72E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs9820192	chr3:41889281	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9822268	chr3:49719729	MST1R	chr3:49924438-49941306:-	-0.21	-4.06	5.82E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9822268	chr3:49719729	RBM6	chr3:49977592-50137484:+	0.15	4.21	3.0E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9822268	chr3:49719729	SEMA3F	chr3:50192848-50226507:+	0.2	4.45	1.05E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9822885	chr3:169486144	LOC100128164	chr3:169661774-169684522:-	-0.21	-3.82	0.00015	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9822885	chr3:169486144	LRRC34	chr3:169511266-169530720:-	-0.29	-5.23	2.52E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.75	13.76	1.18E-36	Diastolic blood pressure	
LGG	cis	1	rs9823546	chr3:49705512	MST1R	chr3:49924438-49941306:-	-0.2	-3.8	0.000163	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9823546	chr3:49705512	RBM6	chr3:49977592-50137484:+	0.16	4.59	5.6E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9823546	chr3:49705512	SEMA3F	chr3:50192848-50226507:+	0.19	4.33	1.81E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.76	14.03	7.94E-38	Diastolic blood pressure	
LGG	cis	1	rs9825119	chr3:128595514	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs9825741	chr3:41761828	ULK4	chr3:41288091-42003660:-	-0.72	-14.18	1.63E-38	Diastolic blood pressure	
LGG	cis	1	rs9826058	chr3:41762062	ULK4	chr3:41288091-42003660:-	0.72	13.79	8.75E-37	Diastolic blood pressure	
LGG	cis	1	rs9826195	chr3:48433635	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs9826195	chr3:48433635	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs9826496	chr3:134224437	CEP63	chr3:134204575-134293852:+	0.19	3.49	0.000522	Height	
LGG	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.3	7.67	9.08E-14	Height	
LGG	cis	1	rs9827987	chr3:134272621	CEP63	chr3:134204575-134293852:+	0.22	3.92	0.000101	Height	
LGG	cis	1	rs9828398	chr3:41895893	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9828701	chr3:20149203	EFHB	chr3:19920968-19988501:-	0.36	4.74	2.77E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs9828815	chr3:134265749	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.29	7.67	9.29E-14	Height	
LGG	cis	1	rs9829092	chr3:134229866	CEP63	chr3:134204575-134293852:+	0.21	3.81	0.000159	Height	
LGG	cis	1	rs9830064	chr3:41881801	ULK4	chr3:41288091-42003660:-	0.77	15.18	5.94E-43	Diastolic blood pressure	
LGG	cis	1	rs9830469	chr3:41762535	ULK4	chr3:41288091-42003660:-	0.72	13.78	9.15E-37	Diastolic blood pressure	
LGG	cis	1	rs9831661	chr3:169528523	LRRC34	chr3:169511266-169530720:-	0.29	5.19	3.11E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.28	7.21	2.06E-12	Height	
LGG	cis	1	rs9832785	chr3:134213070	CEP63	chr3:134204575-134293852:+	0.2	3.57	0.000397	Height	
LGG	cis	1	rs9834098	chr3:41833493	ULK4	chr3:41288091-42003660:-	0.76	14.59	2.71E-40	Diastolic blood pressure	
LGG	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.28	7.29	1.28E-12	Height	
LGG	cis	1	rs9834755	chr3:134206845	CEP63	chr3:134204575-134293852:+	0.2	3.62	0.000329	Height	
LGG	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs9835204	chr3:134261342	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs9836291	chr3:49697459	MST1R	chr3:49924438-49941306:-	-0.2	-3.82	0.000152	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9836291	chr3:49697459	RBM6	chr3:49977592-50137484:+	0.17	4.6	5.35E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9836291	chr3:49697459	SEMA3F	chr3:50192848-50226507:+	0.2	4.37	1.48E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9838618	chr3:48487353	ATRIP	chr3:48488141-48507708:+	0.18	4.57	6.27E-6	Longevity	
LGG	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.43	-11.21	4.04E-26	Longevity	
LGG	cis	1	rs9838965	chr3:41927938	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs9839399	chr3:41928044	ULK4	chr3:41288091-42003660:-	-0.77	-15.36	9.35E-44	Diastolic blood pressure	
LGG	cis	1	rs9840037	chr3:41827522	ULK4	chr3:41288091-42003660:-	0.75	14.46	9.73E-40	Diastolic blood pressure	
LGG	cis	1	rs9840532	chr3:41885697	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9840633	chr3:128568202	RAB43	chr3:128806418-128880029:-	0.32	3.68	0.000263	Dental caries	
LGG	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.04E-14	Height	
LGG	cis	1	rs9841212	chr3:134191938	CEP63	chr3:134204575-134293852:+	0.21	3.9	0.00011	Height	
LGG	cis	1	rs9841454	chr3:114362596	ATP6V1A	chr3:113465908-113530901:+	-0.18	-3.49	0.000526	Gastric cancer	
LGG	cis	1	rs9842132	chr3:49427933	AMIGO3	chr3:49754268-49757238:-	0.18	4.28	2.3E-5	Menarche (age at onset)	
LGG	cis	1	rs9842132	chr3:49427933	GMPPB	chr3:49758932-49761384:-	0.22	4.33	1.82E-5	Menarche (age at onset)	
LGG	cis	1	rs9842132	chr3:49427933	NCKIPSD	chr3:48711280-48723334:-	-0.15	-3.53	0.000458	Menarche (age at onset)	
LGG	cis	1	rs9842132	chr3:49427933	TREX1	chr3:48501186-48509043:+	0.24	5.08	5.31E-7	Menarche (age at onset)	
LGG	cis	1	rs9842261	chr3:41822708	ULK4	chr3:41288091-42003660:-	-0.68	-12.84	1.01E-32	Diastolic blood pressure	
LGG	cis	1	rs9842305	chr3:41998412	ULK4	chr3:41288091-42003660:-	-0.79	-15.87	4.21E-46	Diastolic blood pressure	
LGG	cis	1	rs9846190	chr3:57395037	ASB14	chr3:57302379-57326686:-	0.15	3.47	0.000564	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.75	13.77	1.05E-36	Diastolic blood pressure	
LGG	cis	1	rs9847006	chr3:41755359	ULK4	chr3:41288091-42003660:-	0.71	13.38	4.97E-35	Diastolic blood pressure	
LGG	cis	1	rs9847710	chr3:53062661	ITIH4	chr3:52847007-52866554:-	-0.17	-4.66	4.1E-6	Ulcerative colitis	
LGG	cis	1	rs9847710	chr3:53062661	RFT1	chr3:53122503-53164470:-	-0.19	-3.73	0.000212	Ulcerative colitis	
LGG	cis	1	rs9847759	chr3:128594373	RAB43	chr3:128806418-128880029:-	0.31	3.63	0.000313	Dental caries	
LGG	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.69	12.45	4.09E-31	Diastolic blood pressure	
LGG	cis	1	rs9848323	chr3:101656208	CEP97	chr3:101443494-101486181:+	-0.12	-3.77	0.000185	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs9848323	chr3:101656208	LOC285359	chr3:101431278-101432259:+	0.21	4.57	6.06E-6	Psoriasis vulgaris;Psoriasis	
LGG	cis	1	rs9848754	chr3:41753647	ULK4	chr3:41288091-42003660:-	0.67	11.85	1.16E-28	Diastolic blood pressure	
LGG	cis	1	rs9849509	chr3:48483432	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.85E-6	Longevity	
LGG	cis	1	rs9849509	chr3:48483432	TREX1	chr3:48501186-48509043:+	-0.43	-11.08	1.32E-25	Longevity	
LGG	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.3	7.76	5.11E-14	Height	
LGG	cis	1	rs9850015	chr3:134269541	CEP63	chr3:134204575-134293852:+	0.21	3.75	0.000199	Height	
LGG	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.3	7.96	1.2E-14	Height	
LGG	cis	1	rs9851766	chr3:138121509	MRAS	chr3:138066625-138124376:+	-0.19	-3.47	0.000568	Coronary artery disease;Coronary heart disease	
LGG	cis	1	rs9852303	chr3:41759525	ULK4	chr3:41288091-42003660:-	0.74	14.31	4.61E-39	Diastolic blood pressure	
LGG	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.28	7.27	1.41E-12	Height	
LGG	cis	1	rs9854299	chr3:134206728	CEP63	chr3:134204575-134293852:+	0.2	3.59	0.000365	Height	
LGG	cis	1	rs9854833	chr3:41775577	ULK4	chr3:41288091-42003660:-	0.7	12.56	1.41E-31	Diastolic blood pressure	
LGG	cis	1	rs9854838	chr3:41805670	ULK4	chr3:41288091-42003660:-	0.78	15.52	1.76E-44	Diastolic blood pressure	
LGG	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.78	15.16	7.18E-43	Diastolic blood pressure	
LGG	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.78	15.16	7.18E-43	Diastolic blood pressure	
LGG	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.77	15.44	3.79E-44	Diastolic blood pressure	
LGG	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs9856693	chr3:134306913	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs9857135	chr3:20147790	EFHB	chr3:19920968-19988501:-	0.36	4.74	2.77E-6	Bipolar disorder and schizophrenia	
LGG	cis	1	rs9857175	chr3:41822054	ULK4	chr3:41288091-42003660:-	0.75	14.65	1.37E-40	Diastolic blood pressure	
LGG	cis	1	rs9858213	chr3:49731861	MST1R	chr3:49924438-49941306:-	-0.22	-4.22	2.89E-5	Educational attainment	
LGG	cis	1	rs9858213	chr3:49731861	RBM6	chr3:49977592-50137484:+	0.15	4.14	4.17E-5	Educational attainment	
LGG	cis	1	rs9858213	chr3:49731861	SEMA3F	chr3:50192848-50226507:+	0.2	4.47	9.79E-6	Educational attainment	
LGG	cis	1	rs9858542	chr3:49701983	MST1R	chr3:49924438-49941306:-	0.21	4.09	5.09E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9858542	chr3:49701983	RBM6	chr3:49977592-50137484:+	-0.15	-4.24	2.63E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9858542	chr3:49701983	SEMA3F	chr3:50192848-50226507:+	-0.19	-4.19	3.35E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9860055	chr3:49506900	AMIGO3	chr3:49754268-49757238:-	0.19	4.41	1.29E-5	Menarche (age at onset)	
LGG	cis	1	rs9860055	chr3:49506900	GMPPB	chr3:49758932-49761384:-	0.23	4.47	9.92E-6	Menarche (age at onset)	
LGG	cis	1	rs9860055	chr3:49506900	TREX1	chr3:48501186-48509043:+	0.26	5.36	1.3E-7	Menarche (age at onset)	
LGG	cis	1	rs9860874	chr3:169486271	LOC100128164	chr3:169661774-169684522:-	-0.21	-3.82	0.00015	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9860874	chr3:169486271	LRRC34	chr3:169511266-169530720:-	-0.29	-5.23	2.52E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9862012	chr3:128572219	RAB43	chr3:128806418-128880029:-	0.32	3.75	0.000197	Dental caries	
LGG	cis	1	rs9862461	chr3:128572314	RAB43	chr3:128806418-128880029:-	0.32	3.75	0.000197	Dental caries	
LGG	cis	1	rs9862534	chr3:49598064	AMIGO3	chr3:49754268-49757238:-	-0.17	-3.86	0.000129	Menarche (age at onset)	
LGG	cis	1	rs9862534	chr3:49598064	GMPPB	chr3:49758932-49761384:-	-0.21	-4.24	2.67E-5	Menarche (age at onset)	
LGG	cis	1	rs9862534	chr3:49598064	NCKIPSD	chr3:48711280-48723334:-	0.16	3.74	0.000207	Menarche (age at onset)	
LGG	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs9863786	chr3:134247203	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs9863915	chr3:41762002	ULK4	chr3:41288091-42003660:-	0.74	14.31	4.61E-39	Diastolic blood pressure	
LGG	cis	1	rs9864217	chr3:41762206	ULK4	chr3:41288091-42003660:-	0.68	12.18	5.31E-30	Diastolic blood pressure	
LGG	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.3	7.98	1.01E-14	Height	
LGG	cis	1	rs9864346	chr3:134312352	CEP63	chr3:134204575-134293852:+	0.19	3.53	0.000462	Height	
LGG	cis	1	rs9864371	chr3:48426766	ATRIP	chr3:48488141-48507708:+	0.18	4.4	1.3E-5	Longevity	
LGG	cis	1	rs9864371	chr3:48426766	TREX1	chr3:48501186-48509043:+	-0.42	-10.85	9.98E-25	Longevity	
LGG	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.29	7.8	3.87E-14	Height	
LGG	cis	1	rs9864439	chr3:134298671	CEP63	chr3:134204575-134293852:+	0.19	3.58	0.000375	Height	
LGG	cis	1	rs9864582	chr3:129970462	COL6A4P2	chr3:129931663-129992648:+	0.3	5.32	1.6E-7	Response to amphetamines	
LGG	cis	1	rs9865127	chr3:41807448	ULK4	chr3:41288091-42003660:-	0.78	15.58	9.3E-45	Diastolic blood pressure	
LGG	cis	1	rs986577	chr8:83074924	FABP4	chr8:82390732-82395473:-	0.2	3.92	0.0001	Prostate cancer (gene x gene interaction)	
LGG	cis	1	rs9865780	chr3:41895802	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9866092	chr3:41895967	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9866759	chr3:41758418	ULK4	chr3:41288091-42003660:-	0.73	14.19	1.51E-38	Diastolic blood pressure	
LGG	cis	1	rs9866776	chr3:169487651	LOC100128164	chr3:169661774-169684522:-	-0.2	-3.69	0.000246	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9866776	chr3:169487651	LRRC34	chr3:169511266-169530720:-	-0.3	-5.25	2.26E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.71	-13.33	8.12E-35	Diastolic blood pressure	
LGG	cis	1	rs9868000	chr3:169510789	LOC100128164	chr3:169661774-169684522:-	-0.19	-3.5	0.000511	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9868000	chr3:169510789	LRRC34	chr3:169511266-169530720:-	-0.28	-5.09	5.15E-7	Multiple myeloma and monoclonal gammopathy;Interstitial lung disease	
LGG	cis	1	rs9868809	chr3:48681053	SLC26A6	chr3:48663158-48672926:-	0.23	3.67	0.000268	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs9868809	chr3:48681053	TREX1	chr3:48501186-48509043:+	-0.26	-3.81	0.000158	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs9868809	chr3:48681053	USP4	chr3:49314577-49377536:-	0.37	4.61	5.19E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LGG	cis	1	rs9869207	chr3:41878661	ULK4	chr3:41288091-42003660:-	0.77	15.16	7.06E-43	Diastolic blood pressure	
LGG	cis	1	rs9869282	chr3:41756064	ULK4	chr3:41288091-42003660:-	0.71	13.38	4.97E-35	Diastolic blood pressure	
LGG	cis	1	rs9869440	chr3:41763155	ULK4	chr3:41288091-42003660:-	0.73	13.94	1.91E-37	Diastolic blood pressure	
LGG	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs9869981	chr3:134248801	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs9871024	chr3:49554241	AMIGO3	chr3:49754268-49757238:-	0.2	4.53	7.36E-6	Menarche (age at onset)	
LGG	cis	1	rs9871024	chr3:49554241	GMPPB	chr3:49758932-49761384:-	0.23	4.51	8.15E-6	Menarche (age at onset)	
LGG	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.28	7.25	1.61E-12	Height	
LGG	cis	1	rs9871305	chr3:134213538	CEP63	chr3:134204575-134293852:+	0.2	3.59	0.000359	Height	
LGG	cis	1	rs9871864	chr3:20352766	EFHB	chr3:19920968-19988501:-	0.21	3.54	0.000438	Behavioural disinhibition (generation interaction)	
LGG	cis	1	rs9872999	chr3:133457514	TF	chr3:133419211-133497635:+	-0.11	-4.19	3.35E-5	Iron status biomarkers	
LGG	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.76	13.97	1.36E-37	Diastolic blood pressure	
LGG	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.75	13.76	1.18E-36	Diastolic blood pressure	
LGG	cis	1	rs9874975	chr3:41764300	ULK4	chr3:41288091-42003660:-	0.75	14.43	1.32E-39	Diastolic blood pressure	
LGG	cis	1	rs9875083	chr3:41775786	ULK4	chr3:41288091-42003660:-	0.7	12.55	1.52E-31	Diastolic blood pressure	
LGG	cis	1	rs9875107	chr3:41822313	ULK4	chr3:41288091-42003660:-	0.73	14.17	1.78E-38	Diastolic blood pressure	
LGG	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.27	-7.08	5.08E-12	Height	
LGG	cis	1	rs9876781	chr3:48487338	ATRIP	chr3:48488141-48507708:+	0.2	5.16	3.56E-7	Longevity	
LGG	cis	1	rs9876781	chr3:48487338	TREX1	chr3:48501186-48509043:+	-0.41	-10.51	1.94E-23	Longevity	
LGG	cis	1	rs9876960	chr3:41985812	ULK4	chr3:41288091-42003660:-	-0.78	-15.46	3.26E-44	Diastolic blood pressure	
LGG	cis	1	rs9877910	chr3:159730819	IL12A	chr3:159706629-159713805:+	-0.21	-4.04	6.32E-5	Primary biliary cirrhosis	
LGG	cis	1	rs9879311	chr3:10415343	SEC13	chr3:10342617-10362858:-	-0.19	-4.77	2.45E-6	Schizophrenia	
LGG	cis	1	rs9881491	chr3:48487911	ATRIP	chr3:48488141-48507708:+	0.19	4.64	4.43E-6	Longevity	
LGG	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.42	-11.06	1.5E-25	Longevity	
LGG	cis	1	rs9882329	chr3:41767154	ULK4	chr3:41288091-42003660:-	0.74	14.38	2.23E-39	Diastolic blood pressure	
LGG	cis	1	rs9882740	chr3:49702484	MST1R	chr3:49924438-49941306:-	-0.2	-3.87	0.000124	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9882740	chr3:49702484	RBM6	chr3:49977592-50137484:+	0.16	4.54	7.03E-6	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9882740	chr3:49702484	SEMA3F	chr3:50192848-50226507:+	0.19	4.32	1.86E-5	Crohn's disease;Ulcerative colitis	
LGG	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.29	7.76	4.83E-14	Height	
LGG	cis	1	rs9883753	chr3:134247231	CEP63	chr3:134204575-134293852:+	0.2	3.65	0.000295	Height	
LGG	cis	1	rs9883759	chr3:48463618	ATRIP	chr3:48488141-48507708:+	0.18	4.43	1.16E-5	Longevity	
LGG	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.43	-11.19	4.66E-26	Longevity	
LGG	cis	1	rs9883927	chr3:48463711	ATRIP	chr3:48488141-48507708:+	0.18	4.52	7.94E-6	Longevity	
LGG	cis	1	rs9883927	chr3:48463711	TREX1	chr3:48501186-48509043:+	-0.43	-11.11	9.53E-26	Longevity	
LGG	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.3	7.78	4.45E-14	Height	
LGG	cis	1	rs9884031	chr3:134256500	CEP63	chr3:134204575-134293852:+	0.21	3.8	0.000162	Height	
LGG	cis	1	rs9889618	chr17:40293467	DHX58	chr17:40253422-40264751:-	-0.19	-3.94	9.31E-5	Fibrinogen levels	
LGG	cis	1	rs9889640	chr17:40293497	DHX58	chr17:40253422-40264751:-	-0.19	-3.94	9.31E-5	Fibrinogen levels	
LGG	cis	1	rs9890032	chr17:29165934	SUZ12P	chr17:29035714-29097067:+	0.24	6.7	5.57E-11	Height	
LGG	cis	1	rs9890205	chr17:28382704	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.93	5.72E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9890488	chr17:46386949	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9890886	chr17:28391076	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.89	7.21E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9891018	chr17:61827856	DDX42	chr17:61851567-61896676:+	-0.16	-3.64	0.000303	Body mass index	
LGG	cis	1	rs9891018	chr17:61827856	FTSJ3	chr17:61896795-61905031:-	0.41	8.49	2.54E-16	Body mass index	
LGG	cis	1	rs9891018	chr17:61827856	SMARCD2	chr17:61909441-61920351:-	0.19	4.26	2.5E-5	Body mass index	
LGG	cis	1	rs9891073	chr17:46438249	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9891635	chr17:46503476	HOXB2	chr17:46620021-46622393:-	-0.19	-3.74	0.000208	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9891635	chr17:46503476	HOXB3	chr17:46626233-46667631:-	-0.18	-3.58	0.00038	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9891865	chr17:53060033	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9891865	chr17:53060033	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9891871	chr17:28370191	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.93	5.72E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9892173	chr17:53060214	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9892173	chr17:53060214	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9892976	chr17:53060329	STXBP4	chr17:53046126-53241449:+	-0.16	-3.69	0.000249	Breast cancer	
LGG	cis	1	rs9892976	chr17:53060329	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	1.0E-7	Breast cancer	
LGG	cis	1	rs9893306	chr17:53054749	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9893306	chr17:53054749	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9893348	chr17:61676534	DDX42	chr17:61851567-61896676:+	-0.2	-4.39	1.39E-5	Body mass index	
LGG	cis	1	rs9893348	chr17:61676534	FTSJ3	chr17:61896795-61905031:-	0.35	6.77	3.65E-11	Body mass index	
LGG	cis	1	rs9893490	chr17:52526940	STXBP4	chr17:53046126-53241449:+	0.18	3.63	0.000308	Obesity-related traits	
LGG	cis	1	rs9894057	chr17:33889923	PEX12	chr17:33901815-33905656:-	-0.22	-3.94	9.45E-5	Platelet count	
LGG	cis	1	rs9894370	chr17:37926004	GSDMB	chr17:38060850-38074903:-	-0.22	-3.49	0.00053	Systemic lupus erythematosus	
LGG	cis	1	rs9894429	chr17:79596811	PDE6G	chr17:79617489-79623607:-	-0.23	-5.94	5.52E-9	Eye color traits	
LGG	cis	1	rs9894429	chr17:79596811	TSPAN10	chr17:79609349-79615778:+	0.68	17.35	6.36E-53	Eye color traits	
LGG	cis	1	rs9894529	chr17:53055246	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.99E-8	Breast cancer	
LGG	cis	1	rs9894812	chr17:46389953	HOXB2	chr17:46620021-46622393:-	0.18	3.53	0.000461	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9895808	chr17:53048442	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9895808	chr17:53048442	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9895920	chr17:61852719	FTSJ3	chr17:61896795-61905031:-	0.43	9.03	4.03E-18	Body mass index	
LGG	cis	1	rs9895920	chr17:61852719	SMARCD2	chr17:61909441-61920351:-	0.2	4.63	4.72E-6	Body mass index	
LGG	cis	1	rs9896044	chr17:53048542	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.99E-8	Breast cancer	
LGG	cis	1	rs9896062	chr17:28357047	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.88	7.4E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9896259	chr17:20927835	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9896301	chr17:20927886	USP22	chr17:20902908-20947073:-	-0.19	-4.34	1.75E-5	Blood trace element (Se levels)	
LGG	cis	1	rs9897162	chr17:46424789	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9897206	chr17:28406108	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.98	4.2E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9897447	chr17:53048469	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9897447	chr17:53048469	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs989747	chr5:42018659	C5orf51	chr5:41904470-41921737:+	-0.29	-3.64	0.000302	Response to taxane treatment (docetaxel)	
LGG	cis	1	rs9897982	chr17:65879592	LOC440461	chr17:66194801-66196436:+	0.27	4.47	9.67E-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9898265	chr17:20940688	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9899006	chr17:38017065	GSDMB	chr17:38060850-38074903:-	-0.22	-3.52	0.000472	Systemic lupus erythematosus	
LGG	cis	1	rs9899336	chr17:38017780	GSDMB	chr17:38060850-38074903:-	-0.22	-3.52	0.000472	Systemic lupus erythematosus	
LGG	cis	1	rs9899491	chr17:61934384	DDX42	chr17:61851567-61896676:+	-0.16	-3.78	0.000176	Body mass index	
LGG	cis	1	rs9899491	chr17:61934384	FTSJ3	chr17:61896795-61905031:-	0.4	8.16	2.86E-15	Body mass index	
LGG	cis	1	rs9899491	chr17:61934384	SMARCD2	chr17:61909441-61920351:-	0.19	4.32	1.91E-5	Body mass index	
LGG	cis	1	rs9899788	chr17:61756384	FTSJ3	chr17:61896795-61905031:-	0.44	9.06	3.13E-18	Body mass index	
LGG	cis	1	rs9899788	chr17:61756384	SMARCD2	chr17:61909441-61920351:-	0.2	4.5	8.49E-6	Body mass index	
LGG	cis	1	rs9900511	chr17:46504524	HOXB2	chr17:46620021-46622393:-	-0.19	-3.74	0.000208	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9900511	chr17:46504524	HOXB3	chr17:46626233-46667631:-	-0.18	-3.58	0.00038	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9900541	chr17:37996071	GSDMB	chr17:38060850-38074903:-	-0.23	-3.58	0.000385	Systemic lupus erythematosus	
LGG	cis	1	rs9901112	chr17:61730617	DDX42	chr17:61851567-61896676:+	-0.17	-3.83	0.000144	Body mass index	
LGG	cis	1	rs9901112	chr17:61730617	FTSJ3	chr17:61896795-61905031:-	0.4	8.15	3.04E-15	Body mass index	
LGG	cis	1	rs9901112	chr17:61730617	SMARCD2	chr17:61909441-61920351:-	0.18	4.09	5.15E-5	Body mass index	
LGG	cis	1	rs9901225	chr17:40755811	HSD17B1	chr17:40703984-40707224:+	-0.19	-4.87	1.52E-6	Colorectal or endometrial cancer	
LGG	cis	1	rs9901225	chr17:40755811	TUBG2	chr17:40811266-40819023:+	-0.22	-6.19	1.26E-9	Colorectal or endometrial cancer	
LGG	cis	1	rs9901507	chr17:61765524	FTSJ3	chr17:61896795-61905031:-	0.44	9.08	2.55E-18	Body mass index	
LGG	cis	1	rs9901507	chr17:61765524	SMARCD2	chr17:61909441-61920351:-	0.21	4.69	3.54E-6	Body mass index	
LGG	cis	1	rs990171	chr2:103086770	IL18R1	chr2:102927962-103015215:+	-0.39	-6.19	1.3E-9	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs990171	chr2:103086770	IL1RL1	chr2:102927962-102968497:+	-0.37	-5.45	7.89E-8	Celiac disease;Inflammatory bowel disease	
LGG	cis	1	rs9902303	chr17:20927931	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9902453	chr17:28349095	EFCAB5	chr17:28256874-28435469:+	-0.22	-6.02	3.5E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9902687	chr17:53048924	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9902687	chr17:53048924	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9902718	chr17:53061622	STXBP4	chr17:53046126-53241449:+	-0.16	-3.65	0.000288	Breast cancer	
LGG	cis	1	rs9902718	chr17:53061622	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.45	8.1E-8	Breast cancer	
LGG	cis	1	rs9903146	chr17:53057747	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9903146	chr17:53057747	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9903204	chr17:40288062	DHX58	chr17:40253422-40264751:-	-0.19	-4	7.36E-5	Fibrinogen levels	
LGG	cis	1	rs9903204	chr17:40288062	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs9903220	chr17:53057865	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9903220	chr17:53057865	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9903444	chr17:53057893	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9903444	chr17:53057893	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9903825	chr17:53057914	STXBP4	chr17:53046126-53241449:+	-0.16	-3.67	0.000266	Breast cancer	
LGG	cis	1	rs9903825	chr17:53057914	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.4	1.03E-7	Breast cancer	
LGG	cis	1	rs9903897	chr17:61716705	FTSJ3	chr17:61896795-61905031:-	0.43	8.89	1.16E-17	Body mass index	
LGG	cis	1	rs9903897	chr17:61716705	SMARCD2	chr17:61909441-61920351:-	0.21	4.71	3.26E-6	Body mass index	
LGG	cis	1	rs9903903	chr17:61762044	FTSJ3	chr17:61896795-61905031:-	0.43	8.99	5.24E-18	Body mass index	
LGG	cis	1	rs9903903	chr17:61762044	SMARCD2	chr17:61909441-61920351:-	0.2	4.51	8.06E-6	Body mass index	
LGG	cis	1	rs9905191	chr17:17469918	ATPAF2	chr17:17918373-17942480:-	-0.27	-3.56	0.000412	Obsessive-compulsive symptoms	
LGG	cis	1	rs9905565	chr17:18758641	FAM18B	chr17:18684582-18710026:+	-0.15	-3.5	0.000515	Pancreatic cancer	
LGG	cis	1	rs9905565	chr17:18758641	PRPSAP2	chr17:18759663-18834580:+	0.21	5.43	8.87E-8	Pancreatic cancer	
LGG	cis	1	rs9905704	chr17:56632543	TEX14	chr17:56634039-56769416:-	-0.38	-6.56	1.33E-10	Testicular germ cell tumor	
LGG	cis	1	rs9905881	chr17:38018955	GSDMB	chr17:38060850-38074903:-	-0.22	-3.52	0.000472	Systemic lupus erythematosus	
LGG	cis	1	rs9906340	chr17:28398977	EFCAB5	chr17:28256874-28435469:+	-0.23	-5.93	5.73E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9906340	chr17:28398977	SUZ12P	chr17:29035714-29097067:+	-0.13	-3.57	0.000388	Coffee consumption (cups per day)	
LGG	cis	1	rs9907291	chr17:38010037	GSDMB	chr17:38060850-38074903:-	-0.22	-3.52	0.000472	Systemic lupus erythematosus	
LGG	cis	1	rs9907699	chr17:46434138	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9907994	chr17:52544946	STXBP4	chr17:53046126-53241449:+	0.18	3.64	0.000298	Obesity-related traits	
LGG	cis	1	rs9908044	chr17:61747032	FTSJ3	chr17:61896795-61905031:-	0.43	8.99	5.24E-18	Body mass index	
LGG	cis	1	rs9908044	chr17:61747032	SMARCD2	chr17:61909441-61920351:-	0.2	4.51	8.06E-6	Body mass index	
LGG	cis	1	rs9908446	chr17:20935471	USP22	chr17:20902908-20947073:-	-0.2	-4.52	7.66E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9909002	chr17:46426468	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9909940	chr17:80689036	FN3KRP	chr17:80674582-80685889:+	-0.34	-6.97	1.03E-11	Glycated hemoglobin levels	
LGG	cis	1	rs9909992	chr17:61731931	DDX42	chr17:61851567-61896676:+	-0.16	-3.68	0.000263	Body mass index	
LGG	cis	1	rs9909992	chr17:61731931	FTSJ3	chr17:61896795-61905031:-	0.41	8.39	5.03E-16	Body mass index	
LGG	cis	1	rs9909992	chr17:61731931	SMARCD2	chr17:61909441-61920351:-	0.18	4.04	6.17E-5	Body mass index	
LGG	cis	1	rs9909	chr11:47799775	ACP2	chr11:47260854-47270457:-	0.16	3.5	0.000516	Subjective well-being	
LGG	cis	1	rs9909	chr11:47799775	MTCH2	chr11:47638859-47664206:-	0.24	4.75	2.72E-6	Subjective well-being	
LGG	cis	1	rs9909	chr11:47799775	PSMC3	chr11:47440320-47448024:-	0.15	3.64	0.000299	Subjective well-being	
LGG	cis	1	rs9912084	chr17:65868035	LOC440461	chr17:66194801-66196436:+	0.26	4.27	2.31E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9912088	chr17:40288278	DHX58	chr17:40253422-40264751:-	-0.19	-4.01	7.06E-5	Fibrinogen levels	
LGG	cis	1	rs9912088	chr17:40288278	HSPB9	chr17:40274756-40275371:+	-0.16	-3.5	0.000514	Fibrinogen levels	
LGG	cis	1	rs9912201	chr17:61763208	DDX42	chr17:61851567-61896676:+	-0.17	-3.78	0.000175	Body mass index	
LGG	cis	1	rs9912201	chr17:61763208	FTSJ3	chr17:61896795-61905031:-	0.41	8.35	7.0E-16	Body mass index	
LGG	cis	1	rs9912201	chr17:61763208	SMARCD2	chr17:61909441-61920351:-	0.16	3.64	0.000301	Body mass index	
LGG	cis	1	rs9912741	chr17:28359511	EFCAB5	chr17:28256874-28435469:+	-0.22	-5.93	5.72E-9	Coffee consumption (cups per day)	
LGG	cis	1	rs9912770	chr17:65868233	LOC440461	chr17:66194801-66196436:+	0.26	4.27	2.31E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9912904	chr17:61763534	DDX42	chr17:61851567-61896676:+	-0.16	-3.76	0.000189	Body mass index	
LGG	cis	1	rs9912904	chr17:61763534	FTSJ3	chr17:61896795-61905031:-	0.41	8.31	9.1E-16	Body mass index	
LGG	cis	1	rs9912904	chr17:61763534	SMARCD2	chr17:61909441-61920351:-	0.18	4.02	6.76E-5	Body mass index	
LGG	cis	1	rs9913471	chr17:65874495	LOC440461	chr17:66194801-66196436:+	0.26	4.27	2.35E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9914544	chr17:18787828	FAM18B	chr17:18684582-18710026:+	-0.18	-4.64	4.38E-6	Educational attainment (years of education)	
LGG	cis	1	rs9914544	chr17:18787828	FBXW10	chr17:18647326-18682661:+	-0.2	-4.47	9.55E-6	Educational attainment (years of education)	
LGG	cis	1	rs9914732	chr17:53054367	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9914732	chr17:53054367	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9915108	chr17:65874463	LOC440461	chr17:66194801-66196436:+	0.26	4.27	2.35E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9915183	chr17:53047137	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9915183	chr17:53047137	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9915255	chr17:40284191	DHX58	chr17:40253422-40264751:-	-0.2	-4.2	3.15E-5	Fibrinogen levels	
LGG	cis	1	rs9915591	chr17:65826090	LOC440461	chr17:66194801-66196436:+	0.26	4.17	3.66E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LGG	cis	1	rs9915832	chr17:53054697	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9915832	chr17:53054697	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9916227	chr17:46389912	HOXB2	chr17:46620021-46622393:-	-0.18	-3.5	0.000501	Epithelial ovarian cancer;Ovarian cancer	
LGG	cis	1	rs9916245	chr17:18766825	FAM18B	chr17:18684582-18710026:+	-0.18	-4.65	4.21E-6	Educational attainment (years of education)	
LGG	cis	1	rs9916245	chr17:18766825	FBXW10	chr17:18647326-18682661:+	-0.2	-4.49	8.98E-6	Educational attainment (years of education)	
LGG	cis	1	rs9916642	chr17:53054497	STXBP4	chr17:53046126-53241449:+	-0.15	-3.52	0.000476	Breast cancer	
LGG	cis	1	rs9916642	chr17:53054497	TOM1L1	chr17:52978052-53039328:+	-0.18	-5.41	9.73E-8	Breast cancer	
LGG	cis	1	rs9918016	chr4:159621997	ETFDH	chr4:159593277-159629839:+	-0.37	-7.6	1.5E-13	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
LGG	cis	1	rs9919599	chr11:116745484	SIDT2	chr11:117049939-117068161:+	0.31	3.54	0.000437	Protein quantitative trait loci	
LGG	cis	1	rs9920079	chr15:24795919	PWRN1	chr15:24778839-24832924:+	0.24	4.15	3.97E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs9920762	chr15:90368171	AP3S2	chr15:90373832-90456222:-	-0.47	-9	5.04E-18	Type 2 diabetes	
LGG	cis	1	rs9920775	chr15:90368273	AP3S2	chr15:90373832-90456222:-	-0.48	-9.14	1.7E-18	Type 2 diabetes	
LGG	cis	1	rs9920830	chr15:24795916	PWRN1	chr15:24778839-24832924:+	0.24	4.15	3.97E-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	
LGG	cis	1	rs992416	chr17:61745905	DDX42	chr17:61851567-61896676:+	-0.16	-3.74	0.000205	Body mass index	
LGG	cis	1	rs992416	chr17:61745905	FTSJ3	chr17:61896795-61905031:-	0.41	8.34	7.3E-16	Body mass index	
LGG	cis	1	rs992416	chr17:61745905	SMARCD2	chr17:61909441-61920351:-	0.18	3.97	8.41E-5	Body mass index	
LGG	cis	1	rs9924629	chr16:50095506	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs9925215	chr16:50096130	HEATR3	chr16:50099881-50139373:+	0.28	3.97	8.42E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs9925964	chr16:31129895	BCKDK	chr16:31119662-31124110:+	0.15	3.52	0.000478	Body mass index	
LGG	cis	1	rs9925964	chr16:31129895	MYST1	chr16:31128985-31142713:+	-0.21	-6.25	9.05E-10	Body mass index	
LGG	cis	1	rs9925964	chr16:31129895	PRSS53	chr16:31094747-31106276:-	0.13	3.63	0.000314	Body mass index	
LGG	cis	1	rs9925964	chr16:31129895	VKORC1	chr16:31102176-31106276:-	0.14	4.22	2.97E-5	Body mass index	
LGG	cis	1	rs9925964	chr16:31129895	ZNF668	chr16:31072172-31085504:-	0.15	4.01	7.0E-5	Body mass index	
LGG	cis	1	rs9928374	chr16:67811930	LRRC36	chr16:67360747-67419108:+	-0.42	-3.76	0.000187	Crohn's disease	
LGG	cis	1	rs992894	chr2:166902103	SCN2A	chr2:166095912-166248818:+	0.09	3.49	0.000528	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs992894	chr2:166902103	TTC21B	chr2:166713988-166810348:-	0.12	3.67	0.000269	Febrile seizures (MMR vaccine-unrelated);Febrile seizures	
LGG	cis	1	rs9929423	chr16:67733113	LRRC36	chr16:67360747-67419108:+	0.47	4.56	6.58E-6	Crohn's disease	
LGG	cis	1	rs9929423	chr16:67733113	RANBP10	chr16:67757006-67840555:-	-0.34	-4.23	2.78E-5	Crohn's disease	
LGG	cis	1	rs9932240	chr16:50094227	HEATR3	chr16:50099881-50139373:+	-0.3	-4.14	4.13E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs9936966	chr16:50090366	HEATR3	chr16:50099881-50139373:+	0.31	4.3	2.02E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs9938630	chr16:29837108	LOC440356	chr16:29875004-29879374:+	-0.25	-4.36	1.57E-5	Multiple sclerosis	
LGG	cis	1	rs9938862	chr16:67723801	LRRC36	chr16:67360747-67419108:+	0.48	4.38	1.43E-5	Crohn's disease	
LGG	cis	1	rs9938862	chr16:67723801	RANBP10	chr16:67757006-67840555:-	-0.32	-3.71	0.000228	Crohn's disease	
LGG	cis	1	rs9939085	chr16:67733237	LRRC36	chr16:67360747-67419108:+	0.49	4.44	1.09E-5	Crohn's disease	
LGG	cis	1	rs9939085	chr16:67733237	RANBP10	chr16:67757006-67840555:-	-0.32	-3.76	0.000194	Crohn's disease	
LGG	cis	1	rs9939710	chr16:50093951	HEATR3	chr16:50099881-50139373:+	-0.3	-4.16	3.79E-5	Esophageal cancer (squamous cell)	
LGG	cis	1	rs9939768	chr16:67219107	ACD	chr16:67691416-67694718:-	-0.21	-3.47	0.000566	HDL cholesterol	
LGG	cis	1	rs9941579	chr2:105384506	MRPS9	chr2:105654483-105716417:+	-0.25	-4.18	3.44E-5	Pancreatic cancer	
LGG	cis	1	rs9941641	chr2:105384179	MRPS9	chr2:105654483-105716417:+	-0.25	-4.19	3.24E-5	Pancreatic cancer	
LGG	cis	1	rs9941751	chr20:33645709	PROCR	chr20:33758727-33765164:+	-0.3	-5.88	7.78E-9	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LGG	cis	1	rs9943661	chr11:32893777	CCDC73	chr11:32623627-32816187:-	0.24	4.99	8.47E-7	Parkinson's disease (age of onset)	
LGG	cis	1	rs9943	chr13:40326282	COG6	chr13:40229764-40365802:+	-0.28	-5.99	4.06E-9	Rheumatoid arthritis	
LGG	cis	1	rs9949617	chr18:20879217	CABLES1	chr18:20714528-20840434:+	-0.24	-4.17	3.67E-5	Hypertriglyceridemia	
LGG	cis	1	rs995432	chr8:23522851	NKX3-1	chr8:23536207-23540450:-	0.22	4.59	5.64E-6	Prostate cancer (gene x gene interaction);Prostate cancer	
LGG	cis	1	rs996065	chr17:20936403	USP22	chr17:20902908-20947073:-	-0.2	-4.61	5.2E-6	Blood trace element (Se levels)	
LGG	cis	1	rs9962573	chr18:20881895	CABLES1	chr18:20714528-20840434:+	-0.26	-4.38	1.43E-5	Hypertriglyceridemia	
LGG	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.63	1.22E-13	Height	
LGG	cis	1	rs9968172	chr3:134231251	CEP63	chr3:134204575-134293852:+	-0.21	-3.78	0.000178	Height	
LGG	cis	1	rs9968691	chr5:93509756	FAM172A	chr5:92953432-93447404:-	-0.3	-4.08	5.35E-5	Diabetic retinopathy	
LGG	cis	1	rs9968749	chr5:93509559	FAM172A	chr5:92953432-93447404:-	-0.3	-4.08	5.35E-5	Diabetic retinopathy	
LGG	cis	1	rs9969804	chr9:95429120	BICD2	chr9:95473645-95527083:-	0.17	3.66	0.000277	Height	
LGG	cis	1	rs997153	chr2:66771047	MEIS1	chr2:66662532-66799890:+	-0.19	-4.47	9.68E-6	PR interval	
LGG	cis	1	rs997295	chr15:68016343	IQCH	chr15:67547188-67794139:+	0.13	3.7	0.000239	Motion sickness	
LGG	cis	1	rs9973492	chr2:97498481	FAM178B	chr2:97541620-97652301:-	-0.15	-3.69	0.000249	Erectile dysfunction and prostate cancer treatment	
LGG	cis	1	rs9975986	chr21:44458961	NDUFV3	chr21:44313378-44329772:+	0.3	4.62	4.99E-6	Information processing speed	
LGG	cis	1	rs997781	chr17:67117688	ABCA6	chr17:67074847-67138015:-	0.4	7.1	4.45E-12	MGMT methylation in smokers	
LGG	cis	1	rs997872	chr22:25878614	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.13	4.19E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs997872	chr22:25878614	CRYBB2	chr22:25615612-25627836:+	0.66	8.33	8.14E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs997873	chr22:25878282	ADRBK2	chr22:25960861-26125256:+	-0.24	-4.13	4.19E-5	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs997873	chr22:25878282	CRYBB2	chr22:25615612-25627836:+	0.66	8.33	8.14E-16	Bipolar disorder with mood-incongruent psychosis	
LGG	cis	1	rs9979597	chr21:43040041	UMODL1	chr21:43483068-43563105:+	0.18	3.54	0.000435	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs9980365	chr21:43039535	UMODL1	chr21:43483068-43563105:+	0.19	3.76	0.000191	Amyotrophic lateral sclerosis (sporadic)	
LGG	cis	1	rs9981595	chr21:40560678	WRB	chr21:40752213-40769814:+	0.25	3.69	0.000246	Venous thromboembolism (SNP x SNP interaction)	
LGG	cis	1	rs9981599	chr21:37807927	DOPEY2	chr21:37536839-37666571:+	0.16	3.48	0.000556	Myopia (pathological)	
LGG	cis	1	rs9981659	chr21:37807852	DOPEY2	chr21:37536839-37666571:+	0.16	3.48	0.000556	Myopia (pathological)	
LGG	cis	1	rs9984563	chr21:44423653	NDUFV3	chr21:44313378-44329772:+	0.3	4.45	1.07E-5	Information processing speed	
LGG	cis	1	rs9984793	chr21:30486471	RWDD2B	chr21:30378082-30391685:-	0.22	3.82	0.000149	Dental caries	
LGG	cis	1	rs9985126	chr21:37809408	DOPEY2	chr21:37536839-37666571:+	0.16	3.5	0.000517	Myopia (pathological)	
LGG	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.26	-6.55	1.42E-10	Height	
LGG	cis	1	rs9986382	chr6:26550619	BTN2A3	chr6:26422317-26431927:+	0.13	3.72	0.000218	Educational attainment	
LGG	cis	1	rs9986382	chr6:26550619	HMGN4	chr6:26538572-26547162:+	-0.19	-4.88	1.47E-6	Educational attainment	
LGG	cis	1	rs9986596	chr6:28219661	ZNF165	chr6:28046572-28057338:+	-0.33	-4.78	2.33E-6	Depression	
LGG	cis	1	rs9986596	chr6:28219661	ZNF187	chr6:28234788-28245978:+	-0.26	-4.51	8.16E-6	Depression	
LGG	cis	1	rs9986596	chr6:28219661	ZNF389	chr6:28129551-28137375:+	0.43	6.83	2.54E-11	Depression	
LGG	cis	1	rs9986596	chr6:28219661	ZSCAN12	chr6:28346770-28367544:-	-0.34	-4.69	3.56E-6	Depression	
LGG	cis	1	rs9986596	chr6:28219661	ZSCAN23	chr6:28393287-28411279:-	0.19	4.36	1.59E-5	Depression	
LGG	cis	1	rs9986696	chr7:65704576	ASL	chr7:65540776-65558321:+	0.23	5.74	1.67E-8	Aortic root size	
LGG	cis	1	rs9988866	chr11:18392983	GTF2H1	chr11:18343816-18388590:+	0.4	7.47	3.74E-13	Pancreatic cancer	
LGG	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.29	7.72	6.73E-14	Height	
LGG	cis	1	rs9989967	chr3:134238964	CEP63	chr3:134204575-134293852:+	0.19	3.6	0.000352	Height	
LGG	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.29	-7.53	2.41E-13	Height	
LGG	cis	1	rs9990351	chr3:134239191	CEP63	chr3:134204575-134293852:+	-0.2	-3.64	0.000298	Height	
LGG	cis	1	rs9991307	chr4:17662408	LAP3	chr4:17578927-17609590:+	-0.13	-3.6	0.000357	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs9991307	chr4:17662408	MED28	chr4:17616273-17629791:+	0.17	3.73	0.000218	Parasitemia in Tripanosoma cruzi seropositivity	
LGG	cis	1	rs9992101	chr4:77360431	FAM47E	chr4:77135193-77204923:+	0.22	4.85	1.66E-6	Creatinine levels	
LGG	cis	1	rs9992101	chr4:77360431	STBD1	chr4:77172853-77232282:+	-0.23	-5.62	3.25E-8	Creatinine levels	
LGG	cis	1	rs9995007	chr4:76897791	NAAA	chr4:76831809-76862166:-	-0.45	-11.07	1.4E-25	Longevity	
LGG	cis	1	rs9997288	chr4:56347227	TMEM165	chr4:56262090-56292342:+	-0.18	-5.12	4.34E-7	Personality dimensions	
LGG	cis	1	rs9998146	chr4:56397977	TMEM165	chr4:56262090-56292342:+	0.17	4.97	9.11E-7	Personality dimensions	
LGG	trans	1	rs10037055	chr5:176691279	LOC388955	chr2:63849182-63850159:-	-0.65	-13.18	3.43E-34	Migraine without aura	
LGG	trans	1	rs10124033	chr9:99614104	FAM22F	chr9:97080478-97090926:-	-0.85	-6.46	2.47E-10	Height	
LGG	trans	1	rs10214634	chr6:26564582	ZNF322B	chr9:99957633-99961910:-	0.55	12.77	1.85E-32	Educational attainment	
LGG	trans	1	rs10220371	chr14:88501852	BRF1	chr14:105675623-105781914:-	0.38	6.48	2.2E-10	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	C14orf179	chr14:76452096-76550930:+	0.36	6.44	2.92E-10	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	CHURC1	chr14:65381140-65411309:+	0.44	6.3	6.73E-10	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	COX16	chr14:70791799-70826444:-	0.41	6.65	7.86E-11	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	DCAF5	chr14:69517638-69619914:-	0.41	7.1	4.5E-12	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	FCF1	chr14:75179850-75203497:+	0.44	5.89	7.33E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	MED6	chr14:71050958-71067384:-	0.5	5.99	4.0E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	PPP2R5E	chr14:63841355-64010079:-	0.33	5.92	5.9E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	SNW1	chr14:78183946-78227497:-	0.49	6.02	3.45E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	VIPAR	chr14:77893018-77923944:-	0.38	5.95	5.04E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	VTI1B	chr14:68117869-68141602:-	0.36	6.01	3.59E-9	Multiple sclerosis	
LGG	trans	1	rs10220371	chr14:88501852	ZFYVE1	chr14:73436160-73493839:-	0.47	6.02	3.51E-9	Multiple sclerosis	
LGG	trans	1	rs10456362	chr6:28221816	BTN3A2	chr6:26365398-26378546:+	0.51	7.45	4.1E-13	Depression	
LGG	trans	1	rs10456362	chr6:28221816	RNF5P1	chr8:38457695-38458775:-	-0.46	-5.87	8.07E-9	Depression	
LGG	trans	1	rs10484442	chr6:26555879	ZNF322B	chr9:99957633-99961910:-	0.53	12.14	7.62E-30	Educational attainment	
LGG	trans	1	rs10508921	chr10:52010708	FAM21B	chr10:47894023-47949416:+;chr10	0.56	5.96	4.78E-9	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	trans	1	rs1056667	chr6:26510564	ZNF322B	chr9:99957633-99961910:-	0.51	11.63	8.69E-28	Educational attainment	
LGG	trans	1	rs10742862	chr11:48649316	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.29	1.1E-15	HDL cholesterol	
LGG	trans	1	rs10769371	chr11:48531184	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.97	1.13E-14	HDL cholesterol	
LGG	trans	1	rs10769390	chr11:48618222	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.37E-16	HDL cholesterol	
LGG	trans	1	rs1078679	chr6:26568741	ZNF322B	chr9:99957633-99961910:-	0.55	12.81	1.31E-32	Educational attainment	
LGG	trans	1	rs10825492	chr10:52008730	FAM21B	chr10:47894023-47949416:+;chr10	0.55	5.87	8.22E-9	Thiazide-induced adverse metabolic effects in hypertensive patients	
LGG	trans	1	rs10838801	chr11:48098280	FOLH1B	chr11:89392465-89431885:+	-0.43	-8.05	6.46E-15	Height	
LGG	trans	1	rs10838912	chr11:48496477	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.92	1.59E-14	HDL cholesterol	
LGG	trans	1	rs10838917	chr11:48503127	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.97	1.15E-14	HDL cholesterol	
LGG	trans	1	rs10838931	chr11:48540973	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.09	4.65E-15	HDL cholesterol	
LGG	trans	1	rs10838943	chr11:48557442	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs10838944	chr11:48559571	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs10838954	chr11:48579323	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.25	1.45E-15	HDL cholesterol	
LGG	trans	1	rs10838966	chr11:48589723	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs10838971	chr11:48606624	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.38	5.79E-16	HDL cholesterol	
LGG	trans	1	rs10838975	chr11:48617615	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.37	5.93E-16	HDL cholesterol	
LGG	trans	1	rs10839171	chr11:48923034	FOLH1B	chr11:89392465-89431885:+	0.39	8.11	3.96E-15	HDL cholesterol	
LGG	trans	1	rs10906228	chr10:12849790	PTGS1	chr9:125132809-125157981:+	-0.44	-6.34	5.16E-10	Coronary artery aneurysm in Kawasaki disease	
LGG	trans	1	rs10946834	chr6:26533664	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs10946835	chr6:26533757	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs11039745	chr11:48463811	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.11	3.98E-15	HDL cholesterol	
LGG	trans	1	rs11039777	chr11:48517049	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.04	6.66E-15	HDL cholesterol	
LGG	trans	1	rs11039779	chr11:48517895	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.04	6.66E-15	HDL cholesterol	
LGG	trans	1	rs11039800	chr11:48542579	FOLH1B	chr11:89392465-89431885:+	0.39	7.97	1.1E-14	HDL cholesterol	
LGG	trans	1	rs11039817	chr11:48561480	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs11039819	chr11:48562181	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.96	1.22E-14	HDL cholesterol	
LGG	trans	1	rs11039820	chr11:48562252	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.21	1.95E-15	HDL cholesterol	
LGG	trans	1	rs11039821	chr11:48562875	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.2	2.15E-15	HDL cholesterol	
LGG	trans	1	rs11039851	chr11:48600839	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.23	1.74E-15	HDL cholesterol	
LGG	trans	1	rs11039854	chr11:48607688	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.14E-16	HDL cholesterol	
LGG	trans	1	rs11039857	chr11:48610853	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.38	5.79E-16	HDL cholesterol	
LGG	trans	1	rs11039859	chr11:48611988	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.38	5.79E-16	HDL cholesterol	
LGG	trans	1	rs11039862	chr11:48618306	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.2E-16	HDL cholesterol	
LGG	trans	1	rs11039868	chr11:48622146	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.37E-16	HDL cholesterol	
LGG	trans	1	rs11039871	chr11:48626620	FOLH1B	chr11:89392465-89431885:+	0.39	8.02	7.58E-15	HDL cholesterol	
LGG	trans	1	rs11039890	chr11:48653468	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.35	7.25E-16	HDL cholesterol	
LGG	trans	1	rs11039904	chr11:48682597	FOLH1B	chr11:89392465-89431885:+	0.51	7.27	1.47E-12	Axial length	
LGG	trans	1	rs11039978	chr11:48760237	FOLH1B	chr11:89392465-89431885:+	0.51	7.27	1.47E-12	Axial length	
LGG	trans	1	rs11246602	chr11:51512090	FOLH1B	chr11:89392465-89431885:+	0.54	7.19	2.4E-12	HDL cholesterol	
LGG	trans	1	rs115224187	chr11:48757499	FOLH1B	chr11:89392465-89431885:+	0.42	8.48	2.6E-16	HDL cholesterol	
LGG	trans	1	rs11530232	chr11:48622376	FOLH1B	chr11:89392465-89431885:+	0.54	7.12	3.75E-12	Axial length	
LGG	trans	1	rs115429994	chr11:48761183	FOLH1B	chr11:89392465-89431885:+	0.51	7.27	1.47E-12	Axial length	
LGG	trans	1	rs11756120	chr6:26529808	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs11884476	chr2:206318593	KRR1	chr12:75891421-75905418:-	-0.37	-5.85	9.07E-9	AIDS progression	
LGG	trans	1	rs11965538	chr6:28239915	BTN3A2	chr6:26365398-26378546:+	-0.54	-7.78	4.21E-14	Depression	
LGG	trans	1	rs12225599	chr11:48755868	FOLH1B	chr11:89392465-89431885:+	0.51	7.27	1.47E-12	Axial length	
LGG	trans	1	rs12280020	chr11:48618844	FOLH1B	chr11:89392465-89431885:+	0.51	7.25	1.67E-12	Axial length	
LGG	trans	1	rs12281162	chr11:48650491	FOLH1B	chr11:89392465-89431885:+	0.51	7.25	1.66E-12	Axial length	
LGG	trans	1	rs12293522	chr11:49558425	FOLH1B	chr11:89392465-89431885:+	-0.43	-9.37	2.58E-19	Height	
LGG	trans	1	rs12361812	chr11:48563104	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.2	2.15E-15	HDL cholesterol	
LGG	trans	1	rs12365220	chr11:48555957	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.02	7.74E-15	HDL cholesterol	
LGG	trans	1	rs12366208	chr11:48563128	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.28	1.17E-15	HDL cholesterol	
LGG	trans	1	rs12419576	chr11:48581644	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.25	1.42E-15	HDL cholesterol	
LGG	trans	1	rs12420372	chr11:48497603	FOLH1B	chr11:89392465-89431885:+	0.38	7.8	3.69E-14	HDL cholesterol	
LGG	trans	1	rs12421159	chr11:48624841	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.37E-16	HDL cholesterol	
LGG	trans	1	rs12421879	chr11:48689978	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.19	2.2E-15	HDL cholesterol	
LGG	trans	1	rs12526680	chr6:26550954	ZNF322B	chr9:99957633-99961910:-	0.53	12.38	7.75E-31	Educational attainment	
LGG	trans	1	rs12570188	chr10:100855702	SHOC2	chr10:112679301-112773424:+	-0.4	-5.79	1.23E-8	Asthma (childhood onset)	
LGG	trans	1	rs12570188	chr10:100855702	SMNDC1	chr10:112052799-112064707:-	-0.49	-5.96	4.69E-9	Asthma (childhood onset)	
LGG	trans	1	rs12615721	chr2:81856526	FAM55B	chr11:114549200-114577652:+	-0.48	-5.8	1.2E-8	Pulmonary function decline	
LGG	trans	1	rs12806328	chr11:48647971	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.45	3.28E-16	HDL cholesterol	
LGG	trans	1	rs13195401	chr6:26463574	HCG2P7	chr6:29866808-29870429:+	0.66	5.86	8.53E-9	Schizophrenia	
LGG	trans	1	rs13195402	chr6:26463575	HCG2P7	chr6:29866808-29870429:+	0.66	5.86	8.53E-9	Schizophrenia	
LGG	trans	1	rs13200462	chr6:28218199	BTN3A2	chr6:26365398-26378546:+	-0.53	-7.67	9.38E-14	Depression	
LGG	trans	1	rs1321479	chr6:26501897	ZNF322B	chr9:99957633-99961910:-	-0.46	-10.56	1.23E-23	Educational attainment	
LGG	trans	1	rs1321480	chr6:26532742	ZNF322B	chr9:99957633-99961910:-	0.51	11.92	6.17E-29	Educational attainment	
LGG	trans	1	rs1321481	chr6:26538210	ZNF322B	chr9:99957633-99961910:-	0.51	11.91	6.3E-29	Educational attainment	
LGG	trans	1	rs1351696	chr11:48382471	FOLH1B	chr11:89392465-89431885:+	-0.5	-7.21	2.18E-12	D-dimer levels	
LGG	trans	1	rs1412771	chr9:7729512	FICD	chr12:108909051-108913380:+	-0.38	-5.83	1.03E-8	Myopia (pathological)	
LGG	trans	1	rs1419183	chr6:28242794	BTN3A2	chr6:26365398-26378546:+	-0.54	-7.78	4.21E-14	Depression	
LGG	trans	1	rs1535277	chr6:26567802	ZNF322B	chr9:99957633-99961910:-	0.56	12.89	6.03E-33	Educational attainment	
LGG	trans	1	rs1605364	chr11:48684843	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.06	5.83E-15	HDL cholesterol	
LGG	trans	1	rs1679709	chr6:28228342	BTN3A2	chr6:26365398-26378546:+	0.54	7.78	4.21E-14	Depression	
LGG	trans	1	rs1679732	chr6:28221264	BTN3A2	chr6:26365398-26378546:+	0.54	7.78	4.21E-14	Depression	
LGG	trans	1	rs16929097	chr9:12521826	C9orf123	chr9:7796493-7799799:-	0.57	6.5	1.99E-10	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	DCTN3	chr9:34613548-34620496:-	0.45	5.97	4.45E-9	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	HAUS6	chr9:19053142-19102902:-	0.52	5.85	8.84E-9	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	KDM4C	chr9:6716495-7175647:+	0.67	7.29	1.29E-12	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	KIAA2026	chr9:5919010-6008003:-	0.39	5.93	5.86E-9	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	KLHL9	chr9:21324054-21335429:-	0.57	7.21	2.1E-12	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	PSIP1	chr9:15464066-15511003:-	0.61	6.77	3.66E-11	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	RANBP6	chr9:6011020-6015640:-	0.49	5.98	4.21E-9	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	RRAGA	chr9:19049372-19051019:+	0.55	6.3	6.44E-10	Asthma (childhood onset)	
LGG	trans	1	rs16929097	chr9:12521826	SNAPC3	chr9:15422782-15465830:+	0.55	6.27	7.98E-10	Asthma (childhood onset)	
LGG	trans	1	rs17052824	chr13:53515799	HIRIP3	chr16:30004317-30007387:-	0.4	5.98	4.27E-9	Immune response to anthrax vaccine	
LGG	trans	1	rs17218161	chr4:59213845	HELQ	chr4:84328501-84377025:-	0.5	6.06	2.78E-9	Asthma (childhood onset)	
LGG	trans	1	rs17580966	chr11:55312550	FOLH1B	chr11:89392465-89431885:+	-0.6	-5.86	8.42E-9	Systemic lupus erythematosus	
LGG	trans	1	rs1778508	chr6:28229881	BTN3A2	chr6:26365398-26378546:+	0.54	7.78	4.21E-14	Depression	
LGG	trans	1	rs1778511	chr6:28229411	BTN3A2	chr6:26365398-26378546:+	0.54	7.78	4.21E-14	Depression	
LGG	trans	1	rs1809986	chr11:48987539	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.19	2.33E-15	HDL cholesterol	
LGG	trans	1	rs1814175	chr11:49559172	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.66	2.43E-20	Height	
LGG	trans	1	rs1884946	chr6:26545308	ZNF322B	chr9:99957633-99961910:-	0.52	11.79	1.97E-28	Educational attainment	
LGG	trans	1	rs1884948	chr6:26567988	ZNF322B	chr9:99957633-99961910:-	0.55	12.81	1.31E-32	Educational attainment	
LGG	trans	1	rs1884949	chr6:26568067	ZNF322B	chr9:99957633-99961910:-	0.55	12.81	1.31E-32	Educational attainment	
LGG	trans	1	rs1936365	chr6:28268452	BTN3A2	chr6:26365398-26378546:+	0.5	7.53	2.51E-13	Depression	
LGG	trans	1	rs2208331	chr6:26507319	ZNF322B	chr9:99957633-99961910:-	0.51	11.63	8.69E-28	Educational attainment	
LGG	trans	1	rs2221559	chr11:48707973	FOLH1B	chr11:89392465-89431885:+	0.39	8.1	4.24E-15	HDL cholesterol	
LGG	trans	1	rs2224380	chr6:26553943	ZNF322B	chr9:99957633-99961910:-	0.54	12.54	1.77E-31	Educational attainment	
LGG	trans	1	rs2255070	chr6:26501777	ZNF322B	chr9:99957633-99961910:-	0.51	11.62	9.88E-28	Educational attainment	
LGG	trans	1	rs2305983	chr11:47858755	FOLH1B	chr11:89392465-89431885:+	0.4	6.32	5.88E-10	Intraocular pressure	
LGG	trans	1	rs2342002	chr6:61951860	GUSBL2	chr6:58246159-58287724:-	-0.34	-6.07	2.56E-9	Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)	
LGG	trans	1	rs2393670	chr6:26535541	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs2470002	chr8:120357424	LOC644936	chr5:79594919-79596297:-	0.31	5.91	6.27E-9	Hypertension	
LGG	trans	1	rs2689154	chr1:238908353	C15orf21	chr15:45803334-45848928:+	0.27	5.82	1.08E-8	Pancreatic cancer	
LGG	trans	1	rs2689154	chr1:238908353	SRRM5	chr19:44100738-44118649:+	0.25	6.03	3.18E-9	Pancreatic cancer	
LGG	trans	1	rs270421	chr16:79252324	WWOX	chr16:78133551-79246563:+	-0.26	-6.24	9.35E-10	Serum thyroid-stimulating hormone levels	
LGG	trans	1	rs2736371	chr8:11105529	FLJ10661	chr8:8086092-8102386:+	0.45	9.09	2.45E-18	Retinal vascular caliber	
LGG	trans	1	rs2799077	chr6:28234597	BTN3A2	chr6:26365398-26378546:+	-0.53	-7.7	7.76E-14	Depression	
LGG	trans	1	rs2799079	chr6:28235176	BTN3A2	chr6:26365398-26378546:+	-0.51	-7.49	3.21E-13	Depression	
LGG	trans	1	rs28558133	chr6:26531433	ZNF322B	chr9:99957633-99961910:-	0.51	11.93	5.44E-29	Educational attainment	
LGG	trans	1	rs34636547	chr11:48590103	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs3736781	chr6:26505362	ZNF322B	chr9:99957633-99961910:-	0.51	11.7	4.64E-28	Educational attainment	
LGG	trans	1	rs3736782	chr6:26505403	ZNF322B	chr9:99957633-99961910:-	0.51	11.7	4.64E-28	Educational attainment	
LGG	trans	1	rs41433250	chr13:31495835	C13orf23	chr13:39584003-39612252:-	0.64	6.48	2.28E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	CDADC1	chr13:49822103-49867619:+	0.72	6.8	3.05E-11	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	DHRS12	chr13:52342131-52378293:-	0.73	6.4	3.71E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	DIS3	chr13:73329542-73356344:-	0.56	5.91	6.49E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	EFHA1	chr13:22066840-22178307:-	0.66	5.79	1.23E-8	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	EXOSC8	chr13:37574678-37583749:+	0.56	6.25	8.86E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	GTF2F2	chr13:45694631-45858237:+	0.59	6.05	2.9E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	KPNA3	chr13:50273443-50367057:-	0.7	6.59	1.15E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	LOC100190939	chr13:45915480-45965616:+	0.63	6.72	5.16E-11	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	MED4	chr13:48627462-48669251:-	0.74	5.97	4.6E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	MIPEP	chr13:24304329-24463559:-	0.64	5.79	1.27E-8	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	MRPS31	chr13:41303433-41345347:-	0.74	6.35	4.95E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	MTIF3	chr13:28009783-28024711:-	0.66	6.57	1.31E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	N4BP2L2	chr13:33006930-33112936:-	0.61	5.82	1.04E-8	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	NUDT15	chr13:48611703-48621282:+	0.72	6.26	8.52E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	NUFIP1	chr13:45513384-45563613:-	0.62	6.28	7.53E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	PDS5B	chr13:33160592-33352155:+	0.5	5.79	1.27E-8	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	POMP	chr13:29233241-29253091:+	0.61	6.71	5.52E-11	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	SAP18	chr13:21714653-21723223:+	0.73	7.15	3.08E-12	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	SERP2	chr13:44947978-44971849:+	0.47	6.36	4.67E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	SUCLA2	chr13:48516792-48612125:-	0.52	6.16	1.52E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	SUGT1	chr13:53226831-53262433:+	0.7	5.85	9.2E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	TRIM13	chr13:50571143-50592603:+	0.64	5.89	7.17E-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs41433250	chr13:31495835	UTP14C	chr13:52586550-52607734:+	0.49	6.33	5.51E-10	Influenza A (H1N1) infection;Mild influenza (H1N1) infection	
LGG	trans	1	rs4306571	chr17:40814207	COQ10A	chr12:56660642-56664748:+	0.65	6.04	3.06E-9	Systolic blood pressure change trajectories	
LGG	trans	1	rs4713006	chr6:26519872	ZNF322B	chr9:99957633-99961910:-	0.51	11.64	7.93E-28	Educational attainment	
LGG	trans	1	rs4713008	chr6:26538268	ZNF322B	chr9:99957633-99961910:-	0.51	11.83	1.38E-28	Educational attainment	
LGG	trans	1	rs4844381	chr1:121184898	NBPF14	chr1:148003643-148346791:-	0.31	7.71	6.85E-14	Hip geometry	
LGG	trans	1	rs4844607	chr1:121184059	NBPF14	chr1:148003643-148346791:-	-0.29	-7.11	4.05E-12	Hip geometry	
LGG	trans	1	rs4871	chr6:26545632	ZNF322B	chr9:99957633-99961910:-	0.52	11.8	1.77E-28	Educational attainment	
LGG	trans	1	rs4881994	chr11:48498139	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.97	1.15E-14	HDL cholesterol	
LGG	trans	1	rs4882010	chr11:48559173	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs4882015	chr11:48565573	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.28	1.17E-15	HDL cholesterol	
LGG	trans	1	rs4882016	chr11:48570125	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.22	1.84E-15	HDL cholesterol	
LGG	trans	1	rs4882017	chr11:48570182	FOLH1B	chr11:89392465-89431885:+	0.4	8.25	1.47E-15	HDL cholesterol	
LGG	trans	1	rs4882019	chr11:48598748	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.35E-16	HDL cholesterol	
LGG	trans	1	rs4882021	chr11:48615966	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.37	5.93E-16	HDL cholesterol	
LGG	trans	1	rs4882096	chr11:48534102	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.97	1.13E-14	HDL cholesterol	
LGG	trans	1	rs4882111	chr11:48558447	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs4882117	chr11:48565468	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.28	1.17E-15	HDL cholesterol	
LGG	trans	1	rs4882120	chr11:48573529	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs4882123	chr11:48575739	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs4882129	chr11:48588774	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs4882130	chr11:48588954	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs4882132	chr11:48593125	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.12	3.69E-15	HDL cholesterol	
LGG	trans	1	rs4882134	chr11:48598795	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.35E-16	HDL cholesterol	
LGG	trans	1	rs4882136	chr11:48615311	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.37E-16	HDL cholesterol	
LGG	trans	1	rs4925166	chr17:18210810	LOC162632	chr17:16614993-16707819:+	0.29	6.79	3.23E-11	Multiple sclerosis	
LGG	trans	1	rs4929903	chr11:48913332	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.46	3.09E-16	HDL cholesterol	
LGG	trans	1	rs545854	chr8:9860080	FLJ10661	chr8:8086092-8102386:+	0.46	7.01	8.12E-12	Adiposity	
LGG	trans	1	rs55834832	chr11:48562583	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.56E-15	HDL cholesterol	
LGG	trans	1	rs62026609	chr15:91815768	DDX10	chr11:108535816-108811646:+	0.44	5.79	1.28E-8	Age-related hearing impairment	
LGG	trans	1	rs6453904	chr6:77173869	C4orf48	chr4:2043689-2045697:+	-0.22	-6.37	4.4E-10	Menarche (age at onset)	
LGG	trans	1	rs6453904	chr6:77173869	LOC644936	chr5:79594919-79596297:-	0.35	7.96	1.24E-14	Menarche (age at onset)	
LGG	trans	1	rs6453904	chr6:77173869	PCSK1N	chrX:48689507-48693960:-	-0.26	-6.04	3.06E-9	Menarche (age at onset)	
LGG	trans	1	rs6453904	chr6:77173869	SCARNA7	chr3:160232697-160233024:-	-0.28	-5.9	6.74E-9	Menarche (age at onset)	
LGG	trans	1	rs6453904	chr6:77173869	SNHG9	chr16:2014997-2015503:+	-0.23	-6.34	5.24E-10	Menarche (age at onset)	
LGG	trans	1	rs6453904	chr6:77173869	TMEM160	chr19:47549168-47551882:-	-0.21	-6.01	3.57E-9	Menarche (age at onset)	
LGG	trans	1	rs6456733	chr6:26566804	ZNF322B	chr9:99957633-99961910:-	0.55	12.77	1.85E-32	Educational attainment	
LGG	trans	1	rs6456734	chr6:26566965	ZNF322B	chr9:99957633-99961910:-	0.55	12.77	1.85E-32	Educational attainment	
LGG	trans	1	rs6485774	chr11:47773226	FOLH1B	chr11:89392465-89431885:+	0.41	6.48	2.27E-10	Intraocular pressure	
LGG	trans	1	rs6485784	chr11:47832260	FOLH1B	chr11:89392465-89431885:+	0.4	6.35	4.9E-10	Intraocular pressure	
LGG	trans	1	rs6485788	chr11:47873883	FOLH1B	chr11:89392465-89431885:+	-0.4	-6.31	6.15E-10	Intraocular pressure	
LGG	trans	1	rs6485872	chr11:48579710	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.09	4.82E-15	HDL cholesterol	
LGG	trans	1	rs6485875	chr11:48581034	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs6485882	chr11:48592435	FOLH1B	chr11:89392465-89431885:+	0.35	7.08	4.92E-12	HDL cholesterol	
LGG	trans	1	rs6485888	chr11:48605339	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.38	5.79E-16	HDL cholesterol	
LGG	trans	1	rs6485903	chr11:48639004	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.24	1.58E-15	HDL cholesterol	
LGG	trans	1	rs6485907	chr11:48651695	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.39	5.08E-16	HDL cholesterol	
LGG	trans	1	rs6485908	chr11:48652198	FOLH1B	chr11:89392465-89431885:+	-0.51	-7.41	5.71E-13	Axial length	
LGG	trans	1	rs6485911	chr11:48654784	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.21	2.0E-15	HDL cholesterol	
LGG	trans	1	rs6573333	chr14:61308337	JKAMP	chr14:59951161-59972080:+	0.72	6.29	7.17E-10	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	trans	1	rs6573333	chr14:61308337	MTHFD1	chr14:64854759-64926727:+	0.64	5.99	4.11E-9	Immune reponse to smallpox (secreted IFN-alpha)	
LGG	trans	1	rs68141011	chr6:28217797	BTN3A2	chr6:26365398-26378546:+	-0.53	-7.67	9.38E-14	Depression	
LGG	trans	1	rs6886255	chr5:176718361	LOC388955	chr2:63849182-63850159:-	0.64	12.77	1.85E-32	Migraine without aura	
LGG	trans	1	rs6901575	chr6:28250984	BTN3A2	chr6:26365398-26378546:+	-0.54	-7.75	5.43E-14	Depression	
LGG	trans	1	rs6903973	chr6:26499942	ZNF322B	chr9:99957633-99961910:-	0.51	11.69	4.98E-28	Educational attainment	
LGG	trans	1	rs6905391	chr6:28262686	BTN3A2	chr6:26365398-26378546:+	-0.51	-7.46	3.87E-13	Depression	
LGG	trans	1	rs6905391	chr6:28262686	RNF5P1	chr8:38457695-38458775:-	0.47	5.95	5.21E-9	Depression	
LGG	trans	1	rs6910899	chr6:26524339	ZNF322B	chr9:99957633-99961910:-	0.51	11.71	4.17E-28	Educational attainment	
LGG	trans	1	rs6922824	chr6:26553815	ZNF322B	chr9:99957633-99961910:-	-0.53	-12.45	3.9E-31	Educational attainment	
LGG	trans	1	rs6924838	chr6:26571756	ZNF322B	chr9:99957633-99961910:-	0.56	12.8	1.47E-32	Educational attainment	
LGG	trans	1	rs6925703	chr6:26521589	ZNF322B	chr9:99957633-99961910:-	0.51	11.71	4.27E-28	Educational attainment	
LGG	trans	1	rs6925895	chr6:26572165	ZNF322B	chr9:99957633-99961910:-	0.56	12.8	1.47E-32	Educational attainment	
LGG	trans	1	rs6926629	chr6:26499903	ZNF322B	chr9:99957633-99961910:-	0.51	11.69	5.14E-28	Educational attainment	
LGG	trans	1	rs6930120	chr6:26555484	ZNF322B	chr9:99957633-99961910:-	0.54	12.54	1.77E-31	Educational attainment	
LGG	trans	1	rs6932156	chr6:26571506	ZNF322B	chr9:99957633-99961910:-	0.56	12.8	1.47E-32	Educational attainment	
LGG	trans	1	rs6933176	chr6:26540178	ZNF322B	chr9:99957633-99961910:-	0.51	11.91	6.3E-29	Educational attainment	
LGG	trans	1	rs6940053	chr6:26562122	ZNF322B	chr9:99957633-99961910:-	0.55	12.7	3.6E-32	Educational attainment	
LGG	trans	1	rs6940188	chr6:26562029	ZNF322B	chr9:99957633-99961910:-	0.55	12.7	3.6E-32	Educational attainment	
LGG	trans	1	rs7101582	chr11:47714610	FOLH1B	chr11:89392465-89431885:+	0.37	5.91	6.26E-9	Intraocular pressure	
LGG	trans	1	rs7107184	chr11:48577069	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.26	1.33E-15	HDL cholesterol	
LGG	trans	1	rs7121460	chr11:48545232	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.1	4.24E-15	HDL cholesterol	
LGG	trans	1	rs7121992	chr11:48592582	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs7125559	chr11:48984207	FOLH1B	chr11:89392465-89431885:+	0.5	6.96	1.07E-11	Axial length	
LGG	trans	1	rs7125913	chr11:48984318	FOLH1B	chr11:89392465-89431885:+	0.5	6.96	1.07E-11	Axial length	
LGG	trans	1	rs7129386	chr11:48616694	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.37	5.93E-16	HDL cholesterol	
LGG	trans	1	rs7129556	chr11:77300048	INTS4L1	chr7:64601603-64694599:+	-0.33	-5.82	1.06E-8	Weight loss (gastric bypass surgery)	
LGG	trans	1	rs7131020	chr11:48642132	FOLH1B	chr11:89392465-89431885:+	0.51	7.25	1.66E-12	Axial length	
LGG	trans	1	rs7139978	chr13:38196963	MRPS31	chr13:41303433-41345347:-	-0.28	-5.91	6.32E-9	Life satisfaction	
LGG	trans	1	rs7218686	chr17:40813865	COQ10A	chr12:56660642-56664748:+	0.65	6.04	3.06E-9	Systolic blood pressure change trajectories	
LGG	trans	1	rs72843784	chr6:26498758	HCG2P7	chr6:29866808-29870429:+	0.68	6.03	3.28E-9	Schizophrenia	
LGG	trans	1	rs735765	chr6:28170297	BTN3A2	chr6:26365398-26378546:+	-0.57	-7.97	1.15E-14	Depression	
LGG	trans	1	rs7395662	chr11:48518893	FOLH1B	chr11:89392465-89431885:+	0.39	8.1	4.24E-15	HDL cholesterol	
LGG	trans	1	rs747782	chr11:47940925	FOLH1B	chr11:89392465-89431885:+	0.43	6.57	1.27E-10	Intraocular pressure	
LGG	trans	1	rs7478900	chr11:48544003	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.97	1.13E-14	HDL cholesterol	
LGG	trans	1	rs7479134	chr11:48625409	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.37E-16	HDL cholesterol	
LGG	trans	1	rs7479498	chr11:48660499	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.15	3.08E-15	HDL cholesterol	
LGG	trans	1	rs7481308	chr11:48600067	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.23	1.74E-15	HDL cholesterol	
LGG	trans	1	rs7481880	chr11:48609347	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.14E-16	HDL cholesterol	
LGG	trans	1	rs7482176	chr11:48604620	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.16	2.91E-15	HDL cholesterol	
LGG	trans	1	rs7482528	chr11:48640052	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.34	7.51E-16	HDL cholesterol	
LGG	trans	1	rs7483920	chr11:48599969	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.35E-16	HDL cholesterol	
LGG	trans	1	rs7532615	chr1:121172840	NBPF14	chr1:148003643-148346791:-	-0.31	-7.61	1.38E-13	Hip geometry	
LGG	trans	1	rs76014404	chr6:62391538	GUSBL2	chr6:58246159-58287724:-	-0.33	-5.97	4.56E-9	Esophageal adenocarcinoma	
LGG	trans	1	rs7632427	chr3:89534377	STX19	chr3:93733215-93747454:-	0.38	6.5	2.02E-10	Orofacial clefts	
LGG	trans	1	rs76329678	chr5:49830286	LOC647121	chr1:121260910-121313686:+	-0.25	-6.15	1.62E-9	Schizophrenia	
LGG	trans	1	rs767471	chr6:26557854	ZNF322B	chr9:99957633-99961910:-	0.54	12.54	1.77E-31	Educational attainment	
LGG	trans	1	rs7740487	chr6:28216486	BTN3A2	chr6:26365398-26378546:+	-0.53	-7.64	1.17E-13	Depression	
LGG	trans	1	rs7824557	chr8:11104111	FLJ10661	chr8:8086092-8102386:+	0.45	9.13	1.76E-18	Retinal vascular caliber	
LGG	trans	1	rs7903456	chr10:88919319	FAM35B	chr10:46897641-46939143:+	0.26	5.83	9.9E-9	Renal underexcretion gout;Gout	
LGG	trans	1	rs7924699	chr11:47893120	FOLH1B	chr11:89392465-89431885:+	0.39	6.17	1.42E-9	Intraocular pressure	
LGG	trans	1	rs7925955	chr11:48647533	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.4	4.74E-16	HDL cholesterol	
LGG	trans	1	rs7928083	chr11:48613148	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.37	5.93E-16	HDL cholesterol	
LGG	trans	1	rs7931984	chr11:48580835	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs7938880	chr11:48642154	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.31	9.45E-16	HDL cholesterol	
LGG	trans	1	rs7942031	chr11:47868474	FOLH1B	chr11:89392465-89431885:+	0.4	6.32	5.88E-10	Intraocular pressure	
LGG	trans	1	rs7944356	chr11:48610154	FOLH1B	chr11:89392465-89431885:+	-0.41	-8.38	5.79E-16	HDL cholesterol	
LGG	trans	1	rs7945192	chr11:48580737	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs7948486	chr11:48912140	FOLH1B	chr11:89392465-89431885:+	0.39	8.18	2.45E-15	HDL cholesterol	
LGG	trans	1	rs7949348	chr11:48493801	FOLH1B	chr11:89392465-89431885:+	-0.39	-7.92	1.59E-14	HDL cholesterol	
LGG	trans	1	rs7949554	chr11:48581992	FOLH1B	chr11:89392465-89431885:+	-0.4	-8.18	2.44E-15	HDL cholesterol	
LGG	trans	1	rs804280	chr8:11612698	FLJ10661	chr8:8086092-8102386:+	-0.35	-7.15	3.27E-12	Myopia (pathological)	
LGG	trans	1	rs804281	chr8:11611865	FLJ10661	chr8:8086092-8102386:+	-0.34	-6.77	3.78E-11	Myopia (pathological)	
LGG	trans	1	rs8188963	chr11:48685693	FOLH1B	chr11:89392465-89431885:+	0.51	7.27	1.47E-12	Axial length	
LGG	trans	1	rs8189391	chr11:48859789	FOLH1B	chr11:89392465-89431885:+	0.42	8.72	4.45E-17	HDL cholesterol	
LGG	trans	1	rs853676	chr6:28299687	BTN3A2	chr6:26365398-26378546:+	-0.49	-7.15	3.13E-12	Depression	
LGG	trans	1	rs853678	chr6:28297313	BTN3A2	chr6:26365398-26378546:+	-0.49	-7.2	2.21E-12	Depression	
LGG	trans	1	rs853679	chr6:28296863	BTN3A2	chr6:26365398-26378546:+	-0.49	-7.2	2.21E-12	Depression	
LGG	trans	1	rs853685	chr6:28288785	BTN3A2	chr6:26365398-26378546:+	-0.5	-7.37	7.18E-13	Depression	
LGG	trans	1	rs853685	chr6:28288785	RNF5P1	chr8:38457695-38458775:-	0.46	5.81	1.13E-8	Depression	
LGG	trans	1	rs853694	chr6:28279100	BTN3A2	chr6:26365398-26378546:+	-0.51	-7.44	4.45E-13	Depression	
LGG	trans	1	rs853694	chr6:28279100	RNF5P1	chr8:38457695-38458775:-	0.46	5.89	7.19E-9	Depression	
LGG	trans	1	rs9295695	chr6:26528250	ZNF322B	chr9:99957633-99961910:-	-0.52	-12.12	9.61E-30	Educational attainment	
LGG	trans	1	rs9357010	chr6:26527945	ZNF322B	chr9:99957633-99961910:-	0.5	11.5	2.84E-27	Educational attainment	
LGG	trans	1	rs9393728	chr6:26509330	ZNF322B	chr9:99957633-99961910:-	0.51	11.63	8.69E-28	Educational attainment	
LGG	trans	1	rs9393729	chr6:26514166	ZNF322B	chr9:99957633-99961910:-	0.51	11.64	8.22E-28	Educational attainment	
LGG	trans	1	rs9393731	chr6:26529374	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs9393732	chr6:26530898	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs9461259	chr6:26504835	ZNF322B	chr9:99957633-99961910:-	0.51	11.7	4.64E-28	Educational attainment	
LGG	trans	1	rs9461271	chr6:26554968	ZNF322B	chr9:99957633-99961910:-	0.54	12.54	1.77E-31	Educational attainment	
LGG	trans	1	rs9467176	chr6:24464907	C20orf27	chr20:3734156-3748452:-	0.3	5.84	9.58E-9	Hematological and biochemical traits	
LGG	trans	1	rs9467773	chr6:26498426	ZNF322B	chr9:99957633-99961910:-	0.51	11.69	5.14E-28	Educational attainment	
LGG	trans	1	rs9467774	chr6:26505036	ZNF322B	chr9:99957633-99961910:-	0.51	11.63	8.69E-28	Educational attainment	
LGG	trans	1	rs9467778	chr6:26534743	ZNF322B	chr9:99957633-99961910:-	0.51	11.86	1.02E-28	Educational attainment	
LGG	trans	1	rs9467779	chr6:26536687	ZNF322B	chr9:99957633-99961910:-	-0.53	-12.2	4.52E-30	Educational attainment	
LGG	trans	1	rs9467782	chr6:26542773	ZNF322B	chr9:99957633-99961910:-	0.52	11.95	4.46E-29	Educational attainment	
LGG	trans	1	rs9467783	chr6:26542894	ZNF322B	chr9:99957633-99961910:-	0.51	11.64	8.2E-28	Educational attainment	
LGG	trans	1	rs9467787	chr6:26556769	ZNF322B	chr9:99957633-99961910:-	0.54	12.54	1.77E-31	Educational attainment	
LGG	trans	1	rs9467791	chr6:26562486	ZNF322B	chr9:99957633-99961910:-	-0.56	-12.87	6.93E-33	Educational attainment	
LGG	trans	1	rs9467796	chr6:26568411	ZNF322B	chr9:99957633-99961910:-	0.55	12.81	1.31E-32	Educational attainment	
LGG	trans	1	rs9467797	chr6:26568473	ZNF322B	chr9:99957633-99961910:-	0.55	12.81	1.31E-32	Educational attainment	
LGG	trans	1	rs9645642	chr11:48705455	FOLH1B	chr11:89392465-89431885:+	-0.39	-8.19	2.2E-15	HDL cholesterol	
LGG	trans	1	rs9842133	chr3:179664102	LOC644936	chr5:79594919-79596297:-	-0.31	-7.38	6.62E-13	Blood metabolite levels	
LGG	trans	1	rs9986382	chr6:26550619	ZNF322B	chr9:99957633-99961910:-	0.54	12.58	1.14E-31	Educational attainment	
LGG	trans	1	rs9986596	chr6:28219661	BTN3A2	chr6:26365398-26378546:+	-0.53	-7.69	8.23E-14	Depression	
LGG	trans	1	rs9987353	chr8:9116349	FLJ10661	chr8:8086092-8102386:+	0.41	7.73	5.95E-14	Recombination measurement	
